The O
dose O
of O
risperidone O
was O
titrated O
between O
1 O
and O
2.0 O
mg/d O
, O
and O
the O
dose O
of O
amantadine O
was O
100 O
or O
150 O
mg/d O
for O
patients O
less O
than O
30 O
kg O
or O
more O
than O
30 O
kg O
, O
respectively O
. O
[]

Analysis O
of O
covariance O
models O
were O
used O
to O
compare O
changes O
between O
CRC B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
health I-outcome ['Life-Impact']
belief I-outcome ['Life-Impact']
scores O
at O
baseline O
and O
1 O
week O
post-intervention O
. O
['Life-Impact']

Tissue O
samples O
from O
93 O
de O
novo O
diffuse O
large O
B-cell O
lymphoma O
patients O
seen O
between O
1995 O
and O
2009 O
randomly O
receiving O
either O
standard O
combination O
chemotherapy O
( O
CHOP O
, O
n=48 O
) O
or O
the O
identical O
program O
with O
rituximab O
( O
n=45 O
) O
were O
subtyped O
using O
an O
investigational O
immunohistochemical O
( O
IHC O
) O
based O
tissue O
microarray O
( O
TMA O
) O
and O
contrasted O
to O
the O
approximately O
corresponding O
categories O
as O
defined O
either O
by O
Hans O
and O
associates O
using O
a O
three O
marker O
panel O
into O
germinal O
or O
non-germinal O
centre O
subtypes O
or O
by O
Choi O
and O
colleagues O
with O
two O
additional O
antibodies O
into O
germinal O
centre O
( O
GCB O
) O
or O
activated O
B-cells O
( O
ABC O
) O
. O
[]

After O
ovarian O
stimulation O
with O
GnRH O
agonist/HMG O
, O
the O
luteal O
phase O
seems O
to O
be O
inadequate O
, O
but O
in O
a O
previous O
study O
we O
did O
not O
find O
evidence O
to O
support O
the O
need O
for O
oral O
progesterone O
supplementation O
. O
[]

Height O
and O
weight O
data O
were O
available O
at O
baseline O
for O
788 O
( O
83 O
% O
) O
subjects O
. O
[]

RESULTS O
The O
D-C O
model O
accounted O
for O
15 O
and O
19 O
% O
of O
the O
variance O
in O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
, O
after O
controlling O
for O
age O
, O
gender O
and O
relationship O
to O
the O
patient O
. O
['Life-Impact']

METHODS O
Thirty O
three O
patients O
with O
Huntington O
's O
disease O
participated O
in O
a O
double O
blind O
randomised O
trial O
. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

Maternal B-outcome ['Physiological-Clinical']
salivary I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
throughout O
gestation O
( O
P O
< O
0.001 O
) O
and O
the O
LP O
gilts O
had O
greater O
salivary B-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
compared O
with O
the O
AP O
and O
HP O
gilts O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Pioglitazone O
and O
glimepiride O
improve O
glycemic O
control O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
by O
different O
mechanisms O
. O
[]

METHODS O
STEPs O
was O
a O
3-month O
randomised O
controlled O
trial O
with O
a O
pre O
and O
post-test O
design O
. O
[]

Determinants O
of O
the O
effect O
of O
estrogen O
on O
the O
progression O
of O
subclinical B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
: O
Estrogen O
in O
the O
Prevention O
of O
Atherosclerosis O
Trial O
. O
['Physiological-Clinical']

A O
Phase O
II O
clinical O
study O
that O
was O
not O
completed O
documented O
that O
daily O
oral O
doses O
of O
PPS O
administered O
for O
8 O
weeks O
lowered O
plasma O
levels O
of O
sVCAM-1 O
and O
tended O
to O
improve O
microvascular O
blood O
flow O
in O
patients O
with O
SCD O
. O
[]

The O
extent O
and O
severity O
of O
atopic O
eczema O
, O
the O
growth O
and O
nutrition O
of O
infants O
, O
and O
concentrations O
of O
circulating O
cytokines/chemokines O
and O
soluble O
cell O
surface O
adhesion O
molecules O
in O
serum O
and O
methyl-histamine O
and O
eosinophilic O
protein O
X O
in O
urine O
were O
determined O
. O
[]

Measuring O
acute O
effects O
on O
rCMglu O
with O
FDG-PET O
may O
offer O
a O
method O
for O
defining O
pharmacologically O
active O
doses O
for O
central O
nervous O
system O
targets O
for O
which O
selective O
radiotracers O
are O
lacking O
. O
[]

After O
the O
initial O
clinical O
evaluation O
, O
including O
plain O
radiography O
and O
MRI O
, O
37 O
hips O
with O
early-stage O
osteonecrosis O
( O
ON O
) O
in O
33 O
patients O
were O
randomly O
assigned O
to O
a O
core-decompression O
group O
or O
a O
conservatively-treated O
group O
. O
[]

OBJECTIVES O
Roux-en-Y O
gastric O
bypass O
surgery O
is O
the O
most O
commonly O
performed O
procedure O
for O
the O
treatment O
of O
morbid O
obesity O
. O
[]

Prospective O
comparison O
of O
the O
value O
of O
brushings O
before O
and O
after O
biopsy O
in O
the O
endoscopic O
diagnosis O
of O
gastroesophageal O
malignancy O
. O
[]

PBMC O
obtained O
at O
entry O
, O
6 O
, O
12 O
, O
18 O
, O
and O
24 O
months O
were O
stimulated O
to O
produce O
IL-1 O
beta O
with O
phytohemagglutinin O
( O
PHA O
) O
, O
lipopolysaccharide O
( O
LPS O
) O
, O
Staphylococcus O
epidermidis O
, O
recombinant O
IL-2 O
, O
or O
mitochondrial O
antigen O
. O
[]

As O
for O
cyclophosphamide O
versus O
radiotherapy O
, O
the O
differences O
are O
to O
uncertain O
for O
any O
conclusion O
to O
be O
drawn O
. O
[]

Twenty-five O
sedentary O
healthy O
subjects O
were O
randomized O
into O
an O
endurance O
group O
( O
n O
= O
13 O
) O
or O
strength O
group O
( O
n O
= O
12 O
) O
. O
[]

A O
single O
treatment O
was O
insufficient O
in O
intraventricular O
and O
giant O
cysts O
. O
[]

The O
lead-in O
that O
suggested O
normality O
yielded O
the O
best O
performance O
. O
[]

Journal O
ID: O
100968562 O
[]

Antipyrine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
and O
response O
to O
interferon B-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
in O
patients O
with O
chronic O
active O
hepatitis O
C. O
To O
determine O
whether O
hepatic O
metabolic O
function O
affects O
the O
response O
to O
interferon B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
we O
measured O
antipyrine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
85 O
patients O
with O
chronic O
active O
hepatitis O
C O
and O
compared O
the O
results O
with O
treatment O
outcome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

This O
increased O
slightly O
but O
not O
significantly O
to O
6.8 O
+/-1.8 O
in O
the O
prepared O
section O
( O
P O
< O
0.1 O
) O
. O
[]

The O
opioid O
hypothesis O
suggests O
that O
childhood O
autism O
may O
result O
from O
excessive O
brain O
opioid O
activity O
during O
neonatal O
period O
which O
may O
constitutionally O
inhibit O
social O
motivation O
, O
yielding O
autistic O
isolation O
and O
aloofness O
( O
Panksepp O
, O
1979 O
) O
. O
[]

Relapse O
patterns O
indicate O
that O
patients O
destined O
to O
relapse O
need O
more O
systemic O
, O
rather O
than O
local O
, O
treatment O
. O
[]

In O
total O
218 O
participants O
developed O
subsequent O
HF O
hospitalization O
. O
[]

In O
contrast O
, O
the O
number O
of O
wet B-outcome ['Physiological-Clinical']
nights I-outcome ['Physiological-Clinical']
and O
urodynamic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
in O
group O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
was O
determined O
that O
the O
size O
of O
the O
bruising B-outcome ['Physiological-Clinical']
was O
smaller O
in O
the O
30-second O
injection O
. O
['Physiological-Clinical']

An O
explorative O
study O
on O
the O
clinical O
utility O
of O
baseline O
and O
serial O
serum O
tumour O
marker O
measurements O
in O
advanced O
upper O
gastrointestinal O
cancer O
. O
[]

Dose-response B-outcome ['Physiological-Clinical']
effect O
of O
flecainide O
in O
patients O
with O
symptomatic O
paroxysmal O
atrial O
fibrillation O
and/or O
flutter O
monitored O
with O
trans-telephonic O
electrocardiography O
: O
a O
multicenter O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
['Physiological-Clinical']

Candidate O
predictors O
and O
moderators O
included O
21 O
demographics O
and O
baseline O
measures O
of O
behavior O
. O
[]

The O
findings O
suggest O
an O
increase O
in O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
during O
treatment O
with O
levonorgestrel O
and O
stable O
values O
during O
short-term O
administration O
of O
DMPA O
, O
in O
standard O
clinical O
doses O
for O
contraception O
. O
['Physiological-Clinical']

Changes O
in O
ovarian B-outcome ['Physiological-Clinical']
reserve I-outcome ['Physiological-Clinical']
were O
investigated O
by O
measuring O
the O
levels O
of O
anti-Mullerian B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AMH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
basal B-outcome ['Physiological-Clinical']
follicle-stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
before O
surgery O
and O
at O
3 O
, O
6 O
and O
12 O
months O
from O
surgery O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Dexamethasone O
phosphate O
in O
antibiotic O
ear O
drops O
for O
the O
treatment O
of O
acute O
bacterial O
otitis O
externa O
. O
[]

The O
different O
parameters O
were O
compared O
by O
analysis O
of O
variance O
( O
ANOVA O
) O
. O
[]

From O
a O
clinical O
perspective O
, O
the O
methods O
are O
to O
be O
considered O
equivalent O
. O
[]

CONCLUSION: O
In O
patients O
undergoing O
primary O
cementless O
THA, O
using O
a O
posterior O
approach, O
who O
are O
treated O
with O
rivaroxaban O
for O
thromboembolic O
prophylaxis, O
short- O
and O
long-TXA O
IV O
protocols O
are O
significantly O
more O
effective O
than O
placebo O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL), O
without O
any O
thromboembolic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
Non-inferiority O
of O
a O
short- O
versus O
a O
long-TXA O
protocol O
in O
reducing O
perioperative O
real O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
(RBL) O
was O
supported O
in O
a O
secondary O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVES O
The O
objective O
was O
to O
determine O
whether O
an O
educational O
intervention O
for O
health O
care O
providers O
would O
result O
in O
improved O
documentation B-outcome ['Physiological-Clinical']
of O
cases O
of O
possible O
physical O
child O
abuse O
in O
children O
< O
36 O
months O
old O
treated O
in O
the O
emergency O
department O
( O
ED O
) O
setting O
. O
['Physiological-Clinical']

METHODS O
The O
current O
study O
aimed O
to O
analyze O
alterations O
in O
microvascular B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
at O
4 O
predefined O
time O
points O
( O
T1-T4 O
) O
during O
on-pump O
CABG O
using O
orthogonal O
polarization O
spectral O
imaging O
. O
['Physiological-Clinical']

The O
hypothermic O
patients O
had O
more O
postoperative B-outcome ['Physiological-Clinical']
shivering I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
this O
double-blind O
study O
, O
we O
randomised O
98 O
patients O
to O
receive O
cophenylcaine O
or O
placebo O
nasal O
spray O
before O
flexible O
nasendoscopy O
. O
[]

Publication O
date: O
2019/03/09 O
06:00 O
[medline] O
[]

Age O
, O
FIGO O
stage O
, O
histologic O
grade O
, O
and O
residual O
disease O
all O
exerted O
a O
significant O
effect O
on O
survival O
time O
. O
[]

However O
, O
few O
emotion O
training O
interventions O
have O
been O
trialled O
with O
young O
children O
with O
autism O
and O
co-morbid O
ID O
. O
[]

BACKGROUND O
The O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
Osteoarthritis O
Index O
is O
a O
previously O
described O
self-administered O
questionnaire O
covering O
three O
domains O
: O
pain B-outcome ['Physiological-Clinical']
, O
stiffness B-outcome ['Physiological-Clinical']
and O
function B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

We O
offered O
2 O
individual O
and O
9 O
group O
DASH O
sessions O
to O
intervention O
participants O
and O
1 O
individual O
session O
and O
printed O
DASH O
educational O
materials O
to O
control O
participants O
. O
[]

These O
data O
show O
that O
acute O
nicotine O
administration O
, O
in O
the O
form O
of O
nicotine O
gum O
, O
has O
no O
effect O
on O
cardiovascular B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
stress O
reactivity B-outcome ['Physiological-Clinical']
in O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Both O
citalopram O
and O
reboxetine O
showed O
good O
safety O
and O
tolerability B-outcome ['Life-Impact']
. O
['Life-Impact']

MATERIAL O
AND O
METHODS O
Using O
impressions O
made O
from O
a O
stainless O
steel O
complete-crown O
master O
die O
, O
9 O
stone O
cast O
replicas O
were O
fabricated O
, O
numbered O
, O
and O
distributed O
into O
8 O
ceramic O
ZrO O
( O
2 O
) O
CAD/CAM O
system O
groups O
( O
Lava O
Frame O
0.3 O
and O
0.5 O
, O
IPS O
e.max O
ZirCAD O
, O
VITA O
YZ O
, O
Procera O
AllZircon O
, O
Digizon O
, O
DC O
Zircon O
, O
and O
Cercon O
Base O
) O
and O
to O
a O
lithium O
disilicate O
glass-ceramic O
control O
group O
( O
IPS O
e.max O
Press O
) O
using O
a O
simple O
computer-generated O
randomization O
method O
. O
[]

In O
addition O
, O
it O
had O
some O
degree O
of O
face O
validity O
and O
social B-outcome ['Life-Impact']
validity I-outcome ['Life-Impact']
from O
the O
students O
' O
vantage O
point O
. O
['Life-Impact']

CONCLUSION O
Short-term O
use O
of O
MET O
is O
well O
tolerated B-outcome ['Life-Impact']
by O
obese O
children O
with O
NGT O
and O
has O
a O
beneficial O
effect O
on O
BMI O
and O
autonomic O
control O
of O
the O
heart O
as O
well O
as O
a O
trend O
toward O
improved O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

39 O
patients O
( O
32 O
% O
) O
in O
the O
standard O
diagnosis O
group O
and O
18 O
( O
15 O
% O
) O
in O
the O
biomarker O
diagnosis O
group O
received O
empirical O
antifungal O
treatment O
( O
difference O
17 O
% O
, O
95 O
% O
CI O
4-26 O
; O
p=0?002 O
) O
. O
[]

The O
increase O
in O
[]

On O
September O
27 O
, O
2006 O
, O
the O
U.S. O
Food O
and O
Drug O
Administration O
granted O
accelerated O
approval O
to O
panitumumab O
( O
Vectibix O
; O
Amgen O
, O
Inc. O
, O
Thousand O
Oaks O
, O
CA O
) O
for O
the O
treatment O
of O
patients O
with O
epidermal O
growth O
factor O
receptor-expressing O
, O
metastatic O
colorectal O
carcinoma O
with O
disease O
progression O
on O
or O
following O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan-containing O
chemotherapy O
regimens O
. O
[]

INTRODUCTION O
There O
is O
debate O
about O
the O
type O
and O
intensity O
of O
early O
childhood O
intervention O
that O
is O
most O
helpful O
for O
children O
with O
developmental O
problems O
. O
[]

Failure O
for O
PFS B-outcome ['Mortality']
was O
defined O
as O
the O
first O
occurrence O
of O
local B-outcome ['Physiological-Clinical']
, O
regional B-outcome ['Physiological-Clinical']
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
entacapone O
, O
a O
peripherally O
acting O
catechol-O-methyltransferase O
inhibitor O
, O
on O
the O
motor B-outcome ['Physiological-Clinical']
response O
to O
acute O
treatment O
with O
levodopa B-outcome ['Physiological-Clinical']
in O
patients O
with O
Parkinson O
's O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
shown O
by O
subjective O
symptoms B-outcome ['Physiological-Clinical']
, O
the O
results O
in O
95% O
of O
patients O
were O
rated O
as O
good O
or O
very O
good. O
[['Physiological-Clinical']]

PATIENTS O
Forty-eight O
patients O
having O
IVF O
for O
the O
first O
time O
were O
randomized O
between O
the O
two O
protocols O
. O
[]

10.7? O
) O
and O
mild O
PFOA O
( O
mean O
? O
[]

PRL-8-53 O
: O
enhanced O
learning B-outcome ['Life-Impact']
and O
subsequent O
retention B-outcome ['Life-Impact']
in O
humans O
as O
a O
result O
of O
low O
oral O
doses O
of O
new O
psychotropic O
agent O
. O
['Life-Impact', 'Life-Impact']

METHODS O
One O
hundred O
seventy-six O
patients O
with O
necrotizing O
pancreatitis O
were O
prospectively O
randomized O
to O
prophylactic O
treatment O
with O
0.5 O
g O
meropenem O
t.i.d O
. O
[]

Naltrexone O
treatment O
failed O
to O
have O
therapeutic O
effects O
on O
SIB O
and O
autism O
. O
[]

The O
MSKCC O
trial O
revealed O
a O
significant O
advantage O
of O
idarubicin O
compared O
with O
daunorubicin O
in O
both O
the O
original O
and O
the O
updated O
analyses O
. O
[]

This O
implies O
a O
certain O
need O
for O
maintenance O
where O
a O
one-piece O
single-implant O
protocol O
( O
test O
) O
allows O
both O
for O
a O
simple O
clinical O
procedure O
at O
placement O
without O
cementation O
problems O
, O
as O
well O
as O
for O
an O
easy O
and O
simple O
maintenance O
of O
installed O
single O
implant O
crowns O
in O
long-term O
function O
. O
[]

In O
conclusion O
, O
an O
improved O
fibrinolytic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
was O
observed O
after O
statin O
treatment O
, O
most O
pronounced O
with O
atorvastatin O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
post O
hoc O
subgroup O
analysis O
in O
the O
Veterans O
Affairs O
High-Density O
Lipoprotein O
Intervention O
Trial O
, O
a O
randomized O
double-blind O
trial O
of O
gemfibrozil O
versus O
placebo O
in O
2,531 O
men O
with O
coronary O
disease O
, O
HDL-C O
levels O
of O
40 O
mg/dL O
or O
less O
( O
< O
or O
=1.0 O
mmol/L O
) O
, O
low-density O
lipoprotein O
cholesterol O
levels O
of O
140 O
mg/dL O
or O
less O
( O
< O
or O
=3.6 O
mmol/L O
) O
, O
and O
a O
range O
of O
triglyceride O
values O
. O
[]

The O
trial O
was O
powered O
for O
analyses O
of O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
safety O
. O
['Physiological-Clinical']

Univariate O
and O
multiple O
regression O
analysis O
demonstrated O
discarded O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
to O
be O
a O
significant O
and O
independent O
predictor O
of O
the O
decline O
in O
hemoglobin O
concentration O
. O
['Physiological-Clinical']

The O
primary O
outcome O
included O
symptoms B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
appetite B-outcome ['Physiological-Clinical']
. O
The O
secondary O
outcomes O
included O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
measured O
by O
the O
MD O
Anderson O
Symptom O
Inventory O
(MDASI) O
score, O
and O
functional B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
as O
evaluated O
by O
the O
Karnofsky O
score. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

These O
children O
were O
randomly O
divided O
into O
two O
groups O
: O
Therapy O
Group O
( O
TG O
) O
- O
composed O
by O
six O
subjects O
receiving O
both O
direct O
and O
indirect O
intervention O
; O
and O
Orientation O
Group O
( O
OG O
) O
- O
constituted O
by O
five O
subjects O
receiving O
exclusively O
indirect O
intervention O
. O
[]

The O
correlations O
with O
symptom O
scores O
were O
comparable O
for O
both O
questionnaires O
. O
[]

Randomized O
controlled O
trial O
to O
compare O
the O
early O
and O
mid-term O
results O
of O
stapled O
versus O
open O
hemorrhoidectomy O
. O
[]

RESULTS O
Of O
the O
vacuum O
extractor O
group O
, O
85 O
% O
were O
delivered O
by O
the O
allocated O
instrument O
compared O
to O
90 O
% O
in O
the O
forceps O
group O
( O
odds O
ratio O
( O
OR O
) O
0.64 O
; O
95 O
% O
confidence O
intervals O
( O
CI O
) O
0.4-1.04 O
) O
. O
[]

Further O
studies O
are O
warranted O
to O
evaluate O
the O
mechanism O
( O
s O
) O
for O
increased O
cancer-specific B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
to O
assess O
whether O
weight O
loss B-outcome ['Physiological-Clinical']
after O
prostate O
cancer O
diagnosis O
alters O
disease O
course O
. O
['Mortality', 'Physiological-Clinical']

Six O
HIV-seropositive O
subjects O
with O
elevated O
amounts O
of O
TNF-alpha O
in O
plasma O
at O
least O
at O
two O
occasions O
were O
included O
in O
an O
open O
, O
controlled O
, O
randomized O
, O
cross-over O
study O
consisting O
of O
a O
6 O
week O
treatment O
period O
and O
a O
6 O
week O
control O
period O
. O
[]

The O
first O
treatment O
is O
the O
insertion O
of O
a O
chest O
tube O
( O
ICT O
) O
but O
in O
a O
great O
number O
of O
patients O
there O
is O
recurrence O
of O
the O
disease O
. O
[]

Among O
participants O
with O
1-year O
abstinence, O
those O
in O
the O
e-cigarette O
group O
were O
more O
likely O
than O
those O
in O
the O
nicotine-replacement O
group O
to O
use B-outcome ['Life-Impact']
their O
assigned O
product O
at O
52 O
weeks O
(80% O
[63 O
of O
79 O
participants O
vs. O
9% O
[4 O
of O
44 O
participants]). O
[['Life-Impact']]

Significant O
effects O
of O
age O
group O
( O
below O
median O
age O
34 O
y O
vs O
median O
age O
and O
above O
) O
were O
noted O
on O
the O
tension B-outcome ['Life-Impact']
and O
fatigue B-outcome ['Physiological-Clinical']
scales O
in O
that O
less O
tension B-outcome ['Life-Impact']
( O
p= O
.045 O
) O
and O
less O
fatigue B-outcome ['Physiological-Clinical']
( O
p= O
.000 O
) O
were O
noted O
in O
those O
aged O
34 O
years O
and O
older O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
occurred O
in O
329 O
patients O
( O
6.6 O
% O
) O
assigned O
to O
clonidine O
and O
in O
295 O
patients O
( O
5.9 O
% O
) O
assigned O
to O
placebo O
( O
hazard O
ratio O
, O
1.11 O
; O
95 O
% O
CI O
, O
0.95 O
to O
1.30 O
; O
P=0.18 O
) O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
changes O
in O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
, O
including O
lipoprotein B-outcome ['Physiological-Clinical']
classes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
assessed O
the O
effectiveness O
of O
a O
brief O
, O
situation-specific O
, O
group-administered O
preparatory O
intervention O
in O
a O
nonclient O
school O
population O
undergoing O
mass O
inoculation O
against O
rubella O
. O
[]

Journal O
ID: O
7501160 O
[]

However O
, O
there O
was O
a O
trend O
towards O
fewer O
PUVA O
sessions O
and O
lower O
UVA O
dose O
required O
to O
achieve O
CCR O
in O
the O
combination O
arm O
( O
PUVA O
+ O
bexarotene O
) O
but O
this O
did O
not O
achieve O
statistical O
significance O
due O
to O
insufficient O
power O
. O
[]

The O
development B-outcome ['Life-Impact']
for O
the O
group O
of O
children O
on O
diet O
was O
significantly O
better O
than O
for O
the O
controls O
. O
['Life-Impact']

METHODS O
We O
undertook O
a O
phase O
3 O
, O
double-blind O
, O
placebo-controlled O
study O
in O
adults O
with O
previously O
treated O
immune O
thrombocytopenia O
of O
more O
than O
6 O
months O
' O
duration O
who O
had O
baseline O
platelet O
counts O
lower O
than O
30,000 O
per O
?L O
. O
[]

The O
results O
of O
the O
multiple O
baseline O
design O
showed O
robust O
support O
for O
improvement O
in O
child O
and O
parent B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Households O
with O
young O
children O
and O
use O
of O
freely O
distributed O
bednets O
in O
rural O
Madagascar O
. O
[]

In O
the O
zoledronic O
acid O
group O
, O
bone O
marrow O
was O
not O
collected O
from O
one O
patient O
because O
of O
disease O
progression O
, O
one O
patient O
was O
taken O
off O
study O
because O
of O
severe O
diarrhoea O
, O
and O
two O
patients O
had O
not O
consented O
at O
the O
time O
of O
surgery O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
baseline O
data O
of O
gender, O
gestational O
age, O
birth O
weight, O
age, O
5-minure O
Apgar O
score O
or O
SNAPPE O
II O
score O
between O
the O
two O
groups, O
indicating O
that O
the O
baseline O
data O
of O
the O
two O
groups O
were O
balanced O
and O
comparable. O
[]

CONCLUSIONS O
We O
demonstrated O
that O
intermittent O
pneumatic O
compression O
has O
a O
limited O
clinical O
role O
in O
the O
treatment O
of O
postmastectomy O
lymphedema O
. O
[]

Acid B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
each I-outcome ['Physiological-Clinical']
hour I-outcome ['Physiological-Clinical']
over O
a O
3-h O
postprandial O
( O
PP O
) O
period O
was O
assessed O
as O
the O
percent O
time O
pH O
less O
than O
4.0 O
. O
['Physiological-Clinical']

Risperidone O
has O
antiserotonergic O
and O
antidopaminergic O
properties O
that O
may O
make O
it O
more O
effective O
than O
conventional O
antipsychotic O
agents O
in O
the O
treatment O
of O
the O
negative O
symptoms B-outcome ['Life-Impact']
of O
schizophrenia O
. O
['Life-Impact']

In O
addition O
, O
ORR O
was O
significantly O
higher O
with O
letrozole O
than O
tamoxifen O
in O
the O
human O
epidermal O
growth O
factor O
receptor O
HER1/HER2+ O
subgroup O
( O
P=0.0004 O
) O
. O
[]

BACKGROUND O
A O
24-week O
phase O
II O
trial O
has O
shown O
that O
0.3 O
mg O
of O
laquinimod O
given O
daily O
to O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
was O
well O
tolerated O
and O
reduced O
the O
formation O
of O
active B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
Iron B-outcome ['Physiological-Clinical']
stores I-outcome ['Physiological-Clinical']
and O
Hb B-outcome ['Physiological-Clinical']
in O
infancy O
can O
be O
improved O
in O
neonates O
born O
to O
anemic O
mothers O
by O
delaying O
cord O
clamping O
at O
birth O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
the O
probability O
of O
day O
114 O
grades O
2-4 O
acute O
GVHD-free O
survival O
( O
67 O
% O
vs O
62 O
% O
, O
P O
= O
.38 O
) O
. O
[]

Combined O
typhoid O
fever O
and O
hepatitis O
A O
vaccine O
: O
comparison O
of O
immunogenicity B-outcome ['Physiological-Clinical']
and O
safety O
to O
concomitant O
monovalent O
vaccine O
over O
3 O
years O
. O
['Physiological-Clinical']

However O
, O
the O
prognostic O
value O
of O
sialyl O
Lewis O
( O
a O
) O
expression O
in O
colon O
cancer O
is O
still O
controversial O
. O
[]

By O
week O
10 O
, O
patients O
in O
the O
celecoxib O
group O
showed O
significantly O
greater O
improvement O
in O
the O
Irritability O
( O
P O
< O
0.001 O
) O
, O
Lethargy/Social O
Withdrawal O
( O
P O
< O
0.001 O
) O
, O
and O
Stereotypic O
Behavior O
( O
P O
< O
0.00 O
) O
but O
not O
in O
Hyperactivity/Noncompliance O
( O
P O
= O
0.202 O
) O
and O
Inappropriate O
Speech O
( O
P O
= O
0.802 O
) O
subscales O
than O
the O
placebo O
group O
. O
[]

[ O
Effect O
on O
pressure O
after O
instillation O
of O
a O
drop O
of O
depot-pilocarpine O
. O
[]

CONCLUSIONS O
Pramipexole O
is O
effective O
and O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
in O
RLS O
, O
most O
notably O
among O
objective O
measures O
, O
for O
reducing O
PLM B-outcome ['Physiological-Clinical']
and O
decreasing O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Response O
rates O
to O
surveys O
are O
decreasing O
. O
[]

CONTEXT O
Hyperactivity O
and O
inattention O
are O
common O
symptoms O
in O
children O
with O
autistic O
disorder O
and O
related O
pervasive O
developmental O
disorders O
, O
but O
studies O
of O
stimulants O
in O
these O
conditions O
have O
been O
inconclusive O
. O
[]

Effect O
of O
vitamin O
K2 O
on O
the O
recurrence B-outcome ['Physiological-Clinical']
in O
patients O
with O
hepatocellular O
carcinoma O
. O
['Physiological-Clinical']

Recurrent O
ulcer O
after O
successful O
treatment O
with O
cimetidine O
or O
antacid O
. O
[]

Caregivers O
reported O
on O
the O
frequency O
of O
troublesome B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
their O
reactions B-outcome ['Life-Impact']
to O
them O
at O
baseline O
and O
at O
regular O
follow-up O
interviews O
. O
['Life-Impact']

The O
Low O
Energy O
Safety O
Study O
( O
LESS O
) O
: O
rationale O
, O
design O
, O
patient O
characteristics O
, O
and O
device O
utilization O
. O
[]

We O
used O
linear O
regression O
models O
, O
adjusting O
for O
potentially O
confounding O
factors O
, O
to O
assess O
the O
relation O
between O
economic O
variables O
and O
exposure O
to O
atole O
or O
fresco O
at O
specific O
ages O
between O
birth O
and O
7 O
years O
. O
[]

The O
second O
study O
assessed O
the O
effects O
of O
GH O
( O
2 O
IU/day O
) O
on O
lipid O
oxidation O
and O
on O
protein O
metabolism O
using O
the O
whole O
body O
leucine O
turnover O
technique O
. O
[]

patient-controlled B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
( I-outcome ['Resource-use']
PCA I-outcome ['Resource-use']
) I-outcome ['Resource-use']
device O
. O
['Resource-use']

PURPOSE O
To O
evaluate O
the O
analgesic B-outcome ['Resource-use']
efficacy O
and O
duration O
of O
varying O
doses O
of O
caudal O
neostigmine O
with O
plain O
bupivacaine O
and O
its O
side O
effects O
in O
children O
undergoing O
genito-urinary O
surgery O
. O
['Resource-use']

This O
study O
seeks O
to O
evaluate O
two O
candidate O
regimens O
( O
5-fluorouracil O
and O
interferon O
) O
as O
adjuvants O
to O
optimally O
performed O
laser O
surgery O
in O
the O
treatment O
of O
condylomata B-outcome ['Physiological-Clinical']
acuminata I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

However O
, O
because O
of O
complex O
parameter O
derivation O
, O
the O
method O
is O
rarely O
used O
. O
[]

Six O
children O
were O
randomly O
assigned O
to O
two O
experimental O
groups O
. O
[]

Thus O
it O
was O
concluded O
that O
a O
single O
dose O
of O
cefotiam O
significantly O
reduces O
post-operative B-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Children O
( O
N=296 O
; O
M O
age=10.21 O
years O
) O
received O
information O
about O
an O
unfamiliar O
child O
with O
autism O
from O
one O
of O
the O
following O
sources O
: O
( O
a O
) O
videotape O
, O
( O
b O
) O
teacher O
, O
( O
c O
) O
hypothetical O
mother O
, O
( O
d O
) O
hypothetical O
father O
, O
or O
( O
e O
) O
hypothetical O
doctor O
. O
[]

A O
total O
of O
174 O
patients O
were O
included O
in O
the O
economic O
evaluation O
. O
[]

After O
a O
pseudo-randomization O
, O
usual O
pain O
management O
( O
n O
= O
132 O
) O
was O
compared O
to O
a O
multifactorial O
strategy O
( O
n O
= O
107 O
) O
associating O
preliminary O
application O
of O
an O
anesthesic O
patch O
, O
preferential O
use O
of O
specified O
vaccines O
, O
child O
education O
by O
the O
parents O
and O
the O
doctor O
, O
parental O
accompaniment O
and O
child O
distraction O
with O
soap O
bubbles O
during O
the O
procedure O
. O
[]

Journal-Name:BMC O
gastroenterology O
[]

Renal O
biopsy O
studies O
showed O
no O
differences O
between O
the O
two O
groups O
in O
terms O
of O
incidence O
and O
severity O
of O
the O
histologic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
In O
the O
interest O
of O
preserving O
residual O
insulin O
secretory O
capacity O
present O
at O
the O
time O
of O
diagnosis O
with O
type O
1 O
diabetes O
( O
T1D O
) O
, O
we O
compared O
the O
efficacy O
of O
starting O
insulin O
pump O
therapy O
at O
diagnosis O
with O
standard O
multiple O
daily O
insulin O
injections O
( O
MDIs O
) O
. O
[]

The O
study O
group O
children O
received O
the O
standard O
school O
dental O
screening O
and O
the O
dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
of O
those O
with O
a O
positive O
screening O
result O
was O
assessed O
after O
2 O
months O
by O
means O
of O
a O
questionnaire O
issued O
to O
the O
children O
's O
parents O
. O
['Life-Impact']

Double O
blockade O
decreased O
R-R B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
and O
variability O
in O
both O
age O
groups O
( O
P O
< O
0.0001 O
) O
, O
but O
R-R O
intervals O
decreased O
less O
in O
older O
than O
in O
young O
subjects O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Pharmacokinetic O
parameters O
indicate O
that O
the O
bioavailability B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cyclosporin I-outcome ['Physiological-Clinical']
A O
was O
not O
significantly O
modified O
by O
ticlopidine O
. O
['Physiological-Clinical']

Dietary O
sodium O
intake O
modulates O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
angiotensin O
II O
. O
['Physiological-Clinical']

METHODS O
This O
trial O
extended O
a O
13-week O
, O
Phase O
III O
multicenter O
placebo-controlled O
, O
double-blind O
outpatient O
trial O
for O
an O
additional O
40 O
weeks O
. O
[]

The O
same O
was O
true O
for O
the O
analysis O
of O
protocols O
. O
[]

Cord O
blood O
glucose O
, O
insulin O
, O
and O
lactate O
levels O
were O
also O
increased O
in O
this O
group O
. O
[]

There O
were O
no O
differences O
in O
the O
tolerability B-outcome ['Life-Impact']
of O
the O
two O
antiemetic O
therapy O
modalities O
. O
['Life-Impact']

This O
indicated O
an O
imbalance O
in O
bone B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
with O
a O
high B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
montelukast/levocetirizine O
arm O
, O
montelukast O
decreased O
nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
more O
significantly O
than O
levocetirizine O
, O
whereas O
in O
reduction O
of O
sICAM-1 B-outcome ['Physiological-Clinical']
all O
active O
treatment O
options O
were O
equally O
effective O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
tear B-outcome ['Physiological-Clinical']
breakup I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
(TBUT) I-outcome ['Physiological-Clinical']
, O
Schirmer O
test O
with O
anesthesia, O
and O
fluorescein B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
scores O
were O
measured O
preoperatively O
and O
postoperatively O
on O
days O
7, O
14, O
30 O
and O
90. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Investigator-based O
Global O
Aesthetic O
Improvement O
Scale O
assessment O
at O
9 O
months O
after O
baseline O
indicated O
that O
Perlane O
was O
superior O
in O
48.8 O
percent O
of O
patients O
, O
whereas O
Zyplast O
was O
superior O
in O
14.0 O
percent O
of O
patients O
( O
p O
= O
0.0025 O
) O
. O
[]

CONCLUSIONS O
The O
inclusion O
of O
CRM O
training O
in O
undergraduate O
medical O
education O
reduces O
NFT O
in O
simulated O
CPR O
and O
improves O
TLV O
proportions O
during O
simulated O
CPR O
. O
[]

In O
this O
study O
, O
a O
group O
of O
30 O
senior O
medical O
students O
were O
randomly O
assigned O
to O
one O
of O
four O
different O
training O
groups O
: O
none O
, O
error O
only O
, O
correct O
only O
, O
and O
error+correct O
. O
[]

The O
pharmacological O
and O
CBT O
interventions O
were O
associated O
with O
a O
greater O
clinical B-outcome ['Physiological-Clinical']
improvement O
compared O
with O
usual O
care O
at O
posttest O
. O
['Physiological-Clinical']

Meanwhile, O
active B-outcome ['Physiological-Clinical']
flexional I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
and O
passive B-outcome ['Physiological-Clinical']
flexional I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
in O
preoperative O
analgesia O
group O
were O
larger O
than O
that O
in O
postoperative O
analgesia O
group O
at O
72 O
hours O
post O
operation. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

All O
eight O
products O
were O
effective O
in O
bleaching B-outcome ['Physiological-Clinical']
teeth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Amino O
acids O
derived O
from O
ingested O
protein O
are O
potential O
substrates O
for O
gluconeogenesis O
. O
[]

A O
sequential O
design O
was O
used O
with O
a O
triangular O
continuation O
region. O
[]

A O
prospective O
, O
randomized O
, O
double-blind O
study O
. O
[]

OBJECTIVE O
Peroxisome O
proliferator-activated O
receptor-gamma O
( O
PPAR O
gamma O
) O
agonists O
( O
thiazolidinediones O
[ O
TZDs O
] O
) O
are O
used O
for O
the O
treatment O
of O
diabetes O
. O
[]

A O
contract O
search O
agency O
was O
hired O
to O
locate O
the O
remaining O
participants O
. O
[]

RESULTS O
Seventy-one O
women O
with O
a O
mean O
? O
[]

The O
respective O
modulating O
effects O
of O
continuous O
and O
intermittent O
insulin O
delivery O
on O
pancreatic O
islet O
cell O
function O
were O
studied O
in O
seven O
normal O
men O
and O
nine O
insulin-dependent O
( O
type O
1 O
) O
diabetic O
patients O
. O
[]

After O
6-months O
of O
exercise O
intervention O
, O
we O
observed O
a O
dose O
dependent O
increase O
in O
all O
parasympathetically O
derived O
time O
and O
frequency O
domain O
measurements O
across O
exercise O
groups O
after O
adjustment O
for O
age O
, O
ethnicity O
, O
antidepressants B-outcome ['Resource-use']
, O
and O
baseline O
rMSSD O
( O
all O
, O
P O
< O
0.001 O
) O
. O
['Resource-use']

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O
[]

The O
trial O
was O
complete O
with O
28 O
patients O
randomized O
. O
[]

In O
contrast O
to O
the O
control O
group O
who O
deteriorated O
, O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
the O
intervention O
group O
remained O
stable O
. O
['Life-Impact']

The O
aim O
of O
this O
clinical O
study O
was O
to O
investigate O
the O
acid B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
enamel O
lesions O
remineralized O
in O
situ O
by O
a O
sugar-free O
chewing O
gum O
containing O
casein O
phosphopeptide-amorphous O
calcium O
phosphate O
nanocomplexes O
( O
CPP-ACP O
: O
Recaldent O
) O
. O
['Physiological-Clinical']

We O
assessed O
whether O
daclizumab O
high-yield O
process O
( O
HYP O
) O
would O
be O
effective O
when O
given O
as O
monotherapy O
for O
a O
1 O
year O
treatment O
period O
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
. O
[]

This O
study O
showed O
no O
benefit O
of O
preoperatively O
administered O
oral O
ibuprofen O
10 O
mg.kg-1 O
or O
acetaminophen O
15 O
mg.kg-1 O
over O
placebo O
for O
the O
relief O
of O
postoperative O
pain O
in O
children O
undergoing O
BM O
& O
T O
. O
[]

Sildenafil O
was O
started O
at O
50 O
mg O
and O
increased O
( O
100 O
mg O
) O
or O
decreased O
( O
25 O
mg O
) O
at O
week O
2 O
if O
necessary O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
primarily O
hematological O
and O
bimodal O
: O
32 O
% O
had O
grade O
3 O
or O
4 O
leukopenia B-outcome ['Physiological-Clinical']
and O
24 O
% O
had O
grade O
3 O
or O
4 O
thrombocytopenia B-outcome ['Physiological-Clinical']
; O
22 O
% O
had O
no O
leukopenia B-outcome ['Physiological-Clinical']
and O
44 O
% O
had O
no O
thrombocytopenia B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
a O
slightly O
higher O
incidence O
of O
ovarian B-outcome ['Physiological-Clinical']
hyperstimulation I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
(OHSS) I-outcome ['Physiological-Clinical']
in O
Group O
2 O
compared O
to O
Group O
1 O
although O
the O
difference O
was O
not O
statistically O
significant O
(3/31, O
9.7% O
versus O
1/26, O
3.8%). O
[['Physiological-Clinical']]

The O
residual O
tumor B-outcome ['Physiological-Clinical']
rate O
was O
25.2 O
% O
in O
the O
white O
light O
arm O
versus O
4.5 O
% O
in O
the O
fluorescence O
diagnosis O
arm O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Several O
mechanisms O
of O
actions O
detected O
in O
vivo/in O
vitro O
including O
N-methyl-D-aspartate B-outcome ['Physiological-Clinical']
( O
NMDA O
) O
-receptor O
antagonism B-outcome ['Life-Impact']
, O
blockage O
of O
potassium O
channels O
, O
dopamine O
receptor O
agonism O
, O
enhancement O
of O
noradrenergic O
release O
, O
and O
anticholinergic O
effects O
have O
been O
described O
. O
['Physiological-Clinical', 'Life-Impact']

The O
presence O
of O
a O
laryngoscope B-outcome ['Resource-use']
in O
the O
mouth O
while O
rail-roading O
a O
tube O
over O
the O
bougie O
also O
made O
a O
significant O
difference O
to O
the O
rate O
of O
successful B-outcome ['Life-Impact']
first-time I-outcome ['Life-Impact']
intubations I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact']

This O
study O
provides O
preliminary O
support O
for O
the O
use O
of O
divalproex O
in O
treating O
[]

Changes O
of O
gastric B-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
therapeutic O
times O
and O
cured O
rate O
were O
investigated O
in O
the O
3 O
groups O
. O
['Physiological-Clinical']

Exercise O
for O
methamphetamine O
dependence O
: O
rationale O
, O
design O
, O
and O
methodology O
. O
[]

Of O
147 O
FEC O
( O
75 O
) O
infusions O
, O
4.1 O
% O
were O
delayed O
, O
while O
9.8 O
% O
of O
143 O
FEC O
( O
90 O
) O
infusions O
were O
delayed O
. O
[]

This O
demonstrates O
that O
suppression O
of O
plasma O
angiotensin O
II O
for O
a O
14 O
day O
period O
does O
not O
enhance O
the O
response O
to O
exogenous O
intra-arterial O
angiotensin O
II O
in O
the O
human O
forearm O
of O
healthy O
salt O
replete O
subjects O
. O
[]

METHODS: O
WISDOM O
was O
a O
multinational, O
randomized, O
double-blind, O
active-controlled, O
52-week O
study O
in O
patients O
with O
severe-to-very O
severe O
COPD. O
[]

METHODS O
We O
compared O
total O
BMD B-outcome ['Physiological-Clinical']
changes O
over O
96 O
weeks O
in O
106 O
ART-naive O
HIV-infected O
subjects O
who O
were O
randomized O
to O
receive O
efavirenz O
( O
EFV O
) O
+ O
zidovudine/lamivudine O
( O
n O
= O
32 O
) O
or O
lopinavir/ritonavir O
( O
LPV/r O
) O
+ O
zidovudine/lamivudine O
induction O
( O
n O
= O
74 O
) O
for O
24-48 O
weeks O
followed O
by O
LPV/r O
monotherapy O
. O
['Physiological-Clinical']

Even O
in O
the O
women O
around O
the O
menopausal O
, O
CETP B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
postmenopause O
was O
significantly O
lower O
than O
that O
in O
premenopause O
( O
1.93+/-1.33 O
vs. O
3.42+/-1.35 O
mg/l O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Dietary O
patterns O
differ O
between O
urban O
and O
rural O
older O
, O
long-term O
survivors O
of O
breast O
, O
prostate O
, O
and O
colorectal O
cancer O
and O
are O
associated O
with O
body O
mass O
index O
. O
[]

Gait B-outcome ['Life-Impact']
spatiotemporal I-outcome ['Life-Impact']
parameters O
were O
collected O
by O
use O
of O
the O
Vicon O
system O
at O
JM O
and O
JM O
+ O
30 O
. O
['Life-Impact']

We O
report O
week O
96 O
results O
from O
a O
phase O
3 O
trial O
of O
elvitegravir/cobicistat/emtricitabine/tenofovir O
disoproxil O
fumarate O
( O
EVG/COBI/FTC/TDF O
, O
n O
= O
348 O
) O
vs O
efavirenz/emtricitabine/tenofovir O
disoproxil O
fumarate O
( O
EFV/FTC/TDF O
, O
n O
= O
352 O
) O
. O
[]

The O
incremental O
cost-effectiveness O
ratio O
[ O
95 O
% O
CI O
] O
amounts O
to O
minus O
< O
euro O
> O
78,741.66 O
[ O
-154,987.20 O
; O
110,486.32 O
] O
for O
an O
additional O
unit O
of O
effect O
. O
['Resource-use']

METHODS: O
Ninety-six O
parents O
in O
the O
NICU O
received O
instruction. O
[]

OBJECTIVE O
To O
measure O
the O
effects O
of O
case O
management O
on O
an O
older O
population O
's O
costs O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
. O
['Resource-use']

In O
doing O
this O
, O
one-third O
of O
the O
total O
length O
of O
the O
bone O
was O
removed O
in O
each O
of O
the O
following O
specimens O
to O
include O
( O
1a O
) O
30 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
, O
( O
1b O
) O
37 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
, O
and O
( O
1c O
) O
50 O
percent O
of O
the O
cross-sectional O
area O
of O
the O
total O
bone O
. O
[]

Results O
suggest O
there O
is O
value O
in O
further O
methodologically O
rigorous O
investigations O
into O
improving O
community-based O
health O
system O
functioning O
through O
a O
similar O
approach O
to O
community O
engagement. O
[]

OBJECTIVE O
Forceps O
biopsy O
is O
the O
standard O
method O
to O
obtain O
specimens O
in O
endoscopically O
visible O
lesions O
. O
[]

Comparison O
of O
different O
approaches O
for O
assessment O
of O
HER2 O
expression O
on O
protein O
and O
mRNA O
level O
: O
prediction O
of O
chemotherapy O
response O
in O
the O
neoadjuvant O
GeparTrio O
trial O
( O
NCT00544765 O
) O
. O
[]

SUMMARY O
OF O
BACKGROUND O
DATA O
Evidence O
comparing O
the O
long-term O
relative O
effectiveness O
of O
common O
treatment O
strategies O
offered O
to O
low O
back O
pain O
patients O
in O
managed O
care O
is O
lacking O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
was O
measured O
serially O
. O
['Physiological-Clinical']

This O
paper O
aims O
to O
evaluate O
the O
cost B-outcome ['Resource-use']
, O
from O
the O
UK O
National O
Health O
Service O
perspective O
, O
of O
transfer O
to O
a O
nursing-led O
inpatient O
unit O
for O
intermediate O
care O
and O
to O
discuss O
the O
impact O
of O
these O
findings O
to O
the O
future O
development B-outcome ['Life-Impact']
and O
sustainability B-outcome ['Physiological-Clinical']
of O
the O
nursing-led O
inpatient O
unit O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

A O
randomized O
control O
trial O
comparing O
two O
social-communication O
interventions O
in O
young O
children O
with O
autism O
examined O
far-transfer O
of O
the O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
picture I-outcome ['Life-Impact']
exchange I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
communicate I-outcome ['Life-Impact']
. O
['Life-Impact']

Grades O
2-4 O
acute O
graft-versus-host O
disease O
( O
GVHD O
) O
occurs O
in O
approximately O
35 O
% O
of O
matched O
, O
related O
donor O
( O
MRD O
) O
allogeneic O
hematopoietic O
cell O
transplantation O
( O
HCT O
) O
recipients O
. O
[]

There O
was O
no O
remarkable O
difference O
in O
the O
number O
of O
patients O
, O
gender O
, O
age O
, O
or O
distribution O
of O
primary O
diseases O
between O
the O
two O
groups O
. O
[]

To O
determine O
the O
effect O
of O
two O
levels O
of O
educational O
intervention O
on O
benzodiazepine-prescribing O
behavior O
in O
an O
elderly O
population O
in O
a O
controlled O
prepaid O
group O
practice O
( O
PPGP O
) O
setting O
, O
we O
designed O
a O
prospective O
controlled O
trial O
, O
with O
six-month O
follow-up O
. O
[]

We O
followed O
up O
patients O
for O
time O
to O
recurrence O
, O
and O
recurrence-free O
and O
overall O
survival O
. O
[]

We O
conclude O
that O
, O
at O
infusion O
rates O
in O
the O
low- O
to O
mid-antiarrhythmic O
range O
, O
lidocaine O
has O
no O
effect O
on O
acute B-outcome ['Physiological-Clinical']
nociceptive I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
but O
does O
have O
a O
limited O
and O
selective O
effect O
on O
secondary B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Retinal B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
were O
measured O
with O
a O
retinal O
vessel O
analyzer O
, O
and O
retinal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
speed I-outcome ['Physiological-Clinical']
was O
assessed O
by O
bi-directional O
laser O
Doppler O
velocimetry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
patients O
were O
randomly O
divided O
into O
2 O
groups: O
methylene O
blue O
localization O
group O
(n O
= O
47), O
and O
modified O
localization O
group O
(n O
= O
32), O
where O
the O
patients O
received O
preoperative O
localization O
of O
the O
small O
nodules O
by O
CT-guided O
placing O
wire O
and O
intrapleural O
fibrin O
glue O
near O
the O
nodule O
at O
3 O
days O
before O
the O
operation. O
[]

The O
maximum O
numbers O
of O
repetitions O
in O
each O
station O
was O
12 O
. O
[]

Finally O
, O
1 O
patient O
was O
in O
first O
CRp O
. O
[]

Values O
are O
given O
as O
median O
( O
range O
) O
. O
( O
[]

The O
primary O
outcome O
measure O
was O
the O
Clinical O
Global O
Impressions O
Improvement O
and O
Severity O
Scales O
( O
CGI-I O
and O
CGI-S O
) O
; O
secondary O
outcomes O
were O
the O
Preschool B-outcome ['Life-Impact']
Language I-outcome ['Life-Impact']
Scale-4 O
( O
PLS-4 O
) O
, O
Social O
Responsiveness O
Scale O
( O
SRS O
) O
, O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
, O
and O
Vineland O
Adaptive O
Behavior O
Scales O
( O
Vineland O
) O
. O
['Life-Impact', 'Life-Impact']

The O
influence O
of O
nonhandicapped O
peers O
on O
the O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
of O
children O
with O
a O
pervasive O
development O
disorder O
. O
['Life-Impact']

One-month O
urinalysis O
follow-up O
data O
showed O
a O
significant O
reduction O
in O
heroin B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
in O
the O
experimental O
group O
( O
from O
63 O
% O
positive O
at O
intake O
to O
29 O
% O
positive O
) O
with O
no O
change O
in O
the O
control O
group O
( O
62 O
% O
to O
60 O
% O
positive O
) O
. O
['Life-Impact']

Participants O
were O
randomized O
in O
a O
1:1 O
ratio O
to O
receive O
either O
800 O
mug O
of O
misoprostol O
or O
placebo O
sublingually O
if O
PPH O
was O
diagnosed, O
having O
previously O
received O
a O
prophylactic O
oral O
dose O
of O
600 O
mug O
misoprostol. O
[]

First O
, O
delusional O
patients O
were O
significantly O
more O
likely O
than O
non-delusional O
patients O
and O
healthy O
participants O
to O
classify B-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
unpleasant I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
efficacy O
and O
toxicity O
of O
once-daily O
( O
od O
) O
versus O
twice-daily O
( O
bd O
) O
dosing O
of O
vancomycin O
was O
compared O
in O
121 O
hospitalized O
patients O
. O
[]

STUDY O
DESIGN O
A O
total O
of O
28 O
patients O
with O
mandibular O
retrognathism O
had O
bilateral O
sagittal O
split O
osteotomies O
for O
mandibular O
advancement O
. O
[]

Improvement O
was O
also O
found O
for O
5-point O
decrease O
in O
PHQ-9 O
score O
among O
72.2 O
% O
of O
intervention O
patients O
compared O
with O
59.7 O
% O
of O
EUC O
patients O
( O
OR O
= O
1.99 O
; O
95 O
% O
CI O
, O
1.14 O
to O
3.50 O
; O
P O
= O
.02 O
) O
. O
[]

Concentrations O
of O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
During O
CPAP O
withdrawal O
, O
severe B-outcome ['Physiological-Clinical']
sleep-disordered I-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
was O
evident O
and O
administration O
of O
modafinil O
improved O
simulated O
driving O
performance B-outcome ['Life-Impact']
( O
steering B-outcome ['Life-Impact']
variability I-outcome ['Life-Impact']
, O
P O
< O
0.0001 O
; O
mean O
reaction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
P O
< O
or= O
0.0002 O
; O
lapses B-outcome ['Life-Impact']
, O
P O
< O
or= O
0.01 O
on O
a O
concurrent O
task O
) O
, O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
task O
( O
mean O
1/reaction O
time O
and O
lapses O
, O
both O
P O
< O
or= O
0.0002 O
) O
, O
and O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
effect O
of O
initial O
scores O
on O
the O
MCIC O
was O
also O
assessed O
. O
[]

The O
dose O
of O
risperidone O
was O
1-3 O
mg/day O
and O
the O
dose O
of O
Ginko O
T.D O
. O
[]

Fabrication O
of O
the O
sampling O
lumen O
of O
an O
intra-arterial O
PO2 O
sensor O
is O
performed O
in O
standard O
catheters O
mechanically O
or O
by O
laser O
. O
[]

The O
most O
common O
type O
of O
histologic B-outcome ['Physiological-Clinical']
conversion B-outcome ['Physiological-Clinical']
was O
from O
NLPD O
to O
diffuse O
histiocytic B-outcome ['Physiological-Clinical']
lymphoma B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS: O
Two O
groups O
showed O
no O
difference O
in O
baseline O
characteristics. O
[]

PATIENTS O
AND O
METHODS O
This O
prospective O
, O
randomized O
study O
included O
30 O
consecutive O
eyes O
assigned O
randomly O
to O
either O
ELT O
or O
SLT O
group O
. O
[]

At O
baseline O
, O
week O
2 O
, O
and O
week O
5 O
, O
a O
dermatologist O
performed O
facial O
lesion O
counts O
, O
patients O
reported O
perceived O
severity O
of O
rash-related O
symptoms O
, O
and O
standardized O
facial O
photographs O
were O
obtained O
for O
blinded O
evaluation O
of O
global O
rash O
severity O
. O
[]

Title: O
Grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
can O
be O
used O
to O
evaluate O
postoperative O
residual B-outcome ['Physiological-Clinical']
neuromuscular I-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
general O
anesthesia. O
[['Life-Impact'], ['Physiological-Clinical']]

Satisfaction B-outcome ['Life-Impact']
differed O
significantly O
between O
centres O
for O
4 O
: O
14 O
aspects O
of O
service O
provision O
and O
with O
3 O
: O
17 O
items O
concerning O
communication O
; O
satisfaction O
was O
high O
overall O
. O
['Life-Impact']

French O
Multicentre O
Study O
Group O
. O
[]

PARTICIPANTS O
A O
total O
of O
302 O
patients O
aged O
over O
15 O
years O
. O
[]

The O
experimental O
groups O
performed O
either O
endurance O
or O
resistance O
training O
3 O
days O
a O
week O
for O
12 O
weeks O
. O
[]

RESULTS O
During O
the O
radiofrequency O
exposure O
session O
, O
SkBF B-outcome ['Physiological-Clinical']
increased O
( O
vs. O
baseline O
) O
more O
than O
during O
the O
sham O
exposure O
session O
. O
['Physiological-Clinical']

Follow-up O
over O
12 O
months O
will O
enhance O
understanding O
of O
the O
natural O
history O
of O
depression O
in O
cardiac O
patients O
, O
while O
the O
nested O
trial O
will O
inform O
on O
effectiveness O
of O
an O
intervention O
involving O
tailored O
advice O
and O
support O
to O
general O
practitioners O
. O
[]

Correspondingly O
the O
decrease O
of O
plasma B-outcome ['Physiological-Clinical']
renin I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
prostaglandin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PGE2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
more O
pronounced O
in O
those O
patients O
treated O
initially O
with O
indomethacin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plots O
of O
differences O
of O
IOP O
as O
a O
function O
of O
the O
mean O
for O
each O
pair O
of O
instruments O
were O
obtained O
. O
[]

Major B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
experienced O
by O
622 O
patients O
( O
28 O
% O
) O
in O
the O
placebo O
group O
and O
431 O
patients O
( O
19 O
% O
) O
in O
the O
simvastatin O
group O
, O
corresponding O
to O
a O
risk O
reduction O
of O
34 O
% O
( O
p O
< O
0.00001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Metabolic O
disorders O
were O
common O
among O
adult O
Chinese O
in O
both O
rural O
and O
urban O
areas O
in O
Qingdao O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

For O
postoperative O
analgesia O
, O
0.05 O
mg/kg O
morphine O
was O
administrated O
epidurally O
30 O
min O
before O
the O
end O
of O
the O
operation O
; O
30 O
, O
60 O
, O
90 O
, O
and O
120 O
min O
after O
arriving O
in O
the O
recovery O
room O
, O
vigilance O
was O
assessed O
using O
a O
modified O
Steward O
score O
, O
the O
Trieger O
test O
, O
the O
ability O
to O
recall O
a O
column O
of O
numbers O
( O
KAI O
test O
) O
, O
and O
symbol O
counting O
( O
CI O
test O
) O
. O
[]

The O
vaginal O
insert O
was O
removed O
for O
spontaneous O
rupture O
of O
membranes O
, O
entry O
into O
active O
labor O
, O
adequate O
cervical O
ripening O
, O
or O
abnormality O
of O
uterine O
contractile O
pattern O
or O
fetal O
cardiac O
activity O
. O
[]

We O
subdivided O
the O
patients O
into O
age-related O
groups O
for O
each O
parameter O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
measurements O
were O
carried O
out O
before O
infusion O
( O
T1 O
) O
and O
at O
30 O
min O
( O
T2 O
) O
, O
2 O
h O
( O
T3 O
) O
, O
and O
12 O
h O
( O
T4 O
) O
after O
initiation O
of O
treatment O
in O
the O
intensive O
care O
unit O
. O
['Physiological-Clinical']

Differences O
( O
silodosin O
vs O
placebo O
) O
in O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
and O
subscores O
increased O
by O
week O
12 O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additionally O
40 O
euthyroid O
controls O
were O
studied O
. O
[]

Clinical O
and O
radiographic O
assessments O
of O
abutments B-outcome ['Physiological-Clinical']
and O
crowns B-outcome ['Physiological-Clinical']
, O
peri-implant B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
, O
and O
marginal B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
levels O
were O
recorded. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Falls B-outcome ['Life-Impact']
were O
documented O
using O
diaries O
. O
['Life-Impact']

Around-the-clock O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
with O
once-daily O
application O
of O
latanoprost O
by O
itself O
or O
in O
combination O
with O
timolol O
. O
['Physiological-Clinical']

DESIGN O
Multicentric O
, O
randomized O
, O
single-blind O
, O
parallel-group O
clinical O
trial O
. O
[]

For O
a O
full O
year O
, O
the O
providers O
of O
intervention O
group O
children O
received O
bimonthly O
computer-generated O
letters O
based O
on O
these O
calls O
summarizing O
the O
child O
's O
asthma O
symptoms O
, O
health O
service O
use O
, O
and O
medication O
use O
with O
a O
corresponding O
recommendation O
to O
step O
up O
or O
step O
down O
medications O
. O
[]

Anorexics O
were O
randomly O
assigned O
to O
fluoxetine O
( O
n O
= O
16 O
) O
or O
a O
placebo O
( O
n O
= O
19 O
) O
after O
inpatient O
weight O
gain O
and O
then O
were O
observed O
as O
outpatients O
for O
1 O
year O
. O
[]

Group O
A O
patients O
showed O
a O
significant O
increase O
in O
[]

To O
determine O
whether O
Pgp O
inhibition O
improves O
treatment O
outcome O
in O
CML-BP O
, O
the O
Southwest O
Oncology O
Group O
performed O
a O
randomized O
, O
controlled O
trial O
testing O
the O
benefit O
of O
the O
Pgp O
modulator O
, O
cyclosporin O
A O
( O
CsA O
) O
. O
[]

Daily O
diaries O
were O
used O
to O
record O
changes O
in O
narcolepsy B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

LIMITATIONS O
The O
unblinded O
nature O
of O
the O
study O
, O
exclusion O
of O
patients O
with O
diabetes O
, O
and O
incomplete O
enrollment O
. O
[]

However O
, O
DMI O
and O
gain O
: O
feed O
showed O
cubic O
( O
P O
< O
.10 O
) O
responses O
to O
increasing O
dietary O
level O
of O
RPLM O
. O
[]

0.78 O
hours O
and O
2.25 O
? O
[]

Risperidone O
, O
an O
atypical O
neuroleptic O
, O
has O
become O
a O
popular O
option O
for O
treating O
destructive O
behaviors O
of O
persons O
with O
developmental O
disabilities O
. O
[]

Three O
patients O
experienced O
ocular O
adverse O
events O
considered O
possibly O
related O
to O
study O
drug O
: O
Conjunctival O
edema O
and O
reduced O
visual O
acuity O
were O
reported O
in O
1 O
SCJ O
patient O
each O
and O
iritis O
was O
reported O
in O
1 O
IVT O
patient O
. O
[]

Minor B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
occurred O
in O
5/75 O
( O
6.7 O
% O
) O
patients O
of O
either O
group O
. O
['Adverse-effects']

Of O
all O
PVs O
, O
81 O
% O
showed O
reconnection O
( O
s O
) O
; O
52 O
% O
of O
them O
had O
reconnected O
in O
all O
PVs O
. O
[]

Six O
couples O
did O
not O
attempt B-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
despite O
a O
professed O
interest O
in O
sexual B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact']

After O
6 O
months O
, O
body B-outcome ['Life-Impact']
image I-outcome ['Life-Impact']
and O
cosmetic B-outcome ['Life-Impact']
appearance I-outcome ['Life-Impact']
were O
assessed O
using O
a O
validated O
survey O
. O
['Life-Impact', 'Life-Impact']

Early O
identification O
and O
timely O
transfer O
of O
patients O
requiring O
mechanical O
ventilation O
to O
such O
hospitals O
may O
improve O
the O
efficiency O
of O
inpatient O
care O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Compared O
with O
MIIT O
and O
control O
groups, O
HIIT O
showed O
improvements O
in O
the O
SF-36 O
domains: O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
(p<.001 O
for O
both) O
health B-outcome ['Physiological-Clinical']
changes O
(p<.001 O
for O
both), O
vitality B-outcome ['Physiological-Clinical']
(p=.002 O
and O
p=.001 O
respectively) O
and O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
(p=.036 O
and O
p<.001 O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

The O
two O
groups O
had O
a O
similar O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
progression B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
i.e O
. O
['Mortality', 'Mortality', 'Mortality']

Effects O
of O
sensory-level O
high-volt O
pulsed O
electrical O
current O
ondelayed-onset B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
soreness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

AIM O
In O
high-risk O
hypertensive O
subjects O
( O
HTs O
) O
with O
incidental O
unilateral O
renal O
artery O
stenosis O
( O
RAS O
) O
, O
the O
effectiveness O
of O
percutaneous O
revascularization O
with O
stent O
( O
PR-STENT O
) O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
BP O
) O
and O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
not O
established O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
efficacy O
parameter O
of O
the O
study O
was O
the O
control O
of O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
( O
< O
or O
=1.8 O
mmol/l O
[ O
< O
or O
= O
5.6 O
mg/dl O
] O
) O
. O
['Physiological-Clinical']

The O
diabetic O
patients O
treated O
with O
Mydriasert O
had O
less O
mydriasis B-outcome ['Physiological-Clinical']
than O
those O
treated O
with O
eyedrops O
after O
20 O
and O
40 O
minutes O
, O
and O
diabetic O
patients O
showed O
less O
mydriasis O
than O
the O
nondiabetic O
patients O
after O
60 O
and O
90 O
minutes O
. O
['Physiological-Clinical']

One O
hundred O
and O
sixty O
children O
with O
autism O
spectrum O
disorders O
, O
aged O
4-10 O
years O
, O
suffering O
from O
sleep O
onset O
insomnia O
and O
impaired O
sleep O
maintenance O
, O
were O
assigned O
randomly O
to O
either O
( O
1 O
) O
combination O
of O
controlled-release O
melatonin O
and O
cognitive-behavioural O
therapy O
; O
( O
2 O
) O
controlled-release O
melatonin O
; O
( O
3 O
) O
four O
sessions O
of O
cognitive-behavioural O
therapy O
; O
or O
( O
4 O
) O
placebo O
drug O
treatment O
condition O
for O
12 O
weeks O
in O
a O
1 O
: O
1 O
: O
1 O
: O
1 O
ratio O
. O
[]

Three O
patients O
in O
each O
group O
were O
treated O
for O
croup B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
1.2 O
% O
cuffed O
; O
1.3 O
% O
uncuffed O
) O
. O
['Physiological-Clinical']

This O
may O
explain O
some O
of O
the O
beneficial O
effects O
of O
this O
fixed O
dosed O
combination O
that O
are O
non-related O
to O
its O
antihypertensive O
effects O
. O
[]

INTERVENTIONS O
After O
placement O
of O
catheters O
in O
the O
pulmonary O
artery O
, O
radial O
artery O
, O
peripheral O
and O
right O
hepatic O
vein O
, O
one O
hour O
postoperatively O
either O
enflurane O
or O
isoflurane O
was O
applied O
at O
different O
minimum O
alveolar O
concentration O
( O
MAC O
) O
of O
0.5 O
, O
1.0 O
, O
and O
1.5 O
in O
a O
randomized O
order O
. O
[]

Pooling O
all O
seven O
trials O
, O
a O
risk O
ratio O
was O
found O
for O
persons O
treated O
with O
isoniazid O
for O
developing O
tuberculosis O
of O
0.58 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
0.43-0.80 O
] O
and O
0.94 O
( O
95 O
% O
CI O
, O
0.83-1.07 O
) O
for O
death B-outcome ['Mortality']
. O
['Mortality']

METHODS O
A O
total O
of O
120 O
patients O
, O
American O
Society O
of O
Anesthesiologists O
( O
ASA O
) O
physical O
status O
I-II O
, O
were O
randomized O
into O
two O
equally O
sized O
groups O
( O
n O
= O
60 O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
treatment O
with O
the O
antiherpes O
drug O
valacyclovir O
on O
MRI-evident O
lesions B-outcome ['Physiological-Clinical']
in O
patients O
with O
relapsing-remitting O
MS O
in O
a O
phase O
2 O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Urea O
Breath O
Test O
was O
performed O
at O
inclusion O
and O
after O
a O
minimum O
of O
6 O
weeks O
after O
end O
of O
therapy O
. O
[]

Polymorphonuclear O
leukocyte O
( O
PMN O
) O
chemotaxis O
is O
thought O
to O
play O
an O
essential O
role O
in O
the O
pathogenesis O
of O
rheumatoid O
arthritis O
. O
[]

SETTING O
Twenty-four O
hospital-based O
HIV O
clinics O
in O
16 O
Canadian O
cities O
. O
[]

OBJECTIVE O
We O
compared O
the O
efficacy O
of O
etoricoxib O
30 O
mg O
to O
placebo O
and O
ibuprofen O
2400 O
mg O
for O
the O
treatment O
of O
osteoarthritis O
( O
OA O
) O
of O
the O
hip O
and O
knee O
. O
[]

PURPOSE O
This O
study O
examined O
whether O
safe O
and O
effective O
mydriasis O
can O
be O
achieved O
in O
premature O
infants O
with O
heavily O
pigmented O
irides O
using O
combination O
cyclopentolate O
0.2 O
% O
and O
phenylephrine O
1 O
% O
eyedrops O
. O
[]

The O
endoscopic O
technique O
does O
appear O
to O
have O
[]

Celecoxib O
as O
adjunctive O
treatment O
to O
risperidone O
in O
children O
with O
autistic O
disorder O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

The O
patients O
were O
randomly O
allocated O
to O
Groups O
L O
( O
n O
= O
51 O
) O
and O
LM O
( O
n O
= O
56 O
) O
using O
the O
closed-envelope O
method O
. O
[]

Timing O
for O
delivering O
individualized O
patient O
education O
intervention O
to O
Coronary O
Artery O
Bypass O
Graft O
patients O
: O
An O
RCT O
. O
[]

Administration O
of O
placebo O
to O
a O
different O
group O
of O
seven O
uremic O
patients O
did O
not O
alter O
GH B-outcome ['Physiological-Clinical']
and O
PRL B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
radiotherapy O
was O
performed O
in O
the O
same O
way O
in O
all O
patients O
with O
irradiations O
of O
the O
thoracic O
wall O
and O
the O
regional O
lymph O
nodes O
. O
[]

CONCLUSION: O
Intrathecal O
5 O
mug O
Dex O
enhances O
the O
efficacy O
of O
spinal O
bupivacaine O
by O
24% O
in O
patients O
undergoing O
cesarean O
section O
with O
spinal O
anesthesia. O
[]

RESULTS O
Analysis O
of O
interviews O
identified O
a O
complex O
picture O
concerning O
expectations O
These O
could O
be O
classified O
as O
ideal O
, O
realistic O
, O
normative O
and O
unformed O
. O
[]

The O
addition O
of O
psychotherapy O
to O
hypotensive O
drugs O
contributed O
to O
a O
higher B-outcome ['Physiological-Clinical']
hypotensive I-outcome ['Physiological-Clinical']
effect O
, O
long-term O
improvement O
of O
psychic B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
, O
more O
active B-outcome ['Life-Impact']
attitude I-outcome ['Life-Impact']
to O
the O
treatment O
process B-outcome ['Life-Impact']
and O
psychic B-outcome ['Life-Impact']
adaptation I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVES O
In O
aromatherapy O
, O
lavender O
aroma O
is O
reputed O
to O
assist O
with O
relaxation O
. O
[]

[ O
Propofol O
infusion O
for O
the O
maintenance O
of O
short-term O
anesthesia B-outcome ['Resource-use']
] O
. O
['Resource-use']

OBJECTIVE O
To O
compare O
a O
collaborative O
approach O
, O
the O
Three O
Component O
Model O
( O
3CM O
) O
, O
with O
usual O
care O
for O
treating O
PTSD O
in O
primary O
care O
. O
[]

The O
influence O
of O
fidelity B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
on O
teacher-student O
interaction O
quality B-outcome ['Life-Impact']
in O
the O
context O
of O
a O
randomized O
controlled O
trial O
of O
the O
Responsive O
Classroom O
approach O
. O
['Life-Impact', 'Life-Impact']

GHD O
adults O
are O
frequently O
abdominally O
obese O
and O
display O
features O
of O
the O
metabolic O
syndrome O
. O
[]

It O
was O
found O
that O
no O
in O
vitro O
reaction B-outcome ['Physiological-Clinical']
between O
ferrous O
ion O
and O
paracetamol O
. O
['Physiological-Clinical']

Forty-six O
females O
and O
46 O
males O
completed O
four O
blocks O
of O
64 O
trials O
in O
a O
lateralized O
mental O
rotation O
task O
. O
[]

The O
absorption O
of O
synthetic O
pteroyltriglutamate O
has O
been O
measured O
in O
nine O
normal O
students O
with O
and O
without O
the O
anticonvulsant O
drug O
phenytoin O
. O
[]

Each O
tooth O
was O
then O
placed O
in O
a O
capped O
vial O
containing O
2 O
X O
2 O
inch O
gauze O
pads O
saturated O
with O
distilled O
water O
, O
and O
the O
sealer O
was O
allowed O
to O
set O
at O
37 O
degrees O
C O
in O
the O
humidor O
for O
48 O
hours O
. O
[]

Precordial O
echocardiography O
combined O
with O
femoral O
contrast O
delivery O
was O
significantly O
more O
sensitive B-outcome ['Physiological-Clinical']
than O
cardiac O
catheterization O
for O
assessment O
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
( O
8 O
of O
21 O
patients O
vs. O
2 O
of O
21 O
patients O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However, O
its O
effectiveness O
is O
controversial. O
[]

METHODS O
AND O
RESULTS O
Nine O
patients O
with O
CSX O
and O
14 O
control O
subjects O
underwent O
a O
continuous O
infusion O
of O
L-arginine O
( O
0.125 O
g/min O
) O
or O
saline O
for O
120 O
minutes O
. O
[]

Efficacy O
screening O
trials O
of O
paroxetine O
, O
pentoxifylline O
, O
riluzole O
, O
pramipexole O
and O
venlafaxine O
in O
cocaine O
dependence O
. O
[]

In O
experiment O
3b O
, O
a O
two-diameter O
length O
of O
bone O
was O
removed O
. O
[]

Both O
random O
assignment O
and O
large-scale O
geographic O
area O
research O
designs O
were O
used O
. O
[]

Both O
children O
's O
eyes O
were O
examined O
according O
to O
the O
World O
Health O
Organization O
( O
WHO O
) O
simplified B-outcome ['Physiological-Clinical']
grading I-outcome ['Physiological-Clinical']
system B-outcome ['Physiological-Clinical']
, O
and O
an O
ocular B-outcome ['Physiological-Clinical']
swab I-outcome ['Physiological-Clinical']
was O
taken O
from O
each O
child O
's O
right O
eye O
and O
processed O
by O
Amplicor O
polymerase O
chain O
reaction O
to O
test O
for O
the O
presence O
of O
C. O
trachomatis O
DNA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
This O
prospective O
study O
in O
a O
randomized O
controlled O
trial O
suggests O
that O
sialyl O
Lewis O
( O
a O
) O
expression O
levels O
may O
serve O
as O
an O
indicator O
of O
the O
metastatic O
potential O
of O
colon O
cancer O
cells O
, O
which O
would O
strongly O
predict O
the O
prognosis O
. O
[]

It O
is O
the O
current O
opinion O
that O
an O
ideal O
antihypertensive O
drug O
should O
reduce O
blood O
pressure O
( O
BP O
) O
not O
only O
at O
rest O
but O
also O
during O
stressful O
situations O
. O
[]

The O
number O
of O
treated O
legs O
was O
therefore O
98 O
, O
but O
two O
patients O
were O
lost O
to O
follow-up O
. O
[]

All O
participants O
had O
been O
thoroughly O
assessed O
for O
ASD O
and O
also O
had O
DNA O
testing O
for O
the O
diagnosis O
of O
FXS O
. O
[]

There O
were O
two O
malunions B-outcome ['Physiological-Clinical']
in O
the O
reamed O
group O
and O
four O
malunions B-outcome ['Physiological-Clinical']
in O
the O
unreamed O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

More O
sophisticated O
methods O
of O
acquisition O
and O
interpretation O
are O
needed O
to O
enhance O
the O
feasibility O
of O
this O
technique O
in O
routine O
practice O
. O
[]

Based O
on O
a O
serum B-outcome ['Physiological-Clinical']
Tg I-outcome ['Physiological-Clinical']
level O
of O
2 O
ng/mL O
or O
more O
, O
thyroid O
tissue O
or O
cancer O
was O
detected O
during O
thyroid O
hormone O
therapy O
in O
22 O
% O
, O
after O
recombinant O
human O
TSH O
stimulation O
in O
52 O
% O
, O
and O
after O
thyroid O
hormone O
withdrawal O
in O
56 O
% O
of O
patients O
with O
disease O
or O
tissue O
limited O
to O
the O
thyroid O
bed O
and O
in O
80 O
% O
, O
100 O
% O
, O
and O
100 O
% O
of O
patients O
, O
respectively O
, O
with O
metastatic O
disease O
. O
['Physiological-Clinical']

The O
mean O
successful B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
rate O
for O
ISDN O
was O
6.5 O
micrograms O
kg-1 O
min-1 O
, O
whereas O
for O
NTG O
this O
was O
3.8 O
micrograms O
kg-1 O
min-1 O
. O
['Life-Impact']

Toxicity B-outcome ['Adverse-effects']
and O
efficacy O
of O
6-thioguanine O
versus O
6-mercaptopurine O
in O
childhood O
lymphoblastic O
leukaemia O
: O
a O
randomised O
trial O
. O
['Adverse-effects']

The O
overall O
major O
response O
rate O
was O
13 O
% O
( O
three O
complete O
responders O
and O
three O
partial O
responders O
among O
47 O
evaluable O
patients O
) O
and O
was O
the O
same O
on O
both O
arms O
. O
[]

Of O
the O
patients O
who O
healed B-outcome ['Physiological-Clinical']
, O
5 O
of O
16 O
patients O
in O
the O
Grenz O
ray O
only O
group O
and O
4 O
of O
13 O
patients O
in O
the O
combination O
group O
remained B-outcome ['Physiological-Clinical']
healed I-outcome ['Physiological-Clinical']
at O
6 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUBJECTS O
AND O
METHODS O
Children O
with O
ASD O
were O
randomly O
assigned O
to O
an O
electro-acupuncture O
( O
EA O
) O
group O
( O
n=30 O
) O
or O
a O
sham O
electro-acupuncture O
( O
SEA O
) O
group O
( O
n=25 O
) O
matched O
by O
age O
and O
severity O
of O
autism O
. O
[]

BACKGROUND O
Practice O
nurses O
play O
an O
increasingly O
important O
role O
in O
the O
prevention O
of O
cardiovascular O
diseases O
but O
we O
do O
not O
have O
evidence O
about O
the O
accuracy O
of O
their O
cardiovascular O
risk O
assessments O
during O
real O
practice O
consultations O
. O
[]

We O
measured O
the O
correct O
index O
in O
the O
identification B-outcome ['Life-Impact']
of O
the O
eye O
drops O
of O
the O
two O
groups. O
[['Life-Impact']]

The O
slope O
relating O
symptoms O
to O
ventilation B-outcome ['Physiological-Clinical']
( O
ie O
, O
Borg/VE O
) O
was O
significantly O
reduced O
in O
the O
patients O
after O
bronchodilators O
( O
17 O
% O
+/-8 O
% O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

The O
effect O
of O
nebivolol O
treatment O
on O
oxidative B-outcome ['Physiological-Clinical']
stress O
and O
antioxidant B-outcome ['Physiological-Clinical']
status B-outcome ['Physiological-Clinical']
in O
patients O
with O
cardiac O
syndrome-X O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Study O
design: O
Controlled O
laboratory O
study; O
cross-sectional O
design. O
[]

The O
gain O
of O
shivering B-outcome ['Physiological-Clinical']
was O
determined O
by O
the O
slope O
of O
oxygen O
consumption O
vs O
core B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
regression O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
efficacy O
, O
side O
effects O
and O
acceptability B-outcome ['Life-Impact']
of O
sublingual O
and O
vaginal O
misoprostol O
for O
second O
trimester O
medical O
abortion O
. O
['Life-Impact']

CHVP O
cycles O
comprised O
cyclophosphamide O
( O
750 O
mg/m O
( O
2 O
) O
i.v O
. O
[]

It O
is O
uncertain O
whether O
administration O
of O
intravenous O
( O
IV O
) O
anti-oxidant O
, O
N-acetylcysteine O
( O
NAC O
) O
, O
can O
prevent O
reduction O
in O
renal O
function O
and O
whether O
this O
is O
a O
cost-effective O
approach O
. O
[]

Controls O
received O
no O
intervention O
. O
[]

Biomarker B-outcome ['Physiological-Clinical']
studies I-outcome ['Physiological-Clinical']
confirmed O
the O
superiority O
of O
letrozole O
in O
centrally O
assessed O
estrogen O
receptor-positive O
( O
ER+ O
) O
tumors O
and O
found O
a O
strong O
relationship O
with O
the O
degree O
of O
['Physiological-Clinical']

Sustained O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
and O
use O
of O
toothbrushes O
and O
dentifrice O
by O
previous O
users O
of O
traditional O
materials O
in O
a O
rural O
population O
in O
Andhra O
Pradesh O
, O
India O
. O
['Physiological-Clinical']

The O
effect O
of O
phenytoin O
on O
the O
absorption O
of O
synthetic O
folic O
acid O
polyglutamate O
. O
[]

Her O
pregnancy O
ended O
with O
stillbirth B-outcome ['Mortality']
. O
['Mortality']

Actigraphy O
data O
were O
collected O
a O
second O
time O
2 O
weeks O
after O
the O
parent O
received O
the O
randomization O
assignment O
and O
analyzed O
by O
using O
Student O
's O
t O
test O
. O
[]

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
a O
loyalty O
scheme O
for O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
behaviour O
change O
maintenance: O
results O
from O
a O
cluster O
randomised O
controlled O
trial. O
[['Life-Impact']]

In O
those O
randomised O
to O
receive O
relapse O
chemotherapy O
the O
response O
rate O
was O
improved O
slightly O
for O
those O
who O
had O
originally O
received O
four O
courses O
of O
chemotherapy O
( O
25.6 O
% O
) O
over O
those O
receiving O
eight O
( O
18.7 O
% O
) O
. O
[]

The O
grade O
of O
Lipiodol O
accumulation O
and O
the O
tumor O
regression O
rate O
were O
determined O
2 O
weeks O
after O
TAI O
by O
computerized O
tomography O
. O
[]

From O
January O
1995 O
until O
July O
1999 O
, O
124 O
patients O
with O
histologically O
proven O
locally O
advanced O
non-nasopharyngeal O
head O
and O
neck O
cancer O
( O
HNC O
) O
were O
randomized O
to O
receive O
either O
RT O
monotherapy O
( O
70 O
Gy O
, O
Group O
A O
) O
or O
the O
same O
RT O
concomitantly O
with O
DDP O
( O
100 O
mg/m2 O
on O
d O
2 O
, O
22 O
, O
42 O
, O
Group O
B O
) O
or O
Cb O
( O
7 O
AUC O
on O
d O
2 O
, O
22 O
, O
42 O
, O
Group O
C O
) O
. O
[]

In O
experimental O
group, O
patients O
received O
delayed-start O
GnRH O
antagonist O
protocol O
with O
estrogen O
priming O
followed O
by O
early O
follicular-phase O
GnRH O
antagonist O
treatment O
for O
7 O
days O
before O
ovarian O
stimulation O
with O
gonadotropin O
and O
in O
control O
group, O
patients O
treated O
with O
estrogen O
priming O
antagonist O
protocol. O
[]

In O
this O
study O
, O
we O
compared O
the O
effect O
of O
epidural O
analgesia O
and O
IV O
morphine O
patient-controlled O
analgesia O
( O
PCA O
) O
on O
pain O
relief O
, O
duration O
of O
hospitalization O
, O
oral O
nutrition O
, O
ambulation O
, O
and O
side O
effects O
in O
patients O
undergoing O
a O
major O
surgical O
procedure O
( O
i.e. O
, O
unilateral O
mastectomy O
with O
immediate O
transverse O
rectus O
abdominis O
musculocutaneous O
flap O
reconstruction O
) O
. O
[]

Fifty-one O
patients O
with O
raised O
intraocular O
pressure O
( O
IOP O
) O
were O
treated O
for O
up O
to O
four O
years O
with O
one O
of O
three O
ophthalmic O
solutions O
: O
0.5 O
% O
levobunolol O
, O
1 O
% O
levobunolol O
, O
or O
0.5 O
% O
timolol O
. O
[]

As O
calcium O
is O
important O
in O
the O
regulation O
of O
gastric O
acid O
secretion O
and O
gastrin O
release O
, O
we O
have O
examined O
the O
effect O
of O
the O
calcium O
antagonist O
nifedipine O
on O
these O
processes O
in O
man O
. O
[]

Journal-Name:Nutrients O
[]

Complete B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Operative O
time O
for O
SILS O
averaged O
40 O
% O
longer O
( O
54 O
? O
[]

A O
total O
of O
84 O
evaluable O
women O
provided O
274 O
cycles O
of O
exposure O
in O
the O
LNG/EE O
group O
, O
and O
89 O
women O
provided O
289 O
cycles O
of O
exposure O
in O
the O
NETA/EE O
group O
. O
[]

One O
hundred O
and O
eighty-one O
patients O
in O
the O
CA O
group O
versus O
175 O
in O
the O
placebo O
group O
completed O
the O
three-month O
study O
. O
[]

The O
safety O
profile O
of O
netupitant O
was O
comparable O
in O
the O
three O
arms. O
[]

Forty-three O
required O
re-treatment O
( O
41 O
received O
a O
second O
course O
of O
IFN O
and O
2 O
received O
pentostatin O
) O
. O
[]

In O
21 O
( O
35 O
% O
) O
of O
the O
cases O
, O
a O
three-field O
technique O
with O
two O
lateral O
opposed O
wedge O
fields O
and O
a O
posterior O
field O
was O
used O
, O
while O
in O
39 O
( O
65 O
% O
) O
of O
the O
cases O
a O
four-field O
pelvic O
box O
technique O
was O
used O
. O
[]

Complete B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cords I-outcome ['Physiological-Clinical']
was O
present O
in O
all O
but O
two O
patients O
, O
one O
in O
each O
group O
. O
['Physiological-Clinical']

After O
4 O
weeks, O
the O
levels O
of O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
were O
significantly O
decreased O
in O
the O
treatment O
group O
compared O
to O
placebo O
(63.6% O
vs. O
0.54%, O
respectively, O
P O
< O
0.0001). O
[['Physiological-Clinical']]

Thirty-five O
( O
49 O
% O
) O
of O
72 O
enrolled O
subjects O
were O
classified O
as O
methylphenidate O
responders O
. O
[]

Results O
support O
the O
usefulness O
of O
the O
program O
to O
teach O
the O
detection B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
['Life-Impact']

DESIGN O
Double-blind O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
of O
triamcinolone O
acetonide O
( O
1200 O
microg O
daily O
) O
vs O
placebo O
in O
participants O
with O
mild-to-moderate O
COPD O
. O
[]

Fifteen O
patients O
underwent O
a O
third O
course O
of O
interferon O
therapy O
at O
a O
median O
time O
after O
completion O
of O
a O
second O
course O
of O
IFN O
of O
1.0 O
year O
. O
[]

METHODS O
In O
Bamako O
, O
132 O
patients O
with O
pyoderma O
, O
diagnosed O
and O
graded O
as O
severe O
on O
clinical O
grounds O
, O
were O
randomly O
assigned O
to O
an O
oral O
treatment O
by O
either O
amoxicillin O
( O
50 O
mg/kg O
per O
day O
) O
or O
erythromycin O
; O
infections O
of O
the O
follicular O
appendage O
were O
excluded O
. O
[]

We O
performed O
a O
prospective O
randomized O
trial O
to O
evaluate O
the O
optimum B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
stenting I-outcome ['Life-Impact']
after O
endopyelotomy O
. O
['Life-Impact']

Fifty O
patients O
with O
alcoholic O
liver O
disease O
( O
27 O
with O
cirrhosis O
, O
23 O
without O
cirrhosis O
) O
were O
randomly O
assigned O
to O
receive O
either O
paromomycin O
sulfate O
( O
3 O
x O
1 O
g/day O
) O
or O
placebo O
in O
a O
double-blind O
fashion O
for O
at O
least O
3 O
weeks O
, O
and O
if O
possible O
4 O
weeks O
. O
[]

METHODS O
The O
WRIST O
study O
randomized O
130 O
patients O
to O
double-blinded O
therapy O
with O
gamma O
irradiation O
( O
iridium-192 O
[ O
( O
192 O
) O
Ir O
] O
) O
versus O
placebo O
after O
interventional O
treatment O
of O
diffuse O
in-stent O
restenosis O
. O
[]

Both O
drugs O
were O
administered O
in O
association O
with O
spironolactone O
( O
200 O
mg/day O
) O
in O
28 O
nonazotemic O
cirrhotic O
patients O
with O
controlled O
ascites O
. O
[]

Eligible O
patients O
had O
clinical O
stage O
II-III O
( O
> O
or O
= O
T2 O
and/or O
> O
or O
= O
N1 O
) O
newly O
diagnosed O
breast O
cancer O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
, O
and O
normal O
cardiac O
, O
renal O
, O
and O
liver O
function O
. O
[]

Those O
who O
received O
GLY O
received O
standard O
TPN O
, O
isocaloric O
and O
isonitrogenous O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
study O
valproate O
efficacy O
and O
safety O
for O
aggression O
in O
children O
and O
adolescents O
with O
pervasive O
developmental O
disorders O
( O
PDD O
) O
. O
[]

Controlling O
for O
treatment O
arm O
, O
age O
, O
sex O
, O
presence O
of O
cirrhosis O
or O
hepatitis O
C O
virus O
viral O
load O
before O
treatment O
did O
not O
change O
these O
results O
. O
[]

Second-line O
therapy O
in O
the O
treatment O
failures O
was O
of O
no O
benefit O
. O
[]

Compared O
with O
ETT O
, O
index O
testing O
costs O
were O
higher O
for O
exercise O
MPI O
( O
P O
< O
0.001 O
) O
, O
whereas O
downstream O
procedural O
costs O
were O
slightly O
lower O
( O
P=0.0008 O
) O
. O
[]

Twenty-four O
children O
with O
autism O
were O
randomly O
assigned O
to O
a O
clinic-directed O
group O
, O
replicating O
the O
parameters O
of O
the O
early O
intensive O
behavioral O
treatment O
developed O
at O
UCLA O
, O
or O
to O
a O
parent-directed O
group O
that O
received O
intensive O
hours O
but O
less O
supervision O
by O
equally O
well-trained O
supervisors O
. O
[]

Cough O
responses O
to O
citric O
acid O
were O
similar O
between O
patients O
with O
and O
without O
cough O
, O
and O
SP O
up O
to O
10 O
( O
-5 O
) O
M O
did O
not O
cause O
cough O
in O
any O
of O
the O
subjects O
. O
[]

METHODS O
Sixty-eight O
patients O
with O
peripheral O
obstructive O
arterial O
disease O
and O
intermittent O
claudication O
( O
Fontaine O
stage O
II O
) O
were O
randomly O
assigned O
into O
the O
treadmill O
training O
( O
repetitive O
intervals O
to O
onset O
of O
claudication O
pain O
, O
three O
times O
a O
week O
) O
or O
a O
control O
group O
( O
no O
change O
in O
physical O
activity O
) O
over O
3 O
months O
. O
[]

2 O
) O
Intramuscular O
group O
( O
IM O
Group O
) O
, O
40 O
patients O
given O
an O
intramuscular O
injections O
of O
OK-432 O
. O
[]

In O
the O
absence O
of O
curative O
and O
effective O
treatments O
for O
this O
disabling O
condition O
, O
this O
information O
has O
created O
new O
hope O
among O
parents O
. O
[]

Four O
randomized O
cases O
met O
exclusion O
criteria O
: O
penetrating O
trauma O
( O
1 O
) O
, O
cardiac O
arrest O
( O
2 O
) O
, O
and O
fall O
from O
standing O
( O
1 O
) O
. O
[]

Onset O
and O
complete B-outcome ['Physiological-Clinical']
spread O
of O
sensory B-outcome ['Resource-use']
blockade I-outcome ['Resource-use']
were O
similar O
in O
all O
five O
groups O
. O
['Physiological-Clinical', 'Resource-use']

Near O
normoglycaemia O
was O
achieved O
with O
continuous O
infusion O
and O
multiple O
injections O
but O
not O
with O
conventional O
treatment O
. O
[]

BACKGROUND: O
Chronic O
obstructive O
pulmonary O
disease O
(COPD) O
is O
a O
serious O
lung O
disease O
for O
individuals O
in O
middle O
age O
and O
especially O
in O
old O
people. O
[]

Informed O
physicians O
counseled O
female O
patients O
, O
harmful O
but O
nondependent O
drinkers O
, O
and O
patients O
with O
inactive O
disorders O
more O
often O
than O
their O
uninformed O
colleagues O
, O
although O
only O
the O
last O
variable O
achieved O
statistical O
significance O
. O
[]

The O
GAI-Estimate B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GAI-E I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
algorithms I-outcome ['Physiological-Clinical']
accounted O
for O
58 O
% O
to O
82 O
% O
of O
the O
variance O
. O
['Physiological-Clinical']

Publication O
Type: O
Journal O
Article O
[]

MAIN O
OUTCOME O
MEASURES O
Visual O
field O
progression O
, O
measured O
by O
Humphrey O
24-2 O
full-threshold O
testing O
and O
assessed O
by O
the O
change O
in O
the O
mean O
deviation O
( O
MD O
) O
, O
and O
an O
indicator O
of O
substantial B-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
of O
the O
VF B-outcome ['Physiological-Clinical']
( O
MD O
decrease O
of O
> O
or O
=3 O
dB O
from O
baseline O
) O
, O
assessed O
at O
each O
follow-up O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Main O
outcome O
measures O
included O
mean O
change O
from O
baseline O
at O
Months O
12 O
and O
24 O
for O
area O
of O
classic O
CNV O
and O
total O
area O
of O
leakage O
from O
CNV O
. O
[]

Therefore O
, O
the O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
, O
using O
a O
group O
design O
, O
the O
effectiveness O
of O
medical O
intervention O
alone O
( O
N O
= O
11 O
) O
versus O
behavioral O
plus O
medical O
intervention O
( O
N O
= O
10 O
) O
for O
illness-related O
problem O
behavior O
in O
a O
school O
setting O
. O
[]

Journal O
ID: O
9308586 O
[]

In O
both O
arms O
combined O
, O
declines O
from O
baseline O
to O
3 O
months O
were O
observed O
in O
sexual B-outcome ['Life-Impact']
risk O
behaviors B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
patients O
were O
divided O
into O
two O
groups O
: O
those O
in O
early O
stages O
( O
stage O
I O
or O
II O
) O
and O
those O
in O
advanced O
stages O
( O
stage O
III O
or O
IV O
) O
; O
these O
groups O
were O
further O
subdivided O
into O
an O
immunotherapy O
group O
( O
receiving O
OK-432 O
) O
and O
a O
control O
group O
( O
who O
did O
not O
receive O
OK-432 O
) O
. O
[]

All O
patients O
were O
seen O
in O
follow-up O
period O
after O
16 O
weeks O
; O
clinical O
evaluation O
using O
Melasma O
Area O
and O
Severity O
Index O
( O
MASI O
) O
score O
and O
photography O
were O
recorded O
before O
and O
after O
treatment O
and O
after O
16 O
weeks O
. O
[]

Only O
a O
credentialed O
surgeon O
can O
be O
responsible O
for O
both O
open O
distal O
gastrectomy O
and O
laparoscopy-assisted O
distal O
gastrectomy O
. O
[]

We O
observed O
the O
percent O
improvement O
of O
the O
RP B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
rate O
between O
before O
and O
after O
the O
8-week O
treatment O
. O
['Physiological-Clinical']

In O
group O
2 O
, O
hemodilution O
( O
hematocrit O
30 O
+/- O
3 O
% O
) O
resulted O
in O
a O
steeper O
increase O
in O
the O
albumin B-outcome ['Physiological-Clinical']
diffusion I-outcome ['Physiological-Clinical']
space I-outcome ['Physiological-Clinical']
( O
p O
< O
.05 O
) O
and O
a O
progressive O
decrease O
in O
the O
body B-outcome ['Physiological-Clinical']
electrical I-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( O
p O
< O
.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

During O
dietary O
treatment O
the O
relative O
content B-outcome ['Physiological-Clinical']
of O
saturated O
and O
monounsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
secreased O
and O
the O
polyunsaturated B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
increased O
with O
an O
increasing O
ratio O
between O
pulyunsaturated B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
saturated I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
( O
P/S B-outcome ['Physiological-Clinical']
ratio O
) O
in O
the O
cholesterol O
esters O
and O
triglycerides O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
showed O
that O
triacylglycerol-rich B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
peaked O
at O
6 O
h O
post-ingestion O
for O
all O
formulations O
. O
['Physiological-Clinical']

CONCLUSIONS O
Results O
suggest O
that O
universal O
, O
school-based O
programs O
can O
benefit O
the O
emotional O
health O
of O
youth O
in O
low-income O
, O
urban O
settings O
. O
[]

CONTEXT O
Experimental O
and O
epidemiological O
data O
suggest O
that O
vitamin O
E O
supplementation O
may O
prevent O
cancer O
and O
cardiovascular O
events O
. O
[]

METHODS O
A O
systematic O
search O
of O
the O
literature O
was O
carried O
out O
from O
1985 O
to O
October O
1997 O
for O
randomized O
controlled O
trials O
of O
isoniazid O
prophylaxis O
in O
HIV-infected O
persons O
. O
[]

Contrary O
to O
the O
progress O
in O
the O
management O
of O
severe O
AP, O
the O
MAP O
has O
not O
presented O
significant O
changes O
in O
recent O
years. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Rationale O
and O
design O
of O
a O
randomized O
trial O
to O
evaluate O
an O
evidence-based O
prescription O
drug O
label O
on O
actual O
medication O
use O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
in O
both O
the O
experimental O
acupuncture O
treatment O
group O
and O
the O
comparison O
acupuncture O
treatment O
group O
showed O
a O
significant O
difference O
between O
the O
baseline O
and O
the O
third O
month O
of O
the O
study O
. O
['Life-Impact']

Our O
purpose O
was O
to O
estimate O
costs B-outcome ['Resource-use']
and O
determine O
cost B-outcome ['Resource-use']
predictors O
. O
['Resource-use', 'Resource-use']

After O
starting O
estrogen O
treatment O
, O
the O
decrease O
in O
height B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
( O
HV O
) O
changed O
significantly O
to O
a O
stable O
HV O
, O
without O
affecting O
bone B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
( O
change O
in O
bone O
age/change O
in O
chronological O
age O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
aim O
of O
this O
study O
is O
to O
compare O
the O
effectiveness O
of O
two O
currently O
existing O
health O
care O
programs O
with O
different O
intensity O
and O
mode O
of O
delivery O
on O
daily O
functioning O
in O
patients O
with O
GOA O
. O
[]

Large O
volume O
, O
low O
pressure O
endotracheal O
tube O
cuffs O
are O
claimed O
to O
have O
less O
deleterious O
effect O
on O
tracheal B-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
than O
high O
pressure O
, O
low O
volume O
cuffs O
. O
['Physiological-Clinical']

How O
to O
establish O
equivalence O
when O
data O
are O
censored O
: O
a O
randomized O
trial O
of O
treatments O
for O
B O
non-Hodgkin O
lymphoma O
. O
[]

Optimal O
therapy O
for O
advanced O
chronic O
venous O
insufficiency O
. O
[]

One O
group O
( O
n=127 O
) O
carried O
a O
CER O
during O
4 O
weeks O
. O
[]

In O
Study O
1 O
, O
the O
authors O
found O
that O
in O
the O
made-in-the-U.S. O
scenario O
condition O
, O
European O
Americans O
were O
more O
accurate O
than O
were O
Asian O
Americans O
in O
their O
retrospective O
frequency O
judgments B-outcome ['Life-Impact']
of O
emotions B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
patients O
have O
been O
divided O
into O
two O
groups O
according O
to O
ST-T O
changes O
during O
chest O
pain O
: O
29 O
with O
ST O
elevation O
( O
group O
A O
) O
and O
41 O
with O
other O
repolarization O
abnormalities O
( O
group O
B O
) O
. O
[]

The O
study O
was O
undertaken O
in O
order O
to O
evaluate O
the O
effect O
of O
prednisone- O
and O
triple-treatment O
upon O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intensity O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
opacification I-outcome ['Physiological-Clinical']
was O
also O
greater O
during O
femoral O
vein O
contrast O
injection O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
end O
point O
was O
the O
skeletal-related O
event O
( O
SRE O
) O
rate O
ratio O
between O
treatment O
groups O
. O
[]

Magnetic O
resonance O
imaging O
brain O
scans O
( O
1.5T O
) O
were O
obtained O
and O
images O
were O
analyzed O
by O
using O
BRAINS2 O
. O
[]

However O
, O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
FFS B-outcome ['Mortality']
) O
and O
overall O
survival B-outcome ['Mortality']
( O
OS O
) O
had O
statistical O
differences O
. O
['Mortality', 'Mortality', 'Mortality']

As O
a O
secondary O
objective O
, O
changes O
in O
injected B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
scores O
, O
each O
measured O
on O
a O
four-point O
scale O
, O
were O
evaluated O
. O
['Physiological-Clinical']

The O
response O
rate O
, O
time O
to O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
TTF O
) O
, O
and O
median O
survival O
time O
were O
superior O
in O
the O
premenopausal O
women O
. O
['Physiological-Clinical']

OBJECTIVES O
Few O
studies O
of O
topical O
microbicides O
have O
assessed O
their O
safety O
in O
HIV-infected B-outcome ['Physiological-Clinical']
women O
. O
['Physiological-Clinical']

During O
the O
trial O
, O
a O
process O
of O
central O
review O
was O
established O
to O
monitor O
performance O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
and O
general B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
differences O
with O
regard O
to O
wives O
' O
general B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
or O
cancer-specific B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
were O
noted O
. O
['Life-Impact', 'Life-Impact']

Patients O
were O
randomly O
assigned O
to O
receive O
either O
orally O
administered O
dexamethasone O
with O
0.5 O
mg/kg O
as O
the O
first O
dose O
and O
0.3 O
mg/kg O
for O
the O
next O
2 O
mornings O
, O
or O
an O
equal O
volume O
of O
an O
orally O
administered O
placebo O
with O
an O
identical O
appearance O
. O
[]

Statistical O
analysis O
was O
performed O
using O
paired O
t O
tests O
, O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
test O
, O
or O
multiple O
linear O
regression O
as O
appropriate O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
198 O
English-speaking O
women O
, O
with O
no O
personal O
or O
family O
history O
of O
breast O
cancer O
, O
were O
recruited O
and O
randomized O
to O
four O
groups O
when O
they O
presented O
to O
the O
clinic O
for O
a O
screening O
mammogram O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
low O
, O
with O
occasional B-outcome ['Physiological-Clinical']
gastroenteric I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Adverse-effects', 'Physiological-Clinical']

The O
dipeptidyl O
peptidase-4 O
inhibitor O
PHX1149 O
improves O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
['Physiological-Clinical']

[ O
Local O
application O
of O
anti-cancer O
drugs O
for O
the O
treatment O
of O
malignant O
pleural O
and O
pericardial O
effusion O
] O
. O
[]

DESIGN O
Parallel O
, O
clinical O
intervention O
study O
of O
12 O
weeks O
energy O
restriction O
( O
6.5 O
MJ/day O
) O
and O
4 O
weeks O
energy O
balance O
( O
8.2 O
MJ/day O
) O
in O
two O
groups O
of O
subjects O
randomly O
assigned O
to O
either O
a O
high-protein O
( O
HP O
) O
diet O
( O
27 O
% O
of O
energy O
( O
% O
E O
) O
as O
protein O
, O
45 O
% O
E O
as O
carbohydrate O
) O
or O
a O
lower-protein O
( O
LP O
) O
diet O
( O
16 O
% O
E O
as O
protein O
, O
57 O
% O
E O
as O
carbohydrate O
) O
. O
[]

BACKGROUND O
The O
sliding O
hip O
screw O
has O
gained O
considerable O
acceptance O
in O
the O
treatment O
of O
unstable O
trochanteric O
fractures O
. O
[]

Although O
the O
two O
groups O
were O
equally O
accurate O
in O
detecting O
targets O
, O
the O
ASD O
adults O
improve O
in O
their O
correct B-outcome ['Life-Impact']
elimination O
of O
['Life-Impact']

METHODS:: O
Five O
therapeutic O
radiographers O
contoured O
the O
prostate O
individually O
on O
CT, O
T2 O
weighted O
(T2W) O
and O
T2* O
weighted O
(T2*W) O
imaging O
for O
10 O
patients. O
[]

CONCLUSION O
These O
results O
indicate O
that O
low O
atrial O
DFTs O
can O
be O
achieved O
using O
a O
transvenous O
ventricular O
defibrillation O
lead O
. O
[]

RESULTS O
Overall O
, O
270 O
patients O
were O
enrolled O
, O
but O
13 O
patients O
early O
interrupted O
treatment O
due O
to O
side O
effects O
. O
[]

INTERVENTION O
( O
S O
) O
Metaphase O
II O
oocytes O
were O
divided O
into O
groups O
A O
and O
B O
, O
vitrified O
with O
and O
without O
cumulus O
cells O
, O
respectively O
. O
[]

BACKGROUND O
Penetration O
through O
the O
stratum O
corneum O
limits O
effectiveness O
of O
topical O
anesthetics O
. O
[]

In O
both O
experiments O
, O
subjects O
were O
divided O
into O
two O
groups O
( O
serial O
CE O
and O
integrated O
CE O
) O
matched O
for O
initial O
physical O
condition O
and O
trained O
in O
a O
vigorous O
3-day O
per O
week O
CE O
program O
of O
9 O
( O
men O
) O
to O
11 O
( O
women O
) O
weeks O
. O
[]

Retention O
needles O
on O
the O
head O
with O
simultaneous O
behavior O
training O
was O
applied O
for O
the O
trial O
group O
. O
[]

A O
case O
of O
intraglomerular O
metastases O
observed O
in O
a O
nephrectomy O
specimen O
removed O
for O
primary O
renal O
cell O
carcinoma O
is O
reported O
. O
[]

It O
is O
an O
effective O
, O
modern O
, O
low-invasive O
, O
and O
repeatable O
technique O
and O
is O
technically O
simple O
and O
easy O
to O
master O
. O
[]

At O
15 O
and O
30-day O
follow-ups O
, O
control O
group O
and O
nonsteroid O
leads O
show O
a O
higher O
threshold O
value O
growth O
( O
in O
unipolar O
from O
0.16 O
+/- O
0.11 O
to O
1.19 O
+/- O
0.85 O
microJ O
; O
in O
bipolar O
from O
0.18 O
+/- O
0.13 O
to O
1.24 O
+/- O
0.88 O
microJ O
) O
than O
the O
membrane O
steroid O
leads O
( O
in O
unipolar O
from O
0.13 O
+/- O
0.11 O
to O
0.70 O
+/- O
0.39 O
microJ O
; O
in O
bipolar O
from O
0.23 O
+/- O
0.32 O
to O
0.76 O
+/- O
0.36 O
microJ O
) O
; O
the O
threshold O
of O
nonsteroid O
leads O
decreases O
after O
1-3 O
months O
and O
it O
settles O
at O
the O
same O
threshold O
level O
of O
the O
leads O
with O
membrane O
and O
steroid O
( O
in O
unipolar O
0.60 O
+/- O
0.33 O
microJ O
; O
in O
bipolar O
0.55 O
+/- O
0.26 O
microJ O
) O
, O
which O
has O
been O
stable O
since O
the O
first O
month O
. O
[]

In O
23 O
research O
centers O
in O
Spain, O
6874 O
men O
and O
women O
aged O
55 O
to O
75 O
years O
with O
metabolic O
syndrome O
and O
no O
cardiovascular O
disease O
were O
enrolled O
in O
the O
trial O
between O
September O
2013 O
and O
December O
2016, O
with O
final O
data O
collection O
in O
March O
2019. O
[]

Publication O
date: O
2019/02/13 O
06:00 O
[medline] O
[]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
alpha O
dihidroergocriptine O
in O
patients O
with O
fibrocystic O
mastopathy O
. O
[]

BACKGROUND O
Hyperbaric O
oxygen O
( O
HBO O
) O
attenuates O
lipopolysaccharide O
( O
LPS O
) O
-induced O
acute O
lung O
injury O
. O
[]

OBJECTIVE O
Individuals O
with O
amnestic O
mild O
cognitive O
impairment O
( O
MCI O
) O
have O
few O
empirically O
based O
treatment O
options O
for O
combating O
their O
memory B-outcome ['Life-Impact']
loss I-outcome ['Life-Impact']
. O
['Life-Impact']

Vomiting B-outcome ['Physiological-Clinical']
was O
reduced O
from O
17 O
% O
( O
441/2585 O
) O
to O
11 O
% O
( O
293/2576 O
) O
, O
corresponding O
to O
a O
relative O
risk O
of O
0.67 O
, O
or O
a O
relative O
risk O
reduction O
of O
33 O
% O
. O
['Physiological-Clinical']

[ O
Comparative O
study O
between O
5 O
% O
prilocaine O
and O
2 O
% O
mepivacaine O
by O
the O
subarachnoid O
route O
in O
transurethral O
resections O
] O
. O
[]

BACKGROUND O
Much O
of O
China O
lacks O
well-developed O
services O
for O
people O
with O
schizophrenia O
and O
their O
families O
, O
and O
most O
of O
the O
existing O
services O
focus O
on O
hospitals O
. O
[]

At O
1 O
year O
43.4 O
% O
and O
at O
2 O
years O
41.8 O
% O
of O
the O
intervention O
subjects O
had O
achieved O
a O
weight O
reduction O
of O
at O
least O
5 O
kg O
, O
while O
the O
corresponding O
figures O
for O
the O
control O
subjects O
were O
14.0 O
and O
12.0 O
% O
( O
P O
< O
0.001 O
between O
the O
groups O
) O
. O
[]

In O
conclusion O
, O
atropine O
, O
glycopyrrolate O
, O
and O
scopolamine O
differ O
not O
only O
in O
their O
cardiovascular O
and O
central O
nervous O
system O
effects O
, O
but O
also O
in O
their O
effects O
on O
metabolism O
. O
[]

The O
CSF B-outcome ['Physiological-Clinical']
monocytic I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count O
decreased O
during O
zidovudine O
but O
increased O
during O
didanosine O
treatment O
. O
['Physiological-Clinical']

All O
patients O
were O
treated O
with O
CsA O
for O
the O
first O
10 O
days O
and O
then O
randomized O
to O
receive O
Evr O
in O
combination O
with O
CsA O
up O
to O
day O
30 O
, O
then O
either O
continued O
on O
Evr O
monotherapy O
( O
Evr O
group O
) O
or O
maintained O
on O
CsA O
with/without O
mycophenolate O
mofetil O
( O
CsA O
group O
) O
in O
case O
of O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

Prospective O
analyses O
using O
data O
for O
all O
participants O
will O
provide O
more O
definitive O
information O
on O
GERA O
uptake O
and O
the O
impact O
of O
GERA O
feedback O
. O
[]

Their O
ages O
ranged O
from O
3 O
to O
13 O
years O
, O
and O
all O
belonged O
to O
American O
Society O
of O
Anesthesiologists O
( O
ASA O
) O
class O
I O
or O
II O
. O
[]

Hydrocortisone O
infusion O
induced O
an O
increase O
of O
mean O
arterial O
pressure O
, O
systemic O
vascular O
resistance O
, O
and O
a O
decline O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
and O
norepinephrine B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Impact O
of O
dronedarone O
on O
hospitalization B-outcome ['Resource-use']
burden I-outcome ['Resource-use']
in O
patients O
with O
atrial O
fibrillation O
: O
results O
from O
the O
ATHENA O
study O
. O
['Resource-use']

Using O
dietetic O
assistants O
to O
improve O
the O
outcome O
of O
hip O
fracture O
: O
a O
randomised O
controlled O
trial O
of O
nutritional O
support O
in O
an O
acute O
trauma O
ward O
. O
[]

In O
patients O
remaining O
in O
SR O
for O
15 O
days O
after O
from O
the O
start O
of O
follow-up O
, O
freedom B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
significantly O
more O
prevalent O
in O
the O
aprindine O
group O
than O
in O
the O
placebo O
group O
( O
p=0.0414 O
) O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
digoxin O
and O
placebo O
groups O
. O
['Physiological-Clinical']

The O
results O
do O
not O
support O
any O
suggestion O
that O
information O
about O
the O
existence O
of O
a O
placebo O
condition O
dramatically O
influences O
conclusions O
drawn O
about O
drug O
responses O
in O
placebo-controlled O
trials O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
, O
collateral O
damage O
, O
and O
convenience O
of O
panretinal O
photocoagulation O
for O
proliferative O
diabetic O
retinopathy O
or O
severe O
nonproliferative O
diabetic O
retinopathy O
using O
a O
532-nm O
solid-state O
green O
laser O
( O
GLX O
) O
versus O
a O
multispot O
532-nm O
pattern O
scan O
laser O
( O
PASCAL O
) O
. O
[]

Evaluation O
of O
three O
dosage-prediction O
methods O
for O
initial O
in-hospital O
stabilization O
of O
warfarin O
therapy O
. O
[]

All O
aripiprazole O
doses O
demonstrated O
significantly O
greater O
improvements O
in O
mean O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
than O
placebo O
at O
week O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

FINDINGS O
EMIAT O
enrolled O
1486 O
patients O
( O
743 O
in O
the O
amiodarone O
group O
, O
743 O
in O
the O
placebo O
group O
) O
. O
[]

Overall B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
both O
treatments O
was O
similar O
to O
placebo O
, O
and O
there O
were O
no O
clinically O
relevant O
effects O
on O
cardiac B-outcome ['Physiological-Clinical']
repolarisation I-outcome ['Physiological-Clinical']
with O
either O
mizolastine O
or O
loratadine O
. O
['Life-Impact', 'Physiological-Clinical']

PURPOSE O
To O
compare O
the O
role O
of O
an O
aromatase O
inhibitor O
( O
letrozole O
) O
with O
a O
GnRH O
agonist O
( O
triptorelin O
) O
versus O
case O
control O
on O
the O
pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
recurrence O
of O
symptoms B-outcome ['Physiological-Clinical']
and O
signs B-outcome ['Physiological-Clinical']
in O
patients O
with O
endometriosis O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
TCT O
images O
were O
registered O
to O
the O
TCT O
template O
and O
the O
same O
registration O
parameters O
were O
applied O
to O
the O
ECD O
images O
. O
[]

Participants O
were O
women O
in O
a O
breast O
self-examination O
trial O
in O
Shanghai O
, O
China O
who O
were O
diagnosed O
with O
fibroadenomas O
( O
n O
= O
258 O
) O
and O
1035 O
controls O
. O
[]

With O
the O
exclusion O
of O
those O
whose O
menses O
returned O
before O
18 O
wk O
postpartum O
( O
which O
could O
not O
have O
been O
due O
to O
the O
intervention O
) O
, O
the O
proportion O
of O
women O
who O
were O
amenorrheic B-outcome ['Physiological-Clinical']
at O
6 O
mo O
was O
64.5 O
% O
in O
the O
SF O
group O
, O
80.0 O
% O
in O
the O
FBF O
group O
, O
and O
85.7 O
% O
in O
the O
SF-M O
group O
( O
chi-square O
test O
= O
4.13 O
, O
P O
= O
0.02 O
; O
one-tailed O
test O
with O
the O
latter O
two O
groups O
combined O
) O
. O
['Physiological-Clinical']

Estimated O
5-year O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
RFS B-outcome ['Mortality']
) O
rate O
is O
50 O
% O
in O
arm O
1 O
and O
48 O
% O
in O
arm O
2 O
, O
with O
median O
RFS O
times O
of O
58 O
and O
50 O
months O
, O
respectively O
. O
['Mortality', 'Mortality']

Title: O
Pathways O
leading O
to O
success O
and O
non-success: O
a O
process O
evaluation O
of O
a O
cluster O
randomized O
physical O
activity O
health O
promotion O
program O
applying O
fuzzy-set O
qualitative O
comparative O
analysis. O
[]

AIMS O
To O
assess O
if O
raising O
concentrations O
of O
crude O
protein O
( O
CP O
) O
in O
pasture O
in O
spring O
by O
the O
frequent O
application O
of O
urea O
fertiliser O
would O
affect O
ovarian B-outcome ['Physiological-Clinical']
follicular I-outcome ['Physiological-Clinical']
dynamics I-outcome ['Physiological-Clinical']
, O
luteal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oestrus I-outcome ['Physiological-Clinical']
and O
reproductive B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
of O
dairy O
cows O
under O
farming O
conditions O
in O
New O
Zealand O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
showed O
marked O
decreases O
in O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
and O
density B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
micro-organisms I-outcome ['Physiological-Clinical']
in O
both O
the O
RP O
and O
TC O
+ O
RP O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Prognostic O
factor O
analysis O
in O
patients O
with O
advanced O
prostate O
cancer O
treated O
by O
castration O
plus O
anandron O
or O
placebo O
: O
a O
final O
update O
. O
[]

Dose O
modifications O
were O
necessary O
in O
9 O
patients O
, O
4 O
in O
the O
24 O
week O
and O
5 O
in O
the O
48 O
week O
group O
for O
anaemia B-outcome ['Physiological-Clinical']
, O
neutropenia B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

Title: O
[Clinical O
observation O
of O
LOP O
chemotherapy O
combined O
with O
radiotherapy O
in O
the O
treatment O
of O
early O
nasal O
NK/T O
cell O
lymphoma]. O
[]

However O
, O
the O
uremic O
patients O
did O
not O
show O
the O
habitual O
post-peak O
fall O
, O
remaining O
GH B-outcome ['Physiological-Clinical']
levels O
over O
10 O
micrograms/l O
till O
the O
end O
of O
the O
test O
. O
['Physiological-Clinical']

In O
addition O
, O
systemic O
exposure O
of O
risperidone O
active O
moiety O
( O
risperidone O
plus O
9-hydroxyrisperidone O
) O
, O
the O
most O
clinically O
relevant O
component O
of O
risperidone O
treatment O
, O
was O
not O
affected O
by O
galantamine O
coadministration O
, O
while O
systemic B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
was O
increased O
by O
approximately O
10 O
% O
for O
risperidone O
and O
decreased O
by O
about O
10 O
% O
for O
9-hydroxyrisperidone O
( O
active O
metabolite O
of O
risperidone O
) O
. O
['Life-Impact']

A O
priori O
the O
facial O
affect O
recognition O
test O
had O
shown O
good O
psychometric O
properties O
in O
a O
normative O
sample O
( O
internal O
consistency O
: O
rtt=.91-.95 O
; O
retest O
reliability O
: O
rtt=.89-.92 O
) O
. O
[]

The O
addition O
of O
a O
phone O
call O
did O
not O
further O
increase O
screening O
rates O
. O
[]

These O
data O
do O
, O
however O
, O
provide O
valuable O
information O
on O
RU O
associated O
with O
COPD O
and O
insights O
into O
adjustments O
associated O
with O
changes O
in O
disease O
course O
. O
[]

This O
study O
involves O
118 O
evaluable O
patients O
: O
32 O
in O
the O
laser-CO2 O
group O
, O
34 O
in O
the O
5-fluorouracil O
group O
and O
52 O
in O
the O
interferon O
group O
. O
[]

The O
proportion O
of O
subjects O
with O
negative O
expectations B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
future I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
ability B-outcome ['Life-Impact']
decreased O
in O
both O
groups O
at O
6 O
and O
12 O
months O
; O
however O
, O
the O
proportion O
was O
significantly O
bigger O
in O
TG O
compared O
with O
CG O
( O
P O
= O
0.028 O
) O
. O
['Life-Impact', 'Life-Impact']

MET O
treatment O
was O
associated O
with O
a O
decreased O
BMI O
( O
p O
= O
0.02 O
) O
as O
well O
as O
with O
a O
reduction O
in O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( O
p O
= O
0.03 O
) O
, O
particularly O
the O
deep B-outcome ['Physiological-Clinical']
subcutaneous I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( O
p O
= O
0.04 O
) O
as O
assessed O
by O
magnetic O
resonance O
imaging O
. O
['Physiological-Clinical', 'Physiological-Clinical']

By O
subjective O
IRLS O
ratings O
, O
all O
pramipexole O
doses O
were O
significantly O
superior O
to O
placebo O
. O
[]

Both O
treatments O
provided O
significant O
improvements O
in O
all O
the O
clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
parameters O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blood O
product O
requirements O
during O
OLT O
were O
tendentiously O
higher O
in O
the O
bolus O
group O
but O
not O
significantly O
so O
. O
[]

Several O
aspects O
of O
monkeys O
' O
performance O
suggest O
the O
cognitive O
sophistication O
of O
their O
decisions O
to O
escape O
. O
[]

METHODS: O
The O
study O
was O
a O
randomised, O
double-blinded, O
placebo-controlled O
intervention O
study O
with O
35 O
overweight O
subjects O
with O
mildly O
or O
moderately O
elevated O
blood O
pressure, O
who O
took O
4 O
g O
krill O
oil O
powder O
or O
4 O
g O
of O
placebo O
during O
an O
8-week O
follow-up O
period. O
[]

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
at O
28 O
days. O
[['Mortality']]

Recombinant O
HBV O
vaccine O
induced O
better O
long O
term O
[]

They O
were O
randomized O
to O
either O
operative O
or O
nonoperative O
treatment O
with O
a O
2-year O
follow-up O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
degree O
of O
injured O
vertebra B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
, O
visual O
analogue O
scale O
(VAS) O
score, O
and O
Oswestry O
disability B-outcome ['Life-Impact']
index O
(ODI) O
score O
at O
preoperation, O
immediate O
after O
operation, O
and O
last O
follow-up O
were O
calculated O
and O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Life-Impact']]

Medical O
Research O
Council O
's O
Working O
Party O
on O
Leukaemia O
in O
Adults O
. O
[]

A O
double-blinded O
protocol O
was O
used O
to O
investigate O
the O
patients O
at O
baseline O
and O
one O
month O
after O
recovery O
with O
the O
stimulator O
turned O
on O
and O
off O
( O
1-month O
periods O
) O
. O
[]

This O
is O
a O
prospective O
study O
that O
compares O
the O
effects O
of O
calcium O
acetate O
and O
sevelamer O
on O
coronary B-outcome ['Physiological-Clinical']
calcification I-outcome ['Physiological-Clinical']
( O
CAC O
) O
and O
bone B-outcome ['Physiological-Clinical']
histology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Regardless O
of O
outcome O
, O
there O
was O
no O
change O
in O
APC B-outcome ['Physiological-Clinical']
at O
the O
end O
of O
a O
6-month O
course O
of O
interferon O
treatment O
. O
['Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
the O
study O
was O
to O
investigate O
safety O
, O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
in O
comparison O
with O
haloperidol O
in O
the O
long-term O
treatment O
of O
autistic O
disorder O
. O
['Life-Impact']

In O
a O
double-blind O
, O
placebo-controlled O
study O
the O
effects O
of O
Actovegin O
on O
frontal O
and O
parietal O
electrical O
P300 O
sources O
revealed O
by O
low O
resolution O
electromagnetic O
tomography O
( O
LORETA O
) O
were O
studied O
in O
age-associated O
memory O
impairment O
( O
AAMI O
) O
patients O
. O
[]

Observations O
from O
the O
present O
study O
provide O
benchmark O
data O
for O
improving O
patient O
care O
and O
effectively O
utilizing O
healthcare O
resources O
. O
[]

This O
study O
evaluated O
the O
feasibility O
of O
using O
CM O
to O
promote O
weight O
loss O
in O
individuals O
with O
SMI O
over O
8 O
weeks O
. O
[]

Thus O
, O
188 O
patients O
were O
treated O
and O
included O
in O
the O
ITT O
analysis O
( O
94 O
patients O
per O
treatment O
group O
; O
ITT O
analysis O
) O
; O
161 O
patients O
were O
included O
in O
the O
perprotocol O
( O
PP O
) O
analysis O
( O
n O
= O
80 O
for O
amlodipine O
camsylate O
, O
n O
= O
81 O
for O
amlodipine O
besylate O
) O
( O
14 O
patients O
in O
the O
amlodipine O
camsylate O
group O
and O
13 O
patients O
in O
the O
amlodipine O
besylate O
group O
were O
excluded O
from O
the O
PP O
analysis O
due O
to O
consistent O
withdrawal O
or O
protocol O
violation O
) O
. O
[]

Beta-adrenoceptor O
blockade O
and O
cardiovascular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
cold O
pressor O
test O
. O
['Physiological-Clinical']

BACKGROUND O
Warfarin O
is O
a O
commonly O
used O
anticoagulant O
in O
North O
America O
. O
[]

Between O
January O
1996 O
and O
February O
1998 O
, O
259 O
men O
with O
prostate O
cancer O
underwent O
radical O
retropubic O
prostatectomy O
and O
bilateral O
pelvic O
node O
dissection O
in O
the O
26 O
centres O
participating O
in O
the O
Italian O
randomised O
prospective O
PROSIT O
study O
. O
[]

Identification O
, O
course O
, O
and O
treatment O
of O
depression O
after O
admission O
for O
a O
cardiac O
condition O
: O
rationale O
and O
patient O
characteristics O
for O
the O
Identifying O
Depression O
As O
a O
Comorbid O
Condition O
( O
IDACC O
) O
project O
. O
[]

PATIENTS O
AND O
METHODS O
We O
used O
data O
from O
EORTC O
22881-10882 O
trial O
, O
with O
median O
follow-up O
of O
77.4 O
months O
. O
[]

METHODS O
We O
conducted O
a O
noninferiority O
trial O
at O
48 O
institutions O
and O
randomly O
assigned O
872 O
patients O
with O
adenocarcinoma O
of O
the O
colon O
to O
undergo O
open O
or O
laparoscopically O
assisted O
colectomy O
performed O
by O
credentialed O
surgeons O
. O
[]

The O
oats O
group O
experienced O
a O
significant O
reduction O
in O
both O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
9 O
% O
) O
and O
low-density B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
216 O
patients O
were O
randomized O
. O
[]

Journal O
ID: O
9415084 O
[]

The O
latter O
two O
groups O
were O
rendered O
diabetic O
by O
i.p O
. O
[]

RESULTS O
Thirty-seven O
patients O
completed O
the O
study O
, O
21 O
in O
the O
treatment O
group O
and O
16 O
in O
the O
control O
group O
. O
[]

Integrated O
CE O
in O
women O
discernibly O
reduced O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
-13.2 O
% O
and O
-12.6 O
% O
, O
respectively O
) O
, O
increased O
estimated O
[ O
latin O
capital O
V O
with O
dot O
above O
] O
o2max B-outcome ['Physiological-Clinical']
( O
22.9 O
% O
) O
, O
and O
produced O
a O
trend O
toward O
reduced O
resting B-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
( O
-2.4 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/07/27 O
00:00 O
[accepted] O
[]

Treatment O
included O
weekly O
behavioral O
support O
for O
at O
least O
4 O
weeks. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O
[]

Hypothermia O
is O
a O
common O
problem O
for O
surgical O
patients O
and O
can O
result O
in O
many O
complications O
. O
[]

Cost-effectiveness O
data O
are O
similarly O
in O
accord O
with O
giving O
high O
priority O
to O
the O
treatment O
of O
older O
individuals O
with O
hypertension O
. O
['Resource-use']

Bronchial O
challenge O
with O
both O
agonists O
failed O
to O
alter O
significantly O
the O
airway B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
salbutamol O
, O
with O
the O
deltaFEV1 O
% O
init O
mean O
value O
( O
range O
) O
being O
16.9 O
% O
( O
9.0-31.9 O
) O
and O
17.5 O
% O
( O
11.6-31.2 O
) O
on O
the O
sham O
and O
histamine/methacholine O
challenge O
day O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
was O
designed O
to O
investigate O
the O
validity O
of O
the O
then O
current O
recommendations O
for O
initiation O
of O
therapy O
with O
enalapril O
in O
hypertensive O
patients O
on O
treatment O
with O
a O
diuretic O
. O
[]

BACKGROUND: O
Unhealthy O
foods O
are O
promoted O
heavily, O
through O
food O
company O
sponsorship O
of O
elite O
sport, O
resulting O
in O
extensive O
exposure O
among O
young O
adults O
who O
are O
avid O
sport O
spectators. O
[]

Only O
a O
minority O
of O
tocilizumab-treated O
patients O
with O
DAS28 O
remission O
also O
had O
disease O
remission O
according O
to O
the O
SDAI O
( O
26 O
% O
) O
or O
CDAI O
( O
?21 O
% O
) O
. O
[]

METHODS O
Of O
130 O
patients O
with O
locally O
advanced O
, O
unresectable O
, O
nonmetastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCC O
H O
& O
N O
) O
who O
entered O
a O
prospective O
, O
randomised O
trial O
, O
101 O
patients O
received O
50.6 O
Gy O
to O
a O
portion O
of O
their O
spinal O
cord O
and O
survived O
> O
1 O
year O
following O
the O
beginning O
of O
therapy O
. O
[]

RESULTS O
One O
hundred O
one O
patients O
( O
51 O
in O
enalapril O
group O
and O
50 O
in O
indapamide O
group O
) O
completed O
the O
study O
. O
[]

The O
biological O
factors O
in O
the O
etiopathogenesis O
and O
management O
of O
cervical O
spondylosis O
. O
[]

Results O
of O
a O
prospective O
, O
randomized O
study O
] O
. O
[]

At O
5 O
years O
, O
actuarial O
FFS B-outcome ['Mortality']
for O
patients O
treated O
with O
conventional O
chemotherapy O
was O
51 O
percent O
( O
95 O
percent O
CI O
: O
44-59 O
percent O
) O
compared O
to O
70 O
percent O
( O
95 O
percent O
CI O
: O
65-76 O
percent O
) O
in O
the O
intensive O
arm O
( O
p O
> O
0.01 O
) O
. O
['Mortality']

CONCLUSION O
VLASU O
can O
be O
used O
as O
a O
method O
of O
treatment O
of O
this O
disorder O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
also O
differently O
affected O
the O
power O
distribution O
< O
1 O
Hz O
in O
non-rapid B-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
movement B-outcome ['Physiological-Clinical']
sleep B-outcome ['Physiological-Clinical']
between O
caffeine O
sensitive O
and O
insensitive O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Conclusion: O
The O
results O
suggest O
that O
it O
is O
feasible O
to O
use O
the O
Borg O
rating O
of O
perceived B-outcome ['Physiological-Clinical', 'Life-Impact']
exertion I-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
to O
adjust O
FT O
intensity. O
[['Physiological-Clinical', 'Life-Impact']]

AIMS O
The O
study O
aimed O
to O
determine O
the O
extent O
to O
which O
parents O
and O
teachers O
, O
with O
guidance O
, O
can O
assist O
in O
the O
management O
of O
children O
with O
DCD O
; O
whether O
children O
with O
DCD O
are O
helped O
in O
this O
way O
and O
how O
this O
may O
contribute O
to O
our O
understanding O
of O
the O
condition O
. O
[]

Patients O
in O
the O
treatment O
group O
received O
an O
intravenous O
bolus O
injection O
of O
2.5 O
mg/kg O
of O
CsA O
immediately O
before O
TLT O
. O
[]

The O
mean O
value O
of O
dye B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
for O
AH O
plus O
was O
2.87 O
+/- O
0.43 O
mm O
, O
while O
that O
of O
EndoRez O
was O
4.54 O
+/- O
0.36 O
mm O
. O
['Physiological-Clinical']

Patients O
in O
both O
groups O
improved O
significantly O
after O
treatment O
in O
Barthel O
index O
(BI)], O
elbow B-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
(ROM) I-outcome ['Physiological-Clinical']
, O
and O
elbow B-outcome ['Life-Impact']
muscles I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
. O
However, O
muscle B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
elbow O
joint O
of O
the O
hemiplegic O
upper O
extremity O
improved O
significantly O
after O
SMV O
only O
in O
the O
experimental O
group O
(SPT-SMV). O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Cough B-outcome ['Physiological-Clinical']
was O
more O
often O
reported O
with O
lisinopril O
and O
headache B-outcome ['Physiological-Clinical']
, O
sweating B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Implementing O
a O
simplified O
neonatal O
resuscitation O
protocol-helping O
babies O
breathe O
at O
birth O
( O
HBB O
) O
- O
at O
a O
tertiary O
level O
hospital O
in O
Nepal O
for O
an O
increased O
perinatal B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality']

RESULTS O
There O
were O
no O
between O
group O
differences O
in O
mortality B-outcome ['Mortality']
( O
hazard O
ratio O
= O
1.41 O
, O
0.50 O
to O
3.97 O
; O
P O
= O
0.514 O
) O
or O
CHF B-outcome ['Resource-use']
hospitalizations I-outcome ['Resource-use']
( O
incidence O
rate O
ratio O
[ O
IRR O
] O
= O
1.74 O
95 O
% O
CI O
: O
0.85-3.60 O
P O
= O
0.131 O
) O
over O
the O
6 O
month O
follow-up O
period O
. O
['Mortality', 'Resource-use']

IFN-alpha-2b O
SC O
was O
begun O
on O
week O
4 O
and O
continued O
thrice O
weekly O
at O
5 O
MU/m2 O
for O
2 O
years O
. O
[]

RESULTS O
When O
judged O
on O
the O
last O
month O
of O
IP O
versus O
SC O
periods O
in O
the O
nine O
patients O
who O
completed O
the O
study O
, O
metabolic B-outcome ['Physiological-Clinical']
data O
showed O
better O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
( O
HbA1c O
: O
7.2 O
+/- O
0.2 O
IP O
vs. O
8.5 O
+/- O
0.7 O
% O
SC O
, O
mean O
+/- O
SE O
, O
P O
= O
0.02 O
) O
, O
reduced O
glycemic B-outcome ['Physiological-Clinical']
fluctuations I-outcome ['Physiological-Clinical']
( O
SD O
of O
capillary O
glucose O
values O
: O
3.4 O
+/- O
0.2 O
IP O
vs. O
4.6 O
+/- O
0.2 O
mM O
SC O
, O
P O
< O
0.01 O
) O
, O
and O
fewer O
mild B-outcome ['Physiological-Clinical']
hypoglycemic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
5.7 O
+/- O
2.0 O
IP O
vs. O
10.0 O
+/- O
3.1 O
events/month O
SC O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
best O
overall O
response O
( O
CCR O
+ O
PR O
) O
rate O
was O
71 O
% O
for O
PUVA O
alone O
and O
77 O
% O
for O
the O
combination O
arm O
( O
P O
= O
0?57 O
) O
. O
[]

METHODS O
Two O
randomized O
, O
double-blind O
, O
4-week O
, O
multi-centre O
trials O
with O
identical O
methodology O
compared O
once-daily O
esomeprazole O
, O
40 O
mg O
( O
n O
= O
241 O
) O
or O
20 O
mg O
( O
n O
= O
234 O
) O
, O
with O
placebo O
( O
n O
= O
242 O
) O
for O
the O
rigorous O
end-point O
of O
complete B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Neither O
the O
tolbutamide B-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( O
0.77 O
+/- O
0.28 O
l/h O
before O
and O
0.72 O
+/-0.24 O
l/h O
after O
, O
p O
> O
0.05 O
) O
nor O
the O
tolbutamide B-outcome ['Resource-use']
urinary B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
779 O
+/- O
294 O
before O
and O
681 O
+/- O
416 O
after O
, O
p O
> O
0.05 O
) O
indices O
of O
CYP2C9 O
were O
altered O
by O
clarithromycin O
administration O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

In O
patients O
with O
atrial O
fibrillation O
, O
it O
has O
shown O
excellent O
efficacy O
in O
some O
previous O
trials O
and O
minimal O
efficacy O
in O
others O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

These O
findings O
suggest O
that O
L-carnitine O
is O
of O
benefit O
in O
some O
patients O
with O
Rett O
syndrome O
. O
[]

Rioprostil O
, O
a O
new O
prostaglandin O
E1 O
analogue O
, O
in O
the O
once-daily O
treatment O
for O
the O
prevention O
of O
duodenal O
ulcer O
recurrence O
: O
a O
comparison O
with O
ranitidine O
. O
[]

Each O
operator O
performed O
stone O
extraction O
of O
2 O
, O
5 O
and O
8 O
mm O
calculi O
( O
size O
determined O
by O
digital O
caliper O
with O
3 O
repetitions O
of O
each O
basket O
. O
[]

Interactions O
between O
morphine O
and O
methotrimeprazine O
have O
been O
studied O
in O
mice O
and O
man O
with O
respect O
to O
analgesia B-outcome ['Resource-use']
or I-outcome ['Resource-use']
antinociceptive I-outcome ['Resource-use']
activity I-outcome ['Resource-use']
, O
respiratory B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Sera O
were O
collected O
at O
six O
weeks O
of O
age O
for O
the O
Hib O
groups O
and O
one O
month O
after O
the O
third O
dose O
for O
all O
subjects O
. O
[]

Effect O
of O
sensory O
stimulation O
( O
acupuncture O
) O
on O
sympathetic O
and O
parasympathetic O
activities O
in O
healthy O
subjects O
. O
[]

In O
the O
second O
study O
we O
used O
a O
naturalistic O
follow-up O
design O
. O
[]

RESULTS O
The O
average O
number O
of O
lesions B-outcome ['Physiological-Clinical']
in O
the O
diclofenac O
sodium O
group O
before O
and O
after O
treatment O
was O
13.6 O
and O
6.6 O
( O
p O
< O
0,001 O
) O
, O
respectively O
, O
while O
it O
was O
17.4 O
and O
3.15 O
( O
p O
< O
0.001 O
) O
in O
the O
5-Fluorouracil O
group O
. O
['Physiological-Clinical']

It O
is O
concluded O
that O
in O
clinical O
practice O
it O
will O
be O
very O
difficult O
to O
make O
a O
clear O
cut O
recommendation O
about O
treatment O
goal O
at O
initial O
assessment O
except O
in O
a O
few O
cases O
. O
[]

Unchanged B-outcome ['Physiological-Clinical']
rate, O
transfer B-outcome ['Physiological-Clinical']
rate O
of O
patients, O
rate O
of O
impaired B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
, O
turn B-outcome ['Physiological-Clinical']
normal I-outcome ['Physiological-Clinical']
rate O
and O
other O
biochemical O
indicators O
of O
patients O
and O
people O
with O
impaired O
glucose O
tolerance O
from O
control O
group O
and O
intervention O
group O
were O
analyzed, O
to O
evaluate O
the O
intervention O
effects O
of O
peer O
support O
education O
mode. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS O
After O
3 O
doses O
of O
the O
OPV O
( O
HDC O
) O
vaccine O
, O
the O
systemic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
were O
mild O
. O
['Physiological-Clinical']

Denopamine O
increased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
patients O
with O
atrial O
fibrillation O
but O
had O
little O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
patients O
with O
sinus O
rhythm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
6 O
episodes O
a O
second O
dose O
labetalol O
50 O
mg O
was O
given O
41 O
+/- O
9 O
min O
after O
the O
first O
injection O
. O
[]

METHODS O
Between O
October O
15 O
, O
1996 O
, O
and O
March O
24 O
, O
1999 O
, O
104 O
patients O
at O
13 O
centers O
were O
prospectively O
randomized O
to O
undergo O
embolization O
using O
an O
n-BCA/Tantalum O
Powder/Ethiodol O
mixture O
or O
Trufill O
PVA O
. O
[]

Procedure B-outcome ['Life-Impact']
and O
fluoroscopy B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
shorter O
in O
group O
B O
( O
108 O
? O
['Life-Impact']

For O
23 O
patients O
treated O
with O
gentamicin-cefoxitin O
( O
G-C O
) O
, O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
favorable O
in O
20/21 O
( O
95.2 O
% O
) O
evaluable O
cases O
, O
and O
elimination O
or O
marked O
reduction O
of O
33/34 O
( O
97.1 O
% O
) O
organisms O
was O
achieved O
. O
['Physiological-Clinical']

Placebo-controlled O
acute O
dosage O
naltrexone O
study O
in O
young O
autistic O
children O
. O
[]

Blood O
donation O
had O
to O
be O
cancelled O
if O
the O
haematocrit O
was O
below O
30 O
% O
. O
[]

We O
intend O
to O
build O
on O
our O
work O
by O
using O
the O
survey O
platform O
in O
other O
modalities O
while O
ensuring O
that O
the O
patient O
's O
preferences O
are O
considered O
at O
all O
times O
. O
[]

Journal O
ID: O
2985248R O
[]

The O
data O
showed O
that O
T1/2 B-outcome ['Physiological-Clinical']
increases O
with O
increasing O
Na O
intake O
and O
is O
, O
therefore O
, O
dose-dependent O
or O
zero O
order O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
overall O
remission B-outcome ['Physiological-Clinical']
rate O
between O
the O
2 O
groups O
(3.7% O
vs O
0%, O
P O
= O
.322). O
[['Physiological-Clinical']]

Given O
the O
lack O
of O
significant O
complications O
for O
the O
4-hour O
group O
and O
similar O
comfort B-outcome ['Life-Impact']
levels O
for O
both O
study O
groups O
, O
these O
findings O
suggest O
the O
feasibility O
of O
reducing O
the O
standard O
period O
of O
postcatheterization O
bed O
rest O
from O
6 O
hours O
to O
4 O
hours O
, O
thereby O
possibly O
lowering O
the O
cost B-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
outpatient I-outcome ['Resource-use']
procedure I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

[ O
Pilot O
results O
of O
using O
tamsulone-FS O
in O
patients O
with O
prostatic O
adenoma O
according O
to O
the O
results O
of O
a O
randomized O
multicenter O
comparative O
trial O
] O
. O
[]

BACKGROUND O
A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O
[]

alone O
and O
another O
10 O
( O
Group O
B O
) O
to O
low-dose O
dopamine O
and O
a O
similar O
diuretic O
regimen O
for O
a O
duration O
of O
5 O
days O
or O
less O
if O
clinical O
edema O
remitted O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
describe O
the O
trajectory O
of O
creatinine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
rise O
and O
its O
determinants O
after O
exposure O
to O
radiocontrast O
media O
. O
['Physiological-Clinical']

A O
multicenter O
, O
double-blind O
, O
between-patient O
trial O
comparing O
two O
doses O
of O
ketazolam O
( O
15 O
and O
30 O
mg O
) O
with O
placebo O
, O
each O
given O
once O
daily O
, O
in O
the O
evening O
, O
to O
92 O
outpatients O
affected O
by O
generalized O
anxiety O
disorders O
for O
at O
least O
1 O
month O
, O
was O
carried O
out O
. O
[]

Analyses O
were O
conducted O
on O
a O
final O
sample O
of O
67 O
children O
( O
lost O
to O
follow-up O
= O
8 O
) O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
Active O
controlled O
, O
double-blind O
, O
randomized O
, O
parallel O
group O
, O
multi-center O
clinical O
trial O
in O
ear O
, O
nose O
, O
and O
throat O
( O
ENT O
) O
specialist O
practices O
with O
a O
planned O
interim O
analysis O
for O
sample O
size O
adaptation O
. O
[]

Intraoperative O
conditions O
were O
comparable O
in O
both O
groups O
. O
[]

In O
school-aged O
children O
a O
combination O
of O
galacto-oligosaccharides O
and O
Lactobacillus O
GG O
increases O
bifidobacteria O
more O
than O
Lactobacillus O
GG O
on O
its O
own O
. O
[]

Enteric O
alendronate O
has O
a O
similar O
action O
to O
the O
conventional O
tablets O
on O
biochemical B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Following O
treatment O
withdrawal O
, O
the O
differences O
in O
BMD O
observed O
between O
the O
two O
endocrine O
strategies O
were O
partially O
reversed O
. O
[]

In O
the O
prosthetic O
bypass O
group O
, O
there O
was O
no O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
8-mm O
bypass O
subgroup O
, O
but O
there O
was O
a O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
6-mm O
bypass O
subgroup O
( O
femoral-popliteal O
; O
71.4 O
% O
in O
the O
WASA O
group O
versus O
57.9 O
% O
in O
the O
ASA O
group O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mothers O
' O
attachment O
to O
their O
infants O
was O
measured O
at O
6-8 O
weeks O
postpartum O
using O
the O
Maternal B-outcome ['Life-Impact']
Postnatal I-outcome ['Life-Impact']
Attachment I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

Age O
, O
sex O
, O
body O
mass O
index O
( O
BMI O
) O
, O
previous O
surgery O
and O
associated O
diseases O
were O
similar O
between O
the O
two O
groups O
. O
[]

CONCLUSION O
Fish O
oil O
improves O
BP B-outcome ['Physiological-Clinical']
in O
normotensive O
and O
normolipidemic O
slightly O
overweight O
adolescent O
boys O
. O
['Physiological-Clinical']

The O
primary O
parameter O
was O
the O
diagnostic B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of O
the O
6 O
min O
film O
, O
assessed O
in O
a O
blinded O
fashion O
, O
by O
consensus O
, O
by O
four O
radiologists O
. O
['Life-Impact']

METHODS O
Patients O
were O
treated O
with O
weekly O
bolus O
5-fluorouracil O
( O
5-FU O
) O
and O
leucovorin O
( O
FL O
; O
Roswell O
Park O
Regimen O
) O
or O
the O
same O
regimen O
plus O
oxaliplatin O
( O
FLOX O
) O
. O
[]

Randomized O
, O
placebo-controlled O
, O
phase O
III O
trial O
of O
sunitinib O
plus O
prednisone O
versus O
prednisone O
alone O
in O
progressive O
, O
metastatic O
, O
castration-resistant O
prostate O
cancer O
. O
[]

Time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
recurrence I-outcome ['Life-Impact']
of O
any O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
was O
significantly O
longer O
with O
paliperidone O
ER O
than O
placebo O
( O
p=0.017 O
; O
based O
on O
weighted O
Z-test O
at O
0.0198 O
significance O
level O
; O
hazard O
ratio O
[ O
placebo O
: O
paliperidone O
ER O
; O
unweighted O
95 O
% O
confidence O
interval O
] O
: O
1.43 O
[ O
1.03 O
; O
1.98 O
] O
) O
; O
the O
difference O
was O
significant O
for O
preventing O
['Life-Impact', 'Life-Impact']

Primary O
outcome O
data O
were O
available O
for O
249 O
(54.4%) O
intervention O
and O
236 O
(59.6%) O
control O
participants. O
[]

For O
all O
other O
pain O
outcomes O
and O
length O
of O
treatment O
, O
there O
was O
a O
trend O
for O
lower O
pain B-outcome ['Physiological-Clinical']
scores O
and O
treatment O
['Physiological-Clinical']

Glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
110 O
+/- O
11 O
before O
and O
106 O
+/- O
13 O
ml/min/1.73 O
m2 O
after O
clonidine O
injection O
. O
['Physiological-Clinical']

Our O
study O
was O
designed O
to O
explore O
this O
issue O
. O
[]

Fifty-one O
procedures O
were O
performed O
using O
BP O
and O
44 O
using O
Dacron O
. O
[]

Risperidone O
treatment O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
significantly O
improved O
behavioral B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
associated O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

These O
findings O
replicate O
the O
results O
from O
previous O
studies O
, O
indicating O
that O
RIT O
is O
effective O
for O
teaching O
imitation B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
to O
young O
children O
with O
autism O
in O
a O
naturalistic O
setting O
and O
extend O
the O
findings O
to O
parents O
. O
['Life-Impact']

The O
blood O
samples O
were O
collected O
for O
e O
same O
measurements O
of O
interleukin-8 O
( O
IL-8 O
) O
and O
tumor O
necrosis O
factor O
( O
TNF-? O
) O
by O
enzyme O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
and O
for O
the O
C-reactive O
protein O
( O
CRP O
) O
, O
lactic O
acid O
dehydrogenase O
( O
LDH O
) O
, O
white O
blood O
cell O
( O
WBC O
) O
count O
, O
amylase O
and O
lipase O
by O
biochemistry O
assay O
1 O
day O
before O
intervention O
of O
nutrition O
, O
and O
7 O
days O
and O
14 O
days O
after O
intervention O
. O
[]

The O
results O
of O
this O
study O
suggest O
that O
indomethacin O
phonophoresis O
provides O
significant O
pain B-outcome ['Physiological-Clinical']
relieving O
effect O
over O
the O
TMJ O
pain O
. O
['Physiological-Clinical']

After O
a O
median O
follow-up O
of O
24 O
months O
, O
the O
median O
DFS B-outcome ['Physiological-Clinical']
and O
OS B-outcome ['Physiological-Clinical']
were O
not O
reached O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Endogenous O
insulin O
secretion O
was O
assessed O
by O
measuring O
serum O
insulin O
and O
C-peptide O
before O
and O
6 O
min O
after O
iv O
administration O
of O
glucagon O
; O
insulin O
sensitivity O
was O
determined O
by O
measuring O
insulin O
binding O
to O
erythrocytes O
, O
and O
as O
the O
glucose O
disappearance O
rate O
( O
KITT O
) O
after O
i.v O
. O
[]

Accuracy O
of O
noninvasive O
haemoglobin B-outcome ['Physiological-Clinical']
measurement O
by O
pulse O
oximetry O
depends O
on O
the O
type O
of O
infusion O
fluid O
. O
['Physiological-Clinical']

The O
efficacy O
was O
assessed O
by O
serial O
Holter B-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SETTING O
University O
teaching O
hospital O
. O
[]

Publication O
date: O
2019/01/09 O
06:00 O
[medline] O
[]

Journal O
ID: O
9435674 O
[]

We O
here O
report O
on O
the O
1-year O
results O
of O
a O
prospective O
randomized O
single-center O
study O
in O
patients O
with O
symptomatic O
main-stem O
and O
main-stem-equivalent O
lesions O
with O
substantially O
increased O
risk O
for O
bypass O
surgery O
. O
[]

CONCLUSION O
CRC B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
rates O
increased O
significantly O
among O
patients O
who O
were O
overdue O
for O
screening O
after O
they O
received O
mailed O
educational O
materials O
and O
a O
FIT O
. O
['Resource-use']

Improvements O
were O
unrelated O
to O
changes O
in O
the O
physiological O
parameters O
measured O
. O
[]

CONCLUSIONS O
Physicians O
possessed O
explicit O
and O
implicit O
racial O
biases O
, O
but O
those O
biases O
did O
not O
predict O
treatment O
recommendations O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
Twenty O
type O
2 O
diabetic O
subjects O
participated O
in O
a O
crossover O
trial O
. O
[]

Participants O
made O
a O
significantly O
faster O
decision B-outcome ['Life-Impact']
about O
the O
target O
word O
( O
e.g O
. O
['Life-Impact']

The O
incidence O
of O
adverse O
events O
was O
similar O
in O
both O
groups O
. O
[]

Five O
of O
15 O
prazosin-treated O
patients O
and O
six O
of O
16 O
captopril-treated O
patients O
required O
the O
addition O
of O
thiazide O
to O
achieve O
[]

BACKGROUND O
Neurobiological O
research O
has O
implicated O
the O
dopamine O
and O
serotonin O
systems O
in O
the O
pathogenesis O
of O
autism O
. O
[]

GNCC B-outcome ['Physiological-Clinical']
was O
inversely O
associated O
with O
serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
( O
global O
P O
= O
0.024 O
) O
, O
serum B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
( O
global O
P O
= O
0.060 O
) O
and O
, O
possibly O
, O
transferrin B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
changes O
in O
respiratory O
impedance O
were O
qualitatively O
similar O
for O
all O
three O
drug O
regimens O
, O
but O
larger O
in O
absolute O
terms O
after O
fenoterol O
and O
the O
combination O
regimen O
than O
after O
ipratropium O
. O
[]

PATIENTS O
AND O
METHODS O
Mucociliary O
clearance O
time O
was O
measured O
using O
the O
saccharine O
clearance O
test O
on O
132 O
adults O
before O
and O
after O
10 O
days O
' O
application O
of O
intranasal O
isotonic O
or O
hypertonic O
saline O
. O
[]

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
phase O
III O
study O
evaluated O
efficacy O
and O
safety O
of O
pazopanib O
monotherapy O
in O
treatment-naive O
and O
cytokine-pretreated O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O
[]

vs. O
5 O
% O
for O
b.i.d O
. O
) O
, O
[]

This O
study O
sought O
to O
test O
the O
clinical B-outcome ['Physiological-Clinical']
effectiveness O
of O
PD O
pharmacotherapy O
embedded O
in O
a O
disease O
management O
framework O
of O
collaborative O
care O
( O
CC O
) O
. O
['Physiological-Clinical']

Group O
1 O
( O
15 O
patients O
) O
received O
radiation O
therapy O
totaling O
4000 O
to O
4500 O
rads O
in O
4 O
to O
5 O
weeks O
. O
[]

Primary O
capsulectomy O
, O
anterior O
vitrectomy O
, O
lensectomy O
, O
and O
posterior O
chamber O
lens O
implantation O
in O
children O
: O
limbal O
versus O
pars O
plana O
. O
[]

Visual O
Analogue O
Scale O
and O
Real O
Life O
Rating O
Scale O
were O
used O
to O
register O
changes O
in O
behaviour O
. O
[]

Age O
was O
negatively O
associated O
with O
enrollment O
. O
[]

RESULTS O
From O
pre- O
to O
post-treatment O
, O
all O
children O
had O
less O
parent O
reported O
negativity/lability B-outcome ['Life-Impact']
, O
better O
parent O
reported O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
, O
and O
shorter O
outbursts B-outcome ['Life-Impact']
, O
and O
also O
generated B-outcome ['Life-Impact']
more I-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
in O
response O
to O
vignettes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
adequate O
responses O
to O
treatment B-outcome ['Resource-use']
were O
similar O
for O
the O
two O
treatment O
regimens O
on O
D14 O
, O
PCR-corrected O
( O
99,4 O
% O
in O
the O
one-daily O
intake O
group O
versus O
99,3 O
% O
in O
the O
comparative O
group O
) O
. O
['Resource-use']

CONCLUSION O
We O
find O
the O
analgesic B-outcome ['Resource-use']
efficacy O
of O
diclofenac O
suppository O
combined O
with O
local O
anesthetic O
infiltration O
at O
port O
sites O
comparable O
to O
caudal O
block O
. O
['Resource-use']

METHODS O
Totally O
180 O
patients O
with O
NPC O
were O
divided O
equally O
into O
3 O
groups O
with O
the O
same O
radiotherapeutic O
protocols O
. O
[]

We O
explored O
the O
hypothesis O
that O
RAS O
activation O
by O
diuretic O
therapy O
might O
therefore O
worsen O
hypoxic O
pulmonary O
vasoconstriction O
via O
the O
effects O
of O
ANG O
II O
on O
the O
pulmonary O
vascular O
bed O
. O
[]

CONTEXT: O
Deviations O
in O
scapular O
motions O
and O
subsequent O
alterations O
in O
associated O
soft O
tissues O
are O
thought O
to O
contribute O
to O
overuse O
shoulder O
injuries O
in O
overhead O
athletes. O
[]

Both O
preparations O
produced O
mean O
serum B-outcome ['Physiological-Clinical']
theophylline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
within O
the O
10 O
-- O
20 O
mcg/ml O
range O
, O
the O
sustained-release O
tablet O
giving O
higher O
monitoring O
through O
values O
and O
smaller O
through O
to O
peak O
variation O
. O
['Physiological-Clinical']

Statistically O
significant O
differences O
in O
cumulative O
QALYs O
and O
costs B-outcome ['Resource-use']
were O
found O
at O
six O
and O
12 O
months O
for O
the O
decompression O
versus O
no O
treatment O
comparison O
only. O
[['Resource-use']]

In O
40 O
patients O
( O
56 O
% O
) O
, O
the O
perioperative O
myocardial O
infarction O
was O
the O
first O
manifestation O
of O
coronary O
artery O
disease O
. O
[]

Recent O
animal O
models O
suggest O
that O
enteral O
feeding O
( O
TEN O
) O
compared O
to O
parenteral O
nutrition O
( O
TPN O
) O
improves O
resistance O
to O
infection O
. O
[]

Whether O
heparin O
modulates O
bronchial O
hyperreactivity O
induced O
by O
adenosine O
, O
is O
not O
well O
known O
. O
[]

The O
addition O
of O
labetalol O
did O
not O
confer O
additional O
benefit O
or O
risk O
to O
the O
patients O
. O
( O
[]

Computer-delivered O
tailored O
intervention O
improves O
colon B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
and O
health O
beliefs O
of O
African-Americans O
. O
['Life-Impact']

Direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
, O
including O
['Resource-use']

Forty O
times O
less O
erythema B-outcome ['Physiological-Clinical']
and O
15 O
times O
less O
induration B-outcome ['Physiological-Clinical']
were O
found O
with O
polymerized O
ragweed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
short-term O
efficacy O
and O
safety O
of O
methylphenidate O
( O
MPH O
) O
to O
treat O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
symptoms O
in O
an O
understudied O
population O
of O
preschoolers O
with O
pervasive O
developmental O
disorder O
( O
PDD O
) O
or O
intellectual O
disability O
( O
ID O
) O
. O
[]

Fifty-three O
percent O
of O
the O
patients O
had O
a O
neutropenia B-outcome ['Physiological-Clinical']
less O
than O
0.500 O
x O
10 O
( O
9 O
) O
/L O
, O
58 O
% O
fever O
( O
6 O
% O
grade O
4 O
) O
, O
and O
49 O
% O
a O
documented B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
8 O
% O
grade O
4 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
data O
demonstrate O
for O
the O
first O
time O
in O
humans O
that O
the O
imaging O
of O
central O
5-HT4R O
binding O
may O
be O
used O
as O
an O
in O
vivo O
biomarker O
of O
the O
central O
5-HT O
tonus O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
on O
the O
above O
3 O
dosages O
, O
and O
no O
difference O
in O
the O
duration O
of O
infection-free B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
4 O
weeks O
, O
98 O
% O
or O
more O
of O
the O
subjects O
in O
group O
1 O
had O
circulating B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
and O
D O
['Physiological-Clinical']

Both O
placebo O
and O
treatment O
groups O
were O
balanced O
at O
baseline O
study O
in O
terms O
of O
functional O
class O
, O
ventricular O
performance O
and O
autonomic O
tone O
. O
[]

The O
first O
contribution O
is O
a O
new O
red O
lesion O
candidate O
detection O
system O
based O
on O
pixel O
classification O
. O
[]

The O
KT O
group O
demonstrated O
26.87%MVIC O
(95% O
CI O
= O
26.87, O
7.11) O
higher O
gastrocnemius O
medialis O
muscle O
peak O
activation O
during O
mid O
stance O
phase O
at O
post-test O
when O
compared O
with O
the O
control O
group. O
[]

Journal O
ID: O
101521595 O
[]

Coronary O
sinus O
release O
of O
creatinine B-outcome ['Physiological-Clinical']
phosphokinase-MB I-outcome ['Physiological-Clinical']
5 O
minutes O
after O
reperfusion O
was O
significantly O
less O
in O
group O
II O
( O
1.65 O
EU/min O
) O
than O
in O
group O
I O
( O
3.83 O
units/min O
; O
p O
= O
0.05 O
) O
. O
['Physiological-Clinical']

As O
predicted O
, O
reappraisal O
strategies O
more O
effectively O
attenuated O
children B-outcome ['Physiological-Clinical']
's O
self-reported O
emotional B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
The O
late O
hemodynamic O
effects O
of O
preserving O
the O
papillary O
muscles O
during O
mitral O
valve O
replacement O
have O
not O
been O
evaluated O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
the O
percentage O
of O
patients O
with O
steroid B-outcome ['Physiological-Clinical']
sparing I-outcome ['Physiological-Clinical']
, O
defined O
as O
discontinuation O
of O
steroid O
therapy O
without O
a O
disease O
flare O
( O
Crohn O
's O
Disease O
Activity O
Index O
score O
> O
or O
=220 O
points O
) O
at O
week O
36 O
. O
['Physiological-Clinical']

Only O
a O
formal O
trial O
of O
fever B-outcome ['Physiological-Clinical']
treatment O
or O
prevention O
can O
address O
this O
issue O
. O
['Physiological-Clinical']

Parents O
were O
trained O
in O
monitoring O
untoward O
effects O
. O
[]

CONCLUSIONS: O
Inhalation O
aromatherapy O
using O
lavender O
essential O
oil O
can O
improve O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
postmenopausal O
women O
with O
a O
reduction O
in O
the O
severity O
of O
complications B-outcome ['Adverse-effects']
and O
physical-psychological B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
. O
[['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical', 'Life-Impact']]

The O
objective O
was O
to O
assess O
clinical O
efficacy O
of O
3 O
dosages O
of O
intravenous O
gammaglobulins O
to O
prevent O
infectious O
episodes O
in O
adult O
common O
variable O
immunodeficiency O
. O
[]

It O
was O
therefore O
hypothesized O
that O
cognitive O
therapy O
not O
only O
reduces O
panic O
but O
also O
agoraphobia O
and O
that O
it O
potentiates O
the O
effects O
of O
exposure O
in O
vivo O
. O
[]

In O
many O
previous O
studies O
NTG O
has O
been O
found O
to O
be O
effective O
in O
controlling O
hypertension B-outcome ['Physiological-Clinical']
; O
ISDN O
offers O
and O
alternative O
approach O
in O
reducing O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
clinical O
research O
, O
sensory O
impairment O
is O
considered O
one O
of O
the O
core O
deficits O
in O
autism O
and O
is O
associated O
with O
impaired O
socialization O
, O
behavioral O
disturbances O
and O
bowel O
and O
sleep O
problems O
. O
[]

BACKGROUND O
Recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
is O
associated O
with O
poor O
survival O
. O
[]

Participants O
reported O
an O
average O
of O
12.0 O
drinking B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
at O
baseline O
and O
8.3 O
at O
6 O
months O
. O
['Life-Impact']

The O
effects O
of O
torasemide O
( O
20 O
mg/day O
) O
and O
furosemide O
( O
50 O
mg/day O
) O
, O
each O
given O
over O
4 O
days O
, O
were O
compared O
in O
a O
randomized O
and O
crossover O
study O
carried O
out O
in O
seven O
patients O
with O
cirrhosis O
and O
tense O
ascites O
. O
[]

Title: O
[Randomized O
controlled O
trial O
of O
comparison O
between O
the O
SuperPATH O
and O
posterolateral O
approaches O
in O
total O
hip O
arthroplasty]. O
[]

The O
follow-up O
was O
conducted O
during O
the O
first O
five O
weeks O
of O
life O
and O
the O
evaluation O
was O
carried O
at O
two O
different O
times. O
[]

Doses O
of O
20 O
mg O
, O
and O
in O
some O
cases O
30 O
mg O
, O
per O
day O
were O
compared O
with O
placebo O
over O
predetermined O
ten-day O
periods O
in O
a O
double-blind O
cross-over O
study O
. O
[]

Longitudinal O
quality O
of O
life O
study O
in O
patients O
with O
metastatic O
gastric O
cancer O
. O
[]

A O
total O
of O
63 O
patients O
with O
mild O
or O
mild O
to O
moderate O
ED O
were O
randomized O
to O
receive O
Cappra O
( O
? O
) O
[]

Therefore O
we O
evaluated O
the O
profile O
of O
AP-1 O
activation O
through O
histological O
analysis O
and O
tested O
the O
potential O
benefit O
of O
AP-1 O
inhibition O
in O
a O
clinical O
trial O
. O
[]

The O
median O
follow-up O
duration O
is O
26 O
months O
. O
[]

However O
, O
this O
difference O
was O
not O
statistically O
significant O
( O
p=0.78 O
) O
. O
[]

The O
recent O
availability O
of O
World O
Wide O
Web-based O
directories O
has O
opened O
up O
a O
new O
approach O
for O
tracing O
subjects O
in O
epidemiologic O
studies O
. O
[]

In O
the O
other O
group, O
each O
had O
a O
different O
color. O
[]

[ O
Using O
gaviscon O
preparation O
for O
relief O
of O
esophageal O
, O
extraesophageal O
syndromes O
and O
functional O
dyspepsia O
in O
elderly O
patients O
with O
GERD O
] O
. O
[]

METHODS: O
A O
total O
of O
320 O
treatment-naive O
HBeAg-positive O
CHB O
patients O
who O
received O
randomly O
a O
single O
regimen O
of O
either O
entecavir O
capsule O
(ETV) O
(n O
= O
160) O
or O
tenofovir O
disoproxil O
fumarate O
capsule O
(TDF) O
(n O
= O
160) O
for O
144 O
weeks O
were O
consecutively O
enrolled O
from O
14 O
tertiary O
hospitals O
or O
university O
hospitals O
in O
China O
between O
January O
2012 O
and O
December O
2014. O
[]

All O
hearts B-outcome ['Physiological-Clinical']
functioned I-outcome ['Physiological-Clinical']
adequately O
in O
both O
groups O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
receive O
oral O
treatment O
with O
amlodipine O
camsylate O
or O
amlodipine O
besylate O
. O
[]

There O
was O
less O
intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
a O
lower O
rate O
of O
wound B-outcome ['Physiological-Clinical']
complications B-outcome ['Resource-use']
in O
the O
patients O
treated O
by O
the O
Gamma O
nail O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Across O
all O
measures O
of O
work O
functioning O
and O
productivity O
at O
each O
visit O
, O
patients O
randomized O
to O
pegIFNalpha O
2a O
treatment O
showed O
less O
impairment O
relative O
to O
the O
group O
treated O
with O
IFNalpha O
2b/RBV O
. O
[]

Patients O
received O
eight O
courses O
of O
one O
of O
the O
two O
regimens O
after O
stratification O
according O
to O
the O
stage O
. O
[]

Both O
etoricoxib O
and O
ibuprofen O
demonstrated O
superior O
( O
P O
< O
or O
=0.002 O
) O
efficacy O
for O
all O
primary O
endpoints O
. O
[]

at O
the O
time O
of O
skin O
closure O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
22.8 O
and O
8.5 O
months O
after O
initiation O
of O
second-line O
treatment O
for O
the O
platinum-containing O
and O
platinum-free O
regimens O
, O
respectively O
. O
['Mortality']

Data O
were O
obtained O
at O
age O
0-3 O
days O
( O
n O
= O
43 O
) O
or O
, O
when O
clinically O
stable O
, O
age O
3-5 O
days O
( O
n O
= O
49 O
) O
. O
[]

The O
availability O
of O
hematopoietic O
growth O
factors O
has O
greatly O
facilitated O
the O
mobilization O
and O
collection O
of O
peripheral O
blood O
stem O
cells O
( O
PBSC O
) O
. O
[]

In O
the O
R O
group O
, O
patients O
were O
given O
no O
such O
education O
or O
emphasis O
. O
[]

An O
occupation O
based O
physical O
activity O
intervention O
program O
: O
improving O
fitness B-outcome ['Life-Impact']
and O
decreasing O
obesity B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

The O
primary O
end-point O
was O
an O
increase O
in O
pain-free B-outcome ['Physiological-Clinical']
walking I-outcome ['Physiological-Clinical']
distance I-outcome ['Physiological-Clinical']
[ O
initial O
claudication B-outcome ['Physiological-Clinical']
distance O
( O
ICD O
) O
] O
during O
the O
24 O
weeks O
of O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
groups O
showed O
improvements O
in O
the O
FSFI O
desire B-outcome ['Life-Impact']
score O
, O
but O
with O
statistical O
significance O
only O
for O
EE20/LNG100 O
group O
. O
['Life-Impact']

The O
INR B-outcome ['Physiological-Clinical']
results O
were O
not O
influenced O
by O
whether O
patients O
were O
maintained O
on O
Coumadin O
only O
( O
control O
group O
) O
or O
interchanged O
between O
Coumadin O
and O
generic O
warfarin O
( O
p O
= O
0.98 O
) O
. O
['Physiological-Clinical']

EVR O
and O
SVR B-outcome ['Physiological-Clinical']
rates O
were O
lower O
in O
patients O
assigned O
to O
ribavirin O
800 O
than O
1000/1200 O
mg/day O
( O
EVR O
, O
75 O
% O
vs. O
84 O
% O
, O
respectively O
, O
P O
< O
0.001 O
; O
SVR O
, O
45 O
% O
vs. O
54 O
% O
, O
respectively O
, O
P O
= O
0.011 O
) O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
We O
performed O
the O
following O
studies O
: O
( O
1 O
) O
a O
cross-sectional O
comparison O
of O
smokers O
and O
control O
subjects O
, O
( O
2 O
) O
an O
examination O
of O
the O
dose-response O
relationship O
, O
( O
3 O
) O
an O
exploration O
of O
the O
effect O
of O
smoking O
cessation O
( O
3 O
weeks O
) O
and O
nicotine O
patch O
supplementation O
, O
( O
4 O
) O
the O
effect O
of O
aspirin O
consumption O
, O
and O
( O
5 O
) O
the O
effects O
of O
5 O
days O
' O
dosing O
with O
vitamin O
E O
( O
100 O
and O
800 O
U O
) O
, O
vitamin O
C O
( O
2 O
g O
) O
, O
and O
their O
combination O
. O
[]

The O
global O
efficacy O
evaluation O
, O
rated O
by O
the O
investigators O
, O
was O
significantly O
more O
favorable O
to O
CM O
for O
both O
attacks O
( O
p O
= O
0.001 O
for O
the O
first O
attack O
and O
p O
= O
0.02 O
for O
the O
second O
) O
. O
[]

OBJECTIVE O
To O
compare O
18-month O
outcomes O
of O
N-terminal O
BNP-guided O
vs O
symptom-guided O
heart O
failure O
therapy O
. O
[]

RESULTS O
Nasal O
allergen O
challenge O
led O
to O
an O
increase O
in O
sputum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
( O
pre O
= O
60 O
+/- O
12 O
, O
post O
= O
212 O
+/- O
63 O
micro O
g/L O
, O
P O
= O
0.02 O
vs. O
placebo O
) O
, O
and O
sICAM B-outcome ['Physiological-Clinical']
( O
4.8 O
+/- O
2.7 O
to O
6.5 O
+/- O
2.9 O
ng/mL O
, O
P O
= O
0.02 O
vs. O
placebo O
) O
, O
whereas O
IL-10 B-outcome ['Physiological-Clinical']
decreased O
after O
provocation O
( O
44 O
+/- O
11 O
to O
29 O
+/- O
6 O
pg/mL O
, O
P O
= O
0.06 O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Factors O
significantly O
associated O
with O
late O
attendance O
for O
the O
first O
test O
were O
the O
same O
as O
for O
non-attendance O
, O
plus O
current O
smoking O
and O
having O
children O
. O
[]

Spot O
urine O
samples O
were O
collected O
preoperatively O
, O
postoperatively O
, O
after O
3 O
months O
, O
and O
after O
1 O
, O
2 O
, O
and O
5 O
years O
and O
tested O
with O
inductively O
coupled O
plasma-sector O
field O
mass O
spectrometry O
. O
[]

Although O
statistical O
analysis O
was O
not O
conducted O
because O
of O
the O
small O
number O
of O
subjects O
, O
all O
subjects O
receiving O
repeated O
oral O
administration O
of O
300 O
mg O
twice O
daily O
showed O
a O
25 O
% O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
on O
day O
7 O
, O
but O
also O
the O
simultaneous O
occurrence O
of O
diarrhoea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
Genital O
arousal O
was O
assessed O
as O
vaginal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
amplitude O
( O
VPA O
) O
using O
vaginal B-outcome ['Physiological-Clinical']
photoplethysmography I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
investigated O
whether O
or O
not O
children O
with O
autism O
or O
a O
related O
pervasive O
developmental O
disorder O
( O
PDD O
) O
can O
benefit O
from O
regular O
opportunities O
to O
interact O
with O
a O
normally O
developing O
peer O
, O
matched O
as O
to O
sex O
and O
age O
. O
[]

However O
, O
cross-sectional O
observations O
at O
7 O
years O
showed O
negative O
correlations O
between O
all O
OPs B-outcome ['Physiological-Clinical']
and O
age O
( O
p O
< O
0.0001-0.003 O
) O
, O
and O
between O
OP-3 B-outcome ['Physiological-Clinical']
and O
duration O
( O
p O
= O
0.003 O
) O
and O
counts O
of O
microaneurysms B-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pre-transplant O
pharmacokinetic O
profiling O
and O
tacrolimus B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
post-transplant I-outcome ['Resource-use']
. O
['Resource-use']

The O
pharmacodynamic B-outcome ['Physiological-Clinical']
effects O
and O
acceptability B-outcome ['Life-Impact']
of O
perindopril O
( O
4 O
mg O
daily O
) O
and O
hydrochlorothiazide O
( O
25 O
mg O
daily O
) O
given O
alone O
or O
in O
combination O
for O
1 O
month O
were O
investigated O
in O
a O
double-blind O
, O
placebo O
controlled O
, O
parallel O
group O
study O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
In O
placebo O
treated O
men O
without O
prostate O
cancer O
there O
was O
an O
8.3 O
% O
median O
increase O
in O
PSA O
at O
month B-outcome ['Physiological-Clinical']
24 I-outcome ['Physiological-Clinical']
compared O
with O
-59.5 O
% O
in O
those O
who O
received O
dutasteride O
, O
using O
doubled O
values O
to O
correct O
for O
dutasteride O
treatment O
. O
['Physiological-Clinical']

if O
the O
pre-transplant O
C O
( O
2 O
) O
level O
was O
?20 O
ng/mL O
, O
0.1 O
mg/kg O
b.d O
. O
[]

At O
review O
2-7 O
years O
after O
the O
accidents O
, O
the O
two O
groups O
were O
compared O
with O
reference O
to O
symptoms B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
range O
of O
motion B-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
wrist I-outcome ['Physiological-Clinical']
, O
power O
of O
first B-outcome ['Physiological-Clinical']
closure I-outcome ['Physiological-Clinical']
and O
radiographic B-outcome ['Physiological-Clinical']
appearance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
appearance O
during O
treatment O
of O
febrile B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
( O
RR O
11.5 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
RR O
2.5 O
) O
, O
bullous B-outcome ['Physiological-Clinical']
eruptions I-outcome ['Physiological-Clinical']
( O
RR O
4.5 O
) O
and O
systolic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
( O
RR O
2.6 O
) O
were O
associated O
with O
an O
increased O
risk O
for O
the O
occurrence O
of O
encephalopathic O
syndromes O
especially O
of O
the O
coma O
type O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Outcome O
measures O
will O
be O
assessed O
before O
and O
after O
the O
6 O
month O
intervention O
period O
. O
[]

The O
purpose O
of O
this O
report O
is O
to O
describe O
in O
greater O
detail O
the O
heterogeneity O
of O
this O
population O
at O
baseline O
with O
particular O
reference O
to O
the O
impact O
of O
symptomatic O
severity O
, O
age O
and O
gender O
on O
patient O
characteristics O
. O
[]

In O
groups O
of O
tuberculin O
skin O
test-positive O
and O
negative O
persons O
, O
the O
risk O
ratio O
of O
tuberculosis O
was O
0.40 O
( O
95 O
% O
CI O
, O
0.24-0.65 O
) O
and O
0.84 O
( O
95 O
% O
CI O
, O
0.54-1.30 O
) O
, O
respectively O
, O
and O
the O
difference O
in O
the O
effectiveness O
of O
isoniazid O
versus O
placebo O
between O
these O
groups O
was O
statistically O
significant O
( O
P O
= O
0.03 O
, O
for O
the O
difference O
of O
summary O
estimates O
) O
. O
[]

From O
the O
ICT O
group O
, O
8 O
( O
53 O
% O
) O
patients O
had O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
6 O
( O
40 O
% O
) O
had O
a O
prolonged O
air B-outcome ['Physiological-Clinical']
leak I-outcome ['Physiological-Clinical']
, O
while O
none O
of O
the O
patients O
of O
the O
VATS O
group O
had O
any O
complication B-outcome ['Adverse-effects']
( O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

The O
population-based O
program O
provides O
primarily O
telephonic O
patient O
education O
and O
monitoring O
services O
. O
[]

Baseline O
measurements O
and O
follow O
up O
measures O
( O
3 O
, O
6 O
, O
9 O
and O
12 O
months O
) O
are O
assessed O
using O
questionnaires O
and O
an O
interview O
. O
[]

This O
trial O
is O
registered O
with O
the O
International O
Standard O
Randomised O
Controlled O
Number O
26727615 O
with O
the O
name O
ALL97 O
. O
[]

Assessments O
were O
conducted O
pre-intervention O
, O
immediately O
post-intervention O
, O
and O
, O
to O
assess O
maintenance O
, O
at O
six-month O
follow-up O
. O
[]

Artificial O
tears O
combined O
with O
CC O
reduced O
hyperemia B-outcome ['Physiological-Clinical']
more O
than O
other O
treatments O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Results O
of O
the O
study O
showed O
that O
dexmedetomidine O
is O
more O
effective O
and O
safer O
than O
trimeperidine O
for O
analgesia B-outcome ['Resource-use']
and O
sedation B-outcome ['Physiological-Clinical']
in O
patients O
with O
spontaneous O
breathing O
after O
abdominal O
surgery O
. O
['Resource-use', 'Physiological-Clinical']

On O
serial O
evaluation O
, O
spotty O
calcification O
was O
associated O
with O
greater O
progression O
of O
PAV O
( O
+0.43 O
? O
[]

Depression B-outcome ['Life-Impact']
, O
functioning B-outcome ['Life-Impact']
, O
perceived B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
utilization B-outcome ['Life-Impact']
, O
and O
costs B-outcome ['Resource-use']
were O
secondary O
outcomes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Resource-use']

General B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
systematically O
dropped O
to O
a O
lower O
level O
in O
both O
groups O
, O
but O
participants O
from O
the O
health-promotion O
group O
reported O
fewer B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
Atrial O
fibrillation O
( O
AF O
) O
is O
a O
common O
arrhythmia O
frequently O
associated O
with O
hypertension O
. O
[]

The O
study O
involved O
51 O
subjects O
, O
of O
whom O
20 O
( O
39 O
% O
) O
had O
made O
a O
suicide O
attempt O
in O
the O
current O
depressive O
episode O
, O
31 O
( O
61 O
% O
) O
had O
made O
a O
suicide O
attempt O
in O
their O
lifetime O
, O
and O
46 O
( O
90 O
% O
) O
had O
reported O
suicidal O
ideations O
in O
the O
week O
before O
hospitalization O
. O
[]

Low O
muscle O
combined O
with O
high O
fat O
mass O
had O
more O
functional O
deficits O
and O
poorer O
bone O
health O
, O
which O
has O
implications O
for O
falls O
risk O
and O
fractures O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
9.5 O
months O
for O
group O
A O
versus O
11.4 O
months O
for O
group O
B O
( O
P O
= O
0.16 O
) O
. O
['Mortality']

Analgesics B-outcome ['Resource-use']
were O
required O
earlier O
in O
patients O
receiving O
remifentanil O
; O
median O
time O
0.5 O
vs O
1.08 O
hr O
, O
P O
< O
0.001 O
. O
['Resource-use']

OBJECTIVE O
saliva B-outcome ['Physiological-Clinical']
measurements O
were O
also O
carried O
out O
. O
['Physiological-Clinical']

The O
median O
ventilation O
time O
( O
14 O
hours O
versus O
13 O
hours O
) O
, O
median O
catecholamine O
dose O
, O
frequency O
of O
dialysis-dependent O
acute B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
28 O
% O
versus O
18 O
% O
) O
, O
cardiac O
indices O
, O
and O
frequency O
of O
a O
low O
cardiac O
output O
syndrome O
( O
26 O
% O
versus O
25 O
% O
) O
did O
not O
significantly O
differ O
between O
groups O
. O
['Physiological-Clinical']

Randomised O
, O
double O
blind O
, O
placebo O
controlled O
study O
of O
fluticasone O
propionate O
in O
patients O
with O
moderate O
to O
severe O
chronic O
obstructive O
pulmonary O
disease O
: O
the O
ISOLDE O
trial O
. O
[]

The O
authors O
conclude O
that O
symptomatic B-outcome ['Physiological-Clinical']
weakness I-outcome ['Physiological-Clinical']
due O
to O
neuropathy O
or O
myopathy O
appears O
in O
a O
predictable O
manner O
during O
intensive O
vincristine/corticosteroid-based O
treatment O
protocols O
. O
['Physiological-Clinical']

However O
, O
DAS28 O
remission O
rates O
were O
higher O
( O
even O
when O
using O
the O
lower O
cut O
point O
) O
than O
the O
SDAI O
and O
CDAI O
remission O
rates O
. O
[]

Changes O
in O
the O
exercise O
leg O
were O
compared O
between O
groups O
using O
ANCOVA O
, O
with O
change O
in O
the O
control O
leg O
and O
baseline O
BMD O
as O
covariates O
. O
[]

Results O
showed O
no O
significant O
differences O
between O
barrier O
cream O
and O
vehicle O
. O
[]

Trainees O
put O
emphasis O
on O
the O
development O
of O
their O
personal O
relationship O
with O
the O
client O
. O
[]

Journal O
ID: O
101521595 O
[]

A O
detailed O
description O
of O
clinical O
and O
laboratory O
characteristics O
of O
the O
diseases O
is O
presented O
. O
[]

METHODS O
In O
a O
prospective O
, O
double-blind O
, O
randomized O
controlled O
trial O
conducted O
in O
a O
tertiary O
maternity O
hospital O
622 O
women O
received O
either O
400 O
mug O
of O
oral O
misoprostol O
or O
5 O
U O
of O
intravenous O
oxytocin O
after O
delivery O
of O
the O
anterior O
shoulder O
or O
within O
1 O
min O
of O
delivery O
. O
[]

INTERVENTIONS O
100 O
patients O
with O
anterior O
wall O
ST-elevation O
myocardial O
infarction O
treated O
with O
acute O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
were O
randomised O
to O
receive O
intracoronary O
injection O
of O
mBMCs O
( O
n O
= O
50 O
) O
or O
not O
( O
n O
= O
50 O
) O
. O
[]

There O
was O
no O
significant O
difference O
in O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
between O
intervention O
and O
usual O
care O
groups O
(unadjusted O
cumulative O
incidence, O
10.2% O
vs O
10.6%; O
P O
= O
.65; O
adjusted O
difference, O
0.66% O
[95% O
CI, O
-0.73% O
to O
2.06%]; O
adjusted O
hazard O
ratio, O
1.07 O
[95% O
CI, O
0.93 O
to O
1.25]). O
[['Physiological-Clinical', 'Mortality']]

Journal-Name:BMC O
psychology O
[]

Twenty-five O
per O
cent O
recovery B-outcome ['Physiological-Clinical']
was O
shorter O
with O
rapacuronium O
than O
rocuronium O
during O
propofol O
( O
15.0 O
( O
3.2 O
) O
vs O
39.1 O
( O
14.2 O
) O
min O
, O
P O
< O
0.001 O
) O
and O
sevoflurane O
( O
15.1 O
( O
4.2 O
) O
vs O
47.8 O
( O
19.0 O
) O
min O
, O
P O
< O
0.001 O
) O
anaesthesia O
. O
['Physiological-Clinical']

The O
cytotoxic B-outcome ['Physiological-Clinical']
dose-intensity I-outcome ['Physiological-Clinical']
of O
standard O
every-4-weeks O
ICE O
is O
100 O
% O
. O
['Physiological-Clinical']

In O
previous O
published O
work O
we O
described O
57 O
patients O
undergoing O
emergency O
abdominal O
surgery O
, O
prospectively O
randomised O
to O
receive O
either O
cefotaxime O
or O
cephamandole O
as O
a O
single-antibiotic O
, O
three-dose O
, O
peri-operative O
prophylaxis O
against O
post-operative O
infective O
complications O
. O
[]

bolus O
dose O
of O
240 O
mg O
, O
followed O
by O
a O
continuous O
i.v O
. O
[]

The O
sample O
was O
randomly O
divided O
in O
an O
experimental O
group O
of O
13 O
older O
subjects O
( O
3 O
men O
and O
10 O
women O
, O
mean O
age O
63.5 O
+/- O
3 O
years O
) O
while O
the O
remaining O
9 O
subjects O
( O
3 O
men O
and O
6 O
women O
, O
mean O
age O
64.2 O
+/- O
4 O
years O
) O
served O
as O
inactive O
control O
group O
. O
[]

Inclusion O
criteria O
were O
myocardial O
infarction O
or O
unstable O
ischemic O
attack O
, O
age O
under O
70 O
years O
, O
use O
of O
betablockers O
and O
presence O
of O
sinus O
rhythm O
. O
[]

We O
aimed O
to O
assess O
the O
effects O
of O
training O
with O
N95 O
or O
higher O
filter O
respirators O
on O
the O
protection B-outcome ['Life-Impact']
performance O
of O
respirators O
among O
healthcare O
providers O
in O
the O
emergency O
medical O
center O
(EMC). O
[['Life-Impact']]

Food O
preferences O
are O
established O
in O
early O
childhood O
and O
track O
later O
in O
life O
. O
[]

The O
purpose O
of O
this O
randomized O
pilot O
study O
is O
to O
conduct O
an O
intervention O
with O
68 O
rural O
women O
living O
with O
AIDS O
to O
compare O
the O
effectiveness O
of O
two O
different O
programs O
on O
depressive O
symptoms O
. O
[]

Ambulatory B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP I-outcome ['Physiological-Clinical']
after O
3 O
months O
of O
aspirin O
treatment O
were O
similar O
to O
baseline O
: O
deltaSBP O
-0.5 O
mmHg O
( O
95 O
% O
confidence O
intervals O
[ O
CI O
] O
from O
-1.9 O
to O
+2.9 O
mm O
Hg O
) O
and O
deltaDBP O
-1.1 O
mm O
Hg O
( O
95 O
% O
CI O
from O
-2.5 O
to O
+0.3 O
mm O
Hg O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lapatinib O
plus O
vinorelbine O
offers O
an O
effective O
treatment O
option O
for O
patients O
with O
HER2-overexpressing O
MBC O
, O
having O
displayed O
comparable O
efficacy O
and O
tolerability O
rates O
to O
lapatinib O
plus O
capecitabine O
. O
[]

METHODS O
186 O
patients O
received O
either O
indomethacin O
3 O
times O
daily O
, O
or O
rofecoxib O
twice O
, O
and O
1 O
placebo O
, O
daily O
for O
7 O
days O
. O
[]

Women O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
1 O
) O
control O
: O
continue O
established O
dietary O
intake O
; O
2 O
) O
medium O
dairy O
: O
substitute O
dairy O
products O
to O
achieve O
intake O
of O
calcium O
of O
approximately O
1000-1100 O
mg/d O
and O
maintain O
isocaloric O
intake O
; O
3 O
) O
high O
dairy O
: O
substitute O
dairy O
products O
to O
achieve O
intake O
of O
calcium O
of O
1300-1400 O
mg/d O
and O
maintain O
isocaloric O
intake O
. O
[]

A O
double O
blind O
randomized O
trial O
to O
compare O
the O
effects O
of O
eprosartan O
and O
enalapril O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
platelets B-outcome ['Physiological-Clinical']
, O
and O
endothelium B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
essential O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Title: O
Role O
Of O
0.2% O
Bio-Adhesive O
Chlorhexidine O
Gel O
In O
Reducing O
Incidence O
Of O
Alveolar B-outcome ['Physiological-Clinical']
Osteitis I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

The O
remaining O
66 O
patients O
were O
followed O
up O
for O
3-24 O
months O
after O
randomization O
. O
[]

Plasma O
levels O
of O
naproxen O
were O
measured O
by O
a O
sensitive O
and O
specific O
HPLC O
method O
. O
[]

Of O
the O
angioplasty O
group O
, O
9 O
% O
developed O
exercise-induced B-outcome ['Physiological-Clinical']
periinfarct I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
compared O
with O
60 O
% O
of O
the O
streptokinase O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Patients O
were O
stratified O
prospectively O
for O
platinum O
sensitivity O
and O
for O
the O
presence O
or O
absence O
of O
bulky O
disease O
. O
[]

A O
prospective O
, O
randomized O
study O
of O
5-fluorouracil O
and O
filtration O
surgery O
. O
[]

The O
overall O
median O
survival B-outcome ['Mortality']
was O
not O
improved O
( O
36 O
weeks O
for O
the O
high-dose O
group O
vs O
43 O
weeks O
for O
the O
standard-dose O
group O
) O
; O
however O
, O
the O
median O
survival B-outcome ['Mortality']
in O
patients O
achieving O
CR O
was O
prolonged O
( O
92 O
weeks O
for O
the O
high-dose O
group O
vs O
50 O
weeks O
for O
the O
standard-dose O
group O
) O
. O
['Mortality', 'Mortality']

Several O
generic O
formulations O
have O
been O
approved O
, O
raising O
concern O
over O
the O
safety O
and O
efficacy O
of O
these O
products O
compared O
with O
brand-name O
Coumadin O
. O
[]

The O
allogeneic B-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
transfusion I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
and O
the O
chest-tube B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
drainage I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
were O
lower O
in O
the O
multiple-pass O
hemoconcentration O
group O
as O
compared O
to O
the O
centrifugation O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Third O
, O
the O
curriculum O
is O
briefly O
described O
, O
and O
finally O
, O
the O
role O
of O
the O
students O
and O
community O
in O
the O
video O
production O
is O
described O
. O
[]

We O
conclude O
that O
, O
for O
cardiovascular O
and O
cardiorespiratory O
adaptations O
in O
athletes O
, O
strength O
and O
endurance O
training O
are O
compatible O
and O
that O
exercise O
timing O
and O
sequence O
significantly O
influence O
training O
adaptations O
, O
complimenting O
our O
previous O
similar O
conclusions O
for O
strength B-outcome ['Physiological-Clinical']
, O
muscle B-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

8.3 O
, O
P O
< O
0.0001 O
) O
also O
after O
adjustment O
for O
age O
, O
GFR O
and O
BMI O
. O
[]

severity B-outcome ['Physiological-Clinical']
, O
duration O
and O
frequency O
. O
['Physiological-Clinical']

RESULTS O
Among O
312 O
patients O
enrolled O
, O
30 O
% O
experienced O
at O
least O
one O
SRE B-outcome ['Physiological-Clinical']
during O
the O
12-month O
study O
, O
and O
22 O
% O
experienced O
only O
one O
SRE B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Trachoma O
prevalence O
and O
associated O
risk O
factors O
in O
the O
gambia O
and O
Tanzania O
: O
baseline O
results O
of O
a O
cluster O
randomised O
controlled O
trial O
. O
[]

Matched-pair O
analysis O
of O
all-polyethylene O
versus O
metal-backed O
tibial O
components O
. O
[]

AIMS O
Our O
objective O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
imidafenacin O
over O
fesoterodine O
in O
patients O
with O
overactive O
bladder O
( O
OAB O
) O
. O
[]

Therefore, O
it O
can O
be O
used O
as O
an O
alternative O
method O
for O
patients O
who O
are O
willing O
to O
use O
this O
technique. O
[]

We O
studied O
137 O
women O
and O
treatments O
were O
found O
to O
be O
equivalent O
for O
onset O
, O
duration O
and O
quality O
of O
block O
. O
[]

In O
cycle O
4 O
, O
63.8 O
% O
of O
cycles O
were O
normal O
in O
the O
LNG/EE O
group O
compared O
with O
41.9 O
% O
in O
the O
NETA/EE O
group O
( O
p O
< O
0.005 O
) O
. O
[]

However O
, O
the O
cortisol B-outcome ['Physiological-Clinical']
response O
to O
weaning B-outcome ['Physiological-Clinical']
was O
increased O
in O
LP O
piglets O
( O
P O
< O
0.05 O
) O
, O
and O
in O
HP O
offspring O
the O
basal B-outcome ['Physiological-Clinical']
plasma B-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
authors O
previously O
evaluated O
cytarabine O
3 O
g/m O
( O
2 O
) O
daily O
for O
5 O
days O
with O
mitoxantrone O
80 O
mg/m O
( O
2 O
) O
( O
the O
ALL-2 O
regimen O
) O
as O
a O
novel O
induction O
regimen O
. O
[]

During O
the O
intervention O
period, O
rivaroxaban O
led O
to O
a O
substantially O
lower O
incidence O
of O
such O
events, O
with O
a O
low O
incidence O
of O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
(Funded O
by O
Janssen O
and O
others; O
CASSINI O
ClinicalTrials.gov O
number, O
NCT02555878.). O
[['Physiological-Clinical']]

The O
Bath O
Ankylosing B-outcome ['Physiological-Clinical']
Spondylitis I-outcome ['Physiological-Clinical']
Disease I-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Index O
( O
BASDAI O
) O
score O
was O
the O
primary O
end O
point O
for O
clinical O
response O
. O
['Physiological-Clinical']

However O
, O
a O
slight O
decrease O
in O
early B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
response O
['Physiological-Clinical']

Better O
airway B-outcome ['Physiological-Clinical']
seal I-outcome ['Physiological-Clinical']
was O
detected O
in O
the O
PLMA O
group O
. O
['Physiological-Clinical']

A O
total O
of O
106 O
patients O
were O
randomized O
1:1 O
to O
sildenafil O
( O
n=53 O
) O
or O
placebo O
( O
n=53 O
) O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
link O
between O
work-related O
stress O
and O
early O
atherosclerosis O
as O
measured O
by O
common O
carotid O
artery O
intima-media O
thickness O
and O
focal O
lesions O
in O
the O
common O
carotid O
artery O
and O
bifurcation O
. O
[]

Each O
group O
was O
offered O
an O
instructor-led O
after-school O
program O
every O
school O
day O
for O
approximately O
8 O
months O
. O
[]

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O
[]

We O
re-evaluated O
the O
GHRH O
dose-response O
curve O
in O
patients O
post O
cranial O
irradiation O
and O
in O
controls O
. O
[]

Randomized O
trial O
of O
tailored O
skin O
cancer O
prevention O
for O
children O
: O
the O
Project O
SCAPE O
family O
study O
. O
[]

In O
an O
age-adjusted O
model O
, O
the O
prevalence O
of O
carotid B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
among O
men O
scoring O
in O
the O
highest O
stress O
quintile O
was O
36 O
% O
compared O
with O
21 O
% O
among O
men O
in O
the O
lowest O
quintile O
. O
['Physiological-Clinical']

RESULTS O
One O
hundred O
seventy-five O
eligible O
patients O
( O
mean O
age O
73 O
+/- O
10 O
years O
; O
60 O
% O
women O
) O
were O
randomized O
to O
the O
trial O
: O
pacemaker O
87 O
; O
controls O
88 O
. O
[]

Controlling O
for O
all O
other O
factors O
, O
individuals O
older O
than O
44 O
, O
and O
those O
with O
more O
advanced O
lesions O
were O
more O
likely O
to O
comply O
with O
referral B-outcome ['Life-Impact']
( O
p O
< O
0.001 O
) O
. O
['Life-Impact']

The O
incidence O
of O
morbidity O
as O
measured O
by O
the O
Postoperative O
Morbidity O
Survey O
on O
day O
5 O
was O
55 O
% O
in O
the O
control O
group O
versus O
47 O
% O
in O
the O
dopexamine O
group O
( O
P O
= O
0.14 O
) O
. O
[]

Successful O
production B-outcome ['Physiological-Clinical']
of O
piglets O
derived O
from O
expanded O
blastocysts O
vitrified O
using O
a O
micro O
volume O
air O
cooling O
method O
without O
direct O
exposure O
to O
liquid O
nitrogen O
. O
['Physiological-Clinical']

Reliability O
analysis O
showed O
Cronbach O
's O
alpha O
of O
the O
questionnaire O
was O
0.91 O
. O
[]

Between O
November O
1973 O
and O
July O
1982 O
, O
123 O
women O
younger O
than O
70 O
years O
of O
age O
and O
at O
clinical O
Stages O
I O
and O
II O
were O
enrolled O
. O
[]

The O
current O
study O
protocol O
aims O
at O
scaling O
up O
these O
results O
at O
a O
provincial O
level O
using O
a O
randomized O
controlled O
trial O
design. O
[]

The O
fracture B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
with O
risedronate O
2.5 O
mg O
was O
similar O
to O
that O
in O
the O
5 O
mg O
group O
over O
2 O
years O
. O
['Physiological-Clinical']

Statistically O
significant O
differences O
between O
groups O
indicated O
that O
the O
sensory O
integration O
therapy O
program O
positively O
affected O
treated O
children O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
outcomes O
of O
the O
two O
types O
of O
consultation B-outcome ['Resource-use']
were O
similar O
-- O
almost O
half O
the O
patients O
were O
managed O
after O
a O
single O
consultation O
with O
the O
dermatologist O
. O
['Physiological-Clinical', 'Resource-use']

After O
a O
median O
follow-up O
of O
65 O
months O
, O
26.2 O
% O
( O
37 O
of O
141 O
) O
and O
46.2 O
% O
( O
66 O
of O
143 O
) O
of O
patients O
developed O
tumor B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
in O
the O
CCRT O
and O
RT-alone O
groups O
, O
respectively O
. O
['Physiological-Clinical']

The O
trial O
was O
terminated O
on O
recommendation O
of O
the O
Policy O
and O
Data O
Monitoring O
Board O
9 O
months O
before O
the O
scheduled O
closing O
date O
. O
[]

BACKGROUND O
In O
2005 O
, O
the O
European O
Resuscitation O
Council O
and O
the O
American O
Heart O
Association O
published O
new O
guidelines O
for O
Advanced O
Life O
Support O
. O
[]

Effects O
of O
short- O
and O
long-term O
risperidone O
treatment O
on O
prolactin B-outcome ['Physiological-Clinical']
levels O
in O
children O
with O
autism O
. O
['Physiological-Clinical']

The O
primary O
and O
secondary O
endpoints O
were O
acute B-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
and O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
respectively O
. O
['Physiological-Clinical', 'Mortality']

Impact O
of O
preinduced O
quadriceps O
fatigue O
on O
exercise O
response O
in O
chronic O
obstructive O
pulmonary O
disease O
and O
healthy O
subjects O
. O
[]

Lastly, O
EMLA O
lowered O
overall B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
score O
at O
the O
time O
of O
first O
analgesic O
request O
in O
ward O
compared O
to O
control O
group O
(P O
= O
.02). O
[['Physiological-Clinical']]

Second O
, O
within O
this O
overview O
, O
the O
ways O
in O
which O
selected O
results O
informed O
program O
development O
are O
highlighted O
. O
[]

This O
paper O
targets O
the O
cost-effectiveness O
analysis O
of O
a O
cognitive-behavioral O
group O
therapy O
( O
CBT O
) O
in O
comparison O
to O
a O
client-centered O
, O
supportive-experiential O
group O
therapy O
( O
SET O
) O
in O
cancer O
patients O
with O
dysfunctional O
fear O
of O
progression O
. O
[]

CONCLUSIONS: O
Contrast B-outcome ['Life-Impact']
enhancement I-outcome ['Life-Impact']
was O
equivalent O
under O
both O
protocols. O
[['Life-Impact']]

These O
findings O
were O
potentially O
explained O
by O
within-group O
significance O
for O
the O
same O
variables O
for O
the O
first O
10 O
min O
split O
(P O
</= O
0.01), O
and O
for O
distance O
covered O
(P O
= O
0.01) O
in O
the O
second O
10-min O
split. O
[]

Four O
of O
the O
10 O
CAHB O
patients O
received O
combined O
prednisolone/interferon-alpha2b O
( O
IFN-alpha2b O
) O
therapy O
. O
[]

PURPOSE O
To O
characterize O
the O
maximum-tolerated O
dose O
, O
recommended O
dose O
, O
dose-limiting O
toxicities O
( O
DLT O
) O
, O
pharmacokinetic O
profile O
, O
and O
food O
effect O
of O
orally O
administered O
irinotecan O
formulated O
as O
new O
semisolid O
matrix O
capsules O
. O
[]

In O
a O
survival O
analysis O
of O
treatment O
compliance O
, O
a O
significant O
difference O
was O
found O
between O
groups O
T O
and O
C. O
At O
the O
6- O
and O
12-month O
follow-ups O
, O
a O
significant O
reduction O
in O
myofascial B-outcome ['Physiological-Clinical']
pain O
, O
as O
measured O
on O
a O
visual O
analog O
scale O
, O
was O
found O
in O
all O
three O
groups O
. O
['Physiological-Clinical']

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

No O
significant O
changes O
were O
seen O
in O
left O
ventricular O
ejection O
time O
( O
LVET O
) O
, O
LV O
dimensions O
, O
[]

Title: O
Music O
therapy O
intervention O
in O
cardiac B-outcome ['Physiological-Clinical']
autonomic I-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
mothers O
of O
preterms: O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

METHODS O
Physiological O
, O
plasma O
beta-endorphin O
, O
cortisol O
, O
and O
glucose O
responses O
to O
routine O
treatment O
procedures O
were O
studied O
in O
84 O
mechanically O
ventilated O
distressed O
neonates O
randomized O
into O
groups O
receiving O
1 O
mg/kg O
meperidine O
or O
0.9 O
% O
saline O
15 O
minutes O
before O
tracheal O
suction O
or O
routine O
nursing O
care O
. O
[]

All O
patients O
were O
operated O
on O
under O
spinal O
anesthesia O
. O
[]

These O
findings O
are O
discussed O
in O
relation O
to O
the O
existing O
attitude O
strength O
literature O
. O
[]

It O
is O
widely O
held O
that O
first-order O
modulations O
are O
represented O
by O
the O
firing O
rates O
of O
simple O
and O
complex O
cells O
( O
first-order O
neurons O
) O
in O
primary O
visual O
cortex O
( O
V1 O
) O
that O
, O
likewise O
, O
have O
spatially O
localized O
receptive O
fields O
that O
are O
selective O
for O
orientation- O
and O
SF O
. O
[]

Naltrexone O
in O
young O
autistic O
children O
: O
a O
double-blind O
, O
placebo-controlled O
crossover O
study O
. O
[]

In O
58 O
patients O
, O
traditional O
treatment O
was O
supplemented O
by O
transcranial O
electrotherapy O
using O
a O
TRANSAIR-02 O
apparatus O
. O
[]

An O
evaluation O
of O
an O
adaptive O
automation O
system O
using O
a O
cognitive O
vigilance O
task O
. O
[]

There O
was O
a O
12.5 O
% O
frequency O
of O
allergic B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
in O
the O
CX516 O
group O
and O
1 O
subject O
developed O
a O
substantial B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Patients O
with O
stable O
CHF O
( O
NYHA O
II/III O
; O
59 O
( O
11 O
) O
years O
) O
were O
randomly O
assigned O
to O
a O
training O
group O
( O
n=18 O
; O
3-month O
aerobic O
program O
above O
standard O
treatment O
) O
or O
control O
group O
( O
n=16 O
; O
standard O
treatment O
without O
special O
advice O
for O
exercise O
) O
. O
[]

Increasing O
Ki-67 O
positivity O
was O
associated O
with O
decreasing O
differentiation O
( O
P O
< O
0.001 O
) O
and O
increasing O
N-stage O
( O
P O
< O
0.004 O
) O
. O
[]

The O
median O
volume B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
specimens I-outcome ['Physiological-Clinical']
in O
the O
NETZ O
arm O
was O
739 O
mm O
( O
3 O
) O
larger O
( O
P= O
0.33 O
) O
and O
they O
were O
less O
likely O
to O
be O
removed O
in O
multiple O
pieces O
( O
2.5 O
% O
vs O
29.5 O
% O
, O
RR O
0.09 O
, O
95 O
% O
CI O
0.04 O
to O
0.20 O
) O
. O
['Physiological-Clinical']

DESIGN O
A O
secondary O
analysis O
was O
performed O
of O
baseline O
data O
from O
the O
Reach O
Out O
to O
Enhance O
Wellness B-outcome ['Physiological-Clinical']
( O
RENEW O
) O
trial O
, O
a O
diet O
and O
exercise O
intervention O
among O
overweight O
, O
long-term O
( O
?5 O
years O
) O
, O
older O
survivors O
of O
colorectal O
, O
breast O
, O
and O
prostate O
cancer O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
and O
controlled O
. O
[]

3) O
Results: O
There O
were O
statistically O
significant O
(p O
< O
0.05) O
decreases O
in O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
sVCAM-1 B-outcome ['Physiological-Clinical']
, O
sE-selectin B-outcome ['Physiological-Clinical']
and O
endothelin-1 B-outcome ['Physiological-Clinical']
levels, O
and O
increases O
in O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
oxidized B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
levels. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND O
Corticotropin-releasing O
factor O
receptor O
type O
1 O
( O
CRF O
( O
1 O
) O
) O
antagonists O
have O
been O
proposed O
as O
therapeutic O
agents O
in O
the O
treatment O
of O
mood O
and O
anxiety O
disorders O
although O
clinical O
evidence O
supporting O
their O
development O
and O
understanding O
of O
a O
dose-response O
relationship O
has O
been O
lacking O
. O
[]

OBJECTIVE O
Previous O
studies O
have O
suggested O
that O
post-irradiation O
GH O
insufficiency O
results O
from O
a O
loss O
of O
GHRH O
secretion O
, O
since O
many O
patients O
were O
able O
to O
release O
GH O
following O
exogenous O
GHRH O
stimulation O
. O
[]

Conclusions O
and O
Relevance: O
Among O
patients O
with O
MI, O
provision O
of O
vouchers O
to O
offset O
medication O
co-payments O
for O
P2Y12 O
inhibitors, O
compared O
with O
no O
vouchers, O
resulted O
in O
a O
3.3% O
absolute O
increase O
in O
patient-reported O
persistence B-outcome ['Life-Impact']
with O
P2Y12 O
inhibitors O
and O
no O
significant O
reduction O
in O
1-year O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
outcomes. O
[['Life-Impact'], ['Physiological-Clinical', 'Mortality']]

Women O
were O
followed O
up O
until O
the O
infant O
was O
12 O
mo O
of O
age O
, O
or O
later O
if O
menses O
had O
not O
occurred O
by O
then O
. O
[]

Pulsed O
azithromycin O
treatment O
is O
as O
effective O
and O
safe O
as O
2-week-longer O
daily O
doxycycline O
treatment O
of O
acne O
vulgaris O
: O
a O
randomized O
, O
double-blind O
, O
noninferiority O
study O
. O
[]

Correlations O
with O
ratings O
of O
repetitive O
behavior O
and O
disruptive O
behavior O
were O
examined O
for O
validity O
. O
[]

The O
patients O
, O
114 O
adult O
subjects O
with O
chronic O
plantar O
fasciitis O
, O
recalcitrant O
to O
conservative O
therapies O
for O
at O
least O
6 O
months O
, O
were O
randomized O
to O
two O
groups O
. O
[]

For O
patients O
with O
CrCl O
between O
10 O
and O
50 O
ml/min O
, O
the O
levels O
achieved O
were O
low O
and O
these O
patients O
would O
likely O
benefit O
from O
increased O
doses O
. O
[]

A O
web-based O
computer-tailored O
feedback O
programme O
may O
be O
an O
effective O
intervention O
to O
stimulate O
youngsters O
not O
to O
start O
smoking O
, O
and O
increase O
their O
knowledge O
about O
the O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
of O
smoking O
and O
their O
attitudes O
and O
self-efficacy O
regarding O
non-smoking O
. O
['Adverse-effects']

The O
putty O
material O
was O
characterized O
by O
ease O
of O
handling O
, O
simple O
placement O
, O
and O
enhanced O
graft O
particle O
containment O
. O
[]

The O
primary O
endpoint O
evaluated O
was O
SWI B-outcome ['Physiological-Clinical']
, O
which O
was O
defined O
as O
purulent O
drainage O
or O
active O
wound O
treatment O
. O
['Physiological-Clinical']

Patients O
were O
stratified O
into O
two O
groups O
: O
favorable-prognosis O
, O
group O
1 O
( O
carcinoma O
, O
lymphoma O
, O
multiple O
myeloma O
) O
, O
or O
unfavorable-prognosis O
, O
group O
2 O
( O
acute O
leukemia O
, O
bone O
marrow O
transplantation O
) O
, O
based O
on O
anticipated O
duration O
of O
granulocytopenia O
. O
[]

BACKGROUND O
Measurement O
of O
objective O
response O
to O
chemotherapy B-outcome ['Resource-use']
using O
imaging B-outcome ['Resource-use']
modalities O
is O
sometimes O
difficult O
in O
pancreatic O
cancer O
( O
PC O
) O
. O
['Resource-use', 'Resource-use']

The O
two O
groups O
were O
well O
matched O
for O
age O
, O
sex O
, O
stone O
size O
, O
stone O
laterality O
, O
and O
number O
of O
previous O
renal O
procedures O
. O
[]

The O
seven-day O
course O
of O
metronidazole O
was O
superior O
to O
the O
single-dose O
regimen O
in O
the O
percentage O
of O
patients O
with O
clue O
cells O
and O
the O
percentage O
of O
patients O
with O
a O
positive O
sniff O
test O
at O
the O
first O
follow-up O
visit O
; O
however O
, O
differences O
in O
the O
initial B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
assessed I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
and O
Gram-stained B-outcome ['Physiological-Clinical']
smear I-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
were O
not O
statistically O
significant O
between O
the O
two O
patient O
treatment O
regimens O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Aerosp O
Med O
Hum O
Perform. O
[]

Implants O
with O
reported O
mechanical O
and/or O
mucosal O
problems O
or O
placed O
more O
apically O
in O
relation O
to O
the O
adjacent O
teeth O
did O
not O
present O
more O
bone O
loss O
as O
compared O
with O
implants O
with O
no O
problems O
or O
placed O
more O
coronally O
, O
respectively O
( O
p O
> O
.05 O
) O
. O
[]

The O
rate O
of I-outcome ['Physiological-Clinical']
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptom B-outcome ['Physiological-Clinical']
score O
for O
initial O
therapy O
and O
the O
weekly O
average O
symptom O
score O
and O
weekly O
average O
number O
of O
days O
on O
treatment O
for O
on-demand O
therapy O
were O
evaluated O
as O
secondary O
end O
points O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
STUDY O
AIMS O
Attempts O
have O
been O
made O
to O
improve O
patient O
's O
tolerance O
of O
upper O
gastrointestinal O
endoscopy O
and O
to O
decrease O
the O
need O
for O
sedation O
, O
using O
thinner O
endoscopes O
and O
a O
nasal O
introduction O
route O
. O
[]

We O
performed O
an O
open O
trial O
with O
naltrexone O
in O
2 O
autistic O
girls O
, O
displaying O
serious O
self-injurious O
behavior O
, O
reduced O
crying O
and O
a O
marked O
preference O
for O
salty O
and O
spicy O
foods O
, O
symptoms O
that O
could O
be O
related O
to O
a O
dysfunction O
of O
the O
opioid O
system O
. O
[]

The O
greatest O
benefit O
was O
observed O
in O
patients O
who O
had O
previously O
received O
chemotherapy O
. O
[]

On O
rioprostil O
, O
14.9 O
% O
of O
patients O
showed O
a O
relapse B-outcome ['Physiological-Clinical']
after O
6 O
months O
compared O
to O
10.1 O
% O
on O
ranitidine O
. O
['Physiological-Clinical']

METHODS O
We O
measured O
plasma O
norepinephrine O
content O
during O
ischemic O
events O
from O
blood O
obtained O
from O
automatic O
pump O
withdrawal O
with O
the O
assistance O
of O
a O
real-time O
ST O
segment O
depression O
monitor O
. O
[]

Secondary B-outcome ['Physiological-Clinical']
endpoints I-outcome ['Physiological-Clinical']
were O
changes O
in O
biochemical O
parameters O
related O
to O
androgens O
and O
insulin O
. O
['Physiological-Clinical']

A O
single-center O
prospective O
controlled O
trial O
. O
[]

Energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
amount B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
carbohydrate I-outcome ['Life-Impact']
ingested I-outcome ['Life-Impact']
by O
both O
groups O
diminished O
over O
the O
trial O
, O
whereas O
the O
consumption O
of O
protein B-outcome ['Physiological-Clinical']
and O
fibre B-outcome ['Life-Impact']
increased O
and O
lipid O
ingestion O
remained O
unchanged O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

This O
improvement O
was O
observed O
both O
among O
those O
who O
maintained O
SR O
and O
those O
with O
intermittent O
AF O
. O
[]

METHODS O
Fourteen O
preschoolers O
with O
developmental O
disorders O
( O
DD O
, O
n O
= O
14 O
; O
PDD O
, O
n O
= O
12 O
; O
ID O
, O
n O
= O
2 O
) O
underwent O
MPH O
titration O
in O
a O
single-blind O
manner O
followed O
by O
a O
4-week O
double-blind O
crossover O
phase O
. O
[]

Cholesterol B-outcome ['Physiological-Clinical']
reduction O
is O
achieved O
without O
concomitant O
reduction O
of O
Coenzyme B-outcome ['Physiological-Clinical']
Q10 I-outcome ['Physiological-Clinical']
(CoQ10) I-outcome ['Physiological-Clinical']
, O
in O
contrast O
to O
what O
is O
observed O
with O
statins. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Diagnosis O
of O
pertussis O
was O
confirmed O
by O
laboratory O
tests O
and O
the O
follow-up O
was O
completed O
in O
67 O
children O
. O
[]

To O
assess O
sensitivity O
of O
the O
5-HT1d O
receptor O
, O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
5-HT1d O
receptor O
agonist O
sumatriptan O
was O
studied O
in O
adult O
autistic O
patients O
and O
matched O
normal O
controls O
. O
['Physiological-Clinical']

CONCLUSION O
Folate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
, O
estimated O
by O
food O
composition O
tables O
, O
and O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
are O
not O
predictive O
of O
each O
other O
in O
Canadian O
lactating O
women O
exposed O
to O
high O
levels O
of O
folate B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
comfort B-outcome ['Life-Impact']
and O
local B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
cardiac O
catheterization O
. O
['Life-Impact', 'Adverse-effects']

A O
significant O
difference O
in O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
favour O
of O
paclitaxel/cisplatin O
chemotherapy O
was O
found O
( O
P O
= O
0.001 O
) O
. O
['Mortality']

Adjustments O
in O
spatial B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
were O
evident O
in O
improved O
ball O
catching B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
a O
task O
requiring O
visual O
tracking O
and O
eye-hand O
coordination O
. O
['Life-Impact', 'Life-Impact']

Eighty-six O
nurses O
served O
as O
controls O
. O
[]

OUTCOME O
Eradication B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
GABHS I-outcome ['Physiological-Clinical']
, O
determined O
with O
follow-up O
throat O
cultures O
on O
days O
3-6 O
, O
12-16 O
and O
26-36 O
. O
['Physiological-Clinical']

Patients O
in O
both O
groups O
were O
treated O
for O
a O
total O
of O
12 O
weeks. O
[]

Preparing O
and O
treating O
the O
enamel O
surface O
exclusively O
by O
Er O
: O
YAG O
laser O
resulted O
in O
the O
highest O
degree O
of O
leakage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
We O
randomly O
assigned O
2079 O
men O
and O
women O
who O
were O
35 O
years O
of O
age O
or O
older O
and O
who O
had O
had O
one O
or O
more O
histologically O
confirmed O
colorectal O
adenomas O
removed O
within O
six O
months O
before O
randomization O
to O
one O
of O
two O
groups O
: O
an O
intervention O
group O
given O
intensive O
counseling O
and O
assigned O
to O
follow O
a O
diet O
that O
was O
low O
in O
fat O
( O
20 O
percent O
of O
total O
calories O
) O
and O
high O
in O
fiber O
( O
18 O
g O
of O
dietary O
fiber O
per O
1000 O
kcal O
) O
and O
fruits O
and O
vegetables O
( O
3.5 O
servings O
per O
1000 O
kcal O
) O
, O
and O
a O
control O
group O
given O
a O
standard O
brochure O
on O
healthy O
eating O
and O
assigned O
to O
follow O
their O
usual O
diet O
. O
[]

This O
was O
an O
open-labeled O
, O
randomized O
, O
comparative O
trial O
. O
[]

Masking O
of O
the O
use O
of O
different O
diagnostic O
tests O
was O
not O
possible O
for O
patients O
, O
treating O
physicians O
, O
or O
investigators O
. O
[]

The O
daily O
administration O
of O
60 O
mg O
of O
the O
beta-carotene O
preparation O
( O
30 O
mg O
of O
all-trans O
beta-carotene O
and O
30 O
mg O
of O
9-cis O
beta-carotene O
) O
was O
performed O
and O
beta-carotene O
concentrations O
were O
determined O
in O
the O
plasma B-outcome ['Physiological-Clinical']
, O
red B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
platelets O
( O
PLT O
) O
, O
and O
mononuclear B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
measures O
represent O
the O
exposure O
in O
a O
normal O
workload O
schedule O
of O
ninety O
randomly O
selected O
workers O
over O
a O
3-month O
period, O
extrapolated O
to O
1 O
year. O
[]

METHODS O
Patients O
( O
n=766 O
) O
, O
aged O
18 O
to O
65 O
years O
inclusive O
, O
with O
current O
manic O
or O
mixed O
episodes O
were O
initially O
randomized O
( O
4:1 O
) O
to O
flexibly-dosed O
paliperidone O
ER O
( O
3-12 O
mg/day O
) O
or O
olanzapine O
( O
5-20 O
mg/day O
; O
3-week O
acute O
treatment O
phase O
) O
; O
responders O
continued O
the O
same O
treatment O
( O
12-week O
continuation O
phase O
) O
. O
[]

METHODS O
A O
single-centre O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
performed O
in O
48 O
type O
2 O
diabetic O
patients O
with O
late-term O
failure O
following O
at O
least O
3 O
years O
of O
sulphonylurea O
therapy O
requiring O
additional O
insulin O
therapy O
to O
determine O
the O
impact O
of O
acarbose O
on O
glycaemic O
control O
and O
insulin O
requirements O
. O
[]

CONCLUSION O
We O
conclude O
that O
chronic O
allergen O
exposure O
induces O
inflammatory O
changes O
in O
the O
bronchial O
mucosa O
. O
[]

At O
4 O
years O
post-randomisation O
, O
median O
survival B-outcome ['Mortality']
in O
the O
topotecan O
group O
was O
63.0 O
weeks O
( O
range O
< O
1 O
to O
238.4+ O
weeks O
; O
20.5 O
% O
censored O
) O
and O
, O
for O
paclitaxel O
, O
53.0 O
weeks O
( O
range O
< O
1 O
to O
226.3+ O
weeks O
; O
12.3 O
% O
censored O
) O
; O
P O
= O
0.44 O
. O
['Mortality']

Captopril O
12.5 O
mg O
decreased O
subjective O
activity B-outcome ['Life-Impact']
compared O
with O
placebo O
. O
['Life-Impact']

Combined O
delivery O
approach O
of O
bone O
marrow O
mononuclear O
stem O
cells O
early O
and O
late O
after O
myocardial O
infarction O
: O
the O
MYSTAR O
prospective O
, O
randomized O
study O
. O
[]

Subjects O
in O
all O
three O
groups O
chose O
5 O
mg O
diazepam O
as O
often O
as O
placebo O
but O
preferred O
placebo O
to O
10 O
mg O
diazepam O
. O
[]

Both O
PVP O
and O
NaCl O
improved O
the O
comfort O
of O
contact B-outcome ['Life-Impact']
lens I-outcome ['Life-Impact']
wear I-outcome ['Life-Impact']
( O
P O
= O
0.0003 O
) O
, O
with O
no O
difference O
between O
them O
( O
P O
= O
0.25 O
) O
. O
['Life-Impact']

The O
influence O
of O
nicotine O
delivered O
in O
chewing O
gum O
upon O
cardiac O
hemodynamics O
and O
conduction O
has O
not O
been O
well-characterized O
. O
[]

There O
was O
a O
strong O
inverse O
association O
between O
the O
level O
of O
CD19 B-outcome ['Physiological-Clinical']
values O
at O
diagnosis O
and O
infections O
within O
the O
first O
2 O
months O
of O
diagnosis O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
the O
DSRs O
and O
the O
17-item O
Hamilton O
Depression O
Rating O
Scale O
( O
HAM-D17 O
) O
. O
[]

CONCLUSIONS: O
In O
high-risk O
ambulatory O
patients O
with O
cancer, O
treatment O
with O
rivaroxaban O
did O
not O
result O
in O
a O
significantly O
lower O
incidence O
of O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
due I-outcome ['Mortality']
to I-outcome ['Mortality']
venous I-outcome ['Mortality']
thromboembolism I-outcome ['Mortality']
in O
the O
180-day O
trial O
period. O
[['Physiological-Clinical'], ['Mortality']]

CONCLUSIONS O
Tumor O
budding O
independently O
predicted O
patient O
outcome O
in O
patients O
with O
AJCC/UICC O
stage O
II O
colorectal O
cancer O
and O
may O
therefore O
be O
used O
for O
accurate O
prognostication O
, O
patient O
counseling O
, O
and O
design O
of O
clinical O
trials O
by O
using O
integrated O
multimodal O
therapy O
. O
[]

In O
the O
combination O
treatment O
group O
, O
9 O
( O
52.9 O
% O
) O
patients O
cured O
, O
improvement O
was O
observed O
in O
5 O
( O
29.4 O
% O
) O
and O
failure O
in O
3 O
( O
17.6 O
% O
) O
. O
[]

Data O
collection O
included O
questionnaires O
and O
interviews O
. O
[]

The O
test O
groups O
showed O
significantly O
higher O
reductions O
in O
Gingival B-outcome ['Physiological-Clinical']
Index], O
probing B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
, O
and O
clinical B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
as O
well O
as O
reductions O
in O
Porphyromonas B-outcome ['Physiological-Clinical']
gingivalis I-outcome ['Physiological-Clinical']
and O
Aggregatibacter B-outcome ['Physiological-Clinical']
actinomycetemcomitans I-outcome ['Physiological-Clinical']
counts O
at O
1-, O
3-, O
6-, O
and O
9-month O
follow-ups O
when O
compared O
with O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

For O
the O
syncope O
unit O
and O
standard O
care O
patients O
, O
the O
presumptive B-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
was O
established O
in O
34 O
( O
67 O
% O
) O
and O
5 O
( O
10 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
was O
required O
for O
22 O
( O
43 O
% O
) O
and O
51 O
( O
98 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
and O
total O
patient-hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
were O
reduced O
from O
140 O
to O
64 O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

Studies O
support O
load O
theory O
's O
prediction O
that O
working O
memory O
load O
will O
lead O
to O
larger O
distractor B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
; O
however O
, O
these O
studies O
used O
secondary O
tasks O
that O
required O
only O
verbal O
working O
memory O
and O
the O
central O
executive O
. O
['Life-Impact']

It O
was O
shown O
that O
a O
6-month O
course O
of O
treatment O
with O
afala O
at O
a O
dose O
of O
2 O
tablets O
4 O
times O
a O
day O
resulted O
in O
a O
significant O
reduction O
in O
the O
severity O
of O
urinary O
disorders O
, O
estimated O
by O
total O
IPSS O
score O
, O
relative O
to O
baseline O
values O
and O
compared O
to O
placebo O
therapy O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
a O
combination O
of O
Lactobacillus O
GG O
( O
LGG O
) O
and O
galacto-oligosaccharides O
( O
GOS O
) O
with O
LGG O
on O
its O
own O
, O
and O
their O
effects O
on O
the O
intestinal O
microbiota O
in O
school-aged O
children O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Type-4a B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
was O
diagnosed O
in O
208/2121 O
patients O
( O
9.8 O
% O
) O
when O
cTn O
was O
used O
( O
CK-MB O
mass O
if O
cTn O
not O
available O
) O
, O
and O
in O
93/2121 O
of O
patients O
( O
4.4 O
% O
) O
when O
CK-MB O
mass O
was O
used O
( O
cTn O
if O
CK-MB O
mass O
not O
available O
) O
. O
['Physiological-Clinical']

However O
, O
DPP-4 O
inhibitors O
also O
reduce O
fasting O
blood O
glucose O
, O
an O
unexpected O
effect O
because O
circulating O
levels O
of O
active O
GIP O
and O
GLP-1 O
are O
low O
in O
the O
postabsorptive O
state O
. O
[]

Fistula O
rates O
were O
not O
improved O
in O
the O
enhanced O
diet O
groups O
. O
[]

Differences O
in O
treatment O
efficacy O
were O
assessed O
by O
ANCOVA O
. O
[]

Refractory B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
epilepticus I-outcome ['Physiological-Clinical']
was O
controlled O
in O
80 O
% O
of O
the O
valproate O
and O
85 O
% O
of O
the O
diazepam O
patients O
. O
['Physiological-Clinical']

Higher O
GMFCS O
level O
, O
bilateral O
CP O
, O
and O
higher O
age O
were O
associated O
with O
lower O
ambulatory O
activity O
on O
school O
days O
( O
R O
( O
2 O
) O
ranged O
from O
43-53 O
% O
) O
, O
whereas O
bilateral O
CP O
, O
higher O
age O
, O
and O
no O
sport O
club O
participation O
were O
associated O
with O
lower O
ambulatory O
activity O
in O
the O
weekend O
( O
R O
( O
2 O
) O
ranged O
from O
21-42 O
% O
) O
. O
[]

Clinically O
significant O
depressive O
symptoms O
were O
defined O
as O
a O
score O
of O
7 O
or O
more O
on O
the O
15-item O
Geriatric O
Depression B-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

The O
present O
study O
examined O
attributions O
of O
this O
new O
umbrella O
term O
when O
compared O
with O
CFS O
. O
[]

Outcome O
of O
CNS O
disease O
at O
diagnosis O
in O
disseminated O
small O
noncleaved-cell O
lymphoma O
and O
B-cell O
leukemia O
: O
a O
Children O
's O
Cancer O
Group O
study O
. O
[]

CONCLUSIONS O
Combination O
of O
risperidone O
and O
celecoxib O
was O
superior O
to O
risperidone O
alone O
in O
treating O
irritability O
, O
social O
withdrawal O
, O
and O
stereotypy O
of O
children O
with O
autism O
. O
( O
[]

6 O
) O
Feed O
containing O
rapeseed O
led O
to O
enlargement O
of O
thyroid O
glands O
and O
hearts O
, O
but O
did O
not O
affect O
liver B-outcome ['Physiological-Clinical']
size O
or O
mortality B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

A O
variety O
of O
predictors O
of O
early O
attachment O
were O
explored O
including O
: O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
during I-outcome ['Life-Impact']
pregnancy I-outcome ['Life-Impact']
, O
pregnancy B-outcome ['Life-Impact']
intention I-outcome ['Life-Impact']
, O
feelings B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
pregnancy I-outcome ['Life-Impact']
, O
and O
the I-outcome ['Life-Impact']
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
partner I-outcome ['Life-Impact']
relationship I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
duration O
of O
enteral B-outcome ['Physiological-Clinical']
nutrition I-outcome ['Physiological-Clinical']
in O
the O
three O
groups O
was O
similar O
with O
an O
average O
duration O
of O
14,5 O
+/- O
8 O
days O
. O
['Physiological-Clinical']

Brain B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
correlates O
differentially O
with O
increasing O
temporal O
complexity O
of O
rhythms O
during O
initialisation O
, O
synchronisation O
, O
and O
continuation O
phases O
of O
paced O
finger O
tapping O
. O
['Physiological-Clinical']

The O
5 O
FU-mitomycin O
combination O
produced O
a O
14 O
% O
and O
22 O
% O
response O
rate O
in O
disseminated O
stomach O
and O
pancreatic O
carcinoma O
, O
respectively O
. O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

epidermidis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
randomized O
trial O
of O
a O
behavioral O
intervention O
for O
black O
MSM O
: O
the O
DiSH O
study O
. O
[]

Two O
types O
of O
Hib O
vaccines O
were O
compared O
for O
efficacy O
and O
safety O
in O
71 O
normal O
children O
in O
three O
age O
groups O
: O
36 O
to O
72 O
months O
, O
15 O
to O
18 O
months O
, O
and O
6 O
to O
8 O
months O
. O
[]

AX-CPT B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
was O
assessed O
following O
administration O
of O
a O
single O
dose O
of O
propranolol O
( O
a O
beta O
adrenergic O
antagonist O
) O
and O
following O
placebo O
( O
sugar O
pill O
) O
administration O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
subjects O
were O
randomly O
assigned O
to O
one O
of O
three O
groups O
: O
endurance O
training O
group O
( O
n=8 O
) O
, O
resistance O
training O
group O
( O
n=8 O
) O
and O
control O
group O
( O
n=8 O
) O
. O
[]

A O
bimodal O
pattern O
appeared O
, O
with O
a O
frequency O
of O
57.1 O
% O
for O
20 O
CA O
repeats O
and O
18.6 O
% O
for O
16 O
CA O
repeats O
. O
[]

Recombinant O
human O
granulocyte-macrophage O
colony-stimulating O
factor O
ameliorates O
zidovudine-induced O
neutropenia O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
/AIDS-related O
complex O
. O
[]

Effect O
of O
esmolol O
pretreatment O
on O
EEG B-outcome ['Physiological-Clinical']
seizure I-outcome ['Physiological-Clinical']
morphology I-outcome ['Physiological-Clinical']
in O
RUL O
ECT O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
and O
outcome O
of O
the O
step-down O
approach O
using O
either O
cyclosporin O
A O
( O
CSA O
) O
or O
methotrexate O
( O
MTX O
) O
as O
maintenance O
therapy O
following O
6 O
months O
treatment O
with O
these O
2 O
agents O
in O
combination O
in O
early O
, O
nonerosive O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Life-Impact']

Full-mouth O
scaling O
and O
root O
planing O
(SRP) O
was O
performed O
followed O
by O
the O
application O
of O
curcumin O
gel O
on O
a O
single O
side. O
[]

This O
effect O
was O
more O
marked O
if O
the O
epidural O
catheter O
was O
sited O
in O
the O
thoracic O
rather O
than O
the O
lumbar O
area O
. O
[]

Regression O
analyses O
were O
conducted O
to O
test O
for O
differences O
by O
sponsorship O
condition O
on O
the O
respective O
outcome O
measures. O
[]

The O
introduction O
was O
followed O
by O
three O
test O
sessions O
. O
[]

MATERIAL O
AND O
METHODS O
Two O
hundred O
and O
two O
patients O
were O
randomized O
to O
either O
the O
surgical O
approach O
( O
total O
laryngectomy O
with O
partial O
pharyngectomy O
and O
neck O
dissection O
, O
followed O
by O
irradiation O
) O
or O
to O
the O
chemotherapy O
arm O
up O
to O
three O
cycles O
of O
induction O
chemotherapy O
( O
cisplatin O
100 O
mg/m O
( O
2 O
) O
day O
1 O
+ O
5-FU O
1000 O
mg/m O
( O
2 O
) O
day O
1-5 O
) O
followed O
for O
complete O
responders O
by O
irradiation O
and O
otherwise O
by O
conventional O
treatment O
. O
[]

Effect O
of O
erythromycin O
and O
gentamicin O
on O
abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
in O
suckling O
calves O
. O
['Physiological-Clinical']

3 O
) O
Protein O
digestibility O
coefficients O
of O
rapeseed O
products O
were O
mostly O
0.10 O
to O
0.15 O
units O
lower O
than O
those O
of O
soybean O
products O
. O
[]

Nine O
( O
7 O
% O
) O
eltrombopag-treated O
patients O
and O
two O
( O
3 O
% O
) O
in O
the O
placebo O
group O
had O
mild O
increases O
in O
alanine O
aminotransferase O
concentration O
, O
and O
five O
( O
4 O
% O
) O
eltrombopag-treated O
patients O
( O
vs O
none O
allocated O
to O
placebo O
) O
had O
increases O
in O
total O
bilirubin O
. O
[]

Data O
on O
the O
effect O
of O
hormone O
replacement O
therapy O
on O
hemostasis O
are O
inconsistent O
, O
and O
there O
are O
few O
data O
in O
women O
with O
coronary O
artery O
disease O
. O
[]

Under O
PCV O
mode, O
with O
the O
increase O
in O
oxygen O
atomization O
flow, O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
decreased O
gradually, O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
increased O
gradually, O
with O
significant O
difference O
as O
compared O
with O
those O
before O
atomization O
when O
the O
atomized O
oxygen O
flow O
was O
9 O
L/min O
[ O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
322.78+/-17.75 O
vs. O
518.17+/-8.97, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
730.89+/-31.20 O
vs. O
519.00+/-9.06, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(cmH2O: O
21.44+/-2.23 O
vs. O
21.39+/-2.55, O
P O
> O
0.05). O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Induced O
sputum B-outcome ['Physiological-Clinical']
differential I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
obtained O
at O
baseline O
and O
at O
five O
further O
visits O
. O
['Physiological-Clinical']

A O
double-blind O
cross-over O
study O
in O
coronary O
care O
unit O
. O
[]

After O
upper O
gastrointestinal O
endoscopy O
, O
H. O
pylori-infected O
patients O
with O
a O
gastric O
ulcer O
and/or O
a O
duodenal O
ulcer O
were O
randomly O
assigned O
to O
a O
PAC7 O
group O
( O
omeprazole O
20 O
mg O
or O
equivalent O
dose O
of O
other O
PPIs O
, O
amoxicillin O
1000 O
mg O
, O
and O
clarithromycin O
500 O
mg O
twice O
daily O
for O
7 O
days O
) O
or O
to O
a O
PAC14 O
group O
( O
the O
same O
regimen O
as O
the O
PAC7 O
group O
but O
for O
14 O
days O
) O
. O
[]

The O
WL O
group O
received O
SSBT O
after O
a O
second O
baseline O
assessment O
. O
[]

MATERIALS O
AND O
METHODS O
We O
used O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
, O
100 O
ml O
of O
iopamidol O
300 O
at O
an O
injection O
rate O
of O
3.7 O
ml/s O
, O
and O
80 O
ml O
of O
iopamidol O
370 O
at O
an O
injection O
rate O
of O
3.0 O
ml/s O
. O
[]

Familial O
adenomatous O
polyposis O
( O
FAP O
) O
strikes O
young O
people O
and O
, O
untreated O
, O
confers O
virtually O
a O
100 O
% O
risk O
of O
colorectal O
cancer O
and O
early O
death O
. O
[]

This O
randomized O
phase O
III O
trial O
compared O
concurrent O
chemoradiotherapy O
( O
CCRT O
) O
versus O
radiotherapy O
( O
RT O
) O
alone O
in O
patients O
with O
advanced O
NPC O
. O
[]

To O
evaluate O
the O
direct O
psychophysiologic O
benefits O
of O
non-verbal O
communication O
of O
compassion O
( O
NVCC O
) O
, O
it O
is O
important O
to O
minimize O
the O
effect O
of O
subjects O
' O
expectation O
. O
[]

Increased O
fibrinolytic B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
was O
indicated O
by O
elevated O
activity O
and O
reduced O
antigen O
levels O
of O
tissue O
plasminogen O
activator O
and O
reduced O
activity O
and O
concentration O
of O
tissue B-outcome ['Physiological-Clinical']
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
experiment O
was O
then O
repeated O
and O
brushing O
or O
not O
brushing O
crossed O
over O
. O
[]

This O
effect O
was O
reversible O
among O
patients O
who O
returned O
from O
bicarbonate O
to O
lactate O
fluid O
. O
[]

Journal O
ID: O
8610224 O
[]

An O
objective B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
chemotherapy O
was O
observed O
in O
68 O
% O
in O
the O
first O
study O
and O
85 O
% O
in O
the O
second O
. O
['Physiological-Clinical']

Treatment O
gains O
were O
maintained O
at O
3-month O
follow-up O
. O
[]

RESULTS O
Changes O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
over O
time O
between O
the O
two O
groups O
were O
significantly O
different O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Armodafinil O
200 O
mg O
produced O
a O
plasma B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
above O
the O
EC O
( O
50 O
) O
( O
4.6 O
?g/mL O
) O
for O
9 O
hours O
, O
whereas O
modafinil O
200 O
mg O
did O
not O
exceed O
the O
EC O
( O
50 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Autosomal O
dominant O
polycystic O
kidney O
disease O
( O
ADPKD O
) O
is O
progressive O
, O
resulting O
in O
end-stage O
kidney O
failure O
in O
most O
patients O
. O
[]

Analysis O
of O
prevention O
program O
effectiveness O
with O
clustered O
data O
using O
generalized O
estimating O
equations O
. O
[]

RESULTS O
In O
the O
trimethoprim-sulfamethoxazole O
group O
( O
n O
= O
154 O
) O
there O
were O
14 O
recurrences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCP I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
36 O
recurrences O
( O
including O
1 O
extrapulmonary O
recurrence O
) O
in O
the O
aerosolized-pentamidine O
group O
( O
n O
= O
156 O
) O
. O
['Physiological-Clinical']

0.4 O
and O
5.8 O
? O
[]

Their O
results O
were O
detected O
by O
the O
revised O
Chinese O
version O
of O
Psycho-Educational B-outcome ['Life-Impact']
Profile O
for O
autistic O
and O
developmentally O
disabled O
children O
( O
C-PEP O
) O
. O
['Life-Impact']

Patients O
received O
fluticasone O
propionate O
powder O
50 O
micrograms O
, O
100 O
micrograms O
, O
250 O
micrograms O
, O
or O
placebo O
via O
a O
breath-actuated O
inhalation O
device O
, O
the O
Diskhaler O
, O
twice O
daily O
for O
12 O
weeks O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Two O
homeopaths O
jointly O
performed O
case-taking O
interviews O
. O
[]

EEGs O
were O
reviewed O
for O
clinical O
abnormalities O
, O
including O
IEDs O
, O
by O
readers O
blinded O
to O
participants O
' O
behavioral O
symptoms O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
an O
intravenous O
infusion O
of O
synthetic O
human O
secretin O
improves O
language B-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact']

Following O
this O
demonstration O
that O
early O
intensification O
improves O
survival O
, O
the O
effect O
of O
a O
third O
intensification O
block O
is O
under O
investigation O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
compare O
psychosocial B-outcome ['Life-Impact']
outcomes O
for O
50 O
new O
clinic O
attendees O
, O
referred O
for O
cancer O
genetic O
counselling O
to O
five O
UK O
centres O
. O
['Life-Impact']

Plasma B-outcome ['Physiological-Clinical']
triglycerides I-outcome ['Physiological-Clinical']
, O
a O
univariate O
predictor O
of O
coronary B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
RR O
1.6 O
, O
P O
: O
=0.03 O
) O
, O
was O
not O
related O
to O
coronary B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
RR O
1.3 O
, O
P O
: O
=0.6 O
) O
when O
apoCIII B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
VLDL+LDL I-outcome ['Physiological-Clinical']
was O
included O
in O
the O
model O
, O
whereas O
apoCIII B-outcome ['Physiological-Clinical']
remained O
significant O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
stages O
IA O
and O
II2A O
received O
three O
courses O
of O
mechlorethamine O
, O
Oncovin O
, O
procarbazine O
, O
and O
prednisone O
( O
MOPP O
) O
and O
supradiaphragmatic O
radiotherapy O
( O
40 O
Gy O
) O
, O
and O
no O
laparotomy O
was O
performed O
. O
[]

Based O
on O
similar O
long-term O
outcomes O
, O
more O
rapid O
engraftment O
, O
and O
less O
oropharyngeal O
mucositis O
, O
the O
combination O
of O
Tac/Sir O
is O
an O
acceptable O
alternative O
to O
Tac/Mtx O
after O
MRD O
HCT O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
access O
the O
effects O
of O
pentoxifylline O
plus O
risperidone O
in O
the O
treatment O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
significant O
and O
persistent O
increase O
in O
oxygen B-outcome ['Resource-use']
consumption O
identified O
the O
threshold O
. O
['Resource-use']

Title: O
Examining O
diabetic O
heel O
ulcers O
through O
an O
ecological O
lens: O
microbial O
community O
dynamics O
associated O
with O
healing O
and O
infection. O
[]

The O
median O
follow-up O
was O
8.5 O
years O
. O
[]

Publication O
Type: O
Comparative O
Study O
[]

The O
purpose O
of O
the O
double-blind O
study O
was O
the O
demonstration O
of O
possible O
effects O
on O
the O
cellular B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
as O
determined O
by O
quantitative B-outcome ['Resource-use']
flow I-outcome ['Resource-use']
cytometry I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

However O
, O
failure B-outcome ['Physiological-Clinical']
to O
respond O
, O
delayed B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
, O
partial B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
, O
relapses B-outcome ['Physiological-Clinical']
and O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
remain O
significant O
problems O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

OBJECTIVE O
To O
study O
the O
effect O
of O
vitamin O
B O
on O
treatment O
of O
hyperhomocysteinemia O
and O
endothelial O
dysfunction O
in O
renal-transplant O
recipients O
. O
[]

This O
study O
was O
undertaken O
to O
quantify O
and O
compare O
the O
time O
needed O
to O
treat O
commercial O
beef O
cattle O
with O
three O
fluke O
and O
worm O
combination O
products O
with O
different O
administration O
profiles O
. O
[]

The O
loss O
of O
HBsAg B-outcome ['Physiological-Clinical']
in O
addition O
to O
HBeAg B-outcome ['Physiological-Clinical']
and O
hepatitis B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
was O
more O
likely O
to O
occur O
in O
patients O
with O
chronic O
infection O
of O
less O
than O
2 O
years O
duration O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
6 O
months O
, O
3 O
% O
, O
4 O
% O
, O
and O
13 O
% O
of O
patients O
died O
in O
low- O
, O
medium- O
, O
and O
high-risk O
groups O
, O
respectively O
. O
[]

Hypoglycemia-induced O
responses O
of O
epinephrine O
, O
norepinephrine O
, O
and O
cortisol O
were O
not O
enhanced O
by O
theophylline O
. O
[]

Doses B-outcome ['Life-Impact']
of O
concomitant O
methotrexate O
or O
corticosteroids O
were O
reduced O
in O
many O
patients O
who O
maintained O
clinical O
responses O
. O
['Life-Impact']

Cognitive O
behavioral O
therapy O
for O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
, O
controlled O
trial O
. O
['Life-Impact']

The O
tear O
levels O
of O
matrix B-outcome ['Physiological-Clinical']
metalloproteinase I-outcome ['Physiological-Clinical']
(MMP)-9 I-outcome ['Physiological-Clinical']
and O
serotonin B-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
at O
1 O
month O
after O
injection. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Renal O
function O
was O
studied O
in O
18 O
patients O
with O
Type O
1 O
diabetes O
mellitus O
. O
[]

The O
estimated O
date O
of O
delivery O
( O
EDD O
) O
was O
changed O
if O
there O
was O
a O
discrepancy O
of O
more O
than O
5 O
days O
from O
the O
gestation O
, O
calculated O
from O
the O
last O
menstrual O
period O
( O
LMP O
) O
. O
[]

The O
first O
molar O
, O
first O
premolar O
, O
lateral O
incisor O
, O
and O
contralateral O
canine O
( O
control O
) O
were O
blindly O
tested O
with O
an O
Analytic O
Technology O
pulp O
tester O
at O
3-min O
cycles O
for O
50 O
min O
. O
[]

A O
high O
proportion O
of O
first-time O
donors O
indicated O
that O
they O
had O
experienced O
a O
reaction O
to O
blood O
donation O
. O
[]

By O
intention-to-treat O
analysis O
, O
no O
significant O
differences O
were O
observed O
in O
abstinence B-outcome ['Life-Impact']
rates O
at O
12 O
and O
24 O
weeks O
between O
SJW O
dose O
groups O
and O
placebo O
. O
['Life-Impact']

At O
D29, O
intention-to-treat O
efficacy O
in O
the O
AmBisome O
arm O
was O
70% O
(95% O
CI O
45-87%) O
in O
the O
unadjusted O
analysis, O
and O
50% O
(95% O
CI O
27-73%) O
in O
the O
adjusted O
analysis, O
while O
in O
the O
combination O
arm, O
it O
was O
81% O
(95% O
CI O
67-90%) O
and O
67% O
(95% O
CI O
48-82%) O
respectively. O
[]

On O
three O
trial O
days O
, O
patients O
inhaled O
, O
in O
random O
order O
, O
40 O
micrograms O
ipratropium O
bromide O
, O
200 O
micrograms O
fenoterol O
hydrobromide O
, O
or O
a O
combination O
of O
40 O
micrograms O
ipratropium O
and O
100 O
micrograms O
fenoterol O
from O
a O
powder O
inhaler O
, O
followed O
by O
a O
second O
dose O
of O
the O
same O
drug O
after O
60 O
min O
. O
[]

CONCLUSION O
IOS O
is O
a O
suitable O
procedure O
for O
nasal O
provocation O
testing O
and O
provides O
results O
similar O
to O
the O
aR O
. O
[]

The O
study O
reported O
here O
examined O
the O
efficacy O
of O
acupuncture O
in O
alleviating O
xerostomia O
symptoms O
especially O
dry O
mouth O
. O
[]

The O
authors O
hypothesized O
that O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
( O
DASH O
) O
diet O
and O
reduced O
sodium O
intake O
would O
control O
stage O
1 O
hypertension O
and O
reduce O
high-normal O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
to O
optimal O
levels O
. O
['Physiological-Clinical']

Thus O
, O
the O
use O
of O
concentrate O
of O
factor O
IX O
in O
this O
trial O
, O
as O
well O
as O
potentiating O
intravascular B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
, O
was O
inadequate O
as O
replacement O
for O
the O
clotting O
factor O
deficiencies O
. O
['Physiological-Clinical']

While O
the O
patient O
in O
the O
observation O
group O
were O
treated O
by O
the O
routine O
treatment O
and O
acupuncture O
treatment O
48 O
h O
( O
-1 O
) O
week O
after O
operation O
in O
different O
stages O
with O
different O
acupoints O
selected O
when O
the O
situation O
was O
stable O
. O
[]

The O
amount O
of O
bilirubin B-outcome ['Physiological-Clinical']
removed I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
kilogram I-outcome ['Physiological-Clinical']
is O
directly O
correlated O
to O
plasma B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
r=0.87 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

2.9 O
) O
( O
t O
= O
-4.49 O
, O
P O
< O
0.05 O
) O
. O
[]

PTCA O
also O
resulted O
in O
lower O
rates O
of O
death B-outcome ['Mortality']
or O
reinfarction B-outcome ['Physiological-Clinical']
( O
1.4 O
% O
vs O
18.0 O
% O
, O
p O
= O
0.0009 O
) O
, O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
( O
11.3 O
% O
vs O
28.4 O
% O
, O
p O
= O
0.01 O
) O
, O
and O
stroke B-outcome ['Physiological-Clinical']
( O
0.0 O
% O
vs O
6.0 O
% O
, O
p O
= O
0.037 O
) O
in O
anterior O
wall O
AMI O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Multiple O
logistic O
regression O
analyses O
of O
potential O
risk O
factors O
for O
12-month O
point-prevalent O
smoking O
and O
for O
persistent O
smoking O
( O
point-prevalent O
smoking O
at O
both O
follow-ups O
) O
following O
treatment O
were O
conducted O
for O
men O
and O
women O
combined O
and O
separately O
. O
[]

RESULTS O
Heatwrap O
therapy O
was O
shown O
to O
provide O
significant O
therapeutic B-outcome ['Physiological-Clinical']
benefits O
when O
compared O
with O
placebo O
during O
both O
the O
treatment O
and O
follow-up O
period O
. O
['Physiological-Clinical']

This O
study O
examined O
the O
impact O
of O
esmolol O
pretreatment O
on O
seizure B-outcome ['Physiological-Clinical']
morphology I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Using O
the O
demand-control O
model O
of O
job O
strain O
to O
predict O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
and O
caregiver B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
in O
the O
informal O
caregivers O
of O
heart O
failure O
patients O
. O
['Life-Impact', 'Life-Impact']

The O
trial O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00390221 O
. O
[]

In O
multivariate O
analyses O
, O
greater O
BMI O
was O
significantly O
associated O
with O
higher O
PCSM B-outcome ['Mortality']
( O
for O
BMI O
> O
or O
=25 O
to O
< O
30 O
, O
hazard O
ratio O
[ O
HR O
] O
1.52 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.02-2.27 O
, O
P O
= O
.04 O
; O
for O
BMI O
> O
or O
=30 O
, O
HR O
1.64 O
, O
95 O
% O
CI O
, O
1.01-2.66 O
, O
P O
= O
.04 O
) O
. O
['Mortality']

Speakers O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
( O
trained O
vs O
untrained O
) O
. O
[]

The O
values O
of O
EC B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
50 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
k B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
eo I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastrin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
increased O
with O
multiple O
doses O
of O
rabeprazole O
. O
['Physiological-Clinical', 'Physiological-Clinical']

HOXB13 O
G84E O
mutation O
in O
Finland O
: O
population-based O
analysis O
of O
prostate O
, O
breast O
, O
and O
colorectal O
cancer O
risk O
. O
[]

A O
follow-up O
study O
of O
the O
results O
of O
five O
forms O
of O
treatment O
. O
[]

In O
a O
prespecified O
analysis O
of O
the O
LIFE-study O
we O
compared O
the O
effects O
of O
losartan O
and O
atenolol O
on O
cardiovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
diabetic O
patients O
. O
['Physiological-Clinical', 'Mortality']

One O
dose O
of O
zoster O
vaccine O
( O
ZV O
) O
has O
demonstrated O
substantial O
protection O
against O
HZ O
; O
this O
study O
examined O
impact O
of O
a O
second O
dose O
of O
ZV O
. O
[]

Muscle O
biopsies O
were O
taken O
before O
and O
immediately O
after O
exercise O
and O
after O
1 O
and O
4 O
h O
of O
postexercise O
recovery O
to O
determine O
4E-BP1 O
, O
S6K1 O
( O
both O
T O
( O
421 O
) O
/S O
( O
424 O
) O
and O
T O
( O
389 O
) O
) O
, O
and O
S6 O
phosphorylation O
status O
. O
[]

bradykinin O
in O
21 O
salt-replete O
normal-to-high O
renin O
hypertensive O
patients O
. O
[]

INTERVENTION O
LEAP O
was O
a O
comprehensive O
school-based O
intervention O
emphasizing O
changes O
in O
instruction O
and O
school O
environment O
designed O
to O
increase O
physical O
activity O
among O
black O
and O
white O
adolescent O
girls O
. O
[]

The O
findings O
revealed O
that O
women O
were O
more O
likely O
than O
men O
to O
attend B-outcome ['Resource-use']
aftercare I-outcome ['Resource-use']
. O
['Resource-use']

Journal O
ID: O
9433361 O
[]

MAIN O
OUTCOME O
MEASURES O
The O
primary O
outcome O
measure O
was O
the O
teacher-rated O
hyperactivity B-outcome ['Life-Impact']
subscale O
of O
the O
Aberrant O
Behavior O
Checklist O
. O
['Life-Impact']

ARIX O
: O
a O
randomised O
trial O
of O
acupuncture O
v O
oral O
care O
sessions O
in O
patients O
with O
chronic O
xerostomia O
following O
treatment O
of O
head O
and O
neck O
cancer O
. O
[]

A O
randomized O
, O
crossover O
, O
double-blind O
, O
controlled O
trial O
. O
[]

Twenty-one O
attention O
deficit O
disorder O
with O
hyperactivity O
and O
seven O
autistic O
children O
were O
randomly O
exposed O
to O
negatively O
ionized O
and O
ambient O
atmospheres O
under O
rigorously O
controlled O
experimental O
conditions O
. O
[]

AIMS O
To O
assess O
the O
effects O
of O
synthetic O
GLP-1 O
on O
fundus B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
and O
volume B-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
, O
gastric B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
, O
and O
perception O
of O
gastric B-outcome ['Physiological-Clinical']
distension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Group O
GA O
, O
mean O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
( O
p O
= O
0.006 O
) O
decreased O
when O
compared O
to O
baseline O
preanesthetic O
recordings O
. O
['Physiological-Clinical']

OBJECTIVE O
In O
this O
pilot O
study O
, O
we O
determined O
the O
effectiveness O
of O
a O
weighted O
vest O
on O
attention O
to O
task O
for O
second-grade O
general O
education O
students O
with O
difficulty O
attending O
. O
[]

These O
findings O
suggest O
that O
perceptual B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
emerges O
on O
the O
top O
of O
a O
developing O
or O
even O
mature O
perceptual O
decision O
. O
['Life-Impact']

CONCLUSION O
Concomitant O
boost O
postoperative O
radiation O
therapy O
did O
not O
improve O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
loco-regional B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
disease B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

In O
a O
double-blind O
placebo-controlled O
crossover O
trial O
, O
14 O
autistic O
children O
were O
treated O
with O
the O
neuropeptide O
ORG O
2766 O
, O
a O
synthetic O
analog O
of O
adrenocorticotrophic O
hormone O
( O
ACTH O
) O
( O
4-9 O
) O
. O
[]

Significant O
treatment O
effects O
were O
found O
for O
blind-rated O
perceptions O
of O
conversational B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
for O
parent-reported O
measures O
of O
pragmatic B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
and O
for O
teacher-reported O
ratings O
of O
classroom B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

In O
iron O
depletion O
, O
less O
iron O
may O
be O
available O
for O
carcinogenesis O
through O
free-radical O
mediated O
mechanisms O
and O
for O
promotion O
of O
tumor O
growth O
. O
[]

Consistent O
with O
hypothesis O
, O
AS O
was O
found O
to O
be O
a O
significant O
, O
incremental O
predictor O
of O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
over O
time O
, O
even O
after O
controlling O
for O
sex O
and O
negative O
affectivity O
. O
['Life-Impact']

Nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
serum B-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
intercellular I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
in O
patients O
with O
allergic O
rhinitis O
treated O
with O
montelukast O
alone O
or O
in O
combination O
with O
desloratadine O
or O
levocetirizine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
eradication O
, O
esophageal B-outcome ['Physiological-Clinical']
variceal I-outcome ['Physiological-Clinical']
recurrence B-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
in O
patients O
treated O
by O
ligation O
than O
by O
sclerotherapy O
( O
17.4 O
% O
vs. O
10 O
% O
, O
P O
=.67 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten O
patients O
were O
randomly O
assigned O
to O
receive O
4.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:80,000 O
epinephrine O
as O
a O
local O
anesthetic O
and O
10 O
were O
given O
4.4 O
mL O
of O
3 O
% O
prilocaine O
with O
0.03 O
IU/mL O
felypressin O
. O
[]

Regional O
ischemic O
preconditioning O
enhances O
myocardial B-outcome ['Physiological-Clinical']
performance O
in O
off-pump O
coronary O
artery O
bypass O
grafting O
. O
['Physiological-Clinical']

Electromyography-measured O
eyestrain B-outcome ['Physiological-Clinical']
was O
less O
with O
toric O
versus O
spherical O
contact O
lenses O
at O
fitting O
(least-square O
ratio O
of O
toric O
over O
spherical=0.72; O
P=0.0019) O
but O
not O
at O
follow-up O
(ratio=0.86; O
P=0.11). O
[['Physiological-Clinical']]

Therefore, O
this O
study O
determined O
if O
PC O
affected O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
(Trec) I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
storage I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
ratings O
of O
perceived B-outcome ['Physiological-Clinical']
exertion I-outcome ['Physiological-Clinical']
(RPE), O
thermal B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
, O
sweat B-outcome ['Physiological-Clinical']
rate, O
and O
postexercise O
cold-water O
immersion O
(CWI) O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
cooling O
rates. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Non-inferiority O
was O
defined O
as O
an O
upper O
95 O
% O
confidence O
limit O
( O
CL O
) O
for O
the O
difference O
in O
success O
of O
eradication O
in O
the O
amoxicillin O
and O
penicillin O
V O
treatment O
groups O
of O
< O
or=10 O
% O
. O
[]

Circulating-tissue B-outcome ['Physiological-Clinical']
factor O
antigen B-outcome ['Physiological-Clinical']
rose O
from O
324 O
pg/ml O
, O
[ O
interquartile O
range O
( O
IQR O
) O
282-347 O
pg/ml O
] O
to O
356 O
pg/ml O
, O
( O
IQR O
319-431 O
pg/ml O
) O
in O
controls O
( O
C O
) O
, O
and O
decreased O
in O
the O
dalteparin-treated O
group O
( O
D O
) O
from O
336 O
pg/ml O
( O
IQR O
281-346 O
pg/ml O
) O
to O
303 O
pg/ml O
( O
IQR O
274-339 O
pg/ml O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
instructions O
were O
repeated O
every O
six O
months O
. O
[]

After O
this O
period O
, O
all O
participants O
received O
diethylpropion O
in O
an O
open-label O
extension O
for O
an O
additional O
6 O
months O
. O
[]

Analysis O
of O
covariance O
was O
used O
to O
compare O
differences O
in O
week O
12 O
adjusted O
mean O
changes O
from O
baseline O
on O
the O
17-item O
Hamilton O
Depression O
Rating O
Scale O
( O
HAM-D?? O
) O
( O
primary O
outcome O
) O
and O
Sheehan O
Disability O
Scale O
( O
SDS O
) O
( O
key O
secondary O
outcome O
) O
in O
the O
intent-to-treat O
( O
ITT O
) O
population O
. O
[]

The O
secondary O
endpoints O
included O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
development O
of O
persistent B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
dimension I-outcome ['Physiological-Clinical']
, O
and O
quality-of-life B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
group O
A O
( O
50 O
patients O
) O
, O
the O
surgical B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
, O
previous O
site O
of O
the O
stoma O
, O
was O
packed O
with O
ORC O
, O
whereas O
in O
group O
B O
( O
48 O
patients O
) O
gauze O
soaked O
in O
iodine O
was O
used O
. O
['Physiological-Clinical']

One O
scan O
was O
indeterminate O
and O
a O
follow-up O
venogram B-outcome ['Physiological-Clinical']
was O
negative O
. O
['Physiological-Clinical']

Spontaneous B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
was O
recorded O
in O
nine O
cigarette O
smokers O
who O
had O
been O
abstinent O
from O
tobacco O
for O
12 O
hr O
. O
['Physiological-Clinical']

INTERVENTION O
CGs O
were O
assigned O
to O
the O
REACH O
intervention O
or O
a O
no-treatment O
control O
group O
. O
[]

The O
exon O
12 O
genotype O
was O
not O
associated O
with O
sex O
or O
age O
. O
[]

2 O
. O
[]

Results O
from O
a O
randomized O
clinical O
trial O
. O
[]

General O
anesthesia O
and O
higher O
costs O
are O
reasonable O
compromises O
for O
a O
shorter O
period O
of O
discomfort B-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
low O
ASA O
index O
and O
busy O
job/sport O
activity O
. O
['Physiological-Clinical']

Publication O
Type: O
Journal O
Article O
[]

Regional B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
score O
index O
( O
WMSI O
) O
, O
contrast O
score O
index O
( O
['Physiological-Clinical']

Safety O
, O
tolerability B-outcome ['Life-Impact']
, O
and O
immunogenicity B-outcome ['Physiological-Clinical']
after O
1 O
and O
2 O
doses O
of O
zoster O
vaccine O
in O
healthy O
adults O
?60 O
years O
of O
age O
. O
['Life-Impact', 'Physiological-Clinical']

A O
2 O
mg. O
dose O
of O
butorphanol O
was O
found O
to O
be O
analgesically O
equivalent O
to O
80 O
mg. O
meperidine O
, O
while O
a O
4 O
mg. O
dose O
of O
butorphanol O
was O
found O
to O
be O
more O
effective O
than O
80 O
mg. O
meperidine O
and O
2 O
mg. O
butorphanol O
. O
[]

Participants O
assigned O
to O
3CM O
were O
more O
likely O
to O
have O
a O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
visit I-outcome ['Life-Impact']
, O
fill O
an O
antidepressant O
prescription O
, O
and O
have O
adequate B-outcome ['Life-Impact']
antidepressant I-outcome ['Life-Impact']
refills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Attitudes B-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
application B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
significantly O
improved O
for O
workshop-only O
and O
enriched-model O
nurses O
relative O
to O
controls O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Analyses O
controlled O
for O
the O
effect O
of O
chronological O
age O
, O
verbal O
intelligence O
, O
gender O
and O
DVD O
viewing O
time O
on O
outcomes O
. O
[]

Recently O
, O
compression O
devices O
have O
been O
designed O
that O
produce O
high O
pressure O
and O
rapid O
inflation O
of O
air O
cuffs O
on O
the O
plantar O
plexus O
of O
the O
foot O
and O
the O
calf O
. O
[]

Initiatives O
involving O
health O
educators O
, O
outreach O
workers O
, O
medical O
providers O
, O
health O
care O
insurers O
, O
housing O
agencies O
, O
and O
elected O
officials O
are O
needed O
to O
reduce O
these O
exposures O
. O
[]

RESULTS O
Among O
the O
608 O
women O
diagnosed O
with O
CIN3 O
, O
601 O
( O
98.8 O
% O
) O
cases O
were O
positive O
for O
any O
HPV O
genotype O
and O
95.4 O
% O
for O
any O
carcinogenic B-outcome ['Physiological-Clinical']
HPV I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thirty-eight O
mechanically O
ventilated O
patients O
with O
documented O
nosocomial O
pneumonia O
were O
included O
. O
[]

TRIAL O
REGISTRATION O
Netherlands O
Trial O
Register O
NTR2327 O
. O
[]

METHODS O
The O
present O
clinical O
trial O
compared O
GnRH O
antagonist O
( O
cetrorelix O
) O
and O
GnRH O
agonist O
( O
buserelin O
) O
protocols O
during O
COH O
of O
112 O
infertile O
PCOS O
patients O
entering O
assisted O
reproduction O
cycles O
. O
[]

METHODS O
One O
hundred O
and O
fifty O
ASA O
I-II O
patients O
undergoing O
general O
anaesthesia O
were O
randomly O
allocated O
into O
three O
groups O
. O
[]

SUBJECTS O
AND O
SETTINGS O
we O
randomized O
patients O
aged O
75 O
years O
and O
older O
on O
four O
or O
more O
medicines O
who O
had O
been O
discharged O
from O
three O
acute O
general O
and O
one O
long-stay O
hospital O
to O
a O
pharmacy O
intervention O
or O
usual O
care O
. O
[]

Thirty-eight O
percent O
of O
women O
receiving O
a O
letter O
and O
study O
information O
from O
their O
physicians O
contacted O
the O
study O
office O
about O
participation O
. O
[]

Teacher-report O
data O
also O
confirmed O
that O
children O
receiving O
the O
intervention O
made O
significant O
improvements O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
from O
pre- O
to O
post-treatment O
. O
['Life-Impact']

Only O
3 O
(4.4%) O
Veterans O
declined O
participation O
due O
to O
lack O
of O
interest. O
[]

Patients O
are O
required O
to O
return O
to O
the O
study O
centre O
every O
week O
for O
an O
additional O
6 O
weeks O
of O
follow-up O
for O
wound O
evaluation O
and O
management O
. O
[]

Of O
200 O
evaluable O
patients O
, O
51 O
were O
treated O
intramuscularly O
( O
IM O
) O
with O
3 O
x O
10 O
( O
6 O
) O
U O
( O
3 O
MU O
) O
/m2 O
daily O
for O
3 O
weeks O
( O
total O
dose O
63 O
MU/m2 O
) O
, O
50 O
received O
subcutaneous O
thrice-weekly O
injections O
of O
3 O
MU/m2 O
for O
4 O
weeks O
( O
total O
dose O
36 O
MU/m2 O
) O
, O
51 O
underwent O
diathermocoagulation O
, O
and O
48 O
were O
not O
treated O
and O
were O
used O
as O
a O
control O
group O
. O
[]

Adjunctive O
mitomycin O
C O
significantly O
( O
P O
< O
.05 O
) O
improved O
the O
[]

A O
tested O
curriculum O
was O
adapted O
to O
meet O
the O
needs O
of O
the O
target O
population O
. O
[]

It O
is O
important O
to O
consider O
dietary O
sodium O
intake O
when O
assessing O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
From O
September O
2002 O
to O
December O
2004 O
, O
68 O
closed O
fractures O
of O
the O
distal O
femur O
were O
treated O
by O
bridge O
plate O
osteosynthesis O
using O
DCS O
in O
31 O
and O
RIMSN O
in O
37 O
. O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
by O
visual O
analogue O
scale O
( O
VAS O
) O
and O
the O
lumbar B-outcome ['Physiological-Clinical']
flexion I-outcome ['Physiological-Clinical']
range I-outcome ['Physiological-Clinical']
was O
determined O
before O
and O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Prospective O
, O
randomised O
, O
blinded O
and O
placebo-controlled O
trial O
. O
[]

Intensive O
induction O
chemotherapy O
for O
small O
cell O
anaplastic O
carcinoma O
of O
the O
lung O
. O
[]

Intervention O
infants O
received O
a O
parent-implemented O
EDI O
delivered O
with O
home O
visits O
by O
parent O
trainers O
every O
other O
week O
for O
3 O
years O
starting O
the O
first O
month O
after O
birth O
. O
[]

PURPOSE O
To O
compare O
the O
effectiveness O
and O
safety O
of O
excimer O
laser O
trabeculotomy O
( O
ELT O
) O
ab O
interno O
vs O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
over O
24 O
months O
of O
follow-up O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
refractory O
to O
medical O
therapy O
. O
[]

Ultrasound O
therapy O
for O
recalcitrant B-outcome ['Physiological-Clinical']
diabetic I-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
: O
results O
of O
a O
randomized O
, O
double-blind O
, O
controlled O
, O
multicenter O
study O
. O
['Physiological-Clinical']

Baseline O
demographic O
and O
donor O
characteristics O
were O
similar O
between O
groups O
. O
[]

A O
child O
with O
autism O
, O
which O
was O
diagnosed O
by O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
Third O
Edition O
, O
Revised O
, O
criteria O
, O
was O
studied O
. O
[]

Randomized O
clinical O
trial O
of O
hydrocodone/acetaminophen O
versus O
codeine/acetaminophen O
in O
the O
treatment O
of O
acute O
extremity O
pain O
after O
emergency O
department O
discharge O
. O
[]

The O
mean O
age O
, O
baseline O
serum B-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
, O
and O
Cr B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CrCl I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
69.3 O
+/- O
10.8 O
years O
, O
2.5 O
+/- O
0.9 O
mg/dL O
, O
and O
31.4 O
+/- O
12.1 O
mL/min O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
AND O
RESULTS O
Five O
groups O
of O
8 O
subjects O
each O
were O
randomized O
to O
placebo O
( O
n=2 O
) O
or O
torcetrapib O
( O
n=6 O
) O
at O
10 O
, O
30 O
, O
60 O
, O
and O
120 O
mg O
daily O
and O
120 O
mg O
twice O
daily O
for O
14 O
days O
. O
[]

Determination O
of O
the O
severity O
of O
autism O
was O
made O
with O
video O
films O
at O
day O
0 O
( O
D0 O
) O
and O
D90 O
by O
blind O
, O
independent O
evaluators O
. O
[]

Hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
occurred O
in O
7 O
patients O
( O
8.2 O
% O
) O
receiving O
trimethoprim-sulfamethoxazole O
and O
8 O
patients O
( O
9.4 O
% O
) O
receiving O
ciprofloxacin O
( O
difference O
, O
-1.2 O
% O
; O
95 O
% O
CI O
, O
-9.7 O
to O
7.3 O
; O
P O
= O
.90 O
) O
. O
['Mortality']

In O
Experiment O
2 O
, O
20 O
healthy O
volunteers O
underwent O
quantitative O
sensory O
testing O
to O
determine O
heat O
and O
cold O
pain O
thresholds O
during O
the O
rubber O
hand O
illusion O
or O
during O
a O
control O
condition O
. O
[]

Dose-finding O
study O
] O
. O
[]

Cortisol B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
Alzheimer O
's O
disease O
( O
AD O
) O
are O
relatively O
unaffected O
by O
a O
challenge O
with O
dexamethasone O
( O
DEX O
) O
in O
vivo O
. O
['Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
using O
a O
Deltrac O
monitor O
, O
and O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
EEPA I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
was O
estimated O
using O
a O
Caltrac O
accelerometer O
. O
['Physiological-Clinical', 'Life-Impact']

Covariates O
introduced O
. O
[]

Aspirin-induced O
loss O
of O
stored O
iron O
from O
chronic O
gastrointestinal O
bleeding O
is O
proposed O
as O
a O
mechanism O
underlying O
this O
beneficial O
effect O
. O
[]

Journal-Name:BMC O
neurology O
[]

There O
was O
no O
difference O
between O
treatments O
in O
total O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
ENT O
37.1 O
( O
se O
2.6 O
) O
, O
PLA O
35.9 O
( O
se O
3.2 O
) O
MJ O
) O
, O
macronutrient B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
hunger B-outcome ['Physiological-Clinical']
, O
satiety B-outcome ['Physiological-Clinical']
and O
hedonic B-outcome ['Physiological-Clinical']
scores O
during O
the O
4 O
d O
high-fat O
diet O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
mean O
6-month O
change O
in O
central B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
the O
combination O
group O
was O
-124 O
?m O
( O
-29.7 O
% O
; O
p O
< O
0.001 O
) O
, O
while O
in O
the O
ranibizumab-only O
group O
, O
the O
change O
was O
-86.9 O
?m O
( O
-19.5 O
% O
; O
p=0.001 O
) O
; O
thus O
, O
the O
combination O
treatment O
resulted O
in O
a O
greater O
reduction O
( O
p=0.003 O
) O
. O
['Physiological-Clinical']

It O
is O
therefore O
suggested O
that O
the O
MA-sensitive O
chemotaxis O
plays O
a O
reparative O
role O
in O
the O
inflammatory O
lesions O
of O
rheumatoid O
arthritis O
. O
[]

We O
previously O
conducted O
a O
regional O
study O
in O
the O
Quebec's O
Eastern O
Townships O
region, O
the O
PromoVac O
Study, O
to O
test O
a O
new O
educational O
intervention, O
based O
on O
motivational O
interviewing O
techniques, O
aimed O
at O
promoting O
infant B-outcome ['Life-Impact']
vaccination I-outcome ['Life-Impact']
. O
This O
first O
study O
evidenced O
that O
the O
intervention O
led O
to O
a O
marked O
increase O
in O
mothers' O
intention B-outcome ['Life-Impact']
to O
vaccinate, O
and O
vaccine B-outcome ['Life-Impact']
coverage O
in O
their O
infants. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

METHODS: O
This O
prospective O
study O
included O
113 O
cirrhotic O
patients O
with O
actively O
bleeding O
esophageal O
varices. O
[]

CONCLUSIONS O
Thus O
, O
prior O
treatment O
with O
frusemide O
increased O
baseline O
pulmonary B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and O
significantly O
augmented O
the O
['Physiological-Clinical']

A O
prospective O
multicenter O
trial O
was O
conducted O
in O
155 O
consecutive O
patients O
with O
Stage O
IV O
breast O
cancer O
randomly O
allocated O
to O
receive O
either O
( O
1 O
) O
vincristin O
( O
V O
) O
1.2 O
mg/m2 O
( O
maximum O
dose O
, O
2 O
mg O
) O
, O
Adriamycin O
( O
A O
) O
( O
doxorubicin O
) O
40 O
mg/m2 O
, O
and O
cyclophosphamide O
( O
C O
) O
500 O
mg/m2 O
, O
all O
intravenously O
on O
day O
1 O
, O
every O
4 O
weeks O
, O
in O
combination O
with O
medroxyprogesteron O
acetate O
( O
MPA O
) O
600 O
mg O
orally O
on O
days O
1 O
through O
14 O
, O
500 O
mg O
intramuscularly O
on O
days O
1 O
through O
28 O
, O
and O
twice O
weekly O
afterwards O
( O
combined O
chemoendocrine O
approach O
) O
or O
( O
2 O
) O
the O
same O
combination O
chemotherapy O
( O
VAC O
) O
for O
three O
cycles O
alternating O
with O
MPA O
in O
the O
above-mentioned O
dosage O
during O
8 O
weeks O
( O
alternating O
chemoendocrine O
approach O
) O
. O
[]

The O
estimation O
of O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
is O
important O
for O
the O
medical O
treatment O
of O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O
['Physiological-Clinical']

In O
2 O
separate O
phases O
, O
women O
who O
met O
triage O
criteria O
were O
randomly O
assigned O
to O
either O
the O
triage O
room O
or O
the O
standard O
care O
labor O
room O
. O
[]

For O
pediatric O
patients O
with O
asymptomatic O
low-stage O
and O
intermediate-stage O
Hodgkin O
disease O
, O
chemotherapy O
and O
chemoradiotherapy O
both O
resulted O
in O
3-year O
EFS B-outcome ['Mortality']
of O
approximately O
90 O
% O
and O
statistically O
indistinguishable O
8-year O
EFS B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
without O
significant O
long-term O
toxicity B-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Adverse-effects']

Spironolactone O
for O
heart O
failure O
with O
preserved O
ejection O
fraction O
. O
[]

Overall O
, O
38 O
patients O
( O
19.3 O
% O
) O
had O
cesarean O
deliveries O
. O
[]

RESULTS O
There O
was O
statistically O
significant O
improvement O
from O
the O
baseline O
value O
in O
both O
the O
arms O
, O
i.e O
injection O
papaverine O
and O
oral O
sildenafil O
( O
p O
< O
0.001 O
, O
p O
< O
0.001 O
, O
respectively O
) O
for O
both O
penile B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
and O
circumference B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Efficacy O
was O
evaluated O
using O
standard B-outcome ['Life-Impact']
psychiatric I-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
scales O
, O
and O
patients O
were O
monitored O
for O
safety O
. O
['Life-Impact']

CONCLUSION O
The O
low-tilt O
biphasic O
waveform O
was O
more O
successful O
for O
the O
internal O
cardioversion O
of O
both O
persistent O
and O
induced O
AF O
in O
patients O
( O
in O
terms O
of O
leading O
edge O
voltage O
) O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

PURPOSE O
MDM2 O
regulates O
p53 O
, O
which O
controls O
cell O
cycle O
arrest O
and O
apoptosis O
. O
[]

CONCLUSION O
Prolonged O
subclinical O
hyperthyroidism O
leads O
to O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
, O
which O
is O
reversible O
after O
restoration O
of O
euthyroidism O
. O
['Physiological-Clinical']

All O
intervention O
groups O
received O
modified O
carbohydrate O
nutrition O
classes O
( O
once O
a O
week O
) O
, O
whereas O
the O
N O
+ O
ST O
also O
received O
strength O
training O
( O
twice O
a O
week O
) O
and O
the O
N O
+ O
CAST O
received O
a O
combination O
of O
strength O
and O
aerobic O
training O
( O
twice O
a O
week O
) O
. O
[]

Follow-up O
data O
including O
adherence O
to O
prasugrel O
therapy O
were O
collected O
by O
telephone O
interviews O
or O
outpatient O
visits O
. O
[]

INTERPRETATION O
Our O
data O
suggest O
that O
oral O
sucrose O
does O
not O
significantly O
affect O
activity O
in O
neonatal O
brain O
or O
spinal O
cord O
nociceptive O
circuits O
, O
and O
therefore O
might O
not O
be O
an O
effective O
analgesic O
drug O
. O
[]

Statistical O
analysis O
was O
performed O
by O
linear O
models O
and O
standard O
F O
tests O
. O
[]

Modelling O
of O
the O
predicted O
species O
interactions O
in O
a O
single O
DFU O
with O
high O
diversity O
indicated O
that O
networks O
of O
metabolic O
interactions O
may O
exist O
that O
contribute O
to O
the O
formation O
of O
stable O
communities. O
[]

BACKGROUND O
Children O
with O
autism O
have O
difficulties O
in O
emotion O
recognition O
and O
a O
number O
of O
interventions O
have O
been O
designed O
to O
target O
these O
problems O
. O
[]

For O
Candida O
albicans O
, O
however O
, O
the O
maximum O
reduction O
was O
91 O
% O
on O
the O
first O
day O
and O
67 O
% O
on O
Day O
8 O
, O
maintained O
for O
30 O
minutes O
post-dosing O
. O
[]

METHODS: O
The O
research O
is O
a O
prospective O
comparative O
randomized O
study. O
[]

Clearfil O
Protect O
Bond O
showed O
higher O
bond B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
to O
enamel O
than O
Xeno O
III O
, O
irrespective O
of O
the O
ozone O
treatment O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

These O
models O
included O
a O
dichotomised O
version O
of O
DUP O
( O
short O
versus O
long O
duration O
) O
as O
a O
fixed O
effect O
, O
several O
adjusting O
variables O
to O
account O
for O
patient O
differences O
, O
and O
a O
random O
effect O
to O
incorporate O
the O
longitudinal O
structure O
of O
the O
data O
. O
[]

METHODS O
Thirteen O
healthy O
human O
volunteers O
( O
6 O
men O
and O
7 O
women O
, O
aged O
20-28 O
years O
) O
were O
included O
in O
the O
study O
. O
[]

CONCLUSION O
Fexofenadine O
did O
not O
affect O
recovery O
to O
a O
fixed O
dose O
of O
AMP O
challenge O
or O
any O
other O
surrogate O
inflammatory O
markers O
when O
given O
as O
add-on O
therapy O
to O
corticosteroid-treatedatopic O
asthmatic O
patients O
. O
[]

OBJECTIVE O
To O
test O
the O
effect O
of O
a O
consumer-directed O
model O
( O
Cash O
and O
Counseling O
) O
of O
Medicaid O
personal O
care O
services O
( O
PCS O
) O
or O
home- O
and O
community-based O
waiver O
services O
( O
HCBS O
) O
on O
the O
cost O
of O
Medicaid O
services O
. O
[]

Analysis O
was O
based O
on O
intention O
to O
treat O
, O
with O
statistical O
adjustment O
for O
clustering O
within O
hospitals/clinics O
to O
permit O
inferences O
at O
the O
individual O
level O
. O
[]

Hypogammaglobulinemia O
at O
D15 O
was O
not O
associated O
with O
an O
increased O
risk O
of O
infections O
during O
the O
first O
year O
. O
[]

In O
task O
two O
, O
participants O
brought O
their O
outstretched O
hand O
to O
the O
target O
. O
[]

Experiment O
1 O
compared O
the O
difference O
in O
the O
depth O
of O
the O
osteotomy B-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
use O
of O
a O
simple O
tele-messaging O
device O
as O
an O
adjunct O
to O
symptom O
management O
is O
feasible B-outcome ['Life-Impact']
, O
affordable B-outcome ['Life-Impact']
, O
and O
acceptable B-outcome ['Life-Impact']
to O
patients O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
experimental O
sets O
were O
performed O
to O
momentary O
muscular O
failure. O
[]

The O
incidence O
of O
the O
disease O
is O
rising O
rapidly O
in O
many O
countries O
, O
and O
there O
is O
no O
generally O
accepted O
standard O
treatment O
for O
patients O
with O
unresectable O
disease O
. O
[]

Recent O
studies O
have O
demonstrated O
that O
the O
calcium O
channel O
blocking O
agents O
can O
inhibit O
experimentally B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
bronchoconstriction I-outcome ['Physiological-Clinical']
in O
asthmatics O
, O
but O
their O
protective O
action O
has O
been O
variable O
. O
['Physiological-Clinical']

Forty O
were O
recommended O
one O
or O
more O
behavioural O
changes O
and O
eight O
had O
no O
need O
. O
[]

However O
, O
during O
the O
whole O
12-month O
training O
period O
, O
both O
dynamic B-outcome ['Physiological-Clinical']
and O
isometric B-outcome ['Physiological-Clinical']
back B-outcome ['Physiological-Clinical']
extension I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
difference O
regarding O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
noticed O
. O
['Life-Impact']

These O
effects O
are O
not O
evident O
with O
camazepam O
, O
which O
does O
not O
seem O
to O
distort O
the O
normal O
sleep O
pattern O
. O
[]

Our O
results O
showed O
that O
parahippocampal B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
significantly O
enhanced O
bilaterally O
when O
participants O
viewed O
images O
of O
a O
room O
in O
which O
they O
had O
previously O
encountered O
negatively O
arousing O
events O
. O
['Physiological-Clinical']

FINDINGS O
We O
randomised O
44 O
patients O
to O
combination O
and O
45 O
to O
single O
agent O
. O
[]

In O
the O
Er O
, O
Cr O
: O
YSGG O
laser O
group O
, O
sensitive O
teeth O
were O
irradiated O
with O
Er O
, O
Cr O
: O
YSGG O
laser O
in O
the O
hard O
tissue O
mode O
using O
a O
none-contact O
probe O
at O
an O
energy O
level O
of O
0.25W O
and O
repetition O
rate O
of O
20Hz O
, O
0 O
% O
water O
and O
10 O
% O
air O
. O
[]

In O
total O
, O
42 O
patients O
opted O
to O
cross O
over O
; O
median O
PFS O
was O
3.2 O
months O
( O
95 O
% O
CI O
1.7 O
, O
5.1 O
) O
on O
lapatinib O
plus O
vinorelbine O
and O
4.0 O
months O
( O
95 O
% O
CI O
2.1 O
, O
5.8 O
) O
on O
lapatinib O
plus O
capecitabine O
. O
[]

[ O
The O
sympatho-adrenergic O
stress O
reaction O
in O
ear O
surgery O
using O
various O
anesthesia O
technics O
] O
. O
[]

A O
double-blind O
, O
placebo-controlled O
crossover O
study O
investigating O
the O
effect O
of O
porcine O
secretin O
in O
children O
with O
autism O
. O
[]

CONCLUSIONS: O
Among O
patients O
with O
early O
Parkinson's O
disease O
who O
were O
evaluated O
over O
the O
course O
of O
80 O
weeks, O
treatment O
with O
levodopa O
in O
combination O
with O
carbidopa O
had O
no O
disease-modifying O
effect. O
( O
[]

Of O
the O
40 O
children O
enrolled O
, O
39 O
completed O
the O
trial O
over O
a O
period O
of O
18 O
months O
; O
19 O
received O
risperidone O
, O
and O
20 O
received O
placebo O
. O
[]

Randomized O
controlled O
study O
of O
chemoprophylaxis O
in O
transurethral O
prostatectomy O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
slit-lamp B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
ulceration I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
corrected I-outcome ['Physiological-Clinical']
distance O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
until I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
and O
complications B-outcome ['Resource-use']
were O
documented O
in O
each O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

The O
duration O
of O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
, O
the O
number O
of O
['Resource-use', 'Resource-use']

Intervention O
of O
a O
sleep O
technician O
in O
the O
patient O
's O
home O
was O
the O
least O
expensive B-outcome ['Life-Impact']
strategy O
, O
because O
of O
the O
high O
percentages O
of O
faulty O
studies O
with O
the O
patient O
's O
own O
setup O
of O
the O
equipment O
, O
when O
using O
the O
limited O
sleep-recording O
device O
. O
['Life-Impact']

LIMITATIONS O
Small O
sample O
size O
. O
[]

The O
effects O
of O
dietary O
supplementation O
with O
coconut O
oil O
on O
the O
biochemical B-outcome ['Physiological-Clinical']
and O
anthropometric B-outcome ['Physiological-Clinical']
profiles O
of O
women O
presenting O
waist O
circumferences O
( O
WC O
) O
> O
88 O
cm O
( O
abdominal O
obesity O
) O
were O
investigated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
results O
of O
this O
study O
support O
the O
efficacy O
and O
tolerability O
of O
melatonin O
treatment O
for O
sleep O
problems O
in O
children O
with O
ASD O
and O
FXS O
. O
[]

Impact O
of O
antisecretory O
treatment O
on O
respiratory B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastroesophageal I-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
children O
. O
['Physiological-Clinical']

For O
identified O
cases O
, O
rosters O
were O
prepared O
and O
sent O
to O
the O
physician O
with O
a O
cover O
letter O
and O
study O
description O
. O
[]

Title: O
Effect O
of O
diet O
with O
or O
without O
exercise O
on O
abdominal O
fat O
</> O
in O
postmenopausal O
women O
- O
a O
randomised O
trial. O
[]

Journal-Name:Journal O
of O
ovarian O
research O
[]

A O
precycle B-outcome ['Physiological-Clinical']
risk O
score O
from O
> O
or O
=25 O
to O
< O
40 O
for O
a O
given O
patient O
was O
identified O
as O
being O
the O
optimal O
threshold O
for O
sensitivity O
( O
58.0 O
% O
) O
and O
specificity O
( O
78.7 O
% O
) O
. O
['Physiological-Clinical']

Full O
history, O
clinical O
examination, O
and O
routine O
baseline O
investigations O
were O
performed. O
[]

RESULTS O
Changes O
in O
the O
DAS28 O
, O
the O
SDAI O
score O
, O
and O
the O
CDAI B-outcome ['Physiological-Clinical']
score O
among O
patients O
receiving O
tocilizumab O
were O
significantly O
higher O
than O
those O
among O
patients O
receiving O
placebo O
, O
and O
the O
magnitude O
of O
these O
changes O
was O
similar O
for O
the O
SDAI O
and O
the O
CDAI B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
operative O
laparoscopy O
is O
a O
safe O
procedure O
for O
the O
removal O
of O
dermoid O
ovarian O
cysts O
and O
is O
as O
effective O
as O
laparotomy O
. O
[]

PATIENTS O
AND O
METHODS O
Between O
January O
1983 O
and O
February O
1989 O
, O
a O
total O
of O
165 O
patients O
with O
carcinoma O
of O
the O
uterine O
cervix O
was O
entered O
in O
a O
prospective O
randomized O
study O
concerning O
the O
point O
A O
dose O
of O
HDR O
therapy O
( O
6 O
Gy/fraction O
vs O
7.5 O
Gy/fraction O
) O
and O
external O
irradiation O
dose O
at O
Department O
of O
Radiation O
Therapy O
, O
The O
Center O
for O
Adult O
Diseases O
, O
Osaka O
. O
[]

All O
patients O
that O
were O
operated O
returned O
to O
full B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
However, O
median O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
was O
longer O
and O
lasted O
1 O
hour O
and O
55 O
minutes. O
[['Life-Impact'], ['Life-Impact']]

METHODS O
One O
hundred O
patients O
were O
randomized O
into O
2 O
groups O
to O
undergo O
percutaneous O
transmitral O
commissurotomy O
( O
PTMC O
) O
by O
means O
of O
the O
Inoue O
balloon O
technique O
( O
IBMC O
, O
n O
= O
49 O
) O
or O
metallic O
commissurotomy O
( O
PMMC O
, O
n O
= O
51 O
) O
. O
[]

To O
detect O
trends O
in O
confidence O
, O
confidence O
scores O
were O
plotted O
over O
time O
, O
and O
multiple O
linear O
regression O
analysis O
was O
performed O
. O
[]

Experimental O
and O
clinical O
studies O
have O
shown O
the O
beneficial O
effects O
of O
triiodothyronine O
( O
T3 O
) O
following O
myocardial O
revascularization O
on O
cardiopulmonary O
bypass O
( O
CPB O
) O
. O
[]

Psychoeducational O
group O
intervention O
for O
wives O
of O
men O
with O
prostate O
cancer O
. O
[]

METHODS: O
This O
multicenter, O
double-blind, O
double-dummy, O
parallel O
group, O
randomized, O
placebo-controlled O
trial O
was O
conducted O
in O
Ethiopia, O
Peru, O
Brazil, O
Cambodia, O
Thailand, O
and O
the O
Philippines. O
[]

Three O
long-term O
survivors B-outcome ['Mortality']
were O
seen O
in O
the O
latter O
group O
. O
['Mortality']

BACKGROUND O
Children O
with O
autism O
spectrum O
disorders O
often O
present O
with O
comorbid O
anxiety O
disorders O
that O
cause O
significant O
functional B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
People O
with O
BBTW O
showed O
a O
significant O
improvement O
in O
the O
25-foot B-outcome ['Physiological-Clinical']
walk I-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
no O
weight O
, O
and O
the O
TUG B-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
standard O
weight O
placement O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Multicenter O
Study O
[]

For O
a O
subset O
of O
the O
participants O
( O
53 O
children O
ages O
5-16 O
) O
pre O
and O
post O
measurements O
of O
nutritional O
and O
metabolic O
status O
were O
also O
conducted O
. O
[]

Two O
breasts O
with O
smooth O
prostheses O
were O
contracted O
after O
6 O
months O
( O
Baker O
III O
or O
IV O
) O
. O
[]

25.1 O
U/L O
, O
P O
< O
0.05 O
or O
P O
< O
0.01 O
) O
. O
[]

Treatments O
were O
administered O
4 O
times O
at O
weekly O
intervals O
. O
[]

Analysis O
comparing O
change O
between O
baseline O
and O
week O
8 O
of O
treatment O
for O
L-carnitine O
and O
the O
placebo O
showed O
that O
both O
parents/caregivers O
and O
medical O
follow-up O
detected O
improvements O
in O
the O
subjects O
' O
well-being B-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
L-carnitine O
was O
proposed O
as O
a O
potential O
treatment O
for O
patients O
diagnosed O
with O
an O
autism O
spectrum O
disorder O
to O
improve O
mitochondrial O
dysfunction O
, O
but O
no O
prior O
randomized O
controlled O
trials O
have O
been O
conducted O
. O
[]

Primary O
characteristics O
for O
confirmative O
assessment O
of O
no O
interaction O
were O
AUC O
and O
Cmax O
of O
digoxin O
. O
[]

The O
risk O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
was O
reduced O
by O
62 O
% O
in O
the O
therapy O
group O
, O
p O
= O
.13 O
. O
['Mortality']

RESULTS O
The O
intervention O
reduced O
significantly O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
inflammation B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
was O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
at O
10 O
years. O
[['Mortality']]

The O
objective O
of O
this O
case O
was O
report O
on O
the O
effects O
of O
acute O
whole O
body O
vibration O
exposure O
on O
stereotyped B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
of O
young O
children O
with O
autism O
. O
['Life-Impact']

CONCLUSIONS O
Aliskiren O
significantly O
reduced O
proteinuria B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
value O
of O
P O
< O
or O
= O
.05 O
was O
considered O
significant O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Noncompliance O
to O
blood O
draws O
can O
have O
significant O
ramifications O
in O
both O
research O
and O
clinical O
settings O
. O
[]

METHODS O
Outcomes O
7.5 O
months O
after O
randomisation O
were O
acceptability B-outcome ['Life-Impact']
of O
randomisation O
, O
overall B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
of O
and O
satisfaction B-outcome ['Life-Impact']
with O
conservative B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
, O
impact O
on O
quality O
of O
life O
, O
perceived B-outcome ['Life-Impact']
need I-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
further I-outcome ['Life-Impact']
treatment I-outcome ['Life-Impact']
and O
treatment O
failure B-outcome ['Physiological-Clinical']
( O
defined O
a O
priori O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

5 O
% O
frequency O
in O
the O
total O
group O
) O
AEs O
were O
increased O
appetite O
( O
11 O
% O
[ O
n=9 O
] O
) O
; O
increased O
weight O
and O
vomiting O
( O
9 O
% O
[ O
n=7 O
] O
each O
) O
; O
sedation O
, O
pyrexia O
, O
and O
upper O
respiratory O
tract O
infection O
( O
8 O
% O
[ O
n=6 O
] O
each O
) O
; O
nasopharyngitis O
( O
6 O
% O
[ O
n=5 O
] O
) O
; O
and O
somnolence O
and O
fatigue O
( O
5 O
% O
[ O
n=4 O
] O
each O
) O
. O
[]

STUDY O
DESIGN O
Two O
hundred O
patients O
with O
indications O
for O
induction O
of O
labor O
and O
unfavorable O
cervical O
examinations O
were O
randomly O
assigned O
to O
receive O
vaginally O
administered O
misoprostol O
( O
prostaglandin O
E1 O
) O
or O
the O
dinoprostone O
( O
prostaglandin O
E2 O
) O
vaginal O
insert O
. O
[]

ANIMALS O
Eighteen O
mallard O
ducks O
were O
included O
for O
the O
LD O
( O
50 O
) O
study O
and O
28 O
for O
the O
fluid O
resuscitation O
study O
. O
[]

Contrast O
sensitivity B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
a O
photopic O
condition O
with O
and O
without O
glare O
and O
in O
a O
scotopic O
condition O
without O
glare O
. O
['Physiological-Clinical']

No O
other O
measures O
reached O
statistical O
significance O
. O
[]

RESULTS O
Between O
February O
2003 O
and O
July O
2005 O
, O
25 O
patients O
were O
enrolled O
. O
[]

Physical B-outcome ['Physiological-Clinical']
scores O
declined O
significantly O
over O
time O
, O
independent O
of O
treatment O
, O
and O
patients O
with O
cirrhosis O
reported O
lower O
scores O
. O
['Physiological-Clinical']

OBJECTIVES O
to O
determine O
the O
effectiveness O
of O
a O
health O
information O
package O
in O
terms O
of O
empowering O
the O
pregnant O
women O
to O
modify O
their O
health-care O
behaviour O
and O
take O
appropriate O
action O
to O
combat O
anaemia O
in O
pregnancy O
. O
[]

CONCLUSIONS O
The O
results O
of O
this O
study O
provide O
preliminary O
evidence O
that O
omega-3 O
fatty O
acids O
may O
be O
an O
effective O
treatment O
for O
children O
with O
autism O
. O
[]

These O
observations O
were O
compiled O
in O
detailed O
daily O
notes O
. O
[]

Valsartan B-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
LVMI I-outcome ['Physiological-Clinical']
after O
eight O
months O
, O
but O
amlodipine O
had O
less O
effect O
( O
16 O
% O
vs. O
1.2 O
% O
, O
n O
= O
50 O
, O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
baseline O
drug O
was O
efonidipine O
hydrochloride O
, O
a O
long-acting O
calcium O
antagonist O
. O
[]

OBJECTIVE O
To O
assess O
the O
association O
between O
maternal O
breast-milk O
and O
fecal O
bifidobacteria O
and O
infants O
' O
fecal O
bifidobacteria O
. O
[]

Fifty-five O
women O
in O
5 O
village O
clusters O
received O
the O
ABHR O
and O
used O
it O
from O
birth O
to O
3 O
months O
postnatally, O
with O
use O
guided O
by O
the O
new O
poster. O
[]

Title: O
Application O
of O
intrapulmonary O
wire O
combined O
with O
intrapleural O
fibrin O
glue O
in O
preoperative O
localization O
of O
small O
pulmonary O
nodules. O
[]

A O
placebo O
controlled O
crossover O
trial O
of O
liquid O
fluoxetine O
on O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
childhood O
and O
adolescent O
autism O
. O
['Life-Impact']

Increased O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
neural B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
in O
the O
silent O
ischemia O
of O
hypertension O
: O
disparate O
effects O
of O
immediate O
release O
nifedipine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
randomly O
assigned O
to O
fitting O
with O
NLFC O
( O
Phonak O
Naida O
V O
SP O
or O
UP O
) O
or O
with O
conventional O
processing O
in O
hearing O
aids O
, O
prescribed O
by O
using O
either O
the O
NAL O
or O
the O
DSL O
formula O
. O
[]

Twelve O
dams O
received O
dexamethasone O
( O
2 O
mg/dose O
) O
72 O
, O
48 O
, O
and O
24 O
h O
before O
abdominal O
delivery O
at O
135 O
+/- O
1 O
days O
of O
gestation O
. O
[]

Similarly O
no O
differences O
were O
evident O
in O
subtype O
analysis O
. O
[]

Journal O
ID: O
8109496 O
[]

Ten O
patients O
dropped O
out O
of O
the O
transfusion O
group O
, O
and O
two O
patients O
crossed O
over O
from O
the O
standard-care O
group O
to O
the O
transfusion O
group O
. O
[]

The O
subjects O
were O
randomly O
assigned O
to O
the O
supplemented O
group O
(n O
= O
10), O
receiving O
150 O
mg O
of O
L-theanine O
extract O
for O
6 O
weeks, O
or O
to O
the O
placebo O
group O
(n O
= O
10). O
[]

Title: O
[Evaluation O
of O
intervention O
program O
for O
risk O
behaviors O
of O
unintentional O
injury O
among O
school O
age O
children]. O
[]

METHODS O
Some O
204 O
patients O
with O
mid O
and O
low O
rectal O
adenocarcinomas O
were O
allocated O
randomly O
to O
open O
( O
103 O
) O
or O
laparoscopic O
( O
101 O
) O
surgery O
. O
[]

Results O
of O
a O
phase O
III O
, O
8-week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double-blind O
, O
parallel-group O
clinical O
trial O
to O
assess O
the O
effects O
of O
amlodipine O
camsylate O
versus O
amlodipine O
besylate O
in O
Korean O
adults O
with O
mild O
to O
moderate O
hypertension O
. O
[]

This O
study O
presents O
the O
preliminary O
results O
of O
a O
randomized O
prospective O
two-arm O
study O
in O
which O
bacillus O
Calmette-Gu?rin O
( O
BCG O
) O
RIVM O
, O
a O
Dutch O
BCG O
preparation O
, O
is O
compared O
with O
mitomycin O
C O
( O
MMC O
) O
in O
patients O
with O
primary O
or O
recurrent O
superficial O
bladder O
tumors O
, O
including O
carcinoma O
in O
situ O
( O
CIS O
) O
. O
[]

This O
study O
examined O
the O
relatively O
unexplored O
contribution O
of O
the O
therapist O
's O
performance B-outcome ['Life-Impact']
in O
determining O
outcomes O
of O
treatment O
. O
['Life-Impact']

METHOD O
Fifty O
patients O
with O
blepharitis O
, O
conjuctivitis O
, O
or O
blepharoconjunctivitis O
were O
randomly O
assigned O
to O
treatment O
with O
0.3 O
% O
ofloxacin O
eyedrops O
, O
BID O
or O
QID O
, O
for O
10 O
days O
. O
[]

Times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
two-segment I-outcome ['Physiological-Clinical']
and O
T-10 B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
were O
comparable O
in O
the O
two O
groups O
( O
112 O
+/- O
26 O
min O
in O
Group O
1 O
versus O
122 O
+/- O
28 O
min O
in O
Group O
2 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
clinical O
or O
objective O
improvement O
in O
the O
two O
groups O
. O
[]

Pre-exposure O
studies O
with O
purified O
chick O
embryo O
cell O
culture O
rabies O
vaccine O
and O
human O
diploid O
cell O
vaccine O
: O
serological O
and O
clinical O
responses O
in O
man O
. O
[]

Renal O
function O
was O
assessed O
by O
serially O
measuring O
the O
serum O
creatinine O
, O
glomerular O
filtration O
rate O
( O
using O
Cr51-EDTA O
) O
, O
and O
24-h O
urinary O
protein O
excretion O
. O
[]

PARTICIPANTS O
Two O
hundred O
thirty-eight O
elderly O
men O
and O
women O
aged O
60 O
to O
80 O
at O
high O
risk O
for O
cardiovascular O
disease O
were O
randomly O
assigned O
to O
three O
interventional O
groups O
: O
a O
recommended O
low-fat O
diet O
( O
control O
diet O
group O
) O
, O
a O
Mediterranean O
diet O
supplemented O
with O
virgin O
olive O
oil O
, O
or O
a O
Mediterranean O
diet O
supplemented O
with O
mixed O
nuts O
. O
[]

Vigorous O
, O
aerobic O
exercise O
versus O
general O
motor O
training O
activities O
: O
effects O
on O
maladaptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
stereotypic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
of O
adults O
with O
both O
autism O
and O
mental O
retardation O
. O
['Life-Impact']

Gait B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
increased O
significantly O
between O
JM O
and O
JM O
+ O
30 O
in O
both O
groups O
, O
with O
no O
difference O
between O
groups O
. O
['Life-Impact']

adjuvant O
[ O
chemo O
] O
RT O
) O
in O
patients O
with O
OPSCC O
. O
[]

RESULTS O
The O
SRE B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
at O
1 O
year O
( O
excluding O
HCM O
and O
adjusted O
for O
prior O
fracture O
) O
was O
0.61 O
( O
permutation O
test O
; O
P O
= O
.027 O
) O
, O
indicating O
that O
zoledronic O
acid O
reduced O
the O
rate O
of O
SRE B-outcome ['Physiological-Clinical']
by O
39 O
% O
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
We O
conclude O
that O
CCRT O
is O
superior O
to O
RT O
alone O
for O
patients O
with O
advanced O
NPC O
in O
endemic O
areas O
. O
[]

Follow-on O
oral O
antibiotics O
were O
permitted O
in O
both O
groups. O
[]

Fatigue O
( O
P O
< O
.001 O
) O
, O
nausea O
( O
P O
= O
.01 O
) O
, O
depression O
( O
P O
= O
.02 O
) O
, O
anxiety O
( O
P O
= O
.01 O
) O
, O
drowsiness O
( O
P O
< O
.001 O
) O
, O
appetite O
( O
P O
= O
.009 O
) O
, O
sleep O
( O
P O
< O
.001 O
) O
, O
and O
feeling O
of O
well-being O
( O
P O
< O
.001 O
) O
, O
as O
measured O
by O
the O
ESAS O
, O
significantly O
improved O
in O
patients O
who O
received O
NTI O
. O
[]

The O
communication O
subscale O
of O
the O
CSBS O
, O
specifying O
communication O
function O
, O
reciprocity O
, O
and O
social-affective O
signalling O
was O
videotaped O
and O
scored O
by O
a O
blinded O
, O
trained O
observer O
. O
[]

In O
this O
study, O
for O
the O
first O
time, O
it O
was O
presented O
that O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
asymmetry I-outcome ['Physiological-Clinical']
visible O
in O
ultrasonography O
may O
be O
corrected O
by O
this O
specific O
exercise. O
[['Physiological-Clinical']]

In O
conclusion O
, O
this O
study O
shows O
that O
a O
2-dimensional O
, O
handheld O
ultrasound O
device O
and O
a O
newly O
developed O
ultrasound O
volume O
scanner O
can O
effectively O
identify O
patients O
with O
AAAs O
confirmed O
by O
CT O
. O
[]

Among O
group O
A O
patients O
, O
the O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
risk O
was O
greater O
in O
those O
randomised O
to O
stenting O
( O
odds O
ratios O
6.603 O
v O
1.197 O
, O
p O
= O
0.046 O
) O
, O
whereas O
there O
was O
no O
difference O
in O
risk O
if O
the O
group O
was O
analysed O
according O
to O
whether O
the O
CFVR O
was O
< O
2.5 O
or O
> O
/= O
2.5 O
after O
balloon O
angioplasty O
. O
['Adverse-effects']

Side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
overall O
opinion O
were O
assessed O
. O
['Adverse-effects']

RESULTS O
Between O
July O
4 O
, O
2006 O
and O
March O
12 O
, O
2007 O
, O
a O
total O
of O
41 O
patients O
were O
screened O
and O
34 O
patients O
were O
randomized O
. O
[]

RESULTS O
Four O
hundred O
fifty-three O
children O
with O
ASD O
and O
125 O
DD O
children O
were O
included O
. O
[]

The O
Studies O
to O
Advance O
Autism O
Research O
and O
Treatment O
Network O
conducted O
a O
randomized O
trial O
with O
citalopram O
in O
children O
with O
Pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

RESULTS O
Glycaemia B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
clonidine O
group O
( O
P O
< O
0.01 O
) O
and O
the O
median O
amount O
of O
['Physiological-Clinical']

Parents O
and O
caregivers O
of O
children O
6 O
to O
40 O
months O
age O
group O
in O
intervention O
villages O
received O
intensive O
education O
on O
hand O
hygiene. O
[]

OBJECTIVE O
To O
investigate O
the O
impact O
of O
nasal O
irrigation O
with O
isotonic O
or O
hypertonic O
sodium O
chloride O
solution O
on O
mucociliary O
clearance O
time O
in O
patients O
with O
allergic O
rhinitis O
, O
acute O
sinusitis O
and O
chronic O
sinusitis O
. O
[]

The O
change O
in O
initial O
claudication O
distance O
during O
treatment O
, O
expressed O
as O
integrated O
change O
over O
time O
, O
was O
significantly O
greater O
with O
heparan O
sulfate O
than O
with O
placebo O
( O
306 O
+/- O
494 O
vs. O
250 O
+/- O
510 O
meters O
x O
months O
, O
p O
= O
0.019 O
) O
. O
[]

This O
study O
shows O
final B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
60 O
girls O
with O
Turner O
syndrome O
treated O
in O
a O
randomized O
dose-response O
trial O
, O
combining O
GH O
treatment O
with O
low O
dose O
estrogens O
at O
a O
relatively O
young O
age O
. O
['Physiological-Clinical']

Approved O
by O
the O
Ethics O
Committee O
of O
Lower O
Austria O
(GS4-EK-4/107-2010). O
[]

However O
, O
when O
subjects O
were O
examined O
individually O
both O
the O
GHRH- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
TRH-induced I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
subsequent I-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
were O
not O
different O
in O
both O
groups O
. O
['Physiological-Clinical']

OBJECTIVE O
Ibuprofen O
arginate O
is O
a O
salt O
formulation O
of O
ibuprofen O
designed O
to O
reach O
target O
concentrations O
rapidly O
. O
[]

Hyperalgesia B-outcome ['Physiological-Clinical']
was O
induced O
by O
using O
an O
experimental O
pain O
model O
that O
uses O
heat O
and O
capsaicin O
in O
combination O
. O
['Physiological-Clinical']

4 O
. O
[]

Ropinirole O
as O
a O
treatment O
of O
restless O
legs O
syndrome O
in O
patients O
on O
chronic O
hemodialysis O
: O
an O
open O
randomized O
crossover O
trial O
versus O
levodopa O
sustained O
release O
. O
[]

No O
statistically O
significant O
difference O
was O
observed O
between O
G1 O
( O
10.19 O
+/- O
3.1 O
MPa O
) O
and O
G2 O
( O
10.17 O
+/- O
3.1 O
MPa O
) O
( O
p=0.982 O
) O
( O
Student O
's O
t O
test O
; O
? O
[]

It O
is O
of O
utmost O
importance O
to O
identify O
patients O
at O
risk O
for O
malnutrition O
in O
order O
to O
prevent O
related O
complications O
. O
[]

When O
response O
was O
analyzed O
by O
hematological B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
, O
there O
was O
a O
35.7 O
% O
response O
if O
patients O
had O
leukopenia B-outcome ['Physiological-Clinical']
grade O
3/4 O
( O
versus O
8.3 O
% O
, O
P O
= O
0.08 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additional O
findings O
included O
that O
a O
10 O
% O
increase O
in O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
increased O
session B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
by O
0.4 O
% O
( O
P O
< O
.001 O
) O
and O
a O
10 O
% O
increase O
in O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
predicted O
a O
decrease O
in O
percent O
energy O
from O
fat O
of O
0.3 O
% O
( O
P O
< O
.001 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
same O
questionnaire O
was O
administered O
by O
telephone O
4 O
to O
6 O
weeks O
after O
the O
screening O
experience O
to O
all O
study O
subjects O
. O
[]

The O
risk O
of O
SSI B-outcome ['Physiological-Clinical']
was O
39 O
% O
lower O
in O
the O
80 O
% O
FIO2 O
group O
( O
relative O
risk O
[ O
RR O
] O
, O
0.61 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.38-0.98 O
) O
vs O
the O
30 O
% O
FIO2 O
group O
. O
['Physiological-Clinical']

All O
drugs O
were O
administered O
twice O
daily O
. O
[]

Tailoring O
was O
based O
on O
smoking-related O
beliefs O
, O
personal O
characteristics O
and O
smoking O
patterns O
, O
self-efficacy O
and O
outcome O
expectations O
. O
[]

Bispectral O
index(BIS) O
was O
used O
to O
monitor O
the O
depth O
of O
anesthesia O
and O
maintained O
between O
45-60 O
during O
operation. O
[]

These O
results O
challenge O
previous O
claims O
that O
selective B-outcome ['Life-Impact']
induction I-outcome ['Life-Impact']
in O
children O
is O
the O
product O
of O
implicit O
learning O
. O
['Life-Impact']

Hospitals O
randomized O
to O
usual O
care O
(n O
= O
156 O
[4565 O
patients]) O
did O
not O
provide O
study O
vouchers. O
[]

With O
dacarbazine-vindesine O
8/59 O
patients O
obtained O
a O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
13 O
% O
) O
and O
7/59 O
patients O
a O
partial B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
( O
12 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Caplacizumab, O
an O
anti-von O
Willebrand O
factor O
humanized, O
bivalent O
variable-domain-only O
immunoglobulin O
fragment, O
inhibits O
interaction O
between O
von O
Willebrand O
factor O
multimers O
and O
platelets. O
[]

METHODS: O
In O
this O
double-blind, O
controlled O
trial, O
we O
randomly O
assigned O
145 O
patients O
with O
TTP O
to O
receive O
caplacizumab O
(10-mg O
intravenous O
loading O
bolus, O
followed O
by O
10 O
mg O
daily O
subcutaneously) O
or O
placebo O
during O
plasma O
exchange O
and O
for O
30 O
days O
thereafter. O
[]

At O
the O
end O
of O
the O
first O
hour O
of O
infusion O
, O
compared O
with O
saline O
, O
L-arginine O
infusion O
increased O
basal B-outcome ['Physiological-Clinical']
forearm I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
nitrite B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nitrate I-outcome ['Physiological-Clinical']
( O
NOx B-outcome ['Physiological-Clinical']
) O
, O
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release O
and O
decreased O
endothelin-1 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

plus O
omeprazole O
40 O
mg O
q.d.s. O
, O
or O
dirithromycin O
500 O
mg O
q.d.s O
. O
[]

Troponin O
T O
( O
TnT O
) O
measurements O
and O
electrocardiographic O
( O
ECG O
) O
recordings O
were O
performed O
at O
admission O
, O
before O
operation O
, O
and O
on O
the O
first O
and O
2nd O
postoperative O
days O
, O
which O
were O
used O
for O
diagnosis O
. O
[]

No O
drug-related B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
. O
['Adverse-effects']

STUDY O
DESIGN O
Forty O
individuals O
participated O
in O
this O
two-part O
study O
: O
20 O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
( O
both O
male O
and O
female O
) O
with O
> O
or O
=4 O
times O
the O
upper O
reference O
urinary O
porphobilinogen O
level O
, O
and O
20 O
healthy O
male O
subjects O
. O
[]

RESULTS O
Over O
half O
of O
the O
carers O
reported O
some O
MH B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
and O
a O
minority O
( O
5.4 O
% O
) O
were O
experiencing O
considerable O
difficulties O
. O
['Physiological-Clinical']

At O
12 O
weeks O
after O
injection O
, O
a O
two-point O
decrease O
in O
[]

1 O
to O
2 O
micrograms/kg O
and O
propofol O
i.v O
. O
[]

CONCLUSION O
The O
financial O
and O
quality-of-life O
effects O
of O
DUB O
represent O
a O
substantial O
burden O
. O
[]

Is O
the O
orientation O
of O
the O
apical O
defibrillation O
paddle O
of O
importance O
during O
manual O
external O
defibrillation O
? O
[]

From O
a O
clinical O
point O
of O
view O
, O
important O
differences O
were O
found O
for O
five O
scales O
: O
two O
functioning O
scales O
( O
social B-outcome ['Life-Impact']
and O
role B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
) O
and O
three O
symptom O
scales O
( O
['Life-Impact', 'Life-Impact']

Safety O
was O
evaluated O
for O
28 O
days O
postvaccination O
. O
[]

With O
this O
in O
mind O
, O
we O
aimed O
to O
determine O
the O
efficacy O
and O
safety O
of O
perianal-intrarectal O
( O
PI O
) O
lidocaine O
gel O
, O
lidocaine-ketorolac O
gel O
, O
and O
lidocaine-prilocaine O
cream O
in O
relieving B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
during O
TPB O
. O
['Physiological-Clinical']

Nonetheless O
, O
improved O
glycemic O
control O
was O
observed O
in O
insulin O
pump-treated O
subjects O
( O
more O
time O
spent O
with O
normoglycemia O
, O
better O
mean O
HbA1c O
) O
, O
and O
pump-treated O
subjects O
reported O
comparatively O
greater O
satisfaction O
with O
route O
of O
treatment O
administration O
. O
[]

Long-term O
follow-up O
of O
three O
randomized O
trials O
comparing O
idarubicin O
and O
daunorubicin O
as O
induction O
therapies O
for O
patients O
with O
untreated O
acute O
myeloid O
leukemia O
. O
[]

RESULTS O
No O
serious O
vaccine-related O
AEs O
occurred O
. O
[]

Journal O
ID: O
8900488 O
[]

A O
comparison O
of O
a O
short O
nurse-based O
and O
a O
long O
multidisciplinary O
version O
of O
structured O
patient O
education O
in O
irritable O
bowel O
syndrome O
. O
[]

RESULTS O
Mean O
BCVA B-outcome ['Physiological-Clinical']
over O
6 O
months O
remained O
unchanged O
in O
85 O
% O
of O
patients O
of O
group O
II O
, O
and O
decreased O
in O
53 O
% O
of O
patients O
of O
group O
I O
. O
['Physiological-Clinical']

Results O
suggest O
that O
children O
in O
the O
treatment O
group O
made O
significantly O
greater O
gains O
in O
social B-outcome ['Life-Impact']
interaction O
skills B-outcome ['Life-Impact']
in O
comparison O
to O
the O
community O
treatment O
group O
, O
but O
no O
between-group O
differences O
were O
found O
for O
standard B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
assessments I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

50 O
patients O
were O
investigated O
during O
induction O
of O
anaesthesia O
and O
infrarenal O
aortic O
bypass O
surgery O
. O
[]

METHODS O
Thirty O
premolars O
were O
divided O
into O
three O
groups O
: O
I O
- O
high-speed O
handpiece O
+ O
37 O
% O
phosphoric O
acid O
; O
II O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
37 O
% O
phosphoric O
acid O
; O
and O
III O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
Er O
: O
YAG O
laser O
( O
80 O
mJ O
, O
4 O
Hz O
, O
and O
25 O
mJ/cm O
( O
2 O
) O
) O
. O
[]

We O
compared O
the O
incidence O
and O
frequency O
of O
hypotension B-outcome ['Physiological-Clinical']
and O
vasopressor B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
after O
spinal O
anesthesia O
and O
no O
prehydration O
with O
crystalloid O
and O
colloid O
prehydration O
in O
elderly O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Serious B-outcome ['Adverse-effects']
late I-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rates O
were O
6 O
% O
for O
the O
daily O
regimen O
and O
22 O
% O
for O
the O
weekly O
schedule O
. O
['Adverse-effects']

BACKGROUND O
Rebound O
acid O
hypersecretion O
might O
occur O
after O
treatment O
with O
proton O
pump O
inhibitors O
. O
[]

All O
patients O
were O
asked O
to O
complete O
a O
validated O
questionnaire O
regarding O
presence O
and O
intensity O
of O
drug O
side O
effects O
. O
[]

beta-Carotene O
resulted O
in O
a O
statistically O
significant O
increase O
in O
total O
WBC B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
p O
= O
0.01 O
) O
, O
% O
change O
in O
CD4 B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
, O
and O
% O
change O
in O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( O
p O
= O
0.02 O
) O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
efficacy O
of O
antazoline O
in O
rapid B-outcome ['Physiological-Clinical']
cardioversion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
paroxysmal I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
-- I-outcome ['Physiological-Clinical']
a O
protocol O
of O
a O
single O
center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
( O
the O
AnPAF O
Study O
) O
. O
['Physiological-Clinical']

At O
week O
18 O
, O
WHO O
functional O
class O
was O
improved O
or O
maintained O
in O
more O
patients O
receiving O
sitaxsentan O
100 O
mg O
than O
placebo O
( O
P O
= O
0.038 O
) O
; O
0 O
% O
versus O
12 O
% O
of O
patients O
deteriorated O
, O
respectively O
. O
[]

Studies O
of O
the O
effect O
of O
vascular O
volume O
and O
intraperitoneal O
pressure O
on O
renal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hepatic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
study O
reported O
here O
, O
8 O
healthy O
volunteers O
were O
exposed O
to O
2.0 O
ppm O
NO2 O
and O
to O
filtered O
air O
for O
4 O
h O
while O
undergoing O
intermittent O
moderate O
exercise O
. O
[]

Role O
of O
angiotensin-converting O
enzyme O
inhibitors O
in O
early O
antihypertensive O
treatment O
in O
non-insulin O
dependent O
diabetes O
mellitus O
. O
[]

One O
patient O
in O
each O
arm O
had O
fatal O
pneumonitis O
. O
[]

Thus O
acute O
maternal B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
in O
normal O
patients O
can O
cause O
fetal B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
, O
metabolic B-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
, O
and O
neonatal B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Statistical O
analysis O
of O
cardiovascular B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
frequency O
) O
, O
respiratory B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
and O
pain B-outcome ['Physiological-Clinical']
score O
showed O
an O
overlapping O
progression O
among O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
condition O
included O
15 O
minutes O
of O
running/jogging O
followed O
by O
a O
classroom O
task O
. O
[]

The O
video O
analysis O
showed O
a O
significant O
interrater O
reliability O
. O
[]

Possible O
physiological O
mechanisms O
are O
discussed O
. O
[]

No O
significant O
difference O
in O
median O
CD4 B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
from O
baseline O
to O
week O
48 O
was O
found O
( O
3 O
% O
versus O
1 O
% O
) O
. O
['Physiological-Clinical']

The O
two O
treatment O
groups O
were O
well-matched O
in O
age O
, O
sex O
, O
stage O
and O
performance O
status O
. O
[]

From O
the O
present O
findings O
tocainide O
and O
prajmalium O
bitartrate O
have O
the O
same O
efficient O
antiarrhythmic B-outcome ['Physiological-Clinical']
effects O
in O
the O
majority O
of O
patients O
. O
['Physiological-Clinical']

Overall O
diet O
quality O
was O
determined O
by O
the O
Healthy O
Eating O
Index O
. O
[]

Two O
fellowship-trained O
musculoskeletal O
radiologists O
measured O
the O
TT-TG B-outcome ['Physiological-Clinical']
distances I-outcome ['Physiological-Clinical']
for O
each O
patient O
by O
CT O
and O
MRI O
in O
a O
randomized O
, O
blinded O
fashion O
. O
['Physiological-Clinical']

There O
was O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
the O
group O
receiving O
Triamcinolone O
at O
two O
and O
six O
week O
but O
not O
in O
twelve O
weeks. O
[['Physiological-Clinical']]

METHODS O
Twenty O
moderate O
to O
severe O
persistent O
asthmatics O
completed O
a O
randomized O
double-blind O
crossover O
study O
. O
[]

Contrast O
enhancement B-outcome ['Physiological-Clinical']
and O
diagnostic B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
were O
assessed O
. O
['Physiological-Clinical', 'Life-Impact']

Effect O
of O
a O
nutritional O
supplement O
containing O
vitamin O
E O
, O
selenium O
, O
vitamin O
c O
and O
coenzyme O
Q10 O
on O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
: O
a O
randomised O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Our O
patients O
were O
twenty-one O
adult O
patients O
with O
common O
variable O
immunodeficiency O
. O
[]

Efficacy O
of O
nebulized O
flunisolide O
combined O
with O
salbutamol O
and O
ipratropium O
bromide O
in O
stable O
patients O
with O
moderate-to-severe O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

However O
, O
the O
number O
of O
donors O
to O
whom O
the O
infants O
were O
exposed O
was O
not O
significantly O
different O
( O
2.8 O
+/- O
2.5 O
vs O
2.2 O
+/- O
2.0 O
) O
. O
[]

It O
improved O
the O
clinical O
outcome O
, O
providing O
a O
significantly O
higher O
graft O
patency O
rate O
and O
a O
lower O
incidence O
of O
late O
cardiac O
events O
. O
[]

The O
state O
and O
federal O
VR O
system O
represents O
a O
potential O
access O
point O
for O
delivery O
of O
health-promotion O
activities O
. O
[]

Similar O
gains O
were O
observed O
for O
initiation O
of O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
shared O
positive O
affect O
, O
but O
between-group O
differences O
did O
not O
reach O
statistical O
significance O
. O
['Life-Impact']

As O
a O
conclusion O
, O
the O
present O
study O
does O
not O
provide O
evidence O
in O
favour O
of O
the O
routine O
use O
of O
adjunctive O
metronidazole B-outcome ['Resource-use']
dental I-outcome ['Resource-use']
gel I-outcome ['Resource-use']
in O
the O
treatment O
of O
adult B-outcome ['Physiological-Clinical']
periodontitis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Participants O
in O
the O
patient O
preference O
group O
achieved O
marginally O
better O
outcomes O
than O
those O
randomised O
to O
a O
treatment O
group O
, O
but O
the O
clinical O
significance O
of O
these O
differences O
is O
unclear O
. O
[]

A O
major O
cause O
of O
long-standing O
problems O
is O
adductor-related O
groin O
pain O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
a O
high-dose O
infusion O
of O
beta-endorphin O
, O
an O
opioid O
peptide O
, O
on O
blood O
pressure O
and O
on O
the O
hormonal O
profile O
in O
healthy O
subjects O
and O
in O
hypertensive O
patients O
and O
the O
mediation O
played O
by O
opioid O
receptor O
agonism O
. O
[]

This O
disease O
can O
greatly O
reduce O
the O
affected O
individual O
's O
walking O
capacity O
and O
can O
seriously O
affect O
daily O
life O
activities O
. O
[]

In O
both O
groups O
, O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
was O
measured O
after O
40 O
minutes O
of O
eye O
drops O
instillation O
. O
['Physiological-Clinical']

Children O
received O
2 O
doses O
of O
placebo O
or O
porcine O
secretin O
, O
6 O
weeks O
apart O
. O
[]

There O
was O
no O
statistical O
difference O
between O
the O
two O
groups O
after O
drug O
therapy O
( O
P O
> O
0.05 O
) O
. O
[]

CONCLUSIONS O
Azimilide O
dihydrochloride O
may O
be O
a O
safe O
and O
effective O
drug O
for O
reducing O
the O
frequency O
of O
VT B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
in O
patients O
with O
implanted O
ICDs O
. O
['Physiological-Clinical']

The O
first O
flow O
measurements O
were O
performed O
approximately O
1 O
h O
after O
induction O
of O
anaesthesia O
. O
[]

The O
present O
study O
examined O
the O
effects O
of O
pharmacological O
modulation O
of O
the O
norepinephrine O
system O
on O
the O
severity O
of O
such O
impairments O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
safety O
of O
formoterol O
12 O
microg O
twice O
daily O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical']

18 O
patients O
received O
placebo O
and O
23 O
ones O
were O
given O
enalapril O
. O
[]

METHODS O
To O
study O
the O
effect O
of O
the O
eradication O
of O
H. O
pylori B-outcome ['Physiological-Clinical']
on O
the O
recurrence O
of O
duodenal O
ulcer O
, O
we O
treated O
104 O
patients O
with O
H. O
pylori O
infection O
and O
recurrent O
duodenal O
ulcer O
with O
either O
amoxicillin O
( O
750 O
mg O
three O
times O
daily O
) O
plus O
metronidazole O
( O
500 O
mg O
three O
times O
daily O
) O
or O
identical-appearing O
placebos O
, O
given O
orally O
for O
12 O
days O
. O
['Physiological-Clinical']

The O
primary O
composite O
endpoint O
was O
cardiovascular B-outcome ['Physiological-Clinical']
death I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
or O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
expectant O
management O
group O
, O
40 O
women O
( O
32 O
% O
) O
conceived B-outcome ['Physiological-Clinical']
, O
of O
which O
34 O
pregnancies O
were O
ongoing O
( O
27 O
% O
) O
( O
relative O
risk O
: O
0.85 O
; O
95 O
% O
CI O
: O
0.63-1.1 O
) O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
We O
conducted O
a O
prospective O
, O
nested O
case-control O
study O
in O
the O
Cholesterol O
and O
Recurrent O
Events O
( O
CARE O
) O
trial O
, O
a O
randomized O
placebo-controlled O
trial O
of O
pravastatin O
in O
4159 O
patients O
with O
myocardial O
infarction O
and O
average O
LDL O
concentrations O
at O
baseline O
( O
115 O
to O
174 O
mg/dL O
, O
mean O
139 O
mg/dL O
) O
. O
[]

Few O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
noted O
. O
['Adverse-effects']

To O
study O
the O
comparability O
of O
different O
PSL-LBNP O
protocols O
, O
nine O
subjects O
were O
exposed O
randomly O
to O
five O
PSL-LBNP O
tests O
using O
protocols O
that O
varied O
in O
stage O
duration O
but O
not O
pressure O
profile O
. O
[]

UNLABELLED O
It O
has O
been O
reported O
that O
cytarabine O
, O
acting O
by O
at O
least O
two O
different O
mechanisms O
, O
enhances O
the O
cytotoxic O
effect O
of O
cisplatin O
in O
in O
vitro O
systems O
. O
[]

Losartan O
significantly O
lowered O
t-PA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
levels O
( O
-1.8 O
ng/mL O
, O
P O
= O
0.045 O
) O
, O
but O
had O
no O
effect O
on O
t-PA B-outcome ['Physiological-Clinical']
or O
PAI-1 B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
randomly O
assigned O
to O
a O
nonexercising O
control O
group O
, O
a O
cycle O
training O
group O
( O
cycle O
) O
, O
or O
one O
of O
the O
two O
HCT O
groups O
. O
[]

Journal O
ID: O
101238455 O
[]

A O
per-protocol O
analysis O
did O
not O
show O
appreciably O
different O
results O
. O
[]

Continued O
improvement O
in O
pressure-flow B-outcome ['Physiological-Clinical']
parameters O
in O
men O
receiving O
finasteride O
for O
2 O
years O
. O
['Physiological-Clinical']

CONCLUSION: O
CART O
showed O
significant O
improvement O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
parameters O
indicating O
vagal O
dominance O
in O
middle-aged O
hypertensive O
women. O
[['Physiological-Clinical']]

In O
one O
study O
arm O
, O
patients O
with O
bulimia O
nervosa O
were O
treated O
with O
150 O
mg O
Spironolactone O
per O
day O
; O
in O
the O
other O
arm O
, O
patients O
received O
a O
placebo O
for O
a O
total O
of O
8 O
weeks O
. O
[]

Evaluation O
of O
25-gauge O
Quincke O
and O
24-gauge O
Gertie O
Marx O
needles O
for O
spinal O
anaesthesia O
for O
caesarean O
section O
. O
[]

After O
12 O
months O
this O
successful O
outcome O
was O
improved O
slightly O
further O
. O
[]

Endurance O
training O
has O
little O
effect O
on O
active O
muscle O
free B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
or O
triglyceride B-outcome ['Physiological-Clinical']
net O
balances O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Following O
a O
12 O
hour O
fast O
, O
heart O
rate O
, O
arterial O
blood O
pressure O
, O
light O
reflex O
plethysmography O
of O
the O
finger O
, O
resting O
blood O
flow O
volume O
in O
the O
lower O
arm O
and O
leg O
and O
peripheral B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
were O
measured O
at O
10 O
min O
. O
['Physiological-Clinical']

METHODS O
The O
European O
Myocardial O
Infarct O
Amiodarone O
Trial O
( O
EMIAT O
) O
was O
a O
randomised O
double-blind O
placebo-controlled O
trial O
to O
assess O
whether O
amiodarone O
reduced O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
primary O
endpoint O
) O
and O
cardiac B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
( O
secondary O
endpoints O
) O
in O
survivors O
of O
myocardial O
infarction O
with O
a O
left-ventricular O
ejection O
fraction O
( O
LVEF O
) O
of O
40 O
% O
or O
less O
. O
['Mortality', 'Mortality', 'Mortality']

CONCLUSION O
It O
is O
obvious O
that O
PKRP O
is O
as O
efficient O
as O
TURP O
and O
it O
has O
a O
similar O
morbidity O
. O
[]

After O
12 O
weeks O
of O
care O
, O
the O
proportion O
of O
wounds B-outcome ['Physiological-Clinical']
healed I-outcome ['Physiological-Clinical']
( O
defined O
as O
complete O
epithelialization O
without O
drainage O
) O
in O
the O
active O
ultrasound O
therapy O
device O
group O
was O
significantly O
higher O
than O
that O
in O
the O
sham O
control O
group O
( O
40.7 O
% O
versus O
14.3 O
% O
, O
P O
= O
0.0366 O
, O
Fisher O
's O
exact O
test O
) O
. O
['Physiological-Clinical']

Detection O
of O
traumatic O
arthrotomy O
of O
the O
knee O
using O
the O
saline O
solution O
load O
test O
. O
[]

There O
seems O
no O
benefit O
in O
delaying O
initiation O
of O
everolimus O
. O
[]

This O
study O
of O
plantar O
flexor O
spasticity O
describes O
relationships O
among O
a O
traditional O
qualitative O
spasticity O
scale O
, O
three O
potential O
quantitative O
spasticity O
measures O
and O
a O
measure O
of O
voluntary O
ankle O
muscle O
function O
. O
[]

Scores O
for O
cleansing B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
entire I-outcome ['Physiological-Clinical']
colon I-outcome ['Physiological-Clinical']
as O
determined O
by O
endoscopists O
who O
were O
blinded O
to O
the O
cathartic O
agent O
were O
highest O
in O
patients O
receiving O
sodium O
phosphate O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

Accuracy O
( O
correction O
rate O
) O
, O
recognition O
accuracy O
( O
correction O
rate-commission O
error O
rate O
) O
, O
and O
response O
time O
were O
measured O
during O
each O
experiment O
. O
[]

Dis O
. O
[]

Node O
positive O
patients O
were O
assigned O
to O
CMF- O
( O
cyclophosphamide O
, O
methotrexate O
and O
5-fluorouracil O
) O
chemotherapy O
in O
addition O
to O
endocrine O
therapy O
. O
[]

Changes O
in O
logarithm O
of O
minimum B-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
of O
resolution I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
logMAR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
best-corrected I-outcome ['Physiological-Clinical']
visual I-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCVA I-outcome ['Physiological-Clinical']
) O
, O
central B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
shown O
by O
optical B-outcome ['Physiological-Clinical']
coherence O
tomography-3 O
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
randomized O
trial O
involved O
777 O
volunteers O
from O
the O
U.S. O
Army O
Airborne O
School O
, O
Fort O
Benning O
, O
Ga. O
Of O
this O
group O
, O
745 O
completed O
all O
study O
requirements O
( O
369 O
brace-wearers O
and O
376 O
non-brace-wearers O
) O
. O
[]

30582753_PD.tx O
[]

PURPOSE O
To O
assess O
the O
optimal O
scan O
delays O
and O
contrast O
injection O
durations O
for O
contrast-enhanced O
whole-body O
computed O
tomography O
( O
CT O
) O
. O
[]

LNH-84 O
regimen O
: O
a O
multicenter O
study O
of O
intensive O
chemotherapy O
in O
737 O
patients O
with O
aggressive O
malignant O
lymphoma O
. O
[]

PATIENTS O
Thirty O
patients O
admitted O
to O
the O
intensive O
care O
unit O
who O
had O
a O
thermodilution O
pulmonary O
artery O
catheter O
in O
place O
. O
[]

The O
effect O
of O
the O
micronutrients O
on O
the O
outcome O
variables O
growth O
, O
biochemical O
status O
, O
mental B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
bone B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Life-Impact', 'Physiological-Clinical']

The O
effect O
of O
venlafaxine O
on O
unawareness B-outcome ['Life-Impact']
of O
['Life-Impact']

Of O
seven O
initial O
non-responders O
, O
five O
patients O
achieved O
a O
complete O
response O
by O
subsequent O
instillation O
, O
resulting O
in O
a O
total O
response O
rate O
of O
95 O
% O
. O
[]

Intraperitoneal O
application O
of O
bupivacaine O
plus O
morphine O
for O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

A O
total O
of O
154 O
eyes O
of O
77 O
patients O
were O
randomly O
divided O
into O
2 O
groups O
: O
group O
1 O
consisted O
of O
78 O
eyes O
, O
group O
2 O
consisted O
of O
76 O
eyes O
, O
and O
the O
patients O
were O
monitored O
for O
pupillary O
dilation O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
possible O
adverse O
effects O
at O
0 O
, O
20 O
, O
40 O
, O
60 O
, O
and O
90 O
minutes O
. O
[]

Bile B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
was O
determined O
and O
the O
saturation O
index O
calculated O
before O
and O
after O
treatment O
, O
on O
samples O
collected O
by O
duodenal O
siphonage O
after O
caerulein O
stimulation O
, O
in O
both O
groups O
. O
['Physiological-Clinical']

The O
REMADHE O
[ O
Repetitive O
Education O
and O
Monitoring O
for O
ADherence O
for O
Heart O
Failure O
] O
trial O
is O
a O
long-term O
randomized O
, O
prospective O
, O
parallel O
trial O
designed O
to O
compare O
intervention O
with O
control O
. O
[]

Three O
different O
spatial O
ability O
tasks O
- O
spatial B-outcome ['Life-Impact']
orientation I-outcome ['Life-Impact']
, O
spatial B-outcome ['Life-Impact']
visualization I-outcome ['Life-Impact']
, O
and O
flexibility B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
closure I-outcome ['Life-Impact']
- O
were O
measured O
by O
a O
paper-and-pencil O
test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
There O
were O
no O
intraoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
no O
postoperative B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
or O
revisions B-outcome ['Resource-use']
. O
['Adverse-effects', 'Physiological-Clinical', 'Resource-use']

For O
example O
, O
subjects O
may O
be O
uncommunicative O
and O
extremely O
heterogeneous O
in O
problem O
presentation O
, O
and O
current O
pharmacological O
treatments O
are O
not O
likely O
to O
alter O
most O
core O
features O
of O
autism O
. O
[]

3 O
. O
[]

METHODS O
Sixty O
boys O
with O
ADHD O
, O
Asperger O
syndrome/high-functioning O
autism O
( O
AS/HFA O
) O
, O
and O
reading O
and O
writing O
disorder O
( O
RD/WD O
) O
were O
allocated O
to O
participate O
in O
a O
service O
evaluation O
project O
. O
[]

Therefore O
, O
the O
present O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
wool O
coverage O
on O
water B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
in O
relation O
to O
thermoregulation O
in O
sheep O
by O
using O
the O
deuterium O
dilution O
technique O
to O
predict O
total O
water O
intake O
before O
and O
after O
shearing O
. O
['Physiological-Clinical']

RESULTS O
The O
objective O
response O
rate O
was O
18 O
% O
and O
27.5 O
% O
in O
group O
A O
and O
B O
, O
respectively O
( O
p O
= O
0.413 O
) O
. O
[]

No O
significant O
changes O
in O
species B-outcome ['Physiological-Clinical']
number O
or O
quantitative O
counts O
were O
noted O
after O
LGG O
treatment O
in O
the O
infants O
weighing O
1500 O
to O
1999 O
g O
LGG O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
in O
all O
infants O
. O
['Physiological-Clinical', 'Life-Impact']

Secondary O
outcomes O
were O
clinical O
and O
MRI O
measures O
of O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
. O
Results: O
Of O
200 O
patients O
randomized O
(133 O
women O
[67%]; O
mean O
[SD] O
age, O
61.6 O
[10.5] O
years; O
median O
baseline O
DAS28-CRP, O
1.9 O
[interquartile O
range, O
1.7-2.2]; O
van O
der O
Heijde-modified O
Sharp O
score, O
18.0 O
[interquartile O
range, O
7.0-42.5]), O
76 O
patients O
(76%) O
in O
the O
MRI-guided O
group O
and O
95 O
(95%) O
in O
the O
conventional O
group O
completed O
the O
study. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

The O
main O
outcomes O
were O
: O
diet B-outcome ['Life-Impact']
, O
based O
on O
multiple O
24-hour O
recalls O
( O
total O
fat O
, O
grams O
of O
fiber O
, O
servings O
of O
fruit O
and O
vegetables O
, O
total O
calories O
) O
; O
average O
daily B-outcome ['Life-Impact']
energy I-outcome ['Life-Impact']
expenditure I-outcome ['Life-Impact']
( O
kcals/kg O
) O
based O
on O
7-day O
physical O
activity O
recall O
interviews O
; O
daily B-outcome ['Life-Impact']
minutes I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
moderate-vigorous I-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
minutes O
from O
accelerometery O
; O
and O
self-reported O
daily B-outcome ['Life-Impact']
hours I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sedentary I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Comparisons O
of O
sensitivity B-outcome ['Physiological-Clinical']
, O
positive O
and O
negative O
predictive O
values O
, O
between O
the O
two O
tests O
, O
however O
, O
did O
not O
reveal O
any O
significant O
differences O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

This O
study O
was O
designed O
to O
determine O
the O
effects O
of O
ascorbic O
acid O
supplementation O
on O
circulating O
biomarkers O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
following O
a O
single O
bout O
of O
exercise. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
evaluated O
the O
benefits O
of O
physiological O
pacing O
in O
the O
elderly O
by O
recruiting O
13 O
subjects O
> O
75 O
years O
of O
age O
, O
already O
fitted O
with O
a O
physiological O
pacing O
system O
. O
[]

Secondary O
outcomes O
include O
VAS O
change O
scores O
at O
10 O
, O
60 O
, O
90 O
and O
120 O
min O
, O
analgesia B-outcome ['Resource-use']
use I-outcome ['Resource-use']
, O
mode O
of O
birth B-outcome ['Physiological-Clinical']
and O
maternal B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

Immunodepression O
is O
a O
common O
condition O
in O
patients O
undergoing O
elective O
operations O
and O
it O
constitutes O
a O
high O
risk O
for O
the O
onset O
of O
postoperative O
infective O
complications O
. O
[]

There O
was O
a O
wide O
variability O
( O
up O
to O
ten-fold O
) O
in O
the O
pharmacokinetic O
parameters O
within O
each O
dose O
group O
. O
[]

OBJECTIVES O
To O
estimate O
the O
Minimal O
Clinically O
Important O
Change O
( O
MCIC O
) O
of O
the O
pain O
intensity O
numerical O
rating O
scale O
( O
PI-NRS O
) O
, O
the O
Quebec O
Back O
Pain O
Disability O
Scale O
( O
QBPDS O
) O
, O
and O
the O
Euroqol O
( O
EQ O
) O
in O
patients O
with O
low O
back O
pain O
. O
[]

The O
study O
dropout O
rate O
was O
high O
( O
43 O
% O
) O
. O
[]

STUDY O
DESIGN O
Interdisciplinary O
, O
prospective O
, O
observer-blinded O
, O
randomized O
clinical O
trial O
with O
a O
1-yr O
follow-up O
period O
. O
[]

The O
results O
demonstrated O
no O
differences O
between O
the O
emergence O
or O
discharge O
times O
following O
desflurane O
or O
isoflurane O
. O
[]

BACKGROUND O
Eberconazole O
is O
a O
topical O
, O
broad-spectrum O
imidazole O
derivative O
, O
effective O
in O
dermatophytoses O
, O
candidiasis O
, O
and O
pityriasis O
treatment O
. O
[]

OBJECTIVES O
The O
goal O
of O
this O
study O
was O
to O
assess O
the O
short- O
and O
long-term O
efficacy O
of O
different O
thrombolytic O
therapy O
regimens O
in O
patients O
with O
leg O
or O
pelvic O
deep O
venous O
thrombosis O
( O
DVT O
) O
. O
[]

7.6 O
% O
vs. O
29.0 O
? O
[]

Oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
was O
considered O
to O
have O
occurred O
if O
a O
patient O
reported O
any O
clinical O
sign O
or O
symptom O
of O
oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
with O
or O
without B-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
candidiasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
pilot O
study O
was O
to O
evaluate O
whether O
a O
modified O
version O
of O
the O
Coping O
Cat O
program O
could O
be O
effective O
in O
reducing O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
['Life-Impact']

BACKGROUND: O
To O
compare O
the O
superiority O
of O
teaching O
methods O
for O
acquiring O
a O
proficient O
level O
of O
surgical O
skill B-outcome ['Life-Impact']
in O
a O
robotic O
surgery-naive O
individual O
using O
a O
robotic O
virtual O
reality O
simulator. O
[['Life-Impact']]

Given O
the O
ease O
of O
use O
, O
decreased O
morbidity O
to O
the O
patient O
, O
and O
cost-effectiveness O
, O
FloSeal O
hemostatic O
matrix O
could O
change O
clinical O
practice O
in O
managing O
this O
common O
condition O
. O
[]

The O
results O
indicated O
that O
self-reports O
and O
urinalysis O
are O
complementary O
methods O
of O
[]

Data O
were O
submitted O
to O
repeated O
analysis O
of O
variance O
. O
[]

To O
date, O
methohexital O
has O
not O
been O
compared O
with O
the O
most O
commonly O
used O
induction O
agent, O
propofol. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
following O
appendicectomy O
: O
the O
placebo O
effect O
. O
[]

Bacteremia B-outcome ['Physiological-Clinical']
with O
Streptococcus O
viridans O
was O
not O
related O
to O
the O
use O
of O
a O
CVC O
. O
['Physiological-Clinical']

A O
statistically O
significant O
improvement O
( O
p O
less O
than O
0.05 O
) O
, O
evaluated O
by O
a O
four-stage O
scale O
on O
pains O
, O
infirmity O
, O
and O
consumption B-outcome ['Resource-use']
of I-outcome ['Resource-use']
analgesics I-outcome ['Resource-use']
, O
was O
observed O
in O
the O
actively O
treated O
patients O
. O
['Resource-use']

The O
low O
pressure O
suction O
drain O
removed O
an O
intraperitoneal O
marker O
, O
gentamicin O
, O
more O
effectively O
than O
the O
high O
pressure O
suction O
drain O
, O
but O
not O
more O
effectively O
than O
the O
passive O
drain O
. O
[]

Concurrent O
training O
enhances O
athletes O
' O
cardiovascular O
and O
cardiorespiratory O
measures O
. O
[]

Milk O
protein O
quantity O
and O
quality O
in O
low-birth-weight O
infants O
. O
[]

Acute O
cardiac O
effects O
of O
nicotine O
in O
healthy O
young O
adults O
. O
[]

CONCLUSION O
These O
results O
suggest O
that O
an O
acute O
bout O
( O
4 O
min O
) O
of O
static O
stretching O
of O
the O
lower O
limbs O
during O
recovery O
periods O
between O
efforts O
may O
compromise O
RSA B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
but O
has O
less O
effect O
on O
CODS O
performance O
. O
['Physiological-Clinical']

Journal O
ID: O
101521595 O
[]

At O
each O
of O
three O
60-min O
intervals O
after O
the O
capsule O
was O
ingested O
, O
the O
subjects O
chewed O
two O
pieces O
of O
gum O
containing O
a O
total O
of O
0 O
, O
4 O
or O
8 O
mg O
of O
nicotine O
. O
[]

METHODS O
A O
total O
of O
214 O
patients O
( O
mean O
age O
: O
54.1 O
years O
; O
120 O
male O
, O
94 O
female O
) O
from O
four O
university O
hospitals O
were O
included O
in O
the O
analysis O
. O
[]

A O
comparison O
of O
sclerotherapy O
with O
staple O
transection O
of O
the O
esophagus O
for O
the O
emergency O
control O
of O
bleeding B-outcome ['Physiological-Clinical']
from O
esophageal O
varices O
. O
['Physiological-Clinical']

than O
in O
the O
lower O
fat O
recipe O
( O
990 O
000 O
p.p.m. O
) O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
when O
baseline O
( O
DIAGNOdent O
pen O
(DD) O
values O
were O
compared O
(P O
> O
0.05). O
[]

In O
both O
groups O
, O
there O
were O
no O
significant O
changes O
in O
brachial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
endothelin-1 I-outcome ['Physiological-Clinical']
and O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
femoral B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
, O
and O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
Phase O
I O
study O
demonstrated O
that O
CS O
vaginal O
gel O
was O
safe O
, O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
acceptable B-outcome ['Life-Impact']
by O
HIV-infected O
women O
and O
their O
male O
partners O
. O
['Life-Impact']

Supplements O
( O
200 O
ml O
) O
were O
provided O
every O
20 O
min O
and O
consisted O
of O
placebo O
, O
a O
7.75 O
% O
carbohydrate O
solution O
, O
and O
a O
7.75 O
% O
carbohydrate/1.94 O
% O
protein O
solution O
. O
[]

Changes O
in O
depression B-outcome ['Life-Impact']
appeared O
to O
mediate O
these O
relationships O
. O
['Life-Impact']

Muscular B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
was O
significantly O
different O
between O
limbs O
at O
the O
start O
of O
the O
intervention O
(p O
= O
0.02). O
[['Life-Impact']]

All O
patients O
received O
the O
same O
cementless O
implant O
, O
inserted O
with O
use O
of O
standard O
instruments O
, O
and O
all O
operations O
were O
performed O
by O
a O
single O
, O
experienced O
surgeon O
. O
[]

Secondary O
endpoints O
included O
exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
assessed O
by O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Of O
261 O
eligible O
clinicians O
responding O
to O
the O
statewide O
survey O
, O
about O
half O
provide O
sun O
protection O
counseling O
most O
of O
the O
time O
or O
almost O
always O
during O
summer O
well O
care O
visits O
. O
[]

Assessment O
of O
the O
pain O
of O
blood-sugar O
testing O
: O
a O
randomised O
controlled O
trial O
. O
[]

Randomisation O
was O
stratified O
by O
induction O
regimen, O
pre-induction O
disease O
stage, O
and O
response O
post-transplantation. O
[]

The O
therapeutic O
course O
for O
all O
was O
24 O
weeks O
. O
[]

The O
results O
showed O
that O
there O
were O
no O
color B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
over O
time O
, O
only O
a O
high B-outcome ['Physiological-Clinical']
luminosity I-outcome ['Physiological-Clinical']
equal I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
The O
effects O
of O
antidepressant O
treatment O
on O
efficacy O
of O
antihypertensive O
therapy O
in O
elderly O
hypertension O
] O
. O
[]

CONCLUSIONS O
: O
Transurethral O
surgery O
with O
PlasmaKinetic O
bipolar O
energy O
seems O
to O
be O
a O
promising O
alternative O
to O
prostatic O
tissue O
removal O
with O
shorter O
operative O
, O
catheterization O
and O
hospitalization O
times O
, O
although O
increased O
rates O
of O
postoperative B-outcome ['Physiological-Clinical']
irritative I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
urethral B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
must O
be O
further O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
hemostatic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of O
platelets O
comprises O
two O
mechanisms O
: O
the O
shear-induced O
and O
the O
cyclooxygenase O
pathways O
. O
['Physiological-Clinical']

Results O
of O
the O
initial O
12-month O
study O
demonstrated O
the O
benefit O
of O
finasteride O
treatment O
on O
PFS B-outcome ['Mortality']
parameters O
. O
['Mortality']

A O
significantly O
larger O
proportion O
of O
patients O
achieved O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
and O
improvement O
in O
rectal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
the O
balsalazide O
group O
vs. O
the O
placebo O
group O
( O
55 O
vs. O
40 O
% O
, O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

A O
significant O
ambulatory B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
reduction O
was O
, O
however O
, O
observed O
in O
the O
subjects O
who O
received O
aspirin O
at O
bedtime O
( O
decrease O
of O
6/3 O
mm O
Hg O
in O
the O
24-h O
mean O
of O
systolic B-outcome ['Physiological-Clinical']
( O
SBP O
) O
/diastolic O
BP I-outcome ['Physiological-Clinical']
( O
DBP O
) O
, O
respectively O
; O
P O
< O
0.001 O
) O
, O
without O
changes O
in O
heart B-outcome ['Physiological-Clinical']
rate O
( O
HR O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
the O
IL-6 O
response O
to O
exercise O
has O
been O
extensively O
studied O
, O
little O
is O
known O
about O
the O
regulation O
of O
the O
IL-6R O
response O
. O
[]

Further O
studies O
are O
necessary O
to O
provide O
this O
information O
in O
order O
to O
assess O
the O
need O
for O
subsequent O
booster O
doses O
after O
primary O
immunization O
with O
both O
ADPT O
and O
WCDPT O
vaccines O
. O
[]

The O
course O
of O
misoprostol O
was O
repeated O
if O
the O
woman O
did O
not O
abort O
within O
24 O
hours O
. O
[]

AIM: O
To O
assess O
the O
effectiveness O
of O
a O
self-administered O
rehabilitation O
program O
in O
adults O
with O
shoulder O
pain O
syndrome O
in O
primary O
care. O
[]

One O
patient O
( O
group O
I O
) O
displayed O
a O
hematoma B-outcome ['Physiological-Clinical']
following O
inadvertent O
puncture O
of O
the O
CA O
. O
['Physiological-Clinical']

In O
all O
four O
groups O
, O
neither O
plasma B-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
nor I-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
changed O
. O
['Physiological-Clinical']

The O
treatment O
groups O
( O
clonidine O
vs O
clonidine/naltrexone O
) O
were O
similar O
at O
baseline O
with O
respect O
to O
: O
age O
at O
first O
heroin O
use O
( O
21 O
years O
vs O
23 O
years O
) O
, O
mean O
admission B-outcome ['Life-Impact']
opioid I-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
score O
( O
45/100 O
vs O
49/100 O
) O
, O
and O
withdrawal B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
score O
( O
19/72 O
vs O
18/72 O
) O
. O
['Life-Impact', 'Life-Impact']

We O
found O
no O
effect O
from O
the O
chart O
reminder O
compared O
with O
usual O
care O
( O
odds O
ratio O
[ O
OR O
] O
, O
1.2 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.7-2.0 O
) O
; O
and O
a O
beneficial O
effect O
from O
the O
mailed O
education/FIT O
( O
OR O
, O
6.0 O
; O
95 O
% O
CI O
, O
3.7-9.6 O
) O
and O
the O
mailed O
education/FIT O
plus O
phone O
call O
( O
OR O
, O
6.2 O
; O
95 O
% O
CI O
, O
3.8-9.9 O
) O
. O
[]

Anaesthesia O
was O
induced O
with O
thiopentone O
and O
suxamethonium O
and O
maintained O
with O
atracurium O
, O
nitrous O
oxide O
and O
isoflurane O
. O
[]

Bitolterol O
has O
a O
much O
longer O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
and O
should O
be O
considered O
as O
a O
suitable O
bronchodilator O
for O
regular O
nebulizer O
treatment O
of O
chronic O
asthma O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Forty-five O
patients O
were O
treated O
with O
HFX O
RT O
alone O
and O
fifty-six O
patients O
also O
received O
CDDP O
. O
[]

In O
a O
randomized O
, O
placebo O
controlled O
trial O
, O
eleven O
healthy O
volunteers O
were O
studied O
during O
4 O
separate O
study O
periods O
of O
4 O
days O
each O
. O
[]

In O
rating O
their O
own O
behavioral B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
, O
children O
showed O
no O
differences O
between O
conditions O
. O
['Life-Impact']

Comparing O
microvascular B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
during O
minimal O
extracorporeal O
circulation O
and O
conventional O
cardiopulmonary O
bypass O
in O
coronary O
artery O
bypass O
graft O
surgery O
: O
a O
prospective O
, O
randomized O
study O
. O
['Physiological-Clinical']

METHODS O
A O
randomized O
controlled O
study O
was O
conducted O
to O
assess O
the O
effects O
of O
fat O
gain O
on O
endothelial O
function O
. O
[]

OBJECTIVE O
To O
determine O
whether O
a O
multimodal O
physiotherapy O
programme O
including O
taping O
, O
exercises O
, O
and O
massage O
is O
effective O
for O
knee O
osteoarthritis O
, O
and O
if O
benefits O
can O
be O
maintained O
with O
self O
management O
. O
[]

The O
usual O
combination O
is O
foam O
ear O
plugs O
under O
headset O
or O
helmet O
muffs O
. O
[]

These O
results O
replicate O
the O
findings O
in O
our O
preliminary O
open-label O
study O
. O
[]

Mean O
follow-up O
was O
22.5 O
months O
( O
SD O
9.0 O
) O
. O
[]

In O
the O
US O
3 O
G O
group O
, O
3 O
g O
daily O
of O
stanol O
esters O
lowered O
TC B-outcome ['Physiological-Clinical']
and O
LDL-C B-outcome ['Physiological-Clinical']
levels O
by O
6.4 O
% O
and O
10.1 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
38 O
patients O
who O
completed O
Phase O
1 O
, O
significant O
delay O
in O
pain B-outcome ['Physiological-Clinical']
increase O
was O
observed O
in O
the O
CMZ O
group O
as O
compared O
with O
placebo O
( O
P O
= O
0.038 O
) O
. O
['Physiological-Clinical']

Impact O
of O
triiodothyronine O
on O
the O
survival O
of O
high-risk O
patients O
undergoing O
open O
heart O
surgery O
. O
[]

This O
paper O
presents O
the O
MIM's O
intervention O
effect O
on O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress, O
emotional O
coping B-outcome ['Life-Impact']
response, O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management, O
stress B-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
negative B-outcome ['Life-Impact', 'Life-Impact']
affect E1-outcome ['Life-Impact', 'Life-Impact']
. O
METHODS: O
Participants O
(N O
= O
612) O
were O
recruited O
from O
the O
Special O
Supplemental O
Nutrition O
Program O
for O
Women, O
Infants, O
and O
Children O
in O
Michigan. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact']]

METHODS O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
at O
three O
primary O
care O
centers O
in O
North O
Carolina O
. O
[]

CONCLUSION O
Mifepristone O
in O
doses O
of O
5 O
mg O
or O
10 O
mg O
results O
in O
comparable O
leiomyoma B-outcome ['Physiological-Clinical']
regression I-outcome ['Physiological-Clinical']
, O
improvement O
in O
symptoms O
, O
and O
few O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Since O
left O
heart O
failure O
may O
be O
associated O
with O
pulmonary O
hypertension O
out O
of O
proportion O
to O
left O
heart O
disease O
, O
sildenafil O
may O
have O
beneficial O
effect O
in O
such O
patients O
. O
[]

Patients O
were O
assigned O
at O
random O
to O
group O
1 O
, O
80 O
patients O
undergoing O
total O
arterial O
revascularization O
( O
left O
internal O
thoracic O
artery O
on O
left O
anterior O
descending O
coronary O
artery O
plus O
radial O
artery O
) O
, O
or O
group O
2 O
, O
80 O
patients O
undergoing O
standard O
coronary O
artery O
bypass O
graft O
surgery O
( O
left O
internal O
thoracic O
artery O
on O
left O
anterior O
descending O
coronary O
artery O
plus O
saphenous O
veins O
) O
. O
[]

Investigators O
of O
the O
Children O
's O
Cancer O
Study O
Group O
entered O
73 O
children O
with O
previously O
untreated O
localized O
non-Hodgkin O
's O
lymphoma O
on O
a O
prospective O
randomized O
trial O
of O
systemic O
treatment O
with O
either O
a O
four-drug O
program O
( O
cyclophosphamide O
, O
vincristine O
, O
methotrexate O
, O
prednisone O
[ O
COMP O
] O
) O
or O
a O
10-drug O
( O
LSA2-L2 O
modified O
) O
program O
of O
18 O
months O
duration O
. O
[]

DESIGN O
Randomized O
, O
single-blinded O
, O
placebo-controlled O
study O
. O
[]

The O
median O
length O
of O
follow-up O
in O
surviving O
patients O
was O
58 O
months O
( O
range O
, O
10 O
to O
124 O
) O
. O
[]

METHODS O
Participants O
were O
578 O
children O
who O
were O
part O
of O
an O
ongoing O
population-based O
, O
case-control O
study O
of O
2- O
to O
5-year O
olds O
with O
ASD O
, O
DD O
, O
and O
the O
general O
population O
. O
[]

Baseline O
characteristics O
were O
similar O
in O
both O
groups O
. O
[]

Journal O
ID: O
101521595 O
[]

Angiographic B-outcome ['Life-Impact']
and O
procedural B-outcome ['Life-Impact']
success I-outcome ['Life-Impact']
rates O
and O
in-hospital B-outcome ['Resource-use']
events I-outcome ['Resource-use']
were O
similar O
between O
the O
two O
groups O
. O
['Life-Impact', 'Resource-use']

CONCLUSIONS O
The O
novel O
syncope O
unit O
designed O
for O
this O
study O
significantly O
improved O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
in O
the O
emergency O
department O
and O
reduced O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
and O
total O
length O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
without O
affecting O
recurrent O
syncope O
and O
all-cause O
mortality B-outcome ['Mortality']
among O
intermediate-risk O
patients O
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Mortality']

A O
higher O
percentage O
of O
patients O
in O
the O
intervention O
group O
, O
relative O
to O
the O
control O
group O
, O
were O
able O
to O
reduce O
the O
use O
of O
antihypertensive B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
( O
31 O
vs. O
8 O
% O
, O
P O
< O
0.0001 O
) O
, O
and O
fewer O
patients O
in O
this O
group O
required O
additional B-outcome ['Resource-use']
medications I-outcome ['Resource-use']
or O
increases O
in O
dosage O
relative O
to O
the O
controls O
( O
11 O
vs. O
28 O
% O
, O
P O
= O
0.03 O
) O
. O
['Resource-use', 'Resource-use']

Compared O
with O
group O
C, O
serum O
norepinephrines B-outcome ['Physiological-Clinical']
in O
group O
D O
was O
significantly O
less O
(t=13.276, O
16.027, O
14.319, O
12.771, O
12.296, O
respectively; O
all O
P<0.05) O
at O
T(1), O
T(2), O
T(3), O
T(4), O
T(5).And O
there O
were O
no O
difference O
between O
these O
two O
groups O
at O
T(0), O
T(6), O
T(7), O
T(8)(all O
P>0.05). O
[['Physiological-Clinical']]

Therefore O
, O
bumetanide O
is O
a O
promising O
novel O
therapeutic O
agent O
to O
treat O
autism O
. O
[]

Survival O
curve O
analyses O
revealed O
little O
difference O
between O
these O
groups O
for O
major O
vascular B-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
, O
total O
mortality B-outcome ['Mortality']
, O
all O
amputations B-outcome ['Resource-use']
, O
or O
myocardial B-outcome ['Physiological-Clinical']
infarctions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Resource-use', 'Physiological-Clinical']

No O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
effect O
was O
seen O
with O
sarcalasin O
. O
['Physiological-Clinical']

As O
part O
of O
a O
prospective O
, O
randomized O
trial O
comparing O
ES O
and O
EL O
for O
the O
treatment O
of O
EVH O
, O
we O
estimated O
the O
direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of I-outcome ['Resource-use']
health I-outcome ['Resource-use']
care I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
and O
cost-effectiveness O
for O
the O
prevention O
of O
variceal O
rebleeding O
and O
patient O
survival O
at O
1-year O
follow-up O
. O
['Resource-use', 'Resource-use']

In O
the O
SR O
group O
, O
the O
hazard O
ratios O
( O
VACA O
v O
VAIA O
) O
for O
EFS O
and O
OS O
were O
0.91 O
( O
95 O
% O
CI O
, O
0.55 O
to O
1.53 O
) O
and O
1.08 O
( O
95 O
% O
CI O
, O
0.58 O
to O
2.03 O
) O
, O
respectively O
. O
[]

Results O
of O
a O
multicenter O
, O
8-week O
, O
parallel-group O
, O
randomized O
, O
double-blind O
, O
double-dummy O
, O
Phase O
III O
clinical O
trial O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
amlodipine O
maleate O
versus O
amlodipine O
besylate O
in O
Korean O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

Exclusion O
criteria O
were O
presence O
of O
a O
severe O
congenital O
anomaly, O
anticipated O
enteral O
fasting O
for O
longer O
than O
14 O
days, O
or O
no O
realistic O
prospect O
of O
survival. O
[]

To O
test O
the O
effectiveness O
of O
a O
special O
health O
care O
program O
for O
adolescent O
mothers O
( O
17 O
years O
old O
or O
younger O
) O
and O
their O
infants O
, O
243 O
mother-infant O
pairs O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

The O
data O
suggest O
that O
CHG O
does O
not O
offer O
increased O
protection O
against O
perirectal O
infections O
in O
patients O
undergoing O
intensive O
chemotherapy O
, O
nor O
is O
it O
more O
irritating O
than O
a O
nonmedicated O
skin O
cleanser O
. O
[]

performance O
index O
and O
Durie O
& O
Salmon O
stage O
, O
and O
( O
2 O
) O
the O
sensitivity O
to O
changes O
in O
objective O
disease O
status O
( O
response O
and O
relapse O
) O
. O
[]

On O
intention-to-treat O
analysis, O
Hp B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rates O
in O
FZD O
and O
CLA O
groups O
were O
90.22% O
and O
86.02% O
(P O
= O
.378); O
in O
per-protocol O
analysis, O
their O
eradication B-outcome ['Physiological-Clinical']
rates O
were O
93.26% O
and O
87.91%, O
respectively O
(P O
= O
.220). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
investigate O
whether O
hydrotalcite O
was O
comparable O
to O
esomeprazole O
, O
a O
proton O
pump O
inhibitor O
, O
in O
on-demand O
therapy O
for O
non-erosive O
reflux O
disease O
( O
NERD O
) O
. O
[]

The O
unconscious O
thought O
effect O
refers O
to O
improved O
judgments O
and O
decisions O
after O
a O
period O
of O
distraction O
. O
[]

A O
significant O
decrease O
in O
plasma B-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
levels O
was O
seen O
at O
36 O
and O
60 O
h O
after O
treatment O
compared O
with O
Control O
groups O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

A O
prospective O
study O
of O
plasma O
vitamin O
D O
metabolites O
, O
vitamin O
D O
receptor O
polymorphisms O
, O
and O
prostate O
cancer O
. O
[]

Results: O
Among O
559 O
randomized O
participants O
(mean O
age, O
67 O
years; O
277 O
[50%] O
women), O
556 O
(99.5%) O
completed O
the O
trial O
and O
were O
included O
in O
the O
analysis. O
[]

RESULTS O
Patients O
in O
the O
highest O
quartile O
of O
hsCRP O
compared O
to O
those O
in O
the O
lowest O
quartile O
were O
at O
increased O
risk O
of O
death B-outcome ['Mortality']
at O
30 O
days O
[ O
adjusted O
hazard O
ratio O
( O
adjHR O
) O
4.6 O
, O
P O
< O
0.001 O
] O
and O
10 O
months O
( O
adjHR O
3.9 O
, O
P O
< O
0.001 O
) O
. O
['Mortality']

Adverse O
events O
( O
AEs O
) O
occurring O
more O
frequently O
with O
sitaxsentan O
( O
50 O
or O
100 O
mg O
) O
included O
headache B-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
extremity B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Concentrations O
of O
indinavir B-outcome ['Physiological-Clinical']
, O
coadministered O
with O
amprenavir B-outcome ['Physiological-Clinical']
, O
in O
plasma B-outcome ['Physiological-Clinical']
decreased O
in O
both O
single-dose O
and O
steady-state O
evaluations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Intervention O
in O
the O
TDM O
group O
involved O
patient O
follow-up O
by O
a O
clinical O
pharmacist O
to O
obtain O
and O
pharmacokinetically O
interpret O
serum O
vancomycin O
concentrations O
for O
dosage O
individualization O
. O
[]

Although O
the O
flexible O
cryoprobe O
has O
been O
established O
for O
bronchoscopic O
interventions O
in O
malignant O
stenosis O
, O
the O
obtained O
biopsies O
, O
called O
cryobiopsies O
, O
have O
not O
been O
investigated O
in O
a O
large O
cohort O
of O
patients O
. O
[]

Importance: O
Whether O
using O
magnetic O
resonance O
imaging O
(MRI) O
to O
guide O
treatment O
in O
patients O
with O
rheumatoid O
arthritis O
(RA) O
improves O
disease O
activity O
and O
slows O
joint O
damage O
progression O
is O
unknown. O
[]

The O
primary O
endpoint O
was O
the O
combined O
incidence O
of O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
and O
the O
secondary O
endpoints O
were O
total O
deaths B-outcome ['Mortality']
and O
any O
safety O
problems O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Cystoid B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
edema I-outcome ['Physiological-Clinical']
8 O
( O
4.7 O
% O
) O
, O
postoperative B-outcome ['Physiological-Clinical']
vitreous I-outcome ['Physiological-Clinical']
prolaps I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
anterior I-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
4 O
( O
2.3 O
% O
) O
and O
spontaneous B-outcome ['Physiological-Clinical']
complaints I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
16 O
( O
9.4 O
% O
) O
occurred O
in O
a O
low O
percentage O
after O
ICCE O
with O
ACL O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pathophysiological O
implications O
. O
[]

Topical O
PUVA O
, O
etretinate O
, O
and O
combined O
PUVA O
and O
etretinate O
for O
palmoplantar O
pustulosis O
: O
comparison O
of O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
the O
influences O
of O
tonsillar B-outcome ['Physiological-Clinical']
and O
dental O
focal O
infections O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
study O
evaluated O
the O
prognostic O
significance O
of O
SLN O
metastatic O
deposits O
< O
or O
= O
0.2 O
mm O
in O
patients O
treated O
in O
a O
referral O
cancer O
center O
in O
Brazil O
. O
[]

Pretreatment O
and O
day-of-debond O
digital O
photographic O
images O
were O
taken O
of O
the O
teeth O
and O
assessed O
by O
up O
to O
5 O
clinical O
and O
3 O
lay O
assessors O
for O
the O
presence O
or O
absence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
the O
esthetic B-outcome ['Life-Impact']
impact. O
[['Physiological-Clinical'], ['Life-Impact']]

024 O
liter O
. O
[]

After O
3 O
days O
of O
treatment, O
the O
serum O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
and O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
in O
both O
groups O
were O
significantly O
decreased O
as O
compared O
with O
those O
before O
treatment O
[NSE O
(mug/L): O
30.15+/-15.18 O
vs. O
31.32+/-14.75, O
S100 O
(ng/L): O
387.5 O
(273.3, O
573.0) O
vs. O
890.0 O
(590.5, O
1 O
162.5) O
in O
routine O
treatment O
group; O
NSE O
(mug/L): O
29.09+/-16.22 O
vs. O
32.25+/-15.43, O
S100 O
(ng/L): O
402.5 O
(302.2, O
580.5) O
vs. O
842.0 O
(462.3, O
1 O
200.5) O
in O
SBH O
treatment O
group, O
all O
P O
< O
0.05]. O
There O
was O
no O
significant O
difference O
in O
serum O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
or O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
level O
between O
the O
two O
groups O
(all O
P O
> O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Multicenter O
Study O
[]

rhNGF O
Clinical O
Investigator O
Group O
. O
[]

In O
patients O
with O
ulcerative O
lesions O
, O
healing B-outcome ['Physiological-Clinical']
times I-outcome ['Physiological-Clinical']
were O
reduced O
in O
the O
ME-609 O
and O
acyclovir O
groups O
compared O
with O
placebo O
( O
P O
< O
.01 O
for O
both O
) O
. O
['Physiological-Clinical']

P O
= O
0.001 O
and O
P O
= O
0.048 O
, O
respectively O
. O
[]

Bone O
mineral O
density O
( O
BMD O
) O
of O
lumbar O
spine O
( O
L1-L4 O
) O
and O
proximal O
femur O
were O
determined O
using O
dual O
X-ray O
absorptiometry O
at O
baseline O
and O
after O
one O
year O
. O
[]

Lornoxicam O
8 O
mg O
demonstrated O
significant O
analgesic B-outcome ['Resource-use']
efficacy O
as O
compared O
with O
placebo O
. O
['Resource-use']

Subjects O
made O
a O
fast O
elbow O
extension O
movement O
to O
designated O
target O
in O
response O
to O
a O
go O
signal O
. O
[]

METHODS O
In O
1996 O
, O
survival O
data O
were O
updated O
from O
three O
prospective O
, O
randomized O
comparisons O
of O
idarubicin O
and O
daunorubicin O
that O
began O
in O
1984 O
and O
1985 O
. O
[]

There O
was O
no O
blood B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
on O
the O
bougie O
, O
laryngoscope O
or O
introducer O
tool O
at O
removal O
, O
but O
blood B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
was O
more O
common O
on O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
with O
the O
introducer O
tool O
technique O
( O
9/50 O
vs O
2/50 O
, O
P=0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Allogeneic O
hematopoietic O
stem-cell O
transplantation O
is O
a O
widely O
used O
, O
cost-intensive O
procedure O
. O
[]

Parents O
of O
children O
with O
more O
advanced O
language B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
may O
require O
intervention O
strategies O
that O
go O
beyond O
FPI O
's O
focus O
on O
responsive B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Feline O
leukaemia O
virus O
( O
FeLV O
) O
infection O
is O
still O
one O
of O
the O
leading O
causes O
of O
infection-related O
deaths O
in O
domestic O
cats O
. O
[]

MATERIALS O
AND O
METHODS O
During O
a O
2-year O
period O
101 O
men O
with O
benign O
prostatic O
hyperplasia O
were O
randomly O
assigned O
to O
PlasmaKinetic O
surgery O
or O
standard O
transurethral O
prostate O
resection O
( O
TURP O
) O
. O
[]

BACKGROUND O
AND O
AIM O
Endothelial O
dysfunction O
in O
hypertensive O
type-2 O
diabetic O
patients O
is O
associated O
with O
increased O
levels O
of O
circulating O
soluble B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecules I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Adults O
with O
acute O
leukemia O
undergoing O
remission O
induction O
chemotherapy O
randomly O
were O
assigned O
to O
receive O
antifungal O
prophylaxis O
with O
AMB O
( O
0.5 O
mg/kg O
three O
times O
weekly O
) O
or O
FLU O
( O
400 O
mg O
daily O
) O
. O
[]

FUNDING: O
Seattle O
Genetics O
Inc, O
Millennium O
Pharmaceuticals O
Inc, O
a O
wholly O
owned O
subsidiary O
of O
Takeda O
Pharmacuetical O
Company O
Limited, O
and O
National O
Institutes O
of O
Health O
National O
Cancer O
Institute O
Cancer O
Center. O
[]

METHODS O
Pulse O
and O
mean O
arterial O
pressure O
were O
analyzed O
for O
their O
effect O
on O
mortality B-outcome ['Mortality']
, O
adjusting O
for O
other O
modifiers O
of O
risk O
, O
using O
Cox O
proportional O
hazards O
regression O
analysis O
of O
data O
collected O
from O
6,781 O
patients O
randomized O
into O
the O
Studies O
of O
Left O
Ventricular O
Dysfunction O
trials O
. O
['Mortality']

A O
total O
of O
82 O
older O
adults O
were O
randomly O
assigned O
to O
3 O
groups: O
a O
HIIT O
group O
(n=28), O
a O
continuous O
intensity O
training O
group O
(MIIT O
group, O
n=27), O
or O
a O
control O
group O
(CG, O
n=27). O
[]

filters O
in O
excluding O
the O
large O
particle O
load O
introduced O
by O
i.v O
. O
[]

Enhancing O
the O
self-esteem B-outcome ['Life-Impact']
of O
inpatient O
alcoholics O
. O
['Life-Impact']

Both O
the O
ionic O
and O
the O
non-ionic O
contrast O
media O
produced O
a O
measurable O
but O
asymptomatic O
and O
biologically O
insignificant O
fall O
in O
static B-outcome ['Physiological-Clinical']
ventilatory I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
conclusion O
, O
there O
was O
an O
additive O
effect O
of O
sevelamer O
for O
the O
treatment O
of O
hyperphosphatemia O
with O
CC O
. O
[]

BACKGROUND O
Chemical O
peels O
and O
topical O
depigmenting O
agents O
have O
become O
a O
popular O
modality O
in O
the O
treatment O
of O
melasma O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
compare O
the O
number O
of O
patients O
treated O
in O
the O
2 O
arms O
. O
[]

No O
change O
occurred O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
, O
apo B-outcome ['Physiological-Clinical']
B100/apo B-outcome ['Physiological-Clinical']
A1 B-outcome ['Physiological-Clinical']
ratio O
, O
plasminogen B-outcome ['Physiological-Clinical']
activator B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
additional O
significant O
benefit O
could O
be O
shown O
from O
the O
intervention O
compared O
to O
standard O
management. O
[]

RESULTS O
127 O
patients O
were O
randomised O
to O
either O
desmopressin O
( O
n=61 O
) O
or O
placebo O
( O
n=66 O
) O
. O
[]

RESULTS O
Topical O
capsaicin O
caused O
> O
50 O
% O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
absence O
of O
attack O
in O
17/23 O
patients O
, O
as O
opposed O
to O
two O
with O
vaseline O
. O
['Physiological-Clinical']

Allergic O
mothers O
had O
significantly O
lower O
amounts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
breast-milk O
compared O
with O
non-allergic O
mothers O
[ O
median O
1.3 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
IQR O
22.4-3.0 O
x O
10 O
( O
3 O
) O
) O
vs. O
5.6 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
( O
1.8 O
x O
10 O
( O
3 O
) O
-1.8 O
x O
10 O
( O
4 O
) O
) O
, O
respectively O
, O
( O
P=0.004 O
) O
] O
, O
and O
their O
infants O
had O
concurrently O
lower O
counts O
of O
bifidobacteria B-outcome ['Physiological-Clinical']
in O
feces O
[ O
3.9 O
x O
10 O
( O
8 O
) O
bacterial O
cells/g O
( O
IQR O
6.5 O
x O
10 O
( O
6 O
) O
-1.5 O
x O
10 O
( O
9 O
) O
) O
in O
infants O
of O
allergic O
mothers O
, O
vs. O
2.5 O
x O
10 O
( O
9 O
) O
bacterial O
cells/g O
( O
6.5 O
x O
10 O
( O
8 O
) O
-3.2 O
x O
10 O
( O
10 O
) O
) O
in O
infants O
of O
non-allergic O
mothers O
, O
P=0.013 O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Misoprostol O
( O
400 O
mcg O
) O
or O
its O
matching O
placebo O
were O
administered O
orally O
, O
and O
the O
measurements O
were O
repeated O
at O
10 O
min O
. O
[]

Its O
effects O
may O
be O
maintained O
for O
3 O
months O
. O
[]

The O
results O
are O
discussed O
in O
terms O
of O
the O
impact O
of O
learning O
processes O
specific O
to O
the O
roles O
of O
the O
staff O
members O
and O
motivational O
factors O
on O
learning O
and O
therapy O
outcome O
, O
along O
with O
institutional O
conditions O
influencing O
successful O
learning O
. O
[]

Probiotics O
could O
affect O
disease B-outcome ['Physiological-Clinical']
risk O
either O
directly O
through O
colonization O
or O
indirectly O
by O
promoting O
changes O
in O
gut O
microbial O
ecology O
. O
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
ferritin I-outcome ['Physiological-Clinical']
was O
measured O
in O
the O
first O
trimester O
, O
at O
36 O
weeks O
' O
gestation O
, O
and O
in O
cord O
blood O
. O
['Physiological-Clinical']

The O
dose O
of O
haloperidol O
and O
cyproheptadine O
was O
titrated O
up O
to O
0.05 O
and O
0.2 O
mg/kg/day O
respectively O
. O
[]

The O
patients O
who O
received O
combined O
treatment O
had O
fewer O
local B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.02 O
) O
and O
fewer O
distant B-outcome ['Physiological-Clinical']
( O
P O
less O
than O
0.01 O
) O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Further O
studies O
are O
warranted O
to O
investigate O
the O
potential O
for O
NFlB O
inhibition O
to O
reduce O
cardiovascular O
risk O
. O
[]

All O
patients O
also O
underwent O
digital O
subtraction O
angiography O
( O
DSA O
) O
and/or O
contrast-enhanced O
magnetic O
resonance O
angiography O
( O
CEMRA O
) O
. O
[]

Compared O
to O
control O
, O
this O
therapeutic O
modality O
was O
found O
to O
increase O
the O
healing B-outcome ['Physiological-Clinical']
rate O
of O
recalcitrant O
, O
diabetic O
foot O
ulcers O
. O
['Physiological-Clinical']

Subjects O
showed O
improvement O
on O
the O
CPRS O
Autism B-outcome ['Life-Impact']
Factor O
( O
F1,9 O
= O
24.4 O
, O
p O
= O
.0008 O
) O
. O
['Life-Impact']

The O
3 O
year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
77.7 O
% O
and O
79.2 O
% O
for O
cisplatin O
and O
carboplatin O
groups O
, O
respectively O
( O
p=0.9884 O
) O
( O
HR O
0.83 O
, O
95 O
% O
CI O
: O
0.63-1.010 O
) O
. O
['Mortality']

Effect O
of O
topical O
anesthesia O
and O
age O
on O
pain B-outcome ['Physiological-Clinical']
scores O
during O
retinopathy O
of O
prematurity O
screening O
. O
['Physiological-Clinical']

BACKGROUND O
Intracoronary O
radiation O
therapy O
reduces O
recurrence O
of O
in-stent O
restenosis O
. O
[]

[ O
Study O
on O
safety O
and O
immunogenicity O
of O
oral O
poliomyelitis O
attenuated O
live O
vaccine O
( O
human O
diploid O
cell O
) O
] O
. O
[]

Using O
minimally-invasive O
surgery O
plus O
recombinant O
tissue O
plasminogen O
activator O
( O
rtPA O
) O
, O
MISTIE O
investigators O
explored O
aggressive O
avenues O
to O
treat O
ICH O
. O
[]

The O
primary O
outcome O
is O
freedom O
from O
having O
, O
or O
meeting O
the O
criteria O
for O
, O
a O
major O
amputation O
( O
below O
knee O
amputation O
, O
or O
metatarsal O
level O
) O
up O
to O
12 O
weeks O
after O
randomization O
. O
[]

The O
present O
study O
compares O
the O
pharmacokinetics O
of O
azithromycin O
in O
plasma O
, O
lung O
tissue O
, O
and O
bronchial O
washing O
after O
oral O
administration O
of O
500 O
mg O
( O
standard O
dose O
) O
versus O
1000 O
mg O
daily O
for O
3 O
days O
. O
[]

Nordic O
Walking O
is O
a O
popular O
and O
fast O
growing O
type O
of O
exercise O
in O
Northern O
Europe O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
similar O
between O
groups O
. O
['Physiological-Clinical']

Bacteriologic O
studies O
of O
feces O
and O
colon O
content O
revealed O
no O
significant O
difference O
in O
the O
reduction O
of O
aerobic B-outcome ['Physiological-Clinical']
bacteria I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
. O
['Physiological-Clinical']

PURPOSE O
To O
study O
the O
efficacy O
of O
indirect O
diode O
laser O
photocoagulation O
and O
cryotherapy O
in O
prethreshold B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prematurity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION: O
Compared O
with O
AGS, O
SHM O
could O
decrease O
the O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
during O
hemostatic O
process O
and O
the O
postoperative O
drainage B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
posterior O
operation O
of O
lumbar O
degenerative O
disease. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Each O
person O
shall O
receive O
therapy O
in O
an O
out-patient O
setting O
in O
groups O
of O
3-4 O
. O
[]

There O
was O
no O
significant O
difference O
in O
posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
stress I-outcome ['Physiological-Clinical', 'Life-Impact']
disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
severity I-outcome ['Physiological-Clinical', 'Life-Impact']
at O
6 O
months O
(treatment O
effect O
estimate O
[difference O
in O
differences O
of O
-0.03 O
[95% O
CI, O
-2.58 O
to O
2.52]; O
P O
= O
.98). O
[['Physiological-Clinical', 'Life-Impact']]

Low O
intraoperative B-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
Index O
( O
BIS O
) O
values O
may O
be O
associated O
with O
increased O
mortality O
. O
['Physiological-Clinical']

This O
preliminary O
study O
suggests O
that O
supplementation O
with O
larger O
ARA O
doses O
added O
to O
DHA O
improves O
impaired O
social B-outcome ['Life-Impact']
interaction I-outcome ['Life-Impact']
in O
individuals O
with O
autism O
spectrum O
disorder O
by O
up-regulating O
signal O
transduction O
. O
['Life-Impact']

This O
study O
was O
conducted O
to O
determine O
the O
long-term O
effect O
of O
flosequinan O
, O
a O
new O
orally O
administered O
arterial O
and O
venous O
dilator O
, O
on O
the O
clinical O
course O
of O
patients O
with O
moderate O
to O
severe O
congestive O
heart O
failure O
. O
[]

It O
is O
also O
associated O
with O
ritualistic O
and O
stereotypical O
behaviour O
. O
[]

METHODS O
Recruited O
60 O
patients O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
treated O
by O
conventional O
chemotherapy O
combined O
DJQ O
, O
20 O
mL O
each O
time O
, O
three O
times O
daily O
) O
and O
the O
control O
group O
( O
treated O
by O
chemotherapy O
alone O
) O
, O
30 O
in O
each O
group O
. O
[]

Behavioral O
ratings O
were O
obtained O
on O
the O
morning O
of O
the O
amino O
acid O
drink O
( O
baseline O
) O
and O
180 O
, O
300 O
, O
and O
420 O
minutes O
after O
the O
drink O
. O
[]

Overall B-outcome ['Physiological-Clinical']
tooth I-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
( O
including O
all O
tooth O
groups O
) O
in O
patients O
with O
palatally-displaced O
canines O
was O
significantly O
less O
than O
that O
in O
the O
control O
group O
. O
['Physiological-Clinical']

At O
entry O
, O
systolic/diastolic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
averaged O
176/86 O
mm O
Hg O
in O
the O
clinic O
and O
149/80 O
mm O
Hg O
on O
24-hour O
ambulatory O
monitoring O
. O
['Physiological-Clinical']

In O
intervention O
arm, O
one O
child O
had O
rheumatic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RHD) I-outcome ['Physiological-Clinical']
while O
three O
had O
congenital B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
; O
in O
control O
arm, O
one O
child O
had O
congenital B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
and O
three O
had O
rheumatic B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RHD) I-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
School O
based O
surveillance O
had O
higher O
rate O
of O
suspecting O
children O
with O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
and O
or O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
although O
with O
low O
specificity. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS O
Regarding O
chemical B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

The O
method O
involved O
Responsivity O
education O
for O
the O
parents O
and O
Prelinguistic O
Milieu O
Teaching O
for O
the O
children O
( O
RPMT O
) O
. O
[]

From O
May O
1978 O
until O
November O
1980 O
, O
169 O
previously O
untreated O
patients O
with O
advanced O
epithelial O
ovarian O
cancer O
were O
entered O
into O
a O
prospective O
randomized O
clinical O
trial O
comparing O
the O
combination O
of O
hexamethylmelamine O
, O
Adriamycin O
, O
and O
cyclophosphamide O
( O
HAC O
) O
to O
a O
combination O
of O
melphalan O
and O
cis-platinum O
. O
[]

BACKGROUND O
Although O
percutaneous O
endoscopic O
gastrostomy O
( O
PEG O
) O
has O
become O
popular O
for O
patients O
with O
swallowing O
disorders O
as O
a O
nutrition O
support O
or O
a O
decompressant O
of O
gastrointestine O
, O
perioperative O
complications O
associated O
with O
PEG O
have O
not O
decreased O
, O
especially O
peristomal O
infections O
. O
[]

AIM O
This O
study O
was O
carried O
out O
to O
determine O
the O
effect O
of O
injection O
duration O
on O
bruising O
and O
pain O
following O
the O
administration O
of O
the O
subcutaneous O
injection O
of O
heparin O
. O
[]

Nutritive O
milk O
feeding O
was O
then O
introduced O
to O
both O
groups O
. O
[]

We O
assessed O
the O
relative O
importance O
of O
lipid B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
apo I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
Lp I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
total O
homocysteine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
in O
children O
in O
relation O
to O
premature O
cardiovascular O
disease O
in O
family O
members O
. O
['Physiological-Clinical', 'Physiological-Clinical']

With O
the O
advent O
of O
atypical O
agents O
in O
the O
treatment O
of O
schizophrenia O
, O
physicians O
and O
policy O
makers O
must O
consider O
the O
costs O
that O
may O
accompany O
greater O
clinical O
efficacy O
. O
[]

There O
were O
no O
significant O
changes O
in O
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
, O
apolipoproteins B-outcome ['Physiological-Clinical']
, O
lipoproteins B-outcome ['Physiological-Clinical']
or O
atherosclerotic B-outcome ['Physiological-Clinical']
indices O
after O
both O
SQ29,852 O
and O
atenolol O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Both O
women O
with O
a O
history O
of O
PMS O
and O
women O
without O
responded O
with O
more O
negative O
mood B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
with O
the O
lower O
dose O
of O
MPA O
. O
['Life-Impact']

The O
Oxford O
data O
base O
on O
perinatal O
trials O
, O
MEDLINE O
, O
Excerpta O
Medica O
, O
and O
Index O
Medicus O
were O
searched O
. O
[]

Lipid B-outcome ['Physiological-Clinical']
results O
, O
clinical B-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
and O
safety O
outcomes O
from O
this O
trial O
are O
anticipated O
in O
2010 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Title: O
The O
influence O
of O
high-dose O
intraoperative O
remifentanil O
on O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
: O
a O
prospective O
randomized O
study: O
A O
CONSORT O
compliant O
article. O
[['Physiological-Clinical']]

A O
safety O
and O
tolerability B-outcome ['Life-Impact']
study O
. O
['Life-Impact']

Ketorolac O
did O
not O
alter O
the O
[]

PATIENTS O
Twenty-six O
patients O
within O
3 O
months O
of O
onset O
of O
stroke O
were O
randomised O
to O
receive O
physical O
therapy O
( O
control O
group O
) O
or O
therapy O
and O
retraining O
( O
experimental O
group O
) O
, O
most O
of O
the O
patients O
in O
both O
groups O
with O
left O
hemiplegia O
. O
[]

Although O
the O
reach O
of O
the O
Web-based O
intervention O
is O
lower O
, O
Web-based O
interventions O
can O
be O
a O
good O
channel O
to O
reach O
high-risk O
populations O
( O
lower O
PA O
intention O
and O
higher O
BMI O
) O
. O
[]

In O
conclusion O
, O
in O
clinical O
practice O
, O
major O
and O
minor O
bleeding O
event O
rates O
associated O
with O
prasugrel O
therapy O
are O
comparable O
to O
those O
reported O
in O
controlled O
randomized O
trials O
. O
[]

We O
conducted O
this O
study O
to O
determine O
whether O
gemfibrozil O
reduced O
rates O
of O
renal O
function O
loss O
in O
people O
with O
moderate O
CRI O
. O
[]

Mean O
DBP B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
intervention O
group O
at O
the O
second O
( O
76.0 O
+/- O
11.8 O
vs O
84.9 O
+/- O
6.1 O
) O
and O
fourth O
( O
77.0 O
+/- O
10.2 O
vs O
91.8 O
+/- O
12.0 O
) O
quarters O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

A O
similar O
comparison O
during O
trial O
2 O
revealed O
a O
1.8 O
+/- O
0.3 O
mmol.l-1 O
increase O
in O
lactate B-outcome ['Physiological-Clinical']
, O
signifying O
a O
workload O
above O
LSS O
and O
therefore O
confirming O
trial O
1 O
as O
the O
maximum O
LSS O
( O
MLSS O
) O
. O
['Physiological-Clinical']

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O
[]

CONCLUSIONS O
Our O
study O
provides O
important O
insights O
into O
the O
timing O
of O
adverse O
events O
and O
suggests O
that O
the O
substantial O
proportion O
of O
patients O
suffer O
subsequent O
adverse O
events O
after O
their O
index O
NSTE O
ACS O
. O
[]

Enhancing O
antiepileptic O
drug O
adherence O
: O
a O
randomized O
controlled O
trial O
. O
[]

At O
20 O
months O
of O
age O
, O
all O
children O
but O
one O
had O
detectable O
antibodies O
to O
all O
three O
poliovirus O
types O
. O
[]

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
the O
response O
rate O
, O
the O
duration O
of O
the O
response B-outcome ['Physiological-Clinical']
, O
safety O
, O
and O
the O
quality O
of O
life O
. O
['Mortality', 'Physiological-Clinical']

The O
relationship O
between O
the O
response O
of O
Plasmodium O
falciparum O
malaria O
to O
mefloquine O
in O
African O
children O
and O
its O
sensitivity O
in O
vitro O
. O
[]

No O
significant O
differences O
were O
detected O
between O
the O
treatment O
and O
the O
placebo O
groups O
after O
8 O
weeks O
of O
supplementation O
with O
the O
algal O
extract O
in O
the O
parameters O
analyzed O
, O
except O
for O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
, O
total O
protein B-outcome ['Physiological-Clinical']
, O
and O
eosinophils B-outcome ['Physiological-Clinical']
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
used O
mixed O
linear O
modeling O
of O
log-transformed O
swim O
time O
to O
quantify O
effects O
on O
performance B-outcome ['Life-Impact']
in O
training O
versus O
competition O
, O
in O
morning O
versus O
evening O
swims O
, O
and O
with O
use O
of O
caffeine O
. O
['Life-Impact']

Evidence O
suggests O
that O
the O
elevation O
in O
plasma O
norepinephrine O
levels O
can O
be O
at O
least O
partly O
attributed O
to O
an O
increase O
in O
sympathetic O
nervous O
system O
activity O
. O
[]

Regarding O
safety O
, O
213 O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
observed O
in O
the O
febuxostat O
group O
and O
220 O
events O
in O
the O
allopurinol O
group O
. O
['Adverse-effects']

Between-group O
differences O
in O
glycosylated O
hemoglobin O
( O
HbA1c O
) O
, O
continuous O
glucose O
sensor O
data O
, O
insulin O
utilization O
, O
anthropometric O
measures O
, O
and O
patient O
satisfaction O
with O
therapy O
were O
also O
compared O
at O
multiple O
time O
points O
. O
[]

Serum B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
were O
determined O
after O
dithiothreitol O
treatment O
. O
['Physiological-Clinical']

Likewise O
, O
morning O
and O
evening B-outcome ['Physiological-Clinical']
PEF I-outcome ['Physiological-Clinical']
decreased O
by O
46 O
+/- O
7 O
L/min O
and O
18 O
+/- O
6 O
L/min O
, O
respectively O
. O
['Physiological-Clinical']

Ciclesonide O
is O
an O
intranasal O
corticosteroid O
approved O
for O
the O
treatment O
of O
allergic O
rhinitis O
. O
[]

Another O
secondary O
data O
analysis O
from O
that O
study O
suggested O
that O
marijuana B-outcome ['Life-Impact']
smoking I-outcome ['Life-Impact']
was O
also O
significantly O
decreased O
in O
a O
subgroup O
of O
subjects O
who O
demonstrated O
cannabis O
abuse O
and O
that O
the O
magnitude O
of O
this O
improvement O
was O
robust O
. O
['Life-Impact']

Subjects O
scheduled O
for O
colonoscopies O
were O
approached O
for O
enrollment O
the O
day O
of O
their O
procedure O
. O
[]

They O
were O
randomly O
classified O
into O
two O
groups O
. O
[]

Primary O
end O
points O
were O
frequency O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
safety O
) O
and O
changes O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
test O
and O
Minnesota O
Living O
With O
HF O
score O
( O
efficacy O
) O
. O
['Adverse-effects', 'Life-Impact']

On O
a O
different O
day O
, O
in O
all O
subjects O
we O
determined O
intraarterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
EKG B-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
MSNA B-outcome ['Physiological-Clinical']
) O
both O
supine O
and O
during O
upright O
tilt O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

vaccination O
with O
0.1 O
ml O
compared O
to O
1.0 O
ml O
i.m O
. O
[]

The O
primary O
endpoint O
was O
the O
response B-outcome ['Physiological-Clinical']
rate O
compared O
to O
the O
historical O
response O
rate. O
[['Physiological-Clinical']]

Haemodynamic O
profile O
of O
angiotensin O
II O
antagonism O
in O
essential O
hypertensive O
patients O
. O
[]

According O
uroflowmetry O
, O
peak O
flow B-outcome ['Physiological-Clinical']
rate O
after O
6 O
months O
of O
treatment O
was O
increased O
by O
more O
than O
50 O
% O
. O
['Physiological-Clinical']

[ O
Effects O
of O
an O
intensive O
therapy O
program O
for O
behaviorally O
disordered O
mentally O
handicapped O
patients O
on O
staff O
personnel O
in O
residential O
care O
] O
. O
[]

In O
contrast O
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
levels O
, O
C-peptide B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
indomethacin O
on O
the O
antihypertensive O
effect O
of O
cilazapril O
appears O
to O
depend O
upon O
the O
sequence O
of O
drug O
administration O
. O
[]

METHODS O
In O
an O
open O
, O
randomized O
( O
for O
midazolam O
treatment O
sequence O
) O
study O
, O
18 O
healthy O
male O
subjects O
received O
single O
doses O
of O
midazolam O
( O
2 O
mg O
oral O
and O
1 O
mg O
i.v. O
, O
1 O
day O
apart O
) O
alone O
, O
repeated O
doses O
of O
roflumilast O
( O
500 O
microg O
once O
daily O
for O
14 O
days O
) O
alone O
, O
and O
repeated O
doses O
of O
roflumilast O
together O
with O
single O
doses O
of O
midazolam O
( O
2 O
mg O
oral O
and O
1 O
mg O
i.v. O
, O
1 O
day O
apart O
) O
. O
[]

The O
effect O
of O
cisapride O
on O
delayed O
colonic B-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
patients O
with O
idiopathic O
Parkinson O
's O
disease O
. O
['Physiological-Clinical']

Good O
compliance B-outcome ['Life-Impact']
did O
not O
affect O
the O
results O
. O
['Life-Impact']

The O
safety O
of O
anti-C. O
difficile O
whey O
protein O
concentrate O
( O
anti-CD O
WPC O
) O
is O
supported O
by O
analytical O
data O
comparing O
the O
composition O
of O
raw O
milk O
from O
immunized O
cows O
versus O
that O
from O
non-immunized O
cows O
, O
and O
the O
composition O
of O
anti-CD O
WPC O
versus O
that O
of O
regular O
whey O
protein O
concentrate O
. O
[]

Side O
effects O
were O
mild O
. O
[]

Overall O
, O
the O
clinician O
spent O
a O
total O
mean O
time O
of O
81.54 O
minutes O
( O
SD O
30.91 O
minutes O
) O
contacting O
participants O
during O
the O
program O
. O
[]

Serum O
cytokines O
were O
quantified, O
and O
microbiota O
assessed O
using O
metagenomic O
sequencing. O
[]

A O
prospective O
study O
on O
the O
clinical O
performance O
of O
polysiloxane O
soft O
liners O
: O
one-year O
results O
. O
[]

Subjects O
are O
randomly O
assigned O
to O
either O
the O
control O
group O
or O
to O
the O
treatment O
group O
. O
[]

The O
sample O
consisted O
of O
40 O
patients O
, O
16 O
of O
whom O
were O
randomized O
to O
use O
chlorhexidine O
and O
24 O
of O
whom O
were O
randomized O
to O
use O
nonmedicated O
skin O
cleanser O
. O
[]

Oestrous O
behaviour O
and O
the O
number O
, O
time O
and O
outcome O
of O
inseminations O
were O
also O
recorded O
. O
[]

The O
hemoglobin B-outcome ['Physiological-Clinical']
levels O
increased O
non-significantly O
at O
7 O
hrs O
post O
DE O
[ O
0.3 O
gm/dL O
( O
95 O
% O
CI O
: O
0.2 O
to O
0.5 O
gm/dL O
) O
] O
versus O
FA O
exposure O
[ O
0.2 O
gm/dL O
( O
95 O
% O
CI O
: O
0 O
to O
0.3 O
gm/dL O
) O
] O
; O
p=0.06 O
. O
['Physiological-Clinical']

Efficacy O
measures O
, O
overall O
response O
rate O
, O
time-to-progression B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
equivalent O
in O
both O
arms O
. O
['Physiological-Clinical', 'Mortality']

The O
selection O
of O
proper O
respirators O
and O
training O
would O
be O
beneficial O
to O
the O
safety O
of O
healthcare O
providers. O
[]

Peak O
ground B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
forces I-outcome ['Physiological-Clinical']
during O
exercise O
increased O
from O
2.5 O
to O
2.8 O
times O
body O
weight O
. O
['Physiological-Clinical']

propofol O
and O
midazolam O
for O
induction O
of O
anaesthesia O
in O
200 O
unpremedicated O
female O
patients O
undergoing O
elective O
gynaecological O
surgery O
. O
[]

METHODS O
Heparin O
in O
Acute O
Embolic O
Stroke O
Trial O
( O
HAEST O
) O
was O
a O
multicentre O
, O
randomised O
, O
double-blind O
, O
and O
double-dummy O
trial O
on O
the O
effect O
of O
low-molecular-weight O
heparin O
( O
LMWH O
, O
dalteparin O
100 O
IU/kg O
subcutaneously O
twice O
a O
day O
) O
or O
aspirin O
( O
160 O
mg O
every O
day O
) O
for O
the O
treatment O
of O
449 O
patients O
with O
acute O
ischaemic O
stroke O
and O
atrial O
fibrillation O
. O
[]

Following O
maintenance O
evaluations O
, O
the O
drug O
was O
tapered O
down O
over O
2 O
weeks O
. O
[]

4 O
months O
after O
the O
end O
of O
treatment O
a O
standardised O
examination O
was O
done O
. O
[]

The O
parameters O
studied O
were O
Superoxide B-outcome ['Physiological-Clinical']
dismutase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SOD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
malonyl-dialdehyde B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MDA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reduced O
glutathione B-outcome ['Physiological-Clinical']
( O
GSH B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
view O
of O
the O
correlation O
between O
angiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
subsequent O
clinical B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
as O
demonstrated O
in O
several O
large O
trials O
, O
it O
is O
not O
unrealistic O
to O
also O
anticipate O
in O
this O
population O
, O
a O
beneficial O
effect O
on O
clinical O
events O
with O
longer O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
randomly O
assigned O
291 O
children O
6 O
to O
23 O
months O
of O
age O
, O
with O
acute O
otitis O
media O
diagnosed O
with O
the O
use O
of O
stringent O
criteria O
, O
to O
receive O
amoxicillin-clavulanate O
or O
placebo O
for O
10 O
days O
. O
[]

These O
data O
suggest O
that O
pressure O
garments O
that O
deliver O
a O
pressure O
of O
at O
least O
15 O
mmHg O
pressure O
tend O
to O
accelerate O
scar B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
and O
that O
measurements O
of O
the O
pattern O
of O
change O
of O
the O
erythema O
can O
be O
used O
to O
predict O
changes O
in O
scar O
thickness O
and O
vice O
versa O
. O
['Physiological-Clinical']

Title: O
Effectiveness O
of O
Adjunctive O
Use O
of O
Low-Level O
Laser O
Therapy O
and O
Photodynamic O
Therapy O
After O
Scaling O
and O
Root O
Planing O
in O
Patients O
with O
Chronic O
Periodontitis. O
[]

The O
non-recurrence B-outcome ['Physiological-Clinical']
rates O
in O
the O
THP O
group O
and O
control O
group O
were O
54.1 O
% O
versus O
37.6 O
% O
at O
1 O
year O
and O
40.4 O
% O
versus O
26.8 O
% O
at O
2 O
years O
, O
respectively O
( O
P O
= O
0.086 O
) O
. O
['Physiological-Clinical']

One O
group O
was O
treated O
with O
estramustine O
phosphate O
, O
another O
with O
Epirubicin O
plus O
Medroxyprogesterone O
acetate O
( O
MPA O
) O
, O
while O
the O
third O
arm O
consisted O
of O
Epirubicin O
plus O
placebo O
. O
[]

Results O
of O
48-hour O
phasing O
at O
the O
end O
of O
one O
month O
's O
treatment O
demonstrated O
a O
significantly O
greater O
fall O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
with O
Ganda O
3.0/0.5 O
( O
9.8 O
mm O
Hg O
) O
than O
with O
Timolol O
0.25 O
per O
cent O
( O
7.67 O
mm O
Hg O
) O
P O
less O
than O
0.001 O
. O
['Physiological-Clinical']

Effects O
of O
antihypertensive O
drugs O
on O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
in O
adolescents O
. O
['Life-Impact']

Patients O
were O
randomly O
assigned O
to O
3 O
groups, O
based O
on O
the O
tube O
ETView O
double-lumen O
tube O
(VDT), O
ETView O
single-lumen O
tube O
(VST), O
or O
traditional O
double O
lumen O
tube O
(DT).All O
83 O
patients' O
intubations O
were O
successful O
to O
achieve B-outcome ['Life-Impact']
1-lung I-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
: O
74 O
patients O
at O
the O
first O
attempt O
(22/26 O
in O
VDT, O
26/28 O
in O
VST, O
26/29 O
in O
DT O
group) O
and O
9 O
patients O
at O
the O
second O
attempt. O
[['Life-Impact']]

The O
study O
aims O
to O
evaluate O
the O
effect O
of O
MSAT O
on O
acute O
low O
back O
pain O
with O
severe O
disability O
. O
[]

258 O
patients O
were O
evaluated O
. O
[]

Following O
training O
in O
one O
of O
the O
four O
training O
groups O
, O
each O
subject O
rated O
the O
24 O
performances O
on O
the O
testing O
videotape O
and O
interrater O
reliability O
was O
assessed O
for O
each O
group O
. O
[]

A O
prospective O
, O
randomized O
study O
. O
[]

Title: O
Are O
(All) O
Consumers O
Averse B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
Bitter I-outcome ['Life-Impact']
Taste I-outcome ['Life-Impact']
? O
[['Life-Impact']]

3 O
) O
The O
case O
number O
of O
patients O
in O
need O
of O
receiving O
the O
treatment O
again O
within O
1-month O
follow-up O
and O
the O
difference O
between O
the O
[]

FUNDING O
GlaxoSmithKline O
. O
[]

Guar O
led O
to O
an O
additional O
lowering O
of O
the O
total O
cholesterol B-outcome ['Physiological-Clinical']
in O
the O
plasma O
by O
7 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.05 O
) O
associated O
with O
a O
fall O
of O
the O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-cholesterol I-outcome ['Physiological-Clinical']
( O
LDL-cholesterol O
) O
by O
13 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.01 O
) O
without O
any O
changes O
in O
the O
very O
low O
density O
lipoprotein O
( O
VLDL O
) O
and O
high O
density O
lipoprotein O
( O
HDL O
) O
cholesterols O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Remifentanil O
had O
prototypic O
micro-like O
opioid O
subjective O
effects O
, O
impaired B-outcome ['Life-Impact']
psychomotor I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
produced O
['Life-Impact']

The O
effects O
of O
TB1 O
and O
TB2 O
( O
containing O
ginseng O
leaf O
, O
cistanche O
and O
fleeceflower O
root O
) O
were O
different O
significantly O
( O
P O
< O
0.05 O
, O
P O
< O
0.01 O
) O
. O
[]

Residual O
tumor O
diameter O
( O
less O
than O
or O
greater O
than O
2 O
cm O
) O
exerted O
a O
statistically O
significant O
effect O
on O
response O
-- O
47.8 O
vs O
24.4 O
% O
. O
[]

positive O
) O
subgroup O
of O
the O
randomised O
cohort O
, O
YAP1 O
expression O
was O
inversely O
correlated O
to O
histological O
grade O
and O
proliferation O
( O
p O
= O
0.001 O
and O
p O
= O
0.016 O
, O
respectively O
) O
whereas O
in O
the O
ER- O
( O
Estrogen O
Receptor O
? O
[]

Improved O
intraoperative B-outcome ['Life-Impact']
management I-outcome ['Life-Impact']
of O
anastomotic B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
during O
aortic O
reconstruction O
: O
results O
of O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Physiological-Clinical']

Tumours O
with O
marginal O
proliferation O
pattern O
showed O
a O
lower O
hazard O
ratio O
with O
CHART O
versus O
conventional O
for O
locoregional O
control O
( O
P O
= O
0.005 O
) O
. O
[]

Captopril O
has O
potential O
value O
in O
the O
treatment O
of O
moderate O
essential O
hypertension O
. O
[]

METHODS O
Double-blind O
, O
randomised O
, O
placebo-controlled O
trial O
, O
including O
children O
( O
age O
3-36 O
m O
) O
with O
acute O
diarrhoea O
who O
were O
allocated O
to O
placebo O
or O
synbiotic O
group O
. O
[]

The O
slowly O
progressive O
nature O
of O
this O
disease O
means O
that O
patients O
will O
require O
ongoing O
therapeutic O
management O
for O
many O
years O
, O
or O
even O
decades O
. O
[]

Trunk O
exercise O
combined O
with O
spinal O
manipulative O
or O
NSAID O
therapy O
for O
chronic O
low O
back O
pain O
: O
a O
randomized O
, O
observer-blinded O
clinical O
trial O
. O
[]

An O
intent-to-treat O
comparison O
of O
the O
numbers O
of O
courses O
affected O
by O
acute O
toxicity O
( O
fever O
, O
rigors O
) O
and O
chronic O
toxicity O
( O
nephrotoxicity O
) O
also O
indicated O
that O
there O
was O
no O
significant O
difference O
between O
AmB O
infused O
in O
dextrose O
( O
78 O
courses O
) O
and O
AmB O
infused O
in O
lipid O
emulsion O
( O
84 O
courses O
) O
. O
[]

Total O
sleep B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
8.05 O
h O
( O
95 O
% O
CI O
7.65-8.44 O
) O
baseline O
, O
8.75 O
h O
( O
95 O
% O
CI O
8.56-8.98 O
) O
with O
placebo O
and O
9.84 O
h O
( O
95 O
% O
CI O
9.68-9.99 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

All O
episodes O
of O
PONV O
during O
the O
first O
24 O
hours O
after O
anesthesia O
administration O
were O
recorded O
by O
an O
investigator O
who O
was O
blinded O
to O
treatment O
assignment O
. O
[]

Cats O
were O
assigned O
to O
one O
of O
four O
treatment O
groups O
that O
received O
either O
high O
dose O
huIFN-?2a O
( O
10 O
( O
5 O
) O
IU/kg O
q24h O
; O
12 O
cats O
) O
, O
AZT O
( O
5 O
mg/kg O
q12h O
; O
10 O
cats O
, O
both O
of O
these O
treatments O
( O
12 O
cats O
) O
or O
placebo O
( O
10 O
cats O
) O
. O
[]

The O
vaccine O
Zostavax O
has O
been O
shown O
to O
prevent O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
and O
is O
recommended O
for O
individuals O
> O
or O
=60 O
years O
of O
age O
. O
[]

Subjects O
40 O
years O
or O
older O
with O
cigarette O
smoking O
history O
?10 O
pack-years O
and O
with O
the O
diagnosis O
of O
COPD O
and O
post-bronchodilator O
FEV O
( O
1 O
) O
?40 O
to O
? O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Portal B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
was O
significantly O
different O
between O
protocols O
B O
and O
C O
( O
p O
= O
0.02 O
) O
in O
the O
first O
phase O
and O
between O
protocols O
B O
and O
C O
and O
protocols O
A O
and O
C O
( O
p O
< O
0.01 O
, O
p O
= O
0.02 O
) O
in O
the O
second O
phase O
. O
['Physiological-Clinical']

Topical O
tetracaine O
was O
not O
associated O
with O
a O
significant O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
score O
, O
although O
it O
did O
lead O
to O
faster O
recovery B-outcome ['Physiological-Clinical']
times O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
9301647 O
[]

The O
Self-Care O
Rehabilitation O
in O
Pediatric O
Asthma O
( O
SCRPA O
) O
project O
was O
designed O
to O
ascertain O
the O
level O
to O
which O
children O
with O
asthma O
are O
able O
to O
acquire O
the O
asthma O
knowledge O
and O
skills O
presented O
in O
a O
self-management O
training O
program O
conducted O
by O
the O
American O
Lung O
Association O
of O
Utah O
and O
the O
effect O
of O
such O
training O
on O
the O
asthma O
experience O
. O
[]

RESULTS O
In O
the O
analyses O
of O
time O
to O
PPMD O
recurrence O
, O
poor O
sleep O
quality O
, O
but O
none O
of O
the O
hormones O
, O
was O
associated O
with O
PPMD O
recurrence O
( O
p O
< O
.05 O
) O
after O
controlling O
for O
medication O
assignment O
. O
[]

These O
results O
suggest O
that O
the O
hemodynamic B-outcome ['Physiological-Clinical']
effects O
of O
the O
3 O
drugs O
are O
similar O
within O
the O
first O
30 O
min O
. O
['Physiological-Clinical']

CONCLUSION O
Compared O
with O
usual O
care O
plus O
written O
education O
, O
pharmaceutical O
care O
focused O
on O
patient O
evaluation O
and O
follow-up O
in O
collaboration O
with O
physicians O
improved O
the O
achievement O
of O
BP B-outcome ['Physiological-Clinical']
, O
TC B-outcome ['Physiological-Clinical']
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
treatment O
goals O
in O
patients O
with O
CVD O
and/or O
high O
or O
intermediate O
CV O
risk O
attending O
community O
pharmacies O
in O
Spain O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
GPs O
of O
intervention O
patients O
were O
more O
satisfied B-outcome ['Life-Impact']
when O
compared O
to O
the O
GPs O
receiving O
a O
standard O
level O
of O
communication O
( O
96.4 O
% O
vs O
48.3 O
% O
of O
the O
intervention O
and O
control O
GPs O
, O
respectively O
, O
described O
the O
communication O
as O
good O
or O
extremely O
good O
, O
P O
= O
0.0001 O
) O
. O
['Life-Impact']

The O
sites O
were O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
implemented O
the O
intervention O
) O
or O
the O
control O
group O
( O
continued O
usual O
training O
) O
. O
[]

Conversely O
, O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
increased O
and O
blood B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
preferred O
by O
patients O
, O
is O
more O
convenient B-outcome ['Life-Impact']
, O
and O
probably O
aids O
compliance B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

We O
will O
evaluate O
the O
effect O
of O
providing O
this O
label O
to O
randomly O
sampled O
patients O
who O
receive O
their O
care O
from O
free O
clinics O
, O
mobile O
vans O
and O
federally O
qualified O
health O
centers O
( O
FQHCs O
) O
in O
Northern O
Virginia O
. O
[]

Nutrient O
retention O
in O
preterm O
infants O
fed O
standard O
infant O
formulas O
. O
[]

In O
Korea O
, O
MSAT O
is O
used O
to O
reduce O
musculoskeletal O
pain O
and O
improve O
functional O
status O
. O
[]

Participants O
in O
the O
treatment O
group O
demonstrated O
greater O
play B-outcome ['Life-Impact']
diversity I-outcome ['Life-Impact']
on O
a O
standardized O
assessment O
. O
['Life-Impact']

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

BACKGROUND O
AND O
METHODS O
In O
patients O
with O
the O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
, O
the O
rate O
of O
relapse O
after O
primary O
treatment O
for O
cryptococcal O
meningitis O
remains O
high O
. O
[]

Pairwise O
comparisons O
revealed O
that O
iodixanol O
9 O
gI O
was O
significantly O
better O
than O
both O
iohexol O
9 O
gI O
( O
p O
= O
0.0005 O
) O
and O
12 O
gI O
( O
p O
= O
0.014 O
) O
. O
[]

Journal O
ID: O
0374675 O
[]

Participants O
were O
aged O
between O
5 O
years O
and O
16 O
years O
10 O
months O
, O
with O
a O
confirmed O
ASD O
diagnosis O
and O
severe O
sleep O
problems O
, O
refractory O
to O
community-based O
interventions O
. O
[]

Clinical O
measures O
assessed O
were O
erythema O
, O
scaling O
and O
pruritus O
which O
were O
evaluated O
using O
a O
four-point O
scale O
( O
0-3 O
) O
. O
[]

However O
, O
in O
the O
2-month O
interval O
after O
receipt O
of O
a O
step-up O
letter O
, O
17.1 O
% O
of O
the O
letters O
were O
followed O
by O
scheduled O
visits O
in O
the O
intervention O
group O
compared O
with O
scheduled O
visits O
12.3 O
% O
of O
the O
time O
by O
the O
control O
children O
with O
comparable O
clinical O
symptoms O
. O
[]

Exercise O
has O
been O
recommended O
for O
enhancing O
sleep O
; O
a O
claim O
linked O
to O
the O
belief O
that O
sleep O
need O
- O
defined O
by O
sleep O
duration O
and O
depth O
- O
is O
increased O
post-exercise O
to O
allow O
tissue O
recovery O
. O
[]

OBJECTIVES O
Because O
preventing O
disability B-outcome ['Life-Impact']
and O
falls B-outcome ['Life-Impact']
in O
older O
adults O
is O
a O
national O
priority O
, O
a O
randomized O
controlled O
trial O
was O
conducted O
to O
test O
a O
multicomponent O
intervention O
program O
. O
['Life-Impact', 'Life-Impact']

Morbidity O
was O
estimated O
from O
the O
number O
of O
days O
patients O
were O
unable O
to O
work O
due O
to O
illness O
, O
number O
of O
days O
hospitalized O
and O
AIDS O
events O
. O
[]

Of O
52 O
protocol O
compliant O
placebo O
immunotherapy O
recipients O
in O
Wenzhou O
, O
37 O
were O
disease O
free O
at O
two O
months O
, O
and O
a O
further O
8 O
had O
> O
50 O
% O
disease O
reduction O
. O
[]

METHODS O
In O
SUSTAIN O
, O
172 O
patients O
with O
low O
levels O
of O
HDL-C O
will O
be O
randomized O
to O
receive O
RVX-208 O
100 O
mg O
bid O
or O
placebo O
for O
24 O
weeks O
. O
[]

In O
this O
potentiation O
the O
primary O
substance O
is O
specially O
mixed O
with O
a O
carrier O
( O
typically O
90 O
% O
ethanol O
) O
in O
the O
ratio O
1:10 O
. O
[]

The O
modified O
intent-to-treat O
cohort O
( O
DHA O
= O
33 O
; O
placebo O
= O
27 O
) O
adhered O
to O
the O
protocol O
? O
[]

OBJECTIVE O
To O
test O
the O
efficacy O
of O
a O
graded O
aerobic O
exercise O
programme O
in O
the O
chronic B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Wind-up O
occurred O
only O
with O
the O
2 O
Hz O
train O
in O
the O
UO O
and O
hand O
( O
both O
p=0.01 O
) O
. O
[]

To O
assess O
possible O
beneficial O
effects O
a O
double O
blind O
, O
comparative O
trial O
of O
metronidazole O
and O
placebo O
was O
performed O
. O
[]

PATIENT O
AND O
METHODS: O
We O
propose O
a O
prospective, O
double-blinded, O
randomized O
phase O
2 O
study O
of O
2 O
parallel O
groups O
of O
eligible O
adult O
patients. O
[]

However O
, O
the O
differences O
among O
the O
groups O
were O
statistically O
insignificant O
. O
[]

Subjects O
with O
a O
negative O
history O
for O
HZ O
were O
randomized O
1:1 O
to O
receive O
one O
dose O
of O
either O
formulation O
. O
[]

Calculated O
retinal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
not O
changed O
by O
administration O
of O
histamine O
( O
-7 O
+/- O
14 O
% O
, O
-4 O
+/- O
20 O
% O
, O
and O
-8 O
+/- O
12 O
% O
, O
P O
= O
0.28 O
, O
ANOVA O
) O
. O
['Physiological-Clinical']

On O
the O
other O
hand O
, O
those O
with O
a O
negative O
angiogram O
received O
only O
EVL O
. O
[]

From O
a O
previously O
reported O
5-year O
screening O
programme O
of O
6,956 O
47-49-year-old O
Malm? O
males O
, O
a O
series O
of O
41 O
subjects O
with O
early-stage O
Type O
2 O
( O
non-insulin-dependent O
) O
diabetes O
mellitus O
and O
181 O
subjects O
with O
impaired O
glucose O
tolerance O
were O
selected O
for O
prospective O
study O
and O
to O
test O
the O
feasibility O
aspect O
of O
long-term O
intervention O
with O
an O
emphasis O
on O
life-style O
changes O
. O
[]

Pain O
and O
overall O
well-being O
were O
measured O
using O
a O
visual O
analog O
scale O
( O
VAS O
) O
. O
[]

Typical O
symptoms O
of O
the O
depression O
such O
as O
lack B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
tiredness B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
disturbed B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
, O
were O
especially O
responsive O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
authors O
demonstrated O
that O
total O
and O
conjugated B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
, O
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
alanine B-outcome ['Physiological-Clinical']
aminotransferase I-outcome ['Physiological-Clinical']
, O
aspartate B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
and O
cholinesterase B-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
during O
the O
5-days O
observation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
10 O
minutes O
after O
the O
beginning O
of O
atomization, O
the O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
in O
different O
preset O
suction O
pressure O
groups O
was O
significantly O
lower O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
917.33+/-4.51 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05), O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
1 O
433.33+/-4.73 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Although O
the O
fall O
in O
tcPCO2 B-outcome ['Physiological-Clinical']
associated O
with O
panic O
was O
not O
substantial O
and O
did O
not O
indicate O
clinically O
significant O
acute B-outcome ['Physiological-Clinical']
hyperventilation I-outcome ['Physiological-Clinical']
, O
it O
appears O
to O
be O
a O
sensitive O
index O
for O
epinephrine-induced O
panic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
To O
enter O
the O
study O
, O
children O
with O
sickle O
cell O
anemia O
and O
no O
history O
of O
stroke O
had O
to O
have O
undergone O
two O
transcranial O
Doppler O
studies O
that O
showed O
that O
the O
time-averaged O
mean O
blood-flow O
velocity O
in O
the O
internal O
carotid O
or O
middle O
cerebral O
artery O
was O
200 O
cm O
per O
second O
or O
higher O
. O
[]

Anaesthesia O
was O
induced O
and O
maintained O
with O
midazolam O
, O
fentanyl O
and O
nitrous O
oxide O
. O
[]

There O
were O
no O
significant O
between-group O
differences O
in O
the O
rates O
of O
ongoing B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
multiple B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
ectopic B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
, O
or O
miscarriage B-outcome ['Mortality']
. O
The O
median O
score O
for O
pain B-outcome ['Physiological-Clinical']
from O
endometrial O
scratching O
(on O
a O
scale O
of O
0 O
to O
10, O
with O
higher O
scores O
indicating O
worse O
pain) O
was O
3.5 O
(interquartile O
range, O
1.9 O
to O
6.0). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

The O
Kaplan-Meier O
survivorship O
with O
revision O
as O
the O
end O
point O
at O
10.8 O
years O
was O
98.8 O
% O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.96 O
to O
1.00 O
) O
in O
the O
computernavigated O
total O
knee O
arthroplasty O
group O
and O
99.2 O
% O
( O
95 O
% O
CI O
, O
0.96 O
to O
1.00 O
) O
in O
the O
conventional O
total O
knee O
arthroplasty O
group O
. O
[]

After O
the O
acupuncture O
treatment O
, O
the O
percentages O
of O
OKT3+ B-outcome ['Physiological-Clinical']
, O
OKT4+ B-outcome ['Physiological-Clinical']
, O
OKT8+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
obviously O
higher O
than O
those O
before O
acupuncture O
; O
the O
control O
group O
of O
patients O
showed O
no O
significant O
variation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
[]

In O
Group O
B O
, O
the O
MMC O
+ O
HCFU O
group O
received O
the O
same O
treatment O
in O
Group O
A O
, O
but O
with O
the O
addition O
of O
600 O
mg/day O
of O
HCFU O
from O
the O
second O
week O
, O
orally O
for O
at O
least O
one O
year O
. O
[]

Prospective O
randomized O
controlled O
trial O
comparing O
plasmakinetic O
vaporesection O
and O
conventional O
transurethral O
resection O
of O
the O
prostate O
. O
[]

Anti-Hib B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
determined O
by O
the O
Farr-type O
radioimmunoassay O
. O
['Physiological-Clinical']

RESULTS: O
In O
the O
experimental O
group O
both O
the O
Ober O
and O
Thomas O
tests O
were O
positive O
at O
baseline O
in O
most O
subjects. O
[]

Offering O
a O
self-test O
for O
HPV O
as O
an O
alternative O
to O
Pap O
smears O
increases O
participation B-outcome ['Life-Impact']
among O
long-term O
non-attendees O
. O
['Life-Impact']

Gastric O
emptying O
disorders O
may O
play O
a O
role O
in O
the O
development O
of O
these O
upper O
gastrointestinal O
diseases O
. O
[]

A O
randomised O
study O
was O
carried O
out O
to O
assess O
the O
effect O
of O
tracheal O
tube O
rotation O
on O
the O
passage O
of O
a O
tube O
over O
a O
gum-elastic O
bougie O
into O
the O
trachea O
in O
100 O
patients O
. O
[]

There O
were O
no O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
the O
febuxostat O
group O
other O
than O
a O
high O
frequency O
of O
gout B-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
induced O
by O
the O
sudden O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
during O
the O
early O
treatment O
period O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
current O
study O
investigated O
perceptual B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
in O
two O
optimal O
conditions O
: O
conversational O
speech O
( O
Experiment O
1 O
) O
versus O
clear O
speech O
( O
Experiment O
2 O
) O
, O
and O
three O
adverse O
conditions O
: O
noise O
( O
Experiment O
3a O
) O
versus O
two O
cognitive O
loads O
( O
Experiments O
4a O
and O
4b O
) O
. O
['Life-Impact']

Five O
of O
six O
in O
the O
olanzapine O
group O
and O
three O
of O
six O
in O
the O
haloperidol O
group O
were O
rated O
as O
responders O
according O
to O
the O
CGI O
Improvement O
item O
. O
[]

No O
differences O
in O
chronic B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
were O
detected O
for O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

At O
early O
vaccination O
, O
4-12 O
months O
after O
stem O
cell O
transplantation O
, O
these O
responses O
were O
more O
pronounced O
. O
[]

In O
the O
SSD O
(n O
= O
37) O
and O
NPWT O
(n O
= O
36) O
cohorts, O
the O
superficial O
surgical B-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
(SSI) I-outcome ['Physiological-Clinical']
, O
deep B-outcome ['Physiological-Clinical']
surgical I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
(SSI) I-outcome ['Physiological-Clinical']
, O
seroma B-outcome ['Physiological-Clinical']
, O
and O
dehiscence B-outcome ['Physiological-Clinical']
rates O
were O
16 O
per O
cent O
and O
14 O
per O
cent O
(P O
> O
0.99), O
5 O
per O
cent O
and O
8 O
per O
cent O
(P O
= O
0.67), O
16 O
per O
cent O
and O
11 O
per O
cent O
(P O
= O
0.74), O
and O
5 O
per O
cent O
and O
3 O
per O
cent O
(P O
>/= O
0.99), O
respectively. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Web-based O
randomisation O
minimised O
for O
recruitment O
site, O
gestation O
(completed O
weeks), O
sex, O
and O
single O
versus O
multifetal O
pregnancy. O
[]

METHODS O
AND O
RESULTS O
Six O
dogs O
with O
microembolizations-induced O
HF O
and O
9 O
HF O
patients O
underwent O
CCM O
leads O
and O
generator O
( O
OPTIMIZER O
II O
) O
implantation O
. O
[]

Cyclosporin O
versus O
cyclophosphamide O
for O
patients O
with O
steroid-dependent O
and O
frequently O
relapsing O
idiopathic O
nephrotic O
syndrome O
: O
a O
multicentre O
randomized O
controlled O
trial O
. O
[]

There O
were O
no O
clinical O
characteristics O
that O
differentiated O
patients O
with O
and O
without O
an O
increase O
in O
the O
DFT B-outcome ['Resource-use']
. O
['Resource-use']

Four O
patients O
( O
50 O
% O
) O
in O
the O
control O
group O
had O
HBsAg B-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
after O
HBV O
reactivation O
. O
['Physiological-Clinical']

PURPOSE O
To O
compare O
once-daily O
radiation O
therapy O
( O
qdRT O
) O
with O
hyperfractionated O
accelerated O
radiation O
therapy O
( O
HART O
) O
after O
two O
cycles O
of O
induction O
chemotherapy O
. O
[]

Comparison O
of O
warfarin O
and O
aspirin O
for O
symptomatic O
intracranial O
arterial O
stenosis O
. O
[]

Analyzing O
the O
clinically O
significant O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( O
Brooker O
Score O
III O
and O
IV O
) O
there O
was O
no O
significant O
difference O
between O
the O
two O
treatment O
arms O
( O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

METHOD O
Nefazodone O
and O
placebo O
treatment O
were O
compared O
in O
a O
6-week O
trial O
of O
120 O
patients O
hospitalized O
for O
DSM-III-R O
diagnosed O
major O
depression O
( O
without O
psychosis O
) O
at O
2 O
study O
centers O
. O
[]

Enriched O
sensorimotor O
environments O
enable O
rodents O
to O
compensate O
for O
a O
wide O
range O
of O
neurological O
challenges O
, O
including O
those O
induced O
in O
animal O
models O
of O
autism O
. O
[]

Both O
treatments O
were O
effective O
in O
reducing O
the O
BOP B-outcome ['Physiological-Clinical']
percentage I-outcome ['Physiological-Clinical']
which O
ranged O
from O
17-42 O
% O
at O
baseline O
by O
about O
40 O
% O
after O
10 O
days O
( O
mean O
BOP B-outcome ['Physiological-Clinical']
baseline O
: O
26 O
% O
, O
mean O
BOP B-outcome ['Physiological-Clinical']
after O
10 O
days O
: O
16 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Best O
response O
rates O
during O
follow-up O
were O
identical O
( O
86 O
% O
) O
in O
both O
arms O
. O
[]

Three O
hundred O
and O
forty-seven O
( O
87 O
% O
) O
had O
CIN O
in O
the O
treatment O
specimen O
and O
could O
be O
included O
in O
the O
analysis O
of O
excision O
margins O
. O
[]

Seventy-four O
post-stroke O
depressed O
patients O
were O
diagnosed O
as O
affected O
by O
anxious O
or O
retarded O
depression O
by O
using O
a O
synoptic O
table O
. O
[]

Title: O
The O
immediate O
sensorimotor B-outcome ['Physiological-Clinical']
effects O
of O
elbow O
orthoses O
in O
patients O
with O
lateral O
elbow O
tendinopathy: O
a O
prospective O
crossover O
study. O
[['Physiological-Clinical']]

Here O
, O
we O
studied O
the O
relationship O
between O
peripheral O
FMRP O
level O
, O
visual B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
( O
contrast O
sensitivity B-outcome ['Physiological-Clinical']
, O
perceptual B-outcome ['Physiological-Clinical']
integration I-outcome ['Physiological-Clinical']
, O
motion/form B-outcome ['Physiological-Clinical']
perception I-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Two O
groups O
of O
high-school O
girls O
( O
mean O
age O
13 O
years O
) O
suffering O
dysmenorrhoea O
were O
randomized O
to O
receive O
fennel O
extract O
( O
n O
= O
55 O
) O
or O
mefenamic O
acid O
( O
n O
= O
55 O
) O
for O
2 O
months O
. O
[]

METHODS O
Ninety-six O
patients O
were O
randomly O
divided O
into O
an O
observation O
group O
and O
a O
control O
group O
, O
48 O
cases O
in O
each O
group O
. O
[]

Cure B-outcome ['Physiological-Clinical']
was O
evaluated O
4 O
months O
postoperatively O
primarily O
by O
fasting O
IGF1 O
less O
than O
or O
equal O
to O
age-adjusted O
upper O
limit O
of O
normal O
. O
['Physiological-Clinical']

The O
score O
of O
childhood O
autism O
rating O
scale O
( O
CARS O
) O
and O
clinical B-outcome ['Physiological-Clinical']
efficacy O
in O
both O
groups O
were O
observed O
before O
and O
after O
treatment O
. O
['Physiological-Clinical']

We O
analysed O
event-free B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
on O
an O
intention-to-treat O
basis O
. O
['Mortality', 'Mortality']

The O
results O
showed O
that O
no O
significant O
weight O
change O
took O
place O
during O
the O
study O
period O
. O
[]

CONCLUSION O
CSP O
using O
hydrocolloid O
technology O
provides O
an O
efficacious O
and O
safe O
alternative O
to O
topical O
antivirals O
in O
treating O
HSL O
as O
a O
wound O
while O
affording O
additional O
immediate O
benefits O
of O
wound O
protection O
, O
discretion O
and O
relief O
of O
social O
embarrassment O
. O
[]

We O
consider O
how O
far O
these O
were O
in O
accord O
with O
the O
hospital O
staffs O
' O
views O
. O
[]

An O
unfavorable O
outcome O
was O
significantly O
less O
frequent O
in O
the O
eyes O
undergoing O
cryotherapy O
( O
21.8 O
% O
) O
compared O
with O
the O
untreated O
eyes O
( O
43 O
% O
) O
. O
[]

No O
significant O
effect O
on O
idiopathic B-outcome ['Physiological-Clinical']
pneumonitis I-outcome ['Physiological-Clinical']
or O
survival B-outcome ['Mortality']
was O
observed O
. O
['Physiological-Clinical', 'Mortality']

Similar O
compensatory B-outcome ['Life-Impact']
effect O
was O
also O
demonstrable O
in O
cerebral B-outcome ['Physiological-Clinical']
haemodynamics I-outcome ['Physiological-Clinical']
: O
in O
the O
placebo O
group O
there O
was O
a O
progressive B-outcome ['Physiological-Clinical']
increase O
in O
cerebral B-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
time O
, O
an O
expression O
of O
decreased O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
, O
while O
with O
Hydergine O
cerebral O
circulation O
time O
was O
shortened O
and O
stabilized O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Title: O
The O
effectiveness O
of O
a O
multidisciplinary O
intervention O
strategy O
for O
the O
treatment O
of O
symptomatic O
joint O
hypermobility O
in O
childhood: O
a O
randomised, O
single O
Centre O
parallel O
group O
trial O
(The O
Bendy O
Study). O
[]

AIM O
To O
determine O
whether O
immunotherapy O
with O
HPV6 O
L1 O
virus O
like O
particles O
( O
VLPs O
) O
without O
adjuvant O
( O
VLP O
immunotherapy O
) O
reduces O
recurrence O
of O
genital B-outcome ['Physiological-Clinical']
warts I-outcome ['Physiological-Clinical']
following O
destructive O
therapy O
. O
['Physiological-Clinical']

Publication O
date: O
2018/12/15 O
06:00 O
[entrez] O
[]

Intra-luminal O
nicotine O
reduces O
smooth O
muscle O
tone O
and O
contractile O
activity O
in O
the O
distal O
large O
bowel O
. O
[]

In O
order O
to O
study O
the O
plasma O
levels O
of O
factor O
XaI O
and O
IIaI O
activity O
an O
enzymatically O
depolymerized O
low O
molecular O
weight O
heparin O
( O
LMW-heparin O
; O
Logiparin O
) O
was O
given O
s.c. O
in O
a O
dose O
of O
35 O
XaI O
mu/kg O
b.w O
. O
[]

Does O
tetanus O
immune O
globulin O
interfere O
with O
the O
immune B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
simultaneous O
administration O
of O
tetanus-diphtheria O
vaccine O
? O
['Physiological-Clinical']

With O
Dimerex O
the O
mixing O
of O
the O
contrast O
medium O
with O
the O
synovial B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
was O
slower O
than O
with O
Conray O
Meglumin O
, O
and O
a O
good O
or O
fair O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
as O
evaluated O
subjectively O
, O
lasted O
longer O
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
In O
this O
multi-center O
, O
randomized O
, O
double-masked O
, O
placebo-controlled O
parallel-group O
comparison O
, O
the O
change O
of O
signs O
and O
symptoms O
( O
sum O
score O
) O
of O
blepharitis O
in O
197 O
patients O
( O
ITT O
( O
intention-to-treat-group O
) O
; O
mean O
age O
56 O
? O
[]

Journal O
ID: O
100891112 O
[]

The O
average O
of O
the O
maximum O
pressure B-outcome ['Physiological-Clinical']
rises O
above O
the O
preoperative O
level O
over O
the O
24 O
hour O
period O
was O
greatest O
for O
the O
group O
receiving O
acetazolamide O
only O
at O
8.9 O
mm O
Hg O
; O
for O
the O
acetylcholine O
group O
the O
average O
maximum O
rise O
was O
6.3 O
mm O
Hg O
; O
while O
the O
combined O
treatment O
group O
showed O
a O
decrease O
of O
0.7 O
mm O
Hg O
. O
['Physiological-Clinical']

METHODS O
Pericardial O
blood O
of O
13 O
patients O
was O
retransfused O
in O
9 O
and O
discarded O
in O
4 O
cases O
. O
[]

PURPOSE O
To O
compare O
two O
preservative-free O
hydrating O
agents O
, O
in O
multidose O
( O
ABAK O
) O
bottles O
, O
in O
contact O
lens O
wearers O
experiencing O
symptoms O
of O
ocular B-outcome ['Physiological-Clinical']
dryness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Laparoscopic O
assessment O
was O
correct O
in O
all O
cases O
in O
which O
the O
appendix O
was O
visualized O
. O
[]

Further O
study O
of O
telephone O
interventions O
is O
recommended O
using O
ethnically O
and O
economically O
heterogeneous O
samples O
. O
[]

OBJECTIVE O
The O
renin-angiotensin O
system O
is O
thought O
to O
be O
involved O
in O
the O
progression O
of O
chronic O
renal O
diseases O
of O
both O
diabetic O
and O
non-diabetic O
origin O
. O
[]

Patients O
who O
were O
nonadherent O
to O
medication O
regimens O
were O
more O
likely O
to O
relapse B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
lack O
of O
statistical O
power O
limits O
the O
external O
validity O
of O
these O
findings O
. O
[]

The O
study O
enrolled O
263 O
healthy O
smokers O
( O
M O
( O
age O
) O
= O
49 O
years O
) O
who O
smoked O
a O
mean O
of O
24 O
cigarettes/day O
, O
with O
a O
mean O
of O
31 O
pack-years O
. O
[]

FINDINGS O
The O
5.3 O
year O
median O
follow-up O
( O
range O
8 O
months O
to O
8 O
years O
11 O
months O
) O
showed O
44 O
% O
( O
95 O
% O
CI O
7-66 O
) O
risk O
reduction O
for O
recurrence O
in O
the O
recurrence-free O
period O
in O
all O
patients O
receiving O
ASI O
( O
p=0.023 O
) O
. O
[]

In O
recent O
years O
, O
further O
developments O
have O
included O
so-called O
hi-fi O
plugs O
and O
custom O
made O
ear O
plugs O
which O
are O
claimed O
to O
improve O
speech O
communication O
. O
[]

Models O
of O
couple-responsible O
and O
therapist-responsible O
process O
in O
couple O
therapy O
were O
developed O
. O
[]

There O
were O
no O
differences O
among O
groups O
at O
T1 O
and O
T2 O
. O
[]

Formoterol O
dose-dependently O
protected O
against O
methacholine O
responsiveness O
( O
4.6 O
doubling O
doses O
after O
120 O
micrograms O
) O
. O
[]

Cystectomy O
was O
done O
in O
22 O
of O
280 O
cases O
( O
7.9 O
% O
) O
in O
the O
white O
light O
group O
and O
in O
13 O
of O
the O
271 O
( O
4.8 O
% O
) O
in O
the O
fluorescence O
group O
( O
p O
= O
0.16 O
) O
. O
[]

RESULTS O
In O
the O
MI O
, O
23.8 O
% O
were O
abstinent B-outcome ['Life-Impact']
at O
15 O
days O
; O
the O
same O
percentage O
at O
one O
month O
and O
3 O
months O
; O
19 O
% O
at O
6 O
months O
; O
and O
14.3 O
% O
remained O
abstinent B-outcome ['Life-Impact']
after O
a O
year O
. O
['Life-Impact', 'Life-Impact']

Ascaris O
and O
growth O
rates O
: O
a O
randomized O
trial O
of O
treatment O
. O
[]

The O
primary O
aim O
was O
to O
test O
whether O
treatment O
with O
LMWH O
, O
started O
within O
30 O
h O
of O
stroke O
onset O
, O
is O
superior O
to O
aspirin O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
during O
the O
first O
14 O
days O
. O
['Physiological-Clinical']

A O
double-blind O
study O
evaluated O
the O
effects O
of O
systemic O
and O
topical O
folate O
on O
gingival B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
fourth I-outcome ['Physiological-Clinical']
and O
eighth B-outcome ['Physiological-Clinical']
months I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Both O
eye O
drops O
reduced O
subjective O
and O
objective O
ocular B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
effective O
. O
['Physiological-Clinical']

METHODS O
This O
phase O
III O
trial O
was O
a O
randomized O
, O
placebo-controlled O
crossover O
design O
. O
[]

0.03 O
) O
. O
[]

Usual O
secondary O
efficacy O
endpoints O
were O
assessed O
. O
[]

SETTING O
Urban O
teaching O
hospital O
clinical O
research O
center O
. O
[]

By O
multivariable O
analysis O
side O
branch O
occlusion O
was O
an O
independent O
predictor O
of O
NQMI B-outcome ['Physiological-Clinical']
( O
OR O
4.45 O
; O
95 O
% O
CI O
[ O
1.82 O
, O
10.85 O
] O
) O
. O
['Physiological-Clinical']

Changes O
between O
pre- O
and O
post-treatment O
were O
examined O
using O
clinical O
interviews O
as O
well O
as O
child- O
, O
parent- O
and O
teacher-report O
measures O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
of O
adapalene O
gel O
comparing O
the O
treatment O
with O
adapalene O
gel O
and O
2 O
% O
ketoconazole O
cream O
in O
pityriasis O
versicolor O
. O
[]

PARTICIPANTS O
One O
hundred O
forty-nine O
volunteers O
5 O
to O
17 O
years O
old O
( O
mean O
[ O
SD O
] O
age O
, O
9.4 O
[ O
3.1 O
] O
years O
) O
were O
randomized O
to O
receive O
citalopram O
( O
n O
= O
73 O
) O
or O
placebo O
( O
n O
= O
76 O
) O
. O
[]

On O
follow-up O
, O
the O
sevelamer O
group O
had O
higher O
levels O
of O
intact B-outcome ['Physiological-Clinical']
parathyroid I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( O
498 O
+/- O
352 O
vs. O
326 O
+/- O
236 O
pg/ml O
, O
p O
= O
0.017 O
) O
, O
bone B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
( O
38 O
+/- O
24 O
vs. O
28 O
+/- O
15 O
U/l O
, O
p O
= O
0.03 O
) O
and O
deoxypyridinoline B-outcome ['Physiological-Clinical']
( O
135 O
+/- O
107 O
vs. O
89 O
+/- O
71 O
nmol/l O
, O
p O
= O
0.03 O
) O
and O
lower B-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
74 O
+/- O
21 O
vs. O
91 O
+/- O
28 O
mg/dl O
, O
p O
= O
0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
On O
the O
primary O
efficacy O
endpoint O
, O
sildenafil-treated O
subjects O
had O
significantly O
better O
scores O
on O
the O
International O
Index O
of O
Erectile B-outcome ['Physiological-Clinical']
Function I-outcome ['Physiological-Clinical']
( O
IIEF O
) O
questions O
3 O
and O
4 O
than O
placebo O
( O
p O
< O
0.001 O
, O
both O
questions O
) O
. O
['Physiological-Clinical']

At O
TW24 O
, O
the O
control O
group O
but O
not O
the O
amantadine O
group O
, O
however O
, O
showed O
significant O
deterioration O
of O
the O
modalities B-outcome ['Physiological-Clinical']
depression B-outcome ['Life-Impact']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
vigor B-outcome ['Physiological-Clinical']
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

A O
good O
clinical O
response O
was O
observed O
in O
32/35 O
( O
91 O
% O
) O
of O
the O
OD O
and O
in O
25/32 O
( O
78 O
% O
) O
in O
the O
MD O
group O
( O
difference O
13 O
% O
, O
95 O
% O
confidence O
interval O
-6.4 O
% O
to O
+26.9 O
% O
) O
. O
[]

The O
lower O
97.5 O
% O
confidence O
bound O
of O
this O
difference O
was O
8.6 O
% O
, O
which O
is O
above O
the O
predefined O
noninferiority O
margin O
of O
15 O
% O
. O
[]

Serum B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
levels O
increased O
in O
41.4 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
37.5 O
% O
of O
women O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

After O
the O
treatment O
period O
with O
the O
first O
drug O
, O
there O
was O
a O
2 O
week O
wash-out O
period O
on O
placebo O
( O
PL O
) O
before O
the O
second O
drug O
was O
given O
. O
[]

Surprisingly O
, O
although O
9 O
out O
of O
52 O
patients O
recur O
six O
weeks O
after O
the O
combination O
treatment O
, O
the O
re-administration O
of O
low-dose O
CY O
alone O
completely O
eliminates O
most O
recurred B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mean O
( O
range O
) O
weekly O
doses B-outcome ['Life-Impact']
were O
92.68 O
( O
12.74-398.41 O
) O
IU/kg/wk O
and O
92.58 O
( O
10.53-393.07 O
) O
IU/kg/wk O
for O
patients O
receiving O
epoetin O
zeta O
and O
epoetin O
alfa O
, O
respectively O
( O
95 O
% O
CI O
[ O
test-reference O
] O
: O
-4.67 O
and O
4.29 O
IU/kg/wk O
, O
within O
the O
equivalence O
range O
of O
+/-45.00 O
IU/kg/wk O
) O
. O
['Life-Impact']

RESULTS O
Pulse B-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
were O
related O
positively O
to O
each O
other O
, O
age O
, O
ejection O
fraction O
and O
prevalence O
of O
diabetes O
and O
hypertension O
and O
inversely O
to O
prior O
myocardial O
infarction O
and O
beta-adrenergic O
blocking O
agent O
use O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
we O
compared O
data O
obtained O
by O
questionnaires O
to O
that O
obtained O
with O
actigraphy O
. O
[]

Pemetrexed O
has O
shown O
single-agent O
activity O
in O
SCCHN O
and O
in O
combination O
with O
cisplatin O
for O
other O
tumors O
. O
[]

METHODS O
The O
study O
was O
a O
matched-pair O
, O
cluster-randomized O
controlled O
trial O
involving O
14 O
Chicago O
public O
schools O
. O
[]

Oximetry B-outcome ['Resource-use']
, O
partial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
alveoli/fraction I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
inspired I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
and O
compliance B-outcome ['Life-Impact']
were O
collected O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

Alternatively O
, O
the O
distinctiveness O
heuristic O
assumes O
that O
critical B-outcome ['Physiological-Clinical']
lures I-outcome ['Physiological-Clinical']
are O
actively O
withheld O
by O
the O
use O
of O
a O
retrieval O
strategy O
. O
['Physiological-Clinical']

RESULTS O
Women O
in O
the O
treatment O
condition O
compared O
to O
the O
control O
condition O
reported O
significant O
gains O
in O
attitudes B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

CONCLUSION O
Our O
data O
indicate O
that O
the O
beneficial O
effect O
of O
the O
multiple O
risk O
intervention O
programme O
was O
confined O
to O
those O
patients O
with O
echolucent O
plaques O
. O
[]

METHODS: O
Participants O
were O
randomly O
assigned O
to O
either O
the O
CART O
group O
that O
performed O
combined O
aerobic O
and O
resistance O
exercise O
of O
moderate O
intensity O
[aerobic O
exercise O
50-80% O
of O
HRmax O
(maximum O
heart O
rate) O
and O
resistance O
exercises O
at O
50-80% O
of O
1 O
Repetition O
Maximum O
(RM)], O
5 O
times/week O
for O
4 O
weeks, O
or O
to O
the O
control O
group O
that O
followed O
conventional O
treatment O
without O
any O
supervised O
exercise O
intervention. O
[]

RESULTS O
Forty-one O
patients O
were O
entered O
in O
the O
study O
and O
40 O
were O
evaluable O
for O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

The O
effect O
of O
adjuvant O
immunotherapy O
with O
a O
single O
neighbourhood O
injection O
of O
2 O
mg O
C. O
parvum O
( O
CP O
) O
was O
investigated O
in O
a O
randomized O
study O
involving O
43 O
patients O
with O
carcinoma O
of O
the O
cervix O
uteri O
, O
all O
of O
whom O
were O
treated O
by O
radical O
surgery O
. O
[]

The O
rate O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
the O
3 O
groups O
. O
['Adverse-effects']

Intra-articular O
hyaluronic O
acid O
compared O
to O
intra-articular O
triamcinolone O
hexacetonide O
in O
inflammatory O
knee O
osteoarthritis O
. O
[]

Between O
baseline O
and O
6 O
months O
after O
surgery O
, O
there O
were O
no O
differences O
between O
group O
I O
and O
both O
pre-fed O
groups O
. O
[]

A O
significance O
level O
of O
p O
< O
0.05 O
was O
established. O
[]

IQOS(TM) O
scored O
higher O
in O
terms O
of O
subjective O
reward/satisfaction B-outcome ['Life-Impact']
and O
was O
slightly O
preferred O
to O
the O
e-cigarette. O
[['Life-Impact']]

In O
a O
tamoxifen O
randomised O
patient O
material O
, O
absent O
YAP1 O
protein O
expression O
was O
associated O
with O
impaired O
tamoxifen O
response O
which O
was O
significant O
upon O
interaction O
analysis O
( O
p O
= O
0.042 O
) O
. O
[]

Multivariable O
survey-logistic O
regression O
analyses O
were O
performed O
to O
assess O
predictors O
and O
probability O
of O
the O
outcome O
. O
[]

Finally O
, O
the O
inter-observer O
reliability O
of O
UTC O
was O
determined O
. O
[]

SETTING O
Three O
university O
teaching O
hospitals O
in O
Hamilton O
, O
Ontario O
, O
Canada O
. O
[]

BACKGROUND O
Adverse O
events O
occur O
following O
non-ST O
elevation O
acute O
coronary O
syndromes O
( O
NSTE O
ACS O
) O
. O
[]

However O
, O
for O
placebo O
and O
control O
sites O
, O
bacterial B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
increased O
and O
reached O
the O
baseline O
value O
on O
week O
17 O
. O
['Physiological-Clinical']

Overall O
, O
the O
LNG/EE O
group O
achieved O
a O
consistently O
higher O
percentage O
of O
normal B-outcome ['Physiological-Clinical']
menstrual I-outcome ['Physiological-Clinical']
cycles I-outcome ['Physiological-Clinical']
as O
well O
as O
a O
lower O
rate O
of O
intermenstrual B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
amenorrhea B-outcome ['Physiological-Clinical']
than O
the O
NETA/EE O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
two O
groups O
significant O
improvement O
of O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
ESR B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
are O
discussed O
. O
[]

This O
agent O
improved O
overall O
survival O
in O
a O
phase O
III O
trial O
in O
previously O
treated O
patients O
with O
advanced O
melanoma O
. O
[]

There O
were O
no O
differences O
among O
groups O
in O
the O
number O
of O
patients O
with O
positive O
herpes O
simplex O
virus O
cultures O
. O
[]

Five O
of O
six O
volunteers O
who O
received O
the O
400-mg O
dose O
experienced O
subjective B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
central I-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
when O
the O
cuff O
was O
released O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Most O
patients O
without O
a O
stoma O
( O
7 O
of O
12 O
in O
CRT O
group O
and O
9 O
of O
16 O
in O
RT O
group O
) O
had O
incontinence O
for O
liquid O
stools O
or O
gas O
. O
[]

PE O
was O
less O
than O
5 O
days O
old O
and O
the O
clinical O
diagnosis O
was O
confirmed O
by O
pulmonary O
angiograms O
demonstrating O
a O
vascular O
obstruction O
of O
more O
than O
30 O
% O
( O
Miller O
's O
index O
greater O
than O
11 O
) O
. O
[]

Using O
double-blind O
sham-controlled O
parallel O
design O
, O
we O
evaluated O
the O
effect O
of O
HF-rTMS O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
on O
negative O
symptoms O
in O
patients O
with O
schizophrenia O
. O
[]

Protocol-defined O
cardiotoxicity B-outcome ['Physiological-Clinical']
was O
observed O
in O
13 O
% O
of O
TLC O
D-99 O
patients O
( O
including O
2 O
cases O
of O
CHF O
) O
compared O
to O
29 O
% O
of O
doxorubicin O
patients O
( O
including O
9 O
cases O
of O
CHF O
) O
. O
['Physiological-Clinical']

Comparison O
of O
intermittent O
or O
continuous O
methotrexate O
plus O
6-mercaptopurine O
in O
regimens O
for O
standard-risk O
acute O
lymphoblastic O
leukemia O
in O
childhood O
( O
JCCLSG-S811 O
) O
. O
[]

The O
study O
design O
was O
a O
prospective O
randomised O
controlled O
clinical O
trial O
. O
[]

Short-term O
intravenous O
antibiotic O
treatment O
of O
acute O
hematogenous O
bone O
and O
joint O
infection O
in O
children O
: O
a O
prospective O
randomized O
trial O
. O
[]

Immediately O
following O
balloon O
dilatation O
an O
intra-arterial O
bolus O
of O
either O
150 O
micrograms O
GTN O
, O
with O
or O
without O
a O
10 O
mg O
GTN O
patch O
for O
24 O
h O
, O
or O
a O
saline O
placebo O
was O
administered O
. O
[]

Blood O
losses O
were O
replaced O
with O
5 O
per O
cent O
human O
albumin O
, O
red O
cell O
concentrates O
, O
and O
fresh O
frozen O
plasma O
. O
[]

a O
traditional O
herbal O
medicine O
which O
was O
used O
in O
Thailand O
for O
decades O
, O
for O
the O
treatment O
of O
mild O
and O
mild O
to O
moderate O
ED O
in O
Thai O
patients O
. O
[]

AHs O
do O
not O
inhibit O
the O
wheal O
induced O
by O
the O
intradermal O
injection O
of O
AS O
in O
R-CIU O
. O
[]

Citrated B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
was O
obtained O
before O
and O
after O
1 O
and O
2 O
weeks O
of O
exercise O
: O
tPA B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
was O
assessed O
by O
a O
10 O
min O
venous O
occlusion O
( O
VO O
) O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
and O
zinc B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
and O
GSH B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
over O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS: O
Myocarditis B-outcome ['Physiological-Clinical']
, O
encephalopathy B-outcome ['Physiological-Clinical']
, O
cardiogenic B-outcome ['Physiological-Clinical']
shock I-outcome ['Physiological-Clinical']
, O
ICU B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
, O
need B-outcome ['Resource-use']
for O
mechanical O
ventilation O
, O
mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
mortality B-outcome ['Mortality']
were O
significantly O
lower O
in O
those O
received O
intravenous O
antivenom O
compared O
with O
those O
received O
intramuscular O
one. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Resource-use'], ['Mortality']]

METHODS O
A O
randomised O
, O
multi-centre O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
carried O
out O
at O
19 O
centres O
in O
France O
, O
Germany O
and O
the O
Netherlands O
in O
patients O
with O
a O
clinical O
diagnosis O
of O
acute O
ischaemic O
stroke O
, O
and O
onset O
of O
symptoms O
within O
12 O
hours O
before O
start O
of O
study O
drug O
administration O
. O
[]

Journal O
ID: O
101225531 O
[]

Six O
of O
the O
nine O
women O
also O
received O
a O
dose O
of O
200 O
mg O
. O
[]

Givosiran O
is O
an O
investigational O
RNA O
interference O
therapeutic O
agent O
that O
inhibits O
hepatic O
ALAS1 O
synthesis. O
[]

However, O
blood O
loss O
and O
fibrinolytic O
activity, O
accounting O
for O
a O
poor O
prognosis O
following O
TKA O
operation, O
were O
relieved O
by O
fibrinolytic O
inhibitor O
tranexamic O
acid O
(TXA). O
[]

Changes O
in O
MD O
( O
standard O
error O
[ O
SE O
] O
) O
during O
the O
study O
period O
were O
-0.778 O
( O
0.178 O
) O
and O
-0.071 O
( O
0.195 O
) O
dB/year O
in O
the O
control O
and O
brovincamine O
groups O
, O
respectively O
; O
change O
in O
the O
control O
group O
was O
significantly O
more O
negative O
than O
in O
the O
brovincamine O
group O
. O
[]

Major O
, O
minor O
, O
and O
minimal O
bleedings O
( O
Thrombolysis O
In O
Myocardial O
Infarction O
criteria O
) O
occurred O
in O
2.7 O
% O
, O
4.7 O
% O
, O
and O
15.1 O
% O
of O
enrolled O
patients O
. O
[]

METHODS O
A O
retrospective O
cohort O
study O
was O
conducted O
spanning O
January O
2003 O
to O
June O
2011 O
assessing O
pneumonia O
within O
30 O
days O
and O
potential O
adverse O
effects O
of O
ketorolac O
among O
all O
patients O
with O
rib O
fractures O
who O
received O
ketorolac O
< O
4 O
days O
after O
injury O
compared O
with O
a O
random O
sample O
of O
those O
who O
did O
not O
. O
[]

Journal O
ID: O
101147696 O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
was O
9.4 O
months O
in O
the O
white O
light O
group O
and O
16.4 O
months O
in O
the O
fluorescence O
group O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION: O
The O
study O
is O
registered O
at O
EudraCT O
(2016-003017-10, O
date O
of O
registration: O
22 O
July O
2016) O
and O
( O
NCT02868385 O
, O
date O
of O
registration: O
16 O
August O
2016). O
[]

PATIENTS O
AND O
METHODS O
A O
multicenter O
, O
randomized O
phase O
II O
trial O
evaluated O
the O
safety O
of O
combining O
bevacizumab O
with O
either O
chemotherapy O
( O
docetaxel O
or O
pemetrexed O
) O
or O
erlotinib O
and O
preliminarily O
assessed O
these O
combinations O
versus O
chemotherapy O
alone O
, O
as O
measured O
by O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

RESULTS O
Statistically O
significantly O
greater O
improvement O
was O
seen O
with O
aripiprazole O
versus O
placebo O
( O
p O
< O
0.05 O
) O
for O
all O
arms O
in O
both O
trials O
on O
the O
ABC-Irritability O
total O
subscale O
score O
and O
on O
the O
following O
individual O
ABC-Irritability O
items O
: O
Mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
quickly O
, O
cries/screams B-outcome ['Life-Impact']
inappropriately B-outcome ['Life-Impact']
, O
and O
stamps B-outcome ['Life-Impact']
feet/bangs I-outcome ['Life-Impact']
objects B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CA O
proved O
superior O
to O
placebo O
on O
the O
evolution O
of O
markers O
of O
alcohol O
ingestion O
at O
three O
months O
, O
in O
this O
large-scale O
multicenter O
study O
. O
[]

Data O
for O
high O
grade O
PIN O
and O
LSPC O
were O
gathered O
from O
each O
ERSPC O
centre O
. O
[]

A O
new O
atrial B-outcome ['Physiological-Clinical']
enlargement I-outcome ['Physiological-Clinical']
took O
place O
in O
those O
patients O
who O
remained O
with O
atrial O
fibrillation O
( O
+16.8 O
% O
left O
auricular O
volume O
in O
Group O
I O
vs. O
+8.4 O
% O
in O
Group O
II O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Sequential O
pre-operative/post-operative O
treatment O
with O
anastrozole O
resulted O
in O
lower O
recurrence B-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
rates O
, O
compared O
with O
tamoxifen O
. O
['Physiological-Clinical', 'Mortality']

Children O
with O
autism O
were O
randomly O
allocated O
to O
risperidone O
plus O
memantine O
or O
placebo O
plus O
risperidone O
for O
a O
10-wk O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

The O
frequency O
of O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
for O
the O
ALL-2 O
regimen O
versus O
the O
L-20 O
regimen O
was O
83 O
% O
versus O
71 O
% O
( O
P O
= O
.06 O
) O
. O
['Physiological-Clinical']

INTRODUCTION: O
In O
this O
study, O
we O
aimed O
to O
compare O
the O
incidence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
bond B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
between O
2 O
groups O
of O
participants O
wearing O
fixed O
orthodontic O
appliances O
bonded O
with O
either O
light-cured O
resin-modified O
glass O
ionomer O
cement O
or O
light-cured O
composite. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Group O
I O
was O
given O
600 O
mg O
ipriflavone O
orally O
daily O
and O
group O
II O
was O
weekly O
injected O
intramuscularly O
with O
20 O
units O
elcatonin O
, O
Asu1-7 O
eel O
calcitonin O
( O
carbocalcitonin O
) O
. O
[]

RESULTS O
At O
6 O
months O
, O
similar O
numbers O
of O
events O
occurred O
in O
each O
group O
: O
8 O
( O
placebo O
) O
, O
7 O
( O
low O
dose O
) O
, O
and O
8 O
( O
high O
dose O
) O
, O
without O
deaths O
. O
[]

It O
is O
therefore O
concluded O
that O
EPA O
and O
DHA O
supplementation O
had O
no O
beneficial O
effects O
in O
mild O
to O
moderate O
essential O
hypertensive O
black O
patients O
except O
for O
a O
[]

MAIN O
OUTCOMES O
MEASURE O
( O
S O
) O
Survival B-outcome ['Mortality']
rates O
and O
maintenance O
of O
meiotic O
spindle O
observed O
immediately O
after O
warming O
and O
3 O
hours O
after O
incubation O
. O
['Mortality']

fractionation O
during O
a O
prospective O
, O
randomised O
trial O
of O
hyperfractionated O
radiation O
therapy O
( O
HFX O
RT O
) O
to O
a O
total O
dose O
of O
77 O
Gy O
given O
in O
70 O
fractions O
of O
1.1 O
Gy O
b.i.d. O
, O
with O
and O
without O
concurrent O
low-dose O
, O
daily O
cisplatin O
( O
CDDP O
) O
for O
head O
and O
neck O
cancer O
. O
[]

The O
antibody B-outcome ['Physiological-Clinical']
level O
in O
either O
group O
were O
low O
throughout O
the O
15-day O
study O
period O
. O
['Physiological-Clinical']

SETTING O
Ten O
centers O
in O
the O
United O
States O
. O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

The O
FLT3ITD O
mRNA O
level O
has O
a O
high O
prognostic O
impact O
in O
NPM1 O
mutated O
, O
but O
not O
in O
NPM1 O
unmutated O
, O
AML O
with O
a O
normal O
karyotype O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Cardiac O
failure O
: O
symptoms O
and O
functional O
status O
. O
[]

Journal-Name:Nigerian O
journal O
of O
clinical O
practice O
[]

CONCLUSION O
Ibuprofen O
is O
a O
potent O
antipyretic B-outcome ['Physiological-Clinical']
agent O
and O
is O
a O
safe O
alternative O
for O
the O
selected O
febrile O
child O
who O
may O
benefit O
from O
antipyretic O
medication O
but O
who O
either O
can O
not O
take O
or O
does O
not O
achieve O
satisfactory O
antipyresis B-outcome ['Physiological-Clinical']
with O
acetaminophen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
proportions O
of O
missing O
values O
per O
patient O
were O
low O
for O
both O
questionnaires O
( O
0.54 O
% O
for O
the O
CRQ O
and O
2 O
% O
for O
the O
SGRQ O
) O
. O
[]

Thirty-five O
children O
diagnosed O
with O
autism O
were O
randomly O
assigned O
to O
either O
a O
joint O
attention O
or O
a O
symbolic O
play O
intervention O
. O
[]

BACKGROUND O
The O
benefit O
of O
combined O
mechanical O
and O
pharmacologic O
methods O
for O
venous B-outcome ['Physiological-Clinical']
thromboembolism I-outcome ['Physiological-Clinical']
prevention O
after O
abdominal O
surgery O
has O
not O
been O
clearly O
established O
. O
['Physiological-Clinical']

Riluzole O
is O
a O
glutamate-modulating O
agent O
with O
neuroprotective O
properties O
, O
which O
has O
been O
shown O
to O
have O
positive O
effects O
in O
many O
neuropsychiatric B-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Single-step O
advancement O
was O
achieved O
in O
the O
MA O
group O
until O
an O
edge-to-edge O
incisor O
relationship O
or O
an O
overcorrected O
Class O
I O
molar O
relationship O
was O
obtained. O
[]

Effects O
of O
tryptophan O
depletion O
in O
drug-free O
adults O
with O
autistic O
disorder O
. O
[]

Comparison O
of O
antiresorptive O
activities O
of O
ipriflavone O
, O
an O
isoflavone O
derivative O
, O
and O
elcatonin O
, O
an O
eel O
carbocalcitonin O
. O
[]

The O
PACT O
program O
targeted O
individuals O
newly O
admitted O
to O
nursing O
homes O
and O
worked O
with O
a O
family O
caregiver O
to O
develop O
and O
implement O
a O
nursing O
home O
discharge O
plan O
. O
[]

Thirty O
patients O
( O
mean O
age O
: O
10.38 O
years O
) O
affected O
by O
primary B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
were O
selected O
for O
a O
double-blind O
cross-over O
clinical O
trial O
. O
['Physiological-Clinical']

Twenty-five O
patients O
were O
attributed O
to O
the O
coma O
type O
, O
which O
is O
a O
progredient O
coma O
lasting O
several O
days O
. O
[]

Association O
between O
weight O
loss B-outcome ['Physiological-Clinical']
and O
improvement O
of O
ventricular B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
advanced O
heart O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

HYPOTHESIS O
Dermal O
iontophoretic O
administration O
of O
dexamethasone O
sodium O
phosphate O
will O
be O
significantly O
more O
effective O
in O
controlling O
pain B-outcome ['Physiological-Clinical']
than O
a O
placebo O
in O
patients O
with O
medial O
or O
lateral O
elbow O
epicondylitis O
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
response O
to O
a O
given O
dietary O
intervention O
could O
be O
determined O
by O
the O
effect O
of O
diet O
, O
gene O
variants O
or O
gene-diet O
interactions O
. O
['Physiological-Clinical']

Because O
the O
aim O
of O
prostate O
cancer O
detection O
is O
to O
find O
cancers O
at O
an O
early O
, O
potentially O
curable O
stage O
, O
it O
is O
of O
major O
interest O
that O
71.8 O
% O
of O
evaluable O
cancers O
were O
clinical O
stage O
B O
; O
8.4 O
% O
and O
10.7 O
% O
were O
stages O
C1 O
and O
C2 O
, O
respectively O
; O
only O
9.2 O
% O
were O
stage O
D O
( O
metastatic O
) O
at O
first O
visit O
while O
none O
was O
at O
stage O
D O
at O
follow-up O
visits O
. O
[]

PATIENTS O
Adult O
( O
age O
> O
or=18 O
years O
) O
critically O
ill O
patients O
with O
hemoglobin O
< O
or=12 O
g/dL O
, O
expected O
hospitalization O
of O
> O
or=7 O
days O
, O
with O
no O
ongoing O
acute O
blood O
loss O
. O
[]

Group O
100 O
received O
0.3 O
mg O
kg-1 O
diazepam O
orally O
with O
100 O
ml O
of O
water O
2 O
h O
before O
surgery O
. O
[]

There O
was O
significantly O
less O
severe O
and O
less O
frequent O
toxicity B-outcome ['Adverse-effects']
with O
mitoxantrone O
administration O
. O
['Adverse-effects']

Contribution O
of O
[]

Regression O
analyses O
suggested O
that O
targeting O
different O
beliefs O
for O
those O
donors O
who O
had O
and O
had O
not O
reacted O
would O
yield O
most O
benefit O
in O
bolstering O
donors O
' O
intentions O
to O
remain O
donating O
. O
[]

It O
is O
hoped O
that O
, O
if O
this O
inhibition O
can O
be O
mitigated O
, O
it O
will O
be O
possible O
to O
assist O
the O
compromised O
immune O
system O
and O
maintain O
a O
certain O
level O
of O
immune O
performance O
which O
will O
prevent O
recurrence O
and O
improve O
survival B-outcome ['Mortality']
rate O
. O
['Mortality']

We O
conclude O
that O
there O
is O
no O
utility O
for O
TENS O
in O
the O
postoperative O
management O
of O
pain O
after O
knee O
arthroplasty O
. O
[]

Journal O
ID: O
101291488 O
[]

METHODS O
Post-hoc O
analysis O
of O
data O
from O
a O
randomized O
, O
controlled O
trial O
of O
telcagepant O
( O
150 O
mg O
, O
300 O
mg O
) O
zolmitriptan O
5 O
mg O
, O
or O
placebo O
for O
a O
moderate/severe O
migraine O
. O
[]

An O
additional O
approach O
for O
prevention O
of O
the O
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
is O
calcium O
channel O
blocker O
( O
CCB O
) O
treatment O
. O
['Physiological-Clinical']

Itching B-outcome ['Physiological-Clinical']
, O
a O
pathophysiologically O
complex O
sensation O
, O
is O
favourably O
influenced O
by O
steroids O
within O
10 O
min O
, O
therefore O
presumably O
via O
nongenomic O
mechanisms O
. O
['Physiological-Clinical']

Survival B-outcome ['Mortality']
without O
moderate O
or O
severe O
neurodevelopmental B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
24 O
months O
occurred O
in O
802 O
of O
1224 O
infants O
(65.5%) O
assigned O
to O
the O
faster O
increment O
and O
848 O
of O
1246 O
(68.1%) O
assigned O
to O
the O
slower O
increment O
(adjusted O
risk O
ratio, O
0.96; O
95% O
confidence O
interval O
[CI], O
0.92 O
to O
1.01; O
P O
= O
0.16). O
[['Mortality'], ['Life-Impact']]

Primary O
RP O
were O
screened O
and O
assigned O
to O
either O
the O
nifedipine O
SR O
group O
( O
Group O
N O
) O
or O
the O
Ginkgo O
biloba O
extract O
group O
( O
Group O
G O
) O
in O
the O
ratio O
of O
2:1 O
. O
[]

The O
apparent O
arrest O
of O
progressive B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
seen O
in O
four O
patients O
after O
treatment O
with O
IL-1Ra O
was O
associated O
with O
reduced O
intimal O
layer O
macrophage O
accumulation O
in O
all O
patients O
. O
['Physiological-Clinical']

BACKGROUND O
Dietary O
intake O
of O
soy O
protein O
with O
isoflavones O
may O
be O
associated O
with O
reductions O
in O
serum O
cholesterol O
. O
[]

All O
patients O
continued O
to O
receive O
a O
stable O
dosage O
of O
MTX O
. O
[]

10?/L O
vs. O
9.6 O
? O
[]

CONCLUSIONS O
Aerosolized O
pentamidine O
had O
significant O
prophylactic B-outcome ['Physiological-Clinical']
efficacy O
, O
but O
we O
could O
not O
detect O
any O
major O
effect O
on O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

On O
the O
basis O
of O
the O
presence O
and O
dose O
intensity O
of O
the O
included O
agents O
, O
we O
hypothesised O
that O
PELF O
would O
be O
superior O
to O
FAMTX O
. O
[]

Stent B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
present O
in O
a O
good O
proportion O
of O
patients O
in O
groups O
1 O
and O
2 O
but O
there O
was O
a O
significant O
difference O
in O
the O
incidence O
of O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
11.5 O
% O
versus O
38.1 O
% O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Belatacept O
serum O
concentrations O
were O
determined O
at O
several O
time O
points O
between O
belatacept O
infusions. O
[]

The O
incidence O
of O
shivering B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
misoprostol O
group O
whilst O
that O
of O
vomiting O
was O
significantly O
higher O
in O
the O
syntometrine O
group O
. O
['Physiological-Clinical']

METHODS O
Sixty-eight O
consecutively O
recruited O
, O
premenopausal O
, O
omnivorous O
women O
of O
all O
races O
and O
ethnicities O
between O
the O
ages O
of O
25 O
years O
and O
55 O
years O
were O
admitted O
to O
the O
study O
and O
randomized O
to O
an O
experimental O
group O
supplemented O
with O
soy O
( O
40 O
mg O
genistein O
per O
day O
) O
or O
to O
a O
control O
group O
that O
consumed O
a O
placebo O
for O
a O
12-week O
period O
. O
[]

The O
view O
from O
the O
tip O
appears O
continuously O
on O
a O
portable O
monitor O
in O
the O
anesthesia O
area. O
[]

Both O
the O
degree O
and O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
was O
similar O
in O
both O
groups O
. O
['Physiological-Clinical']

Publication O
Type: O
Journal O
Article O
[]

METHODS O
We O
evaluated O
the O
effects O
of O
calcitriol O
( O
1alpha,25-dihydroxyvitamin O
D3 O
) O
on O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
76 O
patients O
( O
26 O
men O
and O
50 O
women O
) O
with O
cirrhosis O
who O
were O
assigned O
randomly O
to O
receive O
calcitriol O
( O
0.5 O
mg O
twice O
per O
day O
) O
or O
not O
. O
['Physiological-Clinical']

The O
TFP O
group O
(n O
= O
30) O
received O
a O
single O
TFP O
25 O
mug/ O
h O
to O
the O
anterior O
chest O
wall O
14 O
h O
before O
operation. O
[]

The O
primary O
end O
point O
was O
the O
response O
rate O
( O
RR O
) O
. O
[]

Further O
studies O
are O
needed O
to O
assess O
the O
optimal O
treatment O
strategy O
for O
hypertension O
in O
the O
elderly O
. O
[]

The O
treated O
area O
was O
sampled O
by O
the O
scrub-wash O
method O
immediately O
before O
treatment O
began O
and O
after O
2 O
and O
4 O
weeks O
, O
and O
microorganisms O
were O
enumerated O
and O
identified O
. O
[]

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O
[]

CONCLUSION O
ZJC1 O
can O
enhance O
the O
[]

A O
single-blind O
, O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
vacuum-compression B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VCT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
for O
the O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Of O
7788 O
patients O
in O
the O
Digitalis O
Investigation O
Group O
trial O
, O
3527 O
had O
CKD O
, O
defined O
by O
an O
estimated O
glomerular O
filtration O
rate O
( O
GFR O
) O
< O
60 O
ml/min/1.73 O
m O
( O
2 O
) O
body O
surface O
area O
( O
BSA O
) O
. O
[]

Comparison O
of O
the O
Family O
End-of-study O
Up-to-date O
indices O
also O
demonstrated O
that O
families O
of O
patients O
sent O
customized O
letters O
were O
more O
likely O
to O
be O
up-to-date O
than O
families O
not O
sent O
letters O
( O
Kruskal-Wallis O
P O
= O
.0054 O
) O
. O
[]

The O
results O
of O
our O
current O
study O
validate O
the O
use O
of O
low-frequency O
rTMS O
as O
a O
modulatory O
tool O
that O
altered O
the O
disrupted O
ratio O
of O
cortical O
excitation O
to O
inhibition O
in O
autism O
. O
[]

Fasting O
levels O
of O
intact O
neurotensin O
were O
unchanged O
by O
surgery O
, O
whereas O
levels O
of O
NH2-terminal B-outcome ['Physiological-Clinical']
immunoreactivity I-outcome ['Physiological-Clinical']
were O
higher O
in O
bypass O
patients O
with O
a O
long O
ileal O
segment O
( O
37.5 O
cm O
) O
than O
in O
unoperated O
patients O
and O
in O
those O
with O
a O
short O
ileal O
segment O
( O
12.5 O
cm O
) O
. O
['Physiological-Clinical']

Histamine O
in O
food O
at O
non-toxic O
doses O
has O
been O
proposed O
to O
be O
a O
major O
cause O
of O
food O
intolerance O
causing O
symptoms O
like O
diarrhea O
, O
hypotension O
, O
headache O
, O
pruritus O
and O
flush O
( O
histamine O
intolerance O
) O
. O
[]

Our O
power O
calculations O
indicate O
a O
sample O
size O
of O
112 O
is O
required O
for O
both O
primary O
outcomes O
. O
[]

Beneficial O
effects O
regarding O
the O
development O
of O
allergy O
have O
been O
suggested O
to O
come O
through O
probiotic O
supplementation O
. O
[]

The O
authors O
assessed O
the O
safety O
and O
effectiveness O
of O
atomoxetine O
monotherapy O
compared O
with O
combined O
atomoxetine/fluoxetine O
therapy O
in O
a O
population O
of O
children O
and O
adolescents O
with O
ADHD O
and O
concurrent O
symptoms O
of O
depression O
or O
anxiety O
. O
[]

Blast B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Pgp I-outcome ['Physiological-Clinical']
( O
63 O
% O
) O
and O
LRP B-outcome ['Physiological-Clinical']
( O
71 O
% O
) O
was O
common O
, O
whereas O
only O
Pgp O
adversely O
impacted O
the O
rate O
of O
CR/CP B-outcome ['Physiological-Clinical']
( O
P O
=.025 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Registration O
, O
www.irct.ir O
; O
IRCT138711091556N2 O
) O
. O
[]

Main O
outcome O
measures O
were O
body O
mass O
index O
( O
BMI O
) O
, O
serum O
leptin O
and O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
. O
[]

A O
proper B-outcome ['Life-Impact']
fluoroscopic I-outcome ['Life-Impact']
evaluation I-outcome ['Life-Impact']
was O
rapidly O
( O
15 O
+/- O
5 O
seconds O
) O
achieved O
in O
all O
patients O
with O
the O
former O
orientation O
, O
whereas O
it O
was O
impossible O
to O
obtain O
it O
in O
8 O
of O
20 O
( O
40 O
% O
) O
, O
19 O
of O
20 O
( O
95 O
% O
) O
, O
and O
4 O
of O
5 O
( O
80 O
% O
) O
of O
patients O
with O
the O
latter O
orientation O
. O
['Life-Impact']

METHODS O
Lymph O
nodes O
from O
patients O
( O
n=94 O
) O
which O
were O
included O
in O
a O
randomized O
trial O
of O
lymph O
node O
sampling O
( O
LS O
, O
n=41 O
) O
versus O
radical O
systematic O
lymphadenectomy O
( O
LA O
, O
n=53 O
) O
were O
screened O
by O
immunohistochemistry O
for O
disseminated O
tumor O
cells O
using O
the O
antibody O
Ber-Ep4 O
. O
[]

Twenty O
of O
the O
42 O
AML O
patients O
and O
5 O
of O
9 O
CML O
patients O
are O
alive O
with O
a O
projected O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
of O
23 O
months O
. O
['Mortality']

This O
has O
implications O
for O
falls O
risk O
, O
fractures O
, O
and O
interventions O
. O
[]

REVAMP O
comprised O
two O
phases O
: O
1 O
) O
a O
12-week O
open-label O
antidepressant O
trial O
and O
2 O
) O
, O
a O
subsequent O
phase O
, O
in O
which O
phase O
1 O
non-remitters O
( O
N O
= O
491 O
) O
were O
randomized O
to O
either O
receive O
an O
ongoing O
medication O
algorithm O
alone O
, O
medication O
plus O
cognitive O
behavioral O
analysis O
system O
of O
psychotherapy O
, O
or O
medication O
plus O
brief O
supportive O
psychotherapy O
. O
[]

We O
analyzed O
44 O
patients O
with O
hypovitaminosis O
at O
baseline O
and O
after O
six O
months O
of O
two O
different O
regimens O
of O
administration: O
seven O
drops O
(1750 O
IU)/day O
vs. O
50,000 O
IU/month. O
[]

The O
pattern O
of O
ipilimumab-induced O
antibody O
titers O
to O
microbial O
flora O
and O
the O
histologic O
features O
and O
location O
of O
the O
inflammation O
were O
distinct O
from O
classic O
IBD O
. O
[]

Compared O
with O
povidone-iodine O
, O
the O
chlorhexidine-based O
solution O
was O
associated O
with O
a O
50 O
% O
decrease O
in O
the O
incidence O
of O
catheter B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
( O
11.6 O
% O
vs O
22.2 O
% O
[ O
P O
= O
.002 O
] O
; O
incidence O
density O
, O
9.7 O
vs O
18.3 O
per O
1000 O
catheter-days O
) O
and O
with O
a O
trend O
toward O
lower O
rates O
of O
catheter-related B-outcome ['Physiological-Clinical']
bloodstream I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
1.7 O
% O
vs O
4.2 O
% O
[ O
P O
= O
.09 O
] O
; O
incidence O
density O
, O
1.4 O
vs O
3.4 O
per O
1000 O
catheter-days O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Following O
a O
non-randomized O
study O
suggesting O
that O
desmopressin O
acetate O
( O
desmopressin O
) O
reduced O
blood O
product O
requirements O
in O
these O
patients O
, O
we O
conducted O
a O
double-blind O
, O
placebo-controlled O
randomized O
trial O
of O
desmopressin O
( O
0.3 O
micrograms/kg O
, O
i. O
v. O
) O
in O
92 O
patients O
with O
overt O
bleeding O
and O
a O
prolonged O
bleeding O
time O
. O
[]

After O
3 O
months O
of O
treatment O
we O
did O
not O
observe O
statistically O
significant O
differences O
in O
heart B-outcome ['Physiological-Clinical']
diameters I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
between O
treated O
group O
and O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DISCUSSION: O
Our O
study O
suggests O
a O
beneficial O
effect O
of O
oral O
glutamine O
supplementation O
for O
the O
prevention O
from O
radiation-induced O
injury B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
loss O
in O
advanced O
NSCLC O
patients O
who O
receiving O
CCRT. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Effectiveness O
of O
cetrorelix O
for O
the O
prevention O
of O
premature B-outcome ['Physiological-Clinical']
luteinizing I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
surge I-outcome ['Physiological-Clinical']
during O
controlled O
ovarian O
stimulation O
using O
letrozole O
and O
gonadotropins O
: O
a O
randomized O
trial O
. O
['Physiological-Clinical']

In O
patients O
from O
this O
subgroup O
with O
central-medial O
tumors O
, O
comprising O
62 O
% O
of O
the O
total O
, O
survival B-outcome ['Mortality']
after O
RDL O
at O
10 O
years O
was O
60 O
% O
( O
+/- O
8 O
% O
) O
, O
and O
after O
EXT O
86 O
% O
( O
+/- O
6 O
% O
) O
( O
P O
= O
0.025 O
) O
. O
['Mortality']

VPW B-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CVP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
or O
pulmonary B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAOP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
the O
first O
four O
study O
days O
were O
correlated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS:: O
There O
is O
good O
agreement O
when O
comparing O
radiographer O
contours O
to O
the O
gold-standard O
for O
all O
three O
imaging O
types O
with O
Dice O
similarity O
co-efficient O
0.91-0.94, O
Cohen's O
kappa O
0.85-0.91, O
Hausdorff O
distance O
4.6-7.6 O
mm O
and O
mean O
distance O
between O
contours O
0.9-1.2 O
mm. O
[]

Delayed O
anticancer O
effects O
of O
aspirin O
are O
compatible O
with O
the O
proposed O
mechanism O
, O
as O
continual O
microbleeding B-outcome ['Physiological-Clinical']
has O
a O
gradual O
cumulative O
effect O
on O
stored O
iron O
. O
['Physiological-Clinical']

Results O
show O
an O
overall O
response O
rate O
of O
73 O
% O
with O
26 O
% O
complete O
responses O
in O
the O
combined O
treatment O
arm O
, O
whereas O
in O
the O
alternating O
arm O
, O
an O
overall O
response O
rate O
of O
76 O
% O
with O
20 O
% O
complete O
responses O
was O
observed O
. O
[]

All O
patients O
had O
carcinoma O
confined O
to O
the O
cervix O
, O
the O
upper O
part O
of O
the O
vagina O
or O
the O
parametrial O
region O
. O
[]

We O
propose O
a O
pragmatic O
approach O
to O
the O
correction O
or O
amelioration O
of O
venous O
hypertension O
resulting O
from O
hydrodynamic O
and O
hydrostatic O
venous O
reflux O
. O
[]

The O
side O
effects O
of O
most O
concern O
were O
somnolence B-outcome ['Physiological-Clinical']
and O
weight O
gain O
. O
['Physiological-Clinical']

METHODS O
In O
this O
single-center O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
, O
two-arm O
study O
, O
40 O
patients O
with O
persistent O
AR O
were O
randomized O
to O
receive O
either O
montelukast O
and/or O
levocetirizine O
or O
placebo O
( O
n O
= O
20 O
) O
or O
to O
receive O
treatment O
with O
montelukast O
and/or O
desloratadine O
or O
placebo O
( O
n O
= O
20 O
) O
. O
[]

Median O
end-tidal O
volatile O
anesthetic B-outcome ['Life-Impact']
concentration O
was O
significantly O
lower O
in O
the O
guided O
group O
than O
the O
usual O
care O
group O
(0.69 O
vs O
0.80 O
minimum O
alveolar B-outcome ['Physiological-Clinical']
concentration; O
difference, O
-0.11 O
[95% O
CI, O
-0.13 O
to O
-0.10), O
and O
median O
cumulative O
time B-outcome ['Physiological-Clinical']
with O
EEG O
suppression O
was O
significantly O
less O
(7 O
vs O
13 O
minutes; O
difference, O
-6.0 O
[95% O
CI, O
-9.9 O
to O
-2.1]). O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
paper O
presented O
the O
preliminary O
results O
of O
a O
randomized O
clinical O
trial O
of O
Project O
SEARCH O
plus O
ASD O
Supports O
on O
the O
employment O
outcomes O
for O
youth O
with O
ASD O
between O
the O
ages O
of O
18-21 O
years O
of O
age O
. O
[]

Apolipoprotein B-outcome ['Physiological-Clinical']
A-I I-outcome ['Physiological-Clinical']
and O
E B-outcome ['Physiological-Clinical']
were O
elevated O
27 O
% O
and O
66 O
% O
, O
respectively O
, O
and O
apoB B-outcome ['Physiological-Clinical']
was O
reduced O
26 O
% O
with O
120 O
mg O
twice O
daily O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incidence O
of O
grade O
3 O
or O
higher O
[]

RESULTS: O
At O
3 O
and O
6 O
month O
follow O
up, O
Atorvastatin O
40mg O
leads O
to O
mean O
LDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
reduction O
of O
47.18+/-20.81 O
& O
50.03+/-18.06 O
respectively. O
[['Physiological-Clinical']]

This O
study O
demonstrates O
that O
losartan O
reduces O
t-PA B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
levels O
in O
white O
, O
but O
not O
African-American O
hypertensive O
individuals O
. O
['Physiological-Clinical']

Four O
patients O
showed O
loss O
of O
the O
same O
allele O
at O
one O
or O
more O
marker O
loci O
in O
both O
primary O
and O
metastatic O
tumors O
, O
but O
discordant O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
observed O
at O
other O
marker O
loci O
. O
['Physiological-Clinical']

Reflux B-outcome ['Physiological-Clinical']
, O
total O
, O
and O
antacid B-outcome ['Resource-use']
scores O
were O
calculated O
for O
each O
of O
the O
treatment O
periods O
. O
['Physiological-Clinical', 'Resource-use']

Death B-outcome ['Mortality']
( O
not O
due O
to O
pericarditis O
) O
occurred O
in O
two O
patients O
treated O
with O
indomethacin O
and O
one O
patient O
who O
received O
the O
placebo O
. O
['Mortality']

This O
endothelial O
dysfunction O
is O
regarded O
as O
an O
early O
feature O
of O
atherosclerosis O
. O
[]

Furthermore O
, O
Latino O
health O
care O
professionals O
have O
been O
absent O
from O
these O
intervention O
efforts O
even O
though O
the O
epidemic O
has O
affected O
this O
population O
disproportionately O
. O
[]

In O
Study O
1 O
, O
27 O
healthy O
, O
Thai O
adults O
received O
a O
40 O
IU O
kg O
( O
-1 O
) O
dose O
of O
either O
Erig O
PMC O
( O
n O
= O
12 O
) O
or O
PHT-Erig O
( O
n O
= O
15 O
) O
via O
the O
intramuscular O
( O
i.m O
. O
) O
[]

In O
the O
current O
study O
, O
we O
attempted O
to O
address O
this O
question O
by O
categorizing O
stimuli O
as O
high O
, O
middle O
, O
and O
low O
preference O
based O
on O
the O
results O
of O
a O
choice O
assessment O
, O
and O
then O
comparing O
the O
reinforcing O
effectiveness O
of O
these O
stimuli O
using O
a O
concurrent O
operants O
paradigm O
. O
[]

They O
were O
randomly O
assigned O
to O
receive O
12 O
mg O
of O
nicorandil O
or O
a O
placebo O
intravenously O
just O
before O
reperfusion O
. O
[]

The O
effect O
of O
tolrestat O
( O
200 O
mg O
a O
day O
) O
was O
compared O
with O
that O
of O
placebo O
on O
35 O
controls O
with O
diabetes O
mellitus O
, O
of O
similar O
age O
, O
gender O
, O
and O
glycemic O
control O
. O
[]

INTRODUCTION O
Increased O
reliance O
on O
bulbospinal O
motor O
systems O
has O
been O
implicated O
in O
individuals O
with O
chronic O
stroke O
during O
maximum O
voluntary O
arm O
joint O
torque O
generation O
. O
[]

If O
patients O
were O
found O
to O
have O
reflux-related O
heartburn, O
we O
randomly O
assigned O
them O
to O
receive O
surgical O
treatment O
(laparoscopic O
Nissen O
fundoplication), O
active O
medical O
treatment O
(omeprazole O
plus O
baclofen, O
with O
desipramine O
added O
depending O
on O
symptoms), O
or O
control O
medical O
treatment O
(omeprazole O
plus O
placebo). O
[]

Thirty O
of O
these O
patients O
were O
chosen O
randomly O
and O
for O
180 O
days O
, O
500 O
mg O
of O
propionyl-L-carnitine O
was O
orally O
administered O
, O
3 O
times O
a O
day O
in O
addition O
to O
their O
usual O
treatment O
. O
[]

In O
a O
placebo-controlled O
, O
randomised O
, O
double-blind O
clinical O
trial O
, O
the O
authors O
evaluated O
the O
efficacy O
of O
patient-administered O
1 O
% O
fusidic O
acid O
viscous O
eye O
drops O
in O
clearing O
the O
commonest O
organisms O
causing O
pseudophakic O
endophthalmitis O
( O
Staphylococcus O
epidermidis O
and O
aureus O
) O
from O
the O
lids O
and O
conjunctivae O
of O
79 O
patients O
before O
cataract O
surgery O
. O
[]

For O
the O
topotecan O
group O
, O
median O
time O
to O
progression B-outcome ['Physiological-Clinical']
was O
18.9 O
weeks O
( O
range O
< O
1 O
to O
92.6+ O
weeks O
; O
25 O
% O
censored O
) O
, O
and O
, O
for O
paclitaxel O
, O
14.7 O
weeks O
( O
range O
< O
1 O
to O
137.3+ O
weeks O
; O
12.3 O
% O
censored O
) O
; O
P O
= O
0.076 O
. O
['Physiological-Clinical']

PURPOSE O
Cancer B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CRF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O
['Physiological-Clinical']

Insulin O
pump O
therapy O
started O
at O
the O
time O
of O
diagnosis O
: O
effects O
on O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
pancreatic O
?-cell O
function O
in O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

With O
nutritional B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
triceps B-outcome ['Physiological-Clinical']
skinfold I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
and O
mid-arm B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
increased O
( O
mean O
15 O
% O
, O
62 O
% O
, O
and O
95 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

With O
such O
long-term O
treatment O
, O
the O
safety O
profile O
of O
new O
agents O
will O
be O
of O
paramount O
importance O
. O
[]

After O
a O
2-wk O
run-in O
period O
, O
the O
doses O
of O
BDI O
were O
halved O
, O
while O
the O
patients O
were O
assigned O
to O
receive O
orally O
ONO-1078 O
, O
450 O
mg O
twice O
daily O
, O
or O
placebo O
. O
[]

2 O
) O
= O
5.67 O
, O
P O
= O
.02 O
) O
. O
[]

8.8 O
ml? O
kg O
( O
-1 O
) O
? O
[]

[ O
Plasma O
separation O
combined O
with O
CVVHF O
in O
septic O
and O
SIRS O
patients O
] O
. O
[]

CONCLUSION O
The O
combination O
of O
fluoxetine O
plus O
local O
application O
of O
lidocaine O
ointment O
was O
found O
to O
be O
more O
effective O
than O
fluoxetine O
alone O
in O
the O
treatment O
of O
premature O
ejaculation O
. O
[]

For O
dentine O
at O
day O
10 O
, O
many O
specimens O
exceeded O
the O
50 O
microm O
set O
limit O
of O
the O
profilometer O
and O
only O
day O
5 O
data O
were O
considered O
. O
[]

Publication O
date: O
2018/12/10 O
00:00 O
[accepted] O
[]

On O
the O
other O
hand O
, O
indomethacin O
had O
no O
effect O
on O
the O
duration O
of O
chest B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
mean O
days O
+/- O
SE O
: O
placebo O
1.4 O
+/- O
0.6 O
, O
indomethacin O
5.5 O
+/- O
3.3 O
) O
, O
duration O
of O
pericardial B-outcome ['Physiological-Clinical']
friction I-outcome ['Physiological-Clinical']
rub I-outcome ['Physiological-Clinical']
( O
placebo O
10.3 O
+/- O
1.7 O
, O
indomethacin O
16.0 O
+/- O
3.8 O
) O
, O
or O
on O
the O
amount O
of O
pericardial B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forty-six O
patients O
with O
advanced O
gastric O
carcinoma O
( O
Stage O
IV O
) O
were O
evaluated O
in O
a O
prospective O
randomized O
comparison O
of O
two O
chemotherapy O
regimens O
( O
FAM O
versus O
5-FU O
plus O
BCNU O
) O
to O
identify O
therapeutic O
activity O
. O
[]

SETTING O
Outpatient O
with O
sleep O
laboratory O
assessments O
in O
months O
1 O
and O
8 O
of O
treatment O
. O
[]

Journal-Name:The O
western O
journal O
of O
emergency O
medicine O
[]

BACKGROUND: O
A O
high-fidelity O
task O
simulator O
for O
cricothyroidotomy O
was O
created O
using O
data O
from O
a O
3-dimensional O
(3D) O
computed O
tomography O
scan O
using O
a O
3D O
printer. O
[]

In O
order O
to O
evaluate O
subtle O
effects O
on O
electroencephalographic O
vigilance O
within O
stage O
A O
, O
also O
the O
anterior-posterior B-outcome ['Physiological-Clinical']
and O
left-right B-outcome ['Physiological-Clinical']
relations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
alpha-power I-outcome ['Physiological-Clinical']
were O
calculated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

J. O
Radiol. O
[]

Participants O
are O
randomised O
to O
receive O
MCP O
either O
at O
baseline O
(early O
treatment) O
or O
after O
3 O
months O
(delayed O
treatment). O
[]

s.d O
. O
; O
[]

This O
was O
a O
12-month O
randomized O
, O
prospective O
, O
multicenter O
, O
double-masked O
, O
placebo-controlled O
, O
Food O
and O
Drug O
Administration O
approved O
clinical O
trial O
designed O
to O
compare O
rheopheresis O
treatment O
with O
placebo-control O
treatment O
. O
[]

SESSION O
B O
An O
acupuncture O
needle O
( O
Hwato O
, O
& O
emptyv O
; O
0.30x30 O
mm O
) O
was O
inserted O
perpendicular O
into O
the O
Hegu O
point O
( O
LI O
4 O
) O
in O
the O
middle O
of O
the O
right O
dorsal O
thenar O
muscle O
. O
[]

Twice-a-day O
versus O
four-times-a-day O
ofloxacin O
treatment O
of O
external O
ocular O
infection O
. O
[]

Kidney O
biopsies O
were O
examined O
with O
light O
and O
electron O
microscopy O
, O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma O
flow O
determined O
with O
inulin O
and O
para-aminohippuric O
acid O
clearances O
. O
[]

The O
maternal O
and O
fetal O
outcomes O
were O
compared O
. O
[]

Twenty-two O
children O
with O
autism O
spectrum O
disorders O
who O
had O
not O
responded O
to O
supported O
behaviour O
management O
strategies O
for O
severe O
dysomnias O
entered O
a O
double O
blind O
, O
randomised O
, O
controlled O
crossover O
trial O
involving O
3 O
months O
of O
placebo O
versus O
3 O
months O
of O
melatonin O
to O
a O
maximum O
dose O
of O
10 O
mg. O
17 O
children O
completed O
the O
study O
. O
[]

Success O
was O
defined O
as O
> O
or=20 O
% O
reduction O
in O
IOP B-outcome ['Physiological-Clinical']
without O
further O
glaucoma O
intervention O
. O
['Physiological-Clinical']

Lung B-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
was O
higher O
5 O
minutes O
before O
bypass O
in O
group O
1 O
versus O
group O
5 O
( O
34 O
+/- O
13 O
mL/cm O
H O
( O
2 O
) O
O O
vs O
20 O
+/- O
9 O
mL/cm O
H O
( O
2 O
) O
O O
; O
P O
= O
0.048 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Urinary B-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
is O
elevated O
in O
patients O
with O
type O
2 O
DM O
compared O
with O
healthy O
individuals O
and O
increases O
as O
nephropathy O
progresses O
. O
['Physiological-Clinical']

There O
was O
a O
1-week O
washout O
period O
prior O
to O
each O
randomized O
treatment O
. O
[]

Treatment O
with O
enalapril O
significantly O
reduced O
plasma B-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
levels O
and O
supine B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
one O
and O
six O
weeks O
after O
bleaching B-outcome ['Physiological-Clinical']
, O
there O
were O
51 O
% O
and O
65 O
% O
reductions O
in O
deltaE O
, O
respectively O
. O
['Physiological-Clinical']

BACKGROUND O
The O
treatment O
of O
distal O
femoral O
fractures O
remains O
a O
significant O
surgical O
challenge O
. O
[]

In O
addition O
, O
the O
percentage O
of O
patients O
[]

Each O
CT O
scan O
was O
reconstructed O
at O
5 O
, O
2.5 O
and O
1.25 O
mm O
slice O
intervals O
during O
the O
image O
acquisition O
. O
[]

METHODS O
Post-hoc O
analyses O
were O
conducted O
on O
data O
from O
patients O
presenting O
with O
a O
mixed O
index O
episode O
who O
were O
enrolled O
in O
a O
larger O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Satisfaction B-outcome ['Life-Impact']
was O
measured O
for O
attendees O
and O
referring O
doctors O
at O
follow-up O
. O
['Life-Impact']

B1+B6 O
or O
B6 O
treatment O
both O
caused O
an O
increase O
in O
C-peptide B-outcome ['Physiological-Clinical']
( O
P=0.006 O
, O
P=0.004 O
) O
. O
['Physiological-Clinical']

All O
patients O
had O
intravenous O
patient-controlled O
analgesia O
(PCA) O
with O
10 O
mug/kg O
of O
fentanyl O
for O
48 O
hours. O
[]

[ O
Effect O
of O
dopexamine O
in O
splanchnic O
perfusion O
during O
surgery O
of O
the O
abdominal O
aorta O
] O
. O
[]

BACKGROUND O
A O
better O
treatment O
modality O
is O
needed O
to O
control O
the O
pain B-outcome ['Physiological-Clinical']
of O
medial B-outcome ['Physiological-Clinical']
or O
lateral B-outcome ['Physiological-Clinical']
epicondylitis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tennis I-outcome ['Physiological-Clinical']
elbow I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS: O
In O
this O
multicentre, O
randomised, O
double-blind, O
placebo-controlled, O
parallel-group, O
phase O
2a O
study, O
we O
recruited O
adults O
(aged O
21-75 O
years) O
with O
a O
body-mass O
index O
of O
at O
least O
25 O
kg/m(2), O
biopsy-confirmed O
non-alcoholic O
steatohepatitis O
(fibrosis O
stage O
1-3), O
and O
a O
hepatic O
fat O
fraction O
of O
at O
least O
10% O
when O
assessed O
by O
magnetic O
resonance O
imaging-proton O
density O
fat O
fraction. O
[]

Only O
patients O
with O
extensive O
thromboses O
were O
included O
. O
[]

CONCLUSION O
Vitrectomy O
, O
PVD O
with O
or O
without O
ILM O
removal O
does O
not O
improve O
vision O
in O
patients O
with O
DM O
type O
2 O
and O
cystoid O
diabetic O
macular O
edema O
without O
evident O
vitreoretinal O
traction O
. O
[]

The O
PICIHBI O
group O
demonstrated O
a O
significant O
increase O
in O
one O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
item O
score O
at O
midassessment. O
[['Life-Impact']]

RESULTS O
The O
trial O
design O
is O
compared O
to O
a O
trial O
without O
adaptive O
randomization O
and O
produces O
an O
efficient O
trial O
in O
which O
a O
higher O
proportion O
of O
patients O
are O
likely O
to O
be O
randomized O
to O
the O
most O
effective O
treatment O
arm O
while O
generally O
using O
fewer O
total O
patients O
and O
offers O
higher O
power O
than O
an O
analogous O
trial O
with O
fixed O
randomization O
when O
identifying O
a O
superior O
treatment O
. O
[]

These O
results O
are O
not O
concordant O
with O
the O
view O
that O
intentional O
smoking O
abstinence O
exacerbates O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Then O
an O
endoscope O
was O
placed O
in O
the O
duodenum O
without O
premedication O
, O
and O
basal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
duodenal I-outcome ['Physiological-Clinical']
peristaltic I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

Stress O
measures O
were O
administered O
3 O
months O
after O
surgery O
and O
at O
the O
first O
visit O
after O
the O
visual O
acuity O
( O
VA O
) O
assessment O
done O
at O
12 O
months O
of O
age O
. O
[]

This O
phase O
III O
study O
assessed O
the O
impact O
of O
postoperative O
adjuvant O
gefitinib O
on O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

Myoclonic O
astatic O
epilepsy O
is O
therefore O
distinct O
from O
Lennox-Gastaut O
syndrome O
, O
and O
the O
distinction O
appears O
from O
the O
first O
year O
of O
the O
disorder O
. O
[]

Patients O
had O
received O
epoetin O
for O
> O
or O
= O
3 O
months O
upon O
study O
entry O
and O
had O
achieved O
a O
target O
Hb O
level O
of O
10.5-12.5 O
g/dL O
with O
a O
stable O
epoetin O
dose O
. O
[]

CONCLUSIONS O
This O
study O
shows O
that O
triple O
rabeprazole-based O
eradicating O
regimens O
are O
effective O
and O
safe O
. O
[]

Laboratory O
studies O
included O
measurements O
of O
lactoferrin B-outcome ['Physiological-Clinical']
( O
LF O
) O
and O
tumour B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
besides O
standard O
analyses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
who O
satisfy O
the O
trial O
entry O
criteria O
are O
randomised O
to O
treatment O
by O
coronary O
angioplasty O
or O
coronary O
artery O
bypass O
surgery O
, O
with O
prospective O
stratification O
into O
groups O
with O
one O
, O
two O
, O
or O
three O
treatment O
vessels O
. O
[]

We O
performed O
a O
randomized O
study O
comparing O
pneumatic O
compression O
versus O
no O
treatment O
in O
patients O
with O
postmastectomy O
lymphedema O
. O
[]

Concomitant O
use O
of O
an O
anticholinergic O
agent O
increases O
the O
duration O
of O
antacid B-outcome ['Resource-use']
action O
. O
['Resource-use']

The O
likelihood O
for O
cost-effectiveness, O
based O
on O
a O
willingness O
to O
pay O
50,000 O
USD O
per O
QALY, O
was O
0.77-1.00. O
[]

BACKGROUND O
Allopurinol O
has O
been O
widely O
used O
for O
treatment O
of O
hyperuricemia O
, O
however O
, O
it O
may O
be O
associated O
with O
various O
adverse O
effects O
. O
[]

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O
[]

This O
outcome O
was O
assessed O
by O
an O
independent O
data O
review O
committee O
from O
which O
the O
study O
allocations O
were O
masked O
. O
[]

Two O
interim O
analyses O
were O
planned O
. O
[]

Total O
costs B-outcome ['Resource-use']
of O
the O
AS O
group O
were O
significantly O
higher O
compared O
to O
the O
regular O
cardiac O
surgery O
group O
[ O
cost O
difference O
bootstrap O
: O
?4,724 O
; O
95 O
% O
uncertainty O
interval O
( O
UI O
) O
, O
?2,770-?6,678 O
] O
. O
['Resource-use']

This O
was O
a O
prospective O
randomized O
clinical O
trial O
conducted O
in O
the O
Department O
of O
Orthodontics O
at O
the O
University O
of O
Florida O
between O
1990 O
and O
2003 O
. O
[]

BACKGROUND: O
This O
study O
evaluated O
the O
impact O
of O
an O
exercise O
program O
on O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
older O
breast O
cancer O
survivors O
undergoing O
aromatase O
inhibitor O
therapy. O
[['Life-Impact']]

AT O
strain B-outcome ['Physiological-Clinical']
was O
determined O
from O
kinematics O
and O
ultrasound O
images O
of O
medial O
gastrocnemius O
( O
50 O
Hz O
) O
. O
['Physiological-Clinical']

Data O
analyzed O
in O
platinum-sensitive O
patients O
demonstrated O
a O
statistically O
significant O
benefit O
from O
PLD O
for O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.037 O
) O
, O
with O
medians O
of O
28.9 O
for O
PLD O
versus O
23.3 O
weeks O
for O
topotecan O
. O
['Mortality']

A O
single O
drop O
of O
placebo O
or O
levobunolol O
( O
at O
concentrations O
of O
0.03 O
% O
, O
0.3 O
% O
, O
0.6 O
% O
, O
1 O
% O
, O
and O
2 O
% O
) O
was O
administered O
to O
one O
eye O
of O
each O
of O
48 O
patients O
with O
ocular O
hypertension O
. O
[]

Improvement O
with O
treatment O
was O
markedly O
greater O
for O
males O
than O
for O
females O
. O
[]

Recurrences O
of O
arrhythmia O
, O
deaths O
, O
and O
adverse O
drug O
effects O
during O
long-term O
follow-up O
were O
recorded O
for O
the O
296 O
patients O
in O
whom O
an O
antiarrhythmic O
drug O
was O
predicted O
to O
be O
effective O
. O
[]

With O
a O
median O
of O
4.7 O
years O
of O
follow-up O
( O
range O
, O
0.1 O
to O
6.3 O
years O
) O
, O
there O
was O
no O
difference O
in O
OS B-outcome ['Mortality']
( O
hazard O
ratio O
[ O
HR O
] O
, O
1.24 O
; O
95 O
% O
CI O
, O
0.94 O
to O
1.64 O
; O
P O
= O
.14 O
) O
or O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.22 O
; O
95 O
% O
CI O
, O
0.93 O
to O
1.61 O
; O
P O
= O
.15 O
) O
between O
the O
arms O
. O
['Mortality', 'Mortality']

Muscle B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
turnover B-outcome ['Physiological-Clinical']
was O
assessed O
by O
weekly B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
and O
creatinine B-outcome ['Physiological-Clinical']
and O
3-methylhistidine B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

[ O
Acute B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
and O
metabolic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
interval O
and O
endurance O
training O
in O
selected O
patients O
following O
aortocoronary O
bypass O
operation O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Thermal O
destruction O
of O
the O
endometrium O
for O
the O
treatment O
of O
menorrhagia O
should O
be O
considered O
an O
effective O
therapeutic O
option O
because O
of O
its O
acceptability B-outcome ['Life-Impact']
among O
patients O
, O
shorter O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
lower O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
A O
smoker O
was O
present O
in O
37.5 O
% O
of O
homes O
. O
[]

Effects O
of O
formoterol O
, O
salmeterol O
or O
oxitropium O
bromide O
on O
airway B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
salbutamol I-outcome ['Physiological-Clinical']
in O
COPD O
. O
['Physiological-Clinical']

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
73 O
percent O
and O
81 O
percent O
( O
P O
= O
0.11 O
) O
, O
respectively O
. O
['Mortality']

Mitochondrial B-outcome ['Physiological-Clinical']
fragmentation I-outcome ['Physiological-Clinical']
was O
specifically O
presented O
in O
tubules, O
but O
not O
in O
podocytes O
of O
DKD O
patients. O
[['Physiological-Clinical']]

Fifty-one O
pairs O
of O
premenarcheal O
female O
twins O
( O
27 O
monozygotic O
and O
24 O
dizygotic O
; O
mean O
+/- O
sd O
age O
, O
10.3 O
+/- O
1.5 O
yr O
) O
participated O
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
trial O
with O
one O
twin O
of O
each O
pair O
receiving O
a O
1200-mg O
calcium O
carbonate O
( O
Caltrate O
) O
supplement O
. O
[]

There O
was O
no O
difference O
in O
estimated O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Hb I-outcome ['Physiological-Clinical']
( O
3.6 O
g/dl O
vs. O
4.1 O
g/dl O
; O
n.s O
. O
) O
['Physiological-Clinical']

This O
is O
the O
first O
study O
to O
document O
the O
importance O
of O
illness O
perceptions O
in O
recent O
onset O
RA O
. O
[]

Mean O
ddI O
plasma O
levels O
at O
day O
28 O
were O
0.0234 O
mg/L O
for O
group O
1 O
and O
0.0227 O
mg/L O
for O
group O
2 O
( O
P=0.96 O
) O
. O
[]

[ O
One-year O
effect O
of O
health O
counseling O
on O
life O
style O
and O
risk O
factors O
of O
heart O
disease O
] O
. O
[]

Slit-lamp O
biomicroscopy O
and O
circadian O
intra O
ocular O
pressure O
( O
IOP O
) O
curve O
was O
performed O
at O
Day O
3 O
, O
every O
3 O
hours O
from O
6 O
pm O
. O
[]

One O
explanation O
might O
be O
that O
in O
some O
patients O
an O
early O
spread O
of O
tumor O
cells O
has O
occurred O
which O
might O
not O
be O
curable O
by O
surgical O
means O
. O
[]

CONCLUSION O
Ciprodex O
reduced O
early B-outcome ['Physiological-Clinical']
post-operative I-outcome ['Physiological-Clinical']
otorrhea I-outcome ['Physiological-Clinical']
, O
clinically B-outcome ['Physiological-Clinical']
diagnosed I-outcome ['Physiological-Clinical']
OM I-outcome ['Physiological-Clinical']
and O
effusion B-outcome ['Physiological-Clinical']
following O
TT O
insertion O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Clonidine O
, O
as O
compared O
with O
placebo O
, O
did O
not O
reduce O
the O
number O
of O
primary-outcome B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( O
367 O
and O
339 O
, O
respectively O
; O
hazard O
ratio O
with O
clonidine O
, O
1.08 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.93 O
to O
1.26 O
; O
P=0.29 O
) O
. O
['Physiological-Clinical']

This O
has O
implications O
for O
e-learning O
design O
in O
medicine O
and O
other O
disciplines O
. O
[]

The O
additive O
effects O
of O
low-dose O
flutamide O
( O
62.5 O
mg/d O
) O
were O
assessed O
over O
3 O
months O
in O
young O
patients O
with O
hyperinsulinemic O
ovarian O
hyperandrogenism O
( O
n O
= O
40 O
; O
age O
, O
approximately O
17 O
yr O
; O
body O
mass O
index O
, O
approximately O
22 O
kg/m O
( O
2 O
) O
) O
; O
all O
participants O
started O
on O
metformin O
( O
850 O
mg/d O
) O
and O
a O
fourth-generation O
contraceptive O
( O
ethinylestradiol O
30 O
microg O
plus O
drospirenone O
3 O
mg O
, O
21 O
d/month O
) O
, O
and O
they O
were O
randomized O
to O
receive O
flutamide O
in O
addition O
( O
n O
= O
20 O
) O
or O
not O
( O
n O
= O
20 O
) O
. O
[]

METHODS O
This O
prospective O
, O
comparative O
study O
was O
conducted O
with O
healthy O
males O
and O
females O
between O
the O
ages O
of O
19 O
and O
24 O
. O
[]

RESULTS O
Of O
the O
186 O
subjects O
completing O
the O
study O
, O
3 O
( O
1.6 O
% O
) O
exhibited O
evidence O
of O
delayed O
contact O
sensitization O
manifested O
as O
erythema O
with O
or O
without B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
and O
confined O
solely O
to O
sites O
of O
active O
transdermal O
nicotine O
system O
application O
. O
['Physiological-Clinical']

Fifty O
alcoholic O
inpatients O
were O
randomly O
assigned O
to O
the O
PALS O
program O
( O
n O
= O
25 O
) O
or O
to O
the O
library O
for O
free O
reading O
time O
( O
n O
= O
25 O
) O
. O
[]

Previous O
research O
has O
shown O
that O
listeners O
can O
use O
lexical O
information O
to O
guide O
their O
interpretation O
of O
atypical O
sounds O
in O
speech O
( O
Norris O
, O
McQueen O
, O
& O
Cutler O
, O
2003 O
) O
. O
[]

Primary O
non-resectable O
liver O
malignancies O
show O
the O
best O
results O
after O
chemoembolisation O
( O
Frankfurt O
method O
) O
. O
[]

AIM O
The O
aim O
of O
this O
retrospective O
trial O
was O
to O
investigate O
differences O
in O
mesiodistal O
and O
vestibulo-oral O
crown O
sizes O
of O
naturally O
, O
fully-erupted O
permanent O
maxillary O
teeth O
between O
patients O
with O
and O
without O
palatal O
canine O
displacement O
. O
[]

No O
statistically O
significant O
differences O
were O
found O
in O
fasting O
glucose O
, O
insulin O
, O
and O
C-peptide B-outcome ['Physiological-Clinical']
, O
or O
in O
the O
glucose B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
rate O
and O
in O
any O
of O
the O
parameters O
for O
insulin B-outcome ['Resource-use']
and O
C-peptide B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
i.v O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

This O
study O
also O
suggests O
that O
earlier O
use O
of O
pump O
therapy O
might O
help O
to O
preserve O
residual O
?-cell O
function O
, O
although O
a O
larger O
clinical O
trial O
would O
be O
required O
to O
confirm O
this O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Outcomes O
were O
evaluated O
at O
baseline O
, O
immediately O
after O
treatment O
, O
at O
10 O
and O
30 O
min O
. O
[]

CONCLUSION O
The O
longitudinal O
orientation O
of O
a O
rectangular O
defibrillation O
paddle O
provides O
a O
lower O
TTI O
than O
orientation O
horizontally O
. O
[]

Study O
retention B-outcome ['Life-Impact']
rates O
were O
excellent O
, O
with O
95 O
% O
of O
both O
support O
persons O
and O
smokers O
completing O
the O
week O
26 O
assessment O
. O
['Life-Impact']

BACKGROUND O
The O
primary O
focus O
of O
this O
study O
is O
on O
the O
timing O
of O
the O
delivery O
of O
education O
to O
patients O
who O
had O
CABG O
surgery O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
if O
topical O
tetracaine O
reduces O
the O
pain O
of O
intramuscular O
palivizumab O
compared O
to O
placebo O
. O
[]

Purpose: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
toxicities B-outcome ['Adverse-effects']
of O
induction O
chronomodulated O
chemotherapy O
in O
comparison O
with O
conventional O
induction O
chemotherapy O
for O
nasopharyngeal O
carcinoma O
(NPC). O
[['Adverse-effects']]

Forty-seven O
patients O
completed O
the O
study O
. O
[]

The O
T2 O
group O
achieved O
tacrolimus O
trough O
levels O
of O
?10 O
ng/mL O
significantly O
faster O
than O
the O
control O
group O
( O
100 O
% O
achievement O
in O
14 O
days O
( O
Control O
) O
versus O
4 O
days O
( O
T2 O
) O
; O
P=0.01 O
) O
. O
[]

METHODS O
This O
investigation O
assesses O
the O
validity O
of O
the O
Lactate O
Minimum O
Test O
( O
LMT O
) O
, O
which O
consists O
of O
inducing O
lactic O
acidosis O
through O
a O
VO2peak O
test O
, O
followed O
by O
an O
eight-minute O
walking O
recovery O
and O
an O
incremental O
exercise O
test O
, O
to O
determine O
if O
the O
running O
velocity O
associated O
with O
the O
minimum O
lactate O
value O
predicts O
the O
MLSS O
velocity O
. O
[]

Blood O
samples O
were O
withdrawn O
before O
and O
two O
hours O
after O
surgery O
and O
on O
postoperative O
days O
one O
and O
two O
to O
determine O
the O
blood O
NK O
cell O
activity O
using O
a O
chromium O
release O
assay O
with O
K562 O
cells O
as O
targets O
, O
plasma O
catecholamines O
and O
cortisol O
levels O
. O
[]

During O
the O
mitigated O
behavior O
, O
oxytocin O
increased O
the O
originally O
diminished O
brain O
activity O
in O
the O
medial O
prefrontal O
cortex O
( O
P O
< O
.001 O
) O
. O
[]

A O
vaccine O
was O
developed O
against O
bovine O
mastitis O
based O
on O
inactivated O
, O
highly O
encapsulated O
Staphylococcus O
aureus O
cells O
; O
a O
crude O
extract O
of O
Staph O
. O
[]

Twenty-nine O
patients O
with O
attacks O
of O
distal O
ulcerative O
colitis O
were O
treated O
randomly O
with O
3 O
g O
5-aminosalicylic O
acid O
( O
5-ASA O
) O
or O
30 O
mg O
of O
prednisolone O
phosphate O
sodium O
( O
PP O
) O
enemas O
( O
40 O
ml O
) O
. O
[]

RESULTS O
The O
average O
cancer B-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
rate O
was O
3.5 O
% O
, O
3.2 O
% O
and O
3.5 O
% O
for O
the O
completed O
rounds O
1 O
, O
2 O
and O
3 O
, O
respectively O
, O
in O
all O
five O
centres O
. O
['Physiological-Clinical']

After O
6 O
months O
, O
both O
the O
olmesartan O
and O
the O
valsartan O
groups O
showed O
significant O
reduction O
of O
the O
examined O
coronary B-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
46.2 O
? O
['Physiological-Clinical']

Patients O
with O
two O
or O
more O
adenomas O
at O
the O
first O
examination O
were O
more O
likely O
than O
patients O
with O
no O
or O
one O
adenoma O
detected O
at O
the O
first O
examination O
to O
have O
one O
or O
more O
adenomas B-outcome ['Physiological-Clinical']
at O
the O
second O
examination O
( O
odds O
ratio O
, O
3.3 O
; O
95 O
% O
confidence O
interval O
, O
1.69-6.46 O
) O
. O
['Physiological-Clinical']

Interviews O
were O
performed O
at O
baseline O
and O
6 O
months O
. O
[]

TRIAL O
REGISTRATION O
NUMBER: O
ClinicalTrials.gov O
(NCT03196791), O
date O
of O
registration: O
October O
10, O
2017. O
[]

Effects O
of O
pindolol O
and O
clopamide O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
arterial O
hypertensive O
patients O
. O
['Physiological-Clinical']

As O
many O
of O
these O
patients O
are O
older O
, O
with O
a O
compromised O
cardiovascular O
system O
and O
a O
slow O
response O
of O
the O
erythropoietic O
system O
when O
anemia O
occurs O
, O
the O
feasibility O
and O
benefit O
of O
autologous O
blood O
donation O
is O
often O
limited O
. O
[]

In O
six O
patients O
( O
5.6 O
% O
) O
therapy O
was O
discontinued O
as O
a O
result O
of O
adverse O
experiences O
. O
[]

METHODS O
Fifty-six O
male O
patients O
( O
mean O
age O
71.2 O
+/- O
8.2 O
years O
) O
scheduled O
for O
TURP O
were O
enrolled O
in O
the O
study O
. O
[]

The O
rapid O
initial O
treatment O
response O
of O
GHB O
in O
contrast O
to O
CLO O
has O
no O
influence O
on O
duration O
of O
patient B-outcome ['Physiological-Clinical']
withdrawal I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
ADS O
quartiles O
differed O
on O
age O
, O
other O
demographics O
, O
and O
prior O
treatment O
episodes O
. O
[]

acetaminophen O
, O
and O
5 O
ml O
of O
saline O
, O
respectively O
. O
[]

RESULTS O
Clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
was O
achieved O
in O
79 O
% O
of O
the O
trimethoprim-sulfamethoxazole O
group O
and O
in O
84 O
% O
of O
the O
nitrofurantoin O
group O
, O
for O
a O
difference O
of O
-5 O
% O
( O
95 O
% O
confidence O
interval O
, O
-13 O
% O
to O
4 O
% O
) O
. O
['Physiological-Clinical']

Secondary O
outcomes O
include O
glycemic B-outcome ['Physiological-Clinical']
control O
and O
frequency O
of O
infections B-outcome ['Physiological-Clinical']
, O
changes O
in O
REE B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
demonstrates O
that O
ketorolac O
relieves O
pain B-outcome ['Physiological-Clinical']
when O
delivered O
by O
EMDA O
and O
offers O
longer-lasting O
pain B-outcome ['Physiological-Clinical']
relief O
than O
does O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
University-affiliated O
hospital O
. O
[]

Clinicians O
in O
10 O
systematically O
selected O
rural O
towns O
were O
involved O
in O
the O
subsequent O
intervention O
study O
. O
[]

Twenty O
healthy O
subjects O
participated O
in O
this O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
. O
[]

CONCLUSIONS: O
HP O
had O
superior O
rates O
of O
hemostasis B-outcome ['Physiological-Clinical']
, O
shorter O
preparation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
a O
similar O
safety O
profile O
compared O
to O
G O
+ O
T O
in O
this O
prospective, O
randomized O
trial O
using O
quantitative O
bleeding B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
criteria. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

Both O
longer O
and O
shorter O
KC O
before O
and O
throughout O
heel O
stick O
can O
stabilize O
HR B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
, O
and O
longer O
KC O
significantly O
affected O
infants O
' O
sympathetic O
and O
parasympathetic O
responses O
during O
heel O
stick O
compared O
with O
incubator O
care O
. O
['Physiological-Clinical']

Incremental O
cost-effectiveness O
of O
pharmacotherapy O
and O
two O
brief O
cognitive-behavioral O
therapies O
compared O
with O
usual O
care O
for O
panic B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
and O
noncardiac O
chest O
pain O
. O
['Resource-use', 'Physiological-Clinical']

Randomised O
community-based O
trial O
of O
annual O
single-dose O
diethylcarbamazine O
with O
or O
without O
ivermectin O
against O
Wuchereria O
bancrofti O
infection O
in O
human O
beings O
and O
mosquitoes O
. O
[]

The O
drug O
alone O
and O
ECT O
groups O
tended O
to O
have O
the O
best O
outcome O
and O
the O
psychotherapy O
alone O
group O
the O
worst O
. O
[]

Group O
cognitive O
behavior O
therapy O
for O
children O
with O
high-functioning O
autism O
spectrum O
disorders O
and O
anxiety O
: O
a O
randomized O
trial O
. O
[]

Control-group O
participants O
also O
experienced O
significantly O
lower O
rates O
of O
limitation B-outcome ['Life-Impact']
, O
but O
pre- O
to O
postdifferences O
were O
less O
dramatic O
, O
F O
( O
1 O
, O
308 O
) O
= O
4.19 O
, O
p O
= O
.006 O
. O
['Life-Impact']

The O
aim O
of O
the O
present O
study O
was O
to O
test O
whether O
a O
higher O
dose O
of O
G-CSF O
( O
10 O
micro O
g/kg/day O
) O
would O
reduce O
these O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Effects O
of O
temafloxacin O
and O
ciprofloxacin O
on O
the O
pharmacokinetics O
of O
caffeine O
. O
[]

BACKGROUND: O
This O
pilot O
study O
aimed O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
effectiveness O
and O
safety O
of O
transcutaneous O
electrical O
nerve O
stimulation O
(TENS) O
for O
patients O
with O
acute O
tinnitus. O
[['Life-Impact']]

Mothers O
in O
the O
special O
care O
program O
who O
continued O
to O
attend O
clinic O
used O
the O
emergency O
room O
less O
than O
the O
mothers O
who O
continued O
to O
attend O
in O
the O
control O
group O
. O
[]

A O
total O
of O
18 O
of O
102 O
patients O
(18%) O
in O
the O
hybrid-procedure O
group O
had O
a O
major O
pulmonary B-outcome ['Physiological-Clinical']
complication I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
31 O
of O
103 O
(30%) O
in O
the O
open-procedure O
group. O
[['Physiological-Clinical']]

Patients O
who O
viewed O
the O
tape O
that O
portrayed O
the O
recovery O
period O
as O
consisting O
of O
ups O
and O
downs O
also O
reported O
significantly O
more O
frequent O
moderate B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
at O
1 O
month O
and O
more O
frequent O
['Life-Impact']

The O
effects O
of O
treatment O
of O
urinary O
incontinence O
in O
general O
practice O
. O
[]

Reduction O
of O
the O
proportion O
of O
linoleate B-outcome ['Physiological-Clinical']
by O
clofibrate O
but O
not O
by O
niceritrol O
. O
['Physiological-Clinical']

METHODS O
Fifty O
inpatients O
with O
first-ever O
stroke O
and O
PSD O
were O
consecutively O
enrolled O
in O
this O
randomized O
open-label O
study O
. O
[]

Patients O
and O
investigators O
provided O
favorable O
tolerability B-outcome ['Life-Impact']
ratings O
preferring O
bibrocathol O
over O
placebo O
. O
['Life-Impact']

CONCLUSIONS O
The O
main O
barrier O
encountered O
was O
in O
the O
recruitment B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
children I-outcome ['Life-Impact']
: O
it O
was O
not O
possible O
to O
recruit O
the O
target O
of O
60 O
patients O
. O
['Life-Impact']

Ambulatory O
activity O
outcome O
parameters O
served O
as O
dependent O
variables O
, O
and O
disease O
, O
personal O
, O
and O
environmental O
characteristics O
as O
independent O
variables O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
feasibility O
of O
a O
prehospital O
trial O
comparing O
hypertonic O
saline O
and O
dextran O
( O
HSD O
) O
with O
normal O
saline O
( O
NS O
) O
in O
blunt O
head O
injury O
patients O
. O
[]

RESULTS O
The O
GMC O
of O
non-and-low O
response O
children O
in O
group O
A O
( O
before O
booster O
) O
, O
group O
B O
( O
after O
1 O
dose O
booster O
) O
and O
group O
C O
( O
after O
3 O
dose O
booster O
) O
were O
18.66 O
mIUml O
, O
88.82 O
mIU/ml O
, O
178.24 O
mIU/ml O
respectively O
; O
the O
proportion O
of O
non-responders O
in O
three O
groups O
were O
20.4 O
% O
, O
9.1 O
% O
, O
1.9 O
% O
respectively O
. O
[]

Growth O
hormone O
treatment O
in O
GH-deficient O
adults O
has O
proved O
beneficial O
in O
recent O
short-term O
trials O
, O
but O
long-term O
results O
have O
not O
yet O
been O
reported O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Although O
, O
at O
the O
end O
of O
the O
study O
, O
leptin O
levels O
did O
not O
change O
in O
Ex O
patients O
( O
6.7 O
? O
[]

RESULTS O
Both O
treatments O
increased O
HDL-cholesterol B-outcome ['Physiological-Clinical']
, O
but O
decreased O
LDL-cholesterol B-outcome ['Physiological-Clinical']
by O
a O
comparable O
extent O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
initial O
dose O
of O
bupivacaine O
in O
the O
2 O
groups O
was O
4 O
mg, O
and O
the O
subsequent O
dose O
for O
the O
following O
patient O
was O
depended O
on O
the O
probability O
of O
the O
current O
dose. O
[]

No O
patient O
reported O
any O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
during O
treatment O
. O
['Adverse-effects']

In O
20 O
operations O
, O
19 O
children O
were O
randomized O
to O
heparin-coated O
( O
group O
HC O
, O
n O
= O
10 O
) O
or O
standard O
( O
group O
C O
, O
n O
= O
10 O
) O
bypass O
circuits O
. O
[]

BACKGROUND: O
Among O
patients O
with O
metastatic O
pancreatic O
cancer, O
combination O
chemotherapy O
with O
fluorouracil, O
leucovorin, O
irinotecan, O
and O
oxaliplatin O
(FOLFIRINOX) O
leads O
to O
longer O
overall O
survival O
than O
gemcitabine O
therapy. O
[]

Statistical O
analysis O
, O
based O
on O
surface O
area O
and O
ulcer B-outcome ['Physiological-Clinical']
depth O
before O
and O
after O
treatment O
, O
showed O
that O
low-intensity O
direct O
current O
had O
a O
significant O
influence O
on O
the O
healing B-outcome ['Physiological-Clinical']
rates O
for O
these O
ulcers O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However, O
higher O
frequencies O
of O
all O
adverse B-outcome ['Adverse-effects']
outcomes I-outcome ['Adverse-effects']
were O
consistently O
observed O
in O
the O
control O
group. O
[['Adverse-effects']]

The O
subjects O
were O
randomly O
allocated O
into O
2 O
groups O
according O
to O
activation O
type: O
incremental O
advancement O
(IA) O
and O
maximum O
advancement O
(MA). O
[]

Liquid O
fluoxetine O
was O
only O
slightly O
, O
and O
not O
significantly O
, O
superior O
to O
placebo O
on O
CGI O
autism B-outcome ['Life-Impact']
score O
partially O
due O
to O
a O
phase O
order O
effect O
. O
['Life-Impact']

In O
SH O
patients O
, O
the O
standard O
deviation O
of O
N-Ns B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SDNN I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
negatively O
related O
to O
TSH O
( O
r=-0.42 O
, O
P=0.006 O
) O
, O
while O
low O
frequency O
( O
LF B-outcome ['Physiological-Clinical']
) O
/high O
frequency O
( O
HF B-outcome ['Physiological-Clinical']
) O
ratio O
was O
positively O
related O
to O
TSH O
( O
r=0.42 O
, O
P=0.006 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Concurrently O
, O
they O
were O
given O
a O
post-hypnotic O
suggestion O
, O
which O
attempted O
to O
aid O
recognition O
and O
performance O
on O
a O
test O
immediately O
following O
the O
hypnosis O
session O
. O
[]

BACKGROUND O
Microbial O
protein O
synthesised O
in O
the O
rumen O
is O
a O
very O
important O
protein O
source O
for O
ruminants O
. O
[]

Enrollment O
of O
racial O
and O
ethnic O
minorities O
in O
the O
Prostate O
, O
Lung O
, O
Colorectal O
and O
Ovarian O
Cancer O
Screening O
Trial O
. O
[]

After O
each O
injection O
the O
system O
was O
flushed O
with O
sterile O
saline O
and O
closed O
for O
60 O
min O
before O
opening O
to O
spontaneous O
drainage O
. O
[]

Subjects O
were O
treated O
with O
a O
capsule O
containing O
either O
centrally O
acting O
nicotine O
blocker O
, O
mecamylamine O
( O
10 O
mg O
) O
, O
or O
placebo O
. O
[]

Observations O
indicate O
that O
rhTSH O
has O
a O
preconditioning O
effect O
beyond O
increasing O
thyroid O
( O
131 O
) O
I O
uptake O
. O
[]

Title: O
Phase O
1 O
Trial O
of O
an O
RNA O
Interference O
Therapy O
for O
Acute O
Intermittent O
Porphyria. O
[]

RESULTS O
There O
was O
no O
statistically O
significant O
difference O
between O
the O
two O
groups O
of O
patients O
with O
respect O
to O
age O
, O
sex B-outcome ['Physiological-Clinical']
ratio O
, O
chest B-outcome ['Life-Impact']
drainage I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
postprocedural B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
parenteral B-outcome ['Life-Impact']
narcotics I-outcome ['Life-Impact']
requirement I-outcome ['Life-Impact']
, O
complications B-outcome ['Adverse-effects']
, O
or O
procedure B-outcome ['Life-Impact']
failure I-outcome ['Life-Impact']
( O
ie O
, O
recurrence B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Physiological-Clinical']

CONCLCUSION O
: O
Oral O
sildenafil O
was O
as O
effective O
as O
injection O
papaverine O
in O
evaluating O
erectile O
dysfunction O
. O
[]

However O
, O
it O
can O
not O
be O
concluded O
that O
L-carnitine O
provides O
an O
advantageous O
support O
therapy B-outcome ['Resource-use']
for O
well-compensated O
patients O
requiring O
cardiac O
surgery O
. O
['Resource-use']

For O
LMO2 O
similar O
results O
on O
survival O
outcome O
were O
seen O
thus O
showing O
no O
difference O
in O
5 O
years O
OS B-outcome ['Mortality']
or O
EFS B-outcome ['Mortality']
- O
regardless O
of O
subtype O
or O
treatment O
modality O
. O
['Mortality', 'Mortality']

but O
moist O
desquamation O
developed O
in O
42 O
% O
of O
patients O
in O
the O
b.i.d O
. O
[]

These O
visits O
were O
carried O
out O
by O
fieldworkers O
who O
counseled O
the O
mothers O
about O
the O
Ten O
Steps O
for O
Healthy O
Feeding O
from O
Birth O
to O
Two O
Years O
of O
Age O
, O
based O
on O
the O
WHO O
guidelines O
. O
[]

Five O
hundred O
ninety-two O
patients O
were O
evaluated O
: O
283 O
received O
ampicillin/sulbactam O
and O
309 O
received O
cefoxitin O
. O
[]

RESULTS O
Tumors B-outcome ['Physiological-Clinical']
cleared I-outcome ['Physiological-Clinical']
or O
the O
target O
tumor O
area O
was O
reduced O
in O
subjects O
in O
the O
4- O
and O
6-week O
dosing O
regimens O
. O
['Physiological-Clinical']

CONCLUSIONS O
Intravitreous O
fomivirsen O
is O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
with O
an O
acceptable O
safety O
profile O
. O
['Life-Impact']

To O
evaluate O
the O
effect O
of O
recombinant O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
on O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
or O
AIDS-related O
complex O
( O
ARC O
) O
who O
were O
intolerant O
to O
zidovudine O
because O
of O
neutropenia O
, O
we O
performed O
a O
randomized O
, O
open-label O
study O
in O
which O
patients O
were O
assigned O
to O
one O
of O
two O
groups O
. O
[]

Treatment O
of O
adult O
asthma O
: O
controlled O
double-blind O
clinical O
trial O
of O
oxitropium O
bromide O
. O
[]

BACKGROUND O
Extensive O
research O
is O
currently O
ongoing O
to O
prolong O
the O
half-life O
of O
coagulation O
factors O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
diethylpropion O
on O
a O
long-term O
basis O
, O
with O
emphasis O
in O
cardiovascular O
and O
psychiatric O
safety O
aspects O
. O
[]

Following O
SRP O
, O
immediate O
elimination O
occurred O
in O
single O
individuals O
of O
all O
three O
treatment O
groups O
at O
day O
2 O
. O
[]

The O
investigator O
and O
volunteers O
assessed O
cosmetic B-outcome ['Life-Impact']
outcomes I-outcome ['Life-Impact']
on O
day O
31 O
+/- O
2 O
. O
['Life-Impact']

To O
avoid O
this O
complication O
, O
it O
is O
necessary O
to O
better O
understand O
the O
depth O
of O
the O
wound O
produced O
by O
different O
strengths O
and O
combinations O
of O
peeling O
agents O
applied O
to O
living O
eyelid O
tissue O
and O
, O
more O
important O
, O
to O
determine O
the O
concentrations O
of O
TCA O
that O
are O
likely O
to O
lead O
to O
cicatricial O
ectropion O
when O
applied O
in O
a O
consistent O
fashion O
. O
[]

Median O
OS B-outcome ['Mortality']
was O
15.1 O
months O
( O
95 O
% O
CI O
, O
13.5-16.6 O
months O
) O
. O
['Mortality']

Patients O
received O
triple O
therapy O
(long-acting O
muscarinic O
antagonist O
and O
long-acting O
beta2-agonist/inhaled O
corticosteroid O
[ICS]) O
for O
6 O
weeks, O
and O
were O
randomized O
to O
continue O
triple O
therapy O
or O
stepwise O
withdrawal O
of O
the O
ICS O
(dual O
bronchodilator O
group). O
[]

The O
evidence O
that O
breast-feeding O
protects O
against O
obesity O
is O
based O
on O
observational O
studies O
, O
with O
potential O
for O
confounding O
and O
selection O
bias O
. O
[]

There O
were O
no O
statistical O
differences O
between O
the O
two O
groups O
on O
the O
other O
outcome O
measures. O
[]

The O
results O
reveal O
variability O
in O
the O
prolactin B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
the O
artificial O
pumping O
methods O
, O
with O
the O
greatest O
responses O
found O
with O
an O
electric O
pulsatile O
pump O
; O
these O
responses O
compare O
favorably O
with O
those O
of O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

Dose O
dependent O
response O
of O
symptoms O
, O
pituitary O
, O
and O
bone O
to O
transdermal O
oestrogen O
in O
postmenopausal O
women O
. O
[]

During O
the O
ensuing O
two O
months O
either O
clofibrate O
or O
niceritrol O
, O
a O
nicotinic O
acid O
ester O
, O
was O
added O
in O
a O
randomized O
order O
. O
[]

For O
example O
, O
the O
mean O
increase O
in O
[]

RESULTS O
fT O
( O
4 O
) O
and O
TSH O
showed O
a O
strong O
correlation O
with O
GHQ-12 O
scores O
( O
fT4 O
- O
b O
: O
-0.16 O
, O
P O
= O
0.005 O
; O
TSH O
- O
b O
: O
0.663 O
, O
P O
= O
0.04 O
) O
. O
[]

2 O
) O
What O
is O
the O
relationship O
between O
the O
dependent O
variables O
-- O
oxygenation O
saturation O
levels O
, O
blood O
pressure O
, O
pulse O
and O
respiration O
-- O
and O
the O
independent O
variables O
-- O
body O
position O
and O
time O
in O
the O
position O
? O
[]

The O
experimental O
group O
was O
treated O
with O
VCT O
in O
addition O
to O
conventional B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
for O
10 O
sessions O
. O
['Physiological-Clinical']

Further O
technical O
developments O
should O
aim O
at O
improvements O
of O
spatial O
and O
temporal O
coverage O
. O
[]

BACKGROUND O
The O
primary O
objective O
of O
this O
prospective O
randomized O
controlled O
trial O
was O
to O
compare O
functional B-outcome ['Life-Impact']
and O
quality-of-life B-outcome ['Life-Impact']
indices O
and O
rates O
of O
revision B-outcome ['Physiological-Clinical']
surgery I-outcome ['Physiological-Clinical']
in O
arthroscopic O
rotator O
cuff O
repair O
with O
and O
without O
acromioplasty O
. O
['Life-Impact', 'Physiological-Clinical']

Single O
Bond O
adhesive O
system O
was O
applied O
to O
the O
surfaces O
and O
light O
cured O
( O
40 O
s O
) O
. O
[]

Rewarming B-outcome ['Physiological-Clinical']
took O
place O
at O
a O
rate O
of O
0.7 O
+/- O
0.6 O
degrees O
C/h O
( O
range O
0.1-1.8 O
) O
in O
the O
hypothermic O
group O
. O
['Physiological-Clinical']

Clobazam O
in O
catamenial O
epilepsy O
. O
[]

RESULTS O
The O
mean O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
using O
the O
logMAR O
crowded O
Kay O
picture O
test O
( O
0.343+/-0.150 O
) O
was O
comparable O
( O
P=0.084 O
) O
with O
the O
mean O
outcome O
using O
the O
crowded O
logMAR O
acuity O
test O
( O
0.402+/-0.188 O
) O
. O
['Physiological-Clinical']

Walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
, O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
, O
isometric B-outcome ['Physiological-Clinical']
knee I-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
, O
balance B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
web-based O
patient O
activation O
intervention O
to O
improve O
hypertension O
care O
: O
study O
design O
and O
baseline O
characteristics O
in O
the O
web O
hypertension O
study O
. O
[]

for O
5 O
days O
, O
and O
repeated O
at O
21-day O
intervals O
for O
a O
maximum O
of O
four O
cycles O
. O
[]

Intervention O
pilot O
for O
parents O
of O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

DESIGN O
Randomized O
control O
trial O
. O
[]

Individual O
records O
were O
kept O
of O
all O
consumed O
food O
. O
[]

Among O
the O
31 O
patients O
, O
17 O
patients O
who O
received O
pirarubicin O
instillation O
had O
fewer O
recurrences B-outcome ['Physiological-Clinical']
when O
compared O
with O
14 O
patients O
who O
received O
control O
treatment O
( O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

This O
study O
investigated O
the O
influence O
of O
pre-treatment O
proliferation O
characteristics O
, O
assessed O
by O
Ki-67 O
staining O
, O
in O
patients O
treated O
in O
the O
CHART O
trial O
of O
accelerated O
radiotherapy O
in O
head O
and O
neck O
cancer O
. O
[]

RESULTS O
There O
was O
a O
notable O
reduction O
in O
intimal B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
and O
subintimal B-outcome ['Physiological-Clinical']
macrophages I-outcome ['Physiological-Clinical']
and O
lymphocytes B-outcome ['Physiological-Clinical']
after O
treatment O
with O
IL-1Ra O
at O
150 O
mg/day O
( O
n=3 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
Group O
General O
Anesthesia O
( O
GA O
) O
, O
patients O
received O
, O
fentanyl O
intravenous O
( O
i.v O
. O
[]

To O
evaluate O
whether O
the O
inhibitory O
control O
of O
TSH B-outcome ['Physiological-Clinical']
and O
the O
stimulatory B-outcome ['Physiological-Clinical']
control O
of O
prolactin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
secretion B-outcome ['Physiological-Clinical']
exerted O
by O
endogenous O
serotonin O
was O
altered O
in O
obesity O
, O
22 O
obese O
men O
and O
10 O
normal O
controls O
were O
tested O
with O
TRH O
( O
200 O
micrograms O
IV O
bolus O
) O
in O
the O
presence O
( O
experimental O
test O
) O
and O
absence O
( O
control O
test O
) O
of O
the O
serotonergic O
agonist O
fenfluramine O
( O
60 O
mg O
PO O
90 O
min O
before O
TRH O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Lack O
of O
interaction O
between O
pantoprazole O
and O
digoxin O
at O
therapeutic O
doses O
in O
man O
. O
[]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

TLC O
clinical O
sites O
were O
in O
Baltimore O
, O
Cincinnati O
and O
Columbus O
, O
Newark O
and O
Philadelphia O
. O
[]

BACKGROUND O
Free O
radical-induced O
oxidative O
damage O
is O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
diseases O
associated O
with O
cigarette O
smoking O
. O
[]

Linguistic B-outcome ['Life-Impact']
alignment I-outcome ['Life-Impact']
in O
adults O
with O
and O
without O
Asperger O
's O
syndrome O
. O
['Life-Impact']

Compliance B-outcome ['Life-Impact']
rates O
varied O
between O
intervention-arms. O
[['Life-Impact']]

Comparison O
of O
the O
renal O
and O
hepatic O
effects O
of O
enflurane O
and O
halothane O
. O
[]

In O
this O
study O
, O
19 O
subjects O
received O
the O
influenza O
vaccine O
, O
20 O
subjects O
the O
combination O
of O
influenza O
and O
pneumococcal O
vaccine O
. O
[]

Both O
treatment O
groups O
exhibited O
statistically O
significant O
improvement O
in O
standard O
outcome O
parameters O
when O
compared O
with O
baseline O
values O
. O
[]

At O
endpoint O
, O
subjects O
assigned O
to O
ZNS O
were O
taking O
a O
mean O
dosage O
of O
160 O
+/- O
50 O
mg/day O
. O
[]

There O
were O
no O
complications B-outcome ['Resource-use']
in O
the O
4-hour O
group O
. O
['Resource-use']

The O
difference O
between O
groups O
was O
significant O
(p=.045). O
[]

Several O
hypotheses O
are O
discussed O
, O
highlighting O
the O
selective O
nature O
of O
the O
effect O
of O
soy O
consumption O
in O
the O
population O
. O
[]

The O
patients O
were O
randomised O
into O
a O
control O
group O
( O
n O
= O
10 O
) O
and O
an O
experimental O
group O
( O
n O
= O
8 O
) O
. O
[]

The O
most O
important O
prognostic O
feature O
at O
presentation O
was O
the O
quality O
of O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Brief O
report O
: O
imitation O
effects O
on O
children O
with O
autism O
. O
[]

The O
TBW O
group O
(n O
= O
251) O
was O
injected O
with O
600 O
mg O
iodine/kg O
TBW. O
[]

BACKGROUND O
Hydrocolloid O
technology O
has O
been O
proven O
effective O
in O
treating O
dermal O
wounds O
. O
[]

Nonfasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
and O
lipoproteins B-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cysteine I-outcome ['Physiological-Clinical']
levels O
were O
measured O
in O
the O
children O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
determined O
whether O
a O
pamphlet O
alone O
could O
be O
used O
by O
parents O
to O
help O
their O
child O
's O
insomnia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Reduction O
of O
isoflurane O
MAC O
by O
fentanyl O
or O
remifentanil O
in O
rats O
. O
[]

For O
the O
208 O
patients O
evaluable O
for O
safety O
, O
the O
most O
common O
grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
for O
each O
regimen O
was O
neutropaenia B-outcome ['Physiological-Clinical']
, O
with O
64 O
% O
, O
57 O
% O
, O
and O
68 O
% O
for O
GP1 O
, O
GP2 O
, O
and O
GD O
, O
respectively O
. O
['Adverse-effects', 'Physiological-Clinical']

Forty O
unpremedicated O
female O
patients O
aged O
18-59 O
, O
scheduled O
for O
minor O
gynecological O
procedures O
, O
were O
randomly O
assigned O
to O
four O
groups O
. O
[]

FGDs O
were O
audio-recorded, O
transcribed O
then O
translated O
into O
English. O
[]

CONCLUSIONS O
In O
patients O
with O
atrial O
fibrillation O
, O
rivaroxaban O
was O
noninferior O
to O
warfarin O
for O
the O
prevention O
of O
stroke O
or O
systemic O
embolism O
. O
[]

The O
convergence O
of O
cervical O
and O
trigeminal O
afferents O
on O
second-order O
neurons O
in O
the O
trigeminocervical O
nucleus O
may O
refer O
pain O
from O
the O
upper O
cervical O
spine O
into O
the O
head O
and O
face O
. O
[]

Patients O
in O
the O
intervention O
group O
received O
clinical O
pharmacy O
services O
that O
included O
a O
clinical O
pharmacist O
performing O
patient O
medication O
reviews O
, O
with O
emphasis O
on O
preventing O
or O
resolving O
medication-related O
problems O
and O
providing O
medication O
recommendations O
. O
[]

Household B-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
purchasing I-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
three O
24-h O
food B-outcome ['Life-Impact']
recalls, O
Tucker's O
semi-quantitative O
food B-outcome ['Life-Impact']
frequency I-outcome ['Life-Impact']
questionnaire O
(FFQ)], O
and O
weight B-outcome ['Physiological-Clinical']
were O
assessed O
at O
baseline O
and O
after O
8 O
weeks. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

AIM O
In O
the O
present O
study O
, O
the O
effect O
of O
chemo O
and O
radio O
therapies O
on O
serum O
trace O
elements O
content O
and O
antioxidant B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
blood O
serum O
of O
cervical O
cancer O
patients O
was O
evaluated O
. O
['Physiological-Clinical']

The O
study O
comprised O
a O
2-week O
open-label O
titration O
phase O
, O
followed O
by O
a O
double-blind O
efficacy O
phase O
, O
during O
which O
patients O
received O
sublingual O
fentanyl O
citrate O
orally O
disintegrating O
tablet O
( O
sublingual O
fentanyl O
ODT O
) O
or O
placebo O
, O
in O
a O
random O
order O
. O
[]

The O
relative O
risk O
of O
mastitis B-outcome ['Physiological-Clinical']
caused I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
Staph I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Increases O
in O
enjoyment O
partially O
mediated O
the O
positive O
effect O
of O
the O
LEAP O
intervention O
. O
[]

Risperidone O
has O
shown O
safety O
and O
efficacy O
for O
aggressive O
and O
destructive O
behaviors O
in O
short-term O
studies O
. O
[]

Methylphenidate O
dose O
was O
5 O
mg O
every O
2 O
hours O
as O
needed O
up O
to O
20 O
mg O
per O
day O
. O
[]

METHODS O
A O
single-blind O
randomized O
control O
trial O
was O
conducted O
in O
50 O
children O
. O
[]

Publication O
date: O
['2019/10/17 O
06:00' O
[]

Duration O
of O
effect O
was O
dose O
dependent O
. O
[]

A O
randomized O
controlled O
trial O
to O
improve O
colon O
cancer O
screening O
in O
rural O
family O
medicine O
: O
an O
Iowa O
Research O
Network O
( O
IRENE O
) O
study O
. O
[]

Nearly O
13 O
% O
( O
summer/fall O
) O
to O
36 O
% O
( O
winter/spring O
) O
of O
the O
control O
participants O
were O
deficient O
in O
25 O
( O
OH O
) O
D O
( O
< O
20 O
ng/ml O
) O
and O
51 O
% O
( O
summer/fall O
) O
and O
77 O
% O
( O
winter/spring O
) O
had O
insufficient O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
( O
< O
32 O
ng/ml O
) O
. O
['Physiological-Clinical']

SETTING O
For O
menu O
validation O
, O
a O
set O
of O
12 O
menus O
for O
each O
diet O
was O
prepared O
in O
duplicate O
and O
chemically O
assayed O
. O
[]

In O
experiment O
1 O
, O
observers O
threw O
darts O
at O
targets O
that O
were O
fixated O
either O
monocularly O
or O
binocularly O
. O
[]

Severe O
[]

Induction O
of O
anesthesia O
with O
either O
drug O
, O
eltanolone O
or O
propofol O
, O
decreased O
arterial B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
( O
SAP O
) O
and O
diastolic O
( O
DAP O
) O
blood O
pressure O
, O
Q O
, O
and O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
analgesic B-outcome ['Resource-use']
effect O
of O
1,2,6-IP3 O
was O
evaluated O
in O
a O
double-blind O
, O
randomized O
study O
in O
24 O
patients O
undergoing O
cholecystectomy O
. O
['Resource-use']

METHODS O
Eighteen O
patients O
were O
prospectively O
randomized O
to O
receive O
either O
epidural O
analgesia O
or O
PCA O
during O
the O
postoperative O
period O
. O
[]

METHODS O
All O
patients O
with O
patellar O
instability O
who O
underwent O
both O
CT O
and O
MRI O
of O
the O
knee O
from O
2003 O
to O
2011 O
were O
included O
( O
n O
= O
59 O
knees O
in O
54 O
patients O
) O
. O
[]

Injection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
propofol O
. O
['Physiological-Clinical']

The O
quality-of-life B-outcome ['Life-Impact']
questionnaire O
score O
improved O
only O
in O
the O
intervention O
group O
( O
P O
< O
0.003 O
) O
. O
['Life-Impact']

OBJECTIVE O
To O
study O
protective O
effect O
of O
Epimedium O
brevicornum O
( O
EB O
) O
on O
hypothalamus-pituitary-adrenal-thymus O
( O
HPAT O
) O
axis O
inhibited O
by O
exogenous O
glucocorticoid O
. O
[]

BCG O
( O
RIVM O
) O
versus O
mitomycin O
intravesical O
therapy O
in O
superficial O
bladder O
cancer O
. O
[]

The O
objective O
response O
rate O
to O
FAC O
was O
46 O
% O
versus O
44 O
% O
to O
FEC O
. O
[]

This O
international O
phase O
III O
trial O
compared O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
capecitabine/docetaxel O
therapy O
with O
single-agent O
docetaxel O
in O
anthracycline-pretreated O
patients O
with O
MBC O
. O
['Life-Impact']

when O
novel O
stimuli O
were O
presented O
during O
an O
instructional O
task O
. O
[]

0.3 O
) O
, O
12 O
weeks O
( O
7.0 O
? O
[]

We O
collected O
the O
following O
measures O
of O
safety O
and O
tolerability B-outcome ['Life-Impact']
: O
( O
1 O
) O
laboratory B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
assessments O
( O
CBC O
with O
differential O
, O
electrolytes O
, O
and O
liver O
function O
tests O
) O
and O
urinalyses O
, O
( O
2 O
) O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
( O
3 O
) O
Side B-outcome ['Adverse-effects']
Effects I-outcome ['Adverse-effects']
Review O
of O
AEs O
thought O
to O
be O
associated O
with O
risperidone O
, O
( O
4 O
) O
sleep B-outcome ['Physiological-Clinical']
records I-outcome ['Physiological-Clinical']
, O
( O
5 O
) O
Simpson O
Angus O
Neurological O
Rating O
Scale O
( O
SARS O
) O
, O
( O
6 O
) O
Abnormal O
Involuntary O
Movement O
Scale O
( O
AIMS O
) O
, O
and O
( O
7 O
) O
height B-outcome ['Physiological-Clinical']
and O
weight B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
These O
results O
indicate O
that O
eye O
gaze O
attracted O
attention B-outcome ['Life-Impact']
more O
effectively O
than O
the O
arrow O
in O
typically O
developed O
children O
, O
while O
children O
with O
autism O
shifted O
their O
attention O
equally O
in O
response O
to O
eye O
gaze O
and O
arrow O
direction O
, O
failing O
to O
show O
preferential O
['Life-Impact']

ClinicalTrials.gov O
number O
, O
NCT00385138 O
. O
) O
[]

In O
comparison O
to O
aR O
IOS O
is O
not O
dependent O
on O
the O
patients O
cooperation O
. O
[]

DESIGN O
Randomized O
, O
double-masked O
, O
placebo-controlled O
, O
parallel O
group O
multicenter O
study O
of O
6 O
weeks O
duration O
. O
[]

CONCLUSION O
No O
subject O
taking O
dirithromycin O
alone O
or O
in O
combination O
with O
omeprazole O
had O
their O
H. O
pylori O
infection O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Each O
of O
the O
breast-milk O
samples O
contained O
bifidobacteria O
[ O
median O
1.4 O
x O
10 O
( O
3 O
) O
bacterial O
cells/mL O
; O
interquartile O
range O
( O
IQR O
) O
48.7-3.8 O
x O
10 O
( O
3 O
) O
] O
. O
[]

An O
unpaired O
two-tailed O
t O
test O
was O
carried O
out O
for O
both O
studies O
to O
compare O
the O
average O
weight O
loss O
of O
root B-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
with O
the O
modes O
of O
instrumentation O
. O
['Physiological-Clinical']

SETTING O
N/A O
. O
[]

Symptoms O
were O
common O
in O
both O
groups O
. O
[]

Timing B-outcome ['Mortality']
of I-outcome ['Mortality']
death I-outcome ['Mortality']
and O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-ST O
elevation O
acute O
coronary O
syndromes O
: O
insights O
from O
randomized O
clinical O
trials O
. O
['Mortality', 'Physiological-Clinical']

CONCLUSIONS O
Allopurinol O
treatment O
is O
well O
tolerated O
and O
attenuates O
the O
rise O
in O
intercellular O
adhesion O
molecule-1 O
levels O
seen O
after O
stroke O
. O
[]

SETTING O
Tertiary O
referral O
unit O
and O
a O
teaching O
hospital O
. O
[]

This O
study O
was O
aimed O
at O
assessing O
the O
analgesic O
effect O
of O
the O
intraperitoneal O
administration O
of O
bupivacaine O
and O
morphine O
in O
patients O
undergoing O
laparoscopic O
cholecystectomy O
. O
[]

MATERIAL O
AND O
METHODS O
For O
all O
treatment O
groups O
anaesthesia O
was O
induced O
with O
5 O
% O
isoflurane O
in O
oxygen O
using O
an O
induction O
chamber O
. O
[]

RESULTS O
A O
total O
of O
100 O
women O
( O
mean O
[ O
SD O
] O
age O
, O
52 O
[ O
7 O
] O
years O
; O
height O
, O
154 O
[ O
6 O
] O
cm O
; O
weight O
, O
54 O
[ O
7 O
] O
kg O
) O
were O
included O
in O
the O
study O
. O
[]

One O
month O
after O
the O
withdrawal O
of O
ACE O
inhibitors O
, O
5 O
patients O
were O
free O
from O
cough B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
BK O
did O
not O
cause O
cough B-outcome ['Physiological-Clinical']
up O
to O
10 O
( O
-5 O
) O
M O
in O
these O
patients O
, O
except O
for O
one O
who O
coughed O
at O
10 O
( O
-9 O
) O
M O
, O
without O
changes O
in O
responses O
to O
citric O
acid O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Specific O
components O
of O
a O
medical O
home O
less O
prevalent O
among O
children O
with O
autism O
than O
among O
children O
with O
other O
special O
health O
care O
needs O
included O
family-centered O
, O
comprehensive O
, O
and O
coordinated O
care O
. O
[]

A O
meta-analysis O
of O
the O
available O
data O
confirmed O
the O
value O
of O
a O
protective O
ostomy O
for O
patients O
undergoing O
low O
anterior O
resection O
. O
[]

DISCUSSION O
This O
study O
will O
investigate O
the O
effect O
of O
Nordic O
Walking O
on O
pain O
and O
function O
in O
a O
population O
of O
people O
with O
chronic O
LBP O
. O
[]

Twelve O
( O
80 O
% O
) O
of O
15 O
women O
with O
major O
depression O
in O
the O
study O
group O
were O
fully B-outcome ['Physiological-Clinical']
recovered I-outcome ['Physiological-Clinical']
after O
the O
intervention O
compared O
to O
4 O
( O
25 O
% O
) O
of O
16 O
in O
the O
control O
group O
. O
['Physiological-Clinical']

By O
contrast O
these O
variables O
were O
sustained O
above O
baseline O
in O
the O
ONO-1078 O
group O
. O
[]

Peri-operatively O
, O
the O
horses O
received O
phenylbutazone O
, O
butorphanol O
, O
and O
abaxial O
sesamoidean O
nerve O
blocks O
to O
relieve O
pain O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
a O
carbohydrate O
restricted O
versus O
a O
low O
fat O
diet O
on O
weight O
loss O
, O
metabolic O
markers O
, O
body O
composition O
, O
and O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests I-outcome ['Physiological-Clinical']
in O
severely O
obese O
adolescents O
. O
['Physiological-Clinical']

diltiazem O
, O
while O
allowing O
diltiazem O
to O
maintain O
its O
efficacy O
. O
[]

Hospital B-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
and O
other O
variables O
were O
assessed O
. O
['Resource-use']

Augmentation O
of O
preoperative O
blood O
donation O
by O
therapy O
with O
recombinant O
human O
erythropoietin O
( O
rHuEPO O
) O
has O
been O
described O
in O
animal O
models O
and O
in O
patients O
. O
[]

The O
therapy O
was O
either O
active O
40 O
KHz O
ultrasound O
delivered O
by O
a O
saline O
mist O
or O
a O
sham O
device O
which O
delivered O
a O
saline O
mist O
without O
the O
use O
of O
ultrasound O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Telemedicine O
techniques O
can O
be O
used O
to O
address O
the O
rural-metropolitan O
disparity O
in O
acute O
stroke O
care O
. O
[]

After O
9.5 O
? O
[]

On O
the O
telephone O
interview O
, O
100 O
% O
of O
patients O
expressed O
satisfaction O
for O
the O
experienced O
intraoperative B-outcome ['Physiological-Clinical']
tranquillity I-outcome ['Physiological-Clinical']
, O
91.3 O
% O
complained O
for O
not O
having O
received O
in O
the O
past O
a O
similar O
preoperative O
visit O
, O
99.3 O
% O
wished O
a O
diffused B-outcome ['Physiological-Clinical']
application I-outcome ['Physiological-Clinical']
of O
the O
information O
. O
['Physiological-Clinical', 'Physiological-Clinical']

IL-6 B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
levels O
in O
the O
UTI O
group O
were O
significantly O
lower O
than O
those O
in O
the O
control O
group O
during O
the O
time O
points O
of O
T O
( O
2 O
) O
-T O
( O
4 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
controlled O
trial O
was O
designed O
to O
demonstrate O
whether O
an O
implementation O
intention O
intervention O
involving O
the O
completion O
of O
a O
simple O
self-administered O
questionnaire O
linking O
the O
intention O
of O
taking O
medication O
with O
a O
particular O
time O
, O
place O
, O
and O
other O
activity O
can O
improve O
AED O
treatment O
schedule O
adherence O
. O
[]

Tooth O
sensitivity O
was O
measured O
both O
immediately O
and O
at O
7 O
days O
after O
placement O
. O
[]

The O
mean O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
83 O
ml O
( O
group O
A O
) O
and O
210 O
ml O
( O
group O
B O
) O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
distribution O
of O
HIF-1alpha B-outcome ['Physiological-Clinical']
genotypes I-outcome ['Physiological-Clinical']
in O
colorectal O
cancer O
patients O
was O
100 O
C/C O
( O
100 O
% O
) O
, O
0 O
C/T O
( O
0 O
% O
) O
, O
and O
0 O
T/T O
( O
0 O
% O
) O
. O
['Physiological-Clinical']

Complete O
response O
was O
achieved O
by O
four O
( O
20 O
% O
) O
patients O
in O
the O
placebo O
group O
and O
11 O
( O
55 O
% O
) O
patients O
in O
the O
celecoxib O
group O
( O
? O
( O
[]

BACKGROUND O
The O
tension-free O
hernioplasty O
as O
introduced O
by O
Lichtenstein O
has O
gained O
increasing O
acceptance O
during O
the O
last O
decade O
although O
the O
technique O
has O
not O
been O
evaluated O
in O
a O
randomized O
trial O
. O
[]

Efficacy O
of O
intravenous O
acetaminophen O
and O
lidocaine O
on O
propofol O
injection O
pain O
. O
[]

Title: O
Efficacy O
of O
a O
nootropic O
spearmint O
extract O
on O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
: O
a O
randomized, O
double-blind, O
placebo-controlled, O
parallel O
trial. O
[['Life-Impact']]

A O
nationwide O
sample O
of O
129 O
clinicians O
rated O
the O
pathological O
significance O
of O
221 O
symptom O
items O
in O
a O
design O
such O
that O
every O
rater O
rated O
121 O
items O
, O
21 O
of O
which O
were O
rated O
by O
all O
raters O
and O
100 O
of O
which O
were O
rated O
only O
by O
the O
A O
or O
B O
subgroup O
to O
which O
each O
rater O
was O
randomly O
assigned O
. O
[]

The O
rate O
of O
blood O
transfusion O
in O
the O
two O
groups O
was O
similar O
( O
P O
= O
NS O
) O
. O
[]

There O
was O
also O
a O
very O
limited O
relationship O
( O
r O
( O
2 O
) O
< O
0.026 O
) O
between O
visit-to-visit O
and O
within O
24-h O
ambulatory O
BP O
variabilities O
, O
the O
latter O
being O
two O
to O
three O
times O
greater O
than O
the O
former O
. O
[]

Gabapentin O
might O
also O
reduce O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
bupivacaine O
group O
had O
better O
analgesia B-outcome ['Resource-use']
than O
the O
control O
group O
for O
the O
first O
8 O
hours O
, O
after O
which O
there O
was O
no O
difference O
. O
['Resource-use']

CONCLUSION O
On O
the O
basis O
of O
diet O
intervention O
, O
electroacupuncture O
plus O
blood-letting O
puncture O
and O
cupping O
is O
a O
better O
therapy O
for O
acute O
gouty O
arthritis O
. O
[]

However O
, O
the O
decline O
in O
HIV B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
in O
the O
SH O
group O
was O
significantly O
more O
than O
that O
in O
the O
placebo O
group O
. O
['Physiological-Clinical']

Accordingly O
, O
antihypertensive O
drugs O
inhibiting O
sympathetic O
outflow O
represent O
a O
theoretically O
attractive O
therapeutic O
option O
. O
[]

A O
there- O
to O
five-year O
follow-up O
examined O
their O
course O
after O
release O
from O
the O
hospital O
. O
[]

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

We O
conclude O
that O
intramuscular O
administration O
of O
the O
fixed O
combination O
of O
troxerutin O
150 O
mg O
and O
carbazochrome O
1.5 O
mg O
is O
effective O
, O
well O
tolerated O
and O
superior O
to O
placebo O
in O
improving O
hemorrhoidal O
and O
post-surgical O
symptoms O
during O
the O
five O
days O
following O
surgery O
. O
[]

Chemotherapy O
treatments O
are O
intensive O
and O
difficult O
to O
endure O
. O
[]

The O
objectives O
were O
to O
compare O
the O
two O
devices O
with O
regard O
to O
their O
safety O
and O
acceptability O
and O
to O
determine O
whether O
the O
probability O
of O
pregnancy B-outcome ['Physiological-Clinical']
among O
FemCap O
users O
was O
no O
worse O
than O
that O
of O
the O
diaphragm O
( O
meaning O
not O
more O
than O
6 O
percentage O
points O
higher O
) O
. O
['Physiological-Clinical']

Randomized O
evaluation O
of O
octreotide O
vs O
prochlorperazine O
for O
ED O
treatment O
of O
migraine B-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secondary O
end O
points O
included O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
and O
safety O
. O
['Mortality', 'Mortality']

A O
comparison O
of O
single-dose O
cefixime O
with O
ceftriaxone O
as O
treatment O
for O
uncomplicated B-outcome ['Physiological-Clinical']
gonorrhea I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
indicated O
that O
short-term O
treatment O
with O
the O
alkaloid O
improved O
memory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
TCT O
and O
ECD O
data O
were O
acquired O
in O
25 O
randomly O
selected O
patients O
. O
[]

Children O
were O
randomized O
to O
receive O
one O
of O
the O
Hib O
vaccines O
( O
Hib O
groups O
) O
or O
into O
a O
control O
group O
. O
[]

European O
Lung O
Cancer O
Working O
Party O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS O
An O
examiner-blind O
clinical O
trial O
was O
conducted O
among O
30 O
subjects O
with O
moderate O
to O
advanced O
periodontitis O
who O
were O
randomized O
to O
SRP O
alone O
or O
SRP O
combined O
with O
prescription O
custom-tray O
application O
( O
Perio O
Tray O
) O
of O
1.7 O
% O
hydrogen O
peroxide O
gel O
( O
Perio O
Gel O
) O
for O
a O
period O
of O
three O
months O
, O
then O
extended O
to O
six O
months O
. O
[]

Behaviourally O
, O
there O
were O
no O
significant O
differences O
between O
the O
two O
groups O
. O
[]

of O
isotonic O
saline O
, O
then O
0.15 O
mg/kg O
i.v O
. O
[]

If O
the O
pertactin O
value O
was O
> O
or O
= O
7 O
and O
the O
PT O
value O
was O
< O
66 O
EU O
ml-1 O
the O
predicted O
probability O
of O
being O
a O
case O
was O
31 O
% O
( O
15/49 O
) O
. O
[]

RESULTS: O
The O
number O
of O
school O
children O
reported O
from O
intervention O
group O
was O
significantly O
higher O
than O
in O
control O
due O
to O
suspected O
symptoms O
of O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
and O
or O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(RF/RHD) I-outcome ['Physiological-Clinical']
were O
65 O
(2.84/1000) O
and O
15 O
(0.60/1000), O
respectively O
(p<0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Correlation O
of O
adenosinergic O
activity O
with O
superior O
efficacy O
of O
clozapine O
for O
treatment O
of O
chronic O
schizophrenia O
: O
a O
double O
blind O
randomised O
trial O
. O
[]

I O
. O
[]

We O
recommend O
the O
use O
of O
proparacaine O
eye O
drops O
for O
the O
short O
term O
, O
immediate O
relief O
of O
pain O
during O
ROP O
screening O
in O
preterm O
infants O
of O
lesser O
GA O
. O
[]

The O
incidence O
of O
ARDS O
due O
to O
pulmonary O
infection O
per O
case O
was O
25.4 O
% O
and O
was O
significantly O
higher O
in O
the O
G-CSF O
group O
( O
p O
< O
0.025 O
, O
chi2 O
test O
) O
. O
[]

Effectiveness O
of O
vaginal O
tablets O
containing O
lactobacilli O
versus O
pH O
tablets O
on O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
: O
a O
randomized O
, O
double-blind O
study O
. O
['Physiological-Clinical']

CONCLUSIONS O
KC O
11458 O
, O
in O
a O
dose O
of O
8 O
mg O
t.d.s O
. O
[]

METHODS O
Over O
a O
6-year O
period O
, O
patients O
with O
persistent O
H. O
pylori O
infection O
following O
omeprazole-clarithromycin-amoxicillin O
eradication O
therapy O
were O
randomized O
to O
receive O
omeprazole O
, O
20 O
mg O
twice O
daily O
, O
bismuth O
, O
120 O
mg O
four O
times O
daily O
, O
metronidazole O
, O
500 O
mg O
twice O
daily O
, O
and O
either O
tetracycline O
, O
500 O
mg O
four O
times O
daily O
, O
or O
clarithromycin O
, O
500 O
mg O
twice O
daily O
, O
given O
for O
7 O
days O
. O
[]

A O
laser-powered O
hydrokinetic O
system O
for O
caries O
removal O
and O
cavity O
preparation O
. O
[]

In O
a O
prospective O
cohort O
study O
in O
which O
the O
choice O
of O
prophylactic O
therapy O
was O
left O
to O
each O
practitioner O
, O
we O
followed O
cirrhotic O
patients O
with O
medium/large O
varices O
to O
determine O
factors O
predictive O
of O
bleeding O
and O
death O
. O
[]

Impacts O
of O
a O
disease O
management O
program O
for O
dually O
eligible O
beneficiaries O
. O
[]

Patients O
were O
randomly O
assigned O
into O
2 O
groups O
including O
a O
PCT-guided O
group O
( O
study O
group O
) O
and O
a O
prophylactic O
antibiotic O
therapy O
( O
control O
group O
) O
. O
[]

Sinemet O
CR O
, O
a O
controlled O
release O
carbidopa/levodopa O
preparation O
, O
was O
compared O
to O
conventional O
carbidopa/levodopa O
in O
a O
double O
blind O
, O
placebo-controlled O
trial O
. O
[]

METHOD O
Eight O
children O
with O
Down O
syndrome O
who O
displayed O
autistic O
features O
were O
compared O
with O
eight O
Down O
syndrome O
children O
without O
autistic O
features O
. O
[]

Reaching O
out O
, O
inviting O
back O
: O
using O
Interactive O
voice O
response O
( O
IVR O
) O
technology O
to O
recycle O
relapsed O
smokers O
back O
to O
Quitline O
treatment O
-- O
a O
randomized O
controlled O
trial O
. O
[]

CONCLUSIONS O
Alpha O
dihidroergocriptine O
is O
effective O
in O
the O
treatment O
of O
fribrocystic O
breast O
disease O
with O
minimum O
adverse O
events O
when O
compared O
with O
similar O
drugs O
. O
[]

The O
blastocysts O
were O
collected O
from O
gilts O
and O
vitrified O
using O
the O
new O
device O
( O
MVAC O
) O
or O
a O
Cryotop O
( O
CT O
) O
. O
[]

OBJECTIVES O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
a O
new O
twice-daily O
balsalazide O
disodium O
1.1 O
g O
tablet O
dosing O
regimen O
( O
6.6 O
g/day O
, O
three O
tablets O
twice O
daily O
) O
for O
the O
treatment O
of O
mild-to-moderately-active O
ulcerative O
colitis O
( O
UC O
) O
. O
[]

Chronic O
RAO O
occurred O
in O
3.2 O
% O
, O
( O
n O
= O
8 O
) O
of O
the O
intravenous O
group O
compared O
to O
4 O
% O
( O
n O
= O
10 O
) O
of O
the O
intra-arterial O
group O
. O
[]

2 O
. O
[]

The O
5 O
alpha-steroid B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
in O
the O
MPHs O
was O
compared O
with O
that O
of O
men O
with O
benign O
prostatic O
hyperplasia O
who O
were O
administered O
varying O
doses O
of O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
outcomes O
were O
changes O
from O
pretreatment O
to O
posttreatment O
in O
caloric B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
weight O
gain O
. O
['Life-Impact']

In O
the O
intent-to-treat O
sample O
, O
which O
is O
perhaps O
more O
clinically O
relevant O
, O
only O
haloperidol O
proved O
superior O
to O
baseline O
on O
a O
global O
measure O
of O
autistic B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
as O
well O
as O
specific O
measures O
for O
irritability B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Wavefront-guided O
versus O
standard O
LASIK O
enhancement O
for O
residual O
refractive O
errors O
. O
[]

METHOD O
In O
a O
laboratory O
, O
96 O
healthy O
undergraduate O
women O
were O
exposed O
to O
lavender O
, O
placebo O
, O
or O
no O
aroma O
during O
physiologically O
assessed O
relaxation O
after O
an O
arousing O
cognitive O
task O
. O
[]

The O
addition O
of O
MTP O
to O
chemotherapy O
resulted O
in O
a O
statistically O
significant O
improvement O
in O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
and O
a O
trend O
toward O
better O
EFS B-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Upper O
endoscopies O
were O
performed O
before O
and O
at O
the O
end O
of O
the O
treatment O
period O
, O
and O
gastroduodenal B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
graded O
using O
a O
predefined B-outcome ['Physiological-Clinical']
scoring I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
assessor-blind O
, O
( O
3 O
x O
4 O
) O
mixed-model O
repeated O
measures O
. O
[]

Central B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
assessed O
by O
use O
of O
the O
Auditory B-outcome ['Physiological-Clinical']
Steady I-outcome ['Physiological-Clinical']
State I-outcome ['Physiological-Clinical']
Response O
( O
ASSR O
) O
and O
Bispectral B-outcome ['Physiological-Clinical']
Index O
( O
BIS O
) O
analysis O
of O
electrooculogram O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODOLOGY O
One O
hundred O
and O
ninety-three O
( O
193 O
) O
H. O
pylori-positive O
patients O
were O
randomly O
assigned O
to O
one O
of O
the O
following O
7-day O
treatments O
: O
Group O
A O
( O
N O
= O
64 O
) O
: O
amoxicillin O
, O
clarithromycin O
and O
rabeprazole O
; O
Group O
B O
( O
N O
= O
64 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
ranitidine O
bismuth O
citrate O
; O
Group O
C O
( O
N O
= O
65 O
) O
: O
tinidazole O
, O
clarithromycin O
and O
rabeprazole O
Eradication O
was O
assessed O
by O
13C-Urea O
Breath O
Test O
6-8 O
weeks O
after O
the O
end O
of O
the O
therapy O
. O
[]

Thus O
the O
program O
facilitates O
the O
professional O
and O
interpersonal O
learning O
process O
of O
staff O
members O
in O
a O
specific O
way O
with O
success O
as O
well O
as O
with O
limitations O
. O
[]

While O
both O
techniques O
were O
associated O
with O
an O
increase O
in O
bladder O
compliance O
, O
statistical O
significance O
was O
demonstrated O
only O
in O
the O
spinal O
anesthesia O
treatment O
group O
. O
[]

For O
the O
34 O
( O
60 O
% O
) O
patients O
who O
participated O
in O
the O
study O
18 O
months O
after O
treatment O
was O
terminated O
, O
the O
mean O
weight O
loss B-outcome ['Physiological-Clinical']
at O
treatment O
's O
end O
was O
8.5 O
kg O
( O
SD=16.1 O
) O
. O
['Physiological-Clinical']

Single-dose O
metronidazole O
treatment O
of O
the O
sexual O
partner O
of O
women O
with O
bacterial O
vaginosis O
improves O
initial O
bacterial B-outcome ['Physiological-Clinical']
vaginosis I-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thereafter O
there O
was O
no O
difference O
between O
the O
groups O
. O
[]

OBJECTIVE O
To O
compare O
transperitoneal O
, O
extraperitoneal O
and O
laparoscopic O
pelvic O
lymphadenectomy O
in O
terms O
of O
feasibility B-outcome ['Life-Impact']
and O
morbidity B-outcome ['Physiological-Clinical']
in O
patients O
affected O
by O
cervical O
cancer O
undergoing O
radical O
hysterectomy O
. O
['Life-Impact', 'Physiological-Clinical']

In O
order O
to O
compare O
the O
efficacy O
of O
different O
asthma O
treatment O
in O
subjects O
with O
mild-to-moderate O
asthma O
, O
three O
groups O
of O
11 O
patients O
were O
treated O
with O
nedocromil O
sodium O
( O
NS O
) O
, O
beclomethasone O
dipropionate O
( O
BDP O
) O
and O
beclomethasone O
dipropionate O
plus O
salmeterol O
( O
BDP O
+ O
S O
) O
in O
an O
open O
, O
randomized O
study O
. O
[]

Results O
showed O
that O
the O
experimental O
group O
patients O
decreased O
their O
pain O
levels O
more O
than O
the O
control O
group O
patients O
did O
over O
time O
. O
[]

PURPOSE O
To O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
with O
resected O
stage B-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
melanoma I-outcome ['Physiological-Clinical']
administered O
active O
specific O
immunotherapy O
and O
low-dose O
interferon O
alfa-2b O
( O
IFN-alpha-2b O
) O
with O
the O
OS O
achieved O
using O
high-dose O
IFN-alpha-2b O
. O
['Physiological-Clinical']

Effects O
of O
home O
strength O
training O
and O
stretching O
versus O
stretching O
alone O
after O
lumbar O
disk O
surgery O
: O
a O
randomized O
study O
with O
a O
1-year O
follow-up O
. O
[]

The O
primary O
outcome O
variables O
were O
direct O
and O
indirect B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
treatment O
and O
PD B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Primary O
outcome O
measure O
was O
naturalistic B-outcome ['Life-Impact']
observation I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
the O
classroom O
. O
['Life-Impact']

The O
mean O
duration O
for O
obtaining O
good O
contractions B-outcome ['Physiological-Clinical']
was O
shorter O
in O
the O
propranolol O
group O
in O
both O
the O
first O
and O
second O
day O
of O
induction O
The O
mean O
interval O
between O
the O
beginning O
of O
induction O
until O
the O
beginning O
of O
active O
phase O
at O
the O
first O
day O
of O
induction O
was O
shorter O
in O
the O
propranolol O
group O
. O
['Physiological-Clinical']

BACKGROUND O
Rye O
bread O
contributes O
an O
important O
part O
of O
the O
whole O
grain O
intake O
in O
the O
Scandinavian O
diet O
. O
[]

Additional O
controlled O
studies O
are O
needed O
to O
confirm O
these O
findings O
. O
[]

Active O
treatments O
and O
placebo O
were O
comparable O
as O
far O
as O
concerns O
occurrence O
of O
side-effects O
( O
12-20 O
% O
) O
including O
galactorrhoea B-outcome ['Physiological-Clinical']
, O
breast B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and O
menstrual B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Schirmer O
test O
results O
did O
not O
significantly O
change O
postoperatively. O
[]

Although O
EMDA O
has O
been O
used O
to O
treat O
patients O
with O
various O
diseases O
, O
controlled O
studies O
are O
lacking O
in O
patients O
with O
rheumatic O
disease O
. O
[]

GLP-1 O
dose O
dependently O
diminished O
fundus B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
( O
162.9 O
( O
15.0 O
) O
and O
259.5 O
( O
17.2 O
) O
v O
121.1 O
( O
6.0 O
) O
ml O
with O
saline O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

During O
the O
run-in O
and O
treatment O
periods O
, O
symptoms B-outcome ['Life-Impact']
were O
evaluated O
in O
a O
daily O
diary O
using O
a O
0 O
( O
best O
) O
to O
3 O
( O
worst O
) O
scale O
. O
['Life-Impact']

Azelnidipine O
and O
amlodipine O
anti-coronary O
atherosclerosis O
trial O
in O
hypertensive O
patients O
undergoing O
coronary O
intervention O
by O
serial O
volumetric O
intravascular O
ultrasound O
analysis O
in O
Juntendo O
university O
( O
ALPS-J O
) O
. O
[]

Longer O
follow O
up O
time O
may O
be O
needed O
to O
explore O
the O
long O
term O
effects O
of O
different O
vascular O
accesses O
on O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
Weight O
gain O
is O
common O
for O
individuals O
with O
serious O
mental O
illness O
( O
SMI O
) O
receiving O
antipsychotic O
drug O
therapy O
. O
[]

A O
pooled O
analysis O
of O
eastern O
cooperative O
oncology O
group O
and O
intergroup O
trials O
of O
adjuvant O
high-dose O
interferon O
for O
melanoma O
. O
[]

Push B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
increased O
and O
cycle O
frequency O
decreased O
as O
a O
result O
of O
training O
. O
['Life-Impact']

These O
patients O
would O
not O
usually O
be O
referred O
for O
cardiovascular O
assessment O
. O
[]

Economic B-outcome ['Resource-use']
outcomes O
were O
assessed O
using O
a O
state-transition O
Markov O
model O
, O
which O
predicted O
the O
progress O
of O
participants O
through O
five O
health O
states O
relating O
to O
physical O
activity O
and O
dietary O
improvement O
, O
for O
ten O
years O
after O
recruitment O
. O
['Resource-use']

Effect O
of O
adhesive O
system O
type O
and O
tooth O
region O
on O
the O
bond O
strength O
to O
dentin O
. O
[]

OBJECTIVE O
To O
assess O
whether O
or O
not O
standard-dose O
lansoprazole O
( O
30 O
mg O
o.d O
. O
) O
[]

Outcome O
measures O
included O
the O
Brief B-outcome ['Physiological-Clinical']
Fatigue I-outcome ['Physiological-Clinical']
Inventory I-outcome ['Physiological-Clinical']
, O
vitality O
subscale O
of O
the O
Medical O
Outcome O
Scale O
Short O
Form-36 O
( O
SF-36 O
) O
, O
and O
the O
Global B-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
Benefit I-outcome ['Physiological-Clinical']
Scale O
at O
4 O
and O
8 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Effect O
of O
ulinastatin O
on O
inflammatory B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
induced O
by O
oesophagectomy O
] O
. O
['Physiological-Clinical']

The O
volunteers O
were O
continuously O
monitored O
for O
any O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
resulting O
from O
the O
irrigation O
solutions O
or O
MTL O
. O
['Adverse-effects']

mCPP O
raised O
prolactin B-outcome ['Physiological-Clinical']
and O
temperature B-outcome ['Physiological-Clinical']
as O
compared O
to O
placebo O
, O
but O
did O
not O
affect O
plasma B-outcome ['Physiological-Clinical']
homovanillic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Previously O
reported O
equations O
typically O
overestimated O
the O
subjects O
' O
peak O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Our O
objective O
was O
to O
determine O
the O
effect O
of O
7-d O
aerobic O
exercise O
training O
on O
peripheral O
and O
hepatic O
insulin O
sensitivity O
during O
isoglycemic/hyperinsulinemic O
clamp O
conditions O
. O
[]

Over O
the O
28-day O
follow-up O
period O
, O
GMT B-outcome ['Physiological-Clinical']
profiles I-outcome ['Physiological-Clinical']
of O
the O
two O
groups O
were O
statistically O
equivalent O
. O
['Physiological-Clinical']

Complement O
activation O
on O
the O
surface O
of O
cell-derived O
microparticles O
during O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
- O
is O
retransfusion O
of O
pericardial O
blood O
harmful O
? O
[]

The O
link O
between O
emotion O
regulation O
and O
academic B-outcome ['Life-Impact']
achievement I-outcome ['Life-Impact']
is O
well O
documented O
. O
['Life-Impact']

Group O
E O
specimens O
were O
only O
acid-eroded O
and O
those O
of O
group O
F O
were O
only O
brushed O
. O
[]

Spinal B-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
was O
investigated O
by O
distal O
latencies O
and O
M-amplitudes B-outcome ['Physiological-Clinical']
of O
the O
abductor O
digiti O
minimi O
muscle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
relevant O
parameters O
for O
rate O
( O
Cmax O
ss O
, O
Cmin O
ss O
, O
Cav O
ss O
, O
plateau O
time O
, O
peak-trough O
fluctuation O
, O
nocturnal O
excess O
, O
tmax O
ss O
) O
and O
extent B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
( O
AUCss O
) O
were O
calculated O
for O
both O
formulations O
. O
['Physiological-Clinical']

A O
double-blind O
, O
randomized O
study O
of O
gentamicin O
and O
netilmicin O
, O
each O
in O
combination O
with O
cefoxitin O
, O
was O
done O
to O
compare O
their O
respective O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
in O
patients O
with O
serious O
systemic O
infection O
. O
['Adverse-effects']

CONCLUSION O
Provision O
of O
parenteral O
nutrition O
( O
versus O
fluid O
therapy O
) O
in O
critically O
ill O
neonates O
> O
32 O
weeks O
did O
not O
significantly O
affect O
netilmicin B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
and O
therefore O
does O
not O
require O
modification O
of O
recommended O
netilmicin O
dosage O
regimens O
. O
['Physiological-Clinical']

Adjusted O
MHE B-outcome ['Physiological-Clinical']
remained O
constant O
at O
77.9 O
HU O
+/- O
10.2 O
( O
standard O
deviation O
) O
in O
the O
LBW B-outcome ['Physiological-Clinical']
group O
with O
respect O
to O
TBW B-outcome ['Physiological-Clinical']
, O
but O
it O
increased O
in O
the O
TBW B-outcome ['Physiological-Clinical']
( O
r O
= O
0.80 O
, O
P O
< O
.001 O
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
An O
intervention O
including O
patient O
education O
, O
a O
pain B-outcome ['Physiological-Clinical']
diary O
, O
and O
defining O
a O
procedure O
for O
therapeutic O
adjustments O
can O
be O
effective O
to O
improve O
pain B-outcome ['Physiological-Clinical']
relief O
in O
outpatients O
with O
cancer B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
dose-escalation O
study O
of O
subconjunctival O
and O
intravitreal O
injections O
of O
sirolimus O
in O
patients O
with O
diabetic O
macular O
edema O
. O
[]

The O
urea O
end-product O
method O
suggested O
that O
there O
was O
no O
change O
in O
whole-body B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
after O
surgery O
, O
whether O
or O
not O
insulin O
was O
given O
. O
['Physiological-Clinical']

0.3 O
) O
, O
6 O
weeks O
( O
6.3 O
? O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
negative O
and O
positive O
outcomes O
of O
providing O
mammographic O
breast O
density O
( O
MBD O
) O
information O
to O
participants O
of O
a O
screening O
program O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
two O
groups O
for O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and O
redness B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eye I-outcome ['Physiological-Clinical']
postoperatively O
( O
P O
= O
0.609 O
and O
P O
= O
0.123 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

0 O
% O
placebo O
) O
. O
[]

Synovial B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
TNFR I-outcome ['Physiological-Clinical']
: O
Fc B-outcome ['Physiological-Clinical']
protein B-outcome ['Physiological-Clinical']
was O
not O
detected O
( O
nor O
expected O
) O
at O
the O
doses O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN: O
Open O
randomized O
monocentric O
study. O
[]

We O
applied O
a O
structural O
equation O
model O
to O
data O
on O
the O
relationships O
between O
medication O
adherence O
, O
AA O
meeting O
attendance O
and O
abstinent B-outcome ['Physiological-Clinical']
outcome O
to O
clarify O
whether O
medication O
adherence O
or O
AA O
meeting O
attendance O
better O
explains O
the O
positive-outcome O
adherence B-outcome ['Life-Impact']
effect O
we O
observed O
. O
['Physiological-Clinical', 'Life-Impact']

Effect O
sizes O
suggest O
that O
the O
HIV O
intervention O
also O
reduced O
several O
risk O
behaviors B-outcome ['Life-Impact']
( O
e.g. O
, O
vaginal B-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
without O
a O
condom B-outcome ['Life-Impact']
, O
giving B-outcome ['Life-Impact']
oral I-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
results O
can O
be O
considered O
representative O
, O
therefore O
, O
of O
clinical B-outcome ['Physiological-Clinical']
beta-blockade I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
shear-induced B-outcome ['Physiological-Clinical']
pathway I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
aspirin-treated I-outcome ['Physiological-Clinical']
platelets I-outcome ['Physiological-Clinical']
was O
not O
affected O
before O
cardiopulmonary O
bypass O
, O
but O
it O
was O
impaired O
more O
during O
the O
operation O
( O
p O
< O
0.01 O
) O
and O
remained O
worse O
afterward O
( O
p O
< O
0.05 O
) O
, O
compared O
with O
that O
of O
placebo-treated O
platelets O
. O
['Physiological-Clinical']

Age, O
sex, O
type O
of O
femoral O
prosthesis, O
and O
the O
injection O
method O
of O
TXA O
were O
risk O
factors O
for O
HBL O
of O
patients O
after O
receiving O
TKA. O
[]

Studies O
on O
leptin B-outcome ['Physiological-Clinical']
and O
leptin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
myometrium O
and O
uterine O
myomas O
of O
gnRH O
analogue-treated O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Each O
communicative O
act O
is O
scored O
according O
to O
its O
form O
, O
function O
, O
role O
and O
complexity O
. O
[]

Nine O
women O
( O
18.4 O
% O
) O
from O
group O
B O
and O
8 O
women O
( O
16 O
% O
) O
from O
group O
B O
experienced O
spontaneous B-outcome ['Mortality']
abortions I-outcome ['Mortality']
. O
['Mortality']

gamma-Glutamyl O
hydrolase O
expression O
correlated O
with O
grade O
3/4 O
[]

Preterm O
infants O
are O
at O
risk O
for O
copper O
and O
zinc O
depletion O
if O
sufficient O
quantities O
of O
these O
nutrients O
are O
not O
provided O
in O
a O
bioavailable O
form O
in O
postnatal O
life O
. O
[]

BACKGROUND O
Midlife O
women O
are O
an O
underserved O
population O
in O
the O
areas O
of O
unintended O
pregnancy O
and O
STI O
prevention O
yet O
remain O
at O
risk O
for O
both O
health O
conditions O
. O
[]

METHODS O
AND O
RESULTS O
Two O
hundred O
thirty-seven O
consecutive O
women O
patients O
, O
aged O
75 O
years O
or O
younger O
, O
hospitalized O
for O
acute O
myocardial O
infarction O
, O
coronary O
artery O
bypass O
grafting O
, O
or O
percutaneous O
coronary O
intervention O
were O
randomized O
to O
a O
group-based O
psychosocial O
intervention O
program O
or O
usual O
care O
. O
[]

A O
treatment O
period O
of O
1 O
week O
, O
in O
which O
cetirizine/PSE O
was O
administered O
twice O
daily O
, O
was O
followed O
by O
a O
washout O
period O
of O
at O
least O
2 O
weeks O
and O
a O
further O
period O
of O
1 O
week O
in O
which O
the O
alternative O
treatment O
was O
given O
to O
each O
patient O
. O
[]

RESULTS O
The O
mixed-model O
analysis O
of O
variance O
for O
symptoms B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
among O
women O
with O
breast O
cancer O
revealed O
women O
's O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
scores O
decreased O
over O
time O
in O
all O
groups O
. O
['Life-Impact', 'Life-Impact']

Poor O
nutritional O
status O
is O
common O
among O
human O
immunodeficiency O
virus O
(HIV)-infected O
patients O
including O
vitamin O
D O
(vitD(3)) O
deficiency. O
[]

MATERIAL O
AND O
METHODS O
106 O
males O
with O
Q-MI O
entered O
the O
study O
. O
[]

Isoflurane O
was O
added O
as O
needed O
. O
[]

Neither O
enalapril O
alone O
( O
+59 O
+/- O
46 O
mL/min O
, O
P O
= O
0.21 O
) O
nor O
eprosartan O
alone O
( O
+113 O
+/- O
51 O
mL/min O
, O
P O
= O
0.06 O
) O
had O
a O
clear-cut O
significant O
effect O
on O
RPF B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
groups O
were O
balanced O
at O
baseline O
. O
[]

The O
efficacy O
and O
safety O
of O
nizatidine O
was O
evaluated O
in O
comparison O
with O
ranitidine O
in O
230 O
patients O
with O
endoscopically O
documented O
gastric O
( O
71 O
) O
or O
duodenal O
( O
159 O
) O
ulcers O
. O
[]

Mecamylamine O
reduces O
some O
EEG B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
nicotine O
chewing O
gum O
in O
humans O
. O
['Physiological-Clinical']

Follow-up O
telephone O
surveys O
are O
conducted O
at O
1 O
and O
6months O
. O
[]

RESULTS: O
The O
intention-to-treat O
population O
included O
386 O
patients O
in O
the O
omadacycline O
group O
and O
388 O
patients O
in O
the O
moxifloxacin O
group. O
[]

Patient O
and O
hematologic O
factors O
potentially O
associated O
with O
NC O
were O
evaluated O
. O
[]

The O
primary O
endpoint O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
; O
secondary O
endpoints O
were O
time B-outcome ['Mortality']
from I-outcome ['Mortality']
first I-outcome ['Mortality']
progression I-outcome ['Mortality']
to I-outcome ['Mortality']
death I-outcome ['Mortality']
( I-outcome ['Mortality']
TFPTD I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
tolerability B-outcome ['Life-Impact']
. O
['Mortality', 'Mortality', 'Life-Impact']

Such O
enhanced O
suppression O
might O
be O
of O
benefit O
for O
patients O
exhibiting O
a O
progressive O
decline O
in O
renal O
function O
because O
of O
chronic O
renal O
disease O
. O
[]

Suppression O
of O
the O
hypothalamic-pituitary-adrenal O
( O
HPA O
) O
axis O
can O
occur O
after O
repeated O
application O
of O
topical O
corticosteroids O
. O
[]

CONCLUSION O
With O
shorter O
operative O
time O
, O
less O
blood O
loss O
and O
similar O
morbidity O
profile O
exteriorization O
of O
uterus O
during O
caesarean O
section O
seems O
to O
be O
preferred O
except O
where O
it O
is O
not O
possible O
because O
of O
adhesions O
and O
surgeons O
inexperience O
. O
[]

Because O
of O
the O
longer O
half-life O
of O
6.4 O
h O
after O
oral O
administration O
in O
contrast O
to O
2.4 O
h O
after O
i.v O
. O
[]

CBT-i O
group O
is O
superior O
in O
improving O
sleep B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
(SOL) I-outcome ['Physiological-Clinical']
and O
sleep B-outcome ['Physiological-Clinical']
efficiency I-outcome ['Physiological-Clinical']
(SE) I-outcome ['Physiological-Clinical']
. O
Combination O
regimen O
in O
our O
study O
can O
significantly O
reduce O
the O
doses B-outcome ['Resource-use']
of O
medication. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

This O
might O
partly O
account O
for O
the O
lack O
of O
significance O
of O
some O
of O
the O
parameters O
under O
study O
. O
[]

PARTICIPANTS O
111 O
patients O
( O
80 O
women O
and O
31 O
men O
; O
mean O
age O
, O
81 O
years O
) O
admitted O
via O
the O
emergency O
department O
with O
a O
primary O
diagnosis O
of O
fractured O
neck O
of O
femur O
. O
[]

Intrathecal O
morphine O
suppresses O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
following O
abdominal O
surgery O
. O
['Physiological-Clinical']

GH B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
GHRH I-outcome ['Physiological-Clinical']
treatment I-outcome ['Physiological-Clinical']
was O
blunted O
in O
patients O
bearing O
adrenal O
incidentaloma O
compared O
with O
controls O
( O
GH O
peak O
, O
5.7 O
+/- O
5.2 O
vs. O
18.0 O
+/- O
7.0 O
microg/L O
; O
P O
< O
0.0001 O
) O
, O
whereas O
GHRH O
plus O
arginine O
was O
able O
to O
elicit O
a O
comparable O
response O
in O
the O
2 O
groups O
( O
GH O
peak O
, O
33.5 O
+/- O
20.3 O
vs. O
33.7 O
+/- O
17.5 O
microg/L O
; O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION: O
Trial O
registered O
at O
ClinicalTrials.gov O
with O
protocol O
number O
Medical O
College O
of O
Wisconsin O
PRO00019269 O
on O
11/29/2018 O
(Retrospectively O
registered). O
[]

Therefore O
, O
it O
was O
not O
possible O
to O
investigate O
the O
influence O
of O
potentially O
contributing O
factors O
on O
the O
occurrence O
of O
radiation B-outcome ['Physiological-Clinical']
myelitis I-outcome ['Physiological-Clinical']
, O
such O
as O
interfraction B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
, O
cord B-outcome ['Physiological-Clinical']
length I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pain B-outcome ['Physiological-Clinical']
was O
scored O
by O
their O
parents O
and O
a O
pediatric O
nurse O
. O
['Physiological-Clinical']

Patients O
in O
the O
chronomodulated O
chemotherapy O
group O
(n O
= O
30, O
CC O
group) O
received O
cisplatin O
at O
80 O
mg/m(2) O
through O
intravenous O
infusion O
from O
10:00 O
to O
22:00 O
and O
5-fluorouracil O
(5-FU) O
at O
1000 O
mg/m(2) O
plus O
citrovorum O
factor O
at O
200 O
mg/m(2) O
from O
22:00 O
to O
10:00 O
each O
day O
for O
3 O
days. O
[]

METHODS O
A O
consecutive O
series O
of O
100 O
patients O
undergoing O
thoracoscope-assisted O
thoracotomy O
were O
randomized O
into O
5 O
groups O
and O
received O
PCA O
with O
morphine O
doses O
at O
0 O
, O
5 O
, O
10 O
, O
15 O
, O
and O
20 O
mg O
given O
in O
200 O
ml O
saline O
( O
groups O
P O
( O
1 O
) O
, O
P O
( O
2 O
) O
, O
P O
( O
3 O
) O
, O
P O
( O
4 O
) O
, O
and O
P O
( O
5 O
) O
, O
respectively O
) O
. O
[]

T O
Self-rating O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
(SDS) O
and O
self-rating O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
scale O
SAS O
scores O
of O
patients O
in O
the O
rhodiola O
rosea+non-invasive O
ventilator O
group O
decreased O
after O
treatment O
P<0.05 O
compared O
with O
those O
in O
the O
non-invasive O
ventilator O
group. O
[ O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Low O
resource O
was O
defined O
by O
the O
US O
Department O
of O
Housing O
and O
Urban O
Development O
low-income O
index O
or O
1 O
indicator O
, O
( O
e.g. O
, O
Medicaid O
eligibility O
) O
. O
[]

Doses O
were O
titrated O
to O
the O
optimum O
. O
[]

The O
goal O
of O
this O
randomized O
phase O
II O
study O
is O
to O
compare O
QOL B-outcome ['Life-Impact']
, O
functional B-outcome ['Life-Impact']
outcomes O
, O
toxicity B-outcome ['Adverse-effects']
profiles O
, O
and O
survival B-outcome ['Mortality']
following O
primary O
RT O
( O
? O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Mortality']

METHODS O
Between O
1987 O
and O
1992 O
, O
945 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
were O
enrolled O
in O
a O
phase O
3 O
trial O
( O
RTOG O
85-31 O
) O
and O
randomized O
to O
RT O
and O
immediate O
goserelin O
or O
RT O
alone O
followed O
by O
goserelin O
at O
recurrence O
. O
[]

Forty-seven O
of O
the O
61 O
patients O
completing O
the O
intended O
12 O
or O
more O
months O
of O
initial O
IFN O
treatment O
were O
eventually O
considered O
IFN O
failures O
. O
[]

Wilcoxon O
signed-ranks O
test O
was O
used O
to O
pair O
pain O
scores O
. O
[]

Thirty-seven O
healthy O
volunteers O
, O
19 O
of O
whom O
had O
consistently O
elevated O
total O
serum B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TSB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
took O
part O
in O
an O
open O
, O
randomised O
cross-over O
study O
to O
determine O
the O
effect O
of O
fasting O
on O
TSB O
concentrations O
. O
['Physiological-Clinical']

Using O
individualized O
, O
anatomically O
defined O
anterior O
and O
posterior O
insula O
and O
dACC O
as O
regions O
of O
interest O
( O
ROI O
) O
, O
whole O
brain O
rsFC O
was O
performed O
using O
each O
ROI O
as O
a O
seed O
. O
[]

All O
were O
homosexual O
males O
, O
except O
one O
female O
in O
group O
A O
who O
was O
the O
sex O
partner O
of O
a O
bisexual O
male O
with O
AIDS O
. O
[]

Among O
the O
cases O
treated O
with O
oxibendazole O
, O
the O
egg B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
hookworm I-outcome ['Physiological-Clinical']
, O
Ascaris I-outcome ['Physiological-Clinical']
and O
Trichuris B-outcome ['Physiological-Clinical']
were O
70.3-80.6 O
% O
, O
92.5-97.8 O
and O
67.0-71.0 O
% O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Shocks O
were O
delivered O
either O
between O
the O
right O
ventricular O
coil O
and O
proximal O
atrial O
coil O
( O
lead O
) O
or O
between O
the O
right O
ventricular O
coil O
and O
an O
active O
can O
in O
common O
with O
the O
atrial O
coil O
( O
active O
can O
) O
. O
[]

2.9 O
) O
, O
( O
93.5 O
? O
[]

FINDINGS O
From O
June O
, O
2005 O
, O
to O
August O
, O
2008 O
, O
882 O
women O
were O
enrolled O
, O
824 O
of O
whom O
were O
randomised O
and O
gave O
birth O
to O
805 O
singleton O
or O
first O
, O
liveborn O
infants O
. O
[]

Reduction O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
to O
the O
normotensive O
range O
was O
observed O
only O
when O
there O
was O
a O
concomitant O
restriction O
of O
sodium O
intake O
. O
['Physiological-Clinical']

Rates O
of O
prothrombin O
and O
factor O
V O
activation O
( O
FVa O
) O
, O
fibrinogen B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Fbg I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cleavage I-outcome ['Physiological-Clinical']
and O
FVa B-outcome ['Physiological-Clinical']
inactivation I-outcome ['Physiological-Clinical']
showed O
that O
both O
quinapril O
and O
atorvastatin O
decreased O
the O
rates O
of O
: O
formation O
of O
thrombin B-outcome ['Physiological-Clinical']
B-chain I-outcome ['Physiological-Clinical']
( O
by O
30.6 O
% O
, O
P=0.007 O
; O
and O
by O
34.3 O
% O
, O
P=0.003 O
) O
, O
formation O
of O
thrombin-antithrombin B-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
( O
by O
30.4 O
% O
, O
P=0.0002 O
; O
and O
by O
40 O
% O
, O
P=0.001 O
) O
, O
FV B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
( O
by O
19.1 O
% O
, O
P=0.03 O
; O
and O
by O
21.8 O
% O
, O
P=0.005 O
) O
and O
Fbg B-outcome ['Physiological-Clinical']
depletion I-outcome ['Physiological-Clinical']
( O
by O
29.2 O
% O
, O
P=0.004 O
; O
and O
by O
32.7 O
% O
, O
P=0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Phase O
I O
bicenter O
, O
randomized O
, O
parallel-group O
, O
controlled O
, O
partially O
blinded O
trial O
. O
[]

A O
randomized O
double O
blind O
study O
was O
undertaken O
to O
compare O
the O
diagnostic B-outcome ['Life-Impact']
efficacy O
and O
side O
effects O
of O
a O
new O
non-ionic O
contrast O
medium O
Iomeprol O
with O
a O
commonly O
used O
one O
-- O
Iopamidol O
. O
['Life-Impact']

The O
pH O
tablet O
containing O
pH O
lowering O
compounds O
induced O
resolution O
of O
BV O
and O
restoration O
of O
normal O
vaginal O
flora O
in O
74 O
% O
and O
26 O
% O
, O
respectively O
. O
[]

All O
patients O
were O
treated O
with O
a O
standardized O
regimen O
. O
[]

The O
sway B-outcome ['Life-Impact']
velocity I-outcome ['Life-Impact']
of O
the O
children O
was O
measured O
before O
premedication O
and O
1 O
, O
2 O
and O
3 O
h O
after O
the O
end O
of O
anaesthesia O
. O
['Life-Impact']

In O
the O
untreated O
control O
group O
, O
no O
positive O
[]

Thus O
the O
rise O
in O
pressure B-outcome ['Physiological-Clinical']
was O
related O
to O
the O
muscular O
activity O
required O
for O
cuff O
inflation O
. O
['Physiological-Clinical']

The O
primary O
efficacy O
endpoint O
was O
the O
proportion O
of O
subjects O
receiving O
> O
or O
=85 O
% O
relative O
dose O
intensity O
and O
was O
achieved O
by O
96 O
% O
and O
88 O
% O
of O
patients O
in O
the O
FEC O
( O
75 O
) O
and O
FEC O
( O
90 O
) O
arms O
, O
respectively O
. O
[]

The O
incidence O
of O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
among O
the O
ampicillin/sulbactam O
patients O
was O
2 O
% O
and O
among O
cefoxitin O
patients O
it O
was O
7 O
% O
( O
p O
< O
0.004 O
) O
. O
['Physiological-Clinical']

In O
this O
study O
, O
the O
effects O
of O
levosimendan O
and O
dobutamine O
on O
plasma O
levels O
of O
proinflammatory O
and O
proapoptotic O
mediators O
in O
decompensated O
HF O
were O
compared O
and O
correlated O
with O
the O
concomitant O
effects O
on O
cardiac O
function O
and O
prognosis O
. O
[]

However O
, O
retention O
of O
calcium B-outcome ['Physiological-Clinical']
, O
phosphorus B-outcome ['Physiological-Clinical']
( O
both O
formulas O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Laser O
conization O
versus O
cold O
knife O
conization O
. O
[]

All O
patients O
received O
hemostasis O
with O
a O
radial O
compression O
device O
( O
TR O
Band O
) O
, O
applied O
after O
sheath O
removal O
, O
for O
2 O
hours O
. O
[]

Overall O
response O
rate O
was O
42 O
% O
( O
E=44 O
% O
, O
S=44 O
% O
, O
CC=32 O
% O
) O
. O
[]

The O
latest O
research O
into O
the O
prevention O
of O
peri- B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
thromboembolic I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
has O
found O
orthopaedic O
surgery O
patients O
to O
be O
most O
at O
risk O
. O
['Physiological-Clinical']

Caudal O
neostigmine O
with O
bupivacaine O
produces O
a O
dose-independent O
analgesic O
effect O
in O
children O
. O
[]

The O
Collaborative O
Ocular O
Melanoma O
Study O
Group O
. O
[]

After O
12 O
weeks O
, O
we O
observed O
significant O
increases O
in O
fruit B-outcome ['Life-Impact']
and O
vegetable B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
and O
increases O
in O
participants O
' O
confidence B-outcome ['Life-Impact']
in O
their O
ability O
to O
reduce O
salt B-outcome ['Life-Impact']
and O
fat B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
and O
eat B-outcome ['Life-Impact']
healthier O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
A O
randomized O
observer O
blind O
controlled O
trial O
of O
123 O
very O
preterm O
infants O
was O
conducted O
in O
the O
neonatal O
intensive O
care O
unit O
of O
the O
sole O
tertiary O
referral O
centre O
in O
Western O
Australia O
. O
[]

A O
novel O
aspect O
of O
the O
design O
is O
the O
use O
of O
a O
preliminary O
cost-effectiveness O
analysis O
, O
based O
on O
best-guess O
values O
, O
and O
a O
sensitivity O
analysis O
over O
plausible O
ranges O
to O
guide O
the O
choice O
of O
subsample O
size O
. O
[]

PURPOSE O
To O
evaluate O
the O
additional O
therapeutic O
effect O
of O
single O
intravitreal O
bevacizumab O
injection O
on O
standard O
laser O
treatment O
in O
the O
management O
of O
proliferative O
diabetic O
retinopathy O
. O
[]

Journal-Name:Medicine O
[]

Post-operative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
return O
to O
activity O
show O
statistically O
significant O
differences O
. O
['Life-Impact', 'Resource-use']

The O
principle O
symptoms O
were O
fatigue O
, O
breathlessness O
and O
chest O
pain O
. O
[]

The O
pseudo-withdrawal B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
consisted O
of O
an O
increase O
in O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
only O
, O
whereas O
true O
withdrawal B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
also O
included O
perceptual B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
and O
psychotic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Publication O
Type: O
Journal O
Article O
[]

Journal O
ID: O
7501160 O
[]

Participants O
who O
were O
not O
already O
taking O
vitamin O
D O
supplements O
received O
cholecalciferol O
before O
the O
trial O
began O
(a O
single O
dose O
of O
2.5 O
mg) O
and O
during O
the O
trial O
(1.25 O
mg O
per O
month). O
[]

Thus O
, O
endurance O
physical O
activity O
improves O
the O
fibrinolytic O
risk O
factor O
profile O
by O
reducing O
PAI-1 O
while O
leaving O
tPA B-outcome ['Physiological-Clinical']
activity O
unaffected O
, O
independently O
of O
food O
composition O
. O
['Physiological-Clinical']

Higher O
weekly B-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
hours I-outcome ['Physiological-Clinical']
and O
patient O
ratings O
of O
expressed O
emotion B-outcome ['Life-Impact']
( O
EE O
) O
predicted O
a O
negative O
experience O
of O
caregiving O
. O
['Physiological-Clinical', 'Life-Impact']

Overall, O
throat B-outcome ['Physiological-Clinical']
or O
mouth O
irritation O
was O
reported O
more O
frequently O
in O
the O
e-cigarette O
group O
(65.3%, O
vs. O
51.2% O
in O
the O
nicotine-replacement O
group) O
and O
nausea B-outcome ['Physiological-Clinical']
more O
frequently O
in O
the O
nicotine-replacement O
group O
(37.9%, O
vs. O
31.3% O
in O
the O
e-cigarette O
group). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
median O
( O
25th O
and O
75th O
percentiles O
) O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
-0.5 O
( O
-1.8 O
, O
1.3 O
% O
) O
in O
the O
treated O
group O
and O
-1.5 O
( O
-3.8 O
, O
-0.7 O
% O
) O
in O
the O
control O
group O
. O
['Physiological-Clinical']

DESIGN O
AND O
METHOD O
Reported O
are O
the O
results O
of O
a O
randomized O
control O
design O
evaluating O
the O
program O
's O
effectiveness O
. O
[]

Yet O
subjective O
measures O
were O
better O
in O
the O
cisapride O
group O
; O
they O
rated O
themselves O
as O
more O
hungry B-outcome ['Life-Impact']
( O
p O
= O
.02 O
) O
and O
more O
improved O
on O
the O
global O
measure O
of O
change O
in O
symptoms B-outcome ['Physiological-Clinical']
( O
p O
= O
.02 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Significant O
differences O
by O
group O
were O
noted O
in O
Clinician O
Severity O
Ratings O
, O
diagnostic O
status O
, O
and O
clinician O
ratings O
of O
global O
improvement O
. O
[]

Journal-Name:Progress O
in O
community O
health O
partnerships O
: O
research, O
education, O
and O
action O
[]

FUNDING O
Amgen O
. O
[]

The O
differences O
between O
diurnal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nocturnal I-outcome ['Physiological-Clinical']
IOP I-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
( O
handheld O
electronic O
or O
Goldmann O
's O
applanation O
tonometer O
) O
were O
minimal O
( O
> O
0.3 O
mm O
Hg O
) O
and O
statistically O
not O
significant O
( O
P O
> O
.31 O
, O
two-tailed O
paired O
Student O
's O
t O
test O
) O
. O
['Physiological-Clinical']

A O
dietary O
calcium O
intake O
of O
1 O
g O
per O
day O
was O
advised, O
but O
calcium O
supplements O
were O
not O
provided. O
[]

RBR-3x7gz8 O
). O
[]

RESULTS O
One O
hundred O
two O
patients O
were O
enrolled O
, O
with O
a O
median O
age O
of O
6.1 O
years O
. O
[]

A O
prospective O
comparison O
of O
transthoracic O
and O
transhiatal O
resection O
for O
esophageal O
carcinoma O
in O
Asians O
. O
[]

Goodstart O
: O
a O
cluster O
randomised O
effectiveness O
trial O
of O
an O
integrated O
, O
community-based O
package O
for O
maternal O
and O
newborn O
care O
, O
with O
prevention O
of O
mother-to-child O
transmission O
of O
HIV O
in O
a O
South O
African O
township O
. O
[]

A O
pilot O
study O
of O
the O
safety O
and O
efficacy O
of O
supplemental O
arginine O
to O
enhance O
immune O
function O
in O
persons O
with O
HIV/AIDS O
. O
[]

The O
median O
survival O
time O
was O
4.7 O
months O
for O
radiotherapy O
, O
4.7 O
months O
for O
cyclophosphamide O
and O
1.7 O
months O
for O
placebo O
. O
[]

In O
the O
treatment O
group O
, O
we O
found O
significant O
improvements O
in O
the O
social B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
of O
the O
children O
with O
PDD O
. O
['Life-Impact']

Middle B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
were O
measured O
by O
transcranial O
Doppler O
, O
and O
hemodynamics B-outcome ['Physiological-Clinical']
were O
measured O
by O
the O
thermodilution O
technique O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
report O
represents O
the O
first O
such O
study O
of O
diflunisal O
used O
for O
an O
extended O
course O
in O
oral O
surgery O
with O
pain B-outcome ['Physiological-Clinical']
assessment O
over O
the O
same O
period O
. O
['Physiological-Clinical']

Mean O
Ferriman-Gallwey O
scores O
decreased O
significantly O
in O
both O
treatment O
groups O
. O
[]

Sulfadoxine/pyrimethamine O
alone O
or O
with O
amodiaquine O
or O
artesunate O
for O
treatment O
of O
uncomplicated B-outcome ['Physiological-Clinical']
malaria I-outcome ['Physiological-Clinical']
: O
a O
longitudinal O
randomised O
trial O
. O
['Physiological-Clinical']

Randomized O
controlled O
trials O
using O
falls O
as O
primary O
outcome O
are O
needed O
. O
[]

Data O
of O
the O
playroom O
observation O
pointed O
to O
an O
activating B-outcome ['Life-Impact']
influence O
of O
Org O
2766 O
, O
as O
revealed O
by O
a O
significant O
decrease O
of O
stereotypic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
significant O
increases O
in O
change O
toys O
, O
locomote B-outcome ['Life-Impact']
, O
and O
talk B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

There O
was O
a O
tendency O
for O
the O
immunized O
groups O
to O
enjoy O
a O
slightly O
longer O
recurrence-free B-outcome ['Physiological-Clinical']
period O
. O
['Physiological-Clinical']

Nodules B-outcome ['Physiological-Clinical']
decreased O
significantly O
( O
p O
< O
0.0001 O
) O
by O
22 O
% O
after O
2 O
weeks O
( O
6.5 O
ml O
; O
range O
2.4-16.7 O
) O
and O
by O
44 O
% O
after O
30 O
weeks O
( O
4.6 O
ml O
; O
range O
0.69-14.2 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
major O
finding O
of O
the O
study O
was O
the O
significant O
improvement O
in O
submaximal B-outcome ['Physiological-Clinical']
response O
to O
exercise B-outcome ['Life-Impact']
of O
experimental O
subjects O
, O
expressed O
by O
the O
reduction O
in O
HR B-outcome ['Physiological-Clinical']
, O
VO2 B-outcome ['Physiological-Clinical']
VE O
while O
VO2 B-outcome ['Physiological-Clinical']
max O
did O
not O
change O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Left O
internal O
thoracic O
artery-radial O
artery O
composite O
grafts O
proved O
to O
be O
a O
safe O
procedure O
in O
elderly O
patients O
. O
[]

OBJECTIVE O
We O
evaluated O
in O
a O
manikin O
model O
whether O
using O
the O
single-use O
laryngeal O
tube O
with O
suction O
option O
( O
LTS-D O
) O
instead O
of O
endotracheal O
intubation O
( O
ET O
) O
and O
bag-mask-valve O
ventilation O
( O
BMV O
) O
for O
emergency O
airway O
management O
could O
reduce O
the O
no-flow O
time O
( O
NFT O
) O
. O
[]

Clinic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
in O
the O
beginning O
and O
end O
of O
the O
study O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
determine O
the O
extent O
to O
which O
the O
estrogen-induced O
changes O
in O
lipids O
and O
markers O
of O
carbohydrate O
metabolism O
explain O
the O
beneficial O
effect O
of O
estrogen O
therapy O
on O
the O
progression O
of O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IMT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
postmenopausal O
women O
. O
['Physiological-Clinical']

Other O
cycle O
variables O
were O
generally O
similar O
between O
groups O
, O
as O
was O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

The O
inappropriateness O
of O
the O
usual O
anchors O
for O
a O
Clinical O
Global O
Impression O
of O
Severity O
( O
CGI-S O
) O
was O
resolved O
by O
defining O
uncomplicated O
autism O
without O
secondary O
symptoms O
as O
a O
CGI-S O
of O
3 O
, O
mildly O
ill O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Women O
with O
urodynamic O
SUI O
were O
enrolled O
in O
this O
12-mo O
multicenter O
randomized O
study O
. O
[]

In O
the O
PRP O
group O
(n O
= O
40), O
in O
addition O
to O
HRT, O
0.5-1 O
cc O
of O
PRP O
was O
infused O
into O
the O
uterine O
cavity O
on O
the O
13th O
day O
of O
HRT O
cycle. O
[]

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
in O
control O
group O
[ O
( O
16.9 O
? O
[]

There O
was O
a O
significant O
dose O
related O
decrease O
in O
the O
fractional O
recovery O
of O
3-MX O
and O
1-MU O
( O
p O
< O
0.001 O
) O
and O
a O
dose O
related O
increase O
in O
fractional B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DMU I-outcome ['Physiological-Clinical']
and O
unchanged O
theophylline O
( O
p O
< O
0.01 O
and O
p O
< O
0.001 O
respectively O
) O
. O
['Physiological-Clinical']

DESIGN O
AND O
METHOD O
Churches O
were O
randomized O
to O
receive O
either O
the O
spiritually O
based O
or O
the O
non-spiritual O
intervention O
. O
[]

Treatment O
with O
risedronate O
is O
accompanied O
by O
significant O
changes O
in O
bone O
turnover O
and O
bone O
mineral O
density O
. O
[]

To O
measure O
global O
functioning O
in O
treatment O
studies O
, O
the O
Children O
's O
Global O
Assessment O
Scale O
was O
modified O
and O
psychometric O
properties O
of O
the O
revised O
version O
( O
DD-CGAS O
) O
were O
assessed O
in O
children O
with O
PDD O
. O
[]

PURPOSE O
To O
evaluate O
the O
treatment O
outcomes O
after O
guided O
tissue O
regeneration O
( O
GTR O
) O
with O
a O
bioabsorbable O
membrane O
in O
Class O
II O
furcation O
defects O
in O
mandibular O
molars O
. O
[]

The O
study O
was O
focused O
on O
aseptic O
sternal O
complications O
, O
namely O
bone B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
superficial B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
efficacy O
of O
the O
vaccine O
had O
begun O
to O
drop O
11 O
years O
after O
immunization O
, O
which O
should O
be O
followed O
up O
further O
to O
reach O
a O
clear O
conclusion O
. O
[]

Children O
< O
or O
=21 O
years O
old O
with O
biopsy-proven O
, O
pathologically O
staged O
I O
, O
IIA O
, O
or O
IIIA1 O
Hodgkin O
disease O
were O
randomly O
assigned O
6 O
courses O
of O
alternating O
nitrogen O
mustard O
, O
oncovin O
, O
prednisone O
, O
and O
procarbazine/doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
( O
treatment O
1 O
) O
or O
4 O
courses O
of O
alternating O
nitrogen O
mustard O
, O
oncovin O
, O
prednisone O
, O
and O
procarbazine/doxorubicin O
, O
bleomycin O
, O
vinblastine O
, O
and O
dacarbazine O
+2550 O
cGy O
involved-field O
radiotherapy O
( O
treatment O
2 O
) O
. O
[]

Further O
studies O
will O
be O
needed O
with O
new O
formulations O
of O
cyclosporin O
or O
when O
using O
the O
full O
dosage O
of O
ticlopidine O
. O
[]

More O
research O
into O
effective O
methods O
of O
controlling O
demand O
and O
better O
identification O
of O
those O
who O
would O
benefit O
from O
access O
to O
specialist O
care O
is O
needed O
. O
[]

No O
significant O
difference O
was O
observed O
between O
the O
two O
treatment O
groups O
in O
the O
mean O
change O
from O
baseline O
in O
ejaculatory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
on O
day O
29 O
. O
['Physiological-Clinical']

AIM O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
whether O
oxidized B-outcome ['Physiological-Clinical']
regenerated I-outcome ['Physiological-Clinical']
cellulose I-outcome ['Physiological-Clinical']
( O
ORC B-outcome ['Physiological-Clinical']
) O
, O
applied O
to O
dirty O
surgical O
wounds O
, O
is O
able O
to O
reduce O
the O
microbial O
load O
and O
, O
consequently O
, O
the O
infection B-outcome ['Physiological-Clinical']
rate O
as O
compared O
to O
conventional O
local O
wound O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
There O
were O
no O
differences O
between O
the O
two O
groups O
in O
symptomatic B-outcome ['Physiological-Clinical']
relief B-outcome ['Physiological-Clinical']
and O
electrophysiological B-outcome ['Physiological-Clinical']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Secondary O
objectives O
were O
to O
compare O
the O
effects O
of O
atorvastatin O
40mg O
vs O
80mg O
on O
HDL-C B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
and O
also O
comparing O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
myopathy B-outcome ['Physiological-Clinical']
, O
hepatotoxicity B-outcome ['Physiological-Clinical']
and O
new B-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
) O
of O
both O
doses. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
study O
examined O
the O
efficacy O
and O
safety O
of O
nifedipine O
sustained O
release O
( O
nifedipine O
SR O
) O
compared O
with O
Ginkgo O
biloba O
extract O
as O
treatment O
for O
primary O
Raynaud O
's O
phenomenon O
( O
RP O
) O
in O
Korea O
. O
[]

A O
best-case O
scenario O
assumed O
that O
all O
cancers O
showing O
a O
positive O
screen O
result O
earlier O
with O
ROCA O
than O
under O
the O
PLCO O
protocol O
would O
have O
avoided O
mortality B-outcome ['Mortality']
; O
under O
a O
stage-shift O
scenario O
, O
such O
women O
were O
assigned O
survival O
equivalent O
to O
Stage O
I/II O
screen-detected O
cases O
. O
['Mortality']

This O
anti-proteinuric B-outcome ['Physiological-Clinical']
effect O
was O
even O
greater O
after O
9 O
months O
of O
therapy O
: O
losartan O
, O
44.2 O
% O
( O
p O
= O
0.02 O
) O
; O
enalapril O
, O
49.6 O
% O
( O
p O
= O
0.02 O
) O
; O
and O
combined O
therapy O
, O
51 O
% O
( O
p O
= O
0.003 O
) O
. O
['Physiological-Clinical']

METHODS O
Sixty O
cases O
were O
randomly O
divided O
into O
an O
observation O
group O
and O
a O
control O
group O
, O
30 O
cases O
in O
eachgroup O
. O
[]

Between O
December O
1982 O
and O
October O
1986 O
, O
131 O
patients O
with O
stage O
II-III-IV O
squamous O
cell O
carcinoma O
of O
the O
oropharynx O
or O
oral O
cavity O
were O
randomized O
to O
induction O
chemotherapy O
, O
consisting O
of O
bleomycin O
( O
10 O
mg/m2/day O
in O
continuous O
infusion O
from O
day O
1 O
to O
day O
5 O
) O
, O
methotrexate O
( O
120 O
mg/m2 O
on O
day O
2 O
) O
followed O
by O
folinic O
acid O
, O
5-fluorouracil O
( O
5 O
FU O
) O
( O
600 O
mg/m2 O
on O
day O
2 O
) O
, O
and O
cisplatin O
( O
120 O
mg/m2 O
on O
day O
4 O
) O
every O
4 O
weeks O
for O
a O
total O
of O
three O
cycles O
followed O
by O
definitive O
locoregional O
treatment O
versus O
locoregional O
treatment O
alone O
. O
[]

Band O
ligation O
is O
the O
main O
therapeutic O
option, O
but O
it O
may O
be O
technically O
difficult O
to O
perform O
in O
active O
bleeders. O
[]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

Accelerated O
production B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
material I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
phospholipids I-outcome ['Physiological-Clinical']
in O
infants O
from O
dexamethasone-treated O
dams O
was O
indicated O
by O
increases O
in O
total O
lung B-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
84.5 O
+/- O
8.1 O
mg/g O
dry O
lung O
versus O
75.1 O
+/- O
9.9 O
, O
p O
less O
than O
0.025 O
) O
, O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
( O
5.65 O
+/- O
3.33 O
mg/g O
dry O
lung O
versus O
3.01 O
+/- O
1.84 O
, O
p O
less O
than O
0.05 O
) O
, O
and O
alveolar B-outcome ['Physiological-Clinical']
lavage I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
disaturated I-outcome ['Physiological-Clinical']
phosphatidylcholine I-outcome ['Physiological-Clinical']
( O
DPC B-outcome ['Physiological-Clinical']
) O
( O
2.47 O
+/- O
1.84 O
mg/g O
dry O
lung O
versus O
1.06 O
+/- O
1.05 O
, O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
final O
analysis O
digital O
images O
were O
randomised O
( O
in O
time O
order O
) O
and O
a O
panel O
of O
nurses O
who O
were O
not O
otherwise O
involved O
in O
the O
research O
project O
graded O
the O
wound O
's O
progress O
. O
[]

Title: O
Effect O
of O
transcutaneous O
electrical O
acupoint O
stimulation O
on O
the O
effective O
concentration B-outcome ['Life-Impact']
(EC50) O
of O
remifentanil O
suppressing O
responses B-outcome ['Physiological-Clinical']
to O
tracheal O
extubation O
in O
elderly O
patients. O
[['Life-Impact'], ['Physiological-Clinical']]

The O
usefulness O
of O
OK-432 O
was O
studied O
using O
the O
sealed O
envelope O
method O
. O
[]

All O
pretreatment O
drugs O
were O
made O
in O
2 O
mL O
and O
were O
accompanied O
by O
manual O
venous O
occlusion O
for O
1 O
min O
. O
[]

OBJECTIVE O
The O
mechanisms O
underlying O
symptom O
improvement O
in O
gastric O
electrical O
stimulation O
( O
GES O
) O
are O
not O
fully O
understood O
. O
[]

METHODS O
Doses O
of O
febuxostat O
and O
allopurinol O
were O
10 O
and O
100 O
mg/d O
, O
respectively O
, O
during O
a O
12-day O
introduction O
period O
and O
were O
increased O
to O
40 O
and O
200 O
mg/d O
for O
the O
subsequent O
treatment O
period O
of O
44 O
days O
. O
[]

OBJECTIVE O
To O
evaluate O
whether O
the O
same O
or O
different O
patients O
respond B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
triptans I-outcome ['Physiological-Clinical']
and O
telcagepant O
. O
['Physiological-Clinical']

Tacrolimus O
ointment O
0.03 O
% O
is O
approved O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
the O
patient O
population O
between O
two O
to O
seventeen O
years O
of O
age O
and O
Tacrolimus O
0.1 O
% O
ointment O
for O
moderate O
to O
severe O
atopic O
dermatitis O
in O
patients O
18 O
years O
of O
age O
and O
older O
. O
[]

0.04 O
) O
, O
attributable O
to O
a O
narrower O
CIMT O
and O
wider O
lumen O
. O
[]

BACKGROUND O
Chemotherapy-induced O
peripheral O
neuropathy O
( O
CIPN O
) O
continues O
to O
be O
a O
substantial O
problem O
for O
many O
cancer O
patients O
. O
[]

Results O
showed O
that O
tirasemtiv O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
with O
dizziness B-outcome ['Physiological-Clinical']
the O
most O
common O
adverse O
event O
. O
['Life-Impact', 'Physiological-Clinical']

Notably O
, O
low O
YAP1 O
mRNA O
was O
independently O
associated O
with O
decreased O
recurrence-free O
survival O
in O
the O
gene O
expression O
dataset O
, O
specifically O
for O
the O
luminal O
A O
subgroup O
( O
p O
< O
0.001 O
) O
which O
includes O
low O
proliferating O
tumours O
of O
lower O
grade O
, O
usually O
associated O
with O
a O
good O
prognosis O
. O
[]

Reductions O
in O
microalbuminuria B-outcome ['Physiological-Clinical']
occurred O
in O
both O
groups O
, O
with O
mean O
changes O
at O
1 O
year O
of O
-3.9 O
mg/mmol O
creatinine O
( O
95 O
% O
CI O
-5.3 O
, O
-2.5 O
) O
for O
manidipine/delapril O
( O
P O
< O
0.001 O
vs. O
baseline O
) O
and O
-2.7 O
mg/mmol O
creatinine O
( O
95 O
% O
CI O
-4.0 O
, O
-1.3 O
) O
for O
losartan/HCTZ O
( O
P O
< O
0.001 O
vs. O
baseline O
and O
P=0.199 O
between O
groups O
) O
. O
['Physiological-Clinical']

In O
contrast O
, O
aortic O
cross-clamping O
during O
isoflurane O
anesthesia O
was O
not O
associated O
with O
renal B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

OBJECTIVE O
It O
was O
aimed O
to O
investigate O
the O
effect O
of O
standardized O
ginseng O
extract O
on O
fertility B-outcome ['Physiological-Clinical']
parameters O
in O
diabetic O
rats O
. O
['Physiological-Clinical']

METHODS O
The O
paroxetine O
352 O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
19-site O
trial O
comparing O
paroxetine O
and O
imipramine O
in O
117 O
patients O
with O
bipolar B-outcome ['Life-Impact']
type O
I O
major B-outcome ['Life-Impact']
depressive I-outcome ['Life-Impact']
episode B-outcome ['Life-Impact']
which O
was O
unresponsive O
to O
prior O
lithium O
carbonate O
therapy O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

To O
indicate O
the O
magnitude O
of O
the O
treatment O
effects O
, O
effect O
sizes O
were O
calculated O
. O
[]

Ipratropium O
bromide O
nasal O
spray O
for O
treatment O
of O
rhinorrhea O
in O
the O
laryngectomized O
patient O
: O
a O
pilot O
study O
. O
[]

Analysis O
of O
variance O
failed O
to O
demonstrate O
an O
effect O
of O
either O
intervention O
on O
the O
median O
change O
in O
[]

This O
randomized O
placebo-controlled O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
folic O
acid-based O
supplement O
on O
secondary O
prevention O
of O
clinical O
events O
in O
non-ST-segment O
elevation O
acute O
coronary O
syndromes O
. O
[]

Bevacizumab-augmented O
retinal O
laser O
photocoagulation O
in O
proliferative O
diabetic O
retinopathy O
: O
a O
randomized O
double-masked O
clinical O
trial O
. O
[]

Allogeneic O
leucocytes O
are O
assumed O
to O
play O
a O
causal O
role O
. O
[]

Primary O
outcome O
was O
total O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
TST O
) O
recorded O
by O
actigraphy O
over O
each O
2-week O
period O
. O
['Physiological-Clinical']

This O
study O
assessed O
invasively O
the O
hemodynamics O
during O
supine O
rest O
and O
exercise O
before O
and O
after O
4 O
weeks O
treatment O
with O
30 O
mg O
isosorbide O
dinitrate O
( O
ISDN O
) O
or O
placebo O
asymmetrically O
b.i.d O
. O
[]

It O
is O
concluded O
that O
the O
use O
of O
an O
anal O
dilator O
improves O
the O
results O
of O
anal B-outcome ['Physiological-Clinical']
stretch I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Drinking O
orange O
juice O
and O
brushing O
with O
toothpaste O
B O
. O
[]

There O
was O
also O
no O
significant O
difference O
in O
outcome O
after O
PDT O
. O
[]

Besides O
this O
transformation O
the O
effects O
of O
prompts O
will O
be O
examined O
. O
[]

The O
results O
indicate O
that O
no O
clinically B-outcome ['Physiological-Clinical']
meaningful I-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
interactions I-outcome ['Physiological-Clinical']
occurred O
between O
risperidone O
1 O
mg O
daily O
and O
donepezil O
5 O
mg O
daily O
at O
steady O
state O
, O
and O
therefore O
no O
dosage O
adjustment O
is O
required O
when O
both O
drugs O
are O
combined O
with O
the O
dosage O
regimen O
studied O
. O
['Physiological-Clinical']

The O
main O
outcome O
measure O
was O
antibiotic B-outcome ['Resource-use']
concentration I-outcome ['Resource-use']
measured O
by O
chromatographic O
separation O
and O
mass O
spectrometry O
of O
aqueous O
samples O
obtained O
during O
surgery O
. O
['Resource-use']

METHODS O
In O
this O
52-week O
, O
multicentre O
, O
randomised O
, O
double-blind O
, O
parallel-group O
study O
, O
male O
and O
female O
patients O
( O
aged O
at O
least O
40 O
years O
) O
with O
symptomatic O
primary O
OA O
of O
the O
hip O
, O
knee O
, O
hand O
or O
spine O
were O
randomised O
( O
1:2:1 O
) O
to O
lumiracoxib O
100 O
mg O
o.d O
. O
( O
[]

CONCLUSIONS O
Cancer O
patients O
prefer O
shorter O
bisphosphonate B-outcome ['Resource-use']
infusions-and O
at O
home O
, O
where O
practical O
. O
['Resource-use']

One O
of O
the O
219 O
patients O
from O
the O
nonrandomized O
group O
developed O
a O
clinically B-outcome ['Physiological-Clinical']
detectable I-outcome ['Physiological-Clinical']
proximal I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
which O
was O
confirmed O
by O
duplex B-outcome ['Resource-use']
ultra-sonography I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

With O
the O
extended O
historical O
CK-based O
definition O
of O
MI O
, O
PMI B-outcome ['Physiological-Clinical']
was O
diagnosed O
in O
65/2121 O
patients O
( O
3.1 O
% O
) O
. O
['Physiological-Clinical']

Responding O
patients O
received O
decitabine O
as O
consolidation O
therapy O
on O
a O
5-day O
schedule O
for O
up O
to O
24 O
cycles. O
[]

Australian O
adults O
(N O
= O
1132) O
aged O
18-24 O
years O
were O
recruited O
via O
a O
national O
online O
panel. O
[]

Finally, O
participants O
reported O
their O
self-efficacy B-outcome ['Life-Impact']
to O
drink O
less O
and O
their O
alcohol B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
. O
RESULTS: O
There O
was O
no O
clear O
evidence O
that O
enhancing O
self-affirmation O
influenced O
any O
outcome. O
[['Life-Impact'], ['Physiological-Clinical']]

Three O
patients O
of O
colorectal O
cancer O
from O
an O
unresectable O
group O
were O
presumed O
to O
have O
micrometastases O
to O
the O
liver O
as O
suggested O
by O
an O
elevated O
serum O
CEA O
level O
. O
[]

RESULTS O
Both O
groups O
had O
symptom B-outcome ['Life-Impact']
reduction O
. O
['Life-Impact']

The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
a O
home-based O
programme O
provided O
over O
12 O
months O
resulted O
in O
sustained O
improvement O
in O
development B-outcome ['Life-Impact']
and O
behaviour B-outcome ['Life-Impact']
12 O
months O
after O
the O
intervention O
ceased O
. O
['Life-Impact', 'Life-Impact']

PRIMARY O
OUTCOME O
MEASURE O
The O
pain B-outcome ['Physiological-Clinical']
subscale O
of O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis B-outcome ['Physiological-Clinical']
Index O
( O
WOMAC O
pain B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Title: O
[A O
comparison O
study O
of O
cognitive-behavioral O
therapy O
alone O
versus O
combination O
with O
tapered O
hypnotic O
agents O
in O
patients O
with O
chronic O
insomnia]. O
[]

IMPLICATIONS O
Esmolol O
blunted O
the O
postoperative O
increase O
in O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in O
neurosurgical O
patients O
. O
['Physiological-Clinical']

SETTING O
University O
research O
laboratory O
. O
[]

In O
the O
6- O
to O
< O
16-week O
cohort O
, O
more O
influenza O
vaccine O
, O
recipients O
experienced O
irritability B-outcome ['Life-Impact']
( O
66.7 O
% O
vs O
35.7 O
% O
) O
and O
runny B-outcome ['Physiological-Clinical']
nose I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
nasal I-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
( O
63.3 O
% O
vs O
33.3 O
% O
) O
after O
dose O
1 O
but O
not O
dose O
2 O
. O
['Life-Impact', 'Physiological-Clinical']

CLINICAL O
IMPLICATIONS O
Hard-tissue O
cutting O
lasers O
are O
being O
introduced O
for O
use O
in O
operative O
dentistry O
. O
[]

The O
mean/median O
Breslow O
tumor B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
in O
the O
overall O
group O
was O
3.4/2.0 O
mm O
and O
in O
the O
SLN O
positive O
patients O
was O
5.72/4.0 O
mm O
. O
['Physiological-Clinical']

The O
independent O
data O
monitoring O
committee O
concluded O
it O
was O
unlikely O
that O
we O
would O
show O
noninferiority O
in O
the O
final O
results O
for O
the O
experimental O
arm O
and O
advised O
stopping O
random O
assignment O
for O
early O
PET-negative O
patients O
. O
[]

Additionally O
, O
a O
prospective O
clinical O
study O
was O
conducted O
in O
77 O
patients O
with O
CDAD O
to O
demonstrate O
the O
safety O
of O
consuming O
anti-CD O
WPC O
to O
prevent O
relapse O
of O
the O
infection O
. O
[]

The O
effect O
of O
3- O
( O
2-benzylmethylaminoethyl O
) O
benzoic O
acid O
methyl O
ester O
hydrochloride O
( O
PRL-8-53 O
) O
on O
learning B-outcome ['Life-Impact']
and O
on O
retention O
of O
verbal B-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
in O
human O
subjects O
was O
investigated O
. O
['Life-Impact', 'Life-Impact']

Thus O
, O
no O
dose O
adjustment O
for O
either O
risperidone O
orgalantamine O
is O
necessary O
when O
these O
two O
drugs O
are O
administered O
together O
in O
the O
dose O
range O
evaluated O
. O
[]

CLINICAL O
TRIAL O
REGISTRATION O
URL O
: O
http O
: O
//www.clinicaltrials.gov O
. O
[]

Corticosteroids O
and O
antifungals O
are O
the O
mainstay O
of O
therapy O
. O
[]

At O
the O
end O
of O
the O
treatment O
, O
Z O
scores O
were O
1.8 O
+/- O
0.3 O
for O
Crosslaps O
( O
CTx O
) O
and O
deoxypyridinoline O
( O
D-Pyr O
) O
, O
and O
1.1 O
+/- O
0.2 O
for O
bone B-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
B-ALP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
osteocalcin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

0.11 O
) O
ng?ml???h?? O
, O
AII O
( O
162.21 O
? O
[]

Morbidity B-outcome ['Physiological-Clinical']
attributable O
to O
treatment O
or O
to O
renal B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
occurred O
in O
both O
groups O
; O
an O
audit O
showed O
that O
benefits O
of O
therapy O
outweighed O
expected O
or O
minor O
side O
effects O
of O
drugs O
in O
this O
population O
at O
risk O
of O
end-stage O
renal O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
diagnosis O
of O
cortical O
adenoma O
was O
based O
on O
computed O
tomography O
features O
and O
pattern O
of O
uptake O
on O
adrenal O
scintigraphy O
. O
[]

Prevention O
of O
type O
2 O
( O
non-insulin-dependent O
) O
diabetes O
mellitus O
by O
diet O
and O
physical O
exercise O
. O
[]

Additional O
investigations O
are O
warranted O
to O
determine O
the O
potential O
for O
interactions O
in O
elderly O
patients O
with O
dementia O
who O
may O
eliminate O
risperidone O
and O
donepezil O
more O
slowly O
and O
thus O
be O
more O
vulnerable O
to O
clinical O
drug O
interactions O
than O
the O
young O
healthy O
subjects O
examined O
in O
this O
study O
. O
[]

Fifty-six O
patients O
with O
90 O
double O
lumen O
VACs O
were O
randomly O
chosen O
, O
and O
received O
either O
1- O
or O
2-week O
catheterizations O
from O
operators O
experienced O
in O
the O
placement O
of O
such O
catheters O
at O
three O
sites O
such O
as O
the O
internal O
jugular O
, O
subclavian O
, O
or O
femoral O
vein O
. O
[]

The O
efficacy O
and O
safety O
profile O
of O
od O
administration O
of O
vancomycin O
is O
similar O
to O
that O
of O
the O
customary O
, O
but O
less O
convenient O
, O
bd O
administration O
. O
[]

On O
a O
phone O
interview O
they O
had O
to O
evaluate O
their O
appreciation O
of O
the O
anxiolytic O
technique O
, O
their O
perception O
during O
loco-regional O
anesthesia O
and O
incidence O
of O
pain O
and O
edema O
. O
[]

All O
3 O
medications O
significantly O
reduced O
mean O
SeDBP B-outcome ['Physiological-Clinical']
from O
baseline O
compared O
with O
placebo O
at O
weeks O
4 O
, O
8 O
, O
and O
12 O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

The O
primary O
safety O
outcome O
was O
a O
protocol-defined O
decrease O
in O
the O
hemoglobin B-outcome ['Physiological-Clinical']
level O
(>3.0 O
g O
per O
deciliter O
or O
>/=30% O
from O
baseline O
or O
to O
a O
level O
of O
<6.0 O
g O
per O
deciliter). O
[['Physiological-Clinical']]

Subjective O
outcome O
variables O
were O
women O
's O
subjective O
assessment O
of O
change O
in O
urinary B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
based O
on O
the O
PRAFAB O
score O
. O
['Physiological-Clinical']

Each O
eye O
in O
the O
azithromycin O
group O
also O
received O
azithromycin O
solution O
( O
1 O
drop O
) O
twice O
daily O
for O
the O
first O
2 O
days O
followed O
by O
once O
daily O
for O
the O
next O
12 O
days O
. O
[]

CONCLUSION O
There O
appears O
to O
be O
some O
activity O
and O
tolerable O
toxicity O
at O
1,000-2,000 O
mg/day O
doses O
of O
American O
ginseng O
with O
regard O
to O
cancer-related O
fatigue O
. O
[]

CONCLUSIONS O
Although O
the O
patients O
in O
the O
levosimendan O
group O
were O
alive O
for O
more O
days O
and O
thus O
at O
risk O
of O
hospitalisation B-outcome ['Resource-use']
for O
longer O
, O
there O
was O
no O
increase O
in O
hospitalisation B-outcome ['Resource-use']
or O
hospitalisation B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
with O
levosimendan O
treatment O
. O
['Resource-use', 'Resource-use', 'Resource-use']

All O
patients O
received O
central O
nervous O
system O
prophylaxis O
with O
intrathecal O
methotrexate O
and O
most O
received O
local O
or O
regional O
radiation O
treatment O
. O
[]

1 O
. O
[]

In O
the O
capillary O
blood O
samples O
indices O
of O
acid-base B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
level O
, O
and O
glucose B-outcome ['Physiological-Clinical']
level O
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thereafter O
stepwise O
isobaric O
distensions O
were O
performed O
with O
ongoing O
peptide O
infusion O
, O
and O
gastric B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
was O
scored O
. O
['Physiological-Clinical']

METHODS: O
Sixty-six O
female O
patients O
with O
American O
Society O
of O
Anesthesiologists O
I, O
II, O
or O
III, O
aged O
18 O
to O
65 O
years O
who O
were O
scheduled O
for O
laparoscopic O
hysterectomy O
for O
benign O
gynecologic O
pathologies O
were O
recruited O
in O
this O
randomized, O
controlled, O
observer-blinded O
trial. O
[]

OBJECTIVE O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
effectiveness O
of O
an O
applied O
behaviour O
analysis O
( O
ABA O
) O
-based O
intervention O
conducted O
by O
a O
robot O
compared O
to O
an O
ABA-based O
intervention O
conducted O
by O
a O
human O
trainer O
in O
promoting O
self-initiated O
questions O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Conclusion:Compared O
with O
CHOP+IMRT O
regimen, O
the O
LOP+IMRT O
regimen O
for O
nasal O
NK/T-cell O
lymphoma O
patients O
resulted O
in O
higher O
overall O
remission B-outcome ['Physiological-Clinical']
rate, O
survival B-outcome ['Mortality']
rate O
and O
lower O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
so O
it O
is O
worth O
in O
clinical O
promotion. O
[['Physiological-Clinical'], ['Mortality'], ['Adverse-effects']]

Rotational O
angiography O
is O
a O
new O
technique O
which O
involves O
pre-set O
rotation O
of O
the O
X-ray O
tube O
around O
the O
patient O
and O
allows O
visualization O
of O
each O
coronary O
artery O
in O
different O
views O
, O
using O
a O
single O
contrast O
injection O
. O
[]

Treatment O
with O
ramipril O
significantly O
reduced O
the O
rates O
of O
death O
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
, O
coronary B-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
, O
cardiac B-outcome ['Physiological-Clinical']
arrest I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
risk O
of O
diabetes-related B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
of O
diabetes B-outcome ['Physiological-Clinical']
itself O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Stapled B-outcome ['Resource-use']
hemorrhoidopexy I-outcome ['Resource-use']
versus O
milligan-morgan B-outcome ['Resource-use']
hemorrhoidectomy I-outcome ['Resource-use']
: O
a O
prospective O
, O
randomized O
, O
multicenter O
trial O
with O
2-year O
postoperative O
follow O
up O
. O
['Resource-use', 'Resource-use']

RESULTS O
There O
were O
no O
significant O
sequence B-outcome ['Physiological-Clinical']
effects O
for O
responses O
as O
to O
whether O
placebo O
or O
montelukast O
were O
given O
first O
or O
second O
. O
['Physiological-Clinical']

FINDINGS O
Between O
Nov O
22 O
, O
2006 O
, O
and O
July O
31 O
, O
2007 O
, O
197 O
patients O
were O
randomly O
allocated O
to O
treatment O
groups O
and O
were O
included O
in O
the O
intention-to-treat O
analysis O
( O
135 O
eltrombopag O
, O
62 O
placebo O
) O
. O
[]

Interventions: O
Patients O
were O
randomized O
1:1 O
(stratified O
by O
cardiac O
vs O
noncardiac O
surgery O
and O
positive O
vs O
negative O
recent O
fall O
history) O
to O
receive O
EEG-guided O
anesthetic O
administration O
(n O
= O
614) O
or O
usual O
anesthetic O
care O
(n O
= O
618). O
[]

Children O
presenting O
with O
GABHS O
pharyngitis O
were O
randomised O
to O
oral O
amoxicillin O
1500 O
mg O
QD O
( O
or O
750 O
mg O
if O
bodyweight O
was O
< O
or=30 O
kg O
) O
or O
to O
oral O
penicillin O
V O
500 O
mg O
BID O
( O
or O
250 O
mg O
if O
bodyweight O
was O
< O
or=20 O
kg O
) O
for O
10 O
days O
. O
[]

The O
post-ischaemic O
functional O
recovery O
of O
the O
heart O
was O
assessed O
by O
clinical O
parameters O
, O
as O
well O
as O
by O
biochemical O
and O
ultrastructure O
evaluations O
on O
biopsy O
specimens O
. O
[]

Effects O
of O
Thai O
traditional O
massage O
on O
autistic O
children O
's O
behavior O
. O
[]

The O
bupivacaine O
group O
( O
n=30 O
) O
received O
20cc O
of O
0.5 O
% O
bupivacaine O
in O
at O
the O
same O
surgical O
site O
. O
[]

After O
a O
washout O
period O
of O
2 O
weeks O
, O
patients O
were O
randomized O
to O
amlodipine O
maleate O
or O
amlodipine O
besylate O
for O
8 O
weeks O
. O
[]

METHODS O
Fifty-six O
consecutive O
patients O
scheduled O
for O
knee O
arthroscopy O
were O
enrolled O
. O
[]

[ O
Diphtheria O
antitoxin O
level O
2 O
years O
after O
booster O
vaccination O
] O
. O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
leptin I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
T4 B-outcome ['Physiological-Clinical']
, O
T3 B-outcome ['Physiological-Clinical']
, O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
( O
IGF B-outcome ['Physiological-Clinical']
) O
-I O
, O
IGF-binding B-outcome ['Physiological-Clinical']
protein-3 I-outcome ['Physiological-Clinical']
and O
the O
acid-labile B-outcome ['Physiological-Clinical']
subunit O
( O
ALS O
) O
were O
measured O
at O
0900 O
h O
, O
2100 O
h O
, O
and O
0600 O
h O
on O
each O
of O
the O
2 O
study O
days O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
aimed O
to O
investigate O
the O
efficacy O
of O
sodium O
bicarbonate O
by O
comparing O
2 O
other O
regimens O
, O
including O
combination O
of O
N-acetylcysteine O
( O
NAC O
) O
plus O
sodium O
chloride O
and O
sodium O
chloride O
alone O
, O
to O
prevent O
CIN O
in O
patients O
undergoing O
cardiovascular O
procedures O
. O
[]

Late O
after O
surgery O
, O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
was O
greater O
at O
similar O
end-diastolic B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
( O
P O
< O
.005 O
by O
rm O
ANCOVA O
) O
, O
and O
preload O
recruitable O
stroke O
work O
indexes O
( O
P O
< O
.001 O
by O
rm O
ANCOVA O
) O
were O
better O
in O
the O
Pres O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
first B-outcome ['Life-Impact']
out-of-bed I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
first B-outcome ['Physiological-Clinical']
anus I-outcome ['Physiological-Clinical']
exhaust I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
time I-outcome ['Resource-use']
of O
the O
parecoxib O
+ O
TAP O
group O
were O
significantly O
shorter O
than O
those O
of O
the O
other O
groups, O
while O
the O
control O
group O
was O
all O
significantly O
higher O
than O
the O
other O
groups. O
[['Life-Impact'], ['Physiological-Clinical'], ['Resource-use']]

In O
this O
work O
, O
we O
analysed O
the O
frequency O
of O
peripheral O
blood O
lymphocyte O
subsets O
in O
10 O
Chinese O
patients O
with O
histologically O
proven O
CAHB O
and O
seven O
healthy O
Chinese O
individuals O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
two O
treatment O
groups O
with O
regard O
to O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
or O
side O
effects O
. O
['Physiological-Clinical']

The O
VPW O
was O
studied O
in O
ALI O
patients O
to O
determine O
the O
correlation O
between O
VPW O
and O
intravascular O
pressure O
measurements O
and O
whether O
VPW O
could O
predict O
fluid O
status O
. O
[]

SETTING O
The O
study O
was O
conducted O
in O
air O
and O
land O
emergency O
medical O
services O
and O
2 O
trauma O
centers O
serving O
a O
population O
of O
4 O
million O
people O
. O
[]

Stimulus B-outcome ['Physiological-Clinical']
over-selectivity I-outcome ['Physiological-Clinical']
in O
temporal O
brain O
injury O
: O
mindfulness O
as O
a O
potential O
intervention O
. O
['Physiological-Clinical']

As O
the O
strength B-outcome ['Life-Impact']
increased O
, O
so O
did O
the O
depth O
of O
peel O
. O
['Life-Impact']

Journal O
ID: O
101521595 O
[]

This O
study O
shows O
that O
vitamin O
E O
effectively O
and O
safely O
protects O
patients O
with O
cancer O
from O
the O
occurrence O
of O
paclitaxel-induced B-outcome ['Physiological-Clinical']
peripheral I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Treatment O
of O
hirsute O
women O
with O
third O
generation O
OCs O
containing O
desogestrel O
results O
in O
a O
significant O
increase O
in O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
and O
decrease O
in O
free B-outcome ['Physiological-Clinical']
testosterone I-outcome ['Physiological-Clinical']
and O
3alpha-androstanediol B-outcome ['Physiological-Clinical']
glucuronide I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
were O
measured O
after O
3 O
and O
12 O
months O
by O
a O
research O
assistant O
on O
the O
basis O
of O
a O
constructed O
severity O
scale O
, O
an O
incontinence O
diary O
, O
and O
a O
comparison O
by O
the O
patients O
themselves O
of O
their O
previous O
and O
current O
conditions O
. O
[]

In O
the O
28 O
that O
had O
been O
positioned O
, O
changes O
were O
found O
in O
only O
3 O
TMJs B-outcome ['Physiological-Clinical']
( O
11 O
% O
) O
postoperatively O
. O
['Physiological-Clinical']

RESULTS O
The O
study O
group O
included O
thirty-one O
female O
patients O
and O
twenty-five O
male O
patients O
with O
a O
combined O
average O
age O
of O
fifty O
years O
and O
an O
average O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
of O
30.9 O
. O
['Physiological-Clinical']

Four O
children O
( O
18 O
% O
) O
of O
22 O
in O
the O
placebo O
group O
had O
[]

Journal O
ID: O
101643584 O
[]

There O
were O
no O
significant O
changes O
in O
the O
FLS B-outcome ['Physiological-Clinical']
or O
CTR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
receiving O
dexmedetomidine O
vs O
propofol O
had O
no O
significant O
difference O
in O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
(17% O
vs O
21%; O
difference, O
-4% O
[95% O
CI, O
-18% O
to O
10%]; O
P O
= O
.54; O
HR, O
0.8 O
[95% O
CI, O
0.4-1.9]). O
[['Physiological-Clinical', 'Life-Impact']]

Data O
analysis O
methods O
used O
would O
include O
Kaplan-Meier O
plots O
, O
log-rank O
test O
and O
Cox O
modeling O
. O
[]

From O
the O
registries O
, O
90 O
residents O
, O
aged O
20 O
to O
49 O
years O
old O
, O
were O
randomly O
selected O
to O
represent O
each O
sex O
from O
each O
area O
. O
[]

Adverse O
events O
were O
documented O
. O
[]

The O
therapy O
became O
effective O
after O
six O
weeks O
of O
training O
. O
[]

SD O
1.8 O
? O
[]

Two O
HBOT O
patients O
and O
four O
control O
patients O
developed O
positive O
bacterial O
cultures O
. O
[]

C B-outcome ['Physiological-Clinical']
parvum I-outcome ['Physiological-Clinical']
was O
eradicated O
from O
stool O
in O
13 O
( O
52 O
% O
) O
of O
25 O
receiving O
nitazoxanide O
and O
three O
( O
14 O
% O
) O
of O
22 O
receiving O
placebo O
( O
38 O
% O
, O
95 O
% O
CI O
14-63 O
; O
p=0.007 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
Parameters O
of O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
were O
quantitated O
in O
50 O
patients O
with O
type O
2 O
diabetes O
mellitus O
in O
uncontrolled O
state O
and O
after O
control O
using O
oral O
glibenclamide O
or O
gliclazide O
. O
['Physiological-Clinical']

Journal-Name:Ophthalmic O
epidemiology O
[]

Dietary O
status O
and O
impact O
of O
risperidone O
on O
nutritional B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
in O
children O
with O
autism O
: O
a O
pilot O
study O
. O
['Physiological-Clinical']

Monitoring O
of O
the O
central B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
is O
useful O
for O
detecting O
cardiac O
overload O
during O
antiadrenergic O
treatment O
: O
the O
Japan O
Morning O
Surge O
1 O
study O
. O
['Physiological-Clinical']

These O
studies O
used O
both O
new O
and O
commercially O
available O
drugs O
, O
as O
well O
as O
surgery O
and/or O
radiation O
therapy O
in O
1,087 O
patients O
. O
[]

antibiotic O
therapy O
followed O
by O
p.o. O
[]

Eighty-eight O
patients O
determined O
as O
eligible O
for O
treatment O
were O
enrolled O
in O
the O
study O
. O
[]

Cholesterol-lowering O
therapy O
may O
retard O
the O
progression O
of O
diabetic O
nephropathy O
. O
[]

METHODS O
A O
prospective O
study O
was O
carried O
out O
on O
51 O
participants O
with O
amblyopia O
( O
strabismic O
n=17 O
; O
anisometropic O
n=10 O
; O
combined O
n=24 O
) O
, O
mean O
age O
10 O
years O
8 O
months O
. O
[]

The O
primary O
outcomes O
is O
the O
mortality B-outcome ['Mortality']
rate O
at O
6 O
months O
follow-up O
. O
['Mortality']

[ O
Structural O
and O
immunohistochemical O
changes O
of O
conjunctiva O
induced O
by O
topical O
glaucoma O
medication O
] O
. O
[]

A O
double-blind O
comparison O
of O
oral O
ketoprofen O
'controlled O
release O
' O
and O
indomethacin O
suppository O
in O
the O
treatment O
of O
rheumatoid O
arthritis O
with O
special O
regard O
to O
morning O
stiffness O
and O
pain O
on O
awakening O
. O
[]

Results O
demonstrated O
the O
ability O
to O
recruit O
and O
retain O
53 O
rural O
breast O
cancer O
survivors O
, O
that O
the O
experimental O
arm O
showed O
improvement O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
( O
P O
= O
.013 O
) O
, O
and O
that O
there O
were O
significant O
differences O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
between O
the O
experimental O
and O
wait-control O
groups O
at O
both O
months O
3 O
and O
6 O
. O
['Life-Impact', 'Life-Impact']

Regular O
replacement O
of O
extended O
wear O
rigid O
gas O
permeable O
contact O
lenses O
. O
[]

A O
low O
dietary O
fiber O
intake O
appears O
to O
be O
associated O
with O
higher O
[]

Journal-Name:Journal O
of O
personality O
and O
social O
psychology O
[]

Patient O
navigation O
improves O
cancer O
diagnostic O
resolution O
: O
an O
individually O
randomized O
clinical O
trial O
in O
an O
underserved O
population O
. O
[]

Airway B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
inflammation B-outcome ['Physiological-Clinical']
in O
subjects O
with O
asthma O
after O
four O
days O
of O
repeated O
high-single-dose O
allergen O
challenge O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS/DESIGN O
The O
study O
is O
a O
randomized O
, O
waitlist O
controlled O
, O
single-blinded O
trial O
. O
[]

The O
following O
results O
were O
obtained O
: O
Arm O
A O
: O
84 O
patients O
were O
included O
, O
74 O
were O
evaluable O
for O
activity O
; O
RESPONSE O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
8 O
( O
11 O
% O
) O
, O
partial B-outcome ['Physiological-Clinical']
response O
( O
PR O
) O
40 O
( O
54 O
% O
) O
, O
stable B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( O
SD O
) O
11 O
( O
15 O
% O
) O
, O
progressive B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
( O
PD O
) O
15 O
( O
20 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
was O
given O
once O
a O
day O
, O
and O
30 O
days O
made O
one O
session O
. O
[]

A O
small O
statistically O
significant O
improvement O
on O
enzyme O
therapy O
was O
seen O
for O
the O
food O
variety O
scores O
. O
[]

Incidences O
of O
hypercalcemia B-outcome ['Physiological-Clinical']
, O
hyperphosphatemia B-outcome ['Physiological-Clinical']
, O
and O
elevated B-outcome ['Physiological-Clinical']
calcium-phosphorus I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
were O
not O
significantly O
different O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
All O
patients O
in O
both O
groups O
had O
an O
increasing O
tendency O
to O
free O
radical O
production O
during O
early O
reperfusion O
. O
[]

These O
surveys O
suggested O
that O
engaging O
supervisors O
in O
a O
dialogue O
about O
tolerance O
might O
improve O
their O
willingness B-outcome ['Life-Impact']
to O
use O
the O
EAP O
. O
['Life-Impact']

Whereas O
Group O
I O
patients O
did O
not O
receive O
a O
dopexamine O
infusion O
. O
[]

and O
1 O
y, O
with O
pronounced O
differences O
for O
the O
dimensions O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
and O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
the O
mental B-outcome ['Life-Impact']
component O
summary O
score O
(all O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact']]

After O
2 O
years O
of O
follow-up O
, O
the O
differences O
narrowed O
. O
[]

7 O
% O
) O
recipients O
for O
subjects O
receiving O
5 O
?g O
or O
25 O
?g O
of O
VLP O
immunotherapy/dose O
( O
71 O
% O
? O
[]

The O
egg B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hookworm I-outcome ['Physiological-Clinical']
were O
98.1-98.6 O
% O
. O
['Physiological-Clinical']

Treatment O
of O
hypertension O
with O
ascorbic O
acid O
. O
[]

busulfan O
( O
Bu O
) O
and O
fludarabine O
( O
Flu O
) O
is O
a O
safe O
, O
reduced-toxicity O
conditioning O
program O
for O
acute O
myelogenous O
leukemia/myelodysplastic O
syndromes O
( O
AML/MDS O
) O
, O
recurrent O
leukemia O
posttransplantation O
remains O
a O
problem O
. O
[]

A O
highly O
significant O
degree O
of I-outcome ['Physiological-Clinical']
discolouration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
all I-outcome ['Physiological-Clinical']
parts I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
cavity I-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
treated O
with O
CBS O
chewing O
tablets O
, O
whereas O
only O
a O
few O
patients O
treated O
with O
CBS O
coated O
tablets O
experienced O
a O
slight B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
tongue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

WST-1 O
assay O
was O
employed O
to O
measure O
cell B-outcome ['Physiological-Clinical']
viability I-outcome ['Physiological-Clinical']
and O
a O
luciferase B-outcome ['Physiological-Clinical']
ERE I-outcome ['Physiological-Clinical']
( O
estrogen O
responsive O
element O
) O
construct O
was O
used O
to O
study O
the O
effect O
of O
tamoxifen O
, O
following O
downregulation O
of O
YAP1 O
using O
siRNAs O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Therapist-couple O
struggle O
vs. O
cooperation O
is O
linked O
to O
clinical O
outcome O
. O
[]

Offering O
various O
screening O
options O
can O
be O
a O
successful O
method O
for O
increasing O
participation B-outcome ['Life-Impact']
in O
this O
group O
. O
['Life-Impact']

No O
statistically O
significant O
difference O
was O
found O
between O
the O
mean O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
for O
patients O
receiving O
mexiletine O
versus O
placebo O
, O
irrespective O
of O
the O
order O
in O
which O
the O
agents O
were O
received O
. O
['Physiological-Clinical']

[ O
Effects O
of O
dujieqing O
oral O
liquid O
on O
the O
promoter O
methylation O
of O
the O
MGMT O
gene O
in O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
] O
. O
[]

Before O
treatment O
there O
was O
no O
statistical O
difference O
in O
the O
pathological B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cervix I-outcome ['Physiological-Clinical']
and O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hTERT I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101225531 O
[]

Inclusion O
criteria O
were O
: O
age O
18-70 O
years O
, O
active O
participation O
in O
sports O
, O
and O
tendon O
pain O
localised O
at O
2-7 O
cm O
from O
distal O
insertion O
. O
[]

A O
barbed O
suture O
was O
developed O
that O
is O
self-anchoring O
, O
requiring O
no O
knots O
or O
slack O
management O
for O
wound O
closure O
. O
[]

A O
population-based O
sample O
served O
as O
controls O
and O
received O
a O
single O
NPSG O
followed O
by O
MSLT O
. O
[]

This O
study O
was O
undertaken O
to O
evaluate O
the O
efficacy O
of O
different O
r-hGH O
treatment O
schedules O
( O
67 O
microg/kg/day O
in O
a O
discontinuous O
or O
continuous O
regimen O
) O
during O
the O
second O
year O
of O
r-hGH O
treatment O
by O
comparing O
height B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
changes O
and O
total O
gain O
of O
height B-outcome ['Physiological-Clinical']
over O
a O
4-year O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Bradykinin-induced O
release O
of O
active B-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
was O
more O
than O
doubled O
during O
treatment O
with O
quinapril O
in O
comparison O
to O
placebo O
or O
losartan O
( O
two-way O
ANOVA O
: O
p O
< O
0.003 O
for O
treatment O
group O
, O
p O
< O
0.001 O
for O
t-PA O
response O
and O
p O
= O
ns O
for O
interaction O
) O
, O
whereas O
the O
substance B-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
response O
was O
['Physiological-Clinical', 'Physiological-Clinical']

No O
ulcer B-outcome ['Physiological-Clinical']
, O
exulceration B-outcome ['Physiological-Clinical']
, O
or O
de-epithelialization B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sixty-six O
patients O
with O
poorly O
responsive O
tumors O
such O
as O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
, O
bladder O
cancer O
, O
gastrointestinal O
cancers O
, O
kidney O
cancer O
, O
melanoma O
and O
metastatic O
carcinoma O
of O
unknown O
origin O
entered O
the O
study O
. O
[]

Verapamil O
also O
caused O
less O
marked O
ST-segment B-outcome ['Physiological-Clinical']
depressions I-outcome ['Physiological-Clinical']
at O
peak O
exercise B-outcome ['Life-Impact']
( O
p O
less O
than O
0.05 O
) O
at O
a O
similar O
rate-pressure O
product O
, O
suggesting O
a O
favorable O
redistribution O
of O
coronary B-outcome ['Physiological-Clinical']
blood B-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
to O
the O
ischemic O
zone O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
& O
MATERIALS O
This O
double-blind O
study O
at O
three O
centers O
enrolled O
60 O
subjects O
, O
injected O
with O
both O
products O
, O
randomly O
assigned O
to O
left O
or O
right O
nasolabial O
fold O
. O
[]

A O
total O
of O
465 O
patients O
with O
primary O
and O
multiple O
or O
recurrent O
, O
stages O
Ta O
and O
T1 O
superficial O
bladder O
cancer O
were O
included O
in O
this O
randomized O
multicenter O
trial O
to O
compare O
the O
prophylactic O
effect O
by O
17 O
times O
instillation O
of O
40 O
mg O
doxorubicin O
or O
40 O
mg O
epirubicin O
with O
no O
instillation O
after O
transurethral O
resection O
of O
tumor O
( O
s O
) O
. O
[]

RESULTS O
Simvastatin O
, O
but O
not O
placebo O
, O
administered O
to O
these O
patients O
reduced O
plasma B-outcome ['Physiological-Clinical']
levels/activity O
of I-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
( O
from O
3.5 O
? O
['Physiological-Clinical']

The O
occlusion O
was O
released O
after O
2 O
min O
and O
one-fourth O
of O
the O
total O
propofol O
dose O
was O
injected O
into O
the O
vein O
over O
a O
period O
of O
5 O
s. O
During O
the O
injection O
of O
both O
pretreatment O
solution O
and O
propofol O
, O
patients O
' O
pain B-outcome ['Physiological-Clinical']
was O
assessed O
and O
recorded O
as O
0-3 O
, O
corresponding O
to O
no O
, O
mild O
, O
moderate O
or O
severe O
pain O
, O
respectively O
. O
['Physiological-Clinical']

A O
single O
agent O
to O
reduce O
cholesterol O
as O
well O
as O
TG O
is O
rare. O
[]

In O
addition O
, O
the O
introduction O
of O
screening O
programs O
for O
colorectal O
cancer O
will O
also O
increase O
the O
numbers O
of O
procedures O
needed O
. O
[]

RESULTS O
Of O
the O
121 O
patients O
who O
participated O
, O
59 O
received O
C/A O
and O
62 O
received O
H/A O
. O
[]

The O
tumor O
was O
not O
completely O
resected O
when O
the O
patient O
underwent O
TUR O
. O
[]

In O
the O
remaining O
five O
patients O
gabapentin O
improved O
[]

So O
we O
tried O
tobramycin/dexamethasone O
eye O
drops O
as O
a O
replacement. O
[]

Carbohydrate O
supplementation O
significantly O
increased O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
exhaustion I-outcome ['Physiological-Clinical']
( O
carbohydrate O
19.7 O
+/- O
4.6 O
min O
vs. O
placebo O
12.7 O
+/- O
3.1 O
min O
) O
, O
while O
the O
addition O
of O
protein O
enhanced O
the O
effect O
of O
the O
carbohydrate O
supplement O
( O
carbohydrate-protein O
26.9 O
+/- O
4.5 O
min O
, O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

The O
most O
reliable O
combination O
of O
predictive O
factors O
was O
a O
negative O
anti-human B-outcome ['Physiological-Clinical']
immunodeficiency I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
with O
either O
a O
positive O
history O
of O
acute B-outcome ['Physiological-Clinical']
icteric I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
and O
AST O
greater O
than O
45 O
IU O
per O
liter O
or O
no O
history O
of O
acute O
icteric O
hepatitis O
and O
AST O
greater O
than O
85 O
IU O
per O
liter O
, O
which O
predicted O
response O
in O
77 O
% O
with O
a O
specificity O
of O
79 O
% O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
the O
effectiveness O
of O
a O
weighted-blanket O
intervention O
in O
treating O
severe O
sleep O
problems O
in O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

At O
the O
3-month O
follow-up O
assessment O
, O
PSE O
mothers O
were O
significantly O
less O
likely O
than O
those O
serving O
as O
controls O
to O
have O
clinically O
significant O
parental B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
( O
3.8 O
% O
vs O
29.3 O
% O
; O
adjusted O
relative O
risk O
[ O
aRR O
] O
, O
0.17 O
; O
95 O
% O
CI O
, O
0.04 O
to O
0.65 O
) O
. O
['Life-Impact']

METHODS O
A O
prospective O
randomized O
trial O
of O
65 O
eyes O
was O
designed O
, O
with O
31 O
eyes O
receiving O
750 O
rads O
of O
intraoperative O
beta O
radiation O
( O
group O
1 O
) O
, O
and O
34 O
eyes O
receiving O
no O
supplementation O
( O
group O
2 O
) O
. O
[]

OBJECTIVE O
To O
determine O
the O
effectiveness O
of O
a O
quality O
improvement O
program O
to O
improve O
pediatricians O
' O
adherence O
to O
existing O
, O
evidence-based O
, O
attention-deficit/hyperactivity O
disorder O
( O
ADHD O
) O
practice O
guidelines O
. O
[]

Nicotine O
infusion O
acutely O
impairs O
insulin O
sensitivity O
in O
type O
2 O
diabetic O
patients O
but O
not O
in O
healthy O
subjects O
. O
[]

intravenously O
or O
0.5 O
g O
imipenem O
q.i.d O
. O
[]

They O
were O
assessed O
at O
baseline O
and O
one O
year O
after O
randomisation O
with O
validated O
measures O
of O
physical B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
psychological I-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
quality O
of O
life O
( O
SF-36 O
health B-outcome ['Physiological-Clinical']
survey O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Confocal O
microscopy O
was O
used O
for O
the O
6-week O
treatment O
group O
to O
examine O
the O
target O
tumor O
area O
at O
each O
interval O
visit O
and O
immediately O
before O
Mohs O
micrographic O
surgery O
. O
[]

The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
of O
E-PEG O
group O
was O
5-16 O
( O
mean O
+/- O
SD O
: O
10.3 O
+/- O
2.96 O
) O
min O
as O
compared O
to O
14-37 O
( O
mean O
+/- O
SD O
: O
26.9 O
+/- O
8.39 O
) O
min O
with O
pull-method O
PEG O
. O
['Life-Impact']

Goldmann O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
displayed O
a O
significant O
constriction B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
isopters I-outcome ['Physiological-Clinical']
: O
III/4 O
, O
I/4 O
, O
and O
I/3 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Exercise O
participants O
were O
scheduled O
to O
attend O
exercise O
sessions O
lasting O
45 O
minutes O
, O
including O
warm-up O
and O
cool-down O
, O
3 O
times O
a O
week O
for O
8 O
weeks O
( O
24 O
sessions O
) O
. O
[]

In O
this O
controlled O
randomized O
study O
, O
we O
investigated O
the O
influence O
of O
statin O
pretreatment O
and O
its O
withdrawal O
on O
the O
outcome O
of O
acute O
ischemic O
stroke O
patients O
. O
[]

Topical O
retapamulin O
ointment O
( O
1 O
% O
, O
wt/wt O
) O
twice O
daily O
for O
5 O
days O
versus O
oral O
cephalexin O
twice O
daily O
for O
10 O
days O
in O
the O
treatment O
of O
secondarily O
infected O
dermatitis O
: O
results O
of O
a O
randomized O
controlled O
trial O
. O
[]

In O
the O
second-line O
treatment O
of O
advanced O
breast O
carcinoma O
, O
fulvestrant O
was O
shown O
previously O
to O
be O
as O
effective O
as O
the O
third-generation O
aromatase O
inhibitor O
, O
anastrozole O
, O
in O
terms O
of O
time O
to O
disease O
progression O
and O
objective O
response O
rates O
. O
[]

Publication O
date: O
2018/12/23 O
06:00 O
[entrez] O
[]

Torasemide O
induced O
a O
remarkably O
higher O
natriuretic B-outcome ['Physiological-Clinical']
( O
120 O
+/- O
15 O
vs. O
33 O
+/- O
6 O
mmol/day O
, O
p O
< O
0.02 O
) O
and O
diuretic B-outcome ['Physiological-Clinical']
( O
1450 O
+/- O
63 O
vs. O
900 O
+/- O
58 O
ml O
, O
p O
< O
0.005 O
) O
effect O
than O
furosemide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
COX-2-treated O
patients O
had O
less O
difficulty O
coughing B-outcome ['Physiological-Clinical']
on O
postoperative O
day O
1 O
. O
['Physiological-Clinical']

The O
number O
of O
stereotypic B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
percentage O
of O
on-task B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
behaviour O
alone O
was O
thought O
to O
be O
inadequate O
to O
describe O
the O
response O
pattern O
. O
['Physiological-Clinical']

These O
meetings O
were O
held O
over O
a O
period O
of O
20 O
months O
from O
July O
2015 O
to O
March O
2017. O
[]

One O
urban O
and O
one O
rural O
health O
centre O
were O
linked O
to O
a O
regional O
hospital O
in O
Northern O
Ireland O
by O
ISDN O
at O
128 O
kbit/s O
. O
[]

The O
health O
seeking O
behaviour O
outcome O
measure O
included O
knowledge O
regarding O
anaemia O
, O
food O
selection O
ability O
, O
increase O
in O
haemoglobin O
level O
and O
compliance O
to O
iron O
supplementation O
. O
[]

This O
analysis O
was O
completed O
by O
criteria O
concordance O
analysis O
on O
a O
number O
of O
indicators O
of O
alcohol O
intake O
. O
[]

The O
target O
variables O
were O
the O
number O
of O
binges B-outcome ['Life-Impact']
and O
the O
bulimia O
scale O
of O
the O
Eating O
Disorder O
Inventory O
. O
['Life-Impact']

Use O
of O
hyaluronan-based O
sperm O
selection O
for O
ICSI O
(so-called O
physiological O
ICSI O
[PICSI]) O
is O
reported O
to O
reduce O
the O
proportion O
of O
pregnancies O
that O
end O
in O
miscarriage. O
[]

Nervous O
tissues O
may O
be O
less O
prone O
to O
low O
DHA B-outcome ['Physiological-Clinical']
levels O
after O
infancy, O
or O
higher O
doses O
might O
be O
required O
to O
impact O
neurological B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
. O
In O
situations O
of O
minimal O
dietary O
DHA, O
endogenous O
synthesis O
of O
DHA O
from O
alpha-linolenic O
acid O
could O
relevantly O
contribute O
to O
DHA B-outcome ['Physiological-Clinical']
status. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

After O
the O
procedure O
the O
mean O
minimal B-outcome ['Physiological-Clinical']
luminal I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
in O
the O
conventional O
group O
was O
2.34 O
+/- O
0.46 O
mm O
versus O
2.90 O
+/- O
0.41 O
mm O
in O
the O
stented O
group O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical']

Efficacy O
of O
intramuscular O
oxytetracycline O
as O
a O
dry O
cow O
treatment O
for O
Staphylococcus O
aureus O
mastitis O
. O
[]

In O
a O
substudy O
, O
89 O
% O
eyes O
( O
58 O
of O
65 O
) O
varied O
within O
+/- O
0.50 O
D O
over O
the O
course O
of O
a O
day O
. O
[]

CONCLUSION O
The O
use O
of O
large O
biopsy O
forceps O
to O
perform O
TBLB O
via O
rigid O
bronchoscope O
can O
significantly O
increase O
diagnostic O
yield O
in O
the O
pathological O
diagnosis O
of O
diffuse O
infiltrative O
lung O
disease O
. O
[]

With O
respect O
to O
the O
final O
question O
, O
the O
optimal O
treatment O
for O
polycythemia O
vera O
, O
it O
is O
apparent O
that O
the O
expectation O
of O
a O
single O
optimal O
therapy O
that O
would O
apply O
to O
all O
patients O
at O
all O
ages O
and O
stages O
of O
the O
disease O
was O
naive O
. O
[]

Twenty-two O
children O
( O
ages O
8-14 O
; O
IQ O
? O
[]

We O
developed O
a O
moderate-intensity O
intervention O
program O
that O
can O
be O
sustained O
in O
the O
real-world O
setting O
and O
is O
practically O
applicable O
to O
both O
moderate O
and O
severe O
obesity. O
[]

Following O
8 O
weeks O
of O
supplementation, O
the O
subjects O
repeated O
the O
pre-supplementation O
testing O
procedures. O
[]

RESULTS O
Twenty O
participants O
( O
24.4 O
% O
) O
quit O
during O
the O
6-month O
intervention O
period O
. O
[]

BACKGROUND O
The O
proportion O
of O
mothers O
who O
exclusively O
breastfeed O
their O
babies O
up O
to O
6 O
months O
remains O
low O
. O
[]

At O
the O
time O
of O
enrolment O
7/13 O
( O
54 O
% O
) O
and O
6/13 O
( O
46 O
% O
) O
of O
patients O
in O
the O
intervention O
and O
control O
groups O
, O
respectively O
, O
had O
sub B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
hyperthyroidism I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

At O
18 O
months O
of O
follow-up O
, O
the O
percentages O
were O
63 O
% O
and O
75 O
% O
respectively O
. O
[]

DESIGN O
The O
study O
used O
a O
double O
blind O
randomized O
trial O
. O
[]

As O
in O
the O
case O
of O
stimuli O
presented O
over O
headphones O
( O
Grantham O
& O
Wightman O
, O
1979 O
) O
, O
an O
auditory B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
aftereffect I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MAE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
occurred O
: O
subjects O
responded O
left O
to O
probes O
more O
often O
when O
the O
adaptor O
moved O
right O
than O
when O
it O
moved O
left O
. O
['Physiological-Clinical']

Participants O
in O
the O
control O
group O
were O
tested O
again O
after O
1 O
week O
(test-2). O
[]

METHODS O
58 O
growth-retarded O
SGA O
children O
aged O
2-5 O
years O
were O
randomized O
to O
a O
TOTO O
regimen O
( O
4 O
years O
alternating O
treatment O
( O
T O
) O
and O
observation O
( O
O O
) O
, O
n O
= O
30 O
) O
or O
a O
TTOO O
regimen O
( O
2 O
years O
' O
treatment O
, O
followed O
by O
2 O
years O
' O
observation O
, O
n O
= O
28 O
) O
. O
[]

Are O
postural B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
backward O
and O
forward O
perturbations O
processed O
by O
different O
neural O
circuits O
? O
['Physiological-Clinical']

Dropout O
from O
the O
trial O
and O
compliance O
( O
consumption O
of O
?85 O
% O
of O
the O
prescribed O
treatment O
packets O
) O
are O
the O
main O
outcome O
measures O
reported O
. O
[]

In O
the O
current O
article O
, O
we O
address O
the O
existing O
assumption O
in O
the O
literature O
on O
cognitive O
behavioral O
treatment O
of O
PTSD O
that O
patients O
with O
severe O
negative O
trauma-related O
cognitions O
would O
benefit O
more O
from O
a O
treatment O
package O
that O
includes O
exposure O
and O
cognitive O
techniques O
compared O
with O
a O
treatment O
that O
includes O
exposure O
only O
. O
[]

Effect O
of O
exercise O
, O
training O
, O
and O
glycogen O
availability O
on O
IL-6 O
receptor O
expression O
in O
human O
skeletal O
muscle O
. O
[]

The O
experimental O
intervention O
led O
to O
a O
large O
increase O
in O
exclusive B-outcome ['Life-Impact']
breast-feeding I-outcome ['Life-Impact']
at O
3 O
mo O
( O
43.3 O
% O
vs. O
6.4 O
% O
, O
P O
< O
0.001 O
) O
and O
a O
significantly O
higher O
prevalence O
of O
any O
breast-feeding O
throughout O
infancy O
. O
['Life-Impact']

SUMMARY O
The O
effect O
of O
garlic O
and O
onion O
on O
alimentary O
hyperlipemia O
, O
induced O
by O
feeding O
100 O
g O
butter O
, O
has O
been O
studied O
in O
10 O
healthy O
subjects O
. O
[]

Therefore O
, O
it O
is O
important O
to O
promote O
healthy O
feeding O
practices O
as O
early O
as O
possible O
. O
[]

Prostamol O
Uno O
( O
PU O
) O
efficacy O
and O
safety O
were O
studied O
in O
a O
multicenter O
, O
open-population O
, O
randomized O
and O
comparative O
trial O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CONCLUSIONS O
Providing O
drug O
infusions O
in O
syringes O
pre-filled O
by O
pharmacists O
or O
pharmaceutical O
companies O
would O
reduce O
medication B-outcome ['Resource-use']
errors B-outcome ['Life-Impact']
and O
treatment O
['Resource-use', 'Life-Impact']

Efficacy O
and O
safety O
of O
zidovudine O
and O
zalcitabine O
combined O
with O
a O
combination O
of O
herbs O
in O
the O
treatment O
of O
HIV-infected O
Thai O
patients O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
emptying B-outcome ['Physiological-Clinical']
improved O
significantly O
but O
equally O
in O
both O
groups O
over O
the O
study O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
A O
prospective O
, O
randomized O
clinical O
trial O
was O
conducted O
to O
assess O
the O
usefulness O
of O
preoperative O
diclofenac O
eye O
drops O
in O
maintaining O
mydriasis B-outcome ['Physiological-Clinical']
during O
vitrectomy O
and O
in O
reducing O
postoperative B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Feeding O
a O
LS O
or O
a O
HS O
diet O
for O
30 O
d O
before O
breeding O
may O
be O
inadequate O
to O
stimulate O
puberty B-outcome ['Physiological-Clinical']
in O
beef O
heifers O
, O
but O
feeding O
a O
diet O
with O
a O
greater O
amount O
of O
starch O
for O
60 O
d O
before O
breeding O
may O
increase O
the O
incidence O
of O
puberty B-outcome ['Physiological-Clinical']
during O
breeding O
of O
heifers O
that O
have O
inadequate O
yearling O
weight O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Conclusions O
and O
Relevance: O
Among O
patients O
undergoing O
THA, O
paracetamol O
plus O
ibuprofen O
significantly O
reduced O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
compared O
with O
paracetamol O
alone O
in O
the O
first O
24 O
hours O
after O
surgery; O
there O
was O
no O
statistically O
significant O
increase O
in O
SAEs B-outcome ['Adverse-effects']
in O
the O
pooled O
groups O
receiving O
ibuprofen O
alone O
vs O
with O
paracetamol O
alone. O
[['Resource-use'], ['Adverse-effects']]

More O
educated O
women O
and O
those O
with O
higher O
perceived O
risk O
were O
more O
likely O
to O
engage O
in O
leisure B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
and O
married O
women O
were O
less O
likely O
. O
['Life-Impact']

Because O
of O
its O
high O
spontaneous O
regression O
rate O
, O
follow-up O
could O
be O
considered O
as O
a O
management O
option O
of O
CIN2 O
in O
young O
and O
compliant O
women O
. O
[]

All O
side O
effects O
resolved O
spontaneously O
after O
termination O
of O
treatment O
. O
[]

The O
clinical O
relevance O
is O
uncertain O
. O
[]

All O
patients O
, O
irrespective O
of O
training O
form O
, O
were O
able O
to O
exercise O
to O
maximal O
intensity O
( O
80-90 O
% O
of O
estimated O
maximal O
heart O
rate O
) O
. O
[]

While O
a O
chinstrap O
prevents O
the O
mouth O
from O
opening O
during O
sleep O
, O
its O
efficacy O
in O
diminishing O
mouth O
leak O
has O
not O
been O
studied O
. O
[]

The O
No O
Pres O
group O
had O
similar O
cardiac B-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
after O
exercise O
because O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
( O
P O
< O
.005 O
by O
rm O
ANOVA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intranasal O
application O
of O
oxytocin O
( O
OT O
) O
has O
been O
shown O
to O
influence O
behavioral B-outcome ['Life-Impact']
and O
neural O
correlates O
of O
social B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Similar O
data O
were O
obtained O
when O
comparing O
GH O
area O
under O
the O
curve O
after O
GHRH O
plus O
saline O
or O
GHRH O
plus O
arginine O
between O
the O
2 O
groups O
. O
[]

Compared O
with O
the O
treatment O
group O
, O
( O
1 O
) O
control O
group O
members O
were O
less O
likely O
to O
receive B-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
services I-outcome ['Life-Impact']
at O
all O
( O
despite O
being O
authorized O
for O
them O
) O
, O
and O
( O
2 O
) O
service O
recipients O
received O
a O
lower O
proportion O
of O
the O
amount O
of O
['Life-Impact']

Our O
data O
confirm O
that O
the O
rFeIFN-omega O
can O
exert O
a O
significant O
therapeutic O
effect O
on O
dogs O
with O
parvoviral O
enteritis O
by O
improving O
clinical O
signs O
and O
reducing O
mortality O
. O
[]

We O
tested O
the O
hypothesis O
that O
calcium O
supplementation O
may O
improve O
bone B-outcome ['Physiological-Clinical']
accrual I-outcome ['Physiological-Clinical']
in O
premenarcheal O
females O
. O
['Physiological-Clinical']

Moderate O
CRI O
is O
defined O
as O
estimated O
glomerular O
filtration O
rate O
( O
GFR O
) O
of O
30 O
to O
59.9 O
mL/min/1.73 O
m2 O
at O
baseline O
. O
[]

[ O
Treatment O
of O
primary O
osteoporosis O
with O
calcium O
and O
salmon O
calcitonin O
] O
. O
[]

OBJECTIVE O
To O
describe O
the O
process O
and O
results O
of O
diet O
standardization O
, O
diet O
validation O
, O
and O
monitoring O
of O
diet O
composition O
, O
which O
were O
key O
components O
of O
protocol O
1 O
of O
Dietary O
Effects O
on O
Lipoproteins O
and O
Thrombogenic O
Activity O
( O
DELTA-1 O
) O
, O
the O
initial O
protocol O
in O
a O
program O
of O
multicenter O
human O
feeding O
studies O
designed O
to O
evaluate O
the O
effects O
of O
amount O
and O
type O
of O
fat O
on O
lipoproteins O
and O
hemostasis O
parameters O
in O
various O
demographic O
groups O
. O
[]

In O
as-treated O
analyses, O
participants O
in O
the O
decolonization O
group O
who O
adhered O
fully O
to O
the O
regimen O
had O
44% O
fewer O
MRSA B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
than O
the O
education O
group O
(hazard O
ratio, O
0.56; O
95% O
CI, O
0.36 O
to O
0.86) O
and O
had O
40% O
fewer O
infections B-outcome ['Physiological-Clinical']
from O
any O
cause O
(hazard O
ratio, O
0.60; O
95% O
CI, O
0.46 O
to O
0.78). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal-Name:BMC O
public O
health O
[]

Controlled O
studies O
of O
fluvoxamine O
and O
other O
potent O
and O
selective O
serotonin O
uptake O
inhibitors O
seem O
warranted O
in O
children O
and O
adolescents O
with O
autism O
. O
[]

To O
this O
end, O
we O
tested O
the O
effects O
of O
two O
commercially-available O
drinks O
on O
strength O
in O
a O
field-based O
setting O
with O
both O
male O
and O
female O
high O
school O
athletes O
completing O
a O
summer O
training O
program. O
[]

Residual O
stenosis O
of O
the O
infarct-related B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
shown I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
predischarge I-outcome ['Physiological-Clinical']
angiography I-outcome ['Physiological-Clinical']
was O
43.8 O
+/- O
31.4 O
% O
for O
the O
angioplasty O
group O
and O
75.0 O
+/- O
15.6 O
% O
for O
the O
streptokinase O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Low O
power O
laser O
therapy O
of O
shoulder O
tendonitis O
. O
[]

INTERVENTIONS O
Prior O
to O
randomization O
, O
subjects O
entered O
a O
1-week O
test-dose O
phase O
in O
which O
each O
subject O
received O
placebo O
for O
1 O
day O
followed O
by O
increasing O
doses O
of O
methylphenidate O
( O
low O
, O
medium O
, O
and O
high O
doses O
) O
that O
were O
each O
given O
for O
2 O
days O
. O
[]

The O
necessity O
of O
luteal-phase O
supplementation O
in O
an O
IVF O
programme O
is O
of O
continuing O
interest O
. O
[]

As O
a O
comparison O
control, O
26 O
advanced O
colorectal O
cancer O
patients O
with O
comparable O
clinical O
baseline O
characteristics O
including O
age, O
sex, O
Eastern O
Cooperative O
Oncology O
Group O
(ECOG) O
score, O
pathological O
type, O
carcinoembryonic O
antigen O
(CEA) O
level, O
tumor O
location, O
number O
and O
location(s) O
of O
metastasis, O
and O
previous O
chemotherapies O
were O
subject O
to O
observation. O
[]

These O
results O
suggest O
that O
latanoprost O
stored O
at O
30 O
degrees O
C O
for O
4 O
[]

OBJECTIVE O
Intraoperative O
comfort O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
during O
surgical O
procedures O
under O
regional O
anaesthesia O
can O
be O
improved O
with O
the O
use O
of O
supplemental O
intravenous O
sedation O
. O
['Life-Impact']

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
the O
appropriate B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
and O
needle O
location O
for O
the O
diagnosis O
of O
a O
traumatic O
knee O
arthrotomy O
and O
to O
assess O
the O
effect O
of O
associated O
variables O
, O
including O
knee O
circumference O
, O
body O
mass O
index O
, O
and O
sex O
. O
['Physiological-Clinical']

Thirty-seven O
platinum-resistant O
and O
27 O
platinum-sensitive O
tumours O
were O
treated O
with O
carboplatin O
or O
cisplatin O
as O
second-line O
therapy O
. O
[]

This O
longer-duration O
study O
includes O
a O
broad O
sample O
. O
[]

[ O
Long-term O
treatment O
of O
cerebrovascular O
changes O
in O
the O
elderly O
( O
author O
's O
transl O
) O
] O
. O
[]

METHODS O
LSCLC O
patients O
received O
2 O
cycles O
of O
etoposide O
and O
cisplatin O
( O
EP O
) O
induction O
chemotherapy O
and O
were O
randomly O
assigned O
to O
receive O
TRT O
to O
either O
the O
post- O
or O
pre-chemotherapy O
tumor O
extent O
( O
GTV-T O
) O
as O
study O
arm O
and O
control O
arm O
, O
CTV-N O
included O
the O
positive O
nodal O
drainage O
area O
for O
both O
arms O
. O
[]

Twenty O
memory-impaired O
patients O
, O
all O
of O
whom O
had O
been O
diagnosed O
as O
suffering O
from O
a O
memory O
impairment O
following O
acquired O
brain O
damage O
, O
participated O
as O
the O
memory-impaired O
control O
group O
. O
[]

Autism-Spectrum O
Quotient-Japanese O
version O
and O
its O
short O
forms O
for O
screening O
normally O
intelligent O
persons O
with O
pervasive O
developmental O
disorders O
. O
[]

The O
number O
needed O
to O
treat O
to O
avert O
one O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
was O
8.4. O
[['Mortality']]

Respiratory B-outcome ['Physiological-Clinical']
and O
cardiovascular B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
preserved O
, O
and O
the O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
periods O
of O
drowsiness B-outcome ['Physiological-Clinical']
or O
sleep B-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
changes O
in O
RBC B-outcome ['Physiological-Clinical']
EPA I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
were O
inversely O
correlated O
with O
the O
changes O
in O
SBP B-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
and O
directly O
correlated O
with O
the O
increases O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Major B-outcome ['Physiological-Clinical']
hemorrhagic I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
occurred O
more O
frequently O
in O
the O
WASA O
group O
( O
WASA O
, O
n O
= O
35 O
; O
ASA O
, O
n O
= O
15 O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical']

Randomised O
placebo-controlled O
trial O
of O
rhesus-human O
reassortant O
rotavirus O
vaccine O
for O
prevention O
of O
severe B-outcome ['Physiological-Clinical']
rotavirus I-outcome ['Physiological-Clinical']
gastroenteritis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Their O
performance O
pre O
and O
post O
intervention O
was O
assessed O
by O
four O
independent O
raters O
using O
a O
scale O
that O
included O
evaluation O
of O
both O
Content O
and O
Delivery B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Interventions: O
Participants O
were O
randomized O
to O
receive O
paracetamol O
(acetaminophen) O
1000 O
mg O
plus O
ibuprofen O
400 O
mg O
(n O
= O
136; O
PCM O
+ O
IBU), O
paracetamol O
1000 O
mg O
plus O
matched O
placebo O
(n O
= O
142; O
PCM), O
ibuprofen O
400 O
mg O
plus O
matched O
placebo O
(n O
= O
141; O
IBU), O
or O
half-strength O
paracetamol O
500 O
mg O
plus O
ibuprofen O
200 O
mg O
(n O
= O
140; O
HS-PCM O
+ O
IBU) O
orally O
every O
6 O
hours O
for O
24 O
hours O
postoperatively, O
starting O
1 O
hour O
before O
surgery. O
[]

METHODS O
Fifty-nine O
children O
, O
aged O
3-5 O
years O
, O
with O
no O
cerebral O
palsy O
, O
participated O
in O
the O
study O
. O
[]

As O
a O
result O
of O
our O
study O
, O
caution O
seems O
to O
be O
necessary O
if O
acylaminopenicillins O
are O
administered O
in O
the O
early O
postoperative O
period O
. O
[]

RESULTS O
The O
potassium O
titanyl O
phosphate O
laser O
group O
showed O
a O
slightly O
longer O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
mean O
12 O
minutes O
) O
than O
the O
bipolar O
radiofrequency O
group O
( O
mean O
10 O
minutes O
) O
. O
['Life-Impact']

There O
were O
no O
differences O
in O
clinical O
or O
immune O
responses O
between O
the O
treatment O
groups O
. O
[]

UNLABELLED O
Clonidine O
premedication O
reduces O
the O
intraoperative O
requirement O
for O
opioids O
and O
volatile O
anesthetics O
. O
[]

Ratings O
of O
videotapes B-outcome ['Physiological-Clinical']
significantly O
differed O
from O
live B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
data O
showed O
that O
Xuezhikang O
therapy O
resulted O
in O
significant O
reductions O
in O
total O
cholesterol B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TC I-outcome ['Physiological-Clinical']
, O
19 O
% O
) O
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( O
26 O
% O
) O
, O
and O
triglycerides B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
compared O
with O
baseline O
( O
16 O
% O
, O
p O
< O
0.01 O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
calcium O
pre-treatment O
study O
arm O
. O
['Adverse-effects']

Argon O
laser O
trabeculoplasty O
is O
an O
effective O
adjunct O
in O
managing O
to O
control O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
black O
Jamaican O
glaucoma O
patients O
. O
['Physiological-Clinical']

Ten O
children O
were O
trained O
on O
theory O
of O
mind O
, O
whilst O
ten O
were O
trained O
in O
executive O
function O
. O
[]

Exercise B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
in O
atrial O
fibrillation O
: O
a O
substudy O
of O
the O
Sotalol-Amiodarone O
Atrial O
Fibrillation O
Efficacy O
Trial O
( O
SAFE-T O
) O
. O
['Life-Impact']

RESULTS O
The O
results O
show O
statistically O
significant O
differences O
between O
the O
intervention O
and O
control O
groups O
; O
intervention O
group O
participants O
had O
lower O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
levels I-outcome ['Life-Impact']
than O
control O
participants O
after O
the O
intervention O
. O
['Life-Impact']

The O
study O
was O
double O
blinded O
and O
the O
duration O
was O
14 O
mo O
, O
with O
supervised O
feeding O
of O
the O
micronutrient-enriched O
beverage O
. O
[]

RESULTS: O
Over O
17 O
months, O
53 O
patients O
were O
assessed O
for O
eligibility O
and O
36 O
(68%) O
were O
randomised O
(47% O
male; O
mean O
age O
36.9 O
[SD O
11.2 O
years); O
13 O
to O
HIIT, O
12 O
to O
MICT, O
and O
11 O
to O
control. O
[]

Lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
LBM B-outcome ['Physiological-Clinical']
) O
and O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
by O
dual O
energy O
x-ray O
absorptiometry O
, O
and O
total O
body O
water O
( O
TBW O
) O
was O
determined O
by O
bioelectrical O
impedance O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
To O
investigate O
if O
coadministration O
of O
enalapril O
alters O
the O
metabolic O
effect O
of O
glibenclamide O
by O
employing O
an O
euglycemic O
glucose-clamp O
technique O
in O
healthy O
volunteers O
. O
[]

RATIONALE O
AND O
OBJECTIVE O
Depression O
is O
a O
significant O
complication O
of O
stroke O
. O
[]

The O
level O
of O
activity O
has O
been O
assessed O
on O
the O
basis O
of O
a O
questionnaire O
and O
body O
posture O
assessments O
were O
done O
using O
a O
plumb O
line, O
pediscoliometer, O
digital O
inclinometer. O
[]

RESULTS O
After O
deconvolution O
of O
the O
data O
, O
the O
subjective O
( O
nurse O
perception O
) O
method O
of O
evaluation O
determined O
that O
the O
new O
dressing O
resulted O
in O
wound B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
in O
12.7 O
% O
more O
patients O
than O
did O
routine O
practice O
, O
but O
the O
blinded O
assessment O
method O
( O
based O
on O
the O
digital O
images O
) O
showed O
that O
routine O
practice O
was O
better O
by O
6.6 O
% O
. O
['Physiological-Clinical']

However O
, O
its O
clinical O
value O
, O
including O
anticipated O
size O
and O
duration O
of O
the O
treatment O
effects O
, O
remains O
largely O
unknown O
. O
[]

Incidences O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
comparable O
. O
['Adverse-effects']

On O
successive O
days O
, O
patients O
ingested O
one O
of O
the O
meals O
twice O
, O
followed O
by O
random O
assignment O
to O
3 O
h O
upright O
and O
3 O
h O
recumbent O
position O
. O
[]

Prostaglandins O
( O
PGs O
) O
of O
the O
E-type O
are O
potent O
vasodilators O
in O
most O
species O
and O
in O
most O
vascular O
beds O
. O
[]

OBJECTIVES O
To O
investigate O
the O
short-term O
effects O
of O
nonsurgical O
therapy O
( O
scaling O
and O
root O
planing O
, O
SRP O
) O
on O
the O
subgingival O
microbiota O
in O
chronic O
( O
CP O
) O
and O
aggressive O
( O
AP O
) O
periodontal O
disease O
. O
[]

BACKGROUND O
Technological O
innovations O
are O
often O
adopted O
before O
scientific O
comparison O
to O
an O
accepted O
standard O
. O
[]

Three O
attempts O
per O
nurse O
were O
allowed O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O
[]

Both O
dosage O
regimens O
of O
lamotrigine O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

Do O
ACE O
inhibitors O
improve O
the O
response O
to O
exercise B-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
in O
functionally O
impaired O
older O
adults O
? O
['Life-Impact']

Dofequidar O
fumarate O
( O
MS-209 O
) O
in O
combination O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
for O
patients O
with O
advanced O
or O
recurrent O
breast O
cancer O
. O
[]

OBJECTIVES O
To O
determine O
the O
effectiveness O
of O
around-the-clock O
( O
ATC O
) O
analgesic O
administration O
, O
with O
or O
without O
nurse O
coaching O
, O
compared O
with O
standard O
care O
with O
as O
needed O
( O
PRN O
) O
dosing O
in O
children O
undergoing O
outpatient O
tonsillectomy O
. O
[]

The O
cytochrome O
P450 O
probes O
caffeine O
( O
CYP1A2 O
) O
, O
tolbutamide O
( O
CYP2C9 O
) O
, O
and O
dextromethorphan O
( O
CYP2D6 O
) O
were O
administered O
as O
an O
oral O
cocktail O
prior O
to O
and O
7 O
days O
after O
oral O
clarithromycin O
( O
500 O
mg O
twice O
daily O
) O
administration O
to O
12 O
healthy O
male O
subjects O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
median O
duration O
of O
[]

To O
evaluate O
earlier O
observations O
, O
including O
our O
own O
, O
showing O
usefulness O
of O
vitamin O
C O
for O
managing O
the O
common O
cold O
, O
we O
performed O
a O
double-blind O
trial O
of O
vitamin O
C O
versus O
placebo O
in O
868 O
children O
. O
[]

The O
aim O
is O
to O
determine O
anxiety B-outcome ['Life-Impact']
and O
health-related B-outcome ['Physiological-Clinical']
( O
HR B-outcome ['Physiological-Clinical']
) O
-QoL O
and O
evaluate O
the O
burden O
of O
carrying O
a O
CER O
in O
general O
practice O
populations O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Study O
participants O
( O
N=170 O
) O
had O
a O
mean O
age O
of O
28.4 O
years O
( O
SD=9.6 O
; O
range O
18-60 O
) O
and O
formed O
a O
racially O
diverse O
group O
. O
[]

Consistent O
with O
previous O
research O
, O
increased O
age O
, O
female O
gender O
, O
and O
greater O
sun O
sensitivity O
were O
each O
independently O
associated O
with O
more O
sun B-outcome ['Life-Impact']
protective I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
leak O
occurred O
in O
8.3 O
% O
. O
[]

Repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
are O
a O
core O
symptom O
domain O
in O
autism O
that O
has O
been O
linked O
to O
alterations O
in O
the O
serotonin O
system O
. O
['Life-Impact']

Systemic O
hemodynamic B-outcome ['Physiological-Clinical']
data O
recorded O
by O
PRAM O
included O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
(SBP) I-outcome ['Physiological-Clinical']
and O
mean O
(MBP) O
blood O
pressure O
, O
stroke B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
index O
(SVI), O
cardiac B-outcome ['Physiological-Clinical']
index O
(CI), O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
index O
(SVRI), O
the O
maximal O
slope O
of O
systolic B-outcome ['Physiological-Clinical']
upstroke I-outcome ['Physiological-Clinical']
(dp/dtmax) O
and O
cardiac B-outcome ['Physiological-Clinical']
cycle I-outcome ['Physiological-Clinical']
efficiency O
(CCE) O
after O
sedation O
obtained, O
1, O
2, O
5 O
min O
after O
induction O
achieved, O
1, O
2, O
5 O
and O
10 O
min O
after O
intubation. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
vivo O
assessment O
of O
catheter-tip O
PO2 O
sensor O
: O
sampling O
lumen O
fabrication O
. O
[]

A O
prospective O
randomized O
study O
was O
carried O
out O
at O
the O
Detroit O
General O
Hospital O
over O
a O
two O
year O
period O
to O
evaluate O
methods O
of O
management O
in O
165 O
patients O
with O
colonic O
injuries O
. O
[]

4.0 O
years O
, O
9 O
females O
, O
[ O
Vdot O
] O
O O
( O
2 O
) O
max O
35.4 O
? O
[]

The O
impact O
of O
angiotensin O
II O
receptor O
blockade O
and O
the O
DASH O
diet O
on O
markers B-outcome ['Physiological-Clinical']
of O
endogenous O
fibrinolysis O
. O
['Physiological-Clinical']

INTRODUCTION O
Helicobacter O
pylori O
screening O
and O
treatment O
has O
been O
proposed O
as O
a O
cost-effective O
method O
of O
preventing O
gastric O
cancer O
. O
[]

After O
40 O
minutes O
, O
subjects O
were O
again O
given O
nicotine O
gum O
or O
placebo O
in O
cross-over O
fashion O
. O
[]

And O
the O
safety O
of O
berberine O
was O
assessed. O
[]

An O
in O
vitro O
study O
showed O
that O
Pentosan O
Polysulfate O
Sodium O
( O
PPS O
) O
had O
greater O
P-selectin O
blocking O
activity O
than O
heparin O
. O
[]

The O
treatment O
is O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

Single-dose O
pharmacokinetics O
of O
delavirdine O
mesylate O
and O
didanosine O
in O
patients O
with O
human O
immunodeficiency O
virus O
infection O
. O
[]

Journal O
ID: O
101215359 O
[]

Randomized O
Phase O
II O
trial O
assessing O
estramustine O
and O
vinblastine O
combination O
chemotherapy O
vs O
estramustine O
alone O
in O
patients O
with O
progressive O
hormone-escaped O
metastatic O
prostate O
cancer O
. O
[]

At O
the O
end O
of O
treatment O
86 O
% O
of O
patients O
in O
the O
CHOP O
arm O
had O
responded O
with O
58 O
% O
in O
CR O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
fall O
in O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
Ganda O
1.0/0.2 O
( O
8.87 O
mm O
Hg O
) O
and O
Timolol O
0.25 O
per O
cent O
( O
8.24 O
mm O
Hg O
) O
. O
['Physiological-Clinical']

METHODS O
Volunteers O
with O
H. O
pylori O
infection O
( O
by O
13C-urea O
breath O
test O
) O
were O
randomly O
assigned O
to O
2-week O
treatment O
regimens O
. O
[]

BACKGROUND O
Magnesium O
is O
one O
of O
the O
most O
important O
minerals O
in O
the O
body O
. O
[]

We O
did O
not O
find O
a O
significant O
effect O
of O
oral O
contraceptive O
administration O
on O
the O
disappearance B-outcome ['Physiological-Clinical']
rate O
of O
['Physiological-Clinical']

We O
hypothesized O
that O
perioperative O
micronutrient O
supplementation O
would O
augment O
antioxidant O
defenses O
, O
minimize O
muscle B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

The O
results O
suggested O
that O
such O
combined O
modality O
is O
worth O
further O
study O
. O
[]

METHODS O
The O
design O
of O
the O
study O
was O
a O
three-wave O
repeated O
measures O
with O
a O
between-subjects O
factor O
( O
treatment O
group O
) O
. O
[]

Compared O
with O
MAIs, O
lacunar O
infarction O
of O
SAI O
had O
lower O
risk O
of O
stroke B-outcome ['Physiological-Clinical']
recurrence O
(hazard O
ratio O
[HR] O
0.41, O
95% O
confidence O
interval O
[CI] O
0.21-0.80, O
P O
= O
0.009), O
but O
not O
in O
non-lacunar O
infarction O
of O
SAI O
(HR O
1.01, O
95% O
CI O
0.60-1.69, O
P O
= O
0.98). O
[['Physiological-Clinical']]

Oocyst O
excretion B-outcome ['Physiological-Clinical']
increased O
for O
the O
4 O
patients O
initially O
on O
placebo O
compared O
to O
a O
median O
decrease O
of O
128 O
x O
10 O
( O
6 O
) O
/24 O
h O
for O
the O
6 O
initially O
treated O
with O
drug O
( O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

15/28 O
TMJs O
( O
54 O
% O
) O
that O
had O
not O
been O
positioned O
changed O
the O
position O
of O
the O
disc O
from O
physiological O
to O
anterior O
disc O
derangement O
with O
and O
without O
reduction O
postoperatively O
. O
[]

This O
8-week O
trial O
includes O
four O
two-weekly O
standard O
doses O
of O
PZQ O
in O
the O
"intense O
treatment" O
intervention O
group O
and O
one O
standard O
dose O
of O
PZQ O
in O
the O
"standard O
treatment" O
control O
group. O
[]

Lack O
of O
benefit O
of O
a O
single O
dose O
of O
synthetic O
human O
secretin O
in O
the O
treatment O
of O
autism O
and O
pervasive O
developmental O
disorder O
. O
[]

Pharmacologic O
treatment O
is O
usually O
begun O
with O
nonopioid O
analgesics O
, O
most O
frequently O
acetaminophen O
. O
[]

Using O
the O
Quality O
Adjusted O
Life O
Year O
outcome, O
the O
intervention O
was O
not O
cost O
effective O
from O
an O
NHS/PSS O
perspective. O
[]

The O
maternal O
primary O
outcomes O
are O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
during O
the O
first O
3 O
hours O
after O
trial O
analgesia B-outcome ['Resource-use']
and O
specifically O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
after O
60 O
minutes O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

There O
was O
no O
difference O
between O
the O
two O
groups O
in O
the O
quantity O
of O
milk B-outcome ['Life-Impact']
taken I-outcome ['Life-Impact']
but O
the O
amounts O
taken O
lessened O
between O
6 O
and O
18 O
months O
of O
age O
. O
['Life-Impact']

METHODS O
We O
studied O
434 O
treated O
hypertensive O
patients O
whose O
home O
systolic O
blood O
pressure O
was O
135 O
mmHg O
or O
higher O
. O
[]

RESULTS O
Eighty-two O
patients O
were O
enrolled O
; O
41 O
( O
50 O
% O
) O
patients O
in O
group O
A O
and O
41 O
( O
50 O
% O
) O
patients O
in O
group O
B O
were O
evaluated O
. O
[]

It O
should O
be O
emphasized O
that O
we O
have O
not O
encountered O
any O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
with O
intravenous O
trivalent O
saccharose O
ferric O
oxide O
treatment O
. O
['Adverse-effects']

In O
the O
comprehensive O
and O
Weight O
Watchers-only O
groups O
, O
weight O
loss B-outcome ['Physiological-Clinical']
was O
significantly O
related O
to O
frequency O
of O
attendance O
at O
Weight O
Watchers O
meetings O
, O
and O
attendance O
was O
more O
frequent O
in O
the O
comprehensive O
group O
. O
['Physiological-Clinical']

Comparison O
of O
the O
in O
vitro O
and O
in O
vivo O
release O
of O
digoxin B-outcome ['Resource-use']
from O
four O
different O
soft O
gelatin O
capsule O
formulations O
. O
['Resource-use']

Title: O
Effectiveness O
of O
A O
Multifactorial O
Intervention O
in O
Increasing O
Adherence B-outcome ['Life-Impact']
to O
the O
Mediterranean O
Diet O
among O
Patients O
with O
Diabetes O
Mellitus O
Type O
2: O
A O
Controlled O
and O
Randomized O
Study O
(EMID O
Study). O
[['Life-Impact']]

Background O
& O
objectives: O
: O
Three O
doses O
of O
intermittent O
preventive O
treatment O
with O
sulphadoxine-pyrimethamine O
(IPTp-SP) O
has O
been O
adopted O
as O
the O
new O
recommendation O
for O
prevention O
of O
malaria B-outcome ['Physiological-Clinical']
in O
pregnancy. O
[['Physiological-Clinical']]

Title: O
To O
study O
the O
effect O
of O
high O
dose O
Atorvastatin O
40mg O
versus O
80mg O
in O
patients O
with O
dyslipidemia. O
[]

Parent-defined O
target O
symptoms O
respond O
to O
risperidone O
in O
RUPP O
autism O
study O
: O
customer O
approach O
to O
clinical O
trials O
. O
[]

METHODS O
The O
study O
was O
a O
prospective O
analysis O
of O
95 O
patients O
who O
underwent O
fluoroscopy O
guided O
TBLB O
over O
a O
two O
year O
period O
. O
[]

The O
measured O
volumes O
were O
compared O
with O
the O
volumes O
of O
57 O
radical O
prostatectomy O
specimens O
through O
Spearman O
's O
rank O
correlation O
coefficient O
and O
agreement O
tests O
. O
[]

INTERVENTION O
( O
S O
) O
Single-dose O
anastrozole O
at O
5 O
mg O
( O
n O
= O
39 O
) O
, O
10 O
mg O
( O
n O
= O
39 O
) O
, O
20 O
mg O
( O
n O
= O
39 O
) O
, O
or O
30 O
mg O
( O
n O
= O
38 O
) O
or O
a O
5-day O
course O
of O
CC O
at O
50 O
mg/d O
( O
n O
= O
39 O
) O
as O
starting O
doses O
. O
[]

A O
double-blind O
randomly O
controlled O
trial O
of O
one O
particular O
laxative O
, O
Senokot O
, O
used O
in O
moderate O
dosage O
, O
was O
carried O
out O
on O
a O
group O
of O
40 O
children O
with O
severe O
and O
persistent O
soiling O
and O
often O
with O
a O
history O
of O
faecal O
retention O
. O
[]

If O
BP B-outcome ['Physiological-Clinical']
was O
not O
controlled O
with O
either O
agent O
, O
chlorthalidone O
was O
added O
. O
['Physiological-Clinical']

BTX-A O
is O
thus O
a O
potential O
treatment O
option O
for O
patients O
with O
intractable O
DED. O
[]

They O
were O
equally O
divided O
the O
NES O
group O
and O
the O
sham O
group. O
[]

Thirty-nine O
( O
66 O
% O
) O
of O
the O
participants O
experienced O
urogenital B-outcome ['Physiological-Clinical']
AE I-outcome ['Physiological-Clinical']
judged O
as O
probably O
or O
possibly O
related O
to O
gel O
. O
['Physiological-Clinical']

CONTEXT O
Dipeptidyl O
peptidase O
4 O
( O
DPP-4 O
) O
inhibitors O
are O
proposed O
to O
lower O
blood O
glucose O
in O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
by O
prolonging O
the O
activity O
of O
the O
circulating O
incretins O
, O
glucose-dependent O
insulinotropic O
polypeptide O
( O
GIP O
) O
and O
glucagon-like O
peptide O
1 O
( O
GLP-1 O
) O
. O
[]

Differences O
between O
the O
two O
groups O
were O
significant O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Quality O
of O
life O
assessments O
were O
based O
on O
the O
standardized O
rhinoconjunctivitis B-outcome ['Physiological-Clinical']
quality O
of O
life O
questionnaire O
( O
RQLQ O
( O
S O
) O
) O
; O
completed O
weekly O
during O
the O
entire O
grass O
pollen O
season O
. O
['Physiological-Clinical']

The O
first O
study O
involving O
substance-abusing O
suicidal O
patients O
was O
an O
open-label O
trial O
conducted O
in O
the O
early O
1990s O
. O
[]

The O
average O
age O
in O
group O
A O
was O
66 O
years O
and O
in O
group O
B O
it O
was O
68 O
years O
. O
[]

This O
superiority O
proved O
to O
be O
independent O
of O
risk O
group O
. O
[]

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O
[]

A O
three-drug O
regimen O
comprising O
metronidazole O
, O
amoxycillin O
and O
omeprazole O
has O
been O
proposed O
as O
an O
alternative O
therapy O
. O
[]

Alpha O
interferon O
clinical O
trial O
for O
multiple O
sclerosis O
: O
design O
considerations O
. O
[]

Six O
patients O
died B-outcome ['Mortality']
of I-outcome ['Mortality']
infections I-outcome ['Mortality']
( O
A O
= O
four O
patients O
and O
C O
= O
two O
patients O
) O
. O
['Mortality']

The O
primary O
end O
point O
is O
a O
composite O
of O
incident O
or O
recurrent B-outcome ['Physiological-Clinical']
CVD I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
, O
that O
is O
, O
coronary B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
, O
cerebrovascular B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
odds O
ratios O
(95% O
CI) O
for O
gestational B-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
mellitus I-outcome ['Physiological-Clinical']
(GDM) I-outcome ['Physiological-Clinical']
and O
CMFCs O
in O
women O
with O
a O
high O
adherence O
were O
0.35((0.18(-)0.67), O
p O
= O
0.002) O
and O
0.23((0.11(-)0.48), O
p O
< O
0.001), O
respectively. O
[['Physiological-Clinical']]

The O
children O
with O
autism O
were O
overall O
better O
than O
the O
typically O
developing O
children O
at O
visual B-outcome ['Physiological-Clinical']
search I-outcome ['Physiological-Clinical']
, O
thus O
replicating O
demonstrations O
of O
superior O
discrimination O
in O
autism O
. O
['Physiological-Clinical']

Pathology O
parameters O
and O
adjuvant B-outcome ['Physiological-Clinical']
tamoxifen I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
a O
randomised O
premenopausal O
breast O
cancer O
trial O
. O
['Physiological-Clinical']

METHODS O
Before O
the O
experiment O
, O
72 O
rats O
were O
randomly O
allocated O
to O
receive O
HBO O
or O
air O
treatment O
. O
[]

STUDY O
OBJECTIVE O
To O
compare O
the O
intraoperative O
conditions O
and O
postoperative O
recovery O
of O
patients O
following O
the O
use O
of O
either O
propofol-nitrous O
oxide O
( O
N2O O
) O
or O
enflurane-N2O O
for O
maintenance O
of O
outpatient O
anesthesia O
. O
[]

The O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
3.8 O
months O
in O
arm O
A O
and O
5.8 O
months O
in O
arm O
B O
. O
['Physiological-Clinical']

In O
experimental O
group O
one, O
a O
15-minute O
trial O
of O
pelvis O
reposition O
exercise O
was O
carried O
out. O
[ O
[]

However O
, O
in O
experimental O
studies O
hypercapnia O
impairs O
myocardial O
contractility O
and O
hemodynamic O
function O
. O
[]

From O
this O
study O
there O
emerged O
the O
value O
of O
combined O
therapy O
using O
doxorubicine O
as O
much O
because O
of O
the O
frequency O
with O
which O
results O
better O
than O
50 O
% O
were O
obtained O
( O
in O
a O
randomised O
trial O
) O
as O
by O
their O
quality B-outcome ['Life-Impact']
, O
which O
was O
made O
clear O
in O
an O
important O
series O
of O
240 O
cases O
. O
['Life-Impact']

In O
the O
indomethacin O
group O
( O
n O
= O
89 O
) O
, O
77 O
patients O
( O
87 O
% O
) O
showed O
no O
HO O
, O
9 O
showed O
HO O
of O
grade O
1 O
and O
3 O
showed O
HO B-outcome ['Physiological-Clinical']
of O
grade O
2 O
according O
to O
the O
Brooker O
classification O
. O
['Physiological-Clinical']

Children O
were O
randomly O
assigned O
to O
one O
of O
three O
conditions O
: O
intervention O
for O
child O
only O
, O
intervention O
for O
child O
and O
parent O
, O
wait-list O
control O
. O
[]

However O
, O
this O
effect O
lasts O
only O
12 O
hours O
without O
reducing O
the O
morphine B-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
due O
to O
an O
increase O
of O
pain O
from O
the O
primary O
surgical O
site O
. O
['Life-Impact']

CONCLUSION O
Nerve O
monitoring O
aids O
in O
the O
visualization O
of O
the O
EBSLN B-outcome ['Physiological-Clinical']
during O
mini-incision O
thyroidectomy O
under O
local/regional O
anesthesia O
and O
leads O
to O
an O
improvement O
in O
patient-assessed O
['Physiological-Clinical']

BACKGROUND O
Colon O
cancer O
is O
curable O
by O
surgery O
, O
but O
cure O
rate O
depends O
on O
the O
extent O
of O
disease O
. O
[]

In O
patients O
with O
induced O
AF O
the O
mean O
voltage B-outcome ['Physiological-Clinical']
for O
the O
low-tilt O
waveform O
was O
91V O
( O
1.6 O
J O
) O
and O
for O
the O
conventional O
waveform O
was O
158 O
V O
( O
2.0 O
J O
) O
( O
P O
= O
0.005 O
for O
voltage O
, O
P O
= O
ns O
for O
energy O
) O
. O
['Physiological-Clinical']

In O
a O
limited O
study O
of O
adhesion O
molecule O
expression O
, O
down-regulation O
of O
E-selectin B-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule-1 I-outcome ['Physiological-Clinical']
was O
observed O
after O
treatment O
with O
IL-1Ra O
150 O
mg/day O
, O
but O
not O
after O
IL-1Ra O
30 O
mg/day O
or O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Nuclear O
medicine O
laboratory O
in O
a O
university-affiliated O
hospital O
. O
[]

Abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
was O
assessed O
by O
acetaminophen B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
AND O
METHODS O
The O
HERA O
study O
( O
Hyperium O
Effect O
on O
the O
sympathetic O
Reflex O
activation O
and O
Adrenaline O
) O
is O
a O
randomised O
, O
double-blind O
, O
6-week O
cross-over O
trial O
, O
with O
a O
1-week O
placebo O
run-in O
period O
, O
two O
2-week O
active O
treatment O
intervals O
( O
rilmenidine O
1 O
mg O
bid O
, O
placebo O
) O
and O
intervening O
one O
week O
placebo O
wash-out O
. O
[]

This O
report O
summarizes O
the O
entire O
blinded O
treatment O
period O
, O
which O
ended O
on O
January O
31 O
, O
1996 O
. O
[]

Multitomographic O
radiographs O
were O
taken O
before O
( O
T0 O
) O
and O
at O
the O
end O
( O
T1 O
) O
of O
expansion O
while O
the O
patients O
were O
wearing O
an O
acrylic O
mandibular O
appliance O
in O
which O
ball O
bearings O
and O
bars O
were O
embedded O
. O
[]

No O
significant O
differences O
were O
found O
between O
the O
sclerotherapy O
and O
ligation O
groups O
in O
arresting O
active B-outcome ['Life-Impact']
index O
bleeding B-outcome ['Physiological-Clinical']
( O
100 O
% O
each O
) O
and O
achieving B-outcome ['Life-Impact']
variceal B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
( O
91.7 O
% O
vs. O
96 O
% O
, O
P O
=.61 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

The O
experimental O
acupuncture O
treatment O
consisted O
of O
specific O
acupuncture O
body O
points O
related O
to O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Continuous O
hemofiltration O
or O
hemodiafiltration O
is O
the O
representative O
technology O
. O
[]

Improved O
prognostic O
risk O
stratification O
may O
assist O
in O
the O
design O
of O
future O
trials O
and O
in O
patient O
management O
. O
[]

N-9 O
concentration O
in O
the O
gel O
( O
2.5 O
% O
or O
5.0 O
% O
) O
was O
not O
related O
to O
the O
findings O
. O
[]

METHODS: O
This O
study O
was O
designed O
as O
a O
randomized, O
double-blind, O
sham O
control O
trial. O
[]

The O
authors O
studied O
39 O
patients O
being O
treated O
with O
high O
flux O
dialysis O
. O
[]

Median O
( O
interquartile O
range O
) O
PD20 O
in O
the O
three O
groups O
before O
and O
after O
treatment O
with O
clarithromycin O
were O
: O
arm O
A O
: O
0.3 O
( O
0.1-1 O
) O
and O
1.3 O
( O
0.6-2 O
) O
mg O
; O
arm O
B O
: O
0.4 O
( O
0.1-0.9 O
) O
and O
2 O
( O
2-2 O
) O
mg O
; O
and O
arm O
C O
: O
0.4 O
( O
0.1-0.9 O
) O
and O
0.3 O
( O
0.1-0.6 O
) O
mg O
, O
respectively O
. O
[]

Title: O
Effects O
of O
ascorbic O
acid O
supplementation O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
markers O
in O
healthy O
women O
following O
a O
single O
bout O
of O
exercise. O
[['Physiological-Clinical']]

The O
maximum O
observed O
plasma B-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
actual O
C O
( O
max O
) O
) O
and O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
actual I-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
actual I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
, O
and O
pharmacokinetic O
modeling O
was O
used O
to O
calculate O
model O
C O
( O
max O
) O
and O
model O
T O
( O
max O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
nine O
control O
patients O
, O
there O
were O
no O
significant O
changes O
in O
the O
severity O
of O
OSA B-outcome ['Physiological-Clinical']
, O
MSNA B-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
or O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forty-five O
patients O
with O
cured O
or O
possibly O
cured O
HCC O
were O
randomly O
selected O
, O
assigning O
patients O
to O
treatment O
( O
n=21 O
) O
or O
control O
group O
( O
n=24 O
) O
with O
randomization O
list O
. O
[]

Short-term O
metformin O
treatment O
for O
clomiphene O
citrate-resistant O
women O
with O
polycystic O
ovary O
syndrome O
. O
[]

Here O
, O
we O
report O
results O
of O
a O
double-blind O
, O
randomized O
placebo-controlled O
phase O
II O
study O
designed O
to O
test O
the O
hypothesis O
that O
acute O
graft-versus-host O
disease O
could O
be O
prevented O
by O
administration O
of O
oral O
BDP O
, O
beginning O
before O
hematopoietic O
cell O
transplantation O
and O
continuing O
until O
day O
75 O
after O
hematopoietic O
cell O
transplantation O
after O
myeloablative O
conditioning O
. O
[]

Testosterone O
administered O
alone O
or O
in O
combination O
with O
progestogens O
in O
male O
contraception O
induces O
reversible O
oligo-azoospermia O
, O
but O
its O
effects O
on O
body O
composition O
and O
metabolism O
are O
less O
known O
. O
[]

The O
goal O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
mild O
exercise O
training O
or O
statin O
therapy O
on O
forearm O
endothelial O
function O
in O
CAD O
patients O
with O
average O
cholesterol O
levels O
. O
[]

Mean O
final O
dosages O
were O
7.9+/-2.5 O
mg/day O
for O
olanzapine O
and O
1.4+/-0.7 O
mg/day O
for O
haloperidol O
. O
[]

METHODS O
AND O
RESULTS O
We O
investigated O
the O
effects O
of O
a O
disease O
management O
program O
with O
repetitive O
education O
and O
telephone O
monitoring O
on O
primary O
( O
combined O
death B-outcome ['Mortality']
or O
unplanned B-outcome ['Resource-use']
first I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
and O
quality-of-life B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
) O
and O
secondary O
end O
points O
( O
hospitalization B-outcome ['Resource-use']
, O
death B-outcome ['Mortality']
, O
and O
adherence B-outcome ['Life-Impact']
) O
. O
['Mortality', 'Resource-use', 'Life-Impact', 'Resource-use', 'Mortality', 'Life-Impact']

There O
were O
no O
significant O
differences O
in O
terms O
of O
cumulative O
rate O
of O
union B-outcome ['Physiological-Clinical']
( O
p=0.855 O
) O
, O
range O
of O
motion B-outcome ['Physiological-Clinical']
of O
the O
knee B-outcome ['Physiological-Clinical']
( O
p=0.727 O
) O
, O
overall O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
The O
participants O
were O
randomized O
into O
two O
groups O
, O
to O
receive O
pills O
containing O
ethynylestradiol O
( O
EE O
) O
30 O
mcg O
and O
levonorgestrel O
( O
LNG O
) O
150 O
mcg O
or O
EE O
20 O
mcg O
and O
LNG O
100 O
mcg O
, O
for O
six O
cycles O
. O
[]

It O
is O
currently O
unknown O
whether O
migraine O
patients O
who O
can O
not O
be O
adequately O
helped O
with O
triptans O
might O
benefit O
from O
treatment O
with O
telcagepant O
. O
[]

We O
attempted O
to O
verify O
whether O
topical O
periarterial O
capsaicin O
could O
ameliorate O
pain O
in O
absence O
of O
and O
during O
a O
migraine B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
estimated O
reduction O
in O
mean O
post-treatment B-outcome ['Physiological-Clinical']
eggs I-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
gram I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
feces I-outcome ['Physiological-Clinical']
relative O
to O
placebo O
was O
63 O
% O
( O
95 O
% O
CI O
30-81 O
% O
) O
for O
triple O
mebendazole O
, O
75 O
% O
( O
47-88 O
% O
) O
for O
single O
albendazole O
, O
and O
88 O
% O
( O
58-97 O
% O
) O
for O
triple O
albendazole O
. O
['Physiological-Clinical']

The O
results O
of O
this O
trial O
clearly O
support O
the O
plan O
to O
integrate O
simulator O
training O
into O
endoscopic O
education O
curricula O
. O
[]

RESULTS O
No O
significant O
differences O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
rate-pressure O
product O
, O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
index O
were O
observed O
between O
the O
sedated O
and O
non-sedated O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
The O
Family O
Received O
Index O
is O
the O
proportion O
of O
all O
procedures O
for O
which O
a O
family O
was O
overdue O
that O
they O
received O
. O
[]

II O
. O
[]

Of O
21 O
patients O
with O
bladder O
recurrence O
, O
17 O
had O
recurrent B-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
around I-outcome ['Physiological-Clinical']
cystotomy I-outcome ['Physiological-Clinical']
or O
in O
the O
bladder B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
compromised O
by O
the O
urethral O
catheter O
, O
supporting O
the O
notion O
that O
tumor O
cells O
seeded O
in O
the O
injured O
urothelium O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Startle O
pathways O
may O
contribute O
to O
rapid O
accomplishment O
of O
postural O
stability O
. O
[]

The O
reocclusion B-outcome ['Physiological-Clinical']
rates O
were O
7.3 O
% O
and O
8.2 O
% O
, O
respectively O
( O
P O
= O
1.00 O
) O
. O
['Physiological-Clinical']

The O
present O
study O
examined O
which O
other O
working O
memory O
components O
( O
visual O
, O
spatial O
, O
and O
phonological O
) O
influence O
visual B-outcome ['Life-Impact']
selective I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
. O
['Life-Impact']

As O
the O
comparatively O
few O
cases O
made O
it O
risky O
to O
associate O
certain O
predictors O
with O
certain O
time-points O
, O
we O
finally O
considered O
the O
predictors O
which O
were O
represented O
in O
at O
least O
3 O
follow-ups O
. O
[]

Isoflavone B-outcome ['Physiological-Clinical']
concentrations B-outcome ['Physiological-Clinical']
were O
inversely O
associated O
with O
risk O
of O
fibroadenomas B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
ApoA-I O
Synthesis O
Stimulation O
and O
Intravascular O
Ultrasound O
for O
Coronary O
Atheroma O
Regression O
Evaluation O
( O
ASSURE O
, O
NCT01067820 O
) O
study O
aims O
to O
evaluate O
the O
effect O
of O
RVX-208 O
on O
plaque O
burden O
. O
[]

These O
results O
indicate O
that O
polyphenol-rich O
nutrient O
supplementation O
by O
means O
of O
dark O
chocolate O
positively O
modulates O
redox B-outcome ['Physiological-Clinical']
status O
and O
reduced O
exercise-induced O
muscular B-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
biomarkers O
in O
elite O
football O
athletes. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Severe O
enteropathy O
among O
patients O
with O
stage O
II/III O
colon O
cancer O
treated O
on O
a O
randomized O
trial O
of O
bolus O
5-fluorouracil/leucovorin O
plus O
or O
minus O
oxaliplatin O
: O
a O
prospective O
analysis O
. O
[]

Of O
these O
5 O
tasks O
, O
the O
coin-in-the-hand O
, O
when O
administered O
in O
conjunction O
with O
the O
autobiographical O
interview O
, O
identified O
95 O
per O
cent O
of O
the O
simulators O
without O
misclassifying O
any O
of O
the O
memory-impaired O
or O
normal O
participants O
. O
[]

Dedicated O
glucometer O
measurement O
of O
arterial O
glucose O
values O
was O
calibrated O
daily O
to O
values O
measured O
in O
the O
laboratory O
. O
[]

Ethanol O
choosers O
were O
also O
more O
likely O
to O
be O
males O
and/or O
full-time O
students O
than O
non-choosers O
. O
[]

It O
was O
anticipated O
that O
the O
relationship O
between O
milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
and O
ODR O
was O
unlikely O
to O
be O
linear O
, O
so O
fractional O
polynomials O
were O
applied O
to O
the O
continuous O
ODR B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVE O
Controversies O
exists O
with O
regard O
to O
target O
volumes O
as O
far O
as O
thoracic O
radiotherapy O
( O
TRT O
) O
is O
concerned O
in O
the O
multimodality O
treatment O
for O
limited-stage O
small O
cell O
lung O
cancer O
( O
LSCLC O
) O
. O
[]

Renal O
plasma O
flow O
and O
MSA O
increased O
significantly O
during O
the O
insulin O
clamp O
, O
whereas O
renal O
NE O
and O
total O
body O
NE O
spillover O
remained O
unchanged O
, O
suggesting O
nonuniform O
regional O
sympathetic O
nerve O
responses O
to O
acute O
hyperinsulinemia O
. O
[]

Comparison O
of O
the O
mean O
differences O
at O
the O
beginning O
and O
two O
months O
after O
the O
study O
in O
the O
two O
groups O
showed O
that O
the O
scores O
related O
to O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
dimensions O
in O
the O
experimental O
group O
were O
significantly O
greater O
than O
the O
control O
group O
(p</=0.05). O
[['Life-Impact']]

Effectiveness O
of O
hygienic-dietary O
recommendations O
as O
enhancers O
of O
antidepressant O
treatment O
in O
patients O
with O
depression O
: O
study O
protocol O
of O
a O
randomized O
controlled O
trial O
. O
[]

Twenty-five O
microgram O
tablets O
of O
misoprostol O
were O
placed O
in O
the O
posterior O
vaginal O
fornix O
every O
4 O
hours O
for O
a O
maximum O
of O
six O
doses O
. O
[]

Since O
the O
long-term O
prognosis O
for O
patients O
with O
congestive O
heart O
failure O
remains O
very O
poor O
and O
the O
incidence O
of O
arrhythmic O
death O
is O
high O
, O
every O
new O
drug O
to O
be O
employed O
against O
this O
disease O
should O
be O
thoroughly O
tested O
in O
order O
to O
rule O
out O
any O
possible O
arrhythmogenic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Incidence O
and O
clinical O
significance O
of O
false-negative O
sextant O
prostate O
biopsies O
. O
[]

Five O
patients O
had O
a O
relapse B-outcome ['Physiological-Clinical']
: O
four O
of O
these O
were O
in O
the O
group O
with O
no O
further B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Marginal O
benefit/disadvantage O
of O
granulocyte O
colony-stimulating O
factor O
therapy O
after O
autologous O
blood O
stem O
cell O
transplantation O
in O
children O
: O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

INTERVENTIONS O
Participants O
were O
initially O
randomized O
to O
either O
wait-list O
control O
( O
WLC O
) O
or O
treatment O
groups O
to O
receive O
either O
individualized O
CHM O
decoctions O
or O
a O
therapeutically O
inert O
placebo O
decoction O
. O
[]

The O
scores O
for O
the O
bispectral O
index O
may O
not O
reflect O
correct O
values O
in O
children O
, O
but O
may O
be O
helpful O
during O
titration O
of O
sedatives O
such O
as O
midazolam O
and O
ketamine O
. O
[]

METHODS O
In O
this O
randomised O
cross-over O
pilot O
study O
, O
participants O
performed O
a O
self-timed O
30 O
minute O
brisk O
walk O
in O
two O
different O
environments O
, O
park O
and O
urban O
, O
in O
Glasgow O
, O
Scotland O
( O
October O
2009 O
to O
January O
2010 O
) O
. O
[]

The O
effects O
of O
chloroquine O
( O
CQ O
) O
, O
amodiaquine O
( O
AQ O
) O
and O
CQ O
plus O
chlorpheniramine O
( O
a O
histamine O
H O
( O
1 O
) O
antagonist O
that O
reverses O
CQ O
resistance O
in O
vitro O
and O
in O
vivo O
) O
on O
the O
disposition O
of O
the O
enlarged O
liver O
associated O
with O
acute O
, O
symptomatic O
, O
uncomplicated O
, O
Plasmodium O
falciparum O
malaria O
were O
evaluated O
. O
[]

On O
each O
visit O
the O
participants O
consumed O
either O
a O
CA O
+ O
C O
(100 O
mg O
of O
CA O
and O
100 O
mg O
of O
C) O
or O
placebo O
(dextrose) O
capsule. O
[]

There O
were O
24 O
gastrointestinal B-outcome ['Physiological-Clinical']
AEs I-outcome ['Physiological-Clinical']
in O
the O
treatment O
arm O
compared O
with O
1 O
AE O
in O
the O
placebo O
arm O
. O
['Physiological-Clinical']

Patients O
with O
asymmetric O
diseases O
also O
were O
randomized O
for O
treatment O
in O
the O
threshold O
eye O
. O
[]

Follow-up O
through O
April O
, O
1993 O
shows O
that O
only O
14 O
patients O
have O
expired O
. O
[]

Failed O
insertion O
was O
classified O
as O
( O
i O
) O
failed O
passage O
into O
the O
pharynx O
, O
( O
ii O
) O
malposition O
, O
or O
( O
iii O
) O
ineffective O
ventilation O
. O
[]

A O
cognitive O
battery O
was O
administered O
to O
2,166 O
elderly O
persons O
after O
a O
median O
of O
6.9 O
years O
of O
treatment O
. O
[]

Journal O
ID: O
101521595 O
[]

MATERIALS O
AND O
METHODS O
Two O
groups O
of O
40 O
consecutive O
asymptomatic O
patients O
aged O
between O
48 O
and O
72 O
years O
underwent O
CT O
colonography O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Both O
coumarin O
( O
1,2-benzopyrone O
) O
and O
warfarin O
( O
4-hydroxycoumarin O
) O
have O
been O
shown O
to O
prevent O
the O
recurrence O
of O
malignant O
melanoma O
. O
[]

These O
effects O
of O
sleep O
deprivation O
are O
counteracted O
by O
the O
adenosine O
receptor O
antagonist O
caffeine O
, O
implying O
involvement O
of O
the O
adenosine O
neuromodulator/receptor O
system O
. O
[]

The O
main O
measure O
in O
the O
intervention O
group O
is O
individual B-outcome ['Life-Impact']
dietary I-outcome ['Life-Impact']
advice I-outcome ['Life-Impact']
aimed O
at O
reducing O
weight O
and O
intake O
of O
saturated O
fat O
and O
increasing O
intake O
of O
dietary O
fibre O
. O
['Life-Impact']

The O
statistically O
significant O
improvements O
from O
baseline O
in O
efficacy O
parameters O
observed O
for O
each O
tamsulosin O
group O
at O
the O
end O
of O
the O
13-week O
Phase O
III O
trial O
were O
maintained O
during O
the O
long-term O
extension O
phase O
. O
[]

The O
median O
follow-up O
time O
in O
the O
WP-CRT O
arm O
was O
21.7 O
months O
( O
range O
, O
10.7-37.4 O
months O
) O
, O
and O
in O
the O
WP-IMRT O
arm O
it O
was O
21.6 O
months O
( O
range O
, O
7.7-34.4 O
months O
) O
. O
[]

RESULTS O
We O
enrolled O
20 O
patients O
with O
a O
mean O
( O
SD O
) O
Acute B-outcome ['Physiological-Clinical']
Physiology I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
Chronic I-outcome ['Physiological-Clinical']
Health I-outcome ['Physiological-Clinical']
Evaluation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
APACHE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
score O
of O
32 O
( O
10.2 O
) O
; O
14 O
were O
insulin-dependent O
pre-ICU O
, O
and O
all O
were O
medical O
admissions O
. O
['Physiological-Clinical']

Inclusion O
criteria O
were O
known O
vascular O
disease O
or O
diabetes O
plus O
one O
other O
cardiovascular O
risk O
factor O
, O
exclusion O
criteria O
included O
heart O
failure O
or O
known O
impaired O
left O
ventricular O
function O
, O
dipstick-positive O
proteinuria O
( O
> O
1+ O
) O
, O
and O
serum O
creatinine O
> O
2.3 O
mg/dl O
( O
200 O
microM O
) O
. O
[]

Regarding O
overall O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
there O
was O
a O
significant O
difference O
between O
the O
NSAID O
group O
and O
the O
7 O
Gy O
group O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

0.4 O
; O
p O
= O
0.04 O
) O
and O
SILS O
patients O
reported O
better O
scars O
( O
score O
18.4 O
? O
[]

Bovine O
collagen O
is O
widely O
used O
as O
a O
dermal O
filler O
for O
facial O
soft-tissue O
augmentation O
, O
but O
it O
provides O
only O
temporary O
cosmetic O
improvement O
. O
[]

After O
an O
initial O
baseline O
, O
mothers O
were O
taught O
to O
implement O
RIT O
techniques O
with O
their O
child O
twice O
a O
week O
for O
10 O
weeks O
in O
a O
clinic O
setting O
. O
[]

Tumor-liver B-outcome ['Physiological-Clinical']
contrast I-outcome ['Physiological-Clinical']
was O
significantly O
different O
between O
protocols O
A O
and O
B O
( O
p O
= O
0.03 O
, O
p O
= O
0.02 O
) O
and O
protocols O
B O
and O
C O
( O
p O
= O
0.03 O
, O
p O
= O
0.04 O
) O
in O
the O
first O
and O
second O
phases O
but O
not O
between O
protocols O
A O
and O
C. O
There O
was O
no O
significant O
difference O
in O
hepatic B-outcome ['Physiological-Clinical']
enhancement I-outcome ['Physiological-Clinical']
among O
the O
three O
protocols O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
evaluate O
the O
safety O
and O
efficacy O
of O
initial O
treatment O
with O
imatinib O
mesylate O
800 O
mg/d O
( O
400 O
mg O
twice O
daily O
) O
versus O
400 O
mg/d O
in O
patients O
with O
newly O
diagnosed O
chronic O
myeloid O
leukemia O
in O
chronic O
phase O
. O
[]

Changes O
in O
body B-outcome ['Physiological-Clinical']
weight O
, O
total O
fat B-outcome ['Physiological-Clinical']
intake I-outcome ['Physiological-Clinical']
, O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
and O
potassium B-outcome ['Physiological-Clinical']
did O
not O
have O
significant O
predictive O
power O
in O
any O
of O
the O
analyses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Amisulpride O
versus O
bromocriptine O
in O
infantile O
autism O
: O
a O
controlled O
crossover O
comparative O
study O
of O
two O
drugs O
with O
opposite O
effects O
on O
dopaminergic O
function O
. O
[]

A O
significant O
reduction O
of O
61 O
% O
was O
seen O
within O
the O
first O
year O
( O
p O
= O
0.001 O
) O
. O
[]

CONCLUSIONS: O
A O
diet O
intervention O
that O
produced O
clinically O
relevant O
postpartum O
weight O
loss O
also O
resulted O
in O
increased O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
and O
was O
cost-effective. O
[['Life-Impact']]

OBJECTIVE O
To O
study O
whether O
an O
intravenous O
infusion O
dose O
of O
omeprazole O
( O
80 O
mg O
+ O
8 O
mg/h O
) O
during O
24 O
h O
can O
be O
subsequently O
reduced O
with O
maintained O
effect O
. O
[]

This O
dose O
was O
then O
maintained O
for O
4 O
weeks O
. O
[]

In O
PAN O
related O
to O
HBV O
: O
The O
first-line O
treatment O
should O
be O
the O
association O
of O
anti-viral O
agents O
and O
PE O
. O
[]

Indices O
of O
respiratory O
muscle O
strength O
, O
pulmonary O
function O
, O
and O
pulmonary O
diffusing O
capacity O
were O
measured O
in O
11 O
malnourished O
children O
( O
age O
10 O
to O
17 O
years O
) O
with O
cystic O
fibrosis O
, O
before O
and O
after O
improvement O
of O
nutritional O
status O
with O
supplemental O
parenteral O
nutrients O
for O
1 O
month O
. O
[]

AIM O
To O
measure O
the O
variations B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
delivered I-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
minute I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
inspiratory I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
during O
a O
3-min O
period O
of O
mask O
ventilation O
comparing O
VDMV O
with O
three O
commonly O
used O
hand-delivered O
methods O
of O
bag O
and O
mask O
ventilation O
: O
Laerdal O
self-inflating O
bag O
( O
SIB O
) O
; O
anaesthetic O
bag O
and O
T-piece O
Neopuff O
. O
['Physiological-Clinical']

METHOD: O
The O
double-blind O
study O
included O
20 O
members O
of O
the O
Polish O
Rowing O
Team. O
[]

RESULTS: O
menthol O
chewing O
gum O
significantly O
reduced O
the O
intensity O
(p O
<0.001), O
with O
Cohen's O
medium-effect O
d, O
and O
thirst B-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
(p O
<0.001), O
with O
a O
large-effect O
Cohen's O
d. O
CONCLUSION: O
menthol O
chewing O
gum O
was O
effective O
in O
reducing O
the O
intensity B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
discomfort B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
preoperative I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
thirst E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
The O
strategy O
proved O
to O
be O
an O
innovative, O
feasible B-outcome ['Life-Impact']
and O
safe O
option O
in O
the O
use O
for O
the O
surgical O
patient, O
in O
the O
management O
of O
the O
preoperative O
thirst, O
in O
elective O
surgeries. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Life-Impact']]

The O
intensity O
of O
chemotherapy B-outcome ['Resource-use']
was O
not O
considered O
to O
significantly O
differ O
between O
the O
two O
groups O
, O
though O
the O
chemotherapy O
regimens O
administered O
differed O
slightly O
. O
['Resource-use']

In O
contrast O
, O
there O
were O
no O
improvements O
in O
the O
control O
group O
. O
[]

BACKGROUND O
Transfer O
factor O
of O
the O
lung B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
monoxide I-outcome ['Physiological-Clinical']
( O
TLCO B-outcome ['Physiological-Clinical']
) O
was O
measured O
by O
a O
new O
method O
based O
on O
analysis O
of O
the O
ratio O
of O
the O
concentrations O
of O
carbon O
monoxide O
to O
an O
inert O
gas O
( O
methane O
) O
relative O
to O
lung O
volume O
during O
a O
constant O
exhalation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Economic B-outcome ['Physiological-Clinical']
evaluation I-outcome ['Physiological-Clinical']
of O
a O
nursing-led O
inpatient O
unit O
: O
the O
impact O
of O
findings O
on O
management O
decisions O
of O
service O
utility O
and O
sustainability O
. O
['Physiological-Clinical']

Measurement O
of O
transfer B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
during O
constant O
exhalation O
. O
['Physiological-Clinical']

The O
Interceed B-outcome ['Physiological-Clinical']
( O
TC7 O
) O
-treated O
sidewalls O
also O
had O
significantly O
less O
area O
involved B-outcome ['Physiological-Clinical']
with O
adhesions B-outcome ['Physiological-Clinical']
at O
laparoscopy O
( O
P O
less O
than O
.05 O
, O
P O
less O
than O
.001 O
, O
and O
P O
less O
than O
.001 O
in O
the O
three O
groups O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Some O
of O
the O
patients O
lost O
follow-up O
. O
[]

After O
practice O
, O
half O
of O
the O
participants O
were O
immediately O
tested O
and O
the O
other O
half O
were O
tested O
after O
a O
7-day O
delay O
. O
[]

On O
the O
other O
hand O
, O
gagging B-outcome ['Physiological-Clinical']
occurred O
more O
frequently O
during O
oral O
endoscopy O
( O
6/9 O
vs O
1/9 O
, O
p O
= O
0.05 O
) O
. O
['Physiological-Clinical']

Clinical O
trials O
in O
chronic O
schizophrenic O
patients O
have O
shown O
trends O
in O
favor O
of O
risperidone O
in O
the O
control O
of O
negative O
symptoms B-outcome ['Life-Impact']
compared O
with O
haloperidol O
, O
perphenazine O
or O
zuclopenthixol O
, O
but O
the O
differences O
were O
not O
consistently O
statistically O
significant O
. O
['Life-Impact']

Title: O
White O
Sweet O
Potato O
as O
Meal O
Replacement O
for O
Overweight O
White-Collar O
Workers: O
A O
Randomized O
Controlled O
Trial. O
[]

RESULTS O
The O
average O
number O
of O
sessions B-outcome ['Life-Impact']
per O
stone O
was O
1.92 O
and O
1.5 O
and O
the O
average O
number O
of O
shocks B-outcome ['Physiological-Clinical']
per O
stone O
was O
6295 O
and O
5300 O
for O
the O
first O
and O
second O
treatment O
groups O
respectively O
. O
['Life-Impact', 'Physiological-Clinical']

Venous B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
moved O
parallel O
to O
ascitic B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
, O
and O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
, O
and O
urine B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
all O
improved O
sharply O
; O
then O
, O
as O
ascitic O
fluid O
continued O
to O
form O
, O
reducing O
vascular B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
urine O
flow O
, O
glomerular O
filtration O
rate O
, O
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
all O
decreased O
slowly O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Developmental O
disabilities O
modification O
of O
the O
Children O
's O
Global O
Assessment O
Scale O
. O
[]

Number O
of O
presentations O
of O
the O
standard O
never O
affected O
the O
proportion O
of O
identifications O
of O
the O
standard O
when O
it O
was O
presented O
, O
nor O
other O
features O
of O
the O
temporal O
generalization O
gradients O
observed O
. O
[]

Poor O
performance O
on O
the O
SAT O
was O
highly O
correlated O
with O
deficits O
in O
early O
processing O
, O
which O
were O
also O
related O
to O
poor O
performance O
on O
the O
Wechsler O
Memory O
Scale O
Attention/Concentration O
index O
. O
[]

A O
significant O
difference O
was O
found O
in O
the O
range O
of O
[]

The O
memory O
support O
system O
for O
mild O
cognitive O
impairment O
: O
randomized O
trial O
of O
a O
cognitive O
rehabilitation O
intervention O
. O
[]

Inclusion O
of O
lay O
knowledge O
and O
clarification O
of O
treatment O
decision O
processes O
increased O
patients O
' O
perception O
of O
involvement O
in O
disease O
management O
through O
increased O
identification O
and O
awareness O
of O
others O
' O
self-management O
experiences O
. O
[]

Monitoring O
of O
CA19-9 O
and O
SPan-1 O
can O
facilitate O
the O
earlier O
confirmation O
of O
progressing O
pancreatic O
cancer O
during O
chemotherapy O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
2 O
angiotensin O
II O
receptor O
blockers O
( O
olmesartan O
at O
20 O
mg/day O
or O
valsartan O
at O
80 O
mg/day O
) O
on O
coronary O
plaque O
by O
coronary O
intravascular O
ultrasound O
. O
[]

0.05 O
) O
. O
[]

However O
, O
fresh-start O
experiences O
, O
absence O
of O
new O
severe O
stressors O
and O
standard O
attachment O
style O
were O
more O
important O
predictors O
of O
remission O
. O
[]

METHODS O
In O
a O
double-blind O
study O
, O
20 O
patients O
undergoing O
lateral O
thoracotomy O
for O
lung O
resection O
were O
randomized O
to O
receive O
0.5 O
mg O
SM O
preoperatively O
and O
INB O
with O
bupivacaine O
( O
INB+ O
) O
prior O
to O
wound O
closure O
or O
0.5 O
mg O
SM O
with O
INB O
using O
saline O
( O
INB- O
) O
. O
[]

19.2 O
vs. O
42.24 O
? O
[]

OBJECTIVE O
A O
randomized O
, O
controlled O
trial O
of O
screening O
, O
brief O
intervention O
, O
and O
referral O
to O
treatment O
( O
SBIRT O
) O
for O
drinking O
and O
related O
problems O
among O
at-risk O
and O
dependent O
drinkers O
was O
conducted O
in O
an O
emergency O
department O
( O
ED O
) O
in O
Sosnowiec O
, O
Poland O
, O
among O
patients O
ages O
18 O
years O
and O
older O
. O
[]

DESIGN O
Randomized O
repeated O
measures O
experimental O
design O
. O
[]

DESIGN O
A O
randomized O
study O
of O
two O
methods O
of O
endocervical O
sampling O
. O
[]

A O
training O
study O
of O
theory O
of O
mind O
and O
executive O
function O
in O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

The O
3 O
year O
disease B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
63.4 O
% O
for O
the O
cisplatin O
group O
and O
60.9 O
% O
for O
the O
carboplatin O
group O
( O
p=0.9613 O
) O
( O
HR O
0.70 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
: O
0.50-0.98 O
) O
. O
['Mortality']

The O
compression-to-bag-valve O
ventilation O
ratio O
was O
15:2 O
. O
[]

Higher B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
associated O
with O
increased O
prevalence O
of O
female O
gender O
, O
greater O
calcium O
channel O
blocking O
agent O
, O
digoxin O
and O
diuretic O
use O
, O
lower O
heart O
rate O
and O
a O
higher O
rate O
of O
reported O
smoking O
history O
. O
['Physiological-Clinical']

Activity O
of O
the O
supplementary O
motor O
area O
may O
be O
inferred O
from O
movement-related O
potentials O
( O
MRPs O
) O
which O
are O
associated O
with O
the O
preparation O
and O
execution O
of O
voluntary O
, O
or O
internally O
determined O
movements O
. O
[]

SVR B-outcome ['Physiological-Clinical']
rates O
were O
23 O
% O
, O
17 O
% O
, O
10 O
% O
, O
and O
9 O
% O
in O
groups O
A O
, O
B O
, O
C O
, O
and O
D O
, O
respectively O
( O
P O
< O
.0001 O
for O
trend O
) O
. O
['Physiological-Clinical']

The O
percentage O
of O
children B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
detectable I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
and O
the O
reciprocal O
geometric O
mean O
titers O
were O
similar O
for O
both O
groups O
at O
two O
months O
of O
age O
for O
antibodies O
to O
all O
three O
poliovirus O
types O
. O
['Physiological-Clinical']

Eight-eight O
patients O
had O
attempted O
surgical O
resection O
following O
radiotherapy O
failure O
. O
[]

It O
was O
hypothesized O
that O
food O
form O
is O
the O
most O
salient O
attribute O
. O
[]

Zolmitriptan O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
when O
given O
alone O
or O
concomitantly O
with O
fluoxetine O
. O
['Life-Impact']

After O
the O
final O
tightening O
of O
the O
crowns O
, O
no O
significant O
differences O
were O
observed O
between O
the O
test O
and O
control O
groups O
( O
p O
> O
.05 O
) O
. O
[]

The O
amount O
of O
fibrinolytic O
activity O
in O
the O
thyroid O
gland O
equals O
that O
of O
the O
prostate O
. O
[]

In O
both O
training O
groups O
training B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
set O
at O
86 O
% O
of O
individual O
maximum O
heart O
rate O
. O
['Physiological-Clinical']

METHODS O
Background O
infusions O
were O
saline O
, O
or O
GLP-1 O
at O
0.3 O
or O
0.9 O
pmol/ O
kg/min O
on O
separate O
days O
in O
random O
order O
. O
[]

Qualitative O
information O
gathered O
from O
parents O
and O
teachers O
indicated O
some O
generalization O
of O
strategies O
learned O
in O
the O
clinic O
setting O
to O
both O
home O
and O
school O
settings O
. O
[]

Acustimulation O
wrist O
bands O
are O
not O
effective O
for O
the O
control O
of O
chemotherapy-induced B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
women O
with O
breast O
cancer O
. O
['Physiological-Clinical']

Patterns O
of O
management O
of O
atrial O
fibrillation O
complicating O
coronary O
artery O
bypass O
grafting O
: O
Results O
from O
the O
PRoject O
of O
Ex-vivo O
Vein O
graft O
ENgineering O
via O
Transfection O
IV O
( O
PREVENT-IV O
) O
Trial O
. O
[]

A O
variety O
of O
cues O
can O
differentiate O
objects O
from O
their O
surrounds O
. O
[]

These O
increases O
were O
maintained O
after O
1 O
week O
of O
intermittent O
but O
not O
continuous O
treatment O
. O
[]

The O
present O
study O
suggests O
that O
memantine O
may O
be O
a O
potential O
adjunctive O
treatment O
strategy O
for O
autism O
and O
it O
was O
generally O
well O
tolerated O
. O
[]

for O
4 O
consecutive O
days O
starting O
2 O
days O
before O
immunization O
) O
or O
placebo O
. O
[]

and O
vindesine O
( O
3 O
mg/m O
( O
2 O
) O
i.v O
. O
) O
[]

Induced B-outcome ['Physiological-Clinical']
sputum I-outcome ['Physiological-Clinical']
was O
analysed O
before O
and O
after O
the O
allergen O
challenges O
for O
cell O
counts O
, O
ECP O
, O
IL-5 O
, O
INF-? O
, O
IL-8 O
, O
and O
the O
transcription O
factor O
Foxp3 O
. O
['Physiological-Clinical']

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
dysfunction O
in O
three O
core O
behavioral O
domains O
: O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
social O
deficits O
, O
and O
language O
abnormalities O
. O
['Life-Impact']

No O
significant O
differences O
in O
peak O
[]

RESULTS O
The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
was O
11.8 O
% O
( O
6/51 O
) O
in O
the O
S O
group O
, O
14.8 O
% O
( O
8/54 O
) O
in O
the O
M O
group O
, O
1.9 O
% O
( O
1/52 O
) O
in O
the O
S+M O
group O
, O
and O
38 O
% O
( O
19/50 O
) O
in O
the O
CTR O
group O
. O
['Physiological-Clinical']

Following O
consecutive O
administration O
of O
the O
drugs O
the O
effects O
of O
atropine O
predominated O
. O
[]

Reduction O
in O
blood B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
was O
inconsistent O
and O
not O
significant O
. O
['Physiological-Clinical']

The O
main O
outcome O
measures O
included O
TKR O
recommendation O
, O
implicit O
racial O
preference O
, O
and O
medical O
cooperativeness O
stereotypes O
measured O
with O
implicit O
association O
tests O
. O
[]

Control O
and O
intervention O
participants O
provided O
baseline O
and O
four O
waves O
of O
quarterly O
follow-up O
data O
. O
[]

Paired O
comparisons O
revealed O
a O
significant O
difference O
in O
efficacy O
between O
CAE O
and O
CEC O
and O
a O
nearly O
significant O
difference O
between O
AMX-CL O
and O
CEC O
. O
[]

A O
therapeutic O
trial O
] O
. O
[]

Although O
slightly O
elevated O
in O
both O
groups O
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
C-peptide B-outcome ['Physiological-Clinical']
levels O
measured O
during O
oral O
glucose O
tolerance O
tests O
were O
within O
normal O
reference O
ranges O
at O
cycle O
7 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
The O
study O
group O
consisted O
of O
26 O
healthy O
adolescents O
( O
mean O
age O
14.6 O
years O
) O
exhibiting O
60 O
teeth O
with O
152 O
visible O
WSL O
sites O
on O
incisors O
and O
canines O
immediately O
after O
debonding O
of O
fixed O
orthodontic O
appliances O
. O
[]

In O
order O
to O
evaluate O
any O
beneficial O
effect O
of O
such O
an O
administration O
, O
a O
group O
of O
patients O
with O
recurrent O
gastric O
cancer O
was O
studied O
. O
[]

10?/L O
, O
6.3 O
? O
[]

Journal-Name:Taiwanese O
journal O
of O
obstetrics O
& O
gynecology O
[]

The O
effectiveness O
of O
fentanyl O
and O
ketorolac O
in O
providing O
analgesia O
for O
day-case O
gynaecological O
procedures O
was O
evaluated O
in O
55 O
healthy O
volunteers O
in O
a O
single O
blinded O
fashion O
. O
[]

Changes O
in O
continuously O
recorded O
'Finapres O
' O
finger B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
ten O
normotensive O
and O
seven O
hypertensive O
subjects O
induced O
by O
self-inflation O
of O
the O
cuff O
or O
just O
wearing O
the O
inflated O
cuff O
were O
studied O
. O
['Physiological-Clinical']

Effect O
of O
CX516 O
, O
an O
AMPA-modulating O
compound O
, O
on O
cognition B-outcome ['Life-Impact']
and O
behavior B-outcome ['Life-Impact']
in O
fragile O
X O
syndrome O
: O
a O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact']

For O
14 O
days O
, O
patients O
recorded O
pain O
levels O
twice O
daily O
using O
a O
visual O
analogue O
scale O
. O
[]

Similarly O
, O
a O
greater O
proportion O
of O
the O
CBZ O
600 O
group O
required O
a O
change O
in O
dose O
, O
47 O
% O
versus O
20 O
% O
( O
LTG O
100 O
) O
and O
17 O
% O
( O
LTG O
200 O
) O
or O
withdrew O
completely O
due O
to O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
, O
10.3 O
% O
versus O
4.3 O
% O
( O
LTG O
100 O
) O
and O
4.5 O
% O
( O
LTG O
200 O
) O
. O
['Adverse-effects']

The O
experimental O
group O
received O
13 O
months O
of O
combined O
individual O
telephone O
and O
in-person O
group O
support O
and O
education O
, O
Control O
Group O
1 O
received O
13 O
months O
of O
telephone-only O
individual O
support O
and O
education O
, O
and O
Control O
Group O
2 O
received O
one-time O
mailed O
educational O
information O
. O
[]

BACKGROUND O
NovaMin O
( O
NovaMin O
Technology O
, O
Alachua O
, O
Fla. O
) O
was O
introduced O
into O
the O
dental O
market O
as O
a O
desensitizer O
in O
December O
2004 O
. O
[]

Sixty O
and O
59 O
healthy O
young O
adults O
previously O
immunized O
against O
tetanus O
( O
T O
) O
and O
diphtheria O
( O
D O
) O
were O
randomized O
to O
receive O
intramuscularly O
either O
Td O
vaccine O
alone O
( O
group O
1 O
) O
or O
Td O
vaccine O
plus O
500 O
IU O
of O
TIG O
( O
group O
2 O
) O
simultaneously O
. O
[]

Journal-Name:Nutrients O
[]

Subjects O
' O
OAS O
aggression B-outcome ['Life-Impact']
scores O
showed O
significant O
correlation O
with O
the O
already O
validated O
retrospectively O
rated O
Aberrant O
Behavior O
Checklist O
Community O
Scale O
irritability O
subscale O
. O
['Life-Impact']

Hypertension O
and O
non-insulin-dependent O
diabetes O
. O
[]

Larger O
controlled O
trials O
will O
be O
necessary O
to O
detect O
possible O
therapeutic O
effects O
. O
[]

Twenty-four O
patients O
( O
12 O
female O
; O
mean O
age O
51 O
yr O
) O
were O
randomized O
into O
receiving O
either O
inhaled O
fluticasone O
( O
500 O
microgram O
twice O
daily O
) O
via O
the O
Accuhaler O
device O
( O
n O
= O
12 O
) O
or O
placebo O
. O
[]

Mean O
adherence B-outcome ['Life-Impact']
rates O
based O
on O
self-reports O
were O
also O
significantly O
better O
( O
P O
< O
0.001 O
) O
with O
MF-DPI O
400 O
microg O
QD O
PM O
( O
97.2 O
% O
) O
than O
with O
MF-DPI O
200 O
microg O
twice-daily O
( O
95.3 O
% O
) O
. O
['Life-Impact']

Patients O
with O
operative O
findings O
consistent O
with O
our O
criteria O
were O
randomized O
into O
a O
radical O
resection O
group O
and O
a O
radiochemotherapy O
group O
( O
200 O
mg/m O
( O
2 O
) O
/day O
of O
intravenous O
5-fluorouracil O
and O
5040 O
cGy O
of O
radiotherapy O
) O
without O
resection O
. O
[]

Mean O
central B-outcome ['Physiological-Clinical']
corneal I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(CCT) I-outcome ['Physiological-Clinical']
was O
similar O
at O
baseline O
(550 O
+/- O
35 O
mum) O
and O
at O
12 O
months O
(551 O
+/- O
37 O
mum) O
and O
24 O
months O
(555 O
+/- O
35 O
mum). O
[['Physiological-Clinical']]

Logistic-regression O
analysis O
showed O
that O
a O
higher O
risk O
of O
infection O
( O
P O
less O
than O
0.05 O
) O
was O
associated O
with O
increased O
age O
, O
injury O
to O
the O
left O
colon O
necessitating O
colostomy O
, O
a O
larger O
number O
of O
units O
of O
blood O
or O
blood O
products O
administered O
at O
surgery O
, O
and O
a O
larger O
number O
of O
injured O
organs O
. O
[]

Cumulative O
incidence O
and O
relative O
risks O
with O
95% O
confidence O
intervals O
for O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
, O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
, O
and O
metastasis B-outcome ['Physiological-Clinical']
were O
estimated O
in O
intention-to-treat O
and O
per-protocol O
analyses, O
and O
numbers O
of O
years O
of O
life O
gained O
were O
estimated. O
[['Mortality'], ['Mortality'], ['Physiological-Clinical']]

After O
cholestyramine O
treatment O
alone O
for O
12 O
weeks O
, O
serum B-outcome ['Physiological-Clinical']
total O
and O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
decreased O
by O
20 O
percent O
and O
29 O
percent O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
patients O
were O
intubated O
, O
received O
non-depolarising O
muscle O
relaxants O
, O
and O
were O
manually O
ventilated O
with O
nitrous O
oxide-oxygen O
( O
2:1.2 O
) O
. O
[]

No O
beneficial O
effect O
of O
the O
interferon B-outcome ['Physiological-Clinical']
on O
the O
course O
of O
MS O
could O
be O
shown O
. O
['Physiological-Clinical']

Our O
primary O
endpoint O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
with O
secondary O
endpoints O
of O
aneurysm-related B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
HRQL O
) O
, O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Mortality', 'Mortality', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use']

Several O
studies O
demonstrated O
that O
polyphenols O
are O
able O
to O
inhibit O
the O
growth O
of O
TMA-producing O
bacterial O
strains, O
and O
resveratrol O
(RSV) O
reduced O
TMAO O
levels O
in O
mice. O
[]

METHODS O
Forty O
autistic O
children O
receiving O
rehabilitation O
training O
were O
divided O
into O
a O
control O
group O
and O
a O
treatment O
group O
, O
20 O
cases O
in O
each O
group O
. O
[]

We O
hypothesized O
that O
there O
would O
be O
improved O
fixation B-outcome ['Physiological-Clinical']
of O
high-porosity O
trabecular O
metal O
( O
TM O
) O
tibial O
components O
compared O
to O
low-porosity O
titanium O
pegged O
porous O
fiber-metal O
( O
Ti O
) O
polyethylene O
metal O
backings O
. O
['Physiological-Clinical']

METHODS O
Sixty O
wives O
completed O
measures O
prior O
to O
random O
assignment O
to O
either O
the O
psychoeducational O
group O
intervention O
or O
a O
no-treatment O
control O
group O
, O
and O
1 O
month O
after O
completion O
of O
the O
group O
. O
[]

This O
applied O
to O
186 O
uncomplicated O
pregnancies O
in O
which O
there O
was O
no O
clinical O
suspicion O
of O
poor B-outcome ['Physiological-Clinical']
intrauterine B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
there O
was O
a O
significant O
decrease O
from O
baseline O
in O
the O
coronary O
plaque O
volume O
in O
patients O
with O
stable O
angina O
pectoris O
who O
received O
olmesartan O
or O
valsartan O
for O
6 O
months O
. O
[]

METHODS O
Forty-seven O
patients O
with O
schizophrenia O
meeting O
criteria O
for O
deficit O
syndrome O
were O
randomized O
to O
D-cycloserine O
, O
50 O
mg/d O
( O
n=23 O
) O
or O
placebo O
( O
n=24 O
) O
added O
to O
their O
conventional O
neuroleptic O
for O
an O
8-week O
, O
double-blind O
trial O
. O
[]

Amonafide O
: O
An O
active O
agent O
in O
the O
treatment O
of O
previously O
untreated O
advanced O
breast O
cancer O
-- O
a O
cancer O
and O
leukemia O
group O
B O
study O
( O
CALGB O
8642 O
) O
. O
[]

Physicians O
were O
randomized O
to O
view O
either O
a O
seminar O
about O
type O
2 O
diabetes O
or O
a O
seminar O
about O
systolic O
heart O
failure O
. O
[]

This O
study O
sought O
to O
evaluate O
physical O
activity O
in O
women O
at O
moderate O
risk O
for O
breast O
cancer O
, O
the O
correlates O
of O
engaging O
in O
regular O
physical O
activity O
, O
and O
whether O
physical O
activity O
relates O
to O
psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
. O
['Life-Impact']

PARTICIPANTS O
Participants O
( O
N=20 O
) O
who O
were O
community-living O
older O
adults O
at O
least O
65 O
years O
old O
( O
mean O
age O
, O
70y O
) O
, O
50 O
% O
women O
, O
and O
who O
had O
no O
experience O
of O
using O
a O
wheelchair O
were O
randomly O
allocated O
to O
an O
intervention O
( O
n=10 O
) O
or O
control O
( O
n=10 O
) O
group O
. O
[]

To O
investigate O
the O
effect O
of O
these O
COX-2 O
selective O
NSAIDs B-outcome ['Resource-use']
on O
heterotopic B-outcome ['Physiological-Clinical']
ossification I-outcome ['Physiological-Clinical']
( O
HO O
) O
after O
primary O
total O
hip O
arthroplasty O
( O
THA O
) O
, O
we O
conducted O
a O
randomized O
controlled O
trial O
using O
either O
indomethacin O
or O
rofecoxib O
for O
7 O
days O
. O
['Resource-use', 'Physiological-Clinical']

Comparison O
of O
quality O
of O
life O
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
and O
medical B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
of O
peginterferon O
alpha O
2a O
vs O
the O
combination O
of O
interferon O
alpha O
2b O
plus O
ribavirin O
as O
initial O
treatment O
in O
patients O
with O
chronic O
hepatitis O
C. O
The O
on-treatment O
impact O
of O
interferon-based O
therapies O
on O
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
, O
work B-outcome ['Life-Impact']
productivity I-outcome ['Life-Impact']
, O
and O
medical B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
has O
not O
been O
systematically O
studied O
. O
['Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact', 'Resource-use']

Future O
therapeutic O
directions O
for O
factor O
Xa O
inhibition O
in O
the O
prophylaxis O
and O
treatment O
of O
thrombotic O
disorders O
. O
[]

This O
is O
the O
first O
placebo-controlled O
study O
of O
the O
safety O
of O
injectable O
opioids O
in O
a O
controlled O
treatment O
setting O
. O
[]

The O
women O
were O
separated O
into O
those O
who O
were O
given O
2,500 O
IU O
enoxaparin O
once O
daily O
and O
SH O
in O
a O
dose O
of O
5,000 O
IU O
three O
times O
daily O
. O
[]

Journal O
ID: O
8208604 O
[]

Recurrences O
and O
complications O
were O
recorded O
at O
follow-up O
visits O
. O
[]

Vitamin O
D O
and O
probiotic O
co-supplementation O
was O
associated O
with O
a O
significant O
reduction O
in O
total O
testosterone B-outcome ['Physiological-Clinical']
(beta O
- O
0.19 O
ng/mL; O
95% O
CI, O
- O
0.28, O
- O
0.10; O
P O
< O
0.001), O
hirsutism B-outcome ['Physiological-Clinical']
(beta O
- O
0.95; O
95% O
CI, O
- O
1.39, O
- O
0.51; O
P O
< O
0.001), O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
(hs-CRP) I-outcome ['Physiological-Clinical']
(beta O
- O
0.67 O
mg/L; O
95% O
CI, O
- O
0.97, O
- O
0.38; O
P O
< O
0.001) O
and O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
levels O
(beta O
- O
0.25 O
mumol/L; O
95% O
CI, O
- O
0.40, O
- O
0.10; O
P O
= O
0.001), O
and O
a O
significant O
increase O
in O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity O
(TAC) O
(beta O
82.81 O
mmol/L; O
95% O
CI, O
42.86, O
122.75; O
P O
< O
0.001) O
and O
total O
glutathione B-outcome ['Physiological-Clinical']
(GSH) I-outcome ['Physiological-Clinical']
levels O
(beta O
40.42 O
mumol/L; O
95% O
CI, O
4.69, O
76.19; O
P O
= O
0.02), O
compared O
with O
the O
placebo. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Of O
the O
total O
7788 O
participants O
entered O
into O
the O
DIG O
trial O
, O
only O
97 O
participants O
( O
1.2 O
% O
) O
could O
not O
have O
their O
vital B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
as O
of O
December O
31 O
, O
1995 O
determined O
. O
['Physiological-Clinical']

A O
1-month O
washout O
period O
was O
completed O
before O
the O
crossover O
trial O
. O
[]

METHODS: O
Patients O
who O
were O
referred O
to O
Veterans O
Affairs O
(VA) O
gastroenterology O
clinics O
for O
PPI-refractory O
heartburn O
received O
20 O
mg O
of O
omeprazole O
twice O
daily O
for O
2 O
weeks, O
and O
those O
with O
persistent O
heartburn O
underwent O
endoscopy, O
esophageal O
biopsy, O
esophageal O
manometry, O
and O
multichannel O
intraluminal O
impedance-pH O
monitoring. O
[]

Phase O
contrast O
and O
scanning O
electron O
microscopes O
were O
used O
to O
score O
cell B-outcome ['Physiological-Clinical']
quantity I-outcome ['Physiological-Clinical']
, O
morphology B-outcome ['Physiological-Clinical']
and O
cell B-outcome ['Physiological-Clinical']
attachment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Choice O
of O
vitreous O
sampling O
procedure O
must O
depend O
on O
the O
clinical O
judgment O
of O
the O
surgeon O
. O
[]

This O
may O
reflect O
direct O
pituitary O
damage O
and/or O
the O
loss O
of O
the O
tropic O
effects O
of O
chronic O
GHRH O
deficiency O
. O
[]

OBJECTIVE O
This O
study O
aims O
to O
assess O
user O
characteristics O
related O
to O
participation B-outcome ['Life-Impact']
and O
attrition B-outcome ['Life-Impact']
when O
comparing O
Web-based O
and O
print-delivered O
tailored O
interventions O
containing O
similar O
content O
and O
thereby O
to O
provide O
recommendations O
in O
choosing O
the O
appropriate O
delivery O
mode O
for O
a O
particular O
target O
audience O
. O
['Life-Impact']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
similar O
in O
all O
three O
groups O
. O
['Adverse-effects']

Arterial B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SaO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
saturation O
and O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
0 O
, O
15 O
and O
30 O
minutes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Three O
hundred O
forty-one O
Tanzanian O
preschool O
children O
were O
randomly O
assigned O
to O
levamisole O
or O
placebo O
treatment O
given O
at O
three-month O
intervals O
. O
[]

RESULTS O
Spontaneous B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
using I-outcome ['Life-Impact']
picture I-outcome ['Life-Impact']
cards I-outcome ['Life-Impact']
, O
speech B-outcome ['Life-Impact']
, O
or O
both O
increased O
significantly O
following O
training O
( O
rate O
ratio O
[ O
RR O
] O
=1.90 O
, O
95 O
% O
CI O
[ O
1.46 O
, O
2.48 O
] O
, O
p O
< O
.001 O
; O
RR O
= O
1.77 O
, O
95 O
% O
CI O
[ O
1.35 O
, O
2.32 O
] O
, O
p O
< O
.001 O
; O
RR O
= O
3.74 O
, O
95 O
% O
CI O
[ O
2.19 O
, O
6.37 O
] O
, O
p O
< O
.001 O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

The O
folate O
group O
received O
1 O
mg O
folic O
acid O
, O
400 O
microg O
vitamin O
B O
( O
12 O
) O
, O
and O
10 O
mg O
vitamin O
B O
( O
6 O
) O
daily O
. O
[]

It O
is O
suggested O
, O
in O
the O
light O
of O
previous O
findings O
, O
that O
the O
inhibitory O
effect O
of O
ANF O
represents O
a O
non-selective O
action O
of O
ANF O
on O
aldosterone B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

once O
daily O
was O
compared O
with O
that O
of O
dextran O
70 O
in O
patients O
undergoing O
THR O
. O
[]

CONCLUSION O
The O
results O
show O
that O
zinc O
, O
as O
adjuvant O
agent O
for O
obsessive-compulsive O
disorder O
, O
produces O
improved O
outcomes O
. O
[]

PURPOSE O
Survival O
of O
patients O
with O
completely O
resected O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
unsatisfactory O
, O
and O
in O
2002 O
, O
the O
benefit O
of O
adjuvant O
chemotherapy O
was O
not O
established O
. O
[]

Final O
analysis O
was O
done O
1 O
year O
after O
the O
last O
patient O
was O
enrolled O
. O
[]

Pilot O
study. O
[]

insulin O
. O
[]

Analgesia B-outcome ['Resource-use']
was O
supplemented O
whenever O
the O
pain B-outcome ['Physiological-Clinical']
score O
was O
> O
or O
= O
4 O
. O
['Resource-use', 'Physiological-Clinical']

DISCUSSION O
The O
study O
will O
determine O
if O
the O
acquired O
self O
management O
skills O
of O
the O
patients O
continue O
to O
be O
used O
after O
discharge O
from O
hospital O
. O
[]

The O
forearm O
band O
showed O
better O
scores O
on O
joint B-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
reproduction I-outcome ['Physiological-Clinical']
at O
70 O
degrees O
compared O
with O
the O
elbow O
sleeve O
(P O
= O
.006), O
whereas O
the O
elbow O
sleeve O
showed O
better O
scores O
at O
110 O
degrees O
(P O
< O
.001). O
[['Physiological-Clinical']]

CONCLUSION O
The O
addition O
of O
vancomycin O
to O
heparin O
CVC O
flush O
solution O
did O
not O
reduce O
bacteremia B-outcome ['Physiological-Clinical']
with O
vancomycin-susceptible O
organisms O
. O
['Physiological-Clinical']

Only O
1 O
SILS O
case O
was O
converted O
to O
3-port O
. O
[]

Influence O
of O
ibopamine O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
arrhythmic B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
in O
patients O
with O
congestive O
heart O
failure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
conclude O
that O
a O
significant O
placebo O
effect O
is O
present O
in O
the O
treatment O
of O
gastroesophageal O
reflux O
. O
[]

The O
results O
of O
that O
double-blind O
, O
placebo-controlled O
study O
suggest O
that O
fluoxetine O
was O
effective O
in O
decreasing O
but O
not O
eliminating O
both O
the O
depressive O
symptoms O
( O
including O
suicidal O
ideations O
) O
and O
the O
level O
of O
alcohol O
consumption O
among O
a O
study O
group O
of O
subjects O
with O
comorbid O
major O
depressive O
disorder O
and O
alcohol O
dependence O
, O
many O
of O
whom O
displayed O
suicidal O
ideations O
. O
[]

150 O
patients O
will O
be O
included O
and O
randomized O
intraoperatively O
after O
surgical O
exploration O
just O
prior O
to O
resection O
. O
[]

METHOD O
A O
cohort O
of O
youth O
( O
N O
= O
162 O
, O
60 O
% O
male O
) O
treated O
during O
adolescence O
( O
mean O
age O
= O
16 O
years O
) O
was O
followed O
into O
young O
adulthood O
, O
a O
period O
associated O
with O
stabilization O
of O
alcohol O
use O
patterns O
and O
elevated O
risk O
for O
life O
problems O
secondary O
to O
both O
alcohol O
and O
drug O
use O
. O
[]

Effects O
of O
a O
videotape O
information O
intervention O
at O
discharge O
on O
diet O
and O
exercise O
compliance O
after O
coronary O
bypass O
surgery O
. O
[]

No O
other O
plasma B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
essential I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
changed O
during O
the O
trial O
, O
although O
the O
HDL B-outcome ['Physiological-Clinical']
: O
cholesterol B-outcome ['Physiological-Clinical']
increased O
slightly O
but O
non-significantly O
with O
an O
increase O
in O
EPA B-outcome ['Physiological-Clinical']
and O
DHA B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Seventy-two-hour O
metabolic O
balance O
studies O
were O
performed O
at O
an O
average O
postconceptual O
age O
of O
34 O
weeks O
and O
an O
average O
weight O
of O
1,549 O
g. O
All O
infants O
were O
in O
positive O
zinc B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
and O
nine O
of O
ten O
achieved O
the O
in O
utero B-outcome ['Physiological-Clinical']
accretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
for O
a O
34-week O
gestation O
fetus O
( O
greater O
than O
or O
equal O
to O
0.432 O
mg/d O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
the O
basis O
of O
this O
reduced O
nephrotoxicity B-outcome ['Physiological-Clinical']
, O
a O
['Physiological-Clinical']

The O
symptom-specific O
risk O
of O
mortality B-outcome ['Mortality']
was O
significantly O
associated O
with O
diarrhea B-outcome ['Physiological-Clinical']
, O
convulsions B-outcome ['Physiological-Clinical']
, O
and O
other O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Two O
experiments O
investigated O
sensory/motor-based B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of O
man-made O
objects O
: O
manipulation O
features O
associated O
with O
the O
actual O
usage O
of O
objects O
. O
['Life-Impact']

To O
determine O
effects O
of O
aging O
and O
autonomic O
input O
on O
interrelationships O
between O
respiratory O
and O
heart O
rate O
variability O
, O
we O
collected O
5 O
min O
of O
lung O
volume O
of O
R-R O
interval O
data O
from O
7 O
young O
[ O
27 O
+/- O
3 O
( O
SD O
) O
yr O
] O
and O
10 O
older O
( O
69 O
+/- O
6 O
yr O
) O
healthy O
supine O
humans O
before O
and O
after O
double O
pharmacological O
autonomic O
blockade O
with O
propranolol O
( O
0.2 O
mg/kg O
iv O
) O
and O
atropine O
( O
0.04 O
mg/kg O
iv O
) O
. O
[]

After O
8 O
weeks O
, O
the O
TC B-outcome ['Physiological-Clinical']
, O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
TG B-outcome ['Physiological-Clinical']
in O
the O
atorvastatin B-outcome ['Physiological-Clinical']
group O
decreased O
by O
19 O
% O
, O
26 O
% O
, O
and O
17 O
% O
respectively O
compared O
with O
the O
baseline O
values O
( O
all O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
IVUS O
images O
( O
immediately O
after O
the O
procedure O
and O
at O
6-month O
follow-up O
) O
were O
analyzed O
at O
an O
independent O
core O
laboratory O
in O
a O
blind O
manner O
. O
[]

All O
patients O
received O
epidural O
anaesthesia O
with O
0.25 O
% O
bupivacaine O
and O
were O
then O
randomly O
allocated O
to O
one O
of O
three O
groups O
. O
[]

A O
prospective O
randomized O
study O
was O
conducted O
to O
determine O
the O
ablation B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
of O
mitoxantrone O
in O
Ta-T1 O
superficial O
bladder O
tumors O
versus O
mitomycin O
C O
, O
a O
drug O
whose O
intravesical O
ablation O
properties O
are O
well-known O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Secondary O
end O
points O
were O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
blood B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
at O
day O
+120 O
, O
and O
survival B-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

This O
study O
examined O
the O
effects O
of O
MCT O
oil O
consumption O
, O
as O
part O
of O
a O
weight O
loss O
diet O
, O
on O
metabolic O
risk O
profile O
compared O
to O
olive O
oil O
. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O
[]

The O
sources O
of O
dietary B-outcome ['Life-Impact']
CP I-outcome ['Life-Impact']
were O
soybean O
meal O
( O
SBM O
) O
or O
SBM O
and O
urea O
( O
SBM-U O
) O
. O
['Life-Impact']

Twenty O
subjects O
, O
who O
have O
TMJ O
pain O
, O
were O
included O
for O
this O
study O
and O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
n O
= O
10 O
) O
or O
the O
control O
group O
( O
n O
= O
10 O
) O
. O
[]

Blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
collected O
and O
assayed O
for O
each O
of O
the O
compounds O
and O
their O
metabolites O
using O
high-performance O
liquid O
chromatography O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eighteen O
months O
from O
its O
initiation O
, O
140 O
women O
were O
entered O
on O
study O
. O
[]

The O
occurrence O
of O
spasm B-outcome ['Physiological-Clinical']
was O
similar O
, O
independent O
of O
the O
vasodilator O
cocktail O
used O
( O
Group O
A O
: O
12.2 O
% O
, O
Group O
B O
: O
13.4 O
% O
, O
Group O
C O
: O
9.5 O
% O
; O
p O
= O
0.597 O
) O
. O
['Physiological-Clinical']

Low-molecular-weight O
heparin O
offers O
safe O
and O
easily O
administered O
thromboprophylaxis O
in O
total O
hip O
replacement O
. O
[]

Results: O
(1)Compared O
with O
the O
results O
at O
baseline, O
the O
total O
scores O
of O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
(PSQI)], O
Beck O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
index O
(BDI) O
, O
Beck O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
inventory O
(BAI) O
in O
both O
groups O
significantly O
decreased O
at O
the O
end O
of O
treatment: O
CBT-i O
group, O
PSQI O
(4.7+/-2.5) O
vs. O
(12.9+/-3.5); O
BDI O
(3.2+/-4.4) O
vs. O
(9.7+/-6.4); O
BAI O
(4.2+/-5.6) O
vs. O
(10.7+/-8.1); O
and O
combination O
group, O
PSQI O
(5.8+/-2.8) O
vs. O
(13.9+/-3.1); O
BDI O
(4.5+/-4.8) O
vs. O
(13.8+/-8.7); O
BAI O
(4.4+/-4.0) O
vs. O
(14.1+/-6.3) O
(all O
P<0.01). O
( O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

2.8 O
) O
, O
( O
12.1 O
? O
[]

Eye-closure O
led O
to O
an O
increase O
in O
correct O
cued-recall O
, O
with O
no O
increase O
in O
incorrect B-outcome ['Life-Impact']
responses I-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
Targeting O
to O
remission O
with O
tight O
clinical O
controls O
results O
in O
low O
radiologic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
most O
RA O
patients O
. O
['Physiological-Clinical']

Days B-outcome ['Life-Impact']
lost I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
per O
patient O
per O
month O
was O
zero O
on O
three O
times O
12 O
U/kg O
, O
0.4 O
day O
on O
twice O
18 O
U/kg O
and O
once O
36 O
U/kg O
, O
while O
it O
had O
been O
five O
days O
in O
the O
pre-trial O
period O
. O
['Life-Impact']

BACKGROUND O
GS-9620 O
is O
a O
novel O
oral O
agonist O
of O
Toll-like O
receptor O
7 O
( O
TLR7 O
) O
in O
development O
for O
the O
treatment O
of O
chronic O
viral O
hepatitis O
. O
[]

METHODS O
Sixty-one O
patients O
with O
ovarian O
cancer O
or O
endometrial O
cancer O
who O
underwent O
retroperitoneal O
lymph O
node O
resection O
were O
assigned O
at O
random O
to O
a O
retroperitoneal O
partial O
no-closure O
group O
or O
a O
closure O
group O
. O
[]

30 O
% O
) O
within O
10 O
weeks O
. O
[]

Thus O
, O
a O
combination O
product O
of O
buprenorphine O
and O
naloxone O
may O
have O
lower O
abuse B-outcome ['Physiological-Clinical']
liability I-outcome ['Physiological-Clinical']
than O
buprenorphine O
alone O
. O
['Physiological-Clinical']

A O
significant O
difference O
was O
found O
in O
the O
paracetamol O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameter O
oral B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Neither O
enalapril O
alone O
( O
-2 O
+/- O
2/1 O
+/- O
2 O
mm O
Hg O
, O
NS O
vs. O
placebo O
) O
nor O
eprosartan O
alone O
( O
-1 O
+/- O
1/0 O
+/- O
2 O
mm O
Hg O
, O
NS O
vs. O
placebo O
) O
had O
a O
clear-cut O
significant O
effect O
on O
casual B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

1 O
) O
Apparent O
ileal O
and O
total O
tract O
protein O
digestibilities O
of O
rapeseed O
meal O
and O
cake O
and O
soybean O
meal O
and O
cake O
were O
assayed O
in O
growing O
turkeys O
at O
4 O
, O
8 O
and O
12 O
weeks O
of O
age O
. O
( O
[]

No O
differences O
were O
found O
between O
CER O
group O
and O
UC O
group O
at O
6 O
weeks O
. O
[]

The O
patients O
were O
followed O
up O
for O
6 O
months. O
[]

The O
score O
of O
symptoms O
and O
signs O
, O
RI O
, O
ADI O
were O
observed O
and O
compared O
between O
two O
groups O
. O
[]

PURPOSE O
The O
aim O
of O
this O
randomized O
, O
controlled O
, O
blinded O
clinical O
study O
was O
to O
compare O
ridge B-outcome ['Physiological-Clinical']
dimensions I-outcome ['Physiological-Clinical']
and O
histologic B-outcome ['Physiological-Clinical']
characteristics I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ridges I-outcome ['Physiological-Clinical']
preserved O
with O
2 O
different O
graft O
materials O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Consistency O
of O
results O
was O
found O
across O
trials O
( O
P O
> O
0.10 O
, O
heterogeneity O
value O
) O
for O
all O
comparisons O
. O
[]

OBJECTIVE O
To O
study O
the O
symptomatology O
of O
early O
hemorrhoids O
and O
to O
compare O
injection O
sclerotherapy O
( O
IS O
) O
with O
electrocoagulation O
( O
EC O
) O
in O
the O
management O
outcome O
of O
early O
haemorrhoids O
with O
respect O
to O
pain B-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
procedure I-outcome ['Physiological-Clinical']
, O
reduction O
in O
bleeding B-outcome ['Physiological-Clinical']
per I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
, O
and O
overall B-outcome ['Life-Impact']
patient I-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

This O
training O
adopted O
a O
cognitive O
mapping O
technique O
to O
help O
improve O
supervisor O
responsiveness O
. O
[]

PMID: O
31609293 O
[]

Standardized O
Psychological O
tests O
were O
administered O
to O
tap O
the O
behavioral O
differences O
. O
[]

Patients O
treated O
with O
intravenous O
betalactam O
and O
tobramycin O
were O
randomly O
allocated O
to O
receive O
aerosolized O
tobramycin O
( O
6 O
mg/kg/day O
, O
n O
= O
21 O
) O
or O
placebo O
( O
n O
= O
17 O
) O
. O
[]

Conclusion O
Intra-articular O
injection O
of O
Triamcinolone O
acetenoid O
is O
effective O
in O
symptoms B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
improving O
functional B-outcome ['Life-Impact']
outcome O
in O
clinically O
diagnosed O
osteoarthritis O
of O
knees O
in O
community O
set O
up O
during O
health O
camps. O
[['Physiological-Clinical'], ['Life-Impact']]

At O
60 O
minutes O
, O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
was O
required O
by O
48 O
% O
of O
the O
patients O
in O
the O
OC O
group O
, O
whereas O
10 O
% O
of O
the O
PC O
group O
required O
such O
therapy O
( O
P O
< O
.01 O
) O
. O
['Resource-use']

Using O
Centers O
for O
Disease O
Control O
( O
CDC O
) O
standardized O
scores O
, O
both O
weight O
and O
body O
mass O
index O
( O
BMI O
) O
increased O
with O
risperidone O
during O
the O
acute O
trial O
( O
0.5 O
and O
0.6 O
SDs O
, O
respectively O
, O
for O
risperidone O
; O
0.0 O
and O
0.1 O
SDs O
, O
respectively O
, O
for O
placebo O
) O
and O
into O
open-label O
extension O
( O
0.19 O
and O
0.16 O
SDs O
, O
respectively O
) O
, O
although O
the O
amount O
of O
gain O
decelerated O
with O
time O
. O
[]

Survival B-outcome ['Mortality']
curve O
( O
Kaplan-meire O
's O
) O
of O
the O
Chinese O
herb O
group O
was O
better O
than O
that O
of O
the O
control O
group O
. O
['Mortality']

Antiarrhythmic O
efficacy O
of O
azimilide O
in O
patients O
with O
atrial O
fibrillation O
. O
[]

OBJECTIVES O
This O
study O
was O
designed O
to O
a O
) O
document O
the O
efficacy O
of O
a O
device O
intended O
to O
conserve O
blood O
in O
critically O
ill O
patients O
; O
b O
) O
determine O
the O
effect O
of O
this O
blood O
conservation O
on O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
the O
need O
for O
blood O
transfusions O
; O
c O
) O
determine O
if O
the O
blood O
conservation O
device O
resulted O
in O
interference O
with O
arterial O
pressure O
waveforms O
; O
d O
) O
determine O
if O
use O
of O
the O
blood O
conservation O
device O
resulted O
in O
a O
difference O
in O
the O
number O
of O
accidental O
needle O
punctures O
suffered O
by O
healthcare O
workers O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

However O
, O
more O
research O
is O
needed O
to O
fully O
understand O
the O
implications O
of O
these O
findings O
. O
[]

Homocysteinemia O
is O
a O
risk O
factor O
for O
cardiovascular O
diseases O
. O
[]

RESULTS O
There O
were O
no O
significant O
( O
p O
> O
0.05 O
) O
changes O
in O
markers O
of O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
between O
groups O
over O
the O
2 O
years O
despite O
a O
significant O
fall O
in O
total O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
in O
pravastatin-treated O
patients O
( O
p O
= O
0.029 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

infusion O
to O
maintain O
blood O
glucose O
in O
the O
range O
5.5-11.1 O
mmol O
litre O
( O
-1 O
) O
. O
[]

Of O
women O
who O
seek O
reduction O
mammaplasty O
, O
up O
to O
a O
third O
have O
pathological O
degrees O
of O
anxiety B-outcome ['Life-Impact']
or O
depression B-outcome ['Life-Impact']
, O
or O
both O
. O
['Life-Impact', 'Life-Impact']

PURPOSE O
For O
the O
majority O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
CNS O
prophylaxis O
consists O
of O
either O
intrathecal O
( O
IT O
) O
methotrexate O
or O
triple O
IT O
therapy O
( O
ie O
, O
methotrexate O
with O
both O
cytarabine O
and O
hydrocortisone O
) O
. O
[]

22 O
patients O
treated O
with O
basic O
therapy O
were O
as O
a O
control O
group O
. O
[]

In O
a O
prospective O
non-randomized O
trial O
, O
59 O
patients O
with O
sepsis O
( O
n O
= O
43 O
) O
and O
SIRS O
( O
n O
= O
16 O
) O
were O
treated O
on O
a O
surgical O
intensive O
care O
unit O
. O
[]

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
D-cycloserine I-outcome ['Physiological-Clinical']
, O
relevant B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

In O
years O
1 O
and O
2 O
, O
the O
mean O
postvaccination O
strain-specific O
to O
total O
IgA O
ratio O
was O
3.1-fold O
( O
P O
< O
0.01 O
) O
and O
2.0-fold O
( O
P O
< O
0.03 O
) O
higher O
among O
LAIV O
recipients O
with O
no O
evidence O
of O
culture-confirmed O
influenza O
illness O
compared O
with O
LAIV O
recipients O
who O
developed O
culture-confirmed O
influenza O
illness O
; O
a O
similar O
and O
consistent O
trend O
was O
observed O
for O
each O
individual O
study O
and O
type/subtype O
. O
[]

Gefitinib O
versus O
placebo O
in O
completely O
resected O
non-small-cell O
lung O
cancer O
: O
results O
of O
the O
NCIC O
CTG O
BR19 O
study O
. O
[]

To O
study O
the O
acute O
effects O
of O
acid O
fog O
on O
the O
lung O
, O
the O
authors O
generated O
a O
monodisperse O
10 O
microM O
MMAD O
aerosol O
of O
H2SO4 O
with O
a O
pH O
of O
2.0 O
and O
a O
nominal O
concentration O
of O
500 O
micrograms/m3 O
. O
[]

hsCRP B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
compared O
in O
patients O
who O
suffered O
an O
adverse O
cardiac O
outcome O
within O
10 O
months O
of O
study O
entry O
and O
in O
patients O
who O
had O
no O
adverse O
event O
. O
['Physiological-Clinical']

25 O
pairs O
were O
randomly O
selected O
. O
[]

Response O
was O
assessed O
every O
8 O
weeks O
. O
[]

The O
intention-to-treat O
analysis O
showed O
no O
difference O
over O
the O
intervention O
year O
in O
the O
number O
of O
symptom B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
, O
yet O
there O
was O
a O
trend O
toward O
fewer O
days O
of O
limited O
activity O
and O
a O
significant O
decrease O
in O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
by O
the O
intervention O
group O
compared O
with O
controls O
. O
['Physiological-Clinical', 'Resource-use']

PATIENTS O
AND O
METHODS O
Ninety-nine O
eligible O
patients O
with O
T2 O
to O
T4b O
transitional O
cell O
bladder O
cancer O
participated O
, O
64 O
% O
with O
cT3b O
or O
cT4 O
. O
[]

CONCLUSION O
The O
use O
of O
ozone O
gas O
to O
disinfect O
the O
cavity O
before O
placing O
a O
restoration O
had O
no O
influence O
on O
immediate O
enamel O
and O
dentin O
bond O
strength O
. O
[]

Group O
A O
(corneal O
group) O
included O
131 O
cases O
(135 O
eyes), O
receiving O
the O
3 O
layers O
of O
allogeneic O
cornea O
slices O
as O
graft. O
[]

Regulatory O
authorities O
require O
demonstration O
of O
bioequivalence O
through O
comparisons O
of O
different O
pharmacokinetic O
parameters O
, O
the O
area O
under O
the O
plasma B-outcome ['Physiological-Clinical']
concentration-time O
curve O
( O
AUC O
) O
, O
the O
maximum O
plasma B-outcome ['Physiological-Clinical']
concentration O
( O
Cmax B-outcome ['Physiological-Clinical']
) O
, O
and O
the O
time O
to O
reach O
peak O
concentration B-outcome ['Physiological-Clinical']
( O
Tmax B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

7 O
% O
) O
. O
[]

CSA B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
were O
predictable O
and O
manageable O
but O
required O
close O
monitoring O
. O
['Adverse-effects']

INTERVENTIONS O
53 O
women O
were O
randomized O
to O
have O
endocervical O
sampling O
with O
the O
Kevorkian O
curette O
and O
47 O
to O
have O
sampling O
with O
the O
Medscand O
endocervical O
brush O
. O
[]

METHODS O
In O
vitro O
: O
the O
PRV O
was O
set O
to O
10 O
, O
15 O
, O
20 O
or O
25 O
cmH2O O
release O
pressure O
and O
connected O
to O
a O
cuffed O
tube O
placed O
into O
a O
box O
flushed O
with O
66 O
% O
N2O O
in O
O2 O
. O
[]

These O
are O
the O
socio-cultural O
priority O
problems O
that O
demand O
immediate O
attention O
by O
the O
policy O
makers O
and O
health O
professionals O
. O
[]

For O
the O
performance O
of O
clinical O
drug O
trials O
in O
the O
therapy O
for O
bronchial O
hyperresponsiveness O
, O
unspecific O
inhalatory O
provocation O
tests O
are O
generally O
employed O
to O
judge O
therapeutic O
success O
. O
[]

Lethality B-outcome ['Mortality']
was O
56 O
% O
in O
the O
sepsis B-outcome ['Physiological-Clinical']
group I-outcome ['Physiological-Clinical']
; O
in O
the O
therapy O
group O
lethality B-outcome ['Mortality']
was O
significantly O
lower O
in O
patients O
with O
plasmapheresis B-outcome ['Physiological-Clinical']
, O
even O
though O
in O
this O
population O
the O
organic O
failure O
rate O
was O
higher O
. O
['Mortality', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

METHODS O
Two O
hundred O
seven O
consecutive O
coronary O
artery O
bypass O
patients O
( O
mean O
age O
62 O
+/- O
11 O
years O
) O
were O
randomized O
to O
receive O
sotalol O
alone O
( O
80 O
mg O
twice O
daily O
for O
5 O
days O
starting O
from O
the O
morning O
of O
the O
first O
postoperative O
day O
) O
( O
group O
S O
) O
, O
magnesium O
alone O
( O
1.5 O
g O
daily O
for O
6 O
days O
starting O
in O
the O
operating O
room O
just O
before O
cardiopulmonary O
bypass O
) O
( O
group O
M O
) O
, O
both O
pharmacologic O
agents O
at O
the O
same O
dosages O
( O
group O
S+M O
) O
, O
or O
no O
antiarrhythmic O
agents O
( O
group O
CTR O
) O
. O
[]

Effect O
of O
daily O
etidronate O
on O
the O
osteolysis O
of O
multiple O
myeloma O
. O
[]

Evidence O
from O
three O
systematic O
reviews O
demonstrates O
that O
sterile O
water O
injections O
( O
SWI O
) O
provide O
statistically O
and O
clinically O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
women O
experiencing O
continuous O
lower O
back O
pain O
during O
labour O
. O
['Physiological-Clinical']

METHODS O
A O
randomized O
, O
single-blind O
, O
controlled O
trial O
was O
conducted O
in O
30 O
non-diabetic O
patients O
with O
hypertension O
over O
a O
period O
of O
9 O
weeks O
to O
evaluate O
the O
effect O
of O
a O
device O
that O
helps O
to O
slow B-outcome ['Physiological-Clinical']
breathing I-outcome ['Physiological-Clinical']
( O
Resperate O
) O
on O
BP B-outcome ['Physiological-Clinical']
and O
quality O
of O
life O
( O
QoL O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS: O
A O
sample O
of O
2262 O
male O
truckers O
registered O
in O
the O
North O
Star O
Alliance O
electronic O
health O
record O
system O
who, O
based O
on O
these O
records, O
were O
not O
testing O
for O
HIV O
regularly O
were O
randomized O
to O
one O
of O
three O
study O
groups O
in O
which O
they O
were O
sent O
text O
messages O
about O
the O
availability O
of O
(1) O
oral O
HIV O
self-test O
kits O
at O
all O
8 O
North O
Star O
Alliance O
Kenya O
clinics O
that O
was O
sent O
three O
times O
(intervention), O
(2) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
three O
times O
(enhanced O
standard O
of O
care O
[SOC]), O
or O
(3) O
HIV O
testing O
in O
general O
(not O
self-testing) O
at O
all O
North O
Star O
Alliance O
clinics O
sent O
one O
time O
(SOC). O
[]

The O
levels O
of O
prebeta-like B-outcome ['Physiological-Clinical']
HDL I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
alphaHDL I-outcome ['Physiological-Clinical']
in O
the O
delipidated O
plasma O
converted O
from O
5.6 O
% O
to O
79.1 O
% O
and O
92.8 O
% O
to O
20.9 O
% O
, O
respectively O
. O
['Physiological-Clinical']

Conversion B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
was O
achieved O
in O
19 O
of O
22 O
patients O
( O
86 O
% O
) O
when O
AF O
lasted O
less O
than O
24 O
hours O
and O
in O
4 O
of O
10 O
( O
40 O
% O
) O
when O
the O
arrhythmia O
lasted O
greater O
than O
24 O
hours O
. O
['Physiological-Clinical']

OBJECTIVE O
Sleep B-outcome ['Physiological-Clinical']
difficulties I-outcome ['Physiological-Clinical']
are O
common O
reasons O
why O
parents O
seek O
medical O
intervention O
in O
children O
with O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
['Physiological-Clinical']

Injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising B-outcome ['Physiological-Clinical']
at O
48 O
and O
72 O
hours O
after O
each O
injection O
. O
['Physiological-Clinical']

Maximal B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
similarly O
improved O
after O
SP O
( O
4.9+/-1.8 O
% O
) O
and O
MX O
( O
4.9+/-1.4 O
% O
) O
, O
but O
there O
was O
no O
effect O
on O
ventilatory B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Bupivacaine O
produced O
a O
significant O
incidence O
of O
residual O
motor B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
compared O
with O
levobupivacaine O
or O
ropivacaine O
at O
wake-up O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

These O
findings O
support O
advancing O
the O
present O
sirolimus O
formulation O
into O
phase O
II O
studies O
. O
[]

Also O
, O
there O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
individuals O
who O
improved O
by O
> O
or O
[]

There O
were O
24 O
patients O
who O
had O
anti-Xa B-outcome ['Physiological-Clinical']
levels O
measured O
at O
weeks O
1 O
and O
4 O
. O
['Physiological-Clinical']

The O
DASH O
diet O
did O
not O
affect O
markers O
of O
fibrinolysis O
. O
[]

The O
changes O
in O
enzyme B-outcome ['Physiological-Clinical']
levels O
confirm O
the O
cholestatic O
type O
of O
hepatobiliary O
deviations O
without O
clinical O
impact O
on O
short-term O
TPN O
therapy O
. O
['Physiological-Clinical']

PRIMARY O
OUTCOME O
MEASURE O
Postoperative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
the O
acute O
trauma O
unit O
. O
['Mortality']

An O
acute O
bout O
of O
aerobic O
exercise O
results O
in O
a O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
that O
lasts O
several O
hours O
. O
['Physiological-Clinical']

Both O
doses O
of O
piroxicam O
were O
significantly O
more O
effective O
than O
placebo O
from O
Hours O
2 O
to O
12 O
for O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
( O
PID B-outcome ['Physiological-Clinical']
) O
and O
relief B-outcome ['Physiological-Clinical']
scores O
, O
as O
well O
as O
for O
SPID O
and O
TOTAL O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Twelve O
children O
with O
autism O
were O
randomly O
assigned O
to O
either O
an O
experimental O
group O
( O
receiving O
deep O
pressure O
) O
or O
a O
placebo O
group O
( O
not O
receiving O
deep O
pressure O
but O
in O
the O
disengaged O
Hug O
Machine O
) O
. O
[]

A O
randomized O
trial O
of O
intranasal O
beclomethasone O
dipropionate O
after O
polypectomy O
. O
[]

Getting O
a O
high O
response O
rate O
of O
sexual O
behavior O
survey O
among O
the O
general O
population O
in O
Japan O
: O
three O
different O
methods O
of O
survey O
on O
sexual O
behavior O
. O
[]

An O
exploratory O
study O
: O
the O
use O
of O
paroxetine O
for O
methamphetamine B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Visual O
impairment O
is O
common O
among O
rural O
Chinese O
children, O
but O
fewer O
than O
a O
quarter O
of O
children O
who O
need O
glasses O
actually O
own O
and O
use O
them. O
[]

In O
the O
subgroup O
of O
Avastin-treated O
eyes O
, O
multivariate O
analysis O
identified O
hemoglobin O
A1c O
as O
the O
strongest O
predictor O
of O
proliferative B-outcome ['Physiological-Clinical']
diabetic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Adjuvant O
immunochemotherapy O
using O
the O
antitumour O
polysaccharide O
sizofiran O
( O
SPG O
) O
, O
an O
extract O
from O
the O
culture O
broth O
of O
Schizophyllum O
commune O
Fries O
, O
was O
prescribed O
randomly O
for O
386 O
Japanese O
patients O
with O
resectable O
gastric O
cancer O
. O
[]

CONCLUSIONS O
The O
planimetrically O
obtained O
prostate O
volume O
showed O
a O
more O
favorable O
agreement O
with O
the O
radical O
prostatectomy O
volume O
than O
the O
prolate O
ellipsoid O
volume O
. O
[]

METHODS O
Forty O
patients O
were O
divided O
into O
four O
groups O
of O
ten O
. O
[]

Recently, O
we O
revealed O
that O
beta-Eudesmol O
ingestion O
affected O
autonomic O
nerve O
activity O
in O
an O
animal O
model. O
[]

Peak O
block O
height B-outcome ['Physiological-Clinical']
was O
similar O
between O
2-CP O
( O
T8 O
[ O
range O
, O
T6 O
to O
L2 O
] O
) O
and O
2-CP O
with O
clonidine O
( O
T8 O
[ O
range O
, O
T4 O
to O
T11 O
] O
) O
( O
P O
= O
0.57 O
) O
. O
['Physiological-Clinical']

Changes O
in O
cardiac B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
and O
function O
in O
hemodialysis O
patients O
during O
growth O
hormone O
treatment O
. O
['Physiological-Clinical']

Frequency O
and O
percentage O
of O
responses O
to O
different O
measures O
of O
adherence O
were O
carried O
out O
as O
well O
as O
correlation O
between O
the O
measures O
. O
[]

500 O
grains/m O
( O
3 O
) O
, O
then O
randomized O
to O
four O
maintenance O
dose O
groups O
of O
rBet O
v O
1-FV O
and O
one O
placebo O
group O
: O
20 O
?g O
( O
n O
= O
7 O
) O
, O
80 O
?g O
( O
n O
= O
8 O
) O
, O
160 O
?g O
( O
n O
= O
7 O
) O
, O
320 O
?g O
( O
n O
= O
8 O
) O
, O
and O
placebo O
( O
n O
= O
7 O
) O
. O
[]

The O
vertical O
clinical O
attachment O
level O
( O
CAL-v O
) O
gain O
was O
statistically O
significant O
only O
for O
the O
OFD-group O
. O
[]

Ninety-eight O
per O
cent O
of O
the O
intravenous O
digital O
subtraction O
angiograms O
were O
assessed O
as O
adequate O
for O
clinical O
management O
by O
the O
vascular O
surgeon O
. O
[]

Eight O
patients O
( O
13 O
% O
) O
have O
demonstrated O
an O
increase O
in O
their O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
> O
or O
= O
0.044 O
mmol/l O
30 O
days O
after O
administration O
of O
contrast O
agent O
: O
2/19 O
( O
11 O
% O
) O
in O
the O
control O
group O
, O
2/21 O
( O
10 O
% O
) O
in O
the O
600 O
mg O
NAC O
group O
and O
4/20 O
( O
20 O
% O
) O
the O
300 O
mg O
NAC O
group O
( O
p O
= O
0.66 O
) O
. O
['Physiological-Clinical']

BMD B-outcome ['Physiological-Clinical']
was O
measured O
by O
DXA O
at O
baseline O
and O
after O
6 O
months O
of O
exercise O
. O
['Physiological-Clinical']

However O
, O
positive O
effects O
on O
symptoms B-outcome ['Physiological-Clinical']
, O
knowledge B-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
the O
intervention O
were O
found O
in O
both O
the O
short O
and O
the O
long O
version O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Metformin O
does O
not O
enhance O
ovulation O
induction O
in O
clomiphene O
resistant O
polycystic O
ovary O
syndrome O
in O
clinical O
practice O
. O
[]

Mild O
side O
effects O
including O
cough O
( O
n O
= O
9 O
) O
and O
sore O
throat O
( O
n O
= O
6 O
) O
did O
not O
require O
discontinuation O
of O
therapy O
. O
[]

Patients O
received O
oral O
esomeprazole O
40 O
mg O
( O
n O
= O
220 O
) O
or O
20 O
mg O
( O
n O
= O
226 O
) O
or O
placebo O
( O
n O
= O
229 O
) O
once O
daily O
for O
4 O
wk O
. O
[]

It O
can O
be O
used O
in O
cases O
in O
which O
introduction O
of O
a O
22 O
Char O
optical O
urethrotome O
into O
the O
stricture O
site O
is O
impossible O
, O
as O
well O
as O
for O
treatment O
of O
multiple O
strictures O
during O
one O
procedure O
. O
[]

Nurses O
and O
physician O
assistants O
( O
PAs O
) O
were O
presented O
a O
case O
study O
of O
a O
patient O
with O
symptoms O
of O
CFS O
. O
[]

Longitudinally O
, O
these O
correlations O
were O
lower O
( O
coefficients O
ranged O
from O
0.17 O
to O
0.54 O
) O
but O
were O
still O
significant O
. O
[]

Correlational O
studies O
have O
revealed O
a O
positive O
relationship O
between O
parent O
verbal O
responsiveness O
and O
language O
outcomes O
in O
children O
with O
autism O
. O
[]

Recovery O
of O
TOFr O
from O
0.25 O
to O
0.75 O
and O
from O
0.25 O
to O
0.9 O
was O
longer O
in O
patients O
treated O
with O
rocuronium O
than O
in O
those O
treated O
with O
cisatracurium O
(both O
P O
<.001). O
[]

These O
22 O
patients O
constituted O
the O
control O
group O
of O
a O
controlled O
trial O
and O
received O
standard O
outpatient O
clinic O
treatment O
during O
follow-up O
. O
[]

Under O
BF O
, O
pulse B-outcome ['Physiological-Clinical']
and O
respiratory B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
, O
and O
elevation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
due O
to O
mental O
stress O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
all O
, O
2437 O
patients O
with O
a O
history O
of O
HSL O
were O
randomized O
to O
self-initiate O
treatment O
with O
ME-609 O
, O
5 O
% O
acyclovir O
in O
ME-609 O
vehicle O
, O
or O
ME-609 O
vehicle O
( O
placebo O
) O
at O
the O
earliest O
sign O
of O
a O
cold O
sore O
recurrence O
. O
[]

Response O
to O
therapy B-outcome ['Resource-use']
was O
evaluated O
between O
the O
4th O
and O
8th O
week O
and O
classified O
as O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
, O
defined O
as O
no O
gross O
and O
microscopic B-outcome ['Physiological-Clinical']
evidence I-outcome ['Physiological-Clinical']
of O
residual O
tumor B-outcome ['Physiological-Clinical']
, O
or O
no O
response O
( O
NR O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Polydioxanone O
sternal O
sutures O
for O
prevention O
of O
sternal O
dehiscence O
. O
[]

DISCUSSION O
Older O
women O
with O
the O
clinical O
risk O
factors O
identified O
in O
this O
study O
should O
be O
investigated O
for O
osteoporosis O
or O
offered O
preventive O
treatment O
. O
[]

Guided O
imagery O
appeared O
to O
have O
potential O
as O
a O
useful O
nursing O
modality O
for O
chronic O
pain O
sufferers O
. O
[]

Working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
of O
the O
non-ASD O
group O
was O
unaffected O
by O
propranolol/placebo O
administration O
. O
['Life-Impact']

In O
spite O
of O
the O
high O
dropout O
rate O
, O
91 O
% O
of O
the O
mothers O
were O
located O
for O
the O
18 O
month O
follow-up O
interview O
. O
[]

PCA O
morphine O
for O
postoperative O
pain O
. O
[]

OBJECTIVE O
We O
investigated O
the O
changes O
in O
the O
temporomandibular O
joint O
( O
TMJ O
) O
after O
bilateral O
sagittal O
split O
osteotomy O
of O
the O
mandible O
for O
orthognathic O
surgery O
and O
the O
influence O
of O
positioning O
of O
the O
condylar O
process O
in O
the O
centre O
of O
the O
articular O
fossa O
before O
and O
during O
the O
operation O
for O
preventing O
changes O
in O
the O
TMJ O
postoperatively O
. O
[]

The O
volume O
of O
injected O
fluid O
was O
recorded O
. O
[]

Journal-Name:Medicine O
[]

Nine O
healthy O
volunteers O
( O
age O
, O
23.4 O
+/- O
0.2 O
years O
; O
body O
mas O
index O
[ O
BMI O
] O
, O
23.5 O
+/- O
1.6 O
kg/m O
( O
2 O
) O
) O
were O
fed O
, O
in O
random O
order O
, O
with O
a O
high-fat O
diet O
( O
HFD O
) O
( O
65 O
% O
of O
energy O
content O
fat O
, O
15 O
% O
protein O
, O
20 O
% O
carbohydrate O
) O
or O
a O
high-carbohydrate O
diet O
( O
HCD O
) O
( O
70 O
% O
carbohydrate O
, O
15 O
% O
protein O
, O
15 O
% O
fat O
) O
for O
5 O
days O
, O
with O
a O
washout O
period O
of O
10 O
days O
between O
the O
diets O
. O
[]

Outcomes O
of O
Japanese O
breast O
cancer O
patients O
treated O
with O
pre-operative O
and O
post-operative O
anastrozole O
or O
tamoxifen O
. O
[]

RESULTS O
Overall O
10-year O
survival B-outcome ['Mortality']
was O
47.1 O
% O
for O
the O
immunochemotherapy O
group O
( O
P O
< O
0.037 O
vs O
FAM O
and O
P O
< O
0.0006 O
vs O
control O
) O
, O
30 O
% O
for O
the O
chemotherapy O
group O
( O
vs O
control O
, O
NS O
) O
, O
and O
15.2 O
% O
for O
the O
control O
group O
. O
['Mortality']

Patients O
on O
paliperidone O
ER O
who O
achieved O
remission O
during O
this O
phase O
were O
randomized O
( O
1:1 O
) O
to O
fixed-dose O
paliperidone O
ER O
( O
n=152 O
) O
or O
placebo O
( O
n=148 O
) O
; O
those O
on O
olanzapine O
continued O
to O
receive O
that O
at O
fixed O
dose O
( O
n=83 O
) O
( O
maintenance O
phase O
) O
. O
[]

Inadequate O
maternal O
nutrition O
during O
gestation O
may O
cause O
an O
adverse O
environment O
for O
the O
fetus O
leading O
to O
alterations O
of O
the O
hypothalamic-pituitary-adrenal O
( O
HPA O
) O
and O
sympatho-adrenomedullary O
( O
SAM O
) O
systems O
later O
in O
life O
. O
[]

Patients O
with O
stage O
III O
in O
the O
OK-432 O
group O
survived B-outcome ['Mortality']
significantly O
longer O
than O
those O
in O
the O
control O
group O
( O
P O
less O
than O
0.05 O
) O
, O
but O
there O
was O
no O
significance O
between O
in O
patients O
with O
stage O
IV O
of O
both O
treatment O
groups O
. O
['Mortality']

Ninety-three O
women O
with O
FIGO O
stage O
II O
epithelial O
ovarian O
carcinoma O
underwent O
comprehensive O
surgical O
staging O
and O
were O
randomized O
prospectively O
to O
therapy O
consisting O
of O
either O
intraperitoneal O
radioactive O
phosphorus O
or O
oral O
melphalan O
. O
[]

TRIAL O
REGISTRATION O
NUMBER O
http O
: O
//www.ClinicalTrials.gov O
; O
Unique O
identifier O
: O
NCT00617084 O
. O
[]

A O
different O
pattern O
of O
untoward B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
seen O
in O
the O
final O
14 O
weeks O
of O
treatment O
. O
['Adverse-effects']

In O
conclusion O
cuffed O
, O
tunnelled O
central O
venous O
catheters O
are O
less O
prone O
to O
displacement B-outcome ['Life-Impact']
than O
traditional O
percutaneous O
central O
venous O
catheters O
when O
used O
in O
children O
with O
malignant O
diseases O
. O
['Life-Impact']

Participants O
were O
randomized O
into O
one O
of O
two O
intervention O
groups O
: O
a O
tailored O
intervention O
, O
in O
which O
they O
received O
personalized O
skin O
cancer O
education O
through O
the O
mail O
; O
or O
a O
control O
group O
who O
received O
generic O
skin O
cancer O
information O
materials O
. O
[]

Then O
either O
placebo O
or O
piracetam O
4.8 O
g/day O
or O
9.6 O
g/day O
was O
given O
during O
four O
weeks O
with O
measurements O
after O
2 O
weekks O
and O
4 O
weeks O
. O
[]

The O
[]

CONCLUSION O
A O
10 O
mg O
bolus O
dose O
of O
IV O
morphine O
given O
to O
patients O
with O
moderate O
pain O
after O
surgery O
does O
not O
cause O
severe O
[]

At O
T3, O
the O
intervention O
group O
still O
reported O
significantly O
higher O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress O
(d O
= O
0.32) O
and O
better O
emotional O
coping B-outcome ['Life-Impact']
response O
(d O
= O
0.34) O
than O
the O
comparison O
group O
but O
did O
not O
report O
significantly O
higher O
social B-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
for O
stress O
management, O
stress B-outcome ['Life-Impact']
, O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
positive B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
negative B-outcome ['Life-Impact', 'Life-Impact']
affect E1-outcome ['Life-Impact', 'Life-Impact']
. O
CONCLUSIONS: O
To O
help O
young, O
low-income O
women O
with O
overweight O
or O
obesity O
manage O
stress, O
researchers O
and O
program O
planners O
may O
consider O
focusing O
on O
building O
self-efficacy B-outcome ['Life-Impact']
to O
cope O
with O
stress. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact', 'Life-Impact'], ['Life-Impact']]

Thirty-minute O
language O
groups O
were O
targeted O
to O
teach O
receptive O
and O
expressive O
skills O
using O
pictures O
and O
common O
objects O
across O
five O
categories O
( O
e.g. O
, O
household O
items O
, O
foods O
) O
. O
[]

Changes O
( O
mean O
+/- O
SE O
) O
in O
sitting B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
baseline I-outcome ['Physiological-Clinical']
were O
-8.1 O
+/- O
1.4 O
mm O
Hg O
for O
terazosin O
and O
-5.0 O
+/- O
1.5 O
mm O
Hg O
for O
propranolol O
. O
['Physiological-Clinical']

As O
expected O
, O
initial B-outcome ['Physiological-Clinical']
TSAb I-outcome ['Physiological-Clinical']
levels O
had O
no O
predictive O
value O
. O
['Physiological-Clinical']

Based O
upon O
discriminant O
analysis O
, O
a O
total O
of O
26 O
deaths B-outcome ['Mortality']
were O
expected O
from O
the O
entire O
group O
, O
but O
only O
7 O
patients O
died B-outcome ['Mortality']
, O
therefore O
, O
the O
['Mortality', 'Mortality']

RESULTS O
There O
were O
133 O
deaths B-outcome ['Mortality']
in O
the O
WASA O
group O
( O
31.8 O
% O
) O
and O
95 O
deaths B-outcome ['Mortality']
in O
the O
ASA O
group O
( O
23.0 O
% O
; O
risk O
ratio O
, O
1.41 O
; O
95 O
% O
confidence O
interval O
, O
1.09 O
to O
1.84 O
; O
P O
=.0001 O
) O
. O
['Mortality', 'Mortality']

This O
study O
was O
designed O
to O
investigate O
the O
safety O
and O
effectiveness O
of O
open-label O
olanzapine O
as O
a O
treatment O
for O
children O
with O
autistic O
disorder O
by O
using O
haloperidol O
as O
a O
standard O
comparator O
treatment O
. O
[]

Use O
of O
a O
clay O
modeling O
task O
to O
reduce O
chocolate B-outcome ['Life-Impact']
craving I-outcome ['Life-Impact']
. O
['Life-Impact']

Patients O
were O
randomly O
allocated O
into O
one O
of O
the O
two O
regimens O
, O
with O
dosage O
according O
to O
bodyweight O
range O
. O
[]

Metabolism O
of O
enflurane O
resulted O
in O
plasma B-outcome ['Physiological-Clinical']
inorganic I-outcome ['Physiological-Clinical']
fluoride I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
max O
15 O
mumol O
litre O
-1 O
) O
which O
were O
well O
below O
the O
toxic O
value O
. O
['Physiological-Clinical']

Patients O
treated O
in O
the O
current O
study O
with O
rhGM-CSF O
plus O
either O
rHuEPO O
or O
with O
placebo O
had O
a O
higher O
incidence O
of O
rash B-outcome ['Physiological-Clinical']
than O
seen O
in O
our O
historical O
experience O
using O
rhGM-CSF O
. O
['Physiological-Clinical']

Single-use O
plaque O
removal O
efficacy O
of O
three O
power O
toothbrushes O
. O
[]

The O
basic O
therapy O
for O
all O
cases O
was O
radiotherapy O
and O
, O
when O
required O
, O
surgery O
. O
[]

The O
median O
follow-up O
was O
13 O
years O
. O
[]

2 O
) O
( O
1 O
) O
= O
5.227 O
, O
P O
= O
0.022 O
) O
. O
[]

AIMS O
This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
study O
evaluated O
the O
safety O
and O
efficacy O
of O
ezetimibe O
10 O
mg/day O
in O
patients O
with O
primary O
hypercholesterolemia O
. O
[]

Both O
ecASA O
and O
cASA O
inhibited O
14C-serotonin O
release O
; O
no O
significant O
difference O
was O
observed O
in O
the O
maximum O
effect O
between O
these O
two O
products O
( O
p O
less O
than O
0.05 O
) O
. O
[]

By O
study O
endpoint O
, O
risperidone-treated O
subjects O
exhibited O
a O
64 O
% O
improvement O
over O
baseline O
in O
the O
irritability B-outcome ['Life-Impact']
score O
almost O
double O
that O
of O
placebo-treated O
subjects O
( O
31 O
% O
) O
. O
['Life-Impact']

CONCLUSION O
PKVP O
achieved O
comparable O
results O
to O
traditional O
TURP O
and O
was O
an O
effective O
and O
safe O
procedure O
. O
[]

The O
SGRQ O
Total O
score O
and O
[]

Journal O
ID: O
2985248R O
[]

On O
all O
measures O
group O
variability O
in O
scores O
increased O
with O
age O
. O
[]

Radiation-induced O
brachial O
plexopathy O
occurs O
mainly O
as O
diffuse O
damage O
to O
the O
brachial O
plexus O
. O
[]

OUTCOME O
MEASURES O
Parents O
and O
teachers O
assessed O
major B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
using O
the O
Conners O
' O
Rating O
Scales O
at O
0 O
and O
8 O
weeks O
. O
['Life-Impact']

In O
Group O
C O
, O
patients O
were O
pretreated O
with O
lidocaine O
1.0 O
mg/kg O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

However, O
most O
studies O
assessing O
implementation O
success O
focus O
on O
only O
one O
condition, O
although O
more O
conditions O
influence O
this O
process. O
[]

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O
['Physiological-Clinical']

American O
College O
of O
Cardiology/American O
Heart O
Association O
type O
C B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
diabetic O
patients O
( O
17 O
% O
versus O
15 O
% O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Through O
a O
village-based O
surveillance O
system O
, O
diarrhoeal O
morbidity O
data O
( O
severity O
, O
duration O
, O
compliance O
) O
were O
collected O
for O
14 O
days O
. O
[]

Teleconferencing O
Supervision O
is O
a O
method O
for O
training O
community-based O
substance O
abuse O
clinicians O
in O
Motivational O
Interviewing O
( O
MI O
) O
. O
[]

AIMS O
To O
determine O
whether O
metformin O
pretreatment O
has O
beneficial O
effects O
in O
clomiphene O
resistant O
infertile O
women O
with O
polycystic O
ovary O
syndrome O
( O
PCOS O
) O
in O
an O
infertility O
clinic O
. O
[]

In O
order O
to O
more O
precisely O
measure O
the O
effects O
of O
secretin O
, O
this O
study O
investigated O
the O
effect O
of O
a O
single O
intravenous O
dose O
of O
porcine O
secretin O
on O
12 O
autistic O
children O
through O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

This O
study O
showed O
no O
significant O
difference O
of O
contracture B-outcome ['Physiological-Clinical']
with O
smooth O
versus O
fine O
textured O
implants O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
allocated O
to O
control O
( O
n O
= O
13 O
) O
or O
treatment O
groups O
( O
n O
= O
12 O
) O
. O
[]

Including O
additionally O
3 O
patients O
on O
placebo O
and O
1 O
patient O
on O
valproate O
who O
felt O
they O
had O
suffered O
a O
migraine B-outcome ['Physiological-Clinical']
attack B-outcome ['Physiological-Clinical']
, O
but O
who O
had O
as O
associated O
symptoms O
only O
photophobia B-outcome ['Physiological-Clinical']
or O
phonophobia B-outcome ['Physiological-Clinical']
, O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
induced B-outcome ['Resource-use']
migraine B-outcome ['Physiological-Clinical']
after O
valproate O
was O
seen O
( O
P O
= O
0.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

RESULTS O
In O
group O
A O
with O
90 O
evaluable O
patients O
, O
the O
response O
rate O
was O
25.6 O
% O
( O
6 O
CR O
, O
17 O
PR O
) O
whereas O
in O
group O
B O
with O
88 O
evaluable O
patients O
, O
the O
response O
rate O
was O
31.8 O
% O
( O
3 O
CR O
, O
25 O
PR O
) O
, O
P O
= O
0.733 O
. O
[]

The O
only O
difference O
in O
treatment O
lay O
in O
the O
position O
of O
fixation O
in O
plaster O
. O
[]

However O
, O
a O
diagnosis O
for O
major B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
or O
chronic B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
did O
not O
predict O
quitting O
. O
['Life-Impact', 'Life-Impact']

Following O
this O
study O
epidural O
anesthesia O
was O
carried O
out O
with O
20 O
ml O
etidocaine O
1 O
% O
( O
n O
= O
20 O
) O
in O
an O
open O
study O
. O
[]

A O
randomized O
trial O
of O
a O
brief O
alcohol O
intervention O
for O
needle O
exchangers O
( O
BRAINE O
) O
. O
[]

We O
found O
beneficial O
effects O
of O
iTBS O
on O
mood B-outcome ['Life-Impact']
, O
but O
no O
improvement O
of O
gait B-outcome ['Life-Impact']
, O
bradykinesia B-outcome ['Physiological-Clinical']
, O
UPDRS B-outcome ['Physiological-Clinical']
, O
and O
other O
measures O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
From O
January O
2004 O
to O
December O
2006 O
, O
101 O
patients O
with O
high-risk O
breast O
cancer O
after O
surgical O
resection O
were O
enrolled O
into O
this O
study O
. O
[]

Teriparatide O
improves O
early B-outcome ['Physiological-Clinical']
callus I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
in O
distal O
radial O
fractures O
. O
['Physiological-Clinical']

Title: O
A O
randomized O
comparative O
study O
between O
intravenous O
and O
intramuscular O
scorpion O
antivenom O
regimens O
in O
children. O
[]

During O
surgery O
, O
fluid O
boluses O
of O
Voluven O
were O
given O
if O
the O
stroke O
volume O
variation O
was O
> O
10 O
% O
. O
[]

Journal-Name:Therapeutic O
drug O
monitoring O
[]

Assessment O
included O
recording O
of O
: O
visual O
analog O
scores O
( O
VAS O
) O
for O
pain O
; O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
; O
range O
of O
movement B-outcome ['Physiological-Clinical']
; O
joint B-outcome ['Physiological-Clinical']
effusion I-outcome ['Physiological-Clinical']
; O
local B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
; O
synovial B-outcome ['Physiological-Clinical']
thickening I-outcome ['Physiological-Clinical']
; O
joint-line B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
periarticular I-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
0374675 O
[]

No O
differences O
in O
transcription B-outcome ['Physiological-Clinical']
factor O
expression B-outcome ['Physiological-Clinical']
were O
found O
in O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Short-term O
pulmonary O
effects O
of O
total O
parenteral O
nutrition O
in O
children O
with O
cystic O
fibrosis O
. O
[]

A O
controlled O
study O
of O
early O
discharge O
after O
uncomplicated O
myocardial O
infarction O
. O
[]

In O
this O
study O
, O
the O
efficacy O
and O
safety O
of O
tracheal O
intubation O
with O
the O
LFS O
was O
compared O
with O
that O
of O
the O
Macintosh O
laryngoscope O
utilizing O
manual O
in-line O
stabilization O
( O
MILS O
) O
to O
simulate O
difficult O
airways O
. O
[]

Effect O
of O
two O
monophasic O
oral O
contraceptives O
containing O
gestodene O
or O
desogestrel O
on O
serum O
lipoprotein O
lipid O
levels O
. O
[]

Compared O
with O
the O
general O
anesthesia O
group, O
the O
first O
night O
of O
total B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
in O
the O
spinal O
anesthesia O
group O
was O
significantly O
shorter[(357.2+/-83.4)min O
vs O
(275.1+/-64.8)min, O
t=-9.635, O
P<0.05], O
while O
the O
rate O
of O
wakefulness B-outcome ['Physiological-Clinical']
, O
total B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
overall B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
daytime B-outcome ['Life-Impact']
mood I-outcome ['Life-Impact']
and O
daytime B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
were O
significantly O
higher[(25.9%, O
22.2%, O
25.9%, O
18.5%18.5%) O
vs O
(51.7%, O
51.7%, O
55.2%, O
48.3%44.8%), O
chi(2)=3.901, O
5.192, O
4.941, O
5.523 O
and O
4.437, O
all O
P<0.05], O
and O
the O
cases O
of O
postoperative O
urinary B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
limb I-outcome ['Physiological-Clinical']
discomfort I-outcome ['Physiological-Clinical']
were O
significantly O
higher[(8 O
and O
6) O
vs O
(1 O
and O
0), O
all O
P<0.05]. O
Conclusion: O
Both O
anesthesia O
methods O
can O
be O
safely O
and O
effectively O
applied O
to O
middle-aged O
and O
elderly O
patients O
with O
lower O
extremity O
varicose O
veins O
surgery, O
but O
patients O
with O
general O
anesthesia O
show O
fewer O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
on O
the O
first O
night O
after O
surgery O
and O
have O
better O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical']]

Outcome O
measures O
included O
Communication O
and O
Symbolic O
Behavior O
Scale O
( O
CSBS O
) O
, O
Ritvo O
Real-life O
Rating O
Scale O
, O
weekly O
Global O
Rating O
Scale O
( O
GBRS O
) O
by O
parents O
and O
teachers O
, O
and O
daily O
log O
of O
gastrointestinal O
symptoms O
. O
[]

Instent B-outcome ['Physiological-Clinical']
restenoses I-outcome ['Physiological-Clinical']
were O
significantly O
more O
common O
in O
the O
CAS O
group O
( O
4.6 O
% O
vs O
2.2 O
% O
, O
odds O
ratio O
2.14 O
, O
95 O
% O
CI O
1.10-4.18 O
) O
. O
['Physiological-Clinical']

Fifty-six O
patients O
were O
assigned O
to O
5 O
days O
of O
perioperative O
antibiotic O
prophylaxis O
. O
[]

CONCLUSIONS O
Combined O
cardiac O
stem O
cell O
delivery O
induces O
a O
moderate O
but O
significant O
improvement O
in O
myocardial B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

In O
the O
fixed O
duration O
cautery O
group O
, O
11 O
of O
21 O
polyps O
( O
52 O
% O
) O
were O
eradicated B-outcome ['Physiological-Clinical']
, O
compared O
with O
12 O
of O
14 O
polyps O
( O
86 O
% O
) O
in O
the O
variable O
duration O
cautery O
group O
( O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Ninety O
nine O
patients O
( O
group O
A O
) O
were O
randomized O
to O
receive O
paclitaxel O
175 O
mg/m2 O
in O
three-hour O
infusion O
plus O
carboplatin O
dosed O
to O
an O
area O
under O
the O
concentration-time O
curve O
of O
6 O
every O
3 O
weeks O
and O
99 O
( O
group O
B O
) O
to O
receive O
the O
same O
regimen O
with O
paclitaxel O
increased O
to O
225 O
mg/m2 O
. O
[]

Etanercept O
plus O
standard O
therapy O
for O
Wegener O
's O
granulomatosis O
. O
[]

However O
, O
most O
studies O
have O
shown O
that O
people O
with O
ASD O
do O
respond O
to O
eye-gaze O
cues O
in O
experimental O
paradigms O
, O
though O
it O
is O
possible O
that O
this O
behaviour O
is O
based O
on O
an O
atypical O
strategy O
. O
[]

CONCLUSIONS: O
Both O
techniques O
were O
effective O
in O
the O
short-term O
(18-30 O
months) O
in O
treatment O
of O
recurrent O
patellar O
dislocation. O
[]

Propofol O
was O
administered O
after O
release O
of O
venous O
occlusion O
. O
[]

This O
trial O
was O
registered O
before O
commencement O
at O
clinical O
trials.gov O
as O
NCT00117000 O
. O
[]

Results O
will O
be O
disseminated O
through O
workshops, O
conferences O
and O
peer-reviewed O
publications. O
[]

RESULTS O
All O
H. O
pylori O
( O
+ O
) O
patients O
showed O
a O
rapid O
increase O
of O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
with O
a O
mean O
intragastric B-outcome ['Physiological-Clinical']
pH B-outcome ['Physiological-Clinical']
of O
6.7 O
during O
the O
second O
half O
of O
the O
first O
day O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Granisetron O
was O
administered O
as O
a O
single O
intravenous O
dose O
before O
the O
start O
of O
cisplatin O
chemotherapy O
( O
> O
or O
= O
60 O
mg/m2 O
) O
. O
[]

Safety O
of O
an O
astaxanthin-rich O
Haematococcus O
pluvialis O
algal O
extract O
: O
a O
randomized O
clinical O
trial O
. O
[]

The O
risk O
for O
falls B-outcome ['Life-Impact']
decreased O
for O
exercise O
participants O
with O
low O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
.51 O
) O
but O
increased O
for O
exercise O
participants O
with O
high O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
3.51 O
) O
. O
['Life-Impact']

RESULTS O
Sixty O
women O
were O
studied O
. O
[]

INTERVENTIONS O
N/A O
. O
[]

We O
previously O
found O
that O
resting O
state O
functional O
connectivity O
( O
rsFC O
) O
between O
the O
dorsal O
anterior O
cingulate O
( O
dACC O
) O
and O
striatum O
is O
independently O
associated O
with O
nicotine O
addiction O
and O
psychiatric O
illness O
. O
[]

A O
prospective O
randomized O
study O
. O
[]

They O
provide O
supportive O
evidence O
that O
tailored O
intervention O
programs O
should O
be O
developed O
to O
support O
the O
screening O
and O
completion O
of O
treatment O
of O
foreign-born O
adolescents O
. O
[]

Quantitative O
fit O
tests O
(QNFTs) O
were O
performed O
before O
and O
after O
training O
using O
three O
types O
of O
N95 O
or O
higher O
filter O
respirators O
(cup-type, O
fold-type, O
valve-type). O
[]

In O
the O
etidronate O
group O
, O
serum B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
deoxypyridinoline I-outcome ['Physiological-Clinical']
levels O
decreased O
significantly O
during O
the O
study O
period O
, O
whereas O
the O
levels O
in O
the O
placebo O
group O
were O
increased O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Twelve O
patients O
were O
treated O
with O
SuperPATH O
approach O
(SuperPATH O
group) O
and O
12 O
patients O
with O
posterolateral O
approach O
(control O
group). O
[]

BACKGROUND O
Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
accompanied O
by O
a O
number O
of O
adverse O
side O
effects O
including O
reduced O
bone O
mass O
and O
increased O
risk O
for O
fracture O
, O
reduced O
lean O
mass O
and O
muscle O
strength O
, O
mood O
disturbance O
and O
increased O
fat O
mass O
compromising O
physical O
functioning O
, O
independence O
, O
and O
quality O
of O
life O
. O
[]

Pilot O
study O
with O
adjuvant O
hormone O
therapy O
in O
FIGO O
stage O
I O
endometrial O
carcinoma O
with O
myometrial O
invasion O
. O
[]

The O
efficacy O
of O
SI O
vaccines O
is O
well O
established O
under O
experimental O
conditions O
, O
but O
information O
about O
field O
efficacy O
is O
scarce O
. O
[]

Primary O
and O
secondary O
target O
lesion O
patencies O
were O
determined O
by O
Kaplan-Meier O
analysis O
. O
[]

They O
do O
, O
however O
, O
reduce O
the O
symptom B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
breathlessness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
plasma O
levels O
of O
ADA O
in O
patients O
with O
chronic O
schizophrenia O
who O
received O
clozapine O
were O
significantly O
higher O
than O
patients O
who O
received O
haloperidol O
. O
[]

Results O
may O
be O
used O
to O
tailor O
structural, O
organizational, O
provider, O
patient, O
and O
innovation O
factors O
prior O
to O
future O
implementations O
of O
the O
mhGAP-based O
training O
in O
Tunisia. O
[]

The O
control O
group O
( O
n O
= O
40 O
) O
followed O
standard O
CVC O
procedure O
provided O
by O
nurses O
. O
[]

DFS O
after O
testicular B-outcome ['Resource-use']
biopsy I-outcome ['Resource-use']
was O
significantly O
better O
in O
boys O
without O
occult O
TL O
( O
P O
= O
.001 O
) O
. O
['Resource-use']

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
consistently O
higher O
in O
the O
study O
group O
at O
the O
end O
of O
the O
study O
. O
['Life-Impact']

MEASUREMENTS O
Pain O
on O
injection O
was O
measured O
using O
a O
4-point O
scale O
. O
[]

RESULTS O
There O
were O
no O
differences O
in O
any O
of O
the O
primary O
or O
secondary O
outcomes O
when O
fexofenadine O
was O
added O
to O
treatment O
with O
either O
fluticasone O
propionate-salmeterol O
or O
fluticasone O
propionate O
alone O
. O
[]

In O
this O
double-blind O
, O
randomized O
, O
cross-over O
study O
, O
20 O
adult O
patients O
with O
reversible O
chronic O
airway O
obstruction O
( O
intrinsic O
asthma O
or O
COPD O
) O
inhaled O
single O
doses O
of O
formoterol O
9 O
microg O
or O
salbutamol O
100 O
microg O
( O
group O
A O
) O
or O
formoterol O
18 O
microg O
or O
salbutamol O
200 O
microg O
( O
group O
B O
) O
. O
[]

Second O
report O
) O
: O
5-year O
survival O
rate O
. O
[]

There O
were O
a O
total O
of O
three O
deaths B-outcome ['Mortality']
in O
the O
therapy O
group O
and O
eight O
deaths B-outcome ['Mortality']
in O
the O
control O
group O
. O
['Mortality', 'Mortality']

The O
effect O
of O
quality O
and O
amount O
of O
dietary O
fat O
on O
the O
susceptibility O
of O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
in O
subjects O
with O
impaired O
glucose O
tolerance O
. O
['Physiological-Clinical']

Advanced O
age O
and O
diabetes B-outcome ['Physiological-Clinical']
increased O
susceptibility O
to O
the O
composite O
outcome O
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
evaluate O
the O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
KAb201 O
, O
an O
anti-carcinoembryonic O
antigen O
monoclonal O
antibody O
, O
labelled O
with O
I O
( O
131 O
) O
in O
pancreatic O
cancer O
( O
ISRCTN O
16857581 O
) O
. O
['Life-Impact']

degree O
C-1 O
. O
[]

Inflammation O
is O
critical O
for O
atherosclerosis O
development O
and O
may O
be O
a O
target O
for O
risk-reduction O
therapy O
. O
[]

Seventeen O
sighted O
children O
were O
manually O
guided O
to O
perform O
the O
task O
and O
tactually O
prompted O
during O
imitated O
productions O
of O
novel O
words O
for O
the O
event O
. O
[]

The O
characteristics O
of O
the O
contrast O
media O
enhancement O
argue O
for O
an O
active O
concomitant O
process O
of O
destruction O
and O
regeneration O
. O
[]

Calcium O
supplementation O
was O
effective O
in O
increasing O
aBMD B-outcome ['Physiological-Clinical']
at O
regional O
sites O
over O
the O
first O
12-18 O
months O
, O
but O
these O
gains O
were O
not O
maintained O
to O
24 O
months O
. O
['Physiological-Clinical']

METHODS O
Sixty-one O
parturients O
undergoing O
labor O
selected O
for O
delivery O
with O
epidural O
analgesia O
were O
randomized O
into O
two O
groups O
: O
Group O
tramadol O
( O
0.125 O
% O
ropivacaine O
plus O
tramadol O
5 O
mg/mL O
) O
and O
Group O
fentanyl O
( O
0.125 O
% O
ropivacaine O
plus O
fentanyl O
3 O
ug/mL O
) O
. O
[]

The O
findings O
of O
this O
study O
demonstrated O
that O
the O
Asha-Life O
participants O
significantly O
reduced O
their O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
scores O
compared O
to O
the O
Usual O
Care O
participants O
. O
['Life-Impact']

CONCLUSION O
Pethidine O
seems O
to O
be O
a O
better O
alternative O
than O
tramadol O
in O
obstetric O
analgesia O
because O
of O
its O
superiority O
in O
analgesic B-outcome ['Resource-use']
efficacy O
and O
low O
incidence O
of O
maternal B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Resource-use', 'Adverse-effects']

The O
plasma O
half-life O
of O
LY450139 O
was O
approximately O
2.5 O
hours O
. O
[]

In O
both O
groups O
, O
the O
hot B-outcome ['Physiological-Clinical']
flash I-outcome ['Physiological-Clinical']
score O
peaked O
at O
3 O
months O
and O
decreased O
thereafter O
. O
['Physiological-Clinical']

Loss O
of O
tooth O
substance O
during O
root O
planing O
with O
various O
periodontal O
instruments O
: O
an O
in O
vitro O
study O
. O
[]

line B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
when O
analyzed O
separately O
for O
both O
short O
and O
long O
lines O
. O
['Life-Impact']

Effects O
of O
dietary O
coconut O
oil O
on O
the O
biochemical B-outcome ['Physiological-Clinical']
and O
anthropometric B-outcome ['Physiological-Clinical']
profiles O
of O
women O
presenting O
abdominal O
obesity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
control O
group O
(n O
= O
43) O
was O
only O
received O
HRT. O
[]

Visit-to-visit O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
in O
the O
European O
Lacidipine O
Study O
on O
Atherosclerosis O
: O
methodological O
aspects O
and O
effects O
of O
antihypertensive O
treatment O
. O
['Physiological-Clinical']

The O
majority O
of O
younger O
subjects O
with O
high O
blood O
pressure O
had O
low O
risk O
, O
but O
in O
those O
aged O
45-54 O
this O
had O
already O
risen O
to O
a O
medium O
risk O
. O
[]

The O
results O
of O
these O
cultures O
demonstrated O
a O
significant O
bioburden B-outcome ['Physiological-Clinical']
( O
greater O
than O
10 O
( O
5 O
) O
) O
in O
the O
majority O
of O
cases O
, O
despite O
a O
lack O
of O
clinical O
signs O
of O
infection O
. O
['Physiological-Clinical']

The O
use O
of O
desflurane O
as O
part O
of O
a O
balanced O
anesthetic O
technique O
did O
not O
speed O
the O
emergence O
or O
discharge B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
when O
compared O
with O
isoflurane O
. O
['Life-Impact']

METHODS: O
Using O
a O
single-blind, O
counterbalanced, O
crossover O
design, O
we O
compared O
the O
rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
MW O
vs. O
maple-flavored O
bottled O
water O
(control) O
in O
26 O
young O
healthy O
(22 O
+/- O
4 O
yrs., O
[['Physiological-Clinical']]

This O
study O
aimed O
to O
evaluate O
the O
efficacy O
of O
an O
emotion O
training O
programme O
for O
a O
group O
of O
young O
children O
with O
autism O
with O
a O
range O
of O
intellectual O
ability O
. O
[]

We O
examined O
serial O
changes O
in O
spirometry O
and O
Clinical O
COPD O
Questionnaire O
( O
CCQ O
) O
scores O
( O
measuring O
respiratory O
symptoms O
and O
health-related O
quality O
of O
life O
) O
in O
COPD O
participants O
by O
smoking O
status O
during O
a O
smoking O
cessation O
trial O
. O
[]

11.52 O
, O
final O
23.32 O
? O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Little O
is O
known O
about O
the O
effects O
of O
bisphosphonates O
on O
bone O
metastases O
from O
other O
tumors O
and O
in O
particular O
from O
tumors O
for O
which O
no O
effective O
treatment O
is O
available O
. O
[]

One O
patient O
showed O
an O
improvement O
of O
peripheral B-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
after O
induction O
with O
the O
combined O
therapy O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
determine O
the O
effect O
of O
food O
on O
the O
antiviral O
activity O
of O
enteric-coated O
( O
EC O
) O
capsules O
of O
didanosine O
( O
ddI O
) O
. O
[]

Mediastinal O
lymphadenectomy O
in O
non-small O
cell O
lung O
cancer O
: O
effectiveness O
in O
patients O
with O
or O
without O
nodal O
micrometastases O
- O
results O
of O
a O
preliminary O
study O
. O
[]

Intraperitoneal O
cisplatin O
versus O
no O
further O
treatment O
: O
8-year O
results O
of O
EORTC O
55875 O
, O
a O
randomized O
phase O
III O
study O
in O
ovarian O
cancer O
patients O
with O
a O
pathologically O
complete O
remission O
after O
platinum-based O
intravenous O
chemotherapy O
. O
[]

Journal O
ID: O
2985248R O
[]

Of O
the O
discordant O
scans O
, O
8 O
( O
4 O
% O
) O
had O
superior O
scans O
after O
recombinant O
human O
TSH O
administration O
, O
and O
17 O
( O
8 O
% O
) O
had O
superior O
scans O
after O
thyroid O
hormone O
withdrawal O
( O
P O
= O
0.108 O
) O
. O
[]

Men O
with O
the O
less O
functional O
FokI O
ff O
genotype O
( O
14 O
% O
in O
the O
European-descent O
population O
of O
this O
cohort O
) O
are O
more O
susceptible O
to O
this O
cancer O
in O
the O
presence O
of O
low O
25 O
( O
OH O
) O
D O
status O
. O
[]

In O
summary O
, O
the O
irritative B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
caused O
by O
benign B-outcome ['Physiological-Clinical']
prostatic I-outcome ['Physiological-Clinical']
hypertrophy I-outcome ['Physiological-Clinical']
were O
decreased O
and O
urodynamic B-outcome ['Physiological-Clinical']
studies I-outcome ['Physiological-Clinical']
were O
markedly O
improved O
by O
the O
alpha O
1-blocker O
, O
YM617 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
diagnosis O
included O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
( O
n O
= O
27 O
) O
, O
neuroblastoma O
( O
n O
= O
29 O
) O
, O
and O
miscellaneous O
solid O
tumors O
( O
n O
= O
18 O
) O
. O
[]

Mean O
terminal O
half-life O
was O
approximately O
6 O
weeks O
. O
[]

Publication O
date: O
['2019/10/11 O
06:00' O
[]

Patients O
are O
randomized O
to O
2 O
groups O
: O
the O
first O
has O
the O
initial O
2 O
shocks O
for O
ventricular O
fibrillation O
conversion O
programmed O
at O
2 O
energy O
steps O
above O
DFT++ O
( O
typically O
4-6 O
J O
, O
maximum O
10 O
J O
) O
with O
subsequent O
shocks O
at O
maximum O
energy O
, O
and O
the O
second O
has O
all O
shocks O
programmed O
at O
maximum O
energy O
. O
[]

The O
mean O
pain B-outcome ['Physiological-Clinical']
scores O
during O
the O
procedure O
favored O
morcellation O
by O
16.1 O
points O
on O
average O
( O
35.9 O
compared O
with O
52.0 O
; O
95 O
% O
CI O
for O
difference O
, O
-24.7 O
to O
-7.6 O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

The O
LCT O
group O
consisted O
of O
50 O
subjects O
( O
34 O
men O
and O
16 O
women O
) O
, O
while O
the O
MLCT O
group O
consisted O
of O
51 O
subjects O
( O
33 O
men O
and O
18 O
women O
) O
who O
completed O
the O
study O
. O
[]

An O
imaging O
core O
laboratory O
provided O
central O
validation O
, O
and O
2 O
independent O
reviewers O
, O
masked O
to O
assigned O
treatment O
arm O
and O
clinical O
outcomes O
, O
performed O
consensus O
( O
18 O
) O
F-FDG O
PET/CT O
readings O
. O
[]

At O
week O
8 O
, O
losartan O
was O
increased O
to O
50 O
mg O
twice O
daily O
and O
valsartan O
increased O
to O
320 O
mg O
once O
daily O
( O
olmesartan O
remained O
at O
40 O
mg O
once O
daily O
) O
. O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

DESIGN O
Thirty-one O
men O
and O
women O
, O
age O
19-50 O
y O
and O
body O
mass O
index O
27-33 O
kg/m O
( O
2 O
) O
, O
completed O
this O
randomized O
, O
controlled O
, O
16-week O
weight O
loss O
program O
. O
[]

Age O
( O
P O
< O
0.05 O
) O
and O
baseline O
GHBP B-outcome ['Physiological-Clinical']
level O
( O
P O
< O
0.01 O
) O
were O
inversely O
correlated O
with O
the O
increase O
in O
LBM O
. O
['Physiological-Clinical']

A O
final O
patient O
population O
of O
149 O
subjects O
rated O
pain B-outcome ['Physiological-Clinical']
intensity O
and O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
at O
one O
half O
hour O
and O
one O
hour O
following O
treatment O
and O
then O
hourly O
for O
six O
hours O
, O
with O
a O
global O
assessment O
made O
at O
the O
completion O
of O
24 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Best B-outcome ['Life-Impact']
palliation I-outcome ['Life-Impact']
was O
obtained O
by O
the O
combination O
of O
Epirubicin O
and O
MPA O
. O
['Life-Impact']

METHODS O
In O
DaVINCI O
, O
a O
randomised O
phase O
II O
trial O
, O
patients O
with O
advanced O
colorectal O
cancer O
were O
randomly O
allocated O
to O
: O
Combination O
therapy O
( O
FOLFIRI O
) O
, O
irinotecan O
( O
180 O
mg/m O
( O
2 O
) O
IV O
over O
90 O
min O
, O
day O
1 O
) O
, O
5-fluorouracil O
( O
400mg/m O
( O
2 O
) O
IV O
bolus O
and O
2400 O
mg/m O
( O
2 O
) O
by O
46-hour O
infusion O
from O
day O
1 O
) O
and O
folinic O
acid O
( O
20mg/m O
( O
2 O
) O
IV O
bolus O
, O
day O
1 O
) O
, O
2-weekly O
; O
or O
Single-agent O
, O
irinotecan O
( O
350 O
mg/m O
( O
2 O
) O
IV O
over O
90 O
min O
) O
, O
3-weekly O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

OBJECTIVE O
We O
performed O
a O
randomized O
, O
prospective O
trial O
to O
assess O
the O
impact O
of O
fibrin O
glue O
on O
the O
incidence O
of O
lymphocysts O
after O
systematic O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
in O
patients O
with O
gynecologic O
malignancies O
. O
[]

The O
supplement O
group O
had O
significantly O
greater O
improvements O
than O
did O
the O
placebo O
group O
on O
the O
PGI-R O
Average O
Change O
. O
[]

However O
, O
there O
were O
no O
significant O
differences O
in O
patients O
' O
assessment O
of O
symptoms O
and O
in O
review O
of O
facial O
photographs O
for O
rash B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
between O
treatment O
and O
observation O
sides O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
randomized O
double-blinded O
control O
trial O
was O
conducted O
to O
compare O
the O
effectiveness O
of O
tramodol O
and O
placebo O
rectal O
suppository O
for O
the O
management O
of O
postpartum B-outcome ['Physiological-Clinical']
perineal I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
perineorrhaphy O
. O
['Physiological-Clinical']

Between-group O
comparisons O
revealed O
no O
significant O
differences O
in O
clinical B-outcome ['Physiological-Clinical']
outcome O
variables O
. O
['Physiological-Clinical']

The O
main O
study O
group O
consisted O
of O
47 O
children O
with O
less O
than O
or O
equal O
to O
14 O
days O
of O
disease O
before O
therapy O
. O
[]

Diagnostic B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
was O
improved O
from O
75 O
% O
to O
97 O
% O
. O
['Life-Impact']

It O
is O
suggested O
that O
the O
mechanisms O
underlying O
opioid-immune O
interactions O
are O
altered O
in O
this O
population O
of O
autistic O
children O
and O
that O
an O
immunological O
screening O
may O
have O
prognostic O
value O
for O
the O
pharmacological O
therapy O
with O
opiate O
antagonists O
. O
[]

A O
neuropsychological O
examination O
and O
a O
computed O
tomography O
scan O
of O
the O
brain O
were O
performed O
at O
the O
time O
of O
random O
assignment O
and O
repeatedly O
assessed O
at O
6 O
, O
18 O
, O
30 O
, O
and O
48 O
months O
. O
[]

8.7 O
) O
] O
were O
all O
significantly O
lower O
than O
those O
at O
baseline O
[ O
( O
24.7 O
? O
[]

The O
return O
of O
symmetrical B-outcome ['Physiological-Clinical']
pelvic I-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
(PFM) I-outcome ['Physiological-Clinical']
work O
after O
pelvis O
reposition O
exercise O
was O
observed O
in O
the O
experimental O
group. O
[['Physiological-Clinical']]

Patients O
with O
asthma O
stabilized O
on O
CFC O
albuterol O
during O
a O
12-week O
safety O
and O
efficacy O
trial O
were O
randomized O
to O
either O
continue O
receiving O
CFC O
albuterol O
or O
to O
be O
switched O
to O
receive O
HFA O
albuterol O
in O
a O
yearlong O
safety O
and O
efficacy O
trial O
. O
[]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

Estradiol O
and O
the O
addition O
of O
progesterone O
increase O
the O
sensitivity O
to O
a O
neurosteroid O
in O
postmenopausal O
women O
. O
[]

INTERVENTIONS O
The O
patients O
slept O
at O
0 O
degrees O
, O
15 O
degrees O
, O
30 O
degrees O
, O
and O
45 O
degrees O
in O
random O
order O
. O
[]

The O
participants O
were O
randomized O
into O
intervention O
group O
(IG) O
and O
control O
group O
(CG). O
[]

We O
sought O
to O
determine O
if O
the O
combination O
of O
tacrolimus O
and O
sirolimus O
( O
Tac/Sir O
) O
was O
more O
effective O
than O
tacrolimus O
and O
methotrexate O
( O
Tac/Mtx O
) O
in O
preventing O
acute O
GVHD O
and O
early O
mortality O
after O
allogeneic O
MRD O
HCT O
in O
a O
phase O
3 O
, O
multicenter O
trial O
. O
[]

In O
the O
fish O
extract O
treatment O
group O
three O
patients O
withdrew O
from O
the O
study O
before O
the O
fourth O
month O
due O
to O
lack O
of O
therapeutic O
effect O
. O
[]

METHODS O
Data O
from O
a O
recently O
completed O
trial O
that O
included O
subjects O
with O
IPF O
who O
completed O
the O
6MWT O
, O
Saint O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
and O
forced O
vital O
capacity O
( O
FVC O
) O
at O
6 O
and O
12 O
months O
were O
used O
to O
examine O
longitudinal O
changes O
in O
6MWD O
. O
[]

Fever B-outcome ['Physiological-Clinical']
( O
> O
or O
=38.5 O
degrees O
C O
) O
and O
other O
complications B-outcome ['Adverse-effects']
( O
including O
infections B-outcome ['Physiological-Clinical']
) O
occurring O
between O
admission O
and O
discharge O
( O
or O
death B-outcome ['Mortality']
) O
were O
recorded O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Mortality']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
13 O
% O
with O
sodium O
nitroprusside O
, O
remained O
unchanged O
with O
isoflurane O
, O
and O
decreased O
23 O
% O
with O
esmolol O
. O
['Physiological-Clinical']

Ferric B-outcome ['Physiological-Clinical']
reducing I-outcome ['Physiological-Clinical']
ability O
of O
plasma O
and O
vitamin B-outcome ['Physiological-Clinical']
C I-outcome ['Physiological-Clinical']
levels O
in O
AA O
cohort O
significantly O
increased O
after O
exercise O
(p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

OBJECTIVE O
To O
evaluate O
the O
effectiveness O
of O
physical O
therapy O
for O
osteoarthritis O
of O
the O
knee O
, O
applied O
by O
experienced O
physical O
therapists O
with O
formal O
training O
in O
manual O
therapy O
. O
[]

Learning O
through O
interaction O
in O
children O
with O
autism O
: O
preliminary O
data O
from O
asocial-communication-based O
intervention O
. O
[]

The O
final O
analysis O
will O
reveal O
whether O
this O
finding O
is O
maintained O
over O
time O
. O
[]

Eighteen O
months O
later O
their O
mean O
weight O
loss B-outcome ['Physiological-Clinical']
was O
10.4 O
kg O
( O
SD=10.8 O
) O
. O
['Physiological-Clinical']

California O
Collaborative O
Treatment O
Group O
. O
[]

No O
difference O
in O
susceptibility B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
found O
between O
the O
NO2- O
and O
air-exposed O
macrophages O
. O
['Physiological-Clinical']

BACKGROUND O
Marked O
activation O
of O
the O
sympathetic O
nervous O
system O
occurs O
during O
and O
after O
noncardiac O
surgery O
. O
[]

METHODS O
Year O
1 O
medical O
students O
( O
n O
= O
37 O
) O
were O
randomly O
assigned O
to O
practise O
identifying O
seven O
cardiac O
murmurs O
using O
a O
simulator O
and O
video O
only O
( O
SRL O
group O
) O
or O
a O
simulator O
and O
video O
plus O
the O
booklet O
( O
DSRL O
group O
) O
. O
[]

CONCLUSIONS O
Despite O
increases O
having O
been O
found O
in O
straylight O
values O
with O
tinted O
contact O
lenses O
, O
those O
changes O
are O
not O
likely O
to O
induce O
clinically O
significant O
changes O
in O
visual O
function O
under O
photopic O
conditions O
, O
even O
for O
the O
grey-green O
CL O
, O
which O
seems O
to O
increase O
straylight O
values O
more O
significantly O
than O
the O
amber O
CL O
. O
[]

Interactions O
of O
morphine O
and O
methotrimeprazine O
in O
mouse O
and O
man O
with O
respect O
to O
analgesia B-outcome ['Resource-use']
, O
respiration B-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

INCLUSION O
CRITERIA: O
Patients O
with O
stable O
coronary O
artery O
disease O
or O
recent O
acute O
coronary O
syndrome O
( O
>1 O
week O
from O
the O
date O
of O
STEMI), O
being O
taken O
up O
for O
elective O
angioplasty. O
[]

All O
patients O
received O
standardized O
postoperative O
analgesic O
, O
laxative O
and O
antibiotic O
treatment O
. O
[]

BACKGROUND O
An O
open-label O
, O
randomized O
controlled O
trial O
compared O
clozapine O
with O
physicians'-choice O
medications O
among O
long-term O
state O
hospital O
inpatients O
in O
Connecticut O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
test O
whether O
low- O
and O
high-scoring O
individuals O
on O
the O
Autism O
Spectrum O
Quotient O
differ O
on O
a O
measure O
of O
local B-outcome ['Physiological-Clinical']
and O
global B-outcome ['Physiological-Clinical']
processing O
, O
motion O
processing O
and O
visual O
pathway O
integrity O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Training O
in O
use O
of O
a O
notebook/calendar O
system O
significantly O
improved O
adherence O
over O
those O
who O
received O
the O
calendars O
but O
no O
training O
. O
[]

Statistical O
analysis O
was O
performed O
using O
repeated O
measures O
ANOVA O
and O
Fisher O
's O
pairwise O
comparisons O
. O
[]

Patient O
education O
materials O
did O
not O
enhance O
guideline O
effectiveness O
. O
[]

kg(-1).h(-1) O
for O
patients O
in O
group O
D. O
The O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
liquid B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
input I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
output S1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
during O
operation, O
the O
number O
of O
patient O
controlled O
analgesia B-outcome ['Resource-use']
(PCA) O
pressings O
after O
operation O
were O
recorded. O
[['Life-Impact'], ['Physiological-Clinical', 'Physiological-Clinical'], ['Resource-use']]

TnT B-outcome ['Physiological-Clinical']
elevation I-outcome ['Physiological-Clinical']
was O
observed O
in O
36 O
patients O
( O
51 O
% O
) O
already O
before O
surgery O
. O
['Physiological-Clinical']

Previous O
cost O
difference O
estimates O
, O
which O
show O
a O
spike O
around O
the O
time O
of O
cessation O
, O
suggest O
premiums O
might O
rise O
as O
a O
result O
of O
covering O
these O
services O
. O
[]

Human O
papillomavirus O
and O
Papanicolaou O
tests O
to O
screen O
for O
cervical O
cancer O
. O
[]

Diarrhea B-outcome ['Physiological-Clinical']
, O
stomatitis B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
the O
most O
common O
nonhematologic B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
in O
both O
arms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Results O
suggest O
that O
EBTs O
can O
retain O
their O
effectiveness O
when O
transported O
to O
a O
community O
context O
. O
[]

Debriefing O
in O
follow-up O
visits O
provided O
participants O
a O
detailed O
review O
of O
all O
consent O
types O
and O
the O
chance O
to O
change O
data O
sharing O
choices O
or O
decline O
genome O
study O
participation O
. O
[]

Delivered B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
DFT I-outcome ['Physiological-Clinical']
was O
4.2 O
+/- O
4.1 O
J O
in O
the O
lead O
configuration O
and O
5.0 O
+/- O
3.7 O
J O
in O
the O
active O
can O
configuration O
( O
P O
= O
NS O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
demand-control O
( O
D-C O
) O
model O
of O
job O
strain O
has O
generated O
a O
considerable O
body O
of O
empirical O
support O
in O
predicting O
psychological O
health O
outcomes O
in O
the O
context O
of O
work O
. O
[]

CONCLUSIONS O
Cy O
seems O
to O
be O
more O
effective O
than O
MP O
in O
the O
treatment O
of O
acute O
, O
severe O
NPSLE O
. O
[]

It O
is O
estimated O
that O
for O
bladder B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
the O
RBE B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
, O
for O
photon O
dose O
fractions O
of O
2.75 O
Gy O
, O
is O
less O
than O
3.3 O
for O
early O
reactions O
and O
equal O
to O
3.4 O
for O
late O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Autism O
is O
commonly O
associated O
with O
sensory B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulatory I-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
. O
['Life-Impact']

All O
patients O
received O
folic O
acid O
and O
vitamin O
B O
( O
12 O
) O
supplementation O
. O
[]

Cholesterol-lowering O
effect O
of O
stanol O
ester O
in O
a O
US O
population O
of O
mildly O
hypercholesterolemic O
men O
and O
women O
: O
a O
randomized O
controlled O
trial O
. O
[]

9.30 O
?g/L O
; O
TNF-? O
: O
44.3 O
? O
[]

Besides O
, O
20 O
mg/d O
fluoxetine O
was O
additionally O
given O
to O
groups O
A O
and O
one O
tablet O
of O
almitrine O
l/d O
and O
20 O
mg O
oryzanol O
3/d O
were O
given O
to O
group O
B O
. O
[]

The O
capacity O
of O
HMCs O
and O
WDCs O
to O
engage O
with O
the O
local O
health O
system O
was O
also O
measured O
at O
baseline O
and O
endline. O
[]

Journal-Name:BMC O
public O
health O
[]

On O
patient B-outcome ['Life-Impact']
comfort I-outcome ['Life-Impact']
, O
closure O
devices O
performed O
better O
than O
MC O
. O
['Life-Impact']

Dark-phase O
light O
contamination O
disrupts O
circadian O
rhythms O
in O
plasma B-outcome ['Physiological-Clinical']
measures O
of O
endocrine O
physiology B-outcome ['Physiological-Clinical']
and O
metabolism B-outcome ['Physiological-Clinical']
in O
rats O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Twenty-six O
pregnant O
women O
with O
increased O
3-HIA O
excretion O
were O
studied O
in O
a O
randomized O
, O
placebo-controlled O
trial O
; O
10 O
women O
were O
studied O
during O
early O
pregnancy O
( O
6-17 O
wk O
gestation O
) O
and O
16 O
women O
during O
late O
pregnancy O
( O
21-37 O
wk O
gestation O
) O
. O
[]

The O
baseline O
characteristics O
of O
60 O
evaluable O
subjects O
, O
40 O
in O
the O
SH O
group O
and O
20 O
in O
the O
placebo O
group O
, O
were O
not O
significantly O
different O
. O
[]

METHODS O
In O
this O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
, O
Japanese O
women O
were O
randomized O
to O
1 O
of O
4 O
groups O
to O
receive O
IV O
administration O
of O
propofol O
0.5 O
mg/kg O
, O
droperidol O
20 O
microg/kg O
, O
metoclopramide O
0.2 O
mg/kg O
, O
or O
placebo O
( O
isotonic O
saline O
) O
immediately O
after O
skin O
suture O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
evaluate O
the O
hypothesis O
that O
testosterone O
treatment O
and O
a O
nutritional O
supplement O
have O
additive O
benefits O
. O
[]

These O
were O
trials O
of O
the O
Memorial O
Sloan-Kettering O
Cancer O
Center O
( O
MSKCC O
) O
, O
the O
U.S. O
Multicenter O
Study O
Group O
, O
and O
the O
Southeastern O
Cancer O
Study O
Group O
( O
SEG O
) O
. O
[]

After O
3 O
months O
, O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
increased O
in O
two O
of O
4 O
androgen-treated O
patients O
. O
['Physiological-Clinical']

Oxidant/antioxidant B-outcome ['Physiological-Clinical']
status O
and O
markers O
of O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
were O
evaluated O
in O
24 O
elite O
football O
players O
and O
15 O
controls. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSIONS O
The O
rotational O
angiography O
technique O
leads O
to O
a O
significant O
decrease O
in O
[]

Under O
VCV O
mode, O
the O
levels O
of O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
were O
increased O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
and O
there O
was O
significant O
difference O
at O
9 O
L/min O
as O
compared O
with O
those O
before O
atomization O
[ O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(cmH2O): O
29.44+/-4.58 O
vs. O
24.39+/-4.64, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(mL): O
896.26+/-24.91 O
vs. O
497.61+/-8.67, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(mL: O
494.67+/-3.07 O
vs. O
492.61+/-6.05, O
P O
> O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND/AIMS O
To O
evaluate O
and O
compare O
obtained O
mydriasis O
with O
phenylephrine O
10 O
% O
associated O
with O
tropicamide O
1 O
% O
in O
type O
2 O
diabetics O
and O
non-diabetic O
patients O
. O
[]

RT O
substantially O
reduced O
loco-regional B-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
among O
both O
pre- O
and O
postmenopausal O
patients O
( O
relative O
hazard O
RT O
versus O
CT O
: O
0.67 O
and O
0.43 O
, O
respectively O
) O
. O
['Physiological-Clinical']

METHODS O
42 O
patients O
with O
chronic O
hepatitis O
B O
were O
divided O
randomly O
into O
two O
groups O
. O
[]

EEG/EMG B-outcome ['Resource-use']
monitoring O
recorded O
no O
pathologic O
increase O
of O
cortical B-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
epileptic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O
[]

Data O
from O
eligible O
nonrandomized O
patients O
were O
analyzed O
separately O
. O
[]

CONCLUSIONS O
GM-CSF O
priming O
from O
days O
5 O
to O
1 O
before O
doxorubicin O
and O
cyclophosphamide O
chemotherapy O
was O
associated O
with O
an O
earlier O
neutrophil B-outcome ['Physiological-Clinical']
and O
platelet B-outcome ['Physiological-Clinical']
nadir I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Atorvastatin O
and O
quinapril O
inhibit O
blood O
coagulation O
in O
patients O
with O
coronary O
artery O
disease O
following O
28 O
days O
of O
therapy O
. O
[]

Relationship O
between O
subjective O
effects O
and O
drug O
preferences O
: O
ethanol O
and O
diazepam O
. O
[]

Title: O
The O
influence O
of O
pelvis O
reposition O
exercises O
on O
pelvic B-outcome ['Physiological-Clinical']
floor I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
asymmetry I-outcome ['Physiological-Clinical']
: O
A O
randomized O
prospective O
study. O
[['Physiological-Clinical']]

SETTING O
This O
study O
was O
nested O
in O
the O
IMPALA O
study O
, O
a O
clustered O
randomised O
controlled O
trial O
involving O
24 O
general O
practices O
in O
The O
Netherlands O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
a O
short-term O
cognitive-behavioural O
group O
therapy O
programme O
for O
pathological O
gamblers O
. O
[]

Because O
our O
data O
are O
hampered O
by O
the O
lack O
of O
predictivity O
of O
the O
selected O
biomarkers O
, O
additional O
studies O
are O
necessary O
to O
assess O
the O
activity O
of O
fenretinide O
in O
preventing O
bladder O
cancer O
. O
[]

Few O
controlled O
clinical O
trials O
of O
psychological O
interventions O
for O
cancer B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief O
exist O
in O
spite O
of O
frequent O
support O
for O
their O
importance O
as O
adjuncts O
to O
medical O
treatment O
. O
['Physiological-Clinical']

The O
remaining O
horses O
remained O
healthy O
, O
developed O
a O
grade O
1 O
to O
4 O
lameness O
with O
minimal O
to O
severe O
swelling O
in O
the O
PIJ O
region O
. O
[]

RESULTS O
Pentoxifylline O
therapy O
regularly O
increased O
the O
PBPI O
in O
impotent O
men O
in O
comparison O
with O
the O
placebo O
, O
frequently O
into O
the O
normal O
range O
. O
[]

We O
also O
monitored O
the O
effect O
of O
enoxaparin O
on O
activation O
of O
coagulation B-outcome ['Physiological-Clinical']
and O
fibrinolysis B-outcome ['Physiological-Clinical']
after O
closure O
of O
the O
ruptured O
aneurysm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS: O
At O
a O
median O
follow-up O
of O
33.6 O
months, O
the O
median O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
21.6 O
months O
in O
the O
modified-FOLFIRINOX O
group O
and O
12.8 O
months O
in O
the O
gemcitabine O
group O
(stratified O
hazard O
ratio O
for O
cancer-related B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
, O
second B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
, O
0.58; O
95% O
confidence O
interval O
[CI], O
0.46 O
to O
0.73; O
P<0.001). O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

After O
the O
exacerbation, O
mean O
FEV1 B-outcome ['Physiological-Clinical']
improved O
but O
did O
not O
return O
to O
pre-exacerbation O
levels O
(mean O
Days O
36-56 O
after O
the O
exacerbation, O
0.875 O
L). O
[['Physiological-Clinical']]

Norfloxacin O
, O
trimethoprim/sulfamethoxazole O
, O
cytokines O
, O
nitric O
oxide O
, O
expression O
levels O
of O
nuclear O
factor O
( O
NF O
) O
-kappaB O
and O
inhibitor O
of O
NF-kappaB O
( O
IkB-alpha O
) O
, O
neutrophil O
oxidative O
burst O
, O
and O
rate O
of O
apoptotic O
events O
were O
determined O
. O
[]

RU O
486 O
and O
three O
of O
its O
metabolites O
( O
RU O
42633-monodemethyl O
, O
RU O
42848-didemethyl O
, O
and O
RU O
42698-hydroxymetabolite O
) O
were O
determined O
by O
HPLC O
in O
plasma O
from O
nine O
non-pregnant O
and O
36 O
pregnant O
women O
. O
[]

Secondary O
outcomes O
included O
the O
number O
of O
deaths B-outcome ['Mortality']
, O
attendance O
at O
hospital B-outcome ['Resource-use']
outpatient I-outcome ['Resource-use']
clinics I-outcome ['Resource-use']
and O
general O
practice O
and O
proportion O
of O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
over O
the O
follow-up O
period B-outcome ['Physiological-Clinical']
, O
together O
with O
patients O
' O
general B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
, O
satisfaction B-outcome ['Life-Impact']
with O
the O
service O
and O
knowledge B-outcome ['Life-Impact']
of O
and O
adherence B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
prescribed I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
. O
['Mortality', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Genes O
specific O
for O
benefit O
from O
R-FC O
were O
determined O
by O
assessing O
treatment-gene O
interactions O
in O
Cox O
proportional O
hazards O
models O
. O
[]

The O
pathogens O
were O
Haemophilus O
influenzae O
type O
b O
( O
54 O
cases O
) O
, O
streptococci O
( O
9 O
cases O
) O
, O
meningococci O
( O
9 O
cases O
) O
, O
and O
unknown O
( O
6 O
cases O
) O
. O
[]

One O
half O
of O
the O
home O
studies O
were O
randomly O
assigned O
to O
be O
performed O
with O
a O
sleep O
technician O
's O
set O
up O
of O
the O
equipment O
in O
the O
patient O
's O
home O
( O
group O
1 O
) O
, O
and O
the O
other O
half O
with O
the O
patient O
's O
own O
setup O
of O
the O
sleep-recording O
device O
( O
group O
2 O
) O
, O
after O
an O
instruction O
period O
in O
the O
hospital O
. O
[]

Healing B-outcome ['Physiological-Clinical']
rates O
after O
4 O
weeks O
of O
therapy O
appeared O
to O
be O
76 O
% O
for O
CBS O
coated O
tablets O
and O
72 O
% O
for O
CBS O
chewing O
tablets O
, O
so O
no O
statistically O
significant O
difference O
in O
therapeutic O
efficacy O
was O
seen O
. O
['Physiological-Clinical']

RESULTS O
The O
levels O
of O
homocysteine O
markedly O
decreased O
in O
group O
A O
[ O
( O
13 O
+/- O
4 O
) O
micromol/L O
vs O
( O
20 O
+/- O
5 O
) O
micromol/L O
, O
t O
= O
5.3 O
, O
P O
< O
0.01 O
] O
after O
treatment O
, O
whereas O
no O
significant O
changes O
were O
observed O
in O
group O
B O
. O
[]

Other O
core O
features O
of O
the O
quality O
of O
service O
, O
e.g O
. O
[]

In O
conclusion O
, O
low-dose O
flutamide O
is O
herewith O
identified O
as O
a O
pivotal O
component O
within O
a O
first O
contraceptive O
combination O
therapy O
that O
has O
been O
shown O
to O
attenuate O
the O
hypoadiponectinemia B-outcome ['Physiological-Clinical']
, O
ovarian B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
hyperresistance I-outcome ['Physiological-Clinical']
, O
lean B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
, O
and O
central B-outcome ['Physiological-Clinical']
adiposity I-outcome ['Physiological-Clinical']
of O
young O
women O
with O
polycystic O
ovary O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
undertook O
the O
present O
analysis O
to O
evaluate O
the O
effect O
of O
NHT O
on O
pathologic B-outcome ['Physiological-Clinical']
stage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCa I-outcome ['Physiological-Clinical']
and O
resection B-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
prostate O
cancer O
and O
treated O
with O
total O
androgen O
ablation O
either O
for O
three O
or O
six O
months O
before O
RP O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
spermiogram B-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
enzyme B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
intratesticular B-outcome ['Physiological-Clinical']
steroid B-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
testicular B-outcome ['Physiological-Clinical']
antioxidant I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
were O
estimated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
AND O
RESULTS O
Rates O
of O
virologic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
2 O
arms O
at O
week O
16 O
( O
p O
= O
.509 O
) O
. O
['Physiological-Clinical']

Anticholinergic O
drugs O
: O
effects O
on O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Production O
and O
use O
of O
CFCs O
, O
except O
for O
certain O
critical O
exemptions O
, O
has O
been O
prohibited O
by O
the O
Montreal O
Protocol O
. O
[]

We O
investigated O
the O
benefit O
of O
adding O
all-trans O
retinoic O
acid O
( O
ATRA O
) O
to O
chemotherapy O
for O
younger O
patients O
with O
nonacute O
promyelocytic O
acute O
myeloid O
leukemia O
and O
high-risk O
myelodysplastic O
syndrome O
, O
and O
considered O
interactions O
between O
treatment O
and O
molecular O
markers O
. O
[]

The O
effect O
of O
the O
combined O
intervention O
exceeded O
that O
of O
CBT O
or O
Baduanjin O
alone. O
[]

Direct O
trocar O
insertion O
vs. O
Verres O
needle O
use O
for O
laparoscopic O
sterilization O
. O
[]

METHODS O
To O
further O
investigate O
the O
importance O
of O
G84E O
in O
the O
Finns O
, O
we O
determined O
its O
frequency O
in O
more O
than O
4,000 O
prostate O
cancer O
cases O
and O
5,000 O
controls O
. O
[]

RESULTS O
The O
overall O
sensitivity O
of O
endocervical B-outcome ['Resource-use']
sampling I-outcome ['Resource-use']
was O
56 O
% O
, O
with O
a O
false O
negative O
rate O
of O
44 O
% O
and O
a O
negative O
predictive O
value O
of O
26 O
% O
. O
['Resource-use']

There O
were O
no O
significant O
differences O
in O
length O
of O
stay O
, O
complications O
, O
oral O
pain O
medication O
usage O
after O
discharge O
, O
or O
return O
to O
work O
. O
[]

These O
results O
appear O
to O
warrant O
prospective O
randomized O
trials O
to O
determine O
in O
a O
more O
definitive O
manner O
the O
merits O
of O
this O
combination O
in O
the O
prevention O
of O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Moreover, O
results O
prove O
that O
participants O
positively O
respond B-outcome ['Life-Impact']
to O
health-related O
information, O
whereas O
information O
on O
bitterness-taste O
generates O
lower O
preferences B-outcome ['Life-Impact']
. O
[['Life-Impact'], ['Life-Impact']]

Publication O
date: O
2018/11/20 O
00:00 O
[accepted] O
[]

Exclusion O
criteria O
included O
active O
bleeding O
or O
chronic O
renal O
failure O
at O
the O
time O
of O
ICU O
admission O
. O
[]

L(- O
1); O
PL: O
8.7 O
+/- O
0.9 O
mmol. O
[]

METHODS O
Simplified O
Disease O
Activity O
Index O
( O
SDAI O
) O
scores O
, O
Clinical O
Disease O
Activity O
Index O
( O
CDAI O
) O
scores O
, O
and O
the O
Disease O
Activity O
Score O
in O
28 O
joints O
( O
DAS28 O
) O
were O
calculated O
using O
data O
from O
tocilizumab O
trials O
in O
patients O
with O
RA O
in O
whom O
disease O
had O
remained O
active O
despite O
treatment O
with O
disease-modifying O
antirheumatic O
drugs O
. O
[]

All O
patients O
were O
interviewed O
in O
the O
evening O
and O
time O
of O
ambulation O
and O
rating O
of O
OR O
experience O
was O
noted O
. O
[]

METHOD O
Patients O
were O
randomized O
to O
treatment O
with O
fluoxetine O
( O
n O
= O
127 O
) O
or O
placebo O
( O
n O
= O
46 O
) O
under O
double-blind O
conditions O
for O
8 O
weeks O
, O
with O
concomitant O
atomoxetine O
use O
the O
last O
5 O
weeks O
. O
[]

No O
such O
changes O
were O
observed O
in O
the O
control O
group O
. O
[]

There O
were O
four O
recurrent B-outcome ['Physiological-Clinical']
meningeal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
the O
patients O
taking O
placebo O
, O
but O
none O
in O
those O
taking O
fluconazole O
( O
mean O
duration O
of O
follow-up O
, O
164 O
days O
) O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

When O
considered O
in O
combination O
, O
the O
overexpression O
of O
both O
Ki-67 B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

RESULTS O
Of O
the O
105 O
patients O
alive O
in O
Norway O
and O
Sweden O
after O
4 O
to O
12 O
years O
of O
follow-up O
, O
78 O
( O
74 O
% O
) O
responded O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
primary O
endpoint O
will O
be O
the O
percent O
change O
of O
coronary B-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Thus, O
the O
present O
study O
was O
conducted O
with O
the O
aim O
to O
determine O
the O
effect O
of O
lavender O
aromatherapy O
on O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
of O
postmenopausal O
women. O
[['Life-Impact']]

The O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
-- O
Autism O
Network O
reported O
additional O
benefit O
when O
adding O
parent O
training O
( O
PT O
) O
to O
antipsychotic O
medication O
in O
children O
with O
autism O
spectrum O
disorders O
and O
serious O
behavior O
problems O
. O
[]

RESULTS O
After O
induction O
treatment O
, O
464 O
patients O
were O
assessable O
for O
the O
consolidation O
phase O
. O
[]

Of O
the O
4044 O
girls O
enrolled O
and O
eligible O
, O
2087 O
( O
51.6 O
% O
) O
participated O
in O
the O
measurement O
component O
of O
the O
study O
. O
[]

The O
study O
groups O
( O
TEN O
= O
29 O
vs O
TPN O
= O
30 O
) O
were O
comparable O
in O
age O
, O
injury O
severity O
and O
initial O
metabolic O
stress O
. O
[]

Notwithstanding O
the O
metabolic O
effects O
of O
the O
additional O
therapy O
have O
induced O
a O
positive O
change O
of O
atherogenic B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
prevalence O
of O
RAS O
decreased O
with O
perilla O
oil O
( O
rich O
in O
alpha-linolenic O
acid O
) O
. O
[]

CONCLUSION: O
Significant O
differences O
in O
MBLs O
were O
observed O
at O
different O
implant O
interfaces. O
[]

Serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
were O
measured O
by O
an O
enzyme O
immunoassay O
method O
. O
['Physiological-Clinical']

Treatment-emergent O
adverse O
events O
including O
blood O
chemistry O
metabolites O
were O
recorded O
. O
[]

RESULTS O
A O
total O
of O
154 O
individuals O
joined O
the O
Cancer O
Genetics O
Network O
. O
[]

After O
stratifying O
for O
parity O
, O
we O
compared O
rates O
of O
urinary B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
UI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
sexual B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
at O
3 O
months O
postpartum O
in O
women O
who O
had O
a O
VB O
with O
the O
rates O
in O
women O
who O
had O
a O
CS O
. O
['Physiological-Clinical', 'Life-Impact']

CO B-outcome ['Physiological-Clinical']
was O
measured O
noninvasively O
at O
approximately O
two-minute O
intervals O
, O
using O
continuous-wave O
Doppler O
echocardiography O
. O
['Physiological-Clinical']

OBJECTIVES O
Physicians O
adopt O
evidence-based O
guidelines O
with O
variable O
consistency O
. O
[]

TRIAL O
REGISTRATION: O
current O
controlled O
trials O
PHRC/HC/32/15. O
[]

RESULTS O
Of O
the O
total O
participants O
, O
84.6 O
% O
completed O
the O
study O
( O
mean O
age O
= O
70.2 O
years O
) O
. O
[]

In O
a O
subgroup O
( O
N O
= O
23 O
) O
, O
manual O
motor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
was O
tested O
with O
tasks O
of O
graded O
dexterous O
demand O
. O
['Life-Impact']

Medication O
and O
parent O
training O
in O
children O
with O
pervasive O
developmental O
disorders O
and O
serious O
behavior O
problems O
: O
results O
from O
a O
randomized O
clinical O
trial O
. O
[]

The O
hazard O
reduction O
was O
similar O
for O
both O
radiation O
plans O
. O
[]

Twelve O
months O
after O
primary O
vaccination O
, O
GMTs B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
in O
the O
freeze-dried O
, O
liquid O
ADPT O
groups O
and O
the O
WCDPT O
group O
have O
fallen O
from O
56.23 O
, O
62.63 O
and O
44.97 O
ELISA O
U/ml O
to O
6.08 O
, O
6.18 O
and O
11.30 O
ELISA O
U/ml O
, O
respectively O
. O
['Physiological-Clinical']

After O
screening O
for O
exclusion O
, O
only O
55 O
patients O
were O
included O
in O
the O
first O
3-hour O
investigation O
period O
. O
[]

Aspirin O
treatment O
failed O
to O
suppress O
urinary O
levels O
of O
8-epi-PGF2 O
alpha O
despite O
a O
significant O
reduction O
in O
urinary B-outcome ['Physiological-Clinical']
11-dehydro-TxB2 I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
and O
suppression O
of O
8-epi-PGF2 B-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
and O
TxB2 B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
antibiotic O
combination O
permitted O
a O
dramatic O
decrease O
in O
[]

Furthermore, O
the O
24 O
elite O
football O
players O
were O
randomly O
assigned O
to O
either O
a O
dark O
chocolate O
(>85% O
cocoa) O
intake O
(n O
= O
12) O
or O
a O
control O
group O
(n O
= O
12) O
for O
30 O
days O
in O
a O
randomized O
controlled O
trial. O
[]

No O
significant O
cardiovascular O
changes O
were O
seen O
in O
both O
groups O
. O
[]

Clonidine O
increases O
the O
sweating B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
, O
but O
does O
not O
reduce O
the O
gain O
of O
sweating B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Neither O
the O
distribution O
of O
the O
patients O
among O
Lown B-outcome ['Physiological-Clinical']
classification O
nor O
the O
Final O
Score O
of O
the O
Italian O
['Physiological-Clinical']

Perineal O
wound O
healing O
was O
taken O
as O
endpoint O
of O
this O
study O
. O
[]

They O
represent O
an O
interesting O
model O
for O
studying O
GH O
secretion O
, O
as O
a O
slight O
degree O
of O
cortisol O
excess O
may O
frequently O
be O
observed O
in O
such O
patients O
who O
do O
not O
present O
with O
any O
clear O
Cushingoid O
sign O
. O
[]

METHODS: O
A O
sample O
of O
37 O
patients O
poststroke O
(29 O
males) O
was O
randomly O
allocated O
to O
either O
SPT O
control O
group O
(n O
= O
18) O
or O
SPT O
and O
SMV O
(SPT-SMV) O
experimental O
group O
(n O
= O
19). O
[]

A O
randomized O
experiment O
was O
conducted O
with O
a O
sample O
of O
618 O
women O
50 O
years O
or O
older O
with O
MBD O
greater O
than O
50 O
% O
of O
breast O
volume O
. O
[]

The O
available O
analytical O
and O
clinical O
evidence O
demonstrate O
that O
anti-CD O
WPC O
is O
safe O
for O
use O
by O
individuals O
with O
CDAD O
, O
under O
the O
described O
conditions O
of O
use O
. O
[]

The O
primary O
outcome O
measure O
was O
the O
change O
from O
baseline O
in O
the O
RDAI B-outcome ['Physiological-Clinical']
score O
at O
24 O
hours O
. O
['Physiological-Clinical']

Of O
these O
patients O
, O
31 O
completed O
a O
full O
QOL B-outcome ['Life-Impact']
assessment O
on O
the O
first O
day O
of O
preoperative O
nutritional O
support O
, O
one O
day O
before O
surgery O
, O
and O
6 O
months O
after O
surgery O
. O
['Life-Impact']

The O
distance O
from O
the O
vestibular B-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
plate I-outcome ['Physiological-Clinical']
to O
the O
palatal O
root O
of O
these O
teeth O
( O
1.17 O
and O
1.23 O
mm O
for O
the O
right O
premolars O
, O
2.46 O
and O
1.09 O
mm O
for O
the O
left O
premolars O
, O
2.75 O
and O
0.64 O
mm O
for O
the O
right O
molars O
, O
2.23 O
and O
0.96 O
mm O
for O
the O
left O
molars O
in O
the O
banded O
and O
bonded O
groups O
, O
respectively O
) O
increased O
( O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Effective O
pain O
management O
remains O
a O
challenge O
for O
adolescents O
during O
conscious O
burn O
wound O
care O
procedures O
. O
[]

At O
14 O
days O
, O
there O
were O
no O
differences O
in O
the O
P2Y B-outcome ['Physiological-Clinical']
( O
12 O
) O
reactivity B-outcome ['Physiological-Clinical']
index O
as O
assessed O
by O
vasodilator-stimulated O
phosphoprotein O
phosphorylation O
between O
treatment O
groups O
( O
primary O
endpoint O
; O
p O
= O
0.93 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additional O
irradiation+/-surgery O
was O
performed O
if O
and O
when O
feasible O
. O
[]

24 O
( O
18 O
% O
) O
patients O
receiving O
eltrombopag O
needed O
rescue B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
compared O
with O
25 O
( O
40 O
% O
) O
patients O
receiving O
placebo O
( O
p=0?001 O
) O
. O
['Resource-use']

The O
results O
suggest O
that O
zidovudine O
but O
not O
didanosine O
reduces O
intrathecal B-outcome ['Physiological-Clinical']
immunoactivation I-outcome ['Physiological-Clinical']
during I-outcome ['Physiological-Clinical']
HIV-1 I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secondary O
end O
points O
were O
changes O
in O
BCVA O
and O
retinal O
thickness O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
We O
conducted O
a O
randomized O
crossover O
trial O
of O
the O
effects O
of O
12 O
g O
decaffeinated O
coffee O
, O
1 O
g O
chlorogenic O
acid O
, O
500 O
mg O
trigonelline O
, O
and O
placebo O
( O
1 O
g O
mannitol O
) O
on O
glucose O
and O
insulin O
concentrations O
during O
a O
2-h O
oral O
glucose O
tolerance O
test O
( O
OGTT O
) O
in O
15 O
overweight O
men O
. O
[]

In O
week O
18 O
, O
the O
median O
relative B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
wart I-outcome ['Physiological-Clinical']
area O
was O
100 O
% O
in O
the O
ALA-PDT O
group O
( O
100 O
% O
, O
57 O
% O
) O
versus O
71 O
% O
( O
100 O
% O
, O
0 O
) O
in O
the O
placebo-PDT O
arm O
( O
p=0.008 O
) O
. O
['Physiological-Clinical']

Median O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
longer O
for O
LAVH O
( O
135 O
min O
compared O
with O
120 O
min O
for O
TAH O
; O
P O
= O
0.001 O
) O
, O
but O
patients O
undergoing O
LAVH O
had O
less O
analgesics B-outcome ['Resource-use']
administration I-outcome ['Resource-use']
( O
23 O
% O
compared O
with O
77 O
% O
, O
P O
< O
0.001 O
) O
and O
a O
shorter O
median O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
3.8 O
compared O
with O
5.8 O
days O
; O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Resource-use', 'Resource-use']

CONCLUSIONS O
In O
asymptomatic O
patients O
, O
the O
use O
of O
software O
for O
post-processing O
digital O
elimination O
of O
residue O
from O
images O
in O
conjunction O
with O
reduced O
bowel O
preparation O
does O
not O
reduce O
examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
or O
diagnostic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
when O
compared O
with O
the O
conventional O
CT O
colonography O
technique O
and O
is O
more O
acceptable B-outcome ['Life-Impact']
to O
and O
better O
tolerated B-outcome ['Life-Impact']
by O
the O
patient O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

The O
control O
group O
received O
an O
information O
leaflet O
about O
issues O
related O
to O
alcohol O
consumption. O
[]

Sulfasalazine O
decreases O
acute O
gastrointestinal O
complications O
due O
to O
pelvic O
radiotherapy O
. O
[]

Two O
( O
6 O
% O
) O
patients O
with O
measurable O
disease O
reached O
complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
, O
1 O
( O
3 O
% O
) O
partial O
response O
( O
PR O
) O
, O
12 O
( O
36 O
% O
) O
had O
stable B-outcome ['Physiological-Clinical']
disease B-outcome ['Physiological-Clinical']
( O
SD O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pathological O
features O
and O
inhaled O
corticosteroid O
response O
of O
eosinophilic O
and O
non-eosinophilic O
asthma O
. O
[]

The O
metabolic O
syndrome O
definitions O
of O
National O
Cholesterol O
Education O
Program O
Adult O
Treatment O
Expert O
Panel O
III O
( O
NCEPATPIII O
) O
2004 O
, O
NCEP O
2005 O
and O
International O
Diabetes O
Federation O
( O
IDF O
) O
were O
used O
. O
[]

At O
6 O
months, O
the O
mean O
Posttraumatic B-outcome ['Physiological-Clinical', 'Life-Impact']
Stress I-outcome ['Physiological-Clinical', 'Life-Impact']
Disorder I-outcome ['Physiological-Clinical', 'Life-Impact']
(PTSD) I-outcome ['Physiological-Clinical', 'Life-Impact']
Symptom I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale]-Self-Report O
questionnaire O
score O
in O
intervention O
ICUs O
was O
11.8 O
(baseline O
period) O
compared O
with O
11.5 O
(intervention O
period) O
(difference, O
-0.40 O
[95% O
CI, O
-2.46 O
to O
1.67]) O
and O
in O
control O
ICUs, O
10.1 O
(baseline O
period) O
compared O
with O
10.2 O
(intervention O
period) O
(difference, O
0.06 O
[95% O
CI, O
-1.74 O
to O
1.85]) O
between O
periods. O
[['Physiological-Clinical', 'Life-Impact']]

The O
influence O
of O
preoperative O
antibiotics O
on O
success B-outcome ['Physiological-Clinical']
of O
endosseous O
implants O
up O
to O
and O
including O
stage O
II O
surgery O
: O
a O
study O
of O
2,641 O
implants O
. O
['Physiological-Clinical']

METHODS O
Ninety-five O
consecutive O
primary O
carotid O
endarterectomies O
were O
performed O
in O
a O
prospective O
randomized O
fashion O
in O
92 O
patients O
. O
[]

The O
results O
indicate O
that O
desflurane O
is O
associated O
with O
similar O
operating O
conditions O
and O
faster O
postoperative B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
following O
acoustic O
neuroma O
surgery O
. O
['Physiological-Clinical']

We O
investigated O
the O
performance O
of O
a O
group O
of O
high-functioning O
participants O
with O
ASD O
( O
N=15 O
) O
and O
an O
age- O
and O
IQ-matched O
control O
group O
( O
N=18 O
) O
on O
two O
executive O
function O
tests O
, O
whilst O
undergoing O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
. O
[]

Urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
1.8+/-0.6 O
to O
0.8+/-0.4 O
g/day O
, O
( O
P O
< O
0.01 O
) O
in O
this O
group O
, O
and O
urinary B-outcome ['Physiological-Clinical']
podocyte I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
1.6+/-0.6 O
to O
0.9+/-0.4 O
cells/ml O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tamoxifen O
was O
studied O
in O
176 O
patients O
with O
T1-2N0M0 O
tumors O
. O
[]

Many O
women O
overestimate O
their O
percentage O
risk O
of O
breast O
cancer O
, O
even O
after O
they O
have O
received O
careful O
estimates O
from O
health O
professionals O
. O
[]

DISCUSSION O
Losartan O
was O
very O
effective O
in O
reducing O
cardiovascular B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
as O
compared O
to O
atenolol O
. O
['Physiological-Clinical', 'Mortality']

The O
duration O
of O
each O
level O
of O
embolic O
phenomena O
( O
zero O
, O
moderate O
, O
severe O
) O
was O
used O
to O
determine O
total O
embolic O
load O
with O
various O
steps O
( O
fracture O
manipulation O
, O
proximal O
portal O
opening O
, O
reaming O
, O
and O
nail O
passage O
) O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Researchers O
were O
masked O
to O
allocation, O
but O
participants O
were O
not. O
[]

The O
specific O
role O
of O
isoflavones O
on O
estrogen O
metabolism O
in O
premenopausal O
women O
. O
[]

Vaccination O
was O
carried O
out O
at O
six O
, O
10 O
and O
14 O
weeks O
of O
age O
based O
on O
the O
local O
Expanded O
Program O
of O
Immunization O
schedule O
. O
[]

Radiation B-outcome ['Resource-use']
and O
contrast O
agent B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
were O
evaluated O
. O
['Resource-use', 'Life-Impact']

About O
0.5 O
mL O
of O
each O
solution O
was O
separately O
applied O
to O
the O
skin O
of O
the O
forearm O
( O
3 O
cm2 O
) O
, O
and O
then O
mixed O
with O
a O
sterile O
cotton O
bud O
. O
[]

RESULTS: O
The O
95% O
effective O
dose B-outcome ['Life-Impact']
of O
intrathecal O
ropivacaine O
with O
5 O
mug O
sufentanil O
for O
successful O
anesthesia O
was O
15.2 O
mg O
(95%CI, O
13.5-18.8 O
mg), O
when O
receiving O
prophylactic O
infusion O
of O
phenylephrine. O
[['Life-Impact']]

BACKGROUND O
AND O
OBJECTIVE O
Combined O
spinal-epidural O
is O
an O
alternative O
technique O
to O
epidural O
analgesia O
for O
labour O
, O
but O
its O
benefits O
are O
not O
clearly O
identified O
. O
[]

Clinical O
benefit O
was O
prospectively O
evaluated O
in O
this O
trial O
as O
a O
secondary O
end O
point O
. O
[]

METHODS O
Fundamental O
or O
harmonic O
MCE O
was O
performed O
with O
continuous O
or O
triggered O
imaging O
in O
203 O
patients O
with O
a O
previous O
MI O
using O
bolus O
doses O
of O
a O
perfluorocarbon-filled O
contrast O
agent O
( O
NC100100 O
) O
. O
[]

A O
controlled O
study O
. O
[]

Is O
chronic O
sildenafil O
therapy O
safe O
and O
clinically O
beneficial O
in O
patients O
with O
systolic O
heart O
failure O
? O
[]

A O
randomized O
controlled O
trial O
of O
Hanen O
's O
'More O
Than O
Words O
' O
in O
toddlers O
with O
early O
autism O
symptoms O
. O
[]

There O
were O
no O
false-positive O
cytologic B-outcome ['Physiological-Clinical']
or O
histologic B-outcome ['Physiological-Clinical']
reports O
. O
['Physiological-Clinical']

METHODS: O
Ninety O
patients O
with O
ASA O
I O
or O
II, O
who O
underwent O
cesarean O
section, O
were O
randomized O
into O
2 O
groups: O
group O
D O
(bupivacaine O
+ O
5 O
mug O
Dex) O
and O
group O
C O
(bupivacaine O
+ O
the O
same O
volume O
of O
saline). O
[]

The O
plasma O
levels O
of O
epinephrine O
, O
norepinephrine O
, O
glucose O
, O
lactate O
and O
free O
glycerol O
were O
measured O
in O
addition O
to O
mean O
arterial O
pressure O
( O
MAP O
) O
and O
heart O
rate O
( O
HR O
) O
immediately O
before O
anaesthesia O
, O
10 O
minutes O
after O
skin O
incision O
, O
10 O
minutes O
after O
having O
started O
bone O
drilling O
, O
at O
the O
end O
of O
the O
operation O
and O
3 O
hours O
after O
operation O
. O
[]

Women O
in O
the O
intervention O
group O
received O
a O
6-month O
yoga O
intervention O
in O
addition O
to O
hospital O
routine O
care O
, O
and O
women O
in O
the O
control O
group O
received O
hospital O
routine O
care O
only O
. O
[]

Effect O
sizes O
for O
observational O
measures O
ranged O
from O
d O
= O
0.10 O
to O
d O
= O
1.32 O
favoring O
the O
parent O
+ O
therapist O
group O
, O
with O
the O
largest O
effect O
sizes O
found O
12 O
months O
after O
intervention O
. O
[]

BACKGROUND O
Yes-associated B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
YAP1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
frequently O
reported O
to O
function O
as O
an O
oncogene O
in O
many O
types O
of O
cancer O
, O
but O
in O
breast O
cancer O
results O
remain O
controversial O
. O
['Physiological-Clinical']

Journal-Name:Journal O
of O
global O
health O
[]

Assessments O
were O
performed O
at O
baseline O
and O
3 O
weeks O
after O
each O
injection O
using O
several O
outcome O
measures O
. O
[]

Clinical O
improvement O
was O
measured O
by O
the O
Clinical O
Global O
Impression O
scale O
( O
primary O
outcome O
measure O
) O
, O
the O
Global O
Assessment O
of O
Functioning O
Scale O
( O
GAF O
) O
and O
the O
Positive O
and O
Negative O
Symptom O
Scale O
( O
PANSS O
; O
secondary O
outcome O
measures O
) O
. O
[]

Myoclonic B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
and O
sedation B-outcome ['Physiological-Clinical']
were O
recorded O
on O
a O
scale O
between O
0 O
and O
3 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Missing O
end-point O
data O
(39 O
participants, O
3.7%) O
were O
imputed. O
[]

Secondary O
outcomes O
were O
from O
start O
of O
the O
propofol O
infusion O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
consciousness I-outcome ['Physiological-Clinical']
(LOC) I-outcome ['Physiological-Clinical']
, O
rocuronium B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BIS) I-outcome ['Physiological-Clinical']
60 I-outcome ['Physiological-Clinical']
, O
and O
hemodynamic B-outcome ['Physiological-Clinical']
variables. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

No O
accumulation O
of O
the O
activities O
were O
seen O
. O
[]

This O
could O
fill O
the O
gap O
between O
devices O
that O
fully O
compensate O
for O
walking O
and O
those O
which O
allow O
patients O
to O
maintain O
residual O
mobility. O
[]

There O
was O
a O
dose-dependent O
decrease O
in O
ambulatory B-outcome ['Physiological-Clinical']
daytime I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
and O
mean O
arterial B-outcome ['Physiological-Clinical']
BP B-outcome ['Physiological-Clinical']
with O
the O
progestogen O
treatments O
compared O
with O
placebo O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
infiltrating O
growth O
pattern O
was O
significantly O
associated O
with O
histological O
subtype O
and O
lymphovascular O
invasion O
, O
while O
high-grade O
budding O
was O
significantly O
associated O
with O
tumor B-outcome ['Physiological-Clinical']
grade I-outcome ['Physiological-Clinical']
and O
lymphovascular B-outcome ['Physiological-Clinical']
invasion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Adverse O
effects O
were O
more O
frequent O
. O
[]

RESULTS O
We O
found O
the O
DB O
group?s O
VAS O
scores O
to O
be O
lower O
than O
the O
control O
group O
and O
block O
group?s O
( O
p O
< O
0.05 O
) O
values O
at O
postoperative O
1st O
, O
2nd O
, O
6th O
and O
12th O
hours O
. O
[]

Of O
the O
14 O
patients O
, O
seven O
were O
ACTH O
sufficient O
( O
PHDC+ O
) O
and O
seven O
ACTH O
deficient O
( O
PHDC- O
) O
. O
[]

We O
investigated O
whether O
a O
selective O
angiotensin O
II O
receptor O
blocker O
( O
ARB O
) O
would O
have O
a O
regressive O
effect O
on O
left O
ventricular O
hypertrophy O
( O
LVH O
) O
in O
patients O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

The O
injecting O
physician O
assessed O
severity O
of O
pain B-outcome ['Physiological-Clinical']
and O
ease B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
injection I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Higher O
serum O
concentration O
and O
area O
under O
the O
plasma O
concentration O
curve O
( O
AUC O
) O
were O
not O
associated O
with O
an O
improved O
EFS O
. O
[]

There O
were O
also O
no O
significant O
differences O
between O
treatment O
groups O
in O
cardiovascular B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
, O
laboratory B-outcome ['Physiological-Clinical']
values O
, O
or O
adverse B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Publication O
date: O
2018/09/21 O
00:00 O
[accepted] O
[]

Serum B-outcome ['Physiological-Clinical']
Na+ I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
higher O
predialysis O
and O
postdialysis O
for O
those O
patients O
on O
Na+ O
modeling O
. O
['Physiological-Clinical']

The O
apparatus O
was O
switched O
on O
for O
20 O
min O
every O
time O
and O
3 O
times O
a O
day O
. O
[]

Patients O
receiving O
aromatherapy O
massage O
also O
described O
greater O
improvement O
in O
self-reported O
anxiety B-outcome ['Life-Impact']
at O
both O
6 O
and O
10 O
weeks O
postrandomization O
( O
OR O
, O
3.4 O
; O
95 O
% O
CI O
, O
0.2 O
to O
6.7 O
; O
P O
= O
.04 O
and O
OR O
, O
3.4 O
; O
95 O
% O
CI O
, O
0.2 O
to O
6.6 O
; O
P O
= O
.04 O
) O
, O
respectively O
. O
['Life-Impact']

Intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
postoperative B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

During O
the O
8-week O
acute O
trial O
, O
the O
most O
common O
AEs O
on O
the O
Side O
Effects O
Review O
, O
scored O
as O
moderate O
or O
higher O
, O
were O
as O
follows O
( O
placebo O
and O
risperidone O
, O
respectively O
) O
: O
Somnolence B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
37 O
% O
) O
, O
enuresis B-outcome ['Physiological-Clinical']
( O
29 O
% O
and O
33 O
% O
) O
, O
excessive B-outcome ['Physiological-Clinical']
appetite I-outcome ['Physiological-Clinical']
( O
10 O
% O
and O
33 O
% O
) O
, O
rhinitis B-outcome ['Physiological-Clinical']
( O
8 O
% O
and O
16 O
% O
) O
, O
difficulty B-outcome ['Life-Impact']
waking I-outcome ['Life-Impact']
( O
8 O
% O
and O
12 O
% O
) O
, O
and O
constipation B-outcome ['Physiological-Clinical']
( O
12 O
% O
and O
10 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

For O
statistical O
purposes O
, O
data O
were O
dichotomized O
[ O
( O
0,1 O
) O
( O
2,3 O
) O
] O
for O
the O
gingival O
index O
. O
[]

METHODS O
Twenty-five O
opioid-dependent O
patients O
on O
intravenous O
( O
IV O
) O
heroin O
or O
IV O
methadone O
maintenance O
treatment O
were O
randomly O
assigned O
to O
either O
their O
individual O
prescribed O
IV O
maintenance O
dose O
or O
placebo O
. O
[]

Temporal O
variation O
in O
the O
effects O
of O
ophthalmic O
timolol O
on O
cardiovascular B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
in O
healthy O
men O
. O
['Physiological-Clinical']

This O
could O
be O
observed O
in O
patients O
during O
exercise O
and O
in O
those O
in O
whom O
the O
ischemia B-outcome ['Physiological-Clinical']
was O
provoked O
by O
rapid O
cardiac O
stimulation O
. O
['Physiological-Clinical']

This O
finding O
would O
indicate O
that O
the O
chance O
of O
developing O
cicatricial O
ectropion O
with O
any O
of O
the O
tested O
combinations O
of O
TCA O
should O
be O
very O
remote O
. O
[]

Pharmacokinetics O
and O
disposition O
of O
carvedilol O
in O
humans O
. O
[]

Sixty-three O
adults O
with O
chronic O
pain O
were O
randomised O
to O
either O
a O
Treatment O
Group O
or O
waitlist O
Control O
Group O
. O
[]

PARTICIPANTS O
Patients O
( O
N=60 O
) O
admitted O
to O
our O
department O
postorthopedic O
surgery O
were O
randomly O
assigned O
to O
either O
a O
case O
( O
n=30 O
) O
or O
control O
( O
n=30 O
) O
group O
. O
[]

Maternal B-outcome ['Physiological-Clinical']
oversedation I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
did O
not O
occur O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
phase O
III O
clinical O
trial O
of O
exercise O
modalities O
on O
treatment O
side-effects O
in O
men O
receiving O
therapy O
for O
prostate O
cancer O
. O
[]

LEGO O
therapy O
and O
the O
social O
use O
of O
language O
programme O
: O
an O
evaluation O
of O
two O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
interventions O
for O
children O
with O
high O
functioning O
autism O
and O
Asperger O
Syndrome O
. O
['Life-Impact']

Overall O
, O
13 O
patients O
( O
46.4 O
% O
) O
had O
detrusor B-outcome ['Physiological-Clinical']
overactivity I-outcome ['Physiological-Clinical']
and O
14 O
( O
50 O
% O
) O
had O
decreased O
bladder B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
showed O
that O
adherence O
measures O
varied O
with O
lowest O
adherence B-outcome ['Life-Impact']
from O
two O
items O
of O
['Life-Impact']

Helicobacter B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
in O
children O
and O
adolescents O
by O
a O
once O
daily O
6-day O
treatment O
with O
or O
without O
a O
proton O
pump O
inhibitor O
in O
a O
double-blind O
randomized O
trial O
. O
['Physiological-Clinical']

Improvement O
in O
I-QOL O
and O
domain O
scores O
of O
the O
ICIQ-FLUTS O
( O
filling O
and O
incontinence O
sum O
, O
QOL O
score O
) O
, O
and O
patients O
' O
[]

Clinical O
application O
of O
C-reactive O
protein O
across O
the O
spectrum O
of O
acute O
coronary O
syndromes O
. O
[]

RESULTS O
Therapy O
with O
vaginal O
clindamycin O
had O
no O
significant O
impact O
on O
the O
incidence O
of O
spontaneous B-outcome ['Physiological-Clinical']
preterm I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
prior O
to O
37 O
completed O
weeks O
; O
OR O
0.90 O
, O
95 O
% O
CI O
0.40-2.02 O
( O
primary O
outcome O
variable O
) O
. O
['Physiological-Clinical']

CONCLUSION O
The O
placebo-controlled O
study O
suggested O
that O
S. O
boulardii O
significantly O
reduced O
the O
duration O
of O
[]

Considerations O
for O
feasibility O
and O
effectiveness, O
including O
barriers O
to O
attendance, O
are O
discussed. O
[]

Publication O
date: O
2018/12/28 O
06:00 O
[entrez] O
[]

Already O
after O
the O
first O
week O
of O
the O
skiing O
tour O
there O
were O
significant O
drops O
in O
PAI-1 B-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
, O
cholesterol B-outcome ['Physiological-Clinical']
and O
triglycerides B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Autism O
spectrum O
disorders O
( O
ASDs O
) O
are O
neurodevelopmental O
disorders O
characterized O
by O
social O
and O
language O
deficits O
and O
by O
repetitive O
behaviors O
and O
interests O
. O
[]

One O
of O
the O
components O
of O
abnormal O
social O
functioning O
in O
autism O
is O
an O
impaired O
ability O
to O
direct O
eye O
gaze O
onto O
other O
people O
's O
faces O
in O
social O
situations O
. O
[]

All O
subjects O
received O
intradermal O
injections O
on O
the O
forearm O
of O
a O
0.05 O
ml O
saline O
solution O
containing O
5 O
micrograms O
of O
histamine O
before O
and O
at O
different O
times O
after O
drug O
intake O
. O
[]

A O
randomised O
double-blind O
trial O
of O
cyclosporin O
and O
azathioprine O
in O
refractory O
rheumatoid O
arthritis O
. O
[]

Losartan O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
captopril O
with O
fewer O
patients O
discontinuing B-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
( O
17 O
versus O
23 O
% O
for O
losartan O
and O
captopril O
, O
respectively O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
The O
total O
number O
of O
exacerbations B-outcome ['Physiological-Clinical']
was O
slightly O
lower O
in O
the O
flunisolide O
group O
compared O
to O
the O
placebo O
group O
( O
19 O
vs. O
34 O
, O
p O
= O
0.054 O
) O
; O
the O
number O
of O
patients O
experiencing O
at O
least O
one O
exacerbation B-outcome ['Physiological-Clinical']
during O
the O
study B-outcome ['Life-Impact']
was O
also O
decreased O
( O
16 O
vs. O
26 O
, O
p O
= O
0.059 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Patients O
treated O
with O
concomitant O
chemoradiotherapy O
experienced O
more O
frequently O
[]

Enhancement O
values O
in O
the O
aorta O
, O
liver O
, O
and O
portal O
vein O
and O
tumor-liver O
contrast O
were O
measured O
at O
multiphase O
CT O
. O
[]

Conclusions: O
This O
study O
was O
implemented O
in O
challenging O
circumstances. O
[]

Journal O
ID: O
100968562 O
[]

Perioperative O
randomisation O
was O
to O
Ethicon? O
PROXIMATE? O
ILS? O
or O
Autosuture? O
Premium O
Plus O
CEEA? O
. O
[]

Increased O
loss O
of O
BMD B-outcome ['Physiological-Clinical']
with O
use O
of O
uncemented O
press-fit O
cups O
in O
the O
region O
in O
which O
osteolytic O
lesions O
are O
commonly O
found O
suggests O
that O
stress O
shielding O
may O
initiate O
the O
development O
of O
this O
complication O
. O
['Physiological-Clinical']

Small O
bowel O
capsule O
endoscopy O
was O
performed O
before O
and O
2 O
weeks O
after O
low-dose O
aspirin O
administration. O
[]

Discontinuation O
rates O
due O
to O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
as O
follows O
: O
placebo O
7.7 O
% O
, O
aripiprazole O
5 O
mg/day O
9.4 O
% O
, O
10 O
mg/day O
13.6 O
% O
, O
and O
15 O
mg/day O
7.4 O
% O
. O
['Adverse-effects']

OBJECTIVE O
Our O
purpose O
was O
to O
evaluate O
the O
efficacy O
of O
a O
triphasic O
, O
combination O
OC O
( O
ORTHO O
TRI-CYCLEN O
[ O
Ortho-McNeil O
Pharmaceutical O
, O
Raritan O
, O
N.J. O
] O
, O
norgestimate/ethinyl O
estradiol O
) O
compared O
with O
placebo O
in O
the O
treatment O
of O
moderate O
acne O
vulgaris O
. O
[]

This O
study O
examined O
the O
effectiveness O
of O
the O
CCDE O
program O
for O
those O
with O
a O
diagnosis O
of O
mental O
illness O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
augmented O
soft O
tissue O
mobilization O
( O
ASTM O
) O
on O
the O
treatment O
of O
lateral O
epicondylitis O
. O
[]

CONCLUSION O
The O
eradication O
of O
H. O
pylori O
in O
patients O
with O
DU O
reduces O
the O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DU I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
increase O
in O
the O
proportion O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted O
as O
DMA O
in O
the O
folic O
acid O
group O
( O
72 O
% O
before O
and O
79 O
% O
after O
supplementation O
) O
was O
significantly O
( O
P O
< O
0.0001 O
) O
greater O
than O
that O
in O
the O
placebo O
group O
, O
as O
was O
the O
reduction O
in O
the O
proportions O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted I-outcome ['Physiological-Clinical']
as O
MMA O
( O
13 O
% O
and O
10 O
% O
, O
respectively O
; O
P O
< O
0.0001 O
) O
and O
as O
InAs O
( O
15 O
% O
and O
11 O
% O
, O
respectively O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Demand O
and O
control B-outcome ['Physiological-Clinical']
were O
measured O
using O
both O
patient- O
and O
caregiver-derived O
measures O
. O
['Physiological-Clinical']

Hemolytic O
streptococcus O
preparation O
OK-432 O
; O
beneficial O
adjuvant O
therapy O
in O
recurrent O
gastric O
carcinoma O
. O
[]

In O
patients O
using O
opioid O
PCA O
, O
but O
with O
no O
other O
high O
risk O
factors O
for O
PONV B-outcome ['Physiological-Clinical']
, O
prophylactic O
ondansetron O
does O
not O
have O
any O
clinical O
benefit O
. O
['Physiological-Clinical']

Fifty-four O
patients O
were O
treated O
with O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAID O
) O
( O
Voltaren O
resinat O
2 O
x O
75 O
mg/day O
for O
2 O
weeks O
) O
. O
[]

Conversely O
, O
a O
relatively O
low O
dose O
of O
recombinant O
interferon O
, O
used O
in O
combination O
with O
effective O
surgical O
deleulking O
, O
can O
markedly O
reduce O
the O
risk O
of O
postoperative B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Comparison O
of O
thiopentone/guaifenesin O
, O
ketamine/guaifenesin O
and O
ketamine/midazolam O
for O
the O
induction O
of O
horses O
to O
be O
anaesthetised O
with O
isoflurane O
. O
[]

Tolerance O
was O
very O
good O
, O
particularly O
at O
gastroenteric O
level O
( O
no O
side O
and/or O
undesired O
effects O
were O
observed O
) O
and O
at O
the O
level O
of O
haemopoietic O
, O
renal O
and O
hepatic O
function O
. O
[]

After O
12 O
months O
, O
outcomes O
were O
measured O
to O
determine O
changes O
in O
the O
groups O
in O
social O
interaction O
and O
communication O
. O
[]

Compared O
with O
noninvasive O
breathing O
unit O
after O
treatment, O
rhodiola+noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD B-outcome ['Physiological-Clinical']
, O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
level O
decreased O
P<0.05, O
and O
for O
the O
treatment O
group O
after O
treatment O
in O
patients O
with O
serum O
SOD B-outcome ['Physiological-Clinical']
levels O
drop, O
the O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
levels O
P<0.05, O
and O
the O
after O
rhodiola O
rosea O
treatment O
group O
compared, O
rhodiola+noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD B-outcome ['Physiological-Clinical']
, O
malondialdehyde B-outcome ['Physiological-Clinical']
(MDA) I-outcome ['Physiological-Clinical']
level O
decreased O
P<0.05. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Treatment O
consisted O
of O
approximately O
3,800 O
total O
shock O
waves O
( O
+/-10 O
) O
reaching O
an O
approximated O
total O
energy O
delivery O
of O
1,300 O
mJ/mm O
( O
2 O
) O
( O
ED+ O
) O
in O
a O
single O
session O
versus O
placebo O
treatment O
. O
[]

SETTING O
Private O
infertility O
clinic O
. O
[]

Human O
recombinant O
GM-CSF O
in O
allogeneic O
bone O
marrow O
transplantation O
for O
leukaemia O
: O
double-blind O
placebo O
controlled O
trial O
. O
[]

Secondary O
efficacy O
variables O
included O
investigator-assessed O
shoulder B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
patient-assessed O
quality O
of O
life O
on O
the O
Short-Form-36 O
( O
SF-36 O
) O
Acute O
Health O
Survey O
and O
both O
patients O
' O
and O
investigators O
' O
overall O
assessment O
of O
efficacy O
. O
['Physiological-Clinical']

The O
risk O
of O
nonvertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
was O
reduced O
by O
33 O
% O
compared O
with O
control O
over O
3 O
years O
( O
p O
= O
0.06 O
) O
. O
['Physiological-Clinical']

The O
initial O
dose O
of O
sertraline O
was O
50 O
mg/day O
with O
increases O
of O
50 O
mg/day O
every O
3 O
weeks O
permitted O
after O
the O
fourth O
week O
of O
treatment O
( O
dosing O
was O
flexible O
up O
to O
a O
maximum O
of O
200 O
mg/day O
) O
. O
[]

15.13 O
, O
p O
= O
0.004 O
and O
basal O
citrulline O
= O
49.51 O
? O
[]

METHODS O
Twelve O
patients O
with O
RA O
entering O
a O
randomized O
clinical O
trial O
of O
human O
recombinant O
IL-1Ra O
underwent O
synovial O
biopsies O
before O
and O
after O
treatment O
. O
[]

Strength O
of O
hand O
grip O
was O
the O
best O
predictor O
of O
volume O
delivered O
and O
was O
more O
strongly O
correlated O
with O
volumes O
delivered O
by O
one O
rather O
than O
two O
hands O
. O
[]

In O
the O
0-24 O
h O
interval O
as O
a O
whole O
, O
there O
was O
no O
difference O
between O
treatments O
in O
mean O
pH O
or O
% O
time O
pH O
> O
3 O
or O
> O
4 O
. O
[]

RESULTS O
Results O
indicate O
that O
both O
intervention O
groups O
improved O
significantly O
over O
the O
control O
group O
on O
certain O
behaviors O
. O
[]

Behavioral B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
in O
autistic O
individuals O
as O
a O
result O
of O
wearing O
ambient O
transitional O
prism O
lenses O
. O
['Life-Impact']

In O
the O
present O
study O
, O
while O
initial O
benefits O
were O
observed O
to O
be O
independent O
of O
dental O
prophylaxis O
, O
significant O
reductions O
in O
periodontal B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
sustained O
by O
a O
combination O
of O
dental O
prophylaxis O
and O
swabbing O
protocol O
, O
at O
reduced O
frequency O
of O
application O
and O
over O
prolonged O
time O
. O
['Physiological-Clinical']

Multi-arm O
crossover O
tea O
trials O
might O
pose O
a O
higher O
burden O
on O
participants O
and O
research O
is O
needed O
to O
improve O
adherence O
and O
treatment O
compliance O
in O
such O
trials O
. O
[]

AIMS O
There O
is O
evidence O
that O
plasma O
coenzyme B-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CoQ I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
10 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
decrease O
in O
patients O
with O
advanced O
chronic O
heart O
failure O
( O
CHF O
) O
. O
['Physiological-Clinical']

After O
baseline O
measurements O
, O
CCM O
signals O
were O
delivered O
continuously O
for O
2 O
hours O
in O
dogs O
and O
for O
30 O
minutes O
in O
patients O
. O
[]

CONCLUSION O
Cyclosporin O
bioavailability O
was O
not O
clearly O
modified O
by O
a O
half O
dosage O
of O
ticlopidine O
in O
this O
study O
. O
[]

In O
a O
double-blind O
study O
forty-two O
children O
scheduled O
for O
elective O
adenotonsillectomy O
were O
randomized O
to O
receive O
peritonsillar O
infiltration O
, O
following O
induction O
of O
anaesthesia O
, O
with O
either O
0.25 O
% O
plain O
bupivacaine O
or O
0.9 O
% O
saline O
, O
0.5 O
ml/kg O
to O
a O
maximum O
of O
10 O
ml O
. O
[]

There O
is O
much O
evidence O
suggesting O
that O
the O
decline O
in O
ovarian O
function O
after O
menopause O
is O
associated O
with O
spontaneous O
increases O
in O
proinflammatory O
cytokines O
. O
[]

INTERVENTION O
Participants O
were O
randomized O
to O
receive O
1 O
year O
of O
daily O
supplementation O
with O
71 O
g O
of O
LP O
( O
282 O
kcal O
) O
, O
50 O
g O
of O
FS O
( O
FS50 O
) O
( O
256 O
kcal O
) O
, O
or O
25 O
g O
of O
FS O
( O
FS25 O
) O
( O
130 O
[ O
corrected O
] O
kcal O
) O
. O
[]

Methylphenidate O
and/or O
a O
nursing O
telephone O
intervention O
for O
fatigue B-outcome ['Physiological-Clinical']
in O
patients O
with O
advanced O
cancer O
: O
a O
randomized O
, O
placebo-controlled O
, O
phase O
II O
trial O
. O
['Physiological-Clinical']

These O
data O
provide O
evidence O
that O
OPN B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
is O
an O
independent O
prognostic O
factor O
in O
AML O
. O
['Physiological-Clinical']

Range O
of O
motion B-outcome ['Life-Impact']
, O
Constant O
score O
, O
Oxford O
Shoulder B-outcome ['Physiological-Clinical']
Score O
, O
Short O
Form O
36 O
, O
and O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Disability O
Scale O
( O
HADS O
) O
outcome O
measures O
were O
performed O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
1 O
year O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

In O
both O
groups O
, O
minute O
ventilation B-outcome ['Physiological-Clinical']
( O
VE B-outcome ['Physiological-Clinical']
) O
and O
f O
progressively O
decreased O
as O
resistance O
was O
increased O
by O
decreasing O
the O
aperture O
size O
from O
15 O
to O
16 O
mm O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
changes O
in O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
( O
mg/dL O
) O
at O
week O
96 O
were O
similar O
to O
week O
48 O
. O
['Physiological-Clinical']

[ O
Cooperative O
study O
of O
surgical O
adjuvant O
chemotherapy O
of O
colorectal O
carcinoma O
( O
second O
study O
) O
: O
3-year O
survival O
after O
surgery O
of O
non-curatively O
resected O
patients O
. O
[]

The O
ketamine O
group O
also O
showed O
a O
statistically O
significant O
difference O
24 O
h O
post O
infusion O
of O
the O
effect O
of O
pain B-outcome ['Physiological-Clinical']
on O
their O
general O
activity O
( O
P=0.03 O
) O
and O
on O
their O
enjoyment O
of O
life O
( O
P=0.004 O
) O
. O
['Physiological-Clinical']

The O
relationship O
between O
masticatory O
performance O
and O
chewing O
experience O
has O
not O
yet O
been O
explored O
for O
patients O
with O
implant-retained O
overdentures O
. O
[]

We O
compared O
the O
surgical O
outcomes O
between O
the O
two O
methods O
. O
[]

We O
report O
a O
randomized O
trial O
of O
a O
revised O
Behavioral O
Family O
Systems O
Therapy O
for O
Diabetes O
( O
BFST-D O
) O
intervention O
. O
[]

This O
prospective O
cohort O
study O
is O
a O
re-assessment O
of O
the O
data O
from O
the O
randomized O
trial O
with O
the O
2 O
treatment O
groups O
considered O
as O
a O
single O
cohort O
. O
[]

The O
study O
primarily O
assessed O
risperidone O
's O
safety O
; O
efficacy O
was O
assessed O
as O
a O
secondary O
end-point O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
efficacy O
of O
SJW O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
primary O
outcome O
of O
the O
study O
was O
the O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
the O
caudal B-outcome ['Physiological-Clinical']
block O
during O
the O
operation B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Patients O
were O
randomly O
allocated O
to O
topiramate+risperidone O
( O
Group O
A O
) O
or O
placebo+risperidone O
( O
Group O
B O
) O
for O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

Patient O
follow-up O
to O
3 O
months O
was O
completed O
on O
April O
12, O
2018. O
[]

Dark-phase O
light O
contamination O
can O
significantly O
disrupt O
chronobiologic B-outcome ['Physiological-Clinical']
rhythms I-outcome ['Physiological-Clinical']
, O
thereby O
potentially O
altering O
the O
endocrine O
physiology O
and O
metabolism O
of O
experimental O
animals O
and O
influencing O
the O
outcome O
of O
scientific O
investigations O
. O
['Physiological-Clinical']

RESULTS O
The O
eradication B-outcome ['Physiological-Clinical']
rate O
of O
the O
cimetidine O
group O
the O
omeprazole O
group O
, O
and O
the O
CBS O
group O
were O
0 O
% O
, O
7.7 O
% O
, O
0 O
% O
, O
respectively O
, O
and O
that O
of O
the O
double O
therapy O
group O
and O
the O
triple O
therapy O
group O
were O
44.4 O
% O
and O
89.3 O
% O
, O
respectively O
. O
['Physiological-Clinical']

Twenty O
healthy O
subjects O
received O
lorazepam O
0.5 O
mg O
, O
1 O
mg O
and O
2 O
mg O
, O
sertraline O
50 O
mg O
and O
placebo O
in O
a O
balanced O
, O
repeated O
measures O
study O
design O
. O
[]

Patients O
in O
both O
arms O
were O
well O
balanced O
with O
regard O
to O
clinical O
variables O
. O
[]

Effectiveness O
of O
norgestimate O
and O
ethinyl O
estradiol O
in O
treating O
moderate O
acne O
vulgaris O
. O
[]

We O
conclude O
that O
effective O
normalisation O
of O
hypercholesterolaemia B-outcome ['Physiological-Clinical']
may O
retard O
the O
progression O
of O
diabetic B-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
and O
compare O
laparoscopic O
treatment O
for O
stage O
I O
endometrial O
cancer O
with O
the O
traditional O
transabdominal O
approach O
. O
[]

The O
results O
of O
a O
randomized O
, O
single-blind O
, O
multi-clinic O
study O
comparing O
the O
therapeutic B-outcome ['Physiological-Clinical']
efficacy O
and O
degree O
of O
oral B-outcome ['Physiological-Clinical']
staining I-outcome ['Physiological-Clinical']
of O
new O
colloidal O
bismuth O
subcitrate O
( O
CBS O
) O
coated O
tablets O
over O
4 O
weeks O
of O
treatment O
in O
patients O
suffering O
from O
duodenal O
ulceration O
are O
reported O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Trained O
community O
health O
advisors O
, O
who O
were O
African-American O
male O
church O
members O
, O
led O
an O
educational O
session O
and O
distributed O
educational O
print O
materials O
. O
[]

Limited O
sensory O
blockade O
was O
achieved O
in O
the O
groups O
with O
40 O
ml O
0.5 O
% O
and O
20 O
ml O
1 O
% O
during O
the O
30-minute O
test O
period O
. O
[]

One O
hundred O
twenty-eight O
patients O
were O
treated O
with O
postoperative O
radiotherapy O
with O
50 O
Gy O
in O
25 O
daily O
fractions O
over O
5 O
weeks O
. O
[]

The O
urine O
concentration O
of O
8-iso-PGF O
( O
2? O
) O
[ O
geometric O
mean O
( O
95 O
% O
CI O
) O
] O
was O
greater O
after O
the O
iTFA O
[ O
0.54 O
( O
0.48 O
, O
0.60 O
) O
nmol/mmol O
creatinine O
] O
and O
the O
CLA O
[ O
1.2 O
( O
1.1 O
, O
1.3 O
) O
nmol/mmol O
creatinine O
] O
diet O
periods O
than O
after O
the O
control O
period O
[ O
0.45 O
( O
0.41 O
, O
0.50 O
) O
nmol/mmol O
creatinine O
; O
P O
< O
0.05 O
] O
. O
[]

CONCLUSIONS O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
of O
at O
least O
6 O
weeks O
duration O
is O
not O
associated O
with O
improved O
functioning O
, O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
or O
overall O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
is O
associated O
with O
an O
increase O
in O
GP B-outcome ['Resource-use']
workload I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

These O
patients O
were O
allocated O
to O
one O
of O
two O
groups O
by O
drawing O
lots O
: O
IMV O
group O
( O
IMVG O
; O
n O
= O
35 O
) O
and O
SIMV+PS O
group O
( O
SIMVG O
; O
n O
= O
35 O
) O
. O
[]

When O
analyzed O
according O
to O
whether O
or O
not O
visible B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
was O
achieved O
( O
some O
of O
the O
polyps O
in O
the O
fixed O
duration O
cautery O
group O
showed O
necrosis O
with O
2 O
s O
cautery O
) O
, O
19 O
of O
23 O
polyps O
( O
83 O
% O
) O
were O
eradicated B-outcome ['Physiological-Clinical']
when O
necrosis O
was O
evident O
, O
compared O
to O
5 O
of O
12 O
( O
42 O
% O
) O
without O
necrosis O
( O
p O
= O
0.004 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
took O
one O
tablet O
daily O
and O
rinsed O
twice O
daily O
for O
1 O
min O
with O
the O
mouthwash O
. O
[]

Infant B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
negatively O
correlated O
with O
cigarettes O
smoked O
per O
day O
( O
r O
= O
-0.29 O
, O
P O
< O
.01 O
) O
and O
expired O
carbon O
monoxide O
( O
r O
= O
-0.39 O
, O
( O
P O
< O
.001 O
) O
at O
delivery O
. O
['Physiological-Clinical']

Weight O
loss B-outcome ['Physiological-Clinical']
relative O
to O
control O
was O
statistically O
significant O
in O
the O
comprehensive O
group O
3 O
, O
6 O
, O
and O
12 O
months O
after O
randomization O
, O
whereas O
weight O
loss B-outcome ['Physiological-Clinical']
in O
the O
individualized O
group O
was O
significant O
only O
at O
12 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Long-term O
cultures O
showed O
no O
evidence O
of O
stem-cell B-outcome ['Physiological-Clinical']
depletion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Additionally O
, O
our O
data O
demonstrated O
an O
even O
more O
rapid O
induction O
of O
[]

RESULTS O
A O
total O
of O
226 O
patients O
were O
evaluable O
for O
response O
. O
[]

One O
hundred O
three O
subjects O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
categories O
: O
anti-inflammatory O
, O
accommodative O
, O
or O
mechanical O
. O
[]

The O
reductions O
achieved O
in O
each O
of O
the O
nifedipine O
SR O
groups O
were O
statistically O
significant O
versus O
baseline O
values O
( O
p O
less O
than O
0.001 O
) O
. O
[]

The O
effect O
variables O
were O
daily O
levels O
of O
pain O
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
palpation B-outcome ['Physiological-Clinical']
tenderness I-outcome ['Physiological-Clinical']
and O
isokinetic B-outcome ['Physiological-Clinical']
quadriceps I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Bone B-outcome ['Physiological-Clinical']
SOS I-outcome ['Physiological-Clinical']
decreased O
significantly O
in O
the O
control O
group O
( O
-108.1 O
+/- O
33.7 O
m/second O
, O
P O
< O
0.0001 O
) O
during O
the O
study O
period O
, O
while O
remaining O
stable O
in O
the O
exercise O
group O
( O
11.3 O
+/- O
22.8 O
m/second O
) O
. O
['Physiological-Clinical']

Although O
both O
LOOH B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

Bile O
acid O
replacement O
therapy O
might O
therefore O
be O
of O
clinical O
benefit O
, O
provided O
that O
diarrhoea O
is O
not O
aggravated O
by O
therapy O
. O
[]

A O
randomized O
clinical O
trial O
of O
the O
efficacy O
of O
scheduled O
dosing O
of O
acetaminophen O
and O
hydrocodone O
for O
the O
management O
of O
postoperative O
pain O
in O
children O
after O
tonsillectomy O
. O
[]

The O
effects O
on O
platelet B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
either O
by O
angiotensin O
converting O
enzyme O
inhibitors O
or O
angiotensin O
receptor O
antagonists O
, O
are O
still O
not O
well O
understood O
. O
['Physiological-Clinical']

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O
[]

Twenty-three O
WL O
participants O
completed O
randomly O
assigned O
treatment O
following O
the O
waiting O
period O
. O
[]

Dental O
bacteremia O
in O
children O
. O
[]

Nine O
( O
16 O
% O
) O
patients O
in O
the O
treatment O
group O
and O
19 O
( O
35 O
% O
) O
in O
the O
placebo O
group O
developed O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
diagnosed O
by O
the O
125I-fibrinogen O
uptake O
test O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

Four O
months O
after O
surgery O
, O
the O
motor B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
conduction I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
end-to-side I-outcome ['Physiological-Clinical']
coaptation O
was O
significantly O
slower O
than O
in O
the O
normal O
control O
. O
['Physiological-Clinical']

RESULTS: O
PC O
lowered O
body B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
storage I-outcome ['Physiological-Clinical']
and O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
by O
15.7 O
+/- O
15.0 O
W O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Both O
self-report O
and O
sociometric B-outcome ['Life-Impact']
measures O
were O
used O
to O
evaluate O
treatment O
outcome O
. O
['Life-Impact']

Expression O
of O
OPN B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
was O
increased O
in O
AML O
patients O
both O
in O
BM O
blasts O
( O
IHC O
) O
and O
in O
BM O
serum O
( O
ELISA O
) O
compared O
with O
healthy O
controls O
. O
['Physiological-Clinical']

RESULTS: O
By O
December O
31, O
2017, O
a O
total O
of O
261 O
of O
the O
347 O
men O
in O
the O
radical-prostatectomy O
group O
and O
292 O
of O
the O
348 O
men O
in O
the O
watchful-waiting O
group O
had O
died B-outcome ['Mortality']
; O
71 O
deaths B-outcome ['Mortality']
in O
the O
radical-prostatectomy O
group O
and O
110 O
in O
the O
watchful-waiting O
group O
were O
due O
to O
prostate O
cancer O
(relative O
risk, O
0.55; O
95% O
confidence O
interval O
[CI], O
0.41 O
to O
0.74; O
P<0.001; O
absolute O
difference O
in O
risk, O
11.7 O
percentage O
points; O
95% O
CI, O
5.2 O
to O
18.2). O
[['Mortality'], ['Mortality']]

100 O
mg O
modafinil O
on O
psychomotor O
vigilance O
, O
sleepiness O
, O
and O
the O
waking O
and O
sleep O
EEG O
. O
[]

Gemcitabine O
and O
split-dose O
paclitaxel O
or O
docetaxel O
in O
metastatic O
breast O
cancer O
: O
a O
randomised O
phase O
II O
study O
. O
[]

In O
the O
GeparTrio O
trial O
, O
patients O
were O
not O
treated O
with O
any O
anti-HER2 O
therapy O
, O
as O
this O
was O
not O
standard O
therapy O
at O
this O
time O
. O
[]

Results O
suggest O
that O
youth O
who O
completed O
the O
JobTIPS O
employment O
program O
demonstrated O
significantly O
more O
effective O
verbal B-outcome ['Life-Impact']
content I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
than O
those O
who O
did O
not O
. O
['Life-Impact']

A O
gradual O
increase O
of O
AP-1 O
activation O
was O
found O
in O
non-progressive O
and O
progressive O
phases O
of O
atherosclerosis O
respectively O
( O
P O
< O
0.044 O
) O
. O
[]

Data O
for O
prostate O
cancer O
were O
obtained O
from O
the O
ERSPC O
central O
database O
. O
[]

This O
may O
necessitate O
an O
alternative O
therapy O
for O
this O
group O
of O
patients. O
[]

Among O
the O
552 O
participants O
who O
completed O
the O
follow-up O
examination O
, O
94 O
stopped O
treatment O
early O
. O
[]

Thirty O
observation O
periods O
of O
6 O
months O
each O
were O
studied O
for O
23 O
patients O
. O
[]

Research O
Units O
on O
Pediatric O
Psychopharmacology O
. O
[]

Quality O
of O
life O
, O
judged O
by O
Diabetes B-outcome ['Physiological-Clinical']
Control O
and O
Complications B-outcome ['Adverse-effects']
Trial O
questionnaires O
, O
was O
unaffected O
by O
pump O
therapy O
. O
['Physiological-Clinical', 'Adverse-effects']

BACKGROUND O
In O
heart O
failure O
( O
HF O
) O
, O
a O
defective O
nitric O
oxide O
signaling O
is O
involved O
in O
left O
ventricular O
( O
LV O
) O
diastolic O
abnormalities O
and O
remodeling O
. O
[]

Following O
acid O
infusion O
, O
pain B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
decreased O
( O
17 O
( O
4 O
) O
% O
; O
p=0.01 O
) O
in O
the O
UO O
, O
suggesting O
the O
presence O
of O
secondary O
hyperalgesia O
. O
['Physiological-Clinical']

RESULTS O
Baseline O
BCVA O
( O
logMAR O
) O
and O
CMT O
were O
, O
respectively O
, O
0.89 O
+/- O
0.13 O
and O
650 O
+/- O
140 O
microm O
for O
the O
GLP O
group O
, O
0.87 O
+/- O
0.16 O
and O
690 O
+/- O
120 O
microm O
for O
the O
IB O
group O
. O
[]

The O
intention-to-treat O
analysis O
showed O
a O
difference O
in O
the O
risk O
of O
definitive O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
(oral O
group O
vs. O
intravenous O
group) O
of O
-1.4 O
percentage O
points O
(90% O
confidence O
interval O
[CI], O
-4.9 O
to O
2.2; O
95% O
CI, O
-5.6 O
to O
2.9), O
indicating O
noninferiority. O
[['Physiological-Clinical']]

Perioperative O
myocardial O
infarctions O
are O
common O
and O
often O
unrecognized O
in O
patients O
undergoing O
hip O
fracture O
surgery O
. O
[]

Neuropsychological B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
after O
psychosocial O
intervention O
for O
depression O
in O
Parkinson O
's O
disease O
. O
['Physiological-Clinical']

Journal-Name:Pediatric O
physical O
therapy O
: O
the O
official O
publication O
of O
the O
Section O
on O
Pediatrics O
of O
the O
American O
Physical O
Therapy O
Association O
[]

Impact O
of O
prior O
pharmacotherapy O
on O
remission O
of O
psychotic B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
in O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

In O
Study O
3 O
( O
a O
daily O
event O
sampling O
study O
) O
, O
the O
authors O
showed O
that O
the O
[]

RESULTS O
Response O
in O
Phase O
2 O
did O
not O
differ O
significantly O
between O
verapamil O
and O
continued-lithium O
. O
[]

There O
was O
a O
suggestion O
that O
it O
had O
a O
beneficial O
effect O
on O
decreasing O
self-injurious B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

There O
was O
no O
difference O
in O
challenge O
with O
histamine O
versus O
challenge O
with O
placebo O
. O
[]

The O
primary O
endpoint O
was O
achieved O
in O
similar O
proportions O
of O
patients O
in O
the O
two O
treatment O
groups O
(12 O
[43%] O
of O
28 O
in O
the O
5-day O
schedule O
group, O
95% O
credible O
interval O
26-60, O
and O
17 O
[40%] O
of O
43 O
in O
the O
10-day O
schedule O
group, O
26-54, O
p=0.78; O
difference O
3%, O
-21 O
to O
27). O
[]

The O
quality O
of O
the O
analgesia O
was O
assessed O
with O
a O
Numerical O
Pain O
Rating O
Scale O
( O
NRS O
) O
; O
recovery B-outcome ['Physiological-Clinical']
level O
and O
return O
of O
psychomotor B-outcome ['Life-Impact']
efficiency O
were O
evaluated O
with O
, O
respectively O
, O
the O
Aldrete O
scale O
and O
a O
Modified O
Post O
Anesthesia O
Discharge O
Scoring O
( O
MPADS O
) O
system O
. O
['Physiological-Clinical', 'Life-Impact']

Lymph O
node O
staging O
was O
mandatory O
but O
at O
the O
physician O
's O
discretion O
; O
117 O
( O
26 O
% O
) O
patients O
had O
SL O
, O
while O
332 O
( O
74 O
% O
) O
had O
LAG O
. O
[]

Significant O
improvement O
of O
active O
over O
dummy O
laser O
was O
noted O
for O
all O
seven O
assessments O
. O
[]

METHODS O
One O
hundred O
and O
ten O
patients O
with O
CHD O
and O
its O
equivalents O
with O
serum O
total O
cholesterol O
( O
TC O
) O
> O
or O
= O
3.5 O
mmol/L O
were O
randomly O
assigned O
into O
three O
treatment O
groups O
: O
( O
1 O
) O
atorvastatin O
group O
( O
n O
= O
38 O
) O
, O
receiving O
atorvastatin O
10 O
mg/d O
for O
8 O
weeks O
; O
( O
2 O
) O
niacin O
ER O
group O
( O
n O
= O
38 O
) O
, O
given O
niacin O
ER O
500 O
mg/d O
for O
4 O
weeks O
and O
then O
1000 O
mg/d O
for O
4 O
weeks O
; O
( O
3 O
) O
combination O
treatment O
group O
( O
n O
= O
34 O
) O
, O
treated O
with O
atorvastatin O
( O
10 O
mg/d O
) O
plus O
niacin O
ER O
, O
with O
the O
dose O
initiating O
from O
500 O
mg/d O
, O
and O
increasing O
to O
1000 O
mg/d O
after O
4 O
weeks O
, O
for O
8 O
weeks O
. O
[]

Journal O
ID: O
7511141 O
[]

BACKGROUND O
This O
randomized O
trial O
was O
conducted O
to O
compare O
the O
efficacy O
and O
side O
effects O
of O
intravesical O
mitoxantrone O
instillation O
with O
those O
of O
doxorubicin O
in O
superficial O
bladder O
cancer O
following O
transurethral O
resection O
. O
[]

BACKGROUND O
Daytime B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
elevated O
in O
HF O
patients O
with O
coexisting O
OSA O
. O
['Physiological-Clinical']

After O
6 O
months O
, O
the O
HOA B-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
mean O
square O
( O
RMS B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increased O
on O
average O
by O
a O
factor O
of O
1.44 O
for O
the O
Planoscan O
group O
( O
P O
= O
0.003 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
This O
23-day O
, O
prospective O
, O
double-blind O
, O
randomized O
, O
parallel-group O
study O
was O
conducted O
at O
3 O
Colombian O
centers O
: O
University O
Libre O
, O
Social O
Security O
Institute O
, O
and O
General O
Hospital O
of O
Medell?n O
, O
Cali O
, O
Colombia O
. O
[]

Efficacy O
, O
tolerability B-outcome ['Life-Impact']
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
two O
nelfinavir-based O
regimens O
in O
human O
immunodeficiency O
virus-infected O
children O
and O
adolescents O
: O
pediatric O
AIDS O
clinical O
trials O
group O
protocol O
403 O
. O
['Life-Impact', 'Physiological-Clinical']

Comparison O
between O
obtained O
mydriasis O
in O
type O
2 O
diabetics O
and O
non-diabetic O
patients O
. O
[]

The O
levels O
in O
the O
placebo O
group O
decreased O
gradually O
but O
remained O
high O
during O
the O
study O
period O
. O
[]

STUDY O
OBJECTIVE O
to O
compare O
passive O
heat O
retention O
by O
low-flow O
anesthesia O
, O
alone O
and O
with O
additional O
thermal O
insulation O
by O
reflective O
blankets O
, O
with O
forced-air O
warming O
preventing O
intraoperative O
hypothermia O
during O
combined O
epidural-general O
anesthesia O
. O
[]

A O
six-session O
higher-functioning O
autism O
anti-stigma O
program O
incorporating O
descriptive O
, O
explanatory O
and O
directive O
information O
was O
delivered O
to O
adolescent O
boys O
and O
the O
impact O
upon O
knowledge B-outcome ['Life-Impact']
, O
attitudes B-outcome ['Life-Impact']
and O
behavioural B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
towards O
peers O
with O
autism O
was O
evaluated O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Intra-articular O
injections O
of O
rAAV2-TNFR O
: O
Fc O
were O
well O
tolerated O
with O
no O
major O
safety O
issues O
. O
[]

DESIGN O
Randomized O
, O
prospective O
study O
. O
[]

The O
time B-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
scaling I-outcome ['Physiological-Clinical']
between O
the O
product O
and O
placebo O
side O
was O
not O
significant O
. O
['Physiological-Clinical']

Many O
autistic O
children O
have O
associated O
problems O
of O
inattention B-outcome ['Life-Impact']
, O
impulsivity B-outcome ['Life-Impact']
, O
and O
hyperactivity B-outcome ['Life-Impact']
that O
limit O
the O
effectiveness O
of O
educational O
and O
behavioral O
interventions O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
incidences O
of O
postoperative O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
(PPCs) I-outcome ['Physiological-Clinical']
and O
atelectasis O
(2.9%, O
0.0%) O
in O
the O
AG O
were O
significantly O
lower O
than O
that O
in O
the O
CG O
(20.6%, O
14.7%)(P=0.03, O
P=0.03). O
[['Physiological-Clinical']]

A O
major O
issue O
was O
that O
of O
adapting O
international O
best O
practice O
recommendations O
with O
regard O
to O
home-visiting O
programs O
to O
the O
particularities O
of O
the O
existing O
French O
social O
and O
health O
care O
system O
. O
[]

Patients O
with O
preoperative O
CEA O
levels O
< O
5.0 O
ng/ml O
were O
excluded O
. O
[]

Peripheral O
opioid O
receptors O
have O
been O
found O
in O
inflamed O
synovia O
and O
the O
analgesic O
effect O
of O
intra-articularly O
administered O
morphine O
after O
arthroscopic O
knee O
surgery O
has O
been O
proven O
. O
[]

The O
school O
has O
been O
identified O
as O
a O
key O
setting O
to O
promote O
physical O
activity O
. O
[]

The O
additional O
benefit O
of O
WB O
exercise O
was O
improved O
position O
sense B-outcome ['Physiological-Clinical']
, O
which O
may O
enhance O
complex B-outcome ['Life-Impact']
walking I-outcome ['Life-Impact']
tasks O
( O
walking O
on O
figure O
of O
8 O
route O
and O
spongy O
surface O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Positive O
HER2 B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
levels O
were O
found O
in O
19.8 O
% O
( O
55/278 O
) O
. O
['Physiological-Clinical']

Severe B-outcome ['Adverse-effects']
and I-outcome ['Adverse-effects']
life-threatening I-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
occurred O
in O
44 O
percent O
and O
20 O
percent O
, O
respectively O
, O
of O
the O
patients O
who O
received O
combined O
therapy O
, O
as O
compared O
with O
25 O
percent O
and O
3 O
percent O
of O
those O
treated O
with O
radiation O
alone O
. O
['Adverse-effects']

Publication O
date: O
['2019/10/17 O
06:00' O
[]

Rates O
were O
compared O
between O
groups O
. O
[]

[ O
Prevention O
of O
pneumonia B-outcome ['Physiological-Clinical']
by O
endotracheal O
micronebulization O
of O
tobramycin O
] O
. O
['Physiological-Clinical']

UNLABELLED O
Randomized O
controlled O
study O
in O
80 O
postmenopausal O
women O
with O
osteoporosis O
was O
conducted O
to O
investigate O
the O
effect O
of O
a O
home-based O
, O
simple O
, O
low-intensity O
exercise O
. O
[]

RESULTS O
The O
mean O
age O
of O
patients O
was O
46.02 O
years O
( O
SD O
, O
12.33 O
) O
in O
the O
stapled O
group O
and O
48.64 O
years O
( O
14.57 O
) O
in O
the O
open O
group O
. O
[]

BACKGROUND O
Although O
physical O
therapy O
and O
falls O
prevention O
education O
are O
argued O
to O
reduce O
falls B-outcome ['Life-Impact']
and O
disability B-outcome ['Life-Impact']
in O
people O
with O
idiopathic O
Parkinson O
's O
disease O
, O
this O
has O
not O
yet O
been O
confirmed O
with O
a O
large O
scale O
randomised O
controlled O
clinical O
trial O
. O
['Life-Impact', 'Life-Impact']

The O
mean O
change O
in O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
overall O
: O
1.2 O
+/- O
2.2 O
g/dL O
) O
during O
the O
study O
represents O
a O
statistically O
significant O
( O
p O
< O
.0001 O
) O
decrease O
of O
9.7 O
% O
. O
['Physiological-Clinical']

Study O
patients O
were O
randomized O
to O
the O
two O
treatment O
arms O
, O
Er O
: O
YAG O
( O
3.8 O
J/cm O
( O
2 O
) O
, O
30 O
% O
pattern O
overlap O
, O
0 O
% O
interpulse O
overlap O
, O
15 O
microm O
per O
pass O
with O
no O
coagulation O
) O
and O
IPL O
( O
560-nm O
filter O
, O
30 O
J/cm O
( O
2 O
) O
, O
2.4/4.0-ms O
pulse O
with O
10-ms O
delay O
) O
, O
each O
receiving O
three O
sequential O
treatments O
spaced O
1 O
month O
apart O
. O
[]

Effect O
of O
micronutrient O
supplement O
on O
health B-outcome ['Physiological-Clinical']
and O
nutritional B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
schoolchildren O
: O
study O
design O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
control O
group O
, O
there O
were O
no O
significant O
changes O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P=0.89 O
) O
or O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.70 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

The O
adverse O
reactions O
to O
FZ O
are O
not O
severe O
, O
and O
are O
well O
tolerated B-outcome ['Life-Impact']
in O
most O
patients O
. O
['Life-Impact']

METHOD O
Forty O
children O
( O
7-11 O
years O
old O
) O
were O
randomly O
assigned O
to O
16 O
sessions O
of O
CBT O
or O
a O
3-month O
waitlist O
( O
36 O
completed O
treatment O
or O
waitlist O
) O
. O
[]

The O
clinical O
implications O
of O
these O
findings O
are O
discussed O
. O
[]

Auditory O
integration O
training O
for O
children O
with O
autism B-outcome ['Life-Impact']
: O
no O
behavioral O
benefits O
detected O
. O
['Life-Impact']

Effect O
of O
reduced O
alcohol O
consumption O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
untreated O
hypertensive O
men O
. O
['Physiological-Clinical']

In O
this O
study O
metronidazole O
did O
not O
have O
disease B-outcome ['Physiological-Clinical']
modifying I-outcome ['Physiological-Clinical']
properties I-outcome ['Physiological-Clinical']
and O
was O
unacceptably O
toxic B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

METHODS O
ACS O
patients O
undergoing O
cardiac O
catheterization O
with O
> O
or=1 O
nonobstructive O
native O
coronary O
artery O
atheroma O
were O
randomized O
to O
either O
7 O
weekly O
HDL O
selective O
delipidated O
or O
control O
plasma O
apheresis/reinfusions O
. O
[]

This O
study O
summarizes O
the O
treatment O
effect O
of O
zoledronic O
acid O
infusion O
on O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
in O
different O
subgroups O
with O
glucocorticoid-induced O
osteoporosis O
. O
['Physiological-Clinical']

The O
goal O
of O
our O
study O
was O
to O
investigate O
whether O
reaction O
time O
( O
RT O
) O
, O
error O
rate O
, O
post-error O
RT O
change O
, O
ERN O
, O
and O
Pe O
will O
show O
positive O
changes O
following O
12-week O
long O
slow O
frequency O
repetitive O
TMS O
( O
rTMS O
) O
over O
dorsolateral O
prefrontal O
cortex O
( O
DLPFC O
) O
in O
high O
functioning O
children O
with O
ASD O
. O
[]

Forty-six O
patients O
were O
irradiated O
with O
7 O
Gy O
single O
dose O
within O
16-20 O
h O
before O
operation O
. O
[]

Nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
more O
prevalent O
among O
the O
patients O
given O
the O
infusion O
of O
morphine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subjects O
were O
recruited O
at O
10 O
U.S. O
centers O
between O
1993 O
and O
2001 O
. O
[]

The O
clinical B-outcome ['Physiological-Clinical']
efficacy O
of O
letrozole O
in O
HER2+ O
breast O
cancer O
was O
confirmed O
by O
fluorescent O
in O
situ O
hybridization O
analysis O
and O
was O
found O
to O
be O
comparable O
to O
that O
of O
HER2- O
cases O
( O
ORR O
71 O
% O
in O
both O
subsets O
) O
. O
['Physiological-Clinical']

The O
effects O
of O
hypoxemia O
on O
cardiac O
output O
. O
[]

Moreover O
, O
the O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
shorter O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
was O
superior O
in O
group O
1 O
( O
P O
= O
0.001 O
and O
P O
= O
0.001 O
, O
respectively O
) O
. O
['Resource-use', 'Life-Impact']

bolus O
followed O
by O
continuous O
i.v O
. O
[]

With O
extensive O
pathological O
workup O
, O
increased O
numbers O
of O
small O
metastatic O
deposits O
are O
detected O
in O
SLN O
. O
[]

Subjectively O
, O
the O
children O
enjoyed O
whole O
body O
vibration O
which O
was O
easy B-outcome ['Life-Impact']
to O
integrate O
into O
the O
behavioural O
programme O
. O
['Life-Impact']

Obesity O
and O
mortality O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
: O
analysis O
of O
RTOG O
85-31 O
. O
[]

Individuals O
received O
in O
a O
double O
blinded O
fashion O
either O
1000 O
mg O
of O
calcium O
or O
1000 O
mg O
of O
calcium O
plus O
800 O
IU O
of O
vitamin O
D O
per O
day O
over O
a O
treatment O
period O
of O
12 O
months O
, O
which O
was O
followed O
by O
a O
treatment-free O
but O
still O
blinded O
observation O
period O
of O
8 O
months O
. O
[]

RESULTS O
There O
were O
no O
cases O
of O
wound B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
no O
clinically B-outcome ['Physiological-Clinical']
evident I-outcome ['Physiological-Clinical']
superficial I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
surgical I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
either O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
sample O
consisted O
of O
182 O
prenatal O
Vietnamese O
women O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
most O
salient O
feature O
in O
the O
verum O
group O
was O
a O
drastic O
increase O
in O
the O
absolute O
number O
of O
immunocompetent B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
with O
an O
especially O
pronounced O
effect O
on O
T O
lymphocytes B-outcome ['Physiological-Clinical']
, O
predominantly O
of O
the O
helper/inducer B-outcome ['Physiological-Clinical']
type I-outcome ['Physiological-Clinical']
, O
but O
also O
on O
cytotoxic B-outcome ['Physiological-Clinical']
and O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Our O
results O
show O
that O
FDTV O
produces O
a O
greater O
reduction O
of O
VCAM-1 O
circulating O
levels O
than O
trandolapril O
alone O
. O
[]

Compared O
to O
effects O
of O
oral O
intake O
of O
oxibutinin O
, O
such O
method O
was O
two O
times O
more O
effective O
in O
relation O
to O
overactive B-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
shorter O
duration O
of O
the O
treatment O
and O
reduced O
side O
effects O
. O
['Physiological-Clinical']

The O
energy O
percent O
of O
fat O
in O
the O
food O
had O
no O
differential O
impact O
. O
[]

Adjusted O
total O
body B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
calcium O
group O
at O
6 O
months O
( O
2.0 O
% O
) O
, O
12 O
months O
( O
2.5 O
% O
) O
, O
18 O
months O
( O
4.6 O
% O
) O
, O
and O
24 O
months O
( O
3.7 O
% O
) O
, O
respectively O
( O
all O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

This O
study O
aimed O
to O
evaluate O
the O
influence O
of O
music O
therapy O
intervention O
on O
the O
autonomic O
control O
of O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
in O
mothers. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

We O
aimed O
to O
investigate O
the O
efficacy O
of O
PICSI O
versus O
standard O
ICSI O
for O
improving O
livebirth B-outcome ['Mortality']
rates O
among O
couples O
undergoing O
fertility O
treatment. O
[['Mortality']]

Complications O
occurring O
up O
to O
20 O
days O
after O
the O
procedure O
were O
also O
recorded O
. O
[]

Corresponding O
5-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
60.0 O
and O
56.6 O
per O
cent O
( O
P O
= O
0.482 O
) O
, O
and O
recurrence B-outcome ['Physiological-Clinical']
rates O
32.9 O
and O
34.3 O
per O
cent O
( O
P O
= O
0.864 O
) O
. O
['Mortality', 'Physiological-Clinical']

Between O
March O
2001 O
and O
November O
2001 O
, O
87 O
patients O
with O
99 O
lesions O
were O
enrolled O
in O
this O
study O
and O
were O
treated O
with O
12 O
and O
16 O
mm O
long O
iridium-oxide O
coated O
Lunar O
stents O
. O
[]

Ocular B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
discomfort O
on O
instillation B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
were O
measured O
after O
radial O
keratotomy O
with O
a O
visual O
analog O
scale O
and O
a O
questionnaire O
. O
['Physiological-Clinical', 'Life-Impact']

Hypertension O
after O
treatment O
with O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
receptor O
inhibitors O
is O
associated O
with O
superior O
treatment O
outcomes O
for O
advanced O
cancer O
patients O
. O
[]

It O
can O
also O
correlate O
with O
gamma-aminobutyric O
acid O
( O
GABA O
) O
-homocarnosine O
interaction O
, O
with O
possible O
anticonvulsive O
effects O
. O
[]

The O
efficiency O
synergism O
and O
toxicity O
reducing O
effects O
were O
achieved O
by O
regulating O
the O
activities O
of O
MGMT O
gene O
. O
[]

Journal O
ID: O
2985248R O
[]

METHODS O
AND O
MATERIALS O
Between O
January O
2003 O
and O
December O
2007 O
, O
168 O
patients O
were O
randomized O
to O
receive O
either O
hypofractionated O
( O
62 O
Gy O
in O
20 O
fractions O
within O
5 O
weeks O
, O
4 O
fractions/wk O
) O
or O
conventionally O
fractionated O
( O
80 O
Gy O
in O
40 O
fractions O
within O
8 O
weeks O
) O
three-dimensional O
conformal O
radiotherapy O
to O
the O
prostate O
and O
seminal O
vesicles O
. O
[]

Compared O
with O
patients O
without O
previous O
treatment O
with O
statins O
, O
statin O
withdrawal O
was O
associated O
with O
a O
19.01 O
( O
1.96 O
to O
184.09 O
) O
-fold O
increase O
in O
the O
risk O
of O
END O
and O
an O
increase O
in O
mean O
infarct B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
43.51 O
mL O
( O
SE O
21.91 O
; O
p O
= O
0.048 O
) O
. O
['Physiological-Clinical']

The O
extravasation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
was O
0.052 O
+/- O
0.007 O
mL/kg/min O
in O
group O
2 O
vs. O
0.038 O
+/- O
0.020 O
mL/kg/min O
in O
group O
1 O
( O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
showed O
a O
significant O
increase O
at O
night O
during O
sleep O
deprivation O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

III O
. O
[]

Fe O
intake O
of O
the O
group O
fed O
the O
nonfortified O
formula O
was O
significantly O
lower O
( O
p O
less O
than O
0.0001 O
) O
. O
[]

When O
pleasantness O
ratings O
of O
scent O
were O
covaried O
, O
physiological B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
did O
not O
differ O
based O
on O
scent O
exposure O
, O
but O
mood B-outcome ['Life-Impact']
ratings O
differed O
by O
scent O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Granisetron O
revealed O
an O
excellent O
inhibitory B-outcome ['Physiological-Clinical']
effect O
on O
vomiting B-outcome ['Physiological-Clinical']
induced O
by O
remission O
induction O
chemotherapy O
for O
acute O
myeloid O
leukemia O
, O
but O
combination O
with O
granisetron O
and O
methylprednisolone O
was O
considered O
useful O
for O
nausea B-outcome ['Physiological-Clinical']
in O
the O
latter O
half O
of O
the O
treatment O
period O
and O
for O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Each O
coronary O
segment O
was O
evaluated O
for O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
on O
a O
4-point O
scale O
. O
['Life-Impact']

Mean O
National O
Institutes O
of O
Health O
Stroke O
Scale O
score O
at O
presentation O
was O
7.3 O
( O
SD O
6.2 O
) O
points O
. O
[]

BACKGROUND O
Postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
is O
still O
common O
, O
especially O
among O
female O
patients O
. O
[]

Results O
showed O
increased O
opportunities B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
respond I-outcome ['Life-Impact']
, O
increased O
levels O
of O
responding B-outcome ['Life-Impact']
and O
academic B-outcome ['Life-Impact']
engagement I-outcome ['Life-Impact']
, O
higher O
gains O
on O
weekly O
criterion-referenced O
pre- O
and O
posttests O
, O
and O
decreased O
passive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
inappropriate I-outcome ['Life-Impact']
student I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
during O
interventions O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
increase O
from O
two O
to O
four O
preoperative O
chemotherapy O
cycles O
did O
not O
increase O
the O
pathological O
response O
rate O
. O
[]

In O
the O
IS O
1-2 O
ml O
of O
5 O
% O
phenol O
in O
almond O
oil O
was O
injected O
in O
the O
same O
plane O
in O
each O
pile O
core O
. O
[]

At O
assessment O
of O
final O
outcome O
, O
it O
was O
found O
that O
43 O
of O
52 O
( O
82 O
% O
) O
assessable O
patients O
in O
the O
adjuvant O
interferon O
arm O
were O
controlled B-outcome ['Physiological-Clinical']
by O
a O
single B-outcome ['Physiological-Clinical']
laser I-outcome ['Physiological-Clinical']
ablation I-outcome ['Physiological-Clinical']
as O
compared O
with O
only O
17 O
of O
34 O
( O
50 O
% O
) O
in O
the O
5-fluorouracil O
group O
and O
13 O
of O
32 O
( O
40 O
% O
) O
in O
the O
laser O
alone O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Double-dummy O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
. O
[]

After O
randomization O
, O
patients O
were O
begun O
on O
subcutaneous O
GM-CSF O
at O
a O
dose O
of O
1.0 O
microgram/kg/d O
. O
[]

The O
net O
change O
in O
the O
VO B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
2.5 O
mL O
min/kg O
( O
95 O
% O
CI O
1.5 O
, O
3.5 O
) O
( O
8.7 O
% O
) O
in O
Group O
S1 O
and O
2.5 O
mL O
min/kg O
( O
95 O
% O
CI O
1.5 O
, O
3.5 O
) O
( O
8.8 O
% O
) O
in O
Group O
S2 O
. O
['Physiological-Clinical']

Children O
with O
spastic O
cerebral O
palsy O
6 O
weeks O
after O
multistage O
surgery O
were O
randomly O
divided O
into O
treatment O
group O
(received O
rESWT O
and O
conventional O
rehabilitation O
therapy) O
and O
control O
group O
(received O
conventional O
rehabilitation O
only). O
[]

CONCLUSION O
The O
GH O
response O
to O
bolus O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
is O
attenuated O
in O
adult O
long-term O
survivors O
of O
childhood O
brain O
tumours O
. O
[]

Diastolic B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
calculated O
by O
subtracting O
the O
electromechanical O
systole O
from O
the O
R-R O
interval O
and O
expressed O
as O
a O
percentage O
of O
the O
cardiac O
cycle O
( O
% O
D O
) O
. O
['Physiological-Clinical']

Double O
contrast O
arthrography O
of O
the O
knee O
. O
[]

The O
intervention O
process O
was O
conducted O
by O
speech-language O
pathologists O
who O
were O
part O
of O
a O
graduate O
program O
in O
this O
area O
. O
[]

Forty-five O
patients O
reaching O
maintenance O
therapy O
were O
randomised O
to O
either O
chemo-immunotherapy O
( O
BCG O
plus O
intradermal O
leukaemic O
blast O
cells O
) O
or O
chemotherapy O
alone O
. O
[]

OBJECTIVE O
To O
develop O
a O
cycle-based O
risk O
prediction O
model O
for O
neutropenic B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
during O
chemotherapy O
with O
doxorubicin O
( O
DOX O
) O
or O
a O
pegylated O
liposomal O
formulation O
( O
PLD O
) O
for O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
['Physiological-Clinical']

Survival O
rates O
were O
also O
compared O
. O
[]

Low O
FMRP O
levels O
may O
be O
related O
to O
impaired O
neurodevelopmental O
processes O
and O
synaptic O
plasticity O
. O
[]

The O
benefit O
of O
low-dose O
dopamine O
during O
vigorous O
diuresis O
for O
congestive O
heart O
failure O
associated O
with O
renal O
insufficiency O
: O
does O
it O
protect O
renal O
function O
? O
[]

METHODS O
We O
performed O
a O
cohort O
analysis O
of O
data O
from O
a O
randomized O
controlled O
trial O
of O
episiotomy O
conducted O
in O
3 O
Montreal O
hospitals O
in O
1990-1991 O
. O
[]

1 O
% O
v O
12 O
of O
34 O
or O
35.3 O
% O
, O
respectively O
; O
P O
=.04 O
) O
. O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[medline] O
[]

The O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
first I-outcome ['Life-Impact']
ambulation I-outcome ['Life-Impact']
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
sounds I-outcome ['Physiological-Clinical']
, O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tolerating I-outcome ['Life-Impact']
oral I-outcome ['Life-Impact']
nutrition I-outcome ['Life-Impact']
, O
incidence O
of O
nausea/vomiting B-outcome ['Physiological-Clinical']
or O
pruritus B-outcome ['Physiological-Clinical']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
flatus I-outcome ['Physiological-Clinical']
were O
not O
statistically O
different O
between O
the O
groups O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Liver B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
decreased O
from O
1595 O
+/- O
478 O
ml O
to O
1524 O
+/- O
453 O
ml O
with O
octreotide O
whereas O
they O
did O
not O
appreciably O
change O
with O
placebo O
. O
['Physiological-Clinical']

RESULTS O
On O
postoperative O
day O
( O
POD O
) O
1 O
, O
there O
were O
no O
significant O
differences O
between O
the O
parameters O
of O
the O
two O
groups O
, O
but O
on O
PODs O
2 O
and O
3 O
, O
both O
the O
pain B-outcome ['Physiological-Clinical']
score O
( O
P O
= O
0.033 O
and O
P O
= O
0.011 O
, O
respectively O
) O
and O
the O
number O
of O
patients O
who O
required O
intramuscular B-outcome ['Resource-use']
analgesic I-outcome ['Resource-use']
injections I-outcome ['Resource-use']
were O
significantly O
less O
in O
group O
1 O
( O
P O
= O
0.022 O
and O
P O
= O
0.007 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Resource-use']

METHODS: O
APPAC O
II O
trial O
is O
a O
multicentre, O
open-label, O
non-inferiority O
randomised O
controlled O
trial O
comparing O
per O
oral O
(p.o.) O
[]

The O
Bypass O
Angioplasty O
Revascularization O
Investigation O
( O
BARI O
) O
Investigators O
. O
[]

The O
treatment O
was O
continued O
till O
the O
hematocrit B-outcome ['Physiological-Clinical']
level O
reached O
30 O
% O
. O
['Physiological-Clinical']

The O
combined O
study O
sample O
showed O
improvement O
on O
all O
parent O
measures O
and O
on O
Teacher O
CGI O
and O
SE-Restlessness O
compared O
with O
baseline O
and O
placebo O
. O
['Life-Impact']

They O
were O
divided O
randomly O
into O
experimental O
group O
and O
control O
one O
, O
and O
respectively O
received O
auditory O
integrative O
training O
and O
no O
training O
based O
on O
the O
multiple O
therapies O
. O
[]

Epidemiologic O
and O
experimental O
data O
suggest O
that O
a O
high O
dietary O
intake O
of O
long-chain O
polyunsaturated O
n-3 O
fatty O
acids O
may O
reduce O
the O
risk O
of O
atherothrombotic O
disease O
. O
[]

The O
SBAs B-outcome ['Physiological-Clinical']
were O
measured O
by O
the O
microdilution B-outcome ['Physiological-Clinical']
method O
of O
Reller O
and O
Stratton O
( O
L. O
B. O
Reller O
and O
C. O
W. O
Stratton O
, O
J. O
Infect O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Antipyretic B-outcome ['Physiological-Clinical']
efficacy O
of O
ibuprofen O
vs O
acetaminophen O
. O
['Physiological-Clinical']

The O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
an O
objective O
response O
among O
patients O
who O
had O
a O
response O
was O
9.6 O
months O
(interquartile O
range, O
6.6 O
to O
16.7) O
in O
the O
sorafenib O
group O
and O
13.3 O
months O
(interquartile O
range, O
11.2 O
to O
31.1) O
in O
the O
placebo O
group. O
[['Physiological-Clinical']]

The O
primary O
endpoint O
was O
30-day O
mortality O
. O
[]

Pain B-outcome ['Physiological-Clinical']
scores, O
opioid B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
PT O
test O
results, O
and O
patient-reported O
outcome O
instruments O
were O
compared O
between O
the O
three O
groups. O
[['Physiological-Clinical'], ['Resource-use']]

BACKGROUND O
Primary O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
has O
become O
an O
alternative O
to O
thrombolytic O
therapy O
as O
a O
reperfusion O
strategy O
for O
ST-elevation O
acute O
myocardial O
infarction O
( O
AMI O
) O
. O
[]

Operative O
and O
recovery O
times O
were O
recorded O
. O
[]

No O
allergic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
increased O
respiratory B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
this O
prospective O
, O
double-blind O
study O
, O
31 O
patients O
receiving O
pelvic O
radiotherapy O
were O
randomized O
to O
receive O
two O
sulfasalazine O
500-mg O
tablets O
twice O
daily O
or O
placebo O
, O
administered O
orally O
from O
the O
first O
day O
of O
irradiation O
. O
[]

Abstract O
Tirasemtiv O
is O
a O
fast O
skeletal O
muscle O
activator O
that O
increases O
the O
sensitivity O
of O
the O
sarcomere O
to O
calcium O
, O
increasing O
the O
efficiency O
of O
muscle O
contraction O
when O
the O
muscle O
is O
stimulated O
at O
submaximal O
contraction O
frequencies O
. O
[]

Outcomes O
included O
incidence O
of O
clinically O
significant O
postoperative B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
, O
fever B-outcome ['Physiological-Clinical']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
restoration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
target I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( O
CTV B-outcome ['Physiological-Clinical']
) O
drawn O
on O
the O
CT O
scan O
was O
narrow O
in O
7 O
( O
12 O
% O
) O
cases O
, O
but O
eventually O
the O
actually O
treated O
volumes O
in O
terms O
of O
planned B-outcome ['Physiological-Clinical']
treatment O
volume B-outcome ['Physiological-Clinical']
( O
PTV B-outcome ['Physiological-Clinical']
) O
were O
correct O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/07/01 O
00:00 O
[accepted] O
[]

PURPOSE O
To O
evaluate O
the O
effects O
of O
diltiazem O
and O
propranolol O
in O
patients O
with O
unstable O
angina O
. O
[]

POPULATION O
Twenty-eight O
patients O
with O
symptomatic O
fibroids O
and O
uterine O
sizes O
ranging O
from O
14 O
to O
24 O
weeks O
of O
gestation O
undergoing O
open O
myomectomy O
. O
[]

RESULTS O
Nineteen O
infants O
( O
33 O
eyes O
) O
were O
treated O
, O
ranging O
from O
485 O
to O
863 O
g O
birth O
weight O
( O
23 O
to O
27 O
weeks O
gestational O
age O
) O
; O
18 O
patients O
( O
32 O
eyes O
) O
were O
followed O
for O
3 O
months O
or O
longer O
. O
[]

UNLABELLED O
We O
conducted O
this O
randomized O
, O
double-blinded O
, O
comparative O
, O
parallel-group O
study O
to O
determine O
whether O
adding O
EDTA O
to O
propofol O
would O
affect O
the O
clinical O
profile O
, O
calcium O
and O
magnesium O
homeostasis O
, O
or O
renal O
function O
in O
healthy O
children O
. O
[]

Propranolol O
and O
atenolol O
did O
not O
significantly O
influence O
insulin B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
erythrocytes I-outcome ['Physiological-Clinical']
, O
but O
they O
clearly O
reduced O
the O
glucose B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
KITT I-outcome ['Physiological-Clinical']
was O
compared O
to O
placebo O
( O
p O
= O
0.0036 O
and O
p O
= O
0.0003 O
) O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

9.2 O
ng/ml O
, O
p O
< O
0.001 O
) O
, O
without O
a O
significant O
reduction O
in O
von O
Willebrand O
factor O
levels O
, O
and O
tended O
to O
prolong O
the O
prothrombin O
and O
partial O
thromboplastin O
times O
. O
[]

Standard O
PN O
does O
not O
improve O
antioxidant O
status O
compared O
with O
administration O
of O
micronutrients O
alone O
. O
[]

The O
anti-stigma O
program O
improved O
the O
knowledge O
and O
attitudes O
, O
but O
not O
the O
behavioural O
intentions O
of O
participants O
towards O
their O
peers O
with O
autism O
. O
[]

This O
difference O
may O
reflect O
changes O
in O
the O
source O
of O
rhGM-CSF O
or O
in O
the O
infusion O
schedule O
. O
[]

Journal O
ID: O
8303003 O
[]

The O
acute B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
of O
baseline O
['Adverse-effects']

TRIAL O
REGISTRATION: O
Clinicaltrials.gov O
, O
NCT03236961, O
retrospectively O
registered O
on O
the O
2nd O
of O
August O
2017. O
[]

RESULTS O
The O
incidence O
of O
reperfusion B-outcome ['Physiological-Clinical']
arrhythmias-frequent I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Therefore O
, O
a O
treatment O
with O
Spironolactone O
seems O
to O
have O
no O
effect O
on O
bulimia O
nervosa O
symptoms O
. O
[]

Journal-Name:Medicine O
[]

22 O
; O
95 O
% O
CI O
1.02 O
to O
1.45 O
; O
P=0.032 O
) O
independently O
predicted O
worsened O
clinical B-outcome ['Physiological-Clinical']
outcome O
regardless O
of O
the O
treatment O
modality O
. O
['Physiological-Clinical']

No O
additional O
diagnostic O
information O
was O
obtained O
using O
0.3 O
mM/kg O
gadodiamide O
injection O
compared O
to O
0.1 O
mM/kg O
gadopentate O
dimeglumine O
in O
the O
same O
patients O
. O
[]

Analysis O
was O
performed O
to O
detect O
differences O
between O
the O
intervention O
and O
control O
groups O
in O
baseline O
and O
quarterly B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
for O
one O
year O
post-study O
enrollment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
H-reflex B-outcome ['Physiological-Clinical']
provides O
a O
measure O
of O
alpha O
motorneuron O
( O
neuromuscular O
) O
excitability O
in O
the O
sensory-motor O
pathway O
of O
the O
respective O
muscle O
and O
nerve O
. O
['Physiological-Clinical']

lipid O
emulsion O
( O
LCT O
, O
MCT O
, O
Olive-oil O
and O
Fish-oil O
) O
in O
patients O
undergoing O
elective O
gastrointestial O
surgery O
during O
the O
early O
postoperative O
period O
. O
[]

The O
authors O
have O
studied O
indices O
of O
natriuretic O
peptide O
and O
oxidative O
stress O
in O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
. O
[]

Journal O
ID: O
101578780 O
[]

SUBJECTS O
Parturients O
( O
ASA O
1 O
and O
2 O
) O
scheduled O
for O
elective O
caesarean O
section O
. O
[]

RESULTS O
Compared O
to O
those O
assigned O
to O
ferrous O
sulfate O
, O
more O
patients O
assigned O
to O
ferric O
carboxymaltose O
responded O
with O
a O
hemoglobin B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Hb I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
increase O
of O
2.0 O
g/dL O
or O
more O
( O
82 O
% O
vs. O
62 O
% O
, O
95 O
% O
confidence O
interval O
for O
treatment O
difference O
12.2-28.3 O
, O
p O
< O
0.001 O
) O
, O
more O
achieved O
a O
3.0 O
g/dL O
or O
more O
increase O
( O
53 O
% O
vs. O
36 O
% O
, O
p O
< O
0.001 O
) O
, O
and O
more O
achieved O
correction B-outcome ['Physiological-Clinical']
( O
Hb O
> O
or= O
12 O
g/dL O
) O
of O
anemia O
( O
73 O
% O
vs. O
50 O
% O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
between O
buspirone O
and O
placebo O
on O
any O
of O
the O
outcome O
measures O
. O
[]

Seven O
and O
one-half O
years O
after O
surgery O
, O
six O
patents O
with O
smooth O
and O
four O
with O
textured O
implants O
had O
contracture B-outcome ['Physiological-Clinical']
( O
p O
= O
0.66 O
) O
. O
['Physiological-Clinical']

METHOD O
Twenty-nine O
medically O
healthy O
women O
with O
sexual O
arousal O
disorder O
( O
15 O
premenopausal O
and O
14 O
postmenopausal O
) O
, O
diagnosed O
using O
the O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
, O
4th O
Edition O
( O
DSM-IV O
) O
criteria O
, O
and O
30 O
age-matched O
women O
without O
sexual O
problems O
( O
16 O
premenopausal O
and O
14 O
postmenopausal O
) O
were O
shown O
sexual O
stimuli O
depicting O
cunnilingus O
and O
intercourse O
. O
[]

METHOD O
A O
double-blind O
, O
placebo-crossover O
study O
with O
transdermal O
clonidine O
was O
performed O
in O
nine O
autistic O
males O
( O
aged O
5 O
to O
33 O
years O
) O
. O
[]

The O
participants O
were O
given O
subcutaneous O
injections O
at O
18:00 O
h O
and O
23:00 O
h O
of O
either O
saline O
or O
octreotide O
( O
Sandostatin O
; O
each O
injection O
50 O
microg O
) O
. O
[]

The O
114 O
patients O
with O
healed O
ulcer O
were O
observed O
on O
no O
therapy O
and O
underwent O
additional O
endoscopy O
to O
detect O
recurrences O
when O
symptomatic O
or O
at O
3 O
, O
6 O
, O
and O
12 O
mo O
. O
[]

A O
slight O
interactive O
effect O
was O
observed O
in O
arithmetic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
( O
p O
less O
than O
.05 O
) O
. O
['Life-Impact']

Study O
follow-up O
was O
completed O
July O
2012 O
. O
[]

Measurements O
were O
made O
12 O
hours O
after O
the O
last O
twice O
daily O
dose O
and O
24 O
hours O
after O
the O
last O
once O
daily O
dose O
. O
[]

We O
previously O
described O
significant O
reductions O
in O
resting O
energy O
expenditure O
( O
REE O
) O
, O
as O
measured O
by O
indirect O
calorimetry O
, O
over O
the O
course O
of O
HSCT O
. O
[]

Journal-Name:Medicine O
[]

Journal O
ID: O
2985248R O
[]

CONCLUSIONS O
Prior O
to O
spinal O
anesthesia O
, O
hydration O
with O
small O
amount O
of O
hypertonic O
saline O
is O
effective O
to O
minimize O
hypotension O
associated O
with O
spinal O
anesthesia O
. O
[]

MATERIALS O
AND O
METHODS: O
Tumor O
specimens O
and O
clinical O
information O
were O
collected O
from O
patients O
enrolled O
in O
CLASSIC O
trial, O
a O
randomized O
controlled O
study O
of O
capecitabine O
plus O
oxaliplatin-based O
adjuvant O
chemotherapy. O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
II O
[]

The O
studies O
were O
performed O
in O
healthy O
subjects O
with O
MAO O
less O
than O
30 O
mmol/h O
and O
in O
duodenal O
ulcer O
patients O
with O
MAO O
greater O
than O
35 O
mmol/h O
. O
[]

It O
is O
still O
unresolved O
whether O
survival B-outcome ['Mortality']
is O
prolonged O
by O
adjuvant O
treatment O
of O
the O
liver O
following O
curative O
resection O
of O
colorectal O
liver O
metastases O
. O
['Mortality']

Although O
no O
statistical O
difference O
in O
mortality B-outcome ['Mortality']
rate O
was O
appreciated O
among O
the O
3 O
fluid O
resuscitation O
groups O
, O
a O
trend O
of O
decreased O
mortality B-outcome ['Mortality']
rate O
was O
observed O
in O
the O
HBOCS O
group O
. O
['Mortality', 'Mortality']

Although O
quality O
of O
tapping B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
differed O
between O
the O
single-task O
and O
the O
dual-task O
conditions O
, O
it O
was O
not O
related O
to O
recall B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

A O
slight O
but O
nonsignificant O
increase O
occurred O
in O
fat B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
the O
milk O
of O
vaccinated O
cows O
. O
['Physiological-Clinical']

There O
was O
no O
significant O
treatment O
effect O
for O
any O
outcome O
, O
with O
no O
significant O
interactions O
between O
treatment O
and O
demographics O
, O
or O
cytarabine O
randomization O
. O
[]

Of O
these O
, O
136 O
patients O
were O
eligible O
for O
the O
according-to-protocol O
analysis O
of O
efficacy O
, O
167 O
subjects O
for O
the O
intention-to-treat O
analysis O
of O
efficacy O
, O
and O
181 O
patients O
were O
included O
in O
the O
safety O
analysis O
. O
[]

RESULTS O
Large O
and O
stable O
pre-post O
effect O
sizes O
were O
found O
for O
both O
treatment O
conditions O
in O
the O
study O
( O
d O
= O
1.06-1.24 O
on O
the O
Yale-Brown O
Obsessive B-outcome ['Life-Impact']
Compulsive I-outcome ['Life-Impact']
Scale O
) O
. O
['Life-Impact']

Included O
were O
98 O
subjects O
who O
underwent O
cardiac O
catheterization O
and O
were O
randomized O
to O
forced O
diuresis O
with O
i.v O
. O
[]

RESULTS O
Baseline O
systolic O
BP O
and O
GFR O
values O
were O
not O
different O
between O
groups O
. O
[]

RESULTS: O
Eleven O
out O
of O
fifty O
patients O
in O
the O
study O
group O
developed O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
(CIN) I-outcome ['Physiological-Clinical']
(22%) O
compared O
to O
eighteen O
out O
of O
the O
fifty O
control O
patients O
(36%) O
(p=0.123). O
[['Physiological-Clinical']]

The O
scores O
on O
awakening O
and O
after O
10 O
minutes O
were O
significantly O
lower O
in O
the O
bupivacaine O
group O
( O
P O
< O
0.05 O
, O
Mann-Whitney O
U O
test O
) O
. O
[]

This O
showed O
that O
a O
low-level O
dietary O
intervention O
could O
achieve O
modest O
dietary O
behaviour O
changes O
that O
are O
of O
public O
health O
significance O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Participants O
redeemed O
only O
39% O
(SD O
43%) O
of O
their O
earned O
points. O
[]

Based O
on O
these O
findings O
, O
the O
use O
of O
VRE O
in O
the O
treatment O
of O
FOF O
was O
supported O
in O
this O
controlled O
study O
, O
suggesting O
that O
experiences O
in O
the O
virtual O
world O
can O
change O
experiences O
in O
the O
real O
world O
. O
[]

Dietary O
supplementation O
of O
glutamine O
prevents O
intestinal O
dysfunction O
and O
atrophy O
in O
weanling O
piglets O
, O
but O
the O
underlying O
mechanism O
( O
s O
) O
are O
largely O
unknown O
. O
[]

Jejunal O
feeding O
was O
tolerated B-outcome ['Life-Impact']
unconditionally O
in O
25 O
( O
86 O
% O
) O
of O
the O
TEN O
group O
. O
['Life-Impact']

Although O
sodium O
nitroprusside O
did O
not O
affect O
plasma B-outcome ['Physiological-Clinical']
t-PA I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
they O
were O
increased O
dose-dependently O
in O
the O
infused O
forearm O
by O
substance O
P O
and O
bradykinin O
infusion O
( O
ANOVA O
, O
p O
< O
0.001 O
for O
both O
) O
. O
['Physiological-Clinical']

Transoral O
robotic O
surgery O
( O
TORS O
) O
has O
emerged O
as O
a O
promising O
alternative O
treatment O
, O
with O
preliminary O
case O
series O
demonstrating O
encouraging O
oncologic O
, O
functional O
, O
and O
quality O
of O
life O
( O
QOL O
) O
outcomes O
. O
[]

A O
coronary O
arteriography O
was O
done O
on O
study O
entry O
. O
[]

Dose-response O
relationship O
of O
sertindole O
and O
haloperidol O
using O
the O
pharmacopsychometric O
triangle O
. O
[]

RESULTS O
Overall O
, O
873 O
patients O
were O
randomly O
assigned O
to O
receive O
sunitinib O
( O
n O
= O
584 O
) O
or O
placebo O
( O
n O
= O
289 O
) O
. O
[]

A O
serum B-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
level O
was O
measured O
at O
four O
hours O
. O
['Physiological-Clinical']

Analysis O
of O
the O
data O
showed O
no O
significant O
differences O
between O
groups O
in O
anxiety B-outcome ['Life-Impact']
, O
severity O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
helpfulness O
of O
self-care B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
, O
and O
coping B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
. O
['Life-Impact', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

Each O
maxillary O
tooth O
's O
mesiodistal O
and O
vestibulo-oral O
width O
was O
measured O
using O
a O
dial O
caliper O
on O
each O
dental O
cast O
. O
[]

We O
tested O
the O
hypothesis O
that O
gum O
elastic-bougie-guided O
insertion O
of O
the O
ProSeal O
Laryngeal O
Mask O
Airway O
is O
more O
frequently O
successful O
than O
introducer O
tool O
guided O
insertion O
after O
failed O
digital O
insertion O
. O
[]

Transurethral O
electrovaporization O
of O
the O
prostate O
( O
TUVP O
) O
is O
a O
new O
, O
minimally O
invasive O
and O
a O
promising O
alternative O
to O
standard O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
in O
the O
treatment O
of O
BPH O
. O
[]

Hypothesis O
1 O
was O
that O
high-BP O
individuals O
, O
but O
not O
low-BP O
controls O
, O
would O
show O
greater O
emotional B-outcome ['Life-Impact']
reactivity B-outcome ['Life-Impact']
to O
the O
negative O
evaluation/social O
rejection O
stressor O
, O
compared O
with O
the O
negative O
evaluation/academic O
( O
writing O
) O
stressor O
. O
['Life-Impact', 'Life-Impact']

This O
study O
was O
designed O
to O
compare O
the O
rates O
of O
duodenal O
ulcer O
healing O
and O
recurrence O
after O
treatment O
with O
cimetidine O
or O
antacid O
. O
[]

RESULTS O
The O
data O
include O
223,135 O
person-years O
of O
observation O
. O
[]

Statistical O
differences O
were O
found O
between O
groups O
concerning O
uterine B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
, O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
and O
drop O
in O
hemoglobin B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

at O
week O
8 O
if O
mean O
GH O
> O
2.5 O
microg/l O
on O
GH O
day O
curves O
; O
pretreatment O
group O
, O
Group O
1 O
) O
or O
to O
transsphenoidal O
surgery O
( O
direct O
surgery O
group O
, O
Group O
2 O
) O
. O
[]

This O
figure O
was O
48.9 O
% O
in O
the O
fenretinide O
arm O
and O
41.9 O
% O
in O
the O
control O
arm O
( O
odds O
ratio O
, O
1.16 O
; O
95 O
% O
confidence O
interval O
, O
0.44-3.07 O
) O
. O
[]

Patients O
in O
the O
operative O
group O
showed O
a O
significant O
improvement O
of O
posttraumatic B-outcome ['Physiological-Clinical']
clavicular I-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
; O
they O
were O
also O
more O
satisfied B-outcome ['Life-Impact']
with O
cosmetic O
appearance O
and O
overall O
outcome O
. O
['Physiological-Clinical', 'Life-Impact']

PURPOSE: O
To O
investigate O
the O
rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
MW O
after O
exercise-induced O
dehydration. O
[['Physiological-Clinical']]

MAIN O
OUTCOMES O
MEASURES O
Changes O
in O
FIM O
and O
Tinetti O
scale O
scores O
, O
and O
dependence O
on O
walking O
aids O
. O
[]

Mycological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
at O
4 O
weeks O
was O
33 O
% O
for O
ketoconazole O
and O
29 O
% O
for O
griseofulvin O
, O
and O
at O
8 O
weeks O
was O
53 O
% O
and O
57 O
% O
respectively O
. O
['Physiological-Clinical']

The O
FB O
group O
had O
excessive O
amounts O
of O
omission B-outcome ['Life-Impact']
and O
commission B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
, O
a O
greater O
response O
time O
mean O
( O
i.e. O
, O
slower O
to O
respond O
) O
and O
had O
greater O
variance O
around O
their O
mean O
response O
['Life-Impact', 'Life-Impact']

Although O
many O
relationships O
have O
been O
found O
between O
parameters O
of O
objective O
and O
subjective O
oral O
function O
, O
the O
structure O
of O
these O
relationships O
remain O
unclear O
. O
[]

AIM O
OF O
THE O
STUDY O
To O
investigate O
the O
effects O
on O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
and O
triglyceride B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
meals O
enriched O
with O
soluble O
dietary O
fibres O
from O
oats O
, O
rye O
bran O
, O
sugar O
beet O
fibre O
or O
a O
mixture O
of O
these O
three O
fibres O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

BACKGROUND O
The O
study O
evaluated O
the O
efficacy O
of O
recombinant O
human O
antithrombin O
( O
rhAT O
) O
for O
restoring O
heparin B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
in O
heparin O
resistant O
patients O
undergoing O
cardiac O
surgery O
. O
['Physiological-Clinical']

PURPOSE: O
To O
determine O
the O
effects O
of O
botulinum O
toxin O
type O
A O
(BTX-A) O
injection O
on O
dry B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
eye I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
signs I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, Seperator ['Physiological-Clinical', 'Physiological-Clinical']
symptoms S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
and O
tear O
cytokine B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
intractable O
dry O
eye O
disease O
(DED). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

There O
were O
no O
significant O
( O
P O
> O
0.18 O
) O
differences O
between O
the O
whitening O
dentifrice O
groups O
at O
any O
timepoints O
. O
[]

A O
double-blind O
, O
placebo-controlled O
, O
parallel O
groups O
design O
with O
fixed O
dose O
was O
used O
, O
with O
random O
assignment O
to O
naltrexone O
or O
placebo O
. O
[]

Data O
from O
this O
study O
indicate O
that O
consumption O
of O
medium-and O
long-chain O
triglycerides O
can O
reduce O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
a O
cluster O
specific O
immunotherapy O
in O
children O
with O
bronchial O
asthma O
and O
mite O
allergy O
. O
['Physiological-Clinical']

RESULTS O
A O
large O
and O
highly O
significant O
treatment O
effect O
on O
wrist B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
found O
. O
['Physiological-Clinical']

For O
the O
movement B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
crying I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
midazolam O
also O
proved O
to O
be O
significantly O
more O
effective O
from O
the O
start O
of O
treatment O
through O
the O
35- O
and O
40-min O
markers O
, O
respectively O
( O
P O
< O
.05 O
) O
. O
['Life-Impact']

LDL O
, O
isolated O
before O
and O
after O
treatment O
was O
subjected O
to O
copper-catalysed O
lipid O
peroxidation O
. O
[]

The O
slope O
of O
the O
regression O
line O
for O
the O
delta O
melanin B-outcome ['Resource-use']
index O
against O
delta O
erythema B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

After O
a O
4-week O
, O
single-blind O
placebo O
run-in O
, O
patients O
were O
randomized O
to O
receive O
16 O
weeks O
of O
trandolapril O
2 O
mg/day O
( O
68 O
patients O
) O
, O
hydrochlorothiazide O
( O
HCTZ O
) O
25 O
mg/day O
( O
68 O
patients O
) O
, O
or O
the O
combination O
( O
69 O
patients O
) O
. O
[]

In O
the O
second O
group O
( O
propranolol O
group O
= O
75 O
cases O
) O
, O
before O
the O
beginning O
of O
oxytocin O
, O
2 O
mg O
propranolol O
was O
slowly O
injected O
intravenously O
then O
the O
oxytocin O
was O
initiated O
. O
[]

There O
was O
a O
higher O
incidence O
of O
hematologic B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
in O
the O
VACA O
arm O
. O
['Physiological-Clinical']

Employing O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
design O
, O
95 O
participants O
were O
assigned O
to O
one O
of O
two O
groups O
and O
administered O
a O
single O
dose O
of O
either O
secretin O
or O
placebo O
. O
[]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

Only O
one O
condition O
( O
P O
, O
LD O
, O
or O
HD O
) O
was O
presented O
per O
day O
and O
the O
condition O
order O
was O
randomized O
. O
[]

RESULTS O
Among O
300 O
cases O
of O
VVC O
, O
uncomplicated O
, O
complicated O
and O
recurrent O
VVC O
were O
56.0 O
% O
, O
44.0 O
% O
and O
9.7 O
% O
( O
29/300 O
) O
respectively O
. O
[]

Twenty-four O
patients O
, O
with O
a O
biopsy-proven O
laryngeal O
or O
hypopharyngeal O
carcinoma O
, O
received O
as O
an O
adjunct O
to O
their O
primary O
treatment O
( O
surgery O
and/or O
radiotherapy O
) O
, O
levamisole O
( O
150 O
mg O
daily O
during O
three O
consecutive O
days O
, O
every O
fortnight O
) O
or O
placebo O
, O
following O
a O
single-blind O
, O
but O
randomized O
method O
. O
[]

[ O
Administration O
of O
tobramycin O
aerosols O
in O
patients O
with O
nosocomial O
pneumonia O
: O
a O
preliminary O
study O
] O
. O
[]

There O
were O
significant O
changes O
from O
baseline O
potassium B-outcome ['Physiological-Clinical']
and O
glucose B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
both O
within O
and O
between O
treatments O
in O
the O
early O
postinjection O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
reductions O
probably O
reflect O
an O
improvement O
in O
hepatobiliary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
a O
reduction O
in O
cellular B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
sICAM-1 I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
combination O
of O
wall O
motion O
and O
MCE O
assessment O
gave O
the O
best O
balance O
of O
sensitivity O
( O
46 O
% O
to O
55 O
% O
) O
and O
specificity O
( O
82 O
% O
to O
83 O
% O
) O
. O
[]

Immediately O
restored O
, O
single-tapered O
implants O
in O
the O
anterior O
maxilla O
: O
prosthodontic O
and O
aesthetic O
outcomes O
after O
1 O
year O
. O
[]

METHODS O
Ten O
healthy O
volunteers O
were O
enrolled O
in O
a O
randomized O
, O
double-blinded O
, O
placebo-controlled O
, O
crossover O
trial O
in O
which O
they O
received O
an O
infusion O
of O
saline O
, O
remifentanil O
, O
or O
alfentanil O
for O
120 O
min O
. O
[]

RESULTS O
All O
reinfusion O
sessions O
were O
tolerated B-outcome ['Life-Impact']
well O
by O
all O
patients O
. O
['Life-Impact']

DESIGN O
The O
Baron O
and O
Kenny O
mediator O
model O
, O
a O
series O
of O
4 O
regression O
analyses O
, O
was O
used O
to O
evaluate O
whether O
: O
a O
) O
physical O
and O
emotional O
status O
predicted O
program O
participation O
, O
b O
) O
program O
participation O
predicted O
dietary O
adherence O
, O
c O
) O
physical O
and O
emotional O
status O
factors O
predicted O
dietary O
adherence O
, O
and O
, O
ultimately O
d O
) O
the O
effects O
of O
physical O
and O
emotional O
status O
on O
dietary O
adherence O
were O
mediated O
by O
program O
participation O
. O
[]

The O
primary O
outcomes O
( O
i.e. O
, O
6-month O
point O
prevalence O
) O
were O
23.1 O
% O
versus O
20.8 O
% O
, O
respectively O
( O
OR O
= O
1.31 O
, O
ns O
) O
. O
[]

Including O
results O
obtained O
by O
second-look O
laparotomy O
, O
we O
did O
not O
observe O
a O
statistically O
significant O
difference O
in O
response O
rates O
in O
the O
two O
treatment O
groups O
. O
[]

plasma B-outcome ['Physiological-Clinical']
renin B-outcome ['Physiological-Clinical']
activity B-outcome ['Life-Impact']
, O
leptin B-outcome ['Physiological-Clinical']
and O
interleukin-6 B-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Before O
sitaxsentan O
withdrawal O
, O
this O
18-week O
double-blind O
, O
placebo-controlled O
study O
randomized O
patients O
with O
PAH O
to O
receive O
placebo O
or O
sitaxsentan O
50 O
or O
100 O
mg O
once O
daily O
. O
[]

Subjective O
responses O
were O
measured O
with O
visual O
analog O
scale O
( O
VAS O
) O
. O
[]

Minor B-outcome ['Physiological-Clinical']
omental I-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
occurred O
in O
a O
small O
percentage O
of O
each O
group O
, O
while O
serious O
complications O
occurred O
once O
in O
each O
group O
. O
['Physiological-Clinical']

or O
by O
Behringwerke O
( O
North O
and O
West O
African O
polyvalent O
antivenom O
) O
. O
[]

60 O
eyes O
of O
59 O
patients O
were O
divided O
into O
two O
groups O
, O
31 O
in O
the O
cord O
serum O
group O
and O
29 O
in O
the O
autologous O
serum O
control O
group O
. O
[]

RESULTS O
Hair B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
and O
thicknesses I-outcome ['Physiological-Clinical']
statistically O
significantly O
decreased O
after O
the O
first O
post-treatment O
evaluation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
findings O
suggest O
that O
individual O
telephone O
support O
may O
provide O
an O
effective O
alternative O
to O
in-person O
support O
groups O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Primary O
outcomes O
were O
18-month O
survival B-outcome ['Mortality']
free I-outcome ['Mortality']
of I-outcome ['Mortality']
all-cause I-outcome ['Mortality']
hospitalizations I-outcome ['Mortality']
and O
quality O
of O
life O
as O
assessed O
by O
structured O
validated O
questionnaires O
. O
['Mortality']

intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
were O
staged O
as O
mild O
in O
4 O
patients O
(14.28%) O
and O
moderate O
in O
2 O
patients O
(7.14%) O
in O
group O
2 O
according O
to O
the O
American O
Fertility O
Society O
classification O
of O
IUAs. O
[['Physiological-Clinical']]

CONCLUSIONS O
CYP2C19 O
genotypes O
play O
a O
role O
in O
H. O
pylori O
eradication O
therapy O
. O
[]

The O
implant B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
moment O
of O
implant O
placement O
and O
at O
the O
moment O
of O
the O
delivery O
of O
the O
definitive O
restoration O
. O
['Physiological-Clinical']

Atypical O
neuroleptics O
, O
including O
olanzapine O
, O
may O
have O
less O
risk O
for O
dyskinesia O
, O
but O
their O
efficacy O
in O
autistic O
disorder O
is O
not O
established O
. O
[]

This O
study O
explored O
the O
efficacy O
of O
WPI O
for O
improving O
cognitive B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
via O
delivery O
of O
vitamin O
B12. O
[['Life-Impact']]

Rapid O
tightening O
of O
blood O
glucose O
control O
leads O
to O
transient O
deterioration O
of O
retinopathy B-outcome ['Physiological-Clinical']
in O
insulin O
dependent O
diabetes O
mellitus O
: O
the O
Oslo O
study O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
This O
paper O
uses O
data O
collected O
in O
a O
previous O
clinical O
trial O
registered O
at O
the O
Australian O
Clinical O
Trials O
Registry O
, O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
: O
Anzcrt.org.au O
ACTRN012607000195459 O
. O
[]

CONCLUSIONS: O
Endometrial O
scratching O
did O
not O
result O
in O
a O
higher O
rate O
of O
live B-outcome ['Mortality']
birth I-outcome ['Mortality']
than O
no O
intervention O
among O
women O
undergoing O
IVF. O
( O
[['Mortality']]

Use B-outcome ['Life-Impact']
and O
limitations B-outcome ['Life-Impact']
of O
Holter O
electrocardiography O
in O
assessing O
drug O
therapy O
of O
myocardial O
ischemia O
during O
the O
peri-PTCA O
period O
. O
['Life-Impact', 'Life-Impact']

The O
main O
goal O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
caffeine O
supplementation O
on O
time B-outcome ['Physiological-Clinical']
under O
tension O
(TUT) O
and O
the O
number O
of O
performed O
repetitions B-outcome ['Physiological-Clinical']
(REP) I-outcome ['Physiological-Clinical']
. O
The O
second O
objective O
was O
to O
determine O
the O
effects O
of O
CAF O
supplementation O
on O
power B-outcome ['Physiological-Clinical']
(P) I-outcome ['Physiological-Clinical']
and O
movement B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
(V) I-outcome ['Physiological-Clinical']
during O
the O
bench O
press O
movement. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

rhTPO-treated O
patients O
required O
fewer O
phereses O
to O
achieve O
minimum O
( O
P= O
.011 O
) O
and O
target O
( O
P= O
.015 O
) O
CD34+ B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical']

Two-eighth-grade O
classes O
were O
randomly O
allocated O
to O
the O
intervention O
condition O
and O
all O
remaining O
students O
were O
either O
allocated O
to O
the O
no-intervention O
peer O
or O
no-intervention O
non-peer O
condition O
. O
[]

The O
procedure O
was O
repeated O
with O
NMI O
as O
cost O
function O
. O
[]

For O
PI O
15/29 O
, O
26/29 O
and O
29/29 O
of O
the O
subjects O
met O
the O
sympathectomy B-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
at O
5 O
, O
10 O
and O
20 O
min O
, O
respectively O
, O
compared O
with O
4/29 O
, O
6/29 O
and O
18/29 O
for O
MAP B-outcome ['Physiological-Clinical']
changes O
and O
3/29 O
, O
8/29 O
and O
14/29 O
for O
toe O
['Physiological-Clinical', 'Physiological-Clinical']

Results O
showed O
that O
the O
LEGO O
therapy O
group O
improved O
more O
than O
the O
other O
groups O
on O
autism-specific O
social O
interaction O
scores O
( O
Gilliam O
Autism O
Rating O
Scale O
) O
. O
[]

RESULTS O
Tramadol O
and O
placebo O
had O
no O
statistical O
significances O
in O
analgesic B-outcome ['Resource-use']
properties O
, O
assessed O
by O
the O
means O
of O
pain B-outcome ['Physiological-Clinical']
rating O
at O
the O
different O
time O
intervals O
. O
['Resource-use', 'Physiological-Clinical']

Children O
were O
randomly O
assigned O
to O
an O
intervention O
( O
n O
= O
28 O
) O
or O
control O
group O
( O
n O
= O
27 O
) O
. O
[]

Two O
study O
groups O
were O
randomly O
formed O
: O
enamel O
blocks O
brushed O
with O
( O
a O
) O
the O
Gantrez-NNP O
combination O
and O
( O
b O
) O
conventional O
toothpaste O
, O
for O
1 O
minute O
once O
daily O
for O
4 O
weeks O
, O
then O
rinsed O
with O
distilled O
water O
and O
placed O
in O
thymol O
solution O
. O
[]

RESULTS O
Nurses O
were O
more O
likely O
to O
use O
open-ended O
questions O
, O
back-channel O
responses O
, O
friendly B-outcome ['Life-Impact']
jokes I-outcome ['Life-Impact']
, O
and O
checks O
for O
understanding B-outcome ['Life-Impact']
on O
the O
telephone O
compared O
to O
videophone O
. O
['Life-Impact', 'Life-Impact']

Clinical O
and O
microbial O
evaluation O
of O
a O
histatin-containing O
mouthrinse O
in O
humans O
with O
experimental O
gingivitis O
. O
[]

rHuEPO O
ameliorates O
the O
preoperative O
decrease O
of O
haemoglobin B-outcome ['Physiological-Clinical']
and O
haematocrit O
values O
due O
to O
autologous O
blood O
donations O
in O
a O
dose-related O
fashion O
. O
['Physiological-Clinical']

METHODS: O
An O
open-label, O
randomised O
controlled O
trial O
will O
be O
conducted O
in O
school-aged O
children O
(5 O
to O
18 O
years) O
from O
the O
region O
of O
Taabo, O
Cote O
d'Ivoire, O
an O
area O
endemic O
for O
S. O
mansoni. O
[]

In O
13 O
patients O
in O
whom O
frequency O
of O
crying B-outcome ['Life-Impact']
could O
be O
assessed O
, O
the O
number O
of O
daily B-outcome ['Life-Impact']
crying I-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
decreased O
by O
at O
least O
50 O
% O
in O
all O
cases O
during O
citalopram O
treatment O
vs O
2 O
patients O
during O
placebo O
treatment O
( O
p O
< O
0.005 O
, O
McNemar O
's O
test O
) O
, O
the O
effect O
being O
rapid O
( O
1-3 O
days O
) O
and O
pronounced O
in O
11 O
( O
73 O
% O
) O
. O
['Life-Impact', 'Life-Impact']

Administered O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
, O
it O
is O
the O
first O
trial O
seeking O
to O
demonstrate O
whether O
a O
drug O
, O
tamoxifen O
, O
can O
prevent O
breast O
cancer O
in O
high-risk O
women O
. O
[]

Opposite O
results O
for O
the O
two O
subgroups O
were O
also O
obtained O
for O
the O
left-right B-outcome ['Physiological-Clinical']
relations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
alpha-power I-outcome ['Physiological-Clinical']
over O
the O
anterior O
regions O
. O
['Physiological-Clinical']

Journal-Name:Medicine O
[]

Conclusions O
and O
Relevance: O
Among O
ambulatory O
adults O
with O
hypertension, O
treating O
to O
a O
systolic O
blood O
pressure O
goal O
of O
less O
than O
120 O
mm O
Hg O
compared O
with O
a O
goal O
of O
less O
than O
140 O
mm O
Hg O
did O
not O
result O
in O
a O
significant O
reduction O
in O
the O
risk O
of O
probable O
dementia B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Because O
of O
early O
study O
termination O
and O
fewer O
than O
expected O
cases O
of O
dementia, O
the O
study O
may O
have O
been O
underpowered O
for O
this O
end O
point. O
[['Physiological-Clinical', 'Life-Impact']]

For O
the O
group O
as O
a O
whole O
, O
both O
younger O
child O
age O
at O
the O
start O
of O
intervention O
and O
a O
greater O
number O
of O
intervention B-outcome ['Life-Impact']
hours I-outcome ['Life-Impact']
were O
positively O
related O
to O
the O
degree O
of O
improvement O
in O
children O
's O
behavior O
for O
most O
variables O
. O
['Life-Impact']

The O
magnitude O
of O
nonspecific O
therapeutic O
( O
placebo O
) O
effects O
, O
cost-effectiveness O
and O
relative O
risks O
of O
side O
effects O
associated O
with O
these O
types O
of O
therapy O
need O
to O
be O
addressed O
in O
future O
studies O
. O
[]

There O
is O
little O
robust O
evidence O
of O
effectiveness O
of O
speech-language O
interventions O
which O
target O
the O
language O
, O
pragmatic O
or O
social O
communication O
needs O
of O
these O
children O
. O
[]

CONCLUSIONS O
Ilioinguinal-iliohypogastric O
nerve O
block O
with O
IV O
dexketoprofen O
increases O
patient O
satisfaction O
by O
decreasing O
opioid O
consumption O
, O
increasing O
patient O
satisfaction O
, O
which O
suggests O
that O
dexketoprofen O
trometamol O
is O
an O
effective O
non-steroidal O
anti-inflammatory O
analgesic O
in O
postoperative O
analgesia O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effects O
of O
loteprednol O
etabonate O
( O
LE O
) O
0.2 O
% O
in O
reducing O
the O
signs O
and O
symptoms O
of O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
conjunctivitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Oral O
ondansetron O
in O
the O
prevention B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
costs B-outcome ['Resource-use']
of O
the O
research O
component O
of O
the O
DCCT O
were O
not O
included O
. O
['Resource-use']

NFV O
pharmacokinetic O
measurements O
were O
not O
statistically O
different O
between O
the O
treatment O
groups O
, O
yet O
exposure O
to O
the O
NFV O
metabolite O
, O
M8 O
, O
was O
significantly O
higher O
in O
subjects O
receiving O
RTV O
. O
[]

These O
findings O
underscore O
the O
need O
for O
interventions O
targeting O
high-risk O
populations O
, O
such O
as O
those O
receiving O
high-intensity O
sun O
exposures O
at O
the O
beach O
. O
[]

Title: O
A O
randomized O
placebo-controlled O
trial O
of O
delayed-release O
dimethyl O
fumarate O
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
from O
East O
Asia O
and O
other O
countries. O
[]

Of O
the O
120 O
patients O
enrolled O
, O
112 O
completed O
the O
trial O
; O
58 O
in O
the O
treatment O
group O
and O
54 O
in O
the O
placebo O
group O
. O
[]

We O
compared O
the O
effect O
of O
pegvisomant O
with O
that O
of O
placebo O
before O
and O
after O
3 O
d O
of O
fasting O
. O
[]

A O
randomized O
controlled O
trial O
of O
R-salbutamol O
for O
topical O
treatment O
of O
discoid O
lupus O
erythematosus O
. O
[]

Two O
patients O
in O
each O
group O
had O
elevated O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

The O
addition O
of O
IFN-3 O
to O
5-FU O
significantly O
improved O
response O
rate O
( O
33.3 O
% O
vs O
4.5 O
% O
for O
evaluable O
patients O
; O
P O
= O
0.021 O
) O
, O
time O
to O
progression B-outcome ['Physiological-Clinical']
( O
median O
7.2 O
vs O
4.2 O
months O
; O
P O
= O
0.0435 O
) O
, O
and O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
( O
median O
15.9 O
vs O
7.2 O
months O
; O
P O
= O
0.038 O
) O
without O
significantly O
increasing O
toxicity B-outcome ['Adverse-effects']
compared O
to O
5-FU O
alone O
. O
['Physiological-Clinical', 'Mortality', 'Adverse-effects']

Patients O
were O
sent O
the O
optimal O
recommendations O
by O
both O
the O
cellular O
phone O
and O
the O
Internet O
. O
[]

Journal-Name:Journal O
of O
foot O
and O
ankle O
research O
[]

The O
effectiveness O
of O
epidurally O
administered O
morphine O
in O
the O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
upper O
abdominal O
surgery O
was O
assessed O
in O
a O
controlled O
study O
involving O
20 O
patients O
aged O
61 O
to O
78 O
years O
. O
['Physiological-Clinical']

Theophylline B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
saliva O
have O
been O
compared O
with O
those O
in O
serum O
in O
13 O
asthmatic O
patients O
after O
single O
and O
multiple O
oral O
dosage O
of O
a O
microcrystalline O
theophylline O
tablet O
( O
Nuelin O
) O
and O
a O
sustained-release O
preparation O
( O
Nuelin O
Retard O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
observe O
the O
curative B-outcome ['Physiological-Clinical']
effect O
of O
Shenyanning O
( O
SYN O
) O
on O
non-nephrotic O
syndrome O
IgA O
nephropathy O
( O
IgAN O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
These O
results O
provide O
further O
evidence O
that O
use O
of O
ecstasy O
may O
be O
associated O
with O
impairment O
of O
memory B-outcome ['Life-Impact']
and O
of O
serotonergic B-outcome ['Physiological-Clinical']
['Life-Impact', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

RESULTS O
The O
authors O
found O
a O
cumulative O
incidence O
rate O
of O
20.5 O
% O
adjusted O
for O
dropouts O
. O
[]

The O
therapeutic O
effects O
of O
each O
treatment O
were O
compared O
both O
clinically O
and O
microbiologically O
. O
[]

CONCLUSIONS O
Treatment O
of O
coexisting O
OSA O
by O
CPAP O
in O
HF O
patients O
lowers O
daytime B-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
and O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
determination O
of O
endogenous B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
Clcr I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
a O
24-h O
urine O
collection O
is O
an O
unreliable O
and O
time-consuming O
procedure O
. O
['Physiological-Clinical']

Intervals O
between O
calving O
and O
first O
oestrus O
, O
first B-outcome ['Physiological-Clinical']
insemination I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
conception I-outcome ['Physiological-Clinical']
, O
the O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
emergence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
dominant I-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
, O
milk B-outcome ['Physiological-Clinical']
progesterone I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
and O
the O
diameter O
of O
the O
corpus B-outcome ['Physiological-Clinical']
luteum I-outcome ['Physiological-Clinical']
( O
CL O
) O
in O
the O
first O
luteal O
phase O
did O
not O
differ O
significantly O
between O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Forty O
healthy O
subjects O
were O
randomly O
allocated O
to O
receive O
7 O
days O
of O
treatment O
with O
NCX-4016 O
( O
400 O
and O
800 O
mg O
twice O
daily O
) O
, O
equimolar O
doses O
of O
aspirin O
( O
200 O
and O
420 O
mg O
twice O
daily O
) O
, O
or O
placebo O
. O
[]

110 O
patients O
were O
randomly O
allocated O
in O
a O
1:1 O
ratio O
to O
receive O
catheter O
ablation O
and O
an O
ICD O
( O
ablation O
group O
, O
n=54 O
) O
or O
ICD O
alone O
( O
control O
group O
, O
n=56 O
) O
. O
[]

BACKGROUND O
Bibrocathol O
is O
a O
well-established O
antiseptic O
drug O
for O
the O
treatment O
of O
acute O
eyelid O
diseases O
like O
blepharitis O
. O
[]

The O
cardiovascular O
and O
behavioral O
adaptations O
associated O
with O
a O
4-month O
program O
of O
aerobic O
exercise O
training O
were O
examined O
in O
101 O
older O
men O
and O
women O
( O
mean O
age O
= O
67 O
years O
) O
. O
[]

For O
a O
better O
application O
of O
TXA O
function, O
we O
explored O
the O
effect O
of O
intravenous O
injection O
(IV) O
of O
TXA O
combined O
with O
intra-articular O
injection O
(IA) O
of O
TXA O
in O
patients O
after O
TKA. O
[]

The O
effect O
of O
perindopril O
and O
hydrochlorothiazide O
alone O
and O
in O
combination O
on O
blood O
pressure O
and O
on O
the O
renin-angiotensin O
system O
in O
hypertensive O
subjects O
. O
[]

The O
ID O
Group O
, O
following O
OK-432 O
injection O
, O
had O
a O
4.8 O
% O
incidence O
of O
fever B-outcome ['Physiological-Clinical']
and O
a O
52.4 O
% O
incidence O
of O
local B-outcome ['Physiological-Clinical']
abscess I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
at O
the O
injection O
site O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Paromomycin O
treatment O
resulted O
in O
improvement O
in O
both O
clinical O
and O
parasitologic O
parameters O
in O
cryptosporidiosis O
in O
AIDS O
. O
[]

The O
mean O
survival B-outcome ['Mortality']
time O
was O
6.6 O
months O
in O
arm O
1 O
and O
7.7 O
months O
in O
arm O
2. O
WHO O
grade O
4 O
toxicity B-outcome ['Adverse-effects']
was O
encountered O
in O
25.5 O
and O
15.8 O
% O
of O
patients O
in O
arm O
1 O
and O
2 O
, O
respectively O
. O
['Mortality', 'Adverse-effects']

In O
addition O
, O
a O
significantly O
higher O
proportion O
of O
patients O
receiving O
lanthanum O
carbonate O
had O
controlled O
serum B-outcome ['Physiological-Clinical']
phosphorus I-outcome ['Physiological-Clinical']
levels O
( O
60 O
% O
) O
compared O
with O
the O
placebo O
group O
( O
10 O
% O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Can O
incentives O
undermine O
intrinsic B-outcome ['Life-Impact']
motivation I-outcome ['Life-Impact']
to O
participate O
in O
epidemiologic O
surveys O
? O
['Life-Impact']

SETTING O
University O
laboratory O
. O
[]

7-hexanoyltaxol-eluting O
stent O
for O
prevention O
of O
neointimal O
growth O
: O
an O
intravascular O
ultrasound O
analysis O
from O
the O
Study O
to O
COmpare O
REstenosis O
rate O
between O
QueST O
and O
QuaDS-QP2 O
( O
SCORE O
) O
. O
[]

DISCUSSION O
The O
results O
of O
this O
study O
will O
provide O
detailed O
information O
on O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
for O
the O
treatment O
of O
non-healing O
ulcers O
of O
the O
lower O
limb O
. O
[]

Ten O
subjects O
served O
as O
controls O
and O
received O
symptomatic O
treatments O
. O
[]

OBJECTIVES O
To O
compare O
dietary O
patterns O
of O
urban O
and O
rural O
cancer O
survivors O
and O
to O
examine O
associations O
of O
dietary B-outcome ['Life-Impact']
patterns I-outcome ['Life-Impact']
with O
body O
mass O
index O
( O
BMI O
) O
. O
['Life-Impact']

In O
the O
ward O
, O
patients O
in O
Group O
I O
( O
CEI O
) O
were O
maintained O
by O
continuous O
infusion O
of O
0.125 O
% O
levobupivacaine O
with O
morphine O
0.0125 O
mg/ml O
( O
4 O
ml/hr O
) O
, O
Group O
II O
( O
CFNB O
) O
were O
maintained O
by O
0.125 O
% O
levobupivacaine O
( O
8 O
ml/hr O
) O
. O
[]

The O
mechanisms O
of O
this O
effect O
could O
be O
associated O
with O
plaque O
regression O
due O
to O
the O
anti-atherosclerotic O
properties O
of O
CCBs O
. O
[]

BACKGROUND O
Pretreatment O
with O
statins O
has O
been O
shown O
to O
reduce O
brain O
injury O
in O
cerebral O
ischemia O
. O
[]

CONCLUSIONS: O
Among O
patients O
with O
progressive, O
refractory, O
or O
symptomatic O
desmoid O
tumors, O
sorafenib O
significantly O
prolonged O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
and O
induced O
durable O
responses. O
( O
[['Physiological-Clinical', 'Mortality']]

Group O
receiving O
placebo O
had O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
only O
for O
first O
two O
weeks. O
[['Physiological-Clinical']]

The O
aim O
of O
this O
double-blind O
study O
was O
to O
evaluate O
the O
effect O
of O
low O
power O
Ga-Al-As O
laser O
treatment O
on O
chronic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
related O
to O
osteoarthritis O
of O
the O
knee O
with O
periarticular O
tender O
points O
. O
['Physiological-Clinical']

These O
measures O
were O
compared O
between O
the O
healthy O
controls O
and O
chronic O
pancreatitis O
patients O
. O
[]

During O
the O
two O
basal O
tilts O
, O
all O
the O
control O
subjects O
completed O
the O
study O
, O
whereas O
all O
the O
NMS O
patients O
developed O
syncope O
. O
[]

There O
are O
also O
no O
studies O
that O
establish O
a O
clear O
relationship O
between O
EEN O
in O
MAP O
and O
levels O
of O
albuminemia O
and O
CRP. O
[]

0.12 O
) O
ng?ml???h?? O
, O
AII O
( O
111.25 O
? O
[]

After O
therapy O
, O
the O
expression O
of O
survivin B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
decreased O
in O
clinical O
benefit O
cases O
( O
P O
= O
0.001 O
) O
and O
increased O
in O
disease B-outcome ['Physiological-Clinical']
progressive I-outcome ['Physiological-Clinical']
cases O
( O
P O
= O
0.018 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Procedures O
and O
maps O
from O
the O
mapping O
activity O
( O
two-stage O
conversational O
mapping O
) O
are O
described O
. O
[]

During O
treatment O
, O
HS O
and O
LS O
heifers O
had O
greater O
weight O
gains O
than O
control O
heifers O
. O
[]

In O
the O
healthy O
subjects O
, O
there O
was O
no O
significant O
difference O
in O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
with O
the O
different O
doses O
but O
in O
duodenal O
ulcer O
patients O
a O
tenfold O
increase O
of O
the O
antacid O
dose O
resulted O
in O
a O
doubling O
of O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Sodium-potassium O
pump O
activity O
in O
white O
blood O
cells O
from O
children O
with O
an O
increased O
risk O
of O
developing O
hypertension O
-- O
The O
Odense O
Schoolchild O
Study O
. O
[]

Despite O
an O
observed O
association O
between O
colonic O
inflammation O
and O
grade O
2 O
or O
higher O
diarrhea O
, O
no O
baseline O
biomarkers O
could O
reliably O
predict O
development O
of O
gastrointestinal O
toxicity O
. O
[]

We O
studied O
the O
effect O
on O
microcirculation O
of O
a O
nitric-oxide-generating O
system O
applied O
topically O
to O
the O
finger O
and O
forearm O
of O
healthy O
volunteers O
and O
patients O
with O
primary O
Raynaud O
's O
syndrome O
. O
[]

The O
CSF B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neopterin I-outcome ['Physiological-Clinical']
decreased O
by O
63 O
% O
( O
from O
29.6 O
to O
12.9 O
nmol/l O
, O
p O
< O
0.01 O
) O
during O
zidovudine O
but O
increased O
by O
15 O
% O
( O
from O
22.6 O
to O
25.9 O
nmol/l O
, O
not O
significant O
during O
didanosine O
treatment O
. O
['Physiological-Clinical']

Nine O
healthy O
male O
volunteers O
undergoing O
stable O
maximal O
water O
diuresis O
were O
studied O
on O
four O
separate O
occasions O
. O
[]

A O
high O
Gleason O
score O
and O
the O
presence O
of O
extracapsular O
extension O
in O
the O
radical O
prostatectomy O
specimens O
were O
highly O
predictive O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
. O
(Funded O
by O
the O
Swedish O
Cancer O
Society O
and O
others.). O
[['Mortality']]

These O
results O
support O
the O
use O
of O
this O
novel O
sealant O
for O
the O
intraoperative O
management O
of O
anastomotic O
bleeding O
during O
aortic O
reconstruction O
procedures O
. O
[]

Efficacy O
, O
safety O
, O
and O
durability B-outcome ['Life-Impact']
were O
evaluated O
over O
follow-up O
of O
1 O
to O
9 O
years O
( O
mean O
, O
31/2 O
years O
) O
. O
['Life-Impact']

PURPOSE O
To O
prospectively O
study O
and O
compare O
the O
effectiveness O
and O
the O
safety O
of O
primary O
deep O
sclerectomy O
with O
and O
without O
the O
use O
of O
mitomycin O
C O
in O
eyes O
with O
open-angle O
glaucoma O
. O
[]

DISCUSSION O
. O
[]

2019; O
90(1):12-17. O
[]

CONCLUSIONS: O
The O
results O
of O
this O
study O
showed O
that O
verum O
TENS O
may O
benefit O
patients O
with O
acute O
tinnitus O
after O
4 O
weeks O
of O
treatment. O
[]

RESULTS O
After O
16 O
weeks O
, O
weight O
loss B-outcome ['Physiological-Clinical']
was O
similar O
in O
response O
to O
each O
diet O
; O
the O
overall O
decrease O
was O
7.9+/-0.6 O
kg O
( O
P O
< O
0.001 O
) O
, O
of O
which O
6.8+/-0.5 O
kg O
was O
fat O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
outcome O
measures O
are O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
palliation B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
performance B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
analgesic B-outcome ['Resource-use']
usage I-outcome ['Resource-use']
, O
toxicity B-outcome ['Adverse-effects']
, O
quality O
of O
life O
, O
tumor B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
recurrence/progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
['Mortality', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Adverse-effects', 'Physiological-Clinical', 'Mortality']

PURPOSE O
To O
study O
the O
effect O
of O
CYP17a O
inhibitor O
, O
ketoconazole O
, O
on O
clomiphene O
responsiveness O
in O
PCOS O
patients O
. O
[]

Melatonin O
, O
the O
hormone O
produced O
nocturnally O
by O
the O
pineal O
gland O
, O
is O
an O
endogenous O
regulator O
of O
the O
sleep-wake O
cycle O
. O
[]

A O
25% O
and O
50% O
improvement O
in O
IGAxBSA O
was O
achieved O
within O
1.9 O
and O
4.6 O
weeks, O
respectively, O
and O
47.5% O
of O
patients O
achieved O
IGAxBSA-75 O
by O
week O
8. O
[]

To O
define O
the O
current O
efficacy O
of O
Fansidar O
( O
F. O
Hoffmann-La O
Roche O
Ltd. O
, O
Basel O
Switzerland O
) O
( O
pyrimethamine O
and O
sulfadoxine O
) O
, O
primaquine O
in O
a O
high O
dose O
, O
and O
artesunate O
for O
treating O
acute O
Plasmodium O
vivax O
malaria O
, O
we O
conducted O
a O
comparative O
clinical O
trial O
of O
these O
3 O
drugs O
in O
an O
open-label O
study O
. O
[]

Limitations O
of O
the O
study O
, O
along O
with O
areas O
for O
future O
research O
, O
are O
also O
discussed O
. O
[]

CLINICAL O
SIGNIFICANCE: O
Curcumin O
gel O
as O
an O
adjunct O
to O
SRP O
showed O
a O
marked O
improvement O
in O
restoring O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
by O
an O
improvement O
in O
clinical O
parameters. O
[['Physiological-Clinical']]

BACKGROUND O
Inflammatory O
Bowel O
Disease O
( O
IBD O
) O
impacts O
quality O
of O
life O
( O
QoL O
) O
. O
[]

Amisulpride O
acts O
preferentially O
on O
specific O
autistic O
symptoms O
whereas O
bromocriptine O
acts O
more O
on O
motor B-outcome ['Physiological-Clinical']
hyperactivity I-outcome ['Physiological-Clinical']
and O
attention B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
Significantly O
( O
P O
< O
0.05 O
) O
more O
of O
the O
human O
embryos O
cultured O
in O
Plasmatein O
supplemented O
medium O
reached O
the O
four-cell O
or O
greater O
stage B-outcome ['Physiological-Clinical']
by O
40 O
hr O
postinsemination O
than O
a O
comparable O
group O
cultured O
in O
HSA O
alone O
. O
['Physiological-Clinical']

INTERVENTION O
After O
pre-screening O
and O
a O
washout O
period O
of O
at O
least O
14 O
days O
, O
eligible O
volunteers O
received O
ASA O
81 O
mg O
with O
or O
without O
esomeprazole O
20 O
mg O
once O
daily O
for O
5 O
days O
in O
randomized O
order O
, O
with O
a O
14-day O
washout O
between O
treatments O
. O
[]

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O
[]

BACKGROUND O
Groin O
pain O
is O
common O
among O
athletes O
. O
[]

A O
total O
of O
372 O
patients O
were O
randomized O
to O
receive O
alfuzosin O
( O
n=186 O
) O
or O
placebo O
( O
n=186 O
) O
, O
with O
355 O
completing O
the O
study O
. O
[]

This O
study O
compared O
two O
formats O
of O
a O
social O
story O
targeting O
the O
improvement O
of O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
during O
game O
play O
using O
a O
pretest O
posttest O
repeated O
measures O
randomized O
control O
group O
design O
. O
['Life-Impact']

The O
control O
toothpaste O
was O
a O
conventional O
, O
moderately O
abrasive O
paste O
containing O
0.8 O
% O
sodium O
monofluorophosphate O
. O
[]

We O
conclude O
that O
concurrent O
rituximab O
plus O
infusional O
EPOCH O
is O
an O
effective O
regimen O
for O
HIV-associated O
lymphoma O
. O
[]

Simulations O
of O
plasma O
DPP-4 O
inhibition O
suggest O
that O
5 O
mg O
linagliptin O
once O
daily O
is O
an O
appropriate O
therapeutic O
dose O
for O
Japanese O
patients O
with O
T2DM O
. O
[]

The O
effect O
of O
vaccination B-outcome ['Resource-use']
on O
pig B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

[ O
Preoperative O
chemotherapy O
of O
esophageal O
cancer O
] O
. O
[]

Multidisciplinary O
interventions O
among O
these O
workers O
have O
improved O
fear O
avoidance O
beliefs B-outcome ['Life-Impact']
, O
but O
not O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(LBP) I-outcome ['Physiological-Clinical']
and O
related O
sickness B-outcome ['Life-Impact']
absences I-outcome ['Life-Impact']
, O
cost-effectiveness O
studies O
are O
scarce. O
[['Life-Impact'], ['Physiological-Clinical'], ['Life-Impact']]

METHODS: O
In O
this O
mixed-methods O
pilot O
trial, O
participants O
with O
quiescent O
or O
mildly-active O
CD O
were O
randomly O
assigned O
1:1:1 O
to O
HIIT, O
MICT O
or O
usual O
care O
control, O
and O
followed O
up O
for O
6 O
months. O
[]

Modified O
Navy O
Plaque O
Index O
were O
randomly O
assigned O
to O
treatment O
sequence O
. O
[]

Incidence O
and O
severity O
of O
side O
effects O
were O
examined O
. O
[]

Furthermore O
, O
measures O
to O
further O
increase O
the O
proportion O
of O
ursodeoxycholic O
acid O
in O
circulating O
bile O
acids O
should O
be O
explored O
. O
[]

Efficacy O
and O
safety O
of O
a O
high O
protein O
, O
low O
carbohydrate O
diet O
for O
weight O
loss O
in O
severely O
obese O
adolescents O
. O
[]

Mean O
muscle B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
thigh I-outcome ['Physiological-Clinical']
, O
estimated O
by O
computerised O
tomography O
, O
increased O
significantly O
compared O
with O
that O
of O
the O
initial O
placebo O
period O
( O
p O
= O
0.01 O
) O
, O
and O
a O
slight O
decrease O
was O
recorded O
in O
adipose B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
thigh I-outcome ['Physiological-Clinical']
( O
p O
= O
0.10 O
) O
and O
subscapular B-outcome ['Physiological-Clinical']
skinfold I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( O
p O
= O
0.10 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
All O
patients O
completed O
2 O
face-to-face O
interviews O
, O
which O
were O
2 O
weeks O
apart O
. O
[]

These O
findings O
may O
be O
of O
particular O
clinical O
importance O
when O
fetal B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
or O
fetal B-outcome ['Physiological-Clinical']
hypoxemia I-outcome ['Physiological-Clinical']
is O
due O
to O
other O
perinatal O
events O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Thirty-eight O
patients O
received O
baseline O
MRIs O
as O
part O
of O
a O
larger O
12-week O
, O
randomized O
clinical O
trial O
comparing O
sertraline O
and O
nortriptyline O
in O
the O
treatment O
of O
late-life O
depression O
. O
[]

The O
number O
of O
repetitions B-outcome ['Physiological-Clinical']
in O
each O
test O
was O
recorded O
as O
an O
outcome O
. O
['Physiological-Clinical']

Taken O
together O
in O
our O
small O
study O
group O
, O
our O
findings O
display O
that O
BChE B-outcome ['Physiological-Clinical']
is O
a O
potential O
marker O
for O
synthetic O
function O
of O
liver O
, O
fat O
metabolism O
, O
an O
obesity O
marker O
, O
a O
function O
long O
overlooked O
. O
['Physiological-Clinical']

For O
the O
diagnosis O
of O
sepsis O
, O
patients O
were O
randomly O
divided O
into O
CRRT O
( O
n=10 O
) O
and O
Control O
( O
n=10 O
) O
. O
[]

To O
examine O
the O
effects O
of O
a O
digestive O
enzyme O
supplement O
in O
improving O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, O
behaviour B-outcome ['Life-Impact']
and O
other O
symptoms B-outcome ['Life-Impact']
in O
children O
with O
Autism O
Spectrum O
Disorder O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

A O
prospective O
double-blind O
, O
randomized O
clinical O
trial O
of O
levocarnitine O
to O
treat O
autism O
spectrum O
disorders O
. O
[]

We O
investigated O
whether O
VK2 O
could O
reduce O
incidence O
of O
tumor O
recurrence O
after O
treatment O
of O
HCC O
. O
[]

INTERVENTION O
Stabilization O
of O
tibial O
fractures O
either O
with O
a O
slotted O
, O
stainless O
steel O
reamed O
nail O
or O
a O
solid O
, O
titanium O
unreamed O
nail O
. O
[]

PATIENTS O
A O
total O
of O
100 O
patients O
who O
were O
admitted O
to O
the O
medical O
ICU O
, O
required O
arterial O
line O
monitoring O
for O
clinical O
purposes O
, O
and O
were O
managed O
by O
the O
ICU O
medical O
service O
. O
[]

The O
subjects O
in O
the O
treatment O
group O
received O
ET O
plus O
montelukast, O
while O
the O
participants O
in O
the O
control O
group O
received O
montelukast O
alone. O
[]

Steers O
were O
blocked O
by O
arrival O
at O
the O
feed O
yard O
, O
genotyped O
for O
the O
leptin O
SNP O
, O
allotted O
to O
genotype-specific O
pens O
( O
90 O
steers/pen O
) O
, O
and O
assigned O
randomly O
within O
genotype O
and O
block O
to O
0 O
or O
21 O
d O
of O
dietary O
ZH O
. O
[]

No O
eyes B-outcome ['Physiological-Clinical']
lost I-outcome ['Physiological-Clinical']
> O
or O
=1 O
line O
of O
BCVA B-outcome ['Physiological-Clinical']
; O
in O
the O
ZAR O
group O
, O
2 O
eyes O
gained O
1 O
line O
and O
6 O
eyes O
gained O
> O
or O
=2 O
lines O
; O
in O
the O
Planoscan O
group O
, O
3 O
eyes O
gained O
1 O
line O
. O
['Physiological-Clinical', 'Physiological-Clinical']

At O
baseline O
, O
DTCs O
were O
detected O
in O
26 O
of O
60 O
patients O
in O
the O
zoledronic O
acid O
group O
and O
28 O
of O
58 O
patients O
in O
the O
control O
group O
. O
[]

Data O
were O
collected O
1 O
week O
before O
( O
T1 O
) O
and O
1 O
week O
after O
( O
T2 O
) O
dietary O
intervention O
. O
[]

OBJECTIVE O
To O
compare O
assisted O
vaginal O
delivery O
by O
forceps O
with O
delivery O
by O
vacuum O
extractor O
, O
where O
a O
new O
vacuum O
extractor O
policy O
was O
employed O
which O
dictated O
the O
cup O
to O
be O
used O
in O
specific O
situations O
. O
[]

BACKGROUND O
The O
problem O
of O
ghostwriting O
in O
corporate-sponsored O
clinical O
trials O
is O
of O
concern O
to O
medicine O
, O
bioethics O
, O
and O
government O
agencies O
. O
[]

Glycemic O
control O
was O
assessed O
by O
HbA O
( O
1c O
) O
, O
self-reported O
hypoglycemic O
events O
, O
and O
blood O
glucose O
memory O
meter O
read O
outs O
. O
[]

Dietary B-outcome ['Life-Impact']
protein I-outcome ['Life-Impact']
content I-outcome ['Life-Impact']
in O
the O
LP O
feed O
after O
weaning O
was O
below O
requirements O
; O
evidenced O
by O
lower O
nitrogen O
retention O
( O
p O
< O
0.001 O
) O
preventing O
LP O
mink O
from O
attaining O
their O
growth O
potential O
( O
p O
< O
0.02 O
) O
. O
['Life-Impact']

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
6-week O
treatment O
and O
2-week O
follow-up O
after O
the O
treatment. O
[]

In O
the O
L-arginine O
treated O
group O
a O
lower O
cancellation B-outcome ['Life-Impact']
rate O
, O
an O
increased O
number O
of O
oocytes O
collected O
, O
and O
embryos B-outcome ['Physiological-Clinical']
transferred B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND: O
Schools O
have O
been O
identified O
as O
key O
environments O
to O
promote O
child O
physical O
activity O
(PA). O
[]

Preliminary O
treatment O
effects O
were O
also O
noted O
in O
children B-outcome ['Physiological-Clinical']
's O
prompted B-outcome ['Life-Impact']
and O
spontaneous B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

RESULTS O
In O
the O
treatment O
group O
( O
n=10 O
) O
, O
the O
mean O
index O
score O
of O
EQ-5D O
and O
VAS O
changed O
significantly O
from O
the O
placebo O
group O
( O
by O
0.299 O
and O
2.61 O
, O
respectively O
) O
from O
day O
2 O
( O
P O
< O
0.01 O
) O
. O
[]

RESULTS O
After O
tension-free O
repairs O
five O
hernias B-outcome ['Physiological-Clinical']
recurred I-outcome ['Physiological-Clinical']
( O
5 O
% O
) O
, O
and O
after O
either O
Cooper O
ligament O
or O
abdominal O
ring O
repair O
, O
16 O
recurrences B-outcome ['Physiological-Clinical']
were O
found O
( O
15 O
% O
) O
( O
P O
= O
0.025 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
effect O
was O
not O
observed O
in O
the O
control O
group O
. O
[]

Mean O
sex B-outcome ['Physiological-Clinical']
hormone-binding I-outcome ['Physiological-Clinical']
globulin I-outcome ['Physiological-Clinical']
increased O
significantly O
in O
subjects O
using O
the O
desogestrel-containing O
contraceptive O
compared O
with O
the O
levonorgestrel-containing O
contraceptive O
. O
['Physiological-Clinical']

The O
control O
group O
received O
the O
placebo O
(distilled O
water) O
in O
the O
same O
manner O
as O
the O
intervention O
group. O
[]

BACKGROUND O
AND O
PURPOSE O
Over O
the O
last O
few O
decades O
, O
application O
of O
ultrasound O
has O
been O
attempted O
to O
enhance O
transdermal O
transport O
of O
several O
drugs O
, O
a O
method O
referred O
to O
as O
phonophoresis O
. O
[]

Assessment O
on O
the O
effectiveness O
and O
tolerability B-outcome ['Life-Impact']
as O
expressed O
separately O
by O
the O
physician O
and O
patient O
were O
positive O
in O
almost O
all O
cases O
of O
both O
treatments O
. O
['Life-Impact']

Subjects O
were O
randomly O
divided O
in O
two O
groups O
: O
supplementation O
( O
n O
11 O
) O
with O
100 O
mg O
dl-alpha-tocopheryl O
acetate O
, O
200 O
mg O
ascorbic O
acid O
, O
and O
2 O
mg O
beta-carotene O
, O
and O
placebo O
( O
n O
9 O
) O
. O
[]

The O
functional O
index O
did O
not O
differ O
between O
any O
group O
of O
patients O
. O
[]

The O
analysis O
of O
normalisation O
parameters O
indicated O
that O
z-scaling O
is O
underestimated O
and O
yz-rotation O
overestimated O
with O
TCT/NMI O
registration O
. O
[]

INTRODUCTION O
St. O
John O
's O
wort O
( O
SJW O
) O
is O
a O
widely O
used O
herbal O
supplement O
. O
[]

Retinal B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
significantly I-outcome ['Physiological-Clinical']
increased O
by O
3 O
+/- O
4 O
% O
, O
2 O
+/- O
4 O
% O
, O
and O
3 O
+/- O
5 O
% O
( O
P O
= O
0.047 O
, O
ANOVA O
) O
and O
1 O
+/- O
2 O
% O
, O
3 O
+/- O
2 O
% O
, O
and O
3 O
+/- O
2 O
% O
( O
P O
= O
0.015 O
, O
ANOVA O
) O
, O
respectively O
. O
['Physiological-Clinical']

Endurance O
physical O
activity O
, O
diet O
and O
fibrinolysis O
. O
[]

Mean O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
in O
group O
0 O
was O
8.57 O
and O
8.73 O
in O
group O
1 O
. O
['Physiological-Clinical']

After O
20 O
minutes O
( O
approximate O
time O
to O
peak O
nicotine O
levels O
) O
, O
echocardiograms O
and O
signal-averaged O
electrocardiograms O
( O
SAECG O
) O
were O
obtained O
. O
[]

Venous B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
obtained O
for O
determination O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
including I-outcome ['Physiological-Clinical']
interleukin-1beta I-outcome ['Physiological-Clinical']
( O
IL-1beta B-outcome ['Physiological-Clinical']
) O
, O
tumor B-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor-alpha I-outcome ['Physiological-Clinical']
( O
TNF-alpha B-outcome ['Physiological-Clinical']
) O
, O
RANKL B-outcome ['Physiological-Clinical']
, O
osteoprotegerin B-outcome ['Physiological-Clinical']
, O
and O
markers B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
and O
resorption B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
in O
the O
experimental O
acupuncture O
treatment O
group O
declined O
over O
the O
study O
. O
['Physiological-Clinical']

Our O
data O
suggest O
that O
LTD4 O
recruits O
eosinophils B-outcome ['Physiological-Clinical']
into O
the O
airways O
of O
asthmatics O
in O
vivo O
, O
possibly O
by O
virtue O
of O
direct O
or O
indirect O
chemotactic O
properties O
, O
whereas O
an O
additional O
effect O
of O
vigourous B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
narrowing I-outcome ['Physiological-Clinical']
per O
se O
can O
not O
be O
excluded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Linking O
organized O
medical O
care O
with O
complementary O
community-based O
interventions O
may O
be O
a O
promising O
direction O
for O
research O
and O
practice O
. O
[]

METHOD O
A O
randomized O
, O
group-comparison O
design O
involving O
a O
parent O
education O
and O
counseling O
intervention O
to O
control O
for O
nonspecific O
therapist O
effects O
and O
a O
control O
sample O
was O
used O
. O
[]

Shock O
success O
was O
defined O
as O
return O
of O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
for O
> O
/=30 O
seconds O
. O
['Physiological-Clinical']

The O
development O
of O
a O
web- O
and O
a O
print-based O
decision O
aid O
for O
prostate B-outcome ['Resource-use']
cancer I-outcome ['Resource-use']
screening I-outcome ['Resource-use']
. O
['Resource-use']

All O
institutions O
complied O
with O
the O
protocol O
in O
specifying O
the O
reference O
dose O
at O
the O
ICRU O
point O
. O
[]

RESULTS O
Risperidone O
led O
to O
a O
significant O
greater O
reduction O
on O
CGI O
scale O
. O
[]

Studies O
have O
suggested O
that O
pethidine O
provides O
little O
pain O
relief O
in O
labour O
and O
has O
a O
number O
of O
side O
effects O
affecting O
mother O
and O
neonate O
. O
[]

ADMA B-outcome ['Physiological-Clinical']
levels O
were O
positively O
correlated O
with O
basal O
endothelin-1 B-outcome ['Physiological-Clinical']
levels O
and O
negatively O
correlated O
with O
insulin-induced B-outcome ['Physiological-Clinical']
incremental I-outcome ['Physiological-Clinical']
levels O
of O
NOx B-outcome ['Physiological-Clinical']
and O
forearm B-outcome ['Physiological-Clinical']
cGMP I-outcome ['Physiological-Clinical']
release B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Higher B-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
up O
to O
a O
median O
concentration O
of O
4.5 O
mug/ml O
, O
were O
observed O
in O
patients O
with O
CSF O
protein O
concentrations O
> O
/=75 O
mg/100 O
ml O
. O
['Physiological-Clinical']

Bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
was O
determined O
by O
ICTP O
( O
type O
I O
collagen O
carboxyterminal O
cross-linked O
telopeptide O
) O
as O
parameter O
of O
bone O
resorption O
and O
PICP O
( O
carboxyterminal O
propeptide O
of O
type O
I O
procollagen O
) O
as O
marker O
of O
bone O
formation O
. O
['Physiological-Clinical']

Platinum-based O
chemotherapy O
is O
often O
a O
first-line O
treatment O
. O
[]

We O
report O
characteristics O
of O
a O
representative O
sample O
( O
N O
= O
2,324 O
) O
of O
beachgoers O
in O
Southeastern O
New O
England O
during O
the O
summer O
of O
1995 O
. O
[]

METHOD: O
A O
prospective O
randomised, O
single O
centre O
parallel O
group O
trial O
comparing O
an O
8-week O
individualised O
multidisciplinary O
intervention O
programme O
(bespoke O
physiotherapy O
and O
occupational O
therapy O
in O
the O
clinical, O
home O
and O
school O
environment) O
with O
current O
standard O
management O
(advice, O
information O
and O
therapy O
referral O
if O
deemed O
necessary). O
[]

CONCLUSIONS O
Women O
at O
highest O
risk O
of O
default O
from O
follow-up O
cytology O
tend O
to O
be O
young O
, O
smoke O
, O
lack O
post-secondary O
education O
, O
and O
have O
defaulted O
from O
a O
previous O
surveillance O
appointment O
. O
[]

Gastric O
biopsies O
were O
obtained O
at O
baseline O
, O
and O
at O
3 O
, O
6 O
, O
and O
12 O
years O
. O
[]

Since O
first O
Korotkoff O
sounds O
may O
already O
be O
heard O
after O
10-15 O
s O
when O
following O
recommended O
procedures O
, O
self-recorded B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
may O
be O
recorded O
as O
too O
high O
when O
subjects O
inflate O
their O
cuff O
at O
too O
low O
a O
pressure O
or O
deflate O
it O
too O
fast O
. O
['Physiological-Clinical']

Once-daily O
amoxicillin O
versus O
twice-daily O
penicillin O
V O
in O
group O
A O
beta-haemolytic O
streptococcal O
pharyngitis O
. O
[]

METHOD O
Eighty-five O
children O
with O
autism O
without O
other O
medical O
conditions O
and O
not O
taking O
other O
psychotropic O
medications O
participated O
( O
ages O
between O
3 O
and O
12 O
years O
, O
mean O
IQ O
= O
55 O
) O
. O
[]

Nicotine O
0.3 O
microg O
kg-1 O
min O
( O
-1 O
) O
or O
NaCl O
was O
infused O
( O
2 O
h O
) O
during O
a O
euglycaemic O
hyperinsulinaemic O
clamp O
( O
4 O
h O
) O
to O
assess O
insulin O
sensitivity O
. O
[]

A O
total O
of O
296 O
patients O
fulfilling O
the O
International O
Headache O
Society O
diagnostic O
criteria O
for O
migraine O
were O
enrolled O
. O
[]

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
impairment O
in O
three O
core O
symptom O
domains O
: O
socialization O
, O
communication O
, O
and O
repetitive/stereotyped O
behaviours O
. O
[]

This O
difference O
was O
counteracted O
by O
caffeine O
. O
[]

CONCLUSIONS O
Topical O
administration O
of O
diclofenac O
was O
effective O
in O
maintaining B-outcome ['Physiological-Clinical']
mydriasis I-outcome ['Physiological-Clinical']
during O
vitrectomy O
and O
in O
reducing O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
and O
anterior B-outcome ['Physiological-Clinical']
chamber I-outcome ['Physiological-Clinical']
flare I-outcome ['Physiological-Clinical']
as O
determined O
by O
slit-lamp O
evaluations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Before O
and O
after O
treatment O
plaque B-outcome ['Physiological-Clinical']
index O
( O
PlI O
) O
, O
gingival B-outcome ['Physiological-Clinical']
index O
( O
GI O
) O
, O
angulated B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
index O
( O
AngBI B-outcome ['Physiological-Clinical']
) O
, O
tooth B-outcome ['Physiological-Clinical']
stain B-outcome ['Physiological-Clinical']
( O
GMSI B-outcome ['Physiological-Clinical']
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

While O
there O
was O
no O
change O
in O
inflammatory B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
or O
lipid B-outcome ['Physiological-Clinical']
parameters O
, O
cardiovascular B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
by O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
after O
exercise O
improved O
with O
MET O
and O
worsened O
in O
placebo O
( O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Parents O
completed O
an O
interview O
on O
past O
and O
current O
services O
. O
[]

Journal-Name:Medicine O
[]

3.2 O
? O
[]

We O
evaluated O
alternatives O
to O
routine O
primary O
PCP O
prophylaxis O
with O
aerosolized O
pentamidine O
. O
[]

Multiple O
secondary O
end O
points O
included O
clinician-assessed O
healing O
time O
and O
subject O
assessment O
of O
lesion O
protection O
, O
noticeability O
and O
social O
embarrassment O
. O
[]

PURPOSE O
The O
combination O
of O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
is O
a O
standard O
adjuvant O
regimen O
. O
[]

OBJECTIVE: O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
selective O
brain O
hypothermia O
(SBH) O
in O
the O
treatment O
of O
neonates O
with O
moderate O
or O
severe O
neonatal O
hypoxic-ischemic O
encephalopathy O
(HIE), O
and O
the O
effect O
of O
SBH O
treatment O
on O
serum O
levels O
of O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
(NSE) I-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
S100 I-outcome ['Physiological-Clinical']
. O
METHODS: O
A O
prospective O
randomized O
controlled O
trial O
was O
conducted. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
a O
randomized O
, O
double-blind O
study O
design O
, O
group O
1 O
( O
12 O
patients O
; O
7 O
males O
, O
5 O
females O
) O
with O
serum B-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
levels O
higher O
than O
170 O
mg/dL O
and O
without O
any O
other O
risk O
factor O
for O
atherosclerosis O
received O
three O
months O
of O
20 O
mg/day O
atorvastatin O
treatment O
while O
group O
11 O
( O
8 O
males O
, O
4 O
females O
) O
with O
the O
same O
characteristics O
received O
80 O
mg/day O
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
male B-outcome ['Physiological-Clinical']
ED-specific I-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
MED-QoL O
) O
, O
quality-adjusted O
life O
years O
( O
QALYs O
) O
using O
the O
generic O
Euroqol O
measure O
( O
EQ-5D O
) O
, O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
cardiovascular O
risk O
, O
cholesterol B-outcome ['Physiological-Clinical']
and O
health O
service O
costs O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
substrate O
for O
contour O
integration O
may O
be O
based O
on O
contextual O
interactions O
and O
intrinsic O
horizontal O
connections O
seen O
in O
primary O
visual O
cortex O
( O
V1 O
) O
. O
[]

Non-haematological B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
was O
mild O
. O
['Adverse-effects']

CONCLUSIONS O
Telephone O
contact O
by O
regular O
health O
plan O
staff O
was O
more O
successful O
than O
publicity O
in O
encouraging O
continued O
participation O
in O
mammography B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
in O
women O
enrolled O
in O
a O
group-model O
managed O
health O
care O
plan O
. O
['Resource-use']

Only O
a O
subgroup O
of O
patients O
with O
pronounced B-outcome ['Life-Impact']
negative O
symptoms B-outcome ['Physiological-Clinical']
developed I-outcome ['Physiological-Clinical']
some O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
as O
indicated O
by O
significant O
changes O
in O
the O
GAF-scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
Clopidogrel O
in O
Unstable O
angina O
to O
prevent O
Recurrent O
Events O
( O
CURE O
) O
trial O
demonstrated O
the O
effectiveness O
of O
clopidogrel O
plus O
acetylsalicylic O
acid O
( O
ASA O
) O
compared O
with O
ASA O
alone O
in O
reducing O
cardiovascular O
events O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
, O
in O
addition O
, O
patients O
undergoing O
percutaneous O
coronary O
intervention O
in O
the O
Percutaneous O
Coronary O
Intervention O
in O
CURE O
( O
PCI-CURE O
) O
trial O
. O
[]

Patients O
appreciation O
for O
information O
on O
anesthesia O
and O
anxiolysis O
in O
dentistry O
. O
[]

UNLABELLED O
The O
school O
dental O
screening O
programme O
has O
been O
in O
existence O
from O
the O
beginning O
of O
the O
20th O
century O
yet O
its O
value O
in O
encouraging O
attendance O
among O
children O
with O
a O
dental O
health O
need O
is O
not O
fully O
established O
. O
[]

CONCLUSION O
Use O
of O
CEE O
results O
in O
a O
modest O
but O
statistically O
significant O
increase O
in O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
that O
is O
sustained O
over O
at O
least O
a O
2-year O
period O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
the O
effectiveness O
and O
complications B-outcome ['Resource-use']
of O
our O
adaptation O
of O
the O
canalith B-outcome ['Resource-use']
repositioning I-outcome ['Resource-use']
procedure I-outcome ['Resource-use']
( O
CRP B-outcome ['Physiological-Clinical']
) O
with O
the O
expectation O
treatment O
for O
benign O
paroxysmal O
positional O
vertigo O
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical']

Cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
( O
CO B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

We O
assessed O
the O
hypothesis O
that O
the O
change O
in O
the O
central O
PP O
is O
more O
useful O
than O
that O
in O
the O
brachial O
PP O
in O
the O
assessment O
of O
the O
change O
in O
cardiac O
load O
. O
[]

A O
whey O
protein O
concentrate O
prepared O
from O
the O
milk O
of O
cows O
that O
have O
been O
immunized O
against O
Clostridium O
difficile O
( O
C. O
difficile O
) O
and O
its O
toxins O
, O
toxin O
A O
and O
toxin O
B O
, O
is O
produced O
for O
use O
as O
a O
medical O
food O
for O
the O
dietary O
management O
of O
patients O
with O
C. O
difficile-associated O
diarrhea O
( O
CDAD O
) O
to O
prevent O
a O
relapse O
of O
the O
infection O
. O
[]

Sixty O
two O
percent O
( O
n O
= O
26 O
) O
of O
tunnelled O
catheters O
remained B-outcome ['Physiological-Clinical']
within I-outcome ['Physiological-Clinical']
0.5 O
cm O
of O
their O
original O
position O
compared O
to O
38 O
% O
( O
n O
= O
16 O
) O
of O
non-tunnelled O
catheters O
, O
although O
this O
difference O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

Antibodies B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
rHCNTF I-outcome ['Physiological-Clinical']
were O
observed O
in O
sera O
of O
most O
patients O
tested O
after O
2 O
weeks O
of O
continuous O
treatment O
and O
4 O
weeks O
' O
withdrawal O
period O
. O
['Physiological-Clinical']

OBJECTIVES O
The O
objective O
was O
to O
test O
the O
hypothesis O
that O
hydrocodone/acetaminophen O
( O
Vicodin O
[ O
5/500 O
] O
) O
provides O
more O
efficacious O
analgesia O
than O
codeine/acetaminophen O
( O
Tylenol O
# O
3 O
[ O
30/300 O
] O
) O
in O
patients O
discharged O
from O
the O
emergency O
department O
( O
ED O
) O
. O
[]

RESULTS O
In O
both O
methods O
there O
were O
no O
significant O
differences O
in O
systolic O
and O
diastolic B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
, O
rate-pressure O
product O
, O
in O
glucose B-outcome ['Physiological-Clinical']
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ipilimumab O
is O
a O
fully O
human O
, O
monoclonal O
antibody O
that O
blocks O
cytotoxic O
T-lymphocyte O
antigen-4 O
to O
potentiate O
an O
antitumor O
T-cell O
response O
. O
[]

It O
has O
not O
been O
studied O
in O
combination O
with O
2-CP O
. O
[]

BACKGROUND O
The O
maximal O
calcium O
absorption O
in O
response O
to O
vitamin O
D O
has O
been O
proposed O
as O
a O
biomarker O
for O
vitamin O
D O
sufficiency O
. O
[]

The O
fed O
trials O
resulted O
in O
lower O
plasma O
PSE O
concentrations O
at O
all O
time O
points O
compared O
with O
the O
nonfed O
trials O
. O
[]

PATIENTS O
AND O
METHODS O
Individual O
data O
of O
254 O
patients O
were O
merged O
, O
and O
baseline O
features O
potentially O
affecting O
overall O
response O
rate O
( O
ORR O
) O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS B-outcome ['Mortality']
) O
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
, O
and O
occurrence O
of O
severe O
toxicity B-outcome ['Adverse-effects']
were O
analyzed O
by O
univariate O
and O
multivariate O
analyses O
. O
['Mortality', 'Mortality', 'Mortality', 'Mortality', 'Adverse-effects']

Our O
data O
show O
that O
succinate O
sumatriptan O
can O
be O
used O
with O
safety O
in O
patients O
without O
hypertension O
and O
other O
cardiovascular O
disease O
. O
[]

Randomized O
trial O
of O
recombinant O
alpha O
2b-interferon O
with O
or O
without O
indomethacin O
in O
patients O
with O
metastatic O
malignant O
melanoma O
. O
[]

It O
was O
considered O
that O
local O
instillation O
of O
anti-cancer O
agents O
with O
pericardial O
drainage O
was O
a O
useful O
therapeutic O
modality O
for O
malignant O
pericarditis O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

94 O
evaluable O
patients O
with O
metastatic O
breast O
cancer O
were O
randomly O
assigned O
to O
5-fluorouracil O
, O
adriamycin O
, O
and O
cyclophosphamide O
( O
FAC O
) O
or O
5-fluorouracil O
, O
epirubicin O
, O
and O
cyclophosphamide O
( O
FEC O
) O
, O
with O
cycles O
repeated O
every O
3 O
weeks O
. O
[]

The O
30-day O
operative B-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
the O
EVAR O
group O
was O
9 O
% O
( O
13 O
of O
150 O
, O
95 O
% O
CI O
5-15 O
) O
and O
the O
no O
intervention O
group O
had O
a O
rupture O
rate O
of O
9.0 O
per O
100 O
person O
years O
( O
95 O
% O
CI O
6.0-13.5 O
) O
. O
['Mortality']

RESULTS O
No O
significant O
differences O
were O
found O
between O
the O
two O
in-person O
interview O
modes O
for O
subject O
age O
, O
weight O
, O
body O
mass O
index O
, O
percentage O
of O
body O
fat O
, O
total O
energy O
expenditure O
, O
rEI O
, O
and O
misreporting O
of O
energy O
intake O
. O
[]

Multicenter O
randomized O
controlled O
trial O
of O
the O
management O
of O
unresectable O
malignant O
mesothelioma O
proposed O
by O
the O
British O
Thoracic O
Society O
and O
the O
British O
Medical O
Research O
Council O
. O
[]

In O
the O
GHB O
group O
, O
AWS B-outcome ['Physiological-Clinical']
score O
dropped O
from O
6.6 O
+/- O
2.6 O
to O
1.8 O
+/- O
2.1 O
( O
p O
< O
.01 O
) O
, O
while O
in O
the O
CLO O
group O
, O
the O
score O
dropped O
from O
6 O
+/- O
2.5 O
to O
4.1 O
+/- O
2.4 O
( O
n. O
s. O
) O
. O
['Physiological-Clinical']

Anesthesia O
was O
maintained O
with O
N O
( O
2 O
) O
O/O O
( O
2 O
) O
, O
isoflurane O
0.5 O
MAC O
and O
remifentanil O
0.2 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
or O
fentanyl O
0.04 O
micro O
g O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
. O
[]

Patients O
with O
essential O
hypertension O
( O
65-85 O
years O
old O
, O
with O
a O
pretreatment O
systolic O
blood O
pressure O
of O
above O
160 O
mmHg O
) O
were O
randomly O
assigned O
to O
receive O
strict O
treatment O
( O
n=2,212 O
) O
or O
mild O
treatment O
( O
n=2,206 O
) O
. O
[]

Experiment O
4 O
reveals O
that O
these O
constructs O
each O
play B-outcome ['Life-Impact']
an I-outcome ['Life-Impact']
independent I-outcome ['Life-Impact']
role I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
persuasion I-outcome ['Life-Impact']
and O
resistance B-outcome ['Life-Impact']
situations I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Patent O
foramen O
ovale O
was O
detected O
significantly O
more O
often O
during O
femoral O
vein O
versus O
upper O
extremity O
contrast O
delivery O
( O
23 O
of O
70 O
patients O
[ O
prevalence O
33 O
% O
] O
vs. O
9 O
of O
70 O
patients O
[ O
prevalence O
13 O
% O
] O
, O
p O
< O
0.001 O
) O
. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

We O
deprecate O
their O
use O
in O
athletics O
but O
can O
suggest O
no O
way O
of O
stopping O
it O
. O
[]

Results O
suggest O
that O
RMIA O
, O
with O
parent O
training O
, O
catalyzes O
development O
of O
verbal B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
for O
some O
children O
. O
['Life-Impact']

Eligible O
patients O
were O
children O
and O
adolescents O
with O
HFA O
. O
[]

Calf O
birth O
weight O
( O
39 O
+/- O
2 O
kg O
) O
, O
weaning B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
225 O
+/- O
7 O
kg O
) O
, O
and O
age-adjusted B-outcome ['Physiological-Clinical']
weaning I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
234 O
+/- O
8 O
kg O
) O
did O
not O
differ O
because O
of O
dam O
supplementation O
regimen O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Salmeterol O
plus O
fluticasone O
propionate O
versus O
fluticasone O
propionate O
plus O
montelukast O
: O
a O
randomised O
controlled O
trial O
investigating O
the O
effects O
on O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
in O
asthma O
. O
['Physiological-Clinical']

Main O
outcome O
measures O
were O
Humphrey O
Field O
Analyzer O
visual B-outcome ['Physiological-Clinical']
field I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
, O
30-Hz O
electroretinogram O
amplitude O
, O
and O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

It O
is O
uncertain O
whether O
the O
negative O
finding O
was O
because O
of O
a O
lack O
of O
strength O
of O
the O
interventions O
or O
problems O
detecting O
intervention O
effects O
using O
individual-level O
closed-end O
surveys O
. O
[]

Calcium O
chloride O
before O
i.v O
. O
[]

Subjects O
with O
cardiac O
, O
metabolic O
, O
neurological O
disease O
or O
any O
other O
systemic O
disease O
that O
could O
affect O
autonomic O
activity O
were O
excluded O
from O
the O
study O
. O
[]

Women O
have O
low O
coronary B-outcome ['Mortality']
heart I-outcome ['Mortality']
disease I-outcome ['Mortality']
mortality I-outcome ['Mortality']
rates O
, O
which O
do O
not O
correlate O
with O
8-oxo-dG O
. O
['Mortality']

INTERVENTIONS O
Acupuncture O
with O
sham O
device O
twice O
a O
week O
for O
six O
weeks O
or O
placebo O
pill O
once O
a O
day O
for O
eight O
weeks O
. O
[]

Performance O
of O
a O
modified O
starch O
hydrophilic O
matrix O
for O
the O
sustained O
release O
of O
theophylline O
in O
healthy O
volunteers O
. O
[]

MATERIALS O
AND O
METHODS O
This O
study O
was O
performed O
in O
a O
randomized O
, O
multicenter O
, O
prospective O
manner O
. O
[]

The O
present O
findings O
seem O
to O
indicate O
that O
the O
topical O
application O
of O
BAs O
may O
represent O
a O
suitable O
treatment O
option O
for O
selected O
features O
of O
skin O
photoaging O
. O
[]

Purpose O
of O
our O
present O
prospective O
study O
was O
to O
evaluate O
the O
dose B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
relationship O
of O
paclitaxel O
. O
['Physiological-Clinical']

However O
, O
the O
decreased O
5 O
alpha-reduction O
of O
testosterone O
to O
dihydrotestosterone O
is O
the O
only O
impaired O
steroid O
conversion O
to O
have O
clinical O
consequences O
, O
e.g. O
, O
ambiguous B-outcome ['Physiological-Clinical']
genitalia I-outcome ['Physiological-Clinical']
, O
impaired B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
and O
development O
, O
and O
decreased O
facial B-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
hair I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Statistically O
significant O
benefits O
of O
partner O
treatment O
were O
noted O
in O
the O
initial O
cure O
rate O
by O
Gram-stained O
smear O
criteria O
( O
P O
less O
than O
.01 O
) O
and O
in O
percentage O
of O
women O
with O
symptoms O
eight O
weeks O
after O
initiating O
therapy O
( O
P O
less O
than O
.05 O
) O
. O
[]

We O
assessed O
the O
associations O
between O
infarction O
patterns O
and O
stroke B-outcome ['Physiological-Clinical']
recurrence O
using O
multivariable O
Cox O
regression O
models. O
[['Physiological-Clinical']]

Ninety-eight O
patients O
completed O
the O
chemotherapy O
as O
planed O
. O
[]

Addition O
of O
LEV O
to O
high-concentrate O
, O
corn-based O
diets O
did O
not O
improve O
( O
P O
> O
0.10 O
) O
growth B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
of O
feedlot O
steers O
. O
['Physiological-Clinical']

Pharmacokinetic B-outcome ['Physiological-Clinical']
and O
safety O
assessments O
of O
concurrent O
administration O
of O
risperidone O
and O
donepezil O
. O
['Physiological-Clinical']

The O
maternal O
and O
fetal O
metabolic O
effects O
of O
three O
commonly O
used O
intravenous O
fluids O
administered O
before O
regional O
anesthesia O
were O
studied O
in O
32 O
gravid O
women O
undergoing O
elective O
cesarean O
section O
at O
term O
. O
[]

Title: O
Enteral O
lactoferrin O
supplementation O
for O
very O
preterm O
infants: O
a O
randomised O
placebo-controlled O
trial. O
[]

Patients O
with O
a O
baseline O
haemoglobin O
A O
( O
1c O
) O
( O
HbA O
( O
1c O
) O
) O
of O
7.3 O
to O
11.0 O
% O
were O
randomized O
1 O
: O
1 O
: O
1 O
: O
1 O
to O
receive O
once-daily O
oral O
therapy O
with O
either O
PHX1149 O
( O
100 O
, O
200 O
or O
400 O
mg O
) O
or O
placebo O
; O
patients O
were O
on O
a O
constant O
background O
therapy O
of O
either O
metformin O
alone O
or O
metformin O
plus O
a O
glitazone O
. O
[]

Retrospectively O
registered: O
December O
3, O
2010, O
( O
http://www.drks.de/drks_web/setLocale_EN.do O
). O
[]

BACKGROUND O
Torso O
weighting O
has O
sometimes O
been O
effective O
for O
improving O
upright B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
in O
people O
with O
multiple O
sclerosis O
, O
but O
parameters O
for O
weighting O
have O
been O
inconsistent O
. O
['Physiological-Clinical']

CONCLUSION O
Results O
indicate O
the O
efficacy O
of O
the O
program O
in O
a O
research O
setting O
and O
suggest O
a O
potential O
clinical O
application O
. O
[]

CONCLUSION O
during O
a O
4-days O
administration O
hepatic O
effect O
of O
the O
intravenous O
lipid O
emulsions O
did O
not O
differ O
significantly O
. O
[]

METHOD O
Thirty-eight O
children O
, O
ages O
5-17 O
years O
with O
autism O
and O
severe O
behavioral O
disturbance O
, O
were O
randomly O
assigned O
to O
risperidone O
( O
0.5 O
to O
3.5 O
mg/day O
) O
or O
placebo O
for O
8 O
weeks O
. O
[]

Repeated-measures O
multivariate O
analysis O
of O
variance O
performed O
on O
normalized O
relative O
area O
values O
revealed O
that O
ethanol O
had O
significant O
effects O
on O
EEG B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
anterior I-outcome ['Physiological-Clinical']
sites I-outcome ['Physiological-Clinical']
: O
frontal O
( O
F3 O
, O
F4 O
) O
and O
central O
( O
C3 O
, O
C4 O
) O
that O
presented O
as O
increased O
activity O
in O
the O
slow O
alpha O
frequency O
band O
. O
['Physiological-Clinical']

Funded O
by O
the O
Netherlands O
Organization O
for O
Health O
Research O
and O
Development O
and O
others; O
LEAP O
Current O
Controlled O
Trials O
number, O
ISRCTN30518857 O
.). O
[]

CONCLUSIONS O
Administration O
of O
a O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drug O
prior O
to O
and O
following O
outpatient O
inguinal O
herniorrhaphy O
improves O
functional O
outcomes O
when O
compared O
with O
placebo O
and O
increases O
patient O
satisfaction O
. O
[]

Together O
with O
a O
visual O
analog O
scale O
( O
VAS O
, O
range O
0-100 O
) O
on O
overall B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
, O
the O
questionnaire O
was O
applied O
in O
210 O
RA O
patients O
who O
participated O
in O
a O
randomized O
trial O
comparing O
3 O
types O
of O
multidisciplinary O
care O
. O
['Life-Impact']

Subjects O
were O
assigned O
to O
gain O
weight O
( O
approximately O
4 O
kg O
) O
( O
n=35 O
) O
or O
to O
maintain O
weight O
( O
n=8 O
) O
. O
[]

Side-effects O
in O
both O
groups O
were O
those O
commonly O
seen O
with O
non-steroidal O
anti-inflammatory O
drugs O
and O
, O
as O
expected O
, O
gastro-intestinal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
CNS I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
predominated O
. O
['Physiological-Clinical']

The O
children O
were O
assessed O
on O
awakening B-outcome ['Life-Impact']
, O
and O
then O
10 O
minutes O
, O
1 O
hour O
, O
4 O
hours O
and O
24 O
hours O
later O
. O
['Life-Impact']

[ O
Effects O
of O
auditory O
integrative O
training O
on O
autistic O
children O
] O
. O
[]

RESULTS O
Compared O
with O
the O
cisplatin-only O
arm O
, O
there O
was O
a O
9 O
% O
improvement O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
19 O
% O
) O
in O
overall O
response O
rate O
for O
the O
paclitaxel/cisplatin O
arm O
( O
17 O
% O
v O
26 O
% O
, O
respectively O
; O
P=.028 O
) O
. O
[]

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
IFN-alpha O
administered O
as O
an O
adjuvant O
of O
HBV O
vaccine O
in O
healthy O
unvaccinated O
individuals O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS: O
The O
fentanyl O
level O
peaked O
1 O
h O
after O
operation O
in O
the O
TFP O
group O
(3.27 O
+/- O
0.34 O
ng/mL) O
and O
24 O
h O
postoperatively O
in O
the O
IV O
group O
(2.9 O
+/- O
0.42 O
ng/mL). O
[]

Fluconazole O
is O
widely O
used O
as O
antifungal B-outcome ['Resource-use']
prophylaxis I-outcome ['Resource-use']
but O
it O
is O
ineffective O
against O
Aspergillus O
. O
['Resource-use']

Acetylsalicylic O
acid O
( O
ASA O
) O
inhibition O
of O
platelet O
aggregation O
as O
evaluated O
by O
collagen-induced O
14C-serotonin O
release O
, O
has O
been O
measured O
in O
12 O
healthy O
male O
subjects O
. O
[]

Urine O
samples O
for O
analysis O
of O
nocturnal O
urinary O
excretion B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
were O
collected O
. O
['Physiological-Clinical']

In O
the O
same O
groups O
, O
the O
cumulative O
12-month O
incidence O
of O
severe B-outcome ['Physiological-Clinical']
stunting I-outcome ['Physiological-Clinical']
was O
13.3 O
% O
, O
0.0 O
% O
, O
and O
3.5 O
% O
( O
P O
= O
.01 O
) O
, O
of O
severe O
underweight B-outcome ['Physiological-Clinical']
was O
15.0 O
% O
, O
22.5 O
% O
, O
and O
16.9 O
% O
( O
P O
= O
.71 O
) O
, O
and O
of O
severe B-outcome ['Physiological-Clinical']
wasting I-outcome ['Physiological-Clinical']
was O
1.8 O
% O
, O
1.9 O
% O
, O
and O
1.8 O
% O
( O
P O
> O
.99 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND: O
Maintenance O
therapy O
following O
autologous O
stem O
cell O
transplantation O
(ASCT) O
can O
delay O
disease O
progression O
and O
prolong O
survival O
in O
patients O
with O
multiple O
myeloma. O
[]

Alexithymia O
is O
characterized O
by O
difficulties O
identifying O
, O
differentiating O
and O
expressing O
feelings O
, O
a O
limited O
imagination O
and O
fantasy O
life O
, O
and O
an O
externally-oriented O
thinking O
style O
( O
e.g. O
, O
prefer O
talking O
about O
daily O
activities O
rather O
than O
feelings O
) O
. O
[]

The O
primary O
outcome O
was O
percentage O
change O
in O
body O
weight O
. O
[]

No O
differences O
were O
found O
in O
thermal B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
esophagus O
( O
p=0.67 O
) O
and O
duodenum O
( O
p=0.17 O
) O
) O
, O
sensory B-outcome ['Physiological-Clinical']
response O
to O
electrical B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
( O
esophagus O
( O
p=0.57 O
) O
and O
duodenum B-outcome ['Physiological-Clinical']
( O
p=0.52 O
) O
) O
or O
induced O
somatic B-outcome ['Physiological-Clinical']
referred O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Female O
smokers O
had O
higher O
serum O
low-density O
lipoprotein O
( O
LDL O
) O
/high-density O
lipoprotein O
( O
HDL O
) O
ratios O
and O
triglycerides O
. O
[]

Histopathologic O
examinations O
of O
nasopharyngeal O
biopsies O
were O
performed O
for O
all O
36 O
patients O
. O
[]

Being O
65 O
and O
older O
decreased O
the O
chances O
of O
screening B-outcome ['Resource-use']
( O
OR=0.39 O
; O
CI O
: O
0.37-0.42 O
) O
, O
as O
well O
as O
living O
in O
high-size B-outcome ['Life-Impact']
households I-outcome ['Life-Impact']
( O
OR=0.73 O
; O
CI O
: O
0.68-0.78 O
) O
. O
['Resource-use', 'Life-Impact']

Efficacy O
was O
assessed O
by O
total O
amount O
of O
morphine O
consumed O
, O
pain O
intensity O
, O
range O
of O
motion O
( O
ROM O
) O
, O
the O
concentration O
change O
of O
PGE-2 O
and O
IL-6 O
of O
joint O
fluid O
, O
and O
postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
postoperatively O
. O
[]

Ten O
patients O
showed O
anti-HCV B-outcome ['Physiological-Clinical']
positivity O
which O
remained O
unchanged O
after O
the O
treatment O
. O
['Physiological-Clinical']

Anatomical O
benefit O
from O
ranibizumab O
treatment O
of O
predominantly O
classic O
neovascular O
age-related O
macular O
degeneration O
in O
the O
2-year O
anchor O
study O
. O
[]

As O
parameters O
for O
the O
determination O
of O
the O
validity O
of O
fetal O
monitoring O
the O
reliability O
, O
positive O
( O
ppv O
) O
and O
negative O
predictive O
value O
( O
npv O
) O
, O
sensitivity O
and O
specificity O
were O
used O
. O
[]

However O
, O
donepezil O
appeared O
to O
be O
safe O
and O
well O
tolerated O
. O
[]

Obesity O
is O
increasingly O
common O
and O
is O
a O
major O
public O
health O
problem O
. O
[]

Eight O
out O
of O
12 O
had O
melatonin O
first O
. O
[]

Opioid B-outcome ['Life-Impact']
usage I-outcome ['Life-Impact']
during O
the O
first O
24 O
hours O
was O
similar O
( O
INB- O
, O
16.7 O
mg O
vs. O
INB+ O
, O
13.2 O
mg O
, O
P O
= O
.7 O
) O
. O
['Life-Impact']

SETTING O
Primary O
care O
centre O
. O
[]

METHODS O
From O
November O
2002 O
to O
July O
2003 O
, O
80 O
patients O
who O
received O
PPH O
were O
randomly O
divided O
in O
to O
titanoreine O
group O
( O
n=42 O
) O
and O
control O
group O
without O
titanoreine O
( O
n=38 O
) O
. O
[]

In O
order O
to O
assess O
the O
reliability O
of O
intrauterine B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
measurements O
in O
the O
third O
stage O
of O
labour O
, O
catheter-tip O
transducers O
were O
used O
in O
20 O
women O
randomly O
allocated O
into O
two O
groups O
of O
10 O
. O
['Physiological-Clinical']

Logistic O
regression O
models O
indicated O
that O
positive O
affect O
was O
associated O
with O
increased O
and O
negative O
affect O
was O
associated O
with O
decreased O
overall O
and O
leisure B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
['Life-Impact']

Slab O
sections O
of O
the O
PIJ O
were O
evaluated O
grossly O
and O
radiographically O
for O
bony O
fusion O
. O
[]

This O
phase O
II O
study O
assessed O
neoadjuvant O
cetuximab O
with O
capecitabine-based O
CRT O
in O
LARC O
. O
[]

A O
follow-up O
study O
16 O
months O
later O
evaluated O
the O
extent O
to O
which O
the O
skills O
and O
equipment O
necessary O
for O
CPAP O
use O
have O
been O
maintained O
. O
[]

Overall O
, O
after O
34 O
months O
( O
median O
posttreatment O
follow-up O
) O
, O
three O
patients O
were O
long O
term O
responders O
, O
whereas O
three O
showed O
a O
sustained O
remission B-outcome ['Physiological-Clinical']
after O
relapse O
. O
['Physiological-Clinical']

Loads O
ranged O
in O
magnitude O
from O
imperceptible O
( O
R0/E0 O
) O
through O
just O
perceptible O
( O
R1/E1 O
) O
to O
large O
( O
R2/E2 O
) O
and O
resulted O
in O
respiratory O
pattern O
responses O
that O
were O
due O
to O
reflex O
responses O
alone O
( O
R0/E0 O
) O
or O
to O
a O
combination O
of O
reflex O
responses O
and O
behavioral O
reactions O
to O
the O
perception O
of O
impeded O
breathing O
( O
R1/E1 O
and O
R2/E2 O
) O
. O
[]

LX4211 O
, O
a O
dual O
inhibitor O
of O
SGLT1 O
and O
SGLT2 O
, O
reduces O
glucose O
absorption O
from O
the O
GI O
tract O
and O
enhances O
urinary O
glucose O
excretion O
. O
[]

There O
was O
no O
difference O
in O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
between O
those O
in O
the O
enhanced O
SOC O
and O
the O
SOC O
groups. O
[['Life-Impact']]

Three O
patients O
discontinued O
treatment O
early O
( O
two O
due O
to O
moderate O
adverse B-outcome ['Adverse-effects']
events O
, O
one O
due O
to O
non-compliance O
) O
. O
['Adverse-effects']

RATIONALE O
The O
response O
characteristics O
of O
the O
6 O
minute O
walk O
test O
( O
6MWT O
) O
in O
studies O
of O
idiopathic O
pulmonary O
fibrosis O
( O
IPF O
) O
are O
only O
poorly O
understood O
, O
and O
the O
change O
in O
walk O
distance O
that O
constitutes O
the O
minimum O
important O
difference O
( O
MID O
) O
over O
time O
is O
unknown O
. O
[]

Effects O
of O
supervised O
exercise O
therapy O
in O
patients O
receiving O
radiotherapy O
for O
breast O
cancer O
. O
[]

24 O
healthy O
subjects O
( O
10 O
men O
; O
mean O
age O
26.2 O
y O
) O
received O
a O
single O
dose O
of O
rabeprazole O
20 O
mg O
or O
esomeprazole O
40 O
mg O
, O
with O
a O
14-day O
'washout O
' O
. O
[]

In O
the O
intent-to-treat O
sample O
, O
pioglitazone O
and O
glimepirede O
produced O
comparable O
reductions O
in O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
end O
of O
the O
study O
( O
-0.78 O
% O
and O
-0.68 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

Before O
clinicians O
can O
advocate O
PC O
as O
an O
EHS O
prevention O
strategy, O
it O
must O
effectively O
mitigate O
factors O
associated O
with O
EHS O
development O
while O
not O
lessening O
the O
effectiveness O
of O
EHS O
treatment. O
[]

Comparison O
of O
analgesic O
effect O
of O
locally O
and O
systemically O
administered O
ketorolac O
in O
mastectomy O
patients O
. O
[]

All O
247 O
episodes O
were O
evaluable O
by O
intent-to-treat O
analysis O
. O
[]

CONCLUSION O
TTS-scopolamine O
offers O
effective O
prophylaxis B-outcome ['Resource-use']
against O
PONV B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
auriculoemetic I-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

The O
EMID O
study O
is O
a O
randomized O
and O
controlled O
clinical O
trial O
with O
two O
parallel O
groups O
and O
a O
12-month O
follow-up O
period. O
[]

CONCLUSIONS O
Non-eosinophilic O
asthma O
represents O
a O
pathologically O
distinct O
disease O
phenotype O
which O
is O
characterised O
by O
the O
absence O
of O
airway B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
, O
normal O
subepithelial B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
and O
a O
poor O
short-term O
response O
to O
['Physiological-Clinical', 'Physiological-Clinical']

The O
further O
rate O
of I-outcome ['Physiological-Clinical']
progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
from O
their O
levels O
at O
the O
end O
of O
the O
DCCT O
remains O
less O
in O
the O
former O
intensive O
treatment O
group O
. O
['Physiological-Clinical']

Tolerance O
of O
the O
drug O
was O
generally O
excellent O
. O
[]

There O
was O
no O
statistically O
significant O
difference O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
two O
treatment O
groups O
. O
['Adverse-effects']

Efficacy O
and O
safety O
of O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
in O
patients O
with O
seasonal O
allergic O
rhinitis O
. O
[]

The O
AUC O
and O
Cmax B-outcome ['Physiological-Clinical']
after O
fasting O
were O
closely O
similar O
to O
those O
after O
a O
meal O
, O
showing O
that O
bioavailability O
was O
not O
affected O
by O
food O
intake O
. O
['Physiological-Clinical']

The O
treatments O
consisted O
of O
( O
1 O
) O
one O
orally O
administered O
0.25-mg O
triazolam O
tablet O
after O
treatment O
with O
ranitidine O
; O
( O
2 O
) O
one O
orally O
administered O
0.25-mg O
triazolam O
tablet O
, O
with O
no O
ranitidine O
pretreatment O
; O
( O
3 O
) O
a O
0.25-mg O
intravenous O
dose O
of O
triazolam O
after O
treatment O
with O
ranitidine O
; O
and O
( O
4 O
) O
a O
0.25-mg O
intravenous O
dose O
of O
triazolam O
, O
with O
no O
ranitidine O
pretreatment O
. O
[]

DESIGN O
Prospective O
, O
randomized O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
analgesic B-outcome ['Resource-use']
benefits O
and O
physiotherapy B-outcome ['Physiological-Clinical']
(PT) I-outcome ['Physiological-Clinical']
outcomes O
of O
single-shot O
ACB O
to O
two O
different O
regimens O
of O
infusion O
of O
the O
continuous O
ACB, O
24-hour O
and O
48-hour O
infusion. O
[['Resource-use'], ['Physiological-Clinical']]

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT02181413, O
and O
follow-up O
is O
ongoing. O
[]

Treatment O
of O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GERD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
proton O
pump O
inhibitors O
was O
investigated O
in O
three O
controlled O
prospective O
, O
randomized O
open O
studies O
. O
['Physiological-Clinical']

CONCLUSIONS O
During O
this O
OLE O
, O
safety O
findings O
with O
risperidone O
treatment O
( O
maximum O
weight-based O
dose O
of O
1.25 O
mg/day O
or O
1.75 O
mg/day O
) O
were O
consistent O
with O
those O
observed O
in O
the O
DB O
phase O
, O
and O
with O
the O
current O
safety O
information O
for O
risperidone O
in O
autistic O
, O
psychiatric O
, O
and O
behavioral O
disorders O
. O
[]

Title: O
Tobramycin/dexamethasone O
eye O
drops O
as O
a O
better O
choice O
for O
lacrimal O
duct O
probing O
in O
persistent O
congenital O
nasolacrimal O
duct O
obstruction: O
A O
consort O
study. O
[]

This O
approach O
is O
an O
effective O
strategy O
for O
the O
management O
of O
invasive O
aspergillosis O
in O
high-risk O
haematology O
patients O
. O
[]

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

RESULTS O
The O
satisfaction B-outcome ['Life-Impact']
rate O
was O
significantly O
higher O
in O
the O
thermal O
destruction O
group O
. O
['Life-Impact']

Mean O
ratings O
at O
endpoint O
were O
2.8 O
+/- O
1.2 O
on O
risperidone O
and O
4.5 O
+/- O
1.3 O
on O
placebo O
( O
p O
< O
.001 O
) O
. O
[]

In O
the O
same O
group O
, O
increased O
plasma B-outcome ['Physiological-Clinical']
and O
follicular B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
arginine B-outcome ['Physiological-Clinical']
, O
citrulline B-outcome ['Physiological-Clinical']
, O
NO2-/NO3- B-outcome ['Physiological-Clinical']
, O
and O
IGF-1 B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Results O
of O
small O
trials O
suggest O
that O
early O
interventions O
for O
social O
communication O
are O
effective O
for O
the O
treatment O
of O
autism O
in O
children O
. O
[]

Full B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
also O
occurred O
earlier O
in O
the O
D O
group O
( O
D O
: O
22.1 O
+/- O
3.1 O
min O
vs O
I O
: O
37.6 O
+/- O
4.0 O
min O
, O
P O
< O
0.005 O
for O
stating O
name O
) O
. O
['Physiological-Clinical']

Intramuscular O
phenobarbitone O
is O
well O
absorbed O
in O
children O
with O
severe O
malaria O
; O
the O
optimum O
prophylactic O
anticonvulsant O
dose O
remains O
to O
be O
determined O
. O
[]

Furthermore, O
in O
both O
groups, O
mean B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
preoperative O
PR B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
were O
similar O
at O
various O
times. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Only O
standing O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
showed O
a O
dose-dependent O
inhibition O
both O
in O
the O
supine O
and O
upright O
position O
. O
['Physiological-Clinical']

Twenty-nine O
out-patients O
with O
uni- O
or O
bilateral O
osteoarthritis O
of O
the O
knee O
were O
included O
and O
randomly O
assigned O
to O
treatment O
with O
either O
laser O
or O
placebo O
laser O
. O
[]

AIDS O
Clinical O
Trials O
Group O
Protocol O
204/Glaxo O
Wellcome O
123-014 O
International O
CMV O
Prophylaxis O
Study O
Group O
. O
[]

OBJECTIVE O
We O
assessed O
the O
effectiveness O
of O
distraction O
techniques O
in O
reducing O
the O
sensory O
and O
affective O
components O
of O
pain O
among O
pediatric O
patients O
undergoing O
laceration O
repair O
in O
the O
ED O
. O
[]

METHODS O
AND O
RESULTS O
Out O
of O
the O
266 O
AF O
patients O
randomized O
to O
rhythm O
control O
in O
the O
RACE O
study O
, O
49 O
patients O
turned O
to O
long-term O
sinus O
rhythm O
and O
were O
continuously O
treated O
with O
oral O
anticoagulation O
. O
[]

This O
difference O
was O
also O
significant O
in O
the O
silicone O
group O
( O
p O
= O
0.041 O
) O
. O
[]

The O
magnitude O
and O
duration O
of O
the O
therapeutic O
response O
to O
a O
single O
dose O
of O
200 O
mg O
levodopa/50 O
mg O
carbidopa O
was O
evaluated O
after O
concomitant O
placebo O
, O
or O
200 O
or O
800 O
mg O
entacapone O
. O
[]

BACKGROUND O
Low O
Back O
Pain O
is O
a O
major O
public O
health O
problem O
all O
over O
the O
western O
world O
. O
[]

Although O
it O
has O
been O
suggested O
that O
individuals O
with O
an O
Autism O
spectrum O
disorder O
( O
ASD O
) O
process O
faces O
less O
holistically O
than O
typically O
developing O
controls O
, O
there O
are O
few O
direct O
investigations O
of O
this O
hypothesis O
. O
[]

Modest O
visceral O
fat O
gain O
causes O
endothelial O
dysfunction O
in O
healthy O
humans O
. O
[]

CONCLUSION O
In O
women O
with O
a O
large O
uterus O
, O
a O
3-month O
preoperative O
course O
of O
GnRH O
may O
facilitate O
laparoscopic O
hysterectomy O
, O
decreasing O
uterine O
size O
, O
operating O
time O
, O
and O
blood O
loss O
. O
[]

The O
introduction O
of O
artemisinin-based O
combination O
therapy O
in O
sub-Saharan O
Africa O
has O
prompted O
calls O
for O
increased O
use O
of O
parasitologic O
diagnosis O
for O
malaria O
. O
[]

Overall O
lamotrigine O
appeared O
equally O
effective O
but O
better O
tolerated O
compared O
with O
carbamazepine O
. O
[]

Linear O
regression O
analyses O
showed O
that O
gender O
is O
an O
independent O
predictor O
of O
the O
ABP O
responses B-outcome ['Physiological-Clinical']
to O
HCT O
and O
to O
LIS O
. O
['Physiological-Clinical']

This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00435266 O
. O
[]

Oral O
ISDN O
thus O
has O
a O
dose-dependent O
effect O
on O
the O
frequency O
of O
angina B-outcome ['Physiological-Clinical']
and O
ischaemia B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
during O
ergometric O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Tiotropium O
bromide O
is O
an O
effective O
therapy O
for O
COPD O
patients O
. O
[]

s.e.m O
. O
[]

Atracurium O
caused O
unexplained O
elevations O
in O
[]

Effect O
of O
acarbose O
on O
additional O
insulin O
therapy O
in O
type O
2 O
diabetic O
patients O
with O
late O
failure O
of O
sulphonylurea O
therapy O
. O
[]

Thirty-three O
patients O
with O
II O
type O
mixed O
essential O
cryoglobulinemia O
( O
MEC O
) O
were O
randomized O
into O
two O
groups O
: O
one O
to O
receive O
combined O
therapy O
including O
prednisone O
plus O
interferon O
, O
the O
other O
to O
receive O
prednisone O
therapy O
. O
[]

CONCLUSIONS O
Naltrexone O
offers O
promise O
as O
an O
agent O
for O
modest O
improvement O
of O
behavior O
and O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact']

One O
interpretation O
is O
that O
feed-forward O
processes O
lead O
to O
awareness O
of O
the O
movement O
prior O
to O
execution O
. O
[]

Eligible O
participants O
in O
the O
study O
were O
51 O
patients O
with O
chronic O
schizophrenia O
with O
ages O
ranging O
from O
20 O
to O
45 O
years O
. O
[]

P3 O
maxima O
elicited O
by O
rare O
non-targets O
were O
recorded O
more O
rostrally O
after O
fenfluramine O
treatment O
. O
[]

One O
patient O
(4%) O
died B-outcome ['Mortality']
from O
sepsis B-outcome ['Physiological-Clinical']
in O
the O
context O
of O
neutropenic B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
, O
infection B-outcome ['Physiological-Clinical']
, O
and O
haemorrhage B-outcome ['Physiological-Clinical']
in O
the O
5-day O
group, O
and O
in O
the O
10-day O
group O
six O
patients O
(14%) O
died B-outcome ['Mortality']
from O
infection B-outcome ['Physiological-Clinical']
. O
Early O
mortality B-outcome ['Mortality']
was O
similar O
in O
the O
two O
groups. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Mortality']]

One O
hundred O
anaesthetized O
patients O
( O
ASA O
1-2 O
, O
aged O
18 O
to O
80 O
years O
) O
were O
randomized O
for O
the O
second O
insertion O
attempt O
using O
either O
the O
gum O
elastic O
bougie-guided O
or O
introducer O
tool O
techniques O
. O
[]

The O
other O
25 O
patients O
were O
operated O
on O
immediately O
and O
received O
radiotherapy O
postoperatively O
2 O
to O
4 O
weeks O
after O
surgery O
. O
[]

Improvements O
were O
found O
in O
all O
seven O
RQLQ O
( O
S O
) O
domains B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Epithelial O
defects O
measuring O
at O
least O
2 O
mm O
in O
linear O
dimension O
resistant O
to O
conventional O
medical O
management O
were O
included O
. O
[]

Results O
of O
the O
Active O
Schools: O
Skelmersdale O
(AS:Sk) O
multi-component O
pilot O
intervention O
indicated O
no O
significant O
positive O
change O
to O
child O
PA O
levels. O
[]

RESULTS O
There O
were O
no O
differences O
between O
the O
active O
treatment O
and O
sham O
groups O
in O
any O
of O
the O
outcome O
measures O
. O
[]

POPULATION O
Two O
hundred O
and O
twenty-four O
women O
at O
12 O
to O
20 O
weeks O
of O
gestation O
. O
[]

The O
relation O
between O
proliferation O
and O
tamoxifen O
response O
seemed O
to O
be O
more O
complex B-outcome ['Physiological-Clinical']
, O
with O
['Physiological-Clinical']

Interobserver O
variation O
was O
analyzed O
using O
the O
kappa O
statistic O
. O
[]

pCR B-outcome ['Resource-use']
was O
achieved O
in O
3 O
patients O
( O
8 O
% O
) O
. O
['Resource-use']

This O
study O
followed O
the O
previous O
Phase O
II O
study O
to O
confirm O
the O
safety O
of O
laparoscopy-assisted O
distal O
gastrectomy O
( O
JCOG0703 O
) O
and O
began O
in O
March O
2010 O
. O
[]

A O
1-year O
randomized O
clinical O
trial O
. O
[]

DATA O
COLLECTION O
At O
each O
home O
health O
visit O
provided O
by O
a O
study O
nurse O
to O
an O
eligible O
HF O
patient O
during O
the O
45-day O
follow-up O
period O
, O
a O
structured O
chart O
abstraction O
tool O
was O
used O
to O
collect O
information O
on O
whether O
the O
nurse O
provided O
the O
care O
practices O
highlighted O
in O
the O
e-mail O
reminder O
. O
[]

Patients O
with O
clinical O
stage O
I-II O
gastric O
cancer O
with O
a O
body O
mass O
index O
of O
25 O
and O
over, O
who O
undergo O
laparoscopic O
subtotal O
gastrectomy O
will O
be O
eligible O
for O
trial O
inclusion. O
[]

OBJECTIVE O
The O
authors O
' O
goal O
was O
to O
assess O
dexamethasone O
for O
the O
treatment O
of O
depression O
. O
[]

The O
objective O
of O
current O
article O
is O
to O
present O
the O
protocol O
for O
a O
PE O
teacher-delivered O
theory-based O
trial O
to O
promote O
secondary O
school O
students' O
participation B-outcome ['Life-Impact']
in O
physical O
activity O
out-of-school O
contexts. O
[['Life-Impact']]

During O
labetalol O
treatment O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
fell I-outcome ['Physiological-Clinical']
for O
2-3 O
days O
and O
then O
returned O
to O
basal O
values O
. O
['Physiological-Clinical']

All O
three O
studies O
used O
a O
multiple O
baseline O
across O
participants O
. O
[]

CatD B-outcome ['Physiological-Clinical']
and O
TAG-72 B-outcome ['Physiological-Clinical']
were O
quantified O
with O
immunoradiometric B-outcome ['Physiological-Clinical']
( O
IRMA O
) O
methods O
, O
and O
EGFR B-outcome ['Physiological-Clinical']
were O
studied O
by O
radioimmunoassay B-outcome ['Resource-use']
( O
RIA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Patients O
with O
a O
chalazion O
underwent O
either O
of O
the O
three O
treatment O
options O
. O
[]

Resource O
use O
of O
hematopoietic O
stem-cell O
transplant O
recipients O
during O
the O
first O
6 O
months O
posttransplant O
, O
both O
inpatient O
and O
ambulatory O
costs O
, O
in O
85 O
patients O
from O
five O
centers O
were O
collected O
prospectively O
and O
costed O
. O
[]

The O
results O
before O
and O
after O
irrigation O
were O
compared O
using O
the O
Wilcoxon O
t-test O
. O
[]

The O
effects O
of O
therapy O
with O
vitamin O
E O
were O
also O
evaluated O
, O
but O
no O
statistical O
benefits O
were O
shown O
. O
[]

Effect O
of O
age O
and O
radiation O
dose O
on O
local B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
after O
breast O
conserving O
treatment O
: O
EORTC O
trial O
22881-10882 O
. O
['Physiological-Clinical']

Effects O
on O
behaviour B-outcome ['Life-Impact']
were O
measured O
using O
the O
Autism B-outcome ['Life-Impact']
Treatment O
Evaluation O
Checklist O
score O
( O
ATEC O
) O
and O
clinical B-outcome ['Physiological-Clinical']
improvement O
was O
measured O
with O
the O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CGI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
system O
; O
in O
particular O
the O
clinical B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
( O
CGIC O
) O
and O
severity O
( O
CGIS O
) O
sub-scores O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
+/- O
SD O
time O
to O
eye O
opening O
was O
significantly O
longer O
in O
the O
thiopental-enflurane-N2O O
group O
( O
Group O
1 O
) O
than O
in O
the O
propofol-propofol-N2O O
group O
( O
Group O
3 O
) O
( O
6.1 O
+/- O
2.5 O
minutes O
vs. O
3.5 O
+/- O
2.8 O
minutes O
, O
respectively O
) O
. O
[]

METHODS O
Patients O
with O
acute O
nonspecific O
low O
back O
pain O
and O
a O
paid O
job O
were O
included O
for O
analysis O
. O
[]

A O
31 O
% O
increase O
in O
STARS B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
was O
observed O
exclusively O
after O
CONC O
exercise O
( O
P O
< O
0.001 O
) O
, O
while O
pSRF B-outcome ['Physiological-Clinical']
protein O
levels O
increased O
similarly O
by O
48 O
% O
with O
both O
CONC O
and O
ECC O
exercise O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Why O
are O
there O
sometimes O
concreteness B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
for O
prose O
? O
['Life-Impact']

RESULTS O
29 O
% O
of O
the O
study O
participants O
reported O
a O
fall B-outcome ['Life-Impact']
during O
the O
study O
period O
. O
['Life-Impact']

The O
specimens O
were O
stored O
in O
distilled O
water O
at O
room O
temperature O
for O
24 O
hours O
and O
subsequently O
tested O
in O
shear O
mode O
with O
a O
universal O
testing O
machine O
. O
[]

OBJECTIVE O
To O
determine O
if O
early O
developmental O
intervention O
( O
EDI O
) O
improves O
developmental O
abilities O
in O
resuscitated O
children O
. O
[]

The O
likelihood O
of O
finding O
organ-confined O
untreated O
prostate O
cancer O
( O
PCa O
) O
by O
pathological O
examination O
at O
the O
time O
of O
radical O
prostatectomy O
( O
RP O
) O
is O
only O
50 O
% O
in O
patients O
with O
clinically O
organ-confined O
disease O
. O
[]

Background O
Knee O
pain O
is O
one O
of O
the O
common O
complaints O
patients O
present O
with O
in O
any O
community O
based O
health O
camps O
and O
Osteoarthritis O
of O
knee O
is O
a O
usual O
diagnosis. O
[]

Apart O
from O
reinforcing O
the O
belief O
that O
the O
combined O
application O
of O
brushing B-outcome ['Physiological-Clinical']
and O
biopsy B-outcome ['Resource-use']
is O
mandatory O
for O
achieving O
optimal O
results O
, O
this O
study O
indicated O
that O
the O
brushing O
should O
be O
performed O
before O
the O
biopsy O
. O
['Physiological-Clinical', 'Resource-use']

Post-hoc O
analysis O
indicated O
more O
than O
87 O
% O
of O
children O
receiving O
CFT O
showed O
reliable O
change O
on O
at O
least O
one O
measure O
at O
post-test O
and O
66.7 O
% O
after O
3 O
months O
follow-up O
. O
[]

CONCLUSION O
Plasma O
endotoxin O
and O
cytokines O
( O
TNF-alpha O
, O
IL-1 O
beta O
, O
IL-6 O
and O
IL-8 O
) O
can O
be O
removed O
effectively O
with O
CRRT O
in O
severely O
burned O
patients O
with O
sepsis O
. O
[]

METHODS: O
We O
performed O
a O
phase O
3, O
prospective, O
double-blind, O
double-dummy, O
randomized, O
controlled O
trial O
to O
compare O
tafenoquine O
with O
primaquine O
in O
terms O
of O
safety O
and O
efficacy. O
[]

CONCLUSIONS O
The O
results O
revealed O
that O
the O
efficacy O
and O
side O
effects O
of O
mitoxantrone O
were O
similar O
to O
those O
of O
doxorubicin O
. O
[]

No O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
. O
['Adverse-effects']

Parameters O
are O
calculated O
both O
in O
uni- O
and O
bipolar O
configuration O
at O
implant O
and O
at O
follow-up O
after O
1 O
, O
5 O
, O
15 O
, O
30 O
, O
90 O
, O
180 O
, O
and O
360 O
days O
. O
[]

To O
overcome O
these O
methodological O
shortcomings O
, O
this O
study O
evaluated O
the O
effects O
of O
EEG-biofeedback O
in O
ASD O
in O
a O
randomized O
pretest-posttest O
control O
group O
design O
with O
blinded O
active O
comparator O
and O
six O
months O
follow-up O
. O
[]

This O
gender O
effect O
persisted O
after O
adjustment O
for O
a O
number O
of O
potential O
mediators O
. O
[]

CONTEXT O
The O
Diabetic O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
researchers O
kept O
careful O
records O
of O
the O
food O
consumption O
and O
tobacco O
using O
habits O
of O
type O
1 O
diabetic O
subjects O
. O
[]

Mean O
( O
SD O
) O
time O
taken O
for O
complete O
healing O
with O
combination O
treatment O
[ O
1.9 O
( O
0.6 O
) O
weeks O
] O
was O
significantly O
shorter O
than O
that O
with O
minoxidil O
alone O
( O
3.1 O
[ O
1.7 O
] O
weeks O
; O
p=0.001 O
) O
or O
with O
lignocaine O
alone O
( O
3.3 O
[ O
0.8 O
] O
weeks O
; O
p=0.002 O
) O
. O
[]

CONCLUSIONS O
in O
patients O
receiving O
ICDs O
early O
after O
myocardial O
infarction O
, O
those O
factors O
that O
are O
associated O
with O
arrhythmia O
requiring O
ICD O
therapy O
are O
also O
associated O
with O
a O
high O
risk O
of O
[]

Title: O
A O
Fully O
Automated O
Method O
for O
the O
Determination O
of O
Serum O
Belatacept O
and O
Its O
Application O
in O
a O
Pharmacokinetic O
Investigation O
in O
Renal O
Transplant O
Recipients. O
[]

Microtensile O
bond O
strength O
of O
a O
repair O
composite O
to O
leucite-reinforced O
feldspathic O
ceramic O
. O
[]

However O
, O
in O
attributing O
intentions O
to O
their O
classmates O
, O
older O
children O
and O
girls O
gave O
lower O
ratings O
to O
the O
child O
in O
the O
autism O
conditions O
. O
[]

This O
novel O
method O
for O
automatically O
constructing O
a O
patient-specific O
3D O
finite O
element O
model O
from O
standard O
2D O
radiographs O
shows O
encouraging O
results O
in O
estimating O
patient-specific O
failure O
loads O
. O
[]

The O
two O
populations O
were O
well O
matched O
in O
terms O
of O
age O
, O
gender O
, O
underlying O
disease O
, O
chemotherapy O
received O
, O
oral O
decontamination O
, O
clinical O
and O
bacterial O
documentation O
, O
and O
severity O
and O
duration O
of O
neutropenia O
. O
[]

Kawasaki O
disease O
is O
now O
the O
most O
common O
cause O
of O
acquired O
heart O
disease O
in O
America O
's O
children O
. O
[]

2.1% O
reported O
thinking O
they O
would O
be O
better O
off O
dead O
or O
of O
hurting O
themselves O
in O
some O
way O
in O
the O
past O
2 O
weeks. O
[]

BACKGROUND O
We O
examined O
the O
impact O
of O
prophylactic O
IABP O
insertion O
in O
EuroSCORE-stratified O
high-risk O
cardiac O
surgery O
patients O
with O
a O
score O
?8 O
. O
[]

Plasma O
level O
variations O
of O
TAM O
, O
N-desmethyl O
TAM O
and O
MPA O
were O
checked O
at O
various O
intervals O
on O
3 O
patients O
of O
group O
B O
, O
and O
confirmed O
that O
our O
schedule O
is O
able O
to O
produce O
a O
drug O
wash-out O
period O
for O
tumor O
cells O
. O
[]

Healthway O
provides O
sponsorships O
for O
the O
arts O
and O
racing O
and O
sporting O
events O
to O
replace O
funds O
previously O
provided O
by O
tobacco O
companies O
. O
[]

A O
study O
with O
non-invasive O
automated O
cardiac O
flow O
measurement O
by O
color O
Doppler O
echocardiography O
. O
[]

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
after I-outcome ['Physiological-Clinical']
tension-free I-outcome ['Physiological-Clinical']
repairs I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
primary I-outcome ['Physiological-Clinical']
direct I-outcome ['Physiological-Clinical']
inguinal I-outcome ['Physiological-Clinical']
hernias I-outcome ['Physiological-Clinical']
was O
7 O
% O
as O
compared O
with O
30 O
% O
after O
Cooper O
ligament O
repair O
( O
P O
= O
0.0081 O
) O
. O
['Physiological-Clinical']

The O
main O
intervention O
strategies O
were O
: O
information O
about O
the O
risk O
factor O
concept O
to O
participant O
and O
spouse O
( O
in O
groups O
) O
individual O
diet O
and O
anti-smoking O
counselling O
after O
finishing O
an O
extensive O
clinical O
and O
electrocardiographic O
examination O
, O
including O
exercise-ECG O
basis O
and O
background O
for O
the O
counselling O
strategy O
: O
the O
total O
situation O
of O
the O
participant O
. O
[]

More O
proven O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
occurred O
in O
flu O
( O
Aspergillus O
four O
, O
Candida O
tropicalis O
one O
, O
C. O
krusei O
one O
) O
than O
itra O
( O
C. O
albicans O
one O
) O
and O
more O
of O
these O
were O
fatal O
( O
four O
versus O
nil O
) O
. O
['Physiological-Clinical']

CONCLUSION O
Efforts O
to O
counsel O
women O
about O
their O
breast O
cancer O
risks O
are O
not O
likely O
to O
be O
effective O
unless O
their O
breast O
cancer O
anxieties O
are O
also O
addressed O
. O
[]

This O
earlier O
work O
suggested O
that O
cefotaxime O
might O
be O
more O
effective O
than O
cephamandole O
in O
preventing O
wound O
sepsis O
in O
emergency O
abdominal O
surgery O
. O
[]

Inherent O
stent O
related O
problems O
warrant O
a O
minimum O
possible O
duration O
of O
stenting O
without O
compromising O
the O
results O
of O
endopyelotomy O
. O
[]

Different O
prognostic O
factors O
and O
SLN O
tumor O
burden O
were O
recorded O
. O
[]

Anesthesia O
was O
standardized O
( O
laryngeal O
mask O
airway O
, O
fentanyl O
, O
propofol O
, O
sevoflurane O
, O
nitrous O
oxide O
, O
and O
oxygen O
) O
. O
[]

CONCLUSIONS O
AND O
IMPLICATIONS O
A O
theory-driven O
approach O
is O
valuable O
in O
improving O
behavior O
to O
promote O
bone O
health O
in O
this O
population O
. O
[]

We O
evaluated O
the O
efficacy O
of O
smokeless O
tobacco O
and O
group O
support O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
in O
an O
open O
, O
randomized O
study O
that O
compared O
smokeless O
tobacco O
plus O
group O
support O
versus O
group O
support O
only O
. O
['Life-Impact']

The O
MWT O
group O
had O
11 O
( O
range O
0-106 O
) O
outpatient B-outcome ['Resource-use']
treatment O
visits B-outcome ['Resource-use']
during O
the O
study O
versus O
4 O
( O
range O
0-47 O
) O
in O
the O
NPWT O
group O
( O
P O
< O
.05 O
) O
. O
['Resource-use', 'Resource-use']

C-telopeptide B-outcome ['Physiological-Clinical']
( O
A O
: O
40.7 O
% O
; O
B O
: O
34.1 O
% O
and O
C O
: O
38.5 O
% O
) O
; O
hydroxyproline B-outcome ['Resource-use']
( O
A O
: O
31.1 O
% O
; O
B O
: O
25.3 O
% O
and O
C O
: O
31.5 O
% O
) O
and O
osteocalcin B-outcome ['Physiological-Clinical']
( O
A O
: O
27.0 O
% O
; O
B O
: O
25.4 O
% O
and O
C O
: O
25.1 O
% O
) O
decreased O
similarly O
in O
the O
three O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

CONCLUSION O
In O
our O
study O
, O
the O
H2O2 O
mouth O
rinse O
does O
not O
provide O
a O
better O
analgesic B-outcome ['Resource-use']
effect O
than O
the O
water O
rinse O
for O
post-tonsillectomy B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Genotyping O
used O
Affymetrix B-outcome ['Resource-use']
arrays I-outcome ['Resource-use']
( O
Santa O
Clara O
, O
CA O
, O
USA O
) O
. O
['Resource-use']

Subjects O
wore O
removable O
palatal O
appliances O
with O
insets O
of O
human O
enamel O
containing O
demineralized O
subsurface O
lesions O
and O
chewed O
the O
gum O
for O
20 O
min O
4 O
times O
per O
day O
for O
14 O
days O
. O
[]

The O
first O
cohort O
included O
30 O
infants O
with O
DS O
( O
17 O
males O
, O
13 O
females O
; O
mean O
age O
10 O
mo O
[ O
SD O
1.9 O
mo O
] O
) O
who O
were O
randomly O
assigned O
to O
either O
a O
lower-intensity-generalized O
( O
LG O
) O
training O
group O
, O
or O
a O
higher-intensity-individualized O
( O
HI O
) O
training O
group O
. O
[]

Again O
, O
there O
was O
no O
main O
effect O
of O
condition O
on O
heat O
pain O
threshold O
( O
p O
= O
0.17 O
) O
, O
nor O
on O
cold O
pain O
threshold O
( O
p O
= O
0.65 O
) O
, O
nor O
on O
any O
of O
the O
secondary O
measures O
( O
p O
< O
0.56 O
for O
all O
) O
. O
[]

METHODS: O
A O
total O
of O
60 O
cases O
were O
recruited O
during O
August O
2016 O
and O
June O
2017 O
according O
to O
the O
inclusion O
and O
exclusion O
criteria. O
[]

CONCLUSION: O
The O
results O
of O
this O
study O
demonstrated O
that O
NES O
may O
help O
to O
relieve O
CINV O
in O
patients O
with O
AGC. O
[]

Clonidine O
improves O
the O
quality O
of O
spinal B-outcome ['Physiological-Clinical']
bupivacaine I-outcome ['Physiological-Clinical']
and O
ropivacaine B-outcome ['Resource-use']
, O
but O
in O
traditional O
doses O
( O
1-2 O
microg/kg O
) O
it O
produces O
systemic O
side O
effects O
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSIONS O
Depressive O
patients O
are O
able B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
follow I-outcome ['Life-Impact']
prescribed I-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
recommendations I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
short-term I-outcome ['Life-Impact']
. O
['Life-Impact']

Overall O
rectally O
administered O
midazolam O
appeared O
to O
be O
somewhat O
more O
efficacious O
than O
diazepam O
. O
[]

Publication O
date: O
2019/03/08 O
06:00 O
[medline] O
[]

We O
conclude O
that O
resource O
utilization O
was O
similar O
between O
treatment O
groups O
and O
that O
the O
choice O
of O
endoscopic O
therapy O
for O
EVH O
must O
still O
rely O
on O
clinical O
grounds O
. O
[]

The O
diagnosis O
of O
left O
ventricular O
thrombosis O
was O
based O
on O
the O
detection O
of O
an O
echo O
dense O
mass O
with O
defined O
margins O
visible O
throughout O
the O
cardiac O
cycle O
in O
at O
least O
two O
orthogonal O
views O
. O
[]

Rituximab O
plus O
intravenous O
bolus O
chemotherapy O
is O
a O
standard O
treatment O
for O
immunocompetent O
patients O
with O
B-cell O
non-Hodgkin O
lymphoma O
( O
NHL O
) O
. O
[]

Consequently O
, O
folate O
nutritional O
status O
may O
influence O
arsenic B-outcome ['Physiological-Clinical']
methylation I-outcome ['Physiological-Clinical']
and O
toxicity O
. O
['Physiological-Clinical']

Data O
collection O
consisted O
of O
a O
baseline O
and O
two O
annual O
follow-up O
surveys O
. O
[]

Both O
groups O
exercised O
for O
30 O
min O
at O
75-85 O
% O
age O
predicted O
maximum O
heart O
rate O
, O
3-4 O
times O
per O
week O
, O
for O
a O
total O
of O
18 O
sessions O
. O
[]

[ O
Tension-free O
laparoscopic O
versus O
open O
inguinal O
hernia O
repair O
] O
. O
[]

Furthermore O
, O
the O
change O
in O
the O
fasting O
level O
of O
total O
factor O
VII O
after O
therapy O
was O
not O
associated O
with O
the O
change O
in O
the O
fasting O
level O
of O
active O
factor O
VII O
( O
r O
= O
0.27 O
; O
P O
= O
0.21 O
) O
. O
[]

BACKGROUND O
Although O
moderate O
caffeine O
ingestion O
has O
not O
been O
shown O
to O
be O
arrhythmogenic O
, O
caffeine O
toxicity O
can O
cause O
severe O
cardiac O
arrhythmias O
, O
including O
atrial O
fibrillation O
and O
ventricular O
tachycardia O
. O
[]

There O
was O
only O
a O
suggestion O
that O
naltrexone O
reduced O
fidgety B-outcome ['Life-Impact']
and O
hyperactive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
tended O
to O
alleviate O
overall B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
older O
children O
. O
['Life-Impact', 'Life-Impact']

When O
comparing O
olanzapine O
with O
haloperidol O
, O
cost B-outcome ['Resource-use']
savings O
are O
seen O
throughout O
the O
treatment O
period O
( O
1 O
year O
) O
, O
with O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
most O
highly O
affected O
over O
time O
. O
['Resource-use', 'Life-Impact']

The O
purpose O
is O
to O
improve O
stone O
fragmentation O
and O
clearance O
rates O
. O
[]

Insecticide-treated O
bednets O
offer O
effective O
prevention O
, O
but O
it O
is O
unclear O
how O
well O
free O
bednet O
distribution O
programs O
reach O
young O
children O
. O
[]

Terbinafine O
is O
the O
current O
treatment O
of O
choice O
for O
toenail O
onychomycosis O
. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

METHODS O
Eighty O
patients O
suffering O
from O
pityriasis O
versicolor O
were O
randomly O
divided O
into O
two O
groups O
; O
one O
group O
were O
treated O
with O
2 O
% O
ketoconazole O
cream O
topically O
twice O
daily O
for O
2 O
weeks O
, O
adapalene O
gel O
was O
used O
for O
the O
other O
group O
in O
a O
similar O
fashion O
. O
[]

Impaired O
social O
interaction O
, O
communication O
and O
imaginative O
skills O
characterize O
autistic O
syndromes O
. O
[]

After O
12 O
weeks O
, O
the O
mean O
percent O
decrease O
in O
frequency O
of O
hot B-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
in O
the O
10 O
g/day O
group O
was O
12.9 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.15 O
) O
, O
the O
median O
percent O
decrease O
was O
11.7 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.05 O
) O
, O
and O
the O
proportion O
of O
women O
with O
at O
least O
a O
50 O
% O
reduction O
in O
hot B-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
was O
16.2 O
% O
greater O
than O
that O
in O
the O
placebo O
group O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Of O
households O
with O
untested O
wells O
, O
93 O
% O
in O
both O
intervention O
groups O
HE O
and O
HELM B-outcome ['Physiological-Clinical']
purchased I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
As I-outcome ['Physiological-Clinical']
test I-outcome ['Physiological-Clinical']
, O
whereas O
only O
53 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
The O
pain O
in O
sickle O
cell O
anemia O
( O
SCA O
) O
is O
often O
triggered O
by O
dehydration O
, O
acidosis O
, O
and O
fever O
that O
are O
usually O
due O
to O
malaria O
. O
[]

Addition O
or O
exclusion O
of O
PAF O
sperm O
treatment O
in O
the O
same O
patients O
did O
not O
significantly O
alter O
the O
outcome O
. O
[]

Muscle O
sampling O
occurred O
before O
, O
and O
after O
1 O
and O
5 O
d O
of O
treatment O
ingestion O
. O
[]

OBJECTIVE O
To O
observe O
the O
effects O
of O
electro-acupuncture O
on O
T O
cell B-outcome ['Physiological-Clinical']
subpopulations I-outcome ['Physiological-Clinical']
, O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
NK I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
humoral B-outcome ['Physiological-Clinical']
immunity I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
leukocyte I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
naproxen B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
2 O
h O
after O
ingestion O
and O
the O
Cmax O
were O
higher O
on O
the O
second O
occasion O
, O
regardless O
of O
preparation O
, O
suggesting O
that O
the O
subjects O
were O
clinically B-outcome ['Physiological-Clinical']
different O
on O
the O
two O
occasions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
impact O
of O
risperidone O
on O
adaptive O
behavior O
in O
children O
with O
autistic O
disorder O
who O
have O
serious O
behavior O
problems O
and O
to O
examine O
different O
methods O
of O
scoring O
the O
Vineland O
Adaptive O
Behavior O
Scales O
to O
measure O
change O
. O
[]

RESULTS O
In O
total O
, O
155 O
patients O
were O
randomized O
. O
[]

RESULTS O
Down O
syndrome O
children O
without O
Autism O
Spectrum O
Disorder O
had O
better O
communication B-outcome ['Life-Impact']
and O
socialization B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
than O
children O
with O
Down O
syndrome O
with O
Autism O
Spectrum O
Disorder O
. O
['Life-Impact', 'Life-Impact']

Once O
versus O
thrice O
daily O
gentamicin O
in O
patients O
with O
serious O
infections O
. O
[]

The O
goal O
was O
to O
assess O
if O
a O
16-wk O
nutrition O
plus O
CAST O
pilot O
study O
had O
stronger O
effects O
on O
reducing O
adiposity B-outcome ['Physiological-Clinical']
and O
on O
improving O
glucose/insulin B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
compared O
with O
control O
( O
C O
) O
, O
nutrition O
only O
( O
N O
) O
, O
and O
a O
nutrition O
plus O
strength O
training O
( O
N O
+ O
ST O
) O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
observable O
toxicity B-outcome ['Adverse-effects']
, O
but O
phenobarbitone O
recipients O
had O
a O
significant O
tendency O
to O
deepen O
in O
their O
level O
of O
coma B-outcome ['Physiological-Clinical']
or O
to O
become B-outcome ['Physiological-Clinical']
sleepy I-outcome ['Physiological-Clinical']
within O
the O
4 O
h O
after O
drug O
administration O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Pharmacogenetic O
markers O
related O
to O
drug O
metabolism O
and O
mechanisms O
of O
action O
could O
help O
to O
better O
select O
patients O
with O
metastatic O
colorectal O
cancer O
( O
mCRC O
) O
for O
treatment O
. O
[]

A O
randomized O
trial O
of O
continuous O
subcutaneous O
insulin O
infusion O
and O
intensive O
injection O
therapy O
in O
type O
1 O
diabetes O
for O
patients O
with O
long-standing O
poor O
glycemic O
control O
. O
[]

The O
Long-term O
Intervention O
with O
Pravastatin O
in O
Ischemic O
Heart O
Disease O
( O
LIPID O
) O
trial O
is O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
evaluating O
the O
long-term O
effect O
of O
pravastatin O
on O
coronary O
mortality O
in O
patients O
with O
a O
previous O
myocardial O
infarction O
or O
unstable O
angina-ischemic O
heart O
disease O
( O
IHD O
) O
. O
[]

MATERIAL O
AND O
METHOD O
One O
hundred O
women O
who O
gave O
birth O
vaginally O
with O
episiotomy O
and O
a O
second- O
or O
third-degree O
tear O
, O
were O
randomly O
assign O
to O
receive O
two O
tablets O
oftramadol O
50 O
mg O
or O
two O
tablets O
ofplacebo O
, O
the O
pill O
were O
physically O
similar O
to O
the O
real O
drug O
. O
[]

Of O
the O
37 O
patients O
who O
completed O
the O
trial O
16 O
out O
of O
19 O
( O
84 O
% O
) O
of O
the O
patients O
in O
the O
Grenz O
ray O
group O
, O
and O
13 O
out O
of O
18 O
( O
72 O
% O
) O
of O
the O
patients O
in O
the O
combination O
group O
healed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Following O
fluid O
administration O
, O
6 O
birds O
in O
the O
crystalloid O
group O
( O
66 O
% O
) O
, O
4 O
birds O
in O
the O
HES O
group O
( O
40 O
% O
) O
, O
and O
2 O
birds O
in O
the O
HBOCS O
group O
( O
20 O
% O
) O
died O
. O
[]

Sixty O
7x3 O
mm O
pressed O
ceramic O
discs O
of O
IPS O
e.max O
were O
fabricated O
and O
randomly O
assigned O
to O
six O
groups O
of O
different O
dentin O
surface O
treatments O
( O
control O
, O
desensitizer O
, O
disinfectant O
, O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
) O
. O
[]

The O
mean O
numbers O
of O
doses B-outcome ['Life-Impact']
of O
droperidol B-outcome ['Resource-use']
were O
0.8+/-0.9 O
and O
0.3+/-0.6 O
( O
P O
< O
.05 O
) O
, O
respectively O
. O
['Life-Impact', 'Resource-use']

RESULTS O
At O
week O
24 O
, O
both O
donepezil O
groups O
showed O
significant O
improvement O
in O
cognition B-outcome ['Life-Impact']
versus O
placebo O
on O
the O
Alzheimer B-outcome ['Life-Impact']
's O
Disease O
Assessment O
Scale-cognitive O
subscale O
( O
mean O
change O
from O
baseline O
score O
effect O
size O
: O
donepezil O
5 O
mg/d O
, O
-1.90 O
; O
P=0.001 O
; O
donepezil O
10 O
mg/d O
, O
-2.33 O
; O
P O
< O
0.001 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
this O
paper O
we O
report O
on O
individual O
and O
family-level O
factors O
associated O
with O
enrollment O
in O
a O
cancer O
prevention O
research O
project O
. O
[]

Non-linear O
mixed O
models O
were O
used O
to O
estimate O
the O
cumulative O
effect O
of O
H O
pylori O
clearance O
on O
histopathology B-outcome ['Physiological-Clinical']
scores O
adjusted O
for O
follow O
up O
time O
, O
interventions O
, O
and O
confounders O
. O
['Physiological-Clinical']

The O
lead O
system O
evaluated O
was O
a O
dual-coil O
transvenous O
defibrillation O
lead O
with O
a O
left O
pectoral O
pulse O
generator O
emulator O
. O
[]

In O
this O
population O
, O
amlodipine O
maleate O
was O
not O
inferior O
to O
amlodipine O
besylate O
: O
the O
lower O
limit O
of O
the O
2-sided O
95 O
% O
CI O
for O
the O
treatment O
difference O
in O
SiDBP B-outcome ['Physiological-Clinical']
was O
greater O
than O
-4 O
mm O
Hg O
. O
['Physiological-Clinical']

BACKGROUND O
Medication O
errors O
are O
an O
important O
public O
health O
concern O
, O
and O
poor O
understanding O
of O
medication O
labels O
are O
a O
root O
cause O
. O
[]

Hypertension B-outcome ['Physiological-Clinical']
following O
coronary O
artery O
bypass O
grafting O
is O
a O
common O
problem O
that O
may O
result O
in O
postoperative B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infraction I-outcome ['Physiological-Clinical']
or O
bleeding B-outcome ['Physiological-Clinical']
, O
Hemodynamic B-outcome ['Physiological-Clinical']
effects O
were O
compared O
in O
45 O
hypertensive O
coronary O
bypass O
patients O
randomized O
to O
receive O
either O
diltiazem O
, O
nitroglycerin O
, O
or O
sodium O
nitroprusside O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Anhedonia B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
lack I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
pleasure I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
was O
assessed O
as O
one O
of O
the O
core O
symptoms O
of O
major O
depression O
and O
chronic B-outcome ['Physiological-Clinical']
depression O
( O
dysthymia O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Title: O
A O
Feasibility O
RCT O
Evaluating O
a O
Play-Informed, O
Caregiver-Implemented, O
Home-Based O
Intervention O
to O
Improve O
the O
Play B-outcome ['Life-Impact']
of O
Children O
Who O
Are O
HIV O
Positive. O
[['Life-Impact']]

Although O
the O
differences O
in O
these O
three O
parameters O
were O
statistically O
significant O
, O
they O
were O
very O
small O
and O
are O
of O
no O
clinical O
importance O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

MATERIALS O
AND O
METHODS O
Three O
hundred O
consecutive O
patients O
scheduled O
for O
US-guided O
TPB O
were O
randomized O
1:1:1 O
to O
receive O
PI O
administration O
of O
5 O
g O
2.5 O
% O
lidocaine O
gel O
10 O
minutes O
before O
TPB O
( O
Group O
1 O
) O
, O
or O
a O
mixture O
of O
5 O
g O
2.5 O
% O
lidocaine O
gel O
and O
0.3 O
% O
ketorolac O
tromethamine O
solution O
1 O
hour O
before O
TPB O
( O
Group O
2 O
) O
, O
or O
5 O
g O
2.5 O
% O
lidocaine O
and O
2.5 O
% O
prilocaine O
cream O
20 O
minutes O
before O
TPB O
( O
Group O
3 O
) O
. O
[]

RESULTS O
In O
children O
and O
adolescents O
( O
n=10 O
) O
, O
mean O
age O
of O
12.5 O
years O
, O
prolactin B-outcome ['Physiological-Clinical']
increased O
from O
mean O
13.2+/-8.6 O
at O
baseline O
to O
31.0+/-11.6 O
acutely O
and O
remained O
elevated O
at O
37.9+/-10.4 O
in O
maintenance O
. O
['Physiological-Clinical']

Compared O
with O
the O
control O
condition O
, O
the O
intervention O
was O
associated O
with O
a O
significant O
increase O
in O
support O
person B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
to O
help O
their O
smoker B-outcome ['Life-Impact']
( O
p O
= O
.034 O
) O
and O
outcome O
expectancies B-outcome ['Life-Impact']
( O
p O
= O
.025 O
) O
from O
baseline O
to O
week O
6 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
an O
attempt O
to O
develop O
a O
brief O
treatment O
for O
disaster O
survivors O
, O
the O
present O
study O
examined O
the O
effectiveness O
of O
a O
single O
session O
of O
modified O
behavioral O
treatment O
in O
earthquake-related O
posttraumatic O
stress O
disorder O
. O
[]

Thirty-six O
patients O
also O
received O
CNS O
irradiation O
. O
[]

There O
were O
intervals O
of O
4 O
weeks O
without O
medication O
between O
the O
treatment O
periods O
. O
[]

Interferon O
treatment O
for O
hairy B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Safety O
and O
tolerability B-outcome ['Life-Impact']
were O
satisfactory O
throughout O
the O
study O
. O
['Life-Impact']

The O
effectiveness O
of O
educational O
interventions O
to O
enhance O
the O
adoption O
of O
fee-based O
arsenic O
testing O
in O
Bangladesh O
: O
a O
cluster O
randomized O
controlled O
trial O
. O
[]

Phase O
III O
, O
randomized O
, O
open-label O
study O
of O
daily O
imatinib O
mesylate O
400 O
mg O
versus O
800 O
mg O
in O
patients O
with O
newly O
diagnosed O
, O
previously O
untreated O
chronic O
myeloid O
leukemia O
in O
chronic O
phase O
using O
molecular O
end O
points O
: O
tyrosine O
kinase O
inhibitor O
optimization O
and O
selectivity O
study O
. O
[]

CONCLUSION O
The O
results O
suggest O
that O
12 O
g O
RDN O
kg?? O
DOMI O
or O
19 O
g O
RDN O
kg?? O
DOMR O
may O
be O
adequate O
for O
optimum O
MPS O
, O
NCE O
and O
digestibility O
of O
nutrients O
in O
sheep O
fed O
on O
an O
FMS-based O
diet O
. O
[]

Statistical O
analysis O
was O
performed O
with O
ANOVA O
. O
[]

CONCLUSION O
Skills O
acquired O
using O
the O
AccuTouch O
simulator O
transfer O
well O
into O
the O
clinical O
colonoscopy O
environment O
. O
[]

OBJECTIVES O
To O
conduct O
an O
adequately O
powered O
trial O
of O
a O
home-based O
exercise O
intervention O
that O
can O
be O
facilely O
integrated O
into O
established O
delivery O
and O
reimbursement O
structures O
. O
[]

TRIAL O
REGISTRATION: O
The O
project O
is O
approved O
by O
Iranian O
Registry O
of O
Clinical O
Trial O
with O
no. O
[]

Adverse O
reactions O
forced O
trial O
termination O
in O
six O
patients O
and O
dose O
reduction O
in O
another O
eight O
, O
and O
consisted O
mainly O
of O
drowsiness B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
anticholinergic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
CER O
group O
had O
three O
times O
more O
cardiac B-outcome ['Physiological-Clinical']
diagnoses B-outcome ['Physiological-Clinical']
than O
the O
UC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Complete-case, O
per-protocol, O
and O
sensitivity O
analyses O
supported O
this O
result. O
[]

Results O
are O
presented O
as O
mean O
scores O
with O
standard O
deviations O
or O
95 O
% O
confidence O
intervals O
( O
CI O
) O
in O
parentheses O
. O
[]

Patients O
were O
randomly O
assigned O
to O
one O
of O
two O
treatment O
groups O
: O
of O
treatment O
group O
A O
: O
Alpha O
dihidroergocriptine O
tablets O
of O
10 O
mg O
, O
group O
B O
: O
Placebo O
, O
during O
6 O
months O
. O
[]

METHODS/DESIGN O
A O
total O
of O
210 O
participants O
with O
low O
back O
pain O
lasting O
at O
least O
3 O
months O
will O
be O
recruited O
from O
primary O
care O
clinics O
of O
a O
large O
healthcare O
system O
based O
in O
Seattle O
. O
[]

Rapid O
sequential O
intravenous O
infusions O
of O
human O
corticotrophin O
releasing O
factor O
100 O
micrograms O
, O
growth O
hormone O
releasing O
factor O
100 O
micrograms O
, O
luteinising O
hormone O
releasing O
hormone O
100 O
micrograms O
, O
and O
thyrotrophin O
releasing O
hormone O
200 O
micrograms O
were O
administered O
. O
[]

One O
event O
, O
mild O
knee O
pruritus O
, O
was O
considered O
probably O
related O
. O
[]

Peak O
N-acetylcysteine B-outcome ['Physiological-Clinical']
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Intravenous O
levosimendan O
treatment O
is O
cost-effective O
compared O
with O
dobutamine O
in O
severe O
low-output O
heart O
failure O
: O
an O
analysis O
based O
on O
the O
international O
LIDO O
trial O
. O
[]

Depressive O
mood O
symptoms O
associated O
with O
ovarian O
suppression O
. O
[]

This O
study O
evaluated O
a O
tailored O
intervention O
to O
promote O
sun O
protection O
in O
parents O
and O
their O
children O
, O
hypothesizing O
that O
the O
tailored O
intervention O
would O
lead O
to O
improved O
skin B-outcome ['Life-Impact']
cancer I-outcome ['Life-Impact']
prevention I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
compared O
to O
generic O
materials O
. O
['Life-Impact']

RESULTS O
The O
RV O
pacing O
contributed O
to O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
end-systolic I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
LV B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
compared O
to O
BiV O
pacing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pretreatment O
with O
HFLCS O
did O
not O
cause O
a O
statistically O
significant O
change O
in O
the O
shear O
bond O
values O
of O
either O
metal O
or O
ceramic O
brackets O
( O
P O
= O
0.38 O
) O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Variables O
of O
interest O
were O
resting B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( O
RMT B-outcome ['Physiological-Clinical']
) O
, O
short-interval B-outcome ['Physiological-Clinical']
intra-cortical I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SICI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
intracortical B-outcome ['Physiological-Clinical']
facilitation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
cortical B-outcome ['Physiological-Clinical']
silent I-outcome ['Physiological-Clinical']
period O
( O
CSP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Four-mm-thick O
buildups O
were O
built O
on O
the O
adhesives O
, O
then O
specimens O
were O
sectioned O
in O
accordance O
with O
the O
nontrimming O
technique O
. O
[]

RESULTS O
Both O
groups O
incurred O
similar O
costs O
during O
the O
2-year O
study O
period O
, O
with O
a O
trend O
for O
clozapine O
to O
be O
less O
costly O
than O
usual O
care O
in O
the O
second O
study O
year O
. O
[]

RESULTS O
Intranasal O
oxytocin O
enabled O
the O
participants O
to O
make O
NVJs B-outcome ['Physiological-Clinical']
more O
frequently O
( O
P O
= O
.03 O
) O
with O
shorter O
response O
time O
( O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

This O
score O
and O
Blatt-Kuperman O
were O
recorded O
and O
performed O
in O
every O
control O
. O
[]

It O
is O
not O
, O
however O
, O
clear O
whether O
the O
treatment O
should O
be O
started O
with O
a O
high O
or O
a O
low O
dose O
of O
the O
inhaled O
steroid O
. O
[]

Secondary O
end O
points O
were O
change O
from O
baseline O
in O
sitting O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
SiSBP O
) O
at O
week O
8 O
in O
the O
total O
population O
and O
in O
the O
subgroup O
of O
patients O
who O
had O
previously O
received O
antihypertensive O
treatment O
versus O
those O
who O
had O
not O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
groups O
with O
respect O
to O
the O
persistence O
of O
cutaneous B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
after O
starting O
treatment O
; O
the O
mean O
durations O
were O
10.5 O
days O
in O
the O
penicillin O
group O
, O
8.8 O
days O
in O
the O
doxycycline O
group O
and O
8.6 O
days O
in O
the O
azithromycin O
group O
. O
['Physiological-Clinical']

Conclusion: O
The O
approach O
in O
both O
selecting O
the O
patients O
participating O
in O
the O
study O
and O
analyzing O
the O
data O
in O
this O
randomized O
clinical O
trial O
allows O
us O
to O
conclude O
that O
cryotherapy O
is O
an O
aid O
of O
clinical O
procedures O
to O
clean O
and O
shape O
the O
canals O
to O
reduce O
the O
occurrence O
of O
postendodontic O
pain B-outcome ['Physiological-Clinical']
and O
the O
need B-outcome ['Resource-use']
for O
medication O
in O
patients O
presenting O
with O
a O
diagnosis O
of O
vital O
pulp. O
[['Physiological-Clinical'], ['Resource-use']]

CONCLUSION O
Our O
data O
indicate O
that O
functional O
endoscopic O
sinus O
surgery O
, O
combined O
with O
appropriate O
postoperative O
care O
, O
is O
effective O
at O
maintaining O
a O
significant O
improvement O
in O
the O
overall O
general O
health O
status O
of O
patients O
for O
at O
least O
3 O
years O
after O
surgical O
intervention O
and O
that O
the O
overall O
scores O
return O
to O
a O
range O
of O
normative O
values O
for O
the O
general O
population O
. O
[]

Prospective O
randomized O
trials O
seem O
warranted O
to O
determine O
the O
optimum O
antibiotic O
prophylaxis O
regimen O
in O
patients O
undergoing O
biopsy O
with O
a O
periprostatic O
nerve O
block O
. O
[]

Antiinflammatory B-outcome ['Physiological-Clinical']
effects O
of O
the O
phosphodiesterase-4 O
inhibitor O
cilomilast O
( O
Ariflo O
) O
in O
chronic O
obstructive O
pulmonary O
disease O
. O
['Physiological-Clinical']

For O
all O
analyses O
, O
differences O
were O
considered O
to O
be O
significant O
at O
P O
< O
0.05 O
. O
[]

diltiazem O
in O
the O
management O
of O
atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHOD O
In O
this O
study O
, O
97 O
patients O
aged O
6 O
to O
17 O
years O
with O
ADHD O
and O
ASD O
were O
randomly O
assigned O
to O
double-blind O
treatment O
with O
1.2 O
mg/kg/day O
atomoxetine O
or O
placebo O
for O
8 O
weeks O
. O
[]

However O
, O
not O
all O
brain O
regions O
affected O
by O
nicotine O
are O
known O
to O
have O
many O
nicotinic O
cholinoceptors O
. O
[]

A O
study O
to O
evaluate O
safety O
and O
tolerability B-outcome ['Life-Impact']
of O
repeated O
doses O
of O
tirasemtiv O
in O
patients O
with O
amyotrophic O
lateral O
sclerosis O
. O
['Life-Impact']

RESULTS O
After O
controlling O
for O
body O
weight O
, O
there O
was O
a O
significant O
effect O
of O
time O
on O
fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0177 O
) O
and O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.0386 O
) O
concentrations O
, O
and O
on O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0413 O
) O
, O
with O
reductions O
in O
these O
variables O
occurring O
over O
time O
; O
there O
was O
no O
time-by-diet O
interaction O
for O
any O
of O
the O
parameters O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/11/06 O
00:00 O
[accepted] O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

RESULTS O
Patients O
taking O
pentoxifylline O
had O
less O
pain B-outcome ['Physiological-Clinical']
and O
reported O
smaller O
and O
fewer O
['Physiological-Clinical']

The O
mean O
NRS O
pain B-outcome ['Physiological-Clinical']
score O
before O
the O
most O
recent O
dose O
of O
pain O
medication O
after O
ED O
discharge O
was O
7.6 O
NRS O
units O
for O
both O
groups O
. O
['Physiological-Clinical']

Rates O
of O
extrapyramidal O
disorder O
and O
drooling O
, O
but O
not O
akathisia O
or O
tremor O
, O
were O
marginally O
higher O
in O
AN O
subjects O
. O
[]

The O
aims O
of O
this O
study O
were O
to O
examine O
in O
a O
randomised O
, O
double-blind O
fashion O
, O
the O
possible O
interaction O
between O
cyclosporin O
A O
and O
ticlopidine O
( O
250 O
mg O
per O
day O
) O
and O
the O
tolerability O
of O
this O
combination O
in O
heart-transplant O
recipients O
. O
[]

17 O
beta-Oestradiol O
( O
9 O
mg O
) O
or O
progesterone O
( O
300 O
mg O
) O
were O
given O
before O
the O
second O
test O
, O
after O
a O
first O
test O
with O
placebo O
. O
[]

METHOD O
. O
[]

Title: O
Mindfulness O
mechanisms O
and O
psychological B-outcome ['Life-Impact']
effects O
for O
aMCI O
patients: O
A O
comparison O
with O
psychoeducation. O
[['Life-Impact']]

Major B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
nonmajor I-outcome ['Physiological-Clinical']
clinically I-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
occurred O
in O
1475 O
patients O
in O
the O
rivaroxaban O
group O
( O
14.9 O
% O
per O
year O
) O
and O
in O
1449 O
in O
the O
warfarin O
group O
( O
14.5 O
% O
per O
year O
) O
( O
hazard O
ratio O
, O
1.03 O
; O
95 O
% O
CI O
, O
0.96 O
to O
1.11 O
; O
P=0.44 O
) O
, O
with O
significant O
reductions O
in O
intracranial B-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
( O
0.5 O
% O
vs. O
0.7 O
% O
, O
P=0.02 O
) O
and O
fatal B-outcome ['Mortality']
bleeding I-outcome ['Mortality']
( O
0.2 O
% O
vs. O
0.5 O
% O
, O
P=0.003 O
) O
in O
the O
rivaroxaban O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Randomisation O
implies O
an O
intention O
to O
treat O
the O
patient O
by O
the O
assigned O
procedure O
and O
the O
analysis O
of O
long O
term O
results O
will O
include O
all O
randomised O
cases O
. O
[]

Yet O
, O
sleep O
withdrawal O
even O
if O
only O
partial O
, O
has O
a O
negative O
influence O
on O
performance O
, O
particularly O
when O
the O
type O
of O
exercise O
requires O
good O
psychomotor O
performance O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
intake O
of O
a O
hypnotic O
drug O
would O
have O
negative O
effects O
on O
physical O
performance O
capacity O
. O
[]

A O
controlled O
comparison O
between O
single O
doses O
of O
intravenous O
and O
intramuscular O
morphine O
with O
respect O
to O
analgesic B-outcome ['Resource-use']
effects O
and O
patient O
safety O
. O
['Resource-use']

For O
them O
the O
sound-producing O
voice O
prosthesis O
improves B-outcome ['Physiological-Clinical']
voice I-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
and O
increases O
the O
average O
pitch B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
voice I-outcome ['Physiological-Clinical']
, O
without O
decreasing O
intelligibility O
or O
necessitating B-outcome ['Physiological-Clinical']
other O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Use O
of O
Interceed O
( O
TC7 O
) O
absorbable O
adhesion O
barrier O
to O
reduce O
postoperative B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
reformation I-outcome ['Physiological-Clinical']
in O
infertility O
and O
endometriosis O
surgery O
. O
['Physiological-Clinical']

Journal O
ID: O
7501160 O
[]

RESULTS O
Acupuncture O
compared O
with O
oral O
care O
, O
produced O
significant O
reductions O
in O
patient O
reports O
of O
severe B-outcome ['Physiological-Clinical']
dry I-outcome ['Physiological-Clinical']
mouth B-outcome ['Physiological-Clinical']
( O
OR O
= O
2.01 O
, O
P O
= O
0.031 O
) O
sticky B-outcome ['Physiological-Clinical']
saliva I-outcome ['Physiological-Clinical']
( O
OR O
= O
1.67 O
, O
P O
= O
0.048 O
) O
, O
needing B-outcome ['Physiological-Clinical']
to O
sip B-outcome ['Physiological-Clinical']
fluids I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
nested O
case-control O
study O
, O
the O
somatotropic O
axis O
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
glucagon B-outcome ['Physiological-Clinical']
were O
analyzed O
before O
and O
after O
hypoglycemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
the O
patients O
developing O
acute O
toxicity O
, O
no O
difference O
between O
the O
two O
fractionation O
groups O
was O
found O
in O
either O
severity O
or O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
or O
genitourinary B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
ad O
hoc O
analysis O
of O
all O
available O
data O
is O
reported O
here O
. O
[]

At O
week O
24 O
, O
the O
medication O
was O
gradually O
withdrawn O
to O
determine O
whether O
subjects O
in O
the O
combined O
treatment O
group O
could O
be O
managed O
on O
a O
lower O
dose O
or O
off O
medication O
without O
relapse O
. O
[]

Cross O
sectionally O
, O
the O
scores O
of O
the O
two O
questionnaires O
were O
moderately O
to O
highly O
correlated O
( O
coefficients O
ranged O
from O
0.35 O
to O
0.72 O
) O
. O
[]

The O
school-age O
SCRPA O
curriculum O
( O
ages O
6-14 O
) O
consisted O
of O
eight O
90-minute O
classes O
for O
both O
child O
and O
parent O
( O
s O
) O
scheduled O
twice O
a O
week O
for O
4 O
weeks O
. O
[]

The O
results O
of O
our O
pilot O
study O
suggested O
that O
a O
dose O
of O
5000 O
IU O
administered O
intramuscularly O
three O
times O
per O
week O
for O
four O
weeks O
was O
more O
effective O
than O
the O
lower O
doses O
given O
in O
past O
trials O
. O
[]

Care O
managers O
received O
supervision O
from O
a O
psychiatrist O
. O
[]

The O
hypothesis O
was O
that O
, O
although O
the O
concentration O
of O
bupivacaine O
( O
0.1 O
% O
) O
was O
low O
to O
minimize O
its O
adverse O
effects O
, O
if O
the O
infusion O
rate O
of O
a O
fentanyl/bupivacaine O
solution O
was O
closely O
adjusted O
according O
to O
need O
, O
the O
presence O
bupivacaine O
would O
reduce O
the O
requirement O
for O
epidural O
fentanyl O
. O
[]

No O
clinically O
significant O
changes O
were O
found O
on O
the O
lab O
tests O
. O
[]

These O
data O
suggest O
the O
effectiveness O
of O
interferon O
given O
as O
induction O
and O
as O
maintenance O
treatment O
in O
the O
therapy O
of O
II O
type O
mixed O
essential O
cryoglobulinemia O
. O
[]

A O
single O
independent O
physiotherapist O
, O
who O
was O
blinded O
to O
the O
treatment O
groups O
, O
made O
all O
assessments O
. O
[]

CONCLUSION O
Combinative O
assessment O
of O
MSCT O
and O
SAA O
could O
improve O
the O
accuracy O
of O
preoperative O
staging O
, O
and O
thus O
provide O
higher O
predictive O
coincidence O
rate O
of O
operative O
procedures O
. O
[]

Resource O
utilization O
and O
economic O
costs O
of O
care O
based O
on O
a O
randomized O
trial O
of O
vacuum-assisted O
closure O
therapy O
in O
the O
treatment O
of O
diabetic O
foot O
wounds O
. O
[]

The O
addition O
of O
MTP O
to O
chemotherapy O
improved O
6-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
from O
70 O
% O
to O
78 O
% O
( O
P O
= O
.03 O
) O
. O
['Mortality']

The O
experimental O
group O
received O
7 O
weeks O
wheelchair O
training O
( O
3 O
week O
( O
-1 O
) O
, O
70 O
min O
) O
at O
a O
low O
intensity O
( O
30 O
% O
of O
the O
heart O
rate O
reserve O
) O
, O
whereas O
the O
control O
group O
did O
not O
receive O
training O
. O
[]

Participants O
were O
assigned O
to O
receive O
3 O
weeks O
of O
oral O
dosing O
with O
placebo O
or O
fluoxetine O
, O
40 O
mg O
per O
day O
. O
[]

Intravenous O
adenosine O
in O
normal O
humans O
induces O
counterirritation O
, O
fueling O
the O
notion O
that O
C-fiber O
stimulation O
trigger O
DNICs O
in O
humans O
. O
[]

The O
primary O
clinical O
outcome O
was O
the O
variation O
in O
thirst B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
evaluated O
by O
the O
Numeral O
Verbal O
Scale], O
and O
the O
secondary, O
the O
variation O
of O
the O
discomfort B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
thirst I-outcome ['Physiological-Clinical']
, O
evaluated O
by O
the O
Perioperative O
Thirst B-outcome ['Physiological-Clinical']
Discomfort I-outcome ['Physiological-Clinical']
Scale]. O
Mann-Whitney O
test O
was O
used O
to O
compare O
measures O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Supplementing O
beef O
cows O
with O
whole O
corn O
germ O
had O
no O
effect O
on O
cow O
performance O
, O
calf O
performance O
, O
or O
serum O
leptin O
concentrations O
of O
cows O
. O
[]

Separate O
linear O
regressions O
were O
conducted O
for O
each O
standardized O
and O
observational O
measure O
at O
each O
time O
point O
. O
[]

Of O
the O
202 O
patients O
randomized O
to O
placebo O
, O
162 O
reached O
the O
add-on O
and O
only O
12 O
the O
monotherapy O
phase O
. O
[]

Comparison O
of O
laser O
photocoagulation O
for O
diabetic O
retinopathy O
using O
532-nm O
standard O
laser O
versus O
multispot O
pattern O
scan O
laser O
. O
[]

infusion O
of O
Ringer O
's O
solution O
25 O
ml O
kg-1 O
over O
30 O
min O
in O
15 O
healthy O
male O
volunteers O
( O
mean O
age O
31 O
yr O
) O
and O
over O
30 O
, O
45 O
and O
80 O
min O
in O
six O
females O
( O
mean O
age O
32 O
yr O
) O
. O
[]

Further O
investigation O
would O
be O
required O
to O
confirm O
this O
effect O
and O
its O
mechanism O
and O
the O
genotype O
prediction O
of O
effects O
on O
dosing. O
[]

Standard O
12-lead O
electrocardiograms O
were O
recorded O
at O
baseline O
and O
during O
treatment O
. O
[]

The O
patients O
were O
randomly O
assigned O
to O
receive O
oral O
EHDP O
5 O
mg/kg/d O
or O
placebo O
until O
death O
or O
discontinuation O
due O
to O
intolerance O
or O
refusal O
. O
[]

Adjuvant O
therapy O
of O
breast O
cancer O
: O
the O
Southwest O
Oncology O
Group O
experience O
. O
[]

Journal-Name:Journal O
of O
ovarian O
research O
[]

Journal-Name:Journal O
of O
clinical O
psychopharmacology O
[]

People O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
show O
reduced O
interest O
towards O
social O
aspects O
of O
the O
environment O
and O
a O
lesser O
tendency O
to O
follow O
other O
people O
's O
gaze B-outcome ['Physiological-Clinical']
in O
the O
real O
world O
. O
['Physiological-Clinical']

At O
week O
24 O
, O
intent-to-treat O
: O
exposed O
( O
missing O
= O
failure O
) O
analyses O
showed O
no O
statistically O
significant O
differences O
in O
the O
percentage O
of O
patients O
with O
HIV-1 B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
< O
400 O
copies/mL O
( O
95 O
% O
[ O
QD O
] O
vs. O
90 O
% O
[ O
BID O
] O
) O
or O
< O
50 O
copies/mL O
( O
82 O
% O
[ O
QD O
] O
vs. O
81 O
% O
[ O
BID O
] O
) O
or O
in O
the O
median O
change O
from O
baseline O
in O
CD4 B-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
( O
+42 O
cells/mm O
( O
3 O
) O
[ O
QD O
] O
vs. O
+22 O
cells/mm O
( O
3 O
) O
[ O
BID O
] O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Between O
2001 O
and O
2005 O
, O
749 O
women O
aged O
55-75 O
years O
with O
infiltrating O
breast O
carcinoma O
were O
randomly O
assigned O
to O
breast O
conservative O
surgery O
, O
with O
or O
without O
radiotherapy O
( O
RT O
) O
, O
to O
evaluate O
the O
incidence O
of O
in-breast B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IBR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treadmill O
exercise O
testing O
with O
measurement O
of O
expired B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
and O
respiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
performed O
before O
ablation O
and O
4 O
weeks O
after O
pacemaker O
implantation O
, O
with O
the O
pacemaker O
programmed O
to O
both O
the O
fixed-rate O
VVI O
and O
rate-modulating O
minute O
ventilation O
VVIR O
pacing O
modes O
in O
random O
sequence O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Respiratory O
mechanical O
indices O
[ O
peak B-outcome ['Physiological-Clinical']
airway I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(Ppeak) I-outcome ['Physiological-Clinical']
, O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(VTi) I-outcome ['Physiological-Clinical']
, O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(VTe) I-outcome ['Physiological-Clinical']
were O
recorded O
before O
atomization O
(atomized O
oxygen O
flow O
was O
0) O
and O
10 O
minutes O
after O
the O
beginning O
of O
atomization O
under O
the O
condition O
of O
7 O
L/min O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow O
respectively. O
( O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
implantation B-outcome ['Physiological-Clinical']
rate O
and O
per-cycle O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate O
were O
significantly O
higher O
in O
PRP O
group O
(p O
= O
0.002 O
and O
0.044, O
respectively O
(p O
= O
0.002). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Effect O
of O
mild O
endurance O
exercise O
training O
and O
pravastatin O
on O
peripheral O
vasodilatation O
of O
forearm O
resistance O
vessels O
in O
patients O
with O
coronary O
artery O
disease O
. O
[]

Prevention O
of O
body O
posture O
abnormalities O
is O
worth O
promoting O
in O
groups O
of O
children, O
also O
with O
various O
diseases O
including O
asthma O
and O
allergies O
symptoms. O
[]

Quantitative O
side O
effects O
questionnaire O
scores O
were O
used O
to O
guide O
disopyramide O
administration O
in O
20 O
men O
with O
ventricular O
tachycardia O
. O
[]

Mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
compared O
on O
ICU O
admission O
and O
at O
12-hr O
intervals O
. O
['Physiological-Clinical']

Our O
primary O
aim O
was O
to O
examine O
in O
a O
randomized O
controlled O
setting O
whether O
diets O
enriched O
in O
fatty O
fish O
(FF), O
lean O
fish O
(LF) O
or O
ALA-rich O
camelina O
sativa O
oil O
(CSO) O
differ O
in O
their O
effects O
on O
the O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
response O
of O
selected O
inflammation-related O
genes O
in O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
and O
subcutaneous O
adipose O
tissue O
(SAT) O
in O
subjects O
with O
impaired O
fasting O
glucose. O
[['Physiological-Clinical']]

Bisphosphonates O
are O
used O
in O
oncology O
as O
a O
means O
of O
decreasing O
complications O
due O
to O
bone O
metastases O
, O
in O
association O
with O
anticancer O
treatment O
, O
especially O
in O
patients O
with O
breast O
cancer O
, O
prostate O
cancer O
and O
myeloma O
. O
[]

During O
the O
paromomycin O
treatment O
phase O
, O
oocyst B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
decreased O
from O
314 O
x O
10 O
( O
6 O
) O
to O
109 O
x O
10 O
( O
6 O
) O
24 O
h O
( O
P O
< O
.02 O
) O
. O
['Physiological-Clinical']

Oxytocin O
increases O
retention O
of O
social B-outcome ['Life-Impact']
cognition I-outcome ['Life-Impact']
in O
autism O
. O
['Life-Impact']

Medical O
oncology O
represented O
the O
largest O
recruitment O
group O
( O
45.3 O
% O
) O
, O
followed O
by O
stem O
cell O
transplant O
( O
34.5 O
% O
) O
and O
radiation O
oncology O
( O
20.2 O
% O
) O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
in O
vitro O
study O
was O
to O
evaluate O
the O
microleakage O
in O
occlusal B-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
, O
after O
preparation O
with O
Er O
: O
YAG O
laser O
and O
compared O
to O
the O
diamond-bur O
conventional O
technique O
. O
['Physiological-Clinical']

DESIGN O
Subjects O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

Participants O
were O
divided O
into O
groups O
that O
received O
16 O
weeks O
of O
either O
usual O
care O
or O
exercise O
intervention. O
[]

Results O
suggest O
GAS O
descriptions O
can O
be O
evaluated O
for O
equivalency O
, O
that O
teacher O
collected O
behavior O
samples O
are O
representative O
, O
and O
that O
varied O
sources O
of O
behavior O
samples O
can O
be O
reliably O
coded O
. O
[]

In O
particular O
, O
type O
3 O
Anthonisens B-outcome ['Physiological-Clinical']
's O
exacerbations B-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
by O
flunisolide O
( O
p O
= O
0.044 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Compared O
with O
40 O
patients O
of O
the O
control O
group O
after O
the O
six O
months O
of O
the O
auditory O
integrative O
training O
, O
41 O
of O
the O
experimental O
group O
had O
greatly O
improved O
in O
many O
aspects O
, O
such O
as O
the O
disorders B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
their I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
typical I-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
while O
they O
had O
not O
changed O
in O
their O
abnormal B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

VAS O
scores O
decreased O
significantly O
compared O
to O
the O
baseline O
measurements O
in O
all O
groups O
. O
[]

METHODS O
Patients O
were O
randomly O
assigned O
to O
undergo O
sphincterotomy O
over O
a O
non-conductive O
guidewire O
with O
30 O
W/sec O
pure-cut O
current O
or O
30 O
W/sec O
blend-2 O
current O
by O
a O
blinded O
endoscopist O
. O
[]

Alternative O
voice O
after O
laryngectomy O
using O
a O
sound-producing O
voice O
prosthesis O
. O
[]

PMID: O
31618328 O
[]

In O
conclusion O
, O
we O
investigated O
SNP-diet B-outcome ['Physiological-Clinical']
interactions I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

CONCLUSION O
Prefabricated O
wrist O
working O
splints O
are O
highly O
effective O
in O
reducing O
wrist O
pain O
after O
4 O
weeks O
of O
splint O
wearing O
in O
RA O
patients O
with O
wrist O
arthritis O
. O
[]

Other O
studies O
found O
that O
there O
is O
an O
aerobic O
( O
in O
the O
gastrointestinal O
tract O
) O
oxidation O
of O
ferrous O
ion O
to O
ferric O
ion O
caused O
in O
iron-paracetamol O
in O
vivo O
reactions O
. O
[]

Long-term O
therapy O
had O
no O
effect O
on O
the O
concentration O
of O
total O
, O
free B-outcome ['Physiological-Clinical']
and O
complex B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
, O
testosterone B-outcome ['Physiological-Clinical']
( O
total O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Reductions O
in O
BMI B-outcome ['Physiological-Clinical']
were O
observed O
in O
both O
groups O
at O
T2 O
( O
P O
< O
0.05 O
) O
, O
but O
only O
group O
C O
exhibited O
a O
reduction O
in O
WC B-outcome ['Physiological-Clinical']
( O
P O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Heart O
Outcomes O
Prevention O
Evaluation O
( O
HOPE O
) O
study O
was O
important O
because O
it O
showed O
the O
benefits O
of O
ramipril O
- O
an O
angiotensin-converting O
enzyme O
( O
ACE O
) O
inhibitor O
- O
in O
patients O
at O
high O
risk O
for O
cardiovascular O
events O
. O
[]

Students O
spent O
an O
average O
of O
59.1 O
minutes O
per O
week O
outdoors O
while O
attending O
school O
and O
35.5 O
minutes O
during O
peak O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
. O
['Life-Impact']

i.v O
. O
[]

Thirty-one O
, O
25 O
, O
and O
26 O
% O
more O
HS-60 O
heifers O
were O
pubertal O
( O
P O
< O
0.05 O
) O
on O
May O
1 O
compared O
with O
LS-30 O
, O
HS-30 O
, O
and O
control O
heifers O
, O
respectively O
. O
[]

The O
space-analysis O
showed O
excessive O
dental-arch B-outcome ['Physiological-Clinical']
space I-outcome ['Physiological-Clinical']
in O
patients O
with O
a O
palatally-displaced O
canine O
. O
['Physiological-Clinical']

RESULTS O
Children O
took O
more O
steps O
during O
school O
days O
( O
5169 O
steps O
, O
SD O
1641 O
) O
than O
during O
weekend O
days O
( O
4158 O
steps O
, O
SD O
2048 O
; O
p O
< O
0.001 O
) O
. O
[]

Intracellular B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
IL-8 I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNF-R I-outcome ['Physiological-Clinical']
levels O
were O
also O
increased O
after O
ILP O
with O
TNF/IFN/M O
. O
['Physiological-Clinical']

All O
patients O
had O
typical O
grass O
pollen O
hay O
fever O
, O
in O
27 O
% O
associated O
with O
grass O
pollen O
asthma O
and O
in O
13 O
% O
with O
birch O
pollen O
allergy O
. O
[]

BACKGROUND O
Limitations O
of O
the O
surgical O
correction O
for O
myopia O
include O
inaccuracy O
, O
instability O
, O
treatment O
of O
the O
central O
optical O
zone O
, O
and O
lack O
of O
reversibility O
. O
[]

Prospective O
randomized O
controlled O
trial O
to O
evaluate O
fast-track O
elective O
open O
infrarenal O
aneurysm O
repair O
. O
[]

CONCLUSIONS O
Erythromycin O
is O
effective O
in O
significantly O
reducing O
lost O
time O
from O
work O
, O
but O
it O
is O
not O
effective O
in O
reducing O
cough O
or O
other O
symptoms O
in O
patients O
with O
acute O
bronchitis O
, O
regardless O
of O
the O
outcome O
of O
the O
M O
pneumoniae O
antibody O
test O
. O
[]

Patients O
were O
randomly O
allocated O
to O
cyproheptadine O
+ O
haloperidol O
( O
Group O
A O
) O
or O
haloperidol O
+ O
placebo O
( O
Group O
B O
) O
for O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
study O
. O
[]

No O
significant O
difference O
was O
found O
between O
the O
digital-brachial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
of O
group O
A O
compared O
with O
group O
B O
. O
['Physiological-Clinical']

The O
study O
was O
conducted O
in O
the O
operation O
room O
, O
post-anesthesia O
care O
unit O
, O
and O
inpatient O
clinic O
. O
[]

Onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
ciclesonide O
once O
daily O
in O
the O
treatment O
of O
seasonal O
allergic O
rhinitis O
. O
['Physiological-Clinical']

RESULTS: O
The O
multivariate O
analysis O
showed O
that O
lower O
nodal O
stage, O
the O
presence O
of O
squamous O
cell O
carcinoma O
(SCC), O
a O
broader O
surgical O
resection O
in O
patients O
with O
SCC, O
and O
being O
female O
with O
non-SCC O
were O
significantly O
associated O
with O
longer O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
. O
Lower O
nodal O
stage O
and O
smaller O
tumor O
size O
were O
significantly O
associated O
with O
an O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
. O
Compared O
to O
Other O
International, O
enrollment O
in O
East O
Asia O
was O
associated O
with O
an O
improved O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
in O
patients O
with O
non-SCC. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Mortality']]

DESIGN O
A O
randomized O
controlled O
trial O
. O
[]

In O
addition O
to O
the O
constellation O
of O
traditional O
CVD O
risk O
factors O
in O
chronic O
kidney O
disease O
, O
elevated O
total O
homocysteine B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
notably O
more O
prevalent O
among O
the O
general O
population O
. O
['Physiological-Clinical']

10 O
volunteers O
( O
61-78 O
years O
) O
with O
minor O
impairment O
of O
brain O
function O
were O
given O
placebo O
, O
40 O
mg O
and O
60 O
mg O
nimodipine O
( O
Nimotop O
) O
in O
single O
doses O
with O
intervals O
of O
3 O
medication-free O
days O
between O
medications O
under O
double-blind O
conditions O
. O
[]

Because O
children O
at O
each O
grade O
were O
distributed O
across O
two O
classrooms O
( O
clusters O
) O
and O
were O
homogeneous O
, O
each O
grade O
was O
considered O
to O
consist O
of O
a O
matched O
pair O
. O
[]

However O
, O
a O
timolol-induced O
reduction O
in O
respiratory B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
observed O
only O
in O
the O
evening O
: O
percent O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
, O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DISCUSSION O
This O
trial O
will O
provide O
robust O
evidence O
to O
support O
the O
effectiveness O
of O
different O
designs O
of O
virtual O
patients O
, O
based O
on O
student B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
evaluation O
. O
['Life-Impact']

However O
, O
further O
studies O
are O
necessary O
to O
confirm O
these O
results O
. O
[]

Results O
indicated O
that O
the O
hypnosis O
sessions O
predicted O
significantly O
impaired B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
randomized O
, O
placebo-controlled O
phase O
2 O
study O
of O
ganitumab O
or O
conatumumab O
in O
combination O
with O
FOLFIRI O
for O
second-line O
treatment O
of O
mutant O
KRAS O
metastatic O
colorectal O
cancer O
. O
[]

fractions O
) O
. O
[]

Subgroup O
analysis O
found O
some O
significant O
interactions O
between O
intervention O
and O
secondary O
outcomes O
. O
[]

Our O
results O
support O
the O
idea O
that O
each O
of O
these O
two O
biological O
indices O
can O
be O
used O
in O
the O
assessment O
of O
central B-outcome ['Physiological-Clinical']
noradrenergic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

If O
the O
DEA O
reclassifies O
hydrocodone O
as O
a O
Schedule O
II O
narcotic O
, O
as O
recently O
recommended O
by O
its O
advisory O
board O
, O
our O
data O
suggest O
that O
the O
codeine/acetaminophen O
may O
be O
a O
clinically O
reasonable O
Schedule O
III O
substitute O
for O
hydrocodone/acetaminophen O
at O
ED O
discharge O
. O
[]

Determinants O
of O
serum O
creatinine O
trajectory O
in O
acute O
contrast O
nephropathy O
. O
[]

The O
respective O
RBE B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
for O
early O
and O
late O
effects O
in O
the O
bowel O
are O
less O
than O
3.4 O
and O
3.8 O
. O
['Physiological-Clinical']

Sixteen O
outpatients O
with O
a O
brain O
injury O
were O
included O
in O
the O
study O
. O
[]

Physiological O
measures O
included O
measurement O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
bone B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
, O
and O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
including O
direct O
measurements O
of O
peak O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
VO2 B-outcome ['Physiological-Clinical']
) O
and O
anaerobic B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/03/12 O
06:00 O
[medline] O
[]

CONCLUSIONS O
This O
study O
confirms O
the O
findings O
in O
a O
previous O
open O
label O
trial O
that O
administration O
of O
VLP O
immunotherapy O
may O
assist O
in O
clearance O
of O
recurrent O
genital O
warts O
in O
patients O
for O
whom O
destructive O
therapy O
is O
unsuccessful O
and O
that O
unsuccessful O
destructive O
therapy O
is O
more O
common O
with O
increasing O
prior O
disease O
duration O
. O
[]

To O
investigate O
the O
underlying O
causal O
mechanisms O
, O
we O
conducted O
a O
randomized O
clinical O
trial O
of O
an O
experimental O
intervention O
( O
Focused O
Playtime O
Intervention O
, O
FPI O
) O
that O
aims O
to O
enhance O
responsive B-outcome ['Life-Impact']
parental I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
( O
N O
= O
70 O
) O
. O
['Life-Impact']

The O
percentage O
of O
patients O
with O
a O
composite O
outcome O
event O
was O
74% O
lower O
with O
caplacizumab O
than O
with O
placebo O
(12% O
vs. O
49%, O
P<0.001). O
[]

The O
effects O
of O
clopamide O
, O
pindolol O
and O
its O
combination O
on O
plasma O
lipids O
in O
49 O
hypertensive O
patients O
( O
WHO O
I-II O
) O
, O
divided O
into O
three O
parallel O
randomized O
groups O
, O
were O
studied O
over O
a O
6 O
months O
period O
. O
[]

BACKGROUND O
Heparin O
is O
an O
effective O
, O
widely O
used O
treatment O
for O
unstable O
angina O
. O
[]

Both O
treatment O
regimens O
-- O
cefoxitin O
given O
alone O
and O
clindamycin O
and O
gentamicin O
given O
together O
-- O
resulted O
in O
similar O
infection B-outcome ['Physiological-Clinical']
rates O
, O
drug B-outcome ['Adverse-effects']
toxicity I-outcome ['Adverse-effects']
, O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
, O
and O
costs O
. O
['Physiological-Clinical', 'Adverse-effects', 'Resource-use']

The O
use O
of O
a O
PSA-D O
threshold O
value O
of O
0 O
. O
[]

RESULTS O
The O
2 O
groups O
were O
comparable O
in O
baseline O
clinical O
and O
urodynamic O
data O
. O
[]

In O
Exp O
. O
[]

Neutrophil O
C3bi O
receptor O
expression O
was O
measured O
at O
0 O
and O
24 O
hours O
. O
[]

In O
the O
placebo O
group O
, O
a O
significant O
deterioration O
of O
the O
indices O
, O
with O
the O
exception O
of O
Valsalva B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
was O
recorded O
, O
while O
tolrestat O
induced O
a O
significant O
beneficial O
change O
in O
the O
values O
of O
most O
standard O
cardiovascular B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
tests O
, O
in O
comparison O
to O
baseline O
and O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However, O
data O
on O
the O
optimal O
route O
of O
administration O
are O
not O
consistent. O
[]

Many O
physicians O
, O
however O
, O
treat O
acute O
bronchitis O
with O
antibiotics O
because O
of O
the O
possibility O
of O
Mycoplasma O
pneumoniae O
or O
other O
pathogens O
. O
[]

The O
mean O
number O
of O
accurate O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
factors I-outcome ['Life-Impact', 'Life-Impact']
(that O
could O
affect O
fertility) O
mentioned O
increased O
from O
3.6 O
to O
4.4 O
(P O
< O
0.001) O
in O
the O
IG. O
[['Life-Impact', 'Life-Impact']]

Magnetic O
resonance O
images O
from O
the O
two O
examinations O
were O
compared O
and O
changes O
in O
rupture O
configuration O
were O
evaluated O
. O
[]

When O
the O
infusion O
was O
stopped O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
returned O
to O
within O
15 O
% O
of O
the O
control O
with O
15 O
minutes O
. O
['Physiological-Clinical']

In O
both O
arms O
of O
the O
study O
, O
the O
supraclavicular O
fossa O
and O
axillary O
apex O
were O
treated O
once O
daily O
to O
50 O
Gy O
. O
[]

Peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( O
220.0 O
+/- O
12.9 O
and O
324.3 O
+/- O
84.3 O
in O
group O
I O
, O
218.0 O
+/- O
16.4 O
and O
260.5 O
+/- O
35.2 O
in O
group O
II O
) O
and O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
844.0 O
+/- O
147.4 O
and O
1100.0 O
+/- O
158.1 O
in O
group O
I O
, O
830.0 O
+/- O
117.4 O
and O
1090 O
+/- O
137 O
in O
group O
II O
) O
were O
significantly O
lower O
before O
and O
after O
surgery O
respectively O
in O
both O
groups O
compared O
to O
normal O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
difference O
between O
the O
ultimate O
cure B-outcome ['Physiological-Clinical']
in O
the O
three O
groups O
was O
significant O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Moreover O
, O
the O
percentage O
of O
patients O
without O
induration B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
the O
active O
group O
compared O
with O
the O
placebo O
group O
( O
P O
= O
0.013 O
) O
, O
and O
a O
statistically O
significantly O
greater O
decrease O
in O
the O
size O
of O
the O
lesional B-outcome ['Physiological-Clinical']
area O
was O
also O
seen O
in O
the O
overall O
analysis O
of O
the O
R-salbutamol-treated O
patients O
( O
P O
= O
0.0197 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
controlled O
study O
of O
psychiatric O
hospital O
versus O
community O
treatment O
- O
the O
effect O
on O
relatives B-outcome ['Life-Impact']
. O
['Life-Impact']

Zolmitriptan O
( O
Zomig O
, O
formerly O
311C90 O
) O
is O
a O
selective O
5-hydroxytryptamine O
( O
5-HT O
) O
1B/1D-receptor O
agonist O
with O
central O
and O
peripheral O
activity O
for O
the O
acute O
treatment O
of O
migraine O
. O
[]

Blinded O
assessments O
may O
miss O
finer O
nuances O
of O
wound B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
but O
are O
likely O
to O
be O
more O
accurate O
. O
['Physiological-Clinical']

Supplementary O
electrocardiography B-outcome ['Resource-use']
( I-outcome ['Resource-use']
ECG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
was O
performed O
before O
and O
after O
6-month O
treatment O
. O
['Resource-use']

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
of O
bilastine O
was O
investigated O
using O
a O
simultaneous O
analysis O
of O
all O
concentration-time O
data O
by O
means O
of O
nonlinear O
mixed-effects O
modelling O
population O
pharmacokinetic O
software O
NONMEM O
version O
6.1 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Oral O
S-adenosylmethionine O
in O
the O
symptomatic O
treatment O
of O
intrahepatic B-outcome ['Physiological-Clinical']
cholestasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
292 O
fractures O
which O
were O
followed O
for O
six O
months O
, O
the O
incidence O
of O
nonunion B-outcome ['Physiological-Clinical']
was O
independent O
of O
the O
type O
of O
cast O
used O
. O
['Physiological-Clinical']

BACKGROUND O
Despite O
recent O
advances O
in O
interventional O
cardiology O
, O
including O
the O
introduction O
of O
drug-eluting O
stents O
for O
de O
novo O
coronary O
lesions O
, O
the O
treatment O
of O
in-stent O
restenosis O
( O
ISR O
) O
remains O
a O
challenging O
clinical O
issue O
. O
[]

Bestatin O
is O
shown O
to O
be O
a O
clinically O
useful O
drug O
for O
immunotherapy O
of O
adult O
ANLL O
, O
since O
it O
has O
prolonged O
survival B-outcome ['Mortality']
and O
remission B-outcome ['Physiological-Clinical']
especially O
in O
elderly O
patients O
, O
with O
few O
side-effects B-outcome ['Adverse-effects']
. O
['Mortality', 'Physiological-Clinical', 'Adverse-effects']

Safety O
of O
intravitreous O
fomivirsen O
for O
treatment O
of O
cytomegalovirus O
retinitis O
in O
patients O
with O
AIDS O
. O
[]

RESULTS: O
Participants O
identified O
more O
barriers O
than O
facilitators O
when O
describing O
contextual O
factors O
influencing O
the O
mhGAP-based O
training's O
expected O
outcomes. O
[]

A O
persistent B-outcome ['Physiological-Clinical']
fibronecrotic I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
found O
in O
150 O
patients O
( O
20 O
% O
) O
and O
did O
not O
influence O
the O
relapse B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
APV I-outcome ['Physiological-Clinical']
AUC O
( O
0-tau O
) O
, O
C B-outcome ['Physiological-Clinical']
( O
max O
) O
, O
and O
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
tau I-outcome ['Physiological-Clinical']
) O
were O
26 O
, O
48 O
, O
and O
32 O
% O
higher O
, O
respectively O
, O
and O
the O
values O
for O
plasma B-outcome ['Physiological-Clinical']
RTV I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
pain B-outcome ['Physiological-Clinical']
score O
was O
lower O
two O
hours O
after O
surgery O
and O
on O
postoperative O
day O
1 O
in O
Group O
IT0.5 O
than O
in O
the O
other O
groups O
. O
['Physiological-Clinical']

Patients O
who O
received O
naloxone O
( O
n O
= O
58 O
) O
showed O
significant O
increases O
in O
mean O
scores O
on O
all O
three O
rating O
scales O
, O
but O
this O
was O
due O
primarily O
to O
increases O
observed O
in O
a O
minority O
of O
patients O
. O
[]

RESULTS O
A O
significant O
increase O
of O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor O
I O
( O
IGF-I O
) O
( O
somatomedin O
C O
) O
levels O
and O
of O
['Physiological-Clinical']

Two O
patients O
in O
the O
placebo O
group O
needed O
antihypertensive O
treatment O
because O
they O
developed O
microalbuminuria B-outcome ['Physiological-Clinical']
and/or O
hypertension B-outcome ['Physiological-Clinical']
, O
but O
no O
patient O
in O
the O
candesartan O
group O
did O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Comparative O
Study O
[]

Clinical B-outcome ['Physiological-Clinical']
pharmacology I-outcome ['Physiological-Clinical']
of O
methadone O
in O
dogs O
. O
['Physiological-Clinical']

The O
effect O
of O
a O
combined O
intervention O
including O
MP O
plus O
a O
nursing O
telephone O
intervention O
( O
NTI O
) O
was O
also O
assessed O
. O
[]

METHODS O
Twenty O
heart-transplant O
recipients O
were O
randomised O
into O
either O
a O
treated O
or O
a O
placebo O
group O
. O
[]

The O
mean O
+/- O
SD O
pain O
score O
was O
4.5 O
+/- O
2.0 O
at O
hysteroscopy O
and O
5.2 O
+/- O
2.1 O
at O
endometrial O
biopsy O
in O
the O
87 O
subjects O
given O
a O
paracervical O
block O
versus O
4.9 O
+/- O
2.2 O
and O
5.7 O
+/- O
2.4 O
in O
the O
90 O
women O
not O
given O
local O
anesthesia O
, O
without O
statistically O
significant O
differences O
. O
[]

Each O
subjects-either O
inactive O
or O
active-performed O
two O
treadmill O
tests O
at O
two-days O
interval O
, O
to O
measure O
maximal O
and O
submaximal O
responses O
to O
exercise O
, O
respectively O
. O
[]

Based O
on O
the O
multivariate O
analysis O
in O
the O
control O
group O
, O
voided O
urine O
cytology O
was O
an O
independent O
predictive O
factor O
of O
bladder O
recurrence O
( O
hazard O
ratio O
, O
5.54 O
; O
95 O
% O
confidence O
interval O
1.12-27.5 O
; O
P O
= O
0.036 O
) O
. O
[]

We O
, O
however O
, O
recommend O
closely O
monitoring O
cyclosporin O
blood O
levels O
when O
prescribing O
ticlopidine O
. O
[]

Patients O
were O
stratified O
by O
sex O
and O
number O
of O
nodes O
and O
were O
randomly O
assigned O
to O
receive O
either O
2 O
years O
of O
treatment O
with O
active O
specific O
immunotherapy O
with O
allogeneic O
melanoma O
lysates O
and O
low-dose O
IFN-alpha-2b O
( O
arm O
1 O
) O
or O
high-dose O
IFN-alpha-2b O
alone O
for O
1 O
year O
( O
arm O
2 O
) O
. O
[]

2.92 O
and O
11.27 O
? O
[]

The O
transition O
from O
rest O
to O
exercise O
resulted O
in O
a O
shift O
from O
net O
leg O
total O
FFA B-outcome ['Physiological-Clinical']
release B-outcome ['Physiological-Clinical']
( O
-44 O
+/- O
16 O
micromol/min O
) O
to O
uptake O
( O
193 O
+/- O
49 O
micromol/min O
) O
that O
was O
unaffected O
by O
either O
exercise O
intensity O
or O
endurance O
training O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Using O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
design O
, O
the O
current O
study O
tested O
the O
effectiveness O
of O
an O
evidence-based O
, O
caregiver-assisted O
social O
skills O
intervention O
known O
as O
PEERS O
for O
Young O
Adults O
with O
high-functioning O
young O
adults O
with O
ASD O
( O
ages O
18-23 O
) O
using O
self- O
and O
caregiver-report B-outcome ['Life-Impact']
measures O
. O
['Life-Impact']

This O
study O
suggests O
that O
the O
addition O
of O
TENS O
, O
applied O
continuously O
during O
the O
immediate O
postoperative O
period O
following O
CABG O
with O
ITA O
, O
may O
not O
be O
advantageous O
in O
pain B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
or O
the O
prevention O
of O
pulmonary B-outcome ['Physiological-Clinical']
dysfunction I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Amoxicillin B-outcome ['Resource-use']
was O
as O
efficacious O
as O
erythromycin O
in O
the O
treatment O
of O
severe B-outcome ['Physiological-Clinical']
pyoderma I-outcome ['Physiological-Clinical']
in O
Mali O
. O
['Resource-use', 'Physiological-Clinical']

The O
study O
was O
conducted O
in O
pharmacies O
operated O
by O
the O
Southern O
California O
region O
Kaiser O
Permanente O
Medical O
Care O
Program O
. O
[]

A O
total O
of O
2242 O
patients O
with O
mild O
to O
moderate O
hypertension O
( O
diastolic O
pressure O
95-120 O
mmHg O
) O
were O
randomised O
on O
a O
double-blind O
basis O
to O
receive O
a O
single O
dose O
of O
placebo O
, O
5 O
mg O
quinapril O
or O
10 O
mg O
quinapril O
. O
[]

Given O
the O
acceptability B-outcome ['Life-Impact']
curve O
, O
there O
is O
a O
92.4 O
% O
chance O
that O
the O
CBT O
, O
compared O
with O
the O
SET O
, O
is O
['Life-Impact']

These O
results O
suggest O
that O
multimodal O
pain O
therapy O
with O
COX-2 O
inhibitors O
may O
have O
a O
role O
in O
outpatient O
inguinal O
hernia O
repair O
. O
[]

UNLABELLED O
Patients O
with O
headaches O
account O
for O
approximately O
2 O
% O
of O
all O
ED O
visits O
, O
with O
migraines O
being O
the O
most O
common O
defined O
primary O
headache O
syndrome O
. O
[]

We O
used O
the O
ambulatory O
24-h O
pH O
monitor O
to O
assess O
esophageal O
acid O
exposure O
in O
10 O
normal O
subjects O
and O
10 O
GER O
patients O
following O
low O
and O
high O
fat O
meals O
eaten O
in O
two O
body O
positions O
. O
[]

METHODS O
Thirty O
patients O
from O
the O
Heart O
Failure O
Clinic O
of O
the O
Instituto O
Nacional O
de O
Ciencias O
M?dicas O
y O
Nutrici?n O
Salvador O
Zubir?n O
underwent O
photoplethysmography O
using O
the O
hyperemia O
technique O
. O
[]

Significant O
shorter O
procedure O
and O
fluoroscopy O
times O
compared O
with O
a O
primary O
4:1 O
ablation O
mode O
during O
repeat O
PVI O
are O
mainly O
attributed O
to O
a O
lower O
incidence O
of O
acutely O
reconnected O
PVs O
within O
the O
first O
30 O
min O
. O
[]

PURPOSE O
The O
purpose O
of O
this O
in O
vitro O
study O
was O
to O
evaluate O
the O
translucency B-outcome ['Physiological-Clinical']
of O
zirconia O
copings O
for O
single O
crowns O
fabricated O
using O
different O
CAD/CAM O
systems O
, O
using O
lithium O
disilicate O
glass O
ceramic O
as O
a O
control O
. O
['Physiological-Clinical']

Effect O
of O
cicloxilic O
acid O
on O
bile B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
in O
patients O
with O
gallstones O
: O
a O
multicenter O
trial O
. O
['Physiological-Clinical']

Black O
tea O
treatment O
was O
associated O
with O
the O
highest O
rates O
of O
dropout B-outcome ['Life-Impact']
among O
smokers O
( O
37 O
% O
) O
, O
but O
was O
associated O
with O
the O
lowest O
rate O
of O
dropout O
among O
non-smokers O
( O
4 O
% O
) O
. O
['Life-Impact']

OBJECTIVE O
We O
postulated O
that O
asymptomatic O
ongoing O
allergen O
exposure O
could O
drive O
airway O
inflammation O
as O
well O
as O
changes O
in O
the O
extracellular O
matrix O
( O
ECM O
) O
, O
and O
that O
inhaled O
steroids O
could O
prevent O
this O
. O
[]

This O
study O
is O
registered O
with O
, O
number O
NCT00149266 O
. O
[]

The O
test O
was O
performed O
under O
examination O
conditions O
. O
[]

At O
follow-up O
, O
qDES O
showed O
reduced O
neointimal B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
by O
70 O
% O
at O
the O
tightest O
cross O
section O
and O
by O
68 O
% O
over O
the O
stented O
segment O
( O
P O
< O
0.0001 O
for O
both O
) O
, O
resulting O
in O
a O
significantly O
larger O
lumen O
in O
qDES O
than O
in O
BMS O
. O
['Physiological-Clinical']

No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
reported O
during O
the O
study O
or O
follow-up O
period O
. O
['Adverse-effects']

The O
primary O
end O
points O
were O
the O
rate O
of O
biopsy-confirmed B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BCAR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Forty O
patients O
were O
assigned O
to O
laparoscopic O
lymphadenectomy O
and O
40 O
patients O
to O
abdominal O
lymphadenectomy O
. O
[]

Using O
daily O
transtelephonic O
monitoring O
, O
we O
examined O
asymptomatic O
and O
symptomatic O
paroxysmal B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
episodes O
during O
a O
maximum O
1 O
year O
treatment O
. O
['Physiological-Clinical']

RESULTS O
Mean O
plasma B-outcome ['Physiological-Clinical']
vWf I-outcome ['Physiological-Clinical']
was O
higher O
among O
patients O
with O
AF O
and O
CHF O
( O
154 O
( O
29 O
) O
v O
144 O
( O
31 O
) O
IU/dl O
, O
p O
< O
0.001 O
) O
, O
particularly O
those O
with O
acute O
or O
recent O
decompensated O
symptoms O
. O
['Physiological-Clinical']

Retinal O
lesions O
placed O
with O
diode O
lasers O
are O
deeper O
than O
similar O
argon O
laser O
lesions O
, O
and O
it O
is O
not O
known O
whether O
this O
difference O
could O
influence O
the O
response O
to O
ablative O
therapy O
. O
[]

These O
findings O
suggest O
that O
PTF O
may O
have O
beneficial O
effects O
on O
tubulointerstitial O
damage O
in O
diabetic O
kidney O
disease O
. O
[]

RESULTS O
A O
total O
of O
249 O
patients O
( O
166 O
balsalazide O
, O
83 O
placebo O
) O
received O
at O
least O
1 O
dose O
of O
study O
medication O
. O
[]

Our O
results O
indicate O
that O
short-term O
strength O
training O
increases O
basal O
femoral O
blood O
flow O
and O
vascular O
conductance O
in O
healthy O
middle-aged O
and O
older O
adults O
. O
[]

The O
dry O
needling O
was O
applied O
in O
active O
trigger O
points O
located O
in O
the O
musculature O
of O
the O
head O
and O
the O
neck. O
[]

METHODOLOGY/PRINCIPAL O
FINDINGS O
We O
used O
event-related O
fMRI O
to O
investigate O
brain B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
to O
images O
of O
the O
subjects O
' O
own O
face O
and O
to O
faces O
of O
others O
. O
['Physiological-Clinical']

Effects O
of O
insufficient O
sleep O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
: O
a O
24-h O
study O
. O
['Physiological-Clinical']

This O
treatment O
should O
only O
be O
applied O
when O
there O
is O
a O
realistic O
increase O
in O
chance O
of O
pregnancy B-outcome ['Physiological-Clinical']
, O
particularly O
because O
it O
carries O
the O
increased O
risk O
of O
multiple O
pregnancies O
. O
['Physiological-Clinical']

BACKGROUND O
Patients O
with O
type O
2 O
diabetes O
are O
at O
high O
risk O
of O
fatal O
and O
non-fatal O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
stroke B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
nurse O
wrote O
28 O
letters O
to O
the O
general O
practitioners O
suggesting O
changes O
in O
epilepsy O
management O
. O
[]

The O
overall O
mean O
number O
of I-outcome ['Life-Impact']
daily B-outcome ['Life-Impact']
doses I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
study I-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
was O
significantly O
less O
in O
the O
HI2 O
group O
( O
2.94+/-0.99 O
) O
than O
in O
the O
HI1 O
group O
( O
3.23+/-0.76 O
) O
( O
P O
= O
0.036 O
) O
or O
the O
CA O
group O
( O
3.26+/-0.75 O
) O
( O
P O
= O
0.014 O
) O
. O
['Life-Impact']

CONCLUSION O
There O
were O
no O
different O
of O
seroconversion B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
between O
study O
population O
received O
1 O
dose O
and O
3 O
dose O
booster O
( O
P O
> O
0.05 O
) O
, O
but O
high O
titer O
was O
observed O
after O
3 O
dose O
booster O
. O
['Physiological-Clinical']

Two O
additional O
assessments O
of O
treatment O
status O
and O
mortality B-outcome ['Mortality']
were O
conducted O
in O
1993-1994 O
and O
1995-1996 O
. O
['Mortality']

In O
both O
males O
and O
females O
, O
tobacco O
users O
consumed B-outcome ['Life-Impact']
more O
fat B-outcome ['Physiological-Clinical']
, O
cholesterol O
, O
and O
alcohol B-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Results O
suggest O
that O
the O
allocation O
to O
an O
individualized O
, O
comprehensive O
, O
home-based O
cardiac O
rehabilitation O
program O
provided O
more O
advantageous O
outcomes O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Mean O
airway B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
18?3 O
cm O
H2O O
during O
conventional O
mechanical O
ventilation O
and O
was O
increased O
until O
33?3 O
cm O
H2O O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
['Physiological-Clinical']

Melatonin O
significantly O
improved O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
( O
by O
an O
average O
of O
47 O
min O
) O
and O
total O
sleep B-outcome ['Physiological-Clinical']
( O
by O
an O
average O
of O
52 O
min O
) O
compared O
to O
placebo O
, O
but O
not O
number O
of O
night O
wakenings O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
groups O
were O
compared O
for O
the O
incidence O
of O
pruritus B-outcome ['Physiological-Clinical']
by O
the O
Mann-Whitney O
nonparametric O
test O
. O
['Physiological-Clinical']

Quantitative O
analysis O
of O
this O
effect O
of O
the O
instruments O
used O
was O
performed O
on O
20 O
freshly O
extracted O
, O
non-periodontally O
involved O
, O
large O
human O
molars O
. O
[]

Changes O
in O
QOL O
were O
measured O
using O
the O
36-item O
Short O
Form O
Health B-outcome ['Physiological-Clinical']
Survey O
and O
EQ-5D]. O
The O
analysis O
of O
cost-effectiveness O
was O
a O
cost-utility O
analysis O
with O
a O
health O
care O
perspective O
and O
included O
costs B-outcome ['Resource-use']
of I-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
for O
stakeholder, O
quality-adjusted O
life-years O
(QALYs) O
gained O
and O
savings B-outcome ['Resource-use']
in O
health O
care O
. O
The O
likelihood O
of O
cost-effectiveness O
was O
examined O
using O
the O
net O
monetary O
benefit O
method. O
[['Physiological-Clinical'], ['Resource-use'], ['Resource-use']]

Differences O
between O
the O
two O
groups O
were O
significant O
( O
p O
less O
than O
0.05 O
) O
. O
[]

One-hundred-and-twelve O
subjects O
were O
enrolled O
and O
divided O
into O
two O
groups O
; O
those O
that O
consumed O
MLCT O
oil O
and O
those O
that O
consumed O
long-chain O
triglyceride O
( O
LCT O
) O
oil O
for O
8 O
weeks O
. O
[]

CONCLUSION O
Uniform O
and O
identical O
standardised O
wounds O
created O
using O
an O
abrasive O
brush O
technique O
can O
be O
used O
to O
reliably O
detect O
differences O
in O
the O
performance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
plasters I-outcome ['Life-Impact']
intended O
for O
superficial O
wounds O
. O
['Life-Impact']

When O
a O
randomized O
trial O
( O
NMSG O
4/90 O
) O
comparing O
treatment O
with O
melphalan/prednisone O
to O
melphalan/ O
prednisone O
+ O
interferon O
alpha-2b O
in O
newly O
diagnosed O
multiple O
myeloma O
was O
initiated O
in O
1990 O
, O
a O
quality-of-life B-outcome ['Life-Impact']
assessment O
was O
integrated O
into O
the O
study O
. O
['Life-Impact']

Recombinant O
human O
nerve O
growth O
factor O
( O
rhNGF O
) O
has O
demonstrated O
efficacy O
as O
treatment O
for O
peripheral O
neuropathy O
in O
experimental O
models O
and O
phase O
2 O
clinical O
trials O
. O
[]

No O
recurrences B-outcome ['Physiological-Clinical']
were O
observed O
over O
a O
12-month O
follow-up O
in O
both O
groups O
. O
['Physiological-Clinical']

Exacerbation O
onset O
was O
the O
first O
day O
of O
a O
reported O
symptom O
of O
exacerbation. O
[]

Resource B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
procedures B-outcome ['Resource-use']
, O
and O
direct B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
calculated O
and O
analyzed O
in O
this O
post O
hoc O
retrospective O
study O
. O
['Resource-use', 'Resource-use', 'Resource-use']

OBJECTIVE O
The O
objective O
of O
this O
research O
was O
to O
explore O
the O
effects O
of O
risperidone O
on O
cognitive B-outcome ['Life-Impact']
processes I-outcome ['Life-Impact']
in O
children O
with O
autism O
and O
irritable O
behavior O
. O
['Life-Impact']

Participants O
will O
be O
recruited O
from O
two O
major O
maternity O
hospitals O
in O
Australia O
. O
[]

Sixty O
children O
participated O
from O
56 O
classrooms O
in O
30 O
schools O
. O
[]

Total O
anthelmintic O
failure O
to O
control O
nematode O
parasites O
of O
small O
ruminants O
on O
government O
breeding O
farms O
in O
Sabah O
, O
East O
Malaysia O
. O
[]

Fifteen O
minutes O
later O
( O
before O
IoA O
) O
, O
each O
dog O
received O
treatment O
IV O
with O
propofol O
, O
K-P O
, O
or O
K-D. O
Cardiorespiratory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
variables I-outcome ['Physiological-Clinical']
were O
assessed O
before O
, O
immediately O
after O
, O
and O
5 O
minutes O
after O
IoA O
. O
['Physiological-Clinical']

INTERVENTIONS O
Guideline O
implementation O
utilized O
an O
education/audit/feedback O
model O
with O
local O
peer O
opinion O
leaders O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
LD O
( O
50 O
) O
for O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
60 O
% O
of O
total O
blood B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
first O
study O
, O
heifers O
receiving O
the O
SG+IVPO O
had O
fewer O
( O
P O
= O
0.02 O
) O
cattle O
retreated O
for O
disease O
and O
73 O
% O
fewer O
( O
P O
= O
0.06 O
) O
worm O
eggs O
per O
fecal O
sample O
98 O
d O
after O
treatment O
than O
heifers O
treated O
with O
IVPO O
. O
[]

Characterization O
of O
early O
thermal O
burns O
and O
the O
effects O
of O
hyperbaric O
oxygen O
treatment O
: O
a O
pilot O
study O
. O
[]

Increased O
atrial O
electromechanical O
coupling O
time O
interval O
measured O
by O
tissue O
Doppler O
is O
accepted O
as O
an O
important O
factor O
for O
prediction O
of O
AF B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
in O
hypertensive O
patients O
. O
['Physiological-Clinical']

A O
feasibility O
study O
exploring O
the O
role O
of O
Chinese O
herbal O
medicine O
in O
the O
treatment O
of O
endometriosis O
. O
[]

OBJECTIVE O
The O
vast O
majority O
of O
children O
with O
an O
autism O
spectrum O
disorder O
( O
ASD O
) O
attend O
public O
preschools O
at O
some O
point O
in O
their O
childhood O
. O
[]

['2018/12/21 O
06:00' O
[]

RESULTS O
At O
24 O
hours O
the O
mean O
change O
( O
SD O
) O
from O
baseline O
in O
the O
RDAI B-outcome ['Physiological-Clinical']
score O
was O
1.6 O
( O
2.3 O
) O
in O
the O
placebo O
group O
( O
n O
= O
28 O
) O
and O
1.4 O
( O
2.0 O
) O
in O
the O
dexamethasone O
group O
( O
n O
= O
33 O
; O
p O
= O
0.74 O
) O
. O
['Physiological-Clinical']

100 O
episodes O
were O
severe O
, O
eight O
in O
RRV-TV O
recipients O
and O
92 O
in O
placebo O
recipients O
( O
vaccine O
efficacy O
91 O
% O
[ O
82-96 O
] O
) O
. O
[]

We O
hope O
to O
show O
the O
oncologic O
benefits O
of O
deep O
NMB O
compared O
with O
moderate O
NMB O
during O
subtotal O
gastrectomy. O
[]

PURPOSE O
Coronary O
angiography O
using O
multidetector O
computed O
tomography O
( O
MDCT-CA O
) O
is O
a O
recent O
technique O
for O
the O
nonivasive O
study O
of O
coronary O
arteries O
. O
[]

G-CSF O
was O
used O
in O
a O
dose O
of O
3 O
microg/kg O
on O
D5-D9 O
during O
each O
cycle O
in O
the O
dose-dense O
group O
. O
[]

Patients O
also O
received O
a O
low-sodium O
( O
40 O
mmol/day O
) O
diet O
and O
the O
aldosterone O
antagonist O
, O
potassium O
canrenoate O
( O
100 O
mg O
b.i.d. O
) O
. O
[]

Title: O
The O
effects O
of O
position O
on O
gastric B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
premature O
infants O
in O
NICU. O
[['Physiological-Clinical']]

These O
changes O
in O
interaction O
were O
clinically O
relevant O
. O
[]

The O
psychopathology O
, O
cognitive O
functioning O
, O
early O
treatment O
history O
, O
and O
duration O
of O
untreated O
psychosis O
of O
these O
subjects O
were O
assessed O
prior O
to O
their O
assignment O
to O
randomized O
, O
double-blind O
treatment O
. O
[]

Incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
were O
comparable O
in O
all O
four O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
onset O
of O
action B-outcome ['Physiological-Clinical']
of O
ciclesonide B-outcome ['Resource-use']
occurred O
within O
1 O
hour O
of O
administration O
( O
p O
= O
0.01 O
vs. O
placebo O
) O
, O
and O
the O
significant O
difference O
in O
total O
['Physiological-Clinical', 'Resource-use']

Eighteen O
children O
with O
ASD O
were O
assessed O
with O
pretreatment O
and O
posttreatment O
measures O
on O
the O
Walker-McConnell O
Scale O
( O
WMS O
) O
and O
the O
MGH O
YouthCare O
Social B-outcome ['Life-Impact']
Competence I-outcome ['Life-Impact']
Development I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact']

Normally O
, O
Healthway O
staff O
attends O
these O
events O
to O
help O
promote O
health O
messages O
. O
[]

PURPOSE O
To O
compare O
the O
toxicity O
between O
hypofractionation O
vs. O
conventional O
fractionation O
schedules O
in O
patients O
with O
high-risk O
prostate O
cancer O
. O
[]

Journal O
ID: O
8200894 O
[]

Excluding O
37 O
% O
of O
the O
treated O
patients O
and O
29 O
% O
of O
the O
placebo O
data O
from O
the O
analysis O
, O
there O
appeared O
to O
be O
statistically O
significant O
improvement O
in O
the O
treated O
patients O
compared O
to O
the O
control O
patients O
at O
1 O
year O
with O
a O
P O
value O
of O
.001 O
( O
repeated O
measures O
P O
value O
= O
.01 O
) O
. O
[]

No O
trial-dependent O
differences O
were O
observed O
in O
the O
Recovery O
period. O
[]

BACKGROUND O
A O
10-J O
energy O
safety O
margin O
has O
traditionally O
been O
used O
in O
programming O
implantable O
cardioverter O
defibrillators O
( O
ICDs O
) O
. O
[]

The O
effects O
of O
enterostatin O
intake O
on O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

DESIGN O
A O
longitudinal O
study O
consisting O
of O
three O
phases O
. O
[]

OBJECTIVE O
One O
type O
of O
test O
commonly O
used O
to O
examine O
auditory O
processing O
disorders O
( O
APD O
) O
is O
the O
low-pass O
filtered O
speech O
test O
( O
LPFST O
) O
, O
of O
which O
there O
are O
various O
versions O
. O
[]

Twenty-five O
deaths B-outcome ['Mortality']
were O
not O
due O
to O
bleeding O
but O
were O
closely O
related O
to O
cirrhosis O
. O
['Mortality']

Subjects O
in O
group O
A O
underwent O
BF O
once O
a O
week O
for O
a O
total O
of O
four O
sessions O
. O
[]

OBJECTIVE O
To O
determine O
the O
clinical O
manifestations O
of O
vulvovaginal O
candidiasis O
( O
VVC O
) O
and O
to O
study O
the O
mycologic B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
rate O
of O
different O
miconazole O
treatment O
courses O
for O
VVC O
. O
['Physiological-Clinical']

MAIN O
RESULTS O
The O
clinician O
intervention O
was O
associated O
with O
an O
absolute O
increase O
in O
guideline-consistent B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
of O
5.4 O
% O
in O
the O
intervention O
group O
versus O
a O
decline O
of O
2.7 O
% O
in O
the O
control O
group O
( O
P O
=.04 O
) O
. O
['Life-Impact']

CLA O
did O
not O
significantly O
affect O
inflammatory O
markers O
. O
[]

METHODS O
Interviews O
were O
conducted O
at O
baseline O
and O
10 O
and O
20 O
weeks O
. O
[]

All O
children O
were O
assessed O
before O
and O
after O
treatment O
on O
two O
behavioral O
measures O
, O
the O
Vineland O
Maladaptive B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Domain O
and O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
. O
['Life-Impact', 'Life-Impact']

The O
combined O
administration O
of O
MMC O
and O
HCFU O
was O
suggested O
to O
be O
a O
safe O
and O
effective O
adjuvant O
chemotherapy O
for O
noncuratively O
resected O
cases O
of O
colorectal O
carcinoma O
. O
[]

Between O
February O
2000 O
and O
August O
2004 O
, O
110 O
patients O
after O
LT O
were O
included O
in O
this O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

The O
antiproteinuric O
effect O
is O
probably O
similar O
to O
that O
of O
perindopril O
, O
for O
equivalent O
hypotensive O
dosages O
. O
[]

Since O
retinal O
detachment O
occurs O
in O
2.5 O
% O
after O
YAG-laser O
capsulotomy O
we O
can O
not O
regard O
capsular O
fibrosis O
as O
a O
totally O
harmless O
complication O
. O
[]

We O
randomized O
465 O
patients O
, O
222 O
in O
the O
2,000-IU O
group O
and O
243 O
in O
the O
5,000-IU O
group O
. O
[]

ALA O
was O
left O
for O
4 O
h O
( O
BCC O
) O
or O
6 O
h O
( O
BD O
) O
. O
[]

RESULTS: O
After O
10-week O
treatment, O
the O
patients O
received O
NMES O
therapy O
showed O
better O
efficacy O
in O
primary O
endpoints O
of O
urodynamic B-outcome ['Physiological-Clinical']
values O
(P O
<.01) O
and O
Overactive B-outcome ['Physiological-Clinical']
Bladder I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
(P O
<.01), O
and O
secondary O
endpoints O
of O
International O
Consultation O
on O
Incontinence B-outcome ['Physiological-Clinical']
Questionnaire-Short O
Form O
(ICIQ-SF) O
(P O
<.01) O
and O
Barthel O
Index O
(BI) O
(P O
<.01), O
compared O
with O
patients O
who O
underwent O
sham O
NMES. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

These O
data O
are O
in O
agreement O
with O
current O
knowledge O
on O
skeletal O
muscle O
physiology O
and O
show O
the O
reliability O
of O
the O
proposed O
method O
. O
[]

On O
subjective O
preference O
measures O
, O
parents O
and O
children O
favored O
the O
weighted O
blanket O
. O
[]

CONCLUSIONS O
The O
lower O
initial O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
the O
noninvasive O
approach O
are O
offset O
by O
greater O
follow-up O
costs O
. O
['Resource-use']

They O
were O
randomized O
according O
to O
a O
single-masked O
design O
and O
stratified O
by O
center O
( O
with O
balancing O
every O
4 O
patients O
) O
. O
[]

Study O
1 O
examined O
supervisor O
response O
to O
and O
tolerance O
of O
coworker O
substance O
use O
and O
ways O
of O
interfacing O
with O
the O
Employee O
Assistance O
Program O
( O
EAP O
) O
in O
two O
workplaces O
( O
n O
= O
244 O
and O
107 O
) O
. O
[]

Although O
some O
complications B-outcome ['Adverse-effects']
occurred O
more O
frequently O
in O
the O
pre-hospital O
group O
in O
the O
pre-hospital O
period O
, O
the O
overall O
incidence O
for O
serious B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
was O
similar O
for O
both O
groups O
. O
['Adverse-effects', 'Adverse-effects']

During O
the O
study O
a O
register O
of O
patients O
undergoing O
coronary O
arteriography O
at O
the O
fourteen O
participating O
centres O
is O
being O
maintained O
to O
assess O
the O
overall O
context O
of O
patient O
recruitment O
. O
[]

We O
followed O
a O
standard O
general O
anesthetic O
technique, O
with O
endotracheal O
intubation. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov, O
NCT03112083 O
, O
retrospectively O
registered. O
[]

The O
use O
of O
flurbiprofen O
did O
not O
affect O
the O
mean O
pupillary B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
for O
any O
of O
these O
groups O
. O
['Physiological-Clinical']

Recommendations O
for O
implementing O
stereotactic O
radiotherapy O
in O
peripheral O
stage O
IA O
non-small O
cell O
lung O
cancer O
: O
report O
from O
the O
Quality O
Assurance O
Working O
Party O
of O
the O
randomised O
phase O
III O
ROSEL O
study O
. O
[]

Patients O
were O
randomized O
into O
exercise O
and O
control O
groups O
. O
[]

Treatment O
with O
either O
17 O
alpha-hydroxyprogesterone O
caproate O
, O
250 O
mg O
by O
intramuscular O
injection O
once O
a O
week O
, O
or O
a O
placebo O
was O
given O
in O
a O
double-blind O
fashion O
. O
[]

It O
is O
difficult O
to O
determine O
the O
best O
method O
when O
only O
considering O
the O
[]

BACKGROUND: O
Radical O
prostatectomy O
reduces O
mortality O
among O
men O
with O
clinically O
detected O
localized O
prostate O
cancer, O
but O
evidence O
from O
randomized O
trials O
with O
long-term O
follow-up O
is O
sparse. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

Zinc B-outcome ['Physiological-Clinical']
and O
copper B-outcome ['Physiological-Clinical']
balances I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

5 O
FU O
infusion O
with O
mitomycin-C O
vs. O
5 O
FU O
infusion O
with O
methyl-CCNU O
in O
the O
treatment O
of O
advanced O
upper O
gastrointestinal O
cancer O
: O
a O
Southwest O
Oncology O
Group O
Study O
. O
[]

Journal O
ID: O
2985248R O
[]

DESIGN O
A O
multi-arm O
, O
modified O
blinded O
, O
placebo-controlled O
design O
was O
used O
. O
[]

PCA B-outcome ['Resource-use']
morphine I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
in O
the O
2-CP O
, O
2-CP+Epi O
and O
Lido+Epi O
groups O
respectively O
was O
20.5 O
+/- O
24 O
, O
33.1.5 O
+/- O
27 O
and O
4.07 O
+/- O
( O
mean O
+/- O
SD O
) O
. O
['Resource-use']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
potential O
advantages O
over O
other O
vaginal O
products O
include O
keeping O
a O
low O
pH O
, O
decrease O
of O
the O
irritating O
effect O
of O
N-9 O
on O
the O
cervix O
or O
vaginal O
mucosa O
associated O
with O
greater O
retention O
of O
the O
product O
after O
application O
, O
and O
decreasing O
messiness O
as O
compared O
to O
other O
vaginal O
products O
. O
[]

SpO2 B-outcome ['Physiological-Clinical']
hardly O
changed O
during O
endoscopy O
in O
the O
non-sedated O
group O
, O
but O
decreased O
slightly O
in O
the O
sedated O
group O
( O
P O
= O
0.075 O
) O
. O
['Physiological-Clinical']

The O
V B-outcome ['Physiological-Clinical']
wave-to-maximal I-outcome ['Physiological-Clinical']
M I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
V/M I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
increased O
significantly O
( O
55.1 O
? O
['Physiological-Clinical']

The O
sample O
was O
composed O
of O
11 O
children O
diagnosed O
with O
Autism O
( O
n=6 O
) O
and O
Asperger O
syndrome O
( O
n=5 O
) O
by O
a O
multidisciplinary O
team O
, O
that O
attended O
specialized O
speech-language O
pathology O
therapy O
at O
the O
institution O
were O
the O
study O
was O
carried O
out O
. O
[]

Significant O
relationships O
were O
found O
between O
VAS O
overall O
well-being O
and O
CDI O
( O
r O
= O
0.29 O
, O
p O
= O
0.03 O
) O
, O
CHAQ O
( O
r O
= O
0.37 O
, O
p O
= O
0.000 O
) O
, O
and O
VAS O
pain O
( O
r O
= O
0.41 O
, O
p O
= O
0.000 O
) O
. O
[]

At O
the O
conclusion O
of O
the O
study O
, O
parents O
were O
asked O
to O
guess O
their O
child O
's O
group O
assignment O
. O
[]

They O
were O
randomized O
to O
undergo O
either O
laparoscopic O
or O
open O
appendectomy O
( O
OA O
) O
. O
[]

The O
perioperative O
use O
of O
glucocorticoids O
has O
been O
advocated O
as O
a O
method O
to O
improve O
postoperative O
outcomes O
. O
[]

CONCLUSION O
The O
composite O
restoration O
of O
FRC O
posts O
combined O
with O
resin O
core O
and O
resin O
crown O
can O
improve O
the O
fracture B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
of O
the O
pulpless O
roots O
. O
['Physiological-Clinical']

Objective O
parameters O
( O
heart O
rate O
, O
blood O
pressure O
, O
skin O
temperature O
, O
peak O
flow O
) O
as O
well O
as O
a O
total O
clinical O
symptom O
score O
using O
a O
standardized O
protocol O
were O
recorded O
at O
baseline O
, O
10 O
, O
20 O
, O
40 O
, O
80 O
minutes O
, O
and O
24 O
hours O
. O
[]

Safety O
and O
efficacy O
of O
sitaxsentan O
50 O
and O
100 O
mg O
in O
patients O
with O
pulmonary O
arterial O
hypertension O
. O
[]

Opiates O
carry O
distinct O
disadvantages O
. O
[]

Effect O
of O
antacids O
on O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
and O
duodenal O
ulcer O
patients O
. O
['Physiological-Clinical']

The O
treatment O
was O
well O
tolerated O
overall O
. O
[]

The O
median O
was O
3 O
mg/min O
at O
onset O
and O
2.45 O
mg/min O
after O
2 O
months O
treatment O
with O
the O
placebo O
. O
[]

The O
5 O
alpha-steroid B-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
was O
strikingly O
similar O
to O
that O
of O
MPHs O
with O
inherited O
5 O
alpha-reductase O
deficiency O
. O
['Physiological-Clinical']

Patients O
in O
the O
treatment O
group O
were O
treated O
with O
massage O
combined O
CMM O
footbath O
fumigation O
and O
washing O
, O
while O
those O
in O
the O
control O
group O
were O
treated O
with O
oral O
administration O
of O
meloxicam O
. O
[]

Clinical O
parameters O
and O
standardized O
radiographs O
were O
obtained O
at O
baseline O
and O
6 O
months O
after O
the O
surgeries O
. O
[]

RESULTS O
In O
all O
, O
890 O
patients O
were O
randomised O
to O
Mi+Mo O
and O
873 O
to O
Mo O
alone O
. O
[]

BACKGROUND O
Tailored O
nutrition O
interventions O
have O
been O
shown O
to O
be O
more O
effective O
than O
non-tailored O
materials O
in O
changing O
dietary O
behaviours O
, O
particularly O
fat O
intake O
and O
fruit O
and O
vegetable O
intake O
. O
[]

METHOD O
Participants O
were O
1,820 O
low-risk O
patients O
aged O
65 O
to O
74 O
years O
who O
had O
not O
previously O
been O
in O
a O
recall O
system O
for O
influenza O
immunisation O
at O
their O
general O
practice O
. O
[]

Unlike O
intracoronary O
brachytherapy O
, O
there O
was O
no O
evidence O
of O
negative O
edge O
effects O
, O
unhealed B-outcome ['Physiological-Clinical']
dissections I-outcome ['Physiological-Clinical']
, O
or I-outcome ['Physiological-Clinical']
late I-outcome ['Physiological-Clinical']
stent-vessel I-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Venographic O
assessment O
of O
clot B-outcome ['Physiological-Clinical']
size O
evolution O
between O
day O
0 O
and O
day O
10 O
showed O
a O
statistically O
significant O
superiority O
( O
P O
< O
.002 O
) O
of O
enoxaparin O
over O
the O
reference O
treatment O
with O
UFH O
. O
['Physiological-Clinical']

However O
, O
these O
differences O
between O
the O
two O
groups O
were O
not O
statistically O
significant O
. O
[]

When O
the O
malignancy O
had O
spread O
to O
the O
parametrial O
region O
, O
additional O
postoperative O
radiotherapy O
was O
given O
. O
[]

Alcohol B-outcome ['Life-Impact']
drinking B-outcome ['Life-Impact']
indices O
and O
craving B-outcome ['Life-Impact']
scores O
were O
not O
significantly O
different O
between O
groups O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Research O
shows O
that O
labels O
are O
variable O
, O
of O
poor O
quality O
, O
and O
not O
patient-centered O
. O
[]

RESULTS O
Five O
hundred O
twenty-nine O
patients O
were O
randomised O
( O
58 O
% O
male O
) O
. O
[]

RESULTS O
Of O
59 O
patients O
, O
eight O
were O
excluded O
from O
randomization O
( O
a O
surgeon O
judged O
Steri-Strip O
S O
to O
be O
a O
nonviable O
closure O
technique O
for O
mismatched O
wound O
edges O
) O
. O
[]

RESULTS O
Patients O
classified O
as O
having O
high O
DWMH O
were O
7.14 O
times O
more O
likely O
not O
to O
remit O
following O
antidepressant O
treatment O
compared O
to O
patients O
classified O
as O
having O
low O
DWMH O
( O
p=0.02 O
) O
. O
[]

They O
were O
followed O
for O
6 O
months O
after O
allocation O
to O
either O
a O
control O
group O
or O
an O
added O
treatment O
group O
( O
doxazosin O
1-4 O
mg O
and O
atenolol O
when O
needed O
) O
. O
[]

In O
the O
same O
groups O
bacterial B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
occurred O
in O
17 O
( O
21.8 O
% O
) O
patients O
and O
in O
16 O
( O
18.4 O
% O
) O
patients O
, O
respectively O
. O
['Physiological-Clinical']

Treatment O
was O
continued O
for O
2 O
years O
or O
until O
death O
. O
[]

Fifty-nine O
consecutive O
patients O
( O
19 O
men O
, O
40 O
women O
, O
mean O
age O
60.8 O
[ O
27-80 O
] O
years O
) O
with O
primary O
osteoporosis O
were O
studied O
to O
see O
if O
there O
was O
any O
significant O
gain O
in O
bone O
mass O
after O
treatment O
with O
salmon O
calcitonin O
. O
[]

Additional O
outcomes O
included O
the O
change O
in O
other O
sputum O
markers O
of O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
, O
symptom B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Multicenter O
Study O
[]

For O
needle O
placement O
into O
the O
incisive O
canal O
, O
54 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
58 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eur O
Child O
Adolesc O
Psychiatr O
11:266-272 O
, O
2002 O
) O
. O
[]

Ambulatory O
opioid O
detoxification O
can O
give O
internists O
a O
larger O
role O
in O
initiating O
drug O
treatment O
for O
IDUs O
who O
are O
addicted O
to O
opioids O
. O
[]

Therefore, O
it O
can O
be O
concluded O
that O
MBCT O
is O
effective O
on O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
and O
can O
be O
used O
as O
an O
MBI O
method O
to O
reduce O
the O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
in O
people O
with O
RA. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

OBJECTIVE O
A O
randomized O
phase O
II O
trial O
was O
conducted O
to O
test O
whether O
the O
addition O
of O
gemcitabine O
to O
weekly O
docetaxel O
could O
improve O
the O
objective O
response O
rate O
and O
survival B-outcome ['Mortality']
outcomes O
as O
second-line O
chemotherapy O
in O
patients O
with O
metastatic O
breast O
cancer O
who O
have O
failed O
a O
paclitaxel-containing O
regimen O
. O
['Mortality']

$ O
30 O
, O
000/year O
. O
[]

In O
this O
randomized O
study O
the O
long-term O
results O
of O
Shouldice O
, O
Lichtenstein O
and O
transabdominal O
preperitoneal O
( O
TAPP O
) O
hernia O
repair O
were O
compared O
. O
[]

CONCLUSIONS O
The O
findings O
suggest O
that O
olanzapine O
is O
a O
promising O
treatment O
for O
children O
with O
autistic O
disorder O
. O
[]

There O
is O
no O
significant O
difference O
between O
the O
two O
groups O
. O
[]

OBJECTIVE O
To O
examine O
the O
effect O
of O
early O
educational O
intervention O
after O
discharge O
from O
the O
hospital O
on O
the O
health O
and O
developmental O
status O
of O
very O
low O
birth O
weight O
( O
< O
or O
= O
1500 O
gm O
) O
infants O
. O
[]

Cost B-outcome ['Resource-use']
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
was O
estimated O
using O
trial O
data O
. O
['Resource-use']

After O
participating O
in O
an O
intensive O
skill O
development O
program O
, O
pharmacists O
performed O
in O
an O
interdisciplinary O
team O
in O
a O
rural O
clinic O
. O
[]

CONCLUSION O
Age O
and O
gender O
, O
as O
well O
as O
the O
severity O
of O
cardiac O
dysfunction O
, O
appear O
to O
have O
an O
important O
effect O
on O
the O
severity O
of O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Comparing O
the O
effectiveness O
of O
copper O
intrauterine O
devices O
available O
in O
Canada O
. O
[]

Secondary O
outcomes O
include O
any O
maternal O
or O
fetal O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
miscarriage B-outcome ['Mortality']
, O
pregnancy B-outcome ['Physiological-Clinical']
, O
live B-outcome ['Mortality']
births I-outcome ['Mortality']
, O
and O
neonatal B-outcome ['Physiological-Clinical']
outcomes. O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical']]

Two-year O
prospective O
clinical O
comparison O
of O
immediate O
replacement O
vs. O
immediate O
restoration O
of O
single O
tooth O
in O
the O
esthetic O
zone O
. O
[]

Maintenance O
of O
effect O
during O
the O
double-blind O
phase O
was O
evaluated O
based O
on O
a O
comparison O
of O
the O
percentages O
of O
galcanezumab- O
and O
placebo-treated O
patients O
with O
maintenance O
of O
30, O
50, O
75, O
and O
100% O
response B-outcome ['Physiological-Clinical']
(defined O
as O
>/=30, O
>/=50, O
>/=75, O
and O
100% O
reduction O
from O
baseline O
in O
monthly O
migraine O
headache O
days O
[MHD]) O
at O
an O
individual O
patient O
level. O
[['Physiological-Clinical']]

During O
the O
cardiac O
arrest O
simulation O
, O
establishing O
and O
performing O
ventilation B-outcome ['Resource-use']
took O
an O
average O
of O
57 O
s O
with O
the O
LTS-D O
compared O
to O
116 O
s O
with O
ET O
and O
111 O
s O
with O
the O
BMV O
. O
['Resource-use']

DESIGN O
Randomized O
, O
double-blind O
, O
placebo-controlled O
phase O
3 O
trial O
conducted O
from O
July O
1997 O
through O
May O
1999 O
. O
[]

RESULTS O
A O
total O
of O
191 O
patients O
with O
superficial O
bladder O
carcinoma O
were O
available O
for O
efficacy O
analysis O
. O
[]

Buspirone O
was O
found O
to O
be O
safe O
and O
efficacious O
, O
without O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
for O
decreasing O
hyperactivity B-outcome ['Life-Impact']
and O
increasing O
completed B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
tasks I-outcome ['Life-Impact']
. O
['Adverse-effects', 'Life-Impact', 'Life-Impact']

10.32 O
?g/L O
, O
32.00 O
? O
[]

Principal O
components O
analysis O
was O
used O
to O
construct O
a O
wealth O
and O
malaria O
knowledge O
index O
. O
[]

Sixteen O
schizophrenia O
patients O
with O
predominantly O
negative O
symptoms O
on O
stable O
antipsychotic O
medication O
were O
treated O
with O
20 O
Hz O
rTMS O
( O
90 O
% O
of O
motor O
threshold O
, O
2000 O
stimuli O
per O
session O
) O
over O
ten O
days O
within O
2 O
weeks O
with O
six O
weeks O
follow-up O
. O
[]

The O
antidepressant O
effect O
of O
maprotiline O
was O
reflected O
in O
the O
GDS O
. O
[]

The O
latter O
were O
randomized O
to O
oral O
calcium O
( O
3 O
g/day O
) O
plus O
vitamin O
D O
( O
1 O
mg/day O
) O
( O
Group O
A O
, O
n=49 O
) O
, O
calcium O
alone O
( O
Group O
B O
, O
n=49 O
) O
, O
or O
no O
supplements O
( O
Group O
C O
, O
n=50 O
) O
. O
[]

After O
four O
weeks O
of O
treatment O
82.4 O
% O
, O
81.3 O
% O
, O
and O
93.3 O
% O
of O
the O
low-dose O
group O
, O
high-dose O
group O
, O
and O
placebo O
group O
, O
respectively O
, O
were O
titrated O
to O
the O
maximum O
dose O
level O
. O
[]

Seventeen O
patients O
on O
chronic O
digitalis O
and O
diuretic O
therapy O
were O
randomized O
to O
receive O
either O
flosequinan O
( O
n O
= O
9 O
) O
or O
placebo O
( O
n O
= O
8 O
) O
in O
a O
double-blind O
fashion O
. O
[]

Randomization O
was O
achieved O
by O
the O
envelope O
method O
. O
[]

After O
further O
exclusions, O
75 O
(94%) O
patients O
were O
randomly O
assigned O
to O
groups, O
received O
at O
least O
one O
dose O
of O
treatment O
(25 O
patients O
to O
receive O
10 O
mg O
pegbelfermin O
once O
a O
day; O
24 O
patients O
to O
receive O
20 O
mg O
pegbelfermin O
once O
a O
week, O
and O
26 O
patients O
to O
receive O
placebo), O
and O
were O
included O
in O
the O
primary O
analysis. O
[]

Subjects O
received O
3 O
years O
of O
grass O
AIT O
( O
n O
= O
157 O
) O
or O
placebo O
( O
n O
= O
126 O
) O
, O
followed O
by O
1 O
year O
of O
follow-up O
. O
[]

IFTC O
0702 O
randomized O
phase O
III O
study O
] O
. O
[]

Concomitant O
infusion O
of O
ANF O
3 O
pmol O
kg-1 O
min-1 O
and O
15 O
pmol O
kg-1 O
min-1 O
significantly O
attenuated O
this O
rise O
in O
plasma O
aldosterone O
to O
approximately O
130 O
% O
( O
P O
less O
than O
0.05 O
) O
and O
110 O
% O
( O
P O
less O
than O
0.01 O
) O
of O
baseline O
values O
respectively O
. O
[]

CONCLUSIONS O
The O
addition O
of O
intravenous O
nicorandil O
to O
PCI O
leads O
to O
beneficial O
clinical B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

DESIGN O
Prospective O
randomized O
study O
. O
[]

Comparisons O
were O
also O
made O
for O
self-reported O
breast O
symptoms O
occurring O
during O
the O
study O
period O
and O
for O
changes O
in O
serum O
values O
of O
antinuclear O
antibodies O
, O
rheumatoid O
factor O
, O
and O
cardiolipin O
antibodies O
immunoglobulin O
G O
and O
immunoglobulin O
M. O
The O
majority O
of O
the O
women O
with O
implant O
rupture O
had O
no O
visible O
magnetic B-outcome ['Physiological-Clinical']
resonance I-outcome ['Physiological-Clinical']
imaging I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of O
their O
ruptured O
implants O
. O
['Physiological-Clinical']

Patients O
from O
the O
1st O
group O
were O
to O
take O
nicorandil O
2 O
days O
and O
1 O
day O
before O
the O
PCI O
at O
the O
30 O
mg/day O
dose, O
then O
20 O
mg O
orally O
2 O
hours O
just O
before O
PCI, O
and O
one O
more O
time O
6 O
hours O
after O
the O
PCI O
- O
10 O
mg O
nicorandil. O
[]

Mean O
time O
between O
upper O
and O
lower O
hemi-body O
irradiation O
was O
69 O
days O
( O
range O
35-294 O
) O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
either O
an O
experimental O
or O
a O
control O
group O
. O
[]

Treatment O
of O
acute O
ischaemic O
stroke O
with O
the O
low-affinity O
, O
use-dependent O
NMDA O
antagonist O
AR-R15896AR O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Among O
the O
children O
in O
the O
secretin O
group O
, O
the O
mean O
total O
score O
on O
the O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
at O
base O
line O
was O
59.0 O
( O
range O
of O
possible O
values O
, O
0 O
to O
158 O
, O
with O
a O
larger O
value O
corresponding O
to O
greater O
impairment O
) O
, O
and O
among O
those O
in O
the O
placebo O
group O
it O
was O
63.2 O
. O
['Life-Impact']

Standardised O
photographs O
of O
each O
wart O
were O
taken O
before O
, O
during O
( O
week O
7 O
) O
and O
after O
treatment O
( O
weeks O
14 O
and O
18 O
) O
. O
[]

PATIENTS O
Forty-five O
patients O
with O
displaced O
closed O
and O
open O
Gustilo O
type O
I-IIIA O
fractures O
of O
the O
central O
two O
thirds O
of O
the O
tibia O
. O
[]

Videotaped O
training O
in O
alcohol O
counseling O
for O
obstetric O
care O
practitioners O
: O
a O
randomized O
controlled O
trial O
. O
[]

The O
main O
factors O
were O
two O
sources O
of O
dietary O
CP O
and O
four O
levels O
of O
RPLM O
. O
[]

Prospective O
study O
of O
Clostridium B-outcome ['Physiological-Clinical']
difficile I-outcome ['Physiological-Clinical']
intestinal O
colonization O
and O
disease O
following O
single-dose O
antibiotic O
prophylaxis O
in O
surgery O
. O
['Physiological-Clinical']

Further O
studies O
comparing O
costs O
and O
resource O
utilization O
in O
this O
patient O
population O
are O
needed O
. O
[]

Randomization O
was O
stratified O
on O
the O
basis O
of O
whether O
patients O
had O
untreated O
or O
relapsed O
retinitis O
. O
[]

Plasma O
and O
tissue O
antioxidant O
status O
was O
improved O
by O
supplementation O
. O
[]

For O
this O
intervention O
group O
compared O
with O
the O
usual O
care O
group O
there O
was O
a O
highly O
significant O
improvement O
in O
the O
level O
of O
advice B-outcome ['Life-Impact']
recorded I-outcome ['Life-Impact']
as O
having O
been O
given O
on O
drug B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
, O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
driving B-outcome ['Life-Impact']
, O
alcohol B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Life-Impact']

We O
monitored O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
systolic/diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP/DBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
throughout O
the O
bronchoscopy O
and O
calculated O
the O
rate-pressure O
product O
( O
RPP= O
( O
HRxSBP O
) O
/100 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Data O
collection O
occurred O
in O
a O
simulated O
situation O
. O
[]

The O
basic O
antianginal O
therapy O
was O
allowed O
to O
use O
in O
both O
groups: O
beta-blockers, O
calcium O
antagonists, O
ATE O
inhibitors O
/ O
angiotensin O
II O
receptor O
blockers, O
statins, O
acetylsalicylic O
acid, O
blockers O
of O
P2Y12 O
receptor O
platelets. O
[]

CONCLUSION: O
Patients O
under O
long-term O
treatment O
with O
riociguat O
show O
significantly O
reduced O
right B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
improved O
RV B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
PAH O
and O
CTEPH. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
7501160 O
[]

RESULTS O
Median O
uterine B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
was O
400 O
g O
in O
both O
LAVH O
and O
TAH O
group O
. O
['Physiological-Clinical']

The O
mean O
birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
was O
770 O
g O
in O
the O
vitamin O
A O
group O
and O
769 O
g O
in O
the O
control O
group O
, O
and O
the O
respective O
gestational O
ages O
were O
26.8 O
and O
26.7 O
weeks O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
In O
a O
previous O
study O
we O
showed O
that O
patients O
with O
severe O
aplastic O
anemia O
( O
SAA O
) O
treated O
with O
anti-lymphocyte O
globulin O
( O
ALG O
) O
, O
cyclosporin O
( O
CyA O
) O
and O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
5 O
micro O
g/kg/day O
had O
an O
encouraging O
outcome O
. O
[]

In O
contrast O
, O
the O
control O
group O
demonstrated O
no O
significant O
improvements O
related O
to O
stress O
or O
quality O
of O
life O
. O
[]

METHODS O
Between O
July O
1999 O
and O
December O
2000 O
, O
140 O
patients O
undergoing O
anal O
sphincterotomy O
were O
randomized O
into O
two O
groups O
to O
have O
their O
fibrous O
polyps O
and O
hypertrophied O
anal O
papillae O
either O
removed O
by O
radiofrequency O
surgery O
or O
left O
intact O
. O
[]

Group O
II O
, O
which O
consisted O
of O
27 O
infants O
, O
received O
simple O
exchanges O
. O
[]

The O
results O
are O
discussed O
in O
relation O
to O
theories O
of O
pathogenesis O
of O
perioral B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
and O
steroid B-outcome ['Physiological-Clinical']
acne I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Several O
indicators B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
, O
immunity B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Urine B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
group O
2 O
than O
in O
group O
1 O
( O
0.7 O
+/- O
0.4 O
vs. O
1.4 O
+/- O
1.0 O
mL/min O
, O
respectively O
; O
p O
< O
.05 O
) O
. O
['Physiological-Clinical']

Also O
here O
, O
this O
was O
contrasted O
by O
better O
EFS O
( O
p=0.039 O
) O
in O
the O
LMO2 O
positive O
group O
of O
ABC O
subtypes O
when O
treated O
with O
the O
rituximab O
containing O
regimen O
. O
[]

Improvement O
in O
patient O
safety O
is O
a O
high-priority O
issue O
of O
great O
social O
import O
. O
[]

In O
a O
companion O
study O
, O
chronic O
bumetanide O
treatment O
significantly O
improved O
accuracy O
in O
facial O
emotional O
labelling O
, O
and O
increased O
brain O
activation O
in O
areas O
involved O
in O
social O
and O
emotional O
perception O
( O
Hadjikhani O
et O
al. O
, O
submitted O
) O
. O
[]

We O
evaluated O
the O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
low-dose O
etoposide O
in O
relapsed O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O
['Physiological-Clinical']

Its O
role O
in O
the O
treatment O
of O
HPRC O
remains O
to O
be O
elucidated O
in O
an O
appropriate O
phase O
III O
setting O
. O
[]

METHODS O
From O
March O
2000 O
to O
May O
2003 O
, O
112 O
patients O
with O
potentially O
curable O
pancreatic O
head O
cancer O
were O
enrolled O
and O
intraoperatively O
randomized O
to O
a O
standard O
or O
extended O
lymphadenectomy O
group O
. O
[]

RESULTS O
Coadministration O
of O
enalapril-compared O
with O
placebo-resulted O
in O
a O
temporarily O
higher O
metabolic B-outcome ['Physiological-Clinical']
effect O
of O
glibenclamide B-outcome ['Physiological-Clinical']
( O
AUC O
GIR O
( O
0-120 O
) O
229 O
+/- O
173 O
vs O
137 O
+/- O
44 O
mg O
kg O
( O
-1 O
) O
, O
p O
< O
0.01 O
; O
mean O
+/- O
SD O
) O
, O
which O
lasted O
from O
120 O
min O
to O
240 O
min O
after O
enalapril O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Lowering O
the O
triglyceride/high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
is O
associated O
with O
the O
beneficial O
impact O
of O
pioglitazone O
on O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
in O
diabetic O
patients O
: O
insights O
from O
the O
PERISCOPE O
( O
Pioglitazone O
Effect O
on O
Regression O
of O
Intravascular O
Sonographic O
Coronary O
Obstruction O
Prospective O
Evaluation O
) O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Partly O
based O
on O
between-patient O
dispersion O
of O
BP O
values O
during O
treatment O
( O
interindividual O
variability O
) O
it O
has O
also O
been O
reported O
that O
long-term B-outcome ['Physiological-Clinical']
clinic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
is O
greater O
for O
?-blocker O
than O
for O
calcium O
antagonist O
and O
other O
types O
of O
treatment O
. O
['Physiological-Clinical']

Journal O
ID: O
101234168 O
[]

A O
comparative O
study O
of O
the O
safety O
and O
efficacy O
of O
FemCap O
, O
a O
new O
vaginal O
barrier O
contraceptive O
, O
and O
the O
Ortho O
All-Flex O
diaphragm O
. O
[]

METHODS O
Eighty-four O
cases O
were O
randomly O
divided O
into O
3 O
groups O
, O
28 O
cases O
in O
each O
group O
. O
[]

hemoglobin O
per O
gm O
. O
[]

TRIAL O
REGISTRATION: O
Prospectively O
registered O
at O
ClinicalTrials. O
[]

In O
the O
study O
population O
with O
normal O
metabolic O
status O
the O
two O
oral O
formulations O
proved O
to O
be O
bioequivalent O
with O
regard O
to O
the O
pharmacokinetic O
parameters O
Cmax B-outcome ['Physiological-Clinical']
, O
AUC O
( O
0-Tlast O
) O
, O
AUC O
( O
0-infinity O
) O
and O
Ae B-outcome ['Adverse-effects']
( I-outcome ['Adverse-effects']
24h I-outcome ['Adverse-effects']
) I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Under O
there O
conditions O
, O
tobramycin O
could O
not O
be O
measured O
in O
the O
serum O
. O
[]

Studies O
of O
predictive O
biomarkers O
are O
needed O
to O
subset O
appropriate O
patients O
. O
[]

Taking O
together O
all O
aspects O
assessed O
including O
the O
healing B-outcome ['Physiological-Clinical']
rate O
, O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
examination I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
we O
judged O
the O
hEGF O
to O
be O
a O
useful O
and O
safe O
anticuler O
drug O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Effects O
of O
skin-to-skin O
contact O
on O
autonomic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
preterm O
infants O
. O
['Physiological-Clinical']

Statistically O
significant O
differences O
in O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
found O
for O
cytomegalovirus B-outcome ['Physiological-Clinical']
( O
CMV B-outcome ['Physiological-Clinical']
) O
infection B-outcome ['Physiological-Clinical']
( O
induction O
, O
32.5 O
% O
vs. O
noninduction O
, O
19.0 O
% O
, O
P=0.009 O
) O
, O
leukopenia B-outcome ['Physiological-Clinical']
( O
37.3 O
% O
vs. O
9.5 O
% O
, O
P O
< O
0.001 O
) O
, O
fever B-outcome ['Physiological-Clinical']
( O
25.2 O
% O
vs. O
10.1 O
% O
, O
P=0.001 O
) O
, O
herpes B-outcome ['Physiological-Clinical']
simplex I-outcome ['Physiological-Clinical']
( O
17.9 O
% O
vs. O
5.7 O
% O
, O
P=0.001 O
) O
, O
and O
thrombocytopenia B-outcome ['Physiological-Clinical']
( O
11.3 O
% O
vs. O
3.2 O
% O
, O
P=0.007 O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Teaching O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
to O
young O
children O
with O
autism O
: O
a O
randomised O
controlled O
trial O
of O
an O
emotion O
training O
programme O
. O
['Life-Impact']

Patients O
were O
then O
randomly O
assigned O
to O
receive O
either O
a O
single O
dose O
of O
ciclesonide O
200 O
microg O
( O
n O
= O
251 O
) O
or O
placebo O
( O
n O
= O
251 O
) O
administered O
intranasally O
. O
[]

RESULTS O
Preoperative O
variables O
were O
the O
same O
in O
both O
groups O
. O
[]

In O
total O
, O
173 O
eligible O
men O
with O
untreated O
ED O
were O
randomized O
to O
double-blind O
treatment O
with O
40 O
mg O
of O
simvastatin O
or O
placebo O
once O
daily O
for O
6 O
months O
. O
[]

All O
patients O
presented O
with O
a O
vital O
maxillary O
or O
mandibular O
molar, O
premolar, O
or O
front O
teeth O
designated O
for O
intentional O
endodontic O
RCT O
for O
prosthetic O
reasons. O
[]

[ O
Evaluating O
an O
interactive O
, O
multi-media O
learning O
system O
for O
the O
study O
of O
primary O
open O
angle O
glaucoma O
] O
. O
[]

Bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
following O
cessation O
of O
raloxifene O
therapy O
at O
96 O
weeks O
was O
greater O
than O
in O
the O
control O
group O
, O
suggesting O
accelerated O
bone O
loss O
. O
['Physiological-Clinical']

PURPOSE: O
To O
evaluate O
corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(ECD) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
2 O
years O
after O
phacoemulsification O
in O
subjects O
from O
the O
COMPASS O
trial O
(ClinicalTrials.gov, O
NCT01085357) O
who O
had O
mild-to-moderate O
primary O
open-angle O
glaucoma O
and O
visually O
significant O
cataracts. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Change O
in O
serum O
hydroxymethylglutaryl-CoA B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
(HMGCR) I-outcome ['Physiological-Clinical']
levels O
correlated O
more O
with O
change O
in O
lipid B-outcome ['Physiological-Clinical']
indices O
of O
DR O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS O
Twenty-seven O
patients O
have O
died B-outcome ['Mortality']
; O
6 O
deaths B-outcome ['Mortality']
were O
reported O
by O
the O
clinical O
center O
as O
due O
to O
metastatic B-outcome ['Physiological-Clinical']
melanoma I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

After O
that O
the O
total O
daily O
doses O
was O
adjusted O
to O
240 O
mg O
and O
160 O
mg O
, O
respectively O
, O
until O
the O
7th O
day O
. O
[]

Title: O
Preventive O
effect O
of O
ecabet O
sodium O
on O
low-dose O
aspirin-induced O
small B-outcome ['Physiological-Clinical']
intestinal I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
: O
a O
randomized, O
double-blind, O
pilot O
study. O
[['Physiological-Clinical']]

Activation O
of O
the O
carotid O
chemoreflex O
secondary O
to O
muscle B-outcome ['Physiological-Clinical']
metaboreflex I-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
in O
men O
. O
['Physiological-Clinical']

PARTICIPANTS O
A O
total O
of O
182 O
six-month-old O
infants O
. O
[]

BACKGROUND O
We O
recently O
obtained O
evidence O
of O
long-term B-outcome ['Physiological-Clinical']
adaptation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
to O
changes O
in O
intakes O
of O
carbohydrate O
and O
fiber O
in O
subjects O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

The O
horses O
were O
euthanized O
at O
24 O
weeks O
. O
[]

RESULTS O
: O
The O
proportion O
of O
children O
with O
HIV-1 O
RNA O
< O
or O
=400 O
copies/mL O
and O
on O
randomized O
treatment O
at O
48 O
weeks O
was O
65 O
% O
among O
children O
assigned O
NFV O
+ O
RTV O
+ O
ddI O
versus O
28 O
% O
among O
those O
assigned O
NFV O
+ O
NVP O
+ O
d4T O
( O
P O
= O
0.039 O
) O
. O
[]

CONCLUSION O
Both O
ischaemic O
preconditioning O
and O
cardiopulmonary O
bypass O
induced O
free B-outcome ['Physiological-Clinical']
radicals I-outcome ['Physiological-Clinical']
generation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Prospective O
comparison O
of O
nasal O
versus O
oral O
insertion O
of O
a O
thin O
video O
endoscope O
in O
healthy O
volunteers O
. O
[]

Work-related B-outcome ['Life-Impact', 'Life-Impact']
fear I-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
pain I-outcome ['Life-Impact', 'Life-Impact']
was O
reduced O
in O
both O
the O
Combined- O
(p O
= O
0.003) O
and O
Exercise-arm O
(p O
= O
0.002). O
[['Life-Impact', 'Life-Impact']]

Hypotension B-outcome ['Physiological-Clinical']
induced O
by O
prostaglandin O
E1 O
( O
PGE1 O
) O
infusion O
( O
100-150 O
ng/kg/minute O
) O
during O
halothane O
anaesthesia O
to O
reduce O
operative O
blood O
loss O
during O
mastectomy O
was O
investigated O
. O
['Physiological-Clinical']

During O
radiotherapy O
, O
grade O
I O
, O
II B-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
was O
observed O
in O
29.4 O
% O
, O
5.9 O
% O
and O
56.4 O
% O
, O
7.7 O
% O
patients O
respectively O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Trial O
Registration O
ClinicalTrials.gov O
Identifier O
: O
NCT00235456 O
. O
[]

METHODS O
AND O
MATERIALS O
Between O
January O
2010 O
and O
January O
2012 O
, O
44 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
( O
FIGO O
2009 O
) O
stage O
IIB-IIIB O
squamous O
cell O
carcinoma O
of O
the O
cervix O
were O
randomized O
to O
receive O
50.4 O
Gy O
in O
28 O
fractions O
delivered O
via O
either O
WP-CRT O
or O
WP-IMRT O
with O
concurrent O
weekly O
cisplatin O
40 O
mg/m O
( O
2 O
) O
. O
[]

After O
the O
change O
to O
flecainide O
, O
9 O
of O
15 O
patients O
( O
60 O
% O
) O
with O
AF O
still O
converted B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Due O
to O
easy O
handling O
of O
the O
nasal-spray O
a O
good O
compliance B-outcome ['Life-Impact']
was O
confirmed O
. O
['Life-Impact']

Accordingly O
, O
arzoxifene O
20 O
mg/day O
was O
selected O
for O
further O
study O
in O
patients O
with O
breast O
cancer O
. O
[]

To O
evaluate O
treatment O
withdrawal O
effects O
, O
12- O
and O
24-month O
post O
EOT O
BMD O
results O
are O
available O
for O
122 O
and O
126 O
patients O
, O
respectively O
. O
[]

Chronic B-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
was O
present O
in O
81 O
% O
patients O
. O
['Physiological-Clinical']

METHODS O
Eighty O
patients O
were O
randomised O
to O
receive O
a O
daily O
supplement O
with O
either O
vitamin O
E O
, O
selenium O
, O
vitamin O
C O
, O
coenzyme O
Q10 O
( O
intervention O
group O
) O
or O
placebo O
over O
21 O
weeks O
. O
[]

Group O
1 O
received O
a O
weekly O
session O
of O
posterior O
tibial O
nerve O
stimulation O
for O
12 O
weeks O
and O
group O
2 O
was O
the O
placebo O
group O
. O
[]

Randomized O
study O
of O
continuous O
infusion O
fluorouracil O
versus O
fluorouracil O
plus O
cisplatin O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

BACKGROUND O
Mineralocorticoid-receptor O
antagonists O
improve O
the O
prognosis O
for O
patients O
with O
heart O
failure O
and O
a O
reduced O
left O
ventricular O
ejection O
fraction O
. O
[]

STUDY O
DESIGN O
Thirty O
patients O
with O
gynecologic O
malignancy O
, O
who O
had O
laparoscopic O
pelvic O
lymphadenectomy O
were O
randomly O
assigned O
for O
lymphadenectomy O
in O
1 O
side O
of O
the O
pelvis O
using O
the O
Ligaclip O
, O
whereas O
, O
in O
the O
other O
side O
, O
the O
bipolar O
coagulation O
to O
seal O
lymphatic O
vessels O
was O
used O
. O
[]

Endoscopic O
versus O
operative O
gastrostomy O
: O
final O
results O
of O
a O
prospective O
randomized O
trial O
. O
[]

CONCLUSIONS O
Simple O
drainage O
with O
continuous O
irrigation O
of O
the O
presacral O
space O
, O
in O
patients O
with O
abdominoperineal O
resection O
or O
proctocolectomy O
, O
could O
significantly O
lower O
the O
incidence O
of O
major O
complication O
and O
improve O
wound O
healing O
for O
perineal O
wound O
when O
compared O
with O
simple O
drainage O
only O
. O
[]

The O
participants O
were O
randomly O
assigned O
to O
either O
the O
resin O
infiltration O
group O
or O
the O
fluoride O
varnish O
group. O
[]

Treatment O
with O
coumarin O
to O
prevent O
or O
delay O
recurrence O
of O
malignant O
melanoma O
. O
[]

A O
comparison O
of O
21 O
patients O
with O
a O
DSV O
and O
the O
patients O
with O
DP O
valves O
, O
evaluated O
by O
measuring O
the O
reduction O
of O
the O
Evans O
Index O
, O
revealed O
a O
distinctly O
higher O
percentage O
of O
significant O
regressions O
in O
the O
DP O
valve O
collective O
, O
without O
doubt O
due O
to O
chronic O
overdrainage O
. O
[]

Participants O
will O
be O
recruited O
after O
discharge O
from O
hospital O
and O
up O
to O
12 O
months O
post-stroke O
from O
hospital O
stroke O
services O
and O
community O
therapy-provider O
services O
. O
[]

All O
patients O
will O
receive O
vasodilator O
therapy O
, O
unless O
they O
find O
it O
intolerable O
. O
[]

The O
initial O
3 O
mg O
dose O
was O
increased O
to O
4 O
mg O
from O
cycle O
5 O
if O
tolerated O
during O
cycles O
1-4. O
[]

Markers O
of O
bone B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
-- O
serum O
total O
alkaline B-outcome ['Physiological-Clinical']
phosphatase B-outcome ['Physiological-Clinical']
, O
bone-specific B-outcome ['Physiological-Clinical']
alkaline B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
tartrate-resistant B-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
, O
osteocalcin B-outcome ['Physiological-Clinical']
, O
intact B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

0.05 O
) O
. O
[]

Median O
increase O
above O
baseline O
in O
CD4 B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
study O
comprised O
240 O
patients O
with O
either O
unstable O
angina O
or O
non-ST-elevation O
myocardial O
infarction O
in O
the O
previous O
2 O
weeks O
who O
were O
randomized O
to O
a O
folate O
group O
( O
n O
=116 O
) O
or O
a O
placebo O
group O
( O
n O
=124 O
) O
. O
[]

There O
was O
no O
difference O
in O
the O
rate O
of O
[]

Dental B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
was O
reported O
among O
45.5 O
% O
of O
the O
study O
group O
( O
n=352 O
) O
in O
the O
2 O
months O
following O
screening O
. O
['Life-Impact']

RESULTS: O
The O
levels O
of O
APN O
and O
AdipoR1 O
were O
significantly O
decreased O
in O
T2DM O
group O
and O
T2DM O
+ O
MVC O
group O
compared O
with O
NC O
group, O
with O
the O
lowest O
value O
in O
T2DM O
+ O
MVC O
group O
(all O
P<0.01). O
[]

Five O
of O
10 O
patients O
showed O
abnormalities O
of O
the O
hypothalamic-pituitary-adrenal B-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
, O
including O
borderline B-outcome ['Physiological-Clinical']
or O
increased O
UFC B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
4 O
of O
them O
accompanied O
by O
blunted O
ACTH O
in O
2 O
cases O
and O
failure O
of O
cortisol O
to O
suppress O
after O
dexamethasone O
in O
1 O
; O
the O
fifth O
patient O
displayed O
low O
ACTH O
and O
resistance O
to O
dexamethasone O
suppression O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION: O
The O
results O
of O
this O
study O
showed O
that O
ET O
as O
an O
adjunctive O
therapy O
to O
montelukast O
may O
benefit O
for O
children O
with O
MA. O
[]

Adult O
participants O
performed O
significantly O
better O
on O
the O
UCAST-FW O
in O
comparison O
to O
the O
child O
participants O
. O
[]

BACKGROUND O
Electrical O
cardioversion O
( O
ECV O
) O
of O
atrial O
fibrillation O
( O
AF O
) O
is O
limited O
by O
a O
5-10 O
% O
failure O
rate O
and O
by O
the O
expense O
arising O
from O
a O
perceived O
need O
for O
general O
anesthesia O
. O
[]

The O
authors O
tested O
this O
hypothesis O
. O
[]

METHOD O
Sixty-four O
children O
with O
autism O
( O
ages O
2-7 O
years O
; O
55 O
boys O
and O
9 O
girls O
) O
with O
a O
range O
of O
intelligence O
quotient O
and O
verbal O
ability O
were O
randomly O
assigned O
, O
in O
a O
double-blind O
manner O
, O
to O
secretin O
or O
placebo O
groups O
. O
[]

2018;17(12):1290-1296. O
[]

Publication O
Type: O
Journal O
Article O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

However, O
although O
it O
was O
not O
sufficient O
to O
enhance O
muscle O
recovery O
observed O
by O
testosterone B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
responses, O
it O
was O
observed O
that O
serum O
25(OH)D B-outcome ['Physiological-Clinical']
levels O
could O
be O
a O
predictor O
of O
anabolic B-outcome ['Physiological-Clinical']
and O
catabolic B-outcome ['Physiological-Clinical']
hormones. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
lowering O
effect O
of O
reduced O
alcohol O
consumption O
on O
blood O
pressure O
was O
independent O
of O
changes O
in O
salt O
consumption O
, O
which O
were O
estimated O
by O
24-hour O
urine O
collection O
and O
body O
weight O
. O
( O
[]

BACKGROUND O
We O
report O
the O
10-year O
results O
of O
the O
EORTC O
trial O
24891 O
comparing O
a O
larynx-preservation O
approach O
to O
immediate O
surgery O
in O
hypopharynx O
and O
lateral O
epilarynx O
squamous O
cell O
carcinoma O
. O
[]

Regardless O
of O
the O
dosage O
used O
, O
indobufen O
was O
shown O
to O
induce O
a O
prompt O
normalization O
of O
the O
enhanced B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
of O
these O
patients O
. O
['Physiological-Clinical']

This O
condition O
is O
associated O
with O
activation O
of O
the O
renin O
angiotensin O
system O
( O
RAS O
) O
with O
elevated O
levels O
of O
angiotensin O
II O
( O
ANG O
II O
) O
, O
a O
potent O
pulmonary O
pressor O
agent O
. O
[]

A O
20-gauge O
catheter O
was O
inserted O
into O
a O
superficial O
radial O
vein O
of O
the O
left O
hand O
, O
and O
after O
the O
occlusion O
of O
venous O
drainage O
, O
Groups O
I O
, O
II O
, O
and O
III O
were O
pretreated O
with O
40 O
mg O
of O
lidocaine O
in O
saline O
, O
50 O
mg O
of O
i.v O
. O
[]

The O
effects O
of O
desensitizer O
, O
disinfectant O
, O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
on O
the O
tensile B-outcome ['Life-Impact']
bond I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
between O
adhesive O
and O
ceramic O
as O
well O
as O
between O
adhesive O
and O
dentin O
were O
examined O
. O
['Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

This O
study O
provided O
sleep O
education O
to O
parents O
of O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
to O
determine O
whether O
an O
individual O
or O
group O
format O
was O
more O
effective O
in O
improving O
sleep B-outcome ['Physiological-Clinical']
and O
aspects O
of O
daytime B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
and O
family B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Best O
response O
rates O
and O
median O
time O
to O
tumor B-outcome ['Physiological-Clinical']
progression B-outcome ['Physiological-Clinical']
for O
high O
versus O
low O
thymidine O
phosphorylase O
expression O
were O
27.6 O
% O
versus O
6.3 O
% O
( O
P O
= O
0.023 O
) O
and O
5.4 O
versus O
1.9 O
months O
( O
P O
= O
0.076 O
) O
, O
and O
for O
folylpolyglutamate O
synthetase O
were O
37.5 O
% O
versus O
10.0 O
% O
( O
P O
= O
0.115 O
) O
and O
8.6 O
versus O
3.0 O
months O
( O
P O
= O
0.019 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
for O
patients O
with O
gram-positive O
bacteremia O
and O
for O
all O
other O
patients O
, O
there O
were O
no O
differences O
by O
treatment O
regimens O
in O
the O
proportion O
of O
febrile B-outcome ['Physiological-Clinical']
patients O
on O
each O
trial O
day O
( O
P O
= O
.85 O
, O
P O
= O
.82 O
, O
respectively O
) O
or O
in O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
( O
P O
= O
.22 O
, O
P O
= O
.93 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
benefit O
has O
been O
demonstrated O
from O
the O
addition O
of O
CMF O
chemotherapy O
in O
tamoxifen O
responders O
. O
[]

Data O
analysis O
was O
conducted O
using O
Chi-square, O
independent O
t-test, O
and O
paired O
t-test. O
[]

METHODS O
During O
a O
6-year O
period O
, O
296 O
patients O
with O
visible O
endoluminal O
tumor O
lesions O
were O
included O
in O
the O
study O
at O
the O
bronchoscopy O
unit O
of O
a O
university O
hospital O
. O
[]

[ O
Intra-arterial O
chemotherapy O
in O
advanced O
ovarian O
cancers O
. O
[]

OBJECTIVES O
The O
purpose O
of O
this O
study O
was O
to O
determine O
atheroma B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
patients O
with O
spotty O
calcification O
. O
['Physiological-Clinical']

On O
a O
subsequent O
day O
, O
we O
measured O
neural B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
while O
participants O
were O
shown O
static O
images O
of O
the O
previously O
learned O
virtual O
environment O
, O
now O
in O
the O
absence O
of O
any O
affective O
stimuli O
. O
['Physiological-Clinical']

The O
six-session O
intervention O
that O
emerged O
from O
the O
development O
process O
relied O
on O
both O
social-cognitive O
theories O
and O
peer O
influence O
models O
. O
[]

CONCLUSION O
Interpersonal O
communication O
can O
have O
a O
powerful O
effect O
on O
recruitment O
. O
[]

The O
number O
, O
duration O
, O
and O
[]

We O
assessed O
the O
effect O
of O
oral O
daily O
0.3 O
and O
0.6 O
mg O
laquinimod O
on O
MRI-monitored O
disease B-outcome ['Physiological-Clinical']
activity O
in O
a O
36-week O
double-blind O
, O
placebo-controlled O
phase O
IIb O
study O
. O
['Physiological-Clinical']

To O
test O
this O
hypothesis O
lymph O
nodes O
of O
patients O
which O
were O
treated O
either O
by O
lymph O
node O
sampling O
or O
systematic O
lymphadenectomy O
were O
screened O
for O
micrometastatic O
spread O
of O
tumor O
cells O
and O
the O
influence O
of O
nodal O
micrometastases O
on O
the O
efficacy O
of O
lymphadenectomy O
was O
analyzed O
. O
[]

The O
loco-regional O
anesthesia O
was O
associated O
to O
psychological O
detachment O
in O
84 O
% O
of O
the O
cases O
and O
the O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
of O
36 O
% O
. O
['Physiological-Clinical']

Effects O
of O
four O
dose O
levels O
of O
MPH O
on O
parent O
and O
teacher O
behavioral B-outcome ['Life-Impact']
ratings O
were O
investigated O
using O
a O
within-subject O
, O
crossover O
, O
placebo-controlled O
design O
. O
['Life-Impact']

MBCT O
appears O
to O
be O
a O
valid O
form O
of O
intervention O
for O
children O
with O
autism O
. O
[]

Pathologic O
and O
quantitative O
image O
analyses O
were O
performed O
to O
evaluate O
the O
size O
and O
quality O
of O
the O
obtained O
specimens O
. O
[]

Baseline O
evaluations O
were O
performed O
on O
31 O
patients O
after O
a O
four-week O
placebo O
washout O
period O
. O
[]

5 O
alpha-metabolism O
in O
finasteride-treated O
subjects O
and O
male O
pseudohermaphrodites O
with O
inherited O
5 O
alpha-reductase O
deficiency O
. O
[]

All O
three O
studied O
drugs O
resulted O
in O
a O
significant O
increase O
in O
the O
reactance B-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.01 O
) O
and O
decrease O
in O
resonant B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Flow-cytometric O
studies O
with O
eleutherococcus O
senticosus O
extract O
as O
an O
immunomodulatory O
agent O
. O
[]

Study O
of O
the O
therapeutic O
effects O
of O
a O
hippotherapy O
simulator O
in O
children O
with O
cerebral O
palsy O
: O
a O
stratified O
single-blind O
randomized O
controlled O
trial O
. O
[]

A O
greater O
proportion O
of O
cats O
receiving O
meloxicam O
medication O
showed O
a O
significant O
worsening O
of O
owner O
assessment O
scores O
once O
the O
placed O
was O
introduced O
, O
when O
compared O
to O
the O
Glu-Ch O
group O
. O
[]

We O
also O
observed O
inverse O
associations O
between O
higher O
percentages O
of O
the O
RBC O
( O
n-3 B-outcome ['Physiological-Clinical']
) O
fatty B-outcome ['Physiological-Clinical']
acids B-outcome ['Physiological-Clinical']
, O
eicosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
EPA B-outcome ['Physiological-Clinical']
) O
( O
[ O
0.38 O
( O
0.19-0.77 O
) O
; O
P-trend O
= O
0.007 O
] O
and O
docosapentaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
DPA B-outcome ['Physiological-Clinical']
) O
[ O
0.32 O
( O
0.15-0.70 O
) O
; O
P-trend O
= O
0.024 O
] O
, O
and O
fibroadenoma O
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
SPACE O
trial O
compared O
risk O
and O
effectiveness O
of O
stent-supported O
angioplasty O
( O
CAS O
) O
vs O
carotid O
endarterectomy O
( O
CEA O
) O
using O
a O
noninferiority O
design O
in O
patients O
with O
symptomatic O
stenoses O
. O
[]

It O
aims O
to O
evaluate O
the O
effect O
of O
a O
late O
first-trimester O
(>12 O
gestational O
weeks) O
degree O
of O
adherence O
to O
a O
MedDiet O
pattern-based O
on O
six O
food O
targets-on O
a O
composite O
of O
materno-foetal O
outcomes O
(CMFCs). O
[]

METHODS O
Fourteen O
patients O
with O
stable O
hypercapnic O
COPD O
who O
were O
receiving O
long-term O
NPPV O
were O
included O
in O
the O
study O
. O
[]

RESULTS O
2656 O
patients O
in O
the O
intervention O
arm O
and O
2239 O
in O
the O
control O
arm O
required O
[]

Seventy-one O
patients O
were O
randomized O
to O
receive O
either O
esmolol O
( O
n O
= O
36 O
) O
or O
placebo O
( O
n O
= O
35 O
) O
as O
initial O
treatment O
. O
[]

Hybrid O
surgery O
comprised O
a O
two-field O
abdominal-thoracic O
operation O
(also O
called O
an O
Ivor-Lewis O
procedure) O
with O
laparoscopic O
gastric O
mobilization O
and O
open O
right O
thoracotomy. O
[]

In O
two O
prospective O
, O
randomized O
studies O
the O
frequency O
of O
headache B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Is O
altered O
central O
pain O
processing O
related O
to O
disease O
stage O
in O
chronic O
pancreatitis O
patients O
with O
pain O
? O
[]

Sixty O
two O
children O
with O
autism O
( O
aged O
43-103 O
months O
) O
were O
randomly O
allocated O
to O
two O
groups O
: O
group O
1 O
received O
placebo O
, O
followed O
six O
weeks O
later O
by O
secretin O
, O
and O
group O
2 O
received O
secretin O
followed O
by O
placebo O
. O
[]

In O
the O
CES O
study O
, O
HYPO O
subjects O
reached O
HYD O
status O
at O
45 O
minutes O
in O
all O
conditions O
( O
W O
1.013 O
? O
[]

A O
negative O
relationship O
was O
observed O
between O
minimum O
BG B-outcome ['Physiological-Clinical']
and O
adrenaline B-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
0.37 O
, O
P O
= O
0.01 O
) O
, O
ketone B-outcome ['Physiological-Clinical']
bodies I-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
-0.20 O
, O
P O
= O
0.05 O
) O
and O
NEFA B-outcome ['Physiological-Clinical']
( O
r O
( O
2 O
) O
= O
-0.35 O
, O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparison O
of O
the O
therapeutic O
effects O
of O
epoetin O
zeta O
to O
epoetin O
alfa O
in O
the O
maintenance O
phase O
of O
renal O
anaemia O
treatment O
. O
[]

Many O
who O
have O
had O
a O
total O
laryngectomy O
complain O
of O
unrelenting O
rhinorrhea O
that O
is O
often O
very O
difficult O
to O
control O
. O
[]

The O
current O
study O
has O
been O
designed O
to O
compare O
the O
classical O
mono O
chemotherapy O
docetaxel O
with O
a O
docetaxel O
cisplatin O
doublet O
. O
[]

Recurrence B-outcome ['Physiological-Clinical']
is O
a O
major O
challenge O
for O
CA O
treatment O
. O
['Physiological-Clinical']

Overall O
, O
recurrent B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
significantly O
lower O
( O
14 O
% O
) O
in O
the O
HBI O
group O
( O
mean O
+/- O
SD O
, O
823 O
dollars O
+/- O
1642 O
dollars O
vs O
960 O
dollars O
+/- O
1376 O
dollars O
per O
patient O
per O
year O
; O
P O
= O
.045 O
) O
. O
['Resource-use']

Temporary O
vascular O
access O
catheters O
( O
VACs O
) O
are O
important O
devices O
used O
in O
acute O
blood O
purification O
therapies O
. O
[]

Among O
them O
, O
86 O
% O
were O
successfully O
eradicated B-outcome ['Physiological-Clinical']
by O
the O
tinidazole O
, O
tetracycline O
, O
bismuth O
and O
rabeprazole O
therapy O
. O
['Physiological-Clinical']

In O
a O
previously O
reported O
trial O
to O
prevent O
delirium O
, O
we O
randomized O
patients O
undergoing O
hip B-outcome ['Physiological-Clinical']
fracture B-outcome ['Physiological-Clinical']
repair B-outcome ['Physiological-Clinical']
under O
spinal O
anesthesia O
to O
light O
( O
BIS O
> O
80 O
) O
or O
deep O
( O
BIS O
approximately O
50 O
) O
sedation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Post-myocardial O
infarction O
interventions O
that O
reduce O
psychological O
distress O
have O
the O
potential O
to O
improve O
long-term O
prognosis O
and O
psychological B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
for O
both O
men O
and O
women O
. O
['Life-Impact']

All O
recurrences O
after O
tension-free O
repairs O
were O
diagnosed O
within O
the O
first O
year O
after O
surgery O
. O
[]

Raising O
high-density O
lipoprotein O
in O
humans O
through O
inhibition O
of O
cholesteryl O
ester O
transfer O
protein O
: O
an O
initial O
multidose O
study O
of O
torcetrapib O
. O
[]

There O
was O
no O
survival B-outcome ['Mortality']
benefit O
from O
FAM O
adjuvant O
chemotherapy O
. O
['Mortality']

PSK O
may O
suppress O
CD57 O
( O
+ O
) O
T O
cells O
to O
improve O
survival O
of O
advanced O
gastric O
cancer O
patients O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
in O
terms O
of O
neuropsychological B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
indicated O
by O
computed O
tomography O
brain O
scans O
. O
['Physiological-Clinical']

A O
mindfulness-based O
intervention O
(MBI) O
represents O
a O
promising O
non-pharmacological O
framework O
for O
Alzheimer's O
disease O
prevention. O
[]

OBJECTIVE O
The O
efficacy O
and O
safety O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
lowering I-outcome ['Physiological-Clinical']
in O
elderly O
patients O
have O
not O
been O
sufficiently O
investigated O
in O
patients O
with O
diabetes O
. O
['Physiological-Clinical']

Most O
of O
the O
patients O
were O
discharged O
on O
the O
second O
postoperative O
day O
. O
[]

BACKGROUND O
AND O
OBJECTIVES O
Magnesium O
sulphate O
infusion O
during O
general O
anaesthesia O
reduces O
anaesthetic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use']

Patients O
were O
randomly O
assigned O
in O
a O
single-blind O
fashion O
to O
treatment O
with O
either O
lovastatin O
, O
an O
HMG O
CoA O
reductase O
inhibitor O
( O
n O
= O
16 O
; O
mean O
dose O
30.0 O
+/- O
12.6 O
mg/day O
) O
or O
placebo O
( O
n O
= O
18 O
) O
for O
2 O
years O
. O
[]

Twenty-four O
patients O
with O
chronic O
arthritis O
[ O
20 O
with O
rheumatoid O
arthritis O
( O
RA O
) O
and O
4 O
with O
psoriatic O
arthritis O
( O
PsA O
) O
] O
were O
divided O
into O
2 O
groups O
( O
10 O
RA O
, O
2 O
PsA O
) O
and O
randomly O
given O
CysA O
5 O
mg/kg O
daily O
or O
hydroxychloroquine O
( O
OH-Chlor O
) O
6 O
mg/kg O
daily O
in O
divided O
doses O
. O
[]

The O
role O
of O
the O
MA-sensitive O
leukocyte O
chemotaxis O
in O
rheumatoid O
arthritis O
. O
[]

Ten O
undernourished O
patients O
receiving O
total O
parenteral O
nutrition O
and O
undergoing O
major O
intestinal O
surgery O
were O
restarted O
on O
intravenous O
feeds O
identical O
to O
their O
pre-operative O
regimens O
within O
24 O
h O
of O
their O
operation O
. O
[]

Resulting O
data O
were O
then O
analyzed O
using O
t O
test, O
Pearson O
chi-square O
test, O
and O
Fisher O
exact O
test O
to O
compare O
outcomes O
between O
the O
2 O
groups. O
[]

RESULTS O
As O
the O
drop-out O
rate O
after O
crossover O
was O
high O
( O
17 O
of O
79 O
patients O
[ O
22 O
% O
] O
) O
, O
we O
analyzed O
the O
trial O
as O
a O
parallel O
clinical O
trial O
, O
using O
data O
of O
the O
first O
half O
of O
the O
crossover O
phase O
only O
. O
[]

METHODS O
The O
Collaborative O
Ocular O
Melanoma O
Study O
( O
COMS O
) O
is O
a O
set O
of O
clinical O
trials O
designed O
to O
compare O
the O
role O
of O
radiotherapy O
and O
enucleation O
in O
the O
treatment O
of O
medium O
and O
large-size O
choroidal O
melanoma O
. O
[]

Patients O
were O
stratified O
according O
to O
esophageal O
size O
, O
based O
on O
the O
diameter O
of O
the O
divided O
esophagus O
( O
< O
or O
> O
or O
= O
30 O
mm O
) O
and O
then O
were O
randomized O
to O
have O
either O
a O
hand-sewn O
or O
a O
stapled O
anastomosis O
. O
[]

Objective O
and O
[]

Pre- O
and O
post-treatment O
pain O
levels O
and O
pain O
sensitivity O
were O
assessed O
with O
visual O
analogue O
scales O
( O
VAS O
) O
and O
pressure B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PPT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
outcome O
measure O
was O
frequency O
of O
stereotypic B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
which O
was O
evaluated O
for O
5 O
min O
before O
and O
after O
standing O
on O
the O
vibration O
platform O
. O
['Life-Impact']

Group-B O
streptococci O
were O
found O
in O
the O
urine O
of O
69 O
women O
. O
[]

METHODS O
AND O
MATERIALS O
The O
prospective O
study O
included O
112 O
patients O
with O
advanced O
larynx O
cancer O
after O
radical O
surgical O
treatment O
. O
[]

Grade O
3-4 O
haematological B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
reported O
in O
two O
patients O
in O
the O
FEC O
( O
90 O
) O
arm O
. O
['Physiological-Clinical']

METHODS O
Open O
, O
randomised O
, O
2-way O
crossover O
, O
clinical O
pharmacology O
study O
. O
[]

A O
combined O
analysis O
of O
the O
two O
studies O
was O
prospectively O
defined O
and O
agreed O
to O
by O
both O
groups O
. O
[]

CONCLUSIONS: O
The O
TFP O
(25 O
mug/h) O
affixed O
14 O
h O
before O
surgery O
reached O
a O
higher O
constant B-outcome ['Life-Impact']
concentration I-outcome ['Life-Impact']
than O
the O
same O
dose O
setting O
of O
a O
constant O
IV O
infusion O
of O
fentanyl O
after O
surgery. O
[['Life-Impact']]

Importance: O
A O
meta-analysis O
of O
outcomes O
during O
the O
6 O
months O
after O
intensive O
care O
unit O
(ICU) O
discharge O
indicate O
a O
prevalence O
for O
clinically O
important O
posttraumatic O
stress O
disorder O
(PTSD) O
symptoms O
of O
25%. O
[]

The O
UKEP O
study O
: O
multicentre O
clinical O
trial O
on O
two O
local O
regimens O
of O
urokinase O
in O
massive O
pulmonary O
embolism O
. O
[]

A O
significant O
increase O
in O
86rubidium B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
present O
in O
boys O
as O
compared O
to O
girls O
. O
['Physiological-Clinical']

Following O
a O
total O
of O
70 O
cycles O
, O
70 O
% O
of O
r-hFSH/r-hLH O
treated O
patients O
met O
the O
primary O
endpoint O
vs O
88 O
% O
in O
hMG-HP O
group O
( O
p=0.11 O
) O
. O
[]

In O
order O
to O
bypass O
the O
degenerated O
cortico-striato-pallidal O
loop O
, O
we O
administered O
the O
adrenergic O
agonist O
idazoxan O
( O
IDA O
) O
to O
treat O
PSP O
in O
two O
randomized O
double-blind O
, O
placebo O
controlled O
, O
crossover O
studies O
. O
[]

One O
of O
the O
points O
was O
to O
reduce O
the O
time B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
chest I-outcome ['Physiological-Clinical']
compressions I-outcome ['Physiological-Clinical']
in O
the O
first O
phase O
of O
cardiac O
arrest O
. O
['Physiological-Clinical']

Evaluation O
of O
electrofunctional O
data O
following O
argon-laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
. O
[]

These O
results O
provide O
direct O
evidence O
for O
spinal O
inhibition O
as O
one O
mechanism O
of O
placebo O
analgesia O
and O
highlight O
that O
psychological O
factors O
can O
act O
on O
the O
earliest O
stages O
of O
pain O
processing O
in O
the O
central O
nervous O
system O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

METHODS O
During O
phase O
1 O
treatment O
, O
86 O
subjects O
were O
treated O
with O
a O
bionator O
, O
93 O
were O
treated O
with O
headgear/biteplane O
, O
and O
81 O
served O
as O
the O
observation O
group O
. O
[]

The O
effect O
of O
hydrochlorothiazide O
therapy O
on O
ventricular B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
was O
studied O
in O
45 O
hypertensive O
African-American O
men O
with O
moderate O
to O
severe O
left O
ventricular O
( O
LV O
) O
hypertrophy O
. O
['Physiological-Clinical']

Decolonization O
involved O
chlorhexidine O
mouthwash, O
baths O
or O
showers O
with O
chlorhexidine, O
and O
nasal O
mupirocin O
for O
5 O
days O
twice O
per O
month O
for O
6 O
months. O
[]

PURPOSE O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
bupivacaine O
irrigated O
at O
the O
surgical O
bed O
on O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
laparoscopic O
cholecystectomy O
patients O
. O
['Physiological-Clinical']

Study O
end O
points O
were O
OS B-outcome ['Mortality']
, O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
DFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
and O
toxicity B-outcome ['Adverse-effects']
. O
['Mortality', 'Mortality', 'Adverse-effects']

Using O
a O
double-blind O
protocol O
, O
55 O
premature O
infants O
weighing O
less O
than O
1501 O
g O
at O
birth O
were O
selected O
randomly O
to O
receive O
normal O
saline O
or O
proparacaine O
HCl O
0.5 O
% O
eye O
drops O
as O
a O
corneal O
wetting O
agent O
at O
their O
initial O
eye O
examination O
. O
[]

d O
) O
Occurrence O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
in O
the O
two O
treatment O
groups O
. O
['Adverse-effects']

TXB2 B-outcome ['Physiological-Clinical']
was O
measured O
in O
serum O
from O
blood O
allowed O
to O
clot O
at O
37 O
degrees O
C. O
2 O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
( O
p O
less O
than O
0.05 O
) O
increase O
in O
urinary B-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
after O
CL O
( O
20.7 O
+/- O
11 O
micrograms/24 O
hours O
vs. O
13.3 O
+/- O
8.5 O
after O
PL O
, O
and O
14.5 O
+/- O
7.2 O
after O
MZ O
) O
( O
mean O
values O
+/- O
standard O
deviations O
) O
. O
( O
['Physiological-Clinical']

In O
each O
subject O
, O
positron B-outcome ['Resource-use']
emission I-outcome ['Resource-use']
tomographic I-outcome ['Resource-use']
images I-outcome ['Resource-use']
of O
regional O
cerebral B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
with O
[ O
18F O
] O
fluorodeoxyglucose O
were O
obtained O
in O
two O
conditions O
in O
the O
morning O
on O
different O
days O
: O
about O
3min O
after O
approximately O
1-2mg O
of O
nasal O
nicotine O
spray O
and O
after O
an O
equivalent O
volume O
of O
an O
active O
placebo O
spray O
of O
oleoresin O
of O
pepper O
in O
a O
random O
counterbalanced O
design O
. O
['Resource-use', 'Physiological-Clinical']

The O
primary O
aim O
of O
the O
present O
study O
was O
to O
determine O
whether O
pantoprazole O
modifies O
the O
steady-state O
serum O
concentrations O
of O
orally O
administered O
digoxin O
. O
[]

Significant O
improvements O
were O
observed O
in O
Qmax B-outcome ['Physiological-Clinical']
for O
both O
tamsulosin O
groups O
but O
not O
for O
the O
placebo O
group O
. O
['Physiological-Clinical']

The O
clinical B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
score O
also O
showed O
significant O
improvement O
in O
the O
MgSO4 O
group O
1 O
, O
2 O
, O
3 O
and O
11 O
hours O
after O
stopping O
the O
infusion O
( O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

Compliance O
, O
male O
gender O
, O
no O
antibiotic O
prescription O
in O
the O
subsequent O
2 O
years O
and O
[]

Journal-Name:BMC O
public O
health O
[]

A O
comparison O
of O
the O
efficacy O
of O
heparinized O
and O
nonheparinized O
solutions O
for O
maintenance O
of O
perioperative B-outcome ['Physiological-Clinical']
radial I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
subsequent B-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition, O
lavender O
essential O
oil O
has O
been O
shown O
to O
have O
positive O
effects O
on O
some O
symptoms O
associated O
with O
menopause. O
[]

Hypotensive B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cramps I-outcome ['Physiological-Clinical']
decreased O
50 O
% O
with O
Na+ O
modeling O
. O
['Physiological-Clinical']

Using O
repeated O
measures O
of O
symptom O
score O
, O
uroflowmetry O
and O
prostate O
specific O
antigen O
in O
the O
clinical O
management O
of O
prostate O
disease O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
gather O
data O
on O
the O
safety O
of O
lasalocid O
when O
fed O
to O
Chinese O
ring-necked O
pheasants O
at O
one O
, O
two O
, O
and O
three O
times O
the O
recommended O
high O
dose O
of O
lasalocid O
used O
for O
prevention O
of O
coccidiosis O
in O
other O
poultry O
at O
three O
times O
the O
normal O
treatment O
period O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
preliminary O
data O
suggest O
that O
serotonergic O
agents O
may O
play O
a O
role O
in O
the O
effective O
treatment O
of O
methamphetamine B-outcome ['Physiological-Clinical']
abuse I-outcome ['Physiological-Clinical']
and O
dependence B-outcome ['Physiological-Clinical']
within O
the O
context O
of O
other O
effective O
behavioral O
interventions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
postprandial O
insulin B-outcome ['Physiological-Clinical']
and O
GLP-1 B-outcome ['Physiological-Clinical']
responses O
were O
not O
significantly O
different. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND O
Pneumatic O
compression O
is O
a O
frequently O
prescribed O
physical O
therapy O
for O
patients O
affected O
by O
postmastectomy O
lymphedema O
but O
, O
despite O
its O
wide O
use O
, O
its O
efficacy O
has O
not O
been O
demonstrated O
in O
phase O
III O
studies O
. O
[]

Sixty O
percent O
of O
the O
dose O
is O
recovered O
in O
the O
feces O
. O
[]

MAIN O
OUTCOME O
MEASURES O
The O
main O
outcome O
measures O
were O
survival B-outcome ['Mortality']
and O
bacteriologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
defined O
by O
consecutive O
negative O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
for O
MAC B-outcome ['Physiological-Clinical']
at O
least O
2 O
weeks O
apart O
within O
16 O
weeks O
of O
study O
entry O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
the O
amount O
of O
increase O
between O
women O
who O
underwent O
different O
interventions O
. O
[]

METHODS O
This O
study O
had O
a O
statewide O
group-randomized O
prospective O
trial O
design O
. O
[]

Studies O
in O
animals O
show O
good O
healing O
after O
1 O
to O
2 O
weeks O
of O
ureterotomy O
. O
[]

RESULTS O
By O
36 O
weeks O
' O
postmenstrual O
age O
, O
59 O
of O
the O
405 O
infants O
( O
15 O
percent O
) O
in O
the O
vitamin O
A O
group O
and O
55 O
of O
the O
402 O
infants O
( O
14 O
percent O
) O
in O
the O
control O
group O
had O
died O
. O
[]

The O
range O
of O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
from O
the O
instillation O
of O
anti-cancer O
drug O
was O
3-365 O
days O
( O
average O
days O
) O
. O
['Mortality']

RESULTS: O
We O
observed O
a O
significant O
effect O
of O
the O
treatment O
in O
both O
the O
physical B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
task X ['Life-Impact', 'Life-Impact']
subscales X ['Life-Impact', 'Life-Impact']
of X ['Life-Impact', 'Life-Impact']
the X ['Life-Impact', 'Life-Impact']
global B-outcome ['Life-Impact', 'Life-Impact']
quality I-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
life E3-outcome ['Life-Impact', 'Life-Impact']
(GQoL) O
(P O
= O
.01 O
and O
P O
= O
.04, O
respectively) O
and O
also O
in O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
specific O
for O
CD O
(P O
</=.0001) O
but O
not O
in O
pain B-outcome ['Physiological-Clinical']
score O
(P O
= O
.28). O
[['Life-Impact', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

Greater O
decreases O
were O
also O
seen O
in O
community-specific B-outcome ['Physiological-Clinical']
microfilarial I-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
with O
combined O
therapy O
( O
mean O
reductions O
91.1 O
% O
and O
69.8 O
% O
, O
respectively O
; O
p O
= O
0.0047 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Low-molecular-weight O
heparin O
( O
LMWH O
) O
is O
cleared O
predominantly O
by O
the O
kidneys O
and O
hence O
there O
is O
uncertainty O
about O
the O
safety O
of O
its O
use O
in O
hemodialysis O
( O
HD O
) O
patients O
. O
[]

BACKGROUND O
To O
compare O
the O
combined O
effects O
of O
arteriovenous O
extracorporeal O
lung O
assist O
( O
AV-ECLA O
) O
and O
high-frequency O
oscillatory O
ventilation O
( O
HFOV O
) O
on O
pulmonary B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
, O
hemodynamics B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Indicators O
of O
stress O
( O
ie O
, O
alterations O
in O
behavioral B-outcome ['Life-Impact']
, O
neuroendocrine B-outcome ['Physiological-Clinical']
, O
immune B-outcome ['Physiological-Clinical']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Mirror O
therapy O
( O
MT O
) O
and O
mesh O
glove O
( O
MG O
) O
afferent O
stimulation O
may O
be O
effective O
in O
reducing O
motor O
impairment O
after O
stroke O
. O
[]

Evaluation O
in O
heifers O
. O
[]

ELISA O
showed O
that O
autologous O
SCT O
patients O
with O
breast O
cancer O
who O
received O
GM-CSF O
had O
a O
better O
response O
to O
influenza B-outcome ['Physiological-Clinical']
A O
( O
P O
< O
.05 O
) O
and O
B O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

During O
aortic O
cross-clamping O
Group O
II O
patients O
received O
dopexamine O
infusion O
, O
at O
a O
dose O
of O
1 O
microgram/kg/m O
, O
and O
at O
a O
dose O
of O
0.5 O
micrograms/kg/m O
from O
declamping O
to O
the O
end O
of O
the O
surgery O
. O
[]

This O
study O
will O
assess O
whether O
yoga O
is O
effective O
for O
treating O
chronic B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
compared O
with O
self O
care O
and O
exercise O
and O
will O
explore O
the O
mechanisms O
responsible O
for O
any O
observed O
benefits O
. O
['Physiological-Clinical']

Efficacy O
of O
treatment O
on O
clinical O
condition O
and O
some O
immune B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
IgA B-outcome ['Physiological-Clinical']
, O
IgG B-outcome ['Physiological-Clinical']
, O
CD3 B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
) O
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Three O
weeks O
later O
, O
the O
participants O
returned O
and O
the O
protocol O
was O
repeated O
on O
the O
contralateral O
limb O
, O
using O
the O
opposite O
intervention O
( O
HVPC O
or O
placebo O
) O
. O
[]

Simultaneously O
there O
was O
a O
significant O
( O
P O
< O
0.001 O
) O
increase O
in O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
and O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
and O
significant O
decrease O
( O
P O
< O
0.05 O
) O
in O
malondialdehyde B-outcome ['Physiological-Clinical']
and O
glutathion B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
levels O
in O
the O
serum O
of O
patients O
treated O
with O
chemotherapy O
compared O
to O
the O
patients O
treated O
with O
radiotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
To O
assess O
the O
long-term O
effects O
of O
finasteride O
on O
pressure-flow B-outcome ['Physiological-Clinical']
parameters O
in O
men O
with O
urodynamically O
documented O
bladder O
outflow O
obstruction O
( O
BOO O
) O
. O
['Physiological-Clinical']

GH B-outcome ['Physiological-Clinical']
was O
measured O
before O
stimulation O
, O
every O
2min O
for O
the O
first O
hour O
and O
every O
5min O
for O
the O
second O
hour O
. O
['Physiological-Clinical']

The O
use O
of O
immunomodulatory O
drugs O
has O
proved O
useful O
in O
the O
prophylaxis O
of O
these O
complications O
, O
although O
the O
precise O
indications O
for O
each O
drug O
have O
not O
yet O
been O
clearly O
codified O
. O
[]

The O
postoperative O
analgesic O
requirement O
was O
assessed O
by O
the O
total O
dose O
of O
metamizol B-outcome ['Physiological-Clinical']
administered O
by O
an O
i.v O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
Current O
Controlled O
Trials O
ISRCTN18445519 O
. O
[]

CDP571 O
, O
a O
humanized O
monoclonal O
antibody O
to O
tumour O
necrosis O
factor-alpha O
, O
for O
steroid-dependent O
Crohn O
's O
disease O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

In O
the O
multiple-dose O
studies O
, O
127 O
healthy O
subjects O
received O
bilastine O
10 O
, O
20 O
, O
40 O
, O
50 O
, O
80 O
, O
100 O
, O
140 O
or O
200 O
mg/day O
as O
multiple O
doses O
during O
a O
4- O
, O
7- O
or O
14-day O
period O
. O
[]

Arm O
discomfort O
, O
elbow O
extension O
range O
of O
motion O
and O
isometric O
elbow O
flexion O
strength O
were O
obtained O
as O
baseline O
measurements O
. O
[]

Secondary O
outcomes O
include O
the O
difference O
in O
cure B-outcome ['Physiological-Clinical']
rate O
and O
intensity B-outcome ['Physiological-Clinical']
reduction O
rate O
between O
the O
intense O
and O
standard O
treatment O
groups O
as O
measured O
by O
the O
other O
diagnostic O
tests, O
as O
well O
as O
the O
accuracy O
of O
the O
different O
diagnostic O
tests, O
and O
the O
safety O
of O
PZQ. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
shorter O
and O
simpler O
treatment O
schedule O
of O
azithromycin O
had O
similar O
efficacy O
and O
safety O
as O
doxycycline O
in O
the O
treatment O
of O
moderate O
acne O
vulgaris O
, O
confirming O
noninferiority O
of O
azithromycin O
as O
compared O
with O
doxycycline O
. O
[]

CONCLUSION O
Student O
performance O
in O
simulator-based O
OSCE O
may O
be O
affected O
by O
the O
clinical O
context O
provided O
. O
[]

TEN O
versus O
TPN O
following O
major O
abdominal O
trauma O
-- O
reduced O
septic O
morbidity O
. O
[]

MATERIALS O
AND O
METHODS O
Forty-eight O
osteoporotic O
patients O
with O
prostate O
cancer O
, O
treated O
with O
3-month O
depot O
triptorelina O
, O
were O
enrolled O
and O
randomly O
assigned O
to O
two O
different O
treatment O
groups O
: O
group O
A O
( O
n O
= O
24 O
) O
was O
treated O
with O
a O
daily O
calcium O
and O
cholecalciferol O
supplement O
( O
500 O
mg O
of O
elemental O
calcium O
and O
400 O
IU O
cholecalciferol O
) O
, O
and O
group O
B O
( O
n O
= O
24 O
) O
received O
in O
addition O
to O
the O
same O
daily O
calcium O
and O
cholecalciferol O
supplement O
, O
25 O
mg O
of O
neridronate O
given O
intramuscularly O
every O
month O
. O
[]

Sample O
size O
was O
based O
on O
80 O
% O
power O
to O
reject O
the O
null O
hypothesis O
that O
the O
cost/QALY O
gained O
would O
not O
exceed O
$ O
50,000 O
. O
['Resource-use']

BACKGROUND O
Pulmonary O
rehabilitation O
is O
widely O
advocated O
for O
people O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
to O
improve O
exercise O
capacity O
, O
symptoms O
and O
quality O
of O
life O
, O
however O
only O
a O
minority O
of O
individuals O
with O
COPD O
are O
able O
to O
participate O
. O
[]

Each O
patient O
was O
randomly O
assigned O
to O
a O
normal O
or O
lower O
compression O
class O
treatment O
, O
with O
respectively O
mean O
values O
of O
15 O
and O
10 O
mmHg O
pressure O
after O
wearing O
the O
garment O
for O
1 O
month O
. O
[]

Levels O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
were O
measured O
before O
therapy O
and O
after O
three O
and O
6 O
months O
. O
['Physiological-Clinical']

In O
the O
zinc-treated O
group O
of O
16 O
patients O
, O
serum B-outcome ['Physiological-Clinical']
zinc I-outcome ['Physiological-Clinical']
rose O
from O
a O
normal O
mean O
value O
of O
13.3 O
to O
17.4 O
mumol/l O
, O
whereas O
the O
mean O
serum B-outcome ['Physiological-Clinical']
vitamin I-outcome ['Physiological-Clinical']
A O
level O
remained O
practically O
unaltered O
within O
the O
normal O
range O
, O
1.89 O
at O
the O
entry O
and O
1.83 O
mumol/l O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Rickard O
, O
Lau O
, O
and O
Pashler O
's O
( O
2008 O
) O
investigation O
of O
the O
lag O
effect O
on O
memory-based B-outcome ['Life-Impact']
automaticity I-outcome ['Life-Impact']
, O
response O
times O
were O
faster O
and O
proportion O
of O
trials O
retrieved O
was O
higher O
at O
the O
end O
of O
practice O
for O
short O
lag O
items O
than O
for O
long O
lag O
items O
. O
['Life-Impact']

CONCLUSION O
Markers O
of O
systemic O
inflammation O
contribute O
significantly O
to O
prognostic O
classification O
in O
addition O
to O
established O
factors O
for O
pre-treated O
patients O
with O
advanced O
RCC O
. O
[]

AIMS O
To O
assess O
whether O
aerobic O
training O
leads O
to O
a O
more O
active B-outcome ['Life-Impact']
lifestyle I-outcome ['Life-Impact']
and O
improved O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
CHF O
. O
['Life-Impact']

In O
part O
C, O
all O
6 O
patients O
who O
were O
assigned O
to O
receive O
once-monthly O
injections O
of O
givosiran O
had O
sustained O
reductions O
in O
ALAS1 B-outcome ['Physiological-Clinical']
messenger I-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
(mRNA) I-outcome ['Physiological-Clinical']
, O
delta B-outcome ['Physiological-Clinical']
aminolevulinic I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
and O
porphobilinogen B-outcome ['Physiological-Clinical']
levels O
to O
near O
normal. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

A O
total O
of O
74 O
patients O
who O
have O
low O
back O
pain O
and O
radiating O
pain O
due O
to O
LHIVD O
will O
be O
recruited O
and O
randomly O
allocated O
to O
the O
experimental O
group O
and O
control O
group. O
[]

METHODS O
The O
TIOSPIR O
trial O
( O
NCT01126437 O
) O
compares O
the O
safety O
and O
efficacy O
of O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
( O
marketed O
) O
and O
2.5 O
?g O
once O
daily O
( O
investigational O
) O
with O
tiotropium O
HandiHaler O
18 O
? O
[]

Although O
results O
through O
the O
entire O
blinded O
period O
continued O
to O
show O
that O
selenium O
supplementation O
was O
not O
statistically O
significantly O
associated O
with O
the O
risk O
of O
basal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
( O
hazard O
ratio O
[ O
HR O
] O
= O
1.09 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.94 O
to O
1.26 O
) O
, O
selenium O
supplementation O
was O
associated O
with O
statistically O
significantly O
elevated O
risk O
of O
squamous B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
carcinoma B-outcome ['Physiological-Clinical']
( O
HR O
= O
1.25 O
, O
95 O
% O
CI O
= O
1.03 O
to O
1.51 O
) O
and O
of O
total O
nonmelanoma B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
HR O
= O
1.17 O
, O
95 O
% O
CI O
= O
1.02 O
to O
1.34 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Orthopnea O
is O
a O
cardinal O
symptom O
of O
heart O
failure O
and O
may O
affect O
the O
patient O
's O
sleeping O
angle O
. O
[]

However O
, O
the O
weighted O
blanket O
was O
favored O
by O
children O
and O
parents O
, O
and O
blankets O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
over O
this O
period O
. O
['Life-Impact']

The O
changes O
caused O
by O
the O
diet O
were O
partly O
reversed O
by O
clofibrate O
while O
niceritrol O
did O
not O
cause O
any O
major O
changes O
of O
the O
fatty B-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
composition B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
repeatability O
of O
a O
single O
examiner O
in O
scoring O
the O
index O
was O
performed O
using O
4 O
groups O
of O
10 O
subjects O
. O
[]

CONCLUSIONS O
This O
study O
is O
among O
the O
first O
randomized O
trials O
comparing O
2 O
active O
interventions O
with O
a O
large O
sample O
of O
low-resourced O
families O
. O
[]

In O
part O
A O
of O
the O
trial, O
patients O
without O
recent O
porphyria O
attacks O
(i.e., O
no O
attacks O
in O
the O
6 O
months O
before O
baseline) O
were O
randomly O
assigned O
to O
receive O
a O
single O
subcutaneous O
injection O
of O
one O
of O
five O
ascending O
doses O
of O
givosiran O
(0.035, O
0.10, O
0.35, O
1.0, O
or O
2.5 O
mg O
per O
kilogram O
of O
body O
weight) O
or O
placebo. O
[]

Minimal O
clinically O
important O
change O
for O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
functional B-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
, O
and O
general O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
nonspecific O
low O
back O
pain O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
Clomipramine O
was O
superior O
to O
both O
placebo O
and O
desipramine O
on O
ratings O
of O
autistic B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
including B-outcome ['Life-Impact']
stereotypies I-outcome ['Life-Impact']
) O
, O
anger B-outcome ['Life-Impact']
, O
and O
compulsive B-outcome ['Life-Impact']
, O
ritualized B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
( O
P O
< O
.05 O
) O
, O
with O
no O
differences O
between O
desipramine O
and O
placebo O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS: O
Postdischarge O
MRSA O
decolonization O
with O
chlorhexidine O
and O
mupirocin O
led O
to O
a O
30% O
lower O
risk O
of O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
than O
education O
alone. O
( O
[['Physiological-Clinical']]

METHODS O
A O
cohort O
of O
139 O
nondepressed O
elderly O
patients O
( O
> O
60 O
years O
) O
hospitalized O
for O
hip O
fracture O
surgery O
were O
followed O
up O
for O
six O
months O
. O
[]

Distinct B-outcome ['Physiological-Clinical']
lower O
extremity B-outcome ['Physiological-Clinical']
joint I-outcome ['Physiological-Clinical']
moment B-outcome ['Physiological-Clinical']
and O
power O
patterns B-outcome ['Physiological-Clinical']
were O
observed O
in O
response O
to O
the O
FP O
but O
an O
overall O
positive O
moment O
of O
support B-outcome ['Physiological-Clinical']
( O
M O
( O
s O
) O
) O
was O
maintained O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
we O
evaluated O
whether O
an O
intravenous O
infusion O
of O
L-arginine O
would O
improve O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
these O
subjects O
. O
['Physiological-Clinical']

Feasibility B-outcome ['Life-Impact']
outcomes O
included O
rates O
of O
recruitment B-outcome ['Life-Impact']
, O
retention B-outcome ['Life-Impact']
, O
outcome B-outcome ['Life-Impact']
completion I-outcome ['Life-Impact']
, O
and O
exercise B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
. O
Data O
were O
collected O
on O
cardiorespiratory B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
(e.g., O
peak B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
), O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
intervention O
acceptability B-outcome ['Life-Impact']
(via O
interviews). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Adverse-effects'], ['Life-Impact']]

The O
magnitude O
of O
the O
change O
in O
solid B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
correlated O
with O
the O
change O
in O
the O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
r O
= O
0.49 O
; O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Community-based O
supervised O
intervention O
. O
[]

The O
primary O
endpoint O
was O
polyp O
number O
in O
the O
rectum O
and O
sigmoid O
colon O
( O
at O
the O
end O
of O
intervention O
) O
, O
and O
the O
major O
secondary O
endpoint O
was O
size O
of O
the O
largest O
polyp O
. O
[]

Acute O
effects O
of O
decaffeinated O
coffee O
and O
the O
major O
coffee O
components O
chlorogenic O
acid O
and O
trigonelline O
on O
glucose B-outcome ['Physiological-Clinical']
tolerance O
. O
['Physiological-Clinical']

Administration O
of O
high-dose O
gentamicin O
resulted O
in O
a O
longer O
time O
to O
actual O
T O
( O
max O
) O
( O
P= O
.021 O
) O
but O
did O
not O
change O
model O
T O
( O
max O
) O
( O
P= O
.62 O
) O
. O
[]

The O
valve O
's O
hemodynamic B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
was O
investigated O
through O
Doppler O
study O
. O
['Physiological-Clinical']

METHOD O
Of O
the O
200 O
women O
who O
agreed O
to O
participate O
in O
the O
project O
, O
100 O
were O
randomly O
allocated O
to O
the O
pilot O
scheme O
and O
100 O
to O
the O
traditional O
care O
package O
. O
[]

Junctional B-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
after O
congenital O
heart O
surgery O
in O
the O
current O
surgical O
era O
. O
['Physiological-Clinical']

All O
patients O
who O
received O
TNF/IFN/M O
had O
significantly O
greater O
increases O
in O
systemic B-outcome ['Physiological-Clinical']
interleukin-6 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
levels O
than O
in O
patients O
with O
M O
alone O
( O
12,395 O
+/- O
10,374 O
pg/mL O
v O
79.4 O
+/- O
7.2 O
pg/mL O
, O
respectively O
; O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

Reduction O
in O
[]

Effect O
of O
ibuprofen O
on O
cyclooxygenase B-outcome ['Physiological-Clinical']
and O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
synthase I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
: O
correlation O
with O
endoscopic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

During O
the O
'dark O
' O
interval O
, O
subjects O
were O
asked O
to O
indicate O
when O
the O
movement O
represented O
in O
the O
video O
reached O
its O
end O
by O
clicking O
on O
the O
space O
bar O
of O
the O
keyboard O
. O
[]

A O
similar O
dose-response B-outcome ['Physiological-Clinical']
between O
the O
present O
study O
and O
Caucasian O
study O
was O
demonstrated O
. O
['Physiological-Clinical']

Title: O
Dark O
Chocolate O
Intake O
Positively O
Modulates O
Redox B-outcome ['Physiological-Clinical']
Status O
and O
Markers O
of O
Muscular B-outcome ['Physiological-Clinical']
Damage I-outcome ['Physiological-Clinical']
in O
Elite O
Football O
Athletes: O
A O
Randomized O
Controlled O
Study. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O
[]

The O
sample O
of O
the O
5 O
patients O
per O
institution O
was O
randomly O
selected O
at O
the O
EORTC O
Data O
Center O
. O
[]

There O
were O
no O
within-pair O
differences O
in O
height O
, O
weight O
, O
or O
calcium O
intake O
at O
baseline O
. O
[]

In O
conclusion, O
cashews O
provide O
fewer O
calories O
than O
the O
values O
predicted O
by O
the O
Atwater O
factors, O
as O
found O
on O
current O
food O
labels. O
[]

After O
a O
15-day O
run-in O
period O
with O
controlled O
diet O
( O
45-65 O
g O
protein O
) O
, O
the O
patients O
were O
administered O
, O
in O
addition O
to O
their O
diet O
, O
branched-chain O
amino O
acids O
( O
0.24 O
g/kg O
, O
30 O
patients O
) O
or O
an O
equinitrogenous O
amount O
of O
casein O
( O
34 O
patients O
) O
. O
[]

A O
significant O
survival B-outcome ['Mortality']
benefit O
was O
identified O
at O
study O
completion O
in O
the O
pre-defined O
sub-group O
of O
123 O
patients O
who O
had O
received O
prior O
chemotherapy O
( O
P=0.045 O
, O
hazard O
ratio=1.53 O
( O
1.00-2.34 O
) O
) O
. O
['Mortality']

In O
the O
present O
study O
we O
intended O
to O
verify O
the O
possibility O
of O
using O
electrofunctional O
techniques O
to O
determine O
the O
two O
distinct O
and O
, O
probably O
, O
consecutive O
glaucomatous B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
occurring I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
ganglion I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
: O
functional B-outcome ['Life-Impact']
( O
reversible B-outcome ['Physiological-Clinical']
) O
and O
anatomical B-outcome ['Physiological-Clinical']
( O
irreversible B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recent O
studies O
indeed O
showed O
that O
electrophysiological B-outcome ['Physiological-Clinical']
modulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
Mu-rhythm I-outcome ['Physiological-Clinical']
in O
the O
10-12Hz O
range O
is O
weaker O
when O
individuals O
with O
Asperger O
's O
syndrome O
observe O
actions O
performed O
by O
others O
compared O
to O
controls O
. O
['Physiological-Clinical']

In O
addition, O
they O
also O
underwent O
verum O
or O
sham O
TENS O
30 O
min O
daily, O
3 O
times O
weekly O
for O
4 O
weeks. O
[]

Upper B-outcome ['Physiological-Clinical']
GI I-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
reported O
by O
18 O
( O
5.7 O
% O
) O
subjects O
in O
the O
risedronate O
group O
( O
19 O
events O
) O
and O
28 O
( O
8.8 O
% O
) O
subjects O
in O
the O
alendronate O
group O
( O
32 O
events O
) O
. O
['Physiological-Clinical']

Abdominal O
aortic O
surgery O
has O
significant O
effects O
on O
cardiac O
and O
splanchnic O
perfusion O
. O
[]

We O
tested O
whether O
providing O
physicians O
with O
their O
patients O
' O
results O
on O
the O
alcohol O
module O
of O
the O
Diagnostic O
Interview O
Schedule O
and O
counseling O
directives O
would O
prompt O
them O
to O
counsel O
these O
patients O
. O
[]

BACKGROUND O
To O
evaluate O
resource B-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
and O
direct B-outcome ['Resource-use']
economic I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
of O
care O
for O
patients O
treated O
with O
negative-pressure O
wound O
therapy O
( O
NPWT O
) O
, O
using O
the O
Vacuum-Assisted O
Closure O
( O
V.A.C O
. O
) O
['Resource-use', 'Resource-use']

Four O
patients O
( O
8 O
eyes O
) O
had O
bilateral O
zone O
1 O
disease O
. O
[]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

The O
net O
fat B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
was O
-2.1 O
% O
( O
95 O
% O
CI-2.7 O
, O
-1.4 O
) O
in O
Group O
S1 O
and O
-1.7 O
% O
( O
95 O
% O
CI-2.3 O
, O
-1.0 O
) O
in O
Group O
S2 O
. O
['Physiological-Clinical']

SETTING O
An O
inner-city O
county O
trauma O
center O
with O
70,000 O
patient O
visits O
per O
year O
. O
[]

Bacteriuria O
in O
post-biopsy B-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
in O
the O
anesthesia O
group O
. O
['Physiological-Clinical']

Whereas O
the O
clinical O
and O
CRP O
changes O
among O
ACR20 O
nonresponders O
to O
infliximab O
plus O
MTX O
were O
small O
and O
much O
lower O
than O
among O
ACR20 O
responders O
to O
this O
treatment O
, O
radiographic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
ACR20 O
nonresponders O
to O
infliximab O
plus O
MTX O
was O
significantly O
inhibited O
( O
P O
< O
0.001 O
) O
compared O
with O
ACR20 O
nonresponders O
to O
MTX O
plus O
placebo O
. O
['Physiological-Clinical']

CONCLUSIONS O
EE30/LNG150 O
decreased O
plasma O
androgen O
levels O
, O
but O
there O
was O
no O
impairment O
in O
sexual O
desire O
, O
on O
the O
other O
hand O
, O
sexual O
desire O
score O
increased O
with O
EE20/LNG100 O
formulation O
. O
[]

Objective O
studies O
investigating O
exercise-sleep O
responses O
have O
produced O
mixed O
outcomes O
, O
and O
the O
disparity O
in O
results O
between O
studies O
may O
be O
due O
to O
differences O
in O
individual O
characteristics O
and/or O
exercise O
protocol O
, O
emphasising O
the O
importance O
of O
carefully O
controlled O
trials O
. O
[]

Patients O
with O
complete O
symptom B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
then O
entered O
the O
on-demand O
phase O
. O
['Physiological-Clinical']

26 O
patients O
suffered O
from O
normotensive O
hydrocephalus O
( O
10 O
idiopathic O
and O
16 O
symptomatic O
) O
, O
and O
9 O
patients O
from O
hypertensive O
hydrocephalus O
of O
various O
origin O
. O
[]

According O
to O
the O
random O
number O
table O
method, O
the O
patients O
were O
randomly O
divided O
into O
non-invasive O
ventilator O
group, O
rhodiola O
rosea+non-invasive O
ventilator O
group O
and O
rhodiola O
rosea O
group, O
with O
30 O
cases O
in O
each O
group. O
[]

Otherwise, O
there O
were O
marginal O
benefits O
for O
keeping O
the O
indwelling O
catheter O
for O
48 O
hours O
in O
terms O
of O
reducing O
the O
number O
of O
patients O
with O
moderate O
pain B-outcome ['Physiological-Clinical']
and O
improving O
the O
quality B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
. O
However, O
all O
three O
groups O
had O
similar O
opioid B-outcome ['Resource-use']
usage I-outcome ['Resource-use']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
functional B-outcome ['Life-Impact']
outcomes. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Life-Impact']]

The O
present O
study O
investigated O
the O
effects O
of O
oral O
ENT O
administration O
on O
food B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
in O
subjects O
with O
a O
preference O
for O
a O
high-fat O
diet O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Intrathecal B-outcome ['Physiological-Clinical']
immunoactivation I-outcome ['Physiological-Clinical']
in O
patients O
with O
HIV-1 O
infection O
is O
reduced O
by O
zidovudine O
but O
not O
by O
didanosine O
. O
['Physiological-Clinical']

OBJECTIVE O
We O
tested O
the O
hypothesis O
that O
biotin O
supplementation O
significantly O
decreases O
3-HIA O
excretion O
in O
pregnant O
women O
with O
abnormally O
increased O
3-HIA O
excretion O
. O
[]

Comparison O
of O
enoxaparin O
and O
standard O
heparin O
in O
gynaecologic O
oncologic O
surgery O
: O
a O
randomised O
prospective O
double-blind O
clinical O
study O
. O
[]

The O
data O
are O
in O
line O
with O
recent O
experimental O
studies O
showing O
a O
beneficial O
metabolic O
effect O
of O
captopril O
in O
Type O
II O
diabetes O
. O
[]

The O
iridium O
oxide O
coating O
is O
believed O
to O
reduce O
restenosis B-outcome ['Physiological-Clinical']
by O
decreasing O
the O
inflammatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
stent O
via O
its O
antioxidant O
action O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Methods: O
Seventy-five O
patients O
were O
randomized O
into O
either O
CBT-i O
group O
(n=37) O
or O
combination O
group O
(n=38). O
[]

On O
Day O
8 O
, O
the O
incidences O
of O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
in O
the O
risedronate O
and O
alendronate O
groups O
were O
3.6 O
% O
and O
6.6 O
% O
, O
respectively O
( O
p O
= O
0.133 O
) O
, O
and O
on O
Day O
15 O
, O
they O
were O
3.3 O
% O
and O
8.7 O
% O
( O
p O
= O
0.008 O
) O
. O
['Physiological-Clinical']

METHODS O
Twenty O
eyes O
with O
combined O
RRD O
and O
CD O
that O
underwent O
primary O
vitrectomy O
were O
randomized O
to O
receive O
oral O
steroids O
( O
for O
1 O
week O
) O
or O
no O
oral O
steroids O
before O
surgery O
. O
[]

The O
trial O
is O
expected O
to O
accrue O
a O
minimum O
of O
450 O
events O
with O
a O
minimum O
1-year O
of O
follow-up O
. O
[]

Mood O
status O
and O
quality O
of O
life O
were O
assessed O
using O
the O
Profile O
of O
Mood B-outcome ['Life-Impact']
States O
and O
Medical O
Outcomes O
Study O
36-item O
Short-Form O
Health O
Survey O
at O
baseline O
and O
following O
3 O
and O
6 O
months O
of O
treatment O
. O
['Life-Impact']

There O
was O
no O
significant O
difference O
between O
the O
LAUP O
and O
UPPP O
regarding O
the O
fall O
in O
[]

Subjects O
received O
montelukast O
10 O
mg O
daily O
or O
placebo O
for O
2 O
weeks O
each O
. O
[]

The O
groups O
were O
comparable O
for O
maternal O
age O
, O
parity O
, O
weight O
and O
supplemental O
iron O
intake O
, O
infant O
s O
birth O
weight O
, O
gestation O
and O
sex O
. O
[]

Randomized O
controlled O
trial O
of O
collaborative O
care O
management O
of O
depression O
among O
low-income O
patients O
with O
cancer O
. O
[]

METHODS O
Eight O
normal O
volunteers O
were O
studied O
on O
2 O
separate O
days O
. O
[]

Positive O
correlations O
could O
be O
found O
between O
erythema B-outcome ['Physiological-Clinical']
and O
thickness O
values O
at O
all O
of O
the O
three O
test O
points O
while O
changes O
in O
erythema B-outcome ['Physiological-Clinical']
and O
thickness B-outcome ['Physiological-Clinical']
only O
correlated O
significantly O
after O
the O
first O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
the O
RTD O
group O
, O
the O
effective O
rate O
was O
70 O
% O
, O
the O
mean O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
was O
8.2 O
months O
, O
and O
the O
6-month O
survival B-outcome ['Mortality']
rate O
was O
79.7 O
% O
. O
['Mortality', 'Mortality']

8 O
% O
at O
the O
4th O
min O
, O
P O
< O
0.0001 O
) O
. O
[]

The O
second O
most O
'important O
' O
reason O
for O
sunbathing O
was O
'feeling O
warm O
and O
comfortable O
' O
. O
[]

Journal O
ID: O
2985248R O
[]

Changes O
in O
the O
total O
score O
of O
the O
Gross B-outcome ['Physiological-Clinical']
Motor I-outcome ['Physiological-Clinical']
Function I-outcome ['Physiological-Clinical']
Measure O
and O
the O
Sitting B-outcome ['Life-Impact']
Assessment O
Scale O
were O
not O
significant O
. O
['Physiological-Clinical', 'Life-Impact']

Furthermore O
, O
2.8 O
mg?kg O
BM O
of O
PSE O
taken O
90 O
min O
before O
exercise O
, O
with O
or O
without O
food O
, O
resulted O
in O
urinary O
PSE O
concentrations O
exceeding O
the O
present O
WADA O
threshold O
. O
[]

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
AEs O
) O
was O
higher O
in O
the O
vilazodone O
group O
( O
57.6 O
% O
) O
than O
in O
the O
moxifloxacin O
( O
37.0 O
% O
) O
and O
placebo O
( O
35.6 O
% O
) O
groups O
, O
though O
AEs B-outcome ['Adverse-effects']
were O
generally O
mild O
to O
moderate O
in O
severity O
and O
resulted O
in O
few O
discontinuations O
. O
['Adverse-effects', 'Adverse-effects']

Conization O
for O
treatment O
of O
premalignant O
changes O
of O
the O
cervix O
uteri O
will O
probably O
remain O
the O
treatment O
of O
choice O
for O
some O
time O
to O
come O
. O
[]

Body O
mass O
index O
, O
measured O
at O
31.5+/-2.05 O
kg/m2 O
in O
the O
placebo O
group O
, O
decreased O
to O
30.4+/-2.94 O
kg/m O
( O
2 O
) O
after O
12 O
wk O
( O
P=.07 O
) O
. O
[]

However O
, O
the O
effects O
of O
a O
general O
warm-up O
( O
GWU O
) O
are O
unclear O
but O
seem O
to O
depend O
on O
its O
ability O
to O
increase O
muscle O
temperature O
while O
avoiding O
fatigue O
. O
[]

RESULTS O
Thirty-two O
eyes B-outcome ['Physiological-Clinical']
were O
rescued O
in O
treatment O
group O
with O
the O
cure O
rate O
of O
65.3 O
% O
. O
['Physiological-Clinical']

Double-blind O
comparison O
of O
ketazolam O
, O
diazepam O
and O
placebo O
in O
once-a-day O
vs O
t.i.d O
. O
[]

Equivalence O
in O
the O
per-protocol O
group O
was O
based O
on O
previously O
defined O
ranges O
of O
clinically O
significant O
difference O
. O
[]

Milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
of O
dairy O
cows O
fed O
wet O
corn O
gluten O
feed O
during O
the O
dry O
period O
and O
lactation O
. O
['Physiological-Clinical']

Protocolization O
of O
the O
training O
program O
, O
in O
conjunction O
with O
skills O
and O
knowledge O
assessment O
, O
may O
improve O
acquisition B-outcome ['Life-Impact']
and O
retention B-outcome ['Life-Impact']
among O
second- O
and O
future-generation O
trainees O
. O
['Life-Impact', 'Life-Impact']

Patients O
in O
study O
group O
consumed O
significantly O
less O
morphine O
, O
experienced O
significant O
less O
pain O
scores O
, O
and O
obtained O
significantly O
more O
ROM O
( O
P O
< O
0.01 O
) O
compared O
with O
that O
in O
placebo O
group O
during O
3 O
days O
postoperatively O
. O
[]

Docosahexaenoic O
acid-rich O
fish O
oil O
modulates O
the O
cerebral B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
cognitive O
tasks O
in O
healthy O
young O
adults O
. O
['Physiological-Clinical']

The O
control O
group O
consisted O
of O
19 O
patients O
( O
19 O
eyes O
) O
who O
received O
only O
antimicrobial O
therapy O
. O
[]

Pyridoxine O
has O
been O
reported O
as O
having O
an O
antilactogenic O
effect O
, O
presumably O
by O
suppressing O
prolactin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SUBJECTS O
AND O
METHODS O
Twenty-six O
patients O
with O
knee O
disorders O
requiring O
arthroscopy O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
. O
[]

= O
.71 O
, O
.50 O
respectively O
) O
. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrial.gov O
: O
NCT01015716 O
, O
registration O
data O
14.12.2010 O
(Prospectively O
registered). O
[]

The O
primary O
outcome O
of O
this O
trial O
is O
clinical B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate. O
[['Physiological-Clinical']]

While O
the O
EG O
took O
part O
in O
an O
endurance O
and O
activity O
of O
daily O
living-training O
twice O
a O
day O
, O
the O
CG O
received O
the O
clinic O
's O
standard O
physiotherapy O
program O
once O
a O
day O
. O
[]

In O
our O
patients O
pericarditis O
encompassed O
a O
wide O
spectrum O
ranging O
from O
a O
mild B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
several I-outcome ['Physiological-Clinical']
days O
duration B-outcome ['Physiological-Clinical']
to O
a O
painful O
and O
debilitating B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
purpose O
of O
this O
trial O
was O
to O
determine O
whether O
adjuvant O
AT O
improved O
disease-free O
survival O
compared O
with O
AC O
in O
operable O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

These O
data O
should O
be O
considered O
in O
treatment O
decision-making O
for O
pts O
with O
advanced O
non-small-cell O
lung O
cancer O
and O
for O
the O
design O
of O
future O
trials O
with O
chemotherapy O
plus O
biologics O
. O
[]

Reported O
frequency O
of O
GI B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
including O
abnormal B-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
consistency I-outcome ['Physiological-Clinical']
( O
e.g. O
, O
bulky B-outcome ['Physiological-Clinical']
or O
loose B-outcome ['Physiological-Clinical']
) O
, O
was O
increased O
( O
54 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adverse O
events O
were O
obtained O
by O
diary O
cards O
. O
[]

METHODS O
AND O
RESULTS O
Adult O
and O
pediatric O
patients O
with O
allergic O
rhinoconjunctivitis O
and/or O
asthma O
were O
included O
in O
the O
study O
. O
[]

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Adverse-effects']

In O
patients O
without O
a O
prior O
history O
of O
bleeding O
, O
bleeding O
risk O
was O
higher O
with O
more O
prolonged O
prothrombin O
time O
and O
lower O
when O
patients O
were O
receiving O
propranolol O
. O
[]

Fitting O
of O
the O
ear O
plugs O
was O
performed O
by O
an O
ear O
, O
nose O
and O
throat O
specialist O
to O
ensure O
similar O
conditions O
. O
[]

Introduction: O
Acute O
pancreatitis O
(AP) O
is O
an O
inflammatory O
disease O
of O
the O
pancreas O
that O
spans O
a O
wide O
range O
ranging O
from O
mild O
to O
critical O
forms. O
[]

RESULTS O
Fifty-seven O
( O
92 O
% O
) O
patients O
completed O
treatment O
. O
[]

Bone B-outcome ['Physiological-Clinical']
levels O
were O
recorded O
on O
radiographs O
taken O
prior O
to O
the O
start O
of O
the O
study O
, O
and O
after O
6 O
months O
. O
['Physiological-Clinical']

Forty-five O
patients O
were O
randomly O
treated O
with O
a O
periodontal O
surgery O
approach O
. O
[]

CONCLUSIONS O
Since O
the O
results O
were O
essentially O
identical O
between O
the O
techniques O
, O
it O
seems O
that O
[]

MEASUREMENTS O
Blood B-outcome ['Physiological-Clinical']
gas I-outcome ['Physiological-Clinical']
analysis O
and O
spirometry B-outcome ['Physiological-Clinical']
data O
were O
recorded O
5 O
minutes O
before O
chest O
opening O
, O
5 O
minutes O
before O
inducing O
bypass O
, O
5 O
minutes O
after O
weaning O
from O
bypass O
, O
and O
5 O
minutes O
after O
chest O
closure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Esomeprazole O
resolves O
chronic B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
in O
patients O
without O
erosive O
oesophagitis O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
with O
diagnosis O
of O
fibrocystic O
breast O
disease O
were O
included O
in O
a O
prospective O
longitudinal O
blind O
double O
, O
controlled O
with O
placebo O
study O
. O
[]

Behavioral B-outcome ['Life-Impact']
rating O
scales O
( O
Clinical O
Global O
Impression O
Scale O
[ O
CGI-I O
] O
, O
Ritvo-Freeman O
Real O
Life O
Rating O
Scale O
[ O
RF-RLRS O
] O
) O
, O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
[ O
ABC O
] O
, O
Turgay O
DSM-IV O
Pervasive B-outcome ['Life-Impact']
Developmental I-outcome ['Life-Impact']
Disorder I-outcome ['Life-Impact']
Rating O
Scale O
[ O
TPDDRS O
] O
) O
and O
safety O
assessment O
scales O
( O
Extrapyramidal O
Symptoms O
Rating O
Scale O
[ O
ESRS O
] O
, O
UKU-Side O
Effect O
Rating O
Scale O
) O
were O
performed O
at O
12 O
, O
16 O
, O
20 O
and O
24 O
weeks O
, O
following O
the O
12 O
week O
double-blind O
phase O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Little O
is O
known O
about O
the O
impact O
of O
bracing O
on O
sensory O
function. O
[]

CONCLUSIONS O
Both O
diazepam O
and O
midazolam O
were O
shown O
to O
be O
effective O
sedative O
agents O
, O
successfully O
and O
safely O
used O
to O
sedate O
autistic O
patients O
for O
dental O
treatment O
. O
[]

At O
1 O
wk O
, O
subjects O
were O
exposed O
to O
filtered O
air O
for O
2 O
h O
while O
exercising O
( O
20 O
L/min/m O
( O
2 O
) O
) O
, O
and O
then O
underwent O
bronchoalveolar O
lavage O
( O
BAL O
) O
and O
were O
randomly O
assigned O
to O
receive O
either O
a O
placebo O
or O
250 O
mg O
of O
vitamin O
C O
, O
50 O
IU O
of O
alpha-tocopherol O
, O
and O
12 O
oz O
of O
vegetable O
cocktail O
daily O
for O
2 O
wk O
. O
[]

By O
the O
end O
of O
anaesthesia O
and O
surgery O
and O
by O
24 O
h O
postoperatively O
, O
IL-2 B-outcome ['Physiological-Clinical']
had O
decreased O
significantly O
in O
the O
halothane O
group O
( O
p O
< O
0.001 O
) O
, O
whereas O
it O
increased O
significantly O
in O
the O
isoflurane O
group O
( O
p O
< O
0.001 O
) O
compared O
with O
pre-incision O
and O
end O
of O
anaesthesia O
and O
surgery O
levels O
, O
respectively O
. O
['Physiological-Clinical']

The O
challenge O
induced O
the O
reappearance B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
insomnia I-outcome ['Life-Impact']
and O
agitated B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
all O
except O
one O
child O
. O
['Life-Impact', 'Life-Impact']

Postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
are O
common O
after O
recovery O
from O
anesthesia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
7 O
systemic O
reactions B-outcome ['Adverse-effects']
with O
the O
monomer O
and O
none O
with O
the O
polymer O
. O
['Adverse-effects']

A O
simplified O
approach O
to O
virtual O
colonoscopy O
using O
different O
intestinal O
preparations O
: O
preliminary O
experience O
with O
regard O
to O
quality O
, O
accuracy O
and O
patient O
acceptability O
. O
[]

In O
conclusion O
, O
tolrestat O
improved O
autonomic B-outcome ['Physiological-Clinical']
nervous I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
patients O
with O
definite O
DAN O
, O
in O
comparison O
to O
baseline O
and O
placebo O
. O
['Physiological-Clinical']

Findings O
indicated O
that O
high-BP O
individuals O
showed O
heightened B-outcome ['Life-Impact']
['Life-Impact']

The O
treatment O
ratios O
of O
AUC O
and O
associated O
90 O
% O
confidence O
intervals O
( O
CIs O
) O
for O
risperidone O
active O
moiety O
, O
defined O
as O
risperidone O
plus O
9-hydroxyrisperidone O
( O
ratio O
= O
110.2 O
% O
; O
90 O
% O
CI O
= O
103.7-117.2 O
) O
, O
and O
for O
donepezil O
( O
ratio O
= O
97.1 O
% O
; O
90 O
% O
CI O
= O
90.0-103.6 O
) O
were O
within O
the O
80 O
% O
to O
125 O
% O
of O
bioequivalence O
range O
. O
[]

To O
what O
extent O
a O
reduction O
in O
the O
AER O
could O
ameliorate O
diabetic O
patients O
is O
, O
at O
present O
, O
unknown O
. O
[]

Fasting O
concentrations O
of O
serum O
free O
fatty O
acids O
( O
S-FFA O
) O
and O
plasma O
gastric O
inhibitory O
polypeptide O
( O
P-GIP O
) O
were O
also O
recorded O
during O
the O
three O
study O
periods O
. O
[]

The O
effect O
of O
cognitive-behavioral O
therapy O
versus O
treatment O
as O
usual O
for O
anxiety B-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
, O
controlled O
trial O
. O
['Life-Impact']

RESULTS O
TLT O
failed O
to O
arrest O
progression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
by O
the O
end O
of O
the O
hospital O
stay O
. O
['Physiological-Clinical']

Using O
single O
subject O
research O
design O
, O
we O
performed O
pilot O
research O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
famotidine O
for O
the O
treatment O
of O
children O
with O
autistic O
spectrum O
disorders O
. O
[]

300 O
microns O
and O
best-corrected O
visual O
acuity O
( O
BCVA O
) O
20/40 O
to O
20/200 O
. O
[]

Increased O
pulmonary O
iNOS B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

Promoting O
health O
in O
schools O
through O
a O
board O
game O
. O
[]

The O
Cheyne-Stokes O
apnea B-outcome ['Physiological-Clinical']
index O
decreased O
with O
increasing O
sleeping O
angle O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
modified O
CIMT O
on O
improving O
paretic O
arm O
function O
in O
poststroke O
patients O
during O
a O
subacute O
rehabilitation O
period O
. O
[]

The O
study O
supports O
the O
feasibility O
of O
this O
intervention O
to O
families O
and O
highlights O
challenges O
for O
future O
research O
in O
social O
skills O
intervention O
. O
[]

CONCLUSION O
Malnutrition B-outcome ['Physiological-Clinical']
was O
highly O
prevalent O
in O
this O
setting O
of O
patients O
. O
['Physiological-Clinical']

RESULTS O
Thirty-eight O
percent O
were O
in O
the O
precontemplation O
stage O
, O
45 O
% O
in O
the O
contemplation O
stage O
, O
and O
only O
17 O
% O
in O
the O
preparation O
stage O
. O
[]

However O
, O
anesthesia O
and O
operating O
times O
were O
significantly O
longer O
in O
LA O
for O
both O
overweight O
patients O
and O
those O
with O
a O
normal O
BMI O
. O
[]

Clinical O
efficacy O
was O
shown O
in O
76.1 O
% O
of O
patients O
receiving O
eberconazole O
and O
in O
75.0 O
% O
of O
patients O
receiving O
miconazole O
. O
[]

Outcomes O
were O
performed O
on O
a O
simulated O
cardiac O
arrest O
case O
adapted O
from O
the O
AHA O
Advanced O
Cardiac O
Life O
Support O
(ACLS) O
SimMan(R) O
Scenario O
manual. O
[]

The O
effectiveness O
of O
yoga O
will O
be O
assessed O
using O
analysis O
of O
covariance O
( O
using O
general O
estimating O
equations O
- O
GEE O
) O
within O
an O
intention-to-treat O
context O
. O
[]

Randomized O
trial O
of O
the O
effects O
of O
risedronate O
on O
vertebral B-outcome ['Physiological-Clinical']
fractures I-outcome ['Physiological-Clinical']
in O
women O
with O
established O
postmenopausal O
osteoporosis O
. O
['Physiological-Clinical']

RESULTS O
Physician B-outcome ['Life-Impact']
prompting I-outcome ['Life-Impact']
, O
dependent B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
, O
and O
recent B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
were O
significant O
correlates O
of O
physician O
counseling O
( O
P O
< O
.05 O
) O
, O
while O
male O
gender O
was O
a O
marginally O
significant O
correlate O
( O
P O
= O
.08 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Journal O
ID: O
101234168 O
[]

Two O
CMZ O
patients O
and O
one O
morphine O
patient O
showed O
complete O
pain B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
continuous O
regimen O
does O
not O
result O
in O
any O
further O
benefit O
in O
lumbar O
bone O
density O
over O
the O
cyclical O
one O
, O
probably O
because O
of O
a O
greater O
suppression O
of O
bone O
turnover O
. O
[]

Objective: O
To O
evaluate O
the O
effect O
of O
postoperative O
intravenous O
(IV) O
acetaminophen O
(paracetamol) O
vs O
placebo O
combined O
with O
IV O
propofol O
vs O
dexmedetomidine O
on O
postoperative O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
among O
older O
patients O
undergoing O
cardiac O
surgery. O
[['Physiological-Clinical', 'Life-Impact']]

Although O
the O
mean O
hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
blood O
conservation O
group O
after O
6 O
days O
, O
statistical O
significance O
was O
not O
reached O
until O
9.5 O
days O
of O
ICU O
care O
. O
['Physiological-Clinical']

Interventional O
study O
to O
strengthen O
the O
health O
promoting O
behaviours O
of O
pregnant O
women O
to O
prevent O
anaemia O
in O
southern O
India O
. O
[]

In O
addition O
, O
we O
sought O
to O
compare O
the O
intervention O
's O
impact O
on O
commercially O
and O
Medicaid-insured O
children O
. O
[]

The O
purpose O
of O
this O
randomised O
clinical O
trial O
was O
to O
compare O
an O
active O
training O
programme O
( O
AT O
) O
with O
a O
physiotherapy O
treatment O
without O
active O
training O
( O
PT O
) O
in O
the O
treatment O
of O
adductor-related O
groin O
pain O
in O
athletes O
. O
[]

METHODS O
In O
the O
context O
of O
a O
clinical O
trial O
for O
SLOS O
, O
we O
performed O
cross-sectional O
and O
repeated-measure O
observational O
studies O
of O
the O
relationship O
between O
EEG O
findings O
and O
cognitive/behavioral O
factors O
on O
23 O
children O
( O
aged O
4-17 O
years O
) O
. O
[]

The O
rate O
of O
reporting O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
considered O
to O
be O
drug-related O
and O
the O
rate O
of O
withdrawals O
were O
similar O
for O
both O
treatments O
. O
['Adverse-effects']

OBJECTIVE O
To O
demonstrate O
the O
comparative O
effects O
of O
MG O
+ O
MT O
, O
MT O
, O
and O
a O
control O
treatment O
( O
CT O
) O
on O
the O
outcomes O
of O
motor O
impairments O
, O
manual O
dexterity O
, O
ambulation O
function O
, O
motor O
control O
, O
and O
daily O
function O
. O
[]

The O
effect O
of O
acebutolol O
on O
left O
ventricular O
performance O
was O
examined O
by O
various O
noninvasive O
means O
in O
three O
studies O
. O
[]

CONCLUSIONS O
Brief O
, O
daily O
hopping O
exercises O
increased O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
in O
premenopausal O
women O
but O
less O
frequent O
exercise O
was O
not O
effective O
. O
['Physiological-Clinical']

Angiographic B-outcome ['Physiological-Clinical']
restenosis I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
6-month I-outcome ['Physiological-Clinical']
angiography I-outcome ['Physiological-Clinical']
was O
the O
primary O
end O
point O
of O
the O
study O
. O
['Physiological-Clinical']

Evoked O
potentials O
to O
auditory O
stimulations O
varying O
in O
intensity O
were O
studied O
in O
13 O
children O
with O
autistic O
behavior O
treated O
with O
fenfluramine O
. O
[]

CONCLUSIONS O
Mydriasert O
assures O
an O
adequate O
degree O
of O
mydriasis O
for O
retinal O
angiography O
in O
both O
diabetic O
and O
nondiabetic O
patients O
. O
[]

There O
were O
significantly O
fewer O
reports O
of O
tiredness B-outcome ['Physiological-Clinical']
and O
dizziness B-outcome ['Physiological-Clinical']
among O
the O
health-promotion O
participants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Finally O
, O
we O
investigate O
whether O
there O
is O
a O
difference O
in O
compliance B-outcome ['Life-Impact']
between O
persons O
receiving O
supervised O
Nordic O
Walking O
and O
persons O
doing O
unsupervised O
Nordic O
Walking O
. O
['Life-Impact']

The O
intervention O
was O
DBT O
and O
the O
control O
condition O
was O
treatment O
as O
usual O
plus O
waiting O
list O
for O
DBT O
( O
TAU+WL O
) O
, O
with O
outcomes O
measured O
after O
6 O
months O
. O
[]

Bovine O
pericardium O
vs O
dacron O
for O
patch O
angioplasty O
after O
carotid O
endarterectomy O
: O
a O
prospective O
randomized O
study O
. O
[]

The O
magnitude O
of O
the O
reduction O
in O
the O
intrinsic B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of O
caffeine B-outcome ['Life-Impact']
produced O
by O
ciprofloxacin O
was O
greater O
than O
that O
described O
in O
the O
literature O
for O
ciprofloxacin O
and O
theophylline O
. O
['Physiological-Clinical', 'Life-Impact']

After O
14 O
days O
, O
patients O
were O
switched O
to O
the O
other O
treatment O
for O
14 O
additional O
days O
. O
[]

Uncontrolled O
vasculitis O
was O
responsible O
for O
4 O
deaths B-outcome ['Mortality']
( O
2 O
in O
each O
group O
) O
, O
and O
treatment B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
caused O
the O
death B-outcome ['Mortality']
of O
1 O
patient O
in O
group O
A O
. O
['Mortality', 'Adverse-effects', 'Mortality']

OBJECTIVE O
Phenytoin O
is O
an O
effective O
anticonvulsant O
that O
has O
not O
previously O
been O
studied O
prophylactically O
in O
bipolar O
( O
BP O
) O
patients O
. O
[]

A O
quasi-experimental O
pretest-posttest O
control O
group O
design O
was O
used O
. O
[]

This O
study O
aimed O
to O
compare O
the O
effect O
of O
delayed-start O
GnRH O
antagonist O
protocol O
and O
standard O
GnRH O
antagonist O
in O
patients O
with O
poor O
ovarian O
response O
(POR) O
undergoing O
in O
vitro O
fertilization O
(IVF)/ O
intracytoplasmic O
sperm O
injection O
(ICSI). O
[]

Measuring O
the O
impact O
of O
patient O
counseling O
in O
the O
outpatient O
pharmacy O
setting O
: O
the O
research O
design O
of O
the O
Kaiser O
Permanente/USC O
patient O
consultation O
study O
. O
[]

The O
absence O
of O
suppression O
of O
reflexive O
sympathetic O
responses O
contrasts O
with O
the O
effects O
of O
rilmenidine O
in O
experimental O
animals O
, O
and O
emphasises O
the O
previously O
demonstrated O
unique O
importance O
in O
humans O
of O
suprabulbar O
noradrenergic O
neuronal O
projections O
from O
the O
brainstem O
, O
which O
are O
inhibited O
by O
imidazoline O
binding O
agents O
, O
in O
regulating O
tonic B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
essential O
hypertension O
. O
['Physiological-Clinical']

These O
measures O
offer O
potential O
therapeutic O
targets O
for O
improving O
early O
outcome O
after O
acute O
ischemic O
stroke O
. O
[]

Forty O
children O
with O
ASD O
( O
7-11 O
years O
) O
and O
their O
primary O
caregiver O
were O
randomly O
assigned O
to O
an O
immediate O
treatment O
( O
IT O
; O
n O
= O
17 O
) O
or O
3-month O
waitlist O
( O
WL O
; O
n O
= O
23 O
) O
condition O
. O
[]

BACKGROUND O
Changes O
in O
gait O
patterns O
due O
to O
a O
simultaneously O
performed O
cognitive O
task O
have O
been O
reported O
previously O
and O
associated O
with O
an O
increased O
falling O
risk O
among O
older O
adults O
. O
[]

Mortality B-outcome ['Mortality']
in O
patients O
with O
small O
choroidal O
melanoma O
. O
['Mortality']

Muscular B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
was O
significantly O
different O
between O
limbs O
in O
the O
RT O
group O
at O
the O
end O
of O
the O
intervention O
(p O
= O
0.01). O
[['Life-Impact']]

The O
visual O
analog O
score O
was O
used O
to O
measure O
the O
pain B-outcome ['Physiological-Clinical']
. O
The O
mean O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
patient-controlled O
intravenous O
analgesia B-outcome ['Life-Impact']
pressing I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
time B-outcome ['Life-Impact']
for O
first O
out-of-bed O
activity O
, O
first B-outcome ['Physiological-Clinical']
anus I-outcome ['Physiological-Clinical']
exhaust I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
duration I-outcome ['Resource-use']
, O
and O
complications B-outcome ['Adverse-effects']
were O
recorded. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Resource-use'], ['Adverse-effects']]

Introduction O
In O
patients O
on O
glucocorticoids O
, O
a O
single O
zoledronic O
acid O
infusion O
significantly O
increased O
BMD B-outcome ['Physiological-Clinical']
versus O
daily O
oral O
risedronate O
. O
['Physiological-Clinical']

Nevertheless O
, O
no O
difference O
was O
observed O
between O
both O
slopes O
and O
intercepts O
. O
[]

Ezetimibe O
added O
to O
simvastatin O
improves O
several O
indices O
of O
platelet O
reactivity O
beyond O
statin O
monotherapy O
. O
[]

CONCLUSIONS O
Parents O
did O
not O
report O
statistically O
significant O
behavioral B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
with O
amantadine O
. O
['Life-Impact']

At O
baseline O
, O
88 O
% O
of O
the O
patients O
described O
their O
pain O
intensity O
as O
moderate O
; O
12 O
% O
, O
severe O
. O
[]

Talbot O
Advisors, O
Anna O
Maria, O
FL. O
[]

Before O
and O
three O
months O
after O
AVF O
creation O
patients O
underwent O
an O
echocardiographic O
examination O
. O
[]

Provisional O
screw-retained O
crowns O
, O
out O
of O
occlusion O
, O
were O
placed O
at O
second-stage O
surgery O
after O
26 O
weeks O
for O
the O
conventional O
restoration O
group O
, O
and O
within O
4 O
hours O
of O
implant O
placement O
for O
the O
immediate O
restoration O
group O
. O
[]

Detailed O
assessment O
of O
drug O
safety O
, O
biochemical B-outcome ['Physiological-Clinical']
and O
haematological B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
and O
efficacy O
was O
made O
at O
these O
dates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
The O
nursing-led O
inpatient O
unit O
is O
designed O
to O
substitute O
for O
a O
period O
of O
care O
in O
acute O
hospital O
wards O
and O
to O
improve O
patient O
outcome O
prior O
to O
discharge O
to O
the O
community O
. O
[]

METHODS O
Uncorrected O
visual O
acuity O
( O
UCVA O
) O
, O
best-corrected O
visual O
acuity O
( O
BCVA O
) O
, O
manifest O
refraction O
, O
CS O
by O
means O
of O
the O
Functional O
Acuity O
Contrast O
Test O
, O
and O
HOAs O
by O
means O
of O
Zywave O
aberrometry O
were O
evaluated O
preoperatively O
and O
6 O
months O
after O
retreatment O
. O
[]

In O
Experiment O
1 O
participants O
watched O
a O
video O
, O
before O
a O
cued-recall O
test O
for O
which O
they O
were O
either O
instructed O
to O
close O
their O
eyes O
, O
or O
received O
no-instructions O
. O
[]

The O
patients O
were O
observed O
for O
a O
period O
of O
24 O
hours O
. O
[]

PATIENTS O
2121/2292 O
patients O
( O
92.5 O
% O
) O
had O
an O
analysable O
dataset O
for O
either O
biomarker O
. O
[]

Differences O
were O
not O
statistically O
significant O
. O
[]

Percutaneous O
tracheostomy O
in O
critically O
ill O
patients O
: O
a O
prospective O
, O
randomized O
comparison O
of O
two O
techniques O
. O
[]

Some O
patient O
variables O
were O
associated O
with O
delayed B-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
or O
ulcer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS: O
Findings O
highlight O
the O
complexity O
of O
implementing O
a O
mhGAP-based O
training O
given O
its O
interaction O
with O
contextual O
factors O
to O
influence O
the O
attainment O
of O
expected O
outcomes. O
[]

Family O
education O
for O
people O
with O
schizophrenia O
in O
Beijing O
, O
China O
: O
randomised O
controlled O
trial O
. O
[]

BACKGROUND O
Radiation O
treatment O
of O
head O
and O
neck O
cancer O
can O
cause O
chronic O
xerostomia O
which O
impairs O
patients O
' O
quality O
of O
life O
. O
[]

CONCLUSIONS O
Larger-scale O
studies O
are O
warranted O
to O
determine O
the O
effectiveness O
and O
usability O
in O
comprehensive O
educational O
programs O
. O
[]

Using O
single-subject O
research O
analysis O
and O
medication O
given O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
cross-over O
design O
, O
4 O
of O
9 O
children O
randomized O
( O
44 O
% O
) O
had O
evidence O
of O
behavioral B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
. O
['Life-Impact']

Recatheterization B-outcome ['Resource-use']
was O
necessary O
in O
3 O
cases O
( O
6.1 O
% O
) O
cases O
in O
the O
PlasmaKinetic O
group O
and O
in O
1 O
( O
2.1 O
% O
) O
in O
the O
TURP O
group O
. O
['Resource-use']

A O
randomised O
, O
controlled O
crossover O
trial O
involving O
19 O
patients O
with O
a O
first-ever O
diagnosis O
of O
OSAS O
measured O
the O
effect O
of O
conventional O
heated O
humidification O
added O
to O
CPAP O
compared O
with O
a O
controlled O
heated O
breathing O
tube O
humidifier O
( O
ThermoSmart O
( O
R O
) O
; O
Fisher O
and O
Paykel O
Healthcare O
, O
Auckland O
, O
New O
Zealand O
) O
on O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Does O
waiting O
matter O
? O
[]

However, O
using O
SMV O
may O
have O
superior O
effect O
on O
improving O
muscle B-outcome ['Physiological-Clinical']
tone I-outcome ['Physiological-Clinical']
after O
stroke. O
[['Physiological-Clinical']]

Early O
screening O
for O
BV O
and O
treatment O
with O
clindamycin O
saved O
approximately O
27 O
euro O
per O
woman O
. O
[]

Effects O
of O
conjugated O
linoleic O
acid O
supplementation O
and O
exercise O
on O
post-heparin O
lipoprotein O
lipase O
, O
butyrylcholinesterase O
, O
blood B-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
profile O
and O
glucose B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
young O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Effects O
of O
enflurane O
and O
isoflurane O
on O
splanchnic B-outcome ['Physiological-Clinical']
oxygenation I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

CONCLUSION O
Ixabepilone O
, O
with O
or O
without O
estramustine O
phosphate O
, O
is O
well O
tolerated B-outcome ['Life-Impact']
and O
has O
antitumor B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
patients O
with O
castrate O
metastatic O
prostate O
cancer O
. O
['Life-Impact', 'Physiological-Clinical']

Children O
participating O
in O
a O
daily O
10 O
min O
classroom-based O
activity O
break O
undertake O
more O
physical O
activity O
during O
school O
hours O
than O
controls O
. O
[]

[ O
Complication B-outcome ['Adverse-effects']
rate O
after O
gastrectomy O
and O
pouch O
reconstruction O
with O
Longmire O
interposition O
] O
. O
['Adverse-effects']

Bilateral O
strength O
training O
did O
not O
correct O
the O
unilateral O
strength B-outcome ['Life-Impact']
deficit I-outcome ['Life-Impact']
observed O
in O
this O
group O
of O
survivors O
of O
breast O
cancer. O
[['Life-Impact']]

Maintaining O
vaccine O
coverage O
is O
key O
to O
avoid O
the O
devastating O
consequences O
of O
resurgence. O
[]

To O
objectify O
the O
treatment O
outcomes O
in O
both O
groups O
before O
and O
after O
the O
treatment, O
we O
measured O
myostatin O
concentration O
and O
performed O
the O
urinary B-outcome ['Physiological-Clinical']
incontinence I-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
assessment O
( O
The O
Revised O
Urinary B-outcome ['Physiological-Clinical']
Incontinence I-outcome ['Physiological-Clinical']
Scale]), O
perceived O
self-efficacy B-outcome ['Life-Impact']
assessment O
(General O
Self-Efficacy B-outcome ['Life-Impact']
Scale), O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
severity O
assessment O
( O
Beck O
Depression B-outcome ['Physiological-Clinical', 'Life-Impact']
Inventory]). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Indications O
of O
more O
absence O
in O
the O
exercise O
therapy O
group O
appeared O
to O
be O
based O
largely O
on O
a O
greater O
number O
of O
patients O
with O
absences O
during O
the O
first O
3 O
months O
. O
[]

Operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
difficulty B-outcome ['Life-Impact']
of O
finding O
the O
specimen O
was O
significantly O
lower O
in O
the O
modified O
localization O
group O
than O
in O
the O
methylene O
blue O
localization O
group O
(P O
< O
.05). O
[['Life-Impact'], ['Life-Impact']]

PATIENTS O
AND O
METHODS O
The O
study O
was O
carried O
out O
in O
50 O
cirrhotic O
patients O
. O
[]

s.e.m O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

.01 O
) O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
proportions O
of O
participants O
reporting O
local B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
unsolicited B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
, O
and O
SAEs B-outcome ['Adverse-effects']
among O
the O
3 O
vaccine O
groups O
after O
the O
1st O
and O
2nd O
doses. O
[['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects'], ['Adverse-effects']]

RESULTS O
The O
oral O
treatment O
group O
showed O
significant O
increases O
in O
plasma B-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
glutathione B-outcome ['Physiological-Clinical']
, O
but O
not O
whole-blood O
glutathione B-outcome ['Physiological-Clinical']
levels O
following O
supplementation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CPB B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
were O
significantly O
shorter O
and O
the O
platelet B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
during O
CPB O
[ O
= O
( O
platelets O
before O
CPB-platelets O
after O
CPB O
) O
/platelets O
before O
CPB O
] O
was O
significantly O
lower O
in O
normothermic O
patients O
than O
in O
hypothermic O
patients O
. O
['Life-Impact', 'Physiological-Clinical']

Bronchoscopic B-outcome ['Physiological-Clinical']
findings O
in O
patients O
with O
a O
complete O
radiographic O
regression O
of O
small B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
bronchogenic I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Social O
stories O
: O
mechanisms O
of O
effectiveness O
in O
increasing O
game O
play O
skills O
in O
children O
diagnosed O
with O
autism O
spectrum O
disorder O
using O
a O
pretest O
posttest O
repeated O
measures O
randomized O
control O
group O
design O
. O
[]

Observations B-outcome ['Physiological-Clinical']
and O
tests O
were O
done O
before O
and O
after O
a O
period O
of O
1 O
year O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
differences O
in O
time O
to O
the O
development O
of O
progressive B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
or O
survival B-outcome ['Mortality']
between O
the O
ER O
positive O
and O
ER O
unknown O
patients O
or O
between O
the O
tamoxifen O
and O
tamoxifen O
plus O
CMF O
groups O
. O
['Physiological-Clinical', 'Mortality']

Geometric O
mean O
titres O
( O
GMTs O
) O
, O
measured O
by O
ELISA B-outcome ['Resource-use']
, O
to O
pertussis B-outcome ['Physiological-Clinical']
toxin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
filamentous B-outcome ['Physiological-Clinical']
haemagglutinin I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FHA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
significantly O
higher O
in O
the O
acellular O
vaccine O
groups O
than O
in O
the O
whole-cell O
DPT O
( O
WCDPT O
) O
group O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Implanted O
eyes O
had O
higher O
incidences O
of O
intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
elevation B-outcome ['Physiological-Clinical']
( O
> O
or O
= O
10 O
mm O
Hg O
) O
than O
nonimplanted O
eyes O
( O
P O
< O
.01 O
) O
, O
and O
glaucoma B-outcome ['Physiological-Clinical']
surgery B-outcome ['Resource-use']
was O
required O
in O
40 O
% O
of O
implanted O
eyes O
vs O
2 O
% O
of O
nonimplanted O
eyes O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

BACKGROUOND: O
The O
purpose O
of O
this O
study O
was O
to O
examine O
resting O
the O
metabolic O
response O
to O
the O
ingestion B-outcome ['Physiological-Clinical']
of O
a O
complex O
containing O
Citrus O
Aurantium O
+ O
Caffeine O
(CA O
+ O
C) O
and O
if O
its O
consumption O
influences O
metabolic B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
following O
a O
high-intensity O
anaerobic O
exercise O
bout O
in O
habitual O
caffeine O
users. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
subjects O
walked O
5 O
d/week O
for O
15 O
weeks O
at O
65 O
% O
of O
their O
maximal O
aerobic O
power O
expending O
300 O
kcal O
( O
1255 O
kJ O
) O
in O
exercise O
in O
one O
( O
Group O
S1 O
) O
or O
two O
daily O
sessions O
( O
Group O
S2 O
) O
. O
[]

In O
the O
eastern O
Malaysian O
state O
of O
Sabah O
, O
high-level O
stock O
losses O
have O
been O
recorded O
on O
these O
farms O
for O
several O
years O
, O
frequently O
accompanied O
by O
clinical O
signs O
indicating O
pathogenic O
levels O
of O
infections O
with O
the O
nematode O
parasite O
Haemonchus O
contortus O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
dopexamine O
, O
an O
inodilator O
drug O
, O
on O
hemodynamic O
and O
splanchnic O
perfusion O
with O
measurement O
of O
gastric O
intramucosal O
pH O
, O
by O
the O
method O
of O
gastric O
tonometry O
, O
during O
abdominal O
aneurysm O
resection O
. O
[]

Sunbathing O
and O
sunbed O
use O
related O
to O
self-image O
in O
a O
randomized O
sample O
of O
Swedish O
adolescents O
. O
[]

A O
double-blind O
placebo-controlled O
study O
. O
[]

The O
patients O
of O
each O
group O
were O
given O
1 O
drop O
into O
each O
eye O
: O
1 O
drop O
every O
12 O
hours O
for O
Polym O
, O
1 O
drop O
every O
6 O
hours O
for O
Plc O
. O
[]

CRC O
screening O
was O
completed B-outcome ['Physiological-Clinical']
by O
17.8 O
% O
in O
the O
usual O
care O
group O
, O
20.5 O
% O
in O
the O
chart O
reminder O
group O
, O
56.5 O
% O
in O
the O
mailed O
education/FIT O
group O
, O
and O
57.2 O
% O
in O
the O
mailed O
education/FIT O
plus O
phone O
call O
group O
. O
['Physiological-Clinical']

These O
and O
other O
related O
markers O
(holotranscobalamin, O
methylmalonic O
acid O
and O
homocysteine) O
have O
been O
linked O
with O
cognitive O
health. O
[]

RESULTS O
At O
baseline O
, O
groups O
did O
not O
differ O
in O
clinical O
and O
functional B-outcome ['Life-Impact']
scale O
scores O
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
This O
study O
was O
a O
prospective O
clinical O
trial O
that O
compared O
surface B-outcome ['Physiological-Clinical']
EMG I-outcome ['Physiological-Clinical']
dynamic I-outcome ['Physiological-Clinical']
activities I-outcome ['Physiological-Clinical']
after O
traditional O
bone O
setting O
and O
physical O
therapy O
. O
['Physiological-Clinical']

BACKGROUND O
DATA O
The O
use O
of O
low-level O
laser O
has O
been O
recommended O
for O
the O
management O
of O
tennis O
elbow O
with O
contradictory O
results O
. O
[]

METHODS: O
This O
parallel, O
two-group, O
randomised O
trial O
included O
couples O
undergoing O
an O
ICSI O
procedure O
with O
fresh O
embryo O
transfer O
at O
16 O
assisted O
conception O
units O
in O
the O
UK. O
[]

PATIENTS O
AND O
METHODS: O
This O
was O
a O
prospective, O
randomized, O
unblinded O
study. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

This O
recommendation O
is O
the O
result O
of O
concern O
over O
antidepressant-induced O
manic O
switch O
episodes O
. O
[]

OPTIMAAL O
( O
Optimal O
Trial O
in O
Myocardial O
Infarction O
with O
the O
Angiotensin O
II O
Antagonist O
Losartan O
) O
is O
the O
first O
major O
study O
to O
compare O
an O
angiotensin O
II O
Type O
1 O
antagonist O
losartan O
( O
Cozaar O
trade O
mark O
, O
Merck O
) O
with O
an O
ACE O
inhibitor O
captonpril O
( O
Capoten O
trade O
mark O
, O
Elan O
) O
after O
myocardial O
infarction O
in O
patients O
with O
left O
ventricular O
dysfunction O
. O
[]

The O
above O
findings O
demonstrated O
that O
root O
planning O
is O
effective O
in O
the O
treatment O
of O
furcation O
involvement O
and O
that O
the O
effects O
are O
enhanced O
by O
the O
local O
administration O
of O
TC O
films O
. O
[]

Although O
pre-course O
scores O
were O
similar O
( O
student-directed O
25.3 O
( O
7.3 O
) O
; O
structured O
24.8 O
( O
7.5 O
) O
) O
the O
structured O
approach O
resulted O
in O
higher O
post-course O
scores O
in O
comparison O
with O
the O
student-directed O
approach O
( O
student-directed O
41.8 O
( O
9.4 O
) O
; O
structured O
53.8 O
( O
8.8 O
) O
; O
p O
< O
0.01 O
) O
. O
[]

One-hundred O
and O
twenty O
bovine O
root O
dentine O
slabs O
were O
randomly O
assigned O
into O
six O
groups O
( O
A-F O
) O
and O
placed O
in O
intraoral O
palatal O
devices O
, O
which O
were O
worn O
by O
10 O
volunteers O
for O
4 O
d. O
On O
the O
first O
day O
, O
no O
erosive/abrasive O
procedures O
were O
carried O
out O
. O
[]

The O
serum O
values O
of O
soluble O
transferrin O
receptors O
and O
ferritin O
were O
observed O
as O
markers O
of O
iron B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
reserves I-outcome ['Physiological-Clinical']
, O
too O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
assessed O
the O
correlation O
of O
symptomatic B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
health-related B-outcome ['Physiological-Clinical']
quality O
of O
life O
['Physiological-Clinical', 'Physiological-Clinical']

Outcome O
was O
assessed O
at O
3 O
and O
6 O
months O
postinjury O
using O
the O
extended O
Glasgow O
Outcome O
Scale O
; O
standardized O
assessment O
was O
facilitated O
by O
the O
use O
of O
a O
structured O
interview O
. O
[]

Parametric O
time-to-event O
modeling O
and O
bootstrapping O
were O
used O
to O
identify O
independent O
predictors O
. O
[]

We O
have O
therefore O
performed O
a O
double-blind O
, O
placebo-controlled O
study O
to O
evaluate O
the O
effects O
of O
a O
4-wk O
administration O
of O
inhaled O
fluticasone O
in O
bronchiectasis O
. O
[]

The O
salivary O
glands O
were O
dissected O
from O
all O
female O
anophelines O
caught O
to O
identify O
sporozoites O
by O
microscopy O
. O
[]

RESULTS O
The O
demographic O
data O
were O
not O
statistically O
different O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

One O
hundred O
children O
with O
ASD O
, O
aged O
7 O
to O
12 O
years O
will O
be O
randomly O
assigned O
to O
an O
intervention O
or O
a O
waiting O
list O
control O
group O
. O
[]

Further O
validation O
of O
the O
alcohol O
dependence O
scale O
as O
an O
index O
of O
severity O
. O
[]

In O
both O
groups O
I O
and O
II O
, O
the O
treatment O
was O
stopped O
at O
the O
first O
manifestation O
of O
progression O
of O
the O
disease O
. O
[]

The O
relation O
of O
the O
response O
to O
plasma O
oestradiol O
values O
was O
similar O
for O
each O
variable O
with O
an O
initial O
large O
reduction O
and O
little O
change O
in O
response O
to O
increases O
in O
the O
plasma O
oestradiol O
concentration O
above O
150 O
pmol/l O
( O
41 O
pg/ml O
) O
. O
[]

In O
2 O
patients O
, O
caudal O
block O
was O
technically O
difficult O
and O
they O
were O
excluded O
from O
the O
study O
. O
[]

Folic O
acid-based O
supplementation O
is O
not O
beneficial O
and O
may O
even O
be O
harmful O
in O
the O
secondary O
prevention O
of O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
patients O
with O
unstable O
angina O
and O
non-ST-elevation O
myocardial O
infarction O
. O
['Physiological-Clinical']

BACKGROUND O
The O
use O
of O
warfarin O
reduces O
the O
rate O
of O
ischemic B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
in O
patients O
with O
atrial O
fibrillation O
but O
requires O
frequent O
monitoring O
and O
dose O
adjustment O
. O
['Physiological-Clinical']

A O
statistically O
significant O
difference O
was O
also O
observed O
for O
bleeding B-outcome ['Physiological-Clinical']
and O
pruritus B-outcome ['Physiological-Clinical']
at O
T3 O
and O
for O
these O
two O
parameters O
and O
both O
inflammation B-outcome ['Physiological-Clinical']
and O
edema B-outcome ['Physiological-Clinical']
at O
T4 O
( O
p O
< O
0.001 O
) O
in O
favor O
of O
the O
active O
combination O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
30-day O
mortality B-outcome ['Mortality']
rate O
was O
1.4 O
% O
, O
with O
one O
non-procedure-related O
death O
in O
the O
HPBA O
group O
. O
['Mortality']

Thus O
, O
the O
overall O
response O
rate O
of O
patients O
in O
arm O
1 O
and O
arm O
2 O
was O
41.7 O
% O
( O
25/60 O
patients O
) O
and O
33.3 O
% O
( O
20/60 O
patients O
) O
, O
respectively O
( O
p O
= O
0.37 O
) O
. O
[]

Neither O
the O
number O
of O
infants B-outcome ['Physiological-Clinical']
requiring O
intermittent B-outcome ['Physiological-Clinical']
positive O
pressure B-outcome ['Physiological-Clinical']
ventilation B-outcome ['Physiological-Clinical']
or O
duration O
of O
O2- B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
nor O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Five O
quasimonomorphic O
mononucleotide O
markers O
were O
used O
to O
assess O
tumor O
MSI O
status. O
[]

Eighty O
children O
, O
3-17 O
years O
of O
age O
, O
with O
autism O
or O
Asperger O
syndrome O
and O
mild O
to O
severe O
distress O
in O
the O
presence O
of O
some O
sounds O
, O
were O
randomly O
allocated O
to O
two O
groups O
. O
[]

RESULTS O
Both O
groups O
improved O
their O
knowledge B-outcome ['Life-Impact']
and O
QoL B-outcome ['Life-Impact']
during O
rehabilitation O
; O
however O
, O
knowledge B-outcome ['Life-Impact']
was O
significantly O
higher O
in O
the O
interactive O
group O
compared O
to O
the O
lecture O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Other O
outcomes O
include O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
effectiveness O
, O
safety O
, O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
quality O
of O
life O
, O
and O
cost-effectiveness O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

OBJECTIVE O
To O
investigate O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
and O
effects O
of O
methadone O
on O
behaviour B-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
cortisol I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vasopressin I-outcome ['Physiological-Clinical']
in O
healthy O
dogs O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

We O
conclude O
that O
some O
, O
but O
not O
all O
, O
of O
the O
breast O
cancer O
cases O
detected O
early O
as O
a O
result O
of O
screening O
realized O
a O
benefit O
in O
terms O
of O
elimination O
of O
the O
risk O
of O
breast B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

The O
duration O
of O
sensory B-outcome ['Physiological-Clinical']
and O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
is O
shorter O
with O
prilocaine O
than O
with O
mepivacaine O
, O
making O
prilocaine O
more O
appropriate O
for O
short O
interventions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
( O
sd O
) O
end O
tidal O
isoflurane O
concentration O
( O
per O
cent O
) O
needed O
to O
maintain O
a O
light B-outcome ['Resource-use']
surgical I-outcome ['Resource-use']
anaesthesia I-outcome ['Resource-use']
( O
stage O
III O
, O
plane O
2 O
) O
was O
significantly O
lower O
in O
group O
KM O
( O
0.91 O
[ O
0.03 O
] O
) O
than O
in O
groups O
TG O
( O
1.11 O
[ O
0.03 O
] O
) O
and O
KG O
( O
1.14 O
[ O
0.03 O
] O
) O
. O
['Resource-use']

Journal-Name:Medicine O
[]

CONCLUSION O
VIP O
combination O
chemotherapy O
is O
associated O
with O
an O
improved O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
over O
VP O
therapy O
in O
patients O
with O
extensive O
SCLC O
. O
['Physiological-Clinical', 'Mortality']

In O
all O
groups O
, O
the O
teeth O
were O
etched O
with O
37 O
% O
phosphoric O
acid O
for O
20 O
seconds O
, O
and O
RMGIC O
( O
Fuji O
Ortho O
LC O
, O
GC O
Europe O
, O
Leuven O
, O
Belgium O
) O
was O
used O
for O
bracket O
bonding O
. O
[]

Since O
1991 O
, O
the O
results O
of O
3 O
major O
trials O
-- O
the O
British O
Medical O
Research O
Council O
( O
MRC O
) O
trial O
of O
treatment O
in O
older O
adults O
, O
the O
Swedish O
Trial O
in O
Old O
Patients O
with O
Hypertension B-outcome ['Physiological-Clinical']
( O
STOP-Hypertension O
) O
and O
the O
Systolic O
Hypertension O
in O
the O
Elderly O
Program O
( O
SHEP O
) O
-- O
have O
conclusively O
established O
the O
benefits O
of O
treating O
older O
patients O
( O
> O
60 O
years O
) O
with O
both O
diastolic B-outcome ['Physiological-Clinical']
and O
isolated B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
ovarian O
cancers O
of O
stage O
1 O
and O
stage O
2 O
, O
a O
post-operative O
prophylactic O
chemotherapy O
is O
useful O
only O
in O
cases O
with O
tumor O
cells O
in O
the O
secretions O
of O
the O
pouch O
of O
Douglas O
or O
in O
the O
ascites O
and O
in O
cases O
where O
a O
sensitivity O
to O
the O
chemotherapy O
can O
be O
assumed O
. O
[]

The O
Treatment O
Group O
improved O
on O
the O
DSM-IV O
Criteria O
for O
Pathological O
Gambling B-outcome ['Life-Impact']
, O
but O
did O
not O
show O
a O
significant O
improvement O
on O
['Life-Impact']

However O
, O
overall O
home B-outcome ['Physiological-Clinical']
readiness I-outcome ['Physiological-Clinical']
( O
toleration O
of O
oral O
fluids O
, O
walking O
, O
pain O
tolerable O
by O
oral O
analgesics O
, O
no O
or O
only O
mild O
nausea O
) O
was O
achieved O
faster O
in O
the O
desflurane O
group O
receiving O
ondansetron O
( O
109 O
[ O
21-937 O
] O
min O
, O
P O
< O
0.01 O
) O
and O
in O
the O
propofol O
group O
( O
110 O
[ O
33-642 O
] O
min O
, O
P O
< O
0.001 O
) O
when O
compared O
to O
the O
desflurane O
only O
group O
( O
372 O
[ O
45-723 O
] O
min O
) O
( O
median O
[ O
range O
] O
) O
. O
['Physiological-Clinical']

We O
will O
recruit O
patients O
with O
diabetes O
or O
hypertension O
; O
these O
patients O
will O
be O
randomly O
assigned O
to O
receive O
all O
of O
their O
medications O
with O
improved O
labels O
or O
to O
receive O
prescriptions O
with O
standard O
labels O
. O
[]

METHODS O
Multivariate O
logistic O
regression O
was O
used O
to O
establish O
socio-demographic O
characteristics O
of O
participants O
versus O
non-participants O
in O
the O
intervention O
arm O
. O
[]

10 O
% O
. O
[]

Ibopamine O
is O
a O
dopaminergic O
and O
adrenergic O
receptor O
agonist O
, O
which O
is O
active O
in O
the O
treatment O
of O
congestive O
heart O
failure O
. O
[]

The O
intervention O
was O
developed O
through O
a O
dynamic O
and O
iterative O
process O
that O
involved O
extensive O
development O
activities O
, O
focus O
groups O
with O
the O
target O
population O
to O
pilot O
individual O
activities O
and O
intervention O
sessions O
, O
and O
later O
, O
pilot O
testing O
of O
the O
entire O
intervention O
. O
[]

BACKGROUND O
The O
efficacy O
of O
nebulized O
corticosteroids O
in O
the O
prevention O
of O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
has O
been O
poorly O
studied O
. O
[]

Doxepin O
produced O
a O
greater O
incidence O
of O
anticholinergic B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
, O
including O
dry B-outcome ['Physiological-Clinical']
mouth B-outcome ['Physiological-Clinical']
, O
constipation B-outcome ['Physiological-Clinical']
, O
sleepiness B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Similarly O
, O
significant O
improvement O
was O
observed O
in O
clinician O
and O
parent O
ratings O
. O
[]

INTERVENTION O
Comparison O
of O
isoniazid B-outcome ['Physiological-Clinical']
with O
placebo O
or O
no B-outcome ['Resource-use']
prophylaxis I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Pain B-outcome ['Physiological-Clinical']
was O
assessed O
on O
a O
visual O
analogue O
scale O
before O
and O
after O
TENS O
at O
each O
visit O
and O
the O
data O
were O
analysed O
with O
the O
analysis O
of O
variance O
( O
ANOVA O
) O
for O
repeated O
measures O
. O
['Physiological-Clinical']

Biosafety O
was O
monitored O
during O
the O
4-year O
trial O
to O
determine O
whether O
DHA O
supplementation O
was O
associated O
with O
identifiable O
risks O
. O
[]

In O
multivariate O
analyses O
, O
the O
best O
predictors O
of O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
fluconazole O
treatment O
( O
P O
= O
0.02 O
; O
relative O
hazard O
, O
13.2 O
) O
, O
a O
lower O
serum O
cryptococcal-antigen O
titer O
( O
P O
= O
0.05 O
; O
relative O
hazard O
, O
1.2 O
) O
, O
and O
more O
prolonged O
primary O
therapy O
with O
flucytosine O
( O
P O
= O
0.09 O
; O
relative O
hazard O
, O
1.1 O
) O
. O
['Mortality']

Single-needle O
acupuncture O
alleviates O
gag O
reflex O
during O
transesophageal O
echocardiography O
: O
a O
blinded O
, O
randomized O
, O
controlled O
pilot O
trial O
. O
[]

BACKGROUND O
Antimicrobial O
resistance O
has O
decreased O
eradication O
rates O
for O
Helicobacter O
pylori O
infection O
worldwide O
. O
[]

At O
two O
years O
the O
mean O
cholesterol B-outcome ['Physiological-Clinical']
level O
was O
highest O
in O
the O
Aza O
plus O
MP O
group O
, O
6.8 O
mmol/L O
and O
lowest O
in O
the O
group O
receiving O
triple O
therapy O
, O
5.8 O
mmol/L O
( O
P O
= O
ns O
) O
. O
['Physiological-Clinical']

Overall O
the O
mean O
postoperative B-outcome ['Physiological-Clinical']
Snore I-outcome ['Physiological-Clinical']
Index O
( O
SI O
) O
was O
less O
than O
the O
preoperative O
SI O
( O
P O
< O
0.0001 O
) O
, O
the O
average O
difference O
being O
78.2 O
snores/h O
. O
['Physiological-Clinical']

In O
this O
study O
, O
11 O
adult O
patients O
with O
autism O
or O
Asperger O
's O
disorder O
were O
compared O
with O
nine O
matched O
controls O
. O
[]

A O
potent O
oral O
P-selectin O
blocking O
agent O
improves O
microcirculatory B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
a O
marker O
of O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
injury I-outcome ['Physiological-Clinical']
in O
patients O
with O
sickle O
cell O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

VEGFR2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
increased O
at O
residual O
tumor O
histology O
in O
both O
treatment O
arms O
, O
with O
a O
lesser O
extent O
in O
patients O
receiving O
tamoxifen O
plus O
epirubicin O
. O
['Physiological-Clinical']

Baseline O
patient O
characteristics O
, O
anesthetic O
treatment O
, O
and O
potential O
confounding O
factors O
were O
recorded O
. O
[]

Main O
differences O
consisted O
in O
preoperative O
bowel O
washout O
( O
none O
vs. O
3 O
l O
cleaning O
solution O
) O
and O
analgesia O
( O
patient O
controlled O
analgesia O
vs. O
patient O
controlled O
epidural O
analgesia O
) O
. O
[]

Our O
visual O
system O
can O
link O
components O
of O
contours O
and O
segregate O
contours O
from O
complex O
backgrounds O
based O
on O
geometric O
grouping O
rules O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
compare O
postoperative O
pain O
and O
functional O
outcomes O
in O
patients O
undergoing O
inguinal O
herniorrhaphy O
who O
receive O
a O
COX-2 O
selective O
nonsteroidal O
anti-inflammatory O
drug O
( O
COX-2 O
) O
or O
placebo O
preoperatively O
and O
for O
4 O
days O
postoperatively O
. O
[]

Patients O
with O
platinum-sensitive O
tumours O
survived O
longer O
when O
they O
were O
treated O
with O
platinum-containing O
chemotherapy O
( O
P O
= O
0.005 O
) O
. O
[]

In O
the O
fennel O
group O
, O
80 O
% O
of O
girls O
and O
in O
the O
mefenamic O
acid O
group O
, O
73 O
% O
of O
girls O
showed O
complete O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
or O
pain B-outcome ['Physiological-Clinical']
decrease O
, O
while O
80 O
% O
in O
the O
fennel O
group O
and O
62 O
% O
in O
the O
mefenamic O
acid O
group O
no O
longer O
needed O
to O
rest O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Eligible O
participants O
were O
adults O
with O
a O
confirmed O
diagnosis O
of O
symptomatic O
multiple O
myeloma O
according O
to O
International O
Myeloma O
Working O
Group O
criteria O
who O
had O
achieved O
at O
least O
a O
partial O
response O
after O
undergoing O
standard-of-care O
induction O
therapy O
followed O
by O
high-dose O
melphalan O
(200 O
mg/m(2)) O
conditioning O
and O
single O
ASCT O
within O
12 O
months O
of O
diagnosis. O
[]

The O
key O
finding O
of O
this O
study O
was O
the O
significant O
lowering O
of O
pH B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
umbilical I-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
( O
7.31 O
+/- O
0.04 O
) O
and O
artery B-outcome ['Physiological-Clinical']
( O
7.21 O
+/- O
0.06 O
) O
in O
the O
glucose-infused O
group O
when O
compared O
with O
the O
non-glucose O
infusion O
groups O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
drugs O
significantly O
reduced O
blood O
pressure O
after O
treatment O
, O
with O
similar O
efficacy O
( O
p O
> O
0.05 O
) O
. O
[]

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
clinical O
specialist O
( O
supervised O
by O
a O
psychiatrist O
) O
who O
offered O
education O
, O
structured O
psychotherapy O
, O
and O
maintenance/relapse O
prevention O
support O
. O
[]

CONCLUSION O
Electro-acupuncture O
may O
reduce O
immunologic B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
caused O
by O
chemotherapy O
, O
thus O
it O
can O
be O
used O
as O
the O
auxiliary O
therapy O
for O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical']

Efficacy O
and O
safety O
of O
10 O
% O
HES O
130/0.4 O
versus O
10 O
% O
HES O
200/0.5 O
for O
plasma O
volume O
expansion O
in O
cardiac O
surgery O
patients O
. O
[]

The O
clinical O
relevance O
of O
this O
study O
is O
enhanced O
by O
the O
addition O
of O
an O
extended O
maintenance O
phase O
followed O
by O
a O
placebo O
discontinuation O
. O
[]

RESULTS O
Significant O
changes O
over O
time O
occurred O
for O
group O
II O
in O
all O
outcomes O
( O
p O
< O
or O
= O
0.001 O
) O
. O
[]

DESIGN O
A O
prospective O
, O
randomized O
trial O
. O
[]

METHODS O
A O
total O
of O
1,347 O
stable O
patients O
with O
angiographic O
coronary O
artery O
disease O
underwent O
serial O
evaluation O
of O
atheroma B-outcome ['Physiological-Clinical']
burden I-outcome ['Physiological-Clinical']
with O
intravascular O
ultrasound O
imaging O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

PURPOSE O
To O
determine O
if O
inhibition O
of O
stem-cell O
activity O
induced O
by O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
[ O
GM-CSF O
] O
; O
Sargramostim O
; O
Immunex O
Corporation O
, O
Seattle O
, O
WA O
) O
withdrawal O
or O
priming O
protects O
hematopoietic O
stem O
cells O
from O
the O
cytotoxic O
effects O
of O
adjuvant O
chemotherapy O
for O
early-stage O
breast O
cancer O
. O
[]

RESULTS O
The O
SH B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
17.9 O
per O
100 O
person-years O
, O
and O
a O
higher O
rate O
was O
associated O
with O
the O
occurrence O
of O
SH B-outcome ['Physiological-Clinical']
in O
the O
prior O
6 O
months O
and O
female O
sex O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
the O
interactive O
group O
proved O
superior O
to O
the O
lecture O
group O
regarding O
[]

Contour B-outcome ['Physiological-Clinical']
detectability I-outcome ['Physiological-Clinical']
deteriorated O
with O
increasing O
spacing B-outcome ['Physiological-Clinical']
between O
contour O
elements O
and O
improved O
as O
the O
number O
of O
colinear O
line O
elements O
was O
increased O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Inclusion O
criteria O
were O
: O
1 O
) O
pain O
raising O
suspicion O
of O
ACS O
and O
2 O
) O
pain O
score O
?4 O
. O
[]

RESULTS O
Significant O
improvement O
in O
posttest B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
was O
seen O
only O
in O
the O
error+correct O
training O
group O
. O
['Physiological-Clinical']

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
either O
group. O
[['Adverse-effects']]

Routine O
therapies O
for O
COPD O
were O
given O
to O
patients O
in O
the O
control O
group O
, O
while O
15 O
mL O
SI O
was O
given O
to O
those O
in O
the O
treatment O
group O
by O
intravenous O
dripping O
, O
twice O
daily O
for O
total O
14 O
days O
. O
[]

This O
follow-up O
study O
investigated O
the O
effect O
of O
hearing-aid O
use O
on O
emotional O
experience O
in O
adults O
with O
hearing O
impairment O
. O
[]

The O
composite O
endpoint O
of O
death B-outcome ['Mortality']
, O
nonfatal B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
and O
serious B-outcome ['Resource-use']
re-hospitalization I-outcome ['Resource-use']
was O
significantly O
higher O
in O
the O
folate O
group O
; O
serious O
re-hospitalization O
alone O
was O
significantly O
higher O
in O
this O
group O
. O
['Mortality', 'Physiological-Clinical', 'Resource-use']

Leiomyoma-related B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
comparably O
reduced O
in O
both O
groups O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
definitive O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
within O
1 O
year O
after O
randomization. O
[['Physiological-Clinical']]

Forty O
subjects O
, O
aged O
8-56 O
years O
( O
mean=22 O
) O
, O
all O
with O
mental O
retardation O
and O
36 O
with O
autism O
spectrum O
disorders O
participated O
in O
this O
22-week O
crossover O
study O
, O
with O
24 O
weeks O
of O
open O
maintenance O
thereafter O
. O
[]

Eighty-three O
participants O
with O
FOF O
were O
randomly O
assigned O
to O
VRE O
, O
SE O
, O
or O
WL O
. O
[]

The O
secondary O
aim O
was O
to O
assess O
the O
non-inferiority O
of O
the O
reduction O
of O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of O
the O
short O
protocol O
versus O
the O
long O
protocol. O
[['Physiological-Clinical']]

Likewise, O
significant O
differences O
between O
groups O
were O
observed O
throughout O
the O
study O
in O
the O
group-by-time O
interaction O
and O
changes O
of O
haemoglobin B-outcome ['Physiological-Clinical']
(GC: O
-2.89 O
+/- O
2.29% O
vs. O
VD3G: O
0.71 O
+/- O
1.91%; O
p O
= O
0.009), O
hematocrit B-outcome ['Physiological-Clinical']
(CG: O
-1.57 O
+/- O
2.49% O
vs. O
VD3G: O
1.16 O
+/- O
1.81%; O
p O
= O
0.019) O
and O
transferrin B-outcome ['Physiological-Clinical']
(CG: O
0.67 O
+/- O
4.88% O
vs. O
VD3G: O
6.51 O
+/- O
4.36%; O
p O
= O
0.007). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
degrees O
of O
UVB-induced O
erythema O
and O
pigmentation O
correlate O
linearly O
and O
are O
reduced O
in O
a O
parallel O
manner O
by O
topical O
anti-inflammatory O
agents O
. O
[]

Title: O
Comparison O
of O
analgesic B-outcome ['Resource-use']
efficacy O
of O
oxycodone O
and O
fentanyl O
after O
total O
hip O
replacement O
surgery: O
A O
randomized O
controlled O
trial. O
[['Resource-use']]

MAIN O
OUTCOME O
MEASURES O
Primary O
: O
day O
1 O
mean O
pain O
relief O
( O
0- O
to O
5-point O
verbal O
response O
scale O
) O
. O
[]

CONCLUSION O
It O
appears O
likely O
that O
mitomycin O
C O
plus O
doxorubicin O
instillation O
has O
an O
equivalent O
efficacy O
to O
BCG O
as O
the O
initial O
therapy O
of O
carcinoma O
in O
situ O
and O
the O
combination O
of O
them O
would O
be O
the O
most O
efficient O
treatment O
for O
the O
disease O
. O
[]

All O
eyes O
had O
uncontrolled O
intra-ocular B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
( O
greater O
than O
or O
equal O
to O
22 O
mm O
Hg O
) O
despite O
medical O
therapy O
. O
['Physiological-Clinical']

One O
hundred O
and O
fourteen O
obese O
women O
aged O
from O
18 O
to O
40 O
years O
were O
divided O
into O
insulin O
sensitive O
(IS) O
and O
insulin O
resistant O
(IR) O
groups O
and O
received O
a O
low O
calorie O
diet O
(LC), O
or O
an O
isocaloric O
diet O
and O
500 O
mg O
metformin O
twice O
daily O
(IM), O
or O
isocaloric O
diet O
with O
120 O
mg O
orlistat O
three O
times O
daily O
(IO). O
[]

Randomized O
, O
comparative O
study O
of O
the O
efficacy O
and O
safety O
of O
artesunate O
plus O
amodiaquine O
, O
administered O
as O
a O
single O
daily O
intake O
versus O
two O
daily O
intakes O
in O
the O
treatment O
of O
uncomplicated O
falciparum O
malaria O
. O
[]

Home O
blood O
pressure O
monitoring O
is O
a O
useful O
tool O
for O
clinical B-outcome ['Physiological-Clinical']
management I-outcome ['Physiological-Clinical']
of O
patients O
with O
hypertension O
. O
['Physiological-Clinical']

All O
predictors O
were O
significantly O
( O
P O
< O
.01 O
) O
associated O
with O
a O
hospitalization O
of O
32 O
days O
or O
longer O
; O
having O
a O
tracheostomy O
was O
the O
strongest O
predictor O
( O
odds O
ratio O
, O
4.74 O
) O
. O
[]

INTERPRETATION O
Our O
findings O
do O
not O
support O
the O
systematic O
prophylactic O
use O
of O
amiodarone O
in O
all O
patients O
with O
depressed O
left-ventricular O
function O
after O
myocardial O
infarction O
. O
[]

Journal O
ID: O
8410840 O
[]

A O
one-year O
followup O
study O
. O
[]

Although O
SADQ O
scores O
and O
Rand O
definite O
alcoholism B-outcome ['Life-Impact']
were O
in O
general O
agreement O
, O
there O
were O
a O
number O
of O
borderline O
instances O
and O
cases O
of O
disagreement O
, O
and O
neither O
was O
in O
good O
agreement O
with O
estimates O
of O
problem O
duration O
, O
nor O
with O
reports O
of O
recent O
or O
earlier O
attainment O
of O
abstinence O
or O
control O
. O
['Life-Impact']

Sixty-one O
patients O
( O
mean O
age O
, O
41 O
years O
) O
with O
nonspecific O
low O
back O
pain O
were O
randomized O
into O
two O
subgroups O
by O
treatment O
. O
[]

Journal O
ID: O
2985248R O
[]

Spotty O
calcification O
as O
a O
marker O
of O
accelerated O
progression O
of O
coronary B-outcome ['Physiological-Clinical']
atherosclerosis I-outcome ['Physiological-Clinical']
: O
insights O
from O
serial O
intravascular O
ultrasound O
. O
['Physiological-Clinical']

CONCLUSION O
These O
results O
suggest O
that O
long-lasting O
analgesic O
effects O
of O
intrathecal O
0.5 O
mg O
morphine O
suppress O
the O
immune O
response O
following O
abdominal O
surgery O
. O
[]

Comparison O
of O
the O
2 O
groups O
showed O
that O
there O
were O
no O
significant O
differences O
( O
all O
P O
values O
> O
0.05 O
) O
in O
all O
the O
parameters O
of O
pulse O
wave O
except O
that O
the O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
augmentation B-outcome ['Physiological-Clinical']
and O
augmentation B-outcome ['Physiological-Clinical']
index O
were O
significantly O
lower O
in O
enalapril O
group O
than O
in O
indapamide O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
secondary O
outcomes O
consisted O
of O
stool B-outcome ['Physiological-Clinical']
consistency I-outcome ['Physiological-Clinical']
, O
measured O
by O
the O
Bristol O
Stool O
Form O
Scale, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
flatulence B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
All O
outcomes O
were O
measured O
at O
baseline O
and O
after O
6-weeks O
treatment. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

The O
study O
also O
demonstrated O
the O
potential O
for O
consents O
to O
aid O
the O
student O
provider O
in O
better O
communicating B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
patients I-outcome ['Life-Impact']
. O
['Life-Impact']

We O
investigated O
the O
direct O
effect O
of O
a O
nutrition O
intervention O
in O
early O
childhood O
on O
adult O
economic O
productivity O
. O
[]

Improved O
acidosis O
correction O
and O
recovery O
of O
mesothelial O
cell O
mass O
with O
neutral-pH O
bicarbonate O
dialysis O
solution O
among O
children O
undergoing O
automated O
peritoneal O
dialysis O
. O
[]

The O
implant B-outcome ['Physiological-Clinical']
stability O
quotient O
values O
between O
the O
test O
and O
control O
groups O
were O
significant O
( O
P O
< O
0.05 O
) O
at O
the O
moment O
of O
implant O
placement O
but O
were O
no O
more O
significant O
at O
the O
loading O
of O
the O
definitive O
restoration O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Scar O
development O
was O
investigated O
in O
45 O
young O
patients O
who O
had O
undergone O
thoracic O
surgery O
. O
[]

No O
effective O
therapy O
is O
known O
. O
[]

[ O
A O
controlled O
study O
of O
treating O
haemophilia O
A O
on O
an O
out-patient O
basis O
( O
author O
's O
transl O
) O
] O
. O
[]

Title: O
Reduction O
of O
postendodontic O
pain B-outcome ['Physiological-Clinical']
after O
one-visit O
root O
canal O
treatment O
using O
three O
irrigating O
regimens O
with O
different O
temperature. O
[['Physiological-Clinical']]

Other O
potential O
moments O
for O
hand B-outcome ['Life-Impact', 'Life-Impact']
hygiene I-outcome ['Life-Impact', 'Life-Impact']
were O
introduced O
by O
participants, O
such O
as O
after O
tending O
to O
domestic O
animals O
and O
gardening. O
[['Life-Impact', 'Life-Impact']]

OBJECTIVE O
Assess O
the O
effectiveness O
of O
sildenafil O
in O
Asian O
males O
with O
erectile O
dysfunction O
( O
ED O
) O
and O
one O
or O
more O
of O
the O
co-morbidities O
, O
mild-to-moderate O
hypertension O
, O
dyslipidemia O
, O
and O
diabetes O
. O
[]

The O
increased O
concentration O
of O
serum B-outcome ['Physiological-Clinical']
Se I-outcome ['Physiological-Clinical']
, O
Zn B-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
treated O
with O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

from O
the O
ratio O
of O
detection O
rate O
( O
prevalence O
of O
screen-detected O
cases O
) O
and O
expected O
incidence O
( O
cumulative O
risk O
) O
. O
[]

Fenfluramine O
may O
have O
a O
limited O
place O
in O
the O
management O
of O
some O
patients O
with O
autistic O
disorder O
. O
[]

Some O
patients O
were O
treated O
by O
means O
of O
a O
standard O
activity O
of O
7.4 O
GBq O
131I O
and O
after O
5 O
days O
whole O
body O
scintigraphy O
( O
WBS O
) O
was O
performed O
. O
[]

The O
two O
treatment O
groups O
showed O
no O
statistically O
significant O
differences O
in O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
except O
for O
increased O
incidence O
of O
diaphoresis B-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
) O
and O
diarrhea B-outcome ['Physiological-Clinical']
( O
P O
= O
.05 O
) O
in O
the O
rHuEPO-treated O
group O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Nicotinic O
acid O
as O
therapy O
for O
dyslipidemia O
in O
non-insulin-dependent O
diabetes O
mellitus O
. O
[]

Our O
aim O
with O
this O
pilot O
study O
was O
to O
evaluate O
if O
fiber O
supplementation O
is O
beneficial O
for O
the O
treatment O
of O
children O
with O
idiopathic B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
is O
experimental O
evidence O
to O
suggest O
that O
hypercholesterolaemia O
may O
play O
a O
pathogenetic O
role O
in O
progressive O
glomerular O
injury O
. O
[]

CONCLUSION O
Leucocyte O
depletion O
is O
not O
associated O
with O
better O
long-term O
survival B-outcome ['Mortality']
and O
lower O
recurrence B-outcome ['Physiological-Clinical']
rates O
in O
patients O
with O
gastrointestinal O
cancer O
. O
['Mortality', 'Physiological-Clinical']

BACKGROUND O
It O
has O
been O
suggested O
that O
the O
use O
of O
adjunctive O
hyperbaric O
oxygen O
therapy O
improves O
the O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
, O
and O
decreases O
the O
risk O
of O
lower B-outcome ['Resource-use']
extremity I-outcome ['Resource-use']
amputations I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

The O
incidence O
of O
degeneration B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
squamous I-outcome ['Physiological-Clinical']
epithelium I-outcome ['Physiological-Clinical']
adjacent I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
carcinoma I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
chemotherapy O
group O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

The O
laparoscopic O
approach O
was O
associated O
with O
a O
longer O
operative O
time O
( O
234.1 O
min O
vs O
137.3 O
min O
) O
but O
was O
less O
painful B-outcome ['Physiological-Clinical']
( O
VAS O
5.3 O
vs O
7.9 O
; O
P O
< O
0.000 O
) O
and O
resulted O
in O
a O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
4.4+/-1 O
vs O
7.9+/-1.2 O
days O
; O
P O
< O
0.000 O
) O
. O
['Physiological-Clinical', 'Resource-use']

In O
neither O
group O
was O
milk B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
suppressed O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
validate O
an O
FFQ O
for O
the O
assessment O
of O
dietary O
EPA B-outcome ['Physiological-Clinical']
and O
DHA B-outcome ['Physiological-Clinical']
against O
their O
relative B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RBC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

2) O
Methods: O
a O
prospective, O
randomized, O
parallel O
pilot O
study O
of O
4.5 O
g O
administration O
of O
Spirulina O
maxima O
or O
placebo O
for O
12 O
weeks O
in O
16 O
patients O
with O
systemic O
arterial O
hypertension O
(SAH) O
undergoing O
treatment O
with O
angiotensin-converting O
enzyme O
(ACE) O
inhibitors O
was O
performed O
to O
assess O
the O
effects O
on O
endothelial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
indicators. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Plasma B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
and O
total O
tryptophan B-outcome ['Physiological-Clinical']
levels O
were O
obtained O
at O
baseline O
and O
5 O
hours O
after O
the O
drink O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Fecal B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
secretin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
four O
different O
periods O
during O
the O
first O
28 O
days O
of O
life O
in O
VLBW O
infants O
, O
with O
extremely O
early O
enteral O
feeding O
starting O
within O
24 O
h O
of O
birth O
, O
as O
well O
as O
in O
control O
infants O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AUCMB/day O
values O
were O
0.775 O
log O
( O
10 O
) O
copies/mL O
( O
95 O
% O
CI O
0.33-1.22 O
) O
and O
0.774 O
log O
( O
10 O
) O
copies/mL O
( O
95 O
% O
CI O
0.48-1.07 O
) O
, O
respectively O
, O
showing O
no O
difference O
in O
the O
rate O
of O
decrease O
of O
HIV-1 O
RNA O
( O
P=0.995 O
) O
. O
[]

DESIGN O
This O
was O
a O
16-week O
prospective O
, O
double O
blinded O
, O
randomized O
controlled O
trial O
of O
40 O
women O
with O
laparoscopically O
confirmed O
endometriosis O
. O
[]

An O
initial O
prospective O
, O
randomised O
, O
controlled O
trial O
( O
Study O
1 O
) O
, O
compared O
the O
safety O
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
( O
serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rabies I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
) O
after O
administration O
either O
of O
PHT-Erig O
or O
of O
a O
commercially-available O
, O
equine O
rabies O
immune O
globulin O
( O
Erig O
PMC O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
After O
IV O
administration O
, O
the O
plasma B-outcome ['Physiological-Clinical']
concentration O
of O
methadone B-outcome ['Physiological-Clinical']
at O
10 O
minutes O
was O
82.1 O
+/- O
9.2 O
ng O
mL O
( O
-1 O
) O
( O
mean O
+/- O
SD O
) O
, O
the O
terminal O
half-life O
was O
3.9 O
+/- O
1.0 O
hours O
, O
the O
volume O
of O
distribution O
9.2 O
+/- O
3.3 O
L O
kg O
( O
-1 O
) O
and O
plasma O
clearance O
27.9 O
+/- O
7.6 O
mL O
minute O
( O
-1 O
) O
kg O
( O
-1 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
total O
effective O
rate O
was O
80 O
. O
[]

We O
randomized O
122 O
premenopausal O
women O
to O
receive O
tamoxifen O
or O
to O
undergo O
a O
surgical O
oophorectomy O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
rate O
of O
blood O
transfusion O
( O
1.0 O
% O
in O
the O
cangrelor O
group O
and O
0.6 O
% O
in O
the O
placebo O
group O
, O
P=0.13 O
) O
, O
though O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
on O
one O
scale O
was O
increased O
in O
the O
cangrelor O
group O
, O
from O
3.5 O
% O
to O
5.5 O
% O
( O
P O
< O
0.001 O
) O
, O
because O
of O
more O
groin B-outcome ['Physiological-Clinical']
hematomas I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
all O
analyses O
a O
level O
of O
significance O
of O
95% O
(P O
< O
.05) O
will O
be O
considered. O
[]

There O
were O
no O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
main O
parameter O
was O
a O
video O
rating O
of O
global O
impression O
. O
[]

Journal-Name:Zhong O
nan O
da O
xue O
xue O
bao. O
[]

In O
the O
intra-arterial O
arm O
, O
dose O
limiting O
toxicity B-outcome ['Adverse-effects']
was O
seen O
in O
2/6 O
( O
33 O
% O
) O
patients O
at O
50 O
mCi O
whereas O
in O
the O
intravenous O
arm O
, O
dose O
limiting O
toxicity B-outcome ['Adverse-effects']
was O
noted O
in O
1/6 O
patients O
at O
50 O
mCi O
, O
but O
did O
not O
occur O
at O
75 O
mCi O
( O
0/3 O
) O
.The O
overall O
response O
rate O
was O
6 O
% O
( O
1/18 O
) O
. O
['Adverse-effects', 'Adverse-effects']

P O
less O
than O
0.05 O
) O
and O
this O
change O
was O
sustained O
for O
40 O
min O
. O
[]

A O
sample O
of O
210 O
pregnant O
women O
within O
gestational O
ages O
of O
16-24 O
wk O
were O
recruited O
at O
antenatal O
clinics O
and O
equally O
randomized O
to O
either O
a O
two-dose O
SP O
or O
three-dose O
SP O
group. O
[]

At O
6 O
months O
, O
study O
outcomes O
included O
days O
of O
alcohol B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
measured O
using O
the O
time-line O
follow-back O
method O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
Forty-eight O
patients O
were O
randomized O
to O
receive O
: O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
arm O
A O
; O
or O
FA O
( O
25 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
, O
followed O
by O
5-FU O
( O
750 O
mg/m2 O
iv O
bolus O
days O
1 O
to O
3 O
) O
plus O
IFO O
( O
2,000 O
mg/m2 O
in O
1000 O
mL O
5 O
% O
dextrose O
in O
a O
2-hr O
infusion O
, O
days O
1 O
to O
3 O
) O
, O
arm O
B. O
Mesna O
was O
added O
during O
and O
after O
IFO O
to O
prevent O
hemorrhagic O
cystitis O
. O
[]

The O
reported O
feelings O
of O
relaxation B-outcome ['Life-Impact']
were O
negatively O
correlated O
to O
the O
directionality O
of O
temperature O
change O
and O
were O
primarily O
attributed O
to O
nonspecific O
expectancies O
. O
['Life-Impact']

The O
difference O
in O
the O
change O
from O
baseline O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
scores O
in O
the O
two O
groups O
was O
assessed O
hourly O
for O
12 O
hours O
after O
administration O
. O
['Physiological-Clinical']

After O
72 O
months O
no O
significant O
difference O
between O
the O
patients O
and O
the O
healthy O
controls O
could O
be O
detected O
. O
[]

Activities B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
(ADL) I-outcome ['Life-Impact']
, O
self-evaluated O
loneliness B-outcome ['Life-Impact']
, O
and O
level O
of O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
were O
significantly O
lowered O
(P O
< O
.05) O
in O
the O
group O
receiving O
joint O
Baduanjin O
and O
CBT O
intervention O
at O
3 O
months O
and O
6 O
months, O
as O
compared O
to O
the O
Baduanjin O
only O
group O
or O
the O
CBT O
only O
group. O
[['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

GOALS O
To O
measure O
visit-to-visit O
intraindividual O
variations O
of O
both O
clinic O
and O
24-h O
mean O
BP O
in O
the O
hypertensive O
patients O
of O
the O
European O
Lacidipine O
Study O
on O
Atherosclerosis O
( O
ELSA O
) O
trial O
treated O
for O
4 O
years O
with O
either O
atenolol O
or O
lacidipine O
, O
and O
to O
check O
whether O
interindividual O
clinic O
and O
24-h O
BP O
variabilities O
during O
treatment O
can O
really O
be O
considered O
a O
surrogate O
of O
intraindividual O
variabilities O
in O
exploring O
differences O
between O
?-blocker O
and O
calcium O
antagonist O
treatments O
. O
[]

5-HTTLPR O
( O
long O
( O
l O
) O
or O
short O
( O
s O
) O
) O
, O
was O
analyzed O
by O
the O
PCR O
method O
. O
[]

There O
was O
a O
significant O
increase O
in O
peak O
VO2 O
( O
p O
< O
0.05 O
) O
and O
anaerobic O
threshold O
( O
p O
< O
0.01 O
) O
with O
denopamine O
, O
whereas O
no O
significant O
change O
was O
observed O
in O
peak O
work O
rate O
or O
exercise O
time O
. O
[]

They O
were O
told O
that O
the O
patient O
had O
either O
chronic O
fatigue O
syndrome O
, O
chronic O
neuroendocrineimmune O
dysfunction O
syndrome O
, O
or O
chronic O
neuroendocrineimmune O
dysfunction O
syndrome O
, O
which O
had O
formerly O
been O
called O
chronic O
fatigue O
syndrome O
. O
[]

Quantitative O
measurements O
of O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
At O
a O
median O
follow-up O
of O
10.5 O
years O
on O
194 O
eligible O
patients O
, O
disease O
evolution O
was O
seen O
in O
54 O
and O
49 O
patients O
in O
the O
surgery O
and O
chemotherapy O
arm O
, O
respectively O
, O
and O
81 O
and O
83 O
patients O
had O
died O
. O
[]

OBJECTIVE O
We O
tested O
the O
hypothesis O
that O
supplementation O
with O
a O
micronutrient-fortified O
beverage O
improves O
micronutrient O
status O
and O
physical O
and O
mental O
development O
in O
apparently O
healthy O
schoolchildren O
. O
[]

HI2 O
was O
more O
effective O
than O
HI1 O
and O
CA O
as O
measured O
by O
[]

The O
effect O
of O
a O
parent-implemented O
imitation O
intervention O
on O
spontaneous B-outcome ['Life-Impact']
imitation I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
young O
children O
with O
autism O
. O
['Life-Impact']

A O
total O
of O
53 O
patients O
were O
accessed O
to O
the O
study O
: O
29 O
patients O
for O
the O
OK-432 O
group O
and O
24 O
patients O
for O
the O
control O
group O
. O
[]

At O
a O
cut-off O
of O
26 O
, O
the O
AQ-J B-outcome ['Physiological-Clinical']
had O
satisfactory B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
, O
specificity O
, O
and O
negative O
predictive O
value O
, O
but O
it O
had O
low O
positive O
predictive O
value O
( O
0.24 O
) O
possibly O
due O
to O
the O
facts O
that O
the O
25 O
mild O
HPDD O
patients O
scored O
lower O
and O
the O
controls O
scored O
higher O
on O
the O
AQ-J O
than O
British O
counterparts O
on O
the O
AQ O
. O
['Physiological-Clinical', 'Life-Impact']

Comparison O
of O
arch O
dimension O
changes O
in O
1-phase O
vs O
2-phase O
treatment O
of O
Class O
II O
malocclusion O
. O
[]

that O
tiotropium O
Respimat O
5 O
?g O
once O
daily O
and O
Respimat O
2.5 O
?g O
once O
daily O
are O
non-inferior O
to O
HandiHaler O
in O
terms O
of O
all-cause O
mortality O
, O
and O
2 O
) O
. O
[]

In O
this O
study O
(APEX, O
Part O
I), O
we O
evaluated O
the O
efficacy/safety O
outcomes O
of O
DMF O
in O
a O
predominantly O
East O
Asian O
population O
of O
patients O
with O
RRMS. O
[]

A O
randomised O
prospective O
study O
comparing O
the O
new O
vacuum O
extractor O
policy O
with O
forceps O
delivery O
. O
[]

Language B-outcome ['Life-Impact']
outcome I-outcome ['Life-Impact']
in O
autism O
: O
randomized O
comparison O
of O
joint O
attention O
and O
play O
interventions O
. O
['Life-Impact']

The O
incidence O
of O
tremor B-outcome ['Physiological-Clinical']
was O
similar O
with O
the O
two O
medications O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
OSTAP O
block O
is O
a O
promising O
technique O
for O
producing O
effective O
and O
prolonged O
postoperative O
analgesia O
in O
patients O
undergoing O
laparoscopic O
hysterectomy O
surgeries. O
[]

[ O
Improving O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
after O
nose O
surgery O
by O
combined O
administration O
of O
xylometazoline O
and O
dexpanthenol O
] O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
groups O
in O
change O
of O
[]

Torasemide O
versus O
furosemide O
in O
cirrhosis O
: O
a O
long-term O
, O
double-blind O
, O
randomized O
clinical O
study O
. O
[]

0.3 O
m O
s O
( O
-1 O
) O
; O
P O
= O
0.001 O
) O
. O
[]

Forty O
three O
ASA O
I O
or O
II O
children O
age O
six O
months O
or O
older O
scheduled O
for O
elective O
BM O
& O
T O
were O
randomized O
to O
receive O
acetaminophen O
( O
paracetamol O
) O
15 O
mg.kg-1 O
, O
ibuprofen O
10 O
mg.kg-1 O
, O
or O
placebo O
. O
[]

In O
a O
double-blind O
, O
crossover O
design O
, O
7 O
vegetarians O
( O
VEG O
) O
and O
nonvegetarians O
( O
NVEG O
) O
were O
assigned O
Cr O
or O
placebo O
supplements O
for O
5 O
d O
and O
after O
5 O
wk O
, O
received O
the O
alternative O
treatment O
. O
[]

Impact B-outcome ['Life-Impact']
of O
a O
fixed O
combination O
of O
clindamycin O
phosphate O
1.2 O
% O
-benzoyl O
peroxide O
2.5 O
% O
aqueous O
gel O
on O
health-related O
quality O
of O
life O
in O
moderate O
to O
severe O
acne O
vulgaris O
. O
['Life-Impact']

Quality O
of O
life O
was O
not O
influenced O
by O
either O
treatment O
, O
and O
there O
was O
no O
relevant O
change O
in O
flow-mediated O
dilatation O
in O
patients O
treated O
with O
nebivolol O
or O
metoprolol O
( O
P=0.16 O
) O
. O
[]

In O
a O
2 O
? O
[]

However O
, O
the O
influence O
of O
pH O
on O
cerebral O
lactate O
uptake O
and O
, O
in O
turn O
, O
on O
the O
cerebral O
metabolic O
ratio O
during O
exercise O
is O
not O
known O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
immunological O
and O
functional O
effects O
of O
a O
liposome-entrapped O
D. O
pteronyssinus O
vaccine O
on O
mite O
monosensitive O
, O
mild O
asthma O
patients O
. O
[]

This O
difference O
in O
the O
pattern O
of O
recurrence B-outcome ['Physiological-Clinical']
was O
of O
borderline O
statistical O
significance O
( O
P O
= O
0.07 O
) O
. O
['Physiological-Clinical']

About O
half O
of O
the O
CV B-outcome ['Physiological-Clinical']
hospitalizations B-outcome ['Resource-use']
were O
AF-related B-outcome ['Physiological-Clinical']
, O
with O
a O
median O
duration O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
of O
four O
nights O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Our O
results O
suggest O
that O
single O
dose O
oral O
mebendazole O
has O
low O
efficacy O
against O
hookworm O
[]

Two O
preplanned O
comparisons O
were O
made O
: O
( O
a O
) O
Spinal O
manipulative O
therapy O
( O
SMT O
) O
combined O
with O
trunk O
strengthening O
exercises O
( O
TSE O
) O
vs. O
SMT O
combined O
with O
trunk O
stretching O
exercises O
, O
and O
( O
b O
) O
SMT O
combined O
with O
TSE O
vs. O
nonsteroidal O
anti-inflammatory O
drug O
( O
NSAID O
) O
therapy O
combined O
with O
TSE O
. O
[]

PURPOSE O
This O
randomized O
group O
experiment O
compared O
the O
efficacy O
of O
2 O
communication O
interventions O
( O
Responsive O
Education O
and O
Prelinguistic O
Milieu O
Teaching O
[ O
RPMT O
] O
and O
the O
Picture O
Exchange O
Communication O
System O
[ O
PECS O
] O
) O
on O
spoken O
communication O
in O
36 O
preschoolers O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

BACKGROUND O
This O
study O
aimed O
to O
investigate O
the O
course O
of O
depression B-outcome ['Life-Impact']
for O
patients O
with O
recently O
diagnosed O
rheumatoid O
arthritis O
( O
RA O
) O
and O
to O
investigate O
predictors O
of O
depression O
. O
['Life-Impact']

Group O
A O
consisted O
patients O
who O
received O
Atorvastatin O
40mg O
daily O
and O
Group O
B O
Atorvastatin O
80mg O
daily. O
[]

To O
date O
, O
most O
of O
these O
risk O
factors O
have O
not O
been O
confirmed O
in O
a O
UK O
population O
. O
[]

METHOD O
Caregivers O
( O
n O
= O
77 O
) O
of O
the O
cognitively O
impaired O
living O
at O
home O
were O
randomized O
to O
receive O
nurse O
counseling O
or O
not O
. O
[]

The O
arc O
of O
the O
necrotic O
portion O
in O
the O
mid-coronal O
image O
( O
A O
) O
and O
that O
in O
the O
mid-sagittal O
image O
( O
B O
) O
were O
used O
to O
quantify O
the O
extent O
of O
necrosis O
by O
the O
formula O
: O
( O
A/180 O
) O
x O
( O
B/180 O
) O
x O
100 O
. O
[]

Efforts O
to O
promote O
smoking O
cessation O
should O
highlight O
that O
individuals O
are O
likely O
to O
feel O
more O
rather O
than O
less O
psychologically O
healthy O
when O
they O
successfully O
quit O
smoking O
. O
[]

At O
least O
one O
drug-related B-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
reported O
by O
9.5 O
% O
of O
the O
faropenem O
daloxate-treated O
patients O
and O
by O
10.3 O
% O
of O
those O
who O
received O
cefuroxime O
axetil O
. O
['Adverse-effects']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Prolactin B-outcome ['Physiological-Clinical']
levels O
showed O
a O
decrease O
in O
the O
group O
treated O
with O
alpha O
dihidroergocriptine O
with O
an O
important O
difference O
between O
both O
groups O
at O
the O
end O
of O
the O
6 O
months O
study O
period O
. O
['Physiological-Clinical']

At O
baseline O
and O
after O
6 O
months O
' O
treatment O
, O
a O
biopsy O
was O
taken O
for O
histological O
examination O
. O
[]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India O
- O
rajesh.venkyresearch01@gmail.com. O
[]

2 O
. O
[]

Twenty O
patients O
with O
palmoplantar O
pustulosis O
( O
PPP O
) O
were O
treated O
with O
topical O
PUVA O
, O
oral O
etretinate O
( O
Re O
) O
, O
or O
combined O
PUVA O
and O
etretinate O
( O
Re-PUVA O
) O
. O
[]

Leeds O
Help O
Study O
Group O
. O
[]

STUDY O
DESIGN O
Prospective O
multicenter O
randomized O
controlled O
study O
designed O
to O
assess O
the O
noninferiority O
of O
diet O
versus O
dialysis O
in O
1-year O
mortality O
assessed O
by O
using O
intention-to-treat O
and O
per-protocol O
analysis O
. O
[]

The O
aim O
of O
the O
present O
investigation O
was O
to O
compare O
the O
efficacy O
of O
a O
low-dose O
antacid O
( O
Maalox O
70 O
, O
280 O
mmol/day O
) O
with O
that O
of O
the O
H2-receptor O
antagonist O
cimetidine O
( O
Tagamet O
, O
200 O
mg O
three O
times O
daily O
and O
400 O
mg/day O
) O
after O
14 O
and O
28 O
days O
in O
the O
treatment O
of O
duodenal O
ulcer O
. O
[]

RESULTS O
Higher O
apparent O
temperature O
was O
associated O
with O
higher O
levels O
of O
BNP B-outcome ['Physiological-Clinical']
beginning O
with O
2-day O
moving O
averages O
and O
reached O
statistical O
significance O
for O
3- O
and O
4-day O
moving O
averages O
. O
['Physiological-Clinical']

Teaching O
children O
with O
autism O
to O
seek O
information O
: O
acquisition O
of O
novel O
information O
and O
generalization O
of O
responding O
. O
[]

After O
12 O
months, O
patients O
receiving O
riociguat O
therapy O
showed O
a O
significant O
reduction O
in O
right B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(- X ['Physiological-Clinical', 'Physiological-Clinical']
2.6 X ['Physiological-Clinical', 'Physiological-Clinical']
+/- X ['Physiological-Clinical', 'Physiological-Clinical']
4.4 X ['Physiological-Clinical', 'Physiological-Clinical']
cm2, X ['Physiological-Clinical', 'Physiological-Clinical']
95% X ['Physiological-Clinical', 'Physiological-Clinical']
CI X ['Physiological-Clinical', 'Physiological-Clinical']
-3.84, X ['Physiological-Clinical', 'Physiological-Clinical']
- X ['Physiological-Clinical', 'Physiological-Clinical']
1.33; X ['Physiological-Clinical', 'Physiological-Clinical']
p X ['Physiological-Clinical', 'Physiological-Clinical']
< X ['Physiological-Clinical', 'Physiological-Clinical']
0.001, X ['Physiological-Clinical', 'Physiological-Clinical']
n X ['Physiological-Clinical', 'Physiological-Clinical']
= X ['Physiological-Clinical', 'Physiological-Clinical']
49) X ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
right B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(RV) I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
area E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
(- O
3.5 O
+/- O
5.2 O
cm2, O
95% O
CI O
-5.1, O
- O
1.9; O
p O
< O
0.001; O
n O
= O
44), O
RV B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
(- O
0.76 O
+/- O
2.2 O
mm, O
95% O
CI O
-1.55, O
0.03; O
n O
= O
32), O
and O
a O
significant O
increase O
in O
TAPSE B-outcome ['Physiological-Clinical']
(2.95 O
+/- O
4.78 O
mm, O
95% O
CI O
1.52, O
4.39; O
n O
= O
45) O
and O
RV B-outcome ['Physiological-Clinical']
fractional I-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
change O
(8.12 O
+/- O
8.87 O
mm, O
95% O
CI O
4.61, O
11.62; O
n O
= O
27). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

groups O
( O
46.9 O
% O
vs O
47.5 O
% O
vs O
45.3 O
% O
, O
respectively O
) O
. O
[]

Progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
also O
significantly O
longer O
for O
patients O
receiving O
marimastat O
compared O
to O
placebo O
( O
P=0.009 O
, O
hazard O
ratio=1.32 O
( O
1.07-1.63 O
) O
) O
. O
['Mortality']

Ferumoxytol O
is O
a O
novel O
, O
semisynthetic O
, O
carbohydrate-coated O
, O
superparamagnetic O
iron O
oxide O
nanoparticle O
that O
is O
administered O
IV O
as O
an O
injection O
. O
[]

BACKGROUND: O
This O
study O
aimed O
to O
evaluate O
the O
effectiveness O
of O
neuromuscular O
electrical O
stimulation O
(NMES) O
therapy O
in O
patients O
with O
urinary O
incontinence O
after O
stroke O
(UIAS). O
[]

The O
median O
response O
duration O
was O
151 O
days O
for O
the O
mitoxantrone O
group O
and O
126 O
days O
for O
the O
doxorubicin O
group O
( O
P O
= O
.16 O
) O
. O
[]

Data O
from O
a O
prospective O
randomized O
clinical O
trial O
among O
22 O
premenopausal O
women O
, O
age O
32.6 O
( O
range O
20-45 O
years O
) O
, O
who O
were O
randomly O
assigned O
to O
either O
of O
two O
treatments O
with O
continuous O
progestogens O
for O
contraception O
were O
analyzed O
; O
depot-medroxyprogesterone O
acetate O
( O
DMPA O
) O
or O
continuous O
levonorgestrel O
treatment O
with O
subdermal O
implants O
( O
Norplant O
) O
, O
respectively O
. O
[]

The O
UCAST-FW O
test O
was O
reliable O
over O
repeated O
administrations O
. O
[]

Effects O
of O
large O
doses O
of O
arachidonic O
acid O
added O
to O
docosahexaenoic O
acid O
on O
social O
impairment O
in O
individuals O
with O
autism O
spectrum O
disorders O
: O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
trial O
. O
[]

They O
can O
be O
treated O
with O
either O
an O
implantable O
cardioverter-defibrillator O
or O
antiarrhythmic O
drugs O
, O
but O
the O
relative O
efficacy O
of O
these O
two O
treatment O
strategies O
is O
unknown O
. O
[]

Subtherapeutic O
doses O
of O
amphotericin O
B O
( O
AMB O
) O
have O
been O
considered O
effective O
as O
prophylaxis O
in O
these O
patients O
. O
[]

The O
clinical O
registrations O
were O
mirrored O
by O
a O
statistically O
significant O
decrease O
( O
p O
< O
0.05 O
) O
in O
the O
[]

The O
Japanese O
Cooperative O
Study O
Group O
of O
PBSCT O
. O
[]

Participants O
then O
completed O
the O
Reading O
the O
Mind O
in O
the O
Eyes O
Task O
, O
a O
widely O
used O
and O
reliable O
test O
of O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
. O
['Life-Impact']

Spectra O
were O
measured O
( O
a O
) O
before O
and O
( O
b O
) O
after O
surface O
preparation O
, O
( O
c O
) O
immediately O
before O
and O
( O
d O
) O
after O
laser O
irradiation O
at O
630 O
nm O
. O
[]

METHODS O
We O
analyzed O
the O
safety O
of O
rotigotine O
in O
2 O
groups O
of O
patients O
with O
advanced O
stage O
Parkinson O
Disease O
. O
[]

RESULTS O
Data O
analysis O
showed O
sustained O
, O
statistically O
significant O
improvements O
in O
gingival B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
gingival I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
plaque I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
( O
GBI B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
PI I-outcome ['Physiological-Clinical']
) O
comparing O
users O
and O
non-users O
of O
toothbrushes O
and O
dentifrice O
in O
the O
original O
study O
( O
PI O
: O
p O
= O
0.04 O
; O
GBI O
: O
p O
= O
0.03 O
) O
and O
sustained B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
toothbrushes I-outcome ['Life-Impact']
and O
dentifrice B-outcome ['Resource-use']
by O
60 O
% O
of O
the O
subjects O
at O
follow-up O
one O
year O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Recurrence O
of O
condylomata B-outcome ['Physiological-Clinical']
acuminata I-outcome ['Physiological-Clinical']
following O
cryotherapy O
is O
not O
prevented O
by O
systemically O
administered O
interferon O
. O
['Physiological-Clinical']

A O
randomized O
, O
double-masked O
, O
placebo-controlled O
parallel O
study O
of O
loteprednol O
etabonate O
0.2 O
% O
in O
patients O
with O
seasonal O
allergic O
conjunctivitis O
. O
[]

During O
the O
trial O
treatment O
period, O
three O
patients O
in O
the O
placebo O
group O
died B-outcome ['Mortality']
. O
One O
patient O
in O
the O
caplacizumab O
group O
died B-outcome ['Mortality']
from O
cerebral O
ischemia O
after O
the O
end O
of O
the O
treatment O
period. O
[['Mortality'], ['Mortality']]

The O
present O
study O
demonstrates O
that O
DEX O
is O
less O
inhibitory B-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
phytohemagglutinin I-outcome ['Physiological-Clinical']
( O
PHA O
) O
-induced O
T O
cell O
proliferation O
in O
AD O
patients O
as O
compared O
to O
age-matched O
controls O
. O
['Physiological-Clinical']

A O
demethylated O
product O
of O
C O
exhibits O
only O
minor O
beta-blocking B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
three O
long-acting O
local O
anesthetics O
( O
bupivacaine O
0.75 O
% O
, O
ropivacaine O
1 O
% O
and O
etidocaine O
1 O
% O
) O
and O
to O
try O
, O
with O
reference O
to O
previous O
studies O
, O
to O
make O
some O
statement O
about O
the O
equipotency O
of O
ropivacaine O
relative O
to O
bupivacaine O
and O
etidocaine O
. O
[]

The O
overall O
approach O
includes O
providing O
universal O
access O
to O
diagnosis O
and O
treatment O
of O
malaria, O
and O
sustainable O
preventive O
measures, O
including O
vector O
control. O
[]

The O
effect O
of O
magnesium O
added O
to O
levobupivacaine O
for O
femoral O
nerve O
block O
on O
postoperative O
analgesia O
in O
patients O
undergoing O
ACL O
reconstruction O
. O
[]

The O
influence O
of O
dietary O
fibre O
source O
and O
gender O
on O
the O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
constituted O
part O
of O
a O
wider O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
[]

This O
necessitates O
increased O
focus O
on O
the O
pregnancy O
and O
early O
post-natal O
periods O
, O
developing O
and O
scaling O
up O
appropriate O
models O
of O
community-based O
care O
, O
especially O
to O
reach O
the O
peri-urban O
poor O
. O
[]

METHODS O
This O
was O
a O
2-day O
, O
double-blind O
, O
double-dummy O
, O
randomized O
, O
parallel-group O
, O
placebo-controlled O
study O
of O
diclofenac-K O
( O
12.5 O
mg O
) O
tablets O
vs O
paracetamol O
( O
500 O
mg O
) O
tablets O
and O
placebo O
in O
patients O
with O
moderate O
or O
severe O
pain O
within O
8 O
hours O
of O
extraction O
of O
impacted O
third O
molars O
. O
[]

MATERIALS O
AND O
METHODS O
Twenty O
normotensive O
postmenopausal O
women O
( O
median O
age O
53 O
years O
) O
participated O
in O
the O
study O
which O
used O
a O
double-blind O
crossover O
design O
. O
[]

Finally O
, O
there O
was O
no O
difference O
between O
the O
three O
groups O
in O
the O
average O
intake O
of O
PCA O
morphine O
. O
[]

RESULTS O
Both O
groups O
showed O
a O
significant O
improvement O
during O
observation O
[ O
ISGA O
27.1 O
% O
( O
C/BPO O
) O
and O
24.6 O
% O
( O
C/BPO O
+ O
laser O
) O
, O
total O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
9.2 O
% O
and O
9.0 O
% O
, O
['Physiological-Clinical']

One O
patient O
died O
before O
treatment O
, O
which O
left O
30 O
patients O
in O
each O
group O
. O
[]

There O
was O
some O
evidence O
of O
therapeutic O
carry-over O
effects O
in O
both O
clinical O
and O
biochemical O
measures O
in O
those O
children O
who O
received O
NTX O
before O
PLC O
. O
[]

The O
rate O
of O
wearing B-outcome ['Life-Impact']
glasses I-outcome ['Life-Impact']
was O
55.2% O
in O
the O
treatment O
group O
and O
23.4% O
(p O
< O
0.01) O
among O
the O
control O
group. O
[['Life-Impact']]

The O
effects O
of O
haloperidol O
on O
learning B-outcome ['Life-Impact']
and O
behavior B-outcome ['Life-Impact']
in O
autistic O
children O
. O
['Life-Impact', 'Life-Impact']

Overall O
, O
the O
use O
of O
the O
MTL O
appears O
well O
tolerated O
by O
healthy O
, O
adult O
volunteers O
. O
[]

Animal O
studies O
with O
SSRI O
's O
suggest O
that O
serotonergic O
modulation O
alters O
methamphetamine O
's O
behavioral B-outcome ['Life-Impact']
effects O
. O
['Life-Impact']

However O
, O
the O
present O
data O
can O
not O
exclude O
the O
possibility O
that O
the O
neuroendocrine O
changes O
reflect O
nonspecific O
stress O
responses O
or O
changes O
in O
pituitary O
blood O
flow O
. O
[]

CONCLUSIONS O
Pulsed O
low-intensity O
direct O
current O
represents O
a O
useful O
approach O
for O
the O
treatment O
of O
stage B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
III I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
decubitus I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
by O
increasing O
the O
healing O
rate O
. O
['Physiological-Clinical']

What O
is O
the O
optimum O
maximal O
gonadotropin O
dosage O
used O
in O
microdose O
flare-up O
cycles O
in O
poor O
responders O
? O
[]

In O
the O
onion-treated O
skin O
sites O
the O
wheal B-outcome ['Physiological-Clinical']
areas I-outcome ['Physiological-Clinical']
were O
significantly O
reduced O
( O
20 O
IU O
: O
control O
: O
108 O
+/- O
53 O
mm2 O
; O
onion O
69 O
+/- O
42 O
mm2 O
, O
P O
less O
than O
0.05 O
; O
200 O
IU O
anti-IgE O
: O
control O
: O
152 O
+/- O
25 O
mm2 O
, O
onion O
: O
138 O
+/- O
26 O
mm2 O
, O
P O
less O
than O
0.02 O
) O
. O
['Physiological-Clinical']

Electrocardiography O
and O
laboratory O
values O
( O
including O
CSF O
) O
were O
unremarkable O
. O
[]

In O
comparison O
between O
group O
A O
and O
B O
, O
Bifidobacterium O
was O
detected O
significantly O
earlier O
in O
group O
A O
, O
and O
the O
number O
of O
Enterobacteriaceae O
present O
in O
the O
infants O
at O
2 O
weeks O
after O
birth O
was O
significantly O
lower O
in O
group O
A O
. O
[]

Data O
for O
90 O
children O
( O
49 O
boys O
, O
41 O
girls O
, O
9.3 O
? O
[]

Objective: O
To O
determine O
whether O
removing O
co-payment O
barriers O
increases O
P2Y12 B-outcome ['Physiological-Clinical']
inhibitor I-outcome ['Physiological-Clinical']
persistence I-outcome ['Physiological-Clinical']
and O
lowers O
risk O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
. O
Design, O
Setting, O
and O
Participants: O
Cluster O
randomized O
clinical O
trial O
among O
301 O
hospitals O
enrolling O
adult O
patients O
with O
acute O
MI O
(June O
5, O
2015, O
through O
September O
30, O
2016); O
patients O
were O
followed O
up O
for O
1 O
year O
after O
discharge O
(final O
date O
of O
follow-up O
was O
October O
23, O
2017), O
with O
blinded O
adjudication O
of O
major B-outcome ['Physiological-Clinical', 'Mortality']
adverse I-outcome ['Physiological-Clinical', 'Mortality']
cardiovascular I-outcome ['Physiological-Clinical', 'Mortality']
events I-outcome ['Physiological-Clinical', 'Mortality']
(MACE) I-outcome ['Physiological-Clinical', 'Mortality']
; O
choice O
of O
P2Y12 O
inhibitor O
was O
per O
clinician O
discretion. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical', 'Mortality']]

[ O
Clinical O
study O
on O
treatment O
of O
endometriosis-related O
infertility O
patients O
by O
laparoscopic O
surgery O
in O
combination O
of O
quyu O
jiedu O
recipe O
] O
. O
[]

Both O
the O
development O
of O
nitrate B-outcome ['Physiological-Clinical']
tolerance I-outcome ['Physiological-Clinical']
and O
the O
administration O
of O
N-acetylcysteine O
significantly O
change O
the O
normal O
['Physiological-Clinical']

The O
recurrence O
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
after O
minimally O
invasive O
therapy O
is O
frequent O
. O
[]

Similarly, O
fewer O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
breaks I-outcome ['Life-Impact']
in O
combination O
with O
other O
conditions O
impeded O
the O
program's O
success. O
[['Life-Impact']]

Effects O
of O
a O
brief O
Early O
Start O
Denver O
model O
( O
ESDM O
) O
-based O
parent O
intervention O
on O
toddlers O
at O
risk O
for O
autism O
spectrum O
disorders O
: O
a O
randomized O
controlled O
trial O
. O
[]

Cervico-vaginal O
lavage O
was O
collected O
to O
measure O
the O
concentrations O
of O
IL-1? O
, O
TNF? O
and O
IL-6 O
by O
ELISA O
. O
[]

CONCLUSION O
It O
is O
concluded O
that O
oral O
NaAcetate O
could O
be O
used O
as O
both O
an O
alkalinizing O
agent O
and O
an O
alternative O
energy O
source O
in O
the O
horse O
. O
[]

The O
efficacy O
of O
low O
pressure O
, O
high O
pressure O
and O
passive O
drainage O
systems O
have O
been O
compared O
after O
cholecystectomy O
. O
[]

In O
group O
1 O
, O
placental B-outcome ['Physiological-Clinical']
expulsion I-outcome ['Physiological-Clinical']
occurred O
in O
all O
patients O
and O
the O
duration O
of O
the O
placental B-outcome ['Physiological-Clinical']
expulsion I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
prostaglandin I-outcome ['Physiological-Clinical']
F2 I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
was O
6.8 O
+/- O
1.36 O
( O
mean O
+/- O
SE O
) O
min O
: O
in O
group O
2 O
, O
six O
placental B-outcome ['Physiological-Clinical']
expulsions I-outcome ['Physiological-Clinical']
occurred O
after O
13.3 O
+/- O
1.97 O
min O
( O
mean O
+/- O
SE O
) O
; O
and O
in O
group O
3 O
, O
no O
effect O
was O
recorded O
after O
intraumbilical O
saline O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
results O
can O
provide O
information O
on O
potential O
directions O
for O
future O
family O
recruitment O
. O
[]

Children O
with O
autism O
's O
response O
to O
novel B-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
while O
participating O
in O
interventions O
targeting O
joint O
attention O
or O
symbolic O
play O
skills O
. O
['Physiological-Clinical']

V O
diagnosis O
of O
severe O
mental O
illness O
from O
psychiatric O
disability O
from O
10 O
supported O
housing O
facilities O
and O
41 O
of O
their O
caregivers O
participated O
in O
this O
12-month O
study O
during O
2005-2006 O
in O
Sweden O
. O
[]

The O
cognitive B-outcome ['Life-Impact']
, O
subjective O
, O
and O
['Life-Impact']

Group O
1 O
: O
500 O
mg O
of O
Diamox O
Sustets O
( O
acetazolamide O
) O
1 O
hour O
preoperatively O
( O
10 O
patients O
) O
; O
Group O
2 O
: O
peroperative O
intracameral O
Miochol O
( O
acetylcholine O
) O
( O
11 O
patients O
) O
; O
Group O
3 O
: O
the O
above O
treatments O
combined O
( O
15 O
patients O
) O
. O
[]

Gross B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
scores O
on O
the O
TGMD-2 O
were O
measured O
and O
statistically O
analyzed O
using O
a O
within-subjects O
repeated-measures O
ANOVA O
. O
['Physiological-Clinical']

Eighteen O
subjects O
were O
treated O
in O
a O
crossover O
design O
with O
oral O
placebo/intravenous O
saline O
, O
50 O
mg O
of O
oral O
SDZ O
ENS-163/intravenous O
saline O
, O
oral O
placebo/0.4 O
mg O
of O
intravenous O
scopolamine O
, O
and O
50 O
mg O
of O
oral O
SDZ O
ENS-163/0.4 O
mg O
of O
intravenous O
scopolamine O
. O
[]

METHODS O
Consecutively O
listed O
candidates O
for O
elective O
bypass O
were O
randomly O
assigned O
to O
either O
off-pump O
or O
on-pump O
techniques O
( O
n O
= O
107 O
) O
. O
[]

Journal O
ID: O
101126433 O
[]

Tolfenamic O
acid O
and O
caffeine O
: O
a O
useful O
combination O
in O
migraine B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Hence, O
the O
primary O
objective O
was O
to O
study O
the O
hypothesis O
that O
methohexital O
confers O
a O
better O
hemodynamic B-outcome ['Physiological-Clinical']
profile O
than O
propofol O
for O
anesthetic O
induction, O
in O
patients O
receiving O
AAB. O
[['Physiological-Clinical']]

6.90 O
ml/min/1.73 O
m O
( O
2 O
) O
, O
p O
= O
0.0015 O
) O
. O
[]

The O
fentanyl O
made O
no O
difference O
to O
the O
patients O
' O
postoperative O
analgesic O
requirements O
or O
to O
their O
recovery O
in O
the O
first O
24 O
hours O
. O
[]

Mean O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
score O
and O
mean O
time B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
return I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
normal I-outcome ['Life-Impact']
diet I-outcome ['Life-Impact']
were O
significantly O
lower O
in O
the O
TWT O
group O
. O
['Physiological-Clinical', 'Life-Impact']

We O
introduced O
a O
double-blind O
controlled O
clinical O
study O
to O
compare O
intravenous O
human O
epidermal O
growth O
factor O
( O
hEGF O
) O
to O
cetraxate O
hydrochloride O
( O
CH O
) O
, O
an O
antiulcer O
drug O
, O
for O
their O
healing O
effect O
on O
gastric B-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intra-operative O
antibiotic O
prophylaxis O
in O
neurosurgery O
. O
[]

BACKGROUND: O
The O
onset O
of O
puberty O
and O
menarche O
is O
a O
specifically O
vulnerable O
time O
for O
girls, O
during O
which O
they O
begin O
to O
show O
interest O
in O
the O
opposite O
sex, O
while O
becoming O
exposed O
to O
a O
myriad O
of O
external O
pressures, O
including O
sexual O
coercion O
or O
harassment O
from O
boys O
and O
men, O
expectations O
to O
marry O
from O
their O
families, O
and O
the O
need O
to O
perform O
well O
in O
primary O
school O
in O
order O
to O
qualify O
for O
secondary O
school. O
[]

The O
mean O
time B-outcome ['Life-Impact']
for O
completing O
the O
task O
during O
the O
stabilization O
period O
was O
significantly O
different O
between O
group O
I O
and O
group O
III O
and O
group O
II O
and O
group O
III, O
which O
means O
that O
the O
independent O
training O
method O
was O
inferior O
to O
the O
other O
methods O
(group O
I O
vs. O
group O
II O
vs. O
group O
III: O
187.38 O
vs. O
187.07 O
vs. O
253.47 O
seconds, O
P O
< O
.001). O
[['Life-Impact']]

Publication O
Type: O
Multicenter O
Study O
[]

This O
interaction O
is O
capable O
of O
creating O
toxic O
species O
that O
generate O
cell O
death. O
[]

Most O
subjects O
were O
vitD(3) O
deficient O
at O
enrolment, O
but O
a O
gradual O
and O
significant O
improvement O
of O
vitD(3) B-outcome ['Physiological-Clinical']
status O
was O
demonstrated O
in O
the O
vitD(3) O
+ O
PBA O
group O
compared O
with O
placebo O
(p O
< O
0.0001) O
from O
week O
0 O
to O
16 O
(median O
37.5 O
versus O
115.5 O
nmol/L). O
[['Physiological-Clinical']]

This O
study O
is O
registered O
, O
number O
ISRCTN78390996 O
. O
[]

Iron O
in O
relation O
to O
gastric O
cancer O
in O
the O
Alpha-tocopherol O
, O
Beta-carotene O
Cancer O
Prevention O
Study O
. O
[]

The O
SEPS O
group O
( O
n O
= O
25 O
) O
had O
significantly O
reduced O
AVP B-outcome ['Physiological-Clinical']
( O
P O
< O
.01 O
) O
compared O
with O
the O
control O
group O
( O
n O
= O
26 O
) O
. O
['Physiological-Clinical']

A O
prospective O
, O
randomized O
, O
pilot O
study O
. O
[]

Immune O
response O
was O
similar O
following O
the O
two O
regimens O
with O
100 O
% O
of O
the O
vaccinees O
seroprotected O
for O
HBV O
, O
diphtheria O
, O
tetanus O
, O
Hib O
and O
poliovirus O
types O
2 O
and O
3 O
diseases O
after O
the O
full O
vaccination O
course O
. O
[]

The O
expectation O
is O
that O
674 O
patients O
will O
be O
entered O
into O
the O
study O
from O
25 O
participating O
centers O
. O
[]

DESIGN O
Prospective O
, O
randomized O
clinical O
trial O
. O
[]

DESIGN O
Critical O
review O
of O
safety O
data O
from O
three O
randomized O
controlled O
clinical O
trials O
with O
supplemental O
information O
from O
an O
expanded O
drug O
access O
program O
. O
[]

All O
patients O
received O
a O
vasodilator O
cocktail O
intra-arterially O
and O
underwent O
cardiac O
catheterization O
using O
a O
5F O
introducer O
sheath O
and O
catheters O
. O
[]

To O
determine O
the O
efficacy O
and O
safety O
of O
leukocyte-depleted O
reperfusion O
, O
20 O
patients O
were O
enrolled O
in O
a O
randomized O
, O
double-blind O
clinical O
trial O
to O
be O
treated O
with O
either O
warm O
whole O
blood O
reperfusion O
( O
group O
I O
; O
n O
= O
9 O
) O
or O
warm O
leukocyte-depleted O
blood O
reperfusion O
( O
group O
II O
; O
n O
= O
11 O
) O
. O
[]

ET-1 B-outcome ['Physiological-Clinical']
flux I-outcome ['Physiological-Clinical']
across O
the O
leg O
was O
not O
augmented O
by O
insulin O
alone O
but O
was O
increased O
with O
the O
addition O
of O
BQ-123 O
to O
insulin O
( O
P O
= O
0.01 O
BQ-123 O
effect O
, O
P O
= O
not O
significant O
comparing O
groups O
) O
. O
['Physiological-Clinical']

OBJECTIVE: O
The O
study O
sought O
to O
compare O
the O
efficacy O
of O
a O
lower O
loading O
dose O
of O
prasugrel O
with O
conventional O
loading O
dose O
of O
prasugrel O
in O
Indian O
patients. O
[]

Eye O
movement O
performance O
during O
the O
tasks O
was O
captured O
using O
an O
infrared O
eye O
tracker O
. O
[]

The O
mean O
predicted O
AUC O
of O
flunarizine O
was O
1230 O
+/- O
717 O
ng O
h O
mL-1 O
, O
whereas O
the O
observed O
AUC O
was O
1203 O
+/- O
900 O
ng O
h O
mL-1 O
. O
[]

This O
change O
of O
activation O
is O
analogous O
to O
functional O
modification O
of O
middle-latency O
reflex O
EMG B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
load O
, O
or O
cutaneous O
perturbation O
. O
['Physiological-Clinical']

Anxiolytics O
in O
patients O
suffering O
a O
suspected O
acute O
coronary O
syndrome O
: O
multi-centre O
randomised O
controlled O
trial O
in O
Emergency O
Medical O
Service O
. O
[]

Hemodynamic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
were O
measured O
, O
and O
transesophageal O
echocardiography O
( O
TEE O
) O
was O
used O
to O
determine O
myocardial O
contractility O
. O
['Physiological-Clinical']

High-risk O
patients O
undergoing O
CABG O
surgery O
will O
be O
randomly O
assigned O
to O
receive O
either O
MC-1 O
( O
250 O
mg/d O
) O
or O
matching O
placebo O
immediately O
before O
and O
continuing O
for O
30 O
days O
after O
the O
procedure O
. O
[]

METHODS O
After O
refraining O
from O
all O
oral O
hygiene O
procedures O
for O
23-25 O
hours O
, O
subjects O
received O
an O
oral O
tissue O
examination O
and O
those O
with O
pre-brushing O
whole O
mouth O
mean O
plaque O
scores O
> O
or O
= O
0.6 O
based O
on O
the O
Rustogi O
et O
al O
. O
[]

The O
first O
long-term O
results O
, O
recorded O
after O
2 O
years O
, O
indicate O
statistically O
significant O
differences O
in O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
after O
stenting O
2/62 O
and O
after O
angioplasty O
5/69 O
) O
and O
patency B-outcome ['Physiological-Clinical']
( O
greater O
than O
or O
equal O
to O
70 O
% O
of O
original O
lumen O
size O
upon O
stent O
implantation O
or O
balloon O
inflation O
: O
95 O
% O
after O
stenting O
and O
72 O
% O
after O
angioplasty O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

Twenty O
children O
aged O
6 O
to O
9 O
years O
and O
their O
families O
began O
a O
program O
to O
modify O
the O
family O
diet O
toward O
a O
goal O
of O
70 O
mEq O
sodium O
per O
person O
per O
day O
. O
[]

Urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
phenylethylamine I-outcome ['Physiological-Clinical']
increased O
proportionately O
with O
doses O
up O
to O
24 O
mg. O
No O
changes O
in O
urinary B-outcome ['Physiological-Clinical']
elimination O
of O
catecholamines B-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
indicate O
that O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
gains I-outcome ['Life-Impact']
were O
greater O
for O
both O
treatment O
groups O
compared O
with O
the O
control O
group O
, O
and O
results O
could O
not O
be O
explained O
by O
differences O
in O
other O
interventions O
in O
which O
children O
participated O
. O
['Life-Impact']

PURPOSE O
Bevacizumab O
, O
a O
humanized O
anti-vascular O
endothelial O
growth O
factor O
monoclonal O
antibody O
, O
and O
erlotinib O
, O
a O
reversible O
, O
orally O
available O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitor O
, O
have O
demonstrated O
evidence O
of O
a O
survival O
benefit O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

Use O
of O
ampicillin/sulbactam O
results O
in O
a O
significantly O
lower O
SWI B-outcome ['Physiological-Clinical']
rate O
than O
use O
of O
cefoxitin O
, O
which O
may O
be O
a O
result O
of O
improved O
enterococcal B-outcome ['Physiological-Clinical']
and O
Bacteroides B-outcome ['Physiological-Clinical']
coverage O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101521595 O
[]

DESIGN O
Randomized O
, O
controlled O
trial O
, O
with O
post O
hoc O
analysis O
. O
[]

METHODS O
We O
assessed O
caffeine O
responses O
and O
levels O
of O
saliva O
concentration O
of O
caffeine O
in O
52 O
subjects O
who O
were O
randomly O
assigned O
to O
receive O
one O
of O
two O
drug O
administration O
instructions O
: O
( O
a O
) O
placebo-informed O
instructions O
( O
i.e. O
, O
individuals O
informed O
of O
the O
placebo O
) O
analogous O
to O
those O
used O
in O
double-blind O
studies O
and O
( O
b O
) O
placebo-uninformed O
instructions O
( O
i.e. O
, O
individuals O
informed O
they O
are O
taking O
an O
active O
stimulant O
) O
. O
[]

Basing O
on O
50 O
posttraumatic O
intensive-care O
patients O
with O
medium O
grade O
lesions O
( O
ISS O
criteria O
) O
, O
the O
prophylactic O
effect O
of O
an O
intravenously O
applicable O
IgM O
preparation O
( O
Pentaglobin O
) O
against O
nosocomial O
infections B-outcome ['Physiological-Clinical']
was O
investigated O
. O
['Physiological-Clinical']

The O
design O
of O
these O
and O
similar O
drug O
trials O
in O
children O
with O
autistic O
disorder O
must O
take O
into O
account O
the O
possibility O
of O
a O
large O
placebo O
response O
. O
[]

However O
, O
this O
redistribution O
was O
not O
observed O
in O
patients O
who O
presented O
a O
worsening O
of O
right O
ventricular O
function O
( O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
increase O
> O
40 O
% O
) O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
[]

The O
corresponding O
rates O
between O
weeks O
44 O
and O
80 O
were O
0.10+/-0.25 O
and O
0.03+/-0.28 O
(difference, O
0.07; O
two-sided O
90% O
CI, O
0.03 O
to O
0.10); O
the O
difference O
in O
the O
rate O
of O
progression B-outcome ['Physiological-Clinical']
between O
weeks O
44 O
and O
80 O
did O
not O
meet O
the O
criterion O
for O
noninferiority O
of O
early O
receipt O
of O
levodopa O
to O
delayed O
receipt. O
[['Physiological-Clinical']]

Group O
A O
( O
n O
= O
35 O
) O
received O
2.5 O
ml O
0.75 O
% O
ropivacaine O
and O
group O
B O
( O
n O
= O
35 O
) O
received O
2.5 O
ml O
of O
2 O
% O
lidocaine O
for O
digital O
anesthesia O
. O
[]

Heart O
failure O
is O
the O
leading O
cause O
of O
hospitalization O
. O
[]

Though O
cardiorespiratory O
exercise O
training O
increases O
HRV O
, O
little O
is O
known O
regarding O
the O
exercise O
dose O
necessary O
to O
promote O
this O
improvement O
. O
[]

Repeated O
doses O
of O
porcine O
secretin O
in O
the O
treatment O
of O
autism O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

The O
maxilla O
moves O
slightly O
downward O
in O
SARME O
. O
[]

Publication O
date: O
2019/01/05 O
00:00 O
[accepted] O
[]

Thus O
, O
experimental O
evidence O
on O
the O
beneficial O
effects O
of O
combining O
pharmacotherapy O
and O
exportable O
behavioral O
interventions O
is O
needed O
to O
guide O
clinical O
practice O
. O
[]

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O
[]

BACKGROUND: O
Primary O
care O
physicians O
(PCPs) O
working O
in O
mental O
health O
care O
in O
Tunisia O
often O
lack O
knowledge O
and O
skills O
needed O
to O
adequately O
address O
mental O
health-related O
issues. O
[]

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
RESULTS: O
A O
total O
of O
647 O
patients O
underwent O
randomization O
from O
December O
2008 O
through O
January O
2012, O
were O
assigned O
to O
undergo O
lymphadenectomy O
(323 O
patients) O
or O
not O
undergo O
lymphadenectomy O
(324), O
and O
were O
included O
in O
the O
analysis. O
[['Mortality']]

Videoconferencing O
technology O
, O
as O
a O
scalable O
tool O
, O
has O
promise O
for O
facilitating O
access O
to O
autism O
specialists O
and O
bridging O
the O
research-to-practice O
gap O
. O
[]

INTERVENTION O
The O
subjects O
were O
placed O
in O
one O
of O
two O
groups O
, O
initially O
by O
flipping O
a O
coin O
then O
into O
alternate O
groups O
. O
[]

A O
total O
of O
1000 O
ml O
of O
normal O
saline O
and O
1 O
mCi O
of O
Tc-99m O
SC O
was O
infused O
intraperitoneally O
for O
IDI O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
yoga O
on O
mood O
status O
and O
quality O
of O
life O
among O
women O
undergoing O
detoxification O
for O
heroin O
dependence O
in O
China O
. O
[]

The O
primary O
efficacy O
measure O
was O
the O
Aberrant O
Behavior O
Checklist-Irritability O
( O
ABC-I O
) O
subscale O
. O
['Life-Impact']

The O
primary O
outcome O
was O
total O
induction B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
based O
on O
the O
order O
of O
remifentanil O
administration. O
[['Life-Impact']]

Aminoglycosides O
are O
usually O
given O
in O
two O
or O
three O
divided O
doses O
. O
[]

Publication O
date: O
2017/11/15 O
00:00 O
[accepted] O
[]

MIP B-outcome ['Physiological-Clinical']
was O
the O
primary O
outcome O
. O
['Physiological-Clinical']

Pegfilgrastim O
for O
peripheral O
CD34+ O
mobilization O
in O
patients O
with O
solid O
tumours O
. O
[]

Lung B-outcome ['Physiological-Clinical']
volume-to-heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
spectral I-outcome ['Physiological-Clinical']
coherence I-outcome ['Physiological-Clinical']
was O
highest O
at O
frequencies O
associated O
with O
respiration O
and O
greater O
in O
young O
than O
in O
older O
subjects O
( O
P O
< O
0.07 O
) O
. O
['Physiological-Clinical']

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
did O
not O
significantly O
differ O
in O
the O
2 O
groups O
. O
['Adverse-effects']

Ambulatory O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control O
with O
bedtime O
aspirin O
administration O
in O
subjects O
with O
prehypertension O
. O
['Physiological-Clinical']

5.5 O
kg O
, O
age O
: O
24.6 O
? O
[]

The O
amount O
of O
memory B-outcome ['Life-Impact']
priming I-outcome ['Life-Impact']
, O
however O
, O
was O
positively O
related O
to O
one O
of O
two O
measures O
of O
preoperative O
anxiety B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
Our O
objective O
was O
to O
determine O
whether O
a O
questionnaire O
can O
identify O
individuals O
with O
vitamin B-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
insufficiency I-outcome ['Physiological-Clinical']
( O
VDI O
) O
. O
['Physiological-Clinical']

Survey O
response O
inducements O
for O
registered O
nurses O
. O
[]

The O
aim O
of O
this O
large O
randomised O
controlled O
trial O
was O
to O
collect O
data O
to O
enhance O
the O
validity O
and O
applicability O
of O
the O
evidence O
from O
previous O
trials O
to O
inform O
practice. O
[]

RESULTS O
The O
mean O
ages O
and O
the O
mean O
cyst B-outcome ['Physiological-Clinical']
diameters B-outcome ['Physiological-Clinical']
of O
the O
patients O
for O
each O
group O
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Saccade O
accuracy O
is O
1 O
component O
of O
metrics O
, O
which O
to O
function O
optimally O
requires O
several O
cortical O
brain O
structures O
as O
well O
as O
an O
intact O
cerebellum O
and O
brain-stem O
. O
[]

There O
was O
no O
difference O
between O
the O
groups O
in O
terms O
of O
total O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
P O
= O
0.55 O
) O
. O
['Adverse-effects']

Recently O
, O
we O
demonstrated O
that O
FOXP3 O
( O
+ O
) O
regulatory O
T O
( O
Treg O
) O
cells O
mediate O
the O
immunosuppression O
in O
large O
genital O
warts O
. O
[]

OBJECTIVES O
The O
objective O
of O
this O
randomized O
open-label O
clinical O
trial O
was O
to O
compare O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
pimecrolimus O
in O
comparison O
with O
a O
potent O
corticosteroid O
( O
betamethasone O
17-valerate O
) O
in O
the O
treatment O
of O
seborrhoeic O
dermatitis O
. O
['Life-Impact']

Effects O
of O
age O
at O
introduction O
of O
complementary O
foods O
to O
breast-fed O
infants O
on O
duration O
of O
lactational O
amenorrhea O
in O
Honduran O
women O
. O
[]

INTRODUCTION O
Most O
pharmacological O
treatments O
that O
are O
currently O
being O
developed O
for O
women O
with O
sexual O
arousal O
disorder O
are O
aimed O
at O
remedying O
a O
vasculogenic O
deficit O
. O
[]

There O
were O
no O
mechanical B-outcome ['Physiological-Clinical']
or O
technical B-outcome ['Life-Impact']
errors I-outcome ['Life-Impact']
such I-outcome ['Life-Impact']
as I-outcome ['Life-Impact']
disconnection I-outcome ['Life-Impact']
during O
use O
of O
the O
TAMS O
. O
['Physiological-Clinical', 'Life-Impact']

Differential O
effects O
of O
angiotensin O
converting O
enzyme O
inhibitors O
on O
the O
vasodepressor O
and O
prostacyclin O
responses O
to O
bradykinin O
. O
[]

BACKGROUND O
Although O
psychosocial O
therapy O
has O
been O
shown O
to O
reduce O
mortality B-outcome ['Mortality']
after O
myocardial O
infarction O
, O
it O
is O
unknown O
whether O
the O
benefits O
of O
psychosocial O
therapy O
on O
mortality O
reduction O
extend O
to O
out-of-hospital O
sudden O
cardiac O
arrest O
, O
a O
main O
cause O
of O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Mechanomyographic B-outcome ['Physiological-Clinical']
and O
clinical O
evaluation O
by O
single O
twitch O
and O
TOF B-outcome ['Physiological-Clinical']
stimulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ulnar I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
wrist I-outcome ['Physiological-Clinical']
and O
measurement O
of O
the O
concomitant B-outcome ['Physiological-Clinical']
abductor I-outcome ['Physiological-Clinical']
pollicis I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
was O
applied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Primary O
endpoints O
are O
the O
level O
of I-outcome ['Physiological-Clinical']
educational B-outcome ['Physiological-Clinical']
achievement I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
year I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cessation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first-line I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
VO2max I-outcome ['Physiological-Clinical']
one I-outcome ['Physiological-Clinical']
year I-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cessation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
first-line I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Results O
indicate O
that O
, O
while O
individuals O
with O
autism O
may O
have O
the O
ability O
to O
think O
about O
reputation O
, O
a O
reduced O
expectation O
of O
reciprocal O
behavior O
from O
others O
may O
reduce O
the O
degree O
to O
which O
they O
engage O
in O
reputation O
management O
. O
[]

MAIN O
OUTCOMES O
AND O
MEASURES O
A O
positive O
response O
was O
defined O
as O
having O
a O
score O
of O
at O
least O
much O
improved O
on O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression-Improvement O
scale O
at O
week O
12 O
. O
['Physiological-Clinical']

Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
high-resolution O
vascular O
ultrasound O
. O
['Physiological-Clinical']

SETTING: O
Hospital O
outpatient O
clinics O
at O
six O
hospitals O
in O
Norway. O
[]

OBJECTIVE O
To O
assess O
the O
adherence O
to O
and O
effects O
of O
a O
12-month O
combined O
strength O
and O
stretching O
home O
exercise O
regimen O
versus O
stretching O
alone O
, O
on O
patient O
outcome O
after O
lumbar O
disk O
surgery O
. O
[]

This O
sample O
size O
achieves O
90% O
power O
to O
detect O
a O
difference O
of O
14.6% O
between O
the O
two O
groups O
survival O
using O
a O
one-sided O
binomial O
test. O
[]

Four O
groups O
( O
n=4 O
for O
each O
group O
) O
were O
used O
: O
end-to-end O
coaptation O
( O
six O
months O
postoperatively O
) O
, O
end-to-side O
coaptation O
( O
four O
months O
and O
six O
months O
postoperatively O
) O
and O
normal O
control O
. O
[]

PATIENTS O
35 O
patients O
with O
chronic O
stable O
coronary O
artery O
disease O
. O
[]

One O
patient O
in O
the O
placebo O
group O
became O
paradoxically O
more O
tachycardic B-outcome ['Physiological-Clinical']
and O
apneic B-outcome ['Physiological-Clinical']
after O
the O
diltiazem O
infusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Patients O
with O
post-myocardial O
infarction O
left O
ventricular O
dysfunction O
underwent O
beat-to-beat O
blood O
pressure O
( O
BP O
) O
( O
Finapres O
, O
Ohmeda O
Inc. O
, O
Englewood O
, O
Colorado O
) O
and O
R-R O
interval O
( O
electrocardiogram O
) O
recording O
; O
baroreceptor O
reflexes O
were O
assessed O
from O
the O
bradycardic O
and O
depressor O
responses O
to O
graded O
neck O
suction O
( O
NS O
) O
as O
well O
as O
by O
computation O
of O
the O
alpha O
spontaneous O
baroreflex O
sensitivity O
index O
. O
[]

Assessment O
instructions O
included O
the O
Chinese O
State-Trait O
Anxiety B-outcome ['Life-Impact']
Inventory O
( O
C-STAI O
) O
, O
the O
Quality O
of O
Life O
Index O
for O
Colostomy B-outcome ['Resource-use']
( O
QoL-Colostomy O
) O
and O
the O
Hong O
Kong O
Chinese O
version O
of O
the O
World O
Health O
Organisation O
Quality O
of O
Life O
Scale O
( O
WHOQoL O
['Life-Impact', 'Life-Impact', 'Resource-use', 'Life-Impact']

SPACE O
study O
results O
] O
. O
[]

Patients O
in O
the O
splinting O
group O
received O
a O
prefabricated O
wrist O
working O
splint O
and O
were O
instructed O
to O
use O
this O
splint O
as O
much O
as O
possible O
during O
the O
day O
. O
[]

An O
additional O
aim O
of O
the O
study O
is O
to O
examine O
if O
variation O
in O
dose O
of O
treatment O
( O
i.e. O
, O
number O
of O
music O
therapy O
sessions O
per O
week O
) O
affects O
outcome O
of O
therapy O
, O
and O
to O
determine O
cost-effectiveness O
. O
['Resource-use']

Therefore O
, O
since O
the O
relationship O
between O
R-R O
interval O
and O
% O
D O
was O
unaffected O
by O
alinidine O
, O
it O
was O
possible O
to O
hypothesize O
that O
the O
changes O
in O
[]

All O
the O
patients O
came O
from O
the O
hospitals O
of O
the O
cooperative O
research O
group O
and O
were O
randomized O
into O
chemotherapy O
and O
control O
groups O
. O
[]

MATERIALS O
AND O
METHODS O
Mammograms O
of O
41 O
postmenopausal O
women O
obtained O
before O
and O
1 O
year O
after O
the O
initiation O
of O
HRT O
were O
evaluated O
blindly O
according O
to O
the O
quantitative O
density O
percentage O
method O
and O
the O
Wolfe O
classification O
system O
. O
[]

PoCT O
device O
operators O
were O
provided O
with O
a O
colour-coded O
QC O
Result O
Sheet O
and O
QC O
Action O
Sheet O
for O
on-site O
recording O
and O
interpreting O
of O
their O
results O
. O
[]

PURPOSE O
To O
verify O
the O
efficacy O
to O
obtain O
mydriasis O
and O
cardiovascular O
safety O
of O
Mydriasert O
( O
ophthalmic O
insert O
containing O
tropicamide O
and O
phenylephrine O
) O
in O
diabetic O
and O
nondiabetic O
patients O
undergoing O
retinal O
angiography O
by O
comparing O
it O
with O
usually O
administered O
eyedrops O
( O
tropicamide O
1 O
% O
and O
phenylephrine O
10 O
% O
) O
. O
[]

No O
electrocardiographic O
signs O
of O
ischemia O
were O
associated O
with O
the O
increasing O
muscle O
mass O
and O
only O
one O
patient O
developed O
symptoms O
that O
might O
relate O
to O
ischemia O
. O
[]

A O
comparative O
efficacy O
and O
safety O
study O
of O
clarithromycin O
, O
roxithromycin O
and O
erythromycin O
stearate O
in O
mild O
pneumonia O
. O
[]

OBJECTIVE O
The O
safety O
and O
efficacy O
of O
gemcitabine O
plus O
carboplatin O
( O
GC O
) O
or O
paclitaxel O
plus O
carboplatin O
( O
TC O
) O
induction O
regimens O
with O
or O
without O
paclitaxel O
consolidation O
therapy O
were O
assessed O
in O
ovarian O
cancer O
( O
OC O
) O
. O
[]

In O
the O
early O
postoperative O
period O
, O
hypothermic O
patients O
had O
abnormally O
high B-outcome ['Physiological-Clinical']
systemic I-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
compared O
with O
the O
normothermic B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
numbers O
of O
deflations O
in O
both O
groups O
were O
noted O
and O
compared O
by O
Mann-Whitney O
U-test O
( O
P O
< O
0.05 O
) O
. O
[]

METHODS O
It O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
conducted O
in O
54 O
asthmatic O
children O
allergic O
to O
house O
dust O
mites O
. O
[]

An O
increasing O
number O
of O
patients O
with O
main-stem O
and O
main-stem-equivalent O
stenosis O
are O
treated O
by O
stent O
implantation O
, O
which O
appears O
to O
be O
safe O
in O
the O
short-term O
follow-up O
. O
[]

Analgesia B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
, O
vital B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
and O
incidence O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

The O
rebleeding B-outcome ['Physiological-Clinical']
rate O
was O
significantly O
higher O
in O
the O
sclerotherapy O
group O
( O
25 O
% O
vs. O
4 O
% O
, O
P O
=.049 O
) O
, O
as O
was O
the O
rate O
of O
major O
complications B-outcome ['Adverse-effects']
( O
25 O
% O
vs. O
4 O
% O
, O
P O
=.049 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

At O
baseline O
, O
at O
the O
end O
of O
the O
treatment O
, O
and O
after O
a O
2-month O
follow-up O
, O
clinical O
findings O
were O
assessed O
according O
to O
the O
Dover O
classification O
scale O
for O
photoaging O
and O
by O
biophysical B-outcome ['Physiological-Clinical']
and O
ecographic B-outcome ['Physiological-Clinical']
measurements O
. O
['Physiological-Clinical']

Overall O
, O
increased O
appetite O
occurred O
most O
frequently O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

As O
part O
of O
the O
comprehensive O
Dental O
Implant O
Clinical O
Research O
Group O
clinical O
implant O
study O
, O
the O
preoperative O
or O
postoperative O
use O
of O
antibiotics O
, O
the O
type O
used O
, O
and O
the O
duration O
of O
coverage O
was O
left O
to O
the O
discretion O
of O
the O
surgeon O
. O
[]

Logistic O
regression O
analysis O
was O
used O
to O
estimate O
the O
association O
of O
admission O
BNP O
with O
development O
of O
CI-AKI O
. O
[]

The O
heparin O
increased O
the O
geometric O
mean O
log O
methacholine O
PD20 O
value O
from O
0.47 O
+/- O
0.16 O
( O
2.95 O
mg/ml O
) O
to O
0.96 O
+/- O
0.10 O
( O
8.91 O
mg/ml O
) O
, O
( O
P O
< O
0.0009 O
) O
in O
15 O
patients O
and O
the O
geometric O
mean O
log O
adenosine O
PD20 O
values O
from O
1.59 O
+/- O
0.23 O
( O
38.9 O
mg/ml O
) O
to O
1.98 O
+/- O
0.14 O
( O
97.7 O
mg/ml O
) O
( O
NS O
) O
in O
7 O
patients O
whose O
baseline O
adenosine O
PD20 O
levels O
were O
less O
than O
200 O
mg/ml O
. O
[]

The O
treatment O
is O
usually O
with O
either O
phenobarbital O
or O
phenytoin O
, O
but O
the O
efficacy O
of O
the O
two O
drugs O
has O
not O
been O
compared O
directly O
. O
[]

In O
48 O
instances O
, O
parents O
based O
their O
guess O
on O
perceived O
improvement O
; O
in O
six O
cases O
, O
parents O
based O
their O
guess O
on O
perceived O
deterioration B-outcome ['Life-Impact']
. O
['Life-Impact']

A O
standardized O
postoperative O
fluid O
regime O
with O
Hartmann O
solution O
was O
prescribed O
at O
1.5 O
mL O
? O
[]

A O
large O
body O
of O
evidence O
has O
been O
accumulated O
from O
studies O
of O
patients O
which O
suggests O
that O
such O
eye O
movement O
abnormalities O
may O
arise O
from O
frontal O
lobe O
dysfunction O
. O
[]

UNLABELLED O
In O
242 O
community-dwelling O
seniors O
, O
supplementation O
with O
either O
1000 O
mg O
of O
calcium O
or O
1000 O
mg O
of O
calcium O
plus O
vitamin O
D O
resulted O
in O
a O
decrease O
in O
the O
number O
of O
subjects O
with O
first O
falls O
of O
27 O
% O
at O
month O
12 O
and O
39 O
% O
at O
month O
20 O
. O
[]

Limits O
of O
agreement O
between O
ultrasound O
and O
CT O
( O
-6.6 O
to O
9.4 O
mm O
) O
exceeded O
the O
limits O
of O
clinical O
acceptability O
( O
+/-5 O
mm O
) O
. O
[]

As O
we O
disclosed O
no O
toxic B-outcome ['Adverse-effects']
or I-outcome ['Adverse-effects']
allergic I-outcome ['Adverse-effects']
reaction I-outcome ['Adverse-effects']
post-operatively I-outcome ['Adverse-effects']
which O
could O
be O
related O
to O
the O
use O
of O
PVP-I O
as O
a O
disinfectant O
, O
this O
agent O
seems O
to O
constitute O
an O
effective O
pre-operative B-outcome ['Resource-use']
antimicrobial I-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
, O
taking O
into O
consideration O
the O
broad O
antimicrobial O
spectrum O
of O
PVP-I O
shown O
by O
other O
authors O
. O
['Adverse-effects', 'Resource-use']

However O
, O
platelet B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
to O
> O
20 O
x O
10 O
( O
9 O
) O
/L O
was O
significantly O
longer O
in O
treatment O
group O
than O
control O
group O
( O
26 O
v O
16 O
days O
; O
P O
=.009 O
) O
and O
> O
50 O
x O
10 O
( O
9 O
) O
/L O
tended O
to O
take O
longer O
in O
the O
treatment O
group O
( O
29 O
v O
26 O
days O
; O
P O
=.126 O
) O
, O
with O
significantly O
more O
platelet B-outcome ['Physiological-Clinical']
transfusion-dependent I-outcome ['Physiological-Clinical']
days O
( O
27 O
v O
13 O
days O
; O
t-test O
, O
P O
=.037 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
fentanyl O
infusion O
( O
2 O
micrograms/kg/hour O
) O
reduced O
the O
induction O
dose B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
thiopentone I-outcome ['Life-Impact']
and O
caused O
marked B-outcome ['Physiological-Clinical']
respiratory I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
with O
a O
reduction O
in O
the O
patients O
' O
response O
to O
surgery O
. O
['Life-Impact', 'Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Journal-Name:Medicine O
[]

In O
this O
study O
, O
an O
Er O
, O
Cr O
: O
YSGG O
laser O
has O
been O
shown O
to O
be O
effective O
for O
cavity O
preparation O
and O
restoration O
replacement O
. O
[]

Efficacy O
of O
this O
compound O
would O
support O
the O
usefulness O
of O
the O
model O
in O
prophylactic O
antimigraine O
drug O
development O
. O
[]

Primary O
outcome O
is O
the O
composite O
event O
of O
vascular B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
stroke B-outcome ['Physiological-Clinical']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
controlled O
trial O
. O
[]

METHODOLOGY O
A O
total O
of O
48 O
patients O
with O
acute O
upper O
gastrointestinal O
bleeding O
due O
to O
duodenal O
or O
gastric O
ulcer O
were O
divided O
into O
2 O
groups O
. O
[]

INTRODUCTION O
Patients O
with O
diabetes O
complicated O
by O
hypertension O
and O
microalbuminuria O
have O
elevated O
cardiovascular O
risk O
, O
and O
controlling O
blood O
pressure O
in O
these O
patients O
is O
an O
urgent O
clinical O
priority O
. O
[]

No O
significant O
side-effects O
or O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
were O
encountered O
. O
['Adverse-effects']

Dialysate O
magnesium O
was O
0.375 O
mM/L O
for O
the O
hemodialysis O
and O
0.25 O
mM/L O
for O
the O
CAPD O
patients O
. O
[]

They O
were O
treated O
for O
20 O
days O
( O
times O
) O
. O
[]

The O
more O
effective O
protection O
of O
the O
lower O
airways B-outcome ['Physiological-Clinical']
by O
the O
Hi-Lo-Evac O
tube O
is O
attributed O
to O
the O
facility O
of O
subglottic O
aspiration O
during O
surgery O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Efficacy O
measures O
: O
rate O
of O
decline O
in O
FEV B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
after O
the O
bronchodilator B-outcome ['Physiological-Clinical']
and O
in O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
frequency O
of O
exacerbations B-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
withdrawals I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
differences O
in O
overall O
change O
across O
goal O
domains O
between O
the O
FF O
and O
WEB O
groups O
, O
suggesting O
the O
efficacy O
of O
videoconferencing O
technology O
. O
[]

There O
were O
no O
significant O
differences O
between O
amantadine O
, O
pemoline O
, O
and O
placebo O
. O
[]

Six O
subjects O
were O
randomly O
assigned O
to O
receive O
BMS-181101 O
under O
fasted O
conditions O
from O
days O
1 O
to O
6 O
and O
then O
crossed O
over O
to O
fed O
conditions O
from O
days O
7 O
to O
12 O
. O
[]

Journal O
ID: O
2985213R O
[]

OBJECTIVE O
This O
study O
aimed O
to O
compare O
the O
haemorrhagic O
complications O
and O
efficacy O
of O
enoxaparin O
, O
a O
low O
molecular O
weight O
heparin O
( O
LMWH O
) O
, O
and O
conventional O
standard O
heparin O
( O
SH O
) O
in O
gynaecological O
oncologic O
surgery O
. O
[]

Further O
studies O
are O
required O
to O
assess O
neonatal O
morbidity O
adequately O
. O
[]

Moreover O
, O
the O
technic O
of O
exteriorization O
is O
a O
safe O
adjunct O
to O
management O
and O
is O
recommended O
in O
any O
patient O
with O
a O
colonic O
injury O
above O
18 O
cm O
in O
which O
one O
suture O
line O
is O
required O
and O
in O
which O
the O
additional O
operating O
time O
of O
twenty O
minutes O
will O
not O
compromise O
the O
management O
of O
secondary O
injuries O
. O
[]

BACKGROUND O
Cardioinhibitory O
carotid O
sinus O
syndrome O
causes O
syncope O
, O
and O
symptoms O
respond O
to O
cardiac O
pacing O
. O
[]

Response O
prediction O
in O
metastasised O
colorectal O
cancer O
using O
intratumoural O
thymidylate O
synthase O
: O
results O
of O
a O
randomised O
multicentre O
trial O
. O
[]

RESULTS O
At O
week O
12 O
, O
[]

METHOD: O
This O
Study O
is O
A O
Prospective, O
randomized, O
open-label, O
comparative O
study. O
[]

In O
the O
timolol O
and O
carteolol O
groups O
there O
were O
no O
significant O
changes O
in O
mean O
spirometric B-outcome ['Physiological-Clinical']
values O
. O
['Physiological-Clinical']

SETTING O
Academic O
medical O
centre O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Diagnostic B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
is O
shown O
in O
the O
table O
. O
[ O
['Life-Impact']

Chemotherapy-related B-outcome ['Physiological-Clinical']
toxicities I-outcome ['Physiological-Clinical']
were O
few O
and O
most O
of O
them O
related O
to O
cisplatin O
which O
was O
reduced O
to O
100 O
mg/m2 O
for O
35 O
patients O
. O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
is O
'patient O
distress O
due O
to O
breathlessness O
' O
measured O
on O
a O
numerical O
rating O
scale O
( O
0-10 O
) O
. O
[]

Lomefloxacin O
was O
effective O
therapy O
for O
five O
of O
seven O
( O
71 O
% O
) O
patients O
, O
and O
ciprofloxacin O
was O
effective O
therapy O
for O
two O
of O
five O
patients O
( O
40 O
% O
) O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
Diary O
( O
SD O
) O
, O
recorded O
by O
the O
parents O
, O
assessed O
the O
patient O
's O
sleeping O
patterns O
every O
week O
. O
['Physiological-Clinical']

In O
the O
management O
of O
wounds O
, O
sometimes O
it O
is O
recommended O
to O
give O
an O
adult-type O
tetanus-diphtheria O
( O
Td O
) O
vaccine O
dose O
plus O
tetanus O
immune O
globulin O
( O
TIG O
) O
. O
[]

Hand O
laterality O
recognition O
imparted O
a O
consistent O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
across O
groups O
, O
however O
, O
this O
effect O
was O
limited O
in O
magnitude O
. O
['Physiological-Clinical', 'Life-Impact']

However O
, O
this O
idea O
has O
not O
been O
empirically O
evaluated O
. O
[]

Participants O
were O
recruited O
from O
the O
Institute O
of O
Dentistry, O
Barts O
and O
the O
London O
School O
of O
Medicine O
and O
Dentistry, O
London, O
United O
Kingdom, O
and O
recalled O
at O
6- O
to O
8-week O
intervals. O
[]

Zoledronic O
acid O
is O
significantly O
more O
effective O
than O
risedronate O
in O
increasing O
lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LS I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
both O
prevention O
and O
treatment O
of O
glucocorticoid-induced O
osteoporosis O
. O
['Physiological-Clinical']

Journal O
of O
Autism O
and O
Developmental O
Disorders O
, O
29 O
, O
407-418 O
) O
. O
[]

Patients O
were O
randomized O
to O
receive O
equi-anesthetic O
doses O
of O
either O
propofol O
or O
methohexital O
for O
anesthetic O
induction. O
[]

At O
week O
48 O
, O
EVG/COBI/FTC/TDF O
was O
noninferior O
to O
EFV/FTC/TDF O
( O
88 O
% O
vs O
84 O
% O
, O
difference O
+3.6 O
% O
, O
95 O
% O
confidence O
interval O
: O
-1.6 O
% O
to O
8.8 O
% O
) O
. O
[]

Estrogen O
therapy O
for O
severe O
persistent O
depressions O
in O
women O
. O
[]

Eligible O
infants O
were O
randomly O
assigned O
(1:1) O
to O
receive O
either O
enteral O
bovine O
lactoferrin O
(150 O
mg/kg O
per O
day; O
maximum O
300 O
mg/day; O
lactoferrin O
group) O
or O
sucrose O
(same O
dose; O
control O
group) O
once O
daily O
until O
34 O
weeks' O
postmenstrual O
age. O
[]

RESULTS O
All O
12 O
volunteers O
completed O
the O
study O
without O
incident O
. O
[]

CONCLUSION O
Yoga O
may O
improve O
mood O
status O
and O
quality O
of O
life O
for O
women O
undergoing O
detoxification O
for O
heroin O
dependence O
. O
[]

BACKGROUND O
Contrary O
to O
aerobic O
exercise O
, O
strength O
training O
( O
ST O
) O
is O
associated O
with O
decreased O
central B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
in O
young O
men O
. O
['Physiological-Clinical']

We O
examined O
the O
effects O
these O
same O
cardiac O
contractility O
modulating O
( O
CCM O
) O
electrical O
signals O
on O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
( O
MVO B-outcome ['Physiological-Clinical']
( O
2 O
) O
) O
in O
both O
patients O
and O
dogs O
with O
chronic O
HF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
three O
indicators O
of O
CHW O
functioning O
(as O
measured O
by O
reports O
submitted O
from O
CHWs) O
improved O
more O
in O
the O
intervention O
area O
relative O
to O
the O
comparison O
area, O
with O
2 O
out O
of O
3 O
measures O
of O
improvement O
reaching O
statistical O
significance. O
[]

Their O
median O
age O
was O
31 O
years O
( O
range O
, O
22-59 O
) O
and O
14 O
patients O
were O
males O
and O
12 O
were O
females O
. O
[]

In O
addition O
we O
investigate O
whether O
there O
is O
an O
increase O
in O
the O
cardiovascular O
metabolism O
in O
persons O
performing O
supervised O
Nordic O
Walking O
compared O
to O
persons O
who O
are O
advised O
to O
stay O
active O
. O
[]

Parents O
from O
autism O
assessment O
services O
in O
the O
intervention O
regions O
were O
randomly O
allocated O
to O
parent O
education O
and O
behaviour O
management O
( O
n O
= O
35 O
) O
or O
parent O
education O
and O
counselling O
( O
n O
= O
35 O
) O
. O
[]

Randomization O
began O
on O
November O
8, O
2010. O
[]

TRIAL O
REGISTRATION O
umin.ac.jp/ctr O
Identifier O
: O
UMIN000002241 O
and O
UMIN000004393 O
. O
[]

OBJECTIVE O
To O
compare O
an O
azelastine-fluticasone O
combination O
nasal O
spray O
administered O
in O
a O
single-delivery O
device O
with O
a O
commercially O
available O
azelastine O
nasal O
spray O
and O
fluticasone O
nasal O
spray O
. O
[]

Patients O
randomized O
to O
CDDP/FU O
also O
received O
CDDP O
20 O
mg/m2 O
intravenous O
( O
IV O
) O
bolus O
on O
days O
1 O
to O
5 O
of O
each O
cycle O
. O
[]

Recurrence O
of O
active B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
after O
treatment O
can O
be O
due O
to O
relapse O
of O
infection O
with O
the O
same O
strain O
or O
reinfection O
with O
a O
new O
strain O
of O
Mycobacterium O
tuberculosis O
. O
['Physiological-Clinical']

Modest O
antihypertensive O
effect O
of O
epanolol O
, O
a O
beta O
1-selective O
receptor O
blocker O
with O
beta O
1 O
agonist O
activity O
: O
an O
acute O
and O
long-term O
hemodynamic O
study O
at O
rest O
and O
during O
exercise O
and O
double O
crossover O
comparison O
with O
atenolol O
on O
ambulatory O
blood O
pressure O
. O
[]

Inclusion/exclusion O
criteria O
were O
defined O
according O
to O
the O
clinical O
diagnosis O
of O
ASD O
, O
the O
presence O
or O
absence O
of O
additional O
or O
associated O
disability O
, O
previous O
training O
in O
referential O
communication O
, O
and O
any O
drug O
treatment O
. O
[]

Six O
children O
( O
responders O
) O
were O
clinically O
improved O
by O
the O
treatment O
. O
[]

Coagulation O
factor O
concentrate O
in O
the O
treatment O
of O
the O
haemorrhagic B-outcome ['Physiological-Clinical']
diathesis I-outcome ['Physiological-Clinical']
of O
fulminant O
hepatic O
failure O
. O
['Physiological-Clinical']

Subjects O
are O
randomized O
to O
receive O
PN O
designed O
to O
provide O
100 O
% O
of O
measured O
REE O
, O
or O
standard O
PN O
, O
i.e. O
, O
140 O
% O
of O
estimated O
energy O
expenditure O
. O
[]

RESULTS O
Data O
from O
30 O
patients O
( O
13 O
females O
) O
, O
14 O
on O
R1 O
and O
16 O
on O
R2 O
, O
were O
analysed O
. O
[]

If O
those O
who O
failed O
to O
attend O
visits O
( O
who O
did O
not O
withdraw O
as O
a O
result O
of O
drug-related O
events O
) O
are O
removed O
from O
the O
analysis O
, O
the O
clinical O
success O
rates O
are O
89.9 O
% O
for O
retapamulin O
and O
89.7 O
% O
for O
cephalexin O
. O
[]

H. O
pylori O
status O
was O
evaluated O
by O
( O
13 O
) O
C B-outcome ['Physiological-Clinical']
urea I-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
test O
5 O
weeks O
after O
anti-ulcer O
treatment O
completion O
. O
['Physiological-Clinical']

Similarly O
, O
there O
were O
no O
clinically O
significant O
[]

RESULTS O
After O
8 O
weeks O
of O
initial O
treatment O
, O
the O
mean O
total O
, O
inattention B-outcome ['Life-Impact']
, O
and O
hyperactivity-impulsivity B-outcome ['Life-Impact']
ADHD-RS O
further O
decreased O
significantly O
from O
34.9 O
to O
27.0 O
for O
the O
total O
ADHD-RS O
, O
from O
18.3 O
to O
14.5 O
for O
the O
ADHD-RS O
inattention I-outcome ['Life-Impact']
subscale O
, O
and O
from O
16.5 O
to O
12.6 O
for O
the O
hyperactivity-impulsivity B-outcome ['Life-Impact']
subscale O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Positive O
effects O
of O
methylphenidate O
on O
social B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
self-regulation I-outcome ['Life-Impact']
in O
children O
with O
pervasive O
developmental O
disorders O
and O
hyperactivity O
. O
['Life-Impact']

In O
the O
repeated O
oral O
dose O
study O
, O
the O
subjects O
received O
test O
drug O
at O
150 O
mg O
or O
300 O
mg O
( O
n O
= O
6 O
each O
) O
or O
placebo O
( O
n O
= O
3 O
) O
twice O
a O
day O
( O
after O
breakfast O
and O
after O
dinner O
) O
for O
7 O
days O
. O
[]

Results: O
Among O
1458 O
enrolled O
patients O
(mean O
[SD] O
age, O
58 O
[16] O
years; O
599 O
women O
[41%]), O
1353 O
(93%) O
completed O
the O
study O
and O
were O
included O
in O
the O
final O
analysis. O
[]

In O
Experiment O
1 O
, O
the O
embryos O
vitrified O
by O
the O
MVAC O
or O
CT O
and O
fresh O
embryos O
without O
vitrification O
( O
Control O
) O
were O
used O
. O
[]

RESULTS O
The O
cumulated O
risk O
of O
a O
patient O
having O
new B-outcome ['Physiological-Clinical']
adenomas I-outcome ['Physiological-Clinical']
was O
35.0 O
% O
( O
28.7-41.4 O
% O
) O
in O
group O
A O
and O
35.5 O
% O
( O
28.4-42.7 O
% O
) O
in O
group O
B O
after O
48 O
months O
. O
['Physiological-Clinical']

RESULTS O
With O
a O
median O
follow-up O
of O
26.3 O
months O
( O
range O
3-74.6 O
months O
) O
, O
59 O
% O
of O
patients O
in O
the O
cisplatin O
arm O
completed O
the O
planned O
concurrent O
chemoradiation O
treatment O
, O
compared O
to O
73 O
% O
in O
the O
carboplatin O
arm O
. O
[]

No O
significant B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
due O
to O
the O
combined O
administration O
of O
HCFU O
were O
recognized O
. O
['Adverse-effects']

All O
biomarkers O
of O
metabolic B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
were O
equivalent O
when O
evaluating O
R1 O
v O
R2. O
[['Physiological-Clinical']]

There O
was O
no O
difference O
between O
GP O
and O
TC O
in O
3-year O
OS O
( O
HR=0.97 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
: O
0.76-1.25 O
] O
, O
p=0.80 O
) O
or O
response O
rates O
. O
[]

Our O
study O
demonstrates O
a O
reversible O
depression O
of O
myocardial B-outcome ['Physiological-Clinical']
contractility I-outcome ['Physiological-Clinical']
and O
hemodynamic B-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
during O
rapid O
permissive O
hypercapnia O
which O
were O
attenuated O
by O
buffering O
with O
THAM O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
this O
randomized O
, O
blinded O
, O
multicenter O
comparison O
study O
, O
377 O
infants O
and O
children O
with O
acute O
otitis O
media O
( O
AOM O
) O
received O
a O
10-day O
course O
of O
an O
oral O
suspension O
of O
one O
of O
the O
following O
: O
cefuroxime O
axetil O
( O
CAE O
) O
, O
30 O
mg/kg/day O
; O
cefaclor O
( O
CEC O
) O
, O
40 O
mg/kg/day O
; O
or O
amoxicillin-clavulanate O
potassium O
( O
AMX-CL O
) O
, O
40 O
mg/kg/day O
. O
[]

MAIN O
OUTCOME O
MEASURE O
( O
S O
) O
Delta O
stage-of-change O
and O
rate O
of O
maintained B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
at O
12 O
months O
post O
follow-up O
. O
['Life-Impact']

Double-pulse O
transcranial O
magnetic O
stimulation O
( O
dpTMS O
) O
was O
used O
to O
examine O
inhibition O
by O
means O
of O
short-interval O
intracortical O
inhibition O
( O
SICI O
) O
of O
the O
contralateral O
primary O
motor O
cortex O
in O
a O
sample O
of O
64 O
healthy O
right-handed O
human O
subjects O
covering O
a O
wide O
range O
of O
the O
adult O
lifespan O
( O
age O
range O
20-88 O
years O
, O
mean O
47.6 O
? O
[]

METHODS O
This O
study O
examined O
nonelderly O
Medicaid O
beneficiaries O
in O
New O
Jersey O
with O
a O
diagnosis O
of O
mental O
illness O
and O
compared O
and O
contrasted O
the O
experiences O
of O
those O
in O
New O
Jersey O
's O
CCDE O
program O
( O
N=109 O
) O
and O
those O
who O
received O
services O
provided O
by O
an O
agency O
( O
N=119 O
) O
. O
[]

There O
was O
no O
correlation O
between O
CBFV B-outcome ['Physiological-Clinical']
and O
COe B-outcome ['Physiological-Clinical']
at O
any O
time O
point O
during O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Administration O
of O
sivelestat O
was O
found O
to O
reduce O
[]

RESULTS O
There O
was O
no O
difference O
between O
the O
study O
groups O
with O
respect O
to O
mental O
or O
physical O
health O
, O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
back O
pain O
disability O
, O
neurogenic B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
lost O
work O
time O
, O
likelihood O
of O
recurrence O
of O
an O
episode O
of O
a O
back O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Ninety-eight O
patients O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n O
= O
51 O
) O
or O
aripiprazole O
( O
n O
= O
47 O
) O
. O
[]

The O
prostaglandin-depleted O
mucosa O
has O
increased O
susceptibility O
to O
luminal O
aggressive O
factors O
, O
yet O
the O
role O
of O
acid O
in O
the O
pathogenesis O
of O
the O
NSAID O
ulcer O
is O
controversial O
. O
[]

Effects O
of O
congestive O
heart O
failure O
on O
plasma B-outcome ['Physiological-Clinical']
von I-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
and O
soluble B-outcome ['Physiological-Clinical']
P-selectin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in O
patients O
with O
non-valvar O
atrial O
fibrillation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
communication B-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
, O
compromising O
use O
of O
the O
patient O
as O
an O
informant O
, O
were O
addressed O
by O
several O
strategies O
, O
including O
careful B-outcome ['Life-Impact']
questioning I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
providers I-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

PURPOSE O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
anecortave O
acetate O
treatment O
of O
retinal O
angiomatous O
proliferation O
( O
RAP O
) O
, O
a O
neovascular O
form O
of O
age-related O
macular O
degeneration O
, O
with O
specific O
regard O
to O
inhibition O
of O
neovascularization B-outcome ['Physiological-Clinical']
and O
maintenance B-outcome ['Physiological-Clinical']
of O
vision B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
( O
S O
) O
Performing O
ICSI O
on O
at O
least O
some O
of O
the O
oocytes O
will O
avoid O
unnecessary O
fertilization B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
patients O
with O
borderline O
semen O
: O
in O
this O
study O
, O
26 O
of O
104 O
cycles O
( O
25 O
% O
) O
were O
rescued O
by O
ICSI O
. O
['Physiological-Clinical']

Of O
these O
, O
85 O
patients O
were O
randomized O
to O
the O
treatment O
group O
and O
underwent O
pTBA O
within O
96 O
hours O
after O
subarachnoid O
hemorrhage O
. O
[]

RESULTS O
At O
month O
12 O
, O
biopsy-confirmed B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
were O
reported O
for O
15.2 O
% O
( O
induction O
) O
and O
30.4 O
% O
( O
noninduction O
) O
of O
patients O
( O
P=0.001 O
) O
. O
['Physiological-Clinical']

Entry O
criteria O
included O
the O
presence O
of O
symptomatic O
gastroesophageal O
reflux O
confirmed O
by O
both O
an O
acid O
perfusion O
( O
Bernstein O
) O
test O
and O
by O
intraesophageal O
pH O
probe O
. O
[]

SUBJECTS O
All O
( O
58 O
) O
healthy O
women O
of O
Pakistani O
origin O
referred O
from O
October O
of O
1991 O
to O
January O
of O
1992 O
were O
included O
, O
of O
whom O
38 O
( O
66 O
% O
) O
participated O
. O
[]

This O
result O
could O
be O
assumed O
to O
have O
been O
influenced O
by O
the O
difference O
in O
the O
metastatic O
preponderance O
in O
a O
high O
versus O
low O
sialyl O
Lewis O
( O
a O
) O
expression O
in O
the O
tumor O
cells O
. O
[]

0.3 O
g/l O
, O
p O
< O
0.01 O
) O
, O
factor O
VII O
( O
from O
144.2 O
? O
[]

RESULTS O
The O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
taken O
at O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
15 O
, O
20 O
, O
25 O
, O
and O
30 O
min O
after O
the O
injection O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
results O
suggest O
that O
individuals O
with O
autism O
over-process O
information O
needed O
for O
the O
successful O
differentiation O
of O
target O
and O
novel O
stimuli O
. O
[]

plus O
omeprazole O
20 O
mg O
b.d. O
, O
dirithromycin O
1000 O
mg O
q.d.s O
. O
[]

RESULTS O
The O
pattern O
of O
autistic O
symptom O
severity O
varied O
over O
time O
by O
domain O
. O
[]

Ipilimumab O
efficacy O
and O
safety O
in O
patients O
with O
advanced O
melanoma O
: O
a O
retrospective O
analysis O
of O
HLA O
subtype O
from O
four O
trials O
. O
[]

Our O
objective O
was O
to O
explore O
the O
associations O
of O
creatinine B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CrCl I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
outcomes O
in O
a O
trial O
of O
eptifibatide O
therapy O
in O
patients O
who O
underwent O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
['Physiological-Clinical']

Comparing O
length O
of O
attachment O
, O
microbial O
control O
, O
and O
satisfaction O
. O
[]

Although O
soluble O
tumor O
necrosis O
factor-alpha O
receptor O
II O
concentrations O
at O
baseline O
and O
24 O
weeks O
were O
at O
least O
marginally O
associated O
with O
subsequent O
changes O
in O
BMD B-outcome ['Physiological-Clinical']
( O
P O
= O
0.06 O
and O
P O
= O
0.028 O
, O
respectively O
) O
, O
these O
associations O
were O
no O
longer O
significant O
after O
adjustment O
for O
CD4 O
T O
cell O
count O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
naltrexone O
on O
communication O
skills O
of O
young O
children O
with O
autism O
. O
[]

A O
biochemical O
response O
index O
comprising O
ESR O
, O
CEA O
and O
CA O
15.3 O
was O
evaluated O
in O
67 O
patients O
with O
systemic O
breast O
cancer O
treated O
by O
chemotherapy O
; O
55 O
were O
assessable O
by O
UICC O
criteria O
and O
the O
response O
index O
( O
96 O
% O
of O
all O
UICC O
assessable O
patients O
) O
. O
[]

No O
significant O
differences O
were O
found O
in O
perioperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
between O
patients O
in O
the O
treatment O
group O
( O
n O
= O
39 O
) O
and O
control O
group O
( O
n O
= O
37 O
) O
. O
['Physiological-Clinical']

Effect O
of O
postural O
supports O
on O
neuromotor B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants O
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

Using O
these O
parameters O
retinal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
calculated O
. O
['Physiological-Clinical']

A O
special O
education O
teacher O
provided O
40 O
visits O
over O
12 O
months O
working O
with O
the O
families O
to O
help O
generalize O
skills O
to O
the O
home O
environment O
and O
assist O
with O
their O
concerns O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
compare O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
biofeedback O
treatment O
( O
BF O
) O
effects O
between O
white-coat O
hypertension O
and O
essential O
hypertension O
. O
['Physiological-Clinical']

Examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
diagnostic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
patient B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
( O
rated O
with O
a O
self-completed O
questionnaire O
) O
in O
the O
two O
groups O
of O
patients O
were O
compared O
by O
using O
the O
McNemar O
test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Therapeutic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
in O
the O
CQ-treated O
group O
was O
associated O
with O
an O
age O
< O
15 O
years O
old O
( O
P O
< O
0.01 O
) O
, O
but O
was O
not O
associated O
with O
initial O
parasite O
density O
, O
the O
presence O
of O
CQ O
or O
sulfa-containing O
drugs O
in O
urine O
, O
or O
a O
history O
of O
malaria O
. O
['Physiological-Clinical']

RESULTS O
The O
results O
are O
expressed O
as O
means O
+/- O
SD O
. O
[]

Dogs O
and O
cats O
with O
naturally O
occurring O
flea O
infestations O
, O
some O
of O
which O
also O
had O
signs O
associated O
with O
FAD O
, O
were O
assigned O
randomly O
to O
receive O
three O
months O
of O
topical O
treatment O
with O
selamectin O
( O
220 O
dogs O
, O
189 O
cats O
) O
or O
a O
positive-control O
product O
( O
dogs O
: O
fenthion O
, O
n=81 O
; O
cats O
: O
pyrethrins O
, O
n=66 O
) O
. O
[]

In O
patients O
with O
MDS O
or O
in O
the O
remission-induction O
phase O
of O
chemotherapy O
, O
the O
numbers O
of O
cases O
with O
probable B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
possible I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
lower O
in O
the O
itraconazole O
group O
than O
in O
the O
fluconazole O
group O
, O
whereas O
no O
difference O
was O
seen O
in O
patients O
with O
AML O
or O
in O
the O
consolidation O
phase O
of O
therapy O
. O
['Physiological-Clinical']

These O
data O
support O
the O
prophylactic O
value O
of O
corticosteroid O
treatment O
in O
patients O
at O
high O
risk O
for O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
particularly O
if O
several O
unfavorable O
predictors O
are O
present O
. O
['Physiological-Clinical']

Within O
a O
multicentric O
study O
of O
several O
Social O
Pediatric O
Centers O
( O
SPCs O
) O
and O
further O
clinics/institutions O
in O
Germany O
, O
it O
has O
been O
established O
as O
a O
group O
parenting O
training O
( O
3-7 O
families O
per O
training O
) O
. O
[]

BACKGROUND O
Some O
evidence O
suggests O
an O
increased O
risk O
of O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
and O
dysrhythmia B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
associated O
with O
beta O
( O
2 O
) O
-agonist O
use O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Study O
2 O
, O
71 O
healthy O
volunteers O
received O
40 O
IU O
kg O
( O
-1 O
) O
via O
the O
intramuscular O
route O
of O
either O
Erig O
PMC O
( O
n O
= O
36 O
) O
or O
PHT-Erig O
( O
n O
= O
35 O
) O
on O
D0 O
, O
in O
association O
with O
five O
doses O
of O
PVRV O
on O
D0 O
, O
D3 O
, O
D7 O
, O
D14 O
and O
D28 O
. O
[]

Movement-related O
potentials O
in O
Parkinson O
's O
disease O
. O
[]

Infliximab B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
2 O
hours O
after O
each O
infusion O
and O
at O
1 O
, O
3 O
, O
4 O
, O
5 O
, O
8 O
, O
10 O
, O
14 O
and O
18 O
weeks O
. O
['Physiological-Clinical']

The O
vital O
status O
of O
identified O
women O
was O
confirmed O
using O
Wisconsin O
state O
death O
records O
. O
[]

Amifostine O
( O
300 O
mg/m O
( O
2 O
) O
) O
was O
administered O
in O
the O
study O
group O
only O
15-30 O
min O
before O
RT O
for O
6-7.5 O
weeks O
. O
[]

INTERVENTION O
During O
each O
interview O
, O
the O
patients O
' O
MCIDs O
were O
determined O
by O
using O
( O
1 O
) O
a O
pictorial O
flip O
chart O
to O
describe O
atrial O
fibrillation B-outcome ['Physiological-Clinical']
; O
the O
consequences O
of O
a O
minor O
stroke B-outcome ['Physiological-Clinical']
, O
a O
major B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
, O
and O
a O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
; O
the O
chance O
of O
stroke B-outcome ['Physiological-Clinical']
if O
not O
taking O
warfarin O
; O
the O
chance O
of O
a O
major O
bleeding B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
if O
taking B-outcome ['Resource-use']
warfarin I-outcome ['Resource-use']
; O
examples O
of O
the O
inconvenience B-outcome ['Life-Impact']
, O
minor B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
and O
costs O
of O
warfarin B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
; O
and O
then O
( O
2 O
) O
1 O
of O
the O
2 O
elicitation O
methods O
to O
determine O
their O
MCIDs O
( O
the O
smallest O
reduction O
in O
stroke B-outcome ['Physiological-Clinical']
risk O
at O
which O
the O
patients O
were O
willing B-outcome ['Life-Impact']
to O
take O
warfarin B-outcome ['Resource-use']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Life-Impact', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

In O
study O
2 O
, O
the O
amount O
of O
lansoprazole B-outcome ['Life-Impact']
consumed I-outcome ['Life-Impact']
was O
approximately O
50 O
% O
less O
than O
that O
of O
omeprazole O
, O
and O
this O
translated O
to O
81 O
% O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
lansoprazole O
compared O
with O
only O
9.5 O
% O
for O
omeprazole O
. O
['Life-Impact', 'Life-Impact']

With O
respect O
to O
total O
, O
partial B-outcome ['Physiological-Clinical']
colon I-outcome ['Physiological-Clinical']
, O
and I-outcome ['Physiological-Clinical']
rectum I-outcome ['Physiological-Clinical']
transit I-outcome ['Physiological-Clinical']
time O
, O
there O
seemed O
to O
be O
a O
trend O
, O
although O
statistically O
nonsignificant O
, O
toward O
faster O
transit B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
in O
the O
cocoa O
husk O
group O
than O
in O
the O
placebo O
group O
. O
['Physiological-Clinical', 'Life-Impact']

Histological O
evaluation O
of O
human O
atherosclerosis O
showed O
minimal O
AP-1 O
activation O
in O
non-diseased O
arterial O
wall O
( O
i.e O
. O
[]

OBJECTIVE O
To O
study O
the O
immunomodulatory O
effect O
of O
the O
histamine O
receptor O
antagonist O
, O
ranitidine O
, O
in O
patients O
admitted O
to O
the O
intensive O
care O
unit O
after O
severe O
head O
injury O
. O
[]

The O
mean O
change O
from O
baseline O
( O
day O
1 O
) O
in O
sexual O
function O
on O
day O
29 O
was O
assessed O
using O
the O
Danish O
Prostate O
Symptom O
Score O
Sex O
( O
DAN-PSSsex O
) O
questionnaire O
. O
[]

RESULTS: O
In O
the O
primary O
analysis O
of O
the O
total O
cohort O
at O
one O
year, O
the O
difference O
in O
the O
mean O
Roland-Morris O
Disability B-outcome ['Life-Impact']
Questionnaire O
(RMDQ) O
score O
between O
the O
amoxicillin O
group O
and O
the O
placebo O
group O
was O
-1.6 O
(95% O
confidence O
interval O
-3.1 O
to O
0.0, O
P=0.04). O
[['Life-Impact']]

Smaller O
improvements O
were O
seen O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Four-year O
survival B-outcome ['Mortality']
was O
73.0 O
% O
for O
279 O
high-risk O
patients O
( O
any O
Stage O
IV O
, O
all O
UH O
) O
who O
received O
postoperative O
radiation O
therapy O
( O
RT O
) O
and O
AMD O
+ O
VCR O
+ O
ADR O
+/- O
cyclophosphamide O
( O
CPM O
) O
. O
['Mortality']

The O
clinical O
relevance O
of O
these O
findings O
remains O
to O
be O
determined O
. O
[]

Children O
in O
the O
riluzole O
group O
experienced O
significantly O
more O
increases O
in O
their O
appetite O
and O
bodyweight O
than O
children O
in O
the O
placebo O
group O
by O
the O
end O
of O
the O
study O
. O
[]

Randomized O
trial O
of O
combination O
chemotherapy O
in O
hormone-resistant O
metastatic O
prostate O
carcinoma O
. O
[]

RESULTS O
Results O
indicated O
no O
statistically O
significant O
difference O
in O
outcomes O
between O
the O
two O
time O
points O
. O
[]

After O
a O
general O
clinical O
observation O
period O
of O
over O
4 O
weeks O
, O
20 O
essential O
hypertensive O
subjects O
( O
Japanese O
) O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

These O
improvements O
were O
sustained O
at O
24 O
weeks O
. O
[]

Twenty O
volunteers O
were O
given O
single O
doses O
of O
fluoxetine O
20 O
mg O
or O
an O
identical O
placebo O
daily O
for O
28 O
days O
prior O
to O
receiving O
a O
single O
10 O
mg O
oral O
dose O
of O
zolmitriptan O
. O
[]

The O
prevalences O
of O
PONV O
were O
significantly O
lower O
with O
propofol O
and O
droperidol O
compared O
with O
metoclopramide O
0.2 O
mg/kg O
and O
placebo O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
P-selectin I-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
, O
tissue O
plasminogen O
activator O
( O
tPA O
) O
antigen O
and O
activity O
, O
and O
plasminogen B-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
inhibitor-1 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PAI-1 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
determined O
in O
60 O
acute O
atherosclerotic O
stroke O
patients O
and O
matched O
control O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
height B-outcome ['Physiological-Clinical']
, O
weight O
, O
or O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Specifically O
, O
we O
assessed O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
the O
5-HT O
1d O
agonist O
, O
sumatriptan O
, O
and O
linked O
this O
measure O
of O
serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
to O
the O
severity O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
adult O
autistic O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Effect O
of O
esomeprazole O
on O
nighttime O
heartburn O
and O
sleep O
quality O
in O
patients O
with O
GERD O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

In O
addition O
, O
the O
combined O
treatments O
significantly O
promoted O
healing O
of O
rat B-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
whereas O
each O
agent O
alone O
had O
no O
significant O
effect O
as O
compared O
with O
control O
( O
saline O
) O
. O
['Physiological-Clinical']

Cellular O
markers O
were O
chosen O
to O
assess O
general B-outcome ['Physiological-Clinical']
pediatric I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
emphasizing B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
and O
activation O
of O
B O
, O
T B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
One O
hundred O
eighteen O
patients O
were O
enrolled O
. O
[]

CONCLUSIONS O
R317573 O
appears O
to O
produce O
acute O
dose-dependent O
changes O
in O
rCMglu O
. O
[]

An O
extensive O
evaluation O
was O
performed O
on O
a O
test O
set O
composed O
of O
images O
representative O
of O
those O
normally O
found O
in O
a O
screening O
set O
. O
[]

Two O
patients O
presented O
a O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
during O
the O
study O
(one O
in O
each O
group) O
but O
non-attributable O
to O
the O
treatment O
studied. O
[['Adverse-effects']]

The O
VARS O
of O
EQ-5D O
also O
disclosed O
significant O
changes O
from O
day O
2 O
( O
17 O
, O
P O
< O
0.01 O
) O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
periprostatic O
local O
anesthesia O
for O
prostate O
biopsy O
does O
not O
increase O
the O
risk O
of O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PATIENTS O
OR O
OTHER O
PARTICIPANTS: O
Seventy-two O
elite O
asymptomatic O
overhead O
athletes O
(age O
= O
17.00 O
+/- O
4.09 O
years, O
height O
= O
1.75 O
+/- O
0.11 O
m, O
mass O
= O
67.26 O
+/- O
15.25 O
kg, O
body O
mass O
index O
= O
21.80 O
+/- O
3.00). O
[]

15 O
patients O
received O
metronidazole O
and O
16 O
tinidazole O
, O
in O
random O
order O
. O
[]

No O
significant O
differences O
emerged O
between O
the O
TMI O
and O
the O
IMZ O
group O
. O
[]

Compared O
with O
the O
preoperative O
levels, O
serum O
cortisol B-outcome ['Physiological-Clinical']
level O
at O
the O
end O
of O
the O
operation O
was O
increased O
in O
the O
sedation O
group O
but O
lowered O
in O
the O
control O
group, O
and O
the O
variations O
of O
serum O
cortisol B-outcome ['Physiological-Clinical']
level O
differed O
significantly O
between O
the O
two O
groups O
(t=4.75, O
P O
&lt; O
0.01). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

24 O
cases O
of O
major O
primary O
hypercholesterolemia O
] O
. O
[]

All O
products O
were O
administered O
by O
an O
authorized O
person O
, O
blinded O
to O
both O
the O
investigating O
physician O
and O
the O
biologist O
. O
[]

Milk B-outcome ['Physiological-Clinical']
intolerance I-outcome ['Physiological-Clinical']
in O
children O
with O
persistent O
sleeplessness O
: O
a O
prospective O
double-blind O
crossover O
evaluation O
. O
['Physiological-Clinical']

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
did O
not O
differ O
significantly O
between O
the O
ganitumab O
and O
placebo O
groups O
( O
3?9 O
months O
, O
80 O
% O
CI O
3?6-5?3 O
vs O
5?7 O
months O
, O
4?4-7?4 O
; O
hazard O
ratio O
[ O
HR O
] O
1?17 O
, O
80 O
% O
CI O
0?91-1?50 O
; O
p=0?44 O
) O
. O
['Mortality']

CONCLUSION O
Results O
for O
PFS B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
favor O
combination O
of O
bevacizumab O
with O
either O
chemotherapy O
or O
erlotinib O
over O
chemotherapy O
alone O
in O
the O
second-line O
setting O
. O
['Mortality', 'Mortality']

However O
, O
fluvoxamine O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
clomipramine O
. O
['Life-Impact']

RESULTS O
Patients O
with O
non-eosinophilic O
asthma O
had O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
( O
median O
4.4 O
cells/mm O
( O
2 O
) O
vs O
23 O
cells/mm O
( O
2 O
) O
in O
eosinophilic O
asthma O
and O
0 O
cells/mm O
( O
2 O
) O
in O
normal O
controls O
; O
p O
= O
0.03 O
) O
and O
normal O
subepithelial B-outcome ['Physiological-Clinical']
layer I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
( O
5.8 O
microm O
vs O
10.3 O
microm O
in O
eosinophilic O
asthma O
and O
5.1 O
microm O
in O
controls O
, O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

[ O
Dose-reduced O
antihypertensive O
agents O
-- O
use O
in O
complex O
nonmedicamentous O
therapy O
of O
hypertension O
] O
. O
[]

SETTING O
University O
Hospital O
, O
cardiac O
surgical O
operative O
theatre O
. O
[]

Registry O
information O
from O
the O
last O
9 O
years O
was O
used O
to O
identify O
3,585 O
women O
who O
met O
the O
study O
criteria O
with O
respect O
to O
age O
, O
stage O
, O
and O
previous O
therapy O
. O
[]

Lithium O
, O
in O
a O
dosage O
yielding O
relatively O
low O
plasma B-outcome ['Physiological-Clinical']
levels O
, O
was O
not O
more O
effective O
than O
placebo O
. O
['Physiological-Clinical']

Four O
hundred O
forty-two O
patients O
had O
intermediate-grade O
ML O
, O
221 O
highgrade O
ML O
, O
and O
74 O
unclassified O
ML O
. O
[]

RESULTS O
1233 O
patients O
were O
randomized O
. O
[]

Stepping O
Stones O
Triple O
P O
( O
SSTP O
) O
is O
a O
parenting O
program O
designed O
for O
families O
of O
a O
child O
with O
a O
disability O
. O
[]

These O
results O
show O
that O
a O
significant O
gain O
in O
bone B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
can O
be O
achieved O
by O
administration O
of O
calcitonin O
, O
either O
daily O
or O
on O
alternate O
days O
. O
['Physiological-Clinical']

The O
mean O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
at O
0 O
degrees O
was O
found O
to O
be O
statistically O
significant O
higher O
( O
p O
= O
0.0083 O
) O
than O
the O
mean O
cardiac O
output O
at O
45 O
degrees O
. O
['Physiological-Clinical']

METHODS: O
Patients O
admitted O
from O
Weifang O
People's O
Hospital O
from O
January O
2015 O
to O
December O
2016 O
who O
received O
TKA O
were O
injected O
with O
20 O
mg/kg O
TXA O
by O
IV O
before O
TKA O
(n O
= O
50), O
3.0 O
g O
TXA O
by O
IA O
after O
TKA O
(n O
= O
50), O
or O
combination O
of O
20 O
mg/kg O
TXA O
by O
IV O
before O
TKA O
and O
3.0 O
g O
TXA O
by O
IA O
after O
TKA O
(n O
= O
50). O
[]

Title: O
Increased O
self-care B-outcome ['Life-Impact']
activities O
and O
glycemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
rate O
in O
relation O
to O
health O
education O
via O
Wechat O
among O
diabetes O
patients: O
A O
randomized O
clinical O
trial. O
[['Life-Impact'], ['Physiological-Clinical']]

Cephamandole O
levels O
in O
serum O
and O
drain O
fluid O
were O
measured O
in O
32 O
knee O
replacement O
operations O
to O
determine O
the O
benefit O
of O
an O
intravenous O
dose O
of O
antibiotic O
at O
the O
time O
of O
tourniquet O
deflation O
. O
[]

Phlebitis B-outcome ['Physiological-Clinical']
occurred O
in O
7/51 O
( O
13.7 O
% O
) O
and O
12/52 O
( O
23.0 O
% O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Tamoxifen O
and O
raloxifene O
have O
limited O
patient O
acceptance O
for O
primary O
prevention O
of O
breast O
cancer O
. O
[]

This O
analysis O
confirms O
that O
the O
ESRA-C O
application O
for O
collecting O
symptom O
and O
quality O
of O
life O
information O
is O
easy O
for O
patients O
to O
use O
and O
acceptable O
across O
a O
range O
of O
user O
characteristics O
. O
[]

Tailored O
, O
iterative O
, O
printed O
dietary O
feedback O
is O
as O
effective O
as O
group O
education O
in O
improving O
dietary O
behaviours O
: O
results O
from O
a O
randomised O
control O
trial O
in O
middle-aged O
adults O
with O
cardiovascular O
risk O
factors O
. O
[]

OBJECTIVE O
Stapled O
mucosectomy O
has O
been O
developed O
as O
an O
alternative O
to O
conventional O
haemorrhoidectomy O
for O
the O
elective O
treatment O
of O
haemorrhoids O
, O
but O
has O
not O
been O
assessed O
in O
the O
emergency O
setting O
. O
[]

The O
results O
show O
a O
significant O
training O
effect O
on O
attitudes B-outcome ['Life-Impact']
( O
P O
= O
0.05 O
) O
, O
especially O
on O
those O
related O
to O
['Life-Impact']

BACKGROUND O
The O
platelet O
glycoprotein O
IIb/IIIa O
receptor O
inhibitor O
abciximab O
, O
a O
monoclonal O
antibody O
, O
has O
been O
shown O
to O
improve O
early O
and O
late O
outcomes O
among O
diabetic O
patients O
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O
[]

Clinical O
significance O
and O
prognostic O
importance O
of O
left O
ventricular O
hypertrophy O
in O
non-Q-wave O
acute O
myocardial O
infarction O
. O
[]

Also O
access B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
was O
comparable O
at O
this O
time O
. O
['Physiological-Clinical']

Publication O
date: O
['2019/10/10 O
06:00' O
[]

We O
aimed O
to O
determine O
an O
effective O
and O
safe O
glucose-lowering B-outcome ['Physiological-Clinical']
adjuvant O
exenatide O
dose O
in O
adolescents O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

The O
non-responders O
underwent O
the O
subsequent O
instillation O
of O
the O
other O
intravesical O
therapy O
alternately O
. O
[]

Measurement O
of O
peptidase B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
evaluation O
of O
effectiveness O
of O
administration O
of O
minocycline O
for O
treatment O
of O
dogs O
with O
periodontitis O
. O
['Physiological-Clinical']

Anaesthesia O
was O
maintained O
with O
either O
a O
propofol O
infusion O
( O
100 O
micrograms O
kg-1 O
min-1 O
) O
or O
sevoflurane O
( O
1 O
% O
end-tidal O
) O
with O
66 O
% O
nitrous O
oxide O
( O
N2O O
) O
, O
n O
= O
15 O
in O
each O
subgroup O
. O
[]

During O
the O
pentoxifylline O
treatment O
period O
, O
in O
contrast O
with O
the O
control O
period O
, O
nine O
men O
were O
able O
to O
reestablish B-outcome ['Life-Impact']
coital I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
and O
three O
had O
no O
improvement O
. O
['Life-Impact']

Using O
a O
choice O
assessment O
to O
predict O
reinforcer O
effectiveness O
. O
[]

Possible O
etiology O
of O
improvements O
in O
both O
quality O
of O
life O
and O
overlapping O
gastroesophageal B-outcome ['Physiological-Clinical']
reflux I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
by O
proton O
pump O
inhibitor O
treatment O
in O
a O
prospective O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

The O
total O
number O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
were O
10 O
( O
45.5 O
% O
) O
, O
14 O
( O
33.3 O
% O
) O
and O
11 O
( O
25 O
% O
) O
in O
groups O
1,2 O
and O
3 O
, O
respectively O
. O
['Adverse-effects']

The O
correlation O
of O
the O
FE O
predicted O
failure O
load O
with O
the O
experimental O
failure O
load O
was O
r O
( O
2 O
) O
=64 O
% O
for O
the O
reconstruction O
FE O
model O
, O
which O
was O
significantly O
better O
( O
p O
< O
0.05 O
) O
than O
that O
for O
DXA O
( O
r O
( O
2 O
) O
=24 O
% O
) O
. O
[]

The O
primary O
outcome O
was O
the O
change O
on O
the O
Brief O
Agitation O
Rating O
Scale O
( O
BARS O
) O
. O
[]

METHODS O
Forty-three O
CABG O
patients O
were O
randomised O
into O
an O
ischaemic O
preconditioning O
and O
a O
control O
group O
. O
[]

METHODS: O
A O
single-blind O
randomized O
controlled O
trial O
was O
performed. O
[]

There O
was O
no O
difference O
in O
the O
frequency O
of O
recurrences B-outcome ['Physiological-Clinical']
between O
treatments O
. O
['Physiological-Clinical']

Impact O
of O
a O
single O
intravenous O
administration O
of O
nicorandil O
before O
reperfusion O
in O
patients O
with O
ST-segment-elevation O
myocardial O
infarction O
. O
[]

Small B-outcome ['Physiological-Clinical']
for O
gestational O
age O
at O
birth O
was O
significantly O
more O
often O
detected O
in O
the O
intervention O
group O
than O
in O
the O
usual O
care O
group O
(179 O
of O
556 O
(32%) O
v O
78 O
of O
407 O
(19%), O
P<0.001). O
[['Physiological-Clinical']]

Both O
FIT O
and O
colonoscopy B-outcome ['Resource-use']
rates O
increased O
significantly O
in O
both O
mailed O
education O
groups O
. O
['Resource-use']

Forty O
patients O
were O
randomized O
for O
being O
operated O
on O
with O
either O
MECC O
or O
CECC O
. O
[]

Analyses O
controlled O
for O
level O
of O
acculturation O
and O
immigration O
status O
. O
[]

The O
number O
of O
patients O
who O
required O
a O
continuous O
supply O
of O
oxygen B-outcome ['Resource-use']
2 O
hours O
after O
returning O
to O
the O
ward O
was O
significantly O
lower O
in O
the O
propofol O
group O
( O
midazolam O
18 O
; O
propofol O
6 O
; O
P O
= O
0.010 O
) O
. O
['Resource-use']

If O
increasing O
GABA O
concentrations O
in O
the O
CNS O
are O
critical O
for O
the O
treatment O
of O
nystagmus O
, O
then O
a O
selective O
GABAergic O
drug O
should O
be O
highly O
successful O
. O
[]

At O
3 O
months O
of O
follow-up O
, O
only O
27 O
% O
of O
patients O
in O
the O
study O
group O
experienced O
Grade O
2 O
xerostomia B-outcome ['Physiological-Clinical']
compared O
with O
73.9 O
% O
in O
the O
control O
group O
( O
p O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

All O
included O
patients O
were O
randomly O
allocated O
to O
a O
treatment O
group O
(n O
= O
43) O
or O
a O
sham O
group O
(n O
= O
43). O
[]

However O
, O
there O
are O
no O
reports O
on O
adapalene O
gel O
for O
the O
treatment O
of O
pityriasis O
versicolor O
. O
[]

BACKGROUND O
Experimental O
data O
in O
humans O
on O
the O
contribution O
of O
angiotensin-converting O
enzyme O
inhibitors O
and O
angiotensin O
II O
type O
1 O
receptor O
blockers O
to O
the O
nitric O
oxide O
system O
of O
the O
renal O
vasculature O
are O
inconsistent O
. O
[]

OBJECTIVE O
To O
observe O
the O
effects O
of O
Dujieqing O
Oral O
Liquid O
( O
DJQ O
) O
on O
the O
promoter O
methylation O
of O
the O
O6-methylguanine-DNA O
methyltransferase O
( O
MGMT O
) O
gene O
in O
the O
plasma O
DNA O
samples O
from O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
. O
[]

Several O
centres O
replaced O
one O
of O
the O
staplers O
by O
a O
new O
product O
, O
and O
the O
study O
was O
ended O
before O
the O
stipulated O
number O
of O
patients O
was O
reached O
. O
[]

The O
participants O
' O
self-control O
was O
measured O
by O
three O
neuropsychological B-outcome ['Physiological-Clinical']
tests O
and O
parental B-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
standardized I-outcome ['Life-Impact']
questionnaires I-outcome ['Life-Impact']
, O
and O
the O
underlying O
neural O
mechanism O
was O
assessed O
by O
the O
participants O
' O
brain O
EEG O
activity O
during O
an O
inhibitory-control O
task O
before O
and O
after O
intervention O
. O
['Physiological-Clinical', 'Life-Impact']

Motion O
aftereffects O
with O
horizontally O
moving O
sound O
sources O
in O
the O
free O
field O
. O
[]

RESULTS O
After O
569 O
patients O
had O
undergone O
randomization O
, O
enrollment O
was O
stopped O
because O
of O
concerns O
about O
the O
safety O
of O
the O
patients O
who O
had O
been O
assigned O
to O
receive O
warfarin O
. O
[]

Such O
information O
provides O
important O
knowledge O
that O
may O
help O
to O
inform O
decisions O
of O
municipalities, O
employers O
and O
other O
public O
health O
decision O
makers, O
when O
and O
if O
implementing O
weight O
loss O
interventions. O
[]

Furthermore O
, O
young O
children O
only O
succeeded O
on O
TOM O
items O
that O
tap O
the O
basic O
domains O
of O
theory O
of O
mind O
( O
e.g. O
, O
emotion O
recognition O
) O
, O
whereas O
older O
children O
also O
passed O
items O
that O
measure O
the O
more O
mature O
areas O
of O
theory O
of O
mind O
( O
e.g. O
, O
understanding O
of O
humor O
, O
understanding O
of O
second-order O
beliefs O
) O
. O
[]

METHODS O
Fifty-two O
cases O
were O
randomly O
divided O
into O
a O
treatment O
group O
( O
n=28 O
) O
and O
a O
control O
group O
( O
n=24 O
) O
. O
[]

The O
mean O
CD4 O
( O
+/- O
SD O
) O
lymphocyte O
level O
was O
37 O
( O
+/- O
29 O
) O
/microL O
and O
39 O
( O
+/- O
44 O
) O
/microL O
in O
groups O
A O
and O
B O
, O
respectively O
. O
[]

Adjuvant O
therapy O
with O
pegylated O
interferon O
alfa-2b O
versus O
observation O
in O
resected O
stage O
III O
melanoma O
: O
a O
phase O
III O
randomized O
controlled O
trial O
of O
health-related O
quality O
of O
life O
and O
symptoms O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Melanoma O
Group O
. O
[]

RESULTS O
During O
follow-up O
, O
the O
overall O
RQLQ O
( O
S O
) O
score O
for O
the O
entire O
grass O
pollen O
season O
was O
significantly O
improved O
in O
the O
active O
group O
( O
relative O
difference O
to O
placebo O
: O
23 O
% O
, O
P O
= O
0.004 O
) O
. O
[]

A O
pilot O
study O
of O
extended O
duration O
peginterferon O
alfa-2a O
for O
patients O
with O
hepatitis O
B O
e O
antigen-negative O
chronic O
hepatitis O
B O
. O
[]

One O
examiner O
, O
blinded O
to O
the O
treatment O
sequence O
, O
performed O
all O
clinical O
measurements O
. O
[]

Then O
they O
were O
sent O
to O
the O
Department O
of O
Nuclear O
Medicine O
in O
Ostrava O
in O
the O
Czech O
Republic O
. O
[]

METHODS O
Twenty-six O
alcoholic O
patients O
with O
severe O
AWS B-outcome ['Physiological-Clinical']
and O
concomitant O
medical O
diseases O
were O
randomally O
enrolled O
in O
the O
study O
. O
['Physiological-Clinical']

Patients O
may O
be O
isolated O
both O
physically O
and O
socially O
and O
may O
lack O
the O
self-efficacy O
to O
report O
problems O
and O
participate O
as O
partners O
in O
their O
care O
. O
[]

It O
would O
be O
needed O
to O
investigate O
whether O
the O
differences O
may O
be O
distinct O
or O
not O
the O
same O
when O
other O
dosages O
are O
used O
. O
[]

Human O
maxillary O
central O
incisors O
( O
n O
= O
70 O
) O
were O
instrumented O
with O
a O
rotary O
NiTi O
system O
and O
filled O
. O
[]

The O
CCR B-outcome ['Physiological-Clinical']
rates O
in O
Regimen O
A O
and O
B O
were O
75.1 O
% O
+/- O
5.8 O
% O
( O
mean O
+/- O
1 O
SE O
) O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.01 O
) O
at O
4 O
years O
, O
and O
72.1 O
% O
+/- O
6.3 O
% O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.05 O
) O
at O
5 O
years O
, O
respectively O
. O
['Physiological-Clinical']

We O
aimed O
to O
assess O
effectiveness O
and O
safety O
of O
all O
four O
treatments O
. O
[]

In O
addition O
, O
differences O
in O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
levels O
between O
the O
groups O
were O
sustained O
for O
a O
12-month O
period O
. O
['Life-Impact']

By O
day O
10 O
, O
7 O
patients O
in O
the O
tobramycin O
group O
( O
35 O
% O
) O
had O
been O
extubated B-outcome ['Resource-use']
versus O
3 O
in O
the O
placebo O
group O
( O
18.5 O
% O
, O
p O
= O
0.18 O
) O
. O
['Resource-use']

Injection O
sites O
were O
randomized O
to O
either O
a O
superomedial O
or O
inferomedial O
location O
. O
[]

3.0 O
? O
[]

On O
multivariate O
analysis O
, O
pirarubicin O
instillation O
was O
an O
independent O
predictor O
of O
better O
recurrence-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
in O
the O
patients O
with O
positive O
urine O
cytology O
( O
hazard O
ratio O
, O
0.02 O
; O
95 O
% O
confidence O
interval O
, O
0.00-0.53 O
; O
P O
= O
0.018 O
) O
. O
['Mortality']

The O
study O
can O
detect O
a O
three-point O
difference O
in O
full-scale O
IQ B-outcome ['Life-Impact']
at O
3-year O
follow-up O
. O
['Life-Impact']

We O
investigated O
in O
healthy O
nonobese O
males O
the O
effect O
of O
the O
GH O
receptor O
antagonist O
pegvisomant O
in O
different O
metabolic O
conditions O
. O
[]

We O
can O
not O
recommend O
the O
use O
of O
oral O
premedication O
using O
these O
amounts O
of O
water O
, O
considering O
the O
increased O
risk O
of O
aspiration O
of O
gastric O
contents O
. O
[]

One O
patient O
was O
still O
alive O
at O
the O
time O
of O
this O
analysis O
. O
[]

The O
greatest O
prevalence O
reduction O
occurred O
for O
stimulants O
; O
modest O
changes O
were O
evident O
in O
alcohol O
and O
marijuana O
use O
. O
[]

Clinical O
outcomes O
were O
compared O
and O
the O
variables O
were O
analyzed O
using O
the O
following O
three O
groups O
: O
entire O
populations O
of O
study O
group O
and O
control O
group O
, O
subgroup O
of O
patients O
who O
had O
CABG O
reoperation O
only O
, O
and O
a O
subgroup O
who O
had O
valve O
reoperation O
or O
combined O
valve O
and O
CABG O
reoperation O
. O
[]

Two O
high-dose O
regimens O
, O
FPV O
1,400 O
mg O
twice O
a O
day O
( O
BID O
) O
plus O
RTV O
100 O
mg O
BID O
and O
FPV O
1,400 O
mg O
BID O
plus O
RTV O
200 O
mg O
BID O
, O
were O
planned O
to O
be O
compared O
to O
the O
approved O
regimen O
, O
FPV O
700 O
mg O
BID O
plus O
RTV O
100 O
mg O
BID O
, O
in O
a O
randomized O
three-period O
crossover O
study O
. O
[]

Covariation O
of O
adolescent B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
dietary B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
over O
12 O
months O
. O
['Life-Impact', 'Life-Impact']

PATIENTS O
AND O
METHODS O
Randomized O
verum O
controlled O
parallel-group-comparison O
of O
two O
weeks O
treatment O
of O
a O
nasal-spray O
. O
[]

Again O
, O
there O
were O
no O
significant O
differences O
in O
the O
lag O
phase O
of O
oxidation B-outcome ['Physiological-Clinical']
at O
each O
dose O
for O
RRR-AT O
when O
compared O
with O
all-rac-AT O
. O
['Physiological-Clinical']

In O
group O
I O
, O
all O
thrombi O
were O
mobile O
and O
5-13 O
mm O
in O
diameter O
; O
in O
group O
II O
, O
all O
thrombi O
but O
three O
were O
mobile O
and O
3-18 O
mm O
in O
diameter O
. O
[]

Superior O
visual O
search O
in O
adults O
with O
autism O
. O
[]

The O
impact O
of O
schizophrenic O
patient O
functionality O
on O
service O
utilization O
and O
cost B-outcome ['Resource-use']
. O
['Resource-use']

Pioglitazone O
significantly O
reduced O
FPG B-outcome ['Physiological-Clinical']
compared O
with O
glimepiride O
( O
-0.6 O
vs O
0.6 O
mmol/L O
; O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

Baseline O
risk O
factors O
for O
SH O
were O
evaluated O
over O
12 O
months O
of O
follow-up O
using O
proportional O
hazards O
regression O
. O
[]

All O
patients O
received O
identical O
cumulative O
doses O
of O
cisplatin O
, O
doxorubicin O
, O
and O
methotrexate O
and O
underwent O
definitive O
surgical O
resection O
of O
primary O
tumor O
. O
[]

Gene O
expression O
is O
altered O
in O
piglet O
small O
intestine O
by O
weaning O
and O
dietary O
glutamine O
supplementation O
. O
[]

Daily O
supplementation O
significantly O
increased O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
alpha-tocopherol I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
beta-carotene I-outcome ['Physiological-Clinical']
in O
the O
supplemented O
group O
( O
Delta O
14.4 O
( O
SE O
3.2 O
) O
and O
0.4 O
( O
se O
0.1 O
) O
micromol/l O
; O
P O
< O
0.001 O
and O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

METHODOLOGY O
In O
this O
double-blind O
clinical O
trial O
, O
100 O
patients O
who O
had O
anterior O
or O
premolar O
teeth O
with O
irreversible O
pulpitis O
without O
any O
signs O
and O
symptoms O
of O
acute O
or O
chronic O
apical O
periodontitis O
and O
moderate O
to O
severe O
pain O
were O
divided O
by O
balanced O
block O
random O
allocation O
into O
four O
groups O
of O
25 O
each O
, O
a O
control O
group O
receiving O
a O
placebo O
medication O
, O
and O
three O
experimental O
groups O
receiving O
a O
single O
dose O
of O
either O
Tramadol O
( O
100 O
mg O
) O
, O
Novafen O
( O
325 O
mg O
of O
paracetamol O
, O
200 O
mg O
ibuprofen O
and O
40 O
mg O
caffeine O
anhydrous O
) O
or O
Naproxen O
( O
500 O
mg O
) O
immediately O
after O
the O
first O
appointment O
where O
the O
pulp O
was O
removed O
, O
and O
the O
canals O
were O
fully O
prepared O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
contents I-outcome ['Physiological-Clinical']
and O
pH O
after O
oral O
premedication O
. O
['Physiological-Clinical']

We O
conclude O
that O
postural O
responses O
to O
backward O
and O
forward O
perturbations O
may O
be O
processed O
by O
different O
neural O
circuits O
, O
with O
influence O
of O
startle O
pathways O
on O
postural O
responses O
to O
backward O
perturbations O
. O
[]

Effect O
of O
a O
high-protein O
, O
energy-restricted O
diet O
on O
weight O
loss B-outcome ['Physiological-Clinical']
and O
energy B-outcome ['Physiological-Clinical']
expenditure I-outcome ['Physiological-Clinical']
after O
weight O
stabilization O
in O
hyperinsulinemic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Triple O
therapy O
regimens O
including O
two O
antibiotics O
plus O
acid O
suppression O
have O
become O
the O
new O
standard O
therapy O
in O
Helicobacter O
pylori O
eradication O
because O
of O
success O
rates O
of O
about O
90 O
% O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
was O
recorded O
using O
radiotelemetric B-outcome ['Physiological-Clinical']
technique O
( O
Heidelberg O
capsule O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
melatonin O
enhanced O
the O
activation O
in O
the O
left B-outcome ['Physiological-Clinical']
parahippocampus I-outcome ['Physiological-Clinical']
in O
an O
autobiographic O
memory O
task O
. O
['Physiological-Clinical']

Medial B-outcome ['Physiological-Clinical']
nail I-outcome ['Physiological-Clinical']
protrusion I-outcome ['Physiological-Clinical']
occurred O
in O
7 O
cases O
in O
the O
operative O
group O
. O
['Physiological-Clinical']

The O
haemoglobin B-outcome ['Physiological-Clinical']
level O
at O
presentation O
was O
strongly O
correlated O
with O
prognosis O
among O
patients O
in O
the O
good O
renal-function O
group O
. O
['Physiological-Clinical']

DISCUSSION O
This O
study O
evaluates O
the O
efficacy O
of O
a O
theory O
of O
mind O
intervention O
for O
children O
with O
ASD O
. O
[]

We O
performed O
a O
randomized O
phase O
2 O
trial O
of O
rituximab O
( O
375 O
mg/m O
( O
2 O
) O
) O
given O
either O
concurrently O
before O
each O
infusional O
etoposide O
, O
vincristine O
, O
doxorubicin O
, O
cyclophosphamide O
, O
and O
prednisone O
( O
EPOCH O
) O
chemotherapy O
cycle O
or O
sequentially O
( O
weekly O
for O
6 O
weeks O
) O
after O
completion O
of O
all O
chemotherapy O
in O
HIV-associated O
NHL O
. O
[]

Subsequently O
90 O
% O
in O
the O
study O
group O
defecated B-outcome ['Physiological-Clinical']
, O
compared O
to O
33 O
% O
in O
the O
control O
group O
( O
P O
= O
0.001 O
) O
. O
['Physiological-Clinical']

The O
relationships O
between O
VPW B-outcome ['Physiological-Clinical']
, O
positive O
end-expiratory O
pressure O
( O
PEEP O
) O
, O
cumulative O
fluid O
['Physiological-Clinical']

The O
most O
common O
adverse O
events O
were O
[]

Double-blind O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
on O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
a O
physostigmine O
patch O
in O
patients O
with O
senile O
dementia O
of O
the O
Alzheimer O
type O
. O
['Life-Impact']

A O
total O
of O
12 O
EA O
and O
SEA O
sessions O
over O
four O
weeks O
were O
given O
. O
[]

METHODS O
A O
single O
dose O
of O
sirolimus O
administered O
SCJ O
( O
220 O
, O
440 O
, O
880 O
, O
1320 O
, O
or O
1760 O
?g O
) O
or O
IVT O
( O
44 O
, O
110 O
, O
176 O
, O
264 O
, O
or O
352 O
?g O
) O
on O
day O
0 O
; O
observation O
through O
day O
90 O
. O
[]

Efficacy O
on O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
['Life-Impact']

Publication O
Type: O
Journal O
Article O
[]

1.59 O
years O
, O
respectively O
. O
[]

The O
trial O
was O
stopped O
after O
the O
accumulated O
results O
in O
121 O
patients O
demonstrated O
a O
significant O
advantage O
for O
survival O
in O
the O
patients O
who O
received O
chemotherapy O
and O
radiation O
therapy O
. O
[]

We O
have O
detailed O
our O
efforts O
at O
developing O
print- O
and O
web-based O
DAs O
to O
assist O
men O
in O
determining O
how O
to O
best O
meet O
their O
PCa O
screening O
preferences O
. O
[]

This O
finding O
indicates O
that O
the O
combination O
of O
a O
dihydropyridine O
calcium O
antagonist O
+ O
a O
thiazide O
diuretic O
is O
probably O
devoid O
of O
any O
particular O
clinical O
significance O
in O
the O
treatment O
of O
uncomplicated O
essential O
hypertensives O
. O
[]

'typewriter O
' O
) O
following O
a O
related O
prime O
that O
shared O
manipulation O
features O
with O
the O
target O
( O
e.g O
. O
[]

SETTING O
Anaesthesia O
Service O
. O
[]

The O
control O
group O
complete O
effective O
and O
partial O
effective O
were O
4.6 O
% O
and O
13.6 O
% O
( O
P O
< O
0.05 O
) O
. O
[]

CONCLUSIONS O
Cardiotocography O
is O
not O
useful O
for O
the O
detection O
of O
cord B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Sildenafil O
is O
well O
tolerated B-outcome ['Life-Impact']
in O
left O
heart O
failure O
patients O
and O
does O
not O
decrease O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Group O
I O
consisted O
of O
15 O
patients O
with O
Forrest O
IB O
and O
Group O
II O
consisted O
of O
30 O
patients O
with O
Forrest O
II O
. O
[]

In O
addition O
, O
compared O
to O
the O
No O
Intervention O
group O
, O
the O
CAI O
group O
scored O
significantly O
higher O
on O
the O
scales O
measuring O
[]

Patients O
were O
randomized O
between O
satraplatin O
100 O
mg/m O
( O
2 O
) O
for O
5 O
days O
plus O
prednisone O
10 O
mg O
orally O
BID O
or O
prednisone O
alone O
. O
[]

BACKGROUND O
Nasotracheal O
intubation O
( O
NTI O
) O
has O
greater O
potential O
for O
trauma O
of O
nasopharyngeal O
mucosa O
than O
orotracheal O
intubation O
. O
[]

Title: O
Effect O
of O
the O
soft-tissue O
techniques O
in O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
patients O
with O
Crohn's O
disease: O
A O
randomized O
controlled O
trial. O
[['Life-Impact']]

Findings O
reveal O
that O
respondents O
(N O
= O
205) O
are O
not O
averse B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
bitter I-outcome ['Life-Impact']
taste I-outcome ['Life-Impact']
; O
while, O
socio-demographic O
traits O
influence O
bitter B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
, O
as O
higher O
education O
level O
and O
gender O
(female) O
positively O
affect O
preferences B-outcome ['Life-Impact']
, O
together O
with O
specific O
individual O
characteristics O
as O
high O
compensatory O
health O
beliefs. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Relief O
of O
periorbital O
pain O
after O
acute O
angle O
closure O
glaucoma O
attack O
by O
botulinum O
toxin O
type O
A O
. O
[]

Title: O
Performance O
of O
Litholyme O
compared O
with O
Sodasorb O
carbon O
dioxide O
absorbents O
in O
a O
standard O
clinical O
setting. O
[]

Approximately O
30 O
% O
of O
patients O
in O
both O
groups O
had O
progression B-outcome ['Physiological-Clinical']
of O
their O
disease B-outcome ['Physiological-Clinical']
, O
and O
progression-free B-outcome ['Physiological-Clinical']
survival B-outcome ['Mortality']
was O
nearly O
identical O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Group O
3 O
received O
propofol O
2 O
mg/kg O
i.v. O
, O
followed O
by O
propofol O
50 O
to O
160 O
micrograms/kg/min O
i.v O
. O
[]

By O
contrast O
, O
the O
combination O
of O
verapamil O
plus O
lithium O
was O
highly O
efficacious O
. O
[]

The O
most O
frequently O
noted O
reason O
for O
refusal B-outcome ['Life-Impact']
was O
being O
too O
busy O
or O
having O
no O
time O
. O
['Life-Impact']

Aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
a O
brachial-basilic O
( O
BB O
) O
AVF O
and O
the O
prosthetic O
brachial-antecubital O
forearm O
loop O
access O
( O
PTFE O
) O
on O
cardiac B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
78 O
children O
known O
to O
be O
infected O
with O
Ascaris O
at O
baseline O
, O
the O
rate O
of O
weight O
[]

After O
weaning O
from O
cardiopulmonary O
bypass O
, O
cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
increased O
and O
came O
close O
to O
the O
value O
after O
induction O
in O
all O
groups O
. O
['Physiological-Clinical']

MAIN O
RESULTS O
Plasma O
level O
of O
endotoxin O
and O
all O
the O
cytokines B-outcome ['Physiological-Clinical']
after O
CRRT O
initiation O
were O
significantly O
lower O
than O
those O
before O
the O
treatment O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
sessions O
consisted O
of O
four O
phases O
, O
with O
each O
phase O
lasting O
3 O
minutes O
. O
[]

RESULTS O
ORR B-outcome ['Physiological-Clinical']
for O
patients O
randomly O
assigned O
to O
receive O
EC O
and O
ED O
were O
42 O
% O
and O
47 O
% O
, O
respectively O
( O
P O
= O
0.63 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
It O
is O
possible O
to O
validate O
statistically O
the O
distinction O
between O
discrete O
epileptic O
syndromes O
. O
[]

Developing O
the O
Ho'ouna O
Pono O
substance O
use O
prevention O
curriculum O
: O
collaborating O
with O
Hawaiian O
youth O
and O
communities O
. O
[]

BACKGROUND O
Studies O
have O
shown O
that O
a O
majority O
of O
women O
with O
a O
family O
history O
of O
breast O
cancer O
have O
exaggerated O
perceptions O
of O
their O
own O
risk O
of O
this O
disease O
and O
experience O
excessive O
anxiety O
. O
[]

A O
proposed O
method O
to O
derive O
systolic O
PAP O
should O
be O
used O
while O
screening O
the O
patients O
at O
risk O
for O
pulmonary O
hypertension O
, O
monitoring O
the O
disease O
progression O
and O
the O
effect O
of O
treatment O
. O
[]

Effects O
of O
self-directed O
stress O
management O
training O
and O
home-based O
exercise O
on O
stress O
management B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
cancer O
patients O
receiving O
chemotherapy O
. O
['Life-Impact']

Conclusion: O
The O
protocol O
for O
changing O
the O
attribution O
to O
unintentional O
injury O
and O
negative O
information O
transmission O
for O
risk O
behavior O
consequences O
was O
proved O
to O
effectively O
reduce O
children's O
unintentional O
injury O
risk B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
relevant O
events. O
[['Life-Impact']]

Data O
from O
a O
cross-over O
, O
randomised O
, O
open-label O
bioequivalence O
study O
in O
healthy O
volunteers O
. O
[]

Lamotrigine O
therapy O
for O
autistic O
disorder O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Tegaserod O
, O
a O
5-hydroxytryptamine O
type O
4 O
receptor O
partial O
agonist O
, O
is O
devoid O
of O
electrocardiographic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
lavage O
was O
divided O
into O
a O
predominantly O
bronchial O
washing O
( O
first O
20 O
ml O
of O
lavage O
; O
BL O
) O
and O
a O
predominantly O
alveolar O
washing O
( O
BAL O
) O
. O
[]

Evaluation O
of O
additional O
amine O
fluoride/stannous O
fluoride-containing O
mouthrinse O
during O
supportive O
therapy O
in O
patients O
with O
generalized O
aggressive O
periodontitis O
. O
[]

LPL O
showed O
a O
statistically O
significant O
longer O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
. O
['Life-Impact']

BIS O
delivers O
a O
complex O
intervention O
( O
of O
non-pharmacological O
and O
pharmacological O
treatments O
) O
via O
a O
multi-professional O
team O
. O
[]

RESULTS: O
The O
mean O
age O
(+/-SD) O
of O
the O
60 O
participants O
was O
27.5+/-5.0 O
years, O
spherical O
refractive O
error O
was O
-3.68+/-2.01 O
D, O
and O
cylinder O
was O
-1.28+/-0.36 O
D. O
High- O
and O
low-contrast O
visual B-outcome ['Physiological-Clinical']
acuities I-outcome ['Physiological-Clinical']
with O
toric O
lenses O
were O
better O
than O
with O
spherical O
lenses O
at O
both O
fitting O
(toric O
high-contrast: O
-0.065+/-0.078 O
and O
low-contrast: O
0.133+/-0.103 O
vs. O
spherical O
high-contrast: O
0.001+/-0.104 O
and O
low-contrast: O
0.224+/-0.107) O
and O
follow-up O
(toric O
high-contrast: O
-0.083+/-0.087 O
and O
low-contrast: O
0.108+/-0.107 O
vs. O
spherical O
high-contrast: O
-0.015+/-0.095 O
and O
low-contrast: O
0.211+/-0.104) O
(all O
P<0.0001). O
[['Physiological-Clinical']]

SETTING O
The O
study O
was O
performed O
at O
Ohio O
State O
University O
's O
General O
Clinical O
Research O
Center O
. O
[]

A O
retrospective O
analysis O
of O
29 O
children O
treated O
with O
inhaled O
treprostinil O
for O
?6 O
weeks O
was O
performed O
. O
[]

The O
drug O
Simvastatin O
may O
help O
to O
protect O
donor O
livers O
against O
this O
damage O
and O
improve O
outcomes O
for O
transplant O
recipients. O
[]

Both O
plasma O
epinephrine O
and O
blood O
lactate O
concentrations O
were O
higher O
in O
the O
PSE O
compared O
with O
the O
PLA O
trials O
, O
and O
preexercise O
and O
postexercise O
urinary O
PSE O
concentrations O
were O
significantly O
higher O
than O
the O
threshold O
( O
150 O
?g?mL O
) O
used O
by O
WADA O
to O
determine O
illicit O
PSE O
use O
. O
[]

During O
hyposensitization O
IgG B-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
showed O
a O
slight O
initial O
increase O
followed O
by O
a O
decrease O
below O
pretreatment O
level O
. O
['Physiological-Clinical']

Title: O
Medial O
patellofemoral O
ligament O
reconstruction O
in O
children: O
A O
comparative O
randomized O
short-term O
study O
of O
fascia O
lata O
allograft O
and O
gracilis O
tendon O
autograft O
reconstruction. O
[]

RESULTS O
IL-6 O
, O
IL-8 O
levels O
in O
the O
plasma O
and O
BALF O
collected O
at O
T O
( O
2 O
) O
-T O
( O
4 O
) O
increased O
significantly O
as O
compared O
with O
those O
in O
samples O
collected O
at O
T O
( O
1 O
) O
, O
and O
their O
peak O
concentration O
inplasma B-outcome ['Physiological-Clinical']
and O
BALF B-outcome ['Physiological-Clinical']
samples O
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
evaluated O
the O
cost-effectiveness O
of O
rapid O
diagnostic O
tests O
( O
RDTs O
) O
in O
comparison O
to O
microscopy O
in O
guiding O
treatment O
of O
non-severe O
febrile O
illness O
at O
varying O
levels O
of O
malaria O
endemicity O
using O
data O
on O
test O
accuracy O
and O
costs B-outcome ['Resource-use']
collected O
as O
part O
of O
a O
Tanzanian O
trial O
. O
['Resource-use', 'Resource-use']

Mixed O
method O
interviews O
are O
conducted O
with O
patients O
and O
their O
lay O
carers O
at O
three O
to O
five O
measurement O
points O
depending O
on O
randomisation O
and O
sub-protocol O
. O
[]

Eighteen O
autistic O
individuals O
, O
ranging O
in O
age O
from O
7 O
to O
18 O
years O
, O
participated O
in O
the O
study O
. O
[]

The O
positive O
percent O
of O
coli-form B-outcome ['Physiological-Clinical']
on O
the O
hand O
swabs O
in O
intervention O
group O
(2.00%) O
were O
significantly O
lower O
than O
that O
in O
control O
group O
(9.45%) O
at O
the O
end O
of O
year O
2.The O
intervention O
of O
intensive O
education O
on O
hand O
hygiene O
effectively O
improved O
the O
personal B-outcome ['Life-Impact']
hygiene I-outcome ['Life-Impact']
both O
of O
children O
and O
parents, O
as O
well O
as O
reduced O
the O
incidence O
of O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
We O
suggested O
expanding O
the O
intervention O
measures O
in O
community O
to O
prevent O
HFMD. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

OBJECTIVES O
Reducing O
unnecessary O
antibiotic O
use O
, O
particularly O
among O
children O
, O
continues O
to O
be O
a O
public O
health O
priority O
. O
[]

A O
relation O
between O
plasma O
diltiazem O
concentration O
and O
percent O
change O
in O
[]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

Amphotericin O
versus O
pentamidine O
in O
antimony-unresponsive O
kala-azar O
. O
[]

METHODS O
At O
baseline O
visit O
, O
the O
catheter O
was O
changed O
and O
participants O
were O
followed O
weekly O
for O
8 O
weeks O
, O
with O
checks O
for O
catheter B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE:: O
With O
increasing O
incorporation O
of O
MRI O
in O
radiotherapy, O
we O
investigate O
two O
MRI O
sequences O
for O
prostate O
delineation O
in O
radiographer-led O
image O
guidance. O
[]

The O
final O
results O
. O
[]

RESULTS O
Latent O
variable O
structural O
equation O
modeling O
indicated O
that O
: O
1 O
) O
the O
intervention O
had O
direct O
, O
positive O
effects O
on O
physical O
activity O
and O
factors O
influencing O
enjoyment O
of O
PE O
, O
which O
subsequently O
explained O
the O
effects O
of O
increased O
physical O
activity O
enjoyment O
and O
self-efficacy B-outcome ['Life-Impact']
on O
increased O
physical O
activity O
; O
and O
2 O
) O
an O
additional O
, O
indirect O
effect O
of O
physical O
activity O
enjoyment O
on O
physical O
activity O
operated O
by O
an O
influence O
on O
self-efficacy B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Patients O
receiving O
150 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
had O
prolonged O
median O
OS B-outcome ['Mortality']
compared O
with O
those O
in O
the O
100 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
arm O
( O
hazard O
ratio O
, O
0.575 O
; O
P O
= O
.008 O
) O
. O
['Mortality']

Endoscopic B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
defined O
as O
complete B-outcome ['Physiological-Clinical']
epithelialisation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
all I-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
A-V O
Impulse O
System O
reduces O
deep-vein O
thrombosis O
and O
swelling O
after O
hemiarthroplasty O
for O
hip O
fracture O
. O
[]

An O
additional O
26 O
patients O
were O
treated O
in O
an O
identical O
fashion O
, O
but O
were O
not O
part O
of O
the O
randomized O
trial O
because O
of O
contraindications O
to O
chemotherapy O
, O
refusal O
to O
enter O
the O
randomized O
trial O
, O
or O
because O
they O
were O
treated O
before O
1977 O
in O
a O
trial O
in O
which O
all O
patients O
received O
chemotherapy O
. O
[]

A O
sensitivity O
analysis O
on O
dosage B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
and O
duration B-outcome ['Mortality']
of I-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
performed O
. O
['Life-Impact', 'Mortality']

Duration O
of O
chronic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Volunteers O
displayed O
the O
expected O
rise O
in O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
but O
no O
other O
clinically B-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
hematology I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
median O
duration O
of O
ART B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
was O
3.8 O
years O
. O
['Physiological-Clinical']

Depression B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
were O
at O
clinical O
levels O
premenstrually O
in O
the O
PMS O
and O
PME O
groups O
; O
following O
treatment O
they O
remitted O
in O
the O
PMS O
group O
but O
not O
in O
the O
PME O
leuprolide O
subjects O
. O
['Life-Impact']

AUC O
( O
0-150 O
) O
of O
APAP/pl O
is O
significantly O
different O
from O
pl/pl O
( O
-3452 O
% O
.min O
( O
95 O
% O
CI O
-4705 O
to O
-2199 O
) O
vs. O
-933 O
% O
min O
( O
95 O
% O
CI O
-2273 O
to O
407 O
; O
P O
= O
0.015 O
) O
but O
not O
from O
APAP/Nal O
( O
-1731 O
% O
min O
( O
95 O
% O
CI O
-3676 O
to O
214 O
; O
P O
= O
0.08 O
) O
and O
other O
treatments O
. O
[]

STUDY O
OBJECTIVE O
To O
investigate O
the O
impact O
of O
different O
modes O
of O
ventilation O
during O
cardiopulmonary O
bypass O
( O
CPB O
) O
on O
immediate O
postbypass O
oxygenation O
in O
pediatric O
cardiac O
surgery O
. O
[]

Publication O
date: O
2018/11/04 O
00:00 O
[accepted] O
[]

Naltrexone O
, O
1.0 O
mg/kg O
, O
was O
given O
daily O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
design O
. O
[]

LIMITATIONS O
An O
imbalance O
existed O
in O
the O
number O
of O
patients O
with O
the O
clinical O
outcome O
unable O
to O
determine O
( O
15 O
retapamulin O
, O
2 O
cephalexin O
) O
, O
mainly O
because O
of O
their O
failure O
to O
attend O
the O
study O
visit O
. O
[]

METHODS O
Spring-calved O
dairy O
cows O
were O
grazed O
for O
101 O
days O
in O
paddocks O
that O
were O
either O
not O
fertilised O
( O
Control O
; O
n=20 O
) O
during O
the O
course O
of O
the O
study O
, O
or O
were O
fertilised O
with O
40-50 O
kg O
nitrogen O
( O
N O
) O
/ha O
every O
4-6 O
weeks O
( O
High-N O
; O
n=20 O
) O
. O
[]

In O
order O
to O
better O
understand O
the O
effect O
of O
breast O
cancer O
screening O
on O
mortality O
, O
we O
use O
the O
theory O
of O
competing O
risks O
to O
analyse O
deaths O
from O
the O
long-term O
follow-up O
of O
the O
HIP O
breast O
cancer O
screening O
trial O
. O
[]

Journal O
ID: O
2984818R O
[]

The O
relative O
contributions O
of O
medication O
adherence O
and O
AA O
meeting O
attendance O
to O
abstinent O
outcome O
for O
chronic O
alcoholics O
. O
[]

RESULTS O
Difference O
between O
the O
two O
protocols O
was O
significant O
as O
the O
group O
that O
received O
topiramate O
had O
a O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
irritability O
, O
stereotypic B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
and O
hyperactivity/noncompliance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Administration O
of O
conjugated O
equine O
estrogens O
resulted O
in O
decreased O
levels O
of O
Lp B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
a I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
only O
in O
group O
B O
after O
treatment O
. O
['Physiological-Clinical']

This O
strategy O
offers O
the O
possibility O
to O
improve O
markedly O
morbidity O
and O
mortality B-outcome ['Mortality']
from I-outcome ['Mortality']
prostate I-outcome ['Mortality']
cancer I-outcome ['Mortality']
, O
presently O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
North O
American O
men O
. O
['Mortality']

Attitude O
certainty O
has O
been O
the O
subject O
of O
considerable O
attention O
in O
the O
attitudes O
and O
persuasion O
literature O
. O
[]

Preventive O
programmes O
aimed O
at O
a O
change O
of O
sun O
related O
behaviours O
among O
Swedish O
adolescents O
have O
to O
be O
tailored O
to O
the O
climate O
and O
cultural O
conditions O
and O
must O
take O
into O
account O
that O
having O
a O
tan O
, O
and O
the O
warmth O
of O
the O
sun O
, O
are O
highly O
valued O
by O
most O
adolescents O
. O
[]

Compared O
with O
dexibuprofen O
, O
ibuprofen O
arginate O
demonstrated O
a O
45 O
% O
higher O
maximum O
concentration O
( I-outcome ['Physiological-Clinical']
C B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) O
, O
and O
a O
time O
to O
peak O
concentration O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Clinical B-outcome ['Physiological-Clinical']
outcomes O
within O
6 O
months O
were O
assessed O
. O
['Physiological-Clinical']

Exposure B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
infective I-outcome ['Physiological-Clinical']
third-stage I-outcome ['Physiological-Clinical']
larvae I-outcome ['Physiological-Clinical']
decreased O
in O
all O
monitored O
five O
communities O
. O
['Physiological-Clinical']

220.1 O
vs. O
413.2 O
? O
[]

CONCLUSION O
Uptake O
of O
influenza O
immunisation B-outcome ['Physiological-Clinical']
among O
the O
low-risk O
older O
population O
in O
inner-city O
areas O
can O
be O
boosted O
by O
around O
6 O
% O
using O
a O
simple O
intervention O
by O
receptionists O
. O
['Physiological-Clinical']

One O
hundred O
patients O
received O
1 O
gm O
of O
erythromycin O
base O
by O
mouth O
per O
day O
for O
4 O
weeks O
, O
followed O
by O
333 O
mg/day O
for O
8 O
weeks O
, O
plus O
placebo O
for O
tetracycline O
. O
[]

It O
has O
been O
reported O
that O
autism O
is O
a O
hypoglutamatergic O
disorder O
. O
[]

Journal-Name:BMC O
public O
health O
[]

CONCLUSIONS O
Family O
education O
on O
schizophrenia O
by O
nurses O
in O
China O
was O
effective O
in O
improving O
knowledge O
and O
promoting O
improvement O
in O
patients O
' O
symptoms O
. O
[]

There O
are O
few O
large O
studies O
comparing O
the O
relative O
side O
effects O
and O
efficacy O
of O
different O
opioids O
in O
labour O
. O
[]

Publication O
date: O
['2019/10/10 O
06:00' O
[]

RESULTS O
Oral B-outcome ['Physiological-Clinical']
hygiene I-outcome ['Physiological-Clinical']
around O
both O
test O
and O
control O
implants O
was O
improved O
at O
3 O
and O
6 O
months O
compared O
with O
baseline O
. O
['Physiological-Clinical']

Recombinant O
human O
TSH O
has O
been O
developed O
to O
facilitate O
monitoring O
for O
thyroid O
carcinoma O
recurrence O
or O
persistence O
without O
the O
attendant O
morbidity O
of O
hypothyroidism O
seen O
after O
thyroid O
hormone O
withdrawal O
. O
[]

Nicotine O
caused O
a O
small O
overall O
reduction O
in O
global B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
but O
, O
when O
the O
data O
were O
normalized O
, O
several O
brain O
regions O
showed O
relative O
increases O
in O
activity O
. O
['Physiological-Clinical']

Using O
Martha O
Rogers O
' O
science O
of O
unitary O
human O
beings O
, O
changes O
in O
pain B-outcome ['Physiological-Clinical']
and O
power O
among O
42 O
patients O
were O
examined O
in O
relation O
to O
the O
use O
of O
a O
guided O
imagery O
modality O
. O
['Physiological-Clinical']

Coprimary O
endpoints O
were O
MRI-assessed O
indices O
( O
total O
vessel B-outcome ['Physiological-Clinical']
area O
, O
wall B-outcome ['Physiological-Clinical']
area O
, O
wall B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
and O
normalised O
wall O
index O
[ O
average O
carotid O
] O
) O
after O
24 O
months O
and O
( O
18 O
) O
F-fluorodeoxyglucose O
( O
( O
18 O
) O
F-FDG O
) O
PET/CT O
assessment O
of O
arterial O
inflammation O
within O
an O
index O
vessel O
( O
right O
carotid O
, O
left O
carotid O
, O
or O
ascending O
thoracic O
aorta O
) O
after O
6 O
months O
, O
with O
no-harm O
boundaries O
established O
before O
unblinding O
of O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MPH-ER O
was O
well O
tolerated B-outcome ['Life-Impact']
. O
Conclusion: O
Fluvoxamine O
combined O
with O
MPH-ER O
is O
effective O
in O
the O
treatment O
of O
refractory O
obsessive-compulsive O
disorder. O
[['Life-Impact']]

Kallikrein O
inactivator O
units O
( O
KIU O
) O
on O
three O
occasions O
in O
the O
course O
of O
an O
OLT O
, O
whereas O
10 O
other O
patients O
were O
treated O
with O
continuous O
aprotinin O
infusion O
of O
0.1-0.4 O
Mill O
. O
[]

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
10 O
and O
11.9 O
months O
for O
CP O
and O
cisplatin O
, O
respectively O
( O
non-significant O
) O
. O
['Mortality']

All O
patients O
completed O
the O
program O
. O
[]

Compared O
with O
placebo O
, O
desmopressin O
resulted O
in O
a O
significant O
reduction O
in O
the O
mean O
number O
of O
nocturnal B-outcome ['Physiological-Clinical']
voids I-outcome ['Physiological-Clinical']
( O
39 O
% O
reduction O
with O
desmopressin O
vs. O
15 O
% O
with O
placebo O
; O
absolute O
difference O
-0.84 O
, O
p O
< O
0.0001 O
) O
and O
duration O
of O
the O
first B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
( O
prolonged O
by O
108 O
min O
with O
desmopressin O
vs. O
41 O
min O
with O
placebo O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Various O
ultrasonic O
scalers O
, O
hand O
instruments O
and O
two O
power-driven O
systems O
were O
compared O
by O
assessing O
the O
loss O
of O
tooth B-outcome ['Physiological-Clinical']
substance I-outcome ['Physiological-Clinical']
due O
to O
root O
instrumentation O
. O
['Physiological-Clinical']

Therefore, O
28 O
patients O
were O
randomly O
selected O
from O
the O
diagnostic O
group. O
[]

The O
CRT O
group O
received O
identical O
radiotherapy O
with O
concurrent O
weekly O
cisplatin O
at O
35 O
mg/m O
( O
2 O
) O
for O
6-7 O
cycles O
. O
[]

Nasal B-outcome ['Physiological-Clinical']
eosinophilia I-outcome ['Physiological-Clinical']
and O
concentration O
of O
sICAM-1 O
in O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
were O
assessed O
before O
and O
on O
the O
last O
day O
of O
each O
treatment O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Obesity O
prevention O
campaign O
sponsorship O
promoted O
higher O
campaign O
awareness B-outcome ['Life-Impact']
and O
perceived B-outcome ['Life-Impact']
event-sponsor I-outcome ['Life-Impact']
fit I-outcome ['Life-Impact']
, O
but O
did O
not O
impact O
food O
attitudes B-outcome ['Life-Impact']
or O
preference B-outcome ['Life-Impact']
for O
unhealthy O
versus O
healthier O
foods. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

The O
main O
outcome O
was O
completion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
CRC I-outcome ['Life-Impact']
screening I-outcome ['Life-Impact']
. O
['Life-Impact']

With O
the O
present O
procedure O
, O
an O
evaluation O
with O
inclusion O
of O
all O
test O
participants O
is O
possible O
. O
[]

METHODS O
After O
fulfilling O
the O
selection O
criteria O
, O
84 O
patients O
were O
randomly O
allocated O
to O
the O
stapled O
( O
n O
= O
42 O
) O
or O
open O
group O
( O
n O
= O
42 O
) O
. O
[]

11.51 O
, O
final O
18.81 O
? O
[]

After O
brushing O
with O
the O
assigned O
toothbrush O
and O
a O
commercially O
available O
dentifrice O
for O
2 O
minutes O
, O
oral O
tissues O
were O
then O
re-examined O
and O
post-brushing O
plaque O
scores O
recorded O
. O
[]

The O
quality O
of O
these O
randomized O
controlled O
trials O
was O
scored O
. O
[]

In O
addition O
, O
concomitant O
treatment O
was O
given O
to O
dogs O
presenting O
with O
pulmonary O
oedema O
and/or O
ascites O
, O
supraventricular O
tachyarrhythmia O
and/or O
dilated O
cardiomyopathy O
. O
[]

Individuals O
whose O
BP B-outcome ['Physiological-Clinical']
was O
controlled O
continued O
on O
the O
protocol O
for O
six O
months O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
, O
sustained B-outcome ['Physiological-Clinical']
virologic I-outcome ['Physiological-Clinical']
response O
( O
SVR O
) O
, O
was O
defined O
as O
a O
reduction O
in O
hepatitis B-outcome ['Physiological-Clinical']
B B-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
deoxyribonucleic I-outcome ['Physiological-Clinical']
acid B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HBV I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
> O
or=2 O
log10 O
copies/mL O
and O
HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
< O
20,000 O
copies/mL O
at O
24 O
wk O
of O
follow-up O
( O
week O
84 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHOD O
Thirty-four O
children O
and O
adolescents O
with O
ASD O
( O
age O
range O
8-17 O
years O
; O
IQ O
> O
75 O
) O
were O
enrolled O
in O
a O
10-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
donepezil O
( O
doses O
of O
5 O
and O
10 O
mg O
) O
, O
followed O
by O
a O
10-week O
open O
label O
trial O
for O
placebo O
nonresponders O
. O
[]

Each O
subject O
was O
studied O
twice O
: O
during O
a O
weight O
maintenance O
diet O
and O
during O
ad O
libitum O
food O
intake O
. O
[]

To O
assess O
physiologic B-outcome ['Physiological-Clinical']
effects O
, O
practitioners O
and O
subjects O
wore O
cardiorespiratory O
monitors O
to O
assess O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
( O
HRV B-outcome ['Physiological-Clinical']
) O
throughout O
the O
4 O
10-minute O
study O
periods O
: O
Baseline O
( O
both O
practitioner O
and O
subjects O
read O
neutral O
material O
) O
; O
non-tactile-LKM O
( O
subjects O
read O
while O
the O
practitioner O
practiced O
LKM O
while O
pretending O
to O
read O
) O
; O
tactile-LKM O
( O
subjects O
rested O
while O
the O
practitioner O
practiced O
LKM O
while O
lightly O
touching O
the O
subject O
on O
arms O
, O
shoulders O
, O
hands O
, O
feet O
, O
and O
legs O
) O
; O
Post-Intervention O
Rest O
( O
subjects O
rested O
; O
the O
practitioner O
read O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Within O
48 O
hours O
of O
administration O
, O
there O
was O
a O
significant O
increase O
in O
the O
circulating B-outcome ['Physiological-Clinical']
absolute I-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
( O
ANC B-outcome ['Physiological-Clinical']
) O
at O
5.0 O
micrograms/kg O
twice O
per O
day O
and O
10.0 O
micrograms/kg O
once O
per O
day O
, O
which O
continued O
for O
at O
least O
24 O
hours O
after O
discontinuation O
of O
rhuGM-CSF O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
effects O
were O
found O
for O
sprint B-outcome ['Physiological-Clinical']
variables O
(P O
> O
0.05) O
with O
comparable O
values O
at O
T3 O
for O
mean O
distance B-outcome ['Physiological-Clinical']
(betaA1: O
163.9 O
+/- O
3.8 O
m; O
betaA2: O
161.2 O
+/- O
3.5 O
m; O
PL: O
162.7 O
+/- O
3.6 O
m), O
average O
power B-outcome ['Physiological-Clinical']
(betaA1: O
352.7 O
+/- O
14.5 O
W; O
betaA2: O
342.2 O
+/- O
13.5 O
W; O
PL: O
348.2 O
+/- O
13.9 O
W) O
and O
lactate B-outcome ['Physiological-Clinical']
(betaA1: O
10.0 O
+/- O
0.9 O
mmol. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Analyses O
of O
covariance O
showed O
that O
likely O
confounding O
variables O
including O
recent O
exposure O
to O
ecstasy O
, O
psychosocial O
profiles O
and O
use O
of O
other O
drugs O
did O
not O
explain O
the O
differences O
found O
between O
the O
groups O
. O
[]

and O
increasing O
to O
30 O
mg/week O
i.m O
. O
[]

Unconsciousness B-outcome ['Physiological-Clinical']
was O
associated O
with O
reductions O
in O
ASSR B-outcome ['Physiological-Clinical']
( O
0.10 O
+/- O
0.08 O
microV O
[ O
awake O
baseline O
0.32 O
+/- O
0.18 O
microV O
] O
, O
P O
< O
0.001 O
) O
and O
BIS B-outcome ['Physiological-Clinical']
( O
55.7 O
+/- O
8.8 O
[ O
awake O
baseline O
92.4 O
+/- O
3.9 O
] O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
compared O
live O
ratings O
with O
ratings O
of O
videotapes O
and O
compared O
response O
to O
clomipramine O
with O
response O
to O
haloperidol O
in O
8 O
subjects O
, O
mean O
age O
5.62 O
years O
, O
who O
met O
criteria O
for O
autism O
. O
[]

Nineteen O
participants O
received O
gelcaps O
with O
an O
algal O
extract O
in O
safflower O
oil O
, O
containing O
2 O
mg O
of O
astaxanthin O
each O
( O
treatment O
) O
; O
16 O
participants O
received O
gelcaps O
containing O
safflower O
oil O
only O
( O
placebo O
) O
. O
[]

Divergence O
in O
student O
and O
educator O
conceptual O
structures O
during O
auscultation O
training O
. O
[]

1 O
, O
we O
obtained O
small O
intestine O
from O
28-d-old O
pigs O
weaned O
at O
21 O
d O
of O
age O
and O
from O
age-matched O
suckling O
piglets O
. O
[]

After O
4 O
days O
of O
treatment O
platelet B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
was O
similarly O
inhibited O
by O
all O
combinations O
. O
['Physiological-Clinical']

Journal-Name:Journal O
of O
cancer O
research O
and O
therapeutics O
[]

MAIN O
OUTCOME O
MEASURE O
Clinical B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
condylomata I-outcome ['Physiological-Clinical']
for O
six O
months O
following O
adjuvant B-outcome ['Resource-use']
chemotherapy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

METHOD: O
a O
randomized O
controlled O
trial, O
with O
102 O
patients O
in O
the O
preoperative O
period, O
randomized O
in O
a O
control O
group, O
with O
usual O
care, O
and O
an O
experimental O
group, O
which O
received O
menthol O
gum, O
which O
was O
the O
study O
treatment O
variable. O
[]

This O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
smoking B-outcome ['Life-Impact']
on O
gastric O
emptying O
of O
solids O
in O
Japanese O
smokers O
. O
['Life-Impact']

The O
A-V O
Impulse O
System O
appears O
to O
be O
a O
safe O
and O
effective O
method O
of O
reducing O
the O
incidence O
of O
proximal B-outcome ['Physiological-Clinical']
deep-vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
, O
and O
of O
postoperative B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
performed O
with O
100 O
low-risk O
patients O
having O
well-dated O
pregnancies O
. O
[]

ZH O
, O
P O
= O
0.011 O
) O
. O
[]

No O
significant O
changes O
were O
observed O
in O
carotid B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
or O
carotid-femoral B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
following O
ST B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
ST+aerobic I-outcome ['Physiological-Clinical']
exercise B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
the O
2nd O
group O
35 O
patients O
were O
given O
a O
daily O
dose O
of O
TAM O
of O
20 O
mg/m2 O
for O
15 O
days O
and O
then O
an O
oral O
daily O
dose O
of O
medroxyprogesterone O
acetate O
of O
350 O
mg/m2 O
for O
the O
next O
15 O
days O
. O
[]

The O
carotenoid O
zeaxanthin O
is O
concentrated O
within O
the O
macula O
. O
[]

The O
median O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
granulocytes I-outcome ['Physiological-Clinical']
less O
than O
500/cu O
mm O
also O
favored O
the O
lithium O
group O
but O
only O
approached O
statistical O
significance O
: O
14.0 O
days O
versus O
20.5 O
days O
, O
p O
= O
0.054 O
. O
['Physiological-Clinical']

DISCUSSION O
This O
trial O
will O
identify O
whether O
home-based O
pulmonary O
rehabilitation O
can O
deliver O
equivalent O
benefits O
to O
centre-based O
pulmonary O
rehabilitation O
in O
a O
cost O
effective O
manner O
. O
[]

However O
, O
intraoperative B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
were O
not O
significantly O
different O
( O
Student O
t-test O
) O
. O
['Physiological-Clinical', 'Resource-use']

Assessments O
were O
conducted O
at O
pretreatment O
, O
posttreatment O
, O
and O
three-week O
follow-up O
. O
[]

At O
the O
end O
of O
each O
study O
week O
, O
the O
authors O
assessed O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( O
myocardial B-outcome ['Physiological-Clinical']
relaxation I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
[ O
E O
' O
] O
using O
tissue O
Doppler O
imaging O
) O
and O
RBF B-outcome ['Physiological-Clinical']
( O
para-aminohippurate O
clearance O
) O
at O
baseline O
and O
after O
infusion O
of O
Ang O
II O
( O
3 O
ng/kg/min O
x O
45 O
min O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
will O
be O
assessed O
at O
baseline O
, O
and O
then O
electronically O
randomized O
and O
allocated O
to O
group O
by O
minimization O
, O
based O
on O
the O
time O
post-stroke O
and O
extent O
of O
upper-limb O
impairment O
. O
[]

RESULTS O
Interaction O
between O
HFLCS O
and O
bracket O
type O
was O
not O
statistically O
significant O
( O
P O
= O
0.15 O
) O
. O
[]

The O
corresponding O
risk-group O
pattern O
for O
the O
inadequately O
treated O
hypertensives O
( O
n O
= O
737 O
) O
was O
5.5 O
, O
48.3 O
, O
11.1 O
and O
35.2 O
% O
, O
respectively O
. O
[]

Twelve O
student O
actors O
( O
6 O
males O
, O
6 O
females O
) O
were O
given O
voice O
training O
for O
two O
months O
. O
[]

4 O
) O
Lumbar O
spine O
radiography O
is O
not O
cost-effective O
compared O
with O
usual O
care O
without O
lumbar O
spine O
radiography O
. O
[]

Every O
patient O
evaluated O
the O
information O
received O
at O
the O
end O
of O
the O
preoperative O
visit O
and O
in O
the O
postoperative O
period O
. O
[]

A O
battery O
of O
five O
randomly O
sequenced O
tests O
was O
performed O
for O
each O
subject O
on O
one O
ankle O
. O
[]

Preoperative O
administration O
of O
celecoxib O
exhibits O
better O
efficacy O
and O
equal O
safety O
profiles O
compared O
to O
postoperative O
administration O
of O
celecoxib O
in O
knee O
OA O
patients O
undergoing O
TKA. O
[]

After O
rare O
non-targets O
N1 B-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
Fz I-outcome ['Physiological-Clinical']
decreased O
but O
P3 B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

A O
multicenter O
, O
randomized O
comparison O
of O
levonorgestrel/ethinyl O
estradiol O
( O
100 O
micrograms/20 O
micrograms O
) O
and O
norethindrone/ethinyl O
estradiol O
( O
1000 O
micrograms/20 O
micrograms O
) O
. O
[]

METHODS O
Subjects O
were O
healthy O
volunteers O
who O
were O
told O
the O
study O
was O
evaluating O
the O
effect O
of O
time O
and O
touch O
on O
the O
autonomic O
nervous O
system O
. O
[]

No O
significant O
differences O
were O
detected O
between O
the O
two O
treatment O
groups O
in O
time O
to O
progression B-outcome ['Physiological-Clinical']
, O
objective O
response O
rates O
, O
duration O
of O
response B-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
in O
either O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

Treatment O
was O
repeated O
every O
21 O
days O
in O
both O
arms O
. O
[]

The O
primary O
end O
point O
was O
bypass B-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
, O
and O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
were O
the O
secondary O
endpoints O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

After O
the O
self-affirmation O
manipulation O
was O
administered, O
we O
tracked O
participants' O
eye B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
while O
they O
viewed O
images O
of O
six O
moderately-severe O
and O
six O
highly-severe O
pictorial O
health O
warning O
labels O
presented O
on O
large O
beer O
cans. O
[['Physiological-Clinical']]

Multivariate O
regression O
was O
used O
to O
calculate O
rates O
of O
decline O
in O
estimated O
GFR O
for O
individuals O
administered O
gemfibrozil O
or O
placebo O
, O
controlling O
for O
prospectively O
determined O
potential O
confounders O
. O
[]

By O
the O
end O
of O
the O
study O
the O
mean O
levodopa O
SR O
dosage O
was O
190 O
mg/d O
and O
the O
mean O
ropinirole O
dosage O
was O
1.45 O
mg/d O
. O
[]

Two O
readers O
evaluated O
the O
NCE O
4D O
MRA O
data O
for O
the O
diagnosis O
of O
DAVF O
and O
its O
type O
with O
consensus O
. O
[]

The O
mean O
patient O
age O
and O
mean O
duration O
and O
severity O
of O
baldness O
compared O
well O
between O
the O
two O
groups O
. O
[]

Abomasal B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
rate O
after O
injection O
of O
low-dose O
gentamicin O
was O
similar O
to O
that O
of O
control O
. O
['Physiological-Clinical']

Anthropometric O
indices O
were O
measured O
at O
baseline O
and O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

There O
was O
no O
correlation O
between O
PSA B-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

A O
randomized O
prospective O
controlled O
trial O
of O
oral O
ganciclovir O
versus O
oral O
valacyclovir O
for O
prophylaxis O
of O
cytomegalovirus B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
after O
renal O
transplantation O
. O
['Physiological-Clinical']

To O
achieve O
the O
accrual O
goal O
of O
140 O
subjects O
in O
this O
single O
institution O
study O
, O
the O
Wisconsin O
Cancer B-outcome ['Physiological-Clinical']
Reporting O
System O
( O
WCRS O
) O
, O
a O
population-based O
cancer O
registry O
, O
was O
used O
. O
['Physiological-Clinical']

Similar O
to O
the O
women O
, O
partners O
' O
symptoms B-outcome ['Life-Impact']
of O
anxiety B-outcome ['Life-Impact']
decreased O
significantly O
in O
the O
TIP-C O
and O
exercise O
groups O
, O
but O
not O
in O
the O
AC O
group O
. O
['Life-Impact', 'Life-Impact']

A O
multicentre O
study O
. O
[]

Several O
additional O
items O
measuring O
tantrum-like B-outcome ['Life-Impact']
['Life-Impact']

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(MAP), O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(HR) I-outcome ['Physiological-Clinical']
, O
peripheral B-outcome ['Physiological-Clinical']
capillary I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
SpO(2) I-outcome ['Physiological-Clinical']
, O
partial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
exhaled I-outcome ['Physiological-Clinical']
carbon I-outcome ['Physiological-Clinical']
dioxide I-outcome ['Physiological-Clinical']
P(ET)CO(2) I-outcome ['Physiological-Clinical']
and O
bispectral O
index O
(BIS) O
were O
recorded O
after O
entering O
the O
operating O
room(T(0)), O
after O
anesthesia O
induction(T(1)), O
immediately O
after O
inserting O
laryngeal O
mask O
airway O
or O
tracheal O
tube(T(2)), O
fiberbronchoscopy O
inserting(T(3)), O
at O
the O
end O
of O
the O
operation(T(4)), O
and O
at O
the O
recovery O
of O
patients' O
consciousness(T(5)). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

A O
pilot O
study O
with O
adjuvant O
hormone O
therapy O
in O
FIGO O
stage O
I O
endometrial O
carcinoma O
with O
myometrial O
invasion O
was O
carried O
out O
. O
[]

Atenolol O
was O
shown O
to O
be O
an O
effective O
anti-anginal O
agent O
when O
given O
once O
daily O
, O
and O
there O
were O
no O
major O
differences O
between O
the O
doses O
studied O
. O
[]

Safety O
and O
immunogenicity O
of O
a O
combined O
pentavalent O
diphtheria O
, O
tetanus O
, O
acellular O
pertussis O
, O
inactivated O
poliovirus O
and O
Haemophilus O
influenzae O
type O
b-tetanus O
conjugate O
vaccine O
in O
infants O
, O
compared O
with O
a O
whole O
cell O
pertussis O
pentavalent O
vaccine O
. O
[]

It O
is O
concluded O
that O
an O
addition O
of O
SH O
herbs O
to O
two O
nucleoside O
reverse O
transcriptase O
inhibitors O
has O
greater O
antiviral B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
than O
antiretrovirals O
only O
. O
['Physiological-Clinical']

Visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scores O
after O
operation O
were O
similar O
to O
those O
with O
bupivacaine O
alone O
at O
all O
but O
one O
of O
the O
recording O
times O
but O
were O
greater O
than O
those O
in O
patients O
who O
received O
bupivacaine O
and O
morphine O
at O
4 O
, O
6 O
and O
10 O
h O
after O
operation O
( O
P O
< O
0.001 O
, O
P O
< O
0.04 O
, O
P O
< O
0.02 O
) O
. O
['Physiological-Clinical']

Measurements O
were O
made O
of O
oxygen B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
( O
VO2 B-outcome ['Physiological-Clinical']
) O
, O
['Resource-use', 'Physiological-Clinical']

Local B-outcome ['Life-Impact']
contextual I-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
major O
depressive O
disorder O
. O
['Life-Impact']

RESULTS O
The O
trial O
was O
completed O
by O
71 O
% O
and O
77 O
% O
of O
the O
patients O
from O
the O
STG O
and O
the O
CG O
, O
respectively O
. O
[]

In O
contrast O
to O
previous O
understanding O
, O
mepivacaine O
produces O
significantly O
longer O
anesthesia O
and O
recovery O
times O
and O
may O
not O
be O
optimal O
for O
outpatient O
epidural O
use O
. O
[]

There O
was O
20 O
% O
attrition O
from O
Helping O
HAND O
( O
attended O
< O
4/6 O
sessions O
) O
. O
[]

The O
poster O
will O
be O
adapted O
into O
a O
sticker O
format O
on O
the O
ABHR O
bottle. O
[]

Repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
has O
shown O
promising O
results O
in O
improving B-outcome ['Life-Impact']
gait I-outcome ['Life-Impact']
, O
a O
major O
cause O
of O
disability B-outcome ['Life-Impact']
, O
and O
may O
provide O
a O
therapeutic O
alternative O
. O
['Life-Impact', 'Life-Impact']

This O
study O
evaluated O
the O
immunogenicity B-outcome ['Physiological-Clinical']
and O
reactogenicity B-outcome ['Physiological-Clinical']
of O
a O
group O
C O
meningococcal O
conjugate O
vaccine O
( O
MenC O
) O
compared O
with O
a O
group O
A+C O
meningococcal O
polysaccharide O
vaccine O
( O
MenPS O
) O
in O
healthy O
adolescents O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
this O
prospective O
, O
controlled O
trial O
, O
121 O
gastric O
cancer O
patients O
attending O
inpatient O
rehabilitation O
after O
surgical O
treatment O
received O
either O
the O
interactive O
intervention O
or O
lectures O
providing O
information O
. O
[]

RESULTS O
The O
most O
common O
symptoms O
identified O
by O
parents O
were O
tantrums B-outcome ['Life-Impact']
, O
aggression B-outcome ['Life-Impact']
, O
and O
hyperactivity B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS/DESIGN O
Phase O
III O
comprises O
a O
pragmatic O
, O
fast-track O
, O
single-blind O
randomised O
controlled O
trial O
of O
BIS O
versus O
standard O
care O
. O
[]

Samples O
were O
stable O
during O
storage O
at O
4 O
degrees O
C O
for O
15 O
days O
and O
during O
2 O
freeze-thaw O
cycles. O
[]

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
decreased O
and O
mean O
pulmonary B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
increased O
significantly O
only O
in O
the O
pH-uncorrected O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
onset O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
12 O
min O
for O
both O
drugs O
and O
median O
duration O
was O
49 O
( O
range O
3-129 O
) O
min O
and O
51 O
( O
7-157 O
) O
min O
for O
S O
( O
- O
) O
-bupivacaine O
and O
RS O
bupivacaine O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
in O
the O
PlasmaKinetic O
and O
TURP O
groups O
were O
catheterized O
a O
mean O
of O
2.3 O
+/- O
0.7 O
( O
range O
2 O
to O
4 O
) O
and O
3.8 O
+/- O
0.7 O
days O
( O
range O
3 O
to O
5 O
) O
, O
respectively O
( O
p O
< O
0.05 O
) O
. O
[]

These O
data O
suggest O
a O
potential O
synergism O
of O
these O
two O
drugs O
. O
[]

OBJECTIVES O
Ponezumab O
is O
a O
humanized O
antiamyloid O
beta O
( O
A? O
) O
monoclonal O
antibody O
designed O
to O
treat O
Alzheimer O
disease O
( O
AD O
) O
. O
[]

Risperidone O
in O
children O
with O
autism O
and O
serious O
behavioral O
problems O
. O
[]

SUBJECTS O
Eight O
male O
volunteers O
with O
allergic O
asthma O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

SETTING O
Six O
general O
practices O
in O
the O
South O
Thames O
region O
. O
[]

Investigator-assessed O
shoulder B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
in O
both O
groups O
but O
more O
so O
in O
the O
oxaprozin O
group O
( O
p O
= O
0.028 O
at O
day O
15 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVES O
Sarpogrelate O
has O
been O
shown O
to O
reduce O
albuminuria O
in O
diabetic O
nephropathy O
. O
[]

CHEOP O
scores O
did O
not O
differ O
between O
the O
groups O
at O
any O
time O
. O
[]

Five O
patients O
complained O
of O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
site I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Journal-Name:Revista O
de O
la O
Facultad O
de O
Ciencias O
Medicas O
(Cordoba, O
Argentina) O
[]

Two O
days O
later O
, O
the O
intervention O
arms O
were O
crossed O
over O
. O
[]

METHODS O
Thirty-seven O
patients O
with O
at O
least O
one O
newly O
developed O
DLE O
lesion O
were O
randomized O
- O
19 O
to O
the O
R-salbutamol O
cream O
0.5 O
% O
and O
18 O
to O
placebo O
- O
and O
treated O
twice O
daily O
for O
8 O
weeks O
. O
[]

Incidence O
of O
scoring O
scars O
and O
tissue O
orientation O
loss O
were O
the O
primary O
outcome O
measures O
. O
[]

This O
suggests O
that O
autistic O
patients O
had O
significantly O
greater O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
sumatriptan O
than O
normal O
controls O
, O
independent O
of O
placebo O
effects O
. O
['Physiological-Clinical']

Analgesic B-outcome ['Resource-use']
efficacy O
of O
piroxicam O
in O
the O
treatment O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

MEASUREMENTS O
AND O
RESULTS O
Registration O
included O
hemodynamic O
data O
from O
the O
peripheral O
artery O
and O
the O
pulmonary O
artery O
, O
and O
the O
measurement O
of O
cardiac B-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
I I-outcome ['Physiological-Clinical']
( O
CTnI B-outcome ['Physiological-Clinical']
) O
and O
creatine B-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
isoenzyme I-outcome ['Physiological-Clinical']
MB I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CK-MB O
) O
values O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
responses O
to O
acute O
exercise O
were O
more O
pronounced O
than O
responses O
to O
accumulated O
training O
, O
suggesting O
that O
STARS O
signalling O
is O
primarily O
involved O
in O
the O
initial O
phase O
of O
exercise-induced O
muscle O
adaptations O
. O
[]

The O
atrial B-outcome ['Physiological-Clinical']
flutter I-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
was O
prolonged O
significantly O
less O
( O
p O
< O
0.001 O
) O
, O
and O
the O
atrial O
monophasic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
increased O
significantly O
more O
( O
p O
< O
0.001 O
) O
by O
ibutilide O
than O
by O
procainamide O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ibuprofen O
provided O
greater O
temperature B-outcome ['Physiological-Clinical']
decrement I-outcome ['Physiological-Clinical']
and O
longer O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
antipyresis I-outcome ['Resource-use']
than O
acetaminophen O
when O
the O
two O
drugs O
were O
administered O
in O
approximately O
equal O
doses O
. O
['Physiological-Clinical', 'Resource-use']

For O
11 O
implants O
( O
11 O
percent O
) O
in O
10 O
women O
, O
the O
authors O
observed O
progression O
of O
silicone B-outcome ['Physiological-Clinical']
seepage I-outcome ['Physiological-Clinical']
, O
either O
as O
a O
conversion O
from O
intracapsular O
into O
extracapsular O
rupture O
( O
n O
= O
7 O
) O
, O
as O
progression O
of O
extra-capsular O
silicone O
( O
n O
= O
3 O
) O
, O
or O
as O
increasing O
herniation O
of O
the O
silicone O
within O
the O
fibrous O
capsule O
( O
n O
= O
1 O
) O
; O
however O
, O
in O
most O
cases O
, O
these O
changes O
were O
minor O
. O
['Physiological-Clinical']

Patients O
with O
an O
objective O
response O
to O
chemotherapy O
on O
either O
treatment O
arm O
survived B-outcome ['Mortality']
twice O
as O
long O
as O
the O
nonresponders O
. O
['Mortality']

Superior O
efficacy O
of O
clopidogrel O
plus O
acetylsalicylic O
acid O
compared O
with O
extended-release O
dipyridamole O
plus O
acetylsalicylic O
acid O
in O
preventing O
arterial O
thrombogenesis O
in O
healthy O
volunteers O
. O
[]

SETTING O
The O
sleep-disorders O
unit O
of O
a O
tertiary O
referral O
university O
hospital O
. O
[]

The O
use O
of O
the O
transition O
zone O
volume O
for O
this O
correction O
results O
in O
a O
higher O
discriminatory O
potential O
when O
compared O
to O
the O
use O
of O
the O
total O
prostate O
volume O
; O
however O
, O
the O
observed O
difference O
was O
not O
statistically O
significant O
. O
[]

In O
total O
, O
338 O
patients O
aged O
18-76 O
who O
had O
a O
previous O
episode O
of O
otitis O
externa O
within O
the O
last O
year O
were O
randomized O
to O
receive O
10 O
+/- O
2 O
days O
of O
treatment O
with O
two O
drops O
, O
three O
times O
daily O
, O
of O
either O
PN+Dx O
or O
PN-Dx O
. O
[]

Survival O
analyses O
were O
performed O
via O
the O
Kaplan-Meier O
method. O
[]

The O
75 O
patients O
were O
randomly O
assigned O
to O
1 O
of O
3 O
groups O
: O
group O
exercise O
class O
, O
individual O
physiotherapy O
, O
and O
home O
exercises O
alone O
. O
[]

Initiation B-outcome ['Life-Impact']
['Life-Impact']

These O
results O
suggest O
that O
a O
comprehensive O
health O
care O
program O
is O
one O
way O
to O
bring O
about O
better O
outcomes O
for O
both O
adolescent O
mothers O
and O
their O
infants O
. O
[]

No O
differences O
in O
power O
emerged O
. O
[]

RESULTS O
Before O
debriefing O
, O
83.9 O
% O
of O
participants O
chose O
public O
data O
release O
. O
[]

Ethanol-induced O
alterations O
in O
electroencephalographic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
adult O
males O
. O
['Physiological-Clinical']

DESIGN O
A O
prospective O
, O
randomised O
study O
. O
[]

This O
study O
demonstrated O
the O
favorable O
risk O
: O
benefit O
ratio O
of O
zoledronic O
acid O
for O
the O
prevention O
of O
skeletal O
complications O
. O
[]

The O
presence O
of O
group-B O
streptococci O
in O
the O
urine O
of O
pregnant O
women O
seems O
to O
be O
associated O
with O
preterm O
labour O
. O
[]

A O
total O
of O
136 O
patients O
with O
FS O
were O
recruited O
and O
then O
were O
equally O
randomly O
allocated O
into O
a O
treatment O
group O
(n O
= O
68) O
and O
a O
sham O
group O
(n O
= O
68). O
[]

Effect O
of O
protein O
ingestion O
on O
the O
glucose B-outcome ['Physiological-Clinical']
appearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
people O
with O
type O
2 O
diabetes O
. O
['Physiological-Clinical']

We O
compared O
the O
incidence O
of O
RAO O
with O
2 O
heparin O
dosage O
regimens O
after O
transradial O
coronary O
angiography O
, O
and O
we O
evaluated O
the O
efficacy O
and O
safety O
of O
transient O
homolateral O
ulnar O
artery O
compression O
to O
achieve O
acute O
radial O
artery O
recanalization O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
assess O
stability O
of O
fixation O
and O
analyze O
modes O
of O
failure O
in O
unstable O
trochanteric O
hip O
fractures O
treated O
with O
these O
devices O
. O
[]

h(- O
1) O
followed O
by O
a O
maintenance O
dose O
with O
continuous O
infusion O
of O
3 O
mg.kg(- O
1). O
[]

After O
intravenous O
adrenaline O
there O
was O
a O
good O
clinical B-outcome ['Physiological-Clinical']
and O
biochemical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
but O
after O
endotracheal O
adrenaline O
there O
was O
no O
change O
in O
serum B-outcome ['Physiological-Clinical']
adrenaline I-outcome ['Physiological-Clinical']
and O
no O
measurable O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Parameters O
discriminating O
the O
development O
of O
ESUL B-outcome ['Physiological-Clinical']
in O
a O
specific O
patient O
were O
type O
of O
AF B-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
delivered I-outcome ['Physiological-Clinical']
, O
usage O
of O
a O
nasogastric O
tube O
, O
and O
additional O
left O
atrial O
lines O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Either O
fenoterol O
( O
5 O
mg O
) O
or O
a O
placebo O
was O
given O
orally O
2 O
h O
before O
loading O
in O
a O
randomized O
double-blind O
crossover O
protocol O
. O
[]

In O
pigs O
without O
passively O
acquired O
antibody O
, O
intranasal O
inoculation O
with O
strains O
NIA-3 O
or O
Bartha O
was O
followed O
by O
primary O
IgM B-outcome ['Physiological-Clinical']
and O
IgA B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
serum B-outcome ['Physiological-Clinical']
and O
in O
oropharyngeal B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
as O
well O
as O
primary O
IgG1 O
and O
IgG2 O
responses O
in O
serum O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
predictive O
value O
of O
gastric O
metaplasia O
in O
the O
duodenal O
mucosa O
in O
patients O
Helicobacter O
pylori-positive O
patients O
with O
duodenal O
bulb O
ulcer O
( O
DBU O
) O
was O
investigated O
. O
[]

The O
CMFCs O
were O
defined O
as O
having O
emergency B-outcome ['Resource-use']
C-section I-outcome ['Resource-use']
, O
perineal B-outcome ['Physiological-Clinical']
trauma I-outcome ['Physiological-Clinical']
, O
pregnancy-induced B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
and O
preeclampsia O
, O
prematurity B-outcome ['Physiological-Clinical']
, O
large-for-gestational-age B-outcome ['Physiological-Clinical']
, O
and/or O
small-for-gestational-age B-outcome ['Physiological-Clinical']
. O
A O
total O
of O
874 O
women O
were O
stratified O
into O
three O
groups O
according O
to O
late O
first-trimester O
compliance O
with O
six O
food O
targets: O
>12 O
servings/week O
of O
vegetables, O
>12 O
servings/week O
of O
fruits, O
<2 O
servings/week O
of O
juice, O
>3 O
servings/week O
of O
nuts, O
>6 O
days/week O
consumption O
of O
extra O
virgin O
olive O
oil O
(EVOO), O
and O
>/=40 O
mL/day O
of O
EVOO. O
[['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

This O
study O
evaluated O
whether O
333 O
seronegative O
African O
American O
female O
drug O
users O
( O
aged O
18-59 O
years O
) O
participating O
in O
an O
HIV O
intervention O
and O
with O
higher O
levels O
of O
emotional O
distress O
, O
specifically O
symptoms O
of O
depression O
and O
anxiety O
, O
reduced O
HIV O
risk O
behaviors O
to O
a O
lesser O
extent O
than O
those O
with O
lower O
levels O
of O
emotional O
distress O
. O
[]

CONCLUSION: O
Findings O
suggest O
that O
restricting O
elite O
sport O
sponsorship O
to O
healthier O
food O
brands O
that O
meet O
set O
nutritional O
criteria O
could O
help O
promote O
healthier O
eating O
among O
young O
adults. O
[]

For O
most O
youth O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
, O
employment O
upon O
graduation O
from O
high O
school O
or O
college O
is O
elusive O
. O
[]

PTK2 O
expression O
may O
be O
a O
useful O
biomarker O
for O
patient O
selection O
in O
future O
trials O
. O
[]

The O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
perindopril O
and O
its O
active O
metabolite O
perindoprilat O
and O
the O
time B-outcome ['Physiological-Clinical']
course I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
angiotensin I-outcome ['Physiological-Clinical']
converting I-outcome ['Physiological-Clinical']
enzyme I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
were O
studied O
for O
72 O
h O
following O
the O
last O
dose O
of O
treatment O
in O
the O
two O
appropriate O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Pimecrolimus O
application O
did O
not O
translate O
into O
clinically O
meaningful O
benefit O
for O
patients O
with O
cetuximab-related O
facial O
rash O
. O
[]

In O
61 O
acceptable O
patients O
, O
there O
was O
no O
significant O
difference O
in O
terms O
of O
response O
rate O
, O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
, O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

PATIENTS O
AND O
METHODS O
The O
randomized O
, O
three-arm O
trial O
recruited O
patients O
in O
stages O
IIB O
and O
IIIA O
with O
risk O
factors O
and O
stages O
IIIB O
and O
IV O
. O
[]

In O
a O
double-blind O
multicentric O
trial, O
109 O
PKU O
patients O
were O
randomized O
to O
DHA O
doses O
from O
0 O
to O
7 O
mg/kg&amp;day O
for O
six O
months. O
[]

There O
were O
no O
significant O
differences O
( O
P O
> O
.05 O
) O
between O
the O
lidocaine O
and O
mepivacaine O
solutions O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Title: O
[Nursing O
intervention O
for O
respiratory O
function O
exercise O
in O
patients O
with O
silicosis O
complicated O
by O
stable O
chronic O
obstructive O
pulmonary O
disease]. O
[]

Caries B-outcome ['Physiological-Clinical']
increments I-outcome ['Physiological-Clinical']
after O
3 O
years O
, O
in O
terms O
of O
DMF O
teeth O
and O
DMF O
surfaces O
, O
showed O
no O
significant O
differences O
between O
the O
MFP O
test O
group O
( O
444 O
children O
) O
and O
the O
MFP O
control O
group O
( O
450 O
children O
) O
. O
['Physiological-Clinical']

One O
group O
received O
a O
night O
splint O
in O
addition O
to O
eccentric O
exercises O
. O
[]

BACKGROUND: O
Research O
has O
demonstrated O
that O
low O
fermentable O
oligiosaccharide, O
disaccharide, O
monosaccharide O
and O
polyol O
(FODMAP) O
diets O
improve O
gastrointestinal O
(GI) O
symptoms O
in O
irritable O
bowel O
syndrome O
sufferers. O
[]

RESULTS O
( O
PROPOSAL O
) O
: O
At O
baseline O
, O
the O
group O
of O
patients O
showed O
normal B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
but O
impaired B-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
with O
conventional O
echocardiographic O
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS: O
The O
study O
was O
designed O
as O
a O
prospective, O
delayed-entry O
randomized O
pilot O
trial. O
[]

Following O
resistance O
exercise O
, O
4E-BP1 B-outcome ['Physiological-Clinical']
phosphorylation I-outcome ['Physiological-Clinical']
was O
reduced O
to O
a O
greater O
extent O
in O
the O
CHO O
treatment O
( O
-48 O
+/- O
7 O
% O
) O
than O
in O
the O
CHO+PRO O
treatment O
( O
-15 O
+/- O
14 O
% O
, O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
compare O
peroneal O
reaction O
to O
sudden O
inversion O
following O
ankle O
joint O
cryotherapy O
. O
[]

The O
SEM O
examination O
showed O
both O
sealers O
had O
better O
adaptation B-outcome ['Physiological-Clinical']
and O
penetration B-outcome ['Physiological-Clinical']
in O
coronal O
and O
middle O
thirds O
than O
apical O
third O
of O
root O
canal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

A O
comparative O
randomized O
trial O
. O
[]

Title: O
Vitamin O
D O
and O
probiotic O
co-supplementation O
affects O
mental B-outcome ['Physiological-Clinical', 'Life-Impact']
health I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
hormonal B-outcome ['Physiological-Clinical']
, O
inflammatory B-outcome ['Physiological-Clinical']
and O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
parameters O
in O
women O
with O
polycystic O
ovary O
syndrome. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Also O
, O
granisetron O
was O
found O
to O
be O
more O
effective O
than O
tropisetron O
, O
especially O
in O
patients O
heavier O
than O
25 O
kg O
( O
p O
= O
0.02 O
) O
. O
[]

All O
patients O
must O
have O
shortness O
of O
breath O
with O
minimal O
exertion O
or O
paroxysmal O
nocturnal O
dyspnea O
, O
a O
left O
ventricular O
internal O
dimension O
( O
LVIDd O
) O
by O
echocardiogram O
of O
> O
or O
= O
55 O
mm O
or O
a O
cardiothoracic O
ratio O
of O
> O
0.5 O
and O
an O
ejection O
fraction O
of O
< O
or O
= O
40 O
% O
. O
[]

The O
urogenital B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
sexuality I-outcome ['Physiological-Clinical']
score O
, O
along O
with O
the O
vaginal B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
index O
and O
the O
vaginal B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
index O
( O
VMI B-outcome ['Physiological-Clinical']
) O
, O
was O
calculated O
at O
the O
beginning O
of O
therapy O
and O
12 O
weeks O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
288 O
events O
in O
which O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
exceeded O
a O
predetermined O
trigger O
value O
were O
observed O
. O
['Physiological-Clinical']

The O
volume O
of O
blood O
completely O
cleared O
of O
the O
'hepatic O
pathological O
processes O
' O
which O
led O
to O
the O
hepatomegaly O
( O
CL O
( O
Bhp O
) O
) O
and O
the O
fractional O
reduction O
of O
AUC O
( O
hp O
) O
at O
48 O
and O
96 O
h O
( O
i.e O
. O
[]

Multitomographic O
evaluation O
of O
the O
dental B-outcome ['Physiological-Clinical']
effects O
of O
two O
different O
rapid O
palatal O
expansion O
appliances O
. O
['Physiological-Clinical']

OBJECTIVE: O
To O
observe O
the O
effect O
of O
Ronghuang O
granule O
on O
serum O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
23 I-outcome ['Physiological-Clinical']
(FGF23) I-outcome ['Physiological-Clinical']
, O
fibroblast B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
(FGFRs) I-outcome ['Physiological-Clinical']
and O
Klotho B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
in O
non-dialysis O
patients O
with O
chronic O
kidney O
disease-mineral O
and O
bone O
disorder O
(CKD-MBD) O
and O
kidney O
deficiency O
and O
damp O
heat O
syndrome. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Five O
subjects O
exhibited O
paroxysmal B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
patterns I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Lanthanum O
carbonate O
was O
well O
tolerated B-outcome ['Life-Impact']
; O
only O
one O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
was O
reported O
, O
which O
was O
unrelated O
to O
treatment O
. O
['Life-Impact', 'Adverse-effects']

The O
situation O
was O
then O
reversed O
for O
the O
next O
3 O
weeks O
( O
experimental O
period O
2 O
) O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
sternal O
paddle O
was O
placed O
in O
a O
longitudinal O
orientation O
for O
all O
measurements O
. O
[]

The O
percent O
of O
total O
magnesium O
that O
was O
ionized B-outcome ['Physiological-Clinical']
( O
% O
IMg2+ O
) O
was O
low O
in O
both O
the O
hemodialysis O
and O
CAPD O
patients O
( O
55.6 O
+/- O
0.93 O
and O
59.2 O
+/- O
1.05 O
) O
compared O
with O
that O
of O
control O
subjects O
( O
72 O
+/- O
0.61 O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
slightly O
( O
82 O
+/- O
17 O
to O
86 O
+/- O
14 O
beats/min O
) O
. O
['Physiological-Clinical']

Cilomilast O
( O
Ariflo O
) O
, O
a O
new O
oral O
phosphodiesterase-4 O
selective O
inhibitor O
, O
improves O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Eighty O
patients O
with O
CD20 O
( O
+ O
) O
lymphoma O
and O
resolved O
hepatitis O
B O
were O
randomly O
assigned O
to O
receive O
either O
prophylactic O
entecavir O
( O
ETV O
) O
before O
chemotherapy O
to O
3 O
months O
after O
completing O
chemotherapy O
( O
ETV O
prophylactic O
group O
, O
n O
= O
41 O
) O
or O
to O
receive O
therapeutic O
ETV O
at O
the O
time O
of O
HBV O
reactivation O
and O
hepatitis O
B O
surface O
antigen O
( O
HBsAg O
) O
reverse O
seroconversion O
since O
chemotherapy O
( O
control O
group O
, O
n O
= O
39 O
) O
. O
[]

CGM-derived B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
were O
used O
to O
predict O
episodes O
of O
SH O
over O
a O
24-h O
time O
horizon O
. O
['Physiological-Clinical']

Progression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
was O
statistically O
similar O
in O
stage O
I O
patients O
who O
were O
initially O
left O
untreated O
and O
in O
t O
hose O
who O
received O
MPH-P O
just O
after O
diagnosis O
; O
median O
duration O
of O
first O
response O
was O
similar O
in O
stage O
III O
patients O
receiving O
MPH-P O
and O
in O
those O
on O
combination O
chemotherapy O
. O
['Physiological-Clinical']

This O
effect O
was O
well O
maintained O
in O
the O
supine O
position O
. O
[]

Thus O
, O
a O
source O
of O
metal O
ion O
exposure O
with O
the O
potential O
to O
sensitize O
patients O
is O
present O
. O
[]

TPI O
group O
received O
TPIs O
with O
2 O
mL O
of O
0.2% O
ropivacaine, O
and O
EMLA O
group O
received O
an O
occlusive O
dressing O
with O
EMLA O
cream O
2 O
g O
on O
both O
shoulders. O
[]

Agreement O
between O
the O
home O
and O
laboratory O
study O
recordings O
was O
also O
assessed O
using O
receiver O
operating O
characteristic O
( O
ROC O
) O
curves O
and O
Bland-Altman O
analysis O
. O
[]

METHOD O
Thirty-six O
children O
with O
an O
autism O
spectrum O
disorder O
( O
5-17 O
years O
old O
) O
accompanied O
by O
severe O
tantrums O
, O
aggression O
, O
or O
self-injurious O
behavior O
, O
started O
8-week O
open-label O
treatment O
with O
risperidone O
. O
[]

The O
onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
rapacuronium O
was O
shorter O
than O
rocuronium O
( O
87 O
( O
20 O
) O
vs O
141 O
( O
65 O
) O
s O
, O
P O
< O
0.001 O
) O
, O
and O
the O
degree O
of O
block O
at O
60 O
s O
was O
greater O
( O
69 O
( O
26 O
) O
vs O
50 O
( O
27 O
) O
% O
, O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Forty-four O
children O
, O
ages O
8-11 O
years O
, O
were O
randomly O
assigned O
to O
treatment O
or O
wait O
list O
. O
[]

The O
degree O
to O
which O
individuals O
change O
their O
lifestyle B-outcome ['Life-Impact', 'Life-Impact']
in O
response O
to O
interventions O
differs O
and O
this O
variation O
could O
affect O
cardiometabolic B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
. O
We O
examined O
if O
changes O
in O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
weight B-outcome ['Physiological-Clinical']
of O
obese O
infertile O
women O
during O
the O
first O
six O
months O
of O
the O
LIFEstyle O
trial O
were O
associated O
with O
cardiometabolic B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
3(-)8 O
years O
later O
(N O
= O
50(-)78). O
[['Life-Impact', 'Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
tolerability B-outcome ['Life-Impact']
of O
the O
tested O
substances O
was O
good O
. O
['Life-Impact']

Data O
were O
expressed O
as O
mean O
+/- O
SD O
, O
with O
P O
< O
0.05 O
being O
considered O
significant O
. O
[]

Fifty-nine O
earthquake O
survivors O
in O
Turkey O
were O
randomized O
into O
either O
single-session O
modified O
behavioral O
treatment O
( O
SSBT O
) O
designed O
to O
enhance O
sense O
of O
control O
over O
earthquake-related B-outcome ['Life-Impact']
fears I-outcome ['Life-Impact']
or O
waiting O
list O
control O
condition O
( O
WL O
) O
. O
['Life-Impact']

Diagnosis O
was O
confirmed O
by O
ADI-R O
( O
Autism O
Diagnostic O
Interview-Revised O
) O
algorithm O
. O
[]

[ O
Long O
term O
observation O
in O
effects O
of O
potassium O
and O
calcium O
supplementation O
on O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
sodium B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
higher O
blood O
pressure O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
collected O
baseline O
data O
on O
DUB O
symptoms O
and O
aspects O
of O
the O
financial O
and O
quality-of-life O
burden O
for O
237 O
women O
agreeing O
to O
surgery O
for O
DUB O
in O
a O
randomized O
trial O
comparing O
hysterectomy O
with O
endometrial O
ablation O
. O
[]

The O
OSTAP O
group O
showed O
a O
statistically O
significant O
reduction O
at O
the O
postoperative O
24th O
hour O
tramadol B-outcome ['Resource-use']
consumption O
(mean O
difference O
22 O
mg, O
95% O
confidence O
interval O
-38.4 O
to O
-5.6 O
mL; O
P O
= O
.009). O
[['Resource-use']]

In O
our O
opinion O
, O
PKRP O
makes O
a O
promising O
treatment O
for O
BPH O
with O
its O
advantages O
, O
such O
as O
early O
removal O
of O
postoperative O
urethral O
catheter O
, O
a O
shorter O
hospital O
stay O
and O
the O
absence O
of O
TUR O
syndrome O
risk O
. O
[]

They O
were O
randomly O
allocated O
into O
two O
groups: O
PAR-G O
(BiPAP O
in O
PAR O
for O
one O
hour), O
and O
1PO-G O
(BIPAP O
for O
one O
hour O
on O
the O
1PO). O
[]

BACKGROUND O
In O
a O
large O
cluster O
randomized O
control O
trial O
of O
insecticide-treated O
bed O
nets O
( O
ITN O
) O
in O
Western O
Myanmar O
the O
malaria O
protective B-outcome ['Physiological-Clinical']
effect O
of O
ITN O
was O
found O
to O
be O
highly O
variable O
and O
, O
in O
aggregate O
, O
the O
effect O
was O
not O
statistically O
significant O
. O
['Physiological-Clinical']

Olmesartan O
did O
not O
reduce O
mean O
SeDBP B-outcome ['Physiological-Clinical']
significantly O
compared O
with O
valsartan O
, O
although O
more O
patients O
attained O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
goal O
with O
olmesartan O
( O
P=.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Improving O
the O
transition O
from O
residential O
to O
outpatient O
addiction O
treatment O
: O
gender O
differences O
in O
response O
to O
supportive O
telephone O
calls O
. O
[]

Bilastine O
was O
characterized O
by O
two-compartmental O
kinetics O
with O
a O
rapid-absorption O
phase O
( O
first-order O
absorption O
rate O
constant O
= O
1.50 O
h O
( O
-1 O
) O
) O
, O
plasma B-outcome ['Physiological-Clinical']
peak O
concentrations B-outcome ['Physiological-Clinical']
were O
observed O
at O
1 O
hour O
following O
administration O
and O
the O
maximal O
response O
was O
observed O
at O
approximately O
4 O
hours O
or O
later O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Additionally, O
30 O
healthy O
people O
were O
selected O
as O
control O
group O
(NC O
group). O
[]

II O
: O
parents O
are O
unable O
to O
distinguish O
secretin O
from O
placebo O
under O
double-blind O
conditions O
. O
[]

Therefore O
, O
the O
potentiating O
effect O
of O
sevoflurane O
seems O
to O
be O
mainly O
of O
PD O
origin O
, O
probably O
due O
to O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
junction O
. O
[]

BACKGROUND O
The O
efficacy O
, O
safety O
and O
tolerability O
of O
lumiracoxib O
, O
a O
novel O
selective O
cyclooxygenase-2 O
( O
COX-2 O
) O
inhibitor O
, O
has O
been O
demonstrated O
in O
previous O
studies O
of O
patients O
with O
osteoarthritis O
( O
OA O
) O
. O
[]

Effect O
of O
diuresis O
on O
extracorporeal O
shockwave O
lithotripsy O
treatment O
of O
ureteric O
calculi O
. O
[]

METHODS O
Some O
280 O
men O
with O
a O
primary O
hernia O
were O
randomized O
prospectively O
to O
undergo O
Shouldice O
, O
tension-free O
Lichtenstein O
or O
laparoscopic O
TAPP O
repair O
. O
[]

CONCLUSIONS O
- O
RECOMMENDATIONS O
FOR O
FURTHER O
RESEARCH O
: O
Further O
work O
is O
required O
to O
develop O
and O
test O
an O
educational O
package O
that O
educates O
patients O
and O
GPs O
about O
the O
utility O
of O
radiography O
and O
provides O
strategies O
for O
identifying O
and O
meeting O
the O
information O
needs O
of O
patients O
, O
and O
the O
needs O
of O
patients O
and O
GPs O
to O
be O
reassured O
about O
missing O
serious O
disease O
. O
[]

Clinical O
periodontal O
measurements O
and O
data O
regarding O
patients O
' O
oral B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
( O
perceived B-outcome ['Physiological-Clinical']
impacts I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
gums I-outcome ['Physiological-Clinical']
, O
gingival B-outcome ['Physiological-Clinical']
recession I-outcome ['Physiological-Clinical']
, O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
, O
packing B-outcome ['Life-Impact']
foods I-outcome ['Life-Impact']
, O
aesthetics B-outcome ['Life-Impact']
, O
bad B-outcome ['Physiological-Clinical']
breath I-outcome ['Physiological-Clinical']
, O
and O
tooth B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
) O
were O
collected O
at O
baseline O
and O
3 O
months O
after O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

American O
College O
of O
Cardiology/European O
Society O
of O
Cardiology O
International O
Study O
of O
Angiographic O
Data O
Compression O
Phase O
I O
: O
The O
effect O
of O
lossy O
data O
compression O
on O
recognition O
of O
diagnostic O
features O
in O
digital O
coronary O
angiography O
. O
[]

Body B-outcome ['Physiological-Clinical']
weight O
loss B-outcome ['Physiological-Clinical']
was O
also O
significantly O
higher O
( O
2.5 O
+/- O
1.6 O
vs. O
0.2 O
+/- O
1.3 O
kg O
, O
p O
< O
0.01 O
) O
during O
the O
torasemide O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
CPB O
in O
both O
groups O
greatly O
increased O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
factor O
alpha B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TNF-alpha I-outcome ['Physiological-Clinical']
) O
, O
interleukin B-outcome ['Physiological-Clinical']
( O
IL B-outcome ['Physiological-Clinical']
) O
-1beta O
, O
IL-1beta B-outcome ['Physiological-Clinical']
receptor B-outcome ['Physiological-Clinical']
antagonist B-outcome ['Physiological-Clinical']
, O
IL-6 B-outcome ['Physiological-Clinical']
, O
IL-10 B-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
probrain I-outcome ['Physiological-Clinical']
natriuretic B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
( O
NT-proBNP B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

For O
the O
management O
of O
CLBP O
, O
trunk O
exercise O
in O
combination O
with O
SMT O
or O
NSAID O
therapy O
seemed O
to O
be O
beneficial O
and O
worthwhile O
. O
[]

In O
the O
second O
group O
, O
custom-fit O
MRI-based O
pin O
guides O
were O
used O
. O
[]

One O
hundred O
and O
twenty O
untreated O
patients O
with O
stage O
III/IV O
bladder O
cancer O
were O
randomized O
to O
receive O
either O
gemcitabine O
( O
250 O
mg/m O
( O
2 O
) O
) O
6-h O
infusion O
on O
days O
1 O
and O
8 O
, O
and O
cisplatin O
( O
70 O
mg/m O
( O
2 O
) O
) O
on O
day O
2 O
every O
21-day O
cycle O
( O
arm O
1 O
) O
or O
gemcitabine O
( O
1,250 O
mg/m O
( O
2 O
) O
) O
30-min O
infusion O
on O
days O
1 O
and O
8 O
, O
with O
the O
same O
dose O
of O
cisplatin O
( O
arm O
2 O
) O
. O
[]

Animals O
were O
sacrificed O
and O
the O
L4-5 O
lumbar O
segment O
of O
the O
spinal O
cord O
was O
removed O
for O
determination O
of O
green O
fluorescent O
protein O
( O
GFP O
) O
expression O
. O
[]

OBJECTIVE O
To O
evaluate O
postoperative O
pain O
relief O
of O
intramuscular O
ketorolac O
, O
topical O
bupivacaine O
, O
and O
placebo O
in O
patients O
undergoing O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
. O
[]

CONCLUSION O
Each O
of O
the O
three O
therapeutic O
regimens O
was O
associated O
with O
similar O
and O
clinically O
important O
improvement O
over O
time O
that O
was O
considered O
superior O
to O
the O
expected O
natural O
history O
of O
long-standing O
CLBP O
. O
[]

Also O
, O
the O
Kaplan-Meier O
survival O
curves O
of O
these O
two O
groups O
were O
not O
significantly O
different O
by O
log-rank O
test O
( O
p=0.286 O
) O
. O
[]

METHODS O
We O
did O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
at O
76 O
centres O
in O
the O
Czech O
Republic O
, O
Germany O
, O
Hungary O
, O
India O
, O
Poland O
, O
Russia O
, O
Ukraine O
, O
Turkey O
, O
and O
the O
UK O
between O
Feb O
15 O
, O
2008 O
, O
and O
May O
14 O
, O
2010 O
. O
[]

Comparative O
in O
vitro O
dissolution O
and O
in O
vivo O
bioavailability O
of O
diflunisal/naproxen O
fixed-dose O
combination O
tablets O
and O
concomitant O
administration O
of O
diflunisal O
and O
naproxen O
in O
healthy O
adult O
subjects O
. O
[]

Thirty-four O
children O
, O
with O
autism O
spectrum O
disorders O
, O
ages O
4-14 O
years O
, O
were O
matched O
and O
randomly O
assigned O
to O
one O
of O
two O
conditions O
for O
learning B-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
novel I-outcome ['Life-Impact']
juice-making I-outcome ['Life-Impact']
task I-outcome ['Life-Impact']
and O
producing B-outcome ['Life-Impact']
two I-outcome ['Life-Impact']
novel I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
event I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Cervical B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
spasm I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

A O
paired O
analysis O
compared O
the O
effect O
of O
DE O
and O
FA O
exposures O
for O
the O
change O
from O
pre-exposure O
to O
the O
subsequent O
time O
points O
. O
[]

For O
three O
themes O
, O
the O
proportion O
of O
responses B-outcome ['Physiological-Clinical']
that O
recalled O
the O
theme O
was O
significantly O
greater O
in O
the O
narrative O
arm O
compared O
to O
the O
summary O
arm O
, O
with O
the O
differences O
ranging O
from O
20 O
% O
to O
51 O
% O
. O
['Physiological-Clinical']

All O
patients O
improved O
both O
symptomatically O
and O
by O
objective O
measures O
of O
lung O
function O
. O
[]

In O
a O
competing-risks O
analysis O
, O
those O
factors O
that O
increased O
the O
risk O
of O
arrhythmic B-outcome ['Mortality']
death I-outcome ['Mortality']
also O
increased O
the O
risk O
of O
nonarrhythmic B-outcome ['Mortality']
deaths I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Forty O
volunteers O
were O
randomized O
( O
ten O
each O
) O
to O
three O
different O
pill O
regimens O
or O
to O
nonsteroidal O
contraception O
. O
[]

Patients O
have O
intrinsic O
differences O
in O
sensitivity O
to O
sorafenib O
's O
BP-elevating O
effects O
. O
[]

UNLABELLED O
Reports O
of O
transient O
neurological O
symptoms O
with O
the O
use O
of O
subarachnoid O
lidocaine O
has O
generated O
interest O
in O
alternate O
local O
anesthetics O
of O
intermediate O
duration O
, O
such O
as O
mepivacaine O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
recorded O
and O
blood B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
measurement O
of O
plasma B-outcome ['Physiological-Clinical']
cyclic I-outcome ['Physiological-Clinical']
AMP I-outcome ['Physiological-Clinical']
, O
insulin B-outcome ['Resource-use']
, O
C-peptide B-outcome ['Physiological-Clinical']
, O
glucose B-outcome ['Physiological-Clinical']
, O
lactate B-outcome ['Physiological-Clinical']
, O
glycerol B-outcome ['Physiological-Clinical']
, O
non-esterified B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
( O
NEFA B-outcome ['Physiological-Clinical']
) O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Background: O
Acne O
vulgaris O
(acne) O
is O
the O
most O
common O
dermatologic O
disease O
seen O
in O
a O
racially, O
geographically, O
politically, O
culturally, O
and O
socioeconomically O
diverse O
Hispanic O
population. O
[]

It O
is O
concluded O
that O
tumour O
regression O
may O
be O
accompanied O
by O
scar B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
, O
which O
complicate O
the O
interpretation O
of O
post-treatment B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
, O
and O
that O
further O
regression O
of O
intrabronchial O
lesions O
may O
occur O
beyond O
3-4 O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Falls B-outcome ['Life-Impact']
were O
tracked O
for O
1 O
year O
after O
each O
participant O
's O
baseline O
assessment O
. O
['Life-Impact']

An O
idea O
that O
is O
rapidly O
gaining O
popularity O
in O
clinical O
pain O
medicine O
is O
that O
body O
ownership O
illusions O
can O
be O
used O
to O
modify O
pathological O
pain O
sensations O
and O
induce O
analgesia O
. O
[]

In O
particular O
, O
[]

The O
primary O
endpoint O
was O
first B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
after O
transurethral O
resection O
. O
['Physiological-Clinical']

There O
were O
no O
statistically O
significant O
changes O
in O
the O
control O
group. O
[]

5-HTTLPR O
may O
influence O
the O
individual O
responses O
to O
fluvoxamine O
administration O
. O
[]

CONCLUSION O
The O
results O
of O
our O
study O
demonstrate O
the O
efficacy O
of O
the O
modes O
of O
intervention O
developed O
by O
us O
and O
serve O
as O
a O
new O
training O
tool O
for O
future O
health O
care O
professionals O
with O
regard O
to O
stigma B-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
. O
['Life-Impact']

One O
group O
of O
patients O
was O
treated O
with O
implantation O
of O
a O
cardioverter-defibrillator O
; O
the O
other O
received O
class O
III O
antiarrhythmic O
drugs O
, O
primarily O
amiodarone O
at O
empirically O
determined O
doses O
. O
[]

All O
patients O
received O
tramadol O
patient-controlled O
analgesia O
for O
the O
first O
24th O
hour. O
[]

In O
the O
first O
study O
388 O
patients O
with O
suspected O
acute O
myocardial O
infarction O
were O
randomly O
allocated O
to O
treatment O
with O
propranolol O
, O
atenolol O
, O
or O
placebo O
, O
and O
when O
analysed O
on O
an O
initial O
intention O
to O
treat O
basis O
there O
was O
no O
significant O
difference O
between O
the O
three O
groups O
in O
respect O
of O
the O
mortality B-outcome ['Mortality']
at O
one O
year O
. O
['Mortality']

CONCLUSIONS O
This O
study O
indicated O
that O
flecainide O
exerted O
a O
significant O
dose-dependent O
effect O
on O
the O
prevention O
of O
symptomatic O
PAF/PAFL O
recurrence O
and O
showed O
that O
there O
was O
no O
inter-ethnic O
difference O
in O
the O
clinical O
effect O
of O
flecainide O
in O
patients O
with O
PAF/PAFL O
. O
[]

Evidence O
of O
radiographic B-outcome ['Physiological-Clinical']
benefit O
of O
treatment O
with O
infliximab O
plus O
methotrexate O
in O
rheumatoid O
arthritis O
patients O
who O
had O
no O
clinical O
improvement O
: O
a O
detailed O
subanalysis O
of O
data O
from O
the O
anti-tumor O
necrosis O
factor O
trial O
in O
rheumatoid O
arthritis O
with O
concomitant O
therapy O
study O
. O
['Physiological-Clinical']

We O
conclude O
that O
measuring O
individual O
biochemical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
can O
help O
to O
predict O
the O
bone B-outcome ['Physiological-Clinical']
effect O
of O
an O
increase O
in O
the O
circulating O
estradiol O
in O
women O
with O
ovarian O
deficiency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

INTERPRETATION O
Prophylactic O
VT O
ablation O
before O
defibrillator O
implantation O
seemed O
to O
prolong O
time O
to O
recurrence O
of O
VT O
in O
patients O
with O
stable O
VT O
, O
previous O
myocardial O
infarction O
, O
and O
reduced O
LVEF O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
placebo-controlled O
trial O
at O
eight O
centers O
to O
evaluate O
etanercept O
for O
the O
maintenance O
of O
remission O
in O
180 O
patients O
with O
Wegener O
's O
granulomatosis O
. O
[]

The O
results O
of O
the O
aspirin O
trial O
are O
reported O
here O
. O
[]

[ O
Potentials O
of O
monocular O
augmented O
reality O
technology O
in O
automobile O
production O
] O
. O
[]

Changes O
in O
metabolic B-outcome ['Physiological-Clinical']
variables O
did O
not O
differ O
between O
the O
groups O
, O
except O
for O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
that O
increased O
in O
the O
3M O
group O
but O
not O
in O
3+3M O
group O
( O
P O
< O
0.033 O
for O
group O
difference O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

An O
inferomedial O
injection O
location O
requires O
[]

Larger O
, O
confirmatory O
studies O
are O
now O
needed O
. O
[]

METHODS O
In O
groups O
of O
20 O
, O
60 O
women O
were O
randomly O
assigned O
to O
one O
of O
three O
treatments O
: O
oral O
calcium O
, O
1000 O
mg/day O
; O
oral O
calcium O
plus O
oral O
clodronate O
, O
400 O
mg/day O
; O
oral O
calcium O
plus O
oral O
clodronate O
, O
400 O
mg/day O
for O
30 O
days O
, O
followed O
by O
a O
60-day O
period O
of O
calcium O
supplement O
alone O
. O
[]

We O
developed O
a O
scoring O
system O
to O
predict O
the O
artery O
responsible O
for O
an O
acute O
myocardial O
infarction O
( O
AMI O
) O
using O
ST-segment O
and O
T-wave O
changes O
on O
the O
initial O
electrocardiogram O
( O
ECG O
) O
using O
data O
from O
228 O
patients O
( O
development O
set O
) O
with O
symptoms O
compatible O
with O
AMI O
and O
tested O
in O
a O
similar O
group O
of O
223 O
patients O
( O
test O
set O
) O
from O
the O
Thrombolysis O
and O
Angioplasty O
in O
Myocardial O
Infarction O
( O
TAMI-5 O
) O
Trial O
. O
[]

RESULTS O
At O
basal O
conditions O
there O
were O
no O
significant O
differences O
between O
groups O
. O
[]

All O
patients O
in O
the O
SSA O
group O
were O
awake O
and O
oriented O
at O
the O
end O
of O
surgery O
, O
whereas O
patients O
in O
the O
DES O
group O
required O
7 O
+/- O
2 O
min O
for O
extubation O
and O
orientation O
. O
[]

However O
, O
the O
noninvasive O
approach O
generated O
higher O
follow-up O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
( O
$ O
9,204 O
+/- O
9,217 O
) O
than O
the O
invasive O
approach O
( O
$ O
3,784 O
+/- O
4,944 O
) O
( O
P O
= O
0.01 O
) O
. O
['Resource-use']

The O
difference O
in O
genotype O
distribution O
between O
patients O
and O
control O
subjects O
was O
significant O
( O
p O
< O
0.0005 O
) O
. O
[]

OBJECTIVE O
To O
assess O
post-treatment O
effects O
in O
endometriosis O
patients O
of O
a O
12-month O
course O
of O
GnRH O
agonist O
alone O
or O
with O
one O
of O
three O
add-back O
regimens O
. O
[]

During O
the O
whole O
experimental O
period O
, O
dietary O
choline O
had O
no O
significant O
effects O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
egg B-outcome ['Physiological-Clinical']
weight O
, O
and O
egg B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
P O
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Objective B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CR I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
PR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
observed O
in O
23/46 O
( O
50 O
% O
) O
of O
breast O
cancer O
patients O
treated O
with O
CT O
+ O
MPA O
, O
and O
in O
13/47 O
( O
28 O
% O
) O
of O
those O
given O
CT O
+ O
placebo O
. O
['Physiological-Clinical']

In O
contrast O
to O
this O
, O
gamma-glutamyl B-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GGT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
increased O
by O
2,4 O
times O
during O
5-days O
therapy O
with O
the O
lipid O
emulsions O
mentioned O
above O
( O
SMOF O
lipid O
: O
21,9 O
to O
52,9 O
U/L O
, O
Lipofundin O
: O
from O
32,5 O
to O
79,6 O
U/L O
) O
. O
['Physiological-Clinical']

AD O
patients O
achieved O
longer O
durations O
of O
cocaine B-outcome ['Life-Impact']
abstinence I-outcome ['Life-Impact']
and O
were O
more O
likely O
to O
submit O
a O
cocaine-negative B-outcome ['Life-Impact']
sample I-outcome ['Life-Impact']
at O
follow-up O
than O
non-AD O
patients O
. O
['Life-Impact', 'Life-Impact']

Cardiopulmonary O
bypass O
during O
open-heart O
surgery O
is O
sometimes O
associated O
with O
excessive O
perioperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

However O
, O
to O
the O
authors O
' O
knowledge O
, O
no O
researchers O
yet O
have O
evaluated O
the O
effectiveness O
of O
100 O
percent O
NovaMin O
powder O
with O
NovaMin-containing O
toothpaste O
in O
reducing O
dentin O
hypersensitivity O
compared O
with O
the O
effectiveness O
of O
NovaMin-containing O
toothpaste O
only O
and O
a O
desensitizing O
toothpaste O
containing O
potassium O
nitrate O
as O
a O
control O
. O
[]

METHODS O
We O
did O
a O
single-blind O
, O
randomised O
, O
placebo O
controlled O
, O
cross-over O
study O
of O
the O
microcirculatory B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
topical O
application O
of O
a O
nitric-oxidegenerating O
gel O
in O
20 O
patients O
with O
severe O
Raynaud O
's O
syndrome O
, O
and O
ten O
healthy O
volunteers O
. O
['Physiological-Clinical']

If O
thyroglobulin B-outcome ['Physiological-Clinical']
levels O
were O
low O
and O
WBSs B-outcome ['Physiological-Clinical']
were O
negative O
, O
patients O
were O
followed O
up O
in O
the O
Department O
of O
Nuclear O
Medicine O
in O
Martin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Eight O
hundred O
and O
ninety-one O
patients O
treated O
for O
48 O
weeks O
with O
an O
initial O
ribavirin O
dose O
of O
800 O
or O
1000/1200 O
mg/day O
were O
evaluated O
. O
[]

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

This O
study O
was O
carried O
out O
to O
compare O
patient O
safety O
and O
analgesic B-outcome ['Resource-use']
efficacy O
of O
a O
single O
and O
high O
dose O
of O
morphine O
given O
IM O
or O
IV O
for O
post-operative O
pain O
management O
. O
['Resource-use']

AIM O
OF O
THE O
STUDY: O
To O
evaluate O
the O
safety O
of O
BT-11 O
in O
human O
aged O
from O
9 O
to O
19 O
years O
old. O
[]

PATIENTS O
AND O
METHODS O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
subcutaneous O
denosumab O
120 O
mg O
and O
intravenous O
placebo O
( O
n O
= O
1,026 O
) O
or O
intravenous O
zoledronic O
acid O
4 O
mg O
adjusted O
for O
creatinine O
clearance O
and O
subcutaneous O
placebo O
( O
n O
= O
1,020 O
) O
every O
4 O
weeks O
. O
[]

Compared O
to O
placebo O
, O
sumatriptan O
significantly O
lowered O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
but O
increased O
those O
of O
plasma B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Differences O
in O
straylight O
with O
the O
clear O
CL O
compared O
with O
the O
grey-green O
CL O
were O
also O
statistically O
different O
from O
zero O
( O
p O
= O
0.002 O
) O
showing O
an O
increased O
straylight B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
for O
the O
tinted O
CL O
. O
['Physiological-Clinical']

Significant O
clinical O
benefit O
persisted O
not O
only O
within O
the O
6-month O
course O
of O
therapy O
, O
but O
3 O
months O
after O
. O
[]

CONCLUSIONS: O
Omadacycline O
was O
noninferior O
to O
moxifloxacin O
for O
the O
treatment O
of O
community-acquired O
bacterial O
pneumonia O
in O
adults. O
( O
[]

The O
staff O
members O
rated O
their O
professional O
competence O
, O
quality O
of O
interaction O
with O
the O
client O
, O
team O
culture O
and O
work O
satisfaction O
before O
and O
after O
being O
engaged O
in O
the O
program O
, O
with O
additional O
ratings O
of O
their O
personal O
aims O
at O
the O
beginning O
of O
the O
program O
. O
[]

Terbinafine O
, O
250 O
mg O
daily O
for O
3 O
months O
( O
continuous O
) O
or O
terbinafine O
, O
500 O
mg O
daily O
for O
1 O
week O
per O
month O
for O
3 O
months O
( O
pulse O
) O
was O
administered O
. O
[]

The O
effect O
of O
knee O
position O
on O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
range O
of O
motion B-outcome ['Life-Impact']
following O
total O
knee O
arthroplasty O
. O
['Physiological-Clinical', 'Life-Impact']

[ O
Opiate O
hypothesis O
in O
infantile O
autism O
? O
[]

Training O
of O
physicians O
, O
nurses O
and O
dietitians O
included O
preparation O
of O
operating O
manual O
and O
videos O
, O
interactive O
sessions O
, O
and O
evaluation O
of O
local O
facilities O
and O
resources O
. O
[]

Eligible O
women O
were O
undergoing O
IVF O
(fresh-embryo O
or O
frozen-embryo O
transfer), O
with O
no O
recent O
exposure O
to O
disruptive O
intrauterine O
instrumentation O
(e.g., O
hysteroscopy). O
[]

OBJECTIVES O
The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
mechanism O
of O
cutaneous O
vasodilation O
following O
acupuncture O
stimulation O
by O
investigating O
the O
roles O
of O
nitric O
oxide O
( O
NO O
) O
and O
axon O
reflex O
vasodilation O
. O
[]

The O
total O
sample O
size O
was O
398 O
patients O
. O
[]

Both O
isotonic O
and O
isometric O
training O
resulted O
in O
significant O
cardiovascular B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
but O
seemed O
inadequate O
to O
improve O
vital B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
and O
flow B-outcome ['Physiological-Clinical']
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
safety O
of O
BT-11 O
should O
be O
elucidated O
in O
younger O
person O
further. O
[]

However O
, O
application O
of O
the O
technique O
may O
be O
limited O
by O
the O
magnitude O
of O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
response O
and O
by O
the O
short-lived O
nature O
of O
the O
increase O
in O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Dose O
Dependency O
for O
pharmacokinetics O
of O
theophylline O
and O
the O
formation O
of O
its O
major O
metabolites O
, O
3-methylxanthine O
( O
3-MX O
) O
; O
1-methyluric O
acid O
( O
1-MU O
) O
; O
1,3-dimethyluric O
acid O
( O
DMU O
) O
, O
were O
examined O
by O
administering O
three O
single O
oral O
doses O
( O
250 O
, O
375 O
, O
500 O
mg O
) O
of O
theophylline O
to O
six O
healthy O
adult O
volunteers O
. O
[]

Hydrocele B-outcome ['Physiological-Clinical']
occurred O
only O
in O
the O
group O
which O
received O
the O
Ivanissevich O
technique O
( O
5.5 O
% O
) O
. O
['Physiological-Clinical']

Corresponding O
inverse O
changes O
in O
BTM B-outcome ['Physiological-Clinical']
were O
seen O
, O
with O
an O
increase O
following O
tamoxifen O
withdrawal O
and O
a O
reduction O
after O
exemestane O
. O
['Physiological-Clinical']

Both O
groups O
of O
children O
activated O
a O
right B-outcome ['Physiological-Clinical']
premotor/prefrontal I-outcome ['Physiological-Clinical']
system I-outcome ['Physiological-Clinical']
when O
identifying O
images O
containing O
a O
greater O
percentage O
of O
the O
self O
face O
. O
['Physiological-Clinical']

AIMS O
Scarcity O
of O
resources O
, O
expertise O
and O
evidence-based O
models O
have O
so O
far O
limited O
delivery O
of O
patient-centred O
diabetes O
education O
. O
[]

Low-frequency O
rTMS O
minimized B-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
irrelevant I-outcome ['Physiological-Clinical']
stimuli B-outcome ['Physiological-Clinical']
and O
increased O
responses B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
relevant I-outcome ['Physiological-Clinical']
stimuli I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
ECMO O
circuit O
and O
samples O
of O
blood O
were O
evaluated O
hourly O
for O
phase O
separation O
, O
layering O
out O
of O
the O
emulsion O
from O
blood O
, O
agglutination O
, O
and O
blood O
clots O
. O
[]

SUBJECTS O
A O
total O
of O
36 O
obese O
nondiabetic O
volunteers O
with O
hyperinsulinemia O
( O
10 O
males/26 O
females O
, O
aged O
34-65 O
y O
, O
BMI O
28-43 O
kg/m O
( O
2 O
) O
, O
fasting O
insulin O
12-45 O
mU/l O
) O
. O
[]

BACKGROUND O
This O
pilot O
study O
investigated O
the O
efficacy O
of O
a O
novel O
virtual O
reality-cognitive O
rehabilitation O
( O
VR-CR O
) O
intervention O
to O
improve O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
of O
objects O
in O
children O
with O
autism O
. O
['Life-Impact']

Hemodynamic B-outcome ['Physiological-Clinical']
parameters O
and O
transthoracic B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
were O
the O
variables O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
we O
tested O
the O
hypothesis O
that O
delusional O
schizophrenia O
patients O
are O
more O
likely O
than O
non-delusional O
schizophrenia O
patients O
and O
healthy O
participants O
to O
assign O
affective O
meanings O
to O
neutral O
stimuli O
. O
[]

OBJECTIVE O
To O
conduct O
a O
randomized O
, O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
the O
Early O
Start O
Denver O
Model O
( O
ESDM O
) O
, O
a O
comprehensive O
developmental O
behavioral O
intervention O
, O
for O
improving O
outcomes O
of O
toddlers O
diagnosed O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

METHOD O
Twenty-six O
children O
diagnosed O
with O
autism O
at O
age O
2 O
were O
re-assessed O
at O
ages O
3 O
and O
7 O
years O
. O
[]

Activity B-outcome ['Life-Impact']
in O
premotor O
regions O
, O
IPL B-outcome ['Physiological-Clinical']
and O
MOTG O
correlated O
positively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
whereas O
prefrontal O
Mu-sources O
correlated O
negatively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Treatment O
of O
vaginal O
adenosis O
with O
the O
carbon O
dioxide O
laser O
did O
not O
significantly O
reduce O
the O
incidence O
of O
development O
of O
new B-outcome ['Physiological-Clinical']
dysplasia I-outcome ['Physiological-Clinical']
in O
the O
DES-exposed O
offspring O
. O
['Physiological-Clinical']

Both O
of O
the O
treatments O
caused O
an O
increase O
in O
C-peptide B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
concentration O
of O
5-fluorouracil B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
5-FU I-outcome ['Physiological-Clinical']
) O
in O
tumor B-outcome ['Physiological-Clinical']
tissue B-outcome ['Physiological-Clinical']
was O
measured O
by O
chemical B-outcome ['Physiological-Clinical']
assay O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
FZYLG O
can O
increase O
the O
NF-kappa O
B O
expression O
, O
block O
the O
proliferation O
to O
promote O
the O
apoptosis B-outcome ['Physiological-Clinical']
of O
tumor O
cells O
. O
['Physiological-Clinical']

Rapeseed O
and O
soybean O
products O
as O
protein O
sources O
for O
growing O
turkeys O
of O
different O
ages O
. O
( O
[]

RESULTS O
The O
median O
interval O
from O
randomization O
to O
delivery B-outcome ['Physiological-Clinical']
was O
4 O
days O
in O
the O
prostaglandin O
E2 O
group O
( O
range O
0 O
to O
28 O
days O
) O
versus O
10 O
days O
in O
the O
placebo O
group O
( O
range O
0 O
to O
26 O
days O
, O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

The O
direct O
and O
video O
groups O
performed O
2 O
handling B-outcome ['Life-Impact']
activities O
significantly O
better O
than O
the O
written-pictorial O
group. O
[['Life-Impact']]

BACKGROUND: O
Infections O
acquired O
in O
hospital O
are O
an O
important O
cause O
of O
morbidity O
and O
mortality O
in O
very O
preterm O
infants. O
[]

LDL B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
modification I-outcome ['Physiological-Clinical']
was O
assessed O
by O
calculating O
lag O
time O
, O
propagation B-outcome ['Physiological-Clinical']
rate O
, O
and O
maximum O
production O
of O
conjugated O
dienes B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
in O
the O
level O
of O
pain B-outcome ['Physiological-Clinical']
relief O
. O
['Physiological-Clinical']

There O
were O
also O
major O
re-structuring O
of O
several O
organisations O
which O
presented O
significant O
implementation O
challenges, O
and O
technical O
limitations. O
[]

Five-year O
follow-up O
of O
the O
Fluorouracil O
Filtering O
Surgery O
Study O
. O
[]

Skeletal O
muscle O
STARS O
, O
myocardian-related O
transcription O
factor-A O
( O
MRTF-A O
) O
and O
serum O
response O
factor O
( O
SRF O
) O
mRNA O
and O
protein O
, O
as O
well O
as O
muscle O
cross-sectional O
area O
and O
maximal O
voluntary O
contraction O
, O
were O
measured O
. O
[]

Group O
A O
subjects O
were O
placed O
supine O
, O
and O
after O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

Our O
aim O
was O
to O
perform O
a O
randomised O
controlled O
trial O
( O
RCT O
) O
to O
compare O
anatomical O
knowledge O
of O
two O
groups O
of O
second-year O
medical O
students O
, O
the O
first O
group O
taught O
on O
a O
traditional O
course O
, O
the O
second O
on O
an O
integrated O
course O
. O
[]

The O
trial O
was O
designed O
to O
assess O
the O
impact O
of O
the O
Asha-Life O
intervention O
engaging O
with O
an O
HIV-trained O
village O
woman O
, O
Asha O
( O
Accredited O
Social O
Health O
Activist O
) O
, O
to O
participate O
in O
the O
care O
of O
women O
living O
with O
AIDS O
( O
WLA O
) O
, O
along O
with O
other O
health O
care O
providers O
compared O
to O
a O
Usual O
Care O
group O
. O
[]

Two O
subjects O
receiving O
VPA O
developed O
increased O
serum B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
levels O
, O
one O
with O
an O
associated O
parent O
report O
of O
['Physiological-Clinical']

However O
, O
the O
effect O
of O
an O
active O
pectoral O
can O
on O
atrial O
defibrillation O
is O
unknown O
. O
[]

hemoglobin O
, O
p O
= O
0.011 O
) O
. O
[]

This O
study O
aimed O
to O
determine O
whether O
educating O
diabetic O
patients O
to O
'eat O
vegetables O
before O
carbohydrate O
' O
was O
as O
effective O
on O
long-term B-outcome ['Physiological-Clinical']
glycemic I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
as O
a O
traditional O
exchange-based O
meal O
plan O
. O
['Physiological-Clinical']

Ratings O
from O
the O
matrix O
were O
then O
combined O
to O
generate O
a O
single O
overall O
exposure O
prevention O
rating O
for O
each O
area O
. O
[]

Comparison O
of O
inhaled O
albuterol O
powder O
and O
aerosol O
in O
asthma O
. O
[]

The O
cost O
per O
study O
of O
home O
study O
recordings O
was O
less O
expensive O
than O
that O
of O
polysomnography O
( O
143.86 O
euros O
) O
, O
either O
with O
( O
93.08 O
euros O
) O
or O
without O
( O
129.97 O
euros O
) O
intervention O
of O
the O
technician O
in O
the O
patient O
's O
home O
. O
[]

METHODS O
In O
the O
surgery O
setting O
, O
a O
total O
of O
381 O
patients O
were O
randomised O
to O
chemotherapy O
( O
C O
, O
192 O
patients O
) O
or O
no O
chemotherapy O
( O
NoC O
, O
189 O
patients O
) O
. O
[]

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
longitudinal B-outcome ['Physiological-Clinical']
quality O
of O
life O
( O
QoL O
) O
between O
LV5FU2-irinotecan O
and O
LV5FU2 O
alone O
or O
LV5FU2-cisplatin O
in O
a O
randomized O
Phase O
II O
trial O
in O
patients O
with O
metastatic O
gastric O
adenocarcinoma O
. O
['Physiological-Clinical']

METHODS O
Analyzed O
PRO O
included O
( O
1 O
) O
the O
Medical O
Outcomes O
Study O
Short O
Form O
36 O
, O
version O
2 O
, O
( O
2 O
) O
the O
Surgical O
Pain O
Scale O
, O
( O
3 O
) O
the O
Activities O
Assessment O
Scale O
, O
and O
( O
4 O
) O
patient O
satisfaction O
. O
[]

These O
regimens O
are O
associated O
with O
a O
very O
low O
risk O
of O
Grade O
3-4 O
toxicity B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Thus O
, O
the O
Lightwand O
( O
Intubating O
Lighted O
Stylet O
) O
is O
associated O
with O
reduced O
C-spine B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
during O
endotracheal O
intubation O
compared O
with O
the O
Macintosh O
laryngoscope O
. O
['Physiological-Clinical']

No O
drug B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
was O
found O
between O
morphine O
in O
MS-sNT O
and O
4 O
% O
or O
20 O
% O
alcohol O
. O
['Physiological-Clinical']

5 O
. O
[]

The O
primary O
end O
point O
was O
the O
proportion O
of O
patients O
achieving O
clinical O
improvement O
( O
> O
or O
=3 O
point O
improvement O
in O
MMDAI O
) O
and O
improvement O
in O
rectal O
bleeding O
( O
> O
or O
=1 O
point O
improvement O
) O
at O
8 O
weeks O
. O
[]

Preliminary O
analysis O
indicates O
that O
clot B-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
rates O
are O
greatly O
dependent O
on O
catheter O
placement O
. O
['Physiological-Clinical']

After O
Actovegin B-outcome ['Physiological-Clinical']
parietal I-outcome ['Physiological-Clinical']
P300 I-outcome ['Physiological-Clinical']
scalp I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
increased O
, O
while O
frontal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
temporal I-outcome ['Physiological-Clinical']
amplitudes I-outcome ['Physiological-Clinical']
decreased O
as O
compared O
to O
placebo O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
event O
of O
an O
adverse O
reaction O
, O
application O
of O
imiquimod O
was O
reduced O
to O
1 O
or O
2 O
times O
per O
week O
. O
[]

PARTICIPANTS O
Fifty O
eyes O
among O
50 O
patients O
with O
DME O
, O
retinal O
thickness O
? O
[]

Eligible O
participants O
are O
HIV-infected O
pregnant O
women O
aged O
15 O
to O
49 O
years O
and O
have O
a O
singleton O
gestation O
at O
14 O
to O
27 O
weeks' O
gestation. O
[]

Why O
were O
the O
results O
of O
the O
Heart O
Outcomes O
Prevention O
Evaluation O
( O
HOPE O
) O
trial O
so O
astounding O
? O
[]

There O
was O
no O
significant O
difference O
between O
groups O
in O
the O
median O
cumulative O
time O
with O
mean O
arterial O
pressure O
below O
60 O
mm O
Hg O
(7 O
vs O
7 O
minutes; O
difference, O
0.0 O
[95% O
CI, O
-1.7 O
to O
1.7]). O
[]

Imitation O
is O
an O
early O
skill O
thought O
to O
play O
a O
role O
in O
social O
development O
, O
leading O
some O
to O
suggest O
that O
teaching O
imitation O
to O
children O
with O
autism O
should O
lead O
to O
improvements O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact']

When O
comparing O
within O
each O
IOL O
type O
, O
patients O
with O
AcrySof O
IOLs O
were O
found O
to O
have O
significantly O
less O
PCO B-outcome ['Physiological-Clinical']
when O
the O
capsulorhexis O
was O
totally O
on O
the O
optic O
( O
p O
= O
0.0048 O
) O
. O
['Physiological-Clinical']

This O
was O
also O
evident O
if O
these O
patients O
were O
pooled O
with O
15 O
patients O
excluded O
from O
the O
double O
blind O
study O
as O
already O
receiving O
DMARD O
treatment O
( O
n O
= O
63 O
; O
p O
< O
0.01 O
) O
. O
[]

There O
were O
significant O
differences O
between O
the O
control O
group O
and O
saliva O
, O
blood O
, O
and O
hydrogen O
peroxide O
groups O
( O
p O
< O
0.05 O
) O
. O
[]

Effects O
of O
vacuum-compression B-outcome ['Physiological-Clinical']
therapy I-outcome ['Physiological-Clinical']
on O
healing O
of O
diabetic B-outcome ['Physiological-Clinical']
foot I-outcome ['Physiological-Clinical']
ulcers I-outcome ['Physiological-Clinical']
: O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intention-to-treat O
eradication B-outcome ['Physiological-Clinical']
rate O
was O
67 O
% O
( O
44 O
of O
66 O
) O
and O
58 O
% O
( O
38 O
of O
65 O
) O
for O
the O
ATL- O
and O
the O
ATP-group O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
take O
the O
drug O
along O
with O
a O
high-fat O
, O
high-calorie O
breakfast O
for O
the O
administration O
at O
day O
1 O
of O
the O
first O
or O
second O
cycle O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Journal-Name:BMC O
neurology O
[]

The O
aim O
was O
to O
exercise O
twice O
a O
week O
for O
12 O
months O
, O
once O
guided O
and O
once O
independently O
. O
[]

The O
primary O
outcome O
was O
the O
Kaplan-Meier O
estimated O
percentage O
of O
patients O
who O
were O
free O
from O
recurrence B-outcome ['Physiological-Clinical']
at O
6 O
months, O
defined O
as O
P. O
vivax O
clearance O
without O
recurrent O
parasitemia. O
[['Physiological-Clinical']]

Data O
on O
operation O
time O
, O
estimated O
blood O
loss O
, O
postoperative O
morbidities O
were O
collected O
and O
analysed O
with O
comparison O
between O
the O
two O
groups O
using O
chi O
square O
, O
Fischer O
's O
exact O
test O
and O
t-test O
as O
appropriate O
. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
occurred O
in O
5/32 O
( O
16 O
per O
cent O
) O
of O
the O
cefotaxime O
group O
and O
9/31 O
( O
29 O
per O
cent O
) O
of O
the O
cephamandole O
group O
. O
['Physiological-Clinical']

Effects O
on O
performance B-outcome ['Physiological-Clinical']
of O
1 O
, O
2 O
and O
4 O
g O
ascorbic O
acid O
were O
studied O
from O
0.5-5.5 O
h O
after O
ingestion O
in O
six O
healthy O
females O
. O
['Physiological-Clinical']

Both O
the O
antacid O
and O
placebo O
groups O
showed O
improvement O
in O
the O
degree O
of O
esophagitis B-outcome ['Physiological-Clinical']
as O
assessed O
endoscopically O
. O
['Physiological-Clinical']

Serum O
for O
rabies O
antibody O
determination O
and O
F O
( O
ab O
' O
) O
2 O
concentration O
was O
collected O
at O
hours O
( O
H O
) O
0 O
, O
6 O
and O
12 O
, O
and O
on O
day O
( O
D O
) O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
and O
15 O
. O
[]

RESULTS O
Both O
treatments O
resulted O
in O
significant O
and O
progressive O
improvement O
in O
overall O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
at O
follow-up O
( O
F O
= O
2 O
, O
97 O
, O
p O
=.007 O
) O
and O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
significantly O
improved O
over O
time O
in O
the O
54 O
% O
of O
principal O
caregivers O
who O
had O
the O
highest O
levels O
of O
mental O
health O
problems O
. O
['Life-Impact', 'Life-Impact']

This O
study O
compared O
the O
efficacy O
of O
these O
two O
techniques O
in O
achieving O
ocular O
and O
lid O
akinesia O
. O
[]

Though O
much O
of O
this O
risk O
is O
mitigated O
with O
trigger O
using O
gonadotropin O
releasing-hormone O
(GnRH) O
agonist O
alone, O
it O
may O
result O
in O
lower O
birth O
rates. O
[]

A O
trend O
toward O
improvement O
in O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
was O
noted O
in O
myoblast-treated O
groups O
( O
?6-minute O
walk O
test O
of O
-3.6 O
vs O
+95.6 O
vs O
+85.5 O
m O
[ O
placebo O
vs O
low O
dose O
vs O
high O
dose O
; O
P O
= O
.50 O
] O
) O
without O
significant O
changes O
in O
Minnesota O
Living O
With O
HF O
scores O
. O
['Life-Impact']

RESULTS O
Both O
groups O
exhibited O
significant O
decreases O
in O
hot B-outcome ['Physiological-Clinical']
flashes I-outcome ['Physiological-Clinical']
, O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
and O
['Physiological-Clinical', 'Life-Impact']

Patients O
were O
re-evaluated O
after O
5 O
weeks O
of O
therapy O
and O
at O
the O
end O
of O
therapy O
( O
10 O
weeks O
) O
. O
[]

Resurfacing O
after O
laser-assisted O
topical O
anesthesia O
was O
well O
tolerated B-outcome ['Life-Impact']
by O
72 O
% O
of O
subjects O
in O
pass O
1 O
and O
58 O
% O
in O
pass O
2 O
. O
['Life-Impact']

Importance: O
Multimodal O
postoperative O
analgesia O
is O
widely O
used O
but O
lacks O
evidence O
of O
benefit. O
[]

[ O
Effects O
of O
electroacupuncture O
combined O
with O
behavior O
therapy O
on O
intelligence O
and O
behavior O
of O
children O
of O
autism O
] O
. O
[]

The O
core O
symptoms O
of O
autism O
are O
abnormalities O
in O
social O
interaction O
, O
communication O
and O
behaviour O
. O
[]

Acupuncture O
is O
becoming O
a O
common O
technique O
within O
the O
physiotherapy O
profession O
as O
a O
treatment O
modality O
for O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
; O
however O
, O
few O
randomised O
controlled O
trials O
have O
been O
undertaken O
to O
assess O
the O
effectiveness O
of O
acupuncture O
, O
particularly O
in O
the O
treatment O
of O
osteoarthritis O
( O
OA O
) O
of O
the O
hip O
. O
['Physiological-Clinical']

The O
original O
trial O
(number, O
NCT00678275) O
and O
follow-up O
extension O
(number, O
NCT03042676) O
are O
registered O
at O
ClinicalTrials.gov. O
[]

These O
results O
were O
consistent O
with O
a O
hypothesized O
dopaminergic O
mechanism O
of O
action O
of O
ascorbic O
acid O
. O
[]

RESULTS O
Patients O
with O
short-term O
GHQ O
success O
were O
more O
likely O
to O
show O
mid-term B-outcome ['Physiological-Clinical']
GHQ I-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
( O
p O
< O
.001 O
) O
, O
marginally O
less O
likely O
to O
die O
of O
any O
causes O
( O
p O
= O
.087 O
) O
, O
less O
likely O
to O
die O
of O
cardiac O
causes O
( O
p O
= O
.043 O
) O
, O
less O
likely O
to O
be O
readmitted B-outcome ['Physiological-Clinical']
for O
any O
reason O
( O
p O
< O
.001 O
) O
and O
for O
cardiac O
reasons O
( O
p O
< O
.001 O
) O
, O
and O
less O
likely O
to O
have O
high O
depression B-outcome ['Life-Impact']
( O
p O
< O
.001 O
) O
and O
anxiety B-outcome ['Life-Impact']
( O
p O
< O
.001 O
) O
at O
1-year O
than O
patients O
with O
short-term O
unsuccessful O
GHQ B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

No O
differences O
between O
the O
two O
arms O
, O
either O
as O
regards O
the O
duration O
of O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
were O
noted O
in O
the O
group O
with O
more O
than O
one O
invaded O
lymph O
node O
whatever O
the O
number O
of O
invaded O
lymph O
nodes O
. O
['Mortality', 'Mortality']

CONCLUSION O
Parent O
verbal O
utterances O
that O
follow O
into O
the O
child O
's O
current O
focus O
of O
attention O
or O
respond O
to O
child O
verbal O
communication O
acts O
may O
facilitate O
the O
process O
of O
early O
vocabulary O
acquisition O
by O
mitigating O
the O
need O
for O
children O
with O
ASD O
to O
use O
attention-following O
as O
a O
word-learning O
strategy O
. O
[]

The O
risk O
of O
death B-outcome ['Mortality']
in O
the O
group O
treated O
with O
vitamin O
A O
was O
less O
than O
half O
that O
in O
the O
control O
group O
( O
relative O
risk O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.30 O
to O
0.71 O
) O
. O
['Mortality']

ORs O
for O
predicting O
wrist O
fracture O
were O
: O
previous B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
, O
2.29 O
( O
95 O
% O
CI O
1.56-3.34 O
) O
; O
and O
a O
fall O
in O
the O
last O
12 O
months O
, O
1.60 O
( O
95 O
% O
CI O
1.10-2.31 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Nonpharmacologic O
interventions O
, O
such O
as O
distraction O
, O
have O
been O
shown O
to O
be O
powerful O
adjuncts O
in O
reducing O
pain O
and O
anxiety O
in O
children O
with O
both O
acute O
and O
chronic O
painful O
conditions O
. O
[]

Famotidine O
treatment O
of O
children O
with O
autistic O
spectrum O
disorders O
: O
pilot O
research O
using O
single O
subject O
research O
design O
. O
[]

On O
two O
separate O
occasions O
at O
the O
same O
time O
of O
day O
, O
concentration-response O
studies O
with O
inhaled O
histamine O
or O
methacholine O
, O
or O
a O
sham O
challenge O
with O
normal O
saline O
were O
carried O
out O
in O
a O
blinded O
, O
randomized O
manner O
. O
[]

Sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
was O
assessed O
using O
a O
standardized O
questionnaire O
[ O
Female O
Sexual O
Function O
Index O
( O
FSFI O
) O
] O
. O
['Life-Impact']

This O
impairment O
of O
tracheal B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
is O
an O
important O
factor O
in O
tracheal B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
associated O
with O
intubation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
The O
aim O
of O
our O
study O
was O
to O
assess O
the O
influence O
of O
oral O
corticosteroids O
and O
oral O
corticosteroids O
combined O
with O
vitamin O
D O
( O
3 O
) O
on O
the O
early O
clinical O
and O
immunological O
effects O
of O
SIT O
. O
[]

When O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
was O
defined O
by O
other O
thresholds O
( O
20/40 O
and O
20/100 O
) O
, O
the O
difference O
was O
not O
significant O
. O
['Physiological-Clinical']

The O
median O
survival B-outcome ['Mortality']
was O
22 O
months O
in O
the O
chemotherapy O
group O
and O
29 O
months O
in O
the O
control O
group O
. O
['Mortality']

In O
the O
NR O
group O
, O
patients O
were O
postoperatively O
educated O
in O
the O
possibility O
of O
mandibular B-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
and O
were O
given O
an O
emphasis O
on O
the O
necessity O
of O
limiting B-outcome ['Physiological-Clinical']
mastication I-outcome ['Physiological-Clinical']
to O
a O
soft O
diet O
for O
4 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
rate O
of O
substitutions O
of O
calcium O
by O
strontium O
ions O
was O
4.5 O
% O
. O
[]

State-Trait B-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
( O
STAI O
) O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
were O
administered O
at O
study O
inclusion O
, O
after O
1 O
, O
6 O
months O
. O
['Life-Impact']

In O
Experiment O
2 O
, O
thirty-two O
4- O
to O
5-year-olds O
learned O
from O
scenarios O
lacking O
pretend O
speech B-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
sound I-outcome ['Life-Impact']
['Life-Impact']

CONCLUSION O
An O
initial O
double-dose O
of O
diclofenac-K O
( O
2 O
x O
12.5 O
mg O
) O
or O
paracetamol O
( O
2 O
x O
500 O
mg O
) O
adequately O
relieved O
the O
most O
intense O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
the O
flexible O
multiple O
dose O
regimen O
( O
1 O
or O
2 O
tablets O
) O
maintained O
adequate O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
thereafter O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
found O
that O
, O
among O
healthy O
sedentary O
menopausal O
women O
, O
yoga O
appears O
to O
improve O
menopausal O
quality O
of O
life O
; O
the O
clinical O
significance O
of O
our O
finding O
is O
uncertain O
because O
of O
the O
modest O
effect O
. O
[]

PURPOSE O
Pazopanib O
is O
an O
oral O
angiogenesis O
inhibitor O
targeting O
vascular O
endothelial O
growth O
factor O
receptor O
, O
platelet-derived O
growth O
factor O
receptor O
, O
and O
c-Kit O
. O
[]

There O
were O
no O
critical O
changes O
in O
heart B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
and O
fecal B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
SsWC I-outcome ['Physiological-Clinical']
, O
LPS B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neither O
H-2 O
receptor O
blockers O
nor O
antacids O
alter O
mucosal B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
or O
parietal B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Metabolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
measured O
through O
blood O
glucose B-outcome ['Physiological-Clinical']
, O
plasma O
insulin B-outcome ['Physiological-Clinical']
, O
plasma O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
plasma O
catecholamines B-outcome ['Physiological-Clinical']
: O
epinephrine B-outcome ['Physiological-Clinical']
(E) I-outcome ['Physiological-Clinical']
and O
norepinephrine B-outcome ['Physiological-Clinical']
(NE) I-outcome ['Physiological-Clinical']
. O
Biomarkers O
were O
taken O
at O
four O
different O
time O
points; O
Ingestion O
period: O
baseline O
(I1), O
post-ingestion O
period O
(I2); O
Recovery O
period: O
immediately O
post-exercise O
(R1), O
post-recovery O
period O
(R2). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Although O
other O
sleep O
parameters O
showed O
lesser O
, O
usually O
insignificant O
change O
, O
patients O
' O
subjective O
ratings O
of O
RLS B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

[ O
Intravenous O
treatment O
of O
postpartum O
anemia O
with O
trivalent O
ferrum O
preparation O
] O
. O
[]

The O
primary O
end O
point O
was O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality']

RESULTS O
The O
ABC-C O
and O
the O
Childhood O
Autism B-outcome ['Physiological-Clinical']
Rating O
Scale O
scores O
improved O
with O
cyproheptadine O
. O
['Physiological-Clinical']

Patients O
were O
instructed O
to O
use O
a O
thin O
layer O
of O
the O
study O
products O
twice O
daily O
at O
the O
lesional O
area O
and O
to O
discontinue O
treatment O
as O
soon O
as O
symptoms O
were O
absent O
. O
[]

Five O
randomized O
controlled O
trials O
regarding O
antenatal O
use O
of O
corticosteroids O
to O
prevent O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
could O
be O
combined O
meta-analytically O
and O
showed O
a O
reduction O
in O
respiratory B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
in O
the O
treatment O
group O
( O
p O
= O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
subjects O
who O
completed O
the O
three-month O
extension O
( O
i.e. O
, O
23 O
weeks O
post-SRP O
) O
, O
mean O
PPD B-outcome ['Physiological-Clinical']
decreases O
were O
0.72 O
mm O
for O
the O
test O
group O
and O
0.13 O
mm O
for O
the O
control O
, O
and O
mean O
BI B-outcome ['Physiological-Clinical']
reductions O
were O
0.05 O
for O
the O
test O
group O
and O
0.01 O
for O
the O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Other O
injuries O
appeared O
unaffected O
by O
the O
brace O
. O
[]

CONCLUSIONS O
In O
this O
randomized O
trial O
, O
no O
long-term O
QOL B-outcome ['Life-Impact']
advantage O
for O
either O
treatment O
was O
apparent O
with O
the O
exception O
of O
poorer O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
reported O
by O
those O
treated O
with O
cryoablation O
. O
['Life-Impact', 'Life-Impact']

Each O
group O
of O
volunteers O
suspended O
tooth O
cleaning O
for O
48 O
h O
and O
the O
index O
scored O
after O
disclosing O
plaque O
deposits O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
telmisartan O
at O
80 O
mg O
day O
( O
-1 O
) O
( O
n O
= O
15 O
) O
or O
enalapril O
at O
10 O
mg O
day O
( O
-1 O
) O
( O
n O
= O
15 O
) O
. O
[]

The O
number O
of O
antenatal B-outcome ['Resource-use']
day I-outcome ['Resource-use']
admissions I-outcome ['Resource-use']
and O
ultrasound B-outcome ['Resource-use']
scans I-outcome ['Resource-use']
performed O
may O
also O
be O
reduced O
. O
['Resource-use', 'Resource-use']

The O
treatment O
was O
acceptable O
to O
families O
, O
subject B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
was O
high O
, O
and O
therapist B-outcome ['Life-Impact']
fidelity I-outcome ['Life-Impact']
was O
high O
. O
['Life-Impact', 'Life-Impact']

Therapy B-outcome ['Resource-use']
effect O
of O
either O
paclitaxel O
or O
cyclophosphamide O
combination O
treatment O
in O
patients O
with O
epithelial O
ovarian O
cancer O
and O
relation O
to O
TP53 O
gene O
status O
. O
['Resource-use']

In O
contrast O
, O
children O
with O
ADHD O
( O
ADHD/ASD+ADHD O
) O
exhibited O
a O
reduced O
face B-outcome ['Life-Impact']
inversion I-outcome ['Life-Impact']
effect O
on O
P1 O
latency O
compared O
to O
TD O
and O
ASD O
. O
['Life-Impact']

Also O
, O
fewer O
subjects O
than O
the O
controls O
had O
significant O
painful O
episodes O
( O
50.0 O
% O
versus O
92.7 O
% O
) O
; O
febrile O
illness O
( O
46.6 O
% O
versus O
87.3 O
% O
) O
and O
admission O
rate O
( O
3.4 O
% O
versus O
34.5 O
% O
) O
( O
p O
< O
0.001 O
) O
. O
[]

After O
a O
mean O
duration O
of O
GH B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
of O
8.6 O
+/- O
1.9 O
yr O
, O
FH O
was O
reached O
at O
a O
mean O
age O
of O
15.8 O
+/- O
0.9 O
yr. O
FH B-outcome ['Physiological-Clinical']
, O
expressed O
in O
centimeters O
or O
SD O
score O
, O
was O
157.6 O
+/- O
6.5 O
or O
-1.6 O
+/- O
1.0 O
in O
group O
A O
, O
162.9 O
+/- O
6.1 O
or O
-0.7 O
+/- O
1.0 O
in O
group O
B O
, O
and O
163.6 O
+/- O
6.0 O
or O
-0.6 O
+/- O
1.0 O
in O
group O
C. O
The O
difference O
in O
FH B-outcome ['Physiological-Clinical']
in O
centimeters O
, O
corrected O
for O
height O
SD O
score O
and O
age O
at O
start O
of O
treatment O
, O
was O
significant O
between O
groups O
A O
and O
B O
[ O
regression O
coefficient O
, O
4.1 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
1.4 O
, O
6.9 O
; O
P O
< O
0.01 O
] O
, O
and O
groups O
A O
and O
C O
( O
coefficient O
, O
5.0 O
; O
95 O
% O
CI O
, O
2.3 O
, O
7.7 O
; O
P O
< O
0.001 O
) O
, O
but O
not O
between O
groups O
B O
and O
C O
( O
coefficient O
, O
0.9 O
; O
95 O
% O
CI O
, O
-1.8 O
, O
3.6 O
) O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
Rotigotine O
( O
Neupro O
) O
is O
formulated O
as O
a O
transdermal O
delivery O
system O
designed O
to O
provide O
a O
selective O
, O
non-ergot O
D3/D2/D1 O
agonist O
to O
the O
systemic O
blood O
flow O
over O
a O
24-hour O
period O
. O
[]

After O
a O
50 O
mg O
oral O
dose O
, O
maximum O
concentrations O
of O
66 O
micrograms/l O
are O
achieved O
within O
1.2 O
h. O
C O
is O
extensively O
distributed O
to O
the O
tissues O
( O
Vz O
= O
132 O
l O
) O
and O
eliminated O
primarily O
by O
hepatic O
metabolism O
( O
total O
clearance O
590 O
ml/min O
, O
renal O
clearance O
4 O
ml/min O
) O
. O
[]

UNLABELLED O
Propofol O
causes O
pain O
on O
IV B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
in O
28 O
% O
-90 O
% O
of O
patients O
. O
['Resource-use']

Statin O
treatment O
withdrawal O
in O
ischemic O
stroke O
: O
a O
controlled O
randomized O
study O
. O
[]

The O
primary O
outcome O
measure O
was O
average O
wrist B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
during O
the O
past O
week O
, O
measured O
using O
a O
visual O
analog O
scale O
( O
VAS O
) O
. O
['Physiological-Clinical']

Moreover O
, O
the O
survival B-outcome ['Mortality']
and O
disease-free B-outcome ['Physiological-Clinical']
rate O
in O
the O
group O
of O
the O
combination O
therapy O
were O
higher O
than O
those O
in O
the O
group O
of O
Futraful O
alone O
, O
and O
the O
relapse B-outcome ['Physiological-Clinical']
rate O
was O
lower O
in O
the O
former O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

There O
ws O
no O
reduction O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
in O
the O
group O
treated O
with O
beta-adrenoreceptor O
blocking O
agents O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Autism O
symptoms O
were O
monitored O
periodically O
. O
[]

TPI O
or O
EMLA O
treatments O
decreased O
shoulder O
pain O
irrespective O
of O
exercise O
habit O
(P O
= O
.001 O
and O
P O
< O
.001, O
respectively), O
but O
decreased O
overall B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
only O
in O
patients O
without O
exercise O
habit O
(P O
= O
.019). O
[['Physiological-Clinical']]

Hospital O
course O
is O
longer O
, O
more O
expensive O
, O
and O
more O
complicated O
. O
[]

To O
determine O
if O
CPX O
testing O
could O
distinguish O
between O
patients O
with O
HF O
with O
normal O
EFs O
( O
> O
50 O
% O
; O
i.e. O
, O
diastolic O
HF O
) O
and O
those O
with O
decreased O
EFs O
( O
> O
or O
=50 O
% O
; O
i.e. O
, O
systolic O
HF O
) O
, O
CPX O
responses O
were O
compared O
between O
185 O
patients O
with O
systolic O
HF O
( O
79 O
% O
men O
, O
mean O
age O
62.6 O
+/- O
10.9 O
years O
) O
and O
43 O
with O
diastolic O
HF O
( O
54 O
% O
men O
, O
mean O
age O
67.4 O
+/- O
9.8 O
years O
) O
enrolled O
in O
a O
phase O
II O
multicenter O
clinical O
trial O
. O
[]

We O
wondered O
whether O
the O
lack O
of O
success B-outcome ['Physiological-Clinical']
with O
pertussis O
immunoglobulins O
might O
be O
attributable O
to O
inadequate O
dose O
, O
so O
we O
designed O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
two O
immunoglobulin O
preparations O
. O
['Physiological-Clinical']

Subjects O
received O
15 O
mg O
of O
MTX O
a O
week O
or O
identical O
placebo O
. O
[]

This O
randomized O
, O
double-blind O
, O
triple-dummy O
, O
parallel-groups O
study O
compared O
rizatriptan O
5 O
mg O
, O
rizatriptan O
10 O
mg O
, O
sumatriptan O
100 O
mg O
, O
and O
placebo O
in O
1268 O
outpatients O
treating O
a O
single O
migraine O
attack O
. O
[]

Two O
blind O
randomized O
cross-over O
trials O
in O
the O
treatment O
of O
primary B-outcome ['Physiological-Clinical']
open I-outcome ['Physiological-Clinical']
angle I-outcome ['Physiological-Clinical']
glaucoma I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

However O
, O
FMD O
and O
digital O
vasodilator O
response O
did O
not O
significantly O
change O
from O
baseline O
with O
long-term O
sulfasalazine O
treatment O
. O
[]

Each O
group O
( O
n=10 O
) O
received O
one O
of O
five O
interventions O
: O
normoxic O
( O
21 O
% O
O? O
) O
resting O
( O
N-C O
) O
, O
hypoxic O
( O
15 O
% O
O? O
) O
resting O
( O
H-C O
) O
, O
normoxic O
exercise O
( O
50 O
% O
W O
( O
max O
) O
under O
21 O
% O
O? O
, O
N-T O
) O
, O
hypoxic-relative O
exercise O
( O
50 O
% O
maximal O
heart O
rate O
reserve O
under O
15 O
% O
O? O
, O
H-RT O
) O
, O
or O
hypoxic-absolute O
exercise O
( O
50 O
% O
W O
( O
max O
) O
under O
15 O
% O
O? O
, O
H-AT O
) O
for O
30 O
min/day O
, O
5 O
days/week O
for O
4 O
weeks O
. O
[]

The O
actuarial O
survival B-outcome ['Mortality']
at O
4 O
years O
is O
72 O
% O
in O
group O
A O
and O
67 O
% O
in O
group O
B O
( O
p=0.3 O
) O
. O
['Mortality']

Calves O
were O
fed O
2 O
L O
of O
cow O
's O
milk O
containing O
acetaminophen O
( O
50 O
mg/kg O
body O
weight O
) O
30 O
minutes O
after O
each O
treatment O
was O
administered O
, O
and O
jugular O
venous O
blood O
samples O
were O
obtained O
periodically O
after O
suckling O
. O
[]

Visualization O
and O
15 O
W O
maximum O
: O
Ablation O
guided O
by O
barium O
visualization O
of O
the O
esophageal O
course O
using O
a O
limit O
of O
15 O
W O
, O
n O
= O
35 O
. O
[]

In O
this O
article O
, O
we O
report O
results O
from O
one O
intervention O
, O
offering O
non-attendees O
a O
high-risk O
human O
papillomavirus O
( O
HPV O
) O
self-test O
. O
[]

BACKGROUND O
In O
older O
people O
, O
undernutrition O
is O
associated O
with O
increased O
hospitalization B-outcome ['Resource-use']
rates O
and O
mortality B-outcome ['Mortality']
. O
['Resource-use', 'Mortality']

The O
total O
incidence O
of O
PONV B-outcome ['Physiological-Clinical']
in O
the O
desflurane-only O
group O
was O
80 O
% O
( O
P O
< O
0.01 O
) O
, O
compared O
to O
40 O
% O
and O
20 O
% O
in O
the O
desflurane O
group O
receiving O
ondansetron O
and O
the O
propofol O
group O
, O
respectively O
. O
['Physiological-Clinical']

Recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
parasitaemia I-outcome ['Physiological-Clinical']
was O
observed O
after O
day O
30 O
in O
2 O
patients O
in O
the O
15 O
mg/kg O
group O
and O
in O
1 O
patient O
in O
the O
25 O
mg/kg O
group O
. O
['Physiological-Clinical']

Similarly O
, O
in O
a O
fifth O
subject O
, O
who O
was O
not O
restudied O
until O
6 O
months O
of O
androgen O
therapy O
were O
completed O
, O
an O
increase O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
increase O
in O
erythron O
iron O
turnover O
. O
['Physiological-Clinical']

DESIGN O
Multicentre O
randomised O
clinical O
study O
. O
[]

UNLABELLED O
We O
conducted O
a O
randomized O
, O
sham-controlled O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
study O
in O
chronic O
schizophrenia O
in-patients O
( O
n=35 O
) O
to O
evaluate O
the O
therapeutic O
efficacy O
of O
10 O
Hz O
stimulation O
. O
[]

11.4 O
years O
) O
and O
valsartan O
160 O
mg O
( O
30 O
patients O
; O
21 O
women O
, O
9 O
men O
; O
mean O
age O
49.8 O
? O
[]

Efficacy O
, O
safety O
, O
and O
[]

RESULTS O
Pregnancy B-outcome ['Physiological-Clinical']
rate O
was O
23.4 O
% O
in O
group O
1 O
, O
27.5 O
% O
in O
group O
2 O
, O
and O
28.1 O
% O
in O
group O
3 O
. O
['Physiological-Clinical']

DESIGN O
28 O
normal O
adult O
volunteers O
were O
administered O
sustained O
low-dose O
caffeine O
or O
placebo O
( O
randomized O
double-blind O
) O
during O
the O
last O
66 O
hours O
of O
an O
88-hour O
period O
of O
extended O
wakefulness O
that O
included O
seven O
2-hour O
naps O
during O
which O
polysomnographical O
recordings O
were O
made O
. O
[]

SIGNIFICANCE O
These O
findings O
suggest O
that O
patients O
with O
major O
depression O
have O
altered B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
local I-outcome ['Physiological-Clinical']
contextual I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Immediately O
after O
placement O
, O
the O
self-etching O
adhesive O
and O
its O
respective O
cement O
resulted O
in O
more O
suppression O
of O
cold B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
than O
no O
treatment O
( O
control O
) O
; O
with O
Linkmax O
treatment O
, O
the O
temperature O
at O
which O
teeth O
responded O
was O
reduced O
by O
8.4 O
degrees O
C. O
The O
conventionally O
etched O
adhesive O
and O
its O
cement O
reduced O
the O
temperature O
at O
which O
teeth B-outcome ['Physiological-Clinical']
responded I-outcome ['Physiological-Clinical']
by O
9.4 O
degrees O
C. O
After O
1 O
week O
, O
these O
temperature B-outcome ['Physiological-Clinical']
reductions I-outcome ['Physiological-Clinical']
were O
7.0 O
degrees O
C O
and O
4.3 O
degrees O
C O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
was O
obtained O
using O
the O
multifactorial O
strategy O
, O
as O
assessed O
by O
self-reported O
VAS O
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

The O
processing O
of O
time-dependent O
features O
of O
movement O
has O
a O
crucial O
role O
in O
predicting O
whether O
the O
outcome O
of O
a O
complex O
motor O
sequence O
, O
such O
as O
handwriting O
or O
playing O
a O
musical O
passage O
, O
will O
be O
consistent O
with O
its O
ultimate O
goal O
, O
or O
results O
instead O
in O
an O
execution O
error O
. O
[]

Women O
who O
lead O
sedentary O
lifestyles O
may O
benefit O
from O
a O
structured O
exercise O
program O
that O
includes O
information O
and O
support O
related O
to O
exercise O
adherence O
strategies O
. O
[]

As O
seen O
from O
the O
parents O
' O
logs O
, O
the O
median O
time B-outcome ['Physiological-Clinical']
needed I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
children I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
decreased O
from O
15 O
minutes O
( O
range O
15 O
to O
60 O
minutes O
) O
to O
10 O
minutes O
( O
range O
10 O
to O
15 O
minutes O
, O
P O
= O
.001 O
) O
. O
['Physiological-Clinical']

Publication O
date: O
2019/01/04 O
00:00 O
[accepted] O
[]

Clinical O
benefit O
assessments O
were O
recorded O
at O
each O
clinic O
visit O
. O
[]

Irrigation O
with O
hypertonic O
saline O
restored O
impaired B-outcome ['Physiological-Clinical']
mucociliary I-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
sinusitis I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
, O
while O
isotonic O
saline O
improved O
mucociliary O
clearance O
times O
significantly O
in O
allergic O
rhinitis O
and O
acute O
sinusitis O
patients O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

The O
respective O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
85 O
% O
, O
74 O
% O
, O
55 O
% O
and O
84 O
% O
, O
71 O
% O
, O
40 O
% O
( O
P O
= O
0.64 O
) O
. O
['Mortality']

Those O
infants O
weighing O
1500 O
to O
1999 O
g O
( O
23 O
treated O
, O
9 O
control O
) O
were O
treated O
for O
8 O
days O
. O
[]

Measurement O
of O
repeatability O
and O
plaque O
removal O
. O
[]

No O
endodontic O
treatment O
was O
performed O
. O
[]

Systemic B-outcome ['Physiological-Clinical']
hemodynamics I-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
throughout O
surgery O
. O
['Physiological-Clinical']

Fat B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
was O
studied O
in O
24 O
patients O
with O
clinically O
definite O
multiple O
sclerosis O
and O
in O
36 O
healthy O
control O
subjects O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
the O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
at O
9 O
months O
, O
defined O
as O
a O
2-fold O
increase O
in O
IgG O
levels O
to O
> O
or O
= O
1 O
microg/mL O
for O
at O
least O
5 O
of O
7 O
of O
the O
7vPnC O
serotypes O
. O
['Resource-use']

The O
reduction O
of O
incidences O
of O
air O
leak O
in O
the O
two O
groups O
was O
subsequently O
compared O
during O
successive O
postoperative O
periods O
. O
[]

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
induction O
treatment O
with O
antithymocyte O
globulins O
( O
ATG O
) O
followed O
by O
tacrolimus O
therapy O
with O
immediate O
tacrolimus O
therapy O
in O
renal O
transplant O
recipients O
. O
[]

RESULTS O
After O
oral O
dosing O
, O
moxifloxacin B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
reached O
a O
maximum O
( O
C O
( O
max O
) O
) O
of O
3.38 O
? O
['Physiological-Clinical']

No O
differences O
between O
the O
2 O
groups O
were O
noted O
in O
the O
rates O
of O
increase O
in O
retinal B-outcome ['Physiological-Clinical']
area O
involved O
by O
CMV B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

RESPIRE O
( O
Randomized O
Exposure O
Study O
of O
Pollution O
Indoors O
and O
Respiratory O
Effects O
) O
was O
a O
randomized O
trial O
of O
a O
chimney O
woodstove O
that O
reduces O
wood O
smoke O
exposure O
. O
[]

In O
a O
prospective O
study O
, O
20 O
patients O
with O
endoscopically O
proven O
duodenal O
ulcers O
were O
randomised O
to O
be O
treated O
with O
cimetidine O
1 O
g O
daily O
or O
with O
antacids O
350 O
mmol O
daily O
. O
[]

The O
Home B-outcome ['Life-Impact']
Situations I-outcome ['Life-Impact']
Questionnaire O
( O
HSQ O
) O
and O
the O
Hyperactivity/Noncompliance O
subscale O
of O
the O
Aberrant O
Behavior B-outcome ['Life-Impact']
Checklist O
were O
used O
as O
outcome O
measures O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
an O
efficacy O
trial O
, O
the O
null O
hypothesis O
specifies O
equality O
of O
the O
two O
survival O
distributions O
, O
but O
in O
an O
equivalence O
trial O
, O
a O
null O
hypothesis O
of O
inequivalence O
H0 O
has O
to O
be O
tested O
. O
[]

OBJECTIVES O
To O
compare O
the O
efficacy O
and O
safety O
of O
polymyxin O
sulfate O
7500 O
IU/neomycin O
sulfate O
3500 O
IU/dexamethasone O
phosphate O
0.1 O
% O
( O
PN+Dx O
) O
otic O
solution O
with O
polymyxin O
sulfate O
7500 O
IU/neomycin O
sulfate O
3500 O
IU O
( O
PN-Dx O
) O
in O
patients O
with O
acute O
bacterial O
otitis O
externa O
( O
AOE O
) O
, O
in O
order O
to O
determine O
the O
possible O
benefit O
of O
the O
addition O
of O
dexamethasone O
. O
[]

Secondary O
outcomes O
were O
changes O
from O
pretreatment O
to O
posttreatment O
in O
percentage O
of O
the O
estimated B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
requirement I-outcome ['Physiological-Clinical']
and O
body O
mass O
index O
z O
score O
. O
['Physiological-Clinical']

RESULTS O
At O
baseline O
, O
56 O
% O
of O
group O
condition O
( O
immediate O
intervention O
) O
and O
54 O
% O
of O
individual O
condition O
( O
delayed O
intervention O
) O
participants O
were O
nonadherent O
by O
pill B-outcome ['Life-Impact']
count I-outcome ['Life-Impact']
and O
23 O
% O
of O
group O
and O
26 O
% O
of O
individual O
condition O
participants O
self-reported O
skipping B-outcome ['Life-Impact']
medication I-outcome ['Life-Impact']
at O
least O
once O
over O
the O
last O
3 O
months O
. O
['Life-Impact', 'Life-Impact']

The O
study O
demonstrated O
a O
cure O
rate O
of O
nearly O
80 O
% O
; O
i.e. O
, O
32 O
% O
of O
the O
women O
could O
restore O
normal O
vaginal O
flora O
and O
47 O
% O
had O
improved O
Nugent O
score O
, O
whereas O
20 O
% O
of O
the O
subjects O
did O
not O
clear O
BV O
in O
the O
first O
follow-up O
( O
after O
8 O
days O
treatment O
) O
. O
[]

The O
high O
salt O
diet O
attenuated O
the O
antihypertensive B-outcome ['Resource-use']
effect O
slightly O
( O
1.6/1.3 O
mm O
Hg O
, O
P O
= O
not O
significant O
) O
. O
['Resource-use']

Efficacy O
( O
based O
upon O
the O
decrease O
in O
PVC/hour O
in O
a O
24 O
hour O
Holter O
) O
and O
tolerability O
were O
evaluated O
at O
the O
end O
of O
each O
sequence O
, O
with O
samples O
drawn O
at O
the O
same O
times O
for O
assay O
of O
the O
study O
drugs O
. O
[]

The O
Family O
End-of-study O
Up-to-date O
Index O
is O
the O
proportion O
of O
procedures O
for O
which O
the O
family O
was O
eligible O
and O
for O
which O
they O
were O
up-to-date O
at O
the O
end O
of O
the O
study O
. O
[]

Angiotensin O
converting O
enzyme O
inhibition O
does O
not O
affect O
the O
response O
to O
exogenous O
angiotensin O
II O
in O
the O
human O
forearm O
. O
[]

Of O
the O
93 O
randomized O
patients O
, O
87 O
started O
treatment O
, O
41 O
received O
PUVA O
and O
46 O
received O
PUVA O
+ O
bexarotene O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
the O
effect O
of O
dried O
purple O
carrot O
on O
body O
mass O
, O
lipids O
, O
blood O
pressure O
, O
body O
composition O
, O
and O
inflammatory O
markers O
in O
overweight O
and O
obese O
adults O
: O
the O
QUENCH O
trial O
. O
[]

The O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
was O
higher O
in O
the O
experimental O
group O
( O
n O
= O
48 O
) O
than O
among O
controls O
( O
n O
= O
49 O
; O
48.8 O
% O
vs O
25.0 O
% O
; O
P O
= O
.02 O
) O
at O
9 O
months O
. O
['Resource-use']

Two O
groups O
of O
12 O
severe O
agoraphobics O
were O
treated O
with O
4 O
sessions O
of O
cognitive O
therapy O
followed O
by O
8 O
sessions O
of O
cognitive O
therapy O
combined O
with O
in O
vivo O
exposure O
. O
[]

Suicidal O
ideation O
was O
independently O
associated O
with O
sexual O
abuse O
(AOR O
11.9 O
(3.0-47.0)) O
and O
a O
lack O
of O
parental O
emotional O
support O
(AOR O
0.2 O
(0.1-0.5)). O
[]

There O
were O
11 O
deaths O
because O
of O
heart O
failure O
or O
refractory O
cardiogenic O
shock O
in O
9 O
, O
pulmonary O
embolism O
in O
1 O
, O
and O
cancer O
in O
1 O
. O
[]

There O
was O
no O
statistical O
difference O
in O
pH B-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
between O
the O
groups O
. O
['Physiological-Clinical']

The O
means O
and O
CVs O
of O
MEP B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
in O
all O
limbs O
were O
significantly O
lower O
in O
group O
I. O
The O
mean O
train-of-four B-outcome ['Physiological-Clinical']
(TOF) I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
from O
30 O
to O
80 O
min O
of O
operation O
were O
significantly O
higher O
in O
group O
B. O
CONCLUSION: O
We O
conclude O
that O
the O
continuous O
infusion O
of O
rocuronium O
effectively O
inhibited O
the O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
and O
spontaneous B-outcome ['Physiological-Clinical']
respiration I-outcome ['Physiological-Clinical']
of O
the O
patient O
while O
enabling O
MEP O
monitoring. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O
[]

In O
addition O
, O
mechanical O
prophylaxis O
with O
graduated O
compression O
stockings O
and O
pneumatic O
compression O
boots O
is O
preferable O
to O
anticoagulation O
therapy O
. O
[]

Data O
were O
collected O
at O
25 O
sites O
across O
the O
state O
of O
North O
Carolina O
. O
[]

Anxiety B-outcome ['Life-Impact']
levels O
did O
not O
differ O
between O
the O
groups O
and O
exposure O
to O
TC+TSE O
resulted O
in O
greater O
perceived B-outcome ['Life-Impact']
message I-outcome ['Life-Impact']
benefit I-outcome ['Life-Impact']
, O
increased O
intention B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
self-examine I-outcome ['Life-Impact']
and O
lower O
message B-outcome ['Life-Impact']
denigration I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Premature O
discontinuation O
for O
toxicity B-outcome ['Adverse-effects']
occurred O
in O
14/59 O
during O
venlafaxine O
and O
5/53 O
during O
clonidine O
( O
P O
= O
.038 O
) O
. O
['Adverse-effects']

BACKGROUND O
In O
1998 O
, O
mandatory O
folic O
acid O
fortification O
of O
white O
flour O
and O
select O
cereal O
grain O
products O
was O
implemented O
in O
Canada O
with O
the O
intention O
to O
increase O
dietary O
folate O
intakes O
of O
reproducing O
women O
. O
[]

The O
primary O
outcome O
was O
the O
lowest O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
observed O
during O
the O
interval O
between O
induction O
and O
2 O
minutes O
after O
tracheal O
intubation. O
[['Physiological-Clinical']]

The O
antiischemic B-outcome ['Physiological-Clinical']
effects O
were O
documented O
by O
relief B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
reduction O
of O
ST-depression B-outcome ['Physiological-Clinical']
, O
improvement O
of O
impaired O
myocardial B-outcome ['Physiological-Clinical']
wall I-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
, O
decrease O
to O
normalization O
of O
pathologically B-outcome ['Physiological-Clinical']
elevated I-outcome ['Physiological-Clinical']
filling I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
amelioration O
of O
coronary B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
as O
evidenced O
by O
myocard O
scintigraphy O
and O
washout O
time O
of O
an O
intracoronarily O
injected O
echo-contrast O
medium O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
78 O
patients O
without O
HBV O
markers O
, O
we O
compared O
prednisone O
and O
PE O
to O
prednisone O
alone O
as O
the O
initial O
therapeutic O
regimen O
. O
[]

Over O
a O
61-month O
follow-up O
1,582 O
deaths B-outcome ['Mortality']
( O
1,397 O
cardiovascular O
) O
occurred O
. O
['Mortality']

Additional O
evidence O
for O
intravascular O
coagulation O
came O
from O
the O
changes O
observed O
in O
factor O
VIII O
levels O
which O
, O
although O
initially O
high O
in O
all O
patients O
, O
fell O
subsequently O
, O
particularly O
in O
those O
given O
concentrate O
alone O
. O
[]

Sitting B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
were O
reduced O
6 O
and O
5 O
mmHg O
more O
by O
lisinopril O
than O
by O
nifedipine O
over O
12 O
weeks O
monotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Some O
of O
the O
most O
important O
items O
: O
personality O
, O
motivation O
, O
diet O
history O
, O
bodyweight O
, O
blood O
lipids O
and O
blood O
sugar O
anti-smoking O
advice O
given O
individually O
to O
all O
smokers O
in O
the O
intervention O
group O
advice O
that O
smoking O
cessation O
was O
expected O
to O
be O
of O
special O
importance O
for O
those O
with O
elevated O
blood O
lipids O
. O
[]

These O
complications O
did O
not O
occur O
after O
ECCE O
with O
PCL O
. O
[]

Melatonin O
, O
but O
not O
placebo O
, O
reduced O
task-related B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
rostro-medial O
aspect O
of O
the O
occipital O
cortex O
during O
a O
visual-search O
task O
and O
in O
the O
auditory O
cortex O
during O
a O
music O
task O
. O
['Physiological-Clinical']

Although O
adjuvant O
chemotherapy O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
the O
use O
of O
this O
therapeutic O
approach O
in O
patients O
with O
early O
stage O
MZBCL O
did O
not O
offer O
any O
advantage O
over O
radiotherapy O
alone O
as O
the O
initial O
treatment O
. O
['Life-Impact']

CONCLUSION O
No O
difference O
in O
the O
leak O
rate O
could O
be O
revealed O
. O
[]

RESULTS O
A O
pathologic O
result O
was O
found O
in O
90 O
% O
of O
the O
patients O
. O
[]

Radial O
artery O
occlusion O
( O
RAO O
) O
is O
an O
infrequent O
, O
asymptomatic O
, O
complication O
of O
transradial O
catheterization O
and O
probably O
1 O
of O
the O
few O
. O
[]

Registered O
1 O
May O
2017 O
- O
Retrospectively O
registered, O
http://www.clinicaltrial.gov O
/ O
NCT03134690. O
[]

The O
sections O
were O
submitted O
to O
push-out O
testing O
in O
a O
universal O
testing O
machine O
EMIC O
( O
1 O
mm/min O
) O
. O
[]

Albumin-glutaraldehyde O
bioadhesive O
( O
Bioglue O
) O
for O
prevention O
of O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
after O
stapled O
hemorrhoidopexy O
: O
A O
randomized O
controlled O
trial O
. O
['Adverse-effects']

AIM O
To O
assess O
ambulatory B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
children O
with O
cerebral O
palsy O
( O
CP O
) O
, O
aged O
7 O
to O
13 O
years O
, O
and O
identify O
associated O
characteristics O
. O
['Life-Impact']

There O
was O
no O
statistically O
significant O
difference O
in O
pain B-outcome ['Physiological-Clinical']
scores O
on O
the O
numeric O
analog O
scale O
( O
0-10 O
) O
between O
the O
groups O
at O
4 O
hrs O
after O
surgery O
( O
P O
= O
0.18 O
) O
or O
during O
the O
24 O
hrs O
after O
surgery O
( O
P O
= O
0.23 O
) O
. O
['Physiological-Clinical']

The O
3-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
+/- O
SE O
for O
all O
patients O
with O
CNS+ O
disease O
was O
45 O
% O
+/- O
7 O
% O
. O
['Mortality']

The O
present O
study O
aims O
to O
compare O
the O
effect O
of O
a O
traditional O
Chinese O
Chan-based O
mind-body O
exercise O
, O
Nei O
Yang O
Gong O
, O
with O
that O
of O
the O
conventional O
Progressive O
Muscle O
Relaxation O
( O
PMR O
) O
technique O
in O
enhancing O
the O
self-control O
of O
children O
with O
ASD O
. O
[]

This O
difference O
is O
statistically O
significant O
( O
p O
= O
0.023 O
) O
. O
[]

The O
pain B-outcome ['Physiological-Clinical']
reported O
by O
the O
patients O
was O
subdivided O
into O
four O
severity O
grades O
, O
and O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
recorded O
. O
['Physiological-Clinical', 'Resource-use']

Apneic B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
requiring I-outcome ['Physiological-Clinical']
intubation I-outcome ['Physiological-Clinical']
resulted O
from O
two O
cryotherapy O
sessions O
but O
no O
diode O
laser O
sessions O
. O
['Physiological-Clinical']

Most O
frequent O
grade O
3/4 O
adverse O
events O
were O
neutropenia O
( O
37 O
% O
) O
, O
fatigue O
( O
33 O
% O
) O
and O
hypertension O
( O
30 O
% O
) O
. O
[]

However O
, O
FEV1 B-outcome ['Physiological-Clinical']
continued O
to O
decline O
in O
the O
INB+ O
group O
at O
24 O
hours O
to O
lower O
than O
the O
INB- O
group O
although O
pain B-outcome ['Physiological-Clinical']
scores O
were O
similar O
beyond O
4 O
hours O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
trial O
of O
immunotherapy O
for O
persistent O
genital O
warts O
. O
[]

One O
case O
was O
not O
informative O
at O
any O
of O
the O
loci O
tested O
and O
was O
excluded O
from O
further O
analysis O
. O
[]

Compared O
with O
before O
treatment O
, O
the O
KPS B-outcome ['Physiological-Clinical']
was O
significantly O
improved O
in O
the O
treatment O
group O
after O
treatment O
, O
while O
it O
significantly O
decreased O
in O
the O
control O
group O
after O
treatment O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

One O
intervention O
group O
were O
given O
a O
health O
check O
which O
included O
being O
screened O
for O
cardiovascular O
risk O
factors O
, O
lung O
and O
liver O
function O
, O
fitness O
, O
sight O
and O
hearing O
and O
an O
optional O
test O
for O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
; O
this O
group O
received O
written O
feedback O
from O
the O
general O
practitioner O
. O
[]

Baseline O
characteristics O
differed O
between O
genders, O
with O
women O
being O
younger, O
having O
better O
lung O
function O
and O
more O
often O
experiencing O
>/=2 O
exacerbations O
in O
the O
previous O
year. O
[]

Decrease O
in O
VEGFR2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
significantly O
associated O
with O
response O
rate O
( O
P O
= O
0.02 O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
to O
ascertain O
the O
effect O
of O
administering O
a O
vasodilator O
, O
glyceryl O
trinitrate O
( O
GTN O
) O
, O
immediately O
following O
PTA O
. O
[]

Ten O
minutes O
later O
the O
variables O
were O
measured O
again O
. O
[]

OBJECTIVE O
Our O
purpose O
was O
to O
compare O
the O
effect O
of O
vaginal O
administration O
of O
misoprostol O
( O
Cytotec O
) O
with O
that O
of O
dinoprostone O
( O
Cervidil O
) O
on O
cervical B-outcome ['Physiological-Clinical']
ripening I-outcome ['Physiological-Clinical']
and O
labor B-outcome ['Physiological-Clinical']
induction O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Two O
hundred O
forty-four O
patients O
( O
125 O
women O
, O
119 O
men O
; O
all O
but O
1 O
Hispanic O
) O
were O
randomized O
to O
receive O
pioglitazone O
( O
n O
= O
121 O
) O
or O
glimepiride O
( O
n O
= O
123 O
) O
. O
[]

We O
will O
also O
assess O
teachers' O
autonomy-supportive B-outcome ['Life-Impact', 'Life-Impact']
techniques I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
behaviours S1-outcome ['Life-Impact', 'Life-Impact']
by O
observation. O
[['Life-Impact', 'Life-Impact']]

The O
ability O
to O
predict O
the O
effect O
of O
anthelmintic O
treatment O
on O
milk O
production O
depends O
on O
the O
level O
of O
parasitism O
quantified O
by O
an O
ELISA O
measuring O
milk B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against O
O. O
ostertagi O
, O
and O
reported O
as O
optical B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
ratios I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ODRs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Based O
on O
the O
results O
of O
combined O
data O
from O
three O
North O
American O
Phase O
II O
studies O
, O
a O
randomised O
Phase O
II O
study O
in O
the O
same O
patient O
population O
was O
performed O
, O
using O
combination O
chemotherapy O
with O
estramustine O
phosphate O
( O
EMP O
) O
and O
vinblastine O
( O
VBL O
) O
in O
hormone O
refractory O
prostate O
cancer O
patients O
. O
[]

In O
addition O
, O
sera O
were O
collected O
from O
a O
randomized O
sample O
of O
subjects O
in O
each O
vaccine O
group O
at O
approximately O
3-month O
intervals O
from O
which O
antibody O
kinetic O
curves O
were O
constructed O
, O
which O
allowed O
us O
to O
estimate O
specific O
antibody O
values O
to O
pertussis O
toxin O
( O
PT O
) O
, O
filamentous O
hemagglutinin O
( O
FHA O
) O
, O
pertactin O
and O
fimbriae-2 O
at O
the O
time O
of O
exposure O
in O
the O
household O
setting O
. O
[]

CSF B-outcome ['Physiological-Clinical']
Abeta O
concentrations B-outcome ['Physiological-Clinical']
were O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Between O
60 O
% O
and O
80 O
% O
of O
patients O
who O
undergo O
mastectomy O
( O
with O
axillary O
dissection O
) O
experience O
PONV B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
and O
glucagon B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
rose O
post-operatively O
whether O
or O
not O
insulin O
was O
given O
, O
but O
the O
increment O
in O
insulin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
when O
insulin O
was O
given O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
area O
of O
images O
that O
give O
confidence O
for O
sinus O
surgery O
at O
one O
time O
was O
higher O
for O
standard-dose O
MDCT O
protocol O
technique O
than O
low-dose O
MDCT O
protocol O
method. O
[]

Prospective O
randomized O
trial O
of O
short-term O
neoadjuvant O
chemotherapy O
for O
advanced O
gastric O
cancer O
. O
[]

The O
6-month O
values O
of O
the O
resin O
infiltration O
group O
were O
statistically O
lower O
than O
those O
of O
the O
fluoride O
varnish O
group O
(P O
= O
0.028, O
P O
< O
0.05). O
[]

Randomised O
Phase O
I/II O
trial O
assessing O
the O
safety O
and O
efficacy O
of O
radiolabelled O
anti-carcinoembryonic O
antigen O
I O
( O
131 O
) O
KAb201 O
antibodies O
given O
intra-arterially O
or O
intravenously O
in O
patients O
with O
unresectable O
pancreatic O
adenocarcinoma O
. O
[]

Peritoneal O
equilibration O
tests O
revealed O
subtle B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
solute I-outcome ['Physiological-Clinical']
transport I-outcome ['Physiological-Clinical']
, O
with O
a O
less O
steep B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
equilibration I-outcome ['Physiological-Clinical']
curve O
during O
bicarbonate O
dialysis O
, O
suggesting O
reduced O
peritoneal O
vasodilation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
combination O
of O
ALVAC-CEA/B7.1 O
vaccine O
and O
systemic O
chemotherapy O
has O
an O
acceptable O
safety O
profile O
in O
patients O
with O
metastatic O
colorectal O
cancer O
. O
[]

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
the O
individual O
effectiveness O
of O
three O
types O
of O
conservative O
therapy O
in O
the O
treatment O
of O
plantar O
fasciitis O
. O
[]

However O
, O
ICD O
shocks O
are O
painful O
and O
do O
not O
provide O
complete O
protection O
against O
sudden O
cardiac O
death O
. O
[]

We O
recorded O
Visual O
Analogue O
Scale O
( O
VAS O
) O
, O
satisfaction B-outcome ['Life-Impact']
scores O
, O
morphine B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
side O
effects O
during O
postoperative O
24 O
hours O
. O
['Life-Impact', 'Resource-use']

There O
was O
a O
significant O
correlation O
between O
propofol B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

This O
study O
examined O
the O
[]

There O
were O
no O
statistically O
significant O
differences O
in O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
according O
to O
the O
Academic O
Research O
Consortium O
criteria O
between O
the O
2 O
groups O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Here O
, O
we O
investigated O
the O
relationship O
between O
gaze B-outcome ['Life-Impact']
onto I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
eye I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
mouth I-outcome ['Life-Impact']
regions I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
faces I-outcome ['Life-Impact']
, O
and O
the O
visual O
information O
that O
was O
present O
within O
those O
regions O
. O
['Life-Impact']

Decisions O
about O
diet O
advancement O
and O
hospital O
discharge O
were O
at O
the O
discretion O
of O
the O
medical O
team O
, O
without O
input O
from O
study O
team O
members O
. O
[]

RESULTS O
Twenty O
patients O
were O
randomized O
to O
the O
imiquimod O
( O
n O
= O
10 O
) O
or O
vehicle O
( O
n O
= O
10 O
) O
treatment O
group O
. O
[]

Anticoagulants O
are O
effective O
as O
venous O
thromboprophylaxis, O
but O
with O
an O
increased O
risk O
of O
bleeding. O
[]

Erythropoietin O
can O
be O
combined O
safely O
with O
rhGM-CSF O
after O
autologous O
transplantation O
. O
[]

The O
absence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
on O
the O
last O
dosage O
schedule O
was O
achieved O
during O
normal O
working O
. O
['Physiological-Clinical']

At O
the O
point O
of O
protocol-defined O
study O
completion O
( O
85 O
% O
mortality O
in O
the O
placebo O
arm O
) O
there O
was O
a O
modest O
difference O
in O
survival O
in O
the O
intention-to-treat O
population O
in O
favour O
of O
marimastat O
( O
P=0.07 O
log-rank O
test O
, O
hazard O
ratio=1.23 O
( O
95 O
% O
confidence O
interval O
0.98-1.55 O
) O
) O
. O
[]

2 O
. O
[]

The O
curative O
effect O
was O
compared O
before O
and O
after O
treatment, O
including O
ulcer B-outcome ['Physiological-Clinical']
surface I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
(VAS O
score), O
time B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ulcer I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
, O
and O
the O
changes O
of O
T B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
( O
CD3(+) B-outcome ['Physiological-Clinical']
, O
CD4(+) B-outcome ['Physiological-Clinical']
, O
CD8(+) B-outcome ['Physiological-Clinical']
and O
CD4(+)/CD8(+) B-outcome ['Physiological-Clinical']
) O
before O
and O
after O
treatment O
were O
compared O
by O
SPSS O
22 O
software O
package. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

There O
is O
currently O
no O
effective O
treatment O
for O
these O
problems O
. O
[]

Secondary B-outcome ['Physiological-Clinical']
postoperative I-outcome ['Physiological-Clinical']
hemorrhage I-outcome ['Physiological-Clinical']
was O
noticed O
in O
1 O
subject O
of O
the O
TWT O
group O
and O
3 O
subjects O
of O
the O
BET O
group O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Patients O
randomised O
to O
the O
RT O
group O
received O
50 O
Gy/25 O
fx/5 O
weeks O
of O
teletherapy O
followed O
1-2 O
weeks O
later O
with O
12 O
Gy/2 O
fx O
of O
high-dose-rate O
intra-lumenal O
brachytherapy O
spaced O
a O
week O
apart O
. O
[]

Povidone-iodine O
was O
associated O
with O
the O
shortest O
attachment B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
was O
most O
liked O
. O
['Life-Impact']

Comparison O
of O
different O
long-term O
asthma O
treatments O
in O
subjects O
with O
mild-to-moderate O
asthma O
. O
[]

Patients O
were O
followed O
clinically O
for O
a O
minimum O
of O
1 O
year O
. O
[]

In O
the O
present O
study O
, O
we O
analyzed O
the O
prognostic O
impact O
of O
OPN O
in O
AML O
by O
investigating O
the O
expression B-outcome ['Physiological-Clinical']
and B-outcome ['Physiological-Clinical']
relevance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
OPN I-outcome ['Physiological-Clinical']
in O
newly O
diagnosed O
AML O
patients O
from O
2 O
large O
study O
groups O
( O
the O
German O
AML O
Cooperative O
Group O
and O
the O
Dutch-Belgian O
Hematology O
Oncology O
Cooperative O
group O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
retrospective O
and O
qualitative O
nature O
of O
RCA O
is O
a O
limitation O
in O
scientific O
analyses O
examining O
causal O
relationships O
. O
[]

Follow-up O
shows O
a O
relapse B-outcome ['Physiological-Clinical']
rate O
of O
5 O
% O
in O
the O
CP O
treated O
group O
and O
of O
29 O
% O
in O
the O
controls O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Accordingly O
, O
development O
of O
new O
treatments O
for O
steroid-dependent O
Crohn O
's O
disease O
is O
a O
research O
priority O
. O
[]

Peak O
AT O
strain B-outcome ['Physiological-Clinical']
was O
less O
for O
18HL O
( O
5.5 O
? O
['Physiological-Clinical']

Few O
randomized O
controlled O
trials O
have O
been O
aimed O
specifically O
at O
lifestyle O
issues O
among O
persons O
with O
a O
psychiatric O
disability O
. O
[]

METHODS O
The O
TSH B-outcome ['Physiological-Clinical']
response O
to O
TRH B-outcome ['Physiological-Clinical']
( O
25 O
micrograms B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
intravenous I-outcome ['Physiological-Clinical']
bolus I-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION: O
The O
findings O
demonstrated O
that O
both O
regimens O
of O
drugs O
can O
control O
the O
hemodynamic B-outcome ['Physiological-Clinical']
status O
of O
patients O
during O
laparoscopic O
cholecystectomy, O
which O
provides O
effective O
postoperative O
analgesia O
for O
pain B-outcome ['Physiological-Clinical']
management. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

CONCLUSION O
Home O
sleep O
studies O
are O
a O
viable O
form O
of O
diagnosing O
SAHS O
, O
and O
are O
less O
expensive B-outcome ['Life-Impact']
than O
polysomnography O
. O
['Life-Impact']

METHODS: O
In O
this O
randomized O
controlled O
trial, O
we O
compared O
the O
efficacy O
of O
DR O
versus O
EODR O
by O
measuring O
lipid B-outcome ['Physiological-Clinical']
indices O
and O
serum O
HMGCR B-outcome ['Physiological-Clinical']
levels O
at O
baseline O
and O
after O
12 O
weeks O
of O
10mg O
atorvastatin O
therapy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Randomized O
controlled O
trial O
of O
the O
focus O
parent O
training O
for O
toddlers O
with O
autism O
: O
1-year O
outcome O
. O
[]

The O
mean O
[]

OBJECTIVE O
To O
evaluate O
the O
clinical O
benefit O
of O
montelukast O
, O
a O
cysteinyl O
leukotriene O
receptor O
antagonist O
, O
administered O
once O
daily O
for O
treating O
seasonal B-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Primary O
end O
points O
of O
effectiveness O
( O
three O
parameters O
) O
and O
secondary O
end O
points O
of O
safety O
during O
ESD O
and O
after O
return O
to O
the O
ward O
were O
compared O
between O
the O
groups O
. O
[]

RESULTS O
The O
primary O
outcome O
occurred O
in O
351 O
of O
4998 O
patients O
( O
7.0 O
% O
) O
in O
the O
aspirin O
group O
and O
in O
355 O
of O
5012 O
patients O
( O
7.1 O
% O
) O
in O
the O
placebo O
group O
( O
hazard O
ratio O
in O
the O
aspirin O
group O
, O
0.99 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.86 O
to O
1.15 O
; O
P=0.92 O
) O
. O
[]

Cigarette O
smoking O
is O
associated O
with O
increased O
circulating O
proinflammatory O
and O
procoagulant O
markers O
in O
patients O
with O
chronic O
coronary O
artery O
disease O
: O
effects O
of O
aspirin O
treatment O
. O
[]

Methodology O
of O
serial O
ECG O
classification O
using O
an O
adaptation O
of O
the O
NOVACODE O
for O
Q O
wave O
myocardial O
infarction O
in O
the O
Bypass O
Angioplasty O
Revascularization O
Investigation O
( O
BARI O
) O
. O
[]

Disease B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
side O
effects O
were O
compared O
using O
Fisher O
's O
exact O
test O
. O
['Physiological-Clinical']

Using O
a O
quasi-experimental O
design O
, O
the O
authors O
studied O
118 O
left-heart O
catheterization O
patients O
who O
were O
randomly O
assigned O
to O
4 O
hours O
or O
6 O
hours O
of O
bed O
rest O
. O
[]

RESULTS O
We O
observed O
an O
advantage O
of O
omega-3 O
fatty O
acids O
compared O
with O
placebo O
for O
hyperactivity B-outcome ['Physiological-Clinical']
and O
stereotypy B-outcome ['Physiological-Clinical']
, O
each O
with O
a O
large O
effect O
size O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
connection O
was O
observed O
between O
gluten O
and O
behaviour B-outcome ['Life-Impact']
typical O
for O
these O
patients O
. O
['Life-Impact']

The O
decrease O
in O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
was O
, O
however O
, O
more O
marked O
in O
the O
high O
dose O
budesonide O
group O
, O
reaching O
a O
borderline O
significance O
( O
P=0.10 O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

However O
, O
there O
were O
not O
significantly O
more O
patients O
on O
atomoxetine O
( O
20.9 O
% O
) O
who O
improved O
much O
, O
or O
very O
much O
according O
to O
the O
CGI-I O
, O
than O
on O
placebo O
( O
8.7 O
% O
; O
p O
= O
0.14 O
) O
. O
[]

In O
this O
study O
, O
we O
evaluated O
if O
increased O
sympathetic O
stimulation O
is O
an O
essential O
requirement O
for O
the O
development O
of O
neurally O
mediated O
syncope O
( O
NMS O
) O
by O
manipulating O
overall O
sympathetic O
outflow O
in O
subjects O
susceptible O
to O
tilt-induced O
syncope O
. O
[]

Efficiency O
of O
slush O
nitrogen O
vitrification O
of O
human O
oocytes O
vitrified O
with O
or O
without O
cumulus O
cells O
in O
relation O
to O
survival B-outcome ['Mortality']
rate O
and O
meiotic B-outcome ['Physiological-Clinical']
spindle I-outcome ['Physiological-Clinical']
competence I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical']

PURPOSE O
Deep O
vein O
thrombosis O
( O
DVT O
) O
is O
a O
preventable O
cause O
of O
morbidity O
and O
mortality O
in O
patients O
who O
are O
hospitalized O
. O
[]

OBJECTIVE O
Transthoracic B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
factor O
determining O
the O
magnitude O
of O
the O
transmyocardial O
current O
during O
external O
defibrillation O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
describe O
the O
authors O
' O
experience O
of O
conducting O
a O
clinical O
drug O
trial O
in O
children O
with O
Asperger O
Syndrome O
, O
including O
the O
pitfalls O
encountered O
and O
lessons O
learnt O
. O
[]

RESULTS O
For O
the O
primary O
end O
point O
, O
mean O
+/- O
sd O
maximum O
negative O
intrathoracic B-outcome ['Physiological-Clinical']
pressures B-outcome ['Physiological-Clinical']
( O
mm O
Hg O
) O
during O
the O
decompression O
phase O
of O
cardiopulmonary B-outcome ['Physiological-Clinical']
resuscitation I-outcome ['Physiological-Clinical']
were O
-1.0 O
+/- O
0.73 O
mm O
Hg O
with O
a O
sham O
vs. O
-4.6 O
+/- O
3.7 O
mm O
Hg O
with O
an O
active O
ITD O
on O
the O
facemask O
( O
p O
= O
.003 O
) O
and O
-1.3 O
+/- O
1.3 O
mm O
Hg O
with O
a O
sham O
ITD O
vs. O
-7.3 O
+/- O
4.5 O
mm O
Hg O
with O
an O
active O
ITD O
on O
an O
ETT O
( O
p O
= O
.0009 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Weekly O
contact O
was O
made O
with O
at O
least O
88 O
percent O
of O
the O
children O
in O
both O
study O
groups O
. O
[]

Limitations O
include O
small O
sample O
size O
and O
the O
crossover O
design O
of O
the O
study O
. O
[]

ASI O
has O
minimal O
adverse O
reactions O
and O
should O
be O
considered O
in O
the O
management O
of O
stage O
II O
colon O
cancer O
. O
[]

The O
mean O
volumes O
of O
contrast O
agent O
used O
and O
prehydration O
given O
for O
each O
of O
the O
three O
groups O
did O
not O
differ O
significantly O
( O
p O
> O
0.83 O
) O
. O
[]

Mood O
forms O
and O
psychomotor O
tests O
were O
completed O
, O
and O
miosis O
was O
assessed O
, O
during O
and O
after O
the O
infusions O
. O
[]

Previous O
studies O
suggest O
that O
less O
costly O
, O
pulsed O
doses O
of O
antifungal O
medications O
may O
be O
as O
effective O
as O
standard O
, O
continuous O
doses O
. O
[]

Heparin O
was O
injected O
over O
10 O
seconds O
on O
the O
right O
abdominal O
site O
and O
30 O
seconds O
on O
the O
left O
abdominal O
site O
. O
[]

Omadacycline O
also O
was O
noninferior O
to O
linezolid O
with O
respect O
to O
investigator-assessed O
clinical B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
at O
the O
post-treatment O
evaluation O
in O
the O
modified O
intention-to-treat O
population O
(rate O
of O
response, O
86.1% O
and O
83.6%, O
respectively; O
difference, O
2.5 O
percentage O
points; O
95% O
CI, O
-3.2 O
to O
8.2) O
and O
in O
the O
clinical O
per-protocol O
population O
(96.3% O
and O
93.5%, O
respectively; O
difference, O
2.8 O
percentage O
points; O
95% O
CI, O
-1.0 O
to O
6.9). O
[['Physiological-Clinical']]

The O
control O
group O
showed O
the O
highest O
levels O
of O
TNFalpha B-outcome ['Physiological-Clinical']
at O
the O
fourteenth O
postoperative O
day O
. O
['Physiological-Clinical']

Patients O
rated O
their O
change O
in O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
functioning B-outcome ['Life-Impact']
, O
and O
overall/global B-outcome ['Life-Impact']
quality O
of O
life O
( O
QOL B-outcome ['Life-Impact']
) O
by O
completing O
a O
seven-category O
SSQ O
at O
weeks O
4 O
and O
7 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Plasma O
level O
of O
ISDN O
and O
the O
mononitrates O
, O
measured O
one O
and O
four O
hours O
after O
drug O
intake O
, O
rose O
almost O
linearly O
in O
relation O
to O
dose O
. O
[]

Listening O
to O
motivational O
music O
during O
the O
recovery O
was O
associated O
with O
increased O
voluntary O
activity O
of O
the O
participants O
, O
determined O
by O
increased O
number O
of O
steps O
( O
499.4 O
? O
[]

QoL B-outcome ['Life-Impact']
improved O
in O
the O
study O
group O
and O
deteriorated O
in O
the O
control O
one O
. O
['Life-Impact']

The O
overall O
difference O
between O
all O
956 O
pairs O
of O
pulse O
oximetry B-outcome ['Physiological-Clinical']
haemoglobin I-outcome ['Physiological-Clinical']
concentration O
and O
true O
haemoglobin O
concentrations O
( O
the O
bias O
) O
averaged O
only O
-0.7 O
g O
l O
whereas O
the O
95 O
% O
prediction O
interval O
was O
wide O
, O
ranging O
from O
-24.9 O
to O
23.7 O
g O
l. O
In O
addition O
to O
the O
choice O
of O
infusion O
fluid O
, O
the O
bias O
was O
strongly O
dependent O
on O
the O
volunteer O
( O
each O
factor O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

When O
the O
pattern O
of O
cognitive B-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
over I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
was O
compared O
using O
sophisticated O
modeling O
techniques O
, O
the O
two O
groups O
were O
again O
comparable O
, O
except O
for O
results O
on O
the O
test O
of O
verbal B-outcome ['Life-Impact']
fluency I-outcome ['Life-Impact']
, O
in O
which O
the O
off-pump O
group O
showed O
more O
rapid O
postsurgical O
cognitive B-outcome ['Life-Impact']
gains I-outcome ['Life-Impact']
than O
the O
on-pump O
group O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

After O
2 O
years O
, O
the O
drug-treatment O
strategy O
became O
unrestricted O
, O
but O
still O
targeted O
remission O
. O
[]

Often O
subjects O
have O
been O
instructed O
to O
refrain O
from O
blinking O
lest O
their O
evoked O
EEG O
potentials O
should O
be O
distorted O
. O
[]

Additionally O
study O
was O
done O
to O
determine O
if O
the O
use O
of O
topical O
anesthetic O
decreased O
the O
pain B-outcome ['Physiological-Clinical']
of O
needle O
insertion O
with O
the O
P-ASA O
injection O
. O
['Physiological-Clinical']

Osteocalcin O
in O
patients O
with O
rheumatoid O
arthritis O
. O
[]

METHODS O
A O
cross-sectional O
and O
prospective O
study O
was O
performed O
. O
[]

There O
was O
no O
difference O
between O
the O
groups O
in O
VAS O
scores O
on O
postoperative O
day O
14 O
. O
[]

Prospective O
, O
randomized O
comparison O
of O
transperitoneal O
versus O
retroperitoneal O
laparoscopic O
adrenalectomy O
. O
[]

Three-year O
OS O
did O
not O
differ O
between O
the O
two O
groups O
( O
67.4 O
% O
and O
67.7 O
% O
, O
respectively O
; O
hazard O
ratio O
( O
HR O
) O
=1.01 O
[ O
0.79-1.30 O
] O
, O
p=0.92 O
) O
, O
nor O
did O
3-year O
disease-free O
survival O
, O
response O
rates O
, O
toxicity O
, O
or O
postoperative O
mortality O
. O
[]

METHODS O
Eighty O
patients O
in O
whom O
ultrasonography O
revealed O
unilateral O
, O
mobile O
, O
unilocular O
, O
thin-walled O
ovarian O
cysts O
without O
internal O
echoes O
and O
greater O
than O
30 O
mm O
but O
not O
exceeding O
60 O
mm O
in O
diameter O
were O
enrolled O
into O
the O
study O
. O
[]

plus O
omeprazole O
20 O
mg O
b.d. O
, O
or O
amoxycillin O
500 O
mg O
q.d.s O
. O
[]

RESULTS: O
Gastrocnemius B-outcome ['Physiological-Clinical']
medialis I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
during O
mid O
stance O
(23.46%MVIC, O
95% O
CI O
= O
-32.53, O
-14.39) O
and O
late O
stance O
phases O
(3.25%MVIC, O
95% O
CI O
= O
-5.67, O
-0.81) O
of O
gait O
increased O
after O
the O
application O
of O
KT O
in O
the O
KT O
group O
compared O
to O
baseline O
values. O
[['Physiological-Clinical']]

CBF B-outcome ['Physiological-Clinical']
and O
the O
arteriovenous B-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
( O
AVDO2 O
) O
were O
measured O
twice O
, O
before O
and O
after O
indomethacin/placebo O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Outcome O
measures O
included O
time O
to O
response O
to O
verbal B-outcome ['Life-Impact']
command B-outcome ['Life-Impact']
, O
Aldrete B-outcome ['Physiological-Clinical']
score O
= O
9 O
, O
Postanesthesia O
Discharge O
Scoring O
System O
= O
7 O
, O
and O
assessment O
by O
the O
Digit O
Symbol B-outcome ['Physiological-Clinical']
Substitution O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Based O
on O
two-sided O
univariate O
log-rank O
analysis O
of O
pooled O
data O
from O
E1684 O
and O
E1690 O
( O
median O
follow-up O
, O
7.2 O
years O
) O
, O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
RFS I-outcome ['Mortality']
) I-outcome ['Mortality']
-but O
not O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
-was O
significantly O
prolonged O
( O
two-sided O
log-rank O
P O
value O
= O
0.006 O
) O
for O
patients O
treated O
with O
HDI O
versus O
Obs O
. O
['Mortality', 'Mortality']

Mecamylamine O
pretreatment O
prevented O
the O
increase O
in O
alpha B-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
caused O
by O
the O
4 O
mg O
gum O
dose O
but O
not O
the O
8 O
mg O
dose O
. O
['Physiological-Clinical']

Before O
initiation O
of O
trial O
centers O
, O
outcome O
ratings O
were O
obtained O
for O
sample O
cases O
to O
establish O
initial O
levels O
of O
agreement O
. O
[]

All O
treatments O
were O
administered O
for O
3 O
consecutive O
days O
with O
2 O
days O
of O
follow-up O
. O
[]

Fundamental O
frequency O
( O
F0 O
) O
, O
sound O
pressure O
level O
( O
SPL O
) O
and O
long-term-average O
spectrum O
( O
LTAS O
) O
analyses O
were O
made O
. O
[]

Journal O
ID: O
100968562 O
[]

A O
clinical O
randomized O
investigation O
was O
undertaken O
to O
determine O
the O
value O
of O
midazolam O
as O
a O
narcotic O
adjuvant O
for O
anesthetic O
induction O
. O
[]

'piano O
' O
) O
than O
an O
unrelated O
prime O
( O
e.g O
. O
[]

The O
control O
group O
had O
significantly O
more O
positive O
blood B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
( O
P=0.002 O
) O
. O
['Physiological-Clinical']

Current O
therapy O
with O
beta O
adrenergic O
antagonists O
is O
designed O
to O
moderate O
the O
up-regulation O
of O
norepinephrine O
and O
sympathetic O
effects O
; O
however O
, O
to O
date O
, O
there O
are O
no O
therapies O
that O
specifically O
address O
the O
withdrawal O
of O
parasympathetic O
influences O
on O
cardiac O
function O
and O
structure O
. O
[]

Four O
of O
22 O
isolates O
were O
resistant B-outcome ['Physiological-Clinical']
to O
chloroquine O
( O
MIC O
> O
108 O
nM/litre O
) O
. O
['Physiological-Clinical']

In O
this O
prospective O
multicentre O
trial O
, O
90 O
patients O
undergoing O
autologous O
stem O
cell O
transplantation O
( O
ASCT O
) O
were O
randomised O
to O
receive O
( O
n=43 O
) O
or O
not O
receive O
( O
n=47 O
) O
amifostine O
910 O
mg/m O
( O
2 O
) O
prior O
to O
melphalan O
200 O
mg/m O
( O
2 O
) O
. O
[]

In O
conclusion O
, O
lamivudine O
is O
suitable O
for O
treatment O
of O
a O
wide O
range O
of O
patients O
with O
chronic O
hepatitis O
B O
, O
including O
those O
with O
pre-core O
mutant O
HBV O
infection O
. O
[]

The O
echocamera O
provided O
improved O
localization O
of O
the O
IJV O
and O
the O
CA O
in O
comparison O
with O
the O
Doppler O
ultrasound O
. O
( O
[]

The O
3,583 O
men O
in O
the O
CARE O
trial O
also O
showed O
a O
reduction O
in O
risk O
, O
but O
the O
magnitude O
tended O
to O
be O
less O
. O
[]

In O
contrast O
, O
lathosterol/TC O
unchanged O
and O
campesterol/TC O
increased O
, O
increasing O
campesterol/lathosterol O
ratio O
for O
52 O
weeks O
in O
double-dose O
statin O
. O
[]

Piritramide B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
was O
identical O
in O
both O
groups O
( O
19.7 O
+/- O
16 O
mg O
vs. O
19.8 O
+/- O
19 O
mg O
) O
. O
['Resource-use']

Based O
on O
the O
findings O
, O
we O
suggest O
an O
approach O
utilising B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
guidebook I-outcome ['Life-Impact']
to O
improve O
patient B-outcome ['Life-Impact']
participation I-outcome ['Life-Impact']
in O
disease O
management O
. O
['Life-Impact', 'Life-Impact']

DESIGN O
AND O
SETTING O
A O
prospective O
, O
double-blind O
, O
placebo-controlled O
and O
randomized O
study O
at O
a O
single O
tertiary O
care O
hospital O
. O
[]

CONCLUSIONS O
The O
current O
report O
calls O
attention O
to O
the O
importance O
of O
central O
pathologic O
review O
in O
large O
multiinstitutional O
trials O
of O
children O
with O
gliomas O
and O
suggests O
that O
aggressive O
front-line O
combined O
chemoradiotherapy O
does O
not O
confer O
a O
survival B-outcome ['Mortality']
advantage O
in O
this O
highly O
selected O
population O
of O
patients O
. O
['Mortality']

Pacing B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
values O
both O
at O
implant O
( O
unipolar O
571 O
+/- O
165 O
omega O
; O
bipolar O
605 O
+/- O
123 O
omega O
) O
and O
at O
follow-ups O
( O
unipolar O
480 O
+/- O
72 O
omega O
; O
bipolar O
518 O
+/- O
75 O
omega O
) O
are O
slightly O
lower O
in O
the O
unipolar O
configuration O
. O
['Physiological-Clinical']

No O
major B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
effect O
was O
observed O
. O
['Adverse-effects']

Study O
2 O
included O
49 O
subjects O
assigned O
to O
risperidone O
only O
and O
75 O
subjects O
assigned O
to O
risperidone O
plus O
parent O
training O
. O
[]

Baseline O
tear O
and O
saliva O
production O
was O
significantly O
reduced O
during O
disopyramide O
therapy O
, O
but O
was O
restored O
toward O
normal O
by O
the O
addition O
of O
pyridostigmine O
. O
( O
[]

The O
area O
under O
the O
receiver-operating O
characteristics O
curve O
for O
BNP O
to O
identify O
heart O
failure O
was O
0.87 O
( O
95 O
% O
confidence O
interval O
, O
0.81-0.93 O
) O
. O
[]

Are O
prenatal O
ultrasound O
scans O
associated O
with O
the O
autism B-outcome ['Life-Impact']
phenotype I-outcome ['Life-Impact']
? O
['Life-Impact']

After O
0.5 O
week O
( O
range O
3 O
to O
4 O
days O
) O
of O
treatment O
patients O
receiving O
silodosin O
vs O
placebo O
achieved O
significant O
improvement O
in O
total O
International O
Prostate B-outcome ['Physiological-Clinical']
Symptom B-outcome ['Physiological-Clinical']
Score O
( O
difference O
-1.9 O
, O
p O
< O
0.0001 O
) O
and O
irritative B-outcome ['Physiological-Clinical']
( O
-0.5 O
, O
p O
= O
0.0002 O
) O
and O
obstructive B-outcome ['Physiological-Clinical']
( O
-1.4 O
, O
p O
< O
0.0001 O
) O
subscores O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
higher O
proportion O
of O
participants O
consulted B-outcome ['Resource-use']
the I-outcome ['Resource-use']
general I-outcome ['Resource-use']
practitioner I-outcome ['Resource-use']
( O
GP O
) O
in O
the O
3 O
months O
following O
an O
X-ray O
( O
OR O
= O
2.72 O
; O
95 O
% O
CI O
, O
1.80 O
to O
4.10 O
) O
. O
['Resource-use']

RESULTS O
The O
following O
GCV B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
mean O
+/-SD O
) O
were O
determined O
: O
with O
CrCl O
of O
> O
or O
=70 O
ml/min O
, O
the O
minimum O
steady-state O
concentration O
( O
Cmin O
) O
and O
maximum O
concentration O
( O
Cmax O
) O
were O
0.78+/-0.46 O
microg/ml O
and O
1.42+/-0.37 O
microg/ml O
, O
respectively O
, O
with O
a O
24-hr O
area O
under O
the O
concentration O
time O
curve O
( O
AUC0-24 O
) O
of O
24.7+/-7.8 O
microg O
x O
hr/ml O
; O
with O
CrCl O
of O
50-69 O
ml/min O
, O
the O
Cmin O
and O
Cmax O
were O
1.93+/-0.48 O
and O
2.57+/-0.39 O
microg/ml O
, O
respectively O
, O
with O
an O
AUC0-24 O
of O
52.1+/-10.1 O
microg O
x O
hr/ml O
; O
with O
CrCl O
of O
25-50 O
ml/min O
, O
the O
Cmin O
and O
Cmax O
were O
0.41+/-0.27 O
and O
1.17+/-0.32 O
microg/ml O
, O
respectively O
, O
with O
an O
AUC0-24 O
of O
14.6+/-7.4 O
microg O
x O
hr/ml O
. O
['Physiological-Clinical']

A O
prospective O
randomized O
clinical O
trial O
assessing O
the O
relative O
effectiveness O
of O
erythromycin-neomycin O
and O
metronidazole-neomycin O
as O
a O
preoperative O
bowel O
preparation O
was O
carried O
out O
. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O
[]

0.25 O
mm O
) O
. O
[]

catheters O
( O
short O
lines O
) O
versus O
long O
( O
30 O
cm O
) O
i.v O
. O
[]

The O
primary O
end O
point O
was O
the O
major B-outcome ['Physiological-Clinical']
molecular I-outcome ['Physiological-Clinical']
response O
( O
MMR O
) O
rate O
at O
12 O
months O
. O
['Physiological-Clinical']

Six O
ovulatory O
cycles O
were O
assessed O
. O
[]

A O
sample O
was O
selected O
of O
85 O
children O
with O
LD O
, O
with O
age O
range O
between O
8 O
years O
and O
10 O
years O
( O
age O
, O
M=111.02 O
, O
SD=9.6 O
) O
, O
whose O
spelling O
performance O
was O
two O
years O
below O
grade O
level O
. O
[]

The O
efficacy O
of O
nicorandil O
was O
compared O
with O
that O
of O
nifedipine O
in O
13 O
patients O
with O
vasospastic O
angina O
enrolled O
in O
a O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

BACKGROUND O
Breathlessness O
in O
advanced O
disease O
causes O
significant O
distress B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
and O
carers O
and O
presents O
management O
challenges O
to O
health O
care O
professionals O
. O
['Physiological-Clinical']

CONCLUSIONS O
Balsalazide O
disodium O
1.1 O
g O
tablets O
administered O
as O
3.3 O
g O
twice O
daily O
are O
effective O
, O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
significantly O
better O
than O
placebo O
for O
improving O
signs B-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
mild-to-moderately-active I-outcome ['Physiological-Clinical']
UC I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Before O
and O
after O
the O
program O
, O
all O
subjects O
participated O
in O
DTI O
scans O
. O
[]

Fifty-one O
patients O
were O
randomized O
to O
the O
syncope O
unit O
. O
[]

BACKGROUND O
To O
understand O
better O
the O
genetic O
basis O
of O
the O
clonal O
evolution O
of O
prostate O
carcinoma O
, O
the O
authors O
analyzed O
the O
pattern O
of O
allelic B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
25 O
matched O
primary O
and O
metastatic O
prostate O
tumors O
. O
['Physiological-Clinical']

Conclusions: O
No O
dose-response O
relationship O
of O
netupitant O
in O
terms O
of O
overall O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
rate O
was O
observed O
in O
this O
study. O
[['Physiological-Clinical']]

CONCLUSIONS O
The O
effectiveness O
of O
i.v O
. O
[]

After O
induction O
of O
general O
anaesthesia O
, O
the O
devices O
were O
inserted O
, O
its O
correct O
placement O
was O
verified O
and O
airway O
leak O
pressure O
was O
measured O
. O
[]

Patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
scores O
were O
lower O
in O
the O
conservative O
treatment O
group O
compared O
with O
each O
of O
the O
other O
two O
groups O
which O
in O
turn O
, O
were O
no O
different O
from O
each O
other O
regarding O
this O
outcome O
( O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Tromethamine O
buffer O
modifies O
the O
depressant B-outcome ['Resource-use']
effect O
of O
permissive O
hypercapnia O
on O
myocardial O
contractility O
in O
patients O
with O
acute O
respiratory O
distress O
syndrome O
. O
['Resource-use']

In O
a O
classical O
test O
of O
executive O
function O
( O
random O
response O
generation O
) O
, O
BOLD B-outcome ['Physiological-Clinical']
signal I-outcome ['Physiological-Clinical']
differed O
between O
the O
groups O
in O
the O
cerebellum O
but O
not O
in O
the O
frontal O
lobes O
. O
['Physiological-Clinical']

The O
treatment O
period O
was O
15 O
+/- O
1 O
days O
. O
[]

Effects O
of O
coronary O
sinus O
occlusion O
on O
myocardial O
ischaemia O
in O
humans O
: O
role O
of O
coronary O
collateral O
function O
. O
[]

Results O
Of O
435 O
patients O
enrolled O
, O
233 O
were O
treatment O
naive O
( O
54 O
% O
) O
and O
202 O
were O
cytokine O
pretreated O
( O
46 O
% O
) O
. O
[]

A O
randomly O
selected O
diet O
and O
control O
group O
with O
10 O
children O
in O
each O
group O
participated O
. O
[]

Among O
63 O
evaluable O
patients O
, O
similar O
response O
rates O
( O
62.1 O
% O
and O
64.7 O
% O
respectively O
) O
were O
recorded O
for O
the O
treatment O
arms O
. O
[]

To O
compare O
interventions O
, O
we O
analysed O
students O
' O
diagnostic O
accuracy O
. O
[]

Parallel O
to O
the O
clinical O
trials O
, O
experimental O
canine O
artery O
stenting O
was O
performed O
to O
evaluate O
differences O
in O
the O
long-term O
patency O
of O
stents O
exposed O
to O
restricted O
flow O
. O
[]

Treatment O
with O
spironolactone O
was O
associated O
with O
increased O
serum B-outcome ['Physiological-Clinical']
creatinine I-outcome ['Physiological-Clinical']
levels O
and O
a O
doubling O
of O
the O
rate O
of O
hyperkalemia B-outcome ['Physiological-Clinical']
( O
18.7 O
% O
, O
vs. O
9.1 O
% O
in O
the O
placebo O
group O
) O
but O
reduced O
hypokalemia O
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
convenient O
, O
low-cost O
interventions O
can O
be O
implemented O
in O
a O
variety O
of O
settings O
and O
should O
be O
tested O
further O
to O
assess O
their O
long-term O
effectiveness O
. O
[]

All O
reactions O
resolved O
without O
incident O
. O
[]

RESULTS O
Eighty O
patients O
were O
enrolled O
in O
the O
study O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
VF I-outcome ['Physiological-Clinical']
was O
longer O
in O
the O
ablation O
group O
( O
median O
18.6 O
months O
[ O
lower O
quartile O
2.4 O
, O
upper O
quartile O
not O
determinable O
] O
) O
than O
in O
the O
control O
group O
( O
5.9 O
months O
[ O
IQR O
0.8-26.7 O
] O
) O
. O
['Physiological-Clinical']

IIT O
did O
not O
increase O
the O
anabolic O
hormone O
IGF-I O
in O
critically O
ill O
adults O
, O
but O
feeding O
in O
critically O
ill O
children O
and O
pediatric O
hormonal O
responses O
may O
differ O
. O
[]

PURPOSE O
This O
phase O
III O
study O
compared O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of O
an O
oral O
regimen O
of O
dihydropyrimidine O
dehydrogenase O
inhibitory O
fluoropyrimidine O
composed O
of O
a O
fixed O
combination O
of O
tegafur O
and O
uracil O
in O
a O
1:4 O
molar O
ratio O
( O
UFT O
) O
and O
leucovorin O
( O
LV O
) O
to O
intravenous O
( O
IV O
) O
fluorouracil O
( O
5-FU O
) O
and O
LV O
in O
previously O
untreated O
metastatic O
colorectal O
carcinoma O
( O
CRC O
) O
patients O
. O
['Physiological-Clinical']

The O
combination O
treatment O
group O
showed O
a O
trend O
to O
outperform O
other O
active O
treatment O
groups O
, O
with O
fewer O
dropouts O
and O
a O
greater O
proportion O
of O
treatment O
responders O
achieving O
clinically O
significant O
changes O
( O
63.38 O
% O
normative O
sleep O
efficiency O
criterion O
of O
> O
85 O
% O
and O
84.62 O
% O
, O
sleep O
onset O
latency O
< O
30 O
min O
) O
. O
[]

End O
points O
were O
patient O
and O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
, O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
, O
and O
incidence O
of O
steroid B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
during O
the O
first O
year O
after O
LT O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects']

The O
population O
studied O
had O
a O
mean O
age O
of O
60.6 O
years. O
[]

These O
results O
suggest O
that O
impaired O
metabolism O
of O
BK O
induced O
by O
ACE O
inhibitors O
may O
relate O
to O
the O
manifestation O
of O
cough O
in O
hypertensive O
patients O
receiving O
ACE O
inhibitors O
. O
[]

There O
was O
not O
significantly O
different O
in O
the O
patient O
satisfaction B-outcome ['Life-Impact']
of O
analgesia, O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
neonatal B-outcome ['Physiological-Clinical']
outcomes O
and O
neurological B-outcome ['Physiological-Clinical']
deficit I-outcome ['Physiological-Clinical']
between O
the O
2 O
groups. O
[['Life-Impact'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

RESULTS O
All O
the O
patients O
were O
followed O
up O
, O
and O
the O
duration O
ranged O
from O
12 O
to O
30 O
months O
, O
with O
an O
average O
of O
15.6 O
months O
. O
[]

Participating O
institutions O
were O
asked O
to O
send O
five O
full O
patient O
records O
with O
the O
chemotherapy O
charts O
, O
surgical O
and O
pathology O
reports O
, O
radiation O
treatment O
charts O
, O
treatment O
planning O
calculations O
, O
computed O
tomography O
( O
CT O
) O
scans O
, O
portal O
images O
and O
follow-up O
charts O
. O
[]

BACKGROUND O
This O
study O
examines O
socio-demographic O
determinants O
of O
participation O
in O
a O
population-based O
randomized O
controlled O
trial O
that O
proved O
that O
oral O
visual O
inspection O
was O
effective O
in O
reducing O
oral B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
high-risk O
individuals O
in O
India O
. O
['Mortality']

Similarly O
, O
Steri-Strip O
S O
versus O
suture O
for O
the O
abdomen O
was O
faster O
( O
p O
< O
0.001 O
; O
4.9 O
minutes O
, O
SD O
= O
2.3 O
versus O
10.1 O
minutes O
, O
SD O
= O
3.4 O
) O
. O
[]

The O
training O
was O
conducted O
for O
five O
weeks O
, O
consisting O
of O
two O
hours O
training O
a O
week O
. O
[]

Confidential O
registration O
in O
health O
services O
: O
randomised O
controlled O
trial O
. O
[]

CS O
and O
OS O
were O
performed O
in O
random O
order O
, O
30 O
minutes O
apart O
. O
[]

This O
study O
has O
been O
submitted O
for O
registration O
with O
ClinicalTrials.gov O
, O
number O
1839IL/709 O
. O
[]

Entacapone O
( O
OR-611 O
) O
, O
a O
novel O
COMT O
inhibitor O
, O
which O
does O
not O
cross O
the O
blood O
brain O
barrier O
, O
was O
assessed O
in O
12 O
patients O
with O
Parkinson O
's O
disease O
and O
motor O
fluctuations O
in O
a O
randomised O
, O
double-blind O
, O
cross-over O
, O
single O
dose O
study O
. O
[]

For O
patients O
reporting O
'a O
little O
' O
change O
in O
[]

LDL O
cholesterol-raising O
effect O
of O
low-dose O
docosahexaenoic O
acid O
in O
middle-aged O
men O
and O
women O
. O
[]

In O
addition O
, O
the O
influence O
of O
regression O
on O
resting O
diastolic O
filling O
and O
on O
cardiac O
output O
and O
ejection O
fraction O
during O
rest O
and O
mild O
upright O
bicycle O
exercise O
were O
determined O
. O
[]

When O
dazmegrel O
was O
orally O
administered O
to O
greyhound O
dogs O
wearing O
leg O
casts O
, O
it O
resulted O
in O
a O
sparring O
effect O
on O
the O
skin O
areas O
of O
potential O
pressure O
ulcer O
development O
. O
[]

Ongoing O
monitoring O
of O
BMD O
is O
therefore O
not O
routinely O
required O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
in O
a O
prospective O
trial O
AV O
conduction O
during O
the O
long-term O
follow-up O
of O
patients O
with O
sick O
sinus O
syndrome O
. O
[]

[ O
Value O
of O
absorbable O
clips O
in O
laparoscopic O
cholecystectomy O
. O
[]

Combination O
chemotherapy O
was O
more O
myelotoxic B-outcome ['Physiological-Clinical']
than O
MPH-P O
and O
, O
in O
particular O
, O
caused O
more O
non-haematological B-outcome ['Adverse-effects']
side-effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Our O
data O
indicate O
that O
aztreonam O
is O
safe O
and O
effective O
for O
the O
prevention O
of O
infections O
following O
biliary O
and O
gastric O
surgery O
. O
[]

Participants O
receiving O
X-rays O
are O
more O
satisfied O
with O
their O
care O
, O
but O
are O
not O
less O
worried O
or O
more O
reassured O
about O
serious O
disease O
causing O
their O
low O
back O
pain O
. O
[]

The O
recovery O
rates O
of O
children O
with O
acute O
diarrhoea O
receiving O
GB O
( O
vs. O
control O
) O
were O
significantly O
more O
by O
day O
3 O
: O
79.9 O
% O
vs O
. O
[]

Coils O
were O
used O
more O
commonly O
with O
PVA O
embolization O
( O
P O
< O
.0001 O
) O
. O
[]

BACKGROUND O
There O
is O
increasing O
evidence O
that O
dietary O
factors O
may O
play O
a O
role O
in O
the O
production O
, O
metabolism O
, O
and O
bioavailability O
of O
sex O
hormones O
and O
their O
impact O
on O
target O
tissues O
. O
[]

All O
patients O
had O
> O
1 O
mm O
ST-depression O
on O
exercise O
test O
. O
[]

Home O
based O
management O
in O
multiple O
sclerosis O
: O
results O
of O
a O
randomised O
controlled O
trial O
. O
[]

Pretreatment O
with O
thiopental O
0.25 O
mg/kg O
and O
0.5 O
mg/kg O
after O
manual O
venous O
occlusion O
for O
1 O
min O
effectively O
attenuated O
pain B-outcome ['Physiological-Clinical']
associated O
with O
propofol O
injection O
. O
['Physiological-Clinical']

We O
examined O
vascular O
function O
and O
structure O
in O
: O
( O
1 O
) O
healthy O
lowlanders O
during O
acute O
hypoxia O
and O
prolonged O
( O
?2 O
weeks O
) O
exposure O
to O
high O
altitude O
, O
and O
( O
2 O
) O
high-altitude O
natives O
at O
5050 O
m O
( O
highlanders O
) O
. O
[]

The O
purpose O
of O
the O
study O
was O
to O
ascertain O
whether O
the O
prognostic O
significance O
of O
staging O
in O
multiple O
myeloma O
( O
MM O
) O
is O
influenced O
by O
the O
aggressiveness O
of O
effective O
induction O
treatment O
and/or O
by O
continuing O
or O
discontinuing O
maintenance O
chemotherapy O
. O
[]

The O
proportion O
of O
recurrent B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
cases I-outcome ['Physiological-Clinical']
caused O
by O
reinfection B-outcome ['Physiological-Clinical']
has O
varied O
widely O
in O
previous O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
studied O
whether O
a O
DHA O
supply O
modified O
plasma O
docosahexaenoic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
(DHA) I-outcome ['Physiological-Clinical']
and O
neurological B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
intellectual B-outcome ['Life-Impact', 'Life-Impact']
functioning E1-outcome ['Life-Impact', 'Life-Impact']
in O
PKU. O
[['Physiological-Clinical'], ['Life-Impact', 'Life-Impact']]

A O
double-blind O
clinical O
trial O
with O
zinc O
sulfate O
, O
0.2 O
g O
three O
times O
daily O
, O
and O
a O
placebo O
was O
performed O
in O
30 O
patients O
with O
biopsy-proven O
alcoholic O
liver O
cirrhosis O
. O
[]

No O
statistically O
significant O
treatment O
effects O
were O
observed O
at O
1 O
and O
2 O
h O
after O
dosing O
, O
even O
after O
stratifying O
by O
baseline O
headache O
intensity O
. O
[]

Experimental O
studies O
suggest O
that O
recombinant O
human O
erythropoietin O
( O
EPO O
) O
independent O
of O
its O
erythropoietic O
effect O
may O
be O
used O
clinically O
as O
an O
anti-inflammatory O
drug O
. O
[]

METHODS O
Eighty O
patients O
undergoing O
laparoscopic O
cholecystectomy O
were O
randomized O
to O
receive O
either O
bilateral O
TAP O
blocks O
or O
local O
anesthetic O
infiltration O
of O
trocar O
insertion O
sites O
with O
ropivacaine O
0.5 O
% O
. O
[]

Group O
C O
( O
52 O
infants O
) O
received O
parenteral O
nutrition O
alone O
. O
[]

Furthermore, O
trends O
for O
sex O
differences O
were O
discovered O
in O
urinary, O
but O
not O
salivary, O
hydration B-outcome ['Physiological-Clinical']
markers, O
with O
discrepancies O
in O
kinetics O
between O
fluid O
compartments O
both O
warranting O
further O
study. O
[['Physiological-Clinical']]

The O
mean O
increase O
was O
+26 O
% O
following O
apalcillin O
, O
+46 O
% O
after O
piperacillin O
, O
+38 O
% O
following O
mezlocillin O
and O
+55 O
% O
following O
azlocillin O
. O
[]

Title: O
Comparison O
the O
cost-efficacy O
of O
furazolidone-based O
versus O
clarithromycin-based O
quadruple O
therapy O
in O
initial O
treatment O
of O
Helicobacter O
pylori O
infection O
in O
a O
variable O
clarithromycin O
drug-resistant O
region, O
a O
single-center, O
prospective, O
randomized, O
open-label O
study. O
[]

Thus O
, O
in O
order O
to O
obtain O
a O
prompt O
improvement O
, O
the O
association O
of O
local O
therapy O
acting O
on O
the O
genital O
epithelium O
to O
the O
systemic O
treatment O
should O
be O
considered O
. O
[]

Patients O
treated O
with O
the O
combination O
tended O
to O
have O
more O
rapid O
recovery B-outcome ['Physiological-Clinical']
to O
an O
absolute B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
of O
500 O
x O
10 O
( O
6 O
) O
/l O
( O
median O
= O
12.5 O
vs O
18 O
days O
for O
concurrent O
and O
19 O
days O
for O
historical O
control O
patients O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Angiotensin-converting O
enzyme O
inhibitor O
therapy O
may O
exert O
a O
beneficial O
effect O
on O
the O
endogenous O
fibrinolytic O
balance O
. O
[]

Clinical O
description O
of O
encephalopathic O
syndromes O
and O
risk O
factors O
for O
their O
occurrence O
and O
outcome O
during O
melarsoprol O
treatment O
of O
human O
African O
trypanosomiasis O
. O
[]

typewriter O
) O
related O
to O
a O
target O
word O
( O
e.g O
. O
[]

Each O
test O
condition O
included O
five O
matched O
pairs O
of O
sheep O
tibiae O
. O
[]

Three O
experiments O
compared O
the O
timing O
performance O
of O
humans O
on O
a O
modified O
temporal O
generalization O
task O
with O
1 O
, O
3 O
, O
or O
5 O
presentations O
of O
the O
standard O
duration O
. O
[]

Moist O
Exposed O
Burn O
Ointment O
( O
MEBO O
) O
in O
partial O
thickness O
burns O
- O
a O
randomized O
, O
comparative O
open O
mono-center O
study O
on O
the O
efficacy O
of O
dermaheal O
( O
MEBO O
) O
ointment O
on O
thermal O
2nd O
degree O
burns O
compared O
to O
conventional O
therapy O
. O
[]

RESULTS O
For O
men O
, O
the O
mean O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
1.1 O
% O
in O
the O
treated O
group O
and O
-0.4 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

A O
double-blind O
, O
placebo-controlled O
randomized O
trial O
of O
13-cis O
retinoic O
acid O
was O
performed O
to O
determine O
if O
the O
drug O
has O
a O
therapeutic O
effect O
in O
patients O
with O
myelodysplastic O
syndromes O
( O
MDS O
) O
. O
[]

Patients O
in O
the O
intervention O
group O
found O
that O
the O
rehabilitation O
sessions O
were O
easier B-outcome ['Life-Impact']
(p O
= O
0.048). O
[['Life-Impact']]

METHODS O
One O
hundred O
and O
twenty O
consecutive O
patients O
with O
a O
BMI O
< O
23.0 O
kg/m O
( O
2 O
) O
and O
a O
low O
calcium O
load O
undergoing O
retrospective O
electrocardiogram O
( O
ECG O
) O
-gated O
dual-source O
CCTA O
were O
randomized O
into O
two O
groups O
[ O
standard-tube O
voltage O
( O
120-kV O
) O
vs. O
low-tube O
voltage O
( O
80-kV O
) O
] O
. O
[]

Diazepam O
choice O
was O
also O
associated O
with O
more O
frequent B-outcome ['Life-Impact']
recreational I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
marijuana I-outcome ['Life-Impact']
and O
stimulants B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Systemic O
thrombolytic O
therapy O
significantly O
reduced O
the O
number O
of O
closed B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
segments I-outcome ['Physiological-Clinical']
after O
12 O
months O
in O
patients O
with O
acute O
DVT O
compared O
with O
conventional O
treatment O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

These O
results O
indicate O
that O
priming O
with O
recombinant O
FSH O
before O
harvesting O
of O
immature O
oocytes O
from O
patients O
with O
PCOS O
may O
improve O
the O
maturational B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
oocytes I-outcome ['Physiological-Clinical']
and O
the I-outcome ['Physiological-Clinical']
implantation B-outcome ['Physiological-Clinical']
rate O
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
cleaved I-outcome ['Physiological-Clinical']
embryos I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
poor O
metabolizer O
demonstrated O
in O
both O
oral O
formulations O
high B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
, O
increased O
AUCs O
and O
prolonged O
terminal O
half-lives O
as O
well O
as O
increased O
renal B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prajmalium I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Hemodynamic O
effects O
during O
induction O
, O
laryngoscopy O
, O
and O
intubation O
with O
eltanolone O
( O
5 O
beta-pregnanolone O
) O
or O
propofol O
. O
[]

CONCLUSIONS O
The O
interventions O
conducted O
by O
a O
robot O
and O
a O
human O
trainer O
were O
both O
effective O
in O
promoting O
self-initiated O
questions O
in O
children O
with O
ASD O
. O
[]

The O
estimated O
7-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
EFS I-outcome ['Mortality']
) I-outcome ['Mortality']
for O
subjects O
randomized O
to O
TG O
was O
84.1 O
% O
( O
+/- O
1.8 O
% O
) O
and O
to O
MP O
was O
79.0 O
% O
( O
+/- O
2.1 O
% O
; O
P O
= O
.004 O
log O
rank O
) O
, O
although O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
91.9 O
% O
( O
+/- O
1.4 O
% O
) O
and O
91.2 O
% O
( O
+/- O
1.5 O
% O
) O
, O
respectively O
( O
P O
= O
.6 O
log O
rank O
) O
. O
['Mortality', 'Mortality']

At O
28-35 O
days O
post-therapy O
, O
the O
continued O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
in O
the O
faropenem O
daloxate O
group O
was O
92.6 O
% O
and O
that O
for O
the O
cefuroxime O
axetil O
group O
was O
94.9 O
% O
( O
95 O
% O
CI O
: O
-6.8 O
% O
; O
+1.2 O
% O
) O
. O
['Physiological-Clinical']

Furthermore O
, O
a O
higher O
percentage O
of O
patients O
in O
the O
azithromycin O
group O
rated O
overall B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
as O
excellent O
or O
good O
. O
['Physiological-Clinical']

The O
effects O
of O
music O
played O
during O
an O
exercise O
task O
on O
athletic O
performance O
have O
been O
previously O
studied O
. O
[]

Perioperative B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
faster O
in O
the O
laparoscopic-surgery O
group O
than O
in O
the O
open-colectomy O
group O
, O
as O
reflected O
by O
a O
shorter O
median O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
five O
days O
vs. O
six O
days O
, O
P O
< O
0.001 O
) O
and O
briefer O
use O
of O
parenteral O
narcotics O
( O
three O
days O
vs. O
four O
days O
, O
P O
< O
0.001 O
) O
and O
oral O
analgesics O
( O
one O
day O
vs. O
two O
days O
, O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Resource-use']

A O
significant O
increase O
of O
initial O
claudication O
distance O
was O
found O
in O
the O
nebivolol O
group O
. O
[]

Immune B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
resulting O
from O
prolonged O
chemoprophylaxis O
and O
potential O
drug-vaccine O
interaction O
were O
investigated O
within O
the O
context O
of O
a O
randomized O
placebo-controlled O
trial O
that O
compared O
daily O
primaquine O
or O
weekly O
chloroquine O
administration O
for O
malaria O
prevention O
. O
['Physiological-Clinical']

Small O
and O
nonsignificant O
treatment O
effects O
were O
found O
with O
regard O
to O
nonsplinted O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Reversal O
of O
skeletal O
effects O
of O
endocrine O
treatments O
in O
the O
Intergroup O
Exemestane O
Study O
. O
[]

CONCLUSIONS O
The O
Junior O
Detective O
Training O
Program O
appeared O
to O
be O
effective O
in O
enhancing O
the O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
emotional B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
of O
children O
with O
AS O
. O
['Life-Impact', 'Life-Impact']

Parametric O
analysis O
revealed O
activity B-outcome ['Life-Impact']
correlating O
with O
temporal O
complexity O
during O
initiate O
in O
bilateral O
supplementary O
and O
pre-supplementary O
motor O
cortex O
( O
SMA O
and O
preSMA O
) O
, O
rostral B-outcome ['Physiological-Clinical']
dorsal I-outcome ['Physiological-Clinical']
premotor I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
PMC O
) O
, O
basal B-outcome ['Physiological-Clinical']
ganglia I-outcome ['Physiological-Clinical']
, O
and O
dorsolateral B-outcome ['Physiological-Clinical']
prefrontal I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
DLPFC O
) O
, O
among O
other O
areas O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Main O
variables O
were O
safety O
, O
tolerability B-outcome ['Life-Impact']
and O
pharmacokinetics B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Session O
analysis O
showed O
significantly O
more O
and I-outcome ['Life-Impact']
lengthier O
events O
of O
eye B-outcome ['Life-Impact']
contact I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
turn-taking I-outcome ['Life-Impact']
in O
improvisational O
music O
therapy O
than O
play O
sessions O
. O
['Life-Impact']

Pearson O
coefficients O
for O
correlation O
of O
quantitative O
spasticity O
measures O
with O
TTT B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
lower O
but O
also O
significant O
( O
P O
< O
or O
= O
0.07 O
) O
. O
['Physiological-Clinical']

We O
hypothesized O
that O
the O
administration O
of O
tromethamine O
( O
THAM O
) O
, O
a O
buffer O
which O
does O
not O
increase O
carbon O
dioxide O
production O
, O
would O
modify O
these O
changes O
. O
[]

Relationship O
between O
biliary O
and O
serum O
bile O
acids O
and O
response O
to O
ursodeoxycholic O
acid O
in O
patients O
with O
primary O
biliary O
cirrhosis O
. O
[]

Following O
endodontic O
treatment O
, O
the O
teeth O
were O
randomly O
assigned O
to O
four O
groups O
: O
cast O
Ni-Cr O
alloy O
dowel-core O
with O
no O
ferrule O
( O
Group O
A1 O
) O
, O
cast O
Ni-Cr O
alloy O
dowel-core O
with O
2.0 O
mm O
ferrule O
( O
Group O
A2 O
) O
, O
prefabricated O
carbon O
fiber-reinforced O
dowel-resin O
core O
with O
no O
ferrule O
( O
Group O
B1 O
) O
and O
carbon O
fiber-reinforced O
dowel-resin O
core O
with O
2.0 O
mm O
ferrule O
( O
Group O
B2 O
) O
. O
[]

Primary O
endpoint O
is O
the O
success B-outcome ['Physiological-Clinical']
of O
the O
randomised O
treatment, O
defined O
as O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
resulting O
in O
discharge B-outcome ['Resource-use']
from I-outcome ['Resource-use']
the O
hospital O
without O
the O
need O
for O
surgical B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
and O
no O
recurrent B-outcome ['Physiological-Clinical']
appendicitis I-outcome ['Physiological-Clinical']
during O
one-year O
follow-up. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Physiological-Clinical']]

Patient-rated O
outcome O
was O
assessed O
at O
baseline O
and O
after O
6 O
weeks O
and O
3 O
months O
using O
a O
visual O
analog O
scale O
and O
the O
Patient-Rated O
Tennis O
Elbow O
Evaluation O
. O
[]

CONTEXT O
The O
opioid O
system O
is O
involved O
in O
blood O
pressure O
regulation O
in O
both O
normal O
humans O
and O
patients O
with O
essential O
hypertension O
. O
[]

For O
all O
patients O
, O
synthesis O
of O
IL-1 B-outcome ['Physiological-Clinical']
beta I-outcome ['Physiological-Clinical']
increased O
constitutively O
and O
in O
response O
to O
immune-mediated O
stimulants O
( O
PHA O
, O
IL-2 O
, O
and O
mitochondrial O
antigen O
) O
but O
not O
the O
bacterial O
stimulants O
LPS O
or O
S O
epidermidis O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
One O
hundred O
forty-two O
patients O
were O
randomized O
into O
three O
groups O
: O
protocol O
A-scan O
delay O
of O
65 O
s O
after O
starting O
contrast O
injection O
over O
30 O
s O
; O
protocol O
B-105 O
and O
70 O
s O
; O
and O
protocol O
C-145 O
and O
110 O
s O
, O
respectively O
. O
[]

Only O
the O
basic O
treatments O
were O
given O
to O
the O
control O
group O
. O
[]

[ O
Effect O
of O
Selaginella O
combined O
with O
radiotherapy O
on O
nasopharyngeal O
carcinoma O
] O
. O
[]

However O
, O
after O
10 O
wk O
of O
training O
, O
the O
skeletal O
muscle O
expressed O
a O
higher O
mRNA O
level O
of O
IL-6R O
compared O
with O
before O
training O
. O
[]

Ipilimumab O
resulted O
in O
dysregulation O
of O
gastrointestinal O
mucosal O
immunity O
as O
evidenced O
by O
altered O
antibody O
levels O
to O
enteric O
flora O
, O
inflammatory B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
into O
gastrointestinal O
mucosa O
, O
and O
increased O
fecal B-outcome ['Physiological-Clinical']
calprotectin I-outcome ['Physiological-Clinical']
associated O
with O
diarrhea B-outcome ['Physiological-Clinical']
and O
clinical O
evidence O
of O
colitis B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Effect O
of O
ozone O
application O
on O
the O
resin-dentin B-outcome ['Physiological-Clinical']
microtensile I-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
Among O
104 O
cervical O
cancer O
patients O
selected O
for O
the O
present O
study O
, O
54 O
and O
50 O
patients O
were O
treated O
with O
chemo- O
and O
radiotherapy O
respectively O
. O
[]

CONCLUSIONS O
Oral O
and O
intravenous O
linezolid O
exhibit O
linear O
pharmacokinetics B-outcome ['Physiological-Clinical']
, O
with O
concentrations O
remaining O
above O
the O
target O
MIC90 O
for O
most O
of O
the O
dosing O
interval O
. O
['Physiological-Clinical']

Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scale O
modified O
for O
pervasive O
developmental O
disorders O
. O
[]

All O
trainees O
performed O
their O
first O
ten O
individual O
colonoscopies O
described O
in O
detail O
in O
a O
separate O
protocol O
. O
[]

Perioperative O
immunotherapy O
with O
recombinant O
interleukin O
2 O
in O
patients O
undergoing O
surgery O
for O
colorectal O
cancer O
. O
[]

Of O
the O
remaining O
50 O
patients O
, O
42 O
( O
84.0 O
% O
) O
were O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
20 O
% O
responders O
, O
30 O
( O
60.0 O
% O
) O
were O
ACR O
50 O
% O
responders O
, O
and O
23 O
( O
46.0 O
% O
) O
were O
ACR O
70 O
% O
responders O
. O
[]

Since O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
is O
characterised O
by O
inflammation O
and O
oxidative O
stress O
, O
low-dose O
CO O
could O
be O
of O
therapeutic O
use O
. O
[]

Mean O
MVD O
for O
the O
hyperplastic B-outcome ['Physiological-Clinical']
portion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
was O
similar O
for O
the O
finasteride O
and O
control O
groups O
( O
14.21 O
+/- O
7.10 O
and O
19.75 O
+/- O
9.73 O
, O
respectively O
, O
p O
> O
0.05 O
) O
. O
['Physiological-Clinical']

METHODS O
A O
randomized O
controlled O
trial O
was O
done O
of O
consecutive O
older O
patients O
( O
> O
50 O
years O
) O
attending O
an O
accident O
and O
emergency O
facility O
because O
of O
a O
non-accidental B-outcome ['Physiological-Clinical']
fall I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
effects O
of O
acute O
administration O
per O
os O
of O
30 O
mg O
camazepam O
and O
the O
same O
dose O
of O
temazepam O
, O
were O
compared O
with O
placebo O
in O
8 O
young O
male O
volunteers O
, O
fully O
adapted O
to O
the O
laboratory O
environment O
by O
6 O
nights O
of O
adaptation O
. O
[]

Primary O
outcome O
measure O
was O
the O
change O
in O
irritability B-outcome ['Life-Impact']
subscale O
of O
ABC-C O
. O
['Life-Impact']

There O
was O
a O
significant O
interaction O
of O
composite O
strength B-outcome ['Life-Impact']
score O
between O
groups, O
(p O
= O
.04, O
engp2 O
= O
.08). O
[['Life-Impact']]

The O
positive O
response O
rate O
to O
the O
paclitaxel/cisplatin O
therapy O
was O
85 O
% O
vs O
61 O
% O
for O
the O
patients O
who O
received O
the O
cyclophosphamide/cisplatin O
regimen O
. O
[]

Publication O
Type: O
Comparative O
Study, O
Journal O
Article, O
Multicenter O
Study, O
Randomized O
Controlled O
Trial, O
Research O
Support, O
U.S. O
Gov't, O
Non-P.H.S., O
[]

Participants O
consisted O
of O
those O
subjects O
in O
the O
WAIS-III O
standardization O
sample O
that O
has O
complete O
demographic O
data O
( O
N=2,401 O
) O
and O
were O
randomly O
divided O
into O
two O
groups O
. O
[]

BACKGROUND O
There O
is O
increasing O
political O
pressure O
on O
the O
medical O
profession O
to O
approach O
welfare O
diseases O
, O
such O
as O
coronary O
heart O
disease O
and O
diabetes O
, O
through O
prevention O
. O
[]

The O
intervention O
group O
was O
on O
250 O
mg/day O
of O
elemental O
Mg O
for O
three O
months O
while O
the O
control O
group O
did O
not O
receive O
any O
type O
of O
supplements O
throughout O
the O
intervention O
period. O
[]

However O
, O
the O
standard O
error O
of O
the O
estimate O
of O
the O
change O
represented O
59 O
% O
of O
the O
observed O
change O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
EVAR O
group O
and O
the O
no O
intervention O
group O
for O
[]

Results O
were O
similar O
for O
all O
(mild/moderate/severe) O
exacerbations B-outcome ['Physiological-Clinical']
. O
Improvements O
in O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
health B-outcome ['Physiological-Clinical']
status O
and O
rescue B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
use I-outcome ['Resource-use']
with O
IND/GLY O
vs O
SFC O
were O
comparable O
between O
men O
and O
women. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

INTRODUCTION O
Reperfusion O
injury O
reduces O
the O
benefits O
of O
early O
reperfusion O
therapies O
after O
acute O
ST-elevation O
myocardial O
infarction O
( O
STEMI O
) O
. O
[]

Journal-Name:Reproductive O
biology O
and O
endocrinology O
: O
RB&E O
[]

The O
primary O
comparison O
was O
the O
alteplase O
20-mg O
group O
vs O
the O
placebo O
group; O
if O
not O
significant, O
the O
alteplase O
10-mg O
group O
vs O
the O
placebo O
group O
was O
considered O
a O
secondary O
analysis. O
[]

METHODS O
Fifty-five O
cases O
of O
patients O
with O
ocular O
burns O
( O
in O
88 O
eyes O
) O
were O
randomly O
divided O
into O
treatment O
and O
control O
groups O
. O
[]

Thus O
succinylcholine O
may O
be O
used O
as O
the O
sole O
paralytic O
agent O
in O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
. O
[]

The O
most O
consistent O
data O
with O
respect O
to O
micronutrient O
antioxidants O
and O
atherosclerosis O
appear O
to O
relate O
to O
alpha-tocopherol O
( O
AT O
) O
, O
the O
predominant O
lipid-soluble O
antioxidant O
in O
LDL O
. O
[]

DESIGN O
Randomized O
, O
controlled O
intervention O
study O
in O
which O
37 O
healthy O
, O
sedentary O
men O
and O
women O
( O
52+/-2 O
years O
) O
performed O
13 O
weeks O
of O
ST O
( O
n=13 O
) O
, O
ST+aerobic O
exercise O
( O
n=12 O
) O
or O
stretching O
exercises O
as O
a O
control O
group O
( O
n=12 O
) O
. O
[]

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O
[]

All O
were O
given O
a O
2 O
g O
loading O
dose O
of O
pralidoxime O
over O
30 O
min O
. O
[]

BACKGROUND O
The O
aims O
of O
this O
study O
were O
to O
evaluate O
the O
oral O
health O
impacts O
perceived O
by O
patients O
submitted O
to O
different O
treatments O
of O
chronic O
periodontitis O
and O
their O
association O
with O
clinical O
parameters O
. O
[]

From O
1985 O
to O
1987 O
80 O
patients O
with O
acute O
cardiogenic O
pulmonary O
edema O
were O
randomly O
chosen O
to O
receive O
either O
serial O
CPAP O
therapy O
or O
high-flow O
face O
mask O
oxygen O
therapy O
without O
CPAP O
( O
control O
) O
for O
the O
purpose O
of O
evaluating O
the O
efficacy O
of O
CPAP O
therapy O
. O
[]

In O
the O
entire O
control O
+ O
A O
group O
, O
dietary O
omega-3 O
fatty O
acid O
intake O
was O
inversely O
related O
to O
loss O
of O
total O
field B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
over O
4 O
years O
( O
intake O
, O
< O
0.20 O
vs O
> O
or O
=0.20 O
g/d O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical']

Patients O
of O
the O
IVF+ O
group O
had O
a O
higher O
total O
motile B-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
after O
preparation O
than O
did O
those O
of O
the O
IVF- O
group O
. O
['Physiological-Clinical']

CONCLUSION O
The O
marine O
lipid O
suppositories O
and O
ointment O
were O
well O
tolerated O
with O
no O
significant O
toxic B-outcome ['Adverse-effects']
side I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
observed O
during O
the O
study O
period O
. O
['Adverse-effects']

FINDINGS: O
Between O
July O
31, O
2014, O
and O
March O
14, O
2016, O
656 O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
ixazomib O
maintenance O
therapy O
(n=395) O
or O
placebo O
(n=261). O
[]

Thus O
, O
the O
higher O
concentration O
of O
glycerol O
required O
to O
provide O
equal O
ultrafiltration O
may O
offset O
any O
calorific O
advantage O
. O
[]

However O
, O
to O
date O
, O
no O
studies O
have O
compared O
the O
clinical O
effectiveness O
of O
amlodipine O
camsylate O
and O
amlodipine O
besylate O
in O
treating O
hypertension O
. O
[]

The O
Social O
Communication O
Assessment O
for O
Toddlers O
with O
Autism O
( O
SCATA O
) O
: O
an O
instrument O
to O
measure O
the O
frequency O
, O
form O
and O
function B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
toddlers O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

ECCE O
with O
PCL O
is O
burdened O
by O
frequent B-outcome ['Physiological-Clinical']
capsular I-outcome ['Physiological-Clinical']
fibrosis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Nasal B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
was O
also O
beneficially O
affected O
by O
both O
steroids O
150 O
and O
240 O
min O
after O
administration O
compared O
with O
placebo O
( O
P O
< O
0.05 O
for O
both O
time O
points O
following O
betamethasone O
) O
. O
['Physiological-Clinical']

Group O
1 O
received O
caudal O
block O
with O
bupivacaine O
1 O
mL/kg O
after O
anesthetic O
induction O
. O
[]

Each O
patient O
was O
thus O
her O
own O
control O
. O
[]

MATERIALS O
AND O
METHODS O
The O
root O
canals O
of O
30 O
human O
incisors O
and O
canines O
were O
instrumented O
and O
prepared O
with O
burs O
. O
[]

However O
, O
the O
HR O
and O
NNT O
suggest O
some O
patients O
will O
benefit O
from O
maintenance O
treatment O
. O
[]

This O
study O
investigated O
acute O
effects O
of O
caffeine O
ingestion O
on O
signal-averaged B-outcome ['Physiological-Clinical']
P-wave I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
In O
a O
prospective O
, O
randomized O
clinical O
trial O
involving O
patients O
with O
dysfunctional O
, O
stenotic O
hemodialysis O
arteriovenous O
fistulas O
( O
AVFs O
) O
, O
patients O
were O
randomized O
to O
receive O
CBA O
or O
HPBA O
if O
conventional O
PTA O
had O
suboptimal O
results O
( O
ie O
, O
residual O
stenosis O
> O
30 O
% O
) O
. O
[]

B O
( O
RANK O
) O
ligand O
, O
with O
zoledronic O
acid O
in O
delaying O
or O
preventing O
skeletal-related O
events O
( O
SREs O
) O
in O
patients O
with O
breast O
cancer O
with O
bone O
metastases O
. O
[]

The O
effect O
of O
valaciclovir O
on O
cytomegalovirus B-outcome ['Physiological-Clinical']
viremia I-outcome ['Physiological-Clinical']
and O
viruria O
detected O
by O
polymerase O
chain O
reaction O
in O
patients O
with O
advanced O
human O
immunodeficiency O
virus O
disease O
. O
['Physiological-Clinical']

Both O
patients O
and O
physicians O
reported O
a O
greater O
overall O
improvement O
in O
symptoms O
for O
the O
triamcinolone O
acetonide O
aqueous O
nasal O
spray O
group O
. O
[]

For O
the O
safety O
evaluation, O
laboratory O
examinations O
including O
complete B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
test, O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
test, O
blood B-outcome ['Physiological-Clinical']
coagulation I-outcome ['Physiological-Clinical']
test, O
inflammation B-outcome ['Physiological-Clinical']
test, O
and O
urine B-outcome ['Physiological-Clinical']
analysis I-outcome ['Physiological-Clinical']
will O
be O
conducted O
before O
and O
after O
taking O
the O
medications. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND O
A O
recent O
report O
showed O
that O
oral O
adjuvant O
immunochemotherapy O
with O
protein-bound O
polysaccharide O
K O
( O
PSK O
) O
and O
tegafur/uracil O
( O
UFT O
) O
for O
stage O
II O
and O
III O
colorectal O
cancer O
improves O
overall O
survival O
compared O
with O
UFT O
alone O
. O
[]

For O
PH-LPL B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
, O
blood O
was O
collected O
15 O
min O
after O
50 O
IU/kg O
iv O
heparin O
injection O
. O
['Physiological-Clinical']

There O
were O
no O
differences O
between O
groups O
on O
the O
AIMS O
. O
[]

These O
results O
support O
a O
twice-daily O
schedule O
for O
linezolid O
and O
demonstrate O
the O
feasibility O
of O
converting O
from O
intravenous O
to O
oral O
dosing O
without O
a O
dose O
adjustment O
. O
[]

Antimicrobial O
photodynamic O
therapy O
(aPDT) O
has O
been O
widely O
used O
with O
very O
satisfactory O
results O
in O
the O
health O
sciences. O
[]

BACKGROUND O
Despite O
enthusiasm O
for O
the O
use O
of O
mild O
hypothermia O
during O
neurosurgical O
procedures O
, O
this O
therapy O
has O
not O
been O
evaluated O
systematically O
. O
[]

CONCLUSION O
Chlorhexidine-based O
solutions O
should O
be O
considered O
as O
a O
replacement O
for O
povidone-iodine O
( O
including O
alcohol-based O
) O
formulations O
in O
efforts O
to O
prevent O
catheter-related B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Treatment O
group O
patients O
( O
n O
= O
22 O
) O
were O
administered O
various O
assessments O
of O
complicated O
grief O
indicators O
, O
including O
the O
Impact O
of O
Event O
Scale O
, O
the O
anxiety B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
subscales O
of O
the O
Brief O
Symptom B-outcome ['Life-Impact']
Inventory O
, O
and O
the O
SF-12 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
effect O
of O
metformin O
and O
insulin O
on O
sympathetic O
nerve O
activity O
, O
norepinephrine O
spillover O
and O
blood O
pressure O
in O
obese O
, O
insulin O
resistant O
, O
normoglycemic O
, O
hypertensive O
men O
. O
[]

Atypical O
antipsychotics O
have O
been O
shown O
to O
improve O
disruptive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
repetitive I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
, O
but O
they O
require O
assessment O
of O
potential O
side O
effects O
. O
['Life-Impact']

VX-770 O
, O
a O
CFTR O
potentiator O
, O
has O
been O
shown O
to O
increase O
the O
activity O
of O
wild-type O
and O
defective O
cell-surface O
CFTR O
in O
vitro O
. O
[]

Radial B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
ulnar I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flows I-outcome ['Physiological-Clinical']
were O
assessed O
using O
Doppler B-outcome ['Resource-use']
probe I-outcome ['Resource-use']
and O
pulse B-outcome ['Resource-use']
oximetry I-outcome ['Resource-use']
before O
, O
just O
after O
, O
and O
24 O
h O
after O
decannulation B-outcome ['Resource-use']
by O
the O
same O
investigator O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use', 'Resource-use']

The O
results O
also O
showed O
that O
when O
the O
light-cured O
glass-ionomer O
liner O
was O
placed O
0.3 O
mm O
from O
the O
cavosurface O
margin O
under O
composite O
resin O
restoration O
, O
the O
artificial B-outcome ['Physiological-Clinical']
recurrent I-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
reduced I-outcome ['Physiological-Clinical']
significantly O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Both O
medications O
induced O
rapid B-outcome ['Physiological-Clinical']
bronchodilation I-outcome ['Physiological-Clinical']
that O
had O
a O
longer O
duration O
after O
bitolterol O
. O
['Physiological-Clinical']

RESULTS: O
Both O
groups O
showed O
a O
significant O
increase O
in O
noggin B-outcome ['Physiological-Clinical']
serum O
levels O
(denosumab O
p O
< O
0.001; O
placebo O
p O
< O
0.0001). O
[['Physiological-Clinical']]

Comparisons O
of O
itraconazole O
alone O
and O
itraconazole O
with O
simultaneous O
ddI O
were O
performed O
on O
days O
1 O
and O
15 O
. O
[]

CONCLUSION O
Clozapine O
demonstrated O
cost-effectiveness O
on O
some O
but O
not O
all O
measures O
of O
effectiveness O
when O
the O
alternative O
was O
a O
range O
of O
conventional O
antipsychotic O
medications O
. O
['Resource-use']

PATIENTS O
Two O
hundred O
and O
one O
functional O
class O
I O
and O
II O
patients O
with O
definite O
or O
classic O
rheumatoid O
arthritis O
, O
previously O
untreated O
with O
disease O
modifying O
antirheumatic O
drugs O
. O
[]

The O
rise O
in O
blocking B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
polymer O
group O
was O
from O
a O
mean O
of O
181 O
ng O
AgE O
bound O
per O
ml O
to O
1,574 O
. O
['Physiological-Clinical']

In O
the O
treatment O
of O
periodontal O
infections O
with O
systemic O
antimicrobial O
agents O
, O
in O
situations O
where O
the O
efficacy O
of O
the O
antimicrobial O
agent O
is O
being O
evaluated O
, O
non-compliance O
could O
underestimate O
the O
true O
efficacy O
of O
the O
agent O
. O
[]

DESIGN: O
Randomized O
control O
trial. O
[]

METHODS O
Forty O
patients O
after O
elective O
sphincter-saving O
low O
anterior O
resection O
were O
eligible O
for O
intraoperative O
randomization O
. O
[]

Exercise B-outcome ['Life-Impact']
intensity I-outcome ['Life-Impact']
during O
out-of-lab O
exercise O
and O
+25d O
post-exercise O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
correlated O
(r=-0.89, O
p=0.02) O
in O
IHE. O
[['Life-Impact'], ['Physiological-Clinical']]

Sequential O
therapy O
includes O
one O
additional O
antibiotic O
( O
tinidazole O
) O
that O
is O
not O
contained O
in O
standard O
therapy O
. O
[]

After O
3 O
months O
about O
60 O
% O
of O
the O
patients O
were O
either O
dry B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
only I-outcome ['Physiological-Clinical']
mildly I-outcome ['Physiological-Clinical']
incontinent I-outcome ['Physiological-Clinical']
; O
the O
mean O
number O
of O
wet B-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
had O
gone O
down O
from O
20 O
to O
7 O
, O
and O
74 O
% O
of O
the O
women O
felt O
improved O
or O
cured B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

However O
, O
the O
selected O
high-risk O
individuals O
in O
group O
I O
developed O
0.25 O
new O
manifest O
caries O
lesions O
approximally/year O
, O
compared O
with O
0.27 O
for O
all O
children O
of O
the O
same O
age O
group O
in O
the O
area O
. O
[]

HR B-outcome ['Physiological-Clinical']
increased O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

Study O
patients O
took O
each O
drug O
for O
five O
3-week O
periods O
, O
with O
international O
normalized O
ratio O
( O
INR B-outcome ['Physiological-Clinical']
) O
measurements O
taken O
twice O
per O
period O
. O
['Physiological-Clinical']

Significantly O
fewer O
patients O
in O
the O
paracetamol O
group O
received O
rescue O
analgesics O
compared O
to O
the O
placebo O
group O
( O
9.5 O
% O
vs. O
65.6 O
% O
, O
respectively O
) O
. O
[]

The O
effect O
of O
aging O
on O
circulating O
levels O
of O
proinflammatory O
cytokines O
during O
septic O
shock O
. O
[]

We O
enrolled O
women O
in O
a O
prospective O
, O
randomized O
study O
to O
determine O
whether O
an O
intensive O
reminder O
system O
would O
improve O
compliance O
in O
women O
receiving O
depot O
medroxyprogesterone O
injections O
. O
[]

Clinically O
, O
46 O
femoral O
shaft O
fractures O
were O
randomized O
to O
treatment O
with O
Gross-Kempf O
nails O
, O
24 O
with O
slotted O
nails O
and O
22 O
with O
non-slotted O
nails O
. O
[]

Comparison O
of O
active-learning O
strategies O
for O
motivational B-outcome ['Life-Impact']
interviewing I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact']

Warfarin O
is O
an O
established O
treatment O
for O
prevention O
of O
ischaemic O
stroke O
in O
patients O
with O
atrial O
fibrillation O
, O
but O
the O
value O
of O
this O
agent O
relative O
to O
aspirin O
in O
unclear O
. O
[]

Poylmerized O
whole O
ragweed O
: O
an O
improved O
method O
of O
immunotherapy O
. O
[]

Preventive O
treatment O
of O
serotonin-migraine O
with O
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo O
( O
b O
, O
f O
) O
pyrazino- O
( O
1,2 O
-- O
d O
) O
- O
( O
1,4 O
) O
-oxazepine O
hydrogen O
maleate O
( O
Org O
GC O
94 O
) O
. O
[]

OBJECTIVE O
To O
assess O
the O
risk O
of O
developing O
multiple B-outcome ['Physiological-Clinical']
sclerosis I-outcome ['Physiological-Clinical']
( O
MS B-outcome ['Physiological-Clinical']
) O
after O
optic O
neuritis O
and O
the O
factors O
predictive O
of O
high O
and O
low O
risk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

IMPLICATIONS O
We O
evaluated O
the O
anesthetic O
and O
recovery O
profiles O
of O
60- O
and O
80-mg O
doses O
of O
plain O
mepivacaine O
for O
ambulatory O
spinal O
anesthesia O
. O
[]

MATERIALS O
AND O
METHODS O
In O
a O
nested O
case O
control O
analysis O
among O
ACTIVE O
W O
study O
patients O
, O
cases O
with O
stroke O
and O
cases O
with O
bleeding O
were O
separately O
matched O
with O
controls O
. O
[]

Only O
clean O
or O
clean O
contaminated O
cases O
were O
included O
. O
[]

METHODS: O
A O
between-subjects O
web-based O
experiment O
was O
conducted, O
consisting O
of O
four O
sponsorship O
conditions O
(A O
through O
D) O
featuring O
three O
product O
categories O
within O
each O
condition. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
controlled O
, O
masked O
clinical O
trial O
for O
one O
year O
in O
southern O
India O
involving O
15,419 O
preschool-age O
children O
who O
received O
either O
8.7 O
mumol O
( O
8333 O
IU O
) O
of O
vitamin O
A O
and O
46 O
mumol O
( O
20 O
mg O
) O
of O
vitamin O
E O
( O
the O
treated O
group O
) O
or O
vitamin O
E O
alone O
( O
the O
control O
group O
) O
. O
[]

It O
is O
known O
that O
cervicogenic O
headache O
sufferers O
present O
with O
several O
musculoskeletal O
changes O
including O
poor O
endurance O
of O
the O
deep O
cervical O
flexor O
muscles O
. O
[]

Title: O
Prevalence O
and O
correlates O
of O
psychological O
distress O
among O
13-14 O
year O
old O
adolescent O
girls O
in O
North O
Karnataka, O
South O
India: O
a O
cross-sectional O
study. O
[]

The O
LKSS B-outcome ['Physiological-Clinical']
at O
10 O
days O
( O
times O
) O
of O
treatment O
was O
lower O
in O
the O
treatment O
group O
than O
in O
the O
control O
group O
, O
but O
with O
no O
statistical O
difference O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS O
Mean O
age O
of O
the O
study O
participants O
was O
37.6 O
+/- O
12.4 O
years O
; O
they O
smoked O
an O
average O
of O
20.0 O
+/- O
6.6 O
cigarettes O
per O
day O
for O
20 O
+/- O
12.1 O
years O
. O
[]

Patients O
who O
had O
had O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
after O
previous O
anesthetics O
had O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
significantly O
more O
frequently O
than O
patients O
who O
did O
not O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
and O
thirty O
adult O
patients O
with O
T2DM O
who O
were O
discharged O
to O
the O
community O
were O
randomly O
assigned O
to O
either O
the O
intervention O
or O
the O
control O
group. O
[]

Of O
251 O
evaluable O
patients O
, O
three O
induction O
regimens O
achieved O
similar O
complete B-outcome ['Physiological-Clinical']
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
were O
evaluated O
openly O
at O
the O
seventh O
day O
of O
treatment O
for O
cure O
or O
marked O
improvement O
of O
the O
clinical B-outcome ['Physiological-Clinical']
features I-outcome ['Physiological-Clinical']
, O
indicating O
successful O
treatment O
. O
['Physiological-Clinical']

METHODS O
Eighty-five O
cases O
with O
chronic O
severe O
hepatitis O
were O
randomly O
divided O
into O
ozone O
therapy O
group O
( O
43 O
cases O
) O
and O
control O
group O
( O
42 O
cases O
) O
. O
[]

However O
, O
at O
the O
8-year O
follow-up O
examination O
, O
substantial O
[]

We O
measured O
the O
concentration O
of O
extracellular B-outcome ['Physiological-Clinical']
glycerol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EGC I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
adipose I-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
in O
response O
to O
( O
1 O
) O
pharmacologic O
stimulation O
with O
isoprenaline O
( O
1 O
and O
10 O
micromol/L O
) O
in O
situ O
, O
( O
2 O
) O
stimulation O
with O
intravenous O
infusion O
of O
epinephrine O
( O
0.0375 O
microg/min/kg O
body O
weight O
) O
, O
and O
( O
3 O
) O
submaximal O
aerobic O
exercise O
( O
50 O
% O
V*O2max O
, O
60-minute O
duration O
) O
. O
['Physiological-Clinical']

6-mercaptopurine O
should O
remain O
the O
thiopurine O
of O
choice O
for O
continuing O
therapy O
of O
childhood O
lymphoblastic O
leukaemia O
. O
[]

RESULTS O
The O
median O
duration O
of O
survival B-outcome ['Mortality']
was O
20.3 O
months O
in O
the O
group O
given O
IFL O
plus O
bevacizumab O
, O
as O
compared O
with O
15.6 O
months O
in O
the O
group O
given O
IFL O
plus O
placebo O
, O
corresponding O
to O
a O
hazard O
ratio O
for O
death O
of O
0.66 O
( O
P O
< O
0.001 O
) O
. O
['Mortality']

MATERIAL O
AND O
METHODS O
Randomized O
crossover O
study O
examining O
20 O
patients O
postcardiac B-outcome ['Physiological-Clinical']
surgery O
. O
['Physiological-Clinical']

DESIGN O
Prospective O
, O
randomized O
, O
double-blind O
, O
controlled O
clinical O
trial O
. O
[]

In O
Arm O
1 O
, O
patients O
with O
N0 O
disease O
will O
receive O
RT O
alone O
, O
whereas O
N1-2 O
patients O
will O
receive O
concurrent O
chemoradiation O
. O
[]

METHODS O
This O
was O
a O
multicenter O
, O
open-label O
, O
pilot O
study O
enrolling O
consecutive O
non-ulcer O
dyspepsia O
patients O
with O
H. O
pylori O
infection O
never O
previously O
treated O
for O
the O
infection O
. O
[]

CONCLUSION: O
The O
therapeutic O
effect O
of O
combined O
treatment O
is O
better O
than O
clomifene O
citrate O
alone O
in O
the O
treatment O
of O
PCOS. O
[]

The O
secondary O
end O
points O
included O
the O
time O
to O
heal O
and O
cosmetic O
appearance O
. O
[]

We O
report O
follow-up O
information O
on O
69 O
hairy B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HCL I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
patients O
treated O
with O
interferon O
alfa-2b O
( O
IFN O
) O
as O
primary O
treatment O
from O
1983 O
to O
1986 O
. O
['Physiological-Clinical']

The O
consumption B-outcome ['Resource-use']
of O
postoperative O
rescued O
sufentanil O
was O
significantly O
lower O
in O
Dex O
group O
than O
in O
the O
Control O
group O
(56.3 O
+/- O
9.4 O
vs O
65.9 O
+/- O
10.7 O
mug). O
[['Resource-use']]

Esmolol O
was O
associated O
with O
a O
decrease O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
from O
6.2 O
+/- O
1.3 O
to O
3.8 O
+/- O
0.8 O
L/min O
, O
which O
, O
because O
of O
a O
22 O
% O
increase O
in O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
, O
far O
exceeded O
the O
reduction O
in O
mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
primary O
school O
in O
Changsha O
city O
was O
selected O
by O
random O
cluster O
sampling. O
[]

Eighty O
percent O
of O
CI O
implants, O
61% O
of O
FI O
implants, O
and O
84% O
of O
PS O
implants O
were O
observed O
to O
have O
a O
clinically O
stable O
peri-implant B-outcome ['Physiological-Clinical']
mucosal I-outcome ['Physiological-Clinical']
zenith I-outcome ['Physiological-Clinical']
position I-outcome ['Physiological-Clinical']
with O
less O
than O
0.5 O
mm O
of O
measured O
recession. O
[['Physiological-Clinical']]

Argatroban O
dose-dependently O
prolonged O
activated O
clotting O
time O
( O
ACT O
) O
with O
more O
patients O
reaching O
the O
minimum O
target O
ACT O
after O
the O
initial O
bolus O
injection O
( O
ARG250 O
: O
86.1 O
% O
, O
ARG300 O
: O
89.5 O
% O
, O
and O
ARG350 O
: O
96.8 O
% O
) O
compared O
to O
45.5 O
% O
in O
UFH O
( O
p O
< O
0.001 O
) O
. O
[]

RESULTS O
Median O
blood B-outcome ['Physiological-Clinical']
folate I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of O
all O
participants O
were O
well O
above O
plasma O
and O
RBC O
folate O
cut-off O
levels O
indicative O
of O
deficiency O
( O
6.7 O
and O
317 O
nmol/L O
, O
respectively O
) O
and O
all O
, O
except O
for O
2 O
subjects O
, O
were O
above O
the O
cut-off O
for O
NTD-risk O
reduction O
( O
> O
906 O
nmol/L O
) O
. O
['Physiological-Clinical']

This O
information O
is O
not O
available O
for O
many O
early O
measurements O
. O
[]

Journal O
ID: O
100967802 O
[]

Similarly O
, O
the O
[]

RESULTS O
Ten O
female O
subjects O
with O
mild O
to O
moderate O
facial O
photodamage O
were O
treated O
with O
one O
pass O
of O
either O
IPL O
or O
Er O
: O
YAG O
in O
a O
split-face O
fashion O
. O
[]

Risperidone O
treatment O
of O
autistic O
disorder O
: O
longer-term O
benefits O
and O
blinded O
discontinuation O
after O
6 O
months O
. O
[]

The O
exercise O
group O
performed O
40 O
min O
of O
resistance O
exercises O
on O
machines O
followed O
by O
30 O
min O
of O
aerobic O
training O
on O
a O
treadmill O
3x/wk. O
[]

CONCLUSIONS O
After O
controlled O
exposure O
to O
grass O
pollen O
, O
CC O
and O
AT O
treatment O
showed O
a O
therapeutic O
effect O
on O
the O
signs O
and O
symptoms O
of O
allergic O
conjunctivitis O
. O
[]

The O
most O
commonly O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
all O
with O
incidence O
of O
5 O
% O
or O
less O
) O
among O
patients O
receiving O
rizatriptan O
were O
dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
, O
dizziness B-outcome ['Physiological-Clinical']
, O
asthenia/fatigue B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Nordic O
walking O
and O
chronic O
low O
back O
pain O
: O
design O
of O
a O
randomized O
clinical O
trial O
. O
[]

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
times O
were O
60 O
weeks O
for O
PLD O
and O
56.7 O
weeks O
for O
topotecan O
. O
['Mortality']

To O
evaluate O
the O
efficacy O
and O
safety O
of O
two O
1-week O
low-dose O
triple-therapy O
drug O
regimens O
involving O
antisecretory O
drugs O
for O
Helicobacter O
pylori O
infection O
, O
99 O
patients O
with O
H. O
pylori O
infection O
were O
treated O
with O
either O
lansoprazole O
( O
LPZ O
) O
or O
ranitidine O
( O
RNT O
) O
used O
together O
with O
clarithromycin O
( O
CAM O
) O
and O
metrinidazole O
( O
MTZ O
) O
. O
[]

Effects O
of O
alcohol O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
morphine O
sulfate O
and O
naltrexone O
hydrochloride O
extended O
release O
capsules O
. O
['Physiological-Clinical']

Journal O
ID: O
2985248R O
[]

BDDrFVIII O
( O
ReFacto O
) O
has O
been O
developed O
with O
the O
additional O
benefit O
of O
being O
formulated O
without O
human O
albumin O
. O
[]

In O
those O
with O
proven O
rhinovirus O
colds O
treated O
within O
24 O
h O
, O
the O
median O
duration O
was O
significantly O
longer O
in O
the O
20-MU O
group O
( O
9 O
days O
) O
than O
in O
the O
placebo O
group O
( O
6 O
days O
) O
. O
[]

The O
current O
analyses O
were O
undertaken O
to O
promote O
an O
understanding O
of O
the O
underlying O
mechanism O
of O
action O
and O
to O
identify O
potential O
biomarkers O
that O
could O
help O
in O
the O
prediction O
and O
management O
of O
ipilimumab-induced O
gastrointestinal O
irAEs O
. O
[]

Isoflurane O
was O
administered O
according O
to O
predetermined O
hemodynamic O
criteria O
. O
[]

Supervisors O
receiving O
this O
training O
( O
n O
= O
29 O
) O
were O
more O
likely O
to O
improve O
on O
several O
dimensions O
of O
responsiveness B-outcome ['Life-Impact']
( O
e.g O
. O
['Life-Impact']

Letrozole O
in O
the O
neoadjuvant O
setting O
: O
the O
P024 O
trial O
. O
[]

From O
April O
1990 O
to O
September O
1992 O
, O
the O
authors O
studied O
8 O
patients O
( O
age O
43-65 O
years O
) O
with O
ovarian O
cancer O
. O
[]

Additionally O
, O
the O
joint O
attention O
group O
improved O
in O
the O
proportion O
of O
time O
spent O
sharing O
coordinated O
joint O
looks O
between O
intervener O
and O
probe O
. O
[]

14 O
( O
11.0 O
% O
) O
patients O
in O
the O
hydrotalcite O
group O
and O
six O
( O
4.8 O
% O
) O
in O
the O
esomeprazole O
group O
[]

INTERVENTION O
Subjects O
were O
randomly O
allocated O
to O
either O
the O
U- O
or O
H-type O
method O
of O
TVT-S. O
MEASUREMENTS O
Pre- O
and O
postoperative O
evaluations O
included O
a O
standing O
stress O
test O
, O
the O
Sandvik O
questionnaire O
, O
the O
Incontinence B-outcome ['Physiological-Clinical']
Quality O
of O
Life O
( O
I-QOL O
) O
questionnaire O
, O
and O
the O
International O
Consultation B-outcome ['Resource-use']
on O
Incontinence B-outcome ['Physiological-Clinical']
Questionnaire-Female O
Lower O
Urinary B-outcome ['Physiological-Clinical']
Tract I-outcome ['Physiological-Clinical']
Symptoms I-outcome ['Physiological-Clinical']
( O
ICIQ-FLUTS O
) O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
1161 O
subjects O
were O
randomized O
to O
OCT O
and O
1163 O
to O
placebo O
; O
over O
80 O
% O
returned O
for O
a O
repeat O
13C-urea O
breath O
test O
on O
at O
least O
one O
occasion O
. O
[]

The O
time O
required O
for O
a O
change O
in O
TOFr O
values O
from O
0.25 O
to O
0.75 O
and O
0.9 O
was O
evaluated. O
[]

INTERPRETATION O
ASI O
gave O
significant O
clinical O
benefit O
in O
surgically O
resected O
patients O
with O
stage O
II O
colon O
cancer O
. O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
quality O
of O
life O
. O
['Mortality', 'Mortality']

The O
initial O
subject O
pool O
was O
the O
24,178 O
members O
of O
a O
managed O
care O
company O
. O
[]

Stress O
reduction O
prolongs O
life O
in O
women O
with O
coronary O
disease O
: O
the O
Stockholm O
Women O
's O
Intervention O
Trial O
for O
Coronary O
Heart O
Disease O
( O
SWITCHD O
) O
. O
[]

S-adenosylmethionine O
significantly O
( O
P O
less O
than O
0.01 O
) O
improved O
subjective O
symptoms B-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
pruritus I-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
feeling O
of O
['Physiological-Clinical', 'Physiological-Clinical']

AIMS O
To O
determine O
the O
effect O
of O
trophic O
feeding O
on O
clinical O
outcome O
in O
ill O
preterm O
infants O
. O
[]

Oral O
fluoroquinolones O
can O
be O
safe O
, O
effective O
therapy O
if O
they O
are O
given O
for O
a O
prolonged O
course O
as O
treatment O
for O
infections O
caused O
by O
susceptible O
gram-positive O
as O
well O
as O
gram-negative O
organisms O
and O
in O
combination O
with O
adequate O
surgical O
debridement O
. O
[]

METHODS O
AND O
RESULTS O
ATHENA O
was O
a O
double-blind O
, O
parallel O
group O
study O
in O
4628 O
patients O
with O
a O
history O
of O
paroxysmal/persistent O
AF O
and O
additional O
risk O
factors O
, O
treated O
with O
placebo O
or O
dronedarone O
. O
[]

Exenatide O
could O
benefit O
type O
1 O
diabetes O
as O
well O
. O
[]

END O
POINTS: O
Primary O
end O
point O
was O
MACE B-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
and O
secondary O
end O
points O
at O
the O
end O
of O
1 O
year O
were O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
urgent O
target O
lesion B-outcome ['Resource-use']
revascularization I-outcome ['Resource-use']
, O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
and O
in-stent B-outcome ['Physiological-Clinical']
re-stenosis I-outcome ['Physiological-Clinical']
. O
RESULTS: O
204 O
patients O
were O
enrolled O
between O
January O
2013 O
to O
July O
2014, O
91 O
in O
the O
polymer-free O
group O
and O
113 O
in O
the O
biodegradable O
polymer O
group. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Unlike O
with O
controls O
, O
in O
uremic O
patients O
GHRH-stimulated O
GH O
and O
TRH-stimulated O
PRL/GH B-outcome ['Physiological-Clinical']
peaks I-outcome ['Physiological-Clinical']
were O
dispersed O
throughout O
the O
120 O
min O
period O
. O
['Physiological-Clinical']

Chemoradiation O
comparing O
cisplatin O
versus O
carboplatin O
in O
locally O
advanced O
nasopharyngeal O
cancer O
: O
randomised O
, O
non-inferiority O
, O
open O
trial O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
between O
the O
delta O
IOPs O
with O
the O
drug O
stored O
at O
4 O
degrees O
C O
and O
30 O
degrees O
C. O
During O
the O
study O
, O
no O
subject O
developed O
a O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event O
. O
['Adverse-effects']

In O
pre-clinical O
studies O
, O
the O
SsWC O
vaccine O
was O
immunogenic O
and O
protected O
against O
S. O
sonnei-induced O
keratoconjunctivitis O
in O
the O
guinea O
pig O
model O
. O
[]

Immediately O
before O
first O
hemi-body O
irradiation O
, O
59 O
patients O
with O
relapsed O
multiple O
myeloma O
were O
randomised O
to O
receive O
or O
not O
to O
receive O
subsequent O
alpha-2b O
interferon O
maintenance O
. O
[]

Hyperbaric O
oxygen O
in O
the O
treatment O
of O
childhood O
autism O
: O
a O
randomised O
controlled O
trial O
. O
[]

The O
actuarial O
survival B-outcome ['Mortality']
curves O
were O
performed O
according O
to O
Kaplan O
and O
Meier O
. O
['Mortality']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Their O
average O
age O
was O
45 O
years O
, O
91 O
% O
were O
male O
, O
58 O
% O
were O
white O
, O
40 O
% O
served O
in O
Iraq O
or O
Afghanistan O
, O
and O
42 O
% O
served O
in O
Vietnam O
. O
[]

All O
rectal O
medications O
were O
very O
well O
accepted O
, O
but O
mask B-outcome ['Life-Impact']
acceptance I-outcome ['Life-Impact']
, O
improvement O
in O
anxiety B-outcome ['Life-Impact']
, O
and O
sedation B-outcome ['Physiological-Clinical']
were O
best O
in O
the O
midazolam O
group O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

We O
failed O
to O
find O
any O
significant O
effect O
of O
active B-outcome ['Physiological-Clinical']
rTMS I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Four O
hundred O
two O
patients O
with O
suspected O
myocardial O
infarction O
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double-blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O
[]

Likewise O
, O
19.5 O
% O
of O
children O
in O
the O
IT O
methotrexate O
group O
had O
a O
Processing B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
Index O
score O
in O
the O
below-average O
range O
compared O
with O
6.9 O
% O
in O
the O
triple O
IT O
therapy O
group O
( O
P O
= O
.02 O
) O
. O
['Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

C. O
albicans O
was O
isolated O
most O
frequently O
90.3 O
% O
( O
271/300 O
) O
, O
followed O
by O
C. O
glabrata O
( O
7.3 O
% O
) O
, O
C. O
tropicalis O
( O
1.3 O
% O
) O
, O
C. O
krusei O
( O
0.7 O
% O
) O
, O
and O
C. O
parapsilosis O
( O
0.3 O
% O
) O
. O
[]

Serum O
levels O
of O
PSA O
were O
assessed O
at O
baseline O
( O
-2 O
, O
-1 O
, O
0 O
weeks O
) O
and O
after O
6 O
, O
13 O
, O
19 O
, O
20 O
and O
21 O
weeks O
. O
[]

In O
each O
study O
, O
samples O
were O
collected O
in O
a O
subset O
of O
patients O
; O
a O
new O
cohort O
was O
enrolled O
each O
year O
. O
[]

Increased O
repetitive O
behaviours O
and O
prolactin O
responsivity O
to O
oral O
m-chlorophenylpiperazine O
in O
adults O
with O
autism O
spectrum O
disorders O
. O
[]

The O
incidence O
of O
preeclampsia B-outcome ['Physiological-Clinical']
in O
the O
randomized O
prophylactic O
antihypertensive O
group O
was O
statistically O
lower O
than O
that O
in O
the O
nonrandomized O
group O
( O
8.7 O
versus O
32.5 O
% O
; O
P O
less O
than O
.01 O
) O
. O
['Physiological-Clinical']

There O
were O
two O
types O
of O
intervention O
: O
a O
) O
Minimal O
Intervention O
( O
MI O
) O
. O
[]

Successful O
appraisal O
induction O
was O
verified O
using O
novel O
vignettes O
and O
via O
change O
scores O
on O
the O
post O
traumatic O
cognitions O
inventory O
. O
[]

There O
were O
insignificant O
changes O
in O
the O
parameters O
in O
the O
control O
group O
between O
baseline O
and O
6 O
months O
later O
. O
[]

Thus O
60 O
attacks O
were O
treated O
. O
[]

During O
on-demand O
treatment O
, O
rates O
of O
discontinuation B-outcome ['Life-Impact']
because O
of O
inadequate O
['Life-Impact']

We O
also O
compared O
changes O
in O
other O
ABC-C O
subscale O
scores O
and O
Clinical O
Global O
Impressions-Improvement O
( O
CGI-I O
) O
scale O
scores O
between O
the O
two O
groups O
. O
[]

All O
groups O
perceived O
the O
instruction O
as O
effective. O
[]

Plasma O
catecholamines O
( O
epinephrine O
and O
norepinephrine O
) O
increased O
significantly O
in O
Group O
4 O
( O
retroauricular O
infiltration O
anaesthesia O
) O
. O
[]

PARTICIPANTS O
Patients O
scheduled O
for O
coronary O
artery O
bypass O
graft O
surgery O
with O
CPB O
. O
[]

Accordingly O
, O
the O
cerebral B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
decreased O
equally O
during O
the O
Sal O
and O
Bicarb O
trials O
: O
from O
5.8?0.6 O
at O
rest O
to O
1.7?0.1 O
and O
1.8?0.2 O
, O
respectively O
. O
['Physiological-Clinical']

PURPOSE O
To O
measure O
changes O
and O
predictors O
of O
change O
in O
mammograms O
obtained O
in O
postmenopausal O
women O
undergoing O
continuous O
combined O
hormonal O
replacement O
therapy O
( O
HRT O
) O
. O
[]

Evoked O
V-wave O
, O
H-reflex O
, O
and O
M-wave O
recruitment O
curves O
, O
maximal O
voluntary O
contraction O
( O
MVC O
) O
, O
and O
time-to-task-failure O
( O
isometric O
contraction O
at O
40 O
% O
MVC O
) O
of O
the O
plantar O
flexors O
were O
recorded O
before O
and O
after O
training O
. O
[]

METHOD O
Eighty-nine O
suppressed O
patients O
> O
or O
=18 O
years O
old O
with O
CD4 O
counts O
> O
50 O
cells/mm O
( O
3 O
) O
were O
enrolled O
in O
this O
phase O
II O
, O
open-label O
, O
multicenter O
, O
randomized O
, O
stratified O
( O
by O
pretrial O
protease O
inhibitor O
[ O
PI O
] O
) O
, O
parallel-group O
clinical O
trial O
. O
[]

Densitometry O
and O
roentgenographic O
scoring O
of O
callus O
formation O
after O
12 O
weeks O
in O
propranolol-treated O
rats O
revealed O
increased O
callus B-outcome ['Physiological-Clinical']
and O
bone B-outcome ['Physiological-Clinical']
union I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
data O
were O
analyzed O
using O
repeated O
measures O
MANOVA. O
[]

RESULTS O
Seven O
children O
completed O
the O
trial O
. O
[]

Similar O
dosage O
and O
fractionation O
of O
RT O
was O
administered O
in O
both O
arms O
. O
[]

Such O
a O
pattern O
is O
consistent O
with O
the O
role O
of O
the O
left O
DLPFC O
in O
implementing O
top-down O
attentional O
control O
. O
[]

The O
primary O
contributor O
to O
the O
plasma B-outcome ['Physiological-Clinical']
alkalosis I-outcome ['Physiological-Clinical']
was O
an O
increased O
[ O
SID B-outcome ['Physiological-Clinical']
] O
, O
as O
a O
result O
of O
increased O
plasma O
[ O
Na+ O
] O
and O
decreased O
plasma O
[ O
Cl- O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Comorbid O
anxiety O
is O
common O
among O
children O
with O
Autism O
Spectrum O
Disorder O
( O
ASD O
) O
, O
and O
parents O
of O
children O
with O
ASD O
are O
more O
likely O
to O
have O
anxiety O
disorders O
. O
[]

Six O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
two O
subjects O
( O
diffuse B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
in O
one O
subject O
and O
five O
incidents O
of O
elevated O
blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
in O
one O
subject O
with O
diabetes B-outcome ['Physiological-Clinical']
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
thirteen O
patients O
, O
under O
reasonably O
good O
control O
, O
clofibrate O
did O
not O
reduce O
fasting B-outcome ['Physiological-Clinical']
or O
post-prandial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
nor O
24 O
h B-outcome ['Physiological-Clinical']
glycosuria I-outcome ['Physiological-Clinical']
; O
no O
improvement O
was O
noted O
in O
the O
M-value B-outcome ['Physiological-Clinical']
, O
an O
index O
of O
diabetes B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
This O
randomized O
double-blind O
phase O
I O
study O
assessed O
the O
safety O
and O
acceptability B-outcome ['Life-Impact']
of O
seven O
consecutive O
daily O
doses O
of O
CS O
versus O
KY O
Jelly O
in O
36 O
HIV-positive O
men O
. O
['Life-Impact']

In O
the O
SMILE O
eyes, O
it O
increased O
from O
52.52 O
+/- O
3.01 O
mum O
to O
57.15 O
+/- O
4.57 O
mum O
and O
also O
remained O
stable O
for O
up O
to O
24 O
months. O
[]

RESULTS O
A O
comparison O
of O
clearance B-outcome ['Physiological-Clinical']
and O
peak O
and O
systemic O
exposure B-outcome ['Physiological-Clinical']
to O
midazolam O
following O
administration O
of O
roflumilast O
indicated O
no O
effect O
of O
roflumilast O
dosed O
to O
steady O
state O
on O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
midazolam I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTERVENTIONS O
Inhaled O
fluticasone O
propionate O
500 O
microgram O
twice O
daily O
from O
a O
metered O
dose O
inhaler O
or O
identical O
placebo O
. O
[]

Chronological O
age O
at O
onset O
of O
pubertal O
signs O
was O
less O
than O
8 O
yr O
in O
girls O
and O
less O
than O
9 O
yr O
in O
boys O
, O
and O
bone O
age O
was O
advanced O
over O
chronological O
age O
at O
least O
1 O
yr O
. O
[]

Oxidative O
DNA O
damage O
measured O
in O
human O
lymphocytes O
: O
large O
differences O
between O
sexes O
and O
between O
countries O
, O
and O
correlations O
with O
heart O
disease O
mortality O
rates O
. O
[]

A O
published O
meta-analysis O
demonstrated O
that O
overall O
, O
producers O
lose O
approximately O
0.35 O
kg O
of O
milk O
per O
parasitized O
cow O
per O
day O
. O
[]

Thus O
, O
the O
benefits O
of O
6.5 O
years O
of O
intensive O
treatment O
extend O
well O
beyond O
the O
period O
of O
its O
most O
intensive O
implementation O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

DESIGN O
Prospective O
, O
blinded O
trial O
. O
[]

Each O
mode O
was O
randomly O
sequenced O
. O
[]

Differences O
between O
treatment O
arms, O
based O
on O
the O
intention-to-treat O
principle, O
were O
adjusted O
for O
covariates O
and O
missing O
data O
were O
handled O
using O
multiple O
imputation. O
[]

Patients O
were O
randomized O
to O
receive O
either O
an O
intraoperative O
bolus O
of O
milrinone O
( O
50 O
microg/kg O
) O
or O
saline O
as O
placebo O
followed O
by O
a O
24-hour O
infusion O
of O
each O
agent O
( O
0.5 O
microg/kg/min O
) O
. O
[]

The O
primary O
end O
point O
was O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Ambient B-outcome ['Physiological-Clinical']
nitrous I-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
exceeded O
25 O
parts O
per O
million O
in O
37 O
% O
of O
cases O
with O
uncuffed O
tubes O
and O
in O
0 O
% O
of O
cases O
with O
cuffed O
tubes O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

In O
the O
exercise O
therapy O
group O
the O
percentage O
of O
patients O
with O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
was O
higher O
and O
the O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
was O
longer O
than O
in O
the O
placebo O
and O
usual O
care O
groups O
, O
but O
these O
differences O
were O
not O
significant O
. O
['Life-Impact', 'Life-Impact']

These O
images O
were O
then O
scanned O
and O
measured O
. O
[]

The O
difference O
was O
not O
statistically O
significant O
( O
chi-square O
= O
0.231 O
, O
p O
> O
0.6 O
) O
. O
[]

Publication O
date: O
2018/05/09 O
00:00 O
[accepted] O
[]

In O
conclusion O
, O
in O
different O
metabolic O
conditions O
the O
GH O
receptor O
antagonist O
pegvisomant O
induces O
no O
significant O
acute O
changes O
in O
the O
major O
risk O
markers O
for O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Secondary O
outcome O
measures O
included O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
and O
complete O
( O
clinical B-outcome ['Physiological-Clinical']
plus O
mycological B-outcome ['Physiological-Clinical']
) O
cure B-outcome ['Physiological-Clinical']
of O
the O
target O
toenail B-outcome ['Physiological-Clinical']
and O
complete B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
of O
all O
10 O
toenails B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Change O
in O
cardiovascular B-outcome ['Physiological-Clinical']
autonomic I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

OBJECTIVE O
To O
further O
explore O
the O
effects O
of O
sodium O
oxybate O
( O
SXB O
) O
administration O
on O
nocturnal B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
in O
narcolepsy O
patients O
during O
a O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
conducted O
with O
228 O
adult O
patients O
with O
narcolepsy/cataplexy O
in O
the O
United O
States O
, O
Canada O
, O
and O
Europe O
. O
['Physiological-Clinical']

CD4+FOXP3+ O
regulatory O
T O
cell O
depletion O
by O
low-dose O
cyclophosphamide O
prevents O
recurrence B-outcome ['Physiological-Clinical']
in O
patients O
with O
large O
condylomata O
acuminata O
after O
laser O
therapy O
. O
['Physiological-Clinical']

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Before O
and O
10 O
minutes O
after O
administration O
of O
each O
desired O
end-expiratory O
anesthetic O
concentration O
, O
the O
following O
parameters O
were O
determined O
: O
hemodynamic B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

Exploratory O
analyses O
suggested O
that O
variation O
in O
a O
guanosine O
triphosphate O
cyclohydrolase O
gene O
predicted O
association O
with O
higher O
doses B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
methylphenidate I-outcome ['Life-Impact']
(P O
< O
0.001). O
[['Life-Impact']]

Surgical O
site O
infection O
(SSI) O
and O
incisional O
hernia O
are O
common O
complications O
after O
major O
pancreatectomy. O
[]

Prognostic O
value O
of O
clinical O
, O
laboratory O
, O
and O
histological O
characteristics O
in O
multiple O
myeloma O
: O
improved O
definition O
of O
risk O
groups O
. O
[]

Statistical O
analysis O
was O
performed O
to O
compare O
the O
DNA O
copy O
numbers O
of O
the O
three O
groups O
. O
[]

Combination O
therapy O
did O
not O
appear O
to O
confer O
additional O
benefit O
. O
[]

The O
levels O
of O
the O
systolic B-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
at O
entry O
were O
not O
predictive O
of O
the O
dose O
of O
nifedipine O
required O
for O
effective O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Serum-free B-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
and O
estrone B-outcome ['Physiological-Clinical']
levels O
decreased O
moderately O
in O
the O
experimental O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
association O
between O
estrogen B-outcome ['Physiological-Clinical']
and O
spatial B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
was O
found O
; O
however O
, O
in O
an O
additional O
exploratory O
data O
analysis O
, O
high O
levels O
of O
testosterone O
, O
LH B-outcome ['Physiological-Clinical']
, O
and O
FSH B-outcome ['Physiological-Clinical']
correlated O
significantly O
with O
performance O
in O
the O
flexibility B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
closure I-outcome ['Life-Impact']
task O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

All O
patients O
were O
on O
100 O
mug O
or O
more O
T O
( O
4 O
) O
. O
[]

It O
impacts O
physical, O
mental, O
and O
social O
functioning O
as O
well O
as O
the O
quality O
of O
life, O
often O
leading O
to O
depression. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
split-face O
randomized O
prospective O
open-label O
trial O
was O
to O
determine O
the O
effectiveness O
of O
sequential O
erbium O
: O
yttrium-aluminum-garnet O
( O
Er O
: O
YAG O
) O
laser O
versus O
intense O
pulsed O
light O
( O
IPL O
) O
for O
the O
treatment O
of O
mild O
to O
moderate O
facial O
photodamage O
. O
[]

The O
colon B-outcome ['Physiological-Clinical']
cleansing I-outcome ['Physiological-Clinical']
efficacy O
of O
the O
different O
preparations O
was O
rated O
using O
the O
Ottawa B-outcome ['Physiological-Clinical']
bowel I-outcome ['Physiological-Clinical']
preparation I-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Approximately O
20 O
% O
of O
patients O
had O
significantly O
increased O
levels O
of O
circulating B-outcome ['Physiological-Clinical']
CD19+ I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Maximal O
bioavailability B-outcome ['Physiological-Clinical']
of O
digoxin O
from O
tablets O
and O
oral O
solution O
in O
steady O
state O
. O
['Physiological-Clinical']

The O
radiographs B-outcome ['Physiological-Clinical']
of O
hands O
and O
feet O
were O
analyzed O
by O
using O
the O
Larsen O
score O
at O
baseline O
, O
2 O
, O
5 O
, O
and O
11 O
years O
, O
and O
the O
radiographs O
of O
large O
joints O
, O
at O
11 O
years O
. O
['Physiological-Clinical']

CONCLUSION: O
RADPAD O
significantly O
reduces O
radiation B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
to O
the O
primary O
operator O
during O
prolonged O
complex O
PCI O
procedures. O
[['Life-Impact']]

Averaged O
convalescence B-outcome ['Life-Impact']
was O
4.7 O
weeks O
in O
the O
TLA O
group O
and O
2.3 O
weeks O
in O
the O
RLA O
group O
( O
p O
= O
0.02 O
) O
. O
['Life-Impact']

Selamectin O
was O
administered O
to O
a O
total O
of O
673 O
dogs O
and O
347 O
cats O
having O
an O
age O
range O
of O
6 O
weeks O
to O
19 O
years O
( O
3954 O
doses O
) O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
booster B-outcome ['Physiological-Clinical']
immunization I-outcome ['Physiological-Clinical']
effect O
to O
non-and-low O
response O
children O
after O
3 O
doses O
HepB O
immunization O
. O
['Physiological-Clinical']

Secondary O
outcomes O
included O
ratings O
of O
pain O
and O
sleep O
quality O
as O
well O
as O
the O
ability O
to O
perform O
daily O
activities O
( O
Ambulatory O
Post O
Acute O
Care O
Daily O
Activities O
Short O
Form O
) O
, O
quality O
of O
life O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
) O
, O
and O
fatigue O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Fatigue O
) O
. O
[]

fractions O
) O
with O
a O
once-daily O
( O
q.d O
. O
) O
[]

Levamisole O
appeared O
to O
adversely O
affect O
CR B-outcome ['Physiological-Clinical']
rates O
in O
nodular O
mixed O
and O
nodular O
large-cell O
lymphoma O
and O
CR B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
in O
patients O
with O
unfavorable O
histology O
ML O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
effect O
was O
fully O
reversed O
when O
the O
patients O
returned O
to O
lactate O
fluid O
. O
[]

Due O
to O
the O
sample O
size O
and O
short O
time O
frame O
, O
results O
of O
a O
repeated O
measures O
analysis O
of O
variance O
did O
not O
reach O
significance O
. O
[]

The O
vascular O
changes O
responsible O
for O
this O
effect O
are O
not O
clear O
. O
[]

PURPOSE O
The O
purpose O
was O
to O
evaluate O
the O
activity B-outcome ['Life-Impact']
and O
toxicity B-outcome ['Adverse-effects']
of O
split-dose O
paclitaxel O
or O
docetaxel O
in O
combination O
with O
gemcitabine O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
who O
had O
previously O
received O
anthracyclines O
. O
['Life-Impact', 'Adverse-effects']

In O
a O
randomized O
controlled O
trial O
, O
the O
effectiveness O
of O
a O
polymeric O
surgical O
sealant O
( O
CoSeal O
) O
was O
compared O
to O
Gelfoam/thrombin O
for O
managing O
anastomotic B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
after O
implantation O
of O
Dacron O
grafts O
during O
aortic O
reconstruction O
for O
nonruptured O
aneurysms O
. O
['Physiological-Clinical']

Effects O
of O
frusemide O
and O
hypoxia O
on O
the O
pulmonary O
vascular O
bed O
in O
man O
. O
[]

Two O
doses O
of O
dabigatran O
( O
110 O
and O
150 O
mg O
BID O
) O
are O
being O
evaluated O
. O
[]

Comparison O
of O
tocainide O
and O
prajmalium O
bitartrate O
for O
the O
treatment O
of O
ventricular O
arrhythmias O
. O
[]

The O
primary O
outcome O
was O
the O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
, O
measured O
by O
the O
visual O
analog O
scale O
(VAS). O
[['Physiological-Clinical']]

[ O
A O
multicenter O
, O
randomized O
clinical O
trial O
of O
intravenous O
diltiazem O
in O
treatment O
of O
unstable O
angina O
] O
. O
[]

After O
the O
12-week O
treatments, O
the O
patients O
were O
examined O
for O
changes O
of O
TCM O
syndromes. O
[]

Bacteremia O
caused O
by O
Bacteroides O
fragilis O
occurred O
in O
four O
of O
75 O
children O
after O
renal O
transplantation O
, O
and O
B. O
fragilis O
was O
the O
most O
common O
cause O
of O
postoperative O
bacteremia O
. O
[]

Results O
indicated O
the O
treatment O
group O
made O
significantly O
more O
gains O
in O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
initiations I-outcome ['Life-Impact']
at O
post-treatment O
and O
follow-up O
and O
social-emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
at O
follow-up O
than O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact']

A O
randomized O
controlled O
trial O
for O
reducing O
risks O
for O
sexually B-outcome ['Life-Impact']
transmitted I-outcome ['Life-Impact']
infections I-outcome ['Life-Impact']
through O
enhanced O
patient-based O
partner O
notification O
. O
['Life-Impact']

A O
total O
of O
51 O
children O
( O
mean O
age O
: O
7.7 O
+/- O
4.8 O
year O
) O
were O
studied O
in O
133 O
chemotherapy O
cycles O
. O
[]

In O
a O
randomized O
, O
2-group O
clinical O
study O
, O
acupuncture O
was O
used O
for O
the O
relief O
of O
menopausal B-outcome ['Physiological-Clinical']
hot I-outcome ['Physiological-Clinical']
flushes I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
, O
and O
mood B-outcome ['Life-Impact']
changes I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

RESULTS O
When O
expressed O
as O
a O
percentage O
, O
the O
improvement O
in O
time O
to O
progression O
, O
overall B-outcome ['Mortality']
and O
cancer B-outcome ['Mortality']
specific I-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
the O
Anandron O
treated O
patients O
was O
identical O
in O
both O
groups O
. O
['Mortality', 'Mortality']

METHODS O
The O
study O
was O
conducted O
with O
21 O
children O
with O
Autism O
Spectrum O
Disorder O
diagnoses O
, O
randomly O
allocated O
into O
two O
groups O
, O
who O
received O
the O
same O
short-term O
intervention O
types O
( O
6 O
weeks O
with O
the O
mother O
and O
6 O
weeks O
with O
the O
support O
of O
an O
educational O
software O
program O
) O
. O
[]

RES O
was O
evaluated O
by O
two O
calibrated O
blind O
periodontists O
one O
year O
after O
the O
treatment. O
[]

Results: O
At O
week O
12, O
mean O
percent O
reduction O
in O
inflammatory O
and O
noninflammatory O
lesion B-outcome ['Physiological-Clinical']
counts O
were O
60.1% O
and O
53.0%, O
respectively, O
compared O
with O
51.1% O
and O
38.7% O
with O
vehicle O
(P</=0.001) O
in O
the O
Hispanic O
population. O
[['Physiological-Clinical']]

Women O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
a O
computer O
generated O
random O
sequence O
to O
either O
triple O
antiretroviral O
prophylaxis O
( O
a O
combination O
of O
300 O
mg O
zidovudine O
, O
150 O
mg O
lamivudine O
, O
and O
400 O
mg O
lopinavir O
plus O
100 O
mg O
ritonavir O
twice O
daily O
until O
cessation O
of O
breastfeeding O
to O
a O
maximum O
of O
6?5 O
months O
post O
partum O
) O
or O
zidovudine O
and O
single-dose O
nevirapine O
( O
300 O
mg O
zidovudine O
twice O
daily O
until O
delivery O
and O
a O
dose O
of O
600 O
mg O
zidovudine O
plus O
200 O
mg O
nevirapine O
at O
the O
onset O
of O
labour O
and O
, O
after O
a O
protocol O
amendment O
in O
December O
, O
2006 O
, O
1 O
week O
post-partum O
zidovudine O
300 O
mg O
twice O
daily O
and O
lamivudine O
150 O
mg O
twice O
daily O
) O
. O
[]

Non-evaporative B-outcome ['Physiological-Clinical']
heat I-outcome ['Physiological-Clinical']
exchange I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
, O
-14.0 O
and O
-10.6 O
W.m-2 O
( O
p O
less O
than O
0.03 O
) O
, O
for O
the O
pyridostigmine-treated O
subjects O
. O
['Physiological-Clinical']

We O
conclude O
that O
Pgp O
has O
prognostic O
relevance O
in O
CML-BP O
but O
that O
the O
modulation O
of O
Pgp O
function O
with O
CsA O
as O
applied O
in O
this O
trial O
is O
ineffective O
. O
[]

CONCLUSION O
Among O
the O
children O
studied O
here O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
IMV O
and O
SIMV+PS O
in O
terms O
of O
time O
on O
MV O
, O
duration O
of O
weaning O
or O
time O
spent O
in O
the O
PICU O
. O
[]

Reputation O
management O
: O
evidence O
for O
ability O
but O
reduced O
propensity O
in O
autism O
. O
[]

Psychiatric B-outcome ['Physiological-Clinical']
assessment O
was O
made O
with O
the O
Hamilton O
depression B-outcome ['Life-Impact']
scale O
( O
HDS O
) O
, O
and O
unwanted B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
measured O
with O
the O
UKU O
side-effect B-outcome ['Adverse-effects']
scale O
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects', 'Adverse-effects']

Pharmacokinetics O
of O
two O
theophylline O
( O
CAS O
58-55-9 O
) O
sustained O
release O
preparations O
( O
T O
: O
Bronchoretard O
Capsules/R O
: O
Capsule O
formulation O
from O
the O
US O
market O
) O
were O
investigated O
in O
an O
open O
randomised O
two-way O
crossover O
design O
. O
[]

IR O
premenopausal O
women O
show O
significant O
increase O
in O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
serum O
concentrations O
regardless O
the O
method O
of O
intervention. O
[['Physiological-Clinical']]

2 O
) O
Compared O
with O
nitroglycerin O
, O
intravenous O
diltiazem O
lowered B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
myocardial B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
consumption I-outcome ['Physiological-Clinical']
index O
( O
systolic O
pressure O
x O
heart O
rate O
) O
to O
more O
extent O
significantly O
. O
( O
['Physiological-Clinical', 'Physiological-Clinical']

There O
are O
multiple O
design O
possibilities O
for O
VPs O
, O
however O
there O
is O
little O
formal O
evidence O
to O
support O
individual O
design O
features O
. O
[]

Noggin B-outcome ['Physiological-Clinical']
was O
measured, O
for O
the O
first O
time O
in O
thalassemia O
patients, O
at O
baseline O
and O
at O
12 O
months, O
using O
a O
recently O
developed O
high O
sensitivity O
fluorescent O
immunoassay. O
[['Physiological-Clinical']]

Observers O
judged O
the O
direction O
of O
motion O
( O
left O
or O
right O
) O
of O
each O
probe O
. O
[]

No O
change O
in O
fibrinogen B-outcome ['Physiological-Clinical']
or O
factor O
VIIc B-outcome ['Physiological-Clinical']
was O
detected O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mastodinia B-outcome ['Physiological-Clinical']
, O
a O
satisfactory O
response O
was O
observed O
in O
100 O
% O
of O
alpha O
dihidroergocriptine O
group O
vs O
61.11 O
% O
of O
placebo O
group O
( O
p O
= O
0.0002 O
) O
. O
['Physiological-Clinical']

Journal O
ID: O
101125284 O
[]

We O
randomly O
grouped O
the O
61 O
patients O
into O
control O
group O
( O
group O
C O
) O
, O
block O
group O
( O
group O
B O
) O
and O
dexketoprofen-block O
group O
( O
group O
DB O
) O
. O
[]

Cognitive-behavioural O
stress O
management O
with O
HIV-positive O
homosexual O
men O
: O
mechanisms O
of O
sustained O
reductions O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

4.5 O
mL?kg?min O
; O
mean O
? O
[]

None O
of O
the O
findings O
that O
favored O
the O
comparison O
area O
were O
statistically O
significant. O
[]

A O
low O
remission B-outcome ['Physiological-Clinical']
rate O
was O
also O
observed O
in O
subjects O
who O
had O
previously O
failed O
to O
respond O
to O
a O
combination O
of O
an O
antipsychotic O
and O
an O
antidepressant O
. O
['Physiological-Clinical']

A O
comparison O
of O
live O
and O
videotape O
ratings O
: O
clomipramine O
and O
haloperidol O
in O
autism O
. O
[]

Five O
of O
eight O
patients O
in O
group O
A O
and O
seven O
of O
nine O
in O
group O
B O
had O
a O
history O
of O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
. O
[]

Scales O
for O
the O
assessment O
of O
neuroleptic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
schizophrenic O
children O
: O
specific O
measures O
derived O
from O
the O
CPRS O
. O
['Physiological-Clinical']

4 O
months O
, O
recurrence O
of O
AF O
was O
detected O
in O
5 O
of O
22 O
patients O
( O
22.7 O
% O
) O
in O
group O
A O
vs. O
3 O
of O
22 O
patients O
( O
13.6 O
% O
) O
in O
group O
B O
( O
p O
= O
0.722 O
) O
. O
[]

Mortality B-outcome ['Mortality']
was O
not O
significantly O
different O
in O
the O
AR-R15896AR O
group O
compared O
with O
the O
placebo O
group O
( O
10 O
% O
vs. O
6 O
% O
) O
. O
['Mortality']

RESULTS: O
TXA O
significantly O
reduced O
perioperative O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
(p O
< O
0.001); O
the O
mean O
differences O
were O
525.3 O
ml O
(short-TXA O
vs O
placebo) O
and O
550.1 O
ml O
(long-TXA O
vs O
placebo). O
[['Physiological-Clinical']]

However O
, O
these O
studies O
did O
not O
control O
for O
nonspecific O
effects O
of O
EEG-biofeedback O
and O
did O
not O
distinguish O
between O
participants O
who O
succeeded O
in O
influencing O
their O
own O
EEG O
activity O
and O
participants O
who O
did O
not O
. O
[]

When O
PAN O
is O
not O
related O
to O
HBV O
and O
in O
CSS O
, O
even O
in O
severe O
cases O
, O
there O
is O
presently O
no O
argument O
supporting O
systematic O
administration O
of O
PE O
at O
the O
time O
of O
diagnosis O
. O
[]

OBJECTIVE O
Compare O
the O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
adults O
after O
0.9 O
vs. O
1.2 O
mg O
of O
atropine O
plus O
neostigmine O
2.5 O
mg O
as O
the O
non-depolarizing O
muscle O
relaxant O
reversal O
agent O
. O
['Physiological-Clinical']

Twelve O
hour O
fasting O
blood O
samples O
, O
taken O
at O
the O
initiation O
and O
on O
the O
third O
month O
of O
therapy O
, O
were O
analyzed O
for O
the O
levels O
of O
malondialdehyde B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MDA B-outcome ['Physiological-Clinical']
) O
, O
nitrite+nitrate B-outcome ['Physiological-Clinical']
( O
NOx O
) O
, O
and O
the O
activity O
of O
myeloperoxidase B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MPO I-outcome ['Physiological-Clinical']
) O
, O
superoxide B-outcome ['Physiological-Clinical']
dismutase B-outcome ['Physiological-Clinical']
( O
SOD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Primary O
deep O
sclerectomy O
versus O
primary O
deep O
sclerectomy O
with O
the O
use O
of O
mitomycin O
C O
in O
primary O
open-angle O
glaucoma O
. O
[]

We O
investigated O
whether O
parents O
of O
young O
children O
on O
the O
autism O
spectrum O
could O
learn O
and O
implement O
the O
specific O
categories O
of O
verbal O
responsiveness O
that O
have O
been O
suggested O
to O
facilitate O
language O
development O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

CGRP O
and O
SP O
are O
considered O
relevant O
in O
the O
genesis O
of O
migraine O
pain O
. O
[]

Journal O
ID: O
2985248R O
[]

In O
general O
, O
the O
degree O
of I-outcome ['Physiological-Clinical']
suppression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
HPA I-outcome ['Physiological-Clinical']
axis I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
related O
to O
the O
daily O
dosage O
of O
steroid O
given O
, O
the O
duration O
of O
its O
administration O
, O
the O
extent O
of O
body O
surface O
covered O
, O
and O
the O
potency O
of O
the O
corticosteroid O
. O
['Physiological-Clinical']

CONCLUSION O
The O
results O
of O
this O
study O
suggest O
that O
the O
triage O
process O
in O
this O
setting O
is O
strongly O
dependent O
on O
the O
provider O
's O
availability O
to O
assess O
, O
triage O
, O
and O
discharge O
patients O
. O
[]

METHODS O
This O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
included O
adults O
with O
GERD-associated B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
and O
moderate-to-severe B-outcome ['Physiological-Clinical']
nighttime I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
( O
recorded O
by O
patient O
diary O
during O
screening O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Women O
in O
the O
educational O
book O
group O
had O
fewer O
risks O
in O
their O
homes O
and O
exercised O
more O
safety O
[]

Ratings O
from O
a O
blinded O
peer O
review O
panel O
indicated O
significant O
improvement O
in O
the O
appropriateness O
of O
the O
blood O
pressure O
regimen O
, O
going O
from O
8.7 O
+/- O
4.7 O
to O
10.9 O
+/- O
4.5 O
in O
the O
study O
group O
( O
p O
< O
0.01 O
) O
, O
but O
they O
did O
not O
change O
in O
the O
control O
group O
. O
[]

In O
the O
patient-level O
meta-analysis, O
the O
percentage O
of O
patients O
who O
were O
free O
from O
recurrence B-outcome ['Physiological-Clinical']
at O
6 O
months O
was O
67.0% O
(95% O
CI, O
61.0 O
to O
72.3) O
among O
the O
426 O
patients O
in O
the O
tafenoquine O
group O
and O
72.8% O
(95% O
CI, O
65.6 O
to O
78.8) O
among O
the O
214 O
patients O
in O
the O
primaquine O
group. O
[['Physiological-Clinical']]

All O
volunteers O
received O
ASA O
81 O
mg O
once O
daily O
for O
5 O
days O
prior O
to O
the O
study O
( O
pre-screen O
) O
. O
[]

The O
study O
, O
however O
, O
failed O
to O
show O
a O
significant O
improvement O
in O
median O
[]

MEASURES O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
early I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
were O
registered O
by O
Tissue O
Doppler O
from O
a O
long-axis O
view O
of O
the O
interventricular O
septum O
or O
the O
anterior O
wall O
of O
the O
left O
ventricle O
. O
['Physiological-Clinical']

DHA B-outcome ['Physiological-Clinical']
intakes O
up O
to O
7 O
mg/kg O
did O
not O
improve O
neurological B-outcome ['Life-Impact']
functions I-outcome ['Life-Impact']
in O
PKU O
children. O
[['Physiological-Clinical'], ['Life-Impact']]

An O
additional O
examination O
was O
performed O
at O
34 O
weeks O
if O
the O
fetal O
weight O
in O
the O
32nd O
week O
was O
estimated O
to O
be O
less O
than O
95 O
% O
of O
the O
expected O
mean O
weight O
. O
[]

Both O
groups O
showed O
significant O
improvements O
in O
mean O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
] O
scores O
for O
pain B-outcome ['Physiological-Clinical']
: O
11 O
( O
7 O
, O
16 O
) O
( O
P O
< O
0.001 O
) O
; O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
: O
4 O
( O
2 O
, O
5 O
) O
( O
P O
< O
0.001 O
) O
; O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
status I-outcome ['Life-Impact']
: O
2 O
( O
0.1 O
, O
4 O
) O
( O
P O
< O
0.02 O
) O
; O
and O
health B-outcome ['Physiological-Clinical']
utility I-outcome ['Physiological-Clinical']
: O
0.11 O
( O
0.07 O
, O
0.16 O
) O
( O
P O
< O
0.001 O
) O
by O
the O
end O
of O
the O
15-month O
period O
of O
the O
study O
, O
but O
there O
was O
no O
significant O
difference O
between O
either O
arm O
of O
the O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Effect O
of O
a O
ferrule O
and O
increased O
clinical O
crown O
length O
on O
the O
in O
vitro O
fracture O
resistance O
of O
premolars O
restored O
using O
two O
dowel-and-core O
systems O
. O
[]

The O
primary O
outcome O
measure O
was O
postoperative O
morbidity O
measured O
by O
the O
Postoperative O
Morbidity O
Survey O
. O
[]

The O
scores O
of O
unintentional O
injury O
risk B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
for O
children O
in O
the O
intervention O
group O
at O
3 O
and O
6 O
months O
after O
intervention O
were O
14.42+/-5.67 O
and O
14.14+/-8.95, O
respectively, O
lower O
than O
those O
before O
the O
intervention O
(16.85+/-8.48) O
and O
in O
the O
control O
group O
(P=0.001). O
[['Life-Impact']]

RESULTS O
Sodium O
nitroprusside O
, O
substance O
P O
and O
bradykinin O
produced O
dose-dependent O
increases O
in O
the O
blood B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
of O
infused O
forearm O
( O
analysis O
of O
variance O
[ O
ANOVA O
] O
, O
p O
< O
0.001 O
for O
all O
) O
. O
['Physiological-Clinical']

The O
patients O
' O
evaluation O
was O
significant O
for O
the O
first B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

The O
role O
of O
glucose-insulin-potassium O
( O
GIK O
) O
infusion O
in O
the O
management O
of O
acute B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
is O
not O
well O
established O
. O
['Physiological-Clinical']

Preoperative O
small-dose O
ketamine O
has O
no O
preemptive O
analgesic O
effect O
in O
patients O
undergoing O
total O
mastectomy O
. O
[]

Learning O
about O
the O
equal O
sign O
: O
does O
comparing O
with O
inequality O
symbols O
help O
? O
[]

Randomization O
was O
stratified O
according O
to O
whether O
CNS O
leukemia O
occurred O
at O
initial O
diagnosis O
of O
acute O
lymphocytic O
leukemia O
( O
ALL O
) O
( O
Stratum O
I O
, O
15 O
patients O
) O
, O
during O
first O
bone O
marrow O
( O
BM O
) O
remission O
( O
Stratum O
II O
, O
49 O
patients O
) O
, O
simultaneous O
with O
first O
BM O
relapse O
( O
Stratum O
III O
, O
12 O
patients O
) O
, O
or O
during O
second O
BM O
remission O
( O
Stratum O
IV O
, O
11 O
patients O
) O
. O
[]

A O
subset O
of O
11 O
subjects O
also O
had O
epinastine O
hydrochloride O
( O
EH O
) O
applied O
alone O
and O
combined O
with O
CC O
in O
random O
order O
or O
instillation O
of O
a O
volume-matched O
saline O
control O
. O
[]

Title: O
beta-Eudesmol, O
an O
Oxygenized O
Sesquiterpene, O
Reduces O
the O
Increase O
in O
Saliva O
3-Methoxy-4-Hydroxyphenylglycol B-outcome ['Physiological-Clinical']
After O
the O
"Trier O
Social O
Stress O
Test" O
in O
Healthy O
Humans: O
A O
Randomized, O
Double-Blind, O
Placebo-Controlled O
Cross-Over O
Study. O
[['Physiological-Clinical']]

The O
IFN O
group O
received O
daily O
intravenous O
injections O
of O
rFeIFN-omega O
( O
2.5 O
MU/kg O
) O
for O
three O
consecutive O
days O
. O
[]

In O
the O
initial O
2 O
weeks O
of O
active O
drug O
listlessness O
, O
food B-outcome ['Life-Impact']
refusal I-outcome ['Life-Impact']
, O
and O
stomach B-outcome ['Physiological-Clinical']
upset I-outcome ['Physiological-Clinical']
were O
frequently O
seen O
. O
['Life-Impact', 'Physiological-Clinical']

PURPOSE O
Tipless O
stone O
baskets O
facilitate O
caliceal O
calculi O
extraction O
during O
flexible O
ureteroscopy O
. O
[]

DESIGN O
Prospective O
, O
comparative O
, O
open-label O
clinical O
trial O
. O
[]

METHODS O
Twenty-four O
patients O
with O
perennial O
rhinitis O
due O
to O
house-dust-mite O
( O
HDM O
) O
allergy O
were O
recruited O
in O
this O
crossover O
study O
. O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

PURPOSE O
To O
centrally O
assess O
the O
safety O
, O
efficacy O
, O
and O
[]

Title: O
Bag-Mask O
Ventilation O
during O
Tracheal O
Intubation O
of O
Critically O
Ill O
Adults. O
[]

The O
contribution O
of O
salvage O
surgery O
to O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
similar O
for O
both O
arms O
of O
the O
study O
as O
was O
the O
surgical B-outcome ['Adverse-effects']
complication I-outcome ['Adverse-effects']
rate O
. O
['Mortality', 'Adverse-effects']

METHODS O
This O
was O
a O
single-center O
, O
randomized O
, O
evaluator-blinded O
, O
parallel-group O
study O
. O
[]

Impact O
of O
the O
quantity O
and O
flavonoid B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
of O
fruits O
and O
vegetables O
on O
markers O
of O
intake O
in O
adults O
with O
an O
increased O
risk O
of O
cardiovascular O
disease O
: O
the O
FLAVURS O
trial O
. O
['Physiological-Clinical']

Three O
dose O
levels O
of O
once-daily O
mizolastine O
( O
5 O
mg O
, O
10 O
mg O
, O
and O
15 O
mg O
) O
were O
compared O
with O
placebo O
during O
5-day O
dose O
periods O
. O
[]

The O
patients O
inhaled O
hydrogen O
gas O
for O
3 O
h/day O
at O
their O
own O
homes O
and O
received O
chemotherapy O
at O
the O
Tamana O
Regional O
Health O
Medical O
Center O
(Tamana, O
Kumamoto, O
Japan). O
[]

Low O
dose O
risperidone O
was O
effective O
for O
aggressive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
persons O
with O
MR. O
More O
long-term O
studies O
are O
needed O
, O
incorporating O
weight O
control O
interventions O
. O
['Life-Impact']

Natural O
coral O
calcium O
BRG O
was O
utilised O
in O
33 O
patients O
. O
[]

The O
difference O
in O
infectious B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
between O
groups O
1 O
and O
3 O
was O
statistically O
highly O
significant O
( O
p O
< O
0.01 O
) O
and O
between O
groups O
2 O
and O
3 O
it O
was O
significant O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

By O
TEE O
, O
valve B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
was O
normal O
in O
all O
patients O
. O
['Physiological-Clinical']

This O
study O
should O
be O
repeated O
on O
a O
larger O
sample O
. O
[]

More O
women O
in O
the O
NETZ O
arm O
had O
clear B-outcome ['Physiological-Clinical']
histological I-outcome ['Physiological-Clinical']
margins I-outcome ['Physiological-Clinical']
( O
84.8 O
% O
vs O
75 O
% O
, O
( O
P= O
0.03 O
) O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
Patients O
were O
randomized O
to O
supervised O
intensive O
lifestyle O
intervention O
group O
( O
N=28 O
) O
or O
to O
control O
group O
( O
N=31 O
) O
, O
which O
received O
routine O
lifestyle O
advices O
. O
[]

The O
age O
range O
was O
13-50 O
years O
( O
mean O
33.6 O
years O
) O
. O
[]

When O
compared O
with O
high-flux O
HD O
, O
online O
HDF O
provided O
significantly O
greater O
percentages O
of O
the O
reduction O
ratio O
in O
plasma B-outcome ['Physiological-Clinical']
cytokine I-outcome ['Physiological-Clinical']
levels O
, O
including O
VEGF B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
, O
IL-6 O
( O
P O
= O
0.001 O
) O
, O
IL-8 O
( O
P O
= O
0.021 O
) O
, O
IL-10 O
( O
P O
= O
0.011 O
) O
, O
and O
tumor O
necrosis O
factor-? O
( O
P O
= O
0.029 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Induction O
deaths B-outcome ['Mortality']
were O
comparable O
at O
9 O
% O
( O
ALL-2 O
) O
versus O
7 O
% O
( O
L-20 O
) O
. O
['Mortality']

Net O
treatment O
effects O
were O
computed O
by O
subtracting O
the O
mean O
changes O
from O
baseline O
during O
placebo O
( O
n O
= O
133 O
) O
from O
those O
during O
active O
treatment O
( O
n O
= O
111 O
) O
. O
[]

Overall O
, O
the O
correct O
treatment O
decision B-outcome ['Life-Impact']
was O
established O
in O
87 O
% O
of O
the O
consultations O
. O
['Life-Impact']

RESULTS O
Infants O
nursed O
with O
a O
postural O
support O
roll O
and O
a O
postural O
support O
nappy O
demonstrated O
improved O
hip B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
to O
term O
equivalent O
age O
compared O
with O
infants O
nursed O
with O
either O
a O
postural O
support O
roll O
only O
, O
or O
a O
postural O
support O
nappy O
only O
. O
['Physiological-Clinical']

Cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
users O
of O
ecstasy O
. O
['Life-Impact', 'Physiological-Clinical']

METHODS O
One O
hundred O
and O
fifty O
patients O
with O
low O
back O
pain O
for O
at O
least O
eight O
weeks O
and O
referred O
to O
a O
specialized O
secondary O
sector O
outpatient O
back O
pain O
clinic O
are O
included O
in O
the O
study O
. O
[]

The O
admission O
of O
prolonged O
form O
of O
nitrates O
before O
the O
PCI O
was O
allowed O
in O
the O
second O
group. O
[]

Low O
grade O
lymphomas O
( O
16 O
patients O
) O
received O
a O
cyclophosphamide O
, O
vincristine O
, O
prednisone O
association O
. O
[]

Effectiveness O
of O
Dader O
Method O
for O
pharmaceutical O
care O
on O
control O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
total O
cholesterol B-outcome ['Physiological-Clinical']
in O
outpatients O
with O
cardiovascular O
disease O
or O
cardiovascular O
risk O
: O
EMDADER-CV O
randomized O
controlled O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Supplementation O
lasted O
for O
14 O
days O
during O
months O
4 O
and O
8 O
. O
[]

The O
trial O
will O
recruit O
at O
least O
1000 O
patients O
who O
will O
be O
followed O
for O
five O
years O
. O
[]

RESULTS O
Results O
of O
intent-to-treat O
analyses O
are O
presented O
in O
this O
study O
. O
[]

Oral O
contraceptive O
use O
is O
associated O
with O
increased O
cardiovascular B-outcome ['Physiological-Clinical']
reactivity I-outcome ['Physiological-Clinical']
in O
nonsmokers O
. O
['Physiological-Clinical']

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

These O
10 O
patients O
experienced O
a O
significantly O
greater O
benefit O
from O
the O
metronidazole B-outcome ['Resource-use']
than O
did O
the O
8 O
patients O
who O
were O
considered O
noncompliant O
, O
i.e. O
, O
a O
reduction O
of O
['Resource-use']

The O
results O
appear O
better O
than O
those O
reported O
in O
iCBT O
studies O
to O
date O
and O
provide O
support O
for O
the O
potential O
of O
clinician-guided O
iCBT O
in O
the O
treatment O
of O
disability B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
, O
and O
depression B-outcome ['Life-Impact']
for O
people O
with O
chronic O
pain O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Seventy O
percent O
( O
n O
= O
30 O
) O
of O
the O
sample O
population O
displayed O
a O
lower B-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
in O
the O
45-degree O
upright O
position O
than O
that O
obtained O
in O
the O
supine O
position O
, O
with O
the O
decrease O
ranging O
from O
1 O
% O
to O
32 O
% O
( O
mean O
decrease O
11 O
% O
) O
. O
['Physiological-Clinical']

METHODS O
A O
retrospective O
cohort O
study O
-- O
secondary O
analysis O
of O
the O
results O
of O
a O
treatment O
trial O
-- O
was O
performed O
in O
Belgium O
and O
The O
Netherlands O
. O
[]

At O
the O
dose O
schedules O
investigated O
, O
and O
in O
a O
heavily O
pretreated O
patient O
population O
, O
AMSA O
had O
activity O
in O
childhood B-outcome ['Physiological-Clinical']
leukemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Funded O
by O
Vertex O
Pharmaceuticals O
and O
others O
; O
ClinicalTrials.gov O
number O
, O
NCT00457821 O
. O
) O
. O
[]

Intravenous O
platelet O
blockade O
with O
cangrelor O
during O
PCI O
. O
[]

RESULTS O
Patients O
who O
received O
IT O
methotrexate O
had O
a O
mean O
Processing B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
Index O
that O
was O
3.6 O
points O
lower O
, O
about O
one O
fourth O
of O
a O
standard O
deviation O
, O
than O
those O
who O
received O
triple O
IT O
therapy O
( O
P O
= O
.04 O
) O
after O
analysis O
was O
adjusted O
for O
age O
, O
sex O
, O
and O
time O
since O
diagnosis O
. O
['Life-Impact']

Effects O
of O
losartan O
and O
enalapril O
on O
high-sensitivity O
C-reactive O
protein O
and O
total O
antioxidant O
in O
renal O
transplant O
recipients O
with O
Renin-Angiotensin O
system O
polymorphisms O
. O
[]

Therefore O
, O
they O
were O
combined O
for O
comparison O
with O
the O
PRN O
group O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
artificial O
tears O
and O
cold O
compress O
alone O
or O
in O
combination O
provide O
a O
treatment O
benefit O
and O
whether O
they O
were O
as O
effective O
as O
or O
could O
enhance O
topical O
antiallergic O
medication O
. O
[]

Title: O
[Effects O
of O
early O
enteral O
nutrition O
in O
patients O
with O
mild O
acute O
pancreatitis. O
[]

METHOD O
Data O
were O
collected O
over O
a O
23-week O
period O
, O
from O
4:00 O
PM O
to O
midnight O
, O
and O
resulted O
in O
446 O
patients O
being O
recruited O
into O
the O
study O
( O
90 O
% O
of O
those O
who O
screened O
positive O
) O
and O
randomized O
to O
three O
conditions O
following O
a O
two-stage O
process O
: O
screened O
only O
( O
n O
= O
147 O
) O
, O
assessed O
( O
n O
= O
152 O
) O
, O
and O
received O
intervention O
( O
n O
= O
147 O
) O
. O
[]

Two O
subgroups O
of O
pancreatitis O
patients O
were O
defined O
based O
on O
the O
M-ANNHEIM O
severity O
index O
of O
chronic O
pancreatitis O
; O
i.e O
. O
[]

Azathioprine O
was O
administered O
at O
1-2 O
mg/kg O
per O
day O
. O
[]

RESULTS O
39 O
patients O
with O
alpha O
dihidroergocriptine O
and O
38 O
with O
placebo O
. O
[]

The O
exercise O
group O
underwent O
a O
moderate-intensity O
( O
50 O
% O
of O
peak O
oxygen O
uptake O
) O
12-week O
training O
program O
, O
progressing O
to O
100 O
minutes O
per O
week O
of O
step O
aerobics O
and O
50 O
minutes O
per O
week O
of O
cycling O
. O
[]

They O
were O
given O
intramuscular O
atropine O
( O
15 O
micrograms/kg O
) O
, O
glycopyrrolate O
( O
8 O
micrograms/kg O
) O
, O
scopolamine O
( O
8 O
micrograms/kg O
) O
, O
and O
placebo O
in O
a O
random O
double-blind O
cross-over O
design O
. O
[]

Results O
showed O
that O
diphenhydramine O
produced O
a O
significant O
inhibition B-outcome ['Physiological-Clinical']
of O
the O
histamine-induced B-outcome ['Physiological-Clinical']
wheal I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
at O
1.5 O
h O
which O
lasted O
up O
to O
4 O
h O
after O
drug O
administration O
, O
reaching O
maximum O
inhibition O
at O
2.5 O
h. O
After O
cinnarizine O
treatment O
no O
significant O
decrease O
of O
the O
histamine-induced B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Long-term O
follow O
up O
is O
needed O
to O
determine O
effects O
and O
side O
effects O
of O
health O
checks O
and O
health O
talks O
. O
[]

RESULTS: O
The O
volunteers O
had O
a O
level O
of O
education O
from O
incomplete O
junior O
school O
to O
complete O
graduate O
course, O
with O
16 O
males O
(48%) O
and O
18 O
females O
(52%), O
age O
range O
of O
21 O
to O
87 O
years. O
[]

Some O
of O
these O
complications O
may O
be O
a O
result O
of O
providing O
PN O
in O
excess O
of O
nutrient O
requirements O
. O
[]

However, O
in O
patients O
with O
a O
low O
BMI, O
the O
LBW O
protocol O
delivered O
a O
significantly O
higher O
dose B-outcome ['Life-Impact']
than O
the O
TBW O
protocol O
(620.7 O
vs O
600.0 O
mg O
iodine/kg, O
P O
< O
0.001). O
[['Life-Impact']]

All O
patients O
were O
examined O
within O
72 O
h O
after O
stroke O
onset O
. O
[]

Several O
ureteral B-outcome ['Physiological-Clinical']
injuries I-outcome ['Physiological-Clinical']
at O
operative O
laparoscopy O
have O
been O
reported O
. O
['Physiological-Clinical']

BACKGROUND O
Randomized O
trials O
have O
demonstrated O
benefits O
of O
biventricular O
( O
BiV O
) O
pacing O
in O
patients O
with O
advanced O
heart O
failure O
, O
intraventricular O
conduction O
delay O
, O
and O
atrial O
fibrillation O
( O
AF O
) O
post-atrioventricular O
( O
AV O
) O
node O
ablation O
. O
[]

Compared O
to O
controls, O
subcutaneous B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
intra-abdominal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
fat E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
reduced O
significantly O
with O
both O
diet O
(- O
12.5% O
and O
- O
12.0%) O
and O
exercise O
plus O
diet O
(- O
16.0% O
and O
- O
14.6%). O
[['Physiological-Clinical', 'Physiological-Clinical']]

RESULTS O
Recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
HCC I-outcome ['Physiological-Clinical']
occurred O
in O
7 O
cases O
( O
33.3 O
% O
) O
for O
the O
treatment O
group O
and O
12 O
cases O
( O
50.0 O
% O
) O
for O
the O
control O
group O
during O
mean O
observation O
periods O
of O
19.5 O
and O
16.5 O
months O
, O
respectively O
. O
['Physiological-Clinical']

FINDINGS: O
We O
recruited O
2203 O
participants O
between O
May O
7, O
2014, O
and O
Sept O
28, O
2017, O
of O
whom O
1099 O
were O
assigned O
to O
the O
lactoferrin O
group O
and O
1104 O
to O
the O
control O
group. O
[]

The O
tolfenamic O
acid-caffeine O
combination O
proved O
the O
most O
effective O
as O
judged O
by O
duration O
and O
intensity O
of O
attacks B-outcome ['Physiological-Clinical']
, O
working O
ability O
, O
vigilance O
, O
and O
['Physiological-Clinical']

Twenty-four O
vs. O
forty-eight O
weeks O
of O
re-therapy O
with O
interferon O
alpha O
2b O
and O
ribavirin O
in O
interferon O
alpha O
monotherapy O
relapsers O
with O
chronic O
hepatitis O
C. O
BACKGROUND/AIM O
Roughly O
50 O
% O
of O
patients O
with O
chronic O
hepatitis O
C O
, O
who O
relapsed O
after O
a O
previous O
monotherapy O
with O
interferon O
alpha O
, O
will O
respond O
in O
a O
sustained O
fashion O
to O
24 O
weeks O
of O
re-therapy O
with O
the O
combination O
of O
interferon O
alpha O
plus O
ribavirin O
. O
[]

OBJECTIVE: O
Primary O
objective O
was O
to O
compare O
the O
effects O
of O
atorvastatin O
40mg O
vs O
80mg O
on O
LDL-C B-outcome ['Physiological-Clinical']
in O
Indian O
patients O
with O
atherosclerotic O
dyslipidemia. O
[['Physiological-Clinical']]

Declining O
resting-state O
inhibition O
was O
associated O
with O
weakened O
event-related O
modulation O
of O
inhibition O
. O
[]

We O
explored O
characteristics O
of O
NSCLC O
that O
could O
predict O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
using O
Cox O
regression O
models. O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

Modulation O
of O
the O
central O
nervous O
system O
excitability O
may O
be O
involved O
. O
[]

BACKGROUND: O
Total O
hip O
replacement O
(THR) O
is O
often O
accompanied O
by O
severe O
postoperative O
pain. O
[]

The O
combination O
did O
not O
offer O
any O
major O
advantage O
over O
conventional O
agents O
. O
[]

RESULTS O
In O
part O
A O
, O
plasma O
AUC O
and O
C O
( O
max O
) O
of O
cediranib O
were O
lower O
in O
the O
presence O
of O
food O
by O
a O
mean O
of O
24 O
and O
33 O
% O
, O
respectively O
( O
94 O
% O
CI O
: O
AUC O
, O
12-34 O
% O
and O
C O
( O
max O
) O
, O
20-43 O
% O
) O
, O
indicating O
food O
reduces O
cediranib O
plasma O
exposure O
. O
[]

Japan O
useful O
medication O
program O
for O
schizophrenia O
( O
JUMPs O
) O
-long-term O
study O
on O
discontinuation O
rate O
, O
resolution O
and O
remission O
, O
and O
improvement O
in O
social O
functioning O
rate O
associated O
with O
atypical O
antipsychotic O
medications O
in O
patients O
with O
schizophrenia O
. O
[]

Blood O
samples O
were O
obtained O
from O
the O
antecubital O
vein O
before O
each O
exercise O
test, O
1 O
min O
after O
completing O
the O
test, O
and O
after O
a O
24-h O
recovery. O
[]

The O
baseline O
characteristics O
was O
comparable O
between O
the O
two O
groups O
. O
[]

The O
latter O
complication O
is O
considered O
by O
our O
surgeons O
to O
be O
a O
contraindication O
to O
the O
inferior-medial O
technique O
in O
patients O
undergoing O
trabeculectomy O
. O
[]

Results O
were O
not O
statistically O
significant O
different O
[ O
group O
I O
: O
mean O
decrease O
log O
MAR O
95 O
% O
CI O
( O
0.06 O
; O
0.32 O
) O
, O
group O
II O
: O
( O
-0.02 O
; O
0.11 O
) O
] O
. O
[]

At O
subsequent O
screening O
examinations O
, O
the O
proportion O
of O
women O
in O
the O
intervention O
group O
who O
were O
found O
to O
have O
grade O
2 O
or O
3 O
lesions B-outcome ['Physiological-Clinical']
or O
cancer B-outcome ['Physiological-Clinical']
was O
42 O
% O
less O
( O
95 O
% O
CI O
, O
4 O
to O
64 O
) O
and O
the O
proportion O
with O
grade O
3 O
lesions O
or O
cancer O
was O
47 O
% O
less O
( O
95 O
% O
CI O
, O
2 O
to O
71 O
) O
than O
the O
proportions O
of O
control O
women O
who O
were O
found O
to O
have O
such O
lesions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
double-blind O
study O
was O
performed O
in O
210 O
ASA O
I O
or O
II O
patients O
undergoing O
cesarean O
delivery O
, O
who O
were O
randomly O
assigned O
to O
six O
groups O
. O
[]

A O
significant O
decrease O
in O
ICP B-outcome ['Physiological-Clinical']
from O
6.5 O
to O
1.5 O
mm O
Hg O
( O
median O
) O
was O
found O
after O
indomethacin O
administration O
. O
['Physiological-Clinical']

The O
aortic O
and O
hepatic O
equivalence O
margins O
were O
100 O
and O
20 O
Hounsfield O
units, O
respectively. O
[]

Modulation O
of O
the O
NO O
system O
with O
these O
agents O
may O
have O
applications O
in O
the O
treatment O
of O
thromboembolic O
disease O
. O
[]

The O
high O
dose O
( O
0.3 O
mM/kg O
) O
gadodiamide O
injection O
in O
7 O
patients O
did O
not O
shorten O
the O
T2 O
value O
sufficiently O
to O
overwhelm O
the O
T1 B-outcome ['Physiological-Clinical']
shortening I-outcome ['Physiological-Clinical']
and O
leave O
pathologic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
hypointense I-outcome ['Physiological-Clinical']
compared O
to O
precontrast O
studies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Assessing O
the O
effect O
of O
CT O
slice O
interval O
on O
unidimensional B-outcome ['Physiological-Clinical']
, O
bidimensional O
and O
volumetric O
measurements O
of O
solid O
tumours O
. O
['Physiological-Clinical']

RESULTS O
Clinically O
and O
statistically O
significant O
improvements O
in O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distance B-outcome ['Physiological-Clinical']
and O
WOMAC O
score O
at O
4 O
weeks O
and O
8 O
weeks O
were O
seen O
in O
the O
treatment O
group O
but O
not O
the O
placebo O
group O
. O
['Life-Impact', 'Physiological-Clinical']

No O
severe B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
. O
['Adverse-effects']

METHODS O
One O
hundred O
and O
ten O
consecutive O
TKA O
patients O
were O
randomized O
into O
flexion O
group O
and O
extension O
group O
. O
[]

Double-blind O
, O
placebo-controlled O
study O
of O
azelastine O
and O
fluticasone O
in O
a O
single O
nasal O
spray O
delivery O
device O
. O
[]

SETTING O
Private O
practices O
and O
hospital O
clinics O
in O
Ontario O
, O
Quebec O
and O
Manitoba O
. O
[]

Early O
after O
surgery O
, O
the O
No O
Pres O
group O
had O
lower B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fractions I-outcome ['Physiological-Clinical']
and O
stroke B-outcome ['Physiological-Clinical']
work I-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
( O
P O
< O
.05 O
by O
repeated-measures O
[ O
rm O
] O
ANOVA O
) O
than O
the O
Pres O
group O
did O
at O
similar O
end-diastolic O
volume O
indexes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Breast O
cancer O
screening O
in O
Sweden O
. O
[]

Journal-Name:Medicine O
[]

STUDY O
DESIGN O
This O
was O
a O
single-center O
, O
open-label O
, O
two-period O
, O
randomized O
crossover O
study O
. O
[]

It O
is O
concluded O
that O
an O
antacid O
dose O
should O
be O
so O
great O
that O
it O
binds O
secreted O
acid O
before O
the O
dose O
leaves O
the O
stomach O
. O
[]

Some O
of O
these O
women O
had O
personal O
or O
family O
histories O
of O
hypertension O
( O
21 O
% O
) O
. O
[]

Patient O
and O
tumor O
characteristics O
were O
well O
balanced O
between O
the O
two O
arms O
. O
[]

RESULTS O
For O
pramipexole O
recipients O
, O
the O
primary O
outcome O
measure O
, O
PLM O
per O
hour B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bed I-outcome ['Physiological-Clinical']
asleep I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
awake I-outcome ['Physiological-Clinical']
( O
the O
PLM O
index O
, O
or O
PLMI O
) O
, O
decreased O
by O
a O
median O
of O
-26.55 O
to O
-52.70 O
depending O
on O
dosage O
group O
, O
vs. O
-3.00 O
for O
placebo O
( O
p O
< O
0.01 O
or O
0.001 O
for O
each O
group O
vs. O
placebo O
; O
Wilcoxon-Mann-Whitney O
test O
) O
. O
['Physiological-Clinical']

In O
contrast O
, O
GH-secretagogues O
elevated O
leptin B-outcome ['Physiological-Clinical']
levels O
within O
12 O
h. O
Infusion O
of O
GHRP-2 O
alone O
induced O
a O
maximal O
leptin B-outcome ['Physiological-Clinical']
increase O
of O
+87 O
% O
after O
24 O
h O
, O
whereas O
GHRH O
+ O
GHRP-2 O
elevated O
leptin B-outcome ['Physiological-Clinical']
by O
up O
to O
+157 O
% O
after O
24 O
h. O
The O
increase O
in O
leptin B-outcome ['Physiological-Clinical']
within O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Three O
infants O
receiving O
the O
high O
copper O
formula O
and O
two O
receiving O
the O
lower O
copper O
formula O
were O
in O
positive O
copper B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Iron O
is O
an O
essential O
micronutrient O
that O
can O
have O
carcinogenic B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
when O
at O
high O
or O
low O
concentrations O
. O
['Physiological-Clinical']

In O
period O
2 O
: O
ErSr O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
reduced O
by O
81.4 O
( O
SEM O
17.8 O
) O
mmol O
( O
mEq O
) O
/24 O
h O
and O
there O
was O
a O
weight O
loss B-outcome ['Physiological-Clinical']
of O
8.2 O
( O
SEM O
0.7 O
) O
kg O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
The O
[]

Title: O
A O
comparative O
study O
on O
the O
prophylactic O
effects O
of O
paracetamol O
and O
dexmedetomidine O
for O
controlling O
hemodynamics B-outcome ['Physiological-Clinical']
during O
surgery O
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
laparoscopic O
cholecystectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Neuromuscular O
monitoring O
is O
usually O
used O
to O
evaluate O
neuromuscular O
recovery O
in O
patients O
undergoing O
general O
anesthesia. O
[]

Further O
studies O
of O
ascorbic O
acid O
to O
treat O
hypertension B-outcome ['Physiological-Clinical']
, O
with O
clinical O
endpoints O
, O
are O
warranted O
. O
['Physiological-Clinical']

Separate O
experiments O
were O
performed O
on O
30 O
women O
( O
mean O
age O
19.6 O
years O
) O
and O
20 O
men O
( O
20.4 O
years O
) O
. O
[]

This O
leads O
to O
the O
fact O
that O
the O
number O
of O
evaluable O
case O
studies O
is O
often O
appreciably O
lower O
than O
the O
number O
of O
test O
participants O
and O
that O
a O
meaningful O
therapy O
group O
comparison O
may O
even O
not O
be O
possible O
under O
certain O
circumstances O
. O
[]

Influence O
of O
two O
different O
resection O
techniques O
( O
conventional O
liver O
resection O
versus O
anterior O
approach O
) O
of O
liver O
metastases O
from O
colorectal O
cancer O
on O
hematogenous O
tumor O
cell O
dissemination O
- O
prospective O
randomized O
multicenter O
trial O
. O
[]

An O
observational O
study O
. O
[]

The O
[]

Statistical O
analysis O
proved O
significant O
effects O
concerning O
dysfunctional B-outcome ['Life-Impact']
parenting I-outcome ['Life-Impact']
, O
parental O
stress O
and O
child B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
problems I-outcome ['Life-Impact']
as O
well O
as O
little O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
and O
a O
positive O
acceptance B-outcome ['Life-Impact']
of O
stepping O
stones O
by O
the O
families O
. O
['Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact']

Design, O
Setting, O
and O
Participants: O
A O
multicenter, O
parallel-group, O
cluster-randomized O
clinical O
trial O
with O
integrated O
economic O
and O
process O
evaluations O
conducted O
in O
24 O
ICUs O
in O
the O
United O
Kingdom. O
[]

The O
study O
compared O
the O
effect O
of O
music O
training O
, O
speech O
training O
and O
no-training O
on O
the O
verbal O
production O
of O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
[]

The O
exercising O
participants O
were O
instructed O
during O
a O
single O
physiotherapy O
visit O
and O
subsequently O
exercised O
four O
days O
or O
more O
per O
week O
; O
training O
and O
step-count O
goals O
were O
advanced O
during O
bimonthly O
telephone O
calls O
. O
[]

RESULTS O
Of O
2,223 O
eligible O
patients O
, O
562 O
( O
25 O
% O
) O
have O
enrolled O
. O
[]

RESULTS O
The O
SCORAD O
score O
reflecting O
the O
extent B-outcome ['Physiological-Clinical']
and O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
atopic I-outcome ['Physiological-Clinical']
eczema I-outcome ['Physiological-Clinical']
was O
16 O
( O
7-25 O
) O
during O
breast-feeding O
, O
median O
( O
interquartile O
range O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
comparing O
the O
efficacy O
of O
the O
three O
randomized O
therapeutic O
regimens O
while O
on O
the O
Na+ O
supplement O
, O
the O
valsartan O
160 O
mg/HCTZ O
12.5 O
mg O
was O
the O
most O
effective O
therapy O
with O
an O
incremental O
reduction O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
-10.5/-6.9 O
mm O
Hg O
( O
P O
< O
.01 O
) O
, O
compared O
to O
valsartan O
160 O
mg/day O
alone O
. O
['Physiological-Clinical']

Effect O
of O
soy O
protein O
containing O
isoflavones O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
in O
moderately O
hypercholesterolemic O
adults O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

The O
treatment O
of O
localized O
non-Hodgkin O
's O
lymphoma O
in O
children O
: O
a O
report O
from O
the O
Children O
's O
Cancer O
Study O
Group O
. O
[]

Intravenous O
adenosine O
activates O
pulmonary O
C O
fibers O
and O
induces O
dyspnea O
. O
[]

This O
article O
presents O
a O
randomized O
controlled O
study O
evaluating O
the O
effect O
of O
a O
5-month O
intervention O
directed O
toward O
improving O
sensory B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
, O
digestion B-outcome ['Physiological-Clinical']
, O
and O
sleep B-outcome ['Physiological-Clinical']
in O
46 O
children O
with O
autism O
< O
age O
6 O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
2985248R O
[]

Most O
of O
these O
metabolic O
biomarkers O
improved O
to O
normal O
or O
near-normal O
levels.The O
supplement O
group O
had O
significantly O
greater O
improvements O
than O
the O
placebo O
group O
on O
the O
Parental B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impressions-Revised O
( O
PGI-R O
, O
Average O
Change O
, O
p O
= O
0.008 O
) O
, O
and O
on O
the O
subscores O
for O
Hyperactivity B-outcome ['Physiological-Clinical']
( O
p O
= O
0.003 O
) O
, O
Tantrumming B-outcome ['Life-Impact']
( O
p O
= O
0.009 O
) O
, O
Overall O
( O
p O
= O
0.02 O
) O
, O
and O
Receptive B-outcome ['Physiological-Clinical']
Language I-outcome ['Physiological-Clinical']
( O
p O
= O
0.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

CONCLUSIONS O
Endocervical O
sampling O
should O
not O
influence O
management O
when O
colposcopy O
is O
unsatisfactory O
. O
[]

The O
bark O
extract O
was O
easy O
to O
apply O
and O
additional O
wound O
care O
was O
not O
usually O
necessary O
, O
while O
the O
treatment O
with O
saline O
gauze O
was O
laborious O
for O
both O
patients O
and O
staff O
and O
was O
much O
more O
expensive B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
data O
collected O
included O
heart O
rate O
, O
mean O
arterial O
pressure O
, O
respiratory O
rate O
, O
saturation O
of O
oxygen O
, O
amount O
of O
sedatives O
, O
awakening O
time O
and O
adverse O
effects O
. O
[]

Seventeen O
patients O
received O
the O
drug O
( O
40 O
mg O
in O
5 O
ml O
i.m O
. O
[]

Journal O
ID: O
0255562 O
[]

BACKGROUND O
AND O
AIM O
An O
oral O
glutamine O
load O
in O
cirrhotic O
patients O
awaiting O
liver O
transplantation O
was O
shown O
to O
cause O
a O
rise O
in O
blood B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
and O
psychometric B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
which O
were O
reversed O
by O
hepatic O
transplantation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Linear O
regression O
was O
used O
to O
examine O
the O
cross-sectional O
associations O
of O
plasma B-outcome ['Physiological-Clinical']
FGF23 I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
with O
BMI O
, O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Vincristine O
typically O
impaired O
fine-motor B-outcome ['Physiological-Clinical']
coordination I-outcome ['Physiological-Clinical']
initially O
, O
whereas O
corticosteroids O
were O
associated O
with O
delayed O
development O
of O
proximal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
weakness I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
previously O
reported O
that O
propofol O
at O
a O
subhypnotic O
dose O
of O
0.5 O
mg/kg O
was O
more O
effective O
than O
placebo O
in O
preventing O
PONV O
in O
women O
who O
undergo O
mastectomy O
. O
[]

In O
the O
entire O
sample O
studied O
, O
the O
mean O
pupillary B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
was O
greater O
in O
the O
eyedrops O
group O
after O
20 O
and O
40 O
minutes O
, O
while O
mydriasis B-outcome ['Physiological-Clinical']
was O
similar O
in O
the O
2 O
groups O
after O
60 O
minutes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
present O
study O
we O
observed O
a O
tendency O
of O
the O
lower O
recurrence O
rate O
in O
the O
immunized O
group O
, O
and O
we O
hypothesize O
that O
OK-432 O
is O
effective O
in O
extending O
the O
recurrence-free O
period O
. O
[]

Measurements O
of O
plasma B-outcome ['Physiological-Clinical']
ALA I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
from O
0 O
to O
24h O
showed O
no O
difference O
in O
ALA O
pharmacokinetics O
between O
the O
two O
formulations O
. O
['Physiological-Clinical']

The O
evaluation O
of O
the O
signal O
intensity O
by O
the O
dynamic B-outcome ['Resource-use']
screening I-outcome ['Resource-use']
sequence I-outcome ['Resource-use']
is O
considered O
as O
an O
objective O
contribution O
for O
the O
staging O
of O
the O
femoral B-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Systematic O
data O
on O
the O
long-term O
course O
of O
and O
therapeutic O
options O
for O
these O
consequences O
are O
limited O
. O
[]

This O
has O
been O
particularly O
thoroughly O
demonstrated O
in O
patients O
with O
schizophrenia O
. O
[]

Also O
during O
last O
administration O
, O
PMN O
count O
in O
filtered O
blood O
cardioplegic O
solution O
was O
decreased O
compared O
to O
samples O
collected O
before O
filter O
passage O
( O
0.66 O
? O
[]

The O
pressure O
profile O
and O
VO2 O
were O
not O
modified O
by O
ACE O
inhibitor O
. O
[]

Of O
the O
26 O
boys O
who O
did O
not O
undergo O
biopsy O
, O
21 O
( O
80.8 O
% O
) O
remained O
in O
CCR O
; O
two O
( O
7.7 O
% O
) O
developed O
isolated B-outcome ['Physiological-Clinical']
overt I-outcome ['Physiological-Clinical']
TL I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Analysis O
will O
be O
on O
an O
intention O
to O
treat O
basis O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
study O
group O
( O
151 O
mm O
Hg O
baseline O
, O
140 O
mm O
Hg O
at O
6 O
mo O
, O
p O
< O
0.001 O
) O
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
at O
2 O
, O
4 O
, O
and O
5 O
months O
compared O
with O
baseline O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:BMC O
public O
health O
[]

In O
this O
severely O
diseased O
population O
of O
patients O
a O
treatment O
period O
limited O
to O
2 O
weeks O
did O
not O
sufficiently O
improve O
ulcer B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSION O
Treatment O
of O
medical O
ozone O
on O
patients O
with O
chronic O
hepatitis O
B O
is O
effective O
. O
[]

Relapsing B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
fatal O
and O
nonfatal O
) O
was O
reduced O
by O
43 O
% O
( O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

Of O
1016 O
patients O
( O
45 O
percent O
of O
whom O
had O
ventricular O
fibrillation O
, O
and O
55 O
percent O
ventricular O
tachycardia O
) O
, O
507 O
were O
randomly O
assigned O
to O
treatment O
with O
implantable O
cardioverter-defibrillators O
and O
509 O
to O
antiarrhythmic-drug O
therapy O
. O
[]

This O
study O
sought O
to O
determine O
the O
comparative O
effects O
of O
0.05 O
percent O
desonide O
and O
2.5 O
percent O
hydrocortisone O
ointments O
on O
the O
HPA O
axis O
of O
children O
with O
atopic O
dermatitis O
. O
[]

Dynamic O
surface B-outcome ['Physiological-Clinical']
electromyographic I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
in O
chronic O
low O
back O
pain O
treated O
by O
traditional O
bone O
setting O
and O
conventional O
physical O
therapy O
. O
['Physiological-Clinical']

RESULTS O
Fifty-eight O
patients O
( O
72.5 O
% O
) O
were O
positive O
for O
hepatitis O
B O
surface O
antibody O
, O
and O
HBV O
DNA O
was O
undetectable O
in O
50 O
patients O
( O
62.5 O
% O
) O
. O
[]

Effects O
of O
preoperative O
intentional O
hemodilution O
on O
the O
extravasation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Berries O
were O
homogenised O
in O
hot O
( O
80 O
degrees O
C O
) O
water O
, O
warm O
( O
40 O
degrees O
C O
) O
skimmed O
milk O
and O
hot O
( O
80 O
degrees O
C O
) O
skimmed O
milk O
, O
with O
freeze O
drying O
of O
each O
preparation O
into O
a O
powdered O
form O
. O
[]

LESSONS O
LEARNED: O
It O
is O
feasible O
to O
engage O
and O
maintain O
a O
network O
of O
CBOs O
linked O
with O
a O
local O
health O
system. O
[]

These O
outcomes O
were O
sustained O
at O
follow-up O
and O
participants O
rated O
the O
program O
as O
highly O
acceptable O
. O
[]

Of O
these O
132 O
subjects O
, O
124 O
( O
94 O
% O
) O
were O
already O
receiving O
treatment O
with O
antihypertensive O
medications O
. O
[]

Attempts O
have O
been O
made O
to O
remove O
endotoxin O
, O
the O
main O
cause O
of O
sepsis O
, O
from O
the O
circulation O
using O
polymyxin O
B O
immobilized O
fiber O
, O
charcoal O
hemoperfusion O
, O
and O
plasma O
or O
whole O
blood O
exchange O
. O
[]

Airway O
pressures O
( O
surrogate O
for O
intrathoracic O
pressure O
) O
were O
measured O
with O
a O
pressure O
transducer O
. O
[]

Both O
interventions O
are O
evaluated O
in O
randomised O
controlled O
trials O
using O
clinical O
management O
as O
the O
control O
condition O
. O
[]

Journal-Name:Journal O
of O
shoulder O
and O
elbow O
surgery O
[]

METHODS O
Patients O
with O
steroid-dependent O
Crohn O
's O
disease O
( O
n O
= O
271 O
) O
were O
enrolled O
in O
a O
36-week O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Polysomnographic O
measures O
of O
sleep B-outcome ['Physiological-Clinical']
and O
self-report O
indexes O
of O
tobacco O
withdrawal O
were O
collected O
pre- O
and O
postcessation O
from O
an O
active O
nicotine O
patch O
group O
and O
a O
placebo O
patch O
group O
in O
a O
randomized O
, O
double-blind O
clinical O
trial O
( O
N O
= O
34 O
) O
. O
['Physiological-Clinical']

In O
a O
prospective O
double-blind O
clinical O
study O
, O
single-dose O
lumbar O
epidural O
blockade O
was O
instituted O
in O
60 O
healthy O
patients O
undergoing O
lower O
abdominal O
surgery O
. O
[]

Factor O
analysis O
confirmed O
the O
original O
domain O
structure O
of O
the O
CRQ O
but O
not O
of O
the O
SGRQ O
. O
[]

These O
results O
provide O
insight O
into O
the O
nature O
of O
multisensory O
processing O
while O
also O
revealing O
a O
continuum O
over O
which O
perceptual O
abilities O
correlate O
with O
symptoms O
of O
autism O
and O
that O
this O
continuum O
is O
not O
just O
specific O
to O
clinical O
populations O
but O
is O
present O
within O
the O
general O
population O
. O
[]

PSK O
has O
been O
supposed O
to O
improve O
survival O
through O
immunological O
mechanisms O
such O
as O
induction O
of O
cytokines O
, O
regulation O
of O
Th1/Th2 O
balance O
, O
and O
inhibition O
of O
immunosuppressive O
molecules O
. O
[]

DESIGN O
Randomized O
, O
controlled O
clinical O
trial O
. O
[]

All O
patients O
suffered O
from O
partial-thickness O
burn O
injuries O
( O
< O
20 O
% O
TBSA O
) O
. O
[]

Furthermore O
, O
PTK2 O
inhibition O
blunted O
R-dependent B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
death I-outcome ['Physiological-Clinical']
in O
vitro O
. O
['Physiological-Clinical']

Eliciting O
symptom O
and O
quality O
of O
life O
information O
from O
patients O
is O
an O
important O
component O
of O
medical O
and O
nursing O
care O
processes O
. O
[]

There O
were O
56 O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
total, O
including O
31 O
in O
the O
PICSI O
group O
and O
25 O
in O
the O
ICSI O
group; O
most O
were O
congenital B-outcome ['Physiological-Clinical']
abnormalities I-outcome ['Physiological-Clinical']
and O
none O
were O
attributed O
to O
treatment. O
[['Adverse-effects'], ['Physiological-Clinical']]

Substituted O
benzimidazole O
inhibitors O
of O
the O
gastric O
H+/K+ATPase O
may O
interact O
with O
the O
cytochrome O
P450 O
enzyme O
system O
and O
alter O
the O
pharmacokinetics O
of O
coadministered O
drugs O
. O
[]

Long-term O
survival O
in O
a O
phase O
III O
, O
randomised O
study O
of O
topotecan O
versus O
paclitaxel O
in O
advanced O
epithelial O
ovarian O
carcinoma O
. O
[]

9.6 O
% O
placebo O
) O
, O
face O
numbness O
( O
1.6 O
% O
Cappra O
( O
? O
) O
, O
[]

Cost-effectiveness O
would O
be O
worse O
if O
prescribers O
do O
not O
comply O
with O
test O
results O
. O
['Resource-use']

The O
higher O
reoperation B-outcome ['Resource-use']
rate O
was O
found O
in O
the O
group O
without O
acromioplasty O
. O
['Resource-use']

The O
primary O
outcome O
measure O
was O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fits I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pilot O
comparison O
between O
potassium O
titanyl O
phosphate O
laser O
and O
bipolar O
radiofrequency O
in O
paediatric O
tonsillectomy O
. O
[]

CONCLUSION O
Simple O
interventions O
of O
minimal O
contact O
time O
focusing O
on O
walking O
can O
significantly O
increase O
physical O
activity O
in O
individuals O
at O
increased O
risk O
of O
developing O
colon O
cancer O
. O
[]

RESULTS O
No O
differences O
were O
found O
in O
analgesic O
administration O
or O
pain B-outcome ['Physiological-Clinical']
intensity O
scores O
between O
the O
2 O
ATC O
groups O
. O
['Physiological-Clinical']

The O
surgeon O
and O
the O
nurse O
were O
asked O
about O
symptoms O
related O
to O
occupational O
exposure O
. O
[]

Cerebral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CBF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cerebral B-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CMRO2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
measured O
by O
a O
modification O
of O
the O
Kety-Schmidt O
technique O
using O
i.v O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
given O
an O
escape O
option O
that O
let O
them O
avoid O
any O
trials O
they O
wished O
and O
receive O
a O
hint O
to O
the O
trial O
's O
answer O
. O
[]

OBJECTIVE O
To O
investigate O
whether O
weight-bearing O
( O
WB O
) O
exercise O
enhances O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
to O
a O
greater O
extent O
than O
nonweight-bearing O
( O
NWB O
) O
exercise O
in O
participants O
with O
knee O
osteoarthritis O
. O
['Life-Impact']

Thus O
, O
medication O
and O
parent O
training O
target O
related O
, O
but O
separate O
, O
outcomes O
. O
[]

Outcomes O
on O
play B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
were O
mixed O
, O
with O
improvement O
of O
symbolic B-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
for O
the O
CMM O
group O
and O
no O
change O
in O
functional B-outcome ['Life-Impact']
play I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Following O
completion O
of O
our O
ongoing O
RCT O
designed O
to O
test O
these O
materials O
, O
our O
goal O
will O
be O
to O
develop O
a O
dissemination O
project O
for O
the O
more O
effective O
tool O
. O
[]

Cardiac B-outcome ['Physiological-Clinical']
event O
rates O
were O
based O
on O
reductions O
in O
left O
ventricular O
ejection O
fraction O
as O
a O
function O
of O
cumulative O
anthracycline O
dose O
. O
['Physiological-Clinical']

The O
behavioural O
evaluation O
was O
conducted O
using O
the O
specific O
BSE O
and O
CARS O
rating O
scales O
NAL O
treatment O
produced O
a O
significant O
reduction O
of O
the O
autistic B-outcome ['Life-Impact']
symptomatology I-outcome ['Life-Impact']
in O
seven O
( O
responders O
) O
out O
of O
12 O
children O
. O
['Life-Impact']

CONCLUSIONS O
Citalopram O
or O
other O
SSRIs O
and O
reboxetine O
may O
be O
of O
first O
choice O
treatment O
in O
PSD O
because O
of O
their O
good O
efficacy O
and O
lack O
of O
severe O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Adverse-effects']

Oral B-outcome ['Physiological-Clinical']
mucositis B-outcome ['Physiological-Clinical']
was O
analyzed O
using O
the O
unadjusted O
chi-square O
test O
, O
and O
time O
to O
first B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
various O
neurohormones O
at O
initial O
measurement O
confer O
prognostic O
value O
in O
heart O
failure O
and O
correlate O
with O
the O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
cardiac B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
, O
the O
significance O
of O
their O
temporal O
changes O
( O
Delta O
) O
remains O
undetermined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
variables O
included O
changes O
in O
other O
lipid B-outcome ['Physiological-Clinical']
, O
hemostatic B-outcome ['Physiological-Clinical']
and O
carbohydrate B-outcome ['Life-Impact']
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

[ O
Platelet O
serotonin O
in O
infantile O
autism O
. O
[]

Cost B-outcome ['Resource-use']
per O
gained O
QALY O
was O
1704-7889 O
USD. O
[['Resource-use']]

Its O
toxicity O
has O
previously O
been O
correlated O
to O
the O
formation O
of O
an O
active O
metabolite O
, O
N-acetyl-amonafide O
. O
[]

CONCLUSIONS O
Patient-specific O
feedback O
to O
inner-city O
providers O
increased O
scheduled O
asthma O
visits O
, O
increased O
asthma O
visits O
in O
which O
medications O
were O
stepped O
up O
when O
clinically O
indicated O
, O
and O
reduced O
emergency O
department O
visits O
. O
[]

CONCLUSIONS: O
Oral O
antibiotic O
therapy O
was O
noninferior O
to O
intravenous O
antibiotic O
therapy O
when O
used O
during O
the O
first O
6 O
weeks O
for O
complex O
orthopedic O
infection, O
as O
assessed O
by O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
at O
1 O
year. O
( O
[['Physiological-Clinical']]

Effect O
of O
the O
dietary O
approaches O
to O
stop O
hypertension O
diet O
and O
reduced O
sodium O
intake O
on O
blood O
pressure O
control O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
MRI O
study O
of O
anti-herpes O
virus O
therapy O
in O
MS O
. O
[]

Day O
1, O
8 O
mg O
orally O
Days O
2-4). O
[]

Despite O
a O
significant O
decline O
in O
symptoms O
of O
emotional O
distress O
during O
the O
study O
period O
, O
the O
women O
in O
this O
sample O
reported O
high O
levels O
of O
depressive B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
at O
baseline O
and O
6-month O
follow-up O
. O
['Life-Impact']

The O
study O
took O
place O
in O
Bad O
Pyrmont O
, O
Germany O
( O
latitude O
52 O
degrees O
) O
and O
Graz O
, O
Austria O
( O
latitude O
46 O
degrees O
) O
. O
[]

Risk O
factors O
for O
fracture O
in O
a O
UK O
population O
: O
a O
prospective O
cohort O
study O
. O
[]

Ropinirole O
was O
superior O
to O
levodopa O
SR O
in O
reducing O
6-item O
IRLS O
scores O
( O
P O
< O
0.001 O
) O
and O
in O
increasing O
sleep B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Lessons O
learnt O
in O
conducting O
a O
clinical O
drug O
trial O
in O
children O
with O
Asperger O
Syndrome O
. O
[]

There O
was O
a O
significantly O
lower O
prevalence O
of O
tachysystole B-outcome ['Physiological-Clinical']
( O
six O
or O
more O
uterine O
contractions O
in O
a O
10-minute O
window O
for O
two O
consecutive O
10-minute O
periods O
) O
in O
the O
misoprostol O
group O
( O
7.1 O
% O
) O
than O
in O
the O
dinoprostone O
group O
( O
18.4 O
% O
) O
( O
relative O
risk O
0.52 O
, O
95 O
% O
confidence O
interval O
0.31 O
to O
0.89 O
, O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

The O
IJV B-outcome ['Physiological-Clinical']
could O
be O
located O
in O
all O
patients O
with O
both O
ultrasound O
methods O
, O
but O
the O
course O
of O
the O
IJV B-outcome ['Physiological-Clinical']
could O
only O
be O
identified O
by O
ultrasonography O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
The O
effectiveness O
of O
heart O
failure O
disease O
management O
programs O
in O
patients O
under O
cardiologists O
' O
care O
over O
long-term O
follow-up O
is O
not O
established O
. O
[]

The O
hASH1 O
mRNA O
level O
might O
represent O
a O
useful O
tool O
for O
distinguishing O
esthesioneuroblastoma O
from O
poorly O
differentiated O
tumors O
of O
the O
sinonasal O
region O
. O
[]

Group O
B O
subjects O
were O
first O
placed O
in O
the O
45-degree O
upright O
position O
, O
and O
after O
5 O
minutes O
had O
cardiac O
output O
measurements O
performed O
. O
[]

METHOD O
307 O
schizophrenia O
subjects O
in O
their O
first O
episode O
of O
illness O
were O
recruited O
to O
participate O
in O
a O
clinical O
trial O
comparing O
the O
long-term O
efficacy O
of O
haloperidol O
and O
risperidone O
. O
[]

METHODS: O
From O
September O
2014 O
to O
September O
2015, O
60 O
patients O
diagnosed O
with O
NSCLC O
were O
included O
to O
the O
study. O
[]

This O
study O
is O
a O
prospective O
, O
randomized O
, O
open-label O
study O
with O
blinded O
assessment O
of O
endpoints O
to O
compare O
the O
2-year O
effect O
of O
strict O
treatment O
to O
maintain O
systolic O
blood O
pressure O
below O
140 O
mmHg O
with O
that O
of O
mild O
treatment O
to O
maintain O
systolic O
blood O
pressure O
below O
160 O
but O
at O
or O
above O
140 O
mmHg O
in O
elderly O
hypertensive O
patients O
. O
[]

The O
children O
presented O
with O
a O
chief O
complaint O
of O
severely O
disruptive O
symptoms O
related O
to O
autistic O
disorder O
. O
[]

A O
placebo-controlled O
, O
double-blind O
, O
randomized O
toxicity O
trial O
of O
tamoxifen O
was O
conducted O
among O
postmenopausal O
women O
with O
node O
negative O
breast O
cancer O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Title: O
School-based O
surveillance O
for O
detection O
of O
children O
with O
acute B-outcome ['Physiological-Clinical']
pharyngitis I-outcome ['Physiological-Clinical']
, O
rheumatic B-outcome ['Physiological-Clinical']
fever/rheumatic I-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
Shimla O
district, O
Himachal O
Pradesh, O
India-A O
cluster O
randomized O
controlled O
trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Comparative O
studies O
proved O
a O
local B-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
5-HT3 I-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
antagonist I-outcome ['Physiological-Clinical']
, O
tropisetron B-outcome ['Physiological-Clinical']
( O
Navoban B-outcome ['Physiological-Clinical']
( O
R O
) O
) O
, O
to O
be O
more O
effective O
than O
an O
injection O
of O
the O
local O
anesthetic O
prilocaine O
in O
treating O
periarthropathies O
of O
different O
localizations O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Long-term O
follow-up O
of O
the O
Stockholm O
randomized O
trials O
of O
postoperative O
radiation O
therapy O
versus O
adjuvant O
chemotherapy O
among O
'high O
risk O
' O
pre- O
and O
postmenopausal O
breast O
cancer O
patients O
. O
[]

This O
study O
examined O
the O
effect O
of O
pairing O
inpatient O
alcoholics O
with O
nursing O
home O
residents O
( O
NHRs O
) O
on O
the O
alcoholics B-outcome ['Life-Impact']
' O
self-esteem B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

The O
resulting O
magnitude O
estimation O
ratings O
of O
symptom B-outcome ['Life-Impact']
['Life-Impact']

Publication O
date: O
2019/02/20 O
06:00 O
[entrez] O
[]

Journal-Name: O
Lin O
chuang O
er O
bi O
yan O
hou O
tou O
jing O
wai O
ke O
za O
zhi O
= O
Journal O
of O
clinical O
otorhinolaryngology, O
head, O
and O
neck O
surgery O
[]

RESULTS O
Mean O
concentrations O
of O
CP O
in O
pasture O
and O
urea B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
High-N O
than O
the O
Control O
group O
( O
25.2 O
vs O
21.6 O
and O
8.3 O
vs O
5.4 O
mmol/L O
for O
CP O
and O
urea O
, O
respectively O
; O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

The O
paired O
sample O
t-test O
or O
Wilcoxon O
test O
were O
employed O
to O
calculate O
the O
differences O
between O
variables O
before O
and O
after O
music O
therapy O
intervention. O
[]

Further O
, O
sprint B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
again O
tended O
to O
be O
slower O
in O
the O
CODS-SS O
trial O
compared O
with O
the O
CODS-CON O
across O
all O
sprint O
variables O
, O
with O
a O
significantly O
slower O
( O
P O
< O
0.05 O
) O
BST O
recorded O
for O
set O
3 O
after O
static O
stretching O
. O
['Life-Impact']

Declamping O
caused O
a O
more O
marked B-outcome ['Physiological-Clinical']
increase O
of O
paCO2 B-outcome ['Physiological-Clinical']
and O
a O
greater O
fall O
of O
pH B-outcome ['Physiological-Clinical']
in O
the O
NA O
group O
as O
compared O
to O
the O
epidural O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

3.63 O
and O
-2.45 O
? O
[]

At O
16 O
weeks O
, O
mean O
HbA B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
1c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
0.84 O
% O
( O
95 O
% O
CI O
-1.31 O
to O
-0.36 O
) O
lower O
in O
the O
continuous O
subcutaneous O
insulin O
infusion O
group O
compared O
with O
the O
insulin O
injection O
group O
( O
P O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Glycaemic B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
on O
the O
two O
treatments O
, O
but O
C-peptide B-outcome ['Physiological-Clinical']
was O
much O
higher O
while O
the O
patients O
were O
on O
glibenclamide O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Title: O
Effect O
of O
Negative O
Pressure O
Wound O
Therapy O
on O
Wound B-outcome ['Physiological-Clinical']
Complications I-outcome ['Physiological-Clinical']
Post-Pancreatectomy. O
[['Physiological-Clinical']]

Treatment O
groups O
received O
either O
topical O
ofloxacin O
or O
topical O
ciprofloxacin O
( O
instillation O
of O
0.3 O
% O
ophthalmic O
solution O
every O
30 O
minutes O
for O
4 O
hours O
before O
surgery O
) O
, O
or O
a O
combined O
topical O
plus O
oral O
regimen O
( O
ciprofloxacin O
hydrochloride O
, O
four O
100-mg O
tablets O
, O
or O
ofloxacin O
, O
one O
400-mg O
tablet O
, O
administered O
24-26 O
, O
12-14 O
, O
and O
2 O
hours O
preceding O
surgery O
) O
. O
[]

METHODS O
We O
conducted O
a O
prospective O
, O
randomized O
, O
multicenter O
trial O
in O
which O
62 O
patients O
were O
randomly O
assigned O
to O
receive O
either O
prednisone O
plus O
cyclophosphamide O
( O
intravenous O
bolus O
) O
( O
group O
A O
; O
n O
= O
28 O
) O
or O
prednisone O
plus O
cyclophosphamide O
( O
intravenous O
bolus O
) O
plus O
plasma O
exchanges O
( O
group O
B O
; O
n O
= O
34 O
) O
as O
first-line O
treatment O
for O
severe O
PAN O
or O
CSS O
. O
[]

CONCLUSIONS O
A O
web-based O
intervention O
that O
tailored O
content O
according O
to O
smoking-related O
beliefs O
, O
personal O
characteristics O
and O
smoking O
patterns O
, O
self-efficacy O
and O
outcome O
expectations O
, O
was O
not O
more O
effective O
than O
web-based O
materials O
presenting O
broadly O
similar O
non-tailored O
information O
. O
[]

We O
therefore O
suggest O
routine O
pretreatment O
with O
thiopental O
0.5 O
mg/kg O
along O
with O
venous O
occlusion O
for O
1 O
min O
for O
prevention O
of O
pain B-outcome ['Physiological-Clinical']
associated O
with O
propofol O
injection O
. O
['Physiological-Clinical']

This O
pilot O
, O
randomized O
controlled O
trial O
evaluated O
the O
feasibility B-outcome ['Life-Impact']
and O
preliminary O
outcomes O
of O
the O
Multimodal O
Anxiety O
and O
Social O
Skills O
Intervention O
( O
MASSI O
) O
program O
in O
a O
sample O
of O
30 O
adolescents O
with O
ASD O
and O
anxiety O
symptoms O
of O
moderate O
or O
greater O
severity O
. O
['Life-Impact']

5-items O
questionnaire O
is O
more O
associated O
with O
the O
physician O
diagnosed O
group O
and O
more O
consistent O
than O
6-items O
clinical B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical']

A O
single-blind O
placebo O
baseline O
was O
followed O
by O
double-blind O
nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
in O
randomized O
sequence O
, O
2 O
to O
5 O
days O
apart O
. O
[]

However O
, O
changes O
in O
serum B-outcome ['Physiological-Clinical']
acetate I-outcome ['Physiological-Clinical']
from O
3 O
to O
6 O
mo O
were O
positively O
related O
to O
changes O
in O
the O
ratio O
of O
total O
to O
HDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.041 O
) O
and O
in O
fasting O
( O
P O
= O
0.013 O
) O
and O
postprandial B-outcome ['Physiological-Clinical']
( O
P B-outcome ['Physiological-Clinical']
= O
0.016 O
) O
triacylglycerols B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Exclusion O
criteria O
were O
diabetic O
ketoacidosis O
, O
severe O
hepatic O
failure O
or O
hepatic O
resection O
, O
pancreatitis O
, O
glucose O
of O
less O
than O
2.2 O
mmol/L O
on O
admission O
to O
hospital O
, O
insulin O
infusion O
on O
admission O
to O
ICU O
, O
planned O
withdrawal O
of O
life O
support O
, O
and O
inability O
to O
obtain O
informed O
consent O
. O
[]

Significant O
difference O
was O
observed O
in O
the O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
convalescence I-outcome ['Life-Impact']
too O
( O
group O
A O
9.3+/-7.2 O
days O
; O
group O
B O
12.1+/-7 O
. O
['Life-Impact']

The O
primary O
outcome O
measurement O
was O
the O
headache B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
. O
Secondary O
outcomes O
were O
frequency O
and O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
, O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
assessed O
by O
the O
Short O
Form-36. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

Using O
data O
from O
a O
large O
randomized O
trial O
, O
we O
explored O
the O
prognostic O
value O
of O
clinical O
variables O
, O
measured O
at O
hospital O
admission O
for O
acute O
heart O
failure O
, O
to O
determine O
whether O
a O
few O
selected O
variables O
were O
inferior O
to O
an O
extended O
data O
set O
. O
[]

Execution O
of O
these O
skills O
in O
social O
interactions O
supports O
both O
the O
exchange O
of O
social O
knowledge O
and O
also O
the O
development O
and O
maintenance O
of O
personal O
relationships O
. O
[]

The O
majority O
of O
men O
had O
severe O
erectile O
dysfunction O
. O
[]

Infants O
' O
eyes O
were O
randomly O
dilated O
twice O
with O
both O
regimens O
within O
a O
2-week O
period O
. O
[]

Among O
diabetic O
patients O
randomized O
to O
tirofiban O
( O
n=560 O
) O
, O
the O
incidence O
of O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
MI B-outcome ['Physiological-Clinical']
) O
, O
or O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Follow-up O
data O
for O
the O
intervention O
group O
will O
be O
collected O
6 O
months O
after O
the O
interventions O
. O
[]

RESULTS O
In O
total O
, O
398 O
patients O
were O
recruited O
in O
the O
initial O
therapy O
group O
, O
among O
whom O
253 O
were O
included O
in O
on-demand O
therapy O
, O
with O
127 O
patients O
in O
the O
hydrotalcite O
group O
and O
the O
remaining O
126 O
in O
the O
esomeprazole O
group O
. O
[]

The O
primary O
outcome O
was O
parasite B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
at O
day O
29, O
after O
the O
first O
round O
of O
treatment. O
[['Physiological-Clinical']]

Auditory O
integration O
training O
and O
a O
control O
treatment O
were O
provided O
for O
16 O
children O
with O
autism B-outcome ['Life-Impact']
in O
a O
crossover O
experimental O
design O
. O
['Life-Impact']

RESULTS O
The O
P600 O
( O
47 O
patients O
) O
and O
P900 O
( O
45 O
patients O
) O
arms O
had O
response O
rates O
of O
17.0 O
% O
( O
95 O
% O
confidence O
interval O
, O
7.7-30.8 O
% O
) O
and O
15.6 O
% O
( O
95 O
% O
confidence O
interval O
, O
6.5-29.5 O
% O
) O
with O
approximately O
50 O
% O
stable O
disease O
per O
arm O
, O
median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
of O
4.2 O
and O
4.1 O
months O
, O
and O
median O
times B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
tumor I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
of O
4.2 O
and O
4.6 O
months O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

Two O
subjects O
from O
the O
active O
group O
and O
one O
subject O
from O
the O
placebo O
group O
discontinued O
the O
study O
because O
of O
either O
a O
lack O
of O
efficacy O
or O
side O
effects O
( O
increased O
irritability O
) O
. O
[]

Effect O
of O
resistance O
exercise O
contraction O
mode O
and O
protein O
supplementation O
on O
members O
of O
the O
STARS O
signalling O
pathway O
. O
[]

Using O
the O
belief O
basis O
of O
the O
theory O
of O
planned O
behavior O
( O
TPB O
) O
, O
the O
current O
study O
explored O
the O
rate O
of O
mild B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
reported O
by O
donors O
in O
relation O
to O
their O
first O
donation O
and O
the O
intention O
and O
beliefs O
of O
those O
donors O
with O
regard O
to O
returning O
to O
donate O
again O
. O
['Physiological-Clinical']

Concerning O
the O
selected O
pharmacodynamic O
model O
to O
fit O
the O
data O
( O
type O
I O
indirect O
response O
model O
) O
, O
this O
selection O
is O
attributable O
to O
the O
presence O
of O
inhibitory O
bilastine O
plasma O
concentrations O
that O
decrease O
the O
input O
response O
function B-outcome ['Life-Impact']
, O
i.e O
. O
['Life-Impact']

Title: O
Traditional O
chest O
drainage O
versus O
drainage O
by O
thoracotomy: O
a O
prospective O
randomized O
study. O
[]

In O
the O
placebo O
group O
, O
there O
was O
a O
loss O
in O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass B-outcome ['Physiological-Clinical']
( O
-2.62 O
+/- O
1.51 O
kg O
) O
and O
a O
negative O
nitrogen B-outcome ['Physiological-Clinical']
balance B-outcome ['Life-Impact']
( O
-4.52 O
+/- O
3.51 O
g/day O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Although O
some O
studies O
reported O
that O
patients O
with O
cystic O
fibrosis O
( O
CF O
) O
lack O
magnesium O
, O
no O
international O
study O
has O
assessed O
the O
importance O
of O
oral O
magnesium O
supplementation O
in O
CF O
patients O
. O
[]

Available O
data O
are O
not O
sufficient O
to O
serve O
as O
a O
basis O
for O
firm O
dietary O
advice O
. O
[]

Additionally O
, O
pretreatment O
with O
gabapentin O
reduced O
the O
degree O
of O
postoperative O
nausea B-outcome ['Physiological-Clinical']
and O
incidence O
of O
vomiting/retching B-outcome ['Physiological-Clinical']
possibly O
either O
due O
to O
the O
diminished O
need O
for O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
treatment O
with O
opioids O
or O
because O
of O
an O
anti-emetic O
effect O
of O
gabapentin O
itself O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
assigned O
to O
either O
a O
target O
treatment O
or O
community O
treatment O
group O
. O
[]

However O
, O
these O
solutions O
should O
be O
selectively O
prescribed O
rather O
than O
used O
based O
on O
anecdotal O
evidence O
. O
[]

These O
reductions O
were O
associated O
with O
a O
79% O
lower O
mean O
annualized O
attack B-outcome ['Physiological-Clinical']
rate O
than O
that O
observed O
with O
placebo O
(exploratory O
efficacy O
end O
point). O
[['Physiological-Clinical']]

Studies O
in O
mink O
have O
mainly O
focused O
on O
short-term O
consequences O
of O
low O
protein O
provision O
in O
utero O
whereas O
the O
long-term O
responses O
to O
low O
protein O
( O
LP O
) O
provision O
in O
metabolically O
programmed O
mink O
are O
unknown O
. O
[]

There O
was O
a O
greater O
increase O
of O
prolactin B-outcome ['Physiological-Clinical']
in O
the O
risperidone O
group O
, O
while O
alanine B-outcome ['Physiological-Clinical']
amino I-outcome ['Physiological-Clinical']
transferase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ALT I-outcome ['Physiological-Clinical']
) O
had O
further O
increased O
in O
the O
haloperidol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
2x2x19 O
analysis O
of O
variance O
was O
conducted O
with O
main O
effects O
of O
treatment O
condition B-outcome ['Physiological-Clinical']
, O
cohort O
, O
and O
baseline O
distress B-outcome ['Physiological-Clinical']
and O
their O
interactions B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
effects O
on O
respiratory O
function O
during O
intravenous O
urography O
of O
the O
ionic O
contrast O
medium O
sodium O
iothalamate O
and O
the O
non-ionic O
contrast O
medium O
iopamidol O
were O
compared O
. O
[]

Journal-Name:Brazilian O
oral O
research O
[]

OBJECTIVES O
We O
investigated O
whether O
anodal O
transcranial O
direct O
current O
stimulation O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
affected O
the O
working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
of O
patients O
after O
a O
stroke O
. O
['Life-Impact']

The O
primary O
endpoint O
of O
overall O
(0-120 O
h O
after O
chemotherapy O
administration) O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
(CR) I-outcome ['Physiological-Clinical']
rate O
(no O
emesis, O
no O
rescue O
medication) O
was O
64.2%, O
60.0% O
and O
54.9% O
in O
the O
30-, O
100- O
and O
300-mg O
arms, O
respectively, O
without O
statistical O
significance O
for O
dose-response. O
[['Physiological-Clinical']]

The O
result O
of O
this O
controlled O
clinical O
study O
confirms O
that O
the O
combination O
Xylometazoline-Dexpanthenol O
is O
an O
enlargement B-outcome ['Physiological-Clinical']
and O
improvement O
of O
effective O
medicinal O
treatment O
of O
rhinitis O
following O
nasal O
operation O
in O
comparison O
to O
therapy O
with O
Xylometazoline O
alone O
. O
['Physiological-Clinical']

Success O
rate O
of O
spinal B-outcome ['Physiological-Clinical']
deformity I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
following O
surgical O
procedure O
regardless O
of O
type O
of O
administered O
rod O
was O
86.76 O
+/- O
11.30 O
percent O
(62.5-100%). O
[['Physiological-Clinical']]

Conclusion: O
High-fidelity O
simulation O
training O
is O
superior O
to O
low-fidelity O
CPR O
manikin O
training O
for O
teaching O
fourth-year O
medical O
students O
implementation O
of O
high-quality O
CPR O
for O
chest B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
and O
compression B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

METHODS O
In O
a O
randomized O
, O
double-blind O
fashion O
; O
subjects O
with O
metabolic O
syndrome O
were O
treated O
with O
allopurinol O
( O
n O
= O
28 O
) O
or O
placebo O
( O
n O
= O
22 O
) O
for O
one O
month O
. O
[]

We O
examined O
the O
prognostic O
value O
of O
inflammatory O
markers O
( O
albumin O
, O
white-cell O
count O
and O
its O
components O
, O
and O
platelets O
) O
in O
pre-treated O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O
[]

A O
subset O
of O
92 O
patients O
with O
C4 O
disease O
were O
prospectively O
randomized O
, O
and O
ambulatory O
venous O
pressure O
( O
AVP O
) O
was O
determined O
preoperatively O
and O
postoperatively O
. O
[]

CONCLUSION O
The O
information O
on O
the O
anxiolytic O
techniques O
, O
loco-regional O
anesthesia O
, O
treatment O
of O
perioperative O
pain O
and O
postoperative O
distress O
was O
enthusiastically O
accepted O
and O
albeit O
initially O
induced O
feelings O
of O
astonishment O
resulted O
to O
be O
appreciated B-outcome ['Life-Impact']
and O
preferred B-outcome ['Life-Impact']
in O
the O
whole O
of O
the O
patients O
. O
['Life-Impact', 'Life-Impact']

Phonophoresis O
versus O
topical O
application O
of O
ketoprofen O
: O
comparison O
between O
tissue O
and O
plasma O
levels O
. O
[]

The O
assessment O
of O
nasal-breathing-resistance B-outcome ['Physiological-Clinical']
according O
to O
scores O
was O
defined O
as O
target-parameter O
. O
['Physiological-Clinical']

The O
achievement O
of O
learning B-outcome ['Life-Impact']
objectives O
was O
predicted O
by O
caregiver B-outcome ['Life-Impact']
factors I-outcome ['Life-Impact']
, O
such O
as O
education B-outcome ['Life-Impact']
, O
presence B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
or O
surrogate B-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
household I-outcome ['Life-Impact']
, O
and O
safety B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
neighborhood I-outcome ['Life-Impact']
, O
but O
not O
by O
child O
factors O
, O
such O
as O
age O
or O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
as O
implied O
by O
the O
prescribed O
asthma O
medication O
regimen O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

For O
subjects O
receiving O
aripiprazole O
, O
regardless O
of O
PAE O
, O
baseline O
weight O
, O
age O
, O
gender O
, O
and O
symptom O
severity O
were O
evaluated O
in O
a O
regression O
model O
predicting O
body O
weight O
change O
. O
[]

The O
subjects O
were O
randomized O
into O
two O
groups O
, O
After O
surgery O
, O
the O
study O
group O
received O
0.9 O
mg O
of O
atropine O
, O
while O
the O
control O
group O
received O
1.2 O
mg O
of O
atropine O
. O
[]

Suppression O
of O
immediate O
and O
late O
anti-IgE-induced B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
by O
topically O
applied O
alcohol/onion O
extract O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
819 O
women O
with O
a O
Nugent O
score O
of O
6 O
and O
above O
were O
considered O
to O
have O
BV O
and O
treated O
according O
to O
Zelen O
allocation O
. O
[]

Publication O
date: O
2018/10/28 O
00:00 O
[accepted] O
[]

Effects O
of O
two O
different O
short-term O
training O
programs O
on O
the O
physical O
and O
technical O
abilities O
of O
adolescent O
basketball O
players O
. O
[]

Although O
there O
was O
a O
general O
trend O
of O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
reduction, O
the O
numbers O
of O
participants O
who O
may O
be O
classified O
as O
pre-diabetes O
and O
diabetes O
groups O
( O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
100 O
mg/dl) O
in O
the O
amla O
group O
were O
only O
8. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
GH-induced B-outcome ['Physiological-Clinical']
increment I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
IGF-I I-outcome ['Physiological-Clinical']
and O
TBW B-outcome ['Physiological-Clinical']
was O
greater O
in O
men O
than O
in O
women O
( O
P O
< O
0.01 O
) O
, O
whereas O
the O
decreases O
in O
BF B-outcome ['Physiological-Clinical']
were O
similar O
in O
men O
and O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Follow-up O
after O
3 O
months O
and O
then O
yearly O
included O
measurement O
of O
the O
PQ B-outcome ['Physiological-Clinical']
interval I-outcome ['Physiological-Clinical']
and O
, O
in O
patients O
with O
atrial O
pacemakers O
, O
determination O
of O
the O
atrial O
stimulus-Q B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
pacing I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
100 I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
120 I-outcome ['Physiological-Clinical']
bpm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
allocated O
to O
the O
splinting O
group O
( O
n O
= O
17 O
) O
or O
the O
control O
group O
( O
n O
= O
16 O
) O
. O
[]

This O
study O
will O
assess O
the O
effect O
of O
selenium O
supplementation O
on O
major O
pregnancy B-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
and O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
among O
HIV-infected O
pregnant O
women O
in O
Lagos, O
Nigeria. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Omega-3 O
fatty O
acids O
supplementation O
in O
children O
with O
autism O
: O
a O
double-blind O
randomized O
, O
placebo-controlled O
pilot O
study O
. O
[]

A O
transesophageal O
approach O
using O
light O
sedation O
has O
been O
proposed O
as O
a O
means O
of O
augmenting O
the O
success O
rate O
and O
avoiding O
the O
need O
for O
general O
anesthesia O
. O
[]

This O
prospective O
, O
randomized O
trial O
evaluated O
the O
effect O
of O
monotherapy O
and O
different O
combination O
therapies O
on O
cardiovascular O
target O
organ O
damage O
and O
metabolic O
profile O
in O
520 O
hypertensive O
patients O
. O
[]

Then O
multivariate O
analyses O
were O
used O
to O
identify O
factors O
predictive O
of O
prolonged O
air O
leaks O
and O
their O
duration O
. O
[]

In O
a O
separate O
cohort O
, O
an O
ascending O
dose O
protocol O
evaluated O
a O
total O
dose O
of O
500 O
mg O
daily O
given O
in O
two O
divided O
doses O
. O
[]

CONCLUSIONS: O
Gua O
Sha O
appears O
to O
be O
an O
acceptable B-outcome ['Life-Impact']
, O
safe, O
and O
effective O
treatment O
for O
patients O
with O
chronic O
low O
back O
pain. O
[['Life-Impact']]

PATIENTS O
Individuals O
free O
from O
tuberculosis O
, O
2367 O
persons O
in O
the O
intervention O
and O
2162 O
in O
the O
control O
groups O
. O
[]

A O
multivariate O
( O
classification O
tree O
) O
analysis O
found O
that O
only O
pertactin O
and O
PT O
were O
significant O
in O
protection O
. O
[]

A O
new O
social O
communication O
intervention O
for O
children O
with O
autism O
: O
pilot O
randomised O
controlled O
treatment O
study O
suggesting O
effectiveness O
. O
[]

CaCl O
( O
2 O
) O
pre-treatment O
; O
the O
other O
half O
received O
placebo O
. O
[]

Random O
effects O
models O
were O
used O
to O
examine O
differences O
between O
groups O
over O
time O
. O
[]

Neurophysiological O
double-blind O
trial O
of O
a O
botulinum O
neurotoxin O
type O
a O
free O
of O
complexing O
proteins O
. O
[]

Publication O
date: O
2018/08/29 O
00:00 O
[accepted] O
[]

Statistical O
power O
for O
the O
other O
end O
points O
is O
more O
difficult O
to O
estimate O
. O
[]

BACKGROUND O
This O
trial O
investigated O
the O
efficacy O
and O
safety O
of O
weekly O
cetuximab O
combined O
with O
two O
different O
schedules O
of O
paclitaxel/carboplatin O
for O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

The O
effect O
of O
hydraulic O
circuit O
training O
( O
HCT O
) O
on O
cardiovascular B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CV I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
assessed O
in O
32 O
healthy O
middle-aged O
males O
( O
X O
age O
= O
42.2 O
+/- O
2.1 O
yr O
) O
. O
['Physiological-Clinical']

MEASUREMENTS/MAIN O
RESULTS O
Oral B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
was O
measured O
before O
dosing O
, O
30 O
minutes O
after O
dosing O
, O
and O
hourly O
thereafter O
for O
8 O
hours O
after O
the O
dose O
. O
['Physiological-Clinical']

A O
community-based O
, O
double-blind O
, O
randomized O
trial O
of O
praziquantel O
was O
carried O
out O
in O
an O
area O
of O
Zambia O
endemic O
for O
schistosomiasis O
. O
[]

The O
2 O
groups O
were O
comparable O
. O
[]

No O
nonocular O
adverse O
events O
were O
considered O
related O
to O
study O
drug O
. O
[]

Both O
groups O
also O
showed O
significant O
decreases O
in O
drinking B-outcome ['Life-Impact']
days I-outcome ['Life-Impact']
per O
week O
, O
drinks O
per O
drinking B-outcome ['Life-Impact']
day I-outcome ['Life-Impact']
, O
maximum B-outcome ['Life-Impact']
drinks I-outcome ['Life-Impact']
per I-outcome ['Life-Impact']
occasion I-outcome ['Life-Impact']
, O
and O
negative O
consequences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
drinking I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

RESULTS O
Significantly O
lower O
peak O
and O
area O
under O
the O
curve O
( O
AUC O
) O
GH O
concentrations O
occurred O
in O
the O
irradiated O
group O
using O
0.15 O
microg/kg O
( O
median O
peak O
Irradiated O
, O
4 O
. O
[]

Two O
patients O
in O
group O
R O
and O
15 O
patients O
in O
group O
LE O
developed O
hypertension B-outcome ['Physiological-Clinical']
( O
odds O
ratio O
[ O
OR O
] O
: O
0.064 O
) O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

RESULTS O
Mean O
+/- O
SD O
baseline O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
and O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-C B-outcome ['Physiological-Clinical']
) O
levels O
were O
233+/-20 O
and O
153+21 O
mg+/-dL O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
IL-6 I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
determined O
before O
surgery O
and O
at O
24 O
, O
48 O
, O
72 O
h O
after O
surgery O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Women O
with O
bone O
metastases O
( O
N O
= O
228 O
) O
were O
randomly O
assigned O
to O
receive O
4 O
mg O
zoledronic O
acid O
( O
n O
= O
114 O
) O
or O
placebo O
( O
n O
= O
114 O
) O
via O
15-minute O
infusions O
every O
4 O
weeks O
for O
1 O
year O
. O
[]

A O
second O
swab O
was O
taken O
from O
the O
superficial O
incisional O
skin O
surface O
for O
culture O
and O
sensitivity O
investigation O
between O
the O
fifth O
to O
seventh O
postoperative O
day O
for O
comparison O
of O
the O
bacterial O
colonisation O
in O
the O
two O
groups O
. O
[]

Mean O
airway B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
decreased O
35.3 O
cm O
H2O/L/s O
, O
mean O
specific B-outcome ['Life-Impact']
airway I-outcome ['Life-Impact']
conductance I-outcome ['Life-Impact']
increased O
0.095 O
1/L/s/cm O
H2O O
, O
and O
mean O
dynamic B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
increased O
1.74 O
mL/cm O
H2O O
during O
treatment O
with O
diuretics O
( O
all O
P O
less O
than O
.001 O
) O
, O
but O
not O
during O
treatment O
with O
placebo O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

There O
was O
no O
difference O
in O
survival B-outcome ['Mortality']
between O
the O
two O
groups O
. O
['Mortality']

A O
total O
of O
412 O
patients O
with O
hepatitis O
C O
infection O
were O
randomized O
to O
open-label O
treatment O
with O
either O
pegIFNalpha O
2a O
( O
n O
= O
206 O
) O
or O
IFNalpha O
2b/RBV O
( O
n O
= O
206 O
) O
. O
[]

Before O
the O
skin O
incision O
performed O
after O
anesthesia O
induction O
, O
we O
performed O
ilioinguinal O
iliohypogastric O
block O
( O
group O
C O
given O
saline O
and O
group O
P O
and O
DB O
given O
levobupivacaine O
) O
. O
[]

RESULTS O
The O
consumption O
of O
L. O
plantarum O
CECT O
7315/7316 O
during O
3 O
months O
after O
influenza O
vaccination O
increased O
the O
levels O
of O
influenza-specific B-outcome ['Physiological-Clinical']
IgA I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intensive O
BP O
control O
significantly O
reduced O
the O
risk O
of O
mild O
cognitive B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
(14.6 O
vs O
18.3 O
cases O
per O
1000 O
person-years; O
HR, O
0.81; O
95% O
CI, O
0.69-0.95) O
and O
the O
combined O
rate O
of O
mild O
cognitive B-outcome ['Physiological-Clinical', 'Life-Impact']
impairment I-outcome ['Physiological-Clinical', 'Life-Impact']
or O
probable O
dementia O
(20.2 O
vs O
24.1 O
cases O
per O
1000 O
person-years; O
HR, O
0.85; O
95% O
CI, O
0.74-0.97). O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

Chewing O
has O
been O
shown O
to O
alleviate O
feelings O
of O
sleepiness O
and O
improve O
cognitive O
performance O
during O
the O
day O
. O
[]

Some O
of O
the O
children O
showed O
improvement O
in O
tests O
of O
cognitive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
although O
the O
results O
did O
not O
achieve O
overall O
statistical O
significance O
. O
['Life-Impact']

In O
the O
last O
week O
of O
training O
the O
exercise O
intensity O
in O
the O
group O
of O
patients O
who O
were O
trained O
by O
the O
continuous O
method O
was O
at O
83 O
watts O
, O
and O
at O
20:121 O
watts O
in O
the O
group O
of O
patients O
who O
were O
trained O
by O
interval O
method O
( O
rest O
: O
work O
each O
1:1 O
min O
) O
. O
[]

RESULTS O
There O
was O
lower O
mean O
drainage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
in O
the O
custom-fit O
group O
( O
391 O
ml O
vs. O
603 O
ml O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

These O
activities O
were O
continued O
for O
5 O
years O
. O
[]

One O
important O
executive O
function O
known O
to O
be O
compromised O
in O
autism O
spectrum O
disorder O
( O
ASD O
) O
is O
related O
to O
response O
error O
monitoring B-outcome ['Life-Impact']
and O
post-error O
response O
correction B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
After O
rTMS O
treatment O
RMT B-outcome ['Physiological-Clinical']
was O
decreased O
by O
about O
1 O
% O
of O
stimulator O
output O
near-significantly O
in O
the O
whole O
group O
of O
patients O
. O
['Physiological-Clinical']

SUBJECTS O
Children O
between O
4 O
and O
18 O
years O
old O
with O
cerebral O
palsy O
. O
[]

Here O
, O
we O
investigated O
whether O
a O
3-week O
administration O
of O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
expected O
to O
increase O
brain O
5-HT O
levels O
, O
is O
associated O
with O
a O
decline O
in O
brain O
5-HT4R O
binding O
. O
[]

METHODS O
Eighty-four O
children O
of O
autism O
were O
randomly O
divided O
into O
a O
tongue O
acupuncture O
group O
( O
group O
A O
) O
and O
a O
conventional O
training O
group O
( O
group O
B O
) O
, O
42 O
cases O
in O
each O
group O
. O
[]

Participants O
were O
recruited O
largely O
during O
the O
era O
prior O
to O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
; O
1992-1997 O
) O
. O
[]

Administration O
of O
VK2 O
was O
not O
an O
independent O
variable O
for O
the O
recurrence B-outcome ['Physiological-Clinical']
on O
univariate O
analysis O
. O
['Physiological-Clinical']

Title: O
Effect O
of O
Kinesio O
taping O
on O
electromyographic O
activity O
of O
leg O
muscles O
during O
gait O
in O
children O
with O
developmental O
coordination O
disorder: O
A O
randomized O
controlled O
trial. O
[]

MAIN O
RESULTS O
Mortality B-outcome ['Mortality']
from O
metastatic O
cancer O
in O
tamoxifen O
group O
was O
7 O
( O
10.6 O
% O
) O
and O
in O
mastectomy O
group O
10 O
( O
15.3 O
% O
) O
( O
NS O
) O
. O
['Mortality']

CONCLUSION O
Although O
there O
was O
a O
greater O
reduction O
in O
the O
number O
of O
sites B-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
BOP I-outcome ['Physiological-Clinical']
following O
treatment O
with O
the O
Vector O
system O
than O
following O
instrumentation O
with O
carbon O
fiber O
curettes O
, O
there O
was O
no O
significant O
difference O
between O
the O
two O
methods O
. O
['Physiological-Clinical']

CONCLUSIONS O
In O
WRIST O
, O
not O
only O
was O
( O
192 O
) O
Ir O
therapy O
effective O
in O
reducing O
restenosis O
, O
but O
it O
also O
reduced O
the O
lesion O
length O
of O
treatment O
failures O
by O
50 O
% O
, O
and O
it O
was O
not O
associated O
with O
edge O
proliferation O
. O
[]

Combined O
therapy O
with O
antibiotics O
and O
superlimf O
promotes O
a O
more O
rapid O
reduction O
in O
the O
duration O
of O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

This O
study O
assessed O
the O
efficacy O
of O
FaceSay O
, O
a O
computer-based O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
training O
program O
for O
children O
with O
Autism O
Spectrum O
Disorders O
( O
ASD O
) O
. O
['Life-Impact']

After O
a O
3-week O
run-in O
period O
during O
which O
all O
subjects O
consumed O
a O
milk O
protein-based O
supplement O
, O
participants O
were O
randomized O
into O
one O
of O
two O
groups O
: O
a O
control O
group O
( O
continued O
milk O
protein O
) O
and O
an O
intervention O
group O
( O
soy O
protein O
) O
for O
a O
five-week O
period O
. O
[]

A O
different O
need O
of O
antihypertensive O
drugs O
was O
simulated O
by O
the O
exacter O
intake O
of O
medicaments O
in O
the O
index-patients O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
16 O
months O
for O
the O
traditional O
Chinese O
Kidney-tonifying O
decoction O
group O
, O
and O
10 O
months O
for O
the O
control O
group O
( O
P O
less O
than O
0.05 O
) O
. O
['Mortality']

Plasma O
3,4-dihydroxyphenylethyleneglycol O
and O
3-methoxy-4-hydroxyphenylethyleneglycol O
as O
indicators O
of O
central O
noradrenergic O
activity O
. O
[]

METHODS O
This O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
clinical O
trial O
with O
initial O
and O
on-demand O
therapy O
. O
[]

In O
the O
diode O
laser O
group O
, O
sensitive O
teeth O
were O
irradiated O
with O
the O
GaAlAs O
laser O
at O
8.5J/cm O
( O
2 O
) O
energy O
density O
. O
[]

In O
addition O
, O
adjusted O
mortality B-outcome ['Mortality']
was O
similar O
in O
both O
groups O
, O
as O
were O
length O
of O
in-hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
physician B-outcome ['Resource-use']
visits I-outcome ['Resource-use']
after I-outcome ['Resource-use']
discharge I-outcome ['Resource-use']
, O
waiting O
times O
for O
invasive O
cardiac O
procedures O
, O
and O
readmissions O
for O
cardiac B-outcome ['Physiological-Clinical']
complications O
. O
['Mortality', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

Patients O
who O
died B-outcome ['Mortality']
or O
experienced O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
had O
larger O
antecedent O
increases O
in O
NT-ANP B-outcome ['Physiological-Clinical']
( O
+293.7 O
vs O
-21.5 O
pmol/ml O
, O
p O
= O
0.006 O
) O
and O
lesser O
decreases O
in O
norepinephrine B-outcome ['Physiological-Clinical']
( O
-22.3 O
vs O
-48.5 O
pg/ml O
, O
p O
= O
0.04 O
) O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

Thirty O
nondiabetic O
stage O
I O
or O
II O
CKD O
patients O
who O
had O
already O
been O
treated O
with O
angiotensin O
II O
receptor O
blockers O
were O
enrolled O
in O
this O
study O
. O
[]

RESULTS: O
Seventy-one O
patients O
(45% O
PAH, O
55% O
CTEPH; O
53.5% O
female; O
60 O
+/- O
13 O
years, O
mean O
pulmonary O
arterial O
pressure O
46 O
+/- O
10 O
mmHg, O
mean O
PVR O
700 O
+/- O
282dynes.sec.cm-5) O
were O
included. O
[]

METHODS: O
This O
randomized O
clinical O
trial O
was O
conducted O
at O
infertility O
department O
of O
Royan O
Institute O
from O
January O
2017 O
to O
June O
2018. O
[]

Angiotensin-converting O
enzyme O
inhibition O
does O
not O
suppress O
plasma O
angiotensin O
II O
increase O
during O
exercise O
in O
humans O
. O
[]

Additionally O
, O
children O
in O
the O
experimental O
group O
, O
whose O
GSR B-outcome ['Life-Impact']
measures O
decreased O
, O
on O
average O
, O
after O
deep O
pressure O
, O
were O
somewhat O
more O
likely O
to O
have O
higher O
GSR B-outcome ['Life-Impact']
arousal I-outcome ['Life-Impact']
a O
priori O
. O
['Life-Impact', 'Life-Impact']

The O
baseline O
and O
procedural O
characteristics O
were O
comparable O
in O
both O
groups O
. O
[]

A O
prospective O
, O
double-blind O
, O
randomized O
, O
controlled O
clinical O
trial O
comparing O
standard O
wound O
care O
with O
adjunctive O
hyperbaric O
oxygen O
therapy O
( O
HBOT O
) O
to O
standard O
wound O
care O
only O
for O
the O
treatment O
of O
chronic O
, O
non-healing O
ulcers O
of O
the O
lower O
limb O
in O
patients O
with O
diabetes O
mellitus O
: O
a O
study O
protocol O
. O
[]

METHODS/DESIGN O
Children O
aged O
between O
4 O
; O
0 O
and O
6 O
; O
11 O
years O
who O
are O
diagnosed O
with O
autism O
spectrum O
disorder O
will O
be O
randomly O
assigned O
to O
one O
of O
three O
conditions O
. O
[]

METHODS O
Seventeen O
subjects O
were O
randomized O
into O
control O
( O
n O
= O
9 O
) O
and O
HBOT O
treatment O
( O
n O
= O
8 O
) O
arms O
. O
[]

No O
routine O
laboratory O
or O
physical O
findings O
reliably O
predicted O
the O
development O
of O
the O
fat B-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
except O
petechial B-outcome ['Physiological-Clinical']
rash I-outcome ['Physiological-Clinical']
, O
which O
occurred O
only O
in O
5 O
placebo-treated O
patients O
who O
developed O
the O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
study O
failed O
to O
show O
significant O
difference O
in O
intelligence B-outcome ['Life-Impact']
quotient I-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
scales O
with O
donepezil O
therapy O
over O
12 O
weeks O
. O
['Life-Impact', 'Life-Impact']

Drug O
efficacy O
was O
measured O
by O
ventricular B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
and O
conversion B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
sinus I-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
Aberrant O
Behavior O
Checklist O
-- O
Community O
Scale O
( O
ABC-C O
) O
Irritability O
subscale O
was O
the O
primary O
outcome O
measure O
( O
p O
= O
0.65 O
) O
, O
and O
CGI O
-- O
Improvement O
( O
p O
= O
0.16 O
) O
and O
OAS O
( O
p O
= O
0.96 O
) O
were O
secondary O
outcome O
measures O
. O
[]

During O
the O
48-hour O
observation O
period O
, O
3 O
( O
7 O
% O
) O
of O
46 O
patients O
given O
phenytoin O
and O
3 O
( O
5 O
% O
) O
of O
56 O
patients O
given O
placebo O
experienced O
a O
posttraumatic B-outcome ['Physiological-Clinical']
seizure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
Monitoring O
+ O
Acceptance O
Theory O
(MAT) O
postulates O
that O
MBI O
improves O
cognition O
through O
monitoring, O
and O
psychological O
well-being, O
through O
acceptance. O
[]

In O
this O
open-label O
, O
multicenter O
, O
phase O
II O
study O
, O
eligible O
patients O
( O
N O
= O
112 O
) O
were O
randomized O
2:1 O
to O
lapatinib O
plus O
vinorelbine O
[ O
( O
N O
= O
75 O
) O
1,250 O
mg O
orally O
once O
daily O
( O
QD O
) O
continuously O
plus O
20 O
mg/m O
( O
2 O
) O
/day O
intravenously O
] O
or O
lapatinib O
plus O
capecitabine O
[ O
( O
N O
= O
37 O
) O
1,250 O
mg O
orally O
QD O
continuously O
plus O
2,000 O
mg/m O
( O
2 O
) O
/day O
orally O
, O
2 O
doses O
] O
. O
[]

CONCLUSIONS O
Our O
results O
reveal O
the O
existence O
of O
a O
specific O
[]

We O
conclude O
that O
B O
vitamins O
may O
decrease O
the O
plasma O
level O
of O
A O
beta O
40 O
and O
have O
a O
role O
in O
the O
prevention O
of O
AD O
. O
[]

A O
single-bout O
of O
exercise O
produced O
increases O
in O
STARS B-outcome ['Physiological-Clinical']
and O
SRF B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
and O
decreases O
in O
MRTF-A B-outcome ['Physiological-Clinical']
mRNA I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
both I-outcome ['Physiological-Clinical']
ECC I-outcome ['Physiological-Clinical']
and O
CONC B-outcome ['Physiological-Clinical']
exercise I-outcome ['Physiological-Clinical']
, O
but O
with O
an O
enhanced O
response O
occurring O
following O
ECC O
exercise O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
treatment O
group O
at O
the O
acute O
stage O
( O
1-10 O
days O
) O
were O
treated O
with O
acupuncture O
at O
Dicang O
( O
ST O
4 O
) O
, O
Jiache O
( O
ST O
6 O
) O
, O
Yangbai O
( O
GB O
14 O
) O
, O
etc. O
, O
with O
less O
than O
4 O
points O
selected O
on O
the O
face O
and O
with O
shallow O
puncture O
, O
and O
10 O
days O
later O
electroacupuncture O
were O
added O
at O
acupoints O
selected O
routinely O
; O
the O
control O
group O
were O
treated O
with O
the O
same O
methods O
as O
the O
treatment O
group O
but O
acupuncture O
was O
not O
given O
at O
the O
acute O
stage O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
the O
annual O
rate O
of O
decline O
in O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
( O
P=0.16 O
) O
. O
['Physiological-Clinical']

With O
the O
addition O
of O
simvastatin O
( O
20 O
mg O
per O
day O
) O
, O
there O
was O
a O
32 O
percent O
total O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
from O
the O
control O
value O
and O
a O
43 O
percent O
decrease O
in O
low O
density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fifty O
pairs O
of O
sheep O
tibiae O
were O
utilized O
in O
the O
experiment O
. O
[]

METHODS O
Seventeen O
sedentary O
adults O
aged O
> O
or=55 O
years O
with O
insomnia O
( O
mean O
age O
61.6 O
[ O
SD?4.3 O
] O
years O
; O
16 O
female O
) O
participated O
in O
a O
randomized O
controlled O
trial O
comparing O
16 O
weeks O
of O
aerobic O
physical O
activity O
plus O
sleep O
hygiene O
to O
non-physical O
activity O
plus O
sleep O
hygiene O
. O
[]

Compared O
with O
those O
with O
plasma B-outcome ['Physiological-Clinical']
25 I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
OH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
D I-outcome ['Physiological-Clinical']
levels O
above O
the O
median O
and O
with O
the O
FokI O
FF O
or O
Ff O
genotype O
, O
men O
who O
had O
low O
25 O
( O
OH O
) O
D O
levels O
and O
the O
less O
functional O
FokI O
ff O
genotype O
had O
increased O
risks O
of O
total O
( O
OR O
= O
1.9 O
, O
95 O
% O
CI O
1.1-3.3 O
) O
and O
aggressive B-outcome ['Physiological-Clinical']
prostate I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
OR O
= O
2.5 O
, O
95 O
% O
CI O
1.1-5.8 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
negative O
experience B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
caregiving I-outcome ['Life-Impact']
predicted O
carer O
MH O
status O
. O
['Life-Impact']

ORG O
2766 O
treatment O
( O
20 O
mg O
per O
day O
during O
4 O
weeks O
) O
was O
associated O
with O
an O
increased O
amount O
and O
an O
improved O
quality O
of O
the O
social O
interaction O
of O
the O
autistic O
children O
with O
a O
familiar O
experimenter O
. O
[]

The O
study O
population O
had O
a O
mortality B-outcome ['Mortality']
of O
23 O
% O
during O
the O
6 O
month O
period O
, O
the O
amputation B-outcome ['Resource-use']
rate O
was O
43.5 O
% O
for O
iloprost O
and O
50 O
% O
for O
placebo O
treated O
patients O
. O
['Mortality', 'Resource-use']

Fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples O
were O
taken O
before O
treatment O
, O
and O
after O
cycles O
3 O
and O
6 O
, O
between O
the O
18th O
and O
the O
22nd O
day O
of O
the O
cycle O
. O
['Physiological-Clinical']

Sphincter-saving O
procedures O
appear O
to O
have O
no O
adverse O
effects O
on O
outcome O
of O
rectal O
cancer O
, O
but O
the O
optimum O
use O
of O
radiotherapy O
is O
still O
to O
be O
defined O
. O
[]

The O
estimated O
treatment O
difference O
for O
duration O
of O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
was O
-4 O
( O
90 O
% O
CI O
-13 O
, O
6 O
) O
min O
. O
['Physiological-Clinical']

RESULTS O
Among O
ZrO O
( O
2 O
) O
copings O
, O
Lava O
( O
0.3 O
mm O
and O
0.5 O
mm O
thick O
) O
showed O
the O
highest O
( O
P O
< O
.05 O
) O
values O
of O
translucency B-outcome ['Physiological-Clinical']
measured O
as O
light O
flow O
units O
( O
3.572 O
+ O
or O
- O
018 O
x O
10 O
( O
3 O
) O
lx O
and O
3.181 O
+ O
or O
- O
0.13 O
x O
10 O
( O
3 O
) O
lx O
, O
respectively O
) O
. O
['Physiological-Clinical']

The O
self-reported B-outcome ['Life-Impact']
alcohol I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
was O
56.1 O
+/- O
3.6 O
( O
SEM O
) O
ml/day O
during O
the O
usual O
alcohol O
drinking O
period O
and O
26.1 O
+/- O
3.0 O
ml/day O
during O
the O
period O
of O
reduced O
alcohol O
consumption O
. O
['Life-Impact']

The O
number O
of O
mild B-outcome ['Physiological-Clinical']
hypoglycemic I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
per O
patient-week O
was O
0.99 O
( O
95 O
% O
CI O
0.11-1.87 O
) O
higher O
in O
the O
insulin O
pump O
group O
( O
P O
= O
0.028 O
) O
. O
['Physiological-Clinical']

Intensive O
insulin O
therapy O
improves O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
microvascular O
reactivity O
in O
young O
people O
with O
type O
1 O
diabetes O
. O
['Physiological-Clinical']

Controlling O
for O
depression B-outcome ['Life-Impact']
, O
previous B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
low B-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
, O
decreased O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
, O
and O
ventricular B-outcome ['Physiological-Clinical']
ectopic I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
had O
little O
impact O
on O
estimated O
treatment O
effect O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
use O
of O
the O
AccuTouch O
flexible O
endoscopy O
simulator O
improves O
the O
early B-outcome ['Life-Impact']
part I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
curve O
in O
colonoscopy O
training O
. O
['Life-Impact']

Ginger O
has O
shown O
downregulation O
of O
COX O
in O
vitro O
and O
decreased O
incidence/multiplicity O
of O
adenomas O
in O
rats O
. O
[]

METHODS O
Patients O
presenting O
for O
cataract O
surgery O
in O
one O
eye O
were O
randomized O
to O
receive O
either O
the O
Tecnis O
Z9000 O
intraocular O
lens O
( O
Pharmacia O
) O
or O
the O
AMO O
AR40e O
Opti-Edge O
intraocular O
lens O
( O
AMO O
) O
. O
[]

Those O
individuals O
randomly O
assigned O
to O
the O
intervention O
group O
( O
n O
= O
33 O
) O
received O
PACT O
case O
management O
in O
addition O
to O
their O
usual O
medical O
and O
nursing O
home O
care O
. O
[]

PATIENTS O
Twenty-six O
patients O
( O
22 O
men O
, O
4 O
women O
; O
mean O
+/- O
SD O
age O
, O
54 O
+/- O
9yrs O
) O
with O
a O
history O
of O
severe O
chronic O
heart O
failure O
( O
left O
ventricular O
ejection O
fraction O
of O
18 O
% O
+/- O
8 O
% O
) O
. O
[]

During O
the O
treatment O
with O
prednisolone O
, O
a O
significant O
increase O
in O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
observed O
in O
all O
treated O
patients O
. O
['Physiological-Clinical']

Early O
effects O
of O
continuous O
low-dosage O
all-norgestrel O
administered O
alone O
or O
with O
estrogen O
. O
[]

VRH O
patients O
reported O
less O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
and O
less O
pain B-outcome ['Physiological-Clinical']
unpleasantness I-outcome ['Physiological-Clinical']
compared O
to O
control O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
each O
arm O
, O
two O
or O
more O
courses O
of O
chemotherapy O
( O
4-week O
cycles O
) O
were O
performed O
. O
[]

The O
75 O
% O
Awassi O
crosses O
were O
least O
profitable B-outcome ['Life-Impact']
. O
['Life-Impact']

In O
all O
other O
respects O
, O
the O
programs O
were O
identical O
. O
[]

This O
was O
confirmed O
by O
another O
self-report O
scale O
( O
the O
facial B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scale O
revised O
: O
P O
= O
0.005 O
) O
, O
as O
well O
as O
with O
hetero-evaluations O
by O
GPs O
and O
parents O
[ O
Children O
's O
Hospital O
of O
Eastern O
Ontario O
Pain B-outcome ['Physiological-Clinical']
Scale O
: O
P O
= O
0.0007 O
; O
GPs O
VAS O
( O
P O
< O
0.0001 O
) O
, O
parents O
VAS O
( O
P O
< O
0.0001 O
) O
] O
, O
which O
were O
secondary O
outcome O
criteria O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Prospective O
analysis O
was O
employed O
with O
the O
setup O
at O
Alexandria O
IVF/ICSI O
center O
. O
[]

Of O
the O
components O
of O
the O
primary O
outcome O
, O
only O
hospitalization O
for O
heart B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
had O
a O
significantly O
lower O
incidence O
in O
the O
spironolactone O
group O
than O
in O
the O
placebo O
group O
( O
206 O
patients O
[ O
12.0 O
% O
] O
vs. O
245 O
patients O
[ O
14.2 O
% O
] O
; O
hazard O
ratio O
, O
0.83 O
; O
95 O
% O
CI O
, O
0.69 O
to O
0.99 O
, O
P=0.04 O
) O
. O
['Physiological-Clinical']

Two O
of O
42 O
patients O
who O
underwent O
resection O
and O
had O
been O
treated O
with O
n-BCA O
experienced O
[]

Eleven O
patients O
complained O
of O
side O
effects O
with O
metoclopramide O
and O
three O
stopped O
therapy O
before O
the O
1-month O
course O
was O
completed O
. O
[]

Glycosaminoglycan O
heparin O
possesses O
multiple O
noncoagulant O
properties O
including O
antiinflammatory O
actions O
. O
[]

We O
hypothesized O
that O
Dex O
could O
enhance O
the O
efficiency O
of O
intrathecal O
bupivacaine O
for O
spinal O
anesthesia O
in O
cesarean O
section. O
[]

Assigned O
group O
was O
the O
major O
predictor O
of O
change O
in O
calcium B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
. O
['Life-Impact']

Alopecia B-outcome ['Physiological-Clinical']
( O
overall O
, O
66 O
% O
versus O
20 O
% O
; O
pronounced O
, O
54 O
% O
versus O
7 O
% O
) O
, O
nausea B-outcome ['Physiological-Clinical']
( O
53 O
% O
versus O
37 O
% O
) O
, O
vomiting B-outcome ['Physiological-Clinical']
( O
31 O
% O
versus O
19 O
% O
) O
and O
neutropenia B-outcome ['Physiological-Clinical']
( O
10 O
% O
versus O
4 O
% O
) O
were O
more O
often O
associated O
with O
doxorubicin O
than O
PLD O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
chlorhexidine O
varnish O
was O
then O
painted O
on O
the O
entire O
dentition O
of O
Group O
T O
subjects O
only O
. O
[]

There O
were O
no O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
, O
bradycardia B-outcome ['Physiological-Clinical']
, O
hypotension B-outcome ['Physiological-Clinical']
, O
nausea B-outcome ['Physiological-Clinical']
, O
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Title: O
A O
randomized O
trial O
of O
AmBisome O
monotherapy O
and O
AmBisome O
and O
miltefosine O
combination O
to O
treat O
visceral O
leishmaniasis O
in O
HIV O
co-infected O
patients O
in O
Ethiopia. O
[]

One-quarter O
were O
African O
American O
or O
Black. O
[]

Nearly O
100 O
% O
of O
patients O
experience O
trauma O
to O
the O
trigeminal O
nerve O
during O
orthognathic O
surgery O
, O
impairing O
sensation O
and O
sensory O
function O
on O
the O
face O
. O
[]

A O
total O
of O
360 O
patients O
were O
required O
after O
considering O
ineligible O
cases. O
[]

p O
< O
0.07 O
) O
. O
[]

We O
are O
performing O
a O
randomized O
controlled O
trial O
of O
parenteral O
nutrition O
among O
children O
undergoing O
allogeneic O
HSCT O
. O
[]

CONCLUSION O
Our O
results O
indicate O
that O
intrathecal O
lentiviral-mediated O
transfer O
of O
IL-10 O
attenuates O
CCI-induced O
neuropathic O
pain O
in O
rats O
. O
[]

They O
were O
done O
at O
( O
a O
) O
uncontrolled O
stage O
( O
FBS O
-- O
165 O
+/- O
16.7 O
mg/dl O
, O
PP O
-- O
240 O
+/- O
30.1 O
mg/dl O
and O
HbA1 O
-- O
10.5 O
+/- O
0.9 O
% O
in O
group O
I O
and O
FBS O
-- O
150 O
+/- O
15.8 O
mg/dl O
, O
PP O
-- O
246 O
+/- O
29.1 O
mg/dl O
HbA1 O
10.6 O
+/- O
0.8 O
% O
in O
group O
II O
) O
and O
during O
controlled O
stage O
at O
12 O
weeks O
( O
FBS O
-- O
120 O
+/- O
18.5 O
mg/dl O
, O
PP O
-- O
180 O
+/- O
19.1 O
mg/dl O
and O
HbA1 O
-- O
8.4 O
+/- O
0.29 O
% O
in O
group O
I O
and O
FBS O
-- O
118 O
+/- O
17.6 O
mg/dl O
, O
PP O
-- O
176 O
+/- O
20.1 O
mg/dl O
and O
HbA1 O
-- O
8.5 O
+/- O
0.39 O
% O
in O
group O
II O
patients O
) O
. O
[]

METHODS O
AND O
RESULTS O
Three O
hundred O
symptomatic O
patients O
with O
ISR O
were O
randomly O
assigned O
to O
1 O
of O
3 O
treatment O
arms O
: O
placebo O
or O
usual-dose O
or O
high-dose O
sirolimus O
. O
[]

After O
a O
mean O
follow-up O
of O
47 O
months O
, O
five O
patients O
( O
12 O
% O
) O
developed O
disease B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical']

BACKGROUND O
Neoadjuvant O
chemoradiotherapy O
( O
CRT O
) O
reduces O
local O
tumor O
recurrence O
in O
locally O
advanced O
rectal O
cancer O
( O
LARC O
) O
. O
[]

The O
results O
indicate O
that O
there O
were O
no O
statistically O
significant O
differences O
among O
the O
three O
treatment O
groups O
in O
terms O
of O
clinical O
success O
rates O
, O
but O
that O
clarithromycin O
and O
roxithromycin O
were O
better O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
occurrence O
of O
AV B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
in O
the O
atrial O
group O
was O
recorded O
. O
['Physiological-Clinical']

A O
randomized O
placebo-controlled O
trial O
comparing O
the O
efficacy O
of O
etoricoxib O
30 O
mg O
and O
ibuprofen O
2400 O
mg O
for O
the O
treatment O
of O
patients O
with O
osteoarthritis O
. O
[]

Comparison O
of O
the O
effect O
of O
intra-arterial O
versus O
intravenous O
heparin O
on O
radial O
artery O
occlusion O
after O
transradial O
catheterization O
. O
[]

Influenza O
and O
pneumococcal O
vaccination O
as O
a O
model O
to O
assess O
C-reactive O
protein O
response O
to O
mild O
inflammation O
. O
[]

Awareness O
of O
the O
role O
of O
context O
was O
assessed O
using O
a O
behavioral O
task O
and O
explicit O
questions O
. O
[]

Thirteen O
patients O
( O
5 O
in O
group O
A O
and O
8 O
in O
group O
B O
) O
died B-outcome ['Mortality']
before O
day O
120 O
( O
p=0.3 O
) O
. O
['Mortality']

A O
cohort O
of O
39 O
patients O
with O
APC O
, O
without O
thrombosis O
, O
receiving O
chemotherapy O
, O
were O
entered O
in O
a O
randomized O
controlled O
trial O
( O
ISRCTN O
= O
76464767 O
) O
of O
thromboprevention O
with O
weight-adjusted O
dalteparin O
( O
WAD O
) O
. O
[]

Of O
the O
12 O
patients O
who O
suffered O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
eight O
relapsed B-outcome ['Physiological-Clinical']
and O
four O
died B-outcome ['Mortality']
of I-outcome ['Mortality']
toxicity I-outcome ['Mortality']
. O
['Adverse-effects', 'Physiological-Clinical', 'Mortality']

High O
fever O
and O
hospitalization B-outcome ['Resource-use']
due O
to O
infectious O
complications O
were O
also O
more O
common O
in O
the O
local O
anesthesia O
group O
, O
although O
not O
statistically O
significant O
. O
['Physiological-Clinical', 'Resource-use']

After O
6 O
months O
, O
47 O
% O
of O
all O
showed O
such O
improvement O
. O
[]

We O
compared O
toxicity O
( O
particularly O
diarrhoea O
) O
, O
quality O
of O
life O
, O
and O
efficacy O
of O
combination O
chemotherapy O
and O
irinotecan O
in O
these O
patients O
. O
[]

SETTING O
Outpatient O
physical O
therapy O
department O
of O
a O
large O
military O
medical O
center O
. O
[]

MATERIALS O
AND O
METHODS O
We O
randomly O
assigned O
28 O
patients O
with O
refractory O
monosymptomatic O
nocturnal O
enuresis O
to O
2 O
equal O
groups O
. O
[]

There O
was O
one O
documented O
case O
of O
osteonecrosis B-outcome ['Physiological-Clinical']
in O
the O
zoledronic O
acid O
group O
. O
['Physiological-Clinical']

AF B-outcome ['Physiological-Clinical']
occurred O
in O
7.14 O
% O
patients O
in O
group O
I O
, O
and O
in O
group O
II O
, O
28.57 O
% O
( O
P=0.035 O
) O
; O
ventricular B-outcome ['Physiological-Clinical']
tachycardia/fibrillation I-outcome ['Physiological-Clinical']
was O
observed O
in O
21.43 O
% O
patients O
in O
group O
I O
and O
46.43 O
% O
patients O
in O
group O
II O
( O
P=0.089 O
) O
after O
release O
of O
aortic O
clamp O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
follow-up O
was O
2.47+/-1.75 O
years O
, O
with O
54 O
% O
adherence O
to O
the O
program O
. O
[]

Three O
groups O
of O
young O
patients O
with O
borderline O
hypertension O
were O
studied O
for O
a O
12 O
months O
period O
. O
[]

Functional O
performance O
was O
assessed O
using O
timed O
up O
and O
go O
, O
chair O
stand O
, O
single O
leg O
stand O
, O
and O
step O
test O
. O
[]

An O
experimental O
design O
with O
random O
assignment O
of O
subjects O
to O
treatment O
and O
control O
groups O
was O
used O
to O
demonstrate O
the O
impact B-outcome ['Life-Impact']
of O
this O
peer-mediated O
intervention O
. O
['Life-Impact']

After O
approval O
of O
institutional O
ethics O
review O
board O
in O
our O
university O
, O
thirty O
patients O
with O
prior O
consent O
participated O
in O
this O
study O
. O
[]

Mortality O
risk O
was O
characterized O
by O
early O
and O
constant O
phases O
; O
transplant O
was O
characterized O
by O
only O
a O
constant O
phase O
. O
[]

OBJECTIVE O
To O
observe O
therapeutic O
effects O
of O
acupuncture O
at O
different O
opportunities O
on O
peripheral O
facial O
paralysis O
. O
[]

DESIGN O
An O
observational O
substudy O
of O
an O
open-label O
randomized O
controlled O
trial O
of O
two O
alternative O
therapeutic O
regimens O
for O
MAC O
. O
[]

All O
treatment O
groups O
demonstrated O
dramatic B-outcome ['Life-Impact']
and O
persistent B-outcome ['Life-Impact']
decreases O
in O
cocaine B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
craving B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
cocaine I-outcome ['Life-Impact']
, O
and O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
consequent O
to O
treatment O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Cardiovascular O
risk O
is O
increased O
in O
GH O
deficiency O
( O
GHD O
) O
. O
[]

The O
main O
group O
consisted O
of O
90 O
children O
diagnosed O
with O
asthma O
and O
allergies O
symptoms O
age O
9 O
to O
12 O
years O
old O
(x O
= O
10.75 O
+/- O
1.08). O
[]

The O
immunoglobulins O
had O
a O
high O
antitoxin O
content O
and O
had O
been O
raised O
with O
acellular O
pertussis O
vaccines O
. O
[]

RESULTS O
Of O
85 O
EEGs O
, O
43 O
( O
51 O
% O
) O
were O
abnormal B-outcome ['Physiological-Clinical']
, O
predominantly O
because O
of O
IEDs O
. O
['Physiological-Clinical']

Our O
primary O
endpoint O
was O
the O
composite O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
, O
non B-outcome ['Physiological-Clinical']
fatal I-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
( O
including O
silent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
) O
, O
stroke B-outcome ['Physiological-Clinical']
, O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
endovascular B-outcome ['Resource-use']
or O
surgical B-outcome ['Resource-use']
intervention I-outcome ['Resource-use']
in I-outcome ['Resource-use']
the I-outcome ['Resource-use']
coronary I-outcome ['Resource-use']
or O
leg B-outcome ['Physiological-Clinical']
arteries I-outcome ['Physiological-Clinical']
, O
and O
amputation B-outcome ['Resource-use']
above I-outcome ['Resource-use']
the I-outcome ['Resource-use']
ankle I-outcome ['Resource-use']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Based O
on O
these O
data O
, O
a O
role O
for O
GHRH O
as O
an O
inducer O
of O
SWS O
was O
proposed O
. O
[]

Significant O
improvements O
in O
patients O
' O
global B-outcome ['Physiological-Clinical']
function B-outcome ['Life-Impact']
were O
seen O
versus O
placebo O
at O
week O
24 O
( O
observed O
cases O
) O
, O
on O
the O
Clinician O
's O
Interview-Based O
Impression O
of O
Change-Plus O
version O
only O
for O
patients O
on O
donepezil O
5 O
mg/d O
( O
P=0.014 O
) O
, O
and O
on O
the O
Sum O
of O
the O
Boxes O
of O
the O
Clinical B-outcome ['Physiological-Clinical']
Dementia I-outcome ['Physiological-Clinical']
Rating O
only O
for O
patients O
on O
10 O
mg/d O
( O
P=0.007 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

A O
global O
evaluation O
to O
assess O
the O
method O
of O
irrigation O
and O
the O
solutions O
used O
for O
irrigation O
was O
completed O
by O
both O
the O
physician O
blinded O
to O
the O
treatment O
groups O
and O
the O
volunteers O
. O
[]

PTSD O
patients O
were O
recruited O
from O
five O
primary O
care O
clinics O
at O
four O
Veterans O
Affairs O
healthcare O
facilities O
and O
randomized O
to O
receive O
usual O
care O
or O
usual O
care O
plus O
3CM O
. O
[]

Subjects O
then O
rinsed O
their O
mouths O
for O
1 O
minute O
3-times O
a O
day O
with O
15 O
ml O
0.1 O
% O
hexetidine O
or O
placebo O
, O
saliva O
samples O
being O
collected O
at O
2 O
minutes O
, O
30 O
minutes O
, O
1 O
hour O
, O
3 O
hours O
and O
5 O
hours O
post-dosing O
. O
[]

Among O
patients O
who O
underwent O
lymphadenectomy, O
the O
median O
number O
of O
removed O
nodes B-outcome ['Physiological-Clinical']
was O
57 O
(35 O
pelvic O
and O
22 O
paraaortic O
nodes). O
[['Physiological-Clinical']]

Treatment O
of O
sperm O
with O
platelet-activating O
factor O
does O
not O
improve O
intrauterine O
insemination O
outcome O
in O
unselected O
cases O
of O
mild O
male O
factor O
infertility O
: O
a O
prospective O
double-blind O
randomized O
crossover O
study O
. O
[]

HER2 B-outcome ['Physiological-Clinical']
overexpression/amplification I-outcome ['Physiological-Clinical']
was O
observed O
in O
37.3 O
% O
( O
91/244 O
) O
and O
17.9 O
% O
( O
41/229 O
) O
of O
the O
informative O
samples O
in O
the O
local O
and O
central O
evaluations O
, O
respectively O
. O
['Physiological-Clinical']

In O
the O
concurrent O
arm O
, O
35 O
of O
48 O
evaluable O
patients O
( O
73 O
% O
; O
95 O
% O
confidence O
interval O
, O
58 O
% O
-85 O
% O
) O
had O
a O
complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Lack O
of O
interaction O
in O
the O
sense O
of O
equivalence O
was O
concluded O
for O
both O
digoxin O
( O
with O
and O
without O
pantoprazole O
) O
and O
pantoprazole O
( O
with O
and O
without O
digoxin O
) O
as O
the O
90 O
% O
-confidence O
intervals O
of O
the O
respective O
AUC- O
and O
Cmax-ratios B-outcome ['Physiological-Clinical']
were O
within O
the O
equivalence O
range O
of O
0.8-1.25 O
. O
['Physiological-Clinical']

Failure O
increased O
the O
subject O
's O
autonomic B-outcome ['Physiological-Clinical']
arousal I-outcome ['Physiological-Clinical']
, O
as O
measured O
by O
photoplethysmographic O
sensors O
, O
in O
all O
stimulation O
conditions O
, O
but O
only O
the O
condition O
with O
aversive O
stimulation O
increased O
the O
speed B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
clenching I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

Of O
the O
four O
patients O
in O
the O
intravenous-access O
group O
, O
one O
had O
layering O
and O
agglutination O
, O
and O
two O
had O
blood O
clots O
. O
[]

All O
patients O
underwent O
classical O
radical O
hysterectomy O
. O
[]

These O
findings O
demonstrate O
that O
a O
local B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
of I-outcome ['Resource-use']
5 I-outcome ['Resource-use']
mg I-outcome ['Resource-use']
tropisetron I-outcome ['Resource-use']
does O
represent O
an O
alternative O
to O
the O
local O
treatment O
with O
corticosteriods O
plus O
local O
anesthetics O
. O
['Resource-use']

Identification O
of O
predictors O
of O
clinical O
improvement O
has O
been O
limited O
by O
the O
power O
of O
the O
study O
. O
[]

Effects O
of O
exposure O
to O
thin-ideal O
media O
images O
on O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
: O
testing O
the O
inclusion O
of O
a O
disclaimer O
versus O
warning O
label O
. O
['Life-Impact']

Baseline O
tumour O
marker O
levels O
provide O
prognostic O
information O
for O
patients O
with O
UGIA O
on O
palliative O
chemotherapy O
. O
[]

Different O
cardiac O
biomarkers O
to O
detect O
peri-procedural O
myocardial O
infarction O
in O
contemporary O
coronary O
stent O
trials O
: O
impact O
on O
outcome O
reporting O
. O
[]

In O
discrimination O
learning O
paradigm O
, O
children O
receiving O
haloperidol O
learned B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
discrimination I-outcome ['Life-Impact']
while O
those O
on O
placebo O
did O
not O
. O
['Life-Impact']

They O
then O
underwent O
ET O
and O
were O
observed O
for O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
for O
another O
30 O
minutes O
post-ET. O
[['Adverse-effects']]

For O
the O
mortality O
outcomes O
, O
neither O
of O
the O
supplement O
group O
outcomes O
was O
significantly O
different O
from O
the O
placebo O
group O
outcomes O
. O
[]

Title: O
Remote O
ischemic O
preconditioning O
for O
prevention O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
-Insights O
from O
an O
Indian O
study. O
[['Physiological-Clinical']]

Inhibition O
of O
awake O
sympathetic O
nerve O
activity O
of O
heart O
failure O
patients O
with O
obstructive O
sleep O
apnea O
by O
nocturnal O
continuous O
positive O
airway O
pressure O
. O
[]

BACKGROUND: O
Dexmedetomidine O
(Dex), O
as O
an O
adjuvant, O
has O
been O
reported O
to O
prolong O
the O
duration O
of O
spinal O
analgesia O
when O
adding O
to O
local O
anesthetic. O
[]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

Treatment-induced O
effects O
were O
assessed O
with O
the O
Childhood B-outcome ['Life-Impact']
Autism I-outcome ['Life-Impact']
Rating O
Scale O
every O
third O
month O
. O
['Life-Impact']

BACKGROUND/AIMS O
Helicobacter O
pylori O
( O
H. O
pylori O
) O
infection O
is O
one O
of O
the O
most O
common O
gastrointestinal O
diseases O
. O
[]

Following O
placebo O
run-in O
, O
86 O
patients O
were O
randomised O
to O
receive O
fluvoxamine O
or O
clomipramine O
( O
100-250 O
mg/day O
) O
for O
8 O
weeks O
. O
[]

DESIGN O
Open O
, O
prospective O
, O
randomized O
, O
multicentre O
, O
controlled O
study O
for O
parallel O
groups O
, O
stratified O
for O
adults O
and O
children O
. O
[]

We O
present O
a O
study O
of O
the O
ghostwritten O
archival O
report O
of O
an O
industry-sponsored O
trial O
comparing O
antidepressant O
treatments O
for O
bipolar B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
: O
GlaxoSmithKline O
( O
GSK O
) O
paroxetine O
study O
352 O
. O
['Life-Impact']

Three-quarters O
were O
African-American O
. O
[]

BACKGROUND O
Controversy O
exists O
on O
how O
the O
length O
and O
diameter O
of O
colonoscopes O
affect O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
colonoscopy I-outcome ['Life-Impact']
. O
['Life-Impact']

This O
study O
evaluated O
the O
effectiveness O
of O
two-dose O
versus O
three-dose O
of O
SP O
for O
IPTp-SP O
in O
the O
prevention O
of O
low B-outcome ['Physiological-Clinical']
birth I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
(LBW) I-outcome ['Physiological-Clinical']
and O
malaria B-outcome ['Physiological-Clinical']
parasitaemia I-outcome ['Physiological-Clinical']
. O
Methods: O
: O
An O
open, O
randomized, O
controlled, O
longitudinal O
trial O
was O
conducted O
in O
a O
secondary O
level O
hospital O
in O
Nsukka O
region O
of O
Enugu O
State, O
Nigeria. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Patients O
with O
PHD O
have O
altered O
sympathetic B-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
The O
safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
Viatim O
, O
a O
combined O
hepatitis O
A O
( O
HA O
) O
and O
typhoid O
fever O
( O
Vi O
) O
vaccine O
, O
were O
compared O
with O
the O
monovalent O
component O
vaccines O
up O
to O
and O
1 O
month O
after O
a O
booster O
dose O
at O
3 O
years O
. O
['Physiological-Clinical']

RESULTS O
Glucocorticoid O
administration O
for O
5 O
weeks O
resulted O
in O
significant O
( O
P O
< O
0.05 O
) O
increases O
in O
BMI O
, O
leptin B-outcome ['Physiological-Clinical']
( O
corrected O
for O
BMI O
) O
and O
the O
leptin B-outcome ['Physiological-Clinical']
: O
SHBG B-outcome ['Physiological-Clinical']
ratio O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Analysing O
response O
to O
[]

Atomoxetine O
alone O
or O
combined O
with O
fluoxetine O
for O
treating O
ADHD O
with O
comorbid O
depressive O
or O
anxiety O
symptoms O
. O
[]

In O
Stratum O
II O
, O
16 O
of O
29 O
( O
55 O
% O
) O
patients O
receiving O
CRT O
+ O
ITC O
experienced O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
: O
3 O
deaths O
during O
continuous O
complete O
remission O
( O
CCR O
) O
and O
13 O
relapses B-outcome ['Physiological-Clinical']
( O
2 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
+ O
testes O
, O
and O
2 O
testes O
) O
as O
compared O
with O
only O
5 O
relapses B-outcome ['Physiological-Clinical']
in O
20 O
( O
25 O
% O
) O
patients O
on O
CSpRT O
( O
1 O
CNS O
, O
1 O
CNS O
+ O
BM O
, O
1 O
BM O
, O
and O
2 O
testes O
) O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

IgG1 B-outcome ['Physiological-Clinical']
increased O
significantly O
in O
all O
active O
groups O
compared O
to O
placebo O
. O
['Physiological-Clinical']

Measures O
included O
the O
number O
and O
character B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
each I-outcome ['Physiological-Clinical']
stool I-outcome ['Physiological-Clinical']
and O
weekly O
24-h O
stool B-outcome ['Physiological-Clinical']
specimens I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
oocyst B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
the O
effect O
of O
pain-free O
treadmill O
training O
on O
changes O
of O
plasma O
fibrinogen O
, O
haematocrit O
, O
lipid O
profile O
, O
and O
walking O
ability O
in O
patients O
with O
claudication O
. O
[]

OBJECTIVES O
We O
hypothesized O
that O
the O
wakefulness O
promoter O
, O
modafinil O
, O
would O
ameliorate O
this O
decline O
. O
[]

BACKGROUND O
Persistent O
infection O
with O
Helicobacter O
pylori O
is O
associated O
with O
the O
recurrence O
of O
duodenal O
ulcer O
. O
[]

The O
median O
effect O
size O
in O
this O
trial O
was O
-0.015 O
( O
seizure O
rate O
increased O
by O
1.5 O
% O
in O
the O
phenytoin O
group O
) O
, O
95 O
% O
probability O
interval O
-0.127 O
to O
0.091 O
( O
12.7 O
% O
higher O
rate O
of O
posttraumatic B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
to O
a O
9.1 O
% O
lower O
rate O
of O
posttraumatic O
seizures O
with O
phenytoin O
) O
. O
['Physiological-Clinical']

Girls O
sunbathed O
and O
used O
sunbeds O
more O
than O
boys O
at O
all O
ages O
. O
[]

Publication O
date: O
2019/02/05 O
06:00 O
[medline] O
[]

AP-1 O
activation O
was O
quantified O
by O
phospho-c-Jun O
nuclear O
translocation O
( O
immunohistochemistry O
) O
on O
a O
biobank O
of O
aortic O
wall O
samples O
from O
organ O
donors O
. O
[]

METHODS O
AND O
MATERIALS O
Fifty O
patients O
were O
randomized O
to O
receive O
conventional O
radiotherapy O
( O
RT O
) O
( O
2-Gy O
fractions O
, O
5 O
days O
weekly O
, O
to O
a O
total O
of O
60-74 O
Gy O
, O
depending O
on O
the O
tumor O
localization O
and O
TNM O
classification O
) O
and O
carboplatin O
( O
90 O
mg/m O
( O
2 O
) O
infusion O
once O
per O
week O
before O
RT O
) O
. O
[]

Median O
time O
to O
progression B-outcome ['Physiological-Clinical']
was O
2.7 O
and O
4.1 O
months O
in O
the O
control O
and O
paclitaxel/cisplatin O
arm O
, O
respectively O
( O
P=.026 O
) O
. O
['Physiological-Clinical']

Diazepam O
and O
midazolam O
were O
rated O
as O
77 O
% O
and O
100 O
% O
successful B-outcome ['Physiological-Clinical']
, O
according O
to O
the O
overall O
behavior B-outcome ['Life-Impact']
evaluation O
criteria O
( O
P=.02 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Untreated O
controls O
at O
the O
2 O
intervals O
showed O
a O
mean O
decrease O
in O
sensitivity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
of O
3.6 O
degrees O
C O
and O
4.1 O
degrees O
C. O
Statistical O
analysis O
showed O
type O
of O
composite O
cement O
to O
be O
a O
significant O
factor O
. O
['Physiological-Clinical']

The O
re-enrollment B-outcome ['Life-Impact']
rate O
was O
3.3 O
% O
for O
the O
control O
group O
and O
28.2 O
% O
for O
the O
intervention O
group O
( O
p O
< O
.001 O
) O
. O
['Life-Impact']

The O
effective O
concentration B-outcome ['Life-Impact']
values O
for O
remifentanil O
TCI O
were O
determined O
using O
sequential O
method O
and O
probit O
analysis. O
[['Life-Impact']]

Treatment O
response O
was O
not O
correlated O
with O
age O
level O
of O
autistic O
behavior O
, O
or O
full-scale O
IQ O
. O
[]

The O
percentage O
of O
patients O
who O
quit B-outcome ['Life-Impact']
on-demand O
therapy O
in O
the O
two O
groups O
and O
the O
cost-effectiveness O
of O
the O
treatment O
were O
evaluated O
as O
primary O
end O
points O
. O
['Life-Impact', 'Resource-use']

The O
patients O
were O
divided O
into O
two O
groups O
. O
[]

Each O
patient O
received O
single O
oral O
doses O
of O
30 O
mg O
nicorandil O
, O
10 O
mg O
nifedipine O
, O
and O
, O
on O
2 O
days O
, O
a O
placebo O
. O
[]

Single-arm O
studies O
have O
suggested O
that O
a O
10-day O
schedule O
of O
decitabine O
cycles O
leads O
to O
better O
outcomes O
than O
the O
usual O
5-day O
schedule. O
[]

Primary O
variables O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS O
; O
stratum O
1 O
) O
and O
clinical O
benefit O
rate O
( O
CBR O
; O
stratum O
2 O
) O
. O
['Mortality']

Autonomic O
function O
was O
assessed O
by O
power O
spectral O
analysis O
and O
RR-variation O
during O
deep O
breathing O
[ O
i.e O
. O
[]

The O
factorial O
analysis O
showed O
that O
both O
1000 O
mg O
acetaminophen O
and O
60 O
mg O
codeine O
made O
a O
statistically O
significant O
( O
P O
less O
than O
0.05 O
) O
contribution O
to O
the O
analgesic B-outcome ['Resource-use']
effectiveness O
of O
the O
combination O
on O
all O
measures O
of O
efficacy O
( O
sum O
of O
pain B-outcome ['Physiological-Clinical']
intensity O
differences O
, O
largest O
pain B-outcome ['Physiological-Clinical']
intensity O
difference O
, O
total O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
, O
largest O
pain B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND: O
Various O
studies O
indicate O
the O
negative O
effects O
of O
menopausal O
symptoms O
and O
complications O
on O
the O
quality O
of O
life O
(QOL) O
of O
women. O
[]

A O
randomized O
, O
prospective O
trial O
of O
adjuvant O
chemotherapy O
in O
adults O
with O
soft O
tissue O
sarcomas O
of O
the O
head O
and O
neck O
, O
breast O
, O
and O
trunk O
. O
[]

Complication B-outcome ['Resource-use']
rates O
were O
similar O
for O
the O
two O
groups O
. O
['Resource-use']

The O
cold O
stress O
resulted O
in O
a O
significant O
increase O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
the O
rate O
pressure O
product O
without O
a O
change O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
It O
can O
be O
suggested O
that O
0.6 O
and O
0.8 O
ml O
of O
4 O
% O
Ar O
+ O
1:100,000 O
Ep O
, O
delivered O
by O
CCLADS O
, O
offer O
high O
success O
rate O
and O
effective O
clinical O
parameters O
of O
ISA O
as O
a O
primary O
anesthesia O
. O
[]

Journal O
ID: O
2985248R O
[]

In O
comparison O
to O
WL O
, O
IT O
parents O
reported O
increases O
in O
children O
's O
total O
and O
personal B-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
, O
and O
reduced O
involvement O
in O
their O
children O
's O
private B-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
routines I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Febrile B-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
rate O
was O
higher O
in O
the O
VNR/CDDP O
arm O
( O
p=0.02 O
) O
as O
well O
as O
G3-4 O
anemia B-outcome ['Physiological-Clinical']
( O
p=0.005 O
) O
and O
G-CSF/EPO O
use O
( O
p=0.019 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
the O
drugs O
were O
given O
individually O
, O
mecamylamine O
decreased O
beta B-outcome ['Physiological-Clinical']
power I-outcome ['Physiological-Clinical']
and O
nicotine O
gum O
( O
4 O
and O
8 O
mg O
) O
increased O
alpha B-outcome ['Physiological-Clinical']
frequency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Children O
wore O
an O
actigraphy O
device O
to O
record O
baseline O
sleep B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
with O
the O
primary O
outcome O
variable O
being O
change O
in O
sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
patients O
were O
randomized O
to O
receive O
nebivolol O
5 O
mg O
( O
30 O
patients O
; O
21 O
women O
, O
9 O
men O
; O
mean O
age O
48.4 O
? O
[]

Breakdown O
of O
disease B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
was O
7.8 O
% O
stage O
III O
, O
22.8 O
% O
stage O
IV O
, O
and O
69.4 O
% O
recurrent O
disease O
. O
['Physiological-Clinical']

Patients O
were O
assessed O
at O
baseline O
and O
after O
2 O
, O
4 O
, O
6 O
and O
8 O
weeks O
after O
starting O
medication O
. O
[]

Mean O
values O
were O
calculated O
for O
groups O
of O
volunteers O
at O
each O
sampling O
time O
according O
to O
country O
, O
sex O
, O
and O
supplementation O
( O
between O
9 O
and O
24 O
individual O
samples O
contributing O
to O
each O
mean O
) O
. O
[]

Following O
randomization O
and O
prior O
to O
any O
intervention O
, O
baseline O
discomfort B-outcome ['Physiological-Clinical']
scores O
were O
obtained O
by O
means O
of O
a O
verbally O
administered O
, O
horizontal O
, O
100-mm O
, O
unnumbered O
analog O
discomfort O
scale O
. O
['Physiological-Clinical']

BACKGROUND O
Beyond O
lipid O
lowering O
, O
various O
antiinflammatory O
properties O
have O
been O
ascribed O
to O
statins O
. O
[]

No O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
test O
beverage O
ingestion O
were O
observed. O
[['Adverse-effects']]

In O
addition O
, O
the O
BOP B-outcome ['Physiological-Clinical']
percentage I-outcome ['Physiological-Clinical']
was O
determined O
10 O
days O
following O
baseline O
. O
['Physiological-Clinical']

Patients O
received O
a O
cumulative O
loading O
dose O
of O
0 O
, O
8 O
, O
or O
24 O
mg O
of O
sirolimus O
2 O
days O
before O
and O
the O
day O
of O
repeat O
intervention O
followed O
by O
maintenance O
therapy O
of O
2 O
mg/d O
for O
7 O
days O
. O
[]

Peri-implant O
mucosal O
stability O
was O
generally O
observed. O
[]

Overall, O
the O
study O
demonstrated O
the O
acceptability B-outcome ['Life-Impact']
of O
an O
adapted O
version O
of O
the O
WHO O
Moments O
for O
Hand O
Hygiene O
poster O
in O
the O
introduction O
of O
an O
intervention O
in O
the O
community. O
[['Life-Impact']]

Craving B-outcome ['Life-Impact']
( O
VAS O
; O
OCDS O
) O
, O
withdrawal B-outcome ['Life-Impact']
( O
CIWA-Ar O
) O
and O
psychiatric B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
SCL-90-R O
) O
rating O
scales O
were O
applied O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Analysis O
by O
stage O
showed O
no O
significant O
benefit O
of O
ASI O
in O
stage O
III O
disease O
. O
[]

Results O
were O
similar O
for O
pedometer O
measured O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
, O
with O
a O
significant O
overall O
increase O
in O
steps/day O
from O
baseline O
to O
follow-up O
, O
but O
no O
between O
arm O
difference O
in O
change O
. O
['Life-Impact', 'Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

POPULATION O
A O
total O
of O
9025 O
women O
were O
screened O
in O
early O
pregnancy O
. O
[]

CONCLUSIONS O
Data O
from O
this O
pilot O
investigation O
support O
the O
potential O
usefulness O
of O
NAC O
for O
treating O
irritability O
in O
children O
with O
autistic O
disorder O
. O
[]

Effects O
of O
two O
combined O
oral O
contraceptives O
containing O
ethinyl O
estradiol O
20 O
microg O
combined O
with O
either O
drospirenone O
or O
desogestrel O
on O
lipids O
, O
hemostatic O
parameters O
and O
carbohydrate O
metabolism O
. O
[]

The O
hippocampal O
component O
contributes O
by O
recalling O
studied O
details O
. O
[]

Sixty O
healthy O
women O
, O
half O
of O
whom O
had O
been O
using O
OCs O
for O
at O
least O
the O
previous O
6 O
months O
, O
participated O
in O
the O
study O
. O
[]

However O
, O
chronic O
use O
of O
corticosteroids O
is O
associated O
with O
side-effects O
such O
as O
skin O
atrophy O
and O
telangiectasia O
. O
[]

The O
increased O
screening-coverage O
rate O
in O
the O
intervention O
zone O
was O
similar O
to O
that O
of O
the O
control O
zone O
( O
43.6 O
vs. O
34.9 O
% O
, O
p=0.119 O
) O
; O
however O
, O
there O
was O
a O
borderline O
significant O
increase O
in O
the O
intervention O
zone O
compared O
with O
baseline O
( O
36.7 O
to O
43.6 O
% O
, O
p=0.070 O
) O
. O
[]

Questionnaires O
evaluating O
the O
likelihood O
of O
recommending O
TKR O
, O
perceived O
medical O
cooperativeness O
, O
and O
measures O
of O
implicit O
racial O
bias O
were O
administered O
. O
[]

The O
performance O
of O
an O
adaptive O
automation O
system O
was O
evaluated O
using O
a O
cognitive O
vigilance O
task O
. O
[]

NWB O
exercise O
alone O
may O
be O
sufficient O
enough O
to O
improve O
function B-outcome ['Life-Impact']
and O
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Evaluation O
of O
a O
novel O
technique O
for O
wound O
closure O
using O
a O
barbed O
suture O
. O
[]

PURPOSE O
To O
evaluate O
the O
effects O
of O
gaseous O
ozone O
application O
on O
enamel O
and O
dentin O
bond O
strength O
produced O
by O
two O
self-etching O
adhesive O
systems O
. O
[]

Twenty O
healthy O
women O
with O
a O
mean O
age O
of O
30 O
years O
were O
operated O
on O
for O
breast O
augmentation O
. O
[]

For O
both O
cohorts O
, O
quarterly O
calls O
over O
3 O
years O
were O
used O
to O
collect O
self-reported O
occupational O
injury O
and O
illness O
information O
, O
including O
costs O
to O
the O
farmers O
and O
their O
insurers O
. O
[]

The O
restenosis O
rate O
obtained O
from O
the O
vessel O
segment O
inclusive O
of O
the O
dose O
fall-off O
zones O
was O
the O
best O
correlate O
of O
TVR O
and O
should O
become O
a O
standard O
analysis O
site O
in O
all O
vascular O
brachytherapy O
trials O
. O
[]

Several O
recent O
studies O
have O
described O
the O
benefits O
of O
fenfluramine O
for O
the O
symptomatic O
treatment O
of O
infantile O
autism O
. O
[]

CONCLUSION O
Paliperidone O
extended-release O
tablets O
are O
effective O
to O
improve O
social O
functions O
and O
psychiatric O
symptoms O
of O
schizophrenics O
. O
[]

The O
four-hour B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
acetaminophen I-outcome ['Physiological-Clinical']
level O
was O
significantly O
lower O
for O
phase O
II O
than O
phase O
I O
( O
P O
< O
.05 O
, O
two-tailed O
paired O
t-test O
) O
. O
['Physiological-Clinical']

Parent O
satisfaction O
in O
a O
multi-site O
acute O
trial O
of O
risperidone O
in O
children O
with O
autism O
: O
a O
social O
validity O
study O
. O
[]

By O
week O
8, O
HP/TAZ O
lotion O
achieved O
a O
63.5% O
reduction O
in O
mean O
IGAxBSA O
composite O
score O
(P<0.001 O
versus O
TAZ O
and O
vehicle), O
that O
was O
sustained O
four O
weeks O
posttreatment O
(P<0.001 O
versus O
TAZ O
and O
vehicle O
and O
P=0.003 O
versus O
HP). O
[]

The O
management O
of O
dermoid O
cysts O
-- O
a O
comparative O
study O
of O
laparoscopy O
and O
laparotomy O
. O
[]

Speech B-outcome ['Life-Impact']
Alone I-outcome ['Life-Impact']
, O
Simultaneous O
Presentation O
, O
and O
Alternating B-outcome ['Life-Impact']
Presentation I-outcome ['Life-Impact']
condition I-outcome ['Life-Impact']
facilitated O
more O
child-initiated O
speech O
during O
treatment O
than O
did O
the O
Sign O
Alone O
condition O
. O
['Life-Impact', 'Life-Impact']

Prognostic O
value O
of O
postoperative O
CEA O
clearance O
in O
rectal O
cancer O
patients O
with O
high O
preoperative O
CEA O
levels O
. O
[]

A O
cluster O
randomised O
trial O
to O
evaluate O
a O
physical O
activity O
intervention O
among O
3-5 O
year O
old O
children O
attending O
long O
day O
care O
services O
: O
study O
protocol O
. O
[]

We O
have O
assessed O
whether O
it O
is O
possible O
to O
derive O
clinically O
useful O
information O
about O
total O
hip O
bone O
mineral O
density O
( O
BMD O
) O
from O
measurements O
at O
other O
hip O
sites O
. O
[]

Adjusting O
for O
baseline O
and O
age O
, O
the O
peroxide O
strip O
group O
had O
-2.45 O
Deltab* O
, O
2.39 O
DeltaL* O
, O
and O
-0.96 O
Deltaa* O
at O
Week O
2 O
. O
[]

Complete B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
controlling O
for O
hepatitis O
C O
virus O
was O
similar O
( O
relative O
risk=1.19 O
; O
95 O
% O
confidence O
interval=0.89-1.60 O
) O
. O
['Physiological-Clinical']

In O
particular O
, O
the O
clinical O
results O
of O
endotoxin O
removal O
with O
polymyxin O
B O
immobilized O
fiber O
are O
summarized O
in O
this O
article O
. O
[]

These O
results O
show O
that O
the O
amla O
extract O
used O
in O
the O
study O
is O
potentially O
a O
hypoglycaemic O
as O
well. O
[]

In O
a O
prospective O
, O
controlled O
, O
randomized O
, O
multicenter O
study O
the O
immunogenicity O
of O
a O
single O
( O
day O
0 O
) O
and O
two O
( O
day O
0 O
, O
28 O
) O
booster O
vaccination O
against O
diphtheria O
were O
compared O
in O
subjects O
who O
had O
received O
their O
last O
diphtheria O
vaccination O
more O
than O
10 O
years O
ago O
. O
[]

In O
a O
series O
of O
studies O
, O
the O
safety O
and O
efficacy O
of O
terazosin O
, O
alone O
and O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
were O
evaluated O
in O
1180 O
black O
patients O
with O
mild O
to O
moderate O
essential O
hypertension O
. O
[]

All O
participants O
received O
either O
placebo O
or O
caffeine O
( O
200 O
mg O
) O
, O
while O
the O
chewing O
condition O
also O
chewed O
on O
a O
tasteless O
and O
odorless O
substance O
for O
15 O
min O
each O
hour O
. O
[]

In O
addition O
, O
four O
cases O
describing O
unusual O
effects O
found O
in O
a O
sample O
of O
170 O
patients O
treated O
with O
fenfluramine O
are O
also O
reported O
. O
[]

RESULTS O
Prior O
AIDS O
diagnosis O
, O
low O
Karnofsky O
score O
, O
active O
unstable O
AIDS-related O
conditions O
, O
absence O
of O
antiretroviral O
therapy O
and O
absence O
of O
Pneumocystis O
carinii O
pneumonia O
prophylaxis O
were O
associated O
with O
shorter O
survival B-outcome ['Mortality']
by O
univariate O
regression O
using O
the O
proportional O
hazards O
model O
. O
['Mortality']

7.89 O
vs O
0.81 O
? O
[]

Physiological O
dose O
( O
< O
1 O
mg O
) O
of O
folic O
acid O
both O
in O
healthy O
and O
60 O
epileptic O
women O
, O
all O
without O
any O
autoimmune O
disease O
, O
did O
not O
increase O
the O
risk O
for O
epileptic B-outcome ['Physiological-Clinical']
seizures I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
low O
and O
high O
doses O
of O
atorvastatin O
on O
arterial O
compliance O
. O
[]

Autism O
is O
heterogeneous O
with O
respect O
to O
clinical O
symptoms O
and O
etiology O
. O
[]

induction O
and O
VEGF O
expression O
and O
may O
serve O
as O
a O
potential O
agent O
in O
the O
prevention O
of O
telangiectasias O
. O
[]

BACKGROUND O
Allergen O
vaccination O
is O
effective O
in O
mite-allergic O
asthma O
. O
[]

Thirty-two O
healthy O
, O
opioid-naive O
adults O
were O
randomized O
to O
MS-sNT O
administered O
with O
240 O
mL O
of O
4 O
% O
, O
20 O
% O
, O
or O
40 O
% O
alcohol O
or O
water O
. O
[]

The O
primary O
end O
points O
were O
glycaemic B-outcome ['Physiological-Clinical']
response O
rate O
( O
responders O
being O
predefined O
as O
patients O
who O
achieve O
a O
decrease O
in O
HbA1c O
to O
less O
than O
8 O
% O
or O
a O
reduction O
by O
at O
least O
15 O
% O
as O
compared O
to O
the O
baseline O
values O
) O
and O
the O
daily B-outcome ['Life-Impact']
insulin I-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
at O
6 O
months O
. O
['Physiological-Clinical', 'Life-Impact']

The O
intervention O
had O
no O
additional O
effect O
among O
children O
aged O
3 O
to O
< O
24 O
months O
but O
was O
responsible O
for O
a O
4.2 O
% O
decrease O
among O
those O
aged O
24 O
to O
< O
48 O
months O
and O
a O
6.7 O
% O
decrease O
among O
those O
aged O
48 O
to O
< O
72 O
months O
. O
[]

During O
treatment O
either O
with O
placebo O
or O
oxitropium O
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
clinical B-outcome ['Physiological-Clinical']
scores O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Long-term O
followup O
was O
assessed O
in O
551 O
participants O
enrolled O
in O
a O
prospective O
, O
randomized O
study O
of O
fluorescence O
cystoscopy O
for O
Ta O
or O
T1 O
urothelial O
bladder O
cancer O
. O
[]

APO-A1 B-outcome ['Physiological-Clinical']
showed O
a O
4 O
% O
increase O
, O
while O
APO-B O
showed O
a O
3 O
% O
reduction O
. O
['Physiological-Clinical']

7.87 O
, O
p O
= O
0.003 O
. O
[]

Lanthanum O
carbonate O
( O
Fosrenol O
) O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
in O
the O
treatment O
of O
hyperphosphatemic O
patients O
with O
end-stage O
renal O
disease O
. O
['Life-Impact']

The O
advantage O
for O
women O
receiving O
CMFVP O
was O
seen O
for O
all O
subsets O
regardless O
of O
menopausal O
status O
except O
among O
women O
who O
were O
premenopausal O
and O
had O
1-3 O
positive O
nodes O
. O
[]

Before O
operation O
( O
T O
( O
1 O
) O
) O
, O
10 O
min O
after O
recovery O
of O
two-lung O
ventilation O
( O
T O
( O
2 O
) O
) O
, O
and O
24 O
h O
( O
T O
( O
3 O
) O
) O
and O
48 O
h O
( O
T O
( O
4 O
) O
) O
after O
operation O
, O
the O
venous O
blood O
sample O
was O
taken O
from O
the O
internal O
jugular O
vein O
and O
the O
plasma O
was O
separated O
and O
stored O
at O
-70 O
degrees O
C O
for O
later O
analysis O
of O
IL-6 O
and O
IL-8 O
with O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O
[]

However O
, O
the O
pattern O
of O
modulation O
during O
arm O
swing O
was O
not O
exactly O
the O
same O
as O
that O
during O
walking O
. O
[]

Effect O
of O
low-intensity O
back O
exercise O
on O
quality O
of O
life O
and O
back B-outcome ['Physiological-Clinical']
extensor I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
in O
patients O
with O
osteoporosis O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

This O
stereotype O
threat O
may O
be O
lessened O
by O
a O
values-affirmation O
intervention O
. O
[]

Title: O
Comparison O
Of O
Simultaneous O
Versus O
Delayed O
Ventriculoperitoneal O
Shunting O
In O
Patients O
Undergoing O
Meningocoele O
Repair O
In O
Terms O
Of O
Infection B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

The O
percentage O
of O
patients O
who O
had O
a O
recurrence B-outcome ['Physiological-Clinical']
of O
TTP O
at O
any O
time O
during O
the O
trial O
was O
67% O
lower O
with O
caplacizumab O
than O
with O
placebo O
(12% O
vs. O
38%, O
P<0.001). O
[['Physiological-Clinical']]

Twenty O
four-hour O
urine O
samples O
were O
collected O
for O
6-beta-hydroxycortisol O
measurements O
, O
before O
and O
after O
14 O
days O
of O
ticlopidine O
. O
[]

Based O
on O
per O
protocol O
repeated O
measures O
analysis O
, O
data O
for O
26 O
diet O
children O
and O
29 O
controls O
were O
available O
at O
12 O
months O
. O
[]

METHODS: O
This O
trial O
was O
a O
multicenter O
(6 O
centers: O
2 O
teaching O
hospitals, O
4 O
specialist O
orthodontic O
practices), O
single-blinded, O
randomized O
controlled O
trial O
with O
2 O
parallel O
groups. O
[]

Risperidone-treated O
subjects O
also O
exhibited O
significantly O
greater O
decreases O
on O
the O
other O
4 O
subscales O
of O
the O
ABC O
; O
on O
the O
conduct O
problem O
, O
insecure/anxious B-outcome ['Life-Impact']
, O
hyperactive B-outcome ['Life-Impact']
, O
and O
overly B-outcome ['Life-Impact']
sensitive I-outcome ['Life-Impact']
subscales O
of O
the O
Nisonger O
Child O
Behavior O
Rating O
Form O
( O
parent O
version O
) O
; O
and O
on O
the O
Visual O
Analog O
Scale O
of O
the O
most O
troublesome O
symptom O
. O
['Life-Impact']

CONCLUSION: O
Our O
study O
indicates O
that O
mitochondrial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
could O
be O
the O
hallmark O
of O
tubular O
injury O
in O
DKD O
patients, O
and O
this O
would O
provide O
a O
novel O
and O
attractive O
therapeutic O
target O
to O
improve O
this O
disease. O
[['Physiological-Clinical']]

Research O
shows O
that O
depression O
and O
anxiety O
disorders O
are O
the O
most O
common O
psychiatric O
concern O
in O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

Paraesthesia O
during O
regional O
anaesthesia O
is O
an O
unpleasant O
sensation O
for O
patients O
and O
, O
more O
importantly O
, O
in O
some O
cases O
it O
is O
related O
to O
neurological O
injury O
. O
[]

At O
1 O
year O
, O
no O
differences O
in O
the O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
observed O
between O
the O
2 O
groups O
, O
and O
over O
2 O
years O
, O
the O
overall O
incidence O
of O
complications B-outcome ['Adverse-effects']
was O
the O
same O
, O
specifically O
fecaloma B-outcome ['Physiological-Clinical']
( O
P O
= O
0.003 O
) O
in O
the O
MM O
group O
and O
external B-outcome ['Physiological-Clinical']
hemorrhoidal I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
( O
P O
= O
0.006 O
) O
in O
the O
SH O
group O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Before O
and O
3 O
months O
after O
treatment O
, O
a O
nutritional O
and O
biochemical O
study O
was O
performed O
. O
[]

When O
the O
total O
experience O
is O
considered O
( O
clindamycin O
or O
cefoxitin O
with O
and O
without O
gentamicin O
) O
, O
20 O
of O
24 O
patients O
( O
83 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
clindamycin O
and O
18 O
of O
22 O
( O
82 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
cefoxitin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
little O
is O
known O
about O
how O
neuronal O
activity O
in O
visual O
cortex O
represents O
second-order B-outcome ['Physiological-Clinical']
modulations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

SHM O
is O
a O
safe O
and O
effective O
hemostatic B-outcome ['Physiological-Clinical']
agent O
in O
lumbar O
posterior O
surgery. O
[['Physiological-Clinical']]

This O
paper O
presents O
the O
rationale O
for O
a O
24-week O
, O
randomized O
trial O
designed O
to O
test O
whether O
risperidone O
plus O
structured O
parent O
training O
would O
be O
superior O
to O
risperidone O
only O
on O
measures O
of O
noncompliance B-outcome ['Life-Impact']
, O
irritability B-outcome ['Life-Impact']
and O
adaptive B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

CONCLUSIONS O
The O
action O
of O
the O
oscillating/rotating/pulsating O
toothbrushes O
( O
Oral-B O
ProfessionalCare O
7000 O
and O
Oral-B O
3D O
Excel O
) O
was O
more O
effective O
in O
plaque O
removal O
than O
the O
high-frequency O
toothbrush O
( O
Sonicare O
Advance O
) O
. O
[]

Statistical O
differences O
was O
found O
in O
the O
accuracy O
of O
preoperative B-outcome ['Physiological-Clinical']
N I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
TNM I-outcome ['Physiological-Clinical']
staging I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
( O
P O
= O
0.009 O
and O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical']

Vaccination O
of O
close O
household O
contacts O
is O
recommended O
to O
provide O
indirect O
protection O
to O
children O
< O
6 O
months O
of O
age O
. O
[]

All O
failed B-outcome ['Life-Impact']
insertions I-outcome ['Life-Impact']
with O
the O
introducer O
tool O
technique O
were O
successful O
with O
the O
bougie-guided O
technique O
. O
['Life-Impact']

The O
effects O
of O
L-carnitine O
on O
cardiac O
performance O
after O
open O
heart O
surgery O
were O
evaluated O
in O
a O
balanced O
, O
placebo-controlled O
, O
double-blind O
study O
in O
38 O
patients O
. O
[]

METHODS O
This O
was O
a O
6-week O
, O
double-masked O
, O
randomised O
multi-centre O
study O
. O
[]

When O
combined O
treatment O
is O
considered O
, O
seizure B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
achieved O
in O
17 O
( O
57 O
percent O
) O
of O
the O
neonates O
assigned O
to O
receive O
phenobarbital O
first O
and O
18 O
( O
62 O
percent O
) O
of O
those O
assigned O
to O
receive O
phenytoin O
first O
( O
P=0.67 O
) O
. O
['Physiological-Clinical']

Histological O
diagnosis O
by O
biopsy O
. O
[]

Heparin O
therapy O
in O
venous O
thromboembolism O
. O
[]

METHODS O
Forty-eight O
nurses O
with O
critical O
care O
experience O
volunteered O
to O
take O
part O
in O
this O
randomized O
, O
blinded O
, O
controlled O
study O
conducted O
in O
the O
simulation O
centre O
of O
an O
urban O
hospital O
. O
[]

The O
primary O
endpoint O
was O
pathological B-outcome ['Physiological-Clinical']
complete I-outcome ['Physiological-Clinical']
response O
( O
pCR O
) O
. O
['Physiological-Clinical']

Title: O
The O
effect O
of O
progressive O
muscle O
relaxation O
on O
cancer O
patients' O
self-efficacy B-outcome ['Life-Impact']
. O
[['Life-Impact']]

These O
hemodynamic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hormonal I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
beta-endorphin O
in O
hypertensive O
patients O
were O
significantly O
( O
P O
< O
0.0001 O
) O
greater O
than O
in O
controls O
but O
were O
annulled O
in O
all O
individuals O
when O
naloxone O
preceded O
beta-endorphin O
infusion O
. O
['Physiological-Clinical']

There O
have O
been O
impressive O
advances O
in O
endoscopic O
procedures O
during O
recent O
years O
, O
and O
there O
is O
an O
emerging O
trend O
that O
the O
number O
of O
procedures O
is O
increasing O
in O
parallel O
with O
these O
. O
[]

The O
type O
of O
deep O
vein O
thrombosis O
prophylaxis O
in O
this O
group O
was O
based O
on O
surgeon O
preference O
. O
[]

Based O
on O
these O
criteria O
, O
nephrotoxicity B-outcome ['Physiological-Clinical']
was O
seen O
in O
2/27 O
( O
7.4 O
% O
) O
patients O
treated O
with O
G-C O
and O
in O
3/19 O
( O
15.8 O
% O
) O
patients O
treated O
with O
N-C. O
Ototoxicity B-outcome ['Physiological-Clinical']
was O
defined O
as O
a O
greater O
than O
20 O
dB O
loss O
at O
any O
frequency O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:Medicine O
[]

RESULTS O
Mean O
ribavirin B-outcome ['Resource-use']
exposure I-outcome ['Resource-use']
in O
week O
0-12 O
was O
70 O
% O
and O
96 O
% O
in O
patients O
assigned O
to O
ribavirin O
800 O
and O
1000/1200 O
mg/day O
, O
respectively O
. O
['Resource-use']

Plasmapheresis O
and O
chemotherapy O
lowered O
the O
serum B-outcome ['Physiological-Clinical']
myeloma O
protein O
value O
much O
more O
rapidly O
than O
chemotherapy O
alone O
. O
['Physiological-Clinical']

subcutaneously O
( O
n O
= O
103 O
) O
. O
[]

BACKGROUND O
Amlodipine O
besylate O
has O
been O
used O
in O
Korea O
for O
the O
treatment O
of O
hypertension O
for O
> O
17 O
years O
, O
with O
well-established O
efficacy O
and O
tolerability O
. O
[]

Parents O
in O
the O
COMB O
group O
( O
n O
= O
75 O
; O
60.5 O
% O
) O
received O
a O
mean O
of O
10.9 O
PT O
sessions O
. O
[]

CONCLUSION O
Risperidone O
given O
to O
children O
with O
autism O
at O
doses O
up O
to O
3.5 O
mg O
for O
up O
to O
8 O
weeks O
appears O
to O
have O
no O
detrimental O
effect O
on O
cognitive B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

RESULTS O
The O
ESDM O
group O
exhibited O
greater O
improvements O
in O
autism B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

Results O
of O
laboratory O
and O
clinical O
analysis O
indicate O
that O
mechanism O
of O
remaxol O
action O
is O
based O
on O
hepatoprotective B-outcome ['Physiological-Clinical']
, O
antioxidative B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Factors O
significantly O
associated O
with O
longer O
TTF B-outcome ['Life-Impact']
and O
longer O
survival B-outcome ['Mortality']
were O
as O
follows O
: O
one O
or O
two O
organs O
with O
metastases O
( O
TTF O
, O
P O
less O
than O
0.0001 O
; O
survival O
, O
P O
less O
than O
0.0001 O
) O
; O
dominant O
site O
other O
than O
soft O
tissue O
( O
TTF O
, O
P O
less O
than O
0.0001 O
; O
survival O
, O
P O
= O
0.05 O
) O
; O
and O
an O
initial O
good O
performance O
status O
( O
TTF O
, O
P O
= O
0.007 O
; O
survival O
, O
P O
= O
0.02 O
) O
. O
['Life-Impact', 'Mortality']

Implementation O
barriers O
could O
limit O
the O
utility O
of O
this O
approach O
in O
usual O
care O
settings O
. O
[]

CONCLUSIONS O
In O
the O
treatment O
of O
uncomplicated B-outcome ['Physiological-Clinical']
gonorrhea I-outcome ['Physiological-Clinical']
, O
a O
single O
dose O
of O
cefixime O
( O
400 O
or O
800 O
mg O
) O
given O
orally O
appears O
to O
be O
as O
effective O
as O
the O
currently O
recommended O
regimen O
of O
ceftriaxone O
( O
250 O
mg O
given O
intramuscularly O
) O
. O
['Physiological-Clinical']

Permissive O
hypercapnia O
resulted O
in O
significant O
decreases O
in O
systemic O
vascular O
resistance O
( O
SVR O
) O
and O
increases O
in O
cardiac O
output O
( O
Q O
) O
. O
[]

PMID: O
31613945 O
[]

Effects O
of O
nootropic O
therapy O
in O
age-associated O
memory O
impairment O
. O
[]

Since O
GABAA-mediated O
intracortical O
inhibition O
has O
been O
shown O
to O
underlie O
plastic O
changes O
throughout O
the O
lifespan O
from O
development O
to O
aging O
, O
here O
, O
the O
aging O
motor O
system O
was O
used O
as O
a O
model O
to O
analyze O
the O
interdependence O
of O
plastic O
alterations O
within O
the O
inhibitory O
motorcortical O
network O
and O
level O
of O
behavioral O
performance O
. O
[]

We O
expected O
to O
find O
post-TMS O
differences O
in O
amplitude O
and O
latency O
of O
early O
and O
late O
ERP O
components O
. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
15 O
patients O
with O
dipyridamole O
and O
in O
12 O
with O
placebo O
( O
7.6 O
% O
vs O
6.0 O
, O
P=0.52 O
) O
. O
['Adverse-effects']

The O
sample O
size O
was O
22 O
. O
[]

This O
randomization O
process O
provided O
a O
suitable O
opportunity O
to O
compare O
the O
effects O
of O
these O
two O
administered O
steroid O
on O
surrogate O
markers O
of O
adipocyte O
activity O
( O
leptin O
) O
and O
hyperinsulinaemia/insulin O
resistance O
( O
SHBG O
) O
. O
[]

Seventy-eight O
women O
were O
randomized O
to O
receive O
45 O
mg O
of O
hyperbaric O
1.5 O
% O
lidocaine O
with O
or O
without O
10 O
microg O
of O
fentanyl O
. O
[]

In O
this O
pilot O
study O
, O
we O
tested O
the O
effects O
of O
a O
novel O
intervention O
( O
JASPER O
, O
Joint O
Attention O
Symbolic O
Play O
Engagement O
and O
Regulation O
) O
on O
3 O
to O
5 O
year O
old O
, O
minimally O
verbal O
children O
with O
autism O
who O
were O
attending O
a O
non-public O
preschool O
. O
[]

The O
primary O
end O
point O
was O
the O
subject O
's O
global O
assessment O
of O
therapy O
( O
SGAT O
; O
0-10 O
scale O
; O
0 O
= O
no O
response O
, O
10 O
= O
excellent O
response O
) O
. O
[]

Eighty-three O
patients O
with O
small O
cell O
lung O
cancer O
were O
randomized O
with O
or O
without O
using O
a O
traditional O
Chinese O
Kidney-tonifying O
decoction O
( O
Liu O
Wei O
Di O
Huang O
or O
Jin O
Gui O
Shen O
Qi O
medicinal O
decoction O
) O
in O
chemotherapy O
or O
radiotherapy O
courses O
. O
[]

Patients O
were O
randomly O
assigned O
to O
begin O
with O
gabapentin O
( O
1200 O
mg O
daily O
) O
or O
vigabatrin O
( O
2000 O
mg O
daily O
) O
. O
[]

During O
two O
10-day O
treatment O
periods O
separated O
by O
a O
14-day O
washout O
period O
, O
23 O
healthy O
male O
volunteers O
received O
once-daily O
clopidogrel O
75 O
mg O
plus O
acetylsalicylic O
acid O
75 O
mg O
, O
or O
twice-daily O
extended-release O
dipyridamole O
200 O
mg O
plus O
acetylsalicylic O
acid O
25 O
mg O
. O
[]

The O
median O
duration O
of O
response O
was O
9?7 O
months O
for O
PUVA O
vs. O
5?8 O
months O
for O
the O
combination O
arm O
( O
P O
= O
0?33 O
) O
. O
[]

CI-AKI O
occurred O
in O
131 O
patients O
( O
13.3 O
% O
) O
. O
[]

Patients O
, O
who O
were O
on O
stable O
antipsychotic O
treatment O
, O
were O
randomly O
assigned O
to O
the O
active O
or O
sham O
condition O
. O
[]

2-Chloroprocaine O
antagonism O
of O
epidural O
morphine O
analgesia O
. O
[]

Future O
studies O
need O
to O
examine O
the O
long-term O
effects O
of O
these O
early O
interventions O
on O
children O
's O
development O
. O
[]

kg O
( O
-1 O
) O
? O
[]

Both O
groups O
were O
treated O
at O
the O
clinic O
twice O
weekly O
for O
4 O
weeks O
. O
[]

OBJECTIVE O
To O
examine O
the O
adhesion B-outcome ['Physiological-Clinical']
prevention I-outcome ['Physiological-Clinical']
effects O
of O
2 O
types O
of O
fibrin O
sealant O
after O
laparoscopic O
myomectomy O
( O
LM O
) O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
in O
the O
logarithm O
of O
the O
[]

METHODS: O
This O
prospective, O
interventional, O
randomized O
clinical O
study O
was O
done O
at O
Alpha O
Vision O
Center, O
Zagazig, O
Egypt. O
[]

RESULTS O
The O
patients O
were O
assigned O
to O
two O
groups O
. O
[]

There O
were O
three O
responses O
among O
77 O
patients O
crossed O
over O
to O
mitoxantrone O
after O
initial O
treatment O
with O
doxorubicin O
. O
[]

RESULTS O
The O
mean O
( O
+/-SD O
) O
of O
reported O
fish O
meals O
per O
week O
was O
4.3 O
+/- O
0.4 O
, O
4.7 O
+/- O
1.1 O
and O
0.6 O
+/- O
0.4 O
in O
the O
groups O
, O
respectively O
. O
[]

No O
adverse O
effects O
were O
reported O
. O
[]

CONCLUSION O
Clinical O
progression O
of O
chronic O
hepatitis O
C O
and O
maintenance O
peginterferon O
therapy O
led O
to O
worsening O
of O
symptoms B-outcome ['Physiological-Clinical']
, O
HRQOL B-outcome ['Life-Impact']
and O
, O
in O
men O
, O
sexual B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
in O
a O
large O
patient O
cohort O
followed O
up O
over O
4 O
years O
( O
NCT00006164 O
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Patients O
were O
randomized O
into O
two O
groups O
( O
with O
and O
without O
CPRV O
) O
. O
[]

The O
study O
consisted O
of O
five O
treatment O
periods O
. O
[]

BACKGROUND O
Conventional O
advice O
on O
immediate O
treatment O
of O
honey-bee O
stings O
has O
emphasised O
that O
the O
sting O
should O
be O
scraped O
off O
, O
never O
pinched O
. O
[]

in O
health O
care O
settings O
devoted O
to O
cancer O
care O
is O
beginning O
to O
be O
recognised O
but O
their O
content O
, O
form O
and O
effectiveness O
need O
further O
investigation O
. O
[]

Median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
favored O
the O
high-dose O
paclitaxel O
( O
4.3 O
vs. O
6.4 O
months O
, O
P O
= O
0.044 O
) O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Goal B-outcome ['Life-Impact']
attainment I-outcome ['Life-Impact']
scaling I-outcome ['Life-Impact']
as O
an O
outcome O
measure O
in O
randomized O
controlled O
trials O
of O
psychosocial O
interventions O
in O
autism O
. O
['Life-Impact']

These O
favorable O
changes O
in O
hemorheological O
parameters O
improves O
myocardial B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
, O
lowers O
the O
strength B-outcome ['Physiological-Clinical']
and O
frequency O
of O
coronary B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
, O
retards O
postinfarction B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
, O
and O
increases O
the O
quality O
of O
life O
of O
patients O
with O
various O
CAD O
forms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Women O
in O
both O
enhanced O
intervention O
conditions O
reduced O
their O
sexual B-outcome ['Life-Impact']
and O
drug-taking B-outcome ['Life-Impact']
risks O
more O
than O
women O
in O
the O
standard O
intervention O
. O
['Life-Impact', 'Life-Impact']

Mutans B-outcome ['Physiological-Clinical']
streptococci I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
root I-outcome ['Physiological-Clinical']
surfaces I-outcome ['Physiological-Clinical']
were I-outcome ['Physiological-Clinical']
suppressed I-outcome ['Physiological-Clinical']
significantly O
( O
p O
less O
than O
0.05 O
) O
during O
the O
whole O
experimental O
period O
in O
the O
chlorhexidine O
varnish O
group O
, O
but O
not O
in O
the O
fluoride O
varnish O
group O
. O
['Physiological-Clinical']

Afterwards O
, O
8 O
transverse O
sections O
( O
1.5 O
mm O
) O
were O
cut O
from O
4 O
mm O
above O
the O
CEJ O
up O
to O
4 O
mm O
short O
of O
the O
root O
canal O
apex O
, O
comprising O
coronal O
and O
root O
canal O
dentin O
. O
[]

Pelvic O
lymphadenectomy O
for O
cervical O
carcinoma O
: O
laparotomy O
extraperitoneal O
, O
transperitoneal O
or O
laparoscopic O
approach O
? O
[]

BACKGROUND: O
Micronutrient O
deficiencies O
are O
common O
during O
pregnancy, O
especially O
in O
pregnant O
women O
from O
economically O
disadvantaged O
settings O
where O
diets O
with O
low O
content O
of O
minerals O
and O
vitamins O
are O
consumed. O
[]

On O
the O
day O
of O
the O
O O
( O
3 O
) O
exposure O
, O
supplemented O
subjects O
were O
found O
to O
have O
significantly O
increased O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
ascorbate I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
tocopherols I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
carotenoids I-outcome ['Physiological-Clinical']
as O
compared O
with O
those O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

They O
had O
normal O
psychiatric O
consultation O
and O
the O
Glombock O
Rast O
Sexual B-outcome ['Life-Impact']
Satisfactory I-outcome ['Life-Impact']
Test O
( O
GRISS O
) O
psychiatric O
test O
were O
in O
accordance O
with O
premature O
ejaculation O
. O
['Life-Impact']

Correlation O
of O
quantitative O
measures O
with O
the O
modified O
Ashworth O
scale O
in O
the O
assessment O
of O
plantar O
flexor O
spasticity O
in O
patients O
with O
traumatic O
brain O
injury O
. O
[]

Only O
21 O
% O
( O
5 O
) O
of O
the O
children O
used O
the O
continuous O
passive O
movement O
machine O
as O
recommended O
. O
[]

Effects O
of O
statins O
on O
progression O
of O
subclinical B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Participants O
( O
14-18 O
years O
old O
) O
were O
consecutive O
admissions O
to O
inpatient O
adolescent O
alcohol O
and O
drug O
treatment O
centers O
in O
San O
Diego O
that O
were O
abstinence O
focused O
and O
based O
on O
the O
12-step O
approach O
. O
[]

The O
mean O
treatment O
duration O
was O
10 O
and O
14 O
weeks O
, O
median O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
was O
27.2 O
and O
30.8 O
weeks O
, O
median O
survival O
time O
was O
44 O
and O
50.9 O
weeks O
, O
and O
PSA B-outcome ['Physiological-Clinical']
response O
rate O
was O
only O
24.6 O
and O
28.9 O
% O
in O
the O
EMP/VBL O
and O
EMP O
arms O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Other O
anticoagulation O
strategies O
, O
including O
no O
bridging O
therapy O
or O
intravenous O
heparin O
, O
need O
comparative O
evaluation O
in O
this O
unique O
patient O
population O
. O
[]

During O
the O
same O
follow-up O
period O
children O
in O
both O
groups O
exhibited O
comparable O
patterns O
of O
weight O
gain O
; O
1 O
y O
after O
the O
intervention O
the O
mean O
weight O
for O
age O
of O
children O
in O
both O
groups O
was O
76 O
% O
of O
the O
NCHS O
standard O
. O
[]

CONCLUSIONS O
Diuresis O
is O
a O
useful O
, O
inexpensive O
and O
safe O
adjunct O
to O
ESWL O
of O
ureteric O
stones O
. O
[]

Alloimmunization O
of O
recipients O
of O
random O
multiple-donor O
platelet O
concentrates O
( O
MD O
group O
) O
was O
compared O
to O
that O
of O
patients O
receiving O
random O
single-donor O
platelets O
( O
SD O
group O
) O
. O
[]

CONCLUSION O
A O
short O
, O
nurse-based O
educational O
intervention O
seems O
to O
be O
as O
efficacious O
as O
a O
longer O
multidisciplinary O
version O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
antihistamine O
activity O
of O
single O
oral O
doses O
of O
75 O
mg O
cinnarizine O
using O
75 O
mg O
diphenhydramine O
as O
control O
, O
both O
being O
compared O
to O
placebo O
. O
[]

Increased O
serum O
OPN O
concentrations O
occur O
in O
chronic O
myeloid O
leukemia O
, O
multiple O
myeloma O
, O
and O
acute O
myeloid O
leukemia O
( O
AML O
) O
. O
[]

Neither O
increase O
nor O
decrease O
was O
statistically O
significant O
. O
[]

The O
unconscious O
thought O
effect O
in O
clinical O
decision O
making O
: O
an O
example O
in O
diagnosis O
. O
[]

16.5 O
mm O
Hg O
, O
p O
< O
0.05 O
) O
and O
the O
citrulline O
( O
56.67 O
? O
[]

Before O
and O
after O
supplementation, O
we O
determined O
plasma O
fatty B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
concentrations, O
latencies O
of O
visually B-outcome ['Physiological-Clinical']
evoked I-outcome ['Physiological-Clinical']
potentials I-outcome ['Physiological-Clinical']
, O
fine B-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
gross B-outcome ['Life-Impact', 'Life-Impact']
motor I-outcome ['Life-Impact', 'Life-Impact']
behaviour E2-outcome ['Life-Impact', 'Life-Impact']
, O
and O
IQ B-outcome ['Life-Impact']
. O
Fatty O
acid O
desaturase O
genotypes O
were O
also O
determined. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact', 'Life-Impact'], ['Life-Impact']]

Global O
contour O
saliency O
and O
local O
colinear O
interactions O
. O
[]

The O
relationship O
between O
the O
improvement O
in O
VT O
and O
reduction O
in O
gradient O
of O
the O
Borg/VE B-outcome ['Physiological-Clinical']
slope I-outcome ['Physiological-Clinical']
was O
significant O
( O
r=.40 O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

MR O
imaging O
of O
pituitary O
region O
lesions O
with O
gadodiamide O
injection O
. O
[]

We O
previously O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
conducted O
from O
2000 O
to O
2003 O
of O
palifermin O
, O
a O
recombinant O
human O
keratinocyte O
growth O
factor O
, O
dosed O
from O
240 O
microg/kg O
to O
720 O
microg/kg O
, O
in O
100 O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
HCT O
) O
recipients O
. O
[]

Findings O
suggest O
the O
potential O
of O
earlier O
intervention O
and O
further O
evaluation O
of O
oxytocin O
nasal O
spray O
as O
a O
treatment O
to O
improve O
social O
communication O
and O
interaction O
in O
young O
people O
with O
autism O
spectrum O
disorders O
. O
[]

The O
amount O
of O
gastric B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
Group O
100 O
than O
in O
Group O
50 O
( O
P O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
effects O
of O
potassium O
and O
calcium O
supplementation O
in O
table O
salt O
on O
reduction O
of O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
sodium B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
adolescents O
with O
higher O
blood O
pressure O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
suggests O
that O
young O
children O
with O
high O
functioning O
ASD O
may O
benefit O
from O
CBT O
to O
improve O
regulation O
of O
anger B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
, O
and O
parent O
training O
may O
improve O
parental B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Following O
cessation O
of O
raloxifene O
( O
group O
2 O
) O
, O
bone B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
returned O
to O
baseline O
levels O
( O
by O
120 O
weeks O
) O
. O
['Physiological-Clinical']

RESULTS O
Although O
given O
at O
half O
the O
recommended O
daily O
dosage O
, O
ticlopidine O
significantly O
reduced O
platelet B-outcome ['Physiological-Clinical']
aggregation O
. O
['Physiological-Clinical']

They O
also O
demonstrate O
that O
oral O
PPS O
is O
beneficial O
to O
microvascular O
sickle O
cell O
blood O
flow O
and O
has O
potential O
as O
an O
efficacious O
agent O
for O
long-term O
prophylactic O
therapy O
of O
SCD O
. O
[]

Publication O
date: O
2019/02/07 O
06:00 O
[entrez] O
[]

The O
primary O
outcome O
was O
defined O
as O
the O
number O
of O
patients O
with O
a O
modified O
Rankin O
score O
[]

During O
phase O
1 O
, O
egg B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
decreased O
linearly O
( O
P O
< O
0.05 O
) O
and O
feed B-outcome ['Life-Impact']
conversion I-outcome ['Life-Impact']
ratio O
( O
FCR O
) O
tended O
to O
increase O
linearly O
( O
P O
= O
0.057 O
) O
with O
increasing O
choline O
level O
in O
the O
diet O
. O
['Physiological-Clinical', 'Life-Impact']

RESULTS O
After O
96 O
weeks O
, O
the O
mean O
percent O
change O
from O
baseline O
in O
total O
BMD B-outcome ['Physiological-Clinical']
was O
-2.5 O
% O
( O
LPV/r O
) O
and O
-2.3 O
% O
( O
EFV O
) O
( O
P O
< O
0.01 O
for O
within-group O
changes O
in O
either O
arm O
; O
P O
= O
0.86 O
for O
between-group O
differences O
) O
. O
['Physiological-Clinical']

METHODS O
Women O
who O
were O
at O
least O
5 O
years O
postmenopausal O
were O
invited O
to O
participate O
in O
the O
study O
. O
[]

This O
effect O
may O
not O
be O
dose O
related O
within O
the O
studied O
range. O
[]

Direct O
evidence O
for O
spinal O
cord O
involvement O
in O
placebo O
analgesia O
. O
[]

At O
follow-up O
, O
39 O
% O
of O
conservative O
management O
patients O
requested O
surgery O
, O
and O
interference O
of O
symptoms B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
immediate O
effectiveness O
of O
2 O
counterforce O
orthoses O
in O
improving O
the O
sensorimotor B-outcome ['Physiological-Clinical']
abilities O
of O
the O
hand O
in O
patients O
with O
lateral O
elbow O
tendinopathy. O
[['Physiological-Clinical']]

Five O
cryotherapy-treated O
eyes O
required O
retreatment B-outcome ['Life-Impact']
because O
of O
persistent O
disease O
with O
adjacent O
skip O
areas O
. O
['Life-Impact']

A O
time O
x O
training O
group O
effect O
was O
found O
for O
Sprint-15m O
performance O
with O
the O
CONTRAST O
group O
showing O
significantly O
better O
scores O
than O
the O
SPRINT O
group O
( O
7.23 O
+/- O
0.18 O
vs. O
7.09 O
+/- O
0.20 O
m.s O
, O
p O
< O
0.01 O
) O
. O
[]

A O
systems O
analysis O
of O
obstetric O
triage O
. O
[]

OBJECTIVE O
We O
sought O
to O
investigate O
the O
effects O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
diphenhydramine O
( O
50 O
mg O
) O
, O
and O
placebo O
on O
memory B-outcome ['Life-Impact']
and O
psychomotor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
after O
acute O
( O
day O
1 O
) O
and O
subchronic O
( O
day O
4 O
) O
daily O
administration O
in O
48 O
healthy O
volunteers O
( O
24 O
men O
and O
24 O
women O
) O
. O
['Life-Impact', 'Life-Impact']

Patients O
on O
acetazolamide O
showed O
a O
slightly O
better O
improvement O
of O
angiographic B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
( O
at O
least O
by O
one O
grade O
improvement O
) O
over O
that O
of O
placebo O
( O
12 O
vs O
five O
eyes O
) O
. O
['Physiological-Clinical']

A O
partial O
support O
of O
the O
MAT O
and O
of O
ruminations O
reduction O
to O
the O
MBI's O
efficacy O
was O
found. O
[]

Funded O
by O
the O
Health O
Research O
Council O
of O
New O
Zealand; O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
number, O
ACTRN12609000593235 O
.). O
[]

Service O
variation O
in O
baseline O
variables O
and O
prediction O
of O
risk O
in O
a O
randomised O
controlled O
trial O
of O
psychological O
treatment O
in O
repeated O
parasuicide O
: O
the O
POPMACT O
Study O
. O
[]

Also O
the O
frequency O
of O
the O
troponin B-outcome ['Physiological-Clinical']
increase O
above O
the O
UNL(upper O
normal O
level) O
in O
the O
nicorandal O
group, O
was O
significantly O
(p O
= O
0.03) O
lower O
(in O
62% O
of O
cases O
compared O
to O
85% O
of O
the O
control O
group). O
[['Physiological-Clinical']]

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
cardiac B-outcome ['Physiological-Clinical']
safety I-outcome ['Physiological-Clinical']
profile O
of O
tegaserod O
through O
analysis O
of O
electrocardiographic O
data O
from O
clinical O
studies O
conducted O
in O
patients O
with O
IBS O
and O
a O
study O
conducted O
in O
healthy O
male O
subjects O
. O
['Physiological-Clinical']

The O
major O
impact O
of O
ASI O
was O
seen O
in O
patients O
with O
stage O
II O
disease O
, O
with O
a O
significantly O
longer O
recurrence-free B-outcome ['Physiological-Clinical']
period I-outcome ['Physiological-Clinical']
( O
p=0.011 O
) O
and O
61 O
% O
( O
18-81 O
) O
risk O
reduction O
for O
recurrences B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
To O
evaluate O
the O
efficacy O
of O
on-demand O
rabeprazole O
maintenance O
therapy O
in O
patients O
with O
non-erosive O
reflux O
disease O
. O
[]

FINANCIAL O
DISCLOSURE O
( O
S O
) O
Proprietary O
or O
commercial O
disclosure O
may O
be O
found O
after O
the O
references O
. O
[]

Rates O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
( O
overall O
rate=14.8 O
events/100 O
patient-yrs O
) O
, O
serious B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
( O
overall O
rate=4.2 O
events/100 O
patient-yrs O
) O
, O
cancer B-outcome ['Physiological-Clinical']
( O
overall O
rate=1.0 O
events/100 O
patient-yrs O
) O
, O
and O
deaths B-outcome ['Mortality']
( O
overall O
rate=0.7 O
events/100 O
patient-yrs O
) O
were O
stable O
each O
year O
, O
through O
8 O
years O
of O
etanercept O
exposure O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

BACKGROUND O
There O
are O
several O
lines O
of O
evidence O
to O
indicate O
that O
the O
immune O
system O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
autism O
. O
[]

The O
washout O
period O
between O
Parts O
A O
and O
B O
was O
2 O
weeks O
. O
[]

The O
outcome O
variables O
were O
total O
scores O
on O
the O
Childhood O
Autism O
Rating O
Scale O
( O
CARS O
) O
and O
the O
Children O
's O
Global O
Assessment O
Scale O
( O
CGAS O
) O
after O
6 O
months O
. O
[]

Phase O
II O
trial O
of O
nab-paclitaxel O
compared O
with O
docetaxel O
as O
first-line O
chemotherapy O
in O
patients O
with O
metastatic O
breast O
cancer O
: O
final O
analysis O
of O
overall O
survival O
. O
[]

The O
statistical O
analyses O
demonstrated O
the O
[]

Transmural B-outcome ['Physiological-Clinical']
dispersion O
of O
repolarisation B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TDR I-outcome ['Physiological-Clinical']
) O
was O
determined O
as O
Tpeak-Tend O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
; O
n O
= O
230 O
) O
. O
[]

Title: O
Cost-effectiveness O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
of O
a O
diet O
intervention O
postpartum: O
2-year O
results O
from O
a O
randomized O
controlled O
trial. O
[['Life-Impact']]

Improvement O
was O
only O
in O
sperm B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
and O
total O
motility B-outcome ['Physiological-Clinical']
for O
all O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
results O
from O
the O
Conners O
' O
[]

Relevant O
participants' O
data O
will O
be O
collected O
at O
enrolment O
and O
at O
delivery. O
[]

INTRODUCTION: O
N95 O
or O
higher O
filtering O
respirators O
have O
been O
recommended O
in O
healthcare O
settings, O
although O
there O
is O
still O
a O
risk O
of O
infection O
due O
to O
the O
improper O
selection O
and O
wearing O
of O
respirators. O
[]

Group O
A O
consisted O
of O
66 O
patients O
who O
received O
dexmedetomidine, O
and O
Group O
B O
included O
66 O
patients O
with O
paracetamol O
administration. O
[]

Seventeen O
patients O
from O
group O
C O
requested O
another O
appliance O
and O
were O
given O
a O
stabilization O
appliance O
, O
thus O
creating O
a O
mixed O
group O
( O
group O
M O
) O
. O
[]

n O
= O
755 O
) O
, O
lumiracoxib O
100 O
mg O
b.i.d O
. O
( O
[]

BACKGROUND/AIMS O
Intravenous O
lipid O
emulsions O
may O
contribute O
to O
the O
development O
of O
total O
parenteral O
nutrition O
( O
TPN O
) O
-- O
induced O
hepatobiliary O
complications O
. O
[]

We O
determined O
the O
effect O
of O
an O
educational O
package O
at O
rural O
schools O
in O
Linxiang O
City O
District O
, O
Hunan O
province O
, O
China O
, O
where O
these O
worms O
are O
prevalent O
. O
[]

During O
the O
first O
period O
the O
percentage O
of O
responders O
was O
almost O
identical O
in O
both O
treatment O
groups O
, O
but O
during O
the O
second O
period O
a O
further O
slight O
improvement O
was O
observed O
in O
the O
early O
placebo O
responders O
, O
while O
the O
HAM-A O
score O
of O
patients O
on O
ketazolam O
continued O
to O
improve O
significantly O
( O
p O
less O
than O
0.01 O
) O
throughout O
the O
study O
. O
[]

BACKGROUND: O
Krill O
powder O
is O
rich O
in O
bioactive O
ingredients O
such O
as O
eicosapentaenoic O
acid O
(EPA), O
docosahexaenoic O
acid O
(DHA), O
phospholipids, O
protein O
and O
astaxanthin. O
[]

Duration O
on O
treadmill O
and O
right O
ventricular O
ejection O
fraction O
post O
exercise O
increased O
, O
while O
diastolic O
and O
systolic O
artery O
pressure O
decreased O
significantly O
in O
both O
groups O
. O
[]

Mean O
change O
in O
A1C B-outcome ['Physiological-Clinical']
level O
from O
baseline O
to O
12 O
months O
was O
-0.4 O
+/- O
0.6 O
% O
( O
P O
< O
0.001 O
) O
in O
subjects O
with O
baseline O
A1C O
> O
or=7.0 O
% O
. O
['Physiological-Clinical']

Journal-Name:Croatian O
medical O
journal O
[]

Children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
and O
attention O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
demonstrate O
face B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
abnormalities I-outcome ['Life-Impact']
that O
may O
underlie O
social O
impairment O
. O
['Life-Impact']

The O
use O
of O
vasoconstrictors O
was O
the O
only O
variable O
that O
had O
a O
statistically O
significant O
change O
in O
cardiac B-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
associated O
with O
a O
change O
in O
position O
. O
['Physiological-Clinical']

Post-treatment O
declines O
in O
prostate-specific B-outcome ['Physiological-Clinical']
antigen I-outcome ['Physiological-Clinical']
of O
> O
or O
= O
50 O
% O
were O
achieved O
in O
21 O
of O
44 O
patients O
( O
48 O
% O
; O
95 O
% O
CI O
, O
33 O
% O
to O
64 O
% O
) O
on O
the O
ixabepilone O
arm O
, O
and O
31 O
of O
45 O
patients O
( O
69 O
% O
; O
95 O
% O
CI O
, O
55 O
% O
to O
82 O
% O
) O
on O
the O
ixabepilone O
+ O
EMP O
arm O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
the O
three O
groups O
with O
respect O
to O
requirements O
for O
supplemental B-outcome ['Resource-use']
pain I-outcome ['Resource-use']
medications I-outcome ['Resource-use']
in O
the O
recovery O
room O
, O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
, O
or O
length O
of O
time O
spent O
in O
the O
recovery O
room O
. O
['Resource-use', 'Physiological-Clinical']

normal O
girls O
) O
, O
chronological B-outcome ['Physiological-Clinical']
age O
at O
start O
of O
treatment B-outcome ['Resource-use']
, O
and O
HV B-outcome ['Physiological-Clinical']
in O
the O
first O
year O
of O
GH O
treatment O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

The O
patients O
were O
examined O
in O
the O
acute O
state O
and O
after O
treatment O
when O
possible O
. O
[]

Thus O
, O
VEGF/VEGFR-2 O
might O
constitute O
promising O
targets O
for O
antiangiogenic O
and O
antileukemic O
treatment O
strategies O
in O
AML O
. O
[]

Antiarrhythmic B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
neoton O
manifested O
on O
MI O
day O
2 O
. O
['Physiological-Clinical']

This O
was O
a O
30 O
% O
reduction O
in O
daily B-outcome ['Resource-use']
steroid I-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
( O
p O
less O
than O
0.01 O
) O
. O
['Resource-use']

The O
Mini-Mental O
State I-outcome ['Life-Impact']
Examination O
( O
MMS O
) O
and O
the O
Geriatric O
Depression B-outcome ['Life-Impact']
Scale O
( O
GDS O
) O
were O
applied O
to O
evaluate O
the O
effect O
of O
maprotiline O
on O
cognitive O
and O
depressive O
symptoms O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
GS-9620 O
was O
well-absorbed B-outcome ['Life-Impact']
and O
well-tolerated B-outcome ['Life-Impact']
in O
oral O
doses O
up O
to O
12 O
mg O
. O
['Life-Impact', 'Life-Impact']

Subjects O
and O
Methods: O
Among O
the O
children O
referred O
to O
the O
our O
University, O
Faculty O
of O
Dentistry, O
Department O
of O
Pediatric O
Dentistry, O
23 O
aged O
between O
8-14 O
with O
81 O
anterior O
white B-outcome ['Physiological-Clinical']
spot I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
were O
included O
in O
the O
study. O
[['Physiological-Clinical']]

A O
web-based O
approach O
to O
address O
cardiovascular B-outcome ['Physiological-Clinical']
risks O
in O
managers O
: O
results O
of O
a O
randomized O
trial O
. O
['Physiological-Clinical']

BACKGROUND O
This O
placebo-controlled O
phase O
III O
study O
investigated O
the O
effect O
on O
survival B-outcome ['Mortality']
of O
gefitinib O
as O
second-line O
or O
third-line O
treatment O
for O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small-cell O
lung O
cancer O
. O
['Mortality']

The O
capability O
of O
the O
DSV O
to O
maintain O
the O
IVP B-outcome ['Physiological-Clinical']
within O
physiological O
limits O
after O
shunting O
, O
especially O
in O
the O
upright O
position O
, O
is O
documented O
by O
a O
comparison O
with O
possible B-outcome ['Physiological-Clinical']
unphysiological I-outcome ['Physiological-Clinical']
IVP I-outcome ['Physiological-Clinical']
variations I-outcome ['Physiological-Clinical']
in O
other O
valve O
constructions O
, O
which O
depend O
on O
the O
level O
of O
implantation B-outcome ['Physiological-Clinical']
, O
subcutaneous B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
CSF I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
through I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
valve I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Study O
protocol O
: O
Rehabilitation O
including O
Social O
and O
Physical O
activity O
and O
Education O
in O
Children O
and O
Teenagers O
with O
Cancer O
( O
RESPECT O
) O
. O
[]

The O
primary O
efficacy O
analysis O
was O
based O
on O
children O
who O
received O
three O
doses O
of O
RRV-TV O
( O
n=1128 O
) O
or O
placebo O
( O
n=1145 O
) O
. O
[]

Mean O
number O
of O
whoops B-outcome ['Physiological-Clinical']
during O
the O
first O
week O
of O
follow-up O
was O
also O
significantly O
reduced O
( O
p O
= O
0.0196 O
) O
. O
['Physiological-Clinical']

Participants O
had O
colonoscopy O
after O
3 O
years O
of O
follow-up O
. O
[]

There O
was O
significant O
improvement O
in O
creatinine B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

BACKGROUND O
Standardised O
measures O
of O
behaviour B-outcome ['Life-Impact']
have O
failed O
to O
detect O
short O
term O
improvement O
in O
children O
with O
autism O
following O
treatment O
with O
secretin O
. O
['Life-Impact']

Serum B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
estradiol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
E I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
FSH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
CETP B-outcome ['Physiological-Clinical']
and O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
were O
determined O
in O
196 O
Chinese O
women O
( O
52 O
premenopausal O
with O
ages O
ranging O
from O
18 O
to O
40 O
years O
, O
57 O
perimenopausal O
from O
41 O
to O
60 O
years O
, O
and O
87 O
postmenopausal O
from O
61 O
to O
81 O
years O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Preliminary O
findings O
from O
a O
prospective O
, O
randomized O
trial O
of O
two O
palatal O
operations O
for O
sleep-disordered O
breathing O
. O
[]

Group O
III O
was O
maintained O
in O
the O
preventive O
program O
provided O
by O
the O
local O
Dental O
Health O
Office O
, O
based O
on O
mechanical O
plaque O
control O
and O
topical O
use O
of O
fluorides O
and O
chlorhexidine O
at O
individualized O
intervals O
. O
[]

1 O
. O
[]

The O
mean O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
intubation I-outcome ['Life-Impact']
( O
TAMS O
62 O
s O
vs. O
OSD O
56 O
s O
) O
and O
the O
success B-outcome ['Physiological-Clinical']
rate O
was O
not O
different O
between O
the O
two O
groups O
( O
P O
> O
0.05 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Amyloid O
beta O
( O
Abeta O
) O
may O
play O
a O
central O
role O
in O
the O
pathogenesis O
of O
Alzheimer O
disease O
. O
[]

The O
time O
to O
reach O
peak O
concentration B-outcome ['Physiological-Clinical']
was O
much O
longer O
after O
drug O
administration O
at O
01.00 O
hours O
( O
135 O
+/- O
16.7 O
min O
) O
than O
at O
07.00 O
( O
73.1 O
+/- O
14.1 O
min O
) O
, O
13.00 O
( O
75 O
+/- O
16.5 O
min O
) O
or O
19.00 O
hours O
( O
82.5 O
+/- O
12.7 O
min O
) O
[ O
p O
less O
than O
0.05 O
] O
. O
['Physiological-Clinical']

Whereas O
older O
HES O
specimen O
tended O
to O
accumulate O
in O
the O
plasma O
and O
to O
cause O
negative O
effects O
on O
hemostasis O
, O
more O
recent O
products O
, O
e.g. O
, O
HES O
130/0.4 O
, O
are O
characterised O
by O
improved O
pharmacological O
properties O
. O
[]

HBOT O
may O
possibly O
have O
a O
broad-spectrum O
antimicrobial O
effect O
worthy O
of O
further O
study O
. O
[]

The O
control O
group O
received O
a O
single O
socialization O
contact O
. O
[]

After O
removal O
of O
the O
connected O
vasculature O
the O
remaining O
objects O
are O
considered O
possible O
red O
lesions O
. O
[]

The O
recording O
device O
( O
Snore O
Box O
) O
is O
simple O
for O
the O
patient O
to O
operate O
, O
portable O
with O
a O
built O
in O
microphone O
, O
and O
able O
to O
produce O
objective O
results O
, O
which O
can O
be O
automatically O
analysed O
. O
[]

Mixed-effects O
modeling O
tested O
the O
hypothesis O
that O
the O
intervention O
reduced O
self-reported O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
( O
Center O
for O
Epidemiological O
Studies O
Depression O
scale O
, O
Profile O
of O
Mood O
States O
Depression O
and O
Fatigue O
subscales O
, O
and O
Medical O
Outcomes O
Study-Short O
Form O
36 O
Bodily O
Pain O
subscale O
) O
and O
immune B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
that O
are O
elevated O
in O
the O
presence O
of O
inflammation O
( O
white O
blood O
cell O
count O
, O
neutrophil O
count O
, O
and O
helper/suppressor O
ratio O
) O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Rates O
of O
complete B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
of O
fissure B-outcome ['Physiological-Clinical']
were O
similar O
in O
the O
three O
groups O
( O
lignocaine O
alone O
8/27 O
, O
minoxidil O
alone O
10/34 O
, O
combination O
7/22 O
; O
p=ns O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Performing O
a O
pre-transplant O
tacrolimus O
C O
( O
2 O
) O
does O
not O
significantly O
increase O
the O
high O
proportion O
of O
subjects O
achieving O
10 O
ng/mL O
tacrolimus O
concentrations O
by O
day O
3 O
using O
routine O
protocols O
. O
[]

Both O
drugs O
were O
ineffective O
as O
sole O
analgesic B-outcome ['Resource-use']
agents O
in O
half O
of O
their O
respective O
groups O
. O
['Resource-use']

However O
, O
concerns O
about O
a O
negative O
impact O
of O
Ca/Mg O
infusions O
on O
outcome O
have O
been O
raised O
. O
[]

BACKGROUND O
After O
major O
burns O
, O
patients O
can O
develop O
nutritional O
deficiencies O
including O
trace B-outcome ['Physiological-Clinical']
element I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TE I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
deficiencies O
. O
['Physiological-Clinical']

In O
the O
study O
group O
, O
there O
was O
a O
significant O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
( O
P O
< O
0.01 O
) O
and O
an O
improvement O
in O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
( O
P=0.06 O
) O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical', 'Life-Impact']

They O
were O
randomly O
divided O
into O
2 O
groups O
of O
120 O
each. O
[]

No O
relevant O
bradycardia B-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical']

When O
patients O
were O
divided O
into O
two O
different O
disease O
cohorts O
, O
ALL O
patients O
showed O
no O
difference O
in O
engraftment B-outcome ['Physiological-Clinical']
kinetics I-outcome ['Physiological-Clinical']
between O
the O
G-CSF O
treatment O
and O
control O
groups O
, O
while O
differences O
were O
seen O
in O
those O
with O
solid O
tumors O
. O
['Physiological-Clinical']

We O
analysed O
anthropometric O
and O
metabolic O
parameters O
in O
five O
groups O
of O
10 O
males O
: O
four O
receiving O
testosterone O
undecanoate O
( O
TU O
: O
1000 O
mg O
) O
plus O
norethisterone O
enanthate O
( O
NETE O
: O
200 O
mg O
) O
at O
different O
intervals O
( O
every O
8 O
weeks O
: O
NETE-8 O
; O
every O
12 O
weeks O
: O
NETE-12 O
; O
every O
6 O
weeks O
for O
12 O
weeks O
and O
then O
every O
12 O
weeks O
: O
NETE-6/12 O
; O
every O
6 O
weeks O
for O
12 O
weeks O
and O
then O
TU O
plus O
placebo O
every O
12 O
weeks O
: O
NETE-6/12/0 O
) O
and O
one O
placebo O
( O
NETE-0/0 O
) O
for O
a O
total O
of O
48 O
weeks O
. O
[]

Improving O
and O
targeting O
nicotine O
replacement O
therapy O
( O
NRT O
) O
are O
cost-effective O
strategies O
for O
reducing O
adverse O
health O
consequences O
for O
smokers O
. O
[]

CONCLUSION O
AT O
did O
not O
improve O
DFS O
or O
overall O
survival O
in O
this O
population O
, O
and O
was O
associated O
with O
more O
toxicity O
. O
[]

The O
groups O
' O
diagnostic O
accuracy O
, O
however O
, O
did O
not O
differ O
significantly O
on O
the O
post-test O
, O
retention O
test O
or O
transfer O
test O
items O
( O
p O
> O
0.12 O
) O
. O
[]

High O
levels O
of O
fibrinogen O
and O
clotting O
factor O
VII O
are O
associated O
with O
an O
increased O
risk O
for O
subsequent O
death B-outcome ['Mortality']
and O
cardiovascular B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
in O
apparently O
healthy O
individuals O
. O
['Mortality', 'Physiological-Clinical']

3 O
months O
, O
daily O
mean O
voiding O
frequency O
( O
DMVF O
) O
? O
[]

We O
evaluated O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
quality O
of O
life O
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
and O
satisfaction B-outcome ['Life-Impact']
of O
patients O
who O
were O
monitored O
by O
specially O
trained O
community O
pharmacists O
in O
a O
group O
medical O
practice O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Only O
scopolamine O
induced O
sedation B-outcome ['Physiological-Clinical']
in O
this O
study O
. O
['Physiological-Clinical']

Late-onset O
sepsis B-outcome ['Physiological-Clinical']
occurred O
in O
414 O
of O
1389 O
infants O
(29.8%) O
in O
the O
faster-increment O
group O
and O
434 O
of O
1397 O
(31.1%) O
in O
the O
slower-increment O
group O
(adjusted O
risk O
ratio, O
0.96; O
95% O
CI, O
0.86 O
to O
1.07). O
[['Physiological-Clinical']]

The O
program O
lasted O
12 O
weeks O
, O
consisted O
of O
1 O
1/2 O
hours O
meeting O
once O
a O
week O
, O
including O
group O
meetings O
and O
home O
visit O
monitoring O
. O
[]

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
VISA-A O
score O
( O
p O
= O
0.815 O
) O
and O
[]

14 O
] O
% O
to O
21 O
[ O
17 O
] O
) O
, O
but O
was O
not O
in O
subjects O
receiving O
casein O
( O
from O
37 O
[ O
13 O
] O
% O
to O
36 O
[ O
12 O
] O
) O
. O
[]

In O
week O
14 O
, O
the O
median O
relative B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
wart I-outcome ['Physiological-Clinical']
area O
was O
98 O
% O
in O
the O
ALA-PDT O
group O
( O
interquartile O
range O
100 O
% O
, O
55 O
% O
) O
versus O
52 O
% O
( O
100 O
% O
, O
0 O
) O
in O
the O
placebo O
group O
( O
p=0.0006 O
) O
. O
['Physiological-Clinical']

A O
response-cost O
program O
was O
applied O
to O
reduce O
problem O
behaviors O
and O
foster O
skills O
acquisition O
. O
[]

The O
relationship O
between O
physical O
activity O
level O
, O
anxiety O
, O
depression O
, O
and O
functional B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
juvenile O
idiopathic O
arthritis O
. O
['Life-Impact']

OBJECTIVES O
To O
determine O
the O
level O
of O
occupational O
exposure O
to O
anesthetic O
gases O
in O
the O
absence O
of O
an O
extractor O
during O
pediatric O
anesthesia O
and O
to O
assess O
the O
efficacy O
of O
a O
purpose-built O
extraction O
system O
. O
[]

A O
controlled O
crossover O
trial O
of O
fenfluramine O
in O
autism O
. O
[]

This O
study O
was O
designed O
to O
determine O
the O
bioavailability O
of O
GCV O
and O
to O
test O
a O
dosing O
algorithm O
in O
transplant O
and O
dialysis O
patients O
with O
different O
levels O
of O
renal O
function O
. O
[]

The O
primary O
endpoint O
occurred O
in O
103 O
patients O
assigned O
losartan O
( O
n O
= O
586 O
) O
and O
139 O
assigned O
atenolol O
( O
n O
= O
609 O
) O
. O
[]

INTERVENTION O
The O
nutrition O
goals O
for O
women O
randomly O
assigned O
to O
the O
low-fat O
intervention O
were O
to O
reduce O
total O
fat O
intake O
to O
20 O
% O
or O
less O
of O
energy O
from O
fat O
and O
to O
consume O
5 O
or O
more O
fruit/vegetable O
servings O
daily O
and O
6 O
or O
more O
grain O
servings O
daily O
. O
[]

The O
remaining O
78 O
patients O
underwent O
randomization. O
[]

CONCLUSIONS O
Initiation O
of O
insulin O
pump O
therapy O
at O
diagnosis O
improved O
glycemic O
control O
, O
was O
well O
tolerated O
, O
and O
contributed O
to O
improved O
patient O
satisfaction O
with O
treatment O
. O
[]

This O
finding O
offers O
surgeons O
, O
for O
now O
, O
enhanced O
flexibility O
in O
planning O
revascularization O
. O
[]

Many O
patients O
with O
venous O
thromboembolism O
are O
being O
treated O
with O
low O
molecular O
weight O
heparin O
for O
extended O
periods O
of O
time O
. O
[]

However O
, O
quinolone-resistant O
strains O
of O
Salmonella O
typhi O
have O
recently O
been O
reported O
from O
Vietnam O
; O
and O
if O
quinolone O
resistance O
becomes O
established O
, O
alternative O
oral O
treatment O
options O
will O
be O
needed O
. O
[]

In O
these O
patients O
with O
normal O
or O
near-normal O
resting O
left O
ventricular O
function O
, O
neither O
drug O
induced O
depression O
of O
left O
ventricular O
function O
. O
[]

Journal-Name:Nutrients O
[]

Especially O
important O
is O
the O
fact O
that O
the O
thalamus O
is O
activated O
by O
nicotine O
. O
[]

This O
study O
examined O
the O
effect O
of O
an O
8-month O
exercise O
intervention O
on O
WMI O
in O
children O
. O
[]

Settings/locations O
: O
Patients O
with O
ischemic O
stroke O
or O
transient O
ischemic O
attack O
undergoing O
TEE O
because O
of O
presumed O
cardioembolic O
origin O
in O
a O
specialized O
stroke O
unit O
of O
the O
Johann O
Wolfgang O
Goethe-University O
, O
Frankfurt/Main O
, O
Germany O
. O
[]

METHODS O
Generalized O
linear O
regression O
models O
were O
used O
to O
analyze O
healthcare B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
data O
on O
individuals O
enrolled O
in O
a O
comparative O
effectiveness O
trial O
of O
cessation O
therapies O
between O
October O
2005 O
and O
May O
2007 O
( O
1346 O
total O
participants O
; O
1338 O
with O
requisite O
data O
for O
further O
analysis O
) O
. O
['Resource-use']

CONCLUSIONS O
Fadrozole O
HCL O
was O
as O
efficacious O
as O
megestrol O
acetate O
in O
postmenopausal O
patients O
with O
metastatic O
breast O
carcinoma O
after O
one O
hormonal O
therapy O
. O
[]

Argon O
laser O
trabeculoplasty O
in O
primary O
open-angle O
glaucoma O
-- O
results O
in O
black O
Jamaican O
population O
. O
[]

Fewer O
patients O
received O
rescue B-outcome ['Resource-use']
antiemetics I-outcome ['Resource-use']
in O
the O
granisetron O
groups O
than O
in O
the O
control O
group O
( O
10 O
% O
, O
10 O
% O
, O
and O
43 O
% O
of O
patients O
in O
granisetron O
20 O
micrograms/kg O
and O
40 O
micrograms/kg O
, O
and O
the O
control O
groups O
, O
respectively O
) O
. O
['Resource-use']

The O
probability O
that O
phenytoin O
has O
any O
prophylactic B-outcome ['Resource-use']
efficacy O
is O
0.383 O
. O
['Resource-use']

Three O
controlled O
dietary O
intervention O
studies O
were O
carried O
out O
in O
1981-1983 O
in O
North O
Karelia O
, O
Finland O
, O
to O
asses O
the O
impact O
of O
dietary O
fat O
intake O
modification O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
group O
1 O
( O
n O
= O
15 O
) O
a O
basal O
period O
with O
no O
dietary O
restriction O
was O
followed O
by O
a O
period O
taking O
an O
energy O
reduced O
diet O
( O
5.1 O
MJ O
; O
1230 O
kcal O
) O
, O
the O
sodium O
intake O
being O
supplemented O
and O
hence O
unchanged O
( O
1 O
: O
ErSn O
) O
. O
[]

A O
double-blind O
, O
placebo-controlled O
study O
of O
the O
efficacy O
of O
transdermal O
clonidine O
in O
autism O
. O
[]

At O
28 O
days O
after O
treatment O
, O
selamectin O
, O
fipronil- O
( O
S O
) O
-methoprene O
, O
and O
imidacloprid O
had O
killed O
99.0 O
% O
, O
86.4 O
% O
, O
and O
72.6 O
% O
of O
the O
fleas O
within O
48 O
hours O
of O
infestation O
, O
respectively O
. O
[]

Group O
1 O
( O
25 O
heels O
) O
was O
treated O
immediately O
with O
three O
sessions O
of O
ESWT O
( O
3000 O
shock O
waves/session O
of O
0.2 O
mJ/mm2 O
) O
at O
weekly O
intervals O
. O
[]

METHODS O
Patients O
undergoing O
elective O
major O
colorectal O
or O
urological O
surgery O
who O
had O
an O
AT O
of O
< O
11 O
mL O
? O
[]

Comparing O
Telephone O
Counselling O
outcomes O
to O
existing O
practice O
( O
Real O
Control O
) O
, O
the O
intervention O
was O
found O
to O
be O
cost-effective O
( O
$ O
29,375 O
per O
quality O
adjusted O
life O
year O
gained O
) O
. O
['Resource-use']

CONCLUSIONS O
Instruction O
about O
common O
errors O
, O
when O
combined O
with O
instruction O
about O
the O
correct O
performance O
enhanced O
the O
acquisition O
of O
this O
surgical O
skill O
. O
[]

Currently O
available O
intravenous O
( O
IV O
) O
iron O
replacement O
therapies O
have O
either O
inconvenient O
regimens O
of O
administration O
or O
adverse O
event O
profiles O
that O
limit O
their O
utility O
in O
the O
outpatient O
setting O
. O
[]

Chemical B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
is O
occasionally O
observed O
, O
especially O
if O
multiple O
instillations O
are O
started O
immediately O
after O
TUR O
, O
or O
in O
the O
presence O
of O
additional O
inflammatory O
conditions O
, O
such O
as O
previous O
irradiation O
or O
bacterial O
cystitis O
. O
['Physiological-Clinical']

The O
results O
show O
that O
an O
improvement O
in O
masticatory O
performance O
does O
not O
imply O
the O
same O
improvement O
in O
chewing O
experience O
and O
vice O
versa O
. O
[]

The O
average O
available O
energy O
(calorie) O
content O
of O
a O
28 O
g O
serving O
of O
cashew O
nuts O
was O
137 O
kcal O
(+/-3.4 O
kcal O
SEM) O
and O
ranged O
from O
105 O
to O
151 O
kcal. O
[]

The O
cumulative O
rate O
of O
HIV O
transmission O
at O
6 O
weeks O
was O
3?3 O
% O
( O
95 O
% O
CI O
1?9-5?6 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
5?0 O
% O
( O
3?3-7?7 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
, O
and O
at O
12 O
months O
was O
5?4 O
% O
( O
3?6-8?1 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
9?5 O
% O
( O
7?0-12?9 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?029 O
) O
. O
[]

BACKGROUND O
Heightened O
central O
sympathetic O
nervous O
outflow O
is O
common O
in O
essential O
hypertension O
, O
contributing O
to O
hypertension O
development O
and O
perhaps O
also O
to O
complications O
. O
[]

Periodontal O
probing O
depth O
( O
PPD O
) O
, O
clinical O
probing O
attachment O
level O
( O
CPAL O
) O
, O
and O
tooth O
mobility O
were O
measured O
using O
desmodontometry O
( O
DDM O
) O
and O
periotest O
( O
PTV O
) O
with O
reproducible O
methods O
before O
surgery O
and O
at O
various O
periods O
up O
to O
1 O
year O
afterwards O
. O
[]

Neither O
10 O
weeks O
of O
pravastatin O
nor O
mild O
endurance O
exercise O
training O
improved O
[]

Journal-Name: O
Revista O
latino-americana O
de O
enfermagem O
[]

In O
a O
double O
blind O
randomized O
study O
, O
epidural O
anesthesia O
was O
carried O
out O
with O
20 O
ml O
bupivacaine O
0.75 O
% O
( O
n O
= O
24 O
) O
and O
ropivacaine O
1 O
% O
( O
n O
= O
21 O
) O
. O
[]

Survival O
and O
resource O
utilisation O
data O
were O
collected O
for O
6 O
months O
; O
survival O
was O
extrapolated O
assuming O
a O
mean O
additional O
lifetime O
of O
3 O
years O
based O
on O
data O
from O
the O
Cooperative O
North O
Scandinavian O
Enalapril O
Survival O
Study O
trial O
. O
[]

Biventricular O
pacing O
improves O
cardiac B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
prevents O
further O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
in O
patients O
with O
symptomatic O
atrial O
fibrillation O
after O
atrioventricular O
node O
ablation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
the O
induction O
of O
anesthesia O
with O
halothane O
, O
69 O
ambulatory O
surgical O
patients O
( O
1 O
mo O
to O
< O
17 O
yr O
old O
) O
, O
received O
propofol O
without O
EDTA O
( O
n O
= O
33 O
) O
or O
propofol O
with O
EDTA O
( O
n O
= O
36 O
) O
. O
[]

OBJECTIVES O
To O
assess O
the O
SHS O
effects O
and O
their O
duration O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
also O
received O
pegfilgrastim O
6 O
mg O
as O
a O
single O
subcutaneous O
injection O
on O
day O
2 O
of O
each O
cycle O
. O
[]

Of O
153 O
patients O
evaluable O
for O
response O
, O
there O
were O
47 O
, O
or O
30.7 O
% O
, O
complete B-outcome ['Physiological-Clinical']
responders I-outcome ['Physiological-Clinical']
( O
all O
determined O
surgically O
) O
, O
6 O
partial O
responders O
, O
and O
100 O
nonresponders O
. O
['Physiological-Clinical']

Findings O
revealed O
one O
child O
( O
engagement O
) O
, O
one O
teacher O
( O
exhaustion O
) O
, O
two O
intervention O
quality O
( O
IEP O
quality O
for O
targeted O
and O
not O
targeted O
elements O
) O
, O
and O
no O
implementation O
quality O
variables O
accounted O
for O
variance O
in O
child O
outcomes O
when O
analyzed O
separately O
. O
[]

CONCLUSIONS O
Our O
results O
suggest O
that O
calcitriol O
can O
prevent O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
, O
therefore O
, O
may O
be O
useful O
for O
the O
treatment O
of O
bone O
disease O
in O
patients O
with O
cirrhosis O
of O
the O
liver O
. O
['Physiological-Clinical']

OBJECTIVE O
This O
study O
was O
designed O
to O
evaluate O
the O
analgesic O
efficacy O
of O
caudal O
midazolam-bupivacaine O
combination O
in O
providing O
post-operative O
pain O
relief O
in O
children O
undergoing O
genitourinary O
surgery O
and O
to O
study O
the O
occurrence O
of O
adverse O
effects O
. O
[]

PARTICIPANTS O
24 O
practice O
nurses O
, O
trained O
in O
10-year O
cardiovascular O
risk O
assessment O
, O
calculated O
the O
risk O
of O
a O
total O
of O
421 O
patients O
without O
established O
cardiovascular O
diseases O
but O
eligible O
for O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
assessment O
. O
['Physiological-Clinical']

The O
major O
causes O
of O
poor O
nutritional O
status O
are O
related O
to O
the O
underlying O
disease O
, O
socio-economic O
factors O
, O
age O
, O
and O
length O
of O
hospitalization O
. O
[]

Thirty O
alpacas O
, O
all O
positive O
for O
Chorioptes O
sp O
. O
[]

1 O
days O
) O
. O
[]

INTERVENTIONS O
Cholecystectomy O
. O
[]

Patient O
demographics O
, O
indications O
for O
surgery O
, O
preoperative O
and O
postoperative O
International O
Prostate O
Symptom O
Score O
, O
uroflowmetry B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
, O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
catheterization B-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
and O
complication B-outcome ['Adverse-effects']
rates O
were O
compared O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Resource-use', 'Adverse-effects']

These O
trials O
have O
reported O
significant O
reductions O
in O
complicated O
grief O
and O
related O
symptoms O
in O
response O
to O
treatment O
relative O
to O
control O
groups O
. O
[]

Such O
findings O
suggest O
that O
self-disclosure O
by O
the O
therapist O
may O
improve O
both O
the O
quality O
of O
the O
therapeutic B-outcome ['Physiological-Clinical']
relationship I-outcome ['Physiological-Clinical']
and O
the O
outcome O
of O
treatment O
. O
['Physiological-Clinical']

RESULTS O
Mean O
baseline O
values O
for O
the O
three O
co-primary O
endpoints O
ranged O
from O
62.52 O
to O
70.14 O
mm O
. O
[]

Intraocular B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
and O
respiratory B-outcome ['Physiological-Clinical']
functions B-outcome ['Life-Impact']
, O
including O
percent B-outcome ['Physiological-Clinical']
forced I-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
and O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
were O
then O
measured O
for O
3 O
hours O
after O
drug O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

The O
number O
of O
mature B-outcome ['Physiological-Clinical']
follicles I-outcome ['Physiological-Clinical']
and O
cervical B-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
score], O
follicular B-outcome ['Physiological-Clinical']
development I-outcome ['Physiological-Clinical']
rate O
and O
single B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
ovulation I-outcome ['Physiological-Clinical']
rate, O
cycle B-outcome ['Physiological-Clinical']
pregnancy I-outcome ['Physiological-Clinical']
rate, O
early B-outcome ['Mortality']
miscarriage I-outcome ['Mortality']
rate, O
ovulation B-outcome ['Physiological-Clinical']
rate, O
endometrial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
, O
positive O
rate O
of O
three B-outcome ['Physiological-Clinical']
lines I-outcome ['Physiological-Clinical']
sign I-outcome ['Physiological-Clinical']
, O
follicle B-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
level O
and O
luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
level O
were O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
specimen O
treatment O
regimens O
were O
: O
1 O
. O
[]

Patients O
in O
Group O
B O
had O
significantly O
better O
scores O
on O
the O
chair B-outcome ['Life-Impact']
stand I-outcome ['Life-Impact']
test O
( O
13.3 O
compared O
with O
11.1 O
in O
Group O
A O
, O
p O
= O
0.04 O
) O
at O
six O
months O
postoperatively O
, O
but O
there O
was O
no O
difference O
at O
twelve O
months O
( O
14.0 O
compared O
with O
13.6 O
) O
. O
['Life-Impact']

Caffeine O
's O
main O
mechanism O
of O
action O
on O
the O
central O
nervous O
system O
is O
antagonism O
of O
adenosine O
receptors O
. O
[]

BACKGROUND O
Atypical O
antipsychotic O
agents O
, O
which O
block O
postsynaptic O
dopamine O
and O
serotonin O
receptors O
, O
have O
advantages O
over O
traditional O
antipsychotic O
medications O
in O
the O
treatment O
of O
adults O
with O
schizophrenia O
and O
may O
be O
beneficial O
in O
children O
with O
autistic O
disorder O
who O
have O
serious O
behavioral O
disturbances O
. O
[]

Ilioinguinal-iliohypogastric O
nerve O
block O
within O
travenous O
dexketoprofen O
improves O
postoperative O
analgesia O
in O
abdominal O
hysterectomies O
. O
[]

Increases O
in O
serum O
creatinine B-outcome ['Physiological-Clinical']
levels O
of O
0.5 O
mg O
or O
more O
per O
deciliter O
(>/=40 O
mumol O
per O
liter) O
above O
baseline O
occurred O
in O
7.0% O
of O
patients O
in O
the O
plazomicin O
group O
and O
in O
4.0% O
in O
the O
meropenem O
group. O
[['Physiological-Clinical']]

The O
experimental O
group O
preferred O
double-looping O
over O
propulsion O
, O
while O
the O
control O
group O
mainly O
used O
single-looping O
over O
propulsion O
patterns O
during O
the O
post-test O
. O
[]

In O
both O
groups O
, O
if O
pain O
intensity O
was O
rated O
as O
> O
3 O
on O
the O
VAS O
at O
week O
1 O
or O
2 O
, O
the O
dosage O
was O
doubled O
. O
[]

Propofol O
and O
isoflurane O
have O
been O
reported O
recently O
to O
offer O
better O
sedation B-outcome ['Life-Impact']
than O
alternative O
agents O
in O
patients O
who O
require O
long-term O
ventilation O
in O
the O
Intensive O
Care O
Unit O
. O
['Life-Impact']

CONCLUSIONS O
The O
study O
suggests O
a O
beneficial O
effect O
of O
risperidone O
after O
several O
months O
of O
treatment O
, O
enhancing O
divided O
attention O
in O
children O
with O
pervasive O
developmental O
disorders O
. O
[]

ClinicalTrials.gov O
number O
, O
NCT00479375 O
[ O
ClinicalTrials.gov O
] O
. O
) O
. O
[]

The O
authors O
studied O
the O
Overt O
Aggression O
Scale O
( O
OAS O
) O
in O
a O
preliminary O
sample O
of O
eight O
outpatients O
who O
participated O
in O
an O
ongoing O
placebo-controlled O
study O
of O
valproate O
for O
aggression O
in O
autism O
. O
[]

Thus O
, O
further O
development O
of O
CS O
is O
warranted O
as O
a O
potential O
method O
to O
prevent O
HIV B-outcome ['Physiological-Clinical']
transmission I-outcome ['Physiological-Clinical']
and O
acquisition B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
we O
surveyed O
clinical O
educators O
( O
n O
= O
17 O
) O
to O
find O
out O
how O
they O
would O
sequence O
their O
teaching O
of O
these O
murmurs O
. O
[]

The O
unaffected O
arm O
was O
restrained O
during O
the O
sessions O
. O
[]

Using O
logistic O
regression O
, O
there O
was O
no O
association O
between O
virologic B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
and O
either O
baseline O
ABC O
resistance B-outcome ['Life-Impact']
or O
regimen B-outcome ['Life-Impact']
sensitivity I-outcome ['Life-Impact']
score O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Main B-outcome ['Physiological-Clinical']
curve I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
success O
rate O
was O
in O
association O
with O
patients' O
age O
and O
type O
of O
rod O
(P-value=0.054, O
r=-1.863 O
and O
P-value=0.001, O
r=8.865 O
respectively). O
[['Physiological-Clinical']]

CONCLUSIONS: O
TPI O
and O
EMLA O
with O
occlusive O
dressing O
effectively O
reduced O
the O
shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
after O
total O
laparoscopic O
hysterectomy. O
[['Physiological-Clinical']]

No O
intergroup O
differences O
were O
found O
with O
respect O
to O
the O
number O
of O
punctures B-outcome ['Physiological-Clinical']
( O
mean O
value O
1.6 O
+/- O
0.83 O
) O
and O
the O
incidence O
of O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Continuous O
event O
recorders O
( O
CERs O
) O
have O
proven O
to O
be O
successful O
in O
diagnosing O
causes O
of O
palpitations O
but O
may O
affect O
patient O
QoL B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

INTERVENTION O
Those O
assigned O
to O
a O
brief O
motivational O
intervention O
( O
MI O
) O
condition O
received O
two O
1-hour O
therapist O
sessions O
following O
assessment O
visits O
, O
1 O
month O
apart O
, O
focusing O
on O
alcohol O
use O
and O
HIV O
risk-taking O
. O
[]

At O
W24 O
, O
12 O
cases O
, O
12 O
cases O
, O
and O
7 O
cases O
showed O
ELISPOT O
positive O
in O
the O
group O
of O
90 O
micrograms O
, O
60 O
micrograms O
, O
and O
placebo O
. O
[]

Research O
questions O
for O
aim O
2 O
were O
as O
follows O
: O
( O
a O
) O
do O
participants O
who O
received O
the O
BCEI O
show O
improvement O
in O
overall B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
, O
and O
( O
b O
) O
is O
the O
QOL O
improvement O
sustained O
over O
time O
. O
['Life-Impact', 'Life-Impact']

Comparison O
of O
fluid O
types O
for O
resuscitation O
after O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
mallard O
ducks O
( O
Anas O
platyrhynchos O
) O
. O
['Physiological-Clinical']

This O
study O
is O
registered O
at O
http O
: O
//clinicaltrials.gov O
as O
NCT00002744 O
. O
[]

OBJECTIVE O
The O
objective O
of O
the O
study O
was O
to O
determine O
the O
effect O
on O
blood B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
of O
a O
daily O
intake O
of O
0.7 O
g O
DHA O
as O
triacylglycerol O
in O
middle-aged O
men O
and O
women O
. O
['Physiological-Clinical']

In O
both O
of O
these O
groups O
of O
patients O
the O
diagnostic O
or O
therapeutic O
radioiodine O
application O
was O
done O
after O
withdrawal O
of O
thyroid O
hormone O
treatment O
. O
[]

However, O
self-testing O
is O
only O
a O
partial O
solution O
to O
increasing O
testing B-outcome ['Life-Impact']
rates O
in O
this O
hard O
to O
reach O
population. O
[['Life-Impact']]

2012 O
American O
Cancer O
Society O
. O
[]

Secretin O
has O
been O
proposed O
as O
a O
treatment O
alternative O
for O
autistic B-outcome ['Life-Impact']
spectrum O
disorders B-outcome ['Life-Impact']
, O
but O
empirical O
support O
is O
lacking O
. O
['Life-Impact', 'Life-Impact']

It O
has O
been O
postulated O
that O
there O
may O
be O
a O
connection O
between O
wheat-gluten/milk-casein O
and O
mental O
disorders O
such O
as O
schizophrenia O
, O
hyperactivity O
and O
autism O
. O
[]

Coverage O
efficiency O
was O
calculated O
as O
coverage O
of O
children O
per O
bednet O
owned O
. O
[]

On O
each O
occasion O
the O
observer O
gave O
the O
child O
a O
pain B-outcome ['Physiological-Clinical']
score O
from O
1 O
( O
no O
pain O
) O
to O
5 O
( O
severe O
pain O
) O
. O
['Physiological-Clinical']

All O
urine O
made O
was O
collected O
. O
[]

0.05). O
[]

Clinical O
usefulness O
of O
serum O
prostate O
specific O
antigen O
for O
the O
detection O
of O
prostate O
cancer O
is O
preserved O
in O
men O
receiving O
the O
dual O
5alpha-reductase O
inhibitor O
dutasteride O
. O
[]

RESULTS O
In O
no O
patient O
group O
was O
there O
a O
late B-outcome ['Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
recorded O
. O
['Physiological-Clinical']

Health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
and O
days B-outcome ['Life-Impact']
missed I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
or O
school B-outcome ['Life-Impact']
were O
also O
reported O
. O
['Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact']

The O
median O
relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
prolonged O
by O
14 O
months O
in O
patients O
treated O
with O
AVCMF O
( O
chi2 O
1 O
= O
11.7 O
; O
P O
= O
0.0006 O
) O
. O
['Mortality']

Group O
I O
had O
normal O
GE O
and O
group O
II O
delayed O
GE O
. O
[]

GNCC B-outcome ['Physiological-Clinical']
was O
associated O
with O
an O
iron O
profile O
similar O
to O
that O
of O
iron O
deficiency O
. O
['Physiological-Clinical']

Women O
who O
had O
prolonged B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
were O
more O
likely O
to O
discontinue O
depot O
medroxyprogesterone O
injections O
. O
['Physiological-Clinical']

Effect O
of O
ranitidine O
on O
the O
disposition B-outcome ['Life-Impact']
of O
orally O
and O
intravenously O
administered O
triazolam O
. O
['Life-Impact']

Ten O
interventions O
were O
given O
during O
8 O
weeks O
followed O
by O
a O
26 O
weeks O
of O
follow O
up O
. O
[]

However O
, O
the O
effects O
on O
residualized O
gains O
in O
parental B-outcome ['Life-Impact']
responsivity I-outcome ['Life-Impact']
from O
Time O
1 O
to O
both O
Times O
2 O
and O
3 O
yielded O
noteworthy O
effect O
sizes O
( O
Glass O
's O
? O
['Life-Impact']

They O
received O
either O
levodopa O
SR O
or O
ropinirole O
for O
6 O
weeks O
, O
followed O
by O
a O
washout O
week O
, O
then O
the O
alternate O
treatment O
for O
6 O
weeks O
. O
[]

0.3 O
, O
4.6 O
? O
[]

Estrone O
decreased O
in O
55.56 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
42.86 O
% O
in O
the O
placebo O
group O
. O
[]

Prolonged O
GnRH O
agonist O
and O
add-back O
therapy O
for O
symptomatic B-outcome ['Physiological-Clinical']
endometriosis I-outcome ['Physiological-Clinical']
: O
long-term O
follow-up O
. O
['Physiological-Clinical']

Publication O
date: O
2019/01/18 O
06:00 O
[entrez] O
[]

Seven O
CSA O
recipients O
became O
hypertensive B-outcome ['Physiological-Clinical']
and O
four O
required O
anti-hypertensive B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Toothbrush O
heads O
were O
vortexed O
and O
cultured O
for O
Prevotella O
species O
( O
Ps O
) O
, O
Porphyromonas O
gingivalis O
( O
Pg O
) O
, O
Actinobacillus O
actinomycetemcomitans O
( O
Aa O
) O
, O
and O
non-specific O
colony-forming O
units O
( O
NS O
) O
. O
[]

The O
effect O
of O
salivary O
exposure O
time O
on O
the O
abrasive B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
of O
acid-eroded O
dentine O
was O
evaluated O
in O
situ O
. O
['Physiological-Clinical']

Of O
interest O
were O
: O
( O
1 O
) O
the O
number O
of O
overlaps O
and O
the O
percentage O
of O
teeth O
showing O
the O
alveolar O
crest O
; O
( O
2 O
) O
proper O
film O
positioning O
; O
and O
( O
3 O
) O
the O
percentage O
of O
cone O
cutting O
. O
[]

The O
OPTIMA O
study O
. O
[]

Journal O
ID: O
9308586 O
[]

Growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
GH-releasing O
hormone O
alone O
or O
combined O
with O
arginine O
in O
patients O
with O
adrenal O
incidentaloma O
: O
evidence O
for O
enhanced O
somatostatinergic O
tone O
. O
['Physiological-Clinical']

For O
the O
first O
( O
6-month O
) O
and O
second O
( O
12-month O
) O
surveillance O
cytology O
tests O
separately O
, O
women O
were O
categorized O
as O
'on-time O
attendees O
' O
( O
attended O
?6 O
months O
of O
test O
being O
due O
) O
, O
'late O
attendees O
' O
( O
attended O
greater O
than O
6 O
months O
after O
test O
was O
due O
) O
or O
'non-attendees O
' O
( O
failed O
to O
attend O
) O
. O
[]

T O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS)], O
Hamilton O
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(HAMA) O
were O
used O
to O
assess O
the O
efficacy, O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
(PSQI) O
was O
used O
to O
evaluate O
the O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
and O
Treatment O
Emergent O
Symptom O
Scale O
(TESS) O
was O
used O
to O
evaluate O
the O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
Data O
were O
analyzed O
in O
the O
intention-to-treat O
sample. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

CONCLUSIONS O
Both O
treatments O
seem O
to O
have O
a O
positive O
influence O
on O
back O
muscle O
function O
by O
improving O
muscle B-outcome ['Physiological-Clinical']
symmetry O
; O
however O
, O
the O
treatments O
had O
no O
effect O
on O
the O
flexion-relaxation B-outcome ['Physiological-Clinical']
phenomenon I-outcome ['Physiological-Clinical']
after O
1 O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
comparison O
of O
a O
non-ionic O
dimer O
, O
iodixanol O
with O
a O
non-ionic O
monomer O
, O
iohexol O
in O
low O
dose O
intravenous O
urography O
. O
[]

[ O
Randomized O
clinical O
trial O
between O
nutritional O
counselling O
and O
commercial O
hypocaloric O
diet O
in O
weight O
loss O
in O
obese O
patients O
with O
chronic O
arthropathy O
] O
. O
[]

Subjects O
were O
treated O
for O
3 O
months O
, O
with O
follow-up O
visits O
at O
2 O
, O
4 O
, O
6 O
, O
and O
12 O
weeks O
. O
[]

A O
randomized O
controlled O
trial O
of O
a O
health-promotion O
programme O
and O
its O
effect O
on O
ADL B-outcome ['Life-Impact']
dependence O
and O
self-reported O
health B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
for O
the O
elderly O
visually O
impaired O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
Physician-observed B-outcome ['Physiological-Clinical']
otorrhea I-outcome ['Physiological-Clinical']
was O
reported O
in O
5 O
( O
4.95 O
% O
) O
patients O
receiving O
Ciprodex O
and O
39 O
( O
39.39 O
% O
) O
patients O
receiving O
no O
treatment O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

Eight O
children O
( O
seven O
on O
CRT O
+ O
ITC O
, O
one O
on O
CSpRT O
) O
developed O
presumed O
therapy B-outcome ['Physiological-Clinical']
related I-outcome ['Physiological-Clinical']
encephalopathy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
increased O
substitution O
of O
affricates B-outcome ['Life-Impact']
by I-outcome ['Life-Impact']
fricatives I-outcome ['Life-Impact']
for O
children O
using O
NLFC O
, O
compared O
to O
children O
using O
conventional O
amplification O
. O
['Life-Impact']

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
parenteral O
nutrition O
on O
netilmicin O
pharmacokinetics B-outcome ['Physiological-Clinical']
in O
critically O
ill O
neonates O
during O
the O
first O
week O
of O
life O
. O
['Physiological-Clinical']

Six O
patients O
dropped O
out O
before O
the O
fifth O
postoperative O
day O
, O
leaving O
79 O
patients O
in O
the O
control O
group O
and O
81 O
patients O
in O
the O
study O
group O
. O
[]

A O
number O
of O
quinolone O
antibacterial O
agents O
, O
particularly O
enoxacin O
, O
pefloxacin O
, O
pipemidic O
acid O
and O
ciprofloxacin O
, O
are O
known O
to O
decrease O
the O
clearance O
of O
methylxanthines O
. O
[]

The O
safety O
profile O
of O
TISSEEL O
VH O
S/D O
was O
very O
similar O
to O
that O
of O
currently O
licensed O
TISSEEL O
VH O
as O
assessed O
by O
the O
safety O
endpoints O
. O
[]

Treatment O
strategies O
targeting O
the O
PF O
joint O
may O
be O
warranted O
to O
mitigate O
the O
specific O
lower O
extremity O
impairments O
and O
functional O
problems O
present O
in O
this O
patient O
population O
. O
[]

Cardiopulmonary O
exercise O
testing O
was O
performed O
at O
baseline O
and O
after O
10 O
weeks O
. O
[]

It O
is O
proposed O
that O
manikin O
training O
alone O
may O
be O
adopted O
as O
a O
future O
training O
modality O
if O
, O
as O
is O
expected O
, O
the O
use O
of O
the O
LMA O
in O
resuscitation O
becomes O
more O
commonplace O
. O
[]

The O
differences O
of O
morbidity B-outcome ['Physiological-Clinical']
, O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
were O
compared O
between O
the O
two O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

In O
addition O
, O
CETP O
concentration O
had O
a O
highly O
positive O
correlation O
with O
serum B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
of O
E O
( O
2 O
) O
( O
r=0.243 O
, O
P O
< O
0.001 O
) O
, O
while O
negative O
correlation O
of O
CETP B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
with O
serum B-outcome ['Physiological-Clinical']
concentration O
of O
FSH B-outcome ['Physiological-Clinical']
was O
found O
( O
r=-0.273 O
, O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
A O
complete O
response O
was O
obtained O
in O
87 O
% O
lesions O
treated O
with O
PLA O
and O
in O
93 O
% O
lesions O
treated O
with O
RFA O
( O
p O
= O
ns O
) O
. O
[]

Dose-response O
comparison O
of O
RRR-alpha-tocopherol O
and O
all-racemic O
alpha-tocopherol O
on O
LDL O
oxidation O
. O
[]

In O
the O
absence O
of O
obesity O
or O
overweight O
, O
the O
presence O
of O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
?100 O
mg/dL O
, O
HOMA-IR O
index O
?3 O
, O
triglyceride O
levels O
?150 O
mg/dL O
and/or O
systolic O
and O
diastolic O
blood O
pressure O
?140 O
and O
90 O
mmHg O
defined O
the O
presence O
of O
the O
MONW O
phenotype O
. O
['Physiological-Clinical']

On O
the O
other O
hand O
, O
orchiectomy O
has O
few O
, O
if O
any O
, O
complications O
. O
[]

Trials O
involving O
larger O
patient O
populations O
will O
be O
necessary O
to O
confirm O
the O
results O
of O
this O
preliminary O
study O
and O
to O
determine O
the O
extent O
of O
clinical O
improvement O
, O
subpopulations O
benefited O
, O
role O
in O
heart O
failure O
therapeutics O
, O
and O
so O
forth O
. O
[]

In O
patients O
with O
dementia O
and O
mild O
depression O
( O
DSM-III-R O
290.21 O
) O
, O
the O
effect O
of O
low O
doses O
of O
the O
antidepressant O
maprotiline O
( O
up O
to O
75 O
mg/d O
) O
was O
examined O
. O
[]

Tacrolimus/sirolimus O
vs O
tacrolimus/methotrexate O
as O
GVHD O
prophylaxis O
after O
matched O
, O
related O
donor O
allogeneic O
HCT O
. O
[]

RESULTS O
The O
time O
taken O
for O
the O
infusion O
to O
be O
started O
and O
the O
final O
concentration O
of O
the O
drugs B-outcome ['Resource-use']
were O
measured O
. O
['Resource-use']

The O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rate O
at O
three O
years O
was O
also O
very O
similar O
in O
the O
two O
groups O
( O
86 O
percent O
in O
the O
laparoscopic-surgery O
group O
and O
85 O
percent O
in O
the O
open-colectomy O
group O
; O
P=0.51 O
; O
hazard O
ratio O
for O
death B-outcome ['Mortality']
in O
the O
laparoscopic-surgery O
group O
, O
0.91 O
; O
95 O
percent O
confidence O
interval O
, O
0.68 O
to O
1.21 O
) O
, O
with O
no O
significant O
difference O
between O
groups O
in O
the O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
or O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
for O
patients O
with O
any O
stage O
of O
cancer O
. O
['Mortality', 'Mortality', 'Physiological-Clinical', 'Mortality']

Progress O
was O
measured O
by O
patient O
's O
assessment O
on O
pain O
at O
rest B-outcome ['Life-Impact']
and O
on O
movement B-outcome ['Physiological-Clinical']
and O
by O
physician O
's O
assessment O
on O
functional O
impairment O
. O
['Life-Impact', 'Physiological-Clinical']

A O
wash-out O
period O
of O
3 O
weeks O
between O
placebo O
and O
lisinopril O
was O
observed O
. O
[]

SCORAD O
decreased O
in O
the O
Bifidobacterium O
lactis O
Bb-12 O
group O
to O
0 O
( O
0-3.8 O
) O
, O
and O
in O
the O
Lactobacillus O
GG O
group O
to O
1 O
( O
0.1-8.7 O
) O
, O
vs O
unsupplemented O
13.4 O
( O
4.5-18.2 O
) O
, O
median O
( O
interquartile O
range O
) O
, O
in O
parallel O
with O
a O
reduction O
in O
the O
concentration O
of O
soluble O
CD4 B-outcome ['Physiological-Clinical']
in O
serum O
and O
eosinophilic O
protein O
X O
in O
urine O
. O
['Physiological-Clinical']

Given O
its O
efficacy O
when O
combined O
with O
other O
therapy O
regimens O
, O
the O
current O
study O
examined O
the O
efficacy O
of O
mental O
practice O
when O
combined O
with O
mCIT O
versus O
mCIT O
only O
using O
randomized O
, O
controlled O
methods O
. O
[]

Two O
separate O
research O
laboratories O
undertook O
independent O
randomized O
repeated O
measures O
experiments O
, O
both O
designed O
to O
detect O
an O
effect O
of O
the O
rubber O
hand O
illusion O
on O
experimentally O
induced O
hand B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
particular O
, O
the O
incidence O
and O
magnitude O
of O
febrile B-outcome ['Physiological-Clinical']
temperatures I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
between O
the O
4th O
and O
8th O
days O
of O
treatment O
. O
['Physiological-Clinical']

AIM O
The O
aim O
of O
this O
study O
was O
to O
examine O
the O
pharmacokinetics O
of O
donepezil O
HCl O
and O
digoxin O
separately O
, O
and O
in O
combination O
, O
following O
administration O
of O
single O
oral O
doses O
. O
[]

Tunnelling O
of O
the O
catheter O
subcutaneously O
for O
a O
distance O
of O
5 O
cm O
reduced O
the O
incidence O
of O
inward O
migration O
of O
1 O
cm O
or O
more O
( O
p O
< O
0.01 O
) O
compared O
to O
a O
standard O
method B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fixation I-outcome ['Physiological-Clinical']
with O
a O
transparent B-outcome ['Physiological-Clinical']
adhesive I-outcome ['Physiological-Clinical']
dressing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Local O
therapy O
with O
glycerol O
lidocaine O
eardrops O
is O
a O
safe O
, O
and O
cost-effective O
treatment O
for O
the O
widely O
spread O
clinical O
picture O
of O
acute O
abacterial O
otitis O
externa O
. O
['Resource-use']

To O
evaluate O
bone O
biochemical O
markers O
as O
predictors O
of O
the O
efficacy O
of O
a O
hormone O
replacement O
therapy O
( O
HRT O
) O
, O
we O
studied O
the O
bone O
changes O
induced O
by O
the O
cessation O
and O
return O
of O
ovarian O
function O
in O
28 O
patients O
treated O
for O
6 O
months O
with O
a O
GnRH O
agonist O
. O
[]

Funded O
by O
Alnylam O
Pharmaceuticals; O
ClinicalTrials.gov O
number, O
NCT02452372 O
.). O
[]

Overall O
, O
99 O
% O
of O
women O
found O
office O
polypectomy O
to O
be O
acceptable B-outcome ['Life-Impact']
, O
with O
only O
one O
woman O
in O
the O
electrosurgical O
resection O
group O
considering O
the O
procedure O
unacceptable B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

All O
patients O
were O
operated O
and O
resected O
without O
difficulty O
. O
[]

NCE O
decreased O
linearly O
( O
P O
< O
0.05 O
) O
as O
the O
level O
of O
RDN O
increased O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

Therefore O
, O
we O
conclude O
that O
4-week O
H-AT O
intervention O
reduced O
senescent O
T-lymphocyte O
subsets O
with O
increasing O
IFN-? O
level O
in O
blood O
, O
which O
responses O
are O
accompanied O
by O
depressed O
oxidative O
stress O
and O
pro-inflammatory O
cytokine O
production O
. O
[]

The O
aim O
of O
the O
study O
was O
to O
compare O
the O
influence O
of O
orlistat O
(IO), O
metformin O
(IM), O
or O
calorie-restricted O
diet O
(LC) O
on O
insulin-like B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
factor-1 I-outcome ['Physiological-Clinical']
, O
with O
special O
respect O
to O
insulin-resistance O
status. O
[['Physiological-Clinical']]

Clinical O
pathway O
for O
fractured O
neck O
of O
femur O
: O
a O
prospective O
, O
controlled O
study O
. O
[]

Patients O
were O
divided O
into O
two O
groups O
of O
20 O
patients. O
[]

GAS O
is O
a O
promising O
measurement O
approach O
. O
[]

Thereafter O
, O
a O
laryngeal O
mask O
airway O
was O
inserted O
and O
, O
with O
spontaneous O
ventilation O
, O
anesthesia O
was O
maintained O
by O
administering O
isoflurane O
( O
end-tidal O
0.7 O
% O
to O
1.2 O
% O
) O
and O
70 O
% O
nitrous O
oxide O
( O
N2O O
) O
in O
oxygen O
. O
[]

In O
comparison O
, O
the O
[]

In O
the O
post-therapy O
period O
, O
there O
were O
no O
group O
differences O
in O
special B-outcome ['Life-Impact']
education I-outcome ['Life-Impact']
['Life-Impact']

In O
HIV-seronegative O
children O
, O
diarrhoea B-outcome ['Physiological-Clinical']
resolved O
in O
14 O
( O
56 O
% O
) O
of O
25 O
receiving O
nitazoxanide O
and O
5 O
( O
23 O
% O
) O
of O
22 O
receiving O
placebo O
( O
difference O
33 O
% O
, O
95 O
% O
CI O
7-59 O
; O
p=0.037 O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
ketorolac O
tromethamine O
10 O
mg O
and O
30 O
mg O
suppositories O
in O
comparison O
to O
placebo O
, O
after O
single O
dose O
administration O
in O
patients O
suffering O
from O
post-operative O
pain O
after O
cholecystectomy O
. O
['Life-Impact']

Analgesia B-outcome ['Resource-use']
after O
caesarean O
section O
with O
intramuscular O
ketorolac O
or O
pethidine O
. O
['Resource-use']

The O
eligible O
subjects O
were O
HIV-infected O
Thai O
adults O
who O
had O
never O
received O
anti-retrovirals O
, O
had O
a O
Karnofski O
Performance O
Score O
( O
KPS O
) O
of O
> O
or O
= O
70 O
, O
and O
had O
no O
opportunistic O
infections O
. O
[]

Normal O
individuals O
who O
evenly O
matched O
with O
the O
study O
group O
were O
assessed O
for O
normal O
respiratory O
function O
parameters O
. O
[]

Further O
outcome O
measures O
included O
predictors O
of O
remission B-outcome ['Physiological-Clinical']
and O
other O
clinical O
variables O
over O
time O
. O
['Physiological-Clinical']

In O
patients O
with O
mitral O
valve O
replacement O
, O
L-carnitine O
therapy O
was O
associated O
with O
significantly O
higher O
concentrations O
of O
pyruvate B-outcome ['Physiological-Clinical']
, O
ATP B-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
in O
papillary O
muscle O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:Nigerian O
journal O
of O
clinical O
practice O
[]

INTACT O
Investigators O
. O
[]

The O
integrity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
lenses I-outcome ['Physiological-Clinical']
and O
the O
ocular B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to O
lens O
wear O
were O
monitored O
in O
both O
groups O
every O
three O
months O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Autonomy O
was O
usually O
recovered O
rapidly O
, O
but O
the O
degree O
of O
recovery O
depended O
on O
the O
patient O
's O
previous O
autonomy O
( O
p O
< O
0.0001 O
) O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Decompression B-outcome ['Physiological-Clinical']
phase O
['Physiological-Clinical']

In O
addition O
, O
trough O
blood O
samples O
were O
collected O
on O
days O
4 O
, O
5 O
, O
10 O
, O
and O
11 O
prior O
to O
the O
morning O
dose O
. O
[]

Title: O
Cobalt O
chromium-Titanium O
rods O
versus O
Titanium-Titanium O
rods O
for O
treatment O
of O
adolescent O
idiopathic O
scoliosis; O
which O
type O
of O
rod O
has O
better O
postoperative O
outcomes? O
[]

Title: O
Bilateral O
versus O
Single O
Internal-Thoracic-Artery O
Grafts O
at O
10 O
Years. O
[]

Up O
to O
650 O
patients O
from O
80 O
sites O
will O
be O
recruited O
and O
randomized O
in O
a O
3:2 O
ratio O
to O
receive O
active O
treatment O
or O
standard O
optimal O
medical O
therapy O
. O
[]

This O
study O
was O
funded O
by O
the O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
and O
the O
National O
Cancer O
Institute O
; O
and O
the O
trial O
was O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00406393 O
. O
[]

SESSION O
C O
An O
acupuncture O
needle O
( O
Hwato O
, O
& O
emptyv O
; O
0.30x30 O
mm O
) O
was O
inserted O
perpendicular O
superficially O
into O
the O
skin O
overlying O
the O
Hegu O
point O
on O
the O
left O
hand O
. O
[]

8.59 O
mm O
Hg O
, O
p O
< O
0.05 O
) O
groups O
. O
[]

BACKGROUND: O
Congenital O
nasolacrimal O
duct O
obstruction O
(CNLDO) O
is O
common O
and. O
[]

Journal-Name:The O
bone O
& O
joint O
journal O
[]

METHODS O
Participants O
were O
236 O
heavy O
drinking O
smokers O
in O
a O
randomized O
clinical O
trial O
testing O
the O
efficacy O
of O
incorporating O
brief O
alcohol O
intervention O
into O
smoking O
cessation O
treatment O
. O
[]

BACKGROUND O
Routine O
oral O
calcium O
and O
vitamin O
D O
supplementation O
may O
prevent O
hypocalcemic O
crisis O
, O
but O
its O
efficacy O
has O
not O
been O
studied O
in O
patients O
undergoing O
thyroidectomy O
plus O
central O
neck O
dissection O
( O
CND O
) O
. O
[]

Differences O
in O
straylight O
between O
baseline O
( O
without O
CL O
) O
and O
with O
the O
clear O
CL O
in O
place O
were O
neither O
statistically O
significant O
( O
p O
= O
0.066 O
) O
nor O
was O
there O
a O
significant O
difference O
between O
baseline O
and O
the O
amber O
CL O
( O
p O
= O
0.052 O
) O
. O
[]

Eighteen O
patients O
who O
had O
undergone O
stoma O
surgery O
were O
assessed O
with O
respect O
to O
their O
anxiety B-outcome ['Life-Impact']
level O
and O
self-reported O
quality O
of O
life O
( O
QoL O
) O
on O
three O
occasions O
; O
namely O
, O
immediately O
after O
surgery O
, O
5 O
weeks O
after O
surgery O
, O
and O
10 O
weeks O
after O
surgery O
. O
['Life-Impact']

At O
week O
8 O
, O
olmesartan O
reduced O
mean O
SeDBP B-outcome ['Physiological-Clinical']
more O
than O
losartan O
( O
P O
< O
.001 O
) O
; O
more O
patients O
in O
the O
olmesartan O
medoxomil O
group O
achieved O
a O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
goal O
of O
< O
140/90 O
mm O
Hg O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
total O
power O
output O
used O
for O
RF O
was O
lower O
in O
group O
1 O
than O
in O
group O
2 O
( O
median O
271 O
vs. O
1,045 O
W.m O
) O
. O
[]

A O
prospective O
randomized O
trial O
. O
[]

SD O
1.4 O
? O
[]

The O
median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
similar O
between O
treatments O
, O
being O
27.4 O
months O
and O
27.7 O
months O
in O
fulvestrant O
and O
anastrozole-treated O
patients O
, O
respectively O
( O
hazards O
ratio O
, O
0.98 O
; O
95 O
% O
confidence O
interval O
, O
0.84-1.15 O
; O
P O
= O
0.809 O
) O
. O
['Mortality']

The O
primary O
outcome O
measure O
was O
the O
irritability B-outcome ['Life-Impact']
subscale O
of O
Aberrant O
Behavior O
Checklist-Community O
( O
ABC-C O
) O
. O
['Life-Impact']

Three O
patients O
had O
ischemic O
heart O
disease O
, O
13 O
had O
dilated O
cardiomyopathy O
, O
and O
three O
had O
valvular O
disease O
; O
16 O
patients O
were O
in O
New O
York O
Heart O
Association O
class O
II O
, O
and O
three O
patients O
were O
in O
New O
York O
Heart O
Association O
class O
III O
. O
[]

TEE O
was O
performed O
for O
peripheral O
embolism O
in O
two O
patients O
, O
stroke O
or O
transient O
ischemic O
attack O
in O
six O
, O
stroke O
and O
fever O
in O
two O
, O
fever O
in O
one O
patient O
, O
as O
a O
routine O
postoperative O
examination O
in O
two O
patients O
, O
and O
for O
other O
reasons O
in O
seven O
. O
[]

These O
changes O
were O
all O
independent O
of O
HbA1c O
level O
. O
[]

Prior O
to O
caries O
elimination O
, O
and O
again O
after O
three O
months O
, O
the O
gingival O
index O
was O
used O
to O
assess O
the O
gingival B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
of O
study O
subjects O
. O
['Physiological-Clinical']

METHODS O
We O
conducted O
a O
study O
including O
15 O
depressive O
patients O
who O
had O
been O
under O
antidepressant O
treatment O
for O
at O
least O
one O
month O
. O
[]

Similar O
compliance O
and O
effect O
of O
treatment O
in O
chronic O
hepatitis O
C O
resulting O
from O
intravenous O
drug O
use O
in O
comparison O
with O
other O
infection O
causes O
. O
[]

Title: O
Efficacy O
of O
different O
interaction O
devices O
using O
non-immersive O
virtual O
tasks O
in O
individuals O
with O
Amyotrophic O
Lateral O
Sclerosis: O
a O
cross-sectional O
randomized O
trial. O
[]

BACKGROUND O
Three-year O
follow-up O
of O
major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
event O
( O
MACE B-outcome ['Physiological-Clinical']
) O
( O
death O
, O
nonfatal O
myocardial O
infarction O
, O
target O
lesion O
revascularization O
) O
and O
the O
predictors O
of O
MACEs O
in O
diabetic O
patients O
after O
sirolimus-eluting O
stent O
( O
SES O
) O
or O
paclitaxel-eluting O
stent O
( O
PES O
) O
implantation O
have O
not O
been O
reported O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Bivariate O
and O
multivariate O
logistic O
regression O
analysis O
assessed O
correlates O
of O
different O
indicators O
of O
psychological O
distress. O
[]

RESULTS: O
In O
the O
per-protocol O
population, O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
occurred O
in O
98 O
of O
1063 O
participants O
(9.2%) O
in O
the O
education O
group O
and O
in O
67 O
of O
1058 O
(6.3%) O
in O
the O
decolonization O
group; O
84.8% O
of O
the O
MRSA B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
led O
to O
hospitalization B-outcome ['Resource-use']
. O
Infection B-outcome ['Physiological-Clinical']
from O
any O
cause O
occurred O
in O
23.7% O
of O
the O
participants O
in O
the O
education O
group O
and O
19.6% O
of O
those O
in O
the O
decolonization O
group; O
85.8% O
of O
the O
infections B-outcome ['Physiological-Clinical']
led O
to O
hospitalization B-outcome ['Resource-use']
. O
The O
hazard O
of O
MRSA B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
decolonization O
group O
than O
in O
the O
education O
group O
(hazard O
ratio, O
0.70; O
95% O
confidence O
interval O
[CI], O
0.52 O
to O
0.96; O
P=0.03; O
number O
needed O
to O
treat O
to O
prevent O
one O
infection B-outcome ['Physiological-Clinical']
, O
30; O
95% O
CI, O
18 O
to O
230); O
this O
lower O
hazard O
led O
to O
a O
lower O
risk O
of O
hospitalization B-outcome ['Resource-use']
due I-outcome ['Resource-use']
to I-outcome ['Resource-use']
MRSA I-outcome ['Resource-use']
infection I-outcome ['Resource-use']
(hazard O
ratio, O
0.71; O
95% O
CI, O
0.51 O
to O
0.99). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Resource-use']]

METHODS O
Phase O
1 O
involved O
65 O
children O
who O
received O
one O
round O
of O
DMSA O
( O
3 O
days O
) O
. O
[]

Ribavirin O
1000 O
mg/day O
( O
< O
75 O
kg O
) O
or O
1200 O
mg/day O
( O
> O
or=75 O
kg O
) O
and O
peginterferon O
alpha-2a O
180 O
microg/week O
were O
considered O
optimal O
. O
[]

There O
were O
no O
significant O
differences O
in O
the O
test O
results O
after O
placebo O
and O
after O
progesterone O
. O
[]

Healing B-outcome ['Physiological-Clinical']
rates O
were O
shown O
to O
be O
comparable O
for O
all O
treatment O
regimens O
. O
['Physiological-Clinical']

Although O
candidiasis O
is O
the O
most O
common O
infection O
, O
mold O
infections O
are O
increasing O
in O
frequency O
. O
[]

RESULTS O
The O
physical O
activity O
group O
improved O
in O
sleep O
quality O
on O
the O
global O
PSQI O
( O
p O
< O
.0001 O
) O
, O
sleep O
latency O
( O
p=.049 O
) O
, O
sleep O
duration O
( O
p=.04 O
) O
, O
daytime O
dysfunction O
( O
p=.027 O
) O
, O
and O
sleep O
efficiency O
( O
p=.036 O
) O
PSQI O
sub-scores O
compared O
to O
the O
control O
group O
. O
[]

However O
, O
the O
patients O
frequently O
reported O
gastrointestinal B-outcome ['Physiological-Clinical']
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Patients O
with O
and O
without O
LV O
hypertrophy O
did O
not O
differ O
significantly O
in O
acute O
mortality B-outcome ['Mortality']
during O
hospitalization B-outcome ['Resource-use']
, O
progression B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Q I-outcome ['Physiological-Clinical']
waves I-outcome ['Physiological-Clinical']
, O
reinfarction O
by O
CK-MB B-outcome ['Physiological-Clinical']
criteria I-outcome ['Physiological-Clinical']
or O
angina B-outcome ['Physiological-Clinical']
associated O
with O
transient O
electrocardiographic O
changes O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
's O
Breast O
Cancer O
Prevention O
Trial O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Differences O
in O
reach O
and O
attrition O
between O
Web-based O
and O
print-delivered O
tailored O
interventions O
among O
adults O
over O
50 O
years O
of O
age O
: O
clustered O
randomized O
trial O
. O
[]

CONCLUSIONS O
All O
three O
interventions O
resulted O
in O
increased O
knowledge B-outcome ['Life-Impact']
about O
breast O
cancer O
and O
screening O
. O
['Life-Impact']

Patients O
most O
frequently O
complain O
of O
dysphagia O
and O
therapy O
resistant O
constipation O
, O
as O
far O
as O
the O
gastrointestinal O
tract O
is O
concerned O
. O
[]

DESIGN O
Participating O
physicians O
were O
randomized O
to O
either O
the O
demonstration O
or O
the O
control O
arm O
, O
and O
patients O
were O
assigned O
to O
a O
study O
arm O
based O
on O
the O
randomization O
of O
their O
physicians O
. O
[]

PATIENTS O
AND O
METHOD O
A O
prospective O
, O
randomized O
, O
clinical O
study O
with O
participation O
of O
medical O
statisticians O
was O
performed O
. O
[]

The O
results O
indicate O
successful B-outcome ['Life-Impact']
implementation I-outcome ['Life-Impact']
of O
the O
HBHS O
program O
. O
['Life-Impact']

RESULTS O
Thirty-three O
subjects O
( O
31 O
male O
subjects O
, O
2 O
female O
subjects O
; O
aged O
3.2-10.7 O
years O
) O
were O
randomized O
in O
the O
study O
. O
[]

In O
general O
, O
the O
Pakistanis O
avoided O
any O
direct O
sunshine O
exposure O
, O
and O
no O
relation O
between O
outdoor O
activity O
and O
serum O
level O
of O
25-hydroxyvitamin O
D3 O
was O
found O
. O
[]

Signal-averaged B-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
were O
recorded O
in O
a O
subgroup O
of O
24 O
patients O
. O
['Physiological-Clinical']

Outcome O
measures O
included O
measures O
of O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
and O
global B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

IMPACT O
This O
study O
confirms O
the O
overall O
importance O
of O
the O
HOXB13 O
G84E O
mutation O
in O
prostate O
cancer O
susceptibility O
. O
[]

A O
randomised O
controlled O
trial O
of O
ranibizumab O
with O
and O
without O
ketorolac O
eyedrops O
for O
exudative B-outcome ['Physiological-Clinical']
age-related I-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
degeneration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
study O
itself O
demonstrates O
that O
it O
is O
possible O
to O
do O
strictly O
controlled O
trials O
for O
homeopathic O
drugs O
and O
with O
medical O
practitioners O
. O
[]

Each O
experimental O
participant O
had O
a O
yoked O
control O
partner O
who O
received O
the O
same O
pattern O
of O
changes O
in O
array O
irrespective O
of O
their O
engagement O
index O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

The O
antimycotic O
antibiotic O
griseofulvin O
inhibits O
the O
MA-sensitive O
PMN O
chemotaxis O
in O
vitro O
in O
concentrations O
far O
below O
those O
obtained O
in O
serum O
during O
antimycotic O
therapy O
. O
[]

Patients O
were O
randomly O
assigned O
to O
WP O
+ O
NCHT O
, O
PO O
+ O
NCHT O
, O
WP O
+ O
AHT O
, O
or O
PO O
+ O
AHT O
. O
[]

CONTRAST O
protocol O
consisted O
of O
alternating O
heavy-light O
resistance O
( O
15-50 O
% O
body O
mass O
) O
with O
soccer-specific O
drills O
( O
small-sided O
games O
or O
technical O
skills O
) O
. O
[]

Publication O
date: O
2019/02/20 O
06:00 O
[medline] O
[]

Seventeen O
individuals O
had O
approximal O
surfaces O
with O
consistently O
high O
or O
consistently O
low O
S. O
mutans B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical']

Following O
a O
4-week O
treatment O
with O
open-label O
TIO O
18 O
mcg O
once O
daily O
, O
subjects O
were O
randomized O
in O
a O
double-blind O
fashion O
to O
either O
the O
addition O
of O
FSC O
250/50 O
DISKUS O
twice O
daily O
or O
matching O
placebo O
. O
[]

Isometric O
back O
extensor O
strength O
, O
spinal O
range O
of O
motion O
, O
and O
scores O
for O
quality O
of O
life O
were O
evaluated O
at O
baseline O
and O
4 O
months O
. O
[]

Effects O
of O
interaction O
of O
RRR-alpha-tocopheryl O
acetate O
and O
fish O
oil O
on O
low-density-lipoprotein O
oxidation O
in O
postmenopausal O
women O
with O
and O
without O
hormone-replacement O
therapy O
. O
[]

There O
was O
a O
paucity O
of O
bacterial O
species O
at O
baseline O
, O
although O
larger O
infants O
had O
more O
bacterial B-outcome ['Physiological-Clinical']
species I-outcome ['Physiological-Clinical']
( O
1.59 O
+/- O
0.13 O
( O
SEM O
) O
vs O
1.11 O
+/- O
0.12 O
; O
P O
< O
0.03 O
) O
and O
higher O
mean O
log B-outcome ['Physiological-Clinical']
colony I-outcome ['Physiological-Clinical']
forming I-outcome ['Physiological-Clinical']
units I-outcome ['Physiological-Clinical']
( O
CFU B-outcome ['Physiological-Clinical']
) O
( O
8.79 O
+/- O
0.43 O
vs O
7.22 O
+/- O
0.63 O
; O
P O
< O
0.05 O
) O
compared O
with O
infants O
weighing O
less O
than O
1500 O
g O
LGG O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Accordingly O
, O
the O
authors O
used O
mood O
inventories O
and O
psychomotor O
tests O
to O
characterize O
the O
effects O
of O
remifentanil O
in O
healthy O
, O
non-drug-abusing O
volunteers O
. O
[]

METHODS: O
Eighty-two O
patients O
with O
T1-3bN0M0 O
prostate O
cancer O
who O
had O
not O
received O
androgen-deprivation O
therapy O
were O
randomized O
to O
one O
of O
five O
arms: O
Arm O
1, O
60 O
cobalt O
gray O
equivalent O
(CGE)/20 O
fractions/5 O
weeks; O
Arm O
2, O
54 O
CGE/15 O
fractions/5 O
weeks; O
Arm O
3, O
47 O
CGE/10 O
fractions/5 O
weeks; O
Arm O
4, O
35 O
CGE/5 O
fractions/2.5 O
weeks; O
and O
Arm O
5, O
35 O
CGE/5 O
fractions/4 O
weeks. O
[]

The O
between-group O
difference O
in O
the O
incidence O
of O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
not O
significant O
(146 O
of O
527 O
participants O
[27.7%] O
in O
the O
intravenous O
group O
and O
138 O
of O
527 O
[26.2%] O
in O
the O
oral O
group; O
P=0.58). O
[['Adverse-effects']]

Capsular O
contracture O
around O
saline-filled O
fine O
textured O
and O
smooth O
mammary O
implants O
: O
a O
prospective O
7.5-year O
follow-up O
. O
[]

Genome-wide O
association O
has O
identified O
groups O
of O
genomic O
markers O
associated O
with O
successful O
quitting O
, O
allowing O
us O
to O
develop O
a O
v1.0 O
quit-success O
genotype O
score O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
8 O
hours O
of O
continuous O
low-level O
heatwrap O
therapy O
for O
the O
treatment O
of O
acute O
nonspecific O
low O
back O
pain O
( O
LBP O
) O
. O
[]

To O
establish O
whether O
or O
not O
glaucomatous B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
is O
reversible O
, O
we O
obtained O
pattern-reversal B-outcome ['Resource-use']
electroretinograms I-outcome ['Resource-use']
( I-outcome ['Resource-use']
PERGs I-outcome ['Resource-use']
) I-outcome ['Resource-use']
and O
visual O
evoked O
potentials O
( O
VEPs O
) O
in O
25 O
eyes O
of O
25 O
patients O
suffering O
from O
bilateral O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
before O
and O
after O
argon-laser O
trabeculoplasty O
. O
['Physiological-Clinical', 'Resource-use']

BACKGROUND O
This O
study O
evaluated O
the O
relative O
effects O
on O
compliance O
with O
recommended O
lifestyle O
changes O
of O
two O
experimental O
videotapes O
that O
involved O
different O
approaches O
for O
preparing O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
patients O
for O
the O
posthospital O
recovery O
period O
. O
[]

We O
enrolled O
73 O
children O
aged O
less O
than O
36 O
months O
who O
were O
admitted O
with O
a O
clinical O
diagnosis O
of O
whooping O
cough O
. O
[]

The O
primary O
indicator O
was O
the O
proportion O
of O
elderly O
survivors O
of O
AMI O
at O
each O
study O
hospital O
who O
filled O
a O
prescription O
for O
a O
beta-blocker O
within O
30 O
days O
after O
discharge O
. O
[]

RESULTS O
In O
the O
590 O
subjects O
enrolled O
, O
the O
rate O
of O
adherence B-outcome ['Life-Impact']
was O
greater O
in O
the O
3RH O
than O
in O
the O
6H O
arm O
( O
72 O
% O
vs. O
52.4 O
% O
, O
P O
= O
0.001 O
) O
. O
['Life-Impact']

Patients O
with O
poor O
general O
condition O
( O
Karnofsky O
score O
less O
than O
30 O
% O
) O
, O
poor O
pulmonary O
function O
( O
forced O
expiratory O
volume O
in O
1 O
second O
less O
than O
0.5 O
L O
) O
, O
or O
trapped O
lungs O
were O
excluded O
from O
this O
study O
. O
[]

Those O
results O
coupled O
with O
the O
known O
composition O
characteristics O
of O
Plasmatein O
were O
used O
as O
the O
starting O
basis O
to O
formulate O
test O
lots O
of O
synthetic O
serum O
substitute O
( O
SSS O
) O
. O
[]

However O
, O
the O
protocols O
used O
and O
the O
results O
found O
in O
the O
3 O
RCTs O
were O
diverse O
. O
[]

Following O
completion O
of O
a O
2-week O
baseline O
period O
, O
435 O
adults O
with O
stable O
, O
symptomatic O
, O
smoking-related O
COPD O
were O
randomized O
to O
receive O
either O
500 O
microg O
sibenadet O
or O
placebo O
delivered O
via O
pressurized O
metered O
dose O
inhaler O
( O
pMDI O
) O
, O
three O
times O
daily O
for O
52 O
weeks O
. O
[]

In O
the O
C O
group O
, O
13 O
% O
received O
no O
chemotherapy O
, O
21 O
% O
one O
or O
two O
cycles O
, O
and O
64 O
% O
all O
three O
cycles O
of O
their O
prescribed O
chemotherapy O
( O
60 O
% O
of O
the O
latter O
with O
no O
delays O
or O
modification O
) O
. O
[]

Two O
of O
three O
control O
subjects O
also O
had O
increased O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnovers I-outcome ['Physiological-Clinical']
, O
which O
in O
one O
case O
was O
related O
to O
increased O
dialysis-associated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Several O
randomised O
controlled O
trials O
have O
been O
undertaken O
to O
evaluate O
the O
efficacy O
of O
alpha-interferon O
in O
the O
therapy O
of O
chronic O
hepatitis O
B O
. O
[]

The O
Studies O
of O
Ocular O
Complications O
of O
AIDS O
Research O
Group O
. O
[]

Ventilation B-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
was O
pneumotachy-graphically O
recorded O
. O
['Physiological-Clinical']

Dentine O
is O
considerably O
more O
susceptible O
than O
enamel O
to O
erosion B-outcome ['Physiological-Clinical']
and O
abrasion B-outcome ['Physiological-Clinical']
alone O
or O
combined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Low O
molecular-weight O
heparin O
versus O
aspirin O
in O
patients O
with O
acute O
ischaemic O
stroke O
and O
atrial O
fibrillation O
: O
a O
double-blind O
randomised O
study O
. O
[]

It O
is O
suggested O
, O
therefore O
, O
that O
the O
new O
aqueous O
nasal O
spray O
provides O
an O
alternative O
method O
of O
intranasal O
administration O
of O
the O
steroid O
for O
patients O
who O
may O
prefer O
an O
aqueous O
product O
. O
[]

One O
quadrant O
sub-Tenon O
's O
capsule O
anesthesia O
in O
anterior O
segment O
surgery O
. O
[]

Cardiopulmonary O
exercise O
variables O
in O
diastolic O
versus O
systolic O
heart O
failure O
. O
[]

BACKGROUND O
Fifty O
consecutive O
patients O
entered O
the O
myocardial O
contrast O
echocardiography O
( O
MCE O
) O
substudy O
of O
the O
REMEDIA O
( O
Randomized O
Evaluation O
of O
the O
Effect O
of O
Mechanical O
Reduction O
of O
Distal O
Embolization O
by O
Thrombus O
Aspiration O
in O
Primary O
and O
Rescue O
Angioplasty O
) O
trial O
, O
which O
defined O
the O
role O
of O
a O
new O
thrombus-aspirating O
device O
in O
preventing O
distal O
microembolization B-outcome ['Physiological-Clinical']
after O
PCI O
. O
['Physiological-Clinical']

The O
PaCO(2) B-outcome ['Physiological-Clinical']
in O
group O
A O
was O
(62.0+/-4.7) O
mmHg O
, O
which O
was O
significantly O
higher O
than O
group O
B O
at O
the O
end O
of O
operation[(51.9+/-4.2) O
mmHg, O
t=2.432, O
P<0.05]. O
The O
time B-outcome ['Life-Impact']
spent I-outcome ['Life-Impact']
successfully I-outcome ['Life-Impact']
positioning I-outcome ['Life-Impact']
the O
insertion O
in O
group O
A O
and O
group O
B O
were O
(17.6+/-7.5), O
(29.8+/-13.6)s, O
the O
endoscope B-outcome ['Life-Impact']
indwelling I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
were(0.8+/-0.1), O
(1.4+/-0.3)min, O
and O
the O
operation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were(32.3+/-4.3), O
(46.8+/-4.8)min, O
there O
were O
significantly O
difference O
between O
group O
A O
and O
group O
B(t=2.670, O
2.214, O
2.166, O
all O
P<0.05). O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

DISCUSSION: O
The O
study O
will O
make O
a O
unique O
contribution O
to O
the O
literature O
by O
testing O
a O
theory-based O
intervention O
delivered O
by O
PE O
teachers O
to O
promote O
school O
students' O
participation B-outcome ['Life-Impact']
in O
out-of-school O
physical O
activity. O
[['Life-Impact']]

Therapists O
worked O
with O
individual O
families O
. O
[]

On O
the O
third O
day O
of O
GnRH-a O
administration O
, O
119 O
patients O
were O
randomized O
in O
three O
groups O
to O
receive O
daily O
fixed O
doses O
of O
300 O
IU O
of O
rFSH O
( O
group O
A O
, O
n O
= O
38 O
) O
, O
or O
450 O
IU O
of O
rFSH O
( O
group O
B O
, O
n O
= O
39 O
) O
, O
or O
600 O
IU O
of O
rFSH O
( O
group O
C O
, O
n O
= O
42 O
) O
. O
[]

Treatment O
was O
not O
found O
to O
induce O
gastritic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in O
the O
mucosa O
. O
['Physiological-Clinical']

PD O
fluids O
with O
neutral O
pH O
and O
reduced O
glucose O
degradation O
product O
contents O
are O
considered O
more O
biocompatible O
, O
because O
they O
preserve O
peritoneal O
cell O
functions O
in O
vitro O
. O
[]

At O
3 O
yr O
follow-up O
, O
17.5 O
% O
of O
patients O
in O
group O
A O
were O
alive B-outcome ['Mortality']
compared O
to O
52 O
% O
in O
group O
B O
and O
42 O
% O
in O
group O
C O
( O
p O
< O
0.001 O
) O
. O
['Mortality']

PATIENTS O
AND O
METHODS O
A O
selection O
of O
17 O
polymorphisms O
in O
genes O
encoding O
drug O
targets O
, O
pathway B-outcome ['Physiological-Clinical']
molecules I-outcome ['Physiological-Clinical']
and O
detoxification B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
was O
analyzed O
in O
279 O
previously O
untreated O
mCRC O
patients O
treated O
with O
capecitabine O
, O
oxaliplatin O
and O
bevacizumab O
( O
CAPOX-B O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Such O
guidelines O
are O
made O
available O
for O
strength O
training O
(ST) O
using O
the O
1 O
repetition O
maximum O
(1RM), O
which O
has O
been O
linked O
to O
individuals' O
self-rated O
level O
of O
exertion O
using O
the O
Borg O
rating O
of O
perceived O
exertion O
(BRPE) O
scale. O
[]

The O
control O
group O
consisted O
of O
sex- O
and O
age-matched O
patents O
with O
allergic O
rhinitis O
. O
[]

REE O
fell O
similarly O
with O
each O
diet O
; O
the O
overall O
decrease O
was O
719+/-106 O
kJ/day O
( O
P O
< O
0.001 O
) O
. O
[]

RESULTS O
Over O
1 O
year O
the O
3M O
group O
reported O
a O
decrease O
in O
the O
number O
of O
snacks B-outcome ['Life-Impact']
whereas O
the O
3+3M O
group O
reported O
an O
increase O
( O
-1.1 O
vs O
+0.4 O
snacks/day O
, O
respectively O
, O
P O
< O
0.0001 O
) O
. O
['Life-Impact']

5-fluorouracil/leucovorin O
) O
. O
[]

MATERIAL O
AND O
METHODS: O
Thirty-six O
elite O
male O
rowers O
(27 O
+/- O
6 O
years) O
were O
assigned O
to O
one O
of O
the O
two O
groups O
randomly: O
1) O
Control O
group O
(CG, O
n O
= O
18, O
height: O
181.05 O
+/- O
3.39 O
cm O
and O
body O
mass: O
77.02 O
+/- O
7.55 O
kg), O
2) O
Group O
treated O
with O
3,000 O
IU O
of O
vitamin O
D3/day O
(VD3G, O
s O
= O
18, O
height: O
179.70 O
+/- O
9.07 O
cm O
and O
body O
mass: O
76.19 O
+/- O
10.07 O
kg). O
[]

Their O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
increased O
in O
a O
slightly O
greater O
than O
dose-dependent O
manner O
from O
3 O
to O
300 O
mg O
. O
['Physiological-Clinical']

BACKGROUND O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
3-year O
clinical O
outcome O
in O
patients O
enrolled O
in O
the O
Primary O
Stenting O
of O
Totally O
Occluded O
Native O
Coronary O
Arteries O
II O
study O
. O
[]

The O
control O
group O
received O
only O
conventional B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
, O
including O
debridement B-outcome ['Resource-use']
, O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
control O
agents B-outcome ['Resource-use']
, O
systemic B-outcome ['Resource-use']
antibiotics I-outcome ['Resource-use']
, O
wound B-outcome ['Physiological-Clinical']
cleaning I-outcome ['Physiological-Clinical']
with O
normal B-outcome ['Resource-use']
saline I-outcome ['Resource-use']
, O
offloading O
( O
pressure O
relief O
) O
, O
and O
daily B-outcome ['Resource-use']
wound I-outcome ['Resource-use']
dressings I-outcome ['Resource-use']
. O
['Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Physiological-Clinical', 'Resource-use', 'Resource-use']

This O
study O
was O
carried O
out O
to O
investigate O
whether O
long-term O
treatment O
with O
Bdp O
after O
polypectomy O
could O
prevent O
formation O
of O
new O
polyps O
and O
reduce O
the O
number O
of O
surgical O
removals O
. O
[]

Rotigotine O
transdermal O
patch O
enables O
rapid O
titration O
to O
effective O
doses O
in O
advanced-stage O
idiopathic O
Parkinson O
disease O
: O
subanalysis O
of O
a O
parallel O
group O
, O
open-label O
, O
dose-escalation O
study O
. O
[]

METHODS O
This O
prospective O
study O
was O
performed O
in O
50 O
consecutive O
patients O
. O
[]

Forty-three O
patients O
were O
selected O
for O
the O
experimental O
group O
, O
and O
31 O
control O
subjects O
used O
the O
sham O
instrument O
( O
placebo O
group O
) O
. O
[]

The O
results O
indicate O
that O
individuals O
with O
ASDs O
, O
like O
controls O
, O
experience B-outcome ['Life-Impact']
interference I-outcome ['Life-Impact']
from O
facial O
features O
that O
they O
are O
told O
to O
ignore O
. O
['Life-Impact']

Four O
parameters O
were O
followed O
: O
serum-specific O
IgE O
against O
antigen O
E O
, O
total O
blocking O
antibody O
against O
antigen O
E O
, O
local O
and O
systemic O
reactions O
to O
injection O
therapy O
, O
and O
symptom O
score O
indices O
. O
[]

Twenty-four O
participants O
with O
type O
2 O
diabetes O
( O
mean O
age O
58 O
years O
; O
14 O
women O
and O
10 O
men O
) O
were O
randomly O
assigned O
to O
one O
of O
the O
two O
possible O
sequence O
permutations O
to O
receive O
an O
ad O
libitum O
diet O
enriched O
with O
56 O
g O
( O
366 O
kcal O
) O
walnuts/day O
and O
an O
ad O
libitum O
diet O
without O
walnuts O
for O
8 O
weeks O
. O
[]

Purpose: O
Intensity O
of O
a O
training O
program O
is O
a O
critical O
variable O
in O
treatment O
gains O
poststroke, O
but O
there O
are O
no O
guidelines O
to O
adequately O
dose O
the O
intensity O
of O
functional O
training O
(FT); O
the O
recommended O
type O
of O
training O
to O
promote O
poststroke O
recovery. O
[]

Plasma B-outcome ['Physiological-Clinical']
high-sensitive I-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
hsCRP B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
minutes O
before O
taking O
the O
Trier O
Social O
Stress O
Test O
(TSST) O
as O
a O
mental O
stressor, O
participants O
in O
each O
group O
ingested O
a O
beverage O
containing O
beta-Eudesmol, O
the O
active O
beverage, O
or O
a O
placebo O
beverage O
that O
did O
not O
contain O
beta-Eudesmol. O
[]

After O
that O
, O
additional O
3 O
cycles O
of O
EP O
consolidation O
were O
administered O
. O
[]

These O
findings O
demonstrated O
that O
medication O
of O
penbutolol O
over O
a O
three-day O
period O
has O
no O
influence O
on O
the O
baseline O
blood O
sugar O
profile O
and O
insulin O
consumption O
or O
on O
insulin O
consumption O
after O
food O
intake O
during O
rest O
and O
physical O
exercise O
. O
[]

These O
results O
support O
the O
results O
of O
previous O
studies O
and O
suggest O
further O
investigation O
of O
this O
novel O
sleep/pharmacologic O
intervention O
is O
warranted O
. O
[]

Arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
for O
analysis O
of O
the O
serum O
propofol O
and O
clonidine O
concentrations O
were O
taken O
immediately O
before O
verbal O
commands O
were O
given O
. O
['Physiological-Clinical']

The O
children O
have O
good O
recovery B-outcome ['Physiological-Clinical', 'Life-Impact']
conditions I-outcome ['Physiological-Clinical', 'Life-Impact']
, O
and O
no O
obvious O
postoperative O
agitation B-outcome ['Life-Impact']
and O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
after O
DEX O
administration. O
[['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Physiological-Clinical']]

CONCLUSIONS O
KeraVision O
Intacs O
are O
effective O
, O
predictable O
, O
stable B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical']

Baseline O
microalbuminuria O
predicted O
subsequent O
clinical B-outcome ['Physiological-Clinical']
proteinuria I-outcome ['Physiological-Clinical']
for O
the O
study O
participants O
overall O
( O
adjusted O
odds O
ratio O
[ O
OR O
] O
, O
17.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
12.6 O
to O
24.4 O
) O
, O
in O
participants O
without O
diabetes O
( O
OR O
, O
16.7 O
; O
95 O
% O
CI O
, O
8.6 O
to O
32.4 O
) O
, O
and O
in O
participants O
with O
diabetes O
( O
OR O
, O
18.2 O
; O
95 O
% O
CI O
, O
12.4 O
to O
26.7 O
) O
. O
['Physiological-Clinical']

Role O
of O
posterior O
tibial O
nerve O
stimulation O
in O
the O
treatment O
of O
refractory O
monosymptomatic O
nocturnal O
enuresis O
: O
a O
pilot O
study O
. O
[]

1.36 O
; O
p O
= O
0.037 O
) O
. O
[]

Tympanic O
membrane O
temperature O
was O
monitored O
at O
anesthetic O
induction O
, O
throughout O
the O
isoflurane-fentanyl-N2O-O2 O
anesthetic O
, O
and O
for O
18 O
h O
postoperatively O
. O
[]

In O
cases O
of O
bone B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

On O
the O
basis O
of O
these O
results O
, O
it O
seems O
that O
ginger O
has O
the O
potential O
to O
decrease O
eicosanoid O
levels O
, O
perhaps O
by O
inhibiting O
their O
synthesis O
from O
arachidonic O
acid O
. O
[]

Concomitant O
radiochemotherapy O
vs O
radiotherapy O
alone O
in O
patients O
with O
head O
and O
neck O
cancer O
: O
a O
Hellenic O
Cooperative O
Oncology O
Group O
Phase O
III O
Study O
. O
[]

DISCUSSION O
These O
data O
indicate O
that O
the O
most O
weight O
loss B-outcome ['Physiological-Clinical']
was O
achieved O
when O
the O
counseling O
approach O
combined O
both O
Weight O
Watchers O
and O
individualized O
contacts O
. O
['Physiological-Clinical']

The O
effect O
of O
reinforcement O
or O
stimulus O
control O
to O
reduce O
sedentary B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
the O
treatment O
of O
pediatric O
obesity O
. O
['Life-Impact']

The O
effects O
of O
aerobic O
exercise O
on O
academic O
engagement O
in O
young O
children O
with O
autism O
spectrum O
disorder O
. O
[]

5 O
% O
imiquimod O
cream O
and O
reflectance-mode O
confocal O
microscopy O
as O
adjunct O
modalities O
to O
Mohs O
micrographic O
surgery O
for O
treatment O
of O
basal O
cell O
carcinoma O
. O
[]

There O
were O
no O
study O
drug-related B-outcome ['Mortality']
deaths I-outcome ['Mortality']
. O
['Mortality']

Supplementation O
with O
larger O
ARA O
doses O
added O
to O
DHA O
may O
therefore O
mitigate O
social O
impairment O
. O
[]

The O
primary O
study O
end O
point O
was O
the O
proportion O
of O
DNA B-outcome ['Physiological-Clinical']
aneuploid I-outcome ['Physiological-Clinical']
histograms I-outcome ['Physiological-Clinical']
after O
12 O
months O
. O
['Physiological-Clinical']

After O
multivariable O
adjustment O
for O
clinical O
, O
laboratory O
, O
and O
angiographic O
variables O
, O
BNP O
remained O
a O
significant O
independent O
predictor O
of O
CI-AKI O
( O
1.29 O
[ O
1.10 O
, O
1.51 O
] O
; O
P O
< O
0.001 O
) O
. O
[]

To O
evaluate O
the O
beneficial O
effect O
of O
human O
chorionic O
gonadotrophin O
( O
HCG O
) O
supplementation O
, O
we O
performed O
a O
multicentre O
, O
double-blind O
, O
randomized O
study O
with O
HCG O
( O
193 O
transfers O
) O
against O
placebo O
( O
194 O
transfers O
) O
. O
[]

acetaminophen O
, O
and O
lidocaine O
groups O
was O
64 O
% O
, O
22 O
% O
and O
8 O
% O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
[]

RESULTS O
Greater O
vital B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
ratings O
( O
mean O
2.9 O
standard O
deviation O
[ O
SD O
] O
0.6 O
) O
correlated O
moderately O
( O
p O
< O
or O
= O
0.005 O
) O
with O
less O
severe O
CGI B-outcome ['Physiological-Clinical']
illness I-outcome ['Physiological-Clinical']
ratings O
by O
the O
homeopaths O
( O
r O
=-0.59 O
) O
, O
decreased O
patient-rated O
mental B-outcome ['Life-Impact']
confusion I-outcome ['Life-Impact']
( O
r O
=-0.43 O
) O
, O
higher O
vigor B-outcome ['Life-Impact']
( O
r O
= O
0.38 O
) O
, O
and O
greater O
positive O
states B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
mind I-outcome ['Life-Impact']
( O
r O
= O
0.36 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Clinical O
Trials O
# O
: O
NCT00065910 O
. O
[]

Indomethacin O
abolished O
the O
prostacyclin B-outcome ['Resource-use']
['Resource-use']

21.1 O
mm? O
at O
6 O
months O
: O
4.7 O
% O
decrease O
, O
p O
= O
0.0002 O
; O
and O
47.2 O
? O
[]

The O
subjects O
of O
the O
control O
group O
( O
n O
= O
12 O
) O
received O
advice O
on O
the O
natural O
evolution O
of O
lateral O
epicondylitis O
, O
computer O
ergonomics O
, O
and O
stretching O
exercises O
. O
[]

AMP O
and O
CB O
are O
equivalent O
for O
the O
treatment O
of O
bacterial O
meningitis O
due O
to O
susceptible O
organisms O
. O
[]

The O
incremental O
cost-effectiveness O
ratio O
is O
?73,359 O
per O
QALY O
. O
[]

Whereas O
standard O
laboratory O
tests O
of O
coagulation O
were O
comparable O
between O
groups O
, O
von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
activity B-outcome ['Life-Impact']
on O
the O
first O
postoperative O
morning O
tended O
to O
be O
higher O
following O
treatment O
with O
10 O
% O
HES O
130/0.4 O
as O
compared O
to O
10 O
% O
HES O
200/0.5 O
( O
P=0.025 O
) O
with O
this O
difference O
being O
statistically O
significant O
only O
in O
the O
per-protocol O
analysis O
( O
P=0.02 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Imagined O
movements O
imparted O
a O
further O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
only O
if O
they O
followed O
hand O
laterality O
recognition O
. O
['Physiological-Clinical', 'Life-Impact']

STUDY O
Sixty-two O
patients O
( O
19 O
men O
and O
43 O
women O
; O
mean O
age O
, O
54 O
years O
; O
range O
, O
32-77 O
years O
) O
with O
heartburn O
and O
regurgitation O
and O
normal O
upper O
endoscopy O
findings O
were O
studied O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
with O
a O
crossover O
design O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
generally O
minimal O
in O
both O
arms O
. O
['Adverse-effects']

Subjects O
were O
grouped O
according O
to O
their O
drug O
choices O
: O
'non-choosers O
' O
never O
chose O
drug O
, O
whereas O
'choosers O
' O
always O
chose O
drug O
. O
[]

Twenty-one O
women O
died B-outcome ['Mortality']
of O
their O
disease O
. O
['Mortality']

During O
the O
first O
48 O
hours O
after O
operation O
the O
degree O
of O
pain B-outcome ['Physiological-Clinical']
was O
almost O
identical O
between O
the O
groups O
. O
['Physiological-Clinical']

Subjects O
exercised O
significantly O
longer O
(PC O
= O
66.7 O
+/- O
16.3 O
min, O
CON O
= O
45.7 O
+/- O
9.5 O
min) O
and O
at O
lower O
rectal B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
(approximately O
0.5 O
+/- O
0.5 O
degrees O
C) O
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
(approximately O
10 O
+/- O
7 O
bpm) O
following O
PC. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Ototoxicity B-outcome ['Physiological-Clinical']
also O
occurred O
less O
frequently O
in O
the O
netilmicin-treated O
patients O
( O
3 O
% O
versus O
10 O
% O
, O
P O
= O
0.4 O
) O
. O
['Physiological-Clinical']

Of O
the O
62 O
patients O
who O
entered O
the O
study O
, O
51 O
were O
considered O
evaluable O
( O
24 O
with O
adjuvant O
hormone O
therapy O
and O
27 O
with O
no O
further O
treatment O
) O
. O
[]

They O
were O
divided O
randomly O
by O
a O
physician O
into O
2 O
groups O
of O
30 O
patients O
each O
for O
5 O
sessions O
of O
active O
treatment O
( O
30 O
mg O
of O
ketorolac O
) O
or O
placebo O
( O
5 O
mL O
of O
normal O
saline O
) O
. O
[]

However O
, O
the O
median O
time O
to O
the O
recurrence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ascites I-outcome ['Physiological-Clinical']
in O
Group O
1 O
was O
4 O
months O
in O
medical O
patients O
, O
as O
compared O
with O
18 O
months O
in O
surgical O
patients O
( O
P O
= O
0.01 O
) O
; O
in O
Group O
2 O
it O
was O
3 O
months O
in O
medical O
patients O
as O
compared O
with O
12 O
months O
in O
surgical O
patients O
( O
P O
= O
0.04 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
A O
walnut-enriched O
ad O
libitum O
diet O
improves O
endothelium-dependent O
vasodilatation O
in O
type O
2 O
diabetic O
individuals O
, O
suggesting O
a O
potential O
reduction O
in O
overall O
[]

It O
is O
therefore O
essential O
to O
evaluate O
current O
drugs O
, O
one O
of O
which O
is O
the O
water O
extract O
of O
the O
bark O
of O
the O
tree O
Choerospondias O
axillaris O
. O
[]

There O
was O
no O
significant O
difference O
in O
the O
similarity O
of O
the O
simulators O
to O
the O
porcine O
larynx O
(P O
= O
.81). O
[]

Participants O
in O
the O
rosemary O
condition O
scored O
higher O
on O
measures O
of O
tension-anxiety B-outcome ['Life-Impact']
and O
confusion-bewilderment B-outcome ['Life-Impact']
relative O
to O
the O
lavender O
and O
control O
conditions O
. O
['Life-Impact', 'Life-Impact']

METHODS O
The O
374 O
patients O
evaluated O
in O
this O
study O
were O
a O
subgroup O
of O
a O
larger O
multicenter O
, O
cross-sectional O
, O
randomized O
study O
that O
was O
carried O
out O
in O
1996 O
. O
[]

The O
majority O
of O
parents O
( O
56 O
% O
) O
were O
unable B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
report I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
retrospect I-outcome ['Life-Impact']
when O
their O
child O
had O
received O
auditory O
integration O
training O
. O
['Life-Impact']

Assessments O
will O
occur O
before O
therapy O
, O
after O
the O
8 O
week O
therapy O
program O
, O
and O
at O
3 O
and O
12 O
months O
after O
the O
intervention O
. O
[]

A O
total O
of O
256 O
unaffected O
adults O
fulfilled O
the O
study O
criteria O
. O
[]

RESULTS O
Repeated-measures O
analysis O
of O
variance O
indicated O
a O
significant O
interaction O
effect O
of O
transcranial O
direct O
current O
stimulation O
type O
and O
time O
on O
the O
recognition B-outcome ['Life-Impact']
accuracy I-outcome ['Life-Impact']
. O
['Life-Impact']

Despite O
this O
reduced O
saliency O
and O
processing O
of O
other O
faces O
, O
recognition O
of O
their O
own O
face O
is O
reported O
to O
be O
more O
typical O
in O
nature O
. O
[]

As O
secondary O
objectives O
we O
examine O
five O
year O
survival B-outcome ['Mortality']
rates O
( O
OS B-outcome ['Mortality']
and O
DFS B-outcome ['Mortality']
) O
, O
['Mortality', 'Mortality', 'Mortality']

clinic O
Main O
outcome O
measures O
were O
the O
numbers O
of O
individuals O
in O
each O
group O
receiving O
immunisation O
, O
and O
practice O
costs B-outcome ['Resource-use']
of O
a O
telephone-appointing O
programme O
. O
['Resource-use']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Effect O
of O
different O
rates O
of O
infusion O
of O
propofol O
for O
induction O
of O
anaesthesia B-outcome ['Resource-use']
in O
elderly O
patients O
. O
['Resource-use']

All O
complications B-outcome ['Adverse-effects']
resolved O
with O
dose O
reduction O
or O
when O
MTX O
was O
stopped O
at O
the O
end O
of O
the O
study O
. O
['Adverse-effects']

A O
recent O
randomized O
multicenter O
trial O
of O
nonoperated O
distal O
radial O
fractures O
showed O
a O
moderate O
shortening O
of O
the O
time O
to O
restoration O
of O
cortical O
continuity O
by O
treatment O
with O
20 O
microg O
( O
low-dose O
) O
teriparatide O
per O
day O
, O
but O
not O
with O
40 O
microg O
( O
high-dose O
) O
. O
[]

OBJECTIVE O
Identify O
factors O
predictive O
of O
severe B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SH I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
assess O
the O
clinical B-outcome ['Life-Impact']
utility I-outcome ['Life-Impact']
of O
continuous B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
monitoring I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CGM I-outcome ['Resource-use']
) I-outcome ['Resource-use']
to O
warn O
of O
impending O
SH O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use']

UNLABELLED O
The O
synthetic O
arginine-derived O
direct O
thrombin O
inhibitor O
argatroban O
is O
an O
attractive O
anticoagulant O
for O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
because O
of O
its O
rapid O
onset O
and O
offset O
, O
and O
its O
hepatic O
elimination O
. O
[]

1.5 O
; O
p O
= O
0.01 O
) O
and O
higher O
inpatient O
opiate O
usage O
( O
hydromorphone O
use O
: O
3.9 O
? O
[]

Atorvastatin O
reduced O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
TC B-outcome ['Physiological-Clinical']
) O
, O
LDL-C B-outcome ['Physiological-Clinical']
, O
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
by O
32 O
% O
( O
P O
< O
0.001 O
) O
, O
40.8 O
% O
( O
P O
< O
0.001 O
) O
, O
and O
19 O
% O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
and O
increased O
HDL-C B-outcome ['Physiological-Clinical']
by O
6.9 O
% O
, O
( O
P O
= O
0.002 O
) O
in O
the O
first O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Seasonal O
allergic O
rhinitis O
( O
SAR O
) O
is O
a O
risk O
factor O
for O
asthma O
in O
affected O
individuals O
. O
[]

We O
compared O
the O
incidence O
of O
ARDS O
due O
to O
pulmonary O
infection O
between O
those O
who O
received O
G-CSF O
and O
those O
who O
did O
not O
. O
[]

This O
reduction O
in O
steroid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
obtained O
without O
altering O
clinical O
status O
and O
without O
significant O
complication O
. O
['Resource-use']

While O
the O
efficacy O
index O
of O
the O
two O
drugs O
was O
similar O
( O
approximately O
60 O
% O
) O
, O
they O
differed O
greatly O
in O
their O
profile O
of O
side-effects B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Phosphate O
binder O
impact O
on O
bone B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
and O
coronary B-outcome ['Physiological-Clinical']
calcification I-outcome ['Physiological-Clinical']
-- O
results O
from O
the O
BRiC O
study O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
eyes O
treated O
with O
10 O
Gy O
because O
of O
classic O
CNV O
, O
the O
corresponding O
figures O
were O
33 O
% O
( O
n O
= O
18 O
) O
and O
57 O
% O
( O
n O
= O
14 O
) O
respectively O
. O
[]

Planned O
radiotherapy O
was O
the O
same O
in O
both O
groups O
. O
[]

There O
was O
a O
group O
by O
time O
by O
attendance O
interaction O
, O
however O
, O
such O
that O
higher O
attendance O
at O
the O
exercise O
intervention O
, O
but O
not O
the O
control O
intervention O
, O
was O
associated O
with O
increased O
WMI O
. O
[]

CONCLUSION O
Although O
the O
trial O
closed O
prematurely O
and O
definitive O
statements O
regarding O
the O
efficacy O
of O
adjuvant O
gefitinib O
can O
not O
be O
made O
, O
these O
results O
indicate O
that O
it O
is O
unlikely O
to O
be O
of O
benefit O
. O
[]

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O
[]

RESULTS: O
Among O
the O
1054 O
participants O
(527 O
in O
each O
group), O
end-point O
data O
were O
available O
for O
1015 O
(96.3%). O
[]

In O
14 O
of O
18 O
patients O
who O
received O
both O
treatments O
clobazam O
was O
superior O
to O
placebo O
, O
and O
in O
4 O
patients O
no O
preference O
was O
established O
. O
[]

RESULTS: O
The O
obtained O
data O
shows O
the O
significant O
differences O
of O
an O
increase O
in O
highly B-outcome ['Physiological-Clinical']
sensitive I-outcome ['Physiological-Clinical']
troponin I-outcome ['Physiological-Clinical']
(HS-Tp) I-outcome ['Physiological-Clinical']
in O
24 O
hours O
after O
PCI O
in O
patients O
with O
no O
admission O
of O
nicorandil O
(117 O
ng/l) O
as O
compared O
with O
the O
nicorandil O
group O
(73 O
ng/l), O
p O
= O
0.04. O
[['Physiological-Clinical']]

Statistically O
significant O
changes O
in O
fatigue B-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
, O
appetite B-outcome ['Physiological-Clinical']
, O
diarrhea B-outcome ['Physiological-Clinical']
, O
and O
global B-outcome ['Life-Impact']
QOL I-outcome ['Life-Impact']
scores O
were O
detected O
during O
RT O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Budesonide O
and O
beclomethasone O
dipropionate O
in O
hay O
fever O
- O
a O
single O
blind O
comparison O
. O
[]

Significant O
differences O
were O
found O
in O
several O
acceptability B-outcome ['Life-Impact']
areas O
with O
respect O
to O
demographics O
and O
quality O
of O
life O
measures O
such O
as O
age O
, O
sex O
, O
and O
severe O
distress O
. O
['Life-Impact']

The O
use O
of O
vascularized O
bone O
grafts O
to O
reconstruct O
extremity O
and O
mandibular O
defects O
is O
now O
commonplace O
in O
reconstructive O
surgery O
. O
[]

TRIAL O
REGISTRATION: O
This O
trial O
was O
registered O
prior O
to O
enrollment O
at O
the O
Registry O
for O
International O
Impact O
Evaluations O
(RIDIE O
STUDY O
ID: O
582a2462ae2ab): O
http://ridie.3ieimpact.org/index.php?r=search/detailView&id=492 O
. O
[]

No O
significant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
any O
patient O
. O
['Adverse-effects']

Studies O
predicting O
mortality O
after O
myocardial O
infarction O
( O
MI O
) O
usually O
rely O
on O
in-hospital O
data O
, O
and O
combine O
patients O
admitted O
for O
the O
first O
MI O
with O
recurrent O
MI O
patients O
. O
[]

DISCUSSION O
This O
study O
, O
if O
successful O
, O
will O
provide O
a O
much-needed O
randomized O
comparison O
of O
the O
conventional O
strategy O
of O
primary O
RT O
vs. O
the O
novel O
strategy O
of O
primary O
TORS O
. O
[]

PPIX B-outcome ['Physiological-Clinical']
fluorescence I-outcome ['Physiological-Clinical']
was O
measured O
using O
an O
excitation O
wavelength O
of O
405+/-5 O
nm O
and O
emission O
spectrum O
recorded O
using O
a O
photodiode O
array O
. O
['Physiological-Clinical']

One O
hundred O
seventy-seven O
women O
aged O
41 O
+/- O
8 O
( O
mean O
+/- O
SD O
) O
years O
, O
referred O
for O
evaluation O
of O
excessive O
uterine O
bleeding O
, O
were O
enrolled O
in O
an O
open-label O
randomized O
trial O
to O
evaluate O
the O
efficacy O
of O
local O
anesthesia O
before O
hysteroscopy B-outcome ['Physiological-Clinical']
in O
an O
outpatient O
population O
. O
['Physiological-Clinical']

The O
study O
was O
performed O
to O
determine O
the O
sensitivity O
and O
short-term O
and O
day-to-day O
variability O
of O
a O
novel O
technique O
based O
on O
laser O
interferometry O
of O
ocular O
fundus O
pulsations O
and O
of O
non-invasive O
methods O
for O
the O
quantification O
of O
haemodynamic O
drug O
effects O
. O
[]

Among O
participants O
who O
completed O
the O
study O
the O
rate O
of O
compliance O
was O
72 O
% O
. O
[]

CONCLUSIONS O
These O
data O
support O
the O
hypothesis O
that O
some O
insomniacs O
show O
a O
reliable O
disorder O
of O
[]

RESULTS O
With O
a O
median O
follow-up O
of O
57 O
months O
, O
the O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
62.3 O
% O
vs. O
48.1 O
% O
vs. O
25 O
% O
and O
the O
5-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
58.6 O
% O
vs. O
52.7 O
% O
vs. O
25 O
% O
among O
groups O
1 O
, O
2 O
, O
and O
3 O
( O
P O
= O
0.014 O
, O
P O
= O
0.027 O
, O
respectively O
) O
in O
patients O
with O
stage O
III O
rectal O
cancer O
. O
['Mortality', 'Mortality']

The O
two O
subtypes O
of O
dementia O
could O
be O
differentiated O
in O
some O
conventional O
EEG O
variables O
but O
mostly O
by O
means O
of O
power O
asymmetry O
indices O
. O
[]

The O
LOP O
regimen O
was O
used O
in O
group O
A O
and O
the O
CHOPcyclophosphamide O
+ O
pirarubicin O
+ O
vincristine O
+ O
dexamethasone O
regimen O
was O
used O
in O
group O
B. O
The O
short-term O
efficacy, O
long-term O
efficacy O
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
of O
the O
two O
groups O
were O
compared. O
[['Adverse-effects']]

Plasma B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
counter-regulatory B-outcome ['Physiological-Clinical']
hormones I-outcome ['Physiological-Clinical']
were O
also O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Other O
associated O
symptom O
domains O
are O
also O
affected O
including O
impulsivity/aggression O
, O
self-injury O
, O
anxiety O
, O
and O
mood O
lability O
. O
[]

of O
aminoglycosides O
, O
was O
significantly O
more O
often O
necessary O
in O
the O
control O
group O
. O
[]

Results O
indicate O
that O
the O
parent-delivered O
component O
of O
the O
program O
provided O
effective O
early O
intervention O
for O
autism O
that O
was O
suitable O
for O
delivery O
at O
home O
. O
[]

Significant O
differences O
in O
neointimal B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
were O
found O
between O
normally O
perfused O
stents O
and O
stents O
with O
artificially O
reduced O
flow O
: O
during O
the O
total O
observation O
period O
of O
6 O
months O
the O
neointimal B-outcome ['Physiological-Clinical']
height I-outcome ['Physiological-Clinical']
was O
up O
to O
200 O
% O
higher O
in O
flow-restricted O
stents O
, O
while O
the O
histological B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
neointima I-outcome ['Physiological-Clinical']
was O
the O
same O
as O
with O
normally O
perfused O
stents O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
interaction O
was O
found O
between O
aspirin O
and O
the O
most O
used O
antihypertensive O
drug O
classes O
( O
angiotensin O
converting O
enzyme O
inhibitors O
and O
calcium O
antagonists O
) O
. O
[]

The O
AV O
Node O
Ablation O
with O
CLS O
and O
CRT O
Pacing O
Therapies O
for O
Treatment O
of O
AF O
trial O
( O
AVAIL O
CLS/CRT O
) O
was O
designed O
to O
demonstrate O
superiority O
of O
BiV O
pacing O
in O
patients O
with O
AF O
after O
AV O
node O
ablation O
, O
to O
evaluate O
its O
effects O
on O
cardiac O
structure O
and O
function O
, O
and O
to O
investigate O
additional O
benefits O
of O
Closed O
Loop O
Stimulation O
( O
CLS O
) O
( O
BIOTRONIK O
, O
Berlin O
, O
Germany O
) O
. O
[]

Both O
studies O
were O
read O
by O
independent O
investigators O
blinded O
to O
the O
results O
of O
the O
other O
study O
. O
[]

Hypotheses B-outcome ['Physiological-Clinical']
, O
strengths B-outcome ['Life-Impact']
, O
and O
limitations B-outcome ['Life-Impact']
of O
the O
study O
are O
discussed O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Eighty O
healthy O
women O
beginning O
active O
labor O
( O
cervical O
dilation O
4 O
cm O
) O
at O
term O
were O
assigned O
to O
receive O
fentanyl O
intravenously O
by O
either O
patient-controlled O
administration O
( O
n=37 O
) O
or O
nurse O
administration O
on O
demand O
( O
n=43 O
) O
. O
[]

The O
new O
brain B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
of O
subjects O
in O
the O
active O
group O
were O
subclinical O
. O
['Physiological-Clinical']

We O
intended O
to O
evaluate O
the O
compliance O
and O
response O
to O
antiviral O
treatment O
for O
CHC O
in O
IVDUs O
compared O
with O
non-IVDUs O
. O
[]

The O
use O
of O
ozone O
in O
Group O
2 O
resulted O
in O
lower O
values O
of O
?TBS O
in O
all O
conditions O
evaluated O
. O
[]

NNRTI O
versus O
PI O
hazard O
ratios O
( O
HRs O
) O
for O
the O
composite O
endpoint O
, O
for O
AIDS B-outcome ['Physiological-Clinical']
or O
death B-outcome ['Mortality']
, O
for O
death B-outcome ['Mortality']
, O
and O
for O
virological B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
were O
1.02 O
( O
95 O
% O
CI O
0.79-1.31 O
) O
, O
1.07 O
( O
0.80-1.41 O
) O
, O
0.95 O
( O
0.66-1.37 O
) O
, O
and O
0.66 O
( O
0.56-0.78 O
) O
, O
respectively O
. O
['Physiological-Clinical', 'Mortality', 'Mortality', 'Physiological-Clinical']

A O
controlled O
prospective O
evaluation O
of O
pregnancy O
complicated O
by O
chronic O
hypertension O
is O
proposed O
and O
preliminary O
data O
on O
population O
selection B-outcome ['Life-Impact']
and O
pregnancy B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
are O
presented O
. O
['Life-Impact', 'Physiological-Clinical']

Patients O
with O
infections O
were O
more O
likely O
to O
have O
low O
levels O
of O
CD19+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Pharmacokinetics O
and O
pharmacodynamics O
of O
intravenous O
diltiazem O
in O
patients O
with O
atrial O
fibrillation O
or O
atrial O
flutter O
. O
[]

Sixty O
Holstein O
calves O
( O
30 O
bulls O
, O
30 O
heifers O
) O
were O
used O
to O
examine O
the O
effects O
of O
supplemental O
lactoferrin O
on O
feed B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
growth B-outcome ['Physiological-Clinical']
, O
and O
health B-outcome ['Physiological-Clinical']
during O
the O
preweaning O
and O
postweaning O
periods O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

This O
phenomenon O
has O
not O
been O
well O
articulated O
in O
the O
medical O
education O
literature O
, O
and O
may O
have O
important O
implications O
in O
many O
( O
especially O
technology-mediated O
) O
educational O
contexts O
. O
[]

Patients O
with O
writer O
's O
cramp O
exhibited O
greater O
absolute O
timing O
error O
compared O
with O
control O
subjects O
in O
the O
human O
body O
motion O
task O
( O
whereas O
no O
difference O
was O
observed O
in O
the O
inanimate O
object O
motion O
task O
) O
. O
[]

Since O
the O
conventional O
angiographic O
parameters O
analysed O
in O
this O
study O
failed O
to O
identify O
individual O
arterial O
sites O
with O
an O
increased O
risk O
for O
progression O
, O
definition O
of O
new O
angiographic O
parameters O
or O
application O
of O
new O
techniques O
seem O
mandatory O
to O
this O
end O
. O
[]

PATIENTS O
97 O
patients O
with O
recurrent O
condylomata O
acuminata O
. O
[]

tmax B-outcome ['Physiological-Clinical']
was O
prolonged O
after O
administration O
of O
the O
tablets O
. O
['Physiological-Clinical']

Gastrointestinal O
side O
effects O
and O
hand-foot B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
were O
more O
common O
with O
combination O
therapy O
, O
whereas O
myalgia B-outcome ['Physiological-Clinical']
, O
arthralgia B-outcome ['Physiological-Clinical']
, O
and O
neutropenic B-outcome ['Physiological-Clinical']
fever/sepsis B-outcome ['Physiological-Clinical']
were O
more O
common O
with O
single-agent O
docetaxel O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
The O
presence O
of O
brain O
MRI O
abnormalities O
at O
the O
time O
of O
an O
optic O
neuritis O
attack O
is O
a O
strong O
predictor O
of O
the O
15-year O
risk O
[]

BACKGROUND O
Incidence O
and O
severity O
of O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
increase O
with O
age O
, O
associated O
with O
age-related O
decrease O
in O
immunity O
to O
varicella-zoster O
virus O
( O
VZV O
) O
. O
[]

The O
difference O
between O
the O
two O
protocols O
was O
significant O
as O
indicated O
by O
the O
effect O
of O
group O
, O
the O
between O
subjects O
factor O
( O
F O
= O
5.85 O
, O
d.f O
. O
[]

Simvastatin O
blunts O
endotoxin-induced O
tissue O
factor O
in O
vivo O
. O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
phase O
I O
study O
of O
MEDI-545 O
, O
an O
anti-interferon-alfa O
monoclonal O
antibody O
, O
in O
subjects O
with O
chronic O
psoriasis O
. O
[]

Secondary O
outcome O
measures O
were O
oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
RDAI B-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
twice I-outcome ['Physiological-Clinical']
daily I-outcome ['Physiological-Clinical']
for O
the O
first O
4 O
days O
, O
and O
the O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Although O
classic O
IBD O
and O
ipilimumab-related O
gastrointestinal O
toxicity O
are O
both O
immune O
mediated O
, O
the O
observed O
pattern O
of O
biomarkers O
suggests O
ipilimumab-related O
gastrointestinal O
toxicity O
may O
be O
a O
distinct O
clinicopathologic O
entity O
. O
[]

Greater O
abstinence-specific B-outcome ['Life-Impact']
structural I-outcome ['Life-Impact']
support I-outcome ['Life-Impact']
( O
operationalized O
as O
fewer O
drug O
users O
in O
the O
social O
network O
) O
and O
decreases O
in O
three O
types O
of O
negative O
abstinence-specific B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
support O
( O
Complaints B-outcome ['Life-Impact']
about I-outcome ['Life-Impact']
Drug I-outcome ['Life-Impact']
Use O
, O
Drug B-outcome ['Life-Impact']
Exposure I-outcome ['Life-Impact']
, O
and O
Demoralization B-outcome ['Life-Impact']
) O
predicted O
cocaine B-outcome ['Life-Impact']
, O
but O
not O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

ZH O
, O
P O
? O
[]

The O
neonates O
were O
randomly O
assigned O
to O
receive O
either O
phenobarbital O
or O
phenytoin O
intravenously O
, O
at O
doses O
sufficient O
to O
achieve O
free O
plasma O
concentrations O
of O
25 O
microg O
per O
milliliter O
for O
phenobarbital O
and O
3 O
microg O
per O
milliliter O
for O
phenytoin O
. O
[]

Cutaneous B-outcome ['Physiological-Clinical']
dissemination I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
occurred O
in O
none O
of O
the O
10 O
acyclovir O
recipients O
and O
in O
5 O
of O
the O
10 O
vidarabine O
recipients O
who O
had O
presented O
with O
localized O
dermatomal O
disease O
( O
P O
= O
0.016 O
) O
. O
['Physiological-Clinical']

Reduced O
albuminuria O
with O
sarpogrelate O
is O
accompanied O
by O
a O
decrease O
in O
monocyte O
chemoattractant O
protein-1 O
levels O
in O
type O
2 O
diabetes O
. O
[]

Changes O
in O
natural B-outcome ['Physiological-Clinical']
killer I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
inversely O
related O
to O
plasma O
beta-endorphin O
levels O
. O
['Physiological-Clinical']

Clinical O
cure O
or O
improvement O
was O
observed O
in O
100 O
and O
99 O
% O
of O
the O
ciprofloxacin O
and O
ceftriaxone O
groups O
, O
respectively O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
analyzed O
for O
both O
analytes O
lamivudine O
and O
stavudine O
by O
a O
validated O
analytical O
method O
. O
['Physiological-Clinical']

Few O
therapeutic O
options O
are O
aimed O
at O
improving O
walking B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Life-Impact']

Twenty O
Type O
2 O
diabetic O
patients O
with O
dyslipidemia O
were O
treated O
3 O
months O
with O
simvastatin O
( O
20 O
mg O
daily O
) O
and O
then O
3 O
months O
with O
fenofibrate O
( O
200 O
mg O
daily O
) O
with O
2 O
months O
of O
wash-out O
between O
the O
two O
treatments O
. O
[]

METHODS O
Study O
patients O
consisted O
of O
197 O
consecutive O
patients O
with O
primary O
open-angle O
glaucoma O
who O
were O
randomly O
assigned O
to O
receive O
either O
no O
adjunctive O
mitomycin O
C O
( O
101 O
eyes O
of O
101 O
patients O
) O
or O
to O
receive O
adjunctive O
subconjunctival O
mitomycin O
C O
( O
96 O
eyes O
of O
96 O
patients O
) O
during O
the O
primary O
glaucoma O
triple O
procedure O
. O
[]

RESULTS O
Patients O
who O
registered O
in O
a O
screened O
area O
felt O
significantly O
more O
able O
to O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
7, O
9, O
11, O
13 O
or O
15 O
mg O
intrathecal O
hyperbaric O
ropivacaine O
respectively. O
[]

CONCLUSION O
The O
results O
suggest O
that O
administration O
of O
oral O
steroids O
before O
primary O
vitrectomy O
in O
eyes O
with O
combined O
RRD O
and O
CD O
improves O
reattachment O
rates O
. O
[]

Participants O
in O
the O
intervention O
group O
received O
a O
rechargeable O
, O
powered O
Oral-B? O
oscillating-rotating-pulsating O
toothbrush O
and O
a O
Reach? O
Access? O
Flosser O
that O
has O
a O
toothbrush-like O
handle O
. O
[]

DESIGN O
Randomised O
, O
placebo-controlled O
, O
double-blind O
study O
. O
[]

Canine O
parvoviral O
enteritis O
continues O
to O
cause O
significant O
morbidity O
and O
mortality O
in O
dogs O
worldwide O
, O
and O
efficacious O
antiviral O
therapies O
are O
lacking O
. O
[]

A O
first-in-man O
, O
randomized O
, O
placebo-controlled O
study O
to O
evaluate O
the O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
autologous O
delipidated O
high-density O
lipoprotein O
plasma O
infusions O
in O
patients O
with O
acute O
coronary O
syndrome O
. O
['Life-Impact']

Conclusion: O
Further O
trials O
are O
needed O
to O
determine O
optimal O
treatment O
protocols O
for O
various O
UI O
types O
and O
to O
evaluate O
long-term O
outcomes O
of O
the O
ExMI O
treatment. O
[]

The O
secondary O
outcomes O
were O
serum O
levels O
of O
neuron-specific B-outcome ['Physiological-Clinical']
enolase I-outcome ['Physiological-Clinical']
and O
S100 B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
. O
The O
occurrences O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
in O
the O
two O
groups O
were O
recorded. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Program O
reach O
was O
low O
, O
which O
may O
reflect O
inaccuracies O
in O
church O
attendance O
rather O
than O
study O
implementation O
issues O
. O
[]

One O
hundred O
twenty O
patients O
( O
54 O
men O
, O
66 O
women O
; O
mean O
age O
, O
64.1 O
years O
; O
range O
, O
19-88 O
years O
) O
who O
underwent O
multidetector O
CT O
of O
the O
upper O
abdomen O
were O
randomized O
into O
three O
groups O
of O
40 O
patients O
each O
: O
( O
a O
) O
TBW O
group O
( O
0.6 O
g O
of O
iodine O
per O
kilogram O
of O
TBW O
) O
, O
( O
b O
) O
LBW O
group O
( O
0.821 O
g O
of O
iodine O
per O
kilogram O
of O
LBW O
) O
, O
and O
( O
c O
) O
BV O
group O
( O
men O
, O
8.6 O
g O
of O
iodine O
per O
liter O
of O
BV O
; O
women O
, O
9.9 O
g O
of O
iodine O
per O
liter O
of O
BV O
) O
. O
[]

Since O
the O
excretion O
of O
cortisol B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
reflects O
the O
production O
rate O
closely O
and O
is O
not O
influenced O
by O
liver O
function O
and O
barbiturates O
, O
the O
results O
in O
group O
2 O
show O
that O
the O
endogenous O
production O
of O
steroids O
is O
an O
adequate O
reaction O
to O
severe O
head O
injury O
. O
['Physiological-Clinical']

Sixty O
patients O
undergoing O
ambulatory O
anterior O
cruciate O
ligament O
repair O
of O
the O
knee O
under O
spinal O
anesthesia O
were O
randomized O
into O
two O
groups O
; O
Group O
1 O
( O
29 O
patients O
) O
received O
4 O
mL O
of O
1.5 O
% O
( O
60-mg O
dose O
) O
and O
Group O
2 O
( O
31 O
patients O
) O
received O
4 O
mL O
of O
2 O
% O
( O
80-mg O
dose O
) O
of O
plain O
mepivacaine O
. O
[]

Comparison O
of O
methods O
for O
intravenous O
infusion O
of O
fat O
emulsion O
during O
extracorporeal O
membrane O
oxygenation O
. O
[]

Most O
modern O
defibrillators O
used O
for O
the O
cardioversion O
of O
atrial O
fibrillation O
( O
AF O
) O
employ O
high-tilt O
, O
capacitor-based O
biphasic O
waveforms O
. O
[]

2 O
) O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
is O
not O
associated O
with O
changes O
in O
patient O
management O
, O
including O
medication O
use O
, O
and O
the O
use O
of O
primary O
and O
secondary O
care O
services O
, O
physical O
therapies O
and O
complementary O
therapies O
. O
( O
[]

Acute O
stress O
consisted O
of O
losing O
against O
a O
competitor O
of O
the O
opposite O
sex O
on O
the O
criterion O
motor O
task O
while O
receiving O
unpleasant O
information O
about O
their O
performance O
over O
30 O
preintervention O
and O
30 O
postintervention O
trials O
. O
[]

The O
preparation O
of O
patients O
for O
cardiac O
surgery O
. O
[]

Trial O
Registration: O
ISRCTN53448131. O
[]

Journal O
ID: O
101266132 O
[]

3 O
) O
Participants O
choosing O
their O
treatment O
group O
( O
i.e O
. O
[]

At O
2 O
years O
, O
there O
was O
no O
difference O
in O
major O
adverse O
cardiac O
events O
( O
98.0 O
% O
for O
ETT O
and O
97.7 O
% O
for O
MPI O
; O
P=0.59 O
) O
. O
[]

In O
both O
groups O
plasma O
levels O
of O
triglycerides O
, O
very O
low-density B-outcome ['Physiological-Clinical']
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Participants O
were O
20 O
children O
with O
ASD O
( O
M O
age O
= O
14.3 O
yr. O
, O
SD O
= O
4.2 O
; O
6 O
girls O
, O
14 O
boys O
) O
in O
the O
role O
of O
speakers O
and O
20 O
control O
children O
, O
who O
acted O
as O
listeners O
. O
[]

RESULTS O
Although O
on O
average O
, O
all O
caregivers O
receiving O
nurse O
counseling O
indicated O
no O
improvement O
in O
psychosocial O
adjustment O
to O
their O
relative B-outcome ['Life-Impact']
's O
illness B-outcome ['Physiological-Clinical']
, O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
or O
caregiver B-outcome ['Life-Impact']
burden I-outcome ['Life-Impact']
, O
they O
found O
counseling O
very O
helpful O
and O
it O
was O
effective O
for O
a O
subgroup O
of O
caregivers O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

[ O
Prevention O
of O
vascular B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
following O
cerebral O
ischemia O
of O
arterial O
origin O
; O
the O
ESPRIT O
trial O
: O
mild O
anticoagulant O
therapy O
, O
combination O
treatment O
with O
acetylsalicylic O
acid O
plus O
dipyridamole O
or O
treatment O
with O
acetylsalicylic O
acid O
alone O
? O
] O
. O
['Physiological-Clinical']

Effect O
of O
L-ornithine-L-aspartate O
on O
patients O
with O
and O
without O
TIPS O
undergoing O
glutamine O
challenge O
: O
a O
double O
blind O
, O
placebo O
controlled O
trial O
. O
[]

Magnesium O
sulphate O
only O
slightly O
reduces O
the O
shivering B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical']

After O
2 O
months O
( O
level O
2 O
) O
, O
nonresponders O
received O
a O
low-dose O
thiazide O
diuretic O
, O
and O
after O
4 O
months O
( O
level O
3 O
) O
, O
amlodipine O
( O
groups O
E O
, O
C O
, O
and O
L O
) O
and O
carvedilol O
( O
group O
A O
) O
. O
[]

DESIGN O
A O
prospective O
, O
randomized O
, O
double-blind O
study O
. O
[]

The O
European O
Myocardial O
Infarction O
Project O
was O
a O
European O
Economic O
Community-supported O
double-blind O
study O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
pre-hospital O
early O
thrombolytic O
treatment O
in O
patients O
with O
suspected O
myocardial O
infarction O
compared O
with O
the O
same O
treatment O
given O
later O
in O
a O
hospital O
setting O
. O
[]

Uvulopalatopharyngoplasty O
versus O
laser O
assisted O
uvulopalatoplasty O
for O
the O
treatment O
of O
snoring O
: O
an O
objective O
randomised O
clinical O
trial O
. O
[]

Recovery B-outcome ['Physiological-Clinical']
was O
rapid O
( O
mean O
12-13 O
minutes O
) O
in O
these O
two O
groups O
. O
['Physiological-Clinical']

The O
AS O
skin O
test O
and O
intradermal O
histamine-induced O
wheal O
and O
flare O
reaction O
were O
performed O
at O
baseline O
( O
without O
AH O
) O
, O
after O
8 O
and O
16 O
weeks O
( O
under O
AH O
treatment O
) O
. O
[]

Title: O
Effect O
of O
a O
Resuscitation O
Strategy O
Targeting O
Peripheral O
Perfusion O
Status O
vs O
Serum O
Lactate O
Levels O
on O
28-Day O
Mortality B-outcome ['Mortality']
Among O
Patients O
With O
Septic O
Shock: O
The O
ANDROMEDA-SHOCK O
Randomized O
Clinical O
Trial. O
[['Mortality']]

Moreover O
, O
most O
studies O
have O
related O
to O
type O
2 O
diabetes O
subjects O
whose O
diabetes O
was O
relatively O
mild O
in O
terms O
of O
therapeutic O
requirements O
. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

Patients O
aged O
at O
least O
40 O
years O
undergoing O
abdominal O
surgery O
were O
randomized O
to O
receive O
either O
fondaparinux O
2.5 O
mg O
or O
placebo O
s.c. O
for O
5-9 O
days O
, O
starting O
6-8 O
h O
postoperatively O
. O
[]

The O
role O
of O
platelet O
glycoprotein O
IIb/IIIa O
inhibitor O
therapy O
in O
patients O
with O
mild O
renal O
impairment O
is O
not O
well O
characterized O
. O
[]

The O
main O
reasons O
for O
not O
participating O
were O
a O
lack O
of O
interest O
and O
time O
requirements O
. O
[]

Demographic O
variables O
included O
age O
, O
education O
, O
ethnicity O
, O
gender O
and O
region O
of O
country O
. O
[]

A O
prospective O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
prophylactic O
intravesical O
instillation O
of O
pirarubicin O
( O
THP O
) O
prior O
to O
transurethral B-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TUR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
superficial I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
There O
were O
102 O
neonates O
randomized O
to O
early O
( O
n O
= O
43 O
) O
or O
delayed O
cord O
clamping O
( O
n O
= O
59 O
) O
. O
[]

One O
hundred O
nine O
women O
participated O
over O
a O
26-month O
interval O
. O
[]

In O
terms O
of O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
, O
the O
incidence O
of O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
, O
gastrointestinal B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
and O
low-protein B-outcome ['Physiological-Clinical']
reaction I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
group O
A O
than O
that O
in O
group O
BP<0.05. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

DESIGN O
Randomised O
consent O
design O
for O
clinical O
trials O
according O
to O
Zelen O
. O
[]

Interference O
on O
metabolism O
induced O
by O
muzolimine O
and O
chlorthalidone O
in O
type O
II O
hypertensive O
diabetics O
. O
[]

Pre-incisionally O
, O
IL-2 B-outcome ['Physiological-Clinical']
increased O
in O
the O
halothane O
group O
( O
p O
< O
0.01 O
) O
, O
whereas O
it O
decreased O
significantly O
in O
the O
isoflurane O
group O
( O
p O
< O
0.001 O
) O
compared O
with O
the O
pre-induction O
level O
. O
['Physiological-Clinical']

Laser O
treatment O
was O
not O
masked O
. O
[]

Bone B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
the O
controls O
( O
group O
3 O
) O
remained O
at O
the O
upper O
limit O
of O
the O
reference O
range O
throughout O
, O
with O
decreases O
in O
BMD B-outcome ['Physiological-Clinical']
of O
2.3 O
% O
( O
spine O
) O
and O
2.8 O
% O
( O
hip O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
of O
7 O
household O
behaviors O
judged O
to O
be O
amenable O
to O
promotion O
by O
CHWs O
improved O
more O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area, O
and O
2 O
out O
of O
the O
5 O
were O
statistically O
significant O
(feeding O
colostrum O
and O
appropriate O
infant O
and O
young O
child O
feeding). O
[]

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O
[]

Elevated B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
counts O
, O
elevated B-outcome ['Physiological-Clinical']
platelet I-outcome ['Physiological-Clinical']
counts O
, O
and O
a O
high O
neutrophil-lymphocyte B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
were O
significant O
independent O
predictors O
for O
shorter O
OS O
in O
a O
model O
with O
established O
prognostic O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Not O
surprisingly O
, O
owner O
compliance O
can O
be O
poor O
resulting O
in O
apparent O
treatment O
failure O
. O
[]

PATIENTS O
The O
study O
population O
was O
aged O
45 O
to O
85 O
years O
. O
[]

Between O
group O
differences O
in O
measures O
of O
impact O
of O
[]

The O
number O
of O
complete B-outcome ['Life-Impact']
arousals I-outcome ['Life-Impact']
decreased O
from O
5 O
( O
range O
1 O
to O
12 O
) O
to O
less O
than O
1 O
per O
night O
( O
range O
0 O
to O
2 O
) O
( O
P O
= O
.001 O
) O
. O
['Life-Impact']

All O
patients O
were O
screened O
by O
computed O
tomography O
every O
2 O
months O
to O
observe O
the O
tumor O
recurrent O
conditions O
. O
[]

DESIGN O
Case-control O
study O
. O
[]

Samples O
were O
tested O
under O
code O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
in O
one O
laboratory O
. O
[]

Overall O
, O
the O
program O
had O
a O
positive O
effect O
on O
attitudes B-outcome ['Life-Impact']
, O
emotions B-outcome ['Life-Impact']
, O
knowledge B-outcome ['Life-Impact']
and O
awareness O
of O
distress B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

MEASUREMENTS O
AND O
RESULTS O
Seventeen O
patients O
had O
Cheyne-Stokes O
apneas O
( O
index O
> O
5/h O
) O
and O
23 O
patients O
had O
hypopneas B-outcome ['Physiological-Clinical']
( O
index O
> O
5/h O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
was O
no O
association O
of O
nutrient O
intake O
to O
changes O
in O
stool O
consistency O
. O
[]

BACKGROUND: O
Few O
studies O
have O
been O
conducted O
on O
the O
utility O
of O
cervical O
spine O
phantoms O
for O
practicing O
cervical O
procedures. O
[]

Terazosin O
and O
enalapril O
had O
a O
comparable O
effect O
on O
resting B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
reducing O
systolic O
( O
SBP B-outcome ['Physiological-Clinical']
) O
and O
diastolic O
( O
DBP B-outcome ['Physiological-Clinical']
) O
blood B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
from O
159.5 O
+/- O
13.9/101.6 O
+/- O
8.8 O
mm O
Hg O
during O
placebo O
by O
7.8 O
% O
/6.7 O
% O
and O
by O
11.3 O
% O
/10.2 O
% O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
follow-up O
extension O
was O
then O
done, O
with O
the O
primary O
endpoint O
cumulative O
incidence O
of O
chronic B-outcome ['Physiological-Clinical']
graft-versus-host I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(cGVHD) I-outcome ['Physiological-Clinical']
. O
Enrolment O
has O
been O
completed O
for O
both O
studies. O
[['Physiological-Clinical']]

Assessments O
included O
gait B-outcome ['Life-Impact']
and O
balance B-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
, O
self-reported B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
the O
number O
of O
medications O
being O
taking O
at O
baseline O
, O
participant O
age O
, O
sex O
, O
and O
history O
of O
falling O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

A O
superiority O
of O
CM O
over O
EC O
was O
observed O
for O
both O
treated O
attacks O
for O
the O
main O
endpoint O
: O
success O
in O
54 O
versus O
36 O
% O
, O
p O
= O
0.003 O
for O
the O
first O
attack O
and O
60 O
versus O
44 O
% O
, O
p O
= O
0.02 O
for O
the O
second O
attack O
. O
[]

A O
rigorous O
statistical O
method O
of O
scale O
construction O
consisting O
of O
a O
modification O
of O
the O
scale O
discrimination O
technique O
was O
employed O
, O
resulting O
in O
a O
45-item O
questionnaire O
representing O
three O
orthogonally O
derived O
scales O
. O
[]

However O
, O
30 O
patients O
receiving O
3 O
x O
0.5 O
mg O
or O
placebo O
daily O
reacted O
only O
rarely O
. O
[]

This O
trial O
demonstrated O
short-term O
efficacy O
of O
smokeless B-outcome ['Physiological-Clinical']
tobacco B-outcome ['Physiological-Clinical']
in O
combination O
with O
group O
support O
for O
smoking O
cessation O
but O
no O
['Physiological-Clinical', 'Physiological-Clinical']

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
2-week, O
and O
1-month O
follow-up O
period. O
[]

Calcium O
and O
fibre O
supplementation O
in O
prevention O
of O
colorectal B-outcome ['Physiological-Clinical']
adenoma I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
: O
a O
randomised O
intervention O
trial O
. O
['Physiological-Clinical']

Long-term O
follow-up O
of O
a O
randomized O
trial O
of O
fludarabine-mitoxantrone O
, O
compared O
with O
cyclophosphamide O
, O
doxorubicin O
, O
vindesine O
, O
prednisone O
( O
CHVP O
) O
, O
as O
first-line O
treatment O
of O
elderly O
patients O
with O
advanced O
, O
low-grade O
non-Hodgkin O
's O
lymphoma O
before O
the O
era O
of O
monoclonal O
antibodies O
. O
[]

METHODS O
A O
prospective O
study O
in O
80 O
patients O
was O
carried O
out O
. O
[]

In O
a O
randomized O
, O
double-blind O
, O
controlled O
study O
, O
we O
compared O
heparinized O
and O
nonheparinized O
infusions O
for O
the O
maintenance O
of O
perioperative B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
catheter I-outcome ['Physiological-Clinical']
patency I-outcome ['Physiological-Clinical']
and O
the O
incidence O
of O
subsequent B-outcome ['Physiological-Clinical']
radial I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
occlusion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cervical O
spine O
motion O
: O
a O
fluoroscopic O
comparison O
during O
intubation O
with O
lighted O
stylet O
, O
GlideScope O
, O
and O
Macintosh O
laryngoscope O
. O
[]

LA O
also O
abolished O
some O
of O
the O
negative O
effects O
that O
overweight O
had O
on O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
with O
the O
open O
technique O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

BACKGROUND O
AND O
AIM O
In O
this O
study O
we O
developed O
a O
new O
methodology O
for O
obtaining O
human O
skeletal O
muscle O
samples O
to O
evaluate O
gene O
expression O
. O
[]

Aliquots O
were O
stained O
with O
a O
tumour-specific O
antibody O
against O
epithelial O
tissue O
( O
Ber O
EP4 O
) O
, O
verified O
as O
a O
good O
marker O
of O
SCLC O
cells O
by O
immunohistochemistry O
. O
[]

At O
52 O
weeks O
, O
patients O
receiving O
the O
implant O
with O
the O
postulated O
biomechanical O
advantage O
achieved O
116 O
% O
of O
the O
power O
output B-outcome ['Physiological-Clinical']
of O
['Physiological-Clinical']

Our O
studies O
do O
not O
characterize O
AP-1 O
as O
a O
therapeutic O
target O
for O
progressive O
human O
atherosclerotic O
disease O
. O
[]

Bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
fell O
by O
4.2 O
+/- O
2.5 O
% O
. O
['Physiological-Clinical']

For O
geometric O
mean O
titers O
( O
GMT O
) O
, O
antibody B-outcome ['Physiological-Clinical']
titers I-outcome ['Physiological-Clinical']
below O
the O
cutoff O
of O
the O
assay O
were O
given O
, O
arbitrarily O
, O
0.05 O
IU/mL O
. O
['Physiological-Clinical']

Superior O
survival B-outcome ['Mortality']
with O
capecitabine O
plus O
docetaxel O
combination O
therapy O
in O
anthracycline-pretreated O
patients O
with O
advanced O
breast O
cancer O
: O
phase O
III O
trial O
results O
. O
['Mortality']

More O
active O
regimens O
than O
FAMTX O
are O
required O
for O
future O
randomised O
trials O
. O
[]

Exclusion O
criteria O
were O
neutropenia O
or O
severely O
impaired O
renal O
function O
. O
[]

PATIENTS O
The O
study O
population O
consisted O
of O
head O
injured O
, O
blunt O
trauma O
adult O
patients O
with O
a O
Glasgow O
Coma O
Scale O
of O
lower O
than O
9 O
. O
[]

RESULTS O
Retapamulin O
was O
as O
effective O
as O
cephalexin O
( O
clinical O
success O
rates O
at O
follow-up O
: O
85.9 O
% O
and O
89.7 O
% O
, O
respectively O
) O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
primary O
endpoints O
studied O
were O
the O
number O
of O
PONV-free B-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
respect I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
PONV I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

5 O
Practolol O
200 O
mg O
had O
the O
same O
effect O
on O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
as O
propranolol O
10 O
mg O
but O
a O
significantly O
smaller O
effect O
on O
the O
forearm B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
responses O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Implications O
of O
these O
findings O
to O
leisure O
services O
and O
the O
quality O
of O
life O
of O
individuals O
with O
ASD O
are O
discussed O
. O
[]

Effects O
of O
mild O
physical O
exercise O
on O
serum B-outcome ['Physiological-Clinical']
lipoproteins I-outcome ['Physiological-Clinical']
and O
metabolites O
of O
arachidonic B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
: O
a O
controlled O
randomised O
trial O
in O
middle O
aged O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
scores O
for O
the O
HMCs O
improved O
less O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area O
for O
all O
six O
components, O
but O
none O
of O
these O
differences O
were O
statistically O
significant. O
[]

CONCLUSIONS O
Tidal B-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
delivered O
by O
healthcare O
providers O
using O
one- O
vs O
two-handed O
compressions O
were O
found O
to O
be O
significantly O
different O
, O
with O
those O
delivered O
by O
two O
hands O
significantly O
greater O
than O
those O
delivered O
by O
one O
hand O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
cases O
( O
200 O
eyes O
) O
were O
divided O
into O
treating O
group O
and O
control O
group O
randomly O
according O
to O
using O
and O
not O
using O
Naphcon O
eye O
drops O
before O
Lasik O
surgery O
. O
[]

A O
repeat O
study O
using O
our O
standard O
technique O
rendered O
free B-outcome ['Physiological-Clinical']
intraperitoneal I-outcome ['Physiological-Clinical']
distribution I-outcome ['Physiological-Clinical']
in O
this O
patient O
, O
as O
well O
as O
in O
the O
other O
seven O
cases O
. O
['Physiological-Clinical']

Predictors O
and O
moderators O
of O
parent O
training O
efficacy O
in O
a O
sample O
of O
children O
with O
autism O
spectrum O
disorders O
and O
serious O
behavioral O
problems O
. O
[]

Compared O
with O
the O
control O
period O
, O
nicotinic O
acid O
therapy O
reduced O
the O
plasma B-outcome ['Physiological-Clinical']
total O
cholesterol B-outcome ['Physiological-Clinical']
level O
by O
24 O
% O
, O
plasma B-outcome ['Physiological-Clinical']
triglyceride I-outcome ['Physiological-Clinical']
level O
by O
45 O
% O
, O
very-low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
by O
58 O
% O
, O
and O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
level O
by O
15 O
% O
, O
and O
it O
increased O
the O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
level O
by O
34 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Double O
blockade O
decreased O
lung B-outcome ['Physiological-Clinical']
volume-to-heart I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability O
transfer O
function O
magnitude B-outcome ['Physiological-Clinical']
( O
P O
< O
0.007 O
) O
and O
increased O
phase O
angle B-outcome ['Physiological-Clinical']
( O
P O
< O
0.02 O
) O
without O
age O
effects O
or O
age-drug O
interactions O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Grade O
3 O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AE I-outcome ['Adverse-effects']
occurred O
in O
5.4% O
and O
2.9% O
of O
the O
participants O
in O
the O
Havrix O
group O
after O
the O
1st O
and O
2nd O
doses, O
respectively. O
[['Adverse-effects']]

No O
side O
effects O
were O
observed O
during O
the O
trial O
or O
afterwards O
( O
observation O
period O
6 O
months O
) O
. O
[]

3 O
. O
[]

The O
skin B-outcome ['Physiological-Clinical']
microvessels I-outcome ['Physiological-Clinical']
' O
vasodilatory B-outcome ['Physiological-Clinical']
ability B-outcome ['Life-Impact']
was O
found O
to O
be O
greater O
during O
radiofrequency O
exposure O
than O
during O
sham O
exposure O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

In O
addition O
, O
in O
spite O
of O
improvements O
in O
accurate O
diagnosis O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
at O
increasingly O
earlier O
ages O
and O
proliferation O
of O
interventions O
, O
research O
associated O
with O
leisure O
and O
quality O
of O
life O
for O
people O
with O
ASD O
is O
lacking O
. O
[]

Dopexamine O
has O
no O
additional O
benefit O
in O
high-risk O
patients O
receiving O
goal-directed O
fluid O
therapy O
undergoing O
major O
abdominal O
surgery O
. O
[]

Hence O
, O
we O
examined O
the O
effect O
of O
inhaled O
LTD4 O
and O
a O
control O
bronchoconstrictor O
agent O
, O
methacholine O
, O
on O
cell B-outcome ['Physiological-Clinical']
differentials I-outcome ['Physiological-Clinical']
in O
hypertonic O
saline-induced O
whole O
sputum O
samples O
of O
12 O
nonsmoking O
atopic O
asthmatic O
subjects O
( O
three O
women O
, O
nine O
men O
; O
21 O
to O
29 O
yr O
of O
age O
; O
FEV1 O
, O
74 O
to O
120 O
% O
pred O
; O
PC20FEV1 O
methacholine O
< O
9.6 O
mg/ml O
) O
. O
['Physiological-Clinical']

The O
efficacy O
of O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
as O
an O
adjunct O
to O
narcotic O
medications O
for O
the O
management O
of O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
in O
a O
prospective O
, O
randomized O
, O
controlled O
study O
of O
patients O
following O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
with O
the O
right O
or O
left O
internal O
thoracic O
artery O
( O
ITA O
) O
. O
['Physiological-Clinical']

The O
shortened O
postpartum O
course O
of O
magnesium O
sulphate B-outcome ['Physiological-Clinical']
is O
as O
effective O
as O
the O
standard O
Pritchard O
regimen O
in O
the O
management B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
eclampsia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Vitamin/mineral O
supplements O
are O
among O
the O
most O
commonly O
used O
treatments O
for O
autism O
, O
but O
the O
research O
on O
their O
use O
for O
treating O
autism O
has O
been O
limited O
. O
[]

Acute O
drug O
effects O
were O
recorded O
, O
focusing O
on O
electrocardiography B-outcome ['Resource-use']
, O
respiratory B-outcome ['Physiological-Clinical']
movements I-outcome ['Physiological-Clinical']
, O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
, O
and O
electroencephalography B-outcome ['Resource-use']
( I-outcome ['Resource-use']
EEG I-outcome ['Resource-use']
) I-outcome ['Resource-use']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Sedation B-outcome ['Physiological-Clinical']
was O
evaluated O
using O
a O
verbal B-outcome ['Life-Impact']
rating O
score O
( O
VRS O
) O
from O
0 O
to O
10 O
and O
bispectral B-outcome ['Physiological-Clinical']
index O
( O
BIS B-outcome ['Physiological-Clinical']
) O
of O
the O
EEG B-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Hyperpigmentation B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
reduced O
progressively O
with O
treatment. O
[['Physiological-Clinical']]

Sleep O
was O
also O
measured O
by O
using O
parent-report O
diaries O
. O
[]

Further O
research O
will O
test O
how O
these O
results O
translate O
into O
clinical O
performance O
and O
patient O
outcome O
. O
[]

After O
4 O
weeks O
, O
if O
either O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
> O
or O
=140/ O
> O
or O
=90 O
mm O
Hg O
or O
SiDBP O
had O
not O
decreased O
by O
> O
or O
=10 O
mm O
Hg O
from O
baseline O
, O
the O
dose O
of O
amlodipine O
was O
increased O
to O
10 O
mg O
QD O
for O
4 O
weeks O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
, O
open-label O
, O
multicenter O
, O
28-day O
clinical O
trial O
. O
[]

Opioid B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
was O
measured O
during O
the O
initial O
24 O
hours O
after O
the O
operation O
. O
['Life-Impact']

Paromomycin O
for O
cryptosporidiosis O
in O
AIDS O
: O
a O
prospective O
, O
double-blind O
trial O
. O
[]

RESULTS O
Women O
who O
were O
iron O
deficient O
at O
baseline O
( O
n=38 O
) O
had O
significantly O
greater O
improvement O
in O
PT O
score O
with O
iron B-outcome ['Physiological-Clinical']
and O
riboflavin B-outcome ['Physiological-Clinical']
supplementation I-outcome ['Physiological-Clinical']
than O
without O
( O
P=0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
predischarge O
angiogram O
showed O
the O
presence O
of O
TIMI B-outcome ['Physiological-Clinical']
3 I-outcome ['Physiological-Clinical']
flow B-outcome ['Physiological-Clinical']
in O
96 O
% O
of O
patients O
who O
received O
PCI O
and O
65 O
% O
of O
patients O
who O
received O
SK O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SUBJECTS O
AND O
METHODS O
The O
study O
included O
149 O
patients O
, O
among O
whom O
36 O
patients O
with O
hypervascular O
hepatocellular O
carcinoma O
were O
identified O
. O
[]

A O
dose O
of O
5 O
x O
10 O
( O
9 O
) O
CFU O
( O
n=186 O
) O
or O
a O
placebo O
( O
n=116 O
) O
containing O
the O
diluent O
buffer O
was O
administered O
. O
[]

The O
aims O
of O
this O
study O
were O
to O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
bowel O
preparation O
protocols O
based O
on O
a O
low O
residue O
diet O
and O
4L O
polyethylene O
glycol O
( O
PEG O
) O
solution O
, O
and O
to O
compare O
these O
new O
options O
with O
the O
traditional O
liquid O
diet O
and O
the O
PEG O
4L O
lavage O
. O
['Life-Impact']

Randomized O
, O
placebo-controlled O
, O
crossover O
study O
of O
methylphenidate O
for O
attention-deficit/hyperactivity O
disorder O
symptoms O
in O
preschoolers O
with O
developmental O
disorders O
. O
[]

RESULTS O
ST O
performed O
alone O
, O
or O
in O
conjunction O
with O
aerobic O
exercise O
, O
improved O
maximal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
and O
increased O
total O
lean B-outcome ['Physiological-Clinical']
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
( O
both O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
hematocrit O
of O
the O
subjects O
( O
26.23?2.03 O
% O
) O
at O
the O
end O
of O
the O
study O
was O
also O
higher O
, O
p O
< O
0.001 O
. O
[]

Patients O
with O
radioiodine O
accumulated O
metastases O
were O
again O
treated O
with O
radioiodine O
in O
Ostrava O
. O
[]

The O
results O
largely O
replicate O
other O
findings O
in O
this O
area O
and O
call O
into O
question O
advocacy O
efforts O
to O
label O
media O
images O
as O
a O
strategy O
to O
decrease O
women O
's O
identification O
with O
the O
stimuli O
. O
[]

In O
HAL O
group O
, O
the O
effective O
rate O
was O
only O
5 O
% O
, O
the O
mean O
survival B-outcome ['Mortality']
time I-outcome ['Mortality']
was O
5.1 O
months O
, O
6 O
months O
survival B-outcome ['Mortality']
rate O
was O
35.8 O
% O
. O
['Mortality', 'Mortality']

Comparison O
of O
ketoconazole O
and O
griseofulvin O
in O
the O
treatment O
of O
tinea O
pedis O
. O
[]

CONCLUSION: O
Both O
drugs O
reduced O
menstrual B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
Ginger O
as O
well O
as O
Novafen O
is O
effective O
in O
relieving O
pain B-outcome ['Physiological-Clinical']
in O
girls O
with O
primary O
dysmenorrhea O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
3 O
studies O
, O
the O
authors O
found O
support O
for O
the O
value-congruence O
model O
that O
accounts O
for O
cultural O
variations O
in O
memory O
for O
emotional B-outcome ['Life-Impact']
experiences I-outcome ['Life-Impact']
. O
['Life-Impact']

This O
individual O
mode O
of O
administration O
allows O
not O
only O
a O
perfect O
dose O
titration O
in O
young O
asthmatics O
, O
but O
is O
also O
helpful O
to O
patients O
who O
have O
difficulty O
in O
swallowing O
large O
dosage O
forms O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Acyclovir O
also O
shortened O
the O
median O
interval O
until O
the O
first O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
( O
4 O
vs. O
7 O
days O
, O
P O
= O
0.005 O
) O
, O
the O
['Physiological-Clinical']

SUBJECTS O
Eleven O
healthy O
male O
volunteers O
. O
[]

Before O
treatment, O
2 O
weeks O
and O
1 O
month O
after O
treatment, O
the O
Gross B-outcome ['Life-Impact']
Motor I-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
Measure O
(GMFM)], O
modified O
Ashworth O
Scale O
(MAS)] O
of O
the O
hamstrings O
and O
triceps O
, O
plantar B-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
and O
plantar B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
examined O
for O
efficacy O
assessment. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

3 O
. O
[]

Some O
effects O
were O
moderated O
by O
location O
and O
risk O
level O
. O
[]

AIM O
TISSEEL O
VH O
is O
the O
only O
commercially O
available O
fibrin O
sealant O
indicated O
as O
an O
adjunct O
to O
conventional O
methods O
of O
hemostasis O
during O
cardiac O
surgery O
. O
[]

However O
, O
glycerol O
provided O
significantly O
lower O
total O
ultrafiltration B-outcome ['Physiological-Clinical']
than O
glucose O
at O
each O
concentration O
, O
despite O
a O
higher O
initial O
osmotic O
pressure O
of O
the O
glycerol-based O
solutions O
. O
['Physiological-Clinical']

The O
results O
suggest O
that O
PlayWisely O
can O
improve O
recognition B-outcome ['Life-Impact']
, O
brain B-outcome ['Physiological-Clinical']
region I-outcome ['Physiological-Clinical']
agility I-outcome ['Physiological-Clinical']
, O
phonemic B-outcome ['Life-Impact']
awareness I-outcome ['Life-Impact']
, O
letter B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

We O
investigated O
the O
feasibility O
of O
two O
intermediate O
dose-dense O
FEC O
regimens O
. O
[]

Through O
primary O
and O
secondary O
review O
with O
preset O
inclusion O
criteria O
, O
two O
independent O
judges O
identified O
27 O
randomized O
controlled O
trials O
, O
of O
which O
13 O
met O
inclusion O
criteria O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Bayley O
Scales O
of O
Infant O
Development O
and O
Wechsler O
Preschool O
and O
Primary O
Scale O
of O
Intelligence O
Revised O
, O
Preschool O
Behaviour O
Checklist O
, O
Bayley O
Behaviour O
Rating O
Scale O
and O
Behaviour O
Screening O
Questionnaire O
. O
[]

SETTING O
A O
university O
medical O
center O
. O
[]

The O
purpose O
of O
this O
study O
is O
to O
investigate O
modulation O
of O
the O
soleus B-outcome ['Physiological-Clinical']
H-reflex I-outcome ['Physiological-Clinical']
during O
rhythmic O
arm O
swing O
in O
humans O
. O
['Physiological-Clinical']

The O
individually O
adjusted O
dosage O
of O
rHuEPO O
and O
iron O
supplementation O
merits O
further O
investigation O
. O
[]

Successful O
treatment O
of O
blepharitis O
with O
bibrocathol O
( O
Posiformin? O
2 O
% O
) O
. O
[]

A O
clinical O
trial O
was O
designed O
to O
evaluate O
the O
efficacy O
of O
azithromycin O
for O
the O
treatment O
of O
chlamydia O
( O
Chlamydophila O
felis O
) O
infection O
in O
cats O
. O
[]

Analysis O
of O
deeper O
pockets O
( O
i.e. O
, O
> O
5 O
mm O
at O
baseline O
) O
showed O
the O
same O
relationship O
for O
PPD O
, O
but O
with O
larger O
differences O
between O
groups O
. O
[]

A O
maximum O
of O
150 O
mg/day O
clozapine O
or O
placebo O
equivalent O
was O
given O
for O
a O
period O
of O
31 O
days O
. O
[]

RESULT O
In O
phase O
1 O
, O
compared O
to O
the O
pharmacotherapy B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
of O
patients O
with O
lower O
DA O
scores O
, O
the O
response O
for O
patients O
with O
higher O
DA O
scores O
was O
steeper O
, O
but O
leveled O
off O
toward O
the O
end O
of O
the O
phase O
. O
['Physiological-Clinical']

CONCLUSION: O
RIPC O
does O
not O
result O
in O
significant O
reduction O
of O
contrast B-outcome ['Physiological-Clinical']
induced I-outcome ['Physiological-Clinical']
nephropathy I-outcome ['Physiological-Clinical']
. O
However O
RIPC O
helps O
in O
the O
prevention O
of O
post O
procedural O
worsening O
in O
eGFR B-outcome ['Physiological-Clinical']
and O
serum O
creatinine B-outcome ['Physiological-Clinical']
even O
up O
to O
6 O
weeks. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Ameliorating B-outcome ['Physiological-Clinical']
intrusive I-outcome ['Physiological-Clinical']
memories I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
distressing I-outcome ['Physiological-Clinical']
experiences I-outcome ['Physiological-Clinical']
using O
computerized O
reappraisal O
training O
. O
['Physiological-Clinical']

Later O
, O
patients O
were O
randomly O
assigned O
to O
receive O
cefoperazone O
sodium O
for O
either O
24 O
hours O
or O
120 O
hours O
. O
[]

BACKGROUND O
The O
role O
of O
bronchodilators O
in O
the O
treatment O
of O
bronchiolitis O
remains O
controversial O
. O
[]

AIMS O
The O
two O
studies O
presented O
here O
were O
conducted O
to O
assess O
the O
efficacy O
of O
paroxetine O
, O
pentoxifylline O
, O
riluzole O
, O
venlafaxine O
and O
pramipexole O
as O
medications O
for O
the O
treatment O
of O
cocaine O
dependence O
. O
[]

The O
10-year O
PFS O
rates O
were O
8.5 O
% O
and O
10.8 O
% O
, O
respectively O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
clonidine I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
0.8 O
+/- O
0.1 O
and O
1.6 O
+/- O
0.2 O
ng/mL O
on O
the O
small- O
and O
large-dose O
days O
, O
respectively O
. O
['Physiological-Clinical']

To O
understand O
better O
the O
ability O
of O
these O
pumps O
to O
assist O
women O
in O
the O
maintenance O
of O
lactation O
, O
the O
current O
study O
was O
undertaken O
to O
evaluate O
their O
effects O
on O
milk O
yield O
and O
prolactin O
and O
oxytocin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
when O
compared O
to O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

BACKGROUND O
AND O
AIM O
OF O
THE O
STUDY O
Non-obstructive O
prosthetic O
valve O
thrombosis O
( O
PVT O
) O
is O
a O
unique O
subset O
that O
features O
clinical O
presentation O
without O
heart O
failure O
, O
and O
may O
be O
asymptomatic O
. O
[]

The O
use O
of O
sedation O
of O
moderate O
depth O
renders O
cardioversion O
by O
either O
approach O
acceptable O
. O
[]

CONCLUSION O
The O
results O
show O
that O
memory B-outcome ['Life-Impact']
, O
attention B-outcome ['Life-Impact']
, O
and O
tracking B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
are O
unaffected O
after O
acute O
and O
subchronic O
administration O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
whereas O
diphenhydramine O
( O
50 O
mg O
) O
significantly O
affected O
divided B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
tracking B-outcome ['Life-Impact']
after O
acute O
administration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

After O
an O
exactly O
controlled O
6-month O
treatment O
hypertensives O
with O
additionally O
recommended O
far-reaching O
CNT O
showed O
an O
economization O
of O
medicaments O
by O
scarcely O
the O
half O
in O
comparison O
to O
the O
reference O
group O
. O
[]

OBJECTIVE O
Wound O
healing O
in O
burn O
wounds O
presents O
a O
challenge O
in O
healthcare O
, O
and O
there O
is O
still O
a O
lack O
of O
alternatives O
in O
topical O
burn O
wound O
treatments O
. O
- O
[]

Virtual O
reality O
exposure O
therapy O
and O
standard O
( O
in O
vivo O
) O
exposure O
therapy O
in O
the O
treatment O
of O
fear O
of O
flying O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
quadriceps O
muscle O
fatigue O
on O
exercise O
tolerance O
and O
ventilatory O
response O
during O
constant-workrate O
cycling O
exercise O
testing O
( O
CWT O
) O
in O
patients O
with O
COPD O
and O
healthy O
subjects O
. O
[]

PURPOSE O
To O
assess O
a O
single O
dose O
of O
intraoperative O
beta O
radiation O
used O
to O
enhance O
the O
success O
rate O
of O
trabeculectomy O
in O
a O
population O
of O
low-risk O
glaucoma O
patients O
in O
whom O
antimetabolites O
might O
not O
be O
indicated O
. O
[]

Before O
the O
target O
appeared O
, O
the O
participant O
's O
attention O
was O
cued O
to O
the O
left O
or O
right O
by O
either O
an O
arrow O
or O
the O
direction O
of O
eye O
gaze O
on O
a O
computerized O
face O
. O
[]

SETTING O
Places O
in O
south O
east O
London O
providing O
antenatal O
care O
for O
women O
receiving O
shared O
care O
and O
planning O
to O
deliver O
in O
one O
of O
three O
hospitals O
or O
at O
home O
. O
[]

TRIAL O
REGISTRATION: O
This O
trial O
has O
been O
assigned O
the O
following O
registry O
number: O
NCT03006406 O
. O
[]

This O
trial O
is O
registered O
at O
ClinicalTrials.gov O
, O
NCT00655473 O
. O
[]

All O
primary O
and O
secondary O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
8-week O
treatment, O
and O
4-week O
follow-up. O
[]

A O
prospective O
randomised O
comparison O
of O
sublingual O
and O
vaginal O
misoprostol O
in O
second O
trimester O
termination O
of O
pregnancy O
. O
[]

MATERIALS O
AND O
METHODS O
The O
Microvasive O
Zerotip O
( O
2.4Fr O
, O
3.0Fr O
) O
, O
Cook O
N-Circle O
( O
2.2Fr O
, O
3.0Fr O
, O
3.2Fr O
) O
, O
Bard O
Dimension O
( O
3.0Fr O
, O
Sacred O
Heart O
Medical O
Halo O
( O
1.9Fr O
) O
, O
Vantage O
( O
1.9Fr O
) O
and O
Circon-ACMI O
Sur-Catch-NT O
( O
3.0Fr O
) O
were O
tested O
by O
3 O
novice O
and O
3 O
experienced O
basket O
operators O
. O
[]

To O
trigger O
immunologic B-outcome ['Physiological-Clinical']
priming I-outcome ['Physiological-Clinical']
, O
patients O
underwent O
between O
one O
and O
five O
priming O
sessions O
with O
exposure O
to O
3,500 O
grains/m O
( O
3 O
) O
( O
+/-500 O
) O
of O
ragweed O
pollen O
in O
an O
environmental O
exposure O
chamber O
. O
['Physiological-Clinical']

Are O
back O
supports O
plus O
education O
more O
effective O
than O
education O
alone O
in O
promoting O
recovery O
from O
low O
back O
pain O
? O
: O
[]

Long-term O
use O
of O
Viozan O
( O
sibenadet O
HCl O
) O
in O
patients O
with O
chronic O
obstructive O
pulmonary O
disease O
: O
results O
of O
a O
1-year O
study O
. O
[]

The O
effects O
of O
ezetimibe/simvastatin O
versus O
simvastatin O
monotherapy O
on O
platelet B-outcome ['Physiological-Clinical']
and O
inflammatory B-outcome ['Physiological-Clinical']
biomarkers I-outcome ['Physiological-Clinical']
in O
patients O
with O
metabolic O
syndrome O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
both O
demographic O
variables O
and O
subjective O
drug O
effects O
were O
related O
to O
drug O
preference O
. O
[]

Effect O
of O
ischemic B-outcome ['Physiological-Clinical']
postconditioning I-outcome ['Physiological-Clinical']
in O
correction O
of O
tetralogy O
of O
Fallot O
. O
['Physiological-Clinical']

Suspected B-outcome ['Physiological-Clinical']
bile-duct I-outcome ['Physiological-Clinical']
stones I-outcome ['Physiological-Clinical']
were O
investigated O
by O
preoperative O
endoscopic O
retrograde O
cholangiography O
( O
LC O
group O
) O
or O
intraoperative O
cholangiography O
( O
OC O
group O
) O
. O
['Physiological-Clinical']

Patients O
randomized O
to O
arm O
B O
received O
simple O
drainage O
only O
to O
presacral O
space O
; O
while O
those O
patients O
in O
arm O
A O
received O
continuous O
irrigation O
in O
addition O
to O
simple O
drainage O
. O
[]

In O
the O
group O
of O
participants O
diagnosed O
with O
asthma, O
percentage O
differences O
of O
participants O
with O
good O
body O
posture O
(without O
postural O
defects) O
were O
statistically O
significant. O
[]

Participants O
were O
randomly O
assigned O
to O
receive O
four O
infusions O
of O
either O
zoledronate O
at O
a O
dose O
of O
5 O
mg O
(zoledronate O
group) O
or O
normal O
saline O
(placebo O
group) O
at O
18-month O
intervals. O
[]

CONCLUSIONS: O
The O
findings O
of O
the O
current O
study O
demonstrate O
that O
consumption O
of O
900 O
mg O
of O
PSE O
improved O
specific O
measures O
of O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
in O
a O
young, O
active O
population. O
[['Life-Impact']]

BACKGROUND O
Cognitive O
difficulties O
have O
been O
reported O
after O
coronary O
artery O
bypass O
graft O
surgery O
using O
cardiopulmonary O
bypass O
. O
[]

Interleukin-6 O
receptor O
inhibition O
with O
tocilizumab O
and O
attainment O
of O
disease O
remission O
in O
rheumatoid O
arthritis O
: O
the O
role O
of O
acute-phase O
reactants O
. O
[]

Conservative O
treatment O
of O
plantar O
fasciitis O
. O
[]

Didanosine O
( O
125 O
to O
200 O
mg O
given O
as O
buffered O
tablets O
) O
and O
delavirdine O
mesylate O
( O
400 O
mg O
) O
pharmacokinetics O
were O
evaluated O
when O
each O
drug O
was O
given O
alone O
( O
treatments O
A O
and O
B O
, O
respectively O
) O
, O
when O
the O
two O
drugs O
were O
given O
concurrently O
( O
treatment O
C O
) O
, O
and O
when O
didanosine O
was O
given O
1 O
h O
after O
delavirdine O
( O
treatment O
D O
) O
. O
[]

CONCLUSIONS O
It O
is O
essential O
that O
the O
median O
length O
of O
follow-up O
be O
clearly O
stated O
in O
any O
clinical O
trial O
. O
[]

Peptide O
infusions O
were O
started O
after O
a O
1-microgram/kg O
bolus O
at O
0900 O
h O
and O
infused O
( O
1 O
microgram/kg.h O
) O
until O
0600 O
h O
the O
next O
morning O
. O
[]

METHODS O
In O
2 O
multiinstitutional O
prospective O
trials O
, O
683 O
postmenopausal O
patients O
were O
randomized O
to O
receive O
either O
fadrozole O
HCL O
, O
1 O
mg O
twice O
daily O
, O
or O
megestrol O
acetate O
, O
40 O
mg O
4 O
times O
daily O
, O
in O
a O
double O
blind O
fashion O
after O
progression O
on O
first-line O
hormonal O
therapy O
. O
[]

Compared O
with O
placebo O
, O
nocturnal B-outcome ['Physiological-Clinical']
voiding I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
is O
reduced O
, O
duration O
of O
the O
first O
sleep O
period O
is O
increased O
, O
and O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
may O
be O
improved O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Five O
outcomes O
related O
to O
wrist O
band O
efficacy O
( O
acute B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
delayed B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
, O
vomiting B-outcome ['Physiological-Clinical']
, O
QOL B-outcome ['Life-Impact']
, O
and O
total O
amount O
of O
antiemetic B-outcome ['Resource-use']
medication I-outcome ['Resource-use']
used I-outcome ['Resource-use']
) O
were O
examined O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Sensorimotor O
enrichment O
also O
produced O
a O
clear O
improvement O
in O
cognition B-outcome ['Life-Impact']
, O
as O
determined O
by O
their O
Leiter-R O
Visualization O
and O
Reasoning O
scores O
. O
['Life-Impact']

Such O
data O
provide O
evidence O
that O
dietary O
counseling O
for O
mothers O
during O
the O
first O
year O
of O
life O
improves O
the O
overall O
dietary O
quality O
of O
children O
in O
a O
low-income O
population O
. O
[]

No O
changes O
in O
menstrual B-outcome ['Physiological-Clinical']
cycle O
length B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
estrogen I-outcome ['Physiological-Clinical']
metabolite I-outcome ['Physiological-Clinical']
ratio O
of O
2-hydroxyestrone B-outcome ['Physiological-Clinical']
to O
16 B-outcome ['Physiological-Clinical']
alpha-hydroxyestrone I-outcome ['Physiological-Clinical']
were O
seen O
with O
soy O
feeding O
in O
the O
non-OC O
or O
the O
OC O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

We O
aimed O
to O
investigate O
the O
effect O
of O
i.v O
. O
[]

ClinicalTrials.govID O
: O
NCT00549809 O
. O
[]

Elevated O
thromboxane O
levels O
are O
associated O
with O
a O
number O
of O
disease O
states O
, O
including O
dermal O
pressure O
ulcers O
. O
[]

In O
the O
first O
100 O
days O
, O
1 O
patient O
died O
of O
pneumonia O
, O
and O
1 O
of O
liver O
GVHD O
. O
[]

Nineteen O
ragweed-sensitive O
patients O
were O
randomized O
into O
2 O
groups O
; O
10 O
received O
the O
polymerized O
form O
and O
9 O
received O
the O
monomeric O
form O
. O
[]

This O
trial O
is O
strategically O
designed O
as O
a O
vanguard O
for O
a O
fully-powered O
trial O
of O
women O
who O
will O
be O
evaluated O
for O
breast O
cancer O
recurrence O
and O
disease-free O
survival O
. O
[]

TRIAL O
DESIGN O
A O
randomized O
placebo O
controlled O
blinded O
study O
of O
treatment O
of O
recurrent O
genital O
warts O
amenable O
to O
destructive O
therapy O
, O
conducted O
independently O
in O
Australia O
and O
China O
. O
[]

The O
treatment O
arms O
were O
balanced O
in O
terms O
of O
pretreatment O
characteristics O
. O
[]

CONCLUSIONS O
Results O
provided O
some O
support O
for O
models O
of O
bupropion O
SR O
treatment O
and O
relapse O
and O
suggested O
that O
motivational O
processes O
may O
partially O
account O
for O
bupropion O
SR O
efficacy O
. O
[]

Transcutaneous O
electrical O
nerve O
stimulation O
after O
thoracotomy O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

They O
affect O
mostly O
younger O
population O
that O
need O
a O
higher O
level O
of O
activities O
as O
compared O
with O
the O
elderly O
. O
[]

The O
benefit-to-risk O
ratio O
for O
longterm O
etanercept O
treatment O
remains O
highly O
favorable O
. O
[]

Prospective O
evaluation O
of O
the O
macrolide O
antibiotic O
dirithromycin O
for O
the O
treatment O
of O
Helicobacter O
pylori O
. O
[]

RESULTS O
Under O
normoglycemic O
conditions O
, O
there O
were O
no O
differences O
between O
theophylline O
and O
placebo O
. O
[]

Spinal O
anaesthesia O
was O
performed O
at O
L3-4 O
or O
L4-5 O
interspace O
with O
12.5 O
mg O
0.5 O
% O
heavy O
bupivacaine O
, O
using O
a O
25 O
G O
Quincke O
needle O
. O
[]

In O
IC O
, O
LF B-outcome ['Physiological-Clinical']
and O
HF B-outcome ['Physiological-Clinical']
significantly O
increased O
from O
Baseline O
to O
Heel O
Stick O
and O
dropped O
from O
Heel O
Stick O
to O
Recovery O
; O
in O
2 O
KC O
conditions O
, O
no O
changes O
across O
study O
phases O
were O
found O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
conclusion O
, O
lisinopril O
administration O
reduces O
arterial B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
and O
improves B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
in O
elderly O
hypertensive O
patients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
present O
study O
used O
the O
physicochemical O
approach O
to O
characterize O
the O
changes O
in O
acid-base B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
occurring O
after O
oral O
NaAcetate/acetic O
acid O
( O
NAA O
) O
administration O
in O
horses O
. O
['Physiological-Clinical']

STUDY O
DESIGN O
A O
prospective O
, O
randomized O
study O
( O
Canadian O
Task O
Force O
I O
) O
was O
conducted O
at O
a O
University-affiliated O
hospital O
. O
[]

Plasma O
levels O
of O
lysozyme O
, O
a O
characteristic O
product O
of O
PMN O
degranulation O
, O
did O
not O
show O
significant O
differences O
between O
the O
study O
groups O
. O
[]

CONCLUSIONS O
Fecal O
incontinence O
and O
erectile O
dysfunction O
are O
frequent O
after O
combined O
treatment O
for O
locally O
advanced O
rectal O
cancer O
. O
[]

Each O
specimen O
was O
embedded O
in O
a O
self-cured O
acrylic O
resin O
block O
from O
2.0 O
mm O
apical O
to O
the O
margins O
of O
a O
cast O
Ni-Cr O
alloy O
crown O
, O
then O
loaded O
at O
150 O
degrees O
from O
the O
long O
axis O
in O
a O
universal O
testing O
machine O
at O
a O
crosshead O
speed O
of O
1.0 O
mm/minute O
until O
fracture O
. O
[]

The O
difficulties O
encountered O
in O
the O
conduct O
of O
RCTs O
for O
pre-school O
children O
with O
autism O
are O
discussed O
. O
[]

The O
present O
study O
examined O
long-term O
efficacy O
outcomes O
in O
a O
subgroup O
of O
postmenopausal O
, O
estrogen O
receptor-positive O
Japanese O
breast O
cancer O
patients O
from O
the O
Pre-Operative O
Arimidex O
Compared O
with O
Tamoxifen O
trial O
, O
following O
pre-operative O
( O
3 O
months O
) O
and O
post-operative O
( O
5 O
years O
) O
adjuvant O
treatment O
with O
either O
anastrozole O
or O
tamoxifen O
. O
[]

AIM O
AND O
DESIGN O
To O
evaluate O
the O
biocompatibility O
of O
glass O
ionomer O
cement O
( O
GIC O
) O
impregnated O
with O
collagen O
or O
bioactive O
glass O
to O
BHK-21 O
fibroblasts O
in O
vitro O
. O
[]

Use O
of O
the O
electrothermal O
bipolar O
vessel O
system O
( O
EBVS O
) O
in O
laparoscopic O
adrenalectomy O
: O
a O
prospective O
study O
. O
[]

CONCLUSIONS: O
The O
main O
finding O
of O
the O
study O
is O
that O
CAF O
ingestion O
increases O
movement B-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
of O
the O
bar O
in O
the O
eccentric O
phase O
of O
the O
movement, O
what O
results O
in O
shortening O
of O
the O
time B-outcome ['Physiological-Clinical']
under O
tension O
(TUT) O
needed O
for O
performing O
a O
specific O
number O
of O
repetitions, O
without O
decreasing O
power B-outcome ['Physiological-Clinical']
and O
velocity B-outcome ['Physiological-Clinical']
in O
the O
CON O
phase O
of O
the O
movement. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Journal O
ID: O
2985248R O
[]

This O
study O
also O
showed O
no O
statistical O
difference O
( O
p O
less O
than O
or O
equal O
to O
0.05 O
) O
in O
the O
incidence O
of O
dysplasia B-outcome ['Physiological-Clinical']
in O
DES-exposed O
offspring O
as O
compared O
to O
a O
control O
population O
. O
['Physiological-Clinical']

BACKGROUND O
Physicians O
in O
the O
general O
medical O
setting O
commonly O
encounter O
but O
rarely O
counsel O
patients O
with O
dependent O
or O
harmful O
drinking O
behaviors O
. O
[]

Journal O
ID: O
100968555 O
[]

Biodistribution O
of O
three O
photosensitizers O
in O
dogs O
with O
spontaneous O
tumors O
. O
[]

Emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
remained O
stable O
in O
both O
groups O
during O
treatment O
, O
whereas O
physical B-outcome ['Life-Impact']
and O
role B-outcome ['Life-Impact']
improved O
slightly O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

AIM O
To O
assess O
the O
efficacy O
and O
safety O
of O
esomeprazole O
in O
patients O
with O
frequent B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
for O
> O
or O
= O
6 O
months O
and O
no O
evidence O
of O
erosive O
oesophagitis O
on O
endoscopy O
. O
['Physiological-Clinical']

For O
SAT, O
39 O
samples O
(n O
= O
8, O
n O
= O
10, O
n O
= O
9, O
n O
= O
12, O
respectively) O
were O
available. O
[]

CONCLUSIONS O
This O
randomized O
controlled O
trial O
provides O
promising O
data O
on O
the O
specificity O
and O
generalizability O
of O
joint B-outcome ['Physiological-Clinical']
attention I-outcome ['Physiological-Clinical']
and O
play B-outcome ['Life-Impact']
interventions I-outcome ['Life-Impact']
for O
young O
children O
with O
autism O
. O
['Physiological-Clinical', 'Life-Impact']

The O
findings O
suggest O
that O
unblinded O
assessment O
by O
trial O
nurses O
is O
unacceptable O
on O
its O
own O
. O
[]

There O
were O
no O
differences O
in O
the O
baseline O
characteristics O
and O
outcome O
of O
ovarian O
stimulation O
between O
the O
two O
groups. O
[]

Both O
LOCF O
and O
BOCF O
showed O
similar O
results O
but O
lower O
effect O
sizes. O
[]

The O
cost O
difference O
ranged O
from O
$ O
270 O
( O
p=0.01 O
) O
during O
the O
quarter O
of O
quit O
, O
to O
$ O
490 O
( O
p O
< O
0.01 O
) O
in O
the O
6th O
quarter O
after O
quitting O
. O
[]

The O
92 O
males O
and O
28 O
females O
included O
in O
the O
study O
had O
a O
median O
age O
of O
62 O
years O
( O
range O
40-85 O
years O
) O
. O
[]

The O
changes O
in O
neuropsychologic O
function O
were O
associated O
with O
an O
improvement O
in O
semiquantitative O
nitrogen O
balance O
, O
which O
became O
consistently O
positive O
in O
amino O
acid-treated O
subjects O
; O
there O
was O
also O
a O
mild O
improvement O
in O
nutritional O
parameters O
and O
in O
liver O
function O
tests O
. O
[]

RE-LY O
is O
a O
phase O
3 O
, O
prospective O
, O
randomized O
, O
open-label O
multinational O
( O
44 O
countries O
) O
trial O
of O
patients O
with O
nonvalvular O
AF O
and O
at O
least O
1 O
risk O
factor O
for O
stroke O
. O
[]

PATIENT O
( O
S O
) O
Infertile O
women O
with O
ovulatory O
dysfunction O
, O
aged O
18-35 O
years O
, O
and O
body O
mass O
index O
< O
35 O
kg/m O
( O
2 O
) O
. O
[]

A O
PaCO2 O
level O
averaging O
4.8 O
kPa O
( O
median O
) O
was O
achieved O
. O
[]

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O
[]

Using O
motivational O
interviewing O
with O
this O
population O
holds O
promise O
for O
helping O
prevent O
alcohol-related O
health O
problems O
. O
[]

Data O
from O
2 O
separate O
multicenter O
, O
double-blind O
clinical O
studies O
following O
the O
same O
protocol O
, O
except O
for O
the O
selection O
of O
doses O
, O
were O
pooled O
to O
evaluate O
the O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
fixed O
doses O
of O
a O
new O
sustained-release O
( O
SR O
) O
formulation O
of O
nifedipine O
compared O
with O
placebo O
in O
388 O
patients O
with O
mild O
to O
moderate O
uncomplicated O
essential O
hypertension O
. O
['Life-Impact']

It O
offers O
the O
possibility O
to O
provide O
context-sensitive O
information O
independently O
of O
the O
user O
's O
location O
and O
position O
. O
[]

mean O
circular O
resultant O
( O
MCR O
) O
, O
expiration/inspiration O
( O
E/I O
) O
ratio O
] O
. O
[]

INTRODUCTION O
Early O
treatment O
of O
rheumatoid O
arthritis O
( O
RA O
) O
has O
been O
shown O
to O
retard O
the O
development O
of O
joint B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
for O
a O
period O
of O
up O
to O
5 O
years O
. O
['Physiological-Clinical']

Controlled O
, O
prospective O
, O
randomized O
, O
clinical O
evaluation O
of O
partial O
ceramic O
crowns O
inserted O
with O
RelyX O
Unicem O
with O
or O
without O
selective O
enamel O
etching O
. O
[]

BACKGROUND O
Upper O
gastrointestinal O
endoscopy O
( O
UGIE O
) O
may O
cause O
some O
cardiac O
stress O
. O
[]

Pulmonary O
function O
testing O
showed O
that O
O O
( O
3 O
) O
-induced O
reductions O
in O
FEV O
( O
1 O
) O
and O
FVC B-outcome ['Physiological-Clinical']
were O
30 O
% O
and O
24 O
% O
smaller O
, O
respectively O
, O
in O
the O
supplemented O
cohort O
. O
['Physiological-Clinical']

BACKGROUND O
The O
absence O
of O
a O
pharmacokinetic B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
between O
the O
proton O
pump O
inhibitor O
esomeprazole O
( O
40 O
mg O
) O
and O
acetylsalicylic O
acid O
( O
aspirin O
, O
ASA O
; O
325 O
mg O
) O
has O
previously O
been O
established O
. O
['Physiological-Clinical']

In O
conclusion O
, O
acebutolol O
is O
safe O
for O
use O
in O
patients O
with O
coronary O
disease O
and O
a O
wide O
range O
of O
ejection O
fractions O
but O
, O
as O
with O
all O
beta O
blockers O
, O
should O
be O
used O
cautiously O
in O
patients O
with O
markedly O
reduced O
resting O
left O
ventricular O
function O
. O
[]

Emphasis O
has O
been O
placed O
on O
TKA O
pain O
management O
for O
postoperative O
care O
and O
during O
rehabilitation. O
[]

In O
contrast O
to O
the O
previously O
used O
evaluation O
procedures O
, O
this O
allows O
a O
reliable O
statistical O
confirmation O
of O
the O
results O
of O
clinical O
tests O
in O
the O
therapy O
for O
bronchial O
hyperresponsiveness O
. O
[]

Median O
TTP O
for O
GP1 O
, O
GP2 O
and O
GD O
was O
7.5 O
, O
7.0 O
and O
7.4 O
months O
, O
respectively O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Efficacy O
, O
safety O
, O
predictability O
, O
stability B-outcome ['Physiological-Clinical']
, O
HOAs B-outcome ['Physiological-Clinical']
, O
and O
CS O
were O
evaluated O
before O
and O
after O
enhancement O
at O
6 O
months O
' O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Implementation O
methods: O
how O
and O
when O
the O
components O
were O
implemented B-outcome ['Life-Impact']
in O
schools. O
[['Life-Impact']]

day O
1 O
. O
[]

The O
myocardial B-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ATP I-outcome ['Physiological-Clinical']
and O
creatine B-outcome ['Physiological-Clinical']
phosphate I-outcome ['Physiological-Clinical']
showed O
no O
significant O
differences O
during O
ischemia O
and O
reperfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
measured O
the O
effect O
of O
a O
single O
dose O
of O
oral O
gabapentin O
( O
900 O
mg O
) O
on O
pain B-outcome ['Physiological-Clinical']
and O
allodynia B-outcome ['Physiological-Clinical']
associated I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
herpes I-outcome ['Physiological-Clinical']
zoster I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cooperative O
Group O
of O
Study O
and O
Treatment O
of O
Multiple O
Myeloma O
. O
[]

Inflammatory O
response O
in O
humans O
exposed O
to O
2.0 O
ppm O
nitrogen O
dioxide O
. O
[]

Calcium O
and O
magnesium O
( O
Ca/Mg O
) O
infusions O
are O
frequently O
used O
to O
prevent O
this O
toxicity O
. O
[]

A O
drawback O
to O
this O
therapeutic O
approach O
is O
the O
relatively O
long O
and O
complex O
management O
of O
the O
induction O
phase O
. O
[]

However O
, O
only O
limited O
information O
is O
available O
on O
the O
ability O
of O
patients O
with O
dystonia O
to O
process O
the O
time-dependent O
features O
( O
e.g O
. O
[]

The O
study O
presents O
the O
results O
of O
prevention O
and O
treatment O
of O
infectious O
and O
inflammatory O
complications O
after O
oral O
surgery O
procedures O
. O
[]

BACKGROUND: O
Health O
education O
has O
been O
considered O
as O
the O
effectiveness O
method O
to O
increase O
the O
self-care O
skills O
of O
diabetes O
patients. O
[]

CONCLUSIONS O
Our O
formula O
for O
cuffed O
tube O
selection O
is O
appropriate O
for O
young O
children O
. O
[]

STUDY O
DESIGN O
AND O
SETTING O
Patients O
( O
n=244 O
) O
participated O
in O
a O
randomized O
trial O
. O
[]

Patients O
were O
randomised O
in O
two O
groups O
: O
the O
training O
group O
( O
n O
= O
21 O
) O
, O
staying O
in O
Cardiac O
Rehabilitation O
Department O
and O
the O
control O
group O
( O
n O
= O
11 O
) O
, O
discharged O
home O
for O
3 O
weeks O
. O
[]

PURPOSE O
To O
compare O
the O
efficacy O
and O
safety O
between O
low-fluence O
photodynamic O
therapy O
( O
PDT O
) O
and O
the O
intravitreal O
ranibizumab O
in O
the O
treatment O
of O
chronic O
central O
serous O
chorioretinopathy O
( O
CSC O
) O
. O
[]

Among O
the O
cases O
treated O
with O
pyrantel O
, O
the O
egg B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

RESULTS O
The O
results O
of O
logistic O
regression O
analysis O
showed O
that O
women O
who O
received O
risk O
counseling O
were O
significantly O
more O
likely O
to O
improve O
their O
risk O
comprehension B-outcome ['Life-Impact']
, O
compared O
with O
women O
in O
the O
control O
condition O
( O
odds O
ratio O
[ O
OR O
] O
= O
3.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
1.3-9.5 O
; O
P O
= O
.01 O
) O
. O
['Life-Impact']

No O
association O
was O
seen O
between O
RBC O
EPA O
and O
plasma O
TAG O
concentration O
or O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Good O
functional O
outcomes O
at O
90 O
days O
were O
not O
significantly O
different O
. O
[]

Relation O
between O
early O
mitral O
regurgitation O
and O
left O
ventricular O
thrombus O
formation O
after O
acute O
myocardial O
infarction O
: O
results O
of O
the O
GISSI-3 O
echo O
substudy O
. O
[]

In O
the O
H. O
pylori-infected O
group O
, O
increase O
in O
GA B-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
corpus O
( O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

Eberconazole O
1 O
% O
cream O
is O
an O
effective O
and O
safe O
alternative O
for O
dermatophytosis O
treatment O
: O
multicenter O
, O
randomized O
, O
double-blind O
, O
comparative O
trial O
with O
miconazole O
2 O
% O
cream O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
latency I-outcome ['Physiological-Clinical']
was O
2.6 O
h O
[ O
95 O
% O
confidence O
intervals O
( O
CI O
) O
2.28-2.93 O
] O
baseline O
, O
1.91 O
h O
( O
95 O
% O
CI O
1.78-2.03 O
) O
with O
placebo O
and O
1.06 O
h O
( O
95 O
% O
CI O
0.98-1.13 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

CONCLUSION O
Laparoscopic O
lymphadenectomy O
was O
associated O
with O
a O
significantly O
lower O
rate O
of O
major O
and O
minor B-outcome ['Adverse-effects']
postoperative I-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
and O
a O
better O
short O
term O
quality O
of O
life O
. O
['Adverse-effects']

Contrary O
to O
group O
1 O
, O
in O
group O
2 O
, O
the O
median O
total O
VHI-10 O
score O
was O
significantly O
higher O
3 O
months O
after O
surgery O
( O
P O
= O
.034 O
) O
compared O
with O
preoperatively O
, O
indicating O
a O
subjective O
voice O
handicap O
. O
[]

BACKGROUND O
AND O
OBJECTIVE O
This O
study O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
toxicity B-outcome ['Adverse-effects']
of O
monthly O
alternating O
ABVD/MOPP O
compared O
to O
ABVD/OPP O
regimens O
in O
patients O
with O
advanced O
stage O
Hodgkin O
's O
disease O
( O
HD O
) O
, O
as O
well O
as O
in O
early O
stage O
patients O
with O
systemic O
symptoms O
and/or O
bulky O
disease O
. O
['Adverse-effects']

STUDY O
DESIGN O
AND O
METHODS O
In O
a O
randomized O
, O
controlled O
trial O
, O
477 O
women O
with O
anemia O
, O
iron O
deficiency O
, O
and O
heavy O
uterine O
bleeding O
were O
assigned O
to O
receive O
either O
IV O
ferric O
carboxymaltose O
( O
< O
or=1000 O
mg O
over O
15 O
min O
, O
repeated O
weekly O
to O
achieve O
a O
total O
calculated O
replacement O
dose O
) O
or O
325 O
mg O
of O
ferrous O
sulfate O
( O
65 O
mg O
elemental O
iron O
) O
prescribed O
orally O
thrice O
daily O
for O
6 O
weeks O
. O
[]

RESULTS O
Forty-nine O
patients O
were O
enrolled O
in O
the O
study O
, O
and O
forty O
children O
completed O
the O
trial O
( O
dropouts O
: O
placebo O
= O
4 O
, O
riluzole O
= O
5 O
) O
. O
[]

TLA O
was O
comparable O
to O
RLA O
in O
terms O
of O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
130 O
vs O
126.5 O
minutes O
, O
p O
= O
0.64 O
) O
, O
estimated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
( O
p O
= O
0.92 O
) O
, O
specimen B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
( O
p O
= O
0.81 O
) O
, O
analgesic B-outcome ['Resource-use']
requirements I-outcome ['Resource-use']
( O
p O
= O
0.25 O
) O
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
p O
= O
0.56 O
) O
and O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
p O
= O
0.58 O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Resource-use', 'Adverse-effects']

The O
first O
study O
compared O
ondansetron O
1 O
, O
8 O
and O
16 O
mg O
to O
placebo O
, O
and O
the O
second O
study O
compared O
8 O
mg O
ondansetron O
to O
placebo O
. O
[]

Altered O
shear-induced O
pathway O
. O
[]

Gender O
differences O
in O
response O
to O
nicotine O
replacement O
therapy O
: O
objective O
and O
subjective O
indexes O
of O
tobacco O
withdrawal O
. O
[]

Mean O
followup O
was O
22.3 O
( O
range O
12 O
to O
36 O
) O
and O
21.3 O
months O
( O
range O
12 O
to O
35 O
) O
in O
groups O
1 O
and O
2 O
, O
respectively O
. O
[]

A O
magnetic O
resonance O
study O
. O
[]

Optimal B-outcome ['Physiological-Clinical']
cosmetic I-outcome ['Physiological-Clinical']
result I-outcome ['Physiological-Clinical']
was O
achieved O
with O
a O
smaller O
volume O
of O
Perlane O
than O
Zyplast O
( O
mean O
, O
1.2 O
ml O
versus O
2.1 O
ml O
) O
. O
['Physiological-Clinical']

Similarly O
, O
right B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improved O
in O
40.9 O
% O
, O
deteriorated O
in O
25.0 O
% O
, O
and O
remained O
stable O
in O
34.1 O
% O
. O
['Physiological-Clinical']

Risk O
factors O
for O
smoking O
at O
both O
endpoints O
in O
the O
combined O
sample O
included O
treatment O
with O
tailored O
mailings O
, O
female O
gender O
, O
younger O
age O
, O
higher O
levels O
of O
tobacco O
dependence O
, O
shorter O
previous O
quit O
attempts O
, O
previous O
use O
of O
nicotine O
replacement O
therapy O
, O
and O
report O
of O
current O
depressive O
symptoms O
or O
lifetime O
depression O
. O
[]

The O
Folic O
Acid O
for O
Vascular O
Outcome O
Reduction O
In O
Transplantation O
( O
FAVORIT O
) O
trial O
is O
designed O
to O
evaluate O
whether O
lowering O
tHcy B-outcome ['Physiological-Clinical']
using O
vitamin O
supplementation O
reduces O
CVD B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
renal O
transplant O
recipients O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
fell O
significantly O
, O
as O
did O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
noradrenaline I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
study O
comprised O
three O
3-week O
periods O
. O
[]

The O
levels O
of O
serum B-outcome ['Physiological-Clinical']
MMP-9 I-outcome ['Physiological-Clinical']
and O
TIMP-1 B-outcome ['Physiological-Clinical']
were O
detected O
using O
ELISA O
before O
and O
after O
treatment O
, O
and O
compared O
with O
20 O
healthy O
subjects O
as O
the O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Two O
tones O
were O
presented O
in O
random O
order O
, O
and O
subjects O
had O
to O
count O
the O
high-pitched O
tones O
. O
[]

Patients O
were O
clinically O
evaluated O
preoperatively O
and O
at O
6 O
weeks O
, O
1 O
year O
, O
and O
a O
minimum O
of O
2 O
years O
after O
treatment O
. O
[]

The O
mean O
change O
of O
IIEF B-outcome ['Physiological-Clinical']
score O
from O
baseline O
for O
erectile O
function O
domain O
of O
Cappra O
( O
? O
) O
['Physiological-Clinical']

RESULTS O
Pioglitazone-treated O
patients O
demonstrated O
greater O
increases O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reductions O
in O
glycated O
hemoglobin B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
CBT O
program O
emphasized O
in O
vivo O
exposure O
supported O
by O
parent O
training O
and O
school O
consultation O
to O
promote O
social O
communication O
and O
emotion O
regulation O
skills O
. O
[]

Compared O
with O
tPA O
, O
however O
, O
primary O
PTCA O
resulted O
in O
a O
markedly O
lower O
rate O
of O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
( O
9.7 O
% O
vs O
27.8 O
% O
, O
p O
= O
0.0002 O
) O
, O
fewer O
unscheduled B-outcome ['Resource-use']
catheterization I-outcome ['Resource-use']
and O
revascularization B-outcome ['Physiological-Clinical']
procedures I-outcome ['Physiological-Clinical']
, O
and O
a O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
7.0 O
vs O
8.6 O
days O
, O
p O
= O
0.01 O
) O
in O
nonanterior O
wall O
AMI O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical', 'Resource-use']

Nutritional O
support O
was O
initiated O
within O
12 O
hours O
postoperatively O
in O
both O
groups O
, O
and O
infused O
at O
a O
rate O
sufficient O
to O
render O
the O
patients O
in O
positive O
nitrogen O
balance O
. O
[]

RESULTS O
There O
was O
no O
significant O
difference O
in O
gender O
( O
66 O
% O
vs. O
67 O
% O
male O
) O
, O
age O
( O
46+/-11 O
years O
vs. O
45+/-10 O
years O
) O
, O
APACHE O
II O
score O
( O
30 O
vs. O
29 O
) O
, O
TISS-28 O
score O
( O
47 O
vs. O
46 O
) O
, O
and O
Glasgow O
Coma B-outcome ['Physiological-Clinical']
Score O
( O
GCS O
, O
5.3 O
vs. O
5.3 O
) O
between O
the O
two O
groups O
. O
['Physiological-Clinical']

Two O
reviewers O
independently O
scored O
the O
responses O
to O
assess O
recall B-outcome ['Life-Impact']
of O
the O
six O
themes O
. O
['Life-Impact']

Stress O
mediated O
hypokalaemia B-outcome ['Physiological-Clinical']
was O
of O
the O
same O
degree O
in O
both O
groups O
, O
the O
median O
values O
of O
the O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
being O
in O
the O
lower O
reference O
range O
( O
3.5-3.7 O
mmol O
X O
1 O
( O
-1 O
] O
, O
although O
large O
amounts O
of O
red O
cell O
concentrates O
were O
given O
. O
['Physiological-Clinical', 'Physiological-Clinical']

morphine B-outcome ['Resource-use']
used O
in O
the O
first O
24 O
hours B-outcome ['Life-Impact']
as O
well O
as O
the O
amount O
of O
the O
drug B-outcome ['Resource-use']
used I-outcome ['Resource-use']
during O
each O
2-h O
period O
were O
noted O
. O
['Resource-use', 'Life-Impact', 'Resource-use']

PD O
was O
more O
often O
the O
reason O
for O
not O
completing O
the O
planned O
four O
courses O
than O
toxicity O
. O
[]

First-line O
cisplatin O
with O
docetaxel O
or O
vinorelbine O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
: O
a O
quality O
of O
life O
directed O
phase O
II O
randomized O
trial O
of O
Gruppo O
Oncologico O
Italia O
Meridionale O
. O
[]

Journal-Name:Lipids O
in O
health O
and O
disease O
[]

In O
cultured O
human O
EPCs O
, O
TZD O
increased O
EPC B-outcome ['Physiological-Clinical']
numbers O
and O
migration B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical']

Acute O
[]

OBJECTIVE O
To O
study O
the O
efficacy O
, O
safety O
, O
and O
compliance O
of O
short-term O
electro-acupuncture O
for O
children O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

When O
the O
ANC O
was O
normalized O
for O
each O
patient O
's O
first O
ANC O
, O
there O
was O
a O
significant O
increase O
in O
the O
ANC B-outcome ['Physiological-Clinical']
on O
days O
6 O
and O
7 O
at O
each O
dose O
level O
. O
['Physiological-Clinical']

Patient-provider O
communication O
in O
the O
intervention O
group O
was O
characterized O
as O
being O
more O
interested B-outcome ['Life-Impact']
, O
friendly B-outcome ['Life-Impact']
, O
responsive B-outcome ['Life-Impact']
, O
interactive B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Journal-Name:Medicine O
[]

Two O
hour O
control O
urine O
collections O
were O
followed O
by O
2 O
h O
postdose O
urine O
collections O
and O
subsequently O
2.5 O
% O
saline O
was O
given O
i.v O
. O
[]

This O
will O
be O
the O
first O
double-blind O
randomized O
controlled O
trial O
for O
this O
health O
technology O
which O
evaluates O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
in O
prevention O
of O
amputations B-outcome ['Resource-use']
in O
diabetic O
patients O
. O
['Resource-use']

Neurodevelopmental O
and O
behavioral O
assessments O
were O
performed O
for O
all O
subjects O
before O
injection O
and O
at O
3 O
and O
6 O
weeks O
after O
injection O
. O
[]

The O
Warfarin O
Re-Infarction O
Study O
( O
WARIS O
) O
studied O
the O
effect O
of O
warfarin O
in O
survivors O
of O
acute O
myocardial O
infarction O
. O
[]

Lung O
injuries O
and O
relevant O
enzymes O
expression O
were O
thus O
assayed O
. O
[]

OBJECTIVE O
A O
randomized O
trial O
of O
breast O
self-examination O
( O
BSE O
) O
Program O
was O
carried O
out O
to O
evaluate O
whether O
the O
intensive O
BSE O
could O
reduce O
the O
number O
of O
deaths O
among O
women O
from O
breast O
cancer O
. O
[]

Treatment O
involved O
12 O
weekly O
group O
sessions O
and O
was O
compared O
with O
a O
waiting O
list O
condition O
. O
[]

Some O
children O
appeared O
to O
respond O
positively O
to O
the O
dimethylglycine O
, O
and O
there O
was O
a O
smaller O
proportion O
of O
negative O
changes O
in O
the O
dimethylglycine O
group O
, O
but O
the O
quantitative O
changes O
in O
the O
dimethylglycine O
behavioral O
assessments O
were O
not O
significantly O
different O
from O
what O
was O
observed O
among O
children O
who O
received O
placebo O
. O
[]

Diameters O
of O
late O
cutaneous O
reactions O
were O
measured O
hourly O
. O
[]

AIMS O
The O
purpose O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
asimadoline O
, O
a O
new O
kappa-opioid O
agonist O
, O
on O
renal O
function O
and O
on O
hormones O
related O
to O
body O
fluid O
balance O
as O
well O
as O
its O
tolerability O
in O
healthy O
subjects O
. O
[]

We O
investigated O
the O
C1772T O
polymorphism O
in O
colorectal O
cancer O
patients O
and O
healthy O
control O
subjects O
to O
clarify O
the O
mechanism O
of O
HIF-1alpha O
activation O
in O
colorectal O
carcinoma O
. O
[]

Adherence B-outcome ['Life-Impact']
for O
both O
placebo O
and O
amoxycillin O
was O
> O
96 O
% O
and O
98.9 O
% O
subjects O
were O
followed O
up O
on O
day- O
4 O
. O
['Life-Impact']

METHODS O
Forty O
patients O
who O
underwent O
digestive O
surgery O
were O
randomly O
received O
parenteral O
nutrition O
with O
either O
BCAA O
enriched O
( O
study O
group O
, O
n=20 O
) O
or O
routine O
amino O
acid O
( O
control O
group O
, O
n=20 O
) O
for O
seven O
consecutive O
days O
. O
[]

If O
so O
, O
this O
would O
be O
a O
great O
support O
for O
doctors O
who O
might O
systematically O
recommend O
these O
simple O
and O
costless O
measures O
, O
especially O
in O
primary O
care O
. O
[]

Efficacy O
and O
safety O
of O
mizolastine O
10 O
mg O
in O
a O
placebo-controlled O
comparison O
with O
loratadine O
in O
chronic O
idiopathic O
urticaria O
: O
results O
of O
the O
MILOR O
Study O
. O
[]

8-oxo-dG B-outcome ['Physiological-Clinical']
is O
significantly O
higher O
( O
up O
to O
about O
threefold O
) O
in O
lymphocyte O
DNA O
from O
men O
in O
Ireland O
and O
the O
U.K. O
Oxidative B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
is O
not O
significantly O
affected O
by O
carotenoid O
supplementation O
; O
nor O
is O
there O
any O
association O
with O
mean O
baseline O
levels O
of O
antioxidants B-outcome ['Physiological-Clinical']
, O
which O
are O
generally O
similar O
in O
the O
five O
countries O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Treated O
patients O
underwent O
surgical O
deactivation O
of O
trigger O
site O
( O
s O
) O
. O
[]

The O
most O
common O
related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
after O
each O
treatment O
included O
symptoms B-outcome ['Physiological-Clinical']
related O
to O
the O
injection/infusion O
site O
, O
dizziness B-outcome ['Physiological-Clinical']
, O
pruritus B-outcome ['Physiological-Clinical']
, O
headache B-outcome ['Physiological-Clinical']
, O
fatigue B-outcome ['Physiological-Clinical']
, O
and O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Survival B-outcome ['Mortality']
rates O
for O
cases O
of O
squamous O
cell O
carcinoma O
, O
small O
cell O
carcinoma O
, O
and O
adrenocarcinoma O
were O
the O
same O
after O
both O
regimens O
of O
therapy O
. O
['Mortality']

As O
the O
coefficient O
of O
variation O
( O
VC O
) O
of O
measured O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
continuously O
increased O
the O
best O
time O
of O
a O
steady O
state O
was O
between O
90 O
and O
130 O
min O
after O
beginning O
the O
infusion O
( O
mean O
VC O
8.9 O
% O
) O
. O
['Physiological-Clinical']

RESULTS O
Mean O
basal B-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
was O
27 O
( O
SEM O
5 O
) O
micromol/l O
in O
non-TIPS O
and O
76 O
( O
10 O
) O
micromol/l O
in O
TIPS O
patients O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Verapamil O
has O
shown O
antimanic O
activity O
in O
some O
but O
not O
all O
studies O
. O
[]

METHOD O
Survivors O
of O
out-of-hospital O
ventricular O
fibrillation O
or O
asystole O
( O
N O
= O
129 O
) O
, O
documented O
by O
electrocardiograms O
from O
registries O
of O
a O
citywide O
Medic O
One O
unit O
and O
two O
countywide O
emergency O
units O
, O
were O
randomized O
into O
a O
two O
group O
, O
experimental O
, O
longitudinal O
design O
. O
[]

DISCUSSION O
Greater O
vital B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
fill I-outcome ['Physiological-Clinical']
in O
the O
PUT O
group O
may O
be O
attributable O
to O
earlier O
and O
greater O
vascular O
invasion O
of O
the O
carrier O
material O
. O
['Physiological-Clinical']

Preservative-free O
2-chloroprocaine O
( O
2-CP O
) O
is O
being O
investigated O
for O
short-acting O
spinal O
anesthesia O
. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

CONCLUSIONS O
Although O
the O
7-day O
PPI-containing O
triple O
anti-H. O
pylori O
therapy O
is O
not O
inferior O
to O
the O
14-day O
therapy O
, O
neither O
treatment O
duration O
provides O
acceptable O
eradication B-outcome ['Physiological-Clinical']
rate O
reaching O
90 O
% O
in O
per-protocol O
analysis O
. O
['Physiological-Clinical']

A O
hierarchy O
of O
outcomes O
was O
hypothesized O
based O
on O
treatments O
received O
prior O
to O
randomization O
and O
randomized O
treatment O
. O
[]

METHODS O
One-hundred O
and O
nineteen O
introductory O
psychology O
students O
who O
either O
had O
two O
episodes O
of O
heavy O
episodic O
drinking O
in O
the O
past O
month O
or O
scored O
?8 O
on O
the O
AUDIT O
participated O
in O
this O
randomized O
controlled O
trial O
for O
course O
credit O
. O
[]

Group O
IV O
) O
. O
[]

The O
occurrence O
of O
bleeding B-outcome ['Physiological-Clinical']
and/or O
spotting B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
cycles O
2 O
and O
3 O
in O
the O
LNG/EE O
group O
( O
41.7 O
% O
and O
34.8 O
% O
, O
respectively O
) O
compared O
with O
the O
NETA/EE O
group O
( O
62.3 O
% O
and O
56.3 O
% O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

On O
the O
first O
day O
before O
surgery, O
the O
patient's O
general O
data O
were O
collected O
and O
the O
Pittsburgh O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
index O
(PSQI) O
was O
used O
to O
assess O
the O
patient's O
sleep B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
the O
past O
month. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Children O
in O
the O
PRN O
group O
had O
higher O
pain B-outcome ['Physiological-Clinical']
intensity O
scores O
compared O
to O
children O
in O
the O
ATC O
group O
, O
both O
at O
rest O
( O
P=0.017 O
) O
and O
with O
swallowing O
( O
P=0.017 O
) O
. O
['Physiological-Clinical']

SETTING O
Twenty-nine O
primary O
care O
physicians O
in O
Switzerland O
and O
Germany O
coordinated O
by O
the O
University O
Hospital O
Basel O
, O
Switzerland O
. O
[]

METHODS O
A O
total O
of O
120 O
patients O
hospitalised O
for O
CHF O
were O
randomised O
to O
receive O
a O
pharmacist O
directed O
post-discharge O
home O
medication O
review O
( O
n O
= O
64 O
, O
53.3 O
% O
) O
or O
standard O
care O
( O
n O
= O
56 O
, O
46.7 O
% O
) O
. O
[]

BACKGROUND: O
To O
investigate O
the O
effectiveness O
of O
Baduanjin O
qigong O
combined O
with O
cognitive-behavior O
therapy O
(CBT) O
on O
the O
physical B-outcome ['Physiological-Clinical']
fitness I-outcome ['Physiological-Clinical']
and O
psychological B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
of O
elderly O
housebound. O
[['Physiological-Clinical'], ['Life-Impact']]

AIMS O
To O
compare O
, O
in O
post-acute O
hemiparetic O
patients O
, O
gait B-outcome ['Life-Impact']
improvement I-outcome ['Life-Impact']
after O
conventional O
physical O
therapy O
alone O
or O
with O
a O
specialised O
balance O
retraining O
program O
. O
['Life-Impact']

The O
vaccine O
or O
the O
placebo O
was O
administered O
subcutaneously O
in O
the O
brachiocephalicus O
muscle O
of O
the O
neck O
. O
[]

Patients O
who O
received O
MOF-Strep O
experienced O
substantially O
greater O
vomiting B-outcome ['Physiological-Clinical']
and O
hematologic B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
than O
patients O
who O
received O
FU O
+ O
HU O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized, O
placebo-controlled, O
cross-over O
trial O
was O
carried O
out O
to O
evaluate O
the O
Trimethylamine B-outcome ['Physiological-Clinical']
N-oxide I-outcome ['Physiological-Clinical']
(TMAO) I-outcome ['Physiological-Clinical']
-reducing O
effect O
of O
Taurisolo((R)). O
[['Physiological-Clinical']]

17.1 O
% O
; O
P O
< O
0.05 O
) O
. O
[]

19.13 O
) O
pg/ml O
, O
ALD O
( O
405.31 O
? O
[]

BACKGROUND O
The O
aim O
of O
this O
paper O
is O
to O
present O
our O
experience O
concerning O
cooperation O
in O
the O
treatment O
of O
Slovak O
patients O
with O
differentiated O
thyroid O
cancer O
in O
Slovak O
and O
Czech O
hospitals O
. O
[]

Health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
was O
measured O
using O
the O
SF12 O
physical B-outcome ['Physiological-Clinical']
and O
mental B-outcome ['Physiological-Clinical']
summary O
component O
T-scores O
and O
pain B-outcome ['Physiological-Clinical']
was O
measured O
with O
a O
100 O
mm O
visual O
analogue O
pain B-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PTF O
administration O
is O
effective O
in O
reducing O
proteinuria B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
NAG I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
these O
patients O
. O
['Physiological-Clinical']

BACKGROUND O
XS0601 O
, O
consisting O
of O
active O
ingredients O
( O
Chuangxiongol O
and O
paeoniflorin O
) O
, O
has O
been O
shown O
to O
inhibit O
arterial O
neointimal O
hyperplasia O
in O
animal O
models O
and O
in O
preliminary O
human O
studies O
. O
[]

After O
3 O
months O
, O
symptoms O
reduced O
significantly O
in O
all O
treatment O
groups O
, O
while O
PEF O
variability O
improved O
in O
BDP O
and O
BDP O
+ O
S O
groups O
; O
FEV1 O
and O
bronchial O
responsiveness O
to O
methacholine O
were O
significantly O
improved O
in O
comparison O
with O
baseline O
value O
in O
the O
BDP O
+ O
S O
group O
only O
. O
[]

A O
randomized O
controlled O
trial O
. O
[]

Journal-Name:Journal O
of O
cardiac O
surgery O
[]

RESULTS O
Thirty-seven O
patients O
were O
eligible O
for O
safety O
and O
efficacy O
. O
[]

They O
considered O
P O
< O
.05 O
to O
be O
statistically O
significant O
. O
[]

Sixty-one O
( O
88 O
percent O
) O
of O
69 O
patients O
have O
experienced O
a O
positive O
response B-outcome ['Physiological-Clinical']
to O
the O
surgery O
after O
5 O
years O
. O
['Physiological-Clinical']

It O
has O
become O
evident O
that O
elevated O
plasma O
norepinephrine O
levels O
are O
directly O
related O
to O
prognosis O
; O
patients O
with O
levels O
> O
900 O
pg/ml O
have O
a O
poor O
prognosis O
and O
shortened O
life O
expectancy O
. O
[]

Background: O
Foot O
and O
ankle O
characteristics O
and O
dynamic O
knee O
valgus O
differ O
in O
people O
with O
and O
without O
patellofemoral O
(PF) O
pain. O
[]

CLINICAL O
TRIALS O
REGISTRY O
This O
phase-4 O
study O
is O
registered O
at O
ClinicalTrials.gov O
( O
NCT00576732 O
) O
. O
[]

This O
study O
raises O
doubts O
about O
the O
clinical O
effectiveness O
of O
HDPM O
in O
autistic O
disorder O
. O
[]

This O
survival B-outcome ['Mortality']
benefit O
was O
maintained O
over O
a O
further O
2 O
years O
of O
follow-up O
( O
P=0.024 O
, O
hazard O
ratio=1.27 O
( O
1.03-1.57 O
) O
) O
. O
['Mortality']

Gains O
correlated O
significantly O
with O
the O
number O
of O
times O
the O
computer O
program O
was O
used O
and O
results O
suggest O
positive O
effects O
. O
[]

The O
current O
study O
involved O
a O
randomized O
controlled O
trial O
of O
Group O
Stepping O
Stones O
Triple O
P O
( O
GSSTP O
) O
for O
a O
mixed-disability O
group O
. O
[]

Fluoroscopic O
functional O
evaluation O
of O
bileaflet O
prostheses O
: O
effect O
of O
different O
intraoperative O
valve O
orientation O
. O
[]

Patients O
were O
monitored O
daily O
for O
recurrence O
of O
pain B-outcome ['Physiological-Clinical']
, O
need B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
stop I-outcome ['Physiological-Clinical']
feeding I-outcome ['Physiological-Clinical']
, O
post-refeeding B-outcome ['Physiological-Clinical']
LOH I-outcome ['Physiological-Clinical']
( O
primary O
end O
point O
) O
, O
and O
for O
28 O
days O
post-refeeding O
to O
capture O
re-admission B-outcome ['Resource-use']
rates O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

There O
was O
no O
difference O
for O
compression B-outcome ['Physiological-Clinical']
rate O
or O
recoil B-outcome ['Physiological-Clinical']
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
AQ-J O
had O
satisfactory B-outcome ['Life-Impact']
internal I-outcome ['Life-Impact']
consistency O
reliability O
( O
Cronbach O
's O
alpha O
> O
0.70 O
in O
the O
two O
groups O
) O
, O
test-retest O
reliability O
, O
and O
discriminant B-outcome ['Physiological-Clinical']
validity B-outcome ['Physiological-Clinical']
[ O
i.e O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Twenty O
patients O
completed O
the O
study O
. O
[]

Significant O
parameters O
for O
survival O
prediction O
at O
univariate O
analysis O
are O
: O
DeltaWMSI O
( O
chi-square O
20.1 O
; O
p O
< O
0.0000 O
) O
, O
New O
York O
Heart O
Association O
( O
NYHA O
) O
class O
( O
chi-square O
17.57 O
; O
p O
< O
0.0000 O
) O
, O
rest O
ejection O
fraction O
( O
chi-square O
10.41 O
; O
p O
= O
0.0013 O
) O
, O
angiotensin-converting O
enzyme O
inhibitors O
( O
chi-square O
8.23 O
; O
p O
= O
0.0041 O
) O
, O
and O
hypertension O
( O
chi-square O
8.08 O
, O
p O
= O
0.0045 O
) O
. O
[]

Journal-Name:Clinical O
interventions O
in O
aging O
[]

Sixty-one O
patients O
were O
randomised O
to O
treatment O
: O
30 O
to O
quinapril O
and O
31 O
to O
captopril O
. O
[]

The O
control O
group O
received O
only O
the O
usual O
care O
post-diagnosis O
, O
which O
consisted O
of O
a O
1-hour O
consultation O
session O
to O
receive O
the O
results O
of O
diagnostic O
tests O
and O
a O
written O
copy O
of O
the O
recommended O
treatment O
plan O
provided O
by O
a O
developmental O
pediatrician O
and/or O
PNP O
. O
[]

Multicenter O
trial O
of O
cryotherapy O
for O
retinopathy O
of O
prematurity O
: O
preliminary O
results O
. O
[]

We O
then O
designed O
a O
4-arm O
clinical O
trial O
in O
patients O
with O
myeloid O
leukemia O
undergoing O
allogeneic O
stem O
cell O
transplantation O
( O
allo-SCT O
) O
. O
[]

Diet O
design O
for O
a O
multicenter O
controlled O
feeding O
trial O
: O
the O
DELTA O
program O
. O
[]

The O
relevance O
of O
the O
chronology O
between O
panic O
disorder O
and O
avoidance O
behavior O
and O
of O
an O
early O
, O
medium O
or O
late O
onset O
of O
panic O
disorder O
was O
tested O
. O
[]

METHODS O
Eight-seven O
angina O
pectoris O
patients O
, O
mean O
age O
of O
57 O
+/- O
9 O
, O
82 O
white O
and O
79 O
male O
were O
evaluated O
in O
a O
randomized O
, O
double-blind O
trial O
of O
two O
groups O
of O
patients O
diltiazem O
and O
placebo O
, O
3 O
to O
4 O
tablets O
a O
day O
( O
diltiazem O
180 O
to O
240 O
mg O
daily O
) O
. O
[]

Both O
second O
and O
third O
generation O
OCs O
were O
clinically O
effective O
in O
treating O
hirsutism O
. O
[]

A O
significant O
loss O
of O
lysozyme O
content O
was O
observed O
in O
the O
PGE1 O
group O
on O
day O
1 O
of O
the O
infusion O
-- O
ratio O
P O
: O
C O
79 O
+/- O
8 O
% O
( O
P O
less O
than O
0.03 O
) O
, O
and O
was O
associated O
with O
a O
reduction O
in O
the O
plasma O
suppressive O
activity O
. O
( O
[]

Patients O
of O
good O
performance O
status O
receiving O
moderate O
dose O
radiation O
therapy O
have O
improved O
survival O
. O
[]

Twenty-two O
maturity-onset O
type O
diabetics O
treated O
with O
oral O
hypoglycaemic O
agents O
entered O
a O
single-blind O
crossover O
study O
using O
placebo O
( O
periods O
A O
and O
C O
, O
2 O
months O
each O
) O
and O
clofibrate O
( O
2 O
g/day O
; O
period O
B O
; O
2 O
months O
) O
. O
[]

The O
double-blind O
crossover O
design O
included O
nine O
measurement O
occasions O
, O
each O
involving O
rCBF B-outcome ['Physiological-Clinical']
measurement I-outcome ['Physiological-Clinical']
by O
the O
133-Xe O
inhalation O
method O
, O
ratings O
of O
symptoms O
of O
dementia O
, O
personality O
changes O
, O
and O
side O
effects O
, O
and O
a O
psychometric O
investigation O
. O
['Physiological-Clinical']

The O
correlations O
between O
the O
changes O
in O
bone O
mineral O
at O
the O
sites O
measured O
were O
all O
significant O
( O
r O
approximately O
0.2-0.4 O
) O
. O
[]

Current O
management O
is O
delivered O
by O
a O
multidisciplinary O
team, O
but O
evidence O
of O
effectiveness O
is O
limited. O
[]

The O
peak O
velocity B-outcome ['Physiological-Clinical']
increased O
linearly O
as O
the O
movement O
amplitude O
increased O
. O
['Physiological-Clinical']

RESULTS O
A O
significant O
difference O
in O
improvement O
of O
overall B-outcome ['Physiological-Clinical']
subjective I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
an O
intent-to-treat O
analysis O
between O
groups O
T O
and O
C O
was O
found O
at O
the O
follow-ups O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
the O
PostureJac O
( O
SomatoCentric O
Systems O
, O
Inc. O
, O
Toronto O
, O
Ontario O
, O
Canada O
) O
, O
a O
posture O
support O
and O
exercise O
jacket O
, O
was O
effective O
in O
enhancing O
deep B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
endurance I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Spatial O
orientation O
adjustments O
in O
children O
with O
autism O
in O
Hong O
Kong O
. O
[]

Typically O
developed O
children O
located B-outcome ['Life-Impact']
targets I-outcome ['Life-Impact']
cued O
by O
eye B-outcome ['Life-Impact']
gaze B-outcome ['Life-Impact']
more O
quickly O
, O
while O
the O
arrow O
cue O
did O
not O
trigger O
such O
reflexive B-outcome ['Life-Impact']
orienting B-outcome ['Life-Impact']
in O
these O
children O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Given O
the O
efficacy O
of O
systemic O
sirolimus O
administration O
to O
prevent O
neointimal B-outcome ['Physiological-Clinical']
hyperplasia I-outcome ['Physiological-Clinical']
in O
animal O
models O
and O
to O
halt O
and O
even O
reverse O
the O
progression O
of O
allograft O
vasculopathy O
, O
the O
aim O
of O
the O
present O
double-blind O
, O
placebo-controlled O
study O
was O
to O
evaluate O
the O
efficacy O
of O
a O
10-day O
oral O
sirolimus O
treatment O
with O
2 O
different O
loading O
regimens O
for O
the O
prevention O
of O
recurrent O
restenosis O
in O
patients O
with O
ISR O
. O
['Physiological-Clinical']

Atrial O
natriuretic O
factor O
15 O
pmol O
kg-1 O
min-1 O
or O
placebo O
( O
P O
) O
was O
concomitantly O
administered O
against O
a O
background O
infusion O
of O
either O
AVP O
0.003 O
pmol O
kg-1 O
min-1 O
or O
P O
; O
thus O
the O
combinations O
P O
+ O
P O
, O
AVP O
+ O
P O
, O
P O
+ O
ANF O
and O
AVP O
+ O
ANF O
were O
studied O
. O
[]

Screening O
for O
abdominal O
aortic O
aneurysms O
( O
AAAs O
) O
in O
patients O
at O
risk O
will O
become O
more O
cost O
effective O
if O
a O
simple O
, O
inexpensive O
, O
and O
reliable O
ultrasound O
device O
is O
available O
. O
[]

Title: O
Randomized O
study O
of O
the O
impact O
of O
a O
therapeutic O
education O
program O
on O
patients O
suffering O
from O
chronic O
low-back O
pain O
who O
are O
treated O
with O
transcutaneous O
electrical O
nerve O
stimulation. O
[]

In O
the O
subgroup O
analysis O
of O
patients O
who O
had O
valve B-outcome ['Physiological-Clinical']
reoperations I-outcome ['Physiological-Clinical']
, O
lower O
blood O
transfusion O
requirements O
in O
the O
intensive O
care O
unit O
( O
p O
= O
0.013 O
) O
were O
found O
in O
the O
study O
group O
. O
['Physiological-Clinical']

In O
the O
added O
treatment O
group O
, O
the O
change O
in O
the O
B-type O
natriuretic O
peptide O
was O
significantly O
correlated O
with O
the O
change O
in O
the O
brachial B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
( O
r O
= O
0.18 O
) O
, O
central B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
r O
= O
0.18 O
) O
, O
central B-outcome ['Physiological-Clinical']
PP I-outcome ['Physiological-Clinical']
( O
r O
= O
0.26 O
) O
, O
and O
PP B-outcome ['Physiological-Clinical']
amplification I-outcome ['Physiological-Clinical']
( O
r O
= O
-0.22 O
) O
even O
after O
adjusting O
for O
the O
confounding O
factors O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
of O
these O
techniques O
is O
glycoPEGylation O
, O
which O
has O
also O
been O
applied O
to O
recombinant O
activated O
factor O
VII O
( O
rFVIIa O
) O
, O
resulting O
in O
a O
rFVIIa O
derivative O
( O
N7-GP O
) O
with O
a O
prolonged O
terminal O
half-life O
( O
t O
( O
1/2 O
) O
) O
. O
[]

CONCLUSIONS O
Breast-milk O
contains O
significant O
numbers O
of O
bifidobacteria O
and O
the O
maternal O
allergic O
status O
further O
deranges O
the O
counts O
of O
bifidobacteria O
in O
breast-milk O
. O
[]

Both O
antibiotics O
were O
well O
tolerated O
in O
this O
single-dose O
administration O
study O
. O
[]

The O
two O
CE O
training O
protocols O
were O
equilibrated O
for O
exercise O
mode O
, O
intensity O
, O
and O
volume O
, O
differing O
only O
in O
the O
timing O
and O
sequence O
of O
exercises O
. O
[]

Eradication B-outcome ['Physiological-Clinical']
rate O
of O
3 O
day O
, O
6 O
day O
and O
7 O
day O
miconazole O
courses O
for O
complicated O
VVC O
at O
day O
35 O
was O
89.7 O
% O
, O
97.3 O
% O
and O
86.8 O
% O
, O
respectively O
( O
P O
> O
0.05 O
) O
. O
['Physiological-Clinical']

Group O
Sham O
( O
Sham O
) O
, O
Group O
CCI?Normal O
Saline O
( O
NS O
) O
, O
Group O
CCI?LV/hIL-10 O
( O
LV/hIL-10 O
) O
, O
and O
Group O
CCI?LV/control O
( O
vector O
) O
. O
[]

Compared O
with O
the O
randomly O
allocated O
placebo O
, O
the O
three O
active O
treatments O
significantly O
reduced O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
without O
changing O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
or O
body B-outcome ['Physiological-Clinical']
weight O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
' O
knowledge B-outcome ['Life-Impact']
of O
their O
stroke B-outcome ['Life-Impact']
risk O
, O
acceptability B-outcome ['Life-Impact']
of O
the O
interview O
process O
, O
and O
factors O
determining O
their O
preferences B-outcome ['Life-Impact']
were O
also O
assessed O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

DESIGN O
Men O
and O
women O
aged O
40-65 O
y O
( O
n O
= O
38 O
) O
underwent O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
trial O
of O
treatment O
with O
0.7 O
g O
DHA/d O
for O
3 O
mo O
. O
[]

Acute O
pain O
outcomes O
including O
adolescent O
self-report O
, O
nursing O
staff O
behavioral O
observation O
, O
caregiver O
observation O
and O
physiological O
measures O
were O
collected O
. O
[]

Significant O
differences O
were O
not O
identified O
between O
patients O
with O
similar O
current O
ages O
and O
cerebrovascular O
disease O
risk O
who O
had O
early-onset O
or O
late-onset O
depression O
. O
[]

METHODS O
Thirty O
patients O
were O
randomized O
prospectively O
to O
postoperative O
diclofenac O
in O
one O
eye O
and O
ketorolac O
in O
the O
other O
. O
[]

Some O
cycles O
are O
cancelled O
due O
to O
inadequate O
endometrial O
growth O
in O
ART. O
[]

The O
eradication O
rates O
of O
the O
PAC7 O
group O
were O
not O
inferior O
to O
those O
of O
the O
PAC14 O
group O
in O
both O
intention-to-treat O
analysis O
( O
71.2 O
% O
vs. O
75.5 O
% O
) O
and O
per-protocol O
analysis O
( O
83.6 O
% O
vs. O
86.6 O
% O
) O
. O
[]

Median O
within-practice O
[]

Double-blind O
comparison O
of O
liquid O
antacid O
and O
placebo O
in O
the O
treatment O
of O
symptomatic O
reflux O
esophagitis O
. O
[]

All O
subjects O
exhibited O
marked O
reductions O
in O
affected O
arm O
impairment B-outcome ['Life-Impact']
and O
functional B-outcome ['Life-Impact']
limitation I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

This O
is O
possibly O
due O
to O
the O
fact O
that O
either O
subacromial O
tissue O
, O
despite O
of O
chronic O
inflammation O
, O
does O
not O
show O
the O
same O
reagibility O
as O
synovia O
or O
it O
is O
a O
problem O
of O
the O
nearly O
complete O
resection O
of O
the O
subacromial O
bursa O
. O
[]

Isoflurane O
and O
propofol O
for O
long-term O
sedation O
in O
the O
intensive O
care O
unit O
. O
[]

RESULTS O
Patients O
who O
received O
aromatherapy O
massage O
had O
no O
significant O
improvement O
in O
clinical B-outcome ['Physiological-Clinical']
anxiety I-outcome ['Physiological-Clinical']
and/or I-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
compared O
with O
those O
receiving O
usual O
care O
at O
10 O
weeks O
postrandomization O
( O
odds O
ratio O
[ O
OR O
] O
, O
1.3 O
; O
95 O
% O
CI O
, O
0.9 O
to O
1.7 O
; O
P O
= O
.1 O
) O
, O
but O
did O
at O
6 O
weeks O
postrandomization O
( O
OR O
, O
1.4 O
; O
95 O
% O
CI O
, O
1.1 O
to O
1.9 O
; O
P O
= O
.01 O
) O
. O
['Physiological-Clinical']

aureus B-outcome ['Physiological-Clinical']
were O
reduced O
from O
18.8 O
% O
for O
heifers O
in O
the O
control O
group O
to O
6.7 O
and O
6.0 O
% O
for O
heifers O
in O
the O
prepartum O
and O
postpartum O
groups O
, O
respectively O
. O
['Physiological-Clinical']

SAR O
patients O
were O
identified O
by O
history O
, O
skin-prick O
test O
and O
specific O
IgE O
. O
[]

We O
hypothesized O
that O
initiating O
oral O
nutrition O
with O
a O
low-fat O
solid O
diet O
( O
LFSD O
) O
after O
mild O
pancreatitis O
would O
be O
well O
tolerated O
and O
would O
result O
in O
a O
shorter O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
( O
LOH O
) O
. O
['Resource-use']

Endobronchial O
ultrasonography-guided O
transbronchial O
needle O
aspiration O
increases O
the O
diagnostic B-outcome ['Life-Impact']
yield I-outcome ['Life-Impact']
of O
peripheral O
pulmonary O
lesions O
: O
a O
randomized O
trial O
. O
['Life-Impact']

Epirubicin O
and O
cyclophosphamide O
versus O
epirubicin O
and O
docetaxel O
as O
first-line O
therapy O
for O
women O
with O
metastatic O
breast O
cancer O
: O
final O
results O
of O
a O
randomised O
phase O
III O
trial O
. O
[]

Successfully O
detoxified O
patients O
were O
referred O
to O
ongoing O
drug O
treatment O
. O
[]

To O
detect O
trends O
in O
additional O
imaging O
recommendations O
, O
logistic O
regression O
analysis O
was O
used O
. O
[]

INTERVENTIONS O
Subjects O
received O
either O
intravenous O
fructose-1,6-diphosphate O
125 O
mg/kg O
or O
normal O
saline O
1.3 O
ml/kg O
every O
12 O
hours O
over O
10 O
minutes O
for O
four O
consecutive O
doses O
. O
[]

In O
non-TIPS O
patients O
, O
ammonia B-outcome ['Physiological-Clinical']
increased O
to O
36 O
( O
10 O
) O
micromol/l O
when O
LOLA O
was O
administered O
and O
to O
62 O
( O
13 O
) O
micromol/l O
with O
placebo O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

There O
were O
also O
no O
differences O
in O
manual O
muscle O
testing O
sum O
scores O
, O
activity O
scale O
scores O
and O
patients O
' O
own O
assessments O
after O
48 O
weeks O
of O
treatment O
. O
[]

Treatments O
were O
administered O
during O
one O
month O
, O
then O
cross-overed O
again O
during O
4 O
weeks O
. O
[]

After O
the O
first O
4 O
weeks O
all O
subjects O
were O
changed O
from O
CC O
to O
sevelamer O
3.0 O
g/day O
for O
another O
4 O
weeks O
, O
then O
allocated O
randomly O
to O
three O
groups O
for O
the O
final O
4 O
weeks O
: O
group O
A O
, O
sevelamer O
6.0 O
g/day O
; O
group O
B O
, O
sevelamer O
3.0 O
g/day O
and O
CC O
3.0 O
g/day O
; O
group O
C O
, O
CC O
3.0 O
g/day O
. O
[]

A O
proof-of-principle O
study O
established O
that O
doses O
of O
heparin O
lower O
than O
what O
are O
used O
for O
anticoagulation O
but O
sufficient O
to O
block O
P-selectin O
improved O
microvascular B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
inpatients O
with O
SCD O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
screen O
for O
bacterial O
vaginosis O
( O
BV O
) O
and O
to O
investigate O
the O
effect O
of O
treatment O
with O
vaginal O
clindamycin O
in O
order O
to O
observe O
the O
effect O
on O
late B-outcome ['Physiological-Clinical']
miscarriage I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
prior I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
37 I-outcome ['Physiological-Clinical']
completed I-outcome ['Physiological-Clinical']
weeks I-outcome ['Physiological-Clinical']
( O
primary O
outcome O
) O
. O
['Physiological-Clinical']

The O
X3 O
condition O
yielded O
the O
greatest O
accrual O
( O
43.2 O
% O
) O
compared O
to O
X1 O
( O
30.9 O
% O
) O
and O
X2 O
( O
29.9 O
% O
; O
p O
< O
0.05 O
) O
. O
[]

Plasma O
Nitrotyrosine B-outcome ['Physiological-Clinical']
(NT) I-outcome ['Physiological-Clinical']
concentrations O
versus O
patient O
satisfaction O
following O
surgery O
are O
significantly O
correlated O
in O
benign O
disease O
and O
cancer. O
[['Physiological-Clinical']]

In O
this O
prospective O
study O
, O
14 O
patients O
with O
colonic O
cancer O
were O
randomly O
assigned O
to O
undergo O
a O
6-hour O
stable O
isotope O
infusion O
study O
( O
3 O
hours O
of O
fasting O
followed O
by O
3-hour O
infusions O
of O
amino O
acids O
, O
Travasol O
[ O
Baxter O
, O
Montreal O
, O
Canada O
] O
10 O
% O
at O
0.02 O
mL.kg O
( O
-1 O
) O
.min O
( O
-1 O
) O
, O
with O
or O
without O
glucose O
at O
4 O
mg.kg O
( O
-1 O
) O
.min O
( O
-1 O
) O
) O
on O
the O
second O
day O
after O
colorectal O
surgery O
. O
[]

In O
the O
ropivacaine O
and O
bupivacaine O
groups O
sensory O
anesthesia O
was O
considered O
adequate O
for O
surgery O
in O
all O
cases O
but O
one O
in O
each O
group O
; O
in O
the O
etidocaine O
group O
, O
however O
60 O
% O
of O
the O
patients O
showed O
[]

were O
given O
until O
discharge O
. O
[]

In O
Group O
S O
, O
mean O
bladder O
compliance O
was O
significantly O
( O
p O
= O
0.003 O
) O
higher O
and O
mean O
intraabdominal B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
lower O
( O
p O
= O
0.007 O
) O
when O
compared O
to O
baseline O
preanesthetic O
values O
. O
['Physiological-Clinical']

Furthermore, O
there O
were O
no O
statistically O
significant O
differences O
between O
all O
measured O
variables O
for O
the O
EG O
and O
the O
CG O
at O
the O
final O
assessment. O
[]

and O
does O
hepatitis O
B O
virus O
( O
HBV O
) O
related O
PAN O
require O
treatment O
? O
[]

BACKGROUND O
Amantadine O
hydrochloride O
and O
pemoline O
, O
both O
frequently O
used O
to O
treat O
the O
fatigue O
of O
multiple O
sclerosis O
( O
MS O
) O
, O
may O
also O
improve O
attention O
and O
other O
cognitive O
functions O
in O
MS. O
To O
our O
knowledge O
, O
these O
agents O
have O
never O
been O
compared O
in O
a O
placebo-controlled O
trial O
of O
patients O
with O
MS O
. O
[]

4.0 O
vs O
9.3 O
? O
[]

Design O
of O
the O
DEFINE O
trial O
: O
determining O
the O
EFficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
CETP O
INhibition O
with O
AnacEtrapib O
. O
['Life-Impact']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
5.2 O
months O
( O
95 O
% O
confidence O
interval O
= O
3.3 O
to O
9 O
months O
) O
, O
with O
no O
significant O
difference O
between O
the O
intravenous O
and O
intra-arterial O
arms O
( O
log O
rank O
test O
p O
= O
0.79 O
) O
. O
['Mortality']

We O
have O
studied O
interactions O
between O
i.v O
. O
[]

The O
success O
of O
public O
health O
efforts O
to O
improve O
the O
health O
status O
of O
all O
Canadians O
depends O
substantially O
on O
the O
success O
of O
educational O
programs O
directed O
toward O
children O
. O
[]

Heparin-coated O
cardiopulmonary O
bypass O
circuits O
reduce O
circulating O
complement O
factors O
and O
interleukin-6 O
in O
paediatric O
heart O
surgery O
. O
[]

in O
97 O
patients O
( O
aged O
31-83 O
years O
) O
belonging O
to O
NYHA O
class O
II O
and O
III O
with O
congestive O
heart O
failure O
of O
different O
aetiology O
, O
but O
without O
any O
complex O
ventricular O
arrhythmias O
in O
basal O
conditions O
( O
couplets O
with O
R'-R O
less O
than O
or O
equal O
to O
400 O
msec O
, O
ventricular O
tachycardia O
, O
R O
on O
T O
phenomena O
) O
. O
[]

METHODS O
A O
randomized O
, O
blinded O
trial O
in O
217 O
postmenopausal O
women O
with O
hot O
flushes O
randomized O
to O
5 O
or O
10 O
g/day O
of O
MF101 O
or O
placebo O
for O
12 O
weeks O
. O
[]

In O
the O
IB O
group O
, O
BCVA B-outcome ['Physiological-Clinical']
had O
improved O
by O
0.31 O
, O
0.32 O
, O
0.30 O
, O
and O
0.31 O
logMAR B-outcome ['Physiological-Clinical']
and O
CMT B-outcome ['Physiological-Clinical']
had O
decreased O
by O
59.5 O
% O
, O
59 O
% O
, O
60 O
% O
, O
and O
60.3 O
% O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
These O
findings O
suggest O
that O
fever B-outcome ['Physiological-Clinical']
is O
associated O
with O
worsened O
outcome O
in O
surgical O
subarachnoid O
hemorrhage O
patients O
, O
although O
, O
because O
the O
association O
between O
fever B-outcome ['Physiological-Clinical']
and O
the O
primary O
outcome O
measure O
for O
the O
trial O
is O
dependent O
on O
the O
covariates O
used O
in O
the O
analysis O
( O
particularly O
operative O
events O
and O
delayed B-outcome ['Physiological-Clinical']
ischemic I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
) O
, O
we O
can O
not O
rule O
out O
the O
possibility O
that O
fever B-outcome ['Physiological-Clinical']
is O
a O
marker O
for O
other O
events O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

To O
assess O
the O
effect O
of O
DUP O
on O
the O
neuropsychological O
status O
of O
the O
patients O
, O
a O
linear O
mixed-effect O
model O
was O
fitted O
to O
each O
neuropsychological O
dimension O
. O
[]

We O
discuss O
possible O
explanations O
for O
this O
null O
effect, O
including O
the O
impact O
of O
participants' O
low O
perceived O
susceptibility O
to O
the O
risks O
shown O
on O
these O
pictorial O
health O
warning O
labels. O
[]

The O
psychopharmacology O
of O
saccadic O
distractibility O
is O
less O
well O
understood O
, O
but O
is O
relevant O
both O
to O
interpreting O
patient O
studies O
and O
to O
establishing O
the O
neurological O
basis O
of O
their O
findings O
. O
[]

Follow-up O
lasted O
32 O
days O
. O
[]

METHODS O
Patients O
( O
n O
= O
160 O
; O
mean O
age O
, O
21.2 O
years O
; O
63 O
% O
males O
) O
with O
CO O
GHD O
were O
randomised O
2:1 O
to O
GH O
or O
no O
treatment O
for O
24 O
months O
. O
[]

BACKGROUND O
Adults O
with O
high-functioning O
autism O
spectrum O
disorders O
( O
ASD O
) O
have O
difficulties O
in O
social O
communication O
; O
thus O
, O
these O
individuals O
have O
trouble O
understanding O
the O
mental O
states O
of O
others O
. O
[]

DESIGN O
Randomized O
and O
placebo-controlled O
study O
. O
[]

They O
were O
diagnosed O
and O
operated O
due O
to O
the O
cancer O
( O
near-total O
thyroidectomy O
and O
removal O
of O
lymph O
node O
metastases O
) O
in O
Slovak O
hospitals O
. O
[]

Therefore O
, O
we O
hypothesized O
that O
enhanced O
mTOR O
signaling O
might O
be O
responsible O
for O
the O
greater O
muscle O
protein O
synthesis O
when O
leucine-enriched O
EAA+CHOs O
are O
ingested O
during O
postexercise O
recovery O
. O
[]

RESULTS O
After O
the O
intervention O
, O
CGs O
reported O
better O
self-rated B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
physical B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
and O
emotional B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
, O
which O
was O
related O
to O
less O
burden O
and O
bother O
with O
their O
caregiving O
role O
than O
for O
CGs O
not O
receiving O
the O
intervention O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

The O
intervention O
spanned O
12 O
months O
, O
with O
assessments O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
months O
. O
[]

3.6 O
) O
, O
( O
26.2 O
? O
[]

CONCLUSIONS O
Thus O
, O
it O
appears O
that O
a O
low O
intensity O
general O
training O
similar O
to O
that O
followed O
in O
the O
present O
study O
may O
represent O
a O
good O
means O
to O
improve O
physical B-outcome ['Life-Impact']
fitness I-outcome ['Life-Impact']
in O
healthy O
elderly O
people O
. O
['Life-Impact']

The O
results O
show O
a O
significant O
improvement O
in O
the O
active O
treatment O
group O
at O
the O
5 O
% O
level O
as O
compared O
to O
placebo O
. O
[]

CONCLUSION O
Stapled O
mucosectomy O
for O
acute O
thrombosed O
circumferential O
piles O
is O
feasible O
and O
may O
result O
in O
less O
pain B-outcome ['Physiological-Clinical']
, O
a O
more O
rapid O
resolution O
of O
symptoms O
and O
an O
earlier O
return O
to O
work O
compared O
with O
a O
conventional O
procedure O
. O
['Physiological-Clinical']

RESULTS O
The O
intensity O
of O
LBP B-outcome ['Physiological-Clinical']
decreased O
significantly O
more O
( O
39 O
% O
) O
in O
the O
TG O
than O
in O
CG O
at O
12 O
months O
. O
['Physiological-Clinical']

CDP571 O
was O
well O
tolerated O
. O
[]

Primary O
prevention O
and O
health O
promotion O
have O
become O
salient O
topics O
in O
Canadian O
society O
and O
in O
nursing O
during O
the O
past O
two O
decades O
. O
[]

CONCLUSIONS O
CDP571 O
was O
ineffective O
for O
sparing B-outcome ['Physiological-Clinical']
steroids I-outcome ['Physiological-Clinical']
in O
patients O
with O
steroid-dependent O
Crohn O
's O
disease O
. O
['Physiological-Clinical']

40 O
patients O
with O
the O
irresectable O
hepatocellular O
carcinoma O
( O
HCC O
) O
admitted O
to O
the O
department O
of O
HPB O
surgery O
in O
the O
First O
Affiliated O
Hospital O
of O
SUMS O
were O
randomized O
into O
two O
groups O
: O
( O
20 O
each O
) O
from O
Feb. O
1994 O
to O
April O
, O
1995 O
. O
[]

Thereafter O
no O
further O
significant O
improvement O
between O
the O
two O
different O
treatments O
over O
time O
could O
be O
obtained O
. O
[]

STUDY O
DESIGN O
Prospective O
randomized O
trial O
. O
[]

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

BACKGROUND O
To O
elucidate O
the O
most O
efficient O
topical O
therapy O
for O
carcinoma O
in O
situ O
of O
the O
bladder O
, O
the O
efficacy O
of O
intravesical O
mitomycin O
C O
plus O
doxorubicin O
therapy O
was O
compared O
with O
bacillus O
Calmette-Guerin O
( O
BCG O
) O
therapy O
. O
[]

Subjects O
were O
randomly O
assigned O
to O
a O
control O
group O
, O
who O
received O
the O
usual O
care O
or O
to O
an O
experimental O
group O
, O
who O
received O
a O
weekly O
telephone O
call O
intervention O
in O
addition O
to O
the O
usual O
care O
. O
[]

CONCLUSION O
After O
three O
months O
of O
follow-up O
, O
changes O
in O
cardiac B-outcome ['Physiological-Clinical']
structure I-outcome ['Physiological-Clinical']
were O
comparable O
between O
patients O
with O
BB O
and O
PTFE O
AVFs O
. O
['Physiological-Clinical']

Although O
dietary O
sodium O
restriction O
is O
a O
widely O
recommended O
nonpharmacological O
measure O
for O
control O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
no O
detailed O
investigation O
has O
been O
conducted O
regarding O
the O
impact O
of O
dietary O
sodium O
restriction O
on O
this O
condition O
. O
['Physiological-Clinical']

Heparin O
plus O
dipyridamole O
in O
childhood O
hemolytic-uremic O
syndrome O
: O
a O
prospective O
, O
randomized O
study O
. O
[]

Inhaled O
nitric O
oxide O
( O
NO O
) O
improves O
systemic O
oxygenation O
( O
PaO2/FIO2 O
) O
in O
adult O
patients O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
. O
[]

OBJECTIVE O
To O
study O
the O
effect O
to O
recommend O
no O
snacks O
vs O
three O
snacks O
per O
day O
on O
1-year O
weight O
loss O
. O
[]

Using O
the O
information O
given O
by O
the O
4 O
leads O
for O
each O
minute O
of O
recording O
the O
number O
of O
epochs B-outcome ['Physiological-Clinical']
which O
correspond O
to O
a O
stage O
A O
or O
non-A O
were O
determined O
. O
['Physiological-Clinical']

METHODS O
We O
selected O
341 O
incident O
gastric O
cancer O
cases O
( O
86 O
cardia O
, O
172 O
noncardia O
, O
and O
83 O
nonspecified O
) O
, O
accrued O
during O
22 O
years O
of O
follow-up O
, O
and O
341 O
individually O
matched O
controls O
. O
[]

The O
patients O
with O
abnormal O
spaces O
, O
coagulopathy O
, O
infection O
, O
pre-eclampsia/eclampsia O
or O
obesity O
were O
excluded O
. O
[]

The O
SPEM O
( O
Studio O
Policentrico O
Elettrocateteri O
Membrane O
) O
: O
a O
multicenter O
study O
on O
membrane O
leads O
. O
[]

PATIENTS O
AND O
METHODS: O
A O
randomized, O
single-blind O
clinical O
trial O
(evaluators) O
with O
an O
experimental O
group O
(self-administered O
rehabilitation) O
and O
a O
control O
group O
(standard O
physical O
therapy) O
was O
carried O
out O
in O
271 O
adult O
patients O
aged O
18 O
or O
older O
with O
unilateral O
shoulder O
pain O
lasting O
more O
than O
six O
weeks O
and O
less O
than O
three O
months. O
[]

CONCLUSION O
Procalcitonin O
is O
a O
helpful O
and O
safe O
tool O
for O
guiding O
duration O
of O
antibiotic O
treatment O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
overweight O
patients O
who O
underwent O
OA O
than O
in O
those O
treated O
with O
the O
laparoscopic O
technique O
. O
['Physiological-Clinical']

In O
this O
first O
randomized O
study O
in O
high-risk O
patients O
for O
stent O
implantation O
and O
bypass O
surgery O
, O
patients O
with O
retroinfusion-supported O
stent O
implantation O
had O
a O
similar O
1-year O
outcome O
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
compared O
to O
patients O
with O
bypass O
surgery O
. O
['Life-Impact']

Catheterization O
and O
echocardiographic B-outcome ['Physiological-Clinical']
assessment O
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
were O
compared O
in O
21 O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Secondary O
endpoints: O
longitudinal O
HIV B-outcome ['Physiological-Clinical']
viral I-outcome ['Physiological-Clinical']
load I-outcome ['Physiological-Clinical']
, O
T B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BMI) I-outcome ['Physiological-Clinical']
, O
middle-upper-arm B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
(MUAC) I-outcome ['Physiological-Clinical']
, O
and O
25(OH)D(3) B-outcome ['Physiological-Clinical']
levels O
in O
plasma. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

0.12 O
mg/dL O
, O
P O
= O
.03 O
) O
and O
poorer O
postoperative O
diuresis O
( O
-96 O
? O
[]

48 O
healthy O
adults O
were O
also O
studied O
as O
normal O
control O
group O
. O
[]

890/2121 O
patients O
( O
42 O
% O
) O
presented O
with O
an O
acute O
coronary O
syndrome O
( O
ACS O
) O
. O
[]

METHODS O
A O
series O
of O
134 O
patients O
were O
included O
at O
7 O
hospital O
centers O
. O
[]

The O
pre-dosing O
oral O
flora O
of O
the O
subjects O
was O
assessed O
from O
saliva O
samples O
cultured O
for O
aerobic O
and O
anaerobic O
bacteria O
, O
as O
well O
as O
Candida O
albicans O
. O
[]

METHODS O
Determining O
the O
EFficacy O
and O
Tolerability O
of O
CETP O
INhibition O
with O
AnacEtrapib O
( O
DEFINE O
) O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
assess O
the O
efficacy O
and O
safety O
profile O
of O
anacetrapib O
in O
patients O
with O
coronary O
heart O
disease O
( O
CHD O
) O
or O
CHD O
risk O
equivalents O
( O
clinical O
trials.gov O
NCT00685776 O
) O
. O
[]

Selection O
criteria O
were O
: O
infertility O
> O
1 O
year O
, O
subnormal O
semen O
, O
sonographic O
diameter O
of O
veins O
> O
3 O
mm O
and O
time O
of O
regurge O
> O
2 O
s. O
Patients O
were O
randomly O
assigned O
to O
the O
groups O
of O
treatment O
, O
with O
follow-up O
every O
3 O
months O
for O
1 O
year O
. O
[]

Estimates O
of O
respiratory O
and O
heart O
rate O
power O
spectra O
and O
linear O
transfer O
functions O
between O
the O
two O
groups O
were O
generated O
by O
Fourier O
analysis O
. O
[]

CONCLUSIONS O
Despite O
advances O
in O
interventional O
techniques O
, O
diabetes O
remains O
a O
significant O
independent O
predictor O
of O
adverse O
events O
in O
the O
intermediate O
term O
after O
PCI O
. O
[]

The O
Autism O
Research O
Units O
on O
Pediatric O
Psychopharmacology O
( O
RUPP O
Autism O
Network O
) O
resolved O
some O
of O
these O
problems O
during O
the O
design O
of O
a O
risperidone O
RCT O
in O
children/adolescents O
. O
[]

Effect O
of O
developmental O
speech O
and O
language O
training O
through O
music O
on O
speech B-outcome ['Life-Impact']
production I-outcome ['Life-Impact']
in O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

The O
aim O
of O
this O
prospective O
randomized O
controlled O
study O
was O
to O
evaluate O
the O
efficacy O
of O
absorbable O
clips O
in O
elective B-outcome ['Physiological-Clinical']
laparoscopic I-outcome ['Physiological-Clinical']
cholecystectomy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Four O
patients O
preferred O
the O
breast O
with O
the O
smooth O
prosthesis O
, O
three O
preferred O
the O
breast O
with O
the O
textured O
prosthesis O
, O
and O
the O
others O
found O
both O
breasts O
equal O
. O
[]

A O
very O
short O
lead-time O
may O
indicate O
poor O
sensitivity O
of O
the O
screening O
test O
, O
while O
a O
very O
long O
lead-time O
suggests O
overdiagnosis O
. O
[]

Results O
demonstrated O
that O
the O
standard O
and O
directive O
story O
formats O
were O
equally O
as O
effective O
in O
eliciting B-outcome ['Physiological-Clinical']
, O
generalizing O
and O
maintaining B-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
targeted I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
participants O
who O
had O
prior O
game O
play O
experience O
and O
Verbal B-outcome ['Life-Impact']
Comprehension I-outcome ['Life-Impact']
Index O
( O
VCI O
) O
scores O
from O
the O
WISC-IV O
intelligence O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Based O
on O
these O
studies O
, O
we O
decided O
to O
assess O
the O
effectiveness O
of O
Ginkgo O
biloba O
extract O
( O
Ginko O
T.D. O
, O
Tolidaru O
, O
Iran O
) O
as O
an O
adjunctive O
agent O
to O
risperidone O
in O
the O
treatment O
of O
autism O
. O
[]

The O
effect O
of O
captopril O
, O
atenolol O
and O
pravastatin O
combined O
with O
life O
style O
intervention O
. O
[]

Failure O
of O
naltrexone O
hydrochloride O
to O
reduce O
self-injurious O
and O
autistic O
behavior O
in O
mentally O
retarded O
adults O
. O
[]

Outcome O
measures O
were O
the O
Fugl-Meyer O
Assessment O
( O
FMA O
) O
and O
muscle O
tone O
measured O
by O
Myoton-3 O
for O
motor B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and O
the O
Box O
and O
Block O
Test O
( O
BBT O
) O
and O
10-Meter O
Walk O
Test O
( O
10 O
MWT O
) O
for O
motor O
function O
. O
['Life-Impact']

Data O
were O
collected O
at O
baseline O
and O
12 O
months O
post-intervention O
. O
[]

Enalapril O
( O
10 O
mg/day O
) O
in O
systemic O
sclerosis O
. O
[]

The O
primary O
end O
point O
was O
investigator-assessed O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
; O
rates O
of O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
evaluated. O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Adverse-effects']]

There O
was O
a O
significant O
reduction O
in O
the O
mean O
of O
metabolic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
['Physiological-Clinical']

A O
24 O
h O
fast O
more O
than O
doubled O
TSB B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
from O
baseline O
values O
in O
both O
the O
normal O
and O
high O
bilirubin O
groups O
. O
['Physiological-Clinical']

Title: O
Corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
Morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
After O
Phacoemulsification O
in O
Patients O
With O
Primary O
Open-Angle O
Glaucoma O
and O
Cataracts: O
2-Year O
Results O
of O
a O
Randomized O
Multicenter O
Trial. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Effects O
of O
Positive O
Action O
on O
the O
emotional O
health O
of O
urban O
youth O
: O
a O
cluster-randomized O
trial O
. O
[]

Our O
findings O
provide O
a O
clear O
demonstration O
in O
man O
of O
the O
important O
homeostatic B-outcome ['Physiological-Clinical']
role I-outcome ['Physiological-Clinical']
of O
renal O
prostaglandins O
in O
preserving O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
particularly O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
, O
under O
conditions O
of O
elevated O
circulating O
angiotensin O
II O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

INTRODUCTION O
Use O
of O
an O
inspiratory O
impedance O
threshold O
device O
( O
ITD O
) O
significantly O
increases O
coronary O
perfusion O
pressures O
and O
survival O
in O
patients O
ventilated O
with O
an O
endotracheal O
tube O
( O
ETT O
) O
during O
active O
compression-decompression O
cardiopulmonary O
resuscitation O
. O
[]

The O
most O
common O
nasal B-outcome ['Physiological-Clinical']
and O
non-nasal B-outcome ['Physiological-Clinical']
adverse B-outcome ['Adverse-effects']
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']
